From 5e6bbdf3d12313ea8a2c7896887ed1b228e7e02f Mon Sep 17 00:00:00 2001
From: Matthijs Berends <m.s.berends@umcg.nl>
Date: Thu, 1 May 2025 11:48:49 +0200
Subject: [PATCH] (v2.1.1.9267) update ATCs
---
DESCRIPTION | 4 +-
NEWS.md | 16 +-
R/antibiogram.R | 6 +-
R/data.R | 11 +-
R/sir.R | 27 +-
R/sysdata.rda | Bin 98220 -> 98864 bytes
data-raw/_generate_python_wrapper.sh | 27 +-
.../reproduction_of_antimicrobials.R | 55 +-
data-raw/ab.md5 | 2 +-
data-raw/datasets/antimicrobials.dta | Bin 10226 -> 10334 bytes
data-raw/datasets/antimicrobials.feather | Bin 134466 -> 137642 bytes
data-raw/datasets/antimicrobials.parquet | Bin 107065 -> 109667 bytes
data-raw/datasets/antimicrobials.rds | Bin 44504 -> 45316 bytes
data-raw/datasets/antimicrobials.sav | Bin 353040 -> 370416 bytes
data-raw/datasets/antimicrobials.txt | 912 +++++++++---------
data-raw/datasets/antimicrobials.xlsx | Bin 77041 -> 78591 bytes
data/antimicrobials.rda | Bin 44532 -> 45376 bytes
index.md | 19 +-
man/antimicrobials.Rd | 10 +-
man/as.sir.Rd | 24 +-
man/eucast_rules.Rd | 2 +-
man/mdro.Rd | 2 +-
pkgdown/extra.css | 5 +-
tests/testthat/test-sir.R | 46 +-
24 files changed, 615 insertions(+), 553 deletions(-)
diff --git a/DESCRIPTION b/DESCRIPTION
index 49f311c2d..8ca8214de 100644
--- a/DESCRIPTION
+++ b/DESCRIPTION
@@ -1,6 +1,6 @@
Package: AMR
-Version: 2.1.1.9266
-Date: 2025-04-30
+Version: 2.1.1.9267
+Date: 2025-05-01
Title: Antimicrobial Resistance Data Analysis
Description: Functions to simplify and standardise antimicrobial resistance (AMR)
data analysis and to work with microbial and antimicrobial properties by
diff --git a/NEWS.md b/NEWS.md
index ba2f2c110..58fa9655b 100644
--- a/NEWS.md
+++ b/NEWS.md
@@ -1,4 +1,4 @@
-# AMR 2.1.1.9266
+# AMR 2.1.1.9267
*(this beta version will eventually become v3.0. We're happy to reach a new major milestone soon, which will be all about the new One Health support! Install this beta using [the instructions here](https://amr-for-r.org/#get-this-package).)*
@@ -47,14 +47,14 @@ This package now supports not only tools for AMR data analysis in clinical setti
### Breaking
* Dataset `antibiotics` has been renamed to `antimicrobials` as the data set contains more than just antibiotics. Using `antibiotics` will still work, but now returns a warning.
* Removed all functions and references that used the deprecated `rsi` class, which were all replaced with their `sir` equivalents over two years ago.
-* Functions `resistance_predict()` and `sir_predict()` is now deprecated and will be removed in a future version. Use the `tidymodels` framework instead, for which we [wrote a basic introduction](https://amr-for-r.org/articles/AMR_with_tidymodels.html).
+* Functions `resistance_predict()` and `sir_predict()` are now deprecated and will be removed in a future version. Use the `tidymodels` framework instead, for which we [wrote a basic introduction](https://amr-for-r.org/articles/AMR_with_tidymodels.html).
### New
* **One Health implementation**
* Function `as.sir()` now has extensive support for veterinary breakpoints from CLSI. Use `breakpoint_type = "animal"` and set the `host` argument to a variable that contains animal species names.
* The `clinical_breakpoints` data set contains all these breakpoints, and can be downloaded on our [download page](https://amr-for-r.org/articles/datasets.html).
- * The (new) `antimicrobials` data set contains all veterinary antibiotics, such as pradofloxacin and enrofloxacin. All WHOCC codes for veterinary use have been added as well.
- * `ab_atc()` now supports ATC codes of veterinary antibiotics (that all start with "Q")
+ * The (new) `antimicrobials` data set contains all veterinary antimicrobials, such as pradofloxacin and enrofloxacin. All WHOCC codes for veterinary use have been added as well.
+ * `ab_atc()` now supports ATC codes of veterinary antimicrobials (that all start with "Q")
* `ab_url()` now supports retrieving the WHOCC url of their ATCvet pages
* **Support for WISCA antibiograms**
* The `antibiogram()` function now supports creating true Weighted-Incidence Syndromic Combination Antibiograms (WISCA), a powerful Bayesian method for estimating regimen coverage probabilities using pathogen incidence and antimicrobial susceptibility data. WISCA offers improved precision for syndrome-specific treatment, even in datasets with sparse data. A dedicated `wisca()` function is also available for easy usage.
@@ -127,13 +127,13 @@ This package now supports not only tools for AMR data analysis in clinical setti
* `eucast_rules()` now has an argument `overwrite` (default: `FALSE`) to indicate whether non-`NA` values should be overwritten
* Disks of 0 to 5 mm are now allowed, the newly allowed range for disk diffusion (`as.disk()`) is now between 0 and 50 mm
* Updated `italicise_taxonomy()` to support HTML output
-* `custom_eucast_rules()` now supports multiple antibiotics and antibiotic groups to be affected by a single rule
+* `custom_eucast_rules()` now supports multiple antimicrobials and antimicrobial groups to be affected by a single rule
* `mo_info()` now contains an extra element `rank` and `group_members` (with the contents of the new `mo_group_members()` function)
* Updated all ATC codes from WHOCC
-* Updated all antibiotic DDDs from WHOCC
+* Updated all antimicrobial DDDs from WHOCC
* Fix for using a manual value for `mo_transform` in `antibiogram()`
* Fixed a bug for when `antibiogram()` returns an empty data set
-* Fix for mapping 'high level' antibiotics in `as.ab()` (amphotericin B-high, gentamicin-high, kanamycin-high, streptomycin-high, tobramycin-high)
+* Fix for mapping 'high level' antimicrobials in `as.ab()` (amphotericin B-high, gentamicin-high, kanamycin-high, streptomycin-high, tobramycin-high)
* Improved overall algorithm of `as.ab()` for better performance and accuracy, including the new function `as_reset_session()` to remove earlier coercions.
* Improved overall algorithm of `as.mo()` for better performance and accuracy, specifically:
* More weight is given to genus and species combinations in cases where the subspecies is miswritten, so that the result will be the correct genus and species
@@ -148,7 +148,7 @@ This package now supports not only tools for AMR data analysis in clinical setti
* Added console colours support of `sir` class for Positron
### Other
-* New website domain: <https://amr-for-r.org>! The old domain (<https://msberends.github.io/AMR/>) will remain to work.
+* New website domain: <https://amr-for-r.org>! The old domain (<http://amr-for-r.org/>) will remain to work.
* Added Dr. Larisse Bolton and Aislinn Cook as contributors for their fantastic implementation of WISCA in a mathematically solid way
* Added Matthew Saab, Dr. Jordan Stull, and Prof. Javier Sanchez as contributors for their tremendous input on veterinary breakpoints and interpretations
* Added Prof. Kathryn Holt, Dr. Jane Hawkey, and Dr. Natacha Couto as contributors for their many suggestions, ideas and bugfixes
diff --git a/R/antibiogram.R b/R/antibiogram.R
index be95a5935..68f7b0e92 100755
--- a/R/antibiogram.R
+++ b/R/antibiogram.R
@@ -257,11 +257,11 @@
#' You can also use functions from specific 'table reporting' packages to transform the output of [antibiogram()] to your needs, e.g. with `flextable::as_flextable()` or `gt::gt()`.
#'
#' @section Explaining WISCA:
-#'
+#'
#' WISCA (Weighted-Incidence Syndromic Combination Antibiogram) estimates the probability of empirical coverage for combination regimens.
-#'
+#'
#' It weights susceptibility by pathogen prevalence within a clinical syndrome and provides credible intervals around the expected coverage.
-#'
+#'
#' For more background, interpretation, and examples, see [the WISCA vignette](https://amr-for-r.org/articles/WISCA.html).
#' @source
#' * Bielicki JA *et al.* (2016). **Selecting appropriate empirical antibiotic regimens for paediatric bloodstream infections: application of a Bayesian decision model to local and pooled antimicrobial resistance surveillance data** *Journal of Antimicrobial Chemotherapy* 71(3); \doi{10.1093/jac/dkv397}
diff --git a/R/data.R b/R/data.R
index 868d5c288..ca91650d9 100755
--- a/R/data.R
+++ b/R/data.R
@@ -50,7 +50,7 @@
#' ### For the [antivirals] data set: a [tibble][tibble::tibble] with `r nrow(antivirals)` observations and `r ncol(antivirals)` variables:
#' - `av`\cr Antiviral ID as used in this package (such as `ACI`), using the official EARS-Net (European Antimicrobial Resistance Surveillance Network) codes where available. ***This is a unique identifier.*** Combinations are codes that contain a `+` to indicate this, such as `ATA+COBI` for atazanavir/cobicistat.
#' - `name`\cr Official name as used by WHONET/EARS-Net or the WHO. ***This is a unique identifier.***
-#' - `atc`\cr ATC codes (Anatomical Therapeutic Chemical) as defined by the WHOCC
+#' - `atc`\cr ATC codes (Anatomical Therapeutic Chemical) as defined by the WHOCC, see *Details*
#' - `cid`\cr Compound ID as found in PubChem. ***This is a unique identifier.***
#' - `atc_group`\cr Official pharmacological subgroup (3rd level ATC code) as defined by the WHOCC
#' - `synonyms`\cr Synonyms (often trade names) of a drug, as found in PubChem based on their compound ID
@@ -59,9 +59,14 @@
#' - `iv_ddd`\cr Defined Daily Dose (DDD), parenteral treatment
#' - `iv_units`\cr Units of `iv_ddd`
#' - `loinc`\cr All codes associated with the name of the antiviral drug from `r TAXONOMY_VERSION$LOINC$citation` Use [av_loinc()] to retrieve them quickly, see [av_property()].
-#' @details Properties that are based on an ATC code are only available when an ATC is available. These properties are: `atc_group1`, `atc_group2`, `oral_ddd`, `oral_units`, `iv_ddd` and `iv_units`.
+#' @details Properties that are based on an ATC code are only available when an ATC is available. These properties are: `atc_group1`, `atc_group2`, `oral_ddd`, `oral_units`, `iv_ddd` and `iv_units`. Do note that ATC codes are not unique. For example, J01CR02 is officially the ATC code for "amoxicillin and beta-lactamase inhibitor". Consequently, these two items from the [antimicrobials] data set both return `"J01CR02"`:
#'
-#' Synonyms (i.e. trade names) were derived from the PubChem Compound ID (column `cid`) and consequently only available where a CID is available.
+#' ```r
+#' ab_atc("amoxicillin/clavulanic acid")
+#' ab_atc("amoxicillin/sulbactam")
+#' ```
+#'
+#' Synonyms (i.e. trade names) were derived from the PubChem Compound ID (column `cid`) and are consequently only available where a CID is available.
#' @inheritSection AMR Download Our Reference Data
#' @source
#'
diff --git a/R/sir.R b/R/sir.R
index d20bcf7d8..3bcfecf70 100755
--- a/R/sir.R
+++ b/R/sir.R
@@ -59,7 +59,7 @@
#'
#' The default `"standard"` setting ensures cautious handling of uncertain values while preserving interpretability. This option can also be set with the package option [`AMR_capped_mic_handling`][AMR-options].
#' @param add_intrinsic_resistance *(only useful when using a EUCAST guideline)* a [logical] to indicate whether intrinsic antibiotic resistance must also be considered for applicable bug-drug combinations, meaning that e.g. ampicillin will always return "R" in *Klebsiella* species. Determination is based on the [intrinsic_resistant] data set, that itself is based on `r format_eucast_version_nr(3.3)`.
-#' @param substitute_missing_r_breakpoint A [logical] to indicate that a missing clinical breakpoints for R (resistant) must be substituted with R - the default is `FALSE`. Some (especially CLSI) breakpoints only have a breakpoint for S, meaning the outcome can only be `"S"` or `NA`. Setting this to `TRUE` will convert the `NA`s to `"R"` only if the R breakpoint is missing. Can also be set with the package option [`AMR_substitute_missing_r_breakpoint`][AMR-options].
+#' @param substitute_missing_r_breakpoint A [logical] to indicate that a missing clinical breakpoints for R (resistant) must be substituted with R - the default is `FALSE`. Some (especially CLSI) breakpoints only have a breakpoint for S, meaning that the outcome can only be `"S"` or `NA`. Setting this to `TRUE` will convert the `NA`s in these cases to `"R"`. Can also be set with the package option [`AMR_substitute_missing_r_breakpoint`][AMR-options].
#' @param include_screening A [logical] to indicate that clinical breakpoints for screening are allowed - the default is `FALSE`. Can also be set with the package option [`AMR_include_screening`][AMR-options].
#' @param include_PKPD A [logical] to indicate that PK/PD clinical breakpoints must be applied as a last resort - the default is `TRUE`. Can also be set with the package option [`AMR_include_PKPD`][AMR-options].
#' @param breakpoint_type The type of breakpoints to use, either `r vector_or(clinical_breakpoints$type)`. ECOFF stands for Epidemiological Cut-Off values. The default is `"human"`, which can also be set with the package option [`AMR_breakpoint_type`][AMR-options]. If `host` is set to values of veterinary species, this will automatically be set to `"animal"`.
@@ -182,11 +182,10 @@
#' @inheritSection AMR Download Our Reference Data
#' @examples
#' example_isolates
-#' summary(example_isolates) # see all SIR results at a glance
#'
-#' # For INTERPRETING disk diffusion and MIC values -----------------------
+#' summary(example_isolates[, 1:10]) # see all SIR results at a glance
#'
-#' # example data sets, with combined MIC values and disk zones
+#' # create some example data sets, with combined MIC values and disk zones
#' df_wide <- data.frame(
#' microorganism = "Escherichia coli",
#' amoxicillin = as.mic(8),
@@ -202,6 +201,11 @@
#' disks = as.disk(c(6, 10, 14, 18)),
#' guideline = c("EUCAST 2021", "EUCAST 2022", "EUCAST 2023", "EUCAST 2024")
#' )
+#' # and clean previous SIR interpretation logs
+#' x <- sir_interpretation_history(clean = TRUE)
+#'
+#'
+#' # For INTERPRETING disk diffusion and MIC values -----------------------
#'
#' # most basic application:
#' as.sir(df_wide)
@@ -322,13 +326,6 @@
#'
#' ## Using base R ------------------------------------------------
#'
-#' as.sir(df_wide)
-#'
-#' # return a 'logbook' about the results:
-#' sir_interpretation_history()
-#'
-#' # using parallel computing, which is available in base R
-#' as.sir(df_wide, parallel = TRUE)
#'
#' # for single values
#' as.sir(
@@ -357,6 +354,7 @@
#'
#' # as common in R, you can use as.integer() to return factor indices:
#' as.integer(as.sir(c("S", "SDD", "I", "R", "NI", NA)))
+#'
#' # but for computational use, as.double() will return 1 for S, 2 for I/SDD, and 3 for R:
#' as.double(as.sir(c("S", "SDD", "I", "R", "NI", NA)))
#'
@@ -372,7 +370,7 @@
#' example_isolates %>%
#' mutate_if(is_sir_eligible, as.sir)
#'
-#' # since dplyr 1.0.0, this can also be:
+#' # since dplyr 1.0.0, this can also be the more impractical:
#' # example_isolates %>%
#' # mutate(across(where(is_sir_eligible), as.sir))
#' }
@@ -680,7 +678,7 @@ as.sir.disk <- function(x,
}
#' @rdname as.sir
-#' @param parallel A [logical] to indicate if parallel computing must be used, defaults to `FALSE`. This requires no additional packages, as the used `parallel` package is part of base \R. On Windows and on \R < 4.0.0 [parallel::parLapply()] will be used, in all other cases the most efficient [parallel::mclapply()] will be used.
+#' @param parallel A [logical] to indicate if parallel computing must be used, defaults to `FALSE`. This requires no additional packages, as the used `parallel` package is part of base \R. On Windows and on \R < 4.0.0 [parallel::parLapply()] will be used, in all other cases the more efficient [parallel::mclapply()] will be used.
#' @param max_cores Maximum number of cores to use if `parallel = TRUE`. Use a negative value to subtract that number from the available number of cores, e.g. a value of `-2` on an 8-core machine means that at most 6 cores will be used. Defaults to `-1`. There will never be used more cores than variables to analyse. The available number of cores are detected using [parallelly::availableCores()] if that package is installed, and base \R's [parallel::detectCores()] otherwise.
#' @export
as.sir.data.frame <- function(x,
@@ -1860,6 +1858,7 @@ as_sir_method <- function(method_short,
sir_interpretation_history <- function(clean = FALSE) {
meet_criteria(clean, allow_class = "logical", has_length = 1)
out <- AMR_env$sir_interpretation_history
+ out <- out[which(!is.na(out$datetime)), , drop = FALSE]
out$outcome <- as.sir(out$outcome)
out$site <- as.character(out$site)
if (isTRUE(clean)) {
@@ -1876,7 +1875,7 @@ sir_interpretation_history <- function(clean = FALSE) {
#' @noRd
print.sir_log <- function(x, ...) {
if (NROW(x) == 0) {
- message_("No results to print. Run `as.sir()` on MIC values or disk diffusion zones first to print a 'logbook' data set here.")
+ message_("No results to print. First run `as.sir()` on MIC values or disk diffusion zones (or on a `data.frame` containing any of these) to print a 'logbook' data set here.")
return(invisible(NULL))
}
class(x) <- class(x)[class(x) != "sir_log"]
diff --git a/R/sysdata.rda b/R/sysdata.rda
index bdf03b9155302d8133109217e767d679b7d86dae..693d6a241d80991faec9d1e7cc21b648f5595286 100755
GIT binary patch
delta 18467
zcmV(lK=i+?{{^sw2CyFR1kfar?Xx2Ak4k^0m>nqdXvo&*K~z>Cd{1((&n&Aju%FJ#
zBs{4a;tfhH!X8qOS*t>{=5iCjA7-Ugc+4Nb?5Y-DYJ~|L(O(<BXZZhr1??m0q6R7z
z9&;fxmpdOKr~<ZV%!HyA&59*}2G<%?W3KHH<QO_PlqwulNZwBx(X*g+p8Uy1u(f|4
zszUWV^jSWfOodfG#(lAf4-NMb*(u|9jL6;AhnrZ4KL*hEs}78NU|JdJxF)QKn`-NG
zxW|cLQ4(0nW>AiKS#kb=k8O-;bb$IsyfH9ga{)B{wgBpv+AP^^x~Q_d$^WoA1v+~0
zQ;%?uGg$GS(KpZ@EbS<=N1gPPe?xyp`vhZ@nE4NeDgss@%Hqj228nDD8;3x_C5;bO
zLwq-)zzcSn^xbA_LVgn|m)v6+6I36)Pn?vq(b<7V;icC1j+u3u@qV)NGMl)n6B6U|
zn>9(x1pPv2ALT@8aJrT{TyvcG4u-yGoL62qYgxaGq^z%SIp-(ao+pOHX)AxKFIkX}
zND_PNps&oX{pDBDRR}lGS0KGZjAW*nmXm8RrD0|Li^-rk^Iam0qkBJPXw!p7<wucj
zl#_)(mAa{{1VD!NoN}-}17|NZ(LNB@Ey3@CX0A`?L2~kUysSzw->nbx9&)=+80+Uy
zd{1MeUKWN3CT_2Xx;-3|4oH7^=C5g;mlPEjL^egYGF{C6yE8+gY_^E^P*9G1bzFDH
z)m7ss_?x)*TqTJA5$++9Y%P#C$#8NNwL@m4dc8!hkQjYnW9WvdBYTQ2RD!!h6qt{>
z!7Ubsh$m-T(Gzqwhu^$EDiCbV&`|f;FJq23d568R>K$ZqF4=f+vzvc4e(X#dgh;yi
za9kO})2il}iwTJMeqgV`i*b|I#y$}gUM83Btt~Z2bE>?d<RdYb{7LUQ&M|keriZ}k
zDpn(3fv##QP#q5DobJThtSk;-ina<_!5t(#m`c(NwgH|#G7u@GyXG=wx3eBY<p{jU
zkhQt)s1ucgD_)o4&5VDqq127EYq*JWTt+6O&8hde2}A*vh9tNzw+Cd1osYAgvNDe<
zg^$bPy4Xonx09?sA>s+)C9uW1Cc{%-iA<y?HaAjrGu+-;(Ff(q-85M>9S1=PV5$C?
zq(I^D^@pA3Q_dsXRA-x{%GNzp-yY=L9<uq&xL<6BoOi3TfiHg|NYg%S1EWMkMwm!8
zJQq)pDEn^<ap**{$oY*?#5*szLVlb&w{Vk%fPxY}%vo5{qfqybzz%_g&pUtA4Ps12
zb<e<5xO;?G)2H3x=_q}`bbFiup#DXbIy8#iyAUiTdI(s`TrJKAJCB&5{dGBxtOy|z
z^N`adYiqSbJIQ}kEPURJ8DDb2h`O&FlKI(X24-$)7-56}_gMmH!2GuN*f+#l<y_BG
zsN&oNYVC@v((`+1jg=CsL`tH_e<`e^a5ZMYE;T22DTgxDxupG*5=0OjD%kRUp|*rM
z$e!LIdj^{)sh2r-jX=6C9P{wwuq)PmfTYmM4r7)bzT<!12O0TaSEeLasS$ryIkSd&
z%Fv9UAA*DzHa;%?OH#IsS|y|vuiLKd>Y9y8aaitaRKsSwxy7Vmym;}(uVG!=<ugGO
z+W-I_fU)M6?})4V%Dc|t!#oqfN)u#O^J47_s~m4~0i}~csSJ0~k8|s?)(5Am(?Xt0
zOBDlT3X^~2|2?lZ8Wbj9*RiJFBd`#r<JIYll%<OaL8GQ7T}rNxz6zJcNIP+yX_R8S
z%Gaq(;$&Hd2wB1b?bLuPnJZJ;FdP}YS*E@so9PNg6IYR*L=jp)V2dEHQxAMpU)Md&
zI%urHe6?%zSXYpQW4SsePGwkm`_3D1iQJ8nqC9`p<P_}p5v}tp<PwtCX~vx}r-mYI
zQj50LpE6>CPk5>WE7(V@n9KsP&(jVLyG_8yQ%5zada-2t;SGyyR5eG@I-oqw&ujxq
z{!mZ*uhGabw)X-5X=tV0thh$jt-Ldsg-t|zUr;n`j(R}?s9zs)z~#l4P(GPVZJ94w
zM+Se!;wN$z1E5MBq!6ig;6>Q5phhd9ZPty?8m>?aq`&Z~OBe{l++}|eof9t6-3gEo
zlabyhlT`crHtjtuyjol+p65zdi1JxXXt(a=e~A|M>%H^nWHr~Ifks_^5wWL53$F7q
z_vrx|2jYlX#lq#ByTZxoaXMP-nv6&jk_UeY50?hJHz-lTSkr@V(5-F|Av>)!fdh=?
z1(jl;1fyP|o;-`2AGP)!LkoH+2G#&Gp6^wcU{fGpRx8)@CVhj12vb^yaRpdA{?WkT
z1e8gKZ6-&~Gg~rsnVun9%ZzbYbhEjOQ+T5YKM^;f-ZlD{`+(@3Aa3W8@)Up<fntB2
zNr0~t;}$A1^Vnk#Q_iknB8wouVCl88cVAIivt!MX{HR~&>Dk(zpB)ngLlaUWwlaZi
z6@|yCD{knGTyuO`Tc&Cvdi48Cmx$O3Je|#qRHxf*H(N@UbeBU#^qv($a{!*D$qMNn
z0FjI-Vp6s16CY_3Ob_)86XVotI`V&=1P5=Jmi+D2=u`1vaI81=r`=)Ko{mCXwW7aS
zu{qF%@tIYWX1SKT&uE5lO4uPM<(9p&Q=qJe)N~LB_S!rCdQIdDxLkt1cfmXmhimO>
zT}Qn?a80aG(cU!_qbZ4^7^%d)+CF~`1JRg%2zWE>PGor(eoFUIr$mlDfnk65_LP(B
zL3Y5WT|SliFb8%^POl+&3;qb%AOIbWp)Z9b02k+CJ$%*)$9&)6;r?(kff2b+M}bO_
zazX559TGBvy`7Q5XoYu8K#mrZ4TKf=%G?VJ(DxU*i<^u3XQ%DM&15;bQpIOi#;jBt
zTzRE}wp(OC>>-H~5B;z%^QC_ZcTe$QxcQipO$>wh(`BmP0-X>;4+{N2^SL*Qk>lcj
z?~2WVN+hD|_Xku-qBpSPc>w~1@9EDOVKw~MD*Z0Gv6I9l{BdAo1UWsGk%ie?a5<wI
zb3>=6Oj2yTi`&W~Fj912@>U2FB;C>-#hm6SNX$gx<};NL^DLL<mmGhgZ40^qQO{Ta
zfv{@QXZyjeK^DY;*I<Fmbj}KdS7iB4|H@{WOjg9_{Q9D(t7*!jX^;asVf|2|j2OuH
z>w;5>;6QR9NY`JUS|r|li7g=qKCdBYcm}+76WP*A4`Iw3i8meGuLX7bz=iou8jcVU
z{`a!-%#jiLO!0H)MV5cQ7~(a|fANCCJ=MR@vzMUU^@x|wO92-X+>M$Iw>~Hv{#IMT
zEv=goY?5A4Wk6+$dArcpASUgueW}zBA$1r2w9uzXFK-DAJ~CbY{^&C#3+T4rGLKl%
zO~qyRI7wQCQFy{t0J>d^T;5Xckf=n<1`Pa%CulQS&ghL28e4xu>XsE_SGpDTm~@c7
zP@1w*fR1&8*V2d)2OBDhINL8C`YfrpB;3?j>5F5};VUzX_EV|J+Wzyra$nY(nsgMt
zP_DtZwpgl$9#h!u2@<#uvKmA0bV{F#ZFrov4vz8?B_8{m^|Q}__(BLl&^L%OX$oi&
zF}mwCua9H(gK~dI4H}<8OK?uBnpqi%64Ps;d}I`h1{;VB<6KjrQ!xpS-kZQ>8(TV_
z2Y!)F(zYd&)m62z->NHI8AF}(__x)DUA{zaBC*z+s!h@I@Khv%J&sY?TI$nQ0L6;Q
zzT>k~E7e6xey|rOZ5w9ZA1hH!{@rQVw$JUnlPsr4a94kTkFX;B&*6~qV3fyiaVmUD
zt#%&)$HU9-Z9*#jFAjOn`lVA$6(2!D$hLNVb9Zgl{}S;cn~BNaB_{4II+S^ZU5otl
zb4BgUKXl<7ZO_Rlp54r-J3s?r&w`lQ`~vWTQf&)PC(>6Lr}#TYlE7tryN3u)n+Y$+
zX^nR+T}OXQQ!$f+g=dn(>ja7j6AUhJGV@y1psKt(VgK<~mh~K8?~T=X+%A<MeSO(}
z<Q*oB2Gv|<GHnqRJG!eezBCI)*A2mW{!SBFtOzcsIlRy@Yq~Y>JK{(E<U<e^3`Wxg
zX+cD}5fyzU2mu!F*3wk8gM$#f&-hU1yW>7rd}V(&JWa2BGX?cGnF(VJJuP*~bC(a>
zW3ZAm`?+j2X_rO)+uvX7>L05=@ICumE7^j_o1fBqJPaCUpOx88>c^lA-=VmpvjDkZ
z`P8YZ`JuC;0v9EQj&F5$%R@j&j=17-6Ds(EOPnpRcR5AfC=(Bg95RL+OCOnyY;1a;
z6Q6&SnawPgRw(V1u^}DDI(%*HoDI1c&!4PzM2g&m2~@l5XFpuM<hXyigXYGQ!GT(v
z$mMNr^J!N(q$GAG*$WX@7ysS;7Z%l`^XIwy)k&=Z$mQprXy%<T2Nut^<6;pX+umVy
zfYco~LF>e0ime~btGN~>Onc&YDgl0HwrqcCCv~=@&AJbB)<K}65)kdayz=g^Km=Y)
zYgh=`B}*}?XdA{pOB7_3fm#&!cPT(o{d!@x&;VmbHAcrFM;u<*jl`JBPr@*-X^iHc
zQy`=oM(KUz4;~ENC1;l2LWfFoVDC&zV<N@>uq3Mm{y(zZp-%}CHhFgYLpnH?w_JaJ
zuBEE(7qEttiPC`N&D7&BUVxXY=J$3xUIC&!P2CnSscr?IBB#c{O#Y>Yw6w-LtR#+!
zCwXxkNZ_p`riID-BLY7FsK0IDpJvn8{ULkK_py-N({}XTxG>N$^?LBGSdOuTRz5@o
z_zhLk0v{>VEiNkv+(NY!qU!-IA%uU*>hc=<)tBL3@19I<%a_&YnNZp0iMruhJ0Fi|
zV*wy=b1^3?bJbD@_4V#7C*Y9!WT8<vagdVl;7uRpvl3(`m7`^t2`0yJSOD>)su_xL
z8lm%ZDY#n_oQd6}xHKki(J;-ELL;*qzRZ74rnzDyS1Pr8&dzo=XD@>q#WjCl(C*}q
zM5!OI#25+Iz9=g-88H5}0FXvPK6j*`f)fhV;#4)$gY<C*<-+H^CjxWZ9LvPQu12<0
zo3fzWwDf31R@0lnq88vKNCC^WG7=p+t=x@UVgc!ZlSkq!+zY=_kT;L!Nc8^VaAw6}
zfPg1zZ)0PyO-FLPa`pfkx;TGlGWeR@k&IYXn|C~Za+V`OZM2o8RbQlvwbtUplzZA4
zu}q=DiQ!YGd7}2xV%4jFHI%utDBMY9=l8pyPhi;o4tCs?9Fj+|CmVE8)P?Fa^B#)q
zKpCxJbrVFvs}Fj_O@sp>dEujmo8kC-a>l13E&Nprk*Fa-o9KB%`PhGcay%KB;wnY6
zo`7O96VYf6*kXZwqqi7#8<v^M7KV<<N%Euo3OMFdKjH*Xr?KXR4Ch^){U&=pEU`kB
z$8)2BwEv)HMWo+KdGGdoTHr5tsMVyW9xH66+S12b4roqkL!50>L0Q72lDysTNp{PT
z7`%+<!+lq6q_%zfYFvNje!NktU*K*#e4K_E+J(7rfze7x<M&Bpg`{&G`>H*uP`yv8
z4!4fL__`^kls>uePaMO~0%xn$(;J>Da&?SB`Ma6ghQmH4smtKJ^i?kZ>YzMDMQKRL
z_)s>)IT7g+(WMA1=d^<OoTpIA%=zzL8W$R?Br=Q=E@Q{?Ta<s5!V9<7ZBrr3O^W~I
zdW6#~et9ks1Oxv;vm$fV^u{rp-=Hs_sVuqqfeD>#6>9>W`^3()Up*SyQKcJO<QG)Q
z9A`k0rgHksotzK=$wus?pMz1c1x1%hifU8az2oqqzc`V)KvcO6ie-J|+F0O7k0@6x
zEE*M!-zPxlmN<U^lhy$1%F<Mi7=9aWd|L*;kqk5osZ?a-+@Lg0j$b2FP4@;+$ssSI
zxg24s`}>a&E>0LJZf}0he-}uE-yrL@hgS=i{su&8oWuahGdZ&jn{^k76A7IZC-4H8
z^gf~eWsi}b#R1c6!q>8%T8)U2P@;l3ymt)@EY~ePreA+p^BfV;P1y%)226k@Rp?mR
zJh`1{`skXKi=<qXG7Xs&%oYMNi-Q66fRg*xeMnZS4c$`N7b;PUlMkCb%83LkDTnj2
zVMoIjJeqGJEkT%-I<jXD$u^_N`xVAcGJ$$AW2{zWuWt}N*t5uY(tI1uzn-GTx`wcH
zUIk4y-jILccg=whd|k3SS%}rgVV)Z}Yw(wy^wwlPC9C*-boYw-tV_aF0+YoID{&nf
zDcE1j)cuNoYqcJr`67?GvmsRaNmRKO#R&8W<%SZw#$Ou<rgAj-NgK|V2>rmf@PgTJ
z562Cv6Jy$5ius#2%CqpHY5=OwO{s$#g0Fxp=rw<WJ?E-LNWWl4*pMN~=TyKCU<^rs
ze%xH6AMeesJcb|h&`J=IPwb5_=G$Br*K0&(P3I!@&!2*rc=@>03|G-E-1w}2LbY?S
z&EjOh)oOrx@}y3d1oRI>D?W@!h70N^$_$!vu#(c@fo&+#YYps_3Ajyc54hf;59685
z-8p|;Y~H@fu>skIGEUtbk!OSjP2E4@KcL4LTzV`yd|h+Fiu=)(1h343!24pff*L)7
z@}7?}64Mh$%2tx`EUg;9;_>8IlGj-XD+=JenaS%$U2rZ14I5K2bC<lRW_0vur(reA
za#)ZxE-f>~Gm;q&@b%z?HXyD-Cb=T$hCP3Q*05yL{-Y<U{j*{E)<f_&D2)(sQDW8k
zh*V-W<yCf0<0@O__;CvFmLnMX0cNMdE;K*aL>&1t3Qf)wSXXh>=Ay+6Csgeje%oPp
zV8yTxFkqk&RQ&9J=y<DB7;8Tr8h@3L15Y1b(%ofrtc{rm+*6Z<VP^~vC9hpo*lK??
z3cImf`H+i;yfe=L4{vgcbR<44BxwBfo`1Ln3<**(BQ-q0K~&|^uxURKW3sf`<b`Pb
z7nGeSE&;%~G*t}y^ZSsP?RE8k|E4!N`rN^TRSt<O#;N0f|CuY;FJhv^@dB5>m&<|#
z%I6l$i31I0`Aw?gn3_zdGn(Ni>*#;nA1=T9=2?7~PKC2@1ZR_ajahr$^;L?$7LyhY
zhqM{=Zh|V@fDoj`e+y!!YuJ>2u$XvfgOKYLWQMY=od#*CErjZTtXZoqW$qY@Zz)0w
ztvv(OfJK5q@_<}c(1I&J<&~2UycBQTLXeYY&$DVmckoVFu^F^y0^Z}vypw++urU`)
z#&4sTLs7ss01lg~tKrFNlNs?!3B>k!!N@u)JDtP#KOz)}SGFdG`t(_&$k@wRdeKB8
z+OJ?;#2q}i8$KIRNjl%_-iHpVjDeeP;ov)CphpL-1G)q+x7N9)*a(fq?v#YG=jmIn
zn&8KC)`WPI(pBSb3(MZ(cWHl;CST!c;7*OzQZnIs)7F{%(P-35+#V#|Bg%eN6;efB
zV!J&n?@NdCK3~$oUC;Z)e(|#o5buW_{!JP2?t8T5v8L&;GzJ)WpgCna#EP#+^z`Y0
z&qOb@9Fy+#Kz}#rYy(}R#iv)!t1Q7UJ(EJ7^%nA3ltM-am9_M5VAFr^%tkWDMFE*j
z4McXjb^QENv=D`9u@E1zP14i>(s>02*}Hi+I<erUrPifTI5+OrA(6qYH*awqGc^$9
zPp@+h5lRG9^F}h(w|Xe8m^3&dIl02t7as$TE*x`il5Eeg&4zm>iP_N*tej<S3(@6v
zgdIwX?=<V=&JYn)ycmCZN1LXZ{Y%ULecvtXBGI=`=rPs&*kR~2tCT>uW^QHlWm@Te
z1bT>c-bou$RU(>%HT}r2uvYUpJJSo*MI(uL{BY3rwF4t#kC1*@e!k3xDx8-IuoQC`
z_n)v=T)<H3kCdI>F^P-*U_JE}mprJ&Di%|KjukO;ks-Mgf*XI@w96e9VnetQ0kLwF
z_AN-F7_H-Vo`yv1)hGE2k)Qv(wVK0TI6OC9B{`gTW%ZDKM#&fmpgri?IcN}oHED?J
zw-S#iNdUZVtmjG>jb9X9ti#D)`8ysly+DvbWC!nq>h1s;uD;Fp^GOMW(wA?{*lxF>
zuixOa!R(EXI(>h48x9S_O5M+O=196D@6jY?SaP9ht}t{FSc32ENbKczvF@1;kFjRU
zDn&yXEKtmSD(_YMexTHQqZR>g=bIYU`~m9JRrkAYV{|SCFZ9t$HG;B(i}u_{?|ij%
zeci{&go&6Ld~xAX+o%#NG*7F(YmFjFP|huXi*htq1!;efRxM8DXwy6`HNQNrsa+Yw
zjvzJ;jSw!fyonYhRN4`EuCA><UEplWOV+G!S&~r*6AuoMm;g-Q;y6enQM|kDkYvRF
zuJBEf{%@p_C)G2jBNY5|*dBTahMwexN4?SwPq=jJ>tzHIo!oezmf5%_{LG=7%mpw4
z!b}|5CDecTHu6YRX>^=!>*^@If@1WG%fd&rbSWmA%?<OSuGHym4}ueB3LTu=F$C@M
zbF{&RzFYD>9i>^H<?^A9qzU!TgkGAvZ|1yT!~)i|m6?#=0)X5c$(}WU5=t<*n6t5a
znmfug_i7BQdl^ojmFd~HvTh}Qxz|;Pb&cZ#w&{P9R9zm>jb)EocrB3nt#-13ppEzs
zODm&EPAF4pT9!>6HS0cEa+}GYMpi2rtC|I$WvZ=NsZezYoW@aALG50)A%+DX;b7Mb
zJBQ4M+Q9h&#U7#4_QD)unI=BxTqLterx|Di?zGMWfLZ_X1tAjjPo$nUVhJN1w4519
zqlbUD*pAzZ{ldf<{e`e1O~>$uyOh;TA=v9r9JecR(vI4_3ATdJcYWgP)P~H-O;=Ez
zeRYof&a<2G_<TO!%;?bcANF5)&IvUr6yvYzOg42Yc}9m{5mOX>fOrB703}-3+V)_h
zdEj>{@TJ(;EplV$IS?FoquL6h6o~bZC$)dS&yqMpR%psjA%{vy5+6uB=<+Zt8&h-p
zPsc;;S4mp95t7mJ?kV9)xL7n9{xO+QyiWz;rP6P13y@Ag194$Y*aPV+_=tG0+Bq)$
zISb>iWWY(9Eo(e`9MoHLEQba5B-lYL4gNM|yQ);NymxpU!@EcwOs?Yu8eh__A&7tA
zI>S?UF}`V_>d{dby_v;Qz$Qm)Dl4?9NjK{g6p=Qy#|ZGL1aRPX5*w71MBG=#Zt{09
zm{jrWm1wzm4!PyiXos?Yy0gVjD0j(oyr<j(nRt3<@x<;c&?)M}S;pTmCL#H`8njRl
zK#aJ92I0~<_v%)Tna*ftv~n@Ma<YFBzvsz-(jeK94xLQwuU9$CErPQ3sJ)pt%O6Jf
z!(!1Irw}5XOO9Jo6}rpFiFdIfqYPsb@2VVKjYx6`S|N+U1a3{3#>~fodj_CEdyZPp
z5Ph%bYK@yFI*jXubtH6V$Ay0pHNN=naFU7U6@XIynO`ruYY<Sm*PeORErWk<jkpnA
zrO@IW5q_T?=36$~!qjCkp(^u1?uwBgjM$nNv^y)FO7uI`lZ}Y&3y@Rk_dSV66d%o>
zD-v;MzM`HU^%j<QM9zObhsLiRl*-7k+ntb8DK8EvZL5vdxUy)!>fot#Q&R>jezMzZ
zEeyqeGO`2x!|3QJkXRJ09r}Oz*iGG>Gz!Kdn*X-i=VtreMjAW0A=S2D<y^U?$CJ8r
z<L8lWub>oQEpHHOX5C@zUAW3>q(C(MM$A(a7w(gPFyx;sT=+=51k8VoUS4+utS)%F
zy9^|J?60@aP(b<!uCOV-LQECU;*s}hTCzL|tRE0W5|y*e<;@y8ZH9lT&ofq6SF`XY
z{UC5th)tL{mEYauKxEG?>URdW*AnofVTD)tPUCZyf?@40TA@2H+zpi>oWR-Z{|^vd
z#JD~|(`oMd%D=}#RNfBw>fao|iAu8)mYd9{a}Y<HUttmH=W?BB$K-=GzeeW_q3P2e
zJ;@YBOomU_`?sGn`r&{5Un_RL%YpJ`*p9ok>;d>v_)cTWl}8(Q<pE%e!A(%QyrT2k
zK%x0;E;(L%Vw`{$cS*`=<>O;97D&g>B-{ANt6}(FaxijNWtRavEP2Rn6xhax-H&J^
zP4QbJ2shbrabWLGCM4)xrzjO^nZyEpo);1@N@K)Ck9a3l0lt6cz48?&HG8}PPJnYA
zAd3p7*+zEhrxX|u5p*T-m5w7`f-rPgk0fJ9y<zTJ><Bvh+rH||^kG#9_x<{%?x5%u
zMc09CMJ1+&(*Ts-CGD#g%lv*Ia=O?-mVNR0cVOk*3hm>M!PM3Rc6_5w<#U!;^g5VS
zF;z-Twl3L`u0DSS^Q!4ml(uW3ytq7Sj=#LgQmIs7>eD?Ap@N$qA@S#~)kykELxksW
z21MBqAn;sfYFCOzIJHVhT*A(>X`XX!q&JG%)zEoQ<&4uV5C{~Pd}#7x@U3KM6pc9m
zR*xCP8W-!DK6s`}x~VbR<|R%Ubk$IGu@^j_?IiZ_Miqa4yX#t{uG<wluG;-nWLt||
zR8lCM1k#t_(X2jTlu3;AHj6UXqn6=qB3P6>4l3P+hYNcGd>@~G)pQAP_nFL`Nx@ob
zH=CVUS>AZ%_sfYGQ1xc?fe<YJ22c8Koq7TqBZiLS?YIf#MoJ3AqH8%~?0Y4J@>%dz
zd%&D;5juaro?Ad{Cb^`L)N<Hwt(`p>+oK18BK<ZS!q#`9Mq{1rmT?|5TaM0{C+Po;
z=Z(Bcrj;F19sZ{R9?=2mIBPxAdRpcmNeNQSy&g-^!1^5<a^-?ZBj_&>-TUUV2U+<E
zc{HKJa+)|61X^lo3MvjeRTbwWxK{Z6N-2$03<rO@1b2+#IxeRenf^3`s)$wR#ciTu
zl>z9WdJd(h6Okh^44A&z05jCde9UQMba_Tpd_ufa*RkbtoJGcX{g;f5+XF@r$hn&J
zLe*qZE>Ja$PXJQHdVQrzZ*`Y2fAT=|EDKVF^C5)QPJ{bW+T@^gKg554KTrN~)W~u&
zwuyh&z;*saT=^di(uoz@^XfdrJ6zZ`9fNXG5#JPYN<T%btY9DN9}pn*PF`xmX-i49
zeFx#dtgVMn_*4!-D2QuAhdSTuOk+~WAdN%SI`j}~2n5w#87%t4c{cIqIxo1$wIWib
z=PBkEtE1mP4ND!_Lx~lCaYEyy;zf~QPHlg7s*)u75M>BYtz=^2XybJsSNp{uwTT=;
ze;LE}_kVG6)TL8tJ6wzRoVgA<xLPJ@D0IH^Lg5u$gr=+LVJ-VK3lDc@`HOaPpHCo=
z8S%X{LHt#FDfg-u#**h5Gi-(1U<!!?bGFV;r=D+AV5X_7c+k<Rs)qnU+2NESt6YB~
zIu8_*MTo78D{Khyr+;n}_tC2Wvw|)>ON}ppJOwEOtqKe%wx1CrEIJV%lIdn6W-(s-
z9&Kq(A>SUEuMb>@4W!b5N%sHv!#}ofZ&vzOSq-1}Hb86pA6zF@-%!;?gGCo@6~W@=
zJ8m`@m2<=#<<|F2k*p)UbZU?+{Pcg7rs+sCnc_@_IC@`G8T%j{!JZl%Nh=E-I7JUd
z=DNu^gSqZriK(b@rv(CQdDu*6I!=Rc6hJr5=(v|QlDAcWaGo0E+uqrw;>wqE7mw^M
z(C5eUj)m@1(Y|!6f$Ha3kkBCl)W9j$+9i(6PuiWvVVa(P_=Tiw3YzUn_-21(ku|>v
z4^$bPd-j<_j?v*fbl|U2I{Y#hdfW4c!q8J|B<?v<o0+`C#Su7Wt?a%)DhfK2zLumR
zyYCZ`L&)EMXCc$x=+vqB>fU1mm)P}YDWjYr$^*AD-1SJl+zu6k-DYqj{E}tSiGg2r
z3@mWzP`g4`_3`_6|F5hc7HWSLov{D9<gFkd2oNnx+%8YBxu^eZXj_0b_8H@^Wb&eW
z<T4rcMZYBhnN2qcw?76k<1`|xT~BtGHtch;^q0ISM#>|lE9-wJPN~Hoti(V>3Dr)0
z!Mcstf+Zo2%3{+)&zZ*rzDN#koG_-8s?<8A9q#<dN}#!oSuIRf00VyjnVJ%WQN+%C
z!Ki4#IT}q#VMcXc98*i7mn*pV@sza)f}O-?>&hGS;$P)rHJ;$f*Vamf+2T~Vb}<H&
zX7|0yf4>1NC`Ovci0%&?A&F;GmAKpT3E>M*FZ$)RRd6o#C^JtLij@>-ej7-aL6kU|
zg;{S=Mc5UyE(FfR$9jKT9P)2gM+WsNP_Z#CKr|bPN;cw5U<#_<wqiVRw-=EMCByOp
zNtJP+(8HG)v@I&5lyQH30pDN{l;GDsdAcB1Uwngb^qj%r7KzZg=Yg<#eT_{HG3KfP
zVji_QZAGVp<s*0M-K2swxLt>2lij^*n5omJWlwf9jC#PV?BIXi^tI-l=6xb#juOxA
zJFjXNKy%NiOU~Y61(vKwD;bwvX9<d$i@`^6ZrJF<f^n(aAecCr`AGt^!UpERm#L#k
zq*9}3%KsZ8vpZTCQG=!gtA>6XMbh?_7#Lsz@zeBm;~b{fMAv~bMFBNqp8e%J)Yb+9
z67szPmKZCPaq)k<lKkOKFaRqrLt&Ez8_uYko;D!65pDbPa#;o9MpnYFmnQq1WIW6x
z;zPhO5NrH+4J64(2Foau>iAw9MdK{G^8Db#rXQ(X)&i9(#{;VYKWa|w6AZF8b(I{;
z3vs%btfvnQ&;*n5QNtpYYrL4$w1C6FyZuu|pMKf1Yo32qu`9$cZ-b!WOTL(qRrh4n
zJ+!MI1bn6jS!{pozvT<FMB=Vj$VI5N>pyG0xwhvP?%|+9>Ux}jayb3kCuoZ<WJ9H?
z9?c$#NR<}qr&Lbz6f<ykz)uwJyp~M`pm)WME}%URxJpf8nrAy`9IbRd+bBk0?^db~
za{m^+i(P-y6Akuv_wG_&EB88RzAL&-b1#OtC_eNAAMvwPUZ<;|Wi#bQOMHxPYKJz1
zvf~|Vd`S|7`kO+YN(`2p*<VTZ1N41E%yWh!qb6>Z@f-{=(2U&o#3f-Nuj?b`PaNB`
zg6nxWj8bie3oHkQLg7C}>+z(Kk_?q)OGyQ8j8uO-RmNt%@zsBJcdq^Bi%SLVGwnIV
zJf@XbX5C@^i;qw@0-%=}u}|8SV}%Ii0!P#p_8Kv&qAMVofUX!zG}QuH8s)b<1}YJS
zTK>xx$en(GY@%oAU^3{a^&gN8zt3|p{E;axVaT&m`&`yb?-c^?%o$tA@rGg4_p&p~
zlRkfM0V2XxSFxgOxyas#b2;Ye`F|XRjMlIh8b`m5o;3!{J=P!GS}O$t_uUg>uwa9r
zASqZm8>B1%H77X7qMDm223tGWokr98Y&mjND&0Y6i|CM5PUPL~cv+lY@N~FMqQ*^q
z0C8SamQ_|fMG9+e=*8cpPdE{<jwi0(FMEH|5W#cR1%^16jD44{NDZm{VVaJP@r_u*
zaOm99fRE!m*)W<tP5U0dRlO97JQm=G7YkPexFOswbrAHnO(u^<loG0+CBk#hK&dUc
z@}_dwvYihL9Y+7G%Kun}!~`XF1t4zq^)XraG0E~@#<vTg{FVwH8sd(gR!_oHjbwkW
z#!UECNCyVq+xJt`sx~C^m<`2|dw-28o0Full5`Ss{Ys(5&U=Z$ZK<yL(eDJrQ0%Y7
zUs{}rhIVaXyEfA+Yq44F`Z*z}LRNV?2j79<O(xhW!6rui<Cf#uLS#ASH=yuKMiD5f
zdTj10tn4ZkSK`{G)X34sq|aU=&I*5{|C~;VDzkv+^7V7jGQVXj+3i8h`gcL#=}9iO
z(aDu~CJ9yotnCapiv{^Gzc%|UQEW3cynMq}`jzINx;N#Zi&doCRP1tt4lG<q-3R8(
z-ru}Yk#hbg!T_*6f|=JIVFWaGCCgTl(F6*xk6XlH>;)yZGQ+>Z^%YNzo%DZhjI+d$
zhJWJIMMfyEET0Am%sFs04CIx|9hs6+{Z}{{Abz*=b<&zKx!pgn$&8|7u2BJQ1$#(J
z50~LXrt+eB^v9?&FzIS<<Uum#kV(2it}Bk@1labe<7dVPG)8N}*s@m-M?|_#rGnmq
z06z(AkI+FR%8W%3tR@Vf>luH62|-`IT)MzeU=}kIUQZfp@TV)JB_mG3(3K)}5-Gvj
zw*5b08#pMH3e&@R0wlqyZYJOClA#@2^LhgmBKr5FGs`9`oeTEDS8yd0be2%>lNyY3
z1wR*H>;D=yi^3F4FG7%K(y%%V{G~pFE#%a}|D~hgXo0F=Z)|b#YgvE7E}hT@_?o9T
z#xLiw18*$BvuaY$Jm0ZCM%>unS>sO!P@1k^fpBc*@mrEV_Ru*qi>Le!!Y#5(@p^5}
zGf%IQZ?ojsckFrwd2-g+OOJ;TvfZM*j@R_ndyOhs<@7skcgbO&tP356j+i{e&8;e4
zv4>iKC<m1byepgz`0Iab9C-j3%}lq|Z0j)rh>FK$!}<s5J0$F-b7~|?WAfQjg?32-
z`X2q}Ufnd=UZ=x@A32ud$xxu}Nw|8f<mVg`kN7-$kZ*~eW=sB?_UU<u85Mq^Ggg!z
zxn^fb{s|*-4s`9{mg>k6-K)^o%V7f}^_yJ~>eL|D4y{`K(L#S(tqdn{X|wXcu6Z~W
zjyxT_o|_!=A9JbYwqbbnYZ3v}ZWM~nHE^{_Y0M9k9D@b4%uPzZnXpuSn@}Fk)^FsI
z@fZ=1hDo~C!(jUE8W=X070gAoPp*d1Yi^KEWE*B_j7OwJ>6q@Ote_#JA`*Y%u0gXv
zud#Aq>%tRUm9Kx|Rw2C6SL`>k68m%b$?t{;I|yg=UnQTW#wy7Ju$ZB@p3!paVAENE
z?=^ZVJBsO^8xf_cprl*FMKlk_##4k|qp_xE>D;=}wb2LQD=g1b-jWLg<A5=--yQpx
zFMQT42`(BTnV`OUCfiOH4-bvLBBJ2&g4#peCkYEEU@w1%%?$9qa^|woPxzZ4_sgXO
zhWsYHw(AM`%(sS-qo?g!z~Lh!lkMd(^f#c~6Q};&BvRT5`AJz>N0N56=)t&V9N|s|
zY}g8d2f-PMI!k`{n*TiD9Hcn!5hz?i5!Dh{bHwDBq+UeFi?`EISlJK5q`F7$?R7S%
zF51$Q1_pmmr*Lv@w0L@FxE^>hp%A%C8FSRm16#>NE|D6q=CTiUZ!pXC+X?(!BAmv~
z2z0OiKgOhj`G#*i^Q(nbt*AjS^^(Q$H{AElqcGEkIOd$1f$6RHdRE%*&@g5m`q|_^
zklB0=fE$yJX;GTt-6>w#SMax6-p#1mB#SC#sc?UYW^_=WhzQ3Dw6Z*>q`)E@>GLC~
z3wPfH2<pU~r*PQx;GyDBph_^{MX-mD-Ps{&9X=WL!|dfnhqq-7Tnr6*RHOaarelyu
z($p@+V#}8Cv!`kyqQ2viC;P&hVm{tk-OxQHUwmqYKV}U!Kn9L7=f0)+Uw=>~NsBNl
zN3wr95QD7zDGa}iks3OuwSBoRA=apY6k*II9o8+7A$t))ahy`lfXqnzBlq2$2^J-I
zRktYWg3xN5omg6gl5bN-y~l~GkbMoaTgwQo5%gkI21p`Q)`pGP6c0L?cmNzm@Yvi7
zFP@=cIuHkyM<9YdQFzcJHD{i^!=S<}sxE&`D(J+pPU;3MZ%fW%cv#D9cS|KndpIoE
z0Nx+qfP5V{%7v1AW`O|&Le@d}F&pC5FMWyk&K006heb=Pk~pM*j{|<IsF?RY<!#^!
zI*n!s+Ps)yW;<?Y+)KOaQLw``5lK!0`3-+SuUjePX8l=^%3dtZq{IF-ha*yWI--9T
zChgx++KqQ>Ra)|@o=|FYoAmkL=C|Q7AA89u@H3XcU>Os!3DBRQq@rYPqrZoKM5qqT
z&#=DXuJJ{Q|H}$-SnE`h*gf0+hV3#^I_cM*6lTwTk1Ha{9MVU#3o+*X=6}^zvd>n7
z<(35i0e&SzR33GO7?q~3dXC#`4Y7Yd$O#T(QQhrSshStp8PFx1p=5ieFvv3H(<yNc
zU{-D~)TS6ECtc{`8ba>_TZ1GZt2to*Axh>Bish?B#qKW%!2)`b&aV1WM=g0Zmmba?
zF6She4a*<e<R6LzkkO0t_A0i8zdgp5EOhc1-zn$^4&9#!L&?4@6n4UIT_u0r*oKtp
zOD)PTPe}W|85MHjb#4h8s_4kg52w(8gD~PXhX;mb^y<s1;K9CBKUD}47b0@5UrIvJ
z*J=}3<PAx^S5sf#me$+`%|6bGV}Nke<=ag|&EC%_h)*GlXa&Db?w^0MCTwS<WxhIZ
zwQK$Bi#!X=kLFeEceV^pb(nvkN->;ZQjj%V0dX^S7lmp_S8fw0D{sZ~RN4X7gG+$(
zDaid&-J?@pZH7u@p%xkN_^DgHry|#MThFWjCWH7N*UaSNc`gOm>_SA7dMn-;fRkFd
z<i266m{XTZ6WRO8PP84=4aTu(`TtpF{rM)A#31V`9GRdb+aPoMauk1|eFX$vXmbOj
z{+|qjvkAq)vbuz_194?tTM{|l#8#1r?9sLs(j@6eI@S0~ejCpasH-YkbcLscL|CXc
z#(N3p5ELd0%&*I%2-K7#CJ#-mK(VwMqq%ecS+1R4aX>Q?R1~^7$VGvCJ3F5vi}c|`
zJ_lZQ)X9D#aZ5QJiZp*f-LR1Hj?g+oR`pUlo&!TOA{nSccqOBmN0Klsc{Xz{y(uab
zaS#R>AJVjvt%OlRdu&e(dusygK+gA&*9%#x6@aFkE6$Vh!S5w46NPi)uD+m*YY@eg
zXwSEQtML1fC!;g+kTAl-l98FiMJg+<QaTs4g&X!=T5%p<m^6QwLJ}0wjx)0Ebn0e~
ze#72V^<IY2bg4<`QoVoz35wMri7=MKBt!weU_zmf<WEQltOIM%mQq5Z6xI>e^I6F?
zkI)DWo6@t1)NTvj5Emn}^}_UjKCah^&etxuj}Ph5SYcKo{XP_jL)RVIa)vSF8S~}$
zZ}z9-qGB?laPWW1h1JP9DS-9^TK=OXv0yQEh?rFlN}oeYq6nE?>C7Y<B@<c~r94@^
zUk^gFHumFiG9DTM%7Th`_yQ9W$noS;@RMh_(qjdpftkTOx7T++Un%|Qc&nZta##CO
z2`f{<tM<+-jDS3ZFf82FDBGTHUK_@?;7~6E5eN~A!LNVSADA>*Y*Gs|fJ2J!?!$Nx
zO{>TM>%}%<yui>wM+GHp%r>FeLs2_a(kqa%Z<sW29r!Pm>AEGo%mo|!uzWN8-BKo{
ztJxo(DJ!zesM~!MA?}LJU)`D*Bp-Bij4|yzR5e$&j$5T@!zA=bMcwvmx7K%8t;p^o
zn~!2;X9s@=<*L^|>)u^^m)Dq)^vAN-U6nY2-$>3=yDcG}UxS^bttM9?NTz67ct}EB
zu4JlJ-ei->mH$W)1--^ZtsFY^4g1sMEiJ=5@@xva=FDhQj%!%jkJ<}bHf}qC=N%Zw
zk^8DfV9oWS1^slrczg6)J8Ejtq)C0iG`;4fctw9n*u9x`e!)BmS8#9~FcTq)-MYHt
zbdmGnr|lZu7-xROI_@+rHL~X}wSR=8M*scX=M2W@0$?|jU%?5elsgUd^c{8cSob98
z8OQ9{CK1_OTjm@C*8ZEqMtTtWSSj^5B3@Mh_&~8@{l3(&iUfz}yM>5mQ@($~P1!17
z9-n{G%V~5Ur-f8)>~%0B6oUAt`YN$t<P6mKTrn<eLjjWd+&GO>qgbHxMd!B-{-kir
zU=!hB^SwZzsKEuY3>98k+os;>5kN)Xq2x}CBLLA+R2di18s#xCM&(*CQ4NI1_1%oB
z`;kVP&Ui_IR~CjFGm82;_;y04qwX)+@K}Fp;Cu5L5%o!#N)?6ejR-{JeH!urRQ3Ed
zCAjIHp+r-m<1%>CfcvtR3&ziio58go=PLzsY{Rsy?p9~HoG)L?n%J<i{&t)qZk6Sx
z&?^u_Kmy&d>*!5Q3TNf_;5wfeT)+V;Zj0C6K0i~yV(Da%M^7~@b+_qbhKhP-|D}JI
zKeY1)lx0CF*X(e6tdp!n(){eY3W}}VvhKOH;Wxl~4(EZ}IHVV6*?&Ia5=oW<wrM=?
zXd6w_?Ip?OiRdkDwcHPa^P>VvE_p$mVcZ8&<Xua1Y%DEHL6QO(W2D=9o*gURj|!SU
zMC4}@MTqcr`uczh!tbtMj|%tF&7^;;Mjya%Sa*lcN#msog@U=Y62){Q@M$2XkjEYB
z!N0my*AS~JWj<4x+s0x;nDse%2m-(2DkvA?U;Ey54*UT-OddW^sT3{_r7npO9fTHI
zBbvRTu=PM)bD<2Fa&l+@SigHwPj1d+Fwj`i9??RSq6IPO9qtO5dV#$#(Xf9dkGCOV
zW;acL4^VWI@=_466Ti75CpB<=gViT_jvpDBSh=;Gpf`t~f5RKIV=5i^2P&YmkAEj}
zWkX>cu-+Y`gKcY|A<<5lY7x3xSGXwKpx9y+`6&;Czz+kF#^8LNK-w1wr71b%*U2}U
zm{aBjlGzcK-={kOZjItFrj>sq%+iF4Rz$|-ODu#*@m!4*r`)3_5sF8uZ?HX@Qw3Y2
zVy-<3cKedu3~$Z{cER~Z_0*y=00(SqIU-UgXOwiOkZ^bfn^CMLUjh68oVUdS)_4*Z
zhLXRv=*0%rWr;K;jgWO!bR#A_2A$nCG!ru|*lpfa`b%qJm3MN|6!3p&UKh#H=9CoJ
zT^wLB8g|aChHkg9H}e@I!$e>$X|B|+mho&42Pn{#-iA{xfSAC2l%0X7^f*~~14zay
zt9MW|5)7;#m=S+s<IN0pbIw7L<bf0&P6ZDp8uuB?-90gf;Dtww^K#vwX=g|eUqVYs
z4jMt@NGV1x6xm~N|HXd~+Mug{|GU^EvfAN&_i9f3JnXzF%raAc4#pWSfmi-ut0p7`
zr}N}wNI^&D$TEyi!;m_&F>xp|iKtBZc!6f(s0sBXATmRmggE5i1_$?BR%;rwD?&~o
zMqFPrWq%penMyYt!E3L<BR}mNll)Vhb}*yI>ZuXp_`cQ!@MVAAD5ni3ri0xE;)nNF
zN&$t(0VK>e9;TsfFz-UIW{xW7=vA?TV@E4=vqGQ@)c5yM>`OH3WzrX1pAaJYLwgft
zl%K(Gh&cuiw1hiGqys5N>vw50XqE$gFBeX1>;EdPB!-TNal3}ZhS1C|W1hiS9E74X
zdm@|zp<Fd9Y1V(R0LxDj@pk69?vzJh#!6R-r-75GNpV(gLb3W68RvB$2mizUmqYqh
z+Gj}mXQN{E{mW@J1j|K=zgu|FBWZGmL|*h|vkB5CWJgmc+4(KJQGySvqROQjwoC!C
z8U)tJKs6djU`Aj67MrhkgU8EAJHQiCL34{k{n<xTE{}h_Dxe#JgXLdxIAX<oB}JFa
zSz!L#ORIfye%5AhRbTu5yUJD9DZx(Xk$qlvuk?CIUOU0)j!=%UI<%=JBt_lh;jjtl
zzzz%xLyHpLg2(;Jyz`NHy|SOn1mefa)MCVM9b(Cu1Ci%(q1`4Iw?qv|S9J+fy7U}7
zctG1({6~LrPT1Ps0=-CBis<D*W-t5?Ukwo%$Szc~z~$5K!AmM>lxP2sJ34d}F_akL
zX34gshTmt*UNfmcOxk~&Dmq(AGZK8aOL{D{wiJA6RN$cGhZ@<m%o_toqauAnm&5e<
zhkpvuNWmf19JeETGB%|A%51fbj)AtMaL#2uCe(jDsS3_Gx=VgqT28j~5I6&1J*82~
zd>A`Xiuh{Syt3A@b!fpflTJpa!_~w5vh24n|7`}k&#ZEImiRM5S`%z*-#TZsyqI&I
zxl0pk!d}kEEMgY%Kg!Ef3qR%VXb0dEE8j4&3%G{*7W8Tug|0h-rC|)h+_Ivc{Ct3L
z1HOOjT-UJ)9SI2~a|DC&bO7~}eAonu?)}T@Uh|+hIJI;Xq~Q`orqb^_oDcjW8cdsA
zif%;r#8n~p@m7N-=}k_5*~C0}X*hQvm7yY@ZJ#wX1y_~OTlmJH{r_vPc|q())aV+O
zH;y@f-FG4#LZ7<0Rd(+_(WJ?)baAk&Bb0xo=S|Y1k*Q61x6{2&Kln#IvZ&If|IPcU
z9zNfkVI;WGe5niaCF1_y!uVhBh4_*1N!^<FU5=_QcY^ldf_pxih!@_qRo*0iJpp@{
z&ZDs~s%2F3T<&-v#dL6mPur;tLIq?<u|}mc*dBjf*nt~HDic?7V9L4><qG$e>)3y}
zD=#PYXFeG}ZXA)G>bC`+duzcg0($vpPNihqil4VlAIaq*Q}TPxzPfE1dnwBkjQDtX
zPM1S)+{Z!-neNZuT=RRiv)8qLc@<Lbk5tv4v_m0EZyS=5Ocew>_I!IK8EN=-e{-c_
zo0BB8WZD?w&~bW+g{r3xx3y4O1-*Zmbb!x@!r+;UL7~XEk8p^MTAF$!c@Ul*fnSdl
z@a`;0@o|a@>Z#36Me*>Qwff-7z4z-|-21xqTP$(r;zX+^TEIUX`cUv$#2R|Dh7MiP
zM<MO(+%pPue1Z-UcZ<P=Zw(=p1x>E><p0DVx?w-@^weN5g<L3bq7!MGuOojG7iFtD
z{GI`g9Fov=0tarp2cn0AW_c)rD+sB44ZG7=p01_7*`5%lv*J#HxB?dPpu+kw{Li|{
zX$YPuH^@R3_k!e``QMS{)Mal9zObmA5O&!?aA-N0IkiyM_+##NLYDcc-@Ct>BI9Vp
z_%4(zp<iHy2?;KE1Yn<c<k5c;Ft`fiYOl2LtY46n4BZe3WrP2jl(-z1S5Ny-L3bE2
zA=ZJ((5aTL9t4dnSv<RFQ-+Agu#60SPS#zY6eNwLKtIh)_48&WGMs8B3M~D<qm%c>
zip;v;7=diu6xY4O#Zgck0PSVVUNc`lrnpJ>ImK!12rzR>viOB+DOP_@1>8nmiC0}6
zrxhYyiZ&LH$I72J2%4`Bz7TwIPfAw^&}GdznPU=B!Kc@p{K>|rkM?|14_EE`tQZU&
zgnat_H1712oDq&hut?kKBQ;Y~Q{}>QPYE!y7-{1+A<$Csyo2b(XsdGR&LIP-D@{1!
zgdgtRkkx=J0MJN0iy(jH9l&JXC+SD~6cEtP8E1VvLt}wMLFLW=3=%wxzM?prC!1RQ
zPRH(j(%hH8ZF8;jrV933*@o2|bTZy;+#5Dd&jdz}J6?ozc&UUlx+{xoflML)I5sx}
zOfmgeS17;xCXfd19vtAkYtq!wnbnNRKq)ne{c;VVEtzE!NSlAg=|p62>GEO35Rohs
zXT07*%3g-eP)tHqT6Gv!Xh-b9QlGLp6ve-b!*d56yF{<{x9osq{&&oBav=n;qA9}+
zsS>BmZ#odNHNr}sBhA8k7X)<#B8eynA3@S9pXj&}I@*^b@;(~4GDD0Snhpc&bZOMe
zJDAT*e^o3DUR{6H84AeVtaZseoouBa-=Fgg@*-K(Aw493dKgpHsKOKZ=FXXr;cpth
z<Q9c0_T<%SBT($=952z~$p`0G4InONIxMkF8#b~H9ToEC>CoKM@vXw3A_hxnWP|-G
zhoPa<GJw>4SAf`I-4vNZ61z}=NH^>Ux?#XNY8v-LhXH>XRE>qu`!(IQ6@nvZ$^NpZ
zTmL#$RO}|w2j_%nDwm%%bS?R!o>_QfSKTx0m#FO(R$}*B$UmC~XeVh3X0j2wSQ0gi
z^?;uihSZ1U%GdEk>5t65YBRMmQ%-Z!KJcjn<?Pypg3N5jd3xpA(<YI}tG{N<W1SS(
z8S4K=(wcu`R#3CUj8w>ehO3rN-4D~C9~|7XzXiNJPNiV3bhWe<f)V^mTLOjGTj%E>
zd)c1jeN7**faMq*33n^-S3pRLJ-Z1|(r&?Q^GBIjRwV|4ON+}<7me=DUkx?<-QXne
z`Qb4`b4@GP`aw&jwzLML-HGC)z2N~E2<P`?MSyKKugTGW4}tCC5QW5PpBd%DR-r5}
zmg+a9;34Q(VJu5G{@u2G{zLrRb#(uB@EyCeO$^9L%)~~j+jA1CS}!X)ALS)Zbm;HC
z3NgbamfC5x|MreFA^IBYr4BoYc%}ir_}IcpTcO6r2`U!}nRNfT!q)c|cQ5-y<%Fe_
zz*Ho2La0}NDeVW3J)=kE!yq(|UGsKNcNJIB5Y+i$Ed6BN>+{^-1}w>7uLxSObUkOE
zD?ODDXuS}&KtwM%ta5zBy29c^rPoa}_&<kiMGhnx8CuH2^{n(C!dOt`D+H&ZRfP+^
zd0_CTF3P=qabYw!3X}$U^=1)sBw=3fM3jkbstGWE!;8>TH@==Vl*7jEQTBv4Kw9`d
zm=P}>X?mWimo(C=u7V5&k?JfYhm~CR9oBV3Nm3m++211^Kl{2?XpsQWJWBdZOjLRR
z;13-!f&$*>K_LQ&y>7XzTS0j0wENAJ*%#gMAH<>VImQ|YQdlBo$SNWPK8s5QP6<|4
z%w3s(vm4<AG*qLnV-UR(s-I<ZLu}PB6tnmJURzPKoS9C*Sz*kwGc0=w-s301iq~3k
zj>%`>M+?)lVG)FOYdl!`8*_7mk{=dk@?j-@u=XyQfYe<2w_Vb|?Op4y79cN+!AFS$
z*UADeU%XA3WOt`_|9Wh|^$xx|NB8_&?__s>Eej#KpT=qmPbJtDr>hvPT^$>R2j5$j
zzGo}<GJGb@Ogfvr7PR50<~LiEHT1dm3ON|vn~lK2^hqtP6_{6`AHjCt#XdJ%f}Hi7
z^G$2@(yd#NmviQ!g-sqzB?%G@!hu=!h!CM>cW_^%W2^7_<l-`>Rch5)>hU3e#vxIE
zQILj5#xmU6S%I^*V0-DnlC@<1yWYNeItr_yTTUZKw;=z!j0ryx#CyGm$%H)MPZ$TN
zu-^K3$ZyRJfg+>M0dg>GO31t3=myB6!A)WI_;xI5?<V&e5HtK)o(Vo|$+Ewn<WMoi
z;rq0d$mYeH?KmbLVgt?cyFmU|T|m-*-%{KLd$0eQc=*Z*<s;8V2-j<qtFixXMk1*?
z@5}E81<+B}o=FEW1G8j>p$SyXmO=38mX7QJDy_T3F-y8aBIxvxqFy;r04pp2aLobV
zXuSc$#OJF(<M0hcVh)s?H`*}JuNP-gp0V=^mQQ`V&S9^G<xjf&5X3IufM;ia7M0B8
z#Tq1lZhYnt^a4#gzXt>NHC7?7H)D%ETX>3dnU>#mfzloQsY`C%OAB7AxBS*7pP)9F
z&Ga2ZEB58{SaP!N%|jp<<j|T=$+AWRv9!#_NHP<bno}NxILE+vj43wS)YJ3?+0caF
z#2O^;Z2Gr%mdD`f_#&{3CZ~{pxpc4$-@9_=G5|K&6rIB06;Ui|_TQ&PNw6&h=sV(j
zU0w5urZM>-H<;|hAEt#6RYIowfUldRe(ayq_SauV%9OnGhymOoy8$Bu;keMuY@XK2
zsxy!NQQ$A?EFOn(EHeqB+H$Fse&VW=W`;=HF!BdSM6!78l^BtcZgv8H`f~kUBCU@f
zp%n4?=p6P;PXX{Cz_v*e4}^Qk8Fi}$OYt&YNTUy;E|IIo0L{y(W>NOtnojy$g=Q{C
z(6VW;Hy%I>{@+&Qp+l$t6k43Kcv~5f_aNZbkS=iR90ha(0E8p2G4sF7i1{8Hgs?Lo
zV-$Q5<I@<SRW{~D!@mW8aZ-IQNlr6ZNvpeBzlcBOH$=IRHeXV}Z>nX=FWg_`hbab=
zCtZKPMn^~emuSTOK7ic97Ayg>zbzc<a;WKq>_txrGz8Dkj9u*|O?_Qg^h#({#J##a
zl-T##xc&)g=R<CiN7D(mFt`M%EChJt1!Wd-@4(=9zk0utaD%9Syo5cz($EPS$aeCO
zCs}JvD}nb0aahYf$CK&v^TqUX105en8ET?^TkR$oDI56tLLwJGyHM+b4dDcZf#A}n
zNaHfWKlJW6gXV7vBe$;R%uuYVq2f6+^^~J_P&Z(t1cc5UoO8t8#I<Bh`0+Qwr>r&p
zl$uy;aFPW8{y?pN{`%MIix~6wodrB-gB+pgD*klHaud5(of%~I^S2z=N5Uc5izA!i
zV{ZsN_v3b2Z^%jJZnRoh=(8HKt5u~Ne-TNk<}{RK-rg#N7I+i$z4j))9=q%3$e<zg
zP#6TV8w!=$>6hNJ0&+zrco=!PSQSV)%Q82Y!3GxMmR0$G@DO<;#^rjxf;<;l%TzLE
zX6+)2eRt5=@+fmAt6$a0akvzCZ>vXT$CAbGiTwT8eq<!EP$@h6HZIB{00x?VU4KUW
zu;T#f_KKZtZ2+ED*TvH-RK732-kyUnxKquJeQQ!N;!RySL?n%AG7RmQ#@OlPbqe&w
zoiTsX#F52+mR+?N``cnWzHS-R1ZRR>WfU94XcHC@`l#w>PhVOlQMDqtp~%vRK51US
z|J-l$CA!nmj3>KC=9oG#1xzPdmkgR%C!HW_UbUpf8x<6XUD|NmuNeGgz`!Y5{k;mk
zapc>XLPj4t=Z>wwt>oJBT{H^&+*FH>@o%<JxoNw9KCSjz)`LR01$<vSxIHZ!Bb}Bz
zpRn&nKk&lV5TCD*)4vl{M!G~6w_wkokODaE$v$jp6q;t&U}kG5AiJV+m_|IMQiccB
zvaSRP?H>A!Oo_r$QY*~|Ci6=9a{|5NXUYZs+5phLO)X&HVUGX+007&UFmC_>iG&8W
W>NTVfg%+qjFb#_W000000a;pbtG=)R
delta 17818
zcmV(uK<mG-ga)kt1+X6Q1h=S<Y_lTpk4k^5SARECC7joxh3T%;P2eBYstKq1u`;O@
z*k;7ish&c?sA_ku!CKIK9oB{{>xrRUV4VQP&El0gy0YNW$)&`b8hYS}ZHS8e5|y#C
zR!&g&p>MKhJ_HrQRxt^RjI2kf13ub7x(sEqKjXJrhoMo1vON2c1G*&PyQ|$WeG-4t
z+s>x4d4A4HUN)4;_$TL#?>__&ESHa9W+>MOKC*57uCE*Ra|!RJ76-;CzLRsy<~P@~
zT;3RJRK1H7f09fJPNs(D`)jT?<5=T8y1%417)MdH$sYp8)382e;SDk|<(1lqq8E$~
zgXAac&Z|b9<@iozrF)vdcyeU0oUMP6WGuJ<F2GkrCQYDzx%7bXtIxyespgA}r-Uy*
zpZq+Tk9(RuSZ$bax=}l|S`>AaVose2UbTQH2Y|XFBoj25TRnkyV)3;YXwrZ5iW3Qz
z40eB$coR?Y+bL|+P>n#u>4Qyaf1%Oze{dF-x#Wi&M-&b0S8Bo!j!83l%}#%oVZFX#
z$x?xip6bD6b9+20T`+{iK9yeg`%@>r<SEn1K;vU=z^b2!LVcS-(T3okfsJLh_)>Y^
zu$~%v>BpCNV$Jugn=nd4J-x%8=e<lfW^O^Rk;gb#wU~g_^e4Rc(ER}oaRDBdi)A;?
zfwKGA{Lj|dXUEyPVxb3SlX-tMKQFf|Hhc%G!|*LvSxz+dVO8h0-I460u?%Tq3x6SJ
zKLY^5Y@MyvETh9I{zPHoNpi^ka4v3BhfSN&4!0y^4V#_BD^z@K+#bkO`^`G~hJq6y
zQdj0Te_!s7_+Gdb`Oua4WJ@xM%`;}&LO6P}O4v;e2`PLDU!exi9Lj&22gK#oa^a|X
zq1y{s{|d1O<WP#R_dB0vs2Xbn?7>{yyy@3k5U<7o7>Y}W@`z<iLPocyeldEm4aFOF
zDwi*2*BT&5ryOwFR_fHSlHDJFcq_FD1MdeKNC24`z{%cl_E$e31W>T?f%jSGFgG{v
z>ztSoRv{Q)Z=xXDQ(Aw(PAQE7v^^i1f?OM06s**Sj>bzQYr<pdmF!B&7@Xq&yt{$>
zWAe3HI|p)Z!X~_R<Mb5_T*|iNV4nhdFSTFUSA*VTCxQ-qX3A=(PpE-{z6QkU@k(=u
z;zrUZ!xg7ZP0Z<7NrWe_(*_(7o}l1~U9w?KO&iA*Odpb-_Hlod0pbo!a-4&4Aa6@U
zDaj%;dxu8EA*d)Ada4!f2`@Ia8_qxvBZFCS*OYT)VJD6M0`1ro;N0L_rEtY$vR&0e
zvkXVb;z+h!q3v0?BBA$Jqw9AqtwULl{ba9JxOMJ=H7p+{Ttl@S%NTJuwP&8peH|Fq
zZC^ifozJ&lFWi67Z{WYYrn}@<$(ud)TO>hqs#pK04k-~6jXqVuT8U5Sjc5z;zpnAO
z#p<Q=OZuQAzhWu%EaxVGmYKhU!_hITvuw26GWsfyoAI8uTdhNJpLdxtsS7d0K)h79
z4oC3SNN-qcwt%8)trx@%q4b}m2OOD{`kjV<RaA2sy;y&$YS@R?R4g$K`MgXFDz(>j
zzM@+X0|j*K<-;znayj))f`kMU@`2*fcoJ)of9~blKWvPglwy{yw(E8-p7FnF*<yol
zgfrG9s`I_$$)0!krexq>NQ^&3po$k+9XfwcmWyUIuZU7T+mVXEPY?Kgo##<*eg_jx
z#(KXot&o4Qx<+7Wzk(_(b!6t|zmkR;R^KHz$IE!q0YPmqOF8UVDR8<8?I%1ao@Do`
z!DT;vWG)2;RU?#BQ#g}B9aJaO4)S-KdR5$m^jS+u$9)?)sd&fnvh|X*MjA(o4TTlz
zVQK235%TTgJ#CF#{0c8PRIC<8ABXStZpgebH~D|)_M{V6u|8D40>Q&X30vSk#V@De
zlB)|tgMfMlMMnSB2%m54KQ-vRbkGeI<kCA{GuEo)8lr<!sZ6I?*X$3WrW)_v0wddl
zPwC8upRchjVF!Oark7G8dQRu_H7ITNeHF6v3W)j~pv;x}DzftK?R7RDGd2q){&q~Z
zJOh7y^7EWNH3uUNVeAGLl@pt~kmML12BHcuc#*M3rjY72>si=ZF}>aX+v1kJb1KiE
zPg0BB<ynZ3>7nK4ql@F>{+D_;AG!U+V7}{3vb&K-sIN<D#Rqsdyq__S<taK;DvV0F
zMf&14*zixy(LwOQYzdd=bbTfYapZazD$##dCNU%Xkuf4h-nbG(>MvxV0{4^J#;1Z1
zZRxMfOR<^r<+p(;x;~Zte{6B`&M~xWtxsO`bXux+=*hq3<~_^~I%CcMx7m1*tW-;0
zE-EECgLM3-fp2ayB9q=Yk#et#K)z`VAzJm7ujt3e>L>+Ox0||;_J($%#A-0wO~QZD
zNrdWb9b{d++XDs5UkH%NAY9%vOCm?1Lw{>y3rOMa$?sdsgTbfVToTK?kCAZ34Pj;*
z@ERF@`cdos7epJagxkcz4kUv3)Qh_?^iijlSW9R$jac@)%amv*;!8`)s>tSq<F3cD
z7ZSTWJ_Fgm--6&PMbQV?5&&^@Tc3X(+Xh%fkaz%tR)fM|I6A|ONx)lJMfrs{t<l~1
zggk8Seg`gM3hKQZ>n4N^z2rKPA*_3gAp@w(zt!?7`}gULpohuxdw0x&KT-SDQQ%}J
zB`=U$PclX}l$@zO*>)gzbA`=*Sc*VpkxZams2r*y5<F<m8T2DY>6&4#CnSHxAVl3D
z!k|(-%g<`PfYl&2wr29fL$yp!w^TlsV*D@ZjxF=GE14CqZ#zH(j$Z6<kKX;j4vXe=
zTO~JAE({m(-z$1K+;P77HvOvNa1k|kF)n>8eMp;N4w5kPN}gswoUI)^WrzzGS_c;N
zl!*%E3n_lWuu3D@9L^QS63u_fS1SY4JKB<F$aK)oASnXBj(^Lv0f<E{D>khU;zML{
zjL&NZS_elZ9qLWN#5U22fBb{6dC-~UzJZcA(x``H@y29q(t+N#2+E{(QM|XWYNg(5
z#MK~2Mw21t4_FTD=;gCxzv@ShUjn0j7&kK(zyME=eVmd|y{6pD)r)`Ke?rb08_w(^
zjIb7?{jgp8_Y7rLx!O~fJ*jc;CL>7wh(;e5+qW;nh=wN;4gs-=H<Zx3GvUT(S{{&k
z-n>^d&02m^)B1JQ!*E@s_z&mu94eI3UDGF5kK>!JGHA%pkt|R0i2o4V$olz_<I1M}
zUPK}t0rSqEU(kq6S89JQY$|vTx^16Datb42BvE<u2-mBO%Qaely5?!R3jPGu8*&AQ
zp3uhyc}DLQ&=BK)2?4c=J*5R59r@X}-TL_IN|fq=Z@n?V-%{?IpCMHa|2r~7X3aLM
zP;~<1SEC)JxvC{46$*D5PPPCZViCZHLy8It+zep?WDd%wAANt#YUWV%st)#u*-exY
zY&SM11!(SpZ!XA&T1x-BVGZCWAh_<9O^#<fD}fH1{c;1>(!^VmcJ#laB^ZAz+?XmD
zuCD>AG84#~{4Bs2Cux+zH*xJw>SW?k54NI6ELP?ev=eQ@*nm`xtIHDjYO{ZavUoO0
zg)+kX&F}aF^EH3-hE$!RHyl3j^%tO10Re{3)FdQMzLW=qAI#m}VvgdLD`An4_We*0
z2ur9x7G_g^SB^yCV$om`66YyMXO2`1*lZW^zo=ch3#9OeSw>W$D&AW6<y#b!3M5En
zg;g8a5Q$j<7+1QXQXK&jiykqWGcgX>kX>)pd}FjFbTNNKI%b{qZH0OuSqY}|o5dm+
z5Ab#b1SVOgO5O4sO&7=62Q0)a^vx3(e_4CZH_JCQ$Wece*f;ba$O!u#pwoAWv^8L7
zTX^ufsFt%Y1^?WjfUt6skv;+1#|XFtEQ^#Y3lP8u@bW+qAD+$|MqsU&o*E}7v$v(_
zG}g%gyLW%ozc8CW_K4jmX_3iVu&0x%sYaKO<B{2vL<$3N31x~l*U~^11R-dcfZ8~<
zOF}>}QKPGOSM+oMq`x2z_k+XWvJmIB6U`&lYdR*zd1PDJ`51p7uMM(t1<Hj*A33Nm
zWRcLHYd@;bpCf0e#LBr)DWiMAT(IBt0vavdw^)B!!}b(6k!q(W!bW<Cz}7s;x4Z<<
ze2zAttT<qo?`sBDxIa|IOB`gH-V;@`0tSVPspH4eDP=yo<Kq$=CA$TV2(!{94){H-
zLP=b#n=xL4fdQ)t%rf&6CI55COz3d$0<7<}s}w~?BnRk<F4bP!JbV#Z^EQI=*c_dz
z(0qR|VvUYonF9ios+IV6N<AQQiAL8vaa%h=uC$FhEQh$MO0o`$#20!0mmq$M#!}GM
z%%e0<lCTuj2u1ckaKMyi&G_`=Kh-J<zT%)aak})z^de>J=&$V(Td{=_x7ffM(uM^G
z2K=^MO+OZHJGAAgA)Rx`an$(+^==ULYTJLSe|itBp;ztui!oO512?E|{s6JR3+B6B
zHg^dONWA-JY}uUV5aYb1XyC0DPRdz!skufN$bKl`7v|=%s~Yd9*s&)6A3C^n=CJ&X
z#nI;}dQM|txRlRVLL=6qJ&T?ml{n$@WLbwHT5w}a2_}Tz)3R<g-hiV$y`$qFhW>xh
zRhRq6*TU5%VLM(L!4!#pI7f4C5MLC^O4knN?B;hkP-<0AA<M}e-k|o7a4`3mGd#n(
zD`fOHAR)<D$b>YHB;qjuYsK8N5L4#B#dEoe;U$oIMI3iMf0@JH=Dvm|AX99`vK5JD
z_(NkJIo=4w^_N1reU|MfF2-e-T19`P*VP6Wk>%l8A;y`4nimIcj{8ua2^WocU@goF
z=Rf_8^-Uu=uxasmWy*~}Kp$c74I*M;@ubd~IG3187+A|xSkDb_e10Y}DeR(emE@-v
zMTG!A2<3jN7ziF6fdo@ASL2J=erKPUZ=DEn2!_0*-u8$v5b)jqCksOW0V98vfk9;L
z*>A(E2vu@+SE6t(dP-~jrlpeS522X`ZT-{KjTGd&xO-i(6t78R&!m>up)Tf_+UFIb
zjp#2}@~+zA>M)|n$RKS#74Rc1iyJ7f&&&s-ftHb=o}_glh(2!#PsUq@n)KNLch9yx
z9|C7<Vqde;*>Dm$NLHbRF0X%MY#a!-p@+!UTTvzO^YW7BbArad7nOU1l-rljSXkx@
zy6^W$z^+&{IfHNAmapSi!Qm1d6Y((QNIcRUch5E?7^DgN@sGDIYv<lzD)qbh&RQUV
ztCI7x*cLc<e8RG#jH1hCnD$SUsx0&0E5{}Rz`VSM3^`NgPO=XOCysx1h~U1I^Lb)>
zolA)b((c-qY|^pGZ=|fM{ty&?;71aG|E)Y3OiAiG^?%lf%xUT!s^zQv8KVR8oYsO`
z0nLl$v{#O>AA`%ew%~w7PxEn{mK*u1JyF0hKCTgqr(U1C5a$9%393Epj<N3r@R(1^
zpYjP|!3SZZ<3S6rn?rx}$1V&1@hjbe10RDIZhlC;rzhumOdwJtEGZeb&BhYqV5PgU
zdP3Su@*{m8(ZU#i*n5qmhkER~1myYM8(kVJ_xnGYS{;H)V{5_!4X76!XgFcji(pz+
zr97Y+aq`azbIR}T)VMnDa{UA?1*(-FMw_ckFtZGqoz*wycE5kH$2!Zh3Ykc#`pu4l
zYsD(o{&)WUHk8Zx$&5t=kjF>iJB5o-I&~vjCwwnI0u86s$g*R$q$`_?$9<twf?GXk
zJdXOp_?le{={Ze#M^KY^i*h>kSj&>nA8{ER)I?<WRGzdH<&Z7)gYHDOzk;)7j55M}
zLJ{Q9gs4Olufl(6OXmQ}r8b)gcLgpDiTq8BSJC5*=nfw6er&!EDR#Go4~Q8odhW`7
zorvZ-FoM2jw?1dxKR7~ZS>Ey_jE#e)hrZj|^%XmadmV%ZK72hzB3@0QD=_vlkaj2r
zVm6Cy=;Qn*yJV`Qd(on|QJ0YI0&Q7t8e;|fl0cF2_lkc3_<Nm%_jvZnX;8P0J2&Lj
zOr1_)g%7(rbGma3SRTF_5tX-cDJg60w$myQ2M6?Ln?~HP?HLO8i-fxLe_lcVp4rkR
zoo(fL4*<ewPxV;jcAZ<ji)4hPkwVT+x<J;HsHzsBIrl47<-odFqyzmfa0eJi<Hj1u
z(kzxe9}s`Y`TS^3&67Y3Qo)@?g>p?=87Z|uQJ-g25O^Cv^ncSaW<3Q*=C{B>>}5IR
zB(QD=v!40wPIz6alV9Kl$k&YiXxq!EUY|D3*uFx@Dxb#TS{;sXF6t)@e)-RhW`dMh
zf#tA`de))PVV)Dp7kr6y0G$kdIUmwP-N*L`q@jO~%Vpi#cWxnrzve|0!eENeP@Tjf
z@hM3&BH$2qPU`H8+L6LQ7@q;ULx)s@`w0aCioGToX#PzOnCSY`;o9xCB<Z1*)`uS|
zJr_cwv2p`OlnyUIKj>8K0Dr;)S+38w8_9aWAab<m9sH}exb2nThQ#<L497L@p%skT
zr15|8yheVWJYJ{gb%|S8PDRrL>Lj>-u2aQV@iXQzO_}ywR`t3I$FGTRjtAHZw7ez{
z=WPP`)LTE2=k%I`C!^(+_(1Y?x3!b8f0B>3CM`ozZV8!&k0WoCB|8M!$RPku1J7Uh
z#Nt?pO_8WHcG-(|humFeOyuFRo6G>S<NSXkWSz$kjybYFmTulmhZ=eO;oYism%9WC
zm_KibHPI7>VSl;W*3JxRpKZbqlfx1`6O`WLayU-rDZ!DZH0Y@D5q|Ijg?@v`JMOF*
zUvkA(G1V$lFtC%)5N;rt9ONVpNU0P9{$bp<PR`B8`sKXG(aIHZ1j}#HhB&k5uD^fm
zgG80z6j6aM=uZR=$`MSV@m}8dkzR*QY`=#hDXe#A3#Iv0@l^sBdVSR1tVhen@8G-D
z#c%F*n}1cL5GT9Y-e!`3f>gfS<#_}W{80I149pPRqxZGkUh0F<QaudoDw;3wck=nV
zHS`L+>5DjIyO^j*6oXG9&%gY`tj>S%$8iZ_6S1)klmL+AqxYy;!<<IcO0u2H5VO6Y
z=pcJZEfP(YlE$!TdcJmf86zl8KP)+d1fw9*&TX$0kL1wIm>#Qp2YtVez>!e7UfS0s
zcv$UiV-#6hb`-&hHlI!wSD;r6*iFXb8|^?`@*?r<S@^G;D1R3x>jtoyH7tLQ{Qq{9
zhV^qu&kq9l_g4A!Bq|JjNs@Jdk_T-d8!!cinu#7}%0gE%E2$}AfuYqrvt5be)0qj!
z*_s~gVw>yr@XaYZt~|)MHD8iK4l`dNx8l&zCKj@9jp(JAY*aN~;~-h@W3*FXDHFg`
zYuxjyz6wl108dqN(=##6++Kepa2?n(bsnNARVVHoi@hnwxl>N_Syq@`4u-ua59!pZ
zFMqAzk6l*CA@IxwDWeA~{Qn=sb~0CUpR~>VH{?WvZtQiFHr=n2c~oAd?K7y4wJ2z|
z`vmj>_vTTRAA}@weT)0C!AE9B3`9DmoqyZV1LN;0S-(bqiqt@WH1~gl42c-^^-hlY
zy?<PQ(e>Q~%J6oH>sNA#L=@Odjgjlf@my^h3&M~Yhan_hlntxIQbOKY(ldPB)hj#Q
zsvu;rS1SvC`uR`~4PAEg+OT6!n0G#IxBtj%ZZC$N36DfEc`jVT<z(TD7>t*@zT`$V
z(4aNK(`N4hV}kCB-@|_$PF+(05k~#eCE_U%QEU+^3r3sO(xYi_uk#1(F!{9GI)0|=
z+~QWmOp2P?FYL6;UGHi6w!YH5S9%A$elyw=byWhJEoyGBgfI6PG@7p8Ud$%M5qZdo
zy*l8t7F5cVNiI#tMte_fyiop4J!%)JP#^m&0wLXO2%tvDWI})F$=vOD9He%_)KvYD
z+4kG$S@GYAkFtYQr9vaukg7Yz%+7Ta#vN3J|M~5OS7Hf90`^L%4y!xm71&AN<yNG>
zF)Kv4&>u@=fBqg3-;&b=1fSHLe7K<FK8ut9<DaU<SX`_X6hIGI&ly=H8+N*7LT)i1
zjsKlV)x*-=H1vPqs~{(^diuWlKt|}XRBg5V%a%Ail>OOK^-~6R4i1&t8wvIhs=FJV
zK66(*cv@g)!9qQzHWO7}Pp*q3(#Ejeg6X4lt-=g9?UT@Eie8mN+l6=8*QL?KUY|}X
z&<gA=|2)5fGkRWsDLXyno=C;(T>R>zuV}BW2aL5d@sxjp6r$4kr(91xuz`pL%BJnl
zJg1vx4+f_ULFJJ4w=U%y^D$rk@g90~iY*i2>ySc&2Biv1febHNa_)Bd0@bhAV^+xB
z9pn-`Sq=(Z?{iC{pM9@&<2_(C?eRRawb*xcY~u<Xj690h=hIuz9$<y}u^id25J78@
zpD=$x3j}|YBzT752)7H{3g{NfV;4Ol11^_t9?MNtl*@+^tEX*gX|ecy9&tkE+*0-&
zNUb$A&zaR>e#5uzzpo;g9h192K2%UhCSQg}UBq&OqQe^sXxtJ4;!5$UQ`D?O*Z7PU
zp*swg_Ud)`jEPNd5&4i5eQN-`ze8Zwjkc=+kVt>z_K7{0$uwD0AE&26gf}ji>a1Rn
zNttn}aZk-%=lu?gTJzQ7nNu!B<6IN<XaA)D)GUhiVseE^&61ufp+;?#bCQ2hy<Vw{
z1zwjsOmKaZXpU=QU&VIQF$NZ0X#(c#4<*Yiu>iC{brEKN0G%~CEfFzKw}K#(3eTF!
zzU6<+mKcOR&}6PkN(YgPxBFP}bo{U5P@CbRt=jB1t{#2z8d~<~0Qzv{I|;=~E>JaL
zRyR?W8MpPr6M(=6>(rESSH_vdD|JEy$4*chFh}EPC{x7L>_Pwh9TrJ35y0IKa@t7t
zb+w2QW(>DCc7}Dri~7~uf0YS87)+2=1Zsa_+(9@|%?7Zznr)gO<X%1iD|kbb_Y3>%
z=&GP72b}rB$$+$A-`;~zIEOCkTVOK(3Ps$hAc-2#L?$HCo*T@W5%&?6);DSHGR}ZW
z(x5qmzSkCkhDhYa!B(MvpWHZj<qD>v_3-z3T`FP9ip0&g2L57@P6kdYWOCQqv}u1$
z>1h_EFMuD=PFz>P_J~1xQoOh$3}>j28Qfcv+2kT;r{tF{{9_;aL-l===&=!Gw+>NL
zm;6dmp=if=&Ug@?NEAMqi3}9nG$s<Gg?lSgnkm+sJQ{tdgGd*$b=MTe&C$vBUs^?*
zHg9SXTaQehz;nVfL>ry|UaHNNXRm)-M{}mnX0!0>ttyI$3JiPAIPEYU=j7VX8#2vt
zF<dlZ+L|5g6+{Q4_z3oi*VhJ-Jgo5ecBw(ptf@}lAWP-)zT!GIyVb`&KoQRLfWw}x
zwQT9m!dme-#q>9wWd!?Swgx-^3WUo;UQBxUTMo~Bb;1d|os+MZ0&;?7sZ)OxjVy>N
zSEg8hsQXMIOPIAK%mJ19E_4lQv^yU0pfUiSud{fEil<P@0-!9^x;*ED_0<K}t>`B8
z*c;r>TWc$k#|55O%ADVm0u6QaQ5HB<nOE}&C`=d2w}pNP@5(*sA8f;>_#YjDa`5pM
zBFyBB(Ku%x?M^Vw><h^cXwQEF9&w3kBQQeO+cieZPRxc0jRKqlsqiyMFqG8aF_|i<
z2I`roCF%pcL3h4gj-v&<N`U5iIp&9ER-_a{MS?5l$Z$28>UOfF&u;M~EW@#_9cdy>
zE99i<F~kxIvRx0*grB&f874(5CXUJkzMl6H5bAEFUe~YSaem5r8PR`-8*x#;VDwV5
zk(%%!WcYJa@f~2?$jY0FA!Qyr$xMw#bON0{pG?A@;om!`12IzDF%+w~EA30hcUP|z
zA@|g>d<ofQce>>w(qX&p=BLAdsWcXFNXx86FEa6%8z)rD2aePn>D&K{EVS^SpQnd4
z*`EMNel$2M75@rZO9X$M%Ez65BQrN4-$gwy`<Jrx+-x!N&wBA0?y+Bk4{+PGpV3a`
z&YtES+@sSgj$0|x^OiqZgYSq0pSyn|;31W!!qn$OETjmPf8eEM!?*LhO(hzU1wP=c
zABIiJW3VMqSduziQ?)b^x4fqlgRlk>jiDa*M3aUB9#6uG<n({P;bvXW6=ZW40qpBQ
za(Y72k;E33FCN$8ClFTODT++pigv-*#>AKBhfMD!PO2%aqS%PtTOgP+LD62$t*<yI
z`!@D*_?x@hn}u7vhff(K$jUSy*&#|~Xj{WTW(=um`6w0&OMR?CGoV0Ndk(HAG@3&i
zvM9Eo@xYw)3EO|E?Mc6`rJ~|th`8-{OI$!s;2y(zD&uDFW<FCDn;iMF!>U6Si^F&L
zz<f0BNWBbB#_LcOgNB=)LO?L)8MI~=G$yxb2`b{G-?SJGCVdUa%QV{L?)%glr0vq8
zm6z3M#*(6wCEA48AE}CpAfpeix(8GQOV`1>@#fy^O-Fx{b6KfgHW&3B8LJ6>cNmZW
zRDubIS)vV)+u30$Tr8FSl%q%AR`4xWqYI~-J8eo%Ht0~!BAqhyvqTmGIWCeL$M9^w
zbAckchyV?all$R`MqR0UEPR2|bgjHVKdlH4V7gSqg!$kVkE>Py>mX(eP?v)=U`X`z
zgESj!jZ%Ns9UEOWD&ucF`le+qf;r$S+Y<=k{X$#E5OusHl9BE{5WOKr^oB3b{c+G^
zx4?IWlOQbS0ta0Xg2f!JFN1>OYMHroIV)v&^hs<i)!o4=4n}gfdh~CFcsT}LSKyJr
z<F}D#Zt$3ux_Vx(!jy0eCWAXb*XcS%*Y!@JeA|EYDX>i5-<|bcTi|*v8j3EmC+gvA
zIpr0Yjd$uIRDjviKp+yPh6>;g(DXHMv-?$ze02fkpbSZYYeK;%itqQYFn9He*)?H2
zsCY*=pz{TKESFgtHyBVw71$cWphm<V-_gC7x)+X_uc4lX=nX~nCZMgwo89w}*U&&&
zLQH?z4?CXCr&4qX2cd?!pm{LWL`N)fQh<pQhi=UXC8400e%e1n`C5<e2-oN{)C9DP
zN}Nsc^lWIhBm$=MwwG3+aN~Mc7VH~K;PnancT)9KD{E0`&$FP?Z4U`fD-?_puf$iS
zRi)&jL^ic<2HB!hp~rYf@H8HU;9^@csV{$ciZ6hx#BqC=*X{ey62?n(Y8vyK!Nmo?
zeC%Ak9M}1~UP~ibawS_>#9|B;>qKEW_7M*ivSZhVWcD)s38SddK<88Aq$W(oh}F#y
z#eXK=Nj%;}d}fWigWhZHjaJDR4YdQa<wHSMnfew0jBH?^%4Tc+w$?uwHr1<0LNtHe
zzHPydI7uDQ6?8q`d{Wd-fO1FTTo0YcL7s<IdqqZeiY%PE!rAr^QeV@a)_ktpBfX|p
zCXc{#dSZPn6V%S+P}Ig#m`4H9i8cW0Na(u)mH1RbEdvUr-l@Hd_X+ZJWrl9yLA-Ku
z7C~v~a)fJ38uWJ#;eIV-O}6^y0-b+J9|etLLSYh-o0mU_sMh=~fo;*)Q_Fe~fCA#n
z5!tD<wnq{pKqFS5xxr_4ikVe2o@hMF>OpN7UFr@uAA_D$KeTbI?*+}mLIuqhDhZ1^
z80mHSIwnpV?<`k+GOs*LN;ZkUMq?3Nb7Kxi7*0&`2BX0v$MG0bI2`NW`5%ATq20++
zX+ttntZO3wz;-1WRB?Sr)8t2sexQ^B%Wn)dt0E*qD`AzdVkj-fCm77&{m_IZ#ICw)
zt`DmIcMyNlK6r8Cf!qgxJ_6*S;ETuozVj=-QS(MCMnz)wywnbavnypUZ$?R`kIyYP
z#=|1tp@%m8XAQ2Aq1&@;d_8}`xDjv{54DtTAH_4i@+A>xHsuc2^_Cpzs?;KY2fvZW
z@qi_2?w#e6)wTO$lWx<;xP>L{y|I{`L?kn;2_98J?=%&iQMD2e>b^0yOv2l2WzJYf
z@hH}<0Ng-e_1AjuoCsEEh^`AZqDMGJT5t*|+eF_@Ni0MwrQ3;zfx3T9yPdVTxexd0
zMHoZkNEi@EHO37`N}Z2{iZm<c0s(eEJ>x>q|HepP*GtCx2k67ajKH`X$KrQ`7m2!|
zo4{*`(+`-<N<OogaF5uEP%-)G(teVGAT4;|9^66^Fs|=ZvD0Cl3mwLsALz><JTdOi
z<h6&SzD&;~2RP_xBWizaAcPl7cP`Q#w$)}6h(J+|*+AcG9+j|eqgs%5L3tyO3!K%y
zu49z3HMt0Vy1cA+Z4q-oc|tE@sZ?I4%>n*lhYg8(FT0aP60LrI+KYRh%`M|>+ao?%
z?}!%=y5myJ)=%04Xu^{>xBV8Y+J}%<?2T+7DPli8Ca^i%PJ@4vEn0d864lqWqf35`
z9(|L$FKr8=HN1yOXqTOiWZ0I^Tqd|(jYaVbm88Q)TrO6g>e|)9<-DpFNiSMH^<;k9
zS_eODJldf^h+ogCaAUz@*uVJ9Gd>eixeK~<)*Pt0tW87=C;LR#lvfApK|ukzXQ4j|
zPLza<iE4rYf@XhCpHIWR!mrP{Wn0JwRW|a9PEf2xb?tF<Z~7tw?e=feaSY5$J|>he
zX%PR;FxgSMQ`oZ!|NdZHou~=m>EM@pYS-PkoCzMk?R=fLX<w(oQ!ZTR!Yb<t0V&8&
zDHt31Z}WZKu%6hnW3#XHy!lQKw;r58`<*0-YCn40X8wQXl71@ObVDJYt5{m4R#;^U
zD3~O8j_aki%oH9w%}847W`<Pgp660Ag9xJ<S0rCua>V_>2!mZ_4pfA%-%Q;*JblqS
z52aE{=v3UYkmz`ryBW1J!!t<GSa9_cHX^2MdEcO!AO?AuA11SUwO&5sXR<4L+`MGt
zlHfB%Q0;%BTKyrR$*xNf4(~VA$}b)>tj*)c+*EZc=14@y4=zrz3I^D!)=P>VG2oPQ
z7zx}`90_3raj!TSAhPh|yZ=Uukei%{qvJu=igpq;A-RgzXVHu0R{z(o`OsD@dyo@c
zI}+T544d|HqDzM~CL@W``oL1ir*4R?JG#uH7u0_pbBpw`p5a?B7B&A1tZB_;J;|x#
zOt)OI?q;&DE{-6w19<aB{SZ70RkSpx6?--P?Tb>xG0kNKhZ2U9tsgpT=gAxGSES)C
zD7i&BYgG{Sw0i($vGxKkJSX@;0#He<cc7-NVvIBO+sbfaH8FqP*U-1$#1;ZOZkF>E
zlfi#a1E%1emwBffMRT<ZCbUWSj7D2P%eFNO;c+c&yxpVW%ntULu)3g&RCR}+-dbK*
z04;@QXs3`8KkMZf7u#Fjc|;54PD~T|&u9V<j7xRKrZ$ep$zARw%~kkC4*M-twNg&u
ze^;k<t;&dy#ghIc44-XJg?s0ciemA4NjiW2ChF8f9}>$PlL!FPU?>E|rZGy<kSkYZ
zy!0B+iG4ik0v)-)dE?N^$L^fX43a5?30J;_A5@%}=?+>vh(s4WAN6{o`z+GdT@icr
zpxly{odH~4Lh)xNwIwkS-yc_BISTD!!iB@H=W^rPV!f-lezX~SM*Y(*k}M4pF^hkv
zt3l$Bw&EQkq88-akg5}H7^KNJRzV11*prC&+_4H3!#DfqyQJ!mhGD)0%Zxh;%Q1O4
zL)Qgehzd0$>}WwuS{R!^EY7`4*5B{w#LltD@>Y6&#ZE%vTN5FoVpMn;tx)PNcI8>#
zG@(n~AJQ5KA2oz5nqX7GE`_tG>#Bc`ESuxgz#p_4jV)|Zj@h4uxr1E@QvYDQln<rf
zR<Wo&fN*ZkULcz7>1sb@w*3L7ZN%5C#XiRYZs(*cwR`>R;Zk>|R$Saa+59O?E%g;m
z|1h3%3VPZ^qn*l5a~^lzlO+g79Zdxp0}$V=6%*NLNXhY<m}SWu*oA&8T%Lb1hXdqu
zmQW3y>Lss=3$^JF4;CpYj$34kXy=IhlDO<?nm*UKSC_jFc#DR2As0hxGlyFfxImGr
zTUo5k<%KfCb<8x?IT3+rK6&9%ZO_bqS)bSvc*_hM*20iR+1^h-lp0Y?8zy(ijaTB!
z_2Owz`&?e@!nQX`Qjr)77e9X@PUR2A`){qgfS7r(yIYPXOa}rj+(mr99H>W;@RcIs
z16^M*`L@&G2TEKp?K!g!CcBXx^eD^<*joB`W@{y_q8aeNl76s1zH1ZdM)Tk$J)%;B
z@3LM-RW&McgFc@OsMxN<B>zNN;?i$lMB<t2a~{65nCIs~So=ga1bu(bM|4K+17SHx
ziH**DGcYpZ-?N}pbUIUikOTCH!SCM_DywfHE#f8iE7vEmY|zGLIA?}T6|KA~ew$7L
z&Gn)VLB>vGnC#_3$)R{(5wK}lQ)ur(Jr-l*d_Z_wq|!@;0abiHgg1ylv9O(ulgsWr
zgBz91oIcXK0biCk0vmsmHelhTl^lC}TLZ~zZNnq?@h<2XQ2mqxJ7C7a$olg*TH8Kr
z1fbdIKjLvyaRN5RC<D&hhMPawaQKGtLDg${WW%}!YMn2lz=NF(LFk`d`A5A#(|crX
zEFoI)**Ta}VA;};udBJDQjb6(>@=i{xK}7+uwT^4<1$1y+68}lD!tI{N4IgrJl&ze
z+H=L!z{WaHuWpvv8R4NiIMGN&1jzco)rp_VkMyC)W;w`z@bpvcmc9E8Rc5F*4Pw`d
zH;hgldaXi7s#y#Lc8+X#czaIw@ffl0Z%4?Vm199DOQqVBp;c6JAw>m6ZgIgfj;tpW
z#CC+Hszi==gE4<chLcG%27Gf6=gFCN*%FhVci99t1EMZ`v#hnOGtXsP?NJ3*qEwl+
zmtYX9)QXT_&Ya{qc;D&9K|{9k9;G*n4bdQjjqp~C`4JJ;6HfGS$+IS4Ich|DxHaXD
z00xwdH{QHf7N%LLI3EvB{gJ6)#6f+MKGLiH5%==iX4HQdX<2rjX5yj;yB6{)tD2oQ
z4gfpAQyR-`sApev^De)_NfEr!q-$@7Y&)Wm&;I1@gS6oYgE6)K-LF@kN|jZkRUVa>
z%&lgt++vsuxIu%@ko<Zr()-QVBz~iVD-(q_!&H$4Z^4Mnc^MP`;!oTty4)dL)C}+6
zK#|6<`P+Z)9+*;gq<MAP^U_{v+pHF`%Wv_vdy$H3mQipFNLzJ8lPhj2I6$`|_WaN4
z^!TR9BJ1S#%dMH5hlV96Nd)K5?P`mQUe9p{DbI@<v4LIXB7Qe7i=PzO^(s@4di5)M
z4)tRo1FguZe_50)yaqLjr(=WLtw2D|1%hkjKres5YMy-DB4&@(B%0L7wFT9UAGb#z
z_ie2%mse8))3BD`Dt;B`rUc0?H0Db^HeafAi-JxQiHt@0g*VPup%UcE4bR<&%nN`i
z;Uyh#H-YA^fyas!6jHu^tDzJREC{iHD*7m@cDEEBhhX)vA5LP%32LRNC>vWf5nZzC
zkmG-^z*1|dflGRvlK!nFj4DF(h03(dD#A6cfw>h3FD_k9VFxa$EmirxtR}oUe)}If
z6-lXdZq79EuF%Y*ZfNCcL0SiIYDq0sAr-4+X}rPY5(FPVL@&upU^5^j^l}_&V$+eG
zTU}Z9`xw6qj9KhDc^MW;c3!w|Y(pus8t8w|dXo8O5<DYf5_Gxpl1fc{<Prow<BYao
zJc7*oBrqO~4=s9ofRvSXBsX4({mh8W*5i<-^n%P))o;XJSYMk52-xq=`_$Ys6Cgn-
z5lyu&#X%)S<XBtiu*7jc_&)5FoJxIn2?Ks3)AAZmP@i68DHUukp~>inZz)zh(wBdp
zO1IL(j!C)Y4SX}*x?*~{+r&fr{MR)=iLEB4m1m$smVnSBi7iHLb2((fmW1TWGPIpu
zVC<_JCH@h({fVq(5)OWS`K5hz_xfaRAXHpC#taZPchw$~*beL5;v`$X<$)M`h@<cK
zze(dEh7JtUoGY6P(B`6o+*4ev_^E%!f55-H3FMNbXG&{5VTL0THFPPDlS8`b7S<N*
zn`8h-I0k*!=$XtP*nAqD@<30qP<28L?f}@J5G;$?66KjR)$pwD_Qdq6wBKd*@W+WD
zEJk=W^yUH_WuYQG)pL#6YWVxqmZ90J*ag&>^wwozPB0hHo4*=vH)JyCm}Y;MX*?k#
z9JR9cw$JXoi8+U1=x@TfGfpT>r>$=?<Gpzf5Iz)ZXmY@LwwhSJAg92d$JyreziiuJ
zV*4Zw%;Js4guPu6!B=l3RY<06=n)%Ag4OlVDB1ZLuB0YR!FB_#e2vad%kZIuUD$Qo
zr$T9m=^$Tj<@F+!N{Z!B@Hv0n#7?J{mf!t*V*eiu)s)#dn}Dp_9TAosqeJ#J?2<m4
z8xuP{TrdhV8IYLCY#q;CAqQuoB?1ps^+;3+yC2N%PygS)s3zEoGAmo>lSg93Su-Tx
zEa+|i*pu-vt_#WmQ-&TU5)JTQ-bs6dT47Y(H2$AKm}Ka`b6S-X-#LG`Y=L|v#h@kq
zA)HcEw|1*z?4JRu9<w3a$|dJ4q|O6{<Ep7CUu+QE%OLA->TwIkx8xpS86jH~4pt%=
zoDDB2RKUxwICvyy#!|TB_1`?u-IuHXJ}JpPOW4}2Ku85E0+L+FI{R)!@EUJ}&xLyX
zxs2qcbYT#uNYy5fV(fn^<cES@@hcTD%o?Tg>#}R6pm6!8fH1_hzYW)JN<P8@3Og6+
zh|osC--d0u_LFQbes!>o+ylpP`6@gTUcHx*c3r{oA0Y3<83iirXIb<D7CbLKKhS(<
zIlclQqc2&)e_N*Vh!+4jx6BSj_{tDp?^P*VYvt26Gket}Nu__TI621;=Dso>H4@B8
z^qdvd?v0(o9-nanu&8yMYRcBOM5id~)CloNSeRdaI+9jLVr-WJ@$TaFtB2Y*(0%E3
z{!!>8zm@TbLKDQ=VeC-QQhrtKB<e<pV%}99?o*X;EiyD?xtO0&!4b7UVRh`Ny{?3_
ze9mSUeDt%AL@0l%Vth<2`AQfkCotDfXTnJMpk__d=lPzQy=Wv7aiKu3hXUwVJto4!
zrjXd)$_dS(Qo%IVVUe{Gjmv0PlARpA(!UHlRy-y0S%qG_uQ5w*zZZY|Y7|<9;zPSq
zh>%v8N>~8t3t(2rcfgRxOe6A(?lr<81j_b?J{6}{wG)4II@CVm5_YYMF)KPKA3!U{
zik}CZK{<FIsX;4O;x8)ZqNON3CoTVWrB%C!ZaH7u5K~|@ves!gXMDAlkW(aJi4m+~
z#*8w_0|J%;w$Bh!K?lST4LywZvbpbg&I)XAUxEz_WFNYH#qp~yv0UMdhlzzhBcQnT
zv&T<uA)J3I;*tPd4sx{g`m5iZE_;sb&g@dW`T}ehIk6{^$Hj-%x9dkrZcc=VTS^l#
z2Dsn7&1Pcmv{H@VsW9B96g438iii;_jN@tp1|)#?qMGfZhza;)=Hjc83$Ku(Mkz4J
zerCta-x6i<o1I-#T5YUhI3K3R#?!W65JI(eq_BT`w<<kHh_9w>%{;bWb?LL62nd9j
zK>TBNxbSvZf8I+ix8t>wVB3nXSh*H8T0#_EI~@Tjy;a=w>YfAz0r`^*yYYZ2t!Dfe
zn##LbiNn0*Sp*%}MD`j4>6}Kl{@P+B>qHVAlcI#loP=&47%oahK#3773B(aq6k*mO
zsjh!8&O0-|ZE`%8^PKnOV2*K_j6#ACnw3J=RibaG+9DR;JM|QfwSaBN;^?B~_$OG|
zVEiAx%Wg{XU2Dq=4|v6uC?5yIe;Vd;#j*67@KH)4&TYwX^$5`gBDO$%nqJxveR+aZ
znk47HPaq?_gf@WLYHIg8X#jZ23z2D^ghhX$K`+E;jY#krJOf2fSi5GvP;T2@oSE-#
zR{g;Yk3gPpRoHoWO64S%d~<Pa$;QKvp$(koE%krRzF>~iSW$s!iJt(#HcKdrH;q7z
zD8Pu!EIK7G<Nu&xT_zF>ZTcUw^cZL{h5f15@+=x4M|ZKp{dcgX2|D_x_q<@<z}J7t
z>mvG2%w3@#;nOIl{b*A%7;p>c6g9Fak|$fnXB_W!b4=N;L%YaS{@HQpK&PY9>3R$W
zpJVOqMkv`y4bKE(FNv1zQzggsnFGC?!th7rbc)o3csP<KH8ZL#Omox9YVL|Q7mq3$
zivo|z9w)>x7Gyr6ayIQ!!BiptBM5)(Z4};R4JrmjUI%7q4F}C%p-`21Ph)v2b6+jm
zOv-v^G6eDXmSnkd7GzklQas<LTc#<)6(i_KgipR-JNTM(qk%Io);}?eT0u2WLa)lC
z2=;PrKelLF37M4u{Cx%yy!2{AMZmvC_%-q>kn{ozjf_F8fyMdYX6$tv1nz&z9p2@6
ziPBu!ht2s7ESe4esaWhG3}L}I=SP_V{in71y5+jC$zB#FuRBt9@kJ{sp2b<g*UEcY
zFZgPwpBAAY?asxcThzeEE^jq=65`ucA2SuCB}*5+QYI-AED2k;-LLM2yTyLIV31fS
z7jJth{O!IUo0&bW3`zS`Iv{_(X13Zk@cf8Q4qhGYKaY#=%4#3IP&-W15ouJN9H*lG
zFjY_*%^^5Z>_}R<d#U!gBHm<hT8DlWL-JjEomHi|?7?5d)uNXtN$UPqi1DrpgKQ%w
zg%$XqehPn>5jQ0Yjo1wH#6&vZZylb}fn9=tTyv&s%|8;q&XnOzHGzLyc#tELyEdhf
z!h@zl%o!^FohFm}*vG(EbJN?0TI=^QG663LXRN0>K6FujaFi@j>IAuqOYqOWPPG?+
z`}#+7)_zW{Ws<{aB{+E!ig5A$!sZ<p)je?jNp*Rma}r;2bRL<-V#7;N{2kLTUYbTZ
zsn}WY6K+Fvcw5c7<|ThSj@@S2B#bh@y(TiE!PPGQ^qLq$-@=nnFC9JH`(bx<jbX&y
z23P;rN^#0Mm}FhelFZPAwXU2BFCmcnEmz<dgiG{Qb=!<dMPja_&f1F9K%#D@k{E9O
z1vue)8l*gax?&da7T8R|lW5gdTuh#e=owLIW??=>NV*9<?w)^5w2U-z2AR#%vEOKz
zKy^;tMMidB2nSA>eDArJvVyMyrv8p0=SLV_cSUAdD-h>&Pjm>^(SPE?s`Rt<bcH4+
zKljoK7y(#z-FW)($AtnpN?m!A;X`vAuU)Q<)PJ?y!ScyVV=`_2Px>J)rV(PUiK<9Q
zcO%5mG4gQpR#1QXCp+k)>p05^EsIp0oDNoe?hf8&22h2p02H_?Z{;388U%^g+xM;k
z_${BL4Ym{G%$-r5zIty)bP+x1`%zC>=|q;KjPZSwDzse7&<c@hd+e`rg`ahebKsdT
zsBOwoh<f<o2`90`kHq24*c@nZd-0~dHy&2ZeM3+c#d3d0<yWT9;;74f>=kX`$$Cc6
z`%R(Lk}xN*<~pg3huo=>0Jp320=)}OOQ*hVl1*~f^_-9j+z-Jm-VexE{27P}`bJ*c
z_H}4*@HK)70*wAUi@yO14;AJ$_$zD>`#1^m4n>0VrYT_dFgU8z#(6(<+NcE8;m)Vy
zcst{-y?lSQowWJ;C;W)<OvTfg`?EF5+c4AK-^in=O(K?&Zjcd8&}MZqjId{YxMQ`L
z-AFU~L^dH{B^o~I=;7W4vncqHOo29CL8*ZN{Iy6RPKug3T1rklRdM7kMa=S6kfy1~
zr~%=G$6+Hsnfht=9#JG~_u-%A`+3lM;#wJhByWFsOWeA15{7%gg_5#Y4~%zKG|wa>
z`Ib}D_1l{r4y@hm3{Z6>R*`B?Nq}hhIZ4F81f<Cf!$Wt5lR&;->=!TM<#hI1ySdbt
zga1W+&?XNS8k68T82!)zGhXi%4MIWmwjxOl8pkAVsc;~){_%38h+&YH;`<CW3-5YG
zlaqg+WsHW+@3fCLgC?EkVXAdms*#|`)YM0oU2iAdnU8U~mP?y9162e7APjYH-8{`g
zzv~MxR*=8fVc@UiC7?cB{6|fiVj?^c!vt)2%JD^qj2Fo-N}rWj<xL562z9R1U+Nt+
zSq1{>KvV{uG}qS6Z<a<j1Llm%`Ecu29tnTrT}9!rv08)FS4><1{F{7nj1+?)y%DA3
zy~%9pV2V$+y3Ep_`k>*IsM*M|U_#G?k7!Q6$+7HRf)F-LS?E@;%@r($7*~Kx*PxNZ
zUPA)-u(P|S%s!gs_M%{@YPNA82zS%7nxWJ?-qTJZh^~{s$9}B|rVL^IQ!%?8b-I6e
z!PsTc*e}Y^>z8obWJ&OKD|vTHkP`^I!=Q!F<=@Vj@Ndiz&YbsaqF%$3IyQrncE)xY
z>URYP1zG7*L=D(*-3=b%i&I=R%labtc(xcaFsDaVML>xuort12rDfC$K9BB_0F=7O
zFR-uS#~QpQ029MNA*Oz279@Mtz-E6FaU)^`?>i}{O5p6Eji(@ep)CsdF14RCnD!8t
zYkWO!a3V;>b5F5c8^uBeZSa`>FaDxwgitGEa`eWYnliBrv3s*k!b}=cb~hLhHYUE?
z6j1hOG;HMpykT0_R%_MuV8`rP`l$Rfgd^Orb71Rsbi}#EH6DsycOy}gXgYrvc!2YQ
zw@uXzK9R9je=#?3!Q5y;uS?3}6+fZN+?BVgWQMRX6Z?qK{X#gckrqtfoZolQk^~x%
z+3)F!a}Kcxp;vC0o;Hbumw?m0s`8J%2rH4`TyYpXUz?2LJm}-ybU7RO`krnz{FZyQ
zVyZ?n>>0as43C31W4KcF{qcX0(E83f|KLu@pd?A`5l`&9aQOi<0qJ}p!=lXlC%m%n
z7%M-X9{+s<E$*M9PGlBckyyDpeT`CT;qa+*FS#U*RZFNgUl!_#Or#wsa}Gw_Ck8J8
z{IlY))5t$V=DA_K<T$M=Qsi(BDPqECB)!hna+`}x^7I7Ta^D+Q16O|%sQKB{^U3%j
zT*(7;sPr%eATr!ly*fa-ZMqt#Kg)%wh-gI<<e1;GW@@0TsJ+A1KB69&&<cW|E-9I?
zKqr-d{x`N5jA@_8Ka3k01u+m;A~W0xofT|E+!J#n45;bkm=f3d(?t4S;Gbr$Lb5R#
z{E)0g{8Mt7_{{P&(YAjyo#`ZOkf9rf^U-Tr^v-{p7bzr%3+lMcc1ryI)oQo^lflMn
z%Xjcw#w`i|cgbPw(n%SxfC-n3Wy@b@Y+{D47toh^%8p03gyZ;W^2(MkA5iZ2bi<_H
z?bsP6hXY6%;m-@Tu0;FBQIqopWP`~`?o<r59$*vXQF|ECYLtHq!?FfKjo)}x#G8<8
z%}*|T(&BH4nU4FOi$+A)f2&U~WM6hCN~m>g)Dp$6r#O_V(p)7?!WqIuHo4sd6~q^`
zh8HOt3{#xL0mt+{CM~iH&&X5qC8rb%$wgFfQb=Q#xDR5`pz_jz$z_mh27Z(U5CkaZ
zU{)eu)L3U<jrD&Z4+ydTh$D;IS|JAj&qi>ILrLZz+{7*Fp$(V2BklNGcR>&y7Tf`#
zH#;Zz#(y7*U2MAG>MvowTS)#-Aly({W(^u>)i*Y+2jR&uvOn%q*>i?~u!Z2F{)=rP
zQ{qM_{=VJr2n!#1iEwM93o-gGIWf%WL7}ADW4-rK%zA%(Pm7)6KP|TjJD8<zZ;b(_
zysZ};iDz=W+OoQ1h$DC$9jU9hA2lK&J{=x~TGuTnK65xZyXxBI<K^QJ=V0QjIhso+
zP4EVxYKFOb^=3r7-reb6-uTUxn0~sp=c4Iv2fBubD83)FvK{J84fMB?CDXFs$oF^$
zy@zWG1(1Is7icy<QcpxrJ8g9_45VC!b~8iSAFF~ZHP&EglDy643`$cmF#<b5NdlVY
zK(t{@&?r=hH?F|Esbt`Rz7|%o?%&<G<leIrkk&l)f%;3Fz6foQ-|$43`SME#U%dTw
z(iY?;mUf%#nr{F9?=lm5EAVC~isMWxP`*((Q(1ojh6Q>0WXHblGninyYDPh;&5PM(
z22IzJQI&%)$^$EWP3pOuEvRdmV8m0(+s|Md1F=r9MoDcVkwtkugjM874*6z2Zr`3=
z&t8X=Iki<Cq;b*LJO7&e-;A{tUKSECir)fcs;l)O26e2s5Jv^%C}b2ZF#e$HQXX=$
z6xPMJ6xrQ>BoVUja;wq7vZ*54wTU~R)RT{6kFti}146)CGQYB@M-^wj<kRrm+h71P
za1yc~83@<Tg0DHtuB~T^1IVD0xJSwz7}R4KCRGjj@{dK59(ZH4f(Vn9fp@v<ou_fV
zl%xUV<_fr(5PZr2p9)Q!>L;PWR1f|$$%yCw;3{x`0viy5%un%Bq0@<6JM^{!YUwCv
zr%I+b+<{$~o0M@D!59%E$fSP$CF4s28QF5)G^41Q!dXUa@Goyu33@#InmOw7+8uXk
z$D!Gstp-{c%m3lEc=EmBjInXcByjS)BA04&=wmWjP(iW5TxuuLP2%n>Arc>&?x`YG
z9zQ;R_eh`VEZkx4PU6Qj!3g=)JrX_A`UWWh(s2-Hakp~UIt0PXDV?I&;Vph@qoj#V
zu$|Ez-iwPw&8`y<5m5d<U)auf?n0RhIGi0A4Kr<dy+DbyI6&eVH*%nQO?PVao{aGP
zY@C;T8%(4M)%Lx~<$^0?2B|;<T#psmI2ECP+J`5dcvzV%RNf&Jc7~XH-<A}0_1_2D
zPI#vP(z1WOzh1<qNHc!0#%1OCd`u;19F>(V>`|(1co78$k@g}qzcK$e4kEuyHrA<i
zlVm@`hA!9vDri58cg@y;ove_E4t*wvkEvpLp}J@Xc&6x_j-%|9)429KHXwv`?uuW3
zLrqXIR__S+xa9$ug7M3{{ZFw0xM-;QomFe&GBt0Ja_gIp93`wnG5gFjof>~F8drKv
zol0cq>xXgWUgtG;g$3qLT7@(4k{Gl;(P{>#jXapdhfDcZ`_ToP5FvQTjnqI(9nva=
zbq~~0(8H1_;ilvWY9uKfQfAr3@(hN5B~qr>|3NOymR9Fb^&HrM><{xH^u*KQ5qRw-
zf*p|)J+tRcp>08nib?WDhvTUrYNPd{sK>a(hSyN0yu?P6uu@iU-5x!@IMN0=fnNQ*
zWw9(9te@Tez90LOs%QJ<k4+N{Yjv$4=s2Qq--w>Uhn27?W+Csp@50ILIz20YACdA^
zswcncTZ|(5Xx6vi2f9GEFnvGk$FOx1+z6jky5Q|EC1UXy4IV(*a534i@2x7KUvYn_
zj-2zeu(y!zjB>de?E9!%5kGvM%HTCfubsz_5d~4K#XQN>vA-itbw+6GI^;$NsH}|L
z>42dqwj{az-R$F{AJDdew@=}J42yYqttX;!f56IwkLmuHPROd=QxKP)@T=cCcJ7($
zpb~gH1_L<dX(!E-(h=acDbdx*i5)*$aeu*wpLfZb;?0Kme`cEqf&bsa`{D}k3LI`S
zR50Mn$}DQk3@KtL<JSJ3l75Uie>~8($Z%F8xTJOq&zWjIo@56V4y|i{sH@*smZJsw
zi<soxQF$!W)cMyh>q^w?7zw+oZtpPAoo36>mGjTd<e43OQQ);`gme?~$*jAh_egIu
zd##~at&7*+Ot{L)84QTWRqq!tYZul<MJU>)|C|0Sxd1)Ba-zXbpSY_LIF~m=Ncx*4
z3E$3%ZleJ3<!l0D^m)jC_OH;A%bTr#DGx6Da~H^hf~sJ!)kFVt$*N-GyyN@nM5Eg4
z!H(U^R))*@i+n9iH5rynY^C`ltMkLD!4t}qSUe$6sVh@`ZAjQ8^gG+td&c+6HE;HZ
x7R&6fi<P{1`hkKr;%!R+0F^S>0{{Vt{{_0aHNxL<XFf0uivj=!00001Sz6f~pgsTq
diff --git a/data-raw/_generate_python_wrapper.sh b/data-raw/_generate_python_wrapper.sh
index eb2a3ccdd..0e759d7a3 100644
--- a/data-raw/_generate_python_wrapper.sh
+++ b/data-raw/_generate_python_wrapper.sh
@@ -73,16 +73,21 @@ if not isinstalled('AMR', lib_loc=r_lib_path):
print(f"AMR: Installing latest AMR R package to {r_lib_path}...", flush=True)
utils.install_packages('AMR', repos='beta.amr-for-r.org', quiet=True)
-# # Retrieve Python AMR version
-# try:
-# python_amr_version = metadata.version('AMR')
-# except metadata.PackageNotFoundError:
-# python_amr_version = ''
-#
-# # Retrieve R AMR version
-# r_amr_version = robjects.r(f'as.character(packageVersion("AMR", lib.loc = "{r_lib_path}"))')
-# r_amr_version = str(r_amr_version[0])
-#
+# Retrieve Python AMR version
+try:
+ python_amr_version = str(metadata.version('AMR'))
+except metadata.PackageNotFoundError:
+ python_amr_version = str('')
+
+# Retrieve R AMR version
+r_amr_version = robjects.r(f'as.character(packageVersion("AMR", lib.loc = "{r_lib_path}"))')
+r_amr_version = str(r_amr_version[0])
+
+print(python_amr_version, flush=True)
+print(r_amr_version, flush=True)
+
+print(r_amr_version != python_amr_version, flush=True)
+
# # Compare R and Python package versions
# if r_amr_version != python_amr_version:
# try:
@@ -248,7 +253,7 @@ for rd_file in "$rd_dir"/*.Rd; do
# Write the Python function definition to the output file
print "def " func_name_py "(" func_args "):" >> "'"$functions_file"'"
- print " \"\"\"See our website of the R package for the manual: https://amr-for-r.org/index.html\"\"\"" >> "'"$functions_file"'"
+ print " \"\"\"Please see our website of the R package for the full manual: https://amr-for-r.org\"\"\"" >> "'"$functions_file"'"
print " return convert_to_python(amr_r." func_name_py "(" func_args "))" >> "'"$functions_file"'"
print "from .functions import " func_name_py >> "'"$init_file"'"
diff --git a/data-raw/_reproduction_scripts/reproduction_of_antimicrobials.R b/data-raw/_reproduction_scripts/reproduction_of_antimicrobials.R
index fd4a27e76..5c8f8d2e0 100644
--- a/data-raw/_reproduction_scripts/reproduction_of_antimicrobials.R
+++ b/data-raw/_reproduction_scripts/reproduction_of_antimicrobials.R
@@ -919,9 +919,7 @@ antimicrobials <- antimicrobials %>%
# last time checked: 2024-02-22
library(rvest)
-updated_atc <- as.list(antimicrobials$atc)
-
-get_atcs <- function(ab_name, type = "human") {
+get_atc_table <- function(ab_name, type = "human") {
if (type == "human") {
url <- "https://atcddd.fhi.no/atc_ddd_index/"
} else if (type == "veterinary") {
@@ -929,13 +927,8 @@ get_atcs <- function(ab_name, type = "human") {
} else {
stop("invalid type")
}
-
- ab_name <- gsub("/", " and ", tolower(ab_name), fixed = TRUE)
-
- # we will do a search on their website, which means:
-
- # go to the url
- atc_tbl <- read_html(url) %>%
+ # we will do a search on their website, which involves:
+ read_html(url) %>%
# get all forms
html_form() %>%
# get the second form (the first form is a global website form)
@@ -950,24 +943,44 @@ get_atcs <- function(ab_name, type = "human") {
html_node("table") %>%
# transform it to an R data set
html_table(header = FALSE)
-
- # and get the ATCs (first column) of only exact hits
- unique(as.character(atc_tbl[which(tolower(atc_tbl[, 2, drop = TRUE]) == ab_name), 1, drop = TRUE]))
}
-# this takes around 4 minutes (some are skipped and go faster)
+get_atc_code <- function(ab_name) {
+ ab_name_full <- gsub("/", " and ", ab_name, fixed = TRUE)
+ if (ab_name %like% "/") {
+ ab_name <- strsplit(ab_name, "[/ ]")[[1]]
+ }
+ ab_name <- tolower(ab_name)
+ ab_name_bla <- paste(ab_name[1], "and beta-lactamase inhibitor")
+ atc_tbl_human <- get_atc_table(ab_name[1], type = "human")
+ atc_tbl_vet <- get_atc_table(ab_name[1], type = "veterinary")
+ atc_tbl <- dplyr::bind_rows(atc_tbl_human, atc_tbl_vet)
+ atc_tbl[, 2] <- tolower(atc_tbl[[2]])
+ if (length(ab_name) == 1 && ab_name %in% atc_tbl[[2]]) {
+ out <- atc_tbl[[1]][which(atc_tbl[[2]] == ab_name)]
+ } else if (ab_name_full %in% atc_tbl[[2]]) {
+ out <- atc_tbl[[1]][which(atc_tbl[[2]] == ab_name_full)]
+ } else if (ab_name_full %like% " and " && ab_name_bla %in% atc_tbl[[2]]) {
+ out <- atc_tbl[[1]][which(atc_tbl[[2]] == ab_name_bla)]
+ } else {
+ out <- NA_character_
+ }
+ unique(out)
+}
+
+updated_atc <- lapply(seq_len(NROW(antimicrobials)),
+ function(x) NA_character_)
+
+# this takes around 10 minutes (some are skipped and go faster)
for (i in seq_len(nrow(antimicrobials))) {
message(percentage(i / nrow(antimicrobials), digits = 1),
" - Downloading ", antimicrobials$name[i],
appendLF = FALSE
)
- atcs <- get_atcs(antimicrobials$name[i], type = "human")
- if (all(is.na(atcs))) {
- atcs <- get_atcs(antimicrobials$name[i], type = "veterinary")
- }
- if (length(atcs) > 0) {
+ atcs <- get_atc_code(antimicrobials$name[i])
+ if (length(atcs[!is.na(atcs)]) > 0) {
updated_atc[[i]] <- atcs
- message(" (", length(atcs), " results)")
+ message(" (", length(atcs[!is.na(atcs)]), " results: ", toString(atcs[!is.na(atcs)]), ")")
# let the WHO server rest for a second - they might have a limitation on the queries per second
Sys.sleep(1)
} else {
@@ -975,6 +988,8 @@ for (i in seq_len(nrow(antimicrobials))) {
}
}
+updated_atc <- lapply(updated_atc, function(x) sort(x[!is.na(x)]))
+# duplicates
antimicrobials$atc <- updated_atc
# update DDDs from WHOCC website ------------------------------------------
diff --git a/data-raw/ab.md5 b/data-raw/ab.md5
index 56f515222..a9356f930 100644
--- a/data-raw/ab.md5
+++ b/data-raw/ab.md5
@@ -1 +1 @@
-624ebfb529db7eca5ff06f8a03591f60
+e4c334f53fca483cf62b88e2a85a1174
diff --git a/data-raw/datasets/antimicrobials.dta b/data-raw/datasets/antimicrobials.dta
index 9c3849c0f46efcc6ebc2af5d746277f8ba4cb0fb..37b1e082c38cc8c102cae6f2d60318329e9f31c9 100644
GIT binary patch
delta 74
zcmez5e=lG{g`k0<f^TA_f{}rdse+-Qm5If~&Maxyt85G)@K%TeOmhiCXfa`q$$X5;
Uj2AW=G1jY0V$a#UQPq(N0L9Z0P5=M^
delta 71
zcmcZ?@X3Edg`km{f@49Ef{}rdse+-Im4W%h&MfJf%xnxG;ONK>rsJS=mLvOQK1OB6
Pl+8wr^(vcX)f|}sedG^Q
diff --git a/data-raw/datasets/antimicrobials.feather b/data-raw/datasets/antimicrobials.feather
index 608565812a1d8152c33cb28d43b41c6f4a5d9a0f..8c86fd59760fa1df21c9caced1c0a6eae3e50413 100644
GIT binary patch
delta 10456
zcmZA73wRXO-T3j}IWv1nBFXG75CjRi2%>V?*<=F|^kuWVAqG-Of^{LbMNkn?xhfYc
z3n+qC5Jf;yE?z*(O(}w<fE596pccVb0jq$v0=BQ9wg_5zzh@Wz&-4ECJfAsdX6JHd
z&UMb@jm7>|8~pQzSrw6r^|$USG2#4frK|Mv4>lYu^{Vu<9?ATTiD$zL%M0tig6x(_
zjoEN?AR8VVmJNTI4W!S_*~k|A{Du+Pu-p0d@EzIp3;WN`uBT=5`5kJ<Wp^m^X2UU)
zvf+j0h4s&U*)0R6Wy9Z|-{CLk*CYPy2LFTE@Z9<H`RASA@qCb7Pm5eQ;ju;8U#e6#
z?EGXlTzx|}{N!XdeE0rr_~KpJ9WUIG+?`#2>ii8YpYnfy|Ka?)&&nPzQ~90iOWpbP
z0cHb#7f$%%`StwsC;a1#|NFahUv~XPojt)HXJ*$cv#WCQ{QCLT|F?eOhW|20Ns;+c
zXOELl=4K=H?X!n;UNiq}$6Ir@TuAVS5uKJ^ll~ngCi6&?EluXqep|lNxkOsP6c<xO
zF1BT#Ie9TkP-e@bPK2Ftg)N~gIk+ovmxJ4u6N#b+s?ZAw)SwpT3H3(<2d0}?TyM*K
zlZHWP<_uT;ipXzp6HLjx1;a5Cx8qKX#dzF>iMR*%!sNjWn0$SJWX&dg$d(`TA0{#v
zrsO<^$Fb1t{R9@9gg;GWDVAd;Uc@S_!8)wR25cnFuku7T6W@Yu_%oM!o$w8Q+sXaB
zN&IcR%cb=mBJX1__TeKA{+RH9N$nvbf3@Y~&k2v<3;fMw!dFC&<7@mA-`djddoE)s
zGRKyu0)!#7v!$>-mnBoa%k9X9%WyfaL<E)S#gA89P2|7O2MN?Du3t-}4!=MnuE#Ht
z!eIOwL%E}y32(u0E;WK17)AUJOu*eFYZBpPTW+|A@LsN#pC&RLreHsShhWO&JUqrp
z7P3=1xP-N3cowU$8f&p08?c>A?;zZTceu<4gnMmi-ba{uj)VvBSA0&fJVN*dj&pYJ
zDI(wEJNyf$afVC(2j@7MPE+J<ZpKfTi;Lj!Lx3>E^KM1P6cWD}?NG#Toe3%Q`??VJ
z#8v3c_G-cesjVTb!!Ou2fUuE^4dgu66Tbl?a0mO1CQOfEG0v9XOdy;@(=dOs*@~GQ
zJ&W)`!iNYS=7`4#AIBo@^GU)Lc!BM!2-jd8CE;aK{RfVDh4oFO@{fdn!dARyp2?qy
zY{w4lGFN&FA9BQgLY`>oW6pSh_^0^HmSu+tkK#*`7y3Ip9%JPMY5oV{H*8#amdH=g
zmdSUU7RC!da&Zw_ARj#2P=K9sL#(v2DF1~-E=D`FM=?dHl(3U6r*&r{SD*{JqB~cQ
z5Jt_9RYa~rZ(NNS=hfE|>4$p!0@rcD0X&9*#IMH<7)0^;72&UKNr#581I0UZGpD|l
zjknoyE`KDE+i@qxU;^&OB+TNDn;s%Uj_jL5_y``wd{fmQC$azw@idll>SsCiO5(pK
zzM6y95?_ax&Hb+@zi3QOs?BUMjq?T6`15}!^Rp4Vw7$)dJ~LRIW;U3v)BMs3m*7%#
zK?O{kTMg6JHo!EkH{mvnfoU;K+n0WT#T=N{@F_fp)iCXxY1`hwyZ8_XaRkR;y3ZeQ
z4nAsC0SeIpozM+Ym?kHQ{uqd641;Ms#wpS;nTTm6X2Y}$i(uM=l~{+3*oK|h4O8zA
z!PN1uVXF37D9WFy#STo3?SM|`hA6H^0{t-%H)5FP8H^$_4yNKw$85~QA}qs7tiwiZ
z!%pnMJ{*Fn8YgfHXCUOEDf$I4g}Vbfp&OzwMKyu`7?@_!jA1Z^ZX70KI%Z=Yp1^Xv
zfS0fduVEM7!$<fOU*c<ghqKTW)ErRXqz$N9av7*ZQi*GjPO_*64V2u7VHgG4B$<Ng
zpb3(Bcmm5nlVh41)4a$w?81AX@sLmP1!x~khh<t@QH(MCa8QU2=!9+_^1qVE)kva0
z2BI0mFcRZ18PhQv^RNiZ@B-Fh6SiR&_Fz8_;R~F=w>SgkB_VLo2E|_TzcZ2U=z(ic
zgL+(#8*wv6VLYZ_1|Gztcmm7uB3{O;_%q(b`}hcd#h3U8zQd2u)ZJVJ(=6Je1f3B^
z4_t#J`ePt&#Lc)J6YyKykB2cIi}4Iz#7o$O*YGCZ$A9B9{2l+q_xKTM%P*3LAljk?
zm%~LBVyMM+_$7XYTW~wZV+v;AAv}gB@eE$X%Xk%k#+!H_AK_Dcfv^4K|93=wgq6c1
zK@e?Gipvp3PxL`8uEP!ZHEzY7xC_6<{dgGj@f4oLDy+w5ypFf<0Y1iOIpqJ}iTn@#
zg`Z&O(q*9~+Mx_rAc89NK`jR02K*Yg;!fO!dodFa<8eHN=dcQYz-Da6+xQ^O;$wV{
zuka22jsL)tM?%mNm!J$+B7&<B!?hTI6o%k7jK)Ny@c`yv0hZu-ti}dxLHZ3A?_w_w
z;4qHiBu?XJcrT)(L2DGDBf6j*y-<xhG-42jU^qr&BGQ<JxmbuLSb;Sck^ip{*@_)_
z7a!sP4&xY3;s==b5kDNXK`}a`J1TKC66lX6G-D`6U@RtM8fIZG7Gh}&@_!|fwb+QQ
z*oocPhl4nZ<2Z#Ma1K8D-2${m5jvtPD$pBo)S(fBF%%;(1`{zAGchO4VgZ(51=eCC
zwqhrCV;>IUD30S4&cM8#nHTy3v_=s+p(~>3jRg9m34<{dBQO?|kWRChg-5UmOR*Ab
zu@PIb6T7hw2XPd~aSCT34hca%THz90iY}-?ZzRwUO&E-!7~zorV~9+|RLsO2EWi@1
zz*=m?R_w%Xe29ZMf@Amwr*RIx00}{Bv`0sDK?Qmvjyg1AaDe>3iO6jjgNaDv0nEih
zEWrw_!3O*Z+wnI3f=_T5$8ZuqK!OxjI4DFBI-(28(F<|ZrCBs!5QbnlM&oWw#Z1h>
z0z8f9u^NBCW^Bhh*o#ka7{_oDr|~m9Au11A;u2hnD^ZU0RV-qt#Q>x*1j8{JcVj9Z
zz#J^V(|8W6upXPS9q(W-4&Vrm<0MYw9K0>b8ni}xbZklfcOg=NUWlU(jTnTRa2v*8
zBGPyObFlzR@I2Pw6>Px{yo(QU07q~PCvh4-!^@C4AFW%F|3ySPp&O#;jX3Jih{3oC
zBQOS&kj5-Lf`wR$6<CW`uoXM78z15zj^H>>;s>0AFWs7ypf!rn5nWJ@UWlU~n$V14
z7>Ti%glU+Cxmbv$Sc!Gmh;7)3J=ljsIEoWEh4dK~s*r&q9JE0PbV4^oaWxX?k0vx@
zC`Mu|CSw|AV;&Y^8CGH~HewrgVh{G=5RMj-|0jrii!)Gds5WrW1|4u2x}y@;pa%6A
zh-M7KNQ}iKOv7wEf`wRu6<CXn*oK|hjeTv%|AR!1;y6y?G=7HXVyX>V;S!YLN<?rK
zVyMLcr0^TuiaT)^?#2Ch81wNIp2aGx$7Z~qX7M&Yz{mIuf5$)ZJ${1SmLVEKXp2%@
zjxc)Qzt9)g;RgH$!!a5Yk;Vg<gU9g{p2KRS|G?r;cmwZXFFwIxe1&iDZ~P2zJDvzy
zq8-X`CCYIXs&OqEFbG319HTK2Q!x{BumDfDBmbW#vKkw(1v{`C`*09Pa2%&_2If`Q
zhXS-l5i)-lBIn<dQ#8Zh<=2HPVzIDGP#p`GC&HDnlpCoFyM3#}l??^bGTq?F_@=NM
zi$z?Y3`r16x}8M%dBJ73cr0Ae&^OA@;qoZulGa?@#&D!SiW|et;xAw~P9Ll0GT|QV
z)uZna84xb73r8N8P(ynZp#zF(NyLqX-NEMU!Kh!<GAT>DRgA(rNvN?CMPCLCh`QCO
z+0qb+rNWi{%_eoT1gc(;K7FgJ!u6RAXT{b^U976(F}G^Gl)6=mrMN13v$)A{MWF<e
z-$|dEm>VuI7g7&NS)`I{bd|DLI3eT0RoqviW_jjR1!)OHKQht$0x5~dHc`<fP`O+=
z;k3k4DK|V<g5|HO;&61Dshwf&{T3Bym@Z}IJOqnTh|+<6UCovBDN(N}(&?6ukZ>~G
zv!BG`1O=iGW-lgz@LJJ+aiZPCo}u(m-hbRlnSI$QAtj00vF1$o^(Te#u-o95MiQHh
zb=RbjH+{FpjsB>@ELVuWQM0S~q`10#gfh`bL>FZe;uGal+|5BLP1FoF*VfDqyrM{}
zQ^5^YA2g{5M9I!{p#<XxRY`(HS)zI?KQ@6qIbl@PPGRdvaloZi6MI%KBBAj&wKUTT
zs(7M0+_Q(J)`@aNlVjslA2#)1N+WXyS#0r&W#0F8nZgsQm@eu)DUG}1BoN=F(vd{M
zO-MN5_UKA#T`rYin#3o%Ndk$tEGNOd2Wd?1kx+7;4uauc&ro8V3MNLX(6u8~&`3<y
zB?%U8A`xW*gG(=wP=YxXV$HfZRz6wBBC(h|QkTcdU9zn!_dV7sO($3e<NGXbX`fY=
zNKjm%hg#;y-mGNuHeiY?MXR!#ZMGMf8>mp>xa$_MOQ8-X;wl6a=CLWho6|SxQ2eB_
z{XDL!CJMR56JskklHf-8H8D-nK^CFpG&W3QLw-iEvO<?7D!XViPqI});n`YuWse+B
zNrDAAGK@SL#+9dMSmOu~?Vz0K_a2i`JGD(R+&xM!Q=#f%XjUP2nUET5wgeNiIii^4
zrX4GE?I@mM8&!I3^lB-&Hu@<)4I~`{b+EFK=TbSv3dJ{?f|aSX^|~y=8@g(vtZfpB
zM<e4s(;^8s9IFYJFSB*C?Nrb3TG^VfHrdvGOBG9Loq2%GnbLXO+t?H?kHtznrLl1O
zRc(^nN>r&&?(n&lu^4mir9R!x7mSRf=kw^hd}^TL9HF|IK0Q)G5emmDpHs1k3hG8^
z#MBF-|LqIaGkxQiK2(_cW^<p^WSOAVMsZxGFPDqDOqD0Y3@j|JcGjzz4dwk?JIbLB
z24W{Hr{-I))mr!_V0ZU9H59zx`Q>X<%hWEf9+@dsA9;dF(IxTZ2q}%lm?GoHuBzDW
zd4Q}PV`f^+8BQ{JVaaSdao+7cf$An5jMG|VpP-zg8LSGo^{Y+dq*GsdEM6hr(^Q|5
z%u~A0s~*f$Z5pE%IX=I*^|7iR+DZM*;#-OCtOKc^EcP}<I8~`iQmNnB>=Jn?lfc0e
z=(pG=&6+9vi*4zu)%QMKsZ>I%w|u&v$pW=Uf{~UvPGo{V?Zjz_zBLuyb|h@BWR=o*
zW{SDCLbWxPQ@bXo4^4c8dA3Kj#aw*7lF6Lm9vWe*ye1qSuL9*?DyQZQqY|wOm6wOl
z*FB~`xfkM##JbPEG#>ksW=ge+JtC?=suQ*0@*3tJ9}%ZUlz9fr6nB*^DM|(0b=rwp
zKJ%R>Q}|4q@V-s6R6HOWu+-%~>b^v-4VN?dd7XCYe130->c?m5Z6_6qzijioORHml
z%-qU;rU8|QTPLm2?uxmiKxDDDX#ds1+%Roz0nKp4Es{WrR8pq0u~2<GzsceWmY$wz
zN9(mRcOm*2D?}}zM<r`WlnU!-s@#S~`odJW=Z2hex<bx!wNgXHNih>i)lc%(rB|L@
zXOc)`Qd|{&Qm38NR?{)c6DpWGD5^C*B?H0biq3}mQs$P^a?<|QG~|WqncU#W9y;I-
zHQ6ZLq$C+`$O|O9>yr9dG?Omc>20c{Z}k<PK0J~trkkfrpa+>o>m2c@-)YrZ)Tunh
zr=n6VPcr`N=a+4{@|CS_r%1a`d&=AjM&{pAxHbueYq56fdx?I~bZ*75@ElwH%OkHT
z32Tc}a*vl=s*b5Eub%Ib9l1<$>*IN5AX}+}v2tH=oCV#9Jnu7)ts+l7p^B5SGLM;%
z9;MT4RELyiog1PrjEAE)35BZ1GnREzp7fJI#e>@PAaN1ChV-MVs8G$5nP=Fn)LGrS
z?+Y!|{a%WWs#C#;_oC8B1@*b-BpK$qwc$v7HPcslG)QWRir2U<gAv7ab+M>Vb)YK!
zq!p}g%%k8(j%J?eJysym)?<>oP^qYtrBW|idWhdV?nOfT5v3T$>0h;}azEO^nq?;Y
zO<$^-M9<ANITRH=(-eHVLv=#*xfZ2~c-Ktvx!6N_7{fTJqB<Pi(Ly(-rOb@Om^e2#
z&@4{X)BaGrU#2P_lwhstYil17J7tQYF47#{Dt^{dMJkZG!^;e{D#{eUDR!XzEf3S(
z6_wSgD}C|{?|>A8xd9XW_VfbB?Wk2pp({{-^Qz0Fv|+%w0vRgSc3(OWKkSo*TBc<h
zh7nR6uIj3-eRe4RNeg)_M-D5w-X}gs4=B*xY}HAuv5ZS;hD0y0tULVH8Y>w2%v
zhHCg<0PcPuO?0tW3T!^fSuc45<@Zp8ExlC9@D`z(F_|v;9D}Aw=89>xK<Vbp^FFCm
zy*H8!_ZVyks_yfd`;B@+4Bhmj-cXdQt|=&u*PP58KUl0InKp8%qqnzk>RaXO4&?c6
zUKDbrQy}P;>tNMHrU|sucYeNgsc4T=7Ip_|dm*E1CddP!XbVUB(bf;OO%ubC?;6MK
zklR75BB8igmt-=!!qh4rUNExNBg_5L+N&p8jP4={T4X*OGn8mB%`MGSFm;s`Os(()
z>%X$4jo&`tQG1o$Pa>(R=nrJBKNwrB<%G}l5O3IKFg@5#>p+fE&*+cBbBsxTQM)DJ
zzU^_6hj|(D1S(Uunw}$_{IW!;L%FJzwi~@_t~Zn#ooVSth~A?5kk#cJeOspcddHIf
zeo6SPqjn%(m?_j(T6(XkM2gRKyOdMUH|LEKsxG&R(~;;=<tg)8Z)jN+lxaEAoI~5E
zF12L4(tEw?j3~0&x=0UHq1ZQp;&4SJH{@2V)ggCsNUk@-E0wmx49|~yLiJ<3<Qp|b
zx|r+np8<j7ev<^<O{wa9>+-zPc#`oQ8#>Yk>R>uPC*P^>>ZM}q<JyT2<X%M&%qfdE
z_Ld;b1Yb8*Qd85P=QLh1O4eOGy1i*G6vw19k&Rk!HIG9d=gnR@sWBG)iQ1%0qxXKE
z?&uYz=s4vXEk&08TFVfJc*t!<|IfFyeN4xjG&N>=T0Uj(wD^#%hT6fty*(v0eRC{Q
z{Y;)|=6i+I;yi0uP9T1uKpxGN{h8u1SoAvqP9Ux6eVa1(dq`R5LPOkghVscBUekd2
zm0GEa`&NH&k&McdwVAzqw7(2exkrBG^c@(a6}DDPI89O%6N?Xao3w62O<?B1HXjqG
zX#TxHy>F>0mdY31Rcu-tzJ4wA^TE#g$a37SIhx!4NUQg>yqT+LzV?{Pq^4-ihe#61
zC(1*nb5vb<elKL28ZPyMsZV;8M|YFrSk-bR2XoAS1hDO6OYX8leILv`>V&8nc{15A
zm4(V~A^S!DBiE^+cu%JN4LS8QJe*c7l~5|XKg|wzz{P%lkxa3izB#$_5+!N6VmGJn
zr)h3PDLy0d-!(7!LUF!KvhP`~FEf3e<`a<iO1)3brmJg+s$g<|&Hy*r;PRbF57Q<Z
zuG;UDmvYTB++%Jp)bN3=UuCpRA4N~<apY%PeWCOdIi<;J%2eWzIn`@<CCS9g-axwg
zM6R@_#QD`hWvY1(K3OfZgViU+NzT&bfsE9ghX-vfvz+QTJ&M+h(R`(8kOK|ly-u=K
zOHBv<wG~W07YrutU`aB5yiKs$XNQu^sW9#vLKp7kdJ!E;-rtg||A!kXx8x_W()3R2
zm6L4YlS^}~&2)_oeA4Kn<d?cM-nco_X*{dcQ$jy_x<$l|_vIg3ctUNpUS*z;IejB7
z&j=p)%uELL(fWB)3H2>n4VGa20p3RVZw+>}w3BStLZ$`v=)B^j8#jGsTDEv)mKmDL
z`?SgT=9yAB#;a{xFIJM5uWNHG{y*fiT;7G`n|!_AQm<>(nejl->f%=qIx^ZXgFMpU
zQB}NJg{v~d>p)#;3q?)kT=R7>GLQF6zxg*K#<Fgz;b-N<TjVl|)E%63NxbnjUbMW@
z-W!VDlxaOawk(F~HL<GIR&ka48soze1raxu*y5L|nH*_ta>V?@#5WfGmi|1`6Fh8L
zwV8%^f%g2{=JU7dp!Z~&zasLImvb_X58|I#3<ER$^`}bj7-X)fhz-x@l_AVUw|a`*
znh8pM>BuODaZE7M(UyK*Cv~HkK`Lz{4fj0^l_HlGmPUGR^vX3#wt1zydOej2M;dtl
pFrnPHX6mbJrmCMt@z05iR-I7E|L>m`r{=z0DiUjKyzU0~e*v(iI)(rM
delta 6784
zcmZA633wDm+Q9Lu?w*+>2+s5*+($AAARyR1IR^yNb0r)jNkADnL=NR#PPtrVI0QsM
z(NRG_K?DWyKv7ua5D`}aL05E9<P$|*6!E|;20_gJn+f0Z?U#q&)LVUb^;^{k&u>lJ
zw=!+naMdg}whyS0@8sA~vXk$5rR43c$9+zjIO!5s{x(KZ<(;WQxTC3{Sz4+zZc3FE
z>8Wyd|5SNPst}*n)pu&C2`dJr%1(9l_ij(suP&cG^h!M;cGNBK<sGR7a-FF%ZCt9n
z`g^s0^?<*dlA3c*-2$WTN(KJ9172G<qqc5)Yv*0vQmRbV6GB|w;Oxbz83CCp_by45
zo9oVO;y0=K!TVBW>FCsgSI=lgU42#E36+fh@A=E>>Mk|4{)$P=XaAySsxH2>C-8T5
zgQb&G^#*ktteE!S^EcMjH!7(ORLo4xFG^L#{dM)a>i^cSp75wSQna*ZDyj9v#JQ;;
z)*`ja-ZjaKt?x{qR=53mTSvEfs$25qHH{N?(%9{6CqoA6;TpK%fft#`LPIn{Q#3<!
z*gLRy-3r;rK`!#p8g0-P*P$Icq7!a_Vb3-R@=<_7*ymh~5(Lm0U6Ofg+jg|`+Ro)N
zl%ogi7Vm}Lh{4Y7KB!3cTiZ4<fM_7>3?7WzFa)<_C`Q0e);lp0qc9p{Fcx;={srSP
z0TVF^lVK;Vov2eW4bw3LGjTWmDnvJ7XYRe2g*liDJA3cLd@R61+>b?g0Cw`)3A;4;
z>Dt`H3Zf^l605KpPhvebViPvw1#H19cokdm8eYdX?7$n?iCx%@J$MWIupjT>?|2vQ
z;h>$>hX~%sVSIpp;3FKx$M^)t@EMNdbDY5c;0v6@m-q^&@Gbs@)A$bG;|zYlS^S8f
z@H2j~d)2Q5)i{qDT)^+Rh(B-{Lh=uG{yX798ZuB1Zg`->i!3xm6EsCLG)D`xL@Q(?
zXB0m^<e@d%pe?RL2V9SiFyTi&3Q&k56vG~dI-?72L|1e}cUTA_l&o0SO!i8ST9=!M
zQ@<4hFc3pA48t)3BViwxJxYziIM^f71WbfI_}Bx^6x@ZWum_j~=3p-7;XcgA0xZP+
zctFzRiwTxsDIUZ_cm$8(aV*CQJb{&1h1FPtwRjrq@C-I$6Q0Lrynq++5?;m@yn<J;
z6|c$uBrU-<Y{%cQ18-m_c40U6;7#nsTiA!U@g5G~AP(Vu9LAC4-e)@0|BUE3KF5jV
z*=JgH{f6j!oWWWAh@bE?e!)5Xifa5D=kXhAa3N`|?-0`%RUL4`g*2oi1NCqX>Z1X!
zg&R7&$V3(zp)r~ym#uHsB$p@;ZO|6ip&i;McdhTzwKGu{+=#B|j#5}CLpge&Cwieb
zVz>!?l4%=SHMx~&00v?Z24e_rPnK+GReuc8Sd7Dj<e&|$=!E>)!>awK`C^T4FP%$u
z_RN|+eY)57uc=Km+h5y%;OYLC{y0<n=LeU6uB{zhd${(;+S(I4Yfrzq{p6Y7FW2lj
zU%TV;+TSkk-v7_qe|9}y`@x&FEca(^i}Qabe!n#Q<n(J&+dq+>D(m*6rIC^31Z}H{
zqYWst&>Xp%NVcc6?;s`2>rNSkeIMwjiE3pa!7z-5J#5d=M2#|=z#eXwVL6`Cg!fry
zIA5e<kC^rdxeo{MA)9G>%szj6D6@wydx)|}BYX6bq(B<3MMJb;Q+epXf%&NiP|6lM
zml52An=uG>PaXrir_O-gGwohzceqDkcPP69*&T-tlDN_l?1X<u6MgN3KB|c!b{c=B
z39Z?8?80ZKtDTmYVJD=Wcy^LCK{o6(>V!hri4)>Dd!mvp#;FgX97#EzX;U?^{2t<Y
zcz}&3oDUN{fv2$vTd<ua_u$GgQRkRyl;Z?n;d`9J1y*;~5;%EQs*g-GgO4@a!C--=
z#Z2gi2zsM024E;gshs}=f@!#yeKfs~U@;!S6IhGq@Dg6fF1(F{T!w#8eu|Uqrs2N`
ze#F0V35rHXg&U2~60KRV+w}zb=z^fe{(BHqpg(TI9T<lxxEph@2+Ob>B$e2J7qFGX
zc!P2u4sgaFvIqSbl`rru&Y~I@AswU?IHdlKC^@9+ris=>*P{S8B7~l(L>xnKC;q}k
zyo>U$n)t2DT!KYdhUIt)8}I_Q;tlM>0epyK_yXVJEUIx4(wX24(wyWu8q(2PQ0Acn
z{LBkbmZFTS)AA;Qn=uH(F$R+`0|_j^QalPCu&ecT1e>r0+wmse#Swgh6IwzX{hHtm
z&Vig7X1@zK84#+S^<5+tn!$&5FldJo%I-9G6fsR4>qmVchGDe5;zWY!n1%URf~0*w
zD+!*)M!bw|_A0xvABXS}ZSWc8mpF}|SW7ui@CVd1Mt*oWhQ^ew*nb-u#@C5TA#Own
zJyD4`hAiK*Q)b%jyolN|kVVO-C^vvC>bsSaEc&(4K7s@I5XbNZzQtKo<051_Yos%d
zl19}^BZ8J_jq8!m#Ei}a7Ru2Fw;(Z?pAnqgSjx$miP@THv``bx9%Pe`QD05@4CV8j
z*DGwP;SMT$@h*<w6WC+;*EoZ7xN^xTT^X#!TTn79gE1V8;h(psG*Ob^hw;)&9`(J6
z_-2}|%^-r|7=uZe0eis(Sc*rn3hS^5Td<wuYOsgk9lVdDIF3^|gL5q4yFgG2XFY}{
zWG47&1|QnNKry-@g5Ipvxi7&048<r+#B|KUd@Ml{EAcco;$>{ZZtTY)kVMs;J|p-N
zr}0xg?lb2J{(#EOFasVmMk};IM--q77@1b}psYZDnvH?U%fNJW9Q7%<8w^a<ZSE&{
z2#@1QtjA`&iXGUCcab>4&nGy6uet7LSUck!l?$kat3Ho0$U<{XT*}BL=zx55hJ|wU
z;S%0LIhZXdBM8P~GG>C5s#X>fJcQ*~gXc7H<EobkUdJwtXRo&j4*nn9aZ`WxMEkGq
z2_ZmY{o+gRp4mLn*Dx*1Z-yx%W>HVW3|U5jOZ=i%8Geh2L8HJjiY=727ga`nPs1PM
zu}XN%?jqX^G!R>=470ML&<w^6f1a@7Mp0#FVFvt_<3we^sO(7xme&e7SA;^A8E7Ni
zg<;`|+#{^0Wg538gxmkHD6L}q%|*6lj1<}7=mDBcc!~}Pw^1S{#^a{J!MrGBiOA0P
zR|`+C=AyJLXy%*3j2MhsIi}$f+D;)&p)?l{hs%w^-i8?t4HKmi%U}&7Y8J+XyeO;!
zE12J1NFIt9cxH*bL^#UZQb6W}gTq8lICO}g;C%b1A4d{wFW63y6CQ29Pcrq&&uL+V
zgT{H`3kSOkPiQyQu&K)IaCnI@&2V@Vn~U@lzADQUdU(3fdz1)IxSz<iCuAFir$woi
zZ}#0I-DV;~`of_K=?N{8x#4gFp|P`Ug^d)sgc&l;=|WBvR0|sjJ@lC{LPqgPnI8@Z
z8VczWdgLqi5TN{x@_jKeWEz!ag=Swxc4lG|g#&4#aGV9q4hnCNE<$w)PvJ7EZwYVk
zjRcKXP%gaTa;Dh&NWI7FBBw{;YUvHPl%ArQ(hM2?M$+vcEcL37Wsp-3+^Wp>hfTwZ
z8u<=I`CeuQd35QjNT)ifuaQr-l(bWMHZhAV>v={7RSpzB!#_ZE7es|JP1R$kq%UU8
z67EEVtnyoyeSMTALLQbmRn{rNk5>kxmJvt_x5=zr;fY?W+7Bi(WKKL@By&QMKZM1K
z=1TIgWInA^BIJt-2^>ACdW)mN6JMj`6j&}{nQ_agl4i^bXwn_$wPiTZMfPUeDT&gU
z<<IvEz1KojVKiwX<q0*%2wWyFUr|d#QNvs-4c43|eNoG)xXa^ODZRpfv(T=SdT6|K
zM<<CkW^5tJI#wvfO!LVst4!$mnUW7LnNi;FI;nhxkS@&~%aj!bR@lg2qh(w177QSb
z6+K@_zT4!)tQ%Bvp_k$dTD*j$3FUg}DYT@BsX@OLGCDc3{U-e)UM=+4Zq=awd?T{s
z@urISSe6!tjX*;=iOxtDENLj^YUztdeh_-RlymN9cUkcui-&mTKPBDy0jWouJM=_s
zq=SYrUvqdOn^YRZES#oz;x~)zvLJ6k0ik}U>IHojQK{LBZMXX<Z)OJ-zGmpw0wHtx
zzM=5EmmRW(sP^ZK#fmr5NY%@KQ;qV%qUJ)mtoq96O=NE2BZ@mZU$_ghCEd>*>&t^W
zht-b{uH&REbMh3HS+<eWESOL38ztSvP}3|o{2{&~9dgKGrx~>Z+oc}tY#+0KvcnVp
zQ+VT*YK~>Tr+OmAieB}C%GL5O=Ioj(G|q!O8Y}MN9I1?S(!I099FnsjXcUGVGTV&*
zE#Z_MggcO@>7jenoN)Ou)d-gt9^u@Ei>wfDwT}vmB*_0rxyz)9i-Pg-s$8LR3C)U_
z%O0jeQ&qk<cna;F9cU@l{)#s=%_%l%d{$8p($d?7$Lgr&My=7p>%XLk=cHJmNnXcz
z>A93p_!{GhDT@8|CMkkkyukg6UX-t@+k|YX*q<nNyOin9+*t5q%^tKayL2;0s!bhy
zqYIXCCR1EW50|)G5kW;So}%!Hi1r>YWe2Uoj7JQ=o%8GL5tXludi)NBj<+aHY3J0d
z;?kR_5^69W4-|4KdpmUNR;di<>F-z79r3GTlFCOcy{dhh9(`7d0S-|{*DX`?;?|3b
z=pahtWb$J|KI{_IvuKNZrO1@ZTIul*R~;Qxb%K-&RFf7@sIo@Qr)f9YZ=4=BBBm&^
zTuCTfRCS_54{cWT&@UwRR65WStu$0+6t+vxiAL|$Jh4^W4AVHn%#fve&BxQlesVk5
z)9JU&5{J~y`=s2Qo)voEp%?S=Hb>2lmaSI>2e!^3UvdebLnLK(%*t_ykRrD`nEkd>
z_%o{Vdm9Ne(ns}_eUm1V4xRg+I@%$JlbRh=+FEA}Rx+j6oRJ}8>5h$>Ui6BP+&;J{
zk2rOcv|P%##HAc1`K+kNO4Y3BQ0X>4a<mQxhdTMH7i5GgI4Y}(8JL4dGW4<$=^V-H
z4skeL#7NS_4T>Hc%ys!xp+5?5Rf+IgZCz4VJY`cA`_tfR;SEJ3r&{!P%^eu2<U}f8
zbLo)_njWc<dgOZy!%;XCUnKZsx{OGl8TnddN5T<lnvw9*G(C8Z+riPaU?gG`KctF#
z6!k0Njc7_j?Jkss={b?G?$9H>)Ah*ZG*5)Qr(dsNUy*%^9_*>;krC{32#Z8A@*+WI
z7P7xHPCZh|NL<x~i#94FCsejg<b}(5ZE7p^IQP8xGR0>`+tV@=Ne<pMc)%L!@&+f@
zlTn_u6tyDZkewA}nH1ezJm0ykVQFH5rkDJnaJ$v3nyVy>(p{(zDpIJvc;&B(Qk<3@
zs>)0gepMz}VX`VNNl)OC!_U~zK3#NF#4d+yEhNKkYnAWOnPoMa{88pJD$H?;XBAJR
z4F?rDrRmYfg|}nuux5`c%XsY>o~H1u;uaqNpNhOK-5Woq`7M9Ra&0zGJ!YKeo8+KJ
i$IeSE-kw-2A0EqpBQ4i!BzL+0_a98NmalE1Wc&xkfs5e)
diff --git a/data-raw/datasets/antimicrobials.parquet b/data-raw/datasets/antimicrobials.parquet
index 54b8bd401e4f6efbe9f4a21d8bda3e36504ba2e0..da6544b27f18f0b055a5e384898f08fea89cf282 100644
GIT binary patch
delta 6193
zcmYLN3s@7^w%#Kd$WCS=K_(Asq6s85Xkvl{303PPnLyAW;h{l6jf#L3PZh1D700)t
zMXOb)J!*woEhtt`eYUk#dHA;0<D<4(AGKOvR1rkILhg#^p6~K~Gqc&V_S$Q${jYzm
z$-&0ZKYj__wa+9y{uRO8W`{FpB@Bu{XiL^7&8A*_zf`j&*=|k{B80rOoTN+&6q#wZ
zuxuR3sl<^^7;+YA5=qfs%E6lBNluY$h1cc*Bqc~SlL~3HAj8ZQ5)>hiWI@_)CbbII
zJP<?%5;Bxbl;QotRC640h8#f~X^J#~uKsYD2^Z$);<w@`gsem*R*+W(78}uDB_>QL
zgVvfT6q#<d*nMX5AW?{XMkmaW&B(_5MJ3y9X8b9#k`z&-D?k=iw6zk<v)HgnW1}gY
zfvj|rz`+>{iD<+bk|M!P7i*ylRTOz1#p!Bb6PtiF^QuB*CIjK{+UZiZ5foh_bh@kt
zBN>gXQn|pvG6C4b#HAs#bcev_qu1dELp2>Oz01T1Gt6<Uh*Xd}(Ewc`Ehq9+GWHL_
zFte0H@emKKVKgqJDOyfBICCO7hUgN)labRkq#Ri+pM!n84J#>RRZ`>%WKmYab%4$z
zw6s_=5T!8n$O3Bk@Zn&cg9cTEJZLG$mKuWLW^W5z7Tg+~*5J}<{^xWn70=oScq2#(
z;!tPpjU2Nk5n`OH!HBgU6@ZJ&2?}$<IM$cF7=+}!(Bib)(t<XSlr$PSm?WZ0nWW?e
zPP>vvc4KdigP{oT>g$AQRw_(R-$00&yD+dYM2S+49B|n^>heQY5u?B}y$M36-CSOZ
zs}_HQ#kEm1C4GwQs;3M^HZcL@$k|I!(j<Y?qAY|PQ^+HyM@R(69wC_GtY44i44-!z
zq;e5gb`f#2E()B^!41ecODb@>RgK84Jb;|WM6$%zTi~?LDhAOK<QzO&N}<f^2WUX~
zcz8ZU7P3E_NRmoM6d=d??}Eoc$`5)4PRCxjIaMa)Tz?Poj=^;ThuPW}IaM43QP41+
zmlPP1kn<0LGl2mFSa1VgK^`E)$eDK-Idk^FW^<6!HU~KdLx4+3<j9)_$P_qjOyTMj
zVkX3-5OH}eh|6gKwe`rUtOs9G5m%ZDIyQi_IU7(yc^gq8;GGG1Cs)6xS%#^ikvXRj
z_ac&@EDaE{Dr8qy!SbfyrP>Mioya<PGqPGYgMz#@?uo>~&ZXe|a^$Q(M?^ywsSXBh
zI0&Lw!MX0pJ-8FOZR-SXtIY;Cs|`8JCcM59*6#-ItaHJCRaek$e*_NX4@Gf{;~+84
zfoB@zFlg?5LUx5aEoRnb$Uidqib!B*>9e%)PY?ZnISd4#Gz(H+<Cjj!zsyj=0W4eo
zHXW^5PHVB4(L|6U*?JMN0<ri2N}ZqVG0<9aIUP+>?xoqn7kpyuzeJeViB)1*he)@b
zxQl!hZ_;v{Coo$G1yN4{-aYDZVgQo7^9n$*aC$BIwElOLNw!%ViVxFT!mH9mJj3fB
zAXn4{Y}l-`6Pppc_Z)Jm?_*laG?<b_$c2-@R*93s(U2~4gIVPB8E4QuWGAFyX*guQ
zT)?uWH-d?!+g`Lv<Ei+L*r6^Jg1wOMK#Va+GEa=`vsNL8^exFLVK8n=g=RXq)<0ss
z$SOlV^+X|XXc2K$s(`4FF~ql$Qq0ID6R^c7u=vy>8W2edJ*<uEr76+Ih<VKz_a<6S
z&m<MNP*b4YDF%+Y*aQ-BMIW$}1Z<pfu7nb+mk5D{xS~+{0Q<t=gasv}f-prSiIpWN
zSxV^=QQV(1RAR$qhC>eTXu}Lf5!@wzC|7qSL*QbsWT2Eo-B3zxH(eKsvta)tvOdW6
ze9=oX+TB}+-MtKHFkzw<^j+kM`<#I6_jr04uGmH(ySA?om@w~l)IJHhT=^Sf<9<V!
zubz)maE<0M1owb0(%2W4*F*IH$NiTKBXo0-CEo{Vsz<{-9-!pAf_V0YLrDqJt@C%2
z98rnfsu~`-aZOPuUI7ALO=8g+?!(%H1o+UIsG<OFFB0KkTmpy7SnYNg>fHl%)w%=f
z>mn34U!{`;J@CJ*uo7~_olror@frKka>j&wv%-)kwpk2|D**>*Xx-e}cK=DK7xJ{W
zf=p70g-)|g`%O3x6Zt-5!z)n6k^V+b*I0WGXk!J?M#;}wfQptqtzH-&EIiTWH~hEg
zR=nJD6b?F0L~C`ugSa3#X$-ld=qp+bmC(g%*M}pIdRI6XDa({%@${iYG^Pj_;);f=
z#MorHLYO>Z!UWc5=%urJ_*!m_F%37#{34A=s<_vBui7*SMN~-X6k`6*pBb94`QF$s
zgZVTwm`{?mLQ<nKB46ptAfe%(4Y@(~XFn;nB4?}t({kMyTA?(N>Ev(H84`I9!**;l
ztOYYUf0(`(hEvpsKvalaLJPr41pH&UWOg|A%2tJwJfYQpLHSqfHtTYfcTjTFcVeP4
zs)-`jAs1Z$!LFtixCF)fPmuEYhl(%a5_}iV%~VYr9_Md!_u_i2TZxj@Q@aB`bCn9+
zWfW&TEoq4)#kgA6i`*<Lr-UiyIK4?Ksg1yEX(Ks?|1Xme2augMll4)!hr|=9-yI%I
z0RzJs0Ij2euP^e@F?2!T7mC~;SQvqat^b<j!1=pS-nXm7q!z`wA3(9qMJ{bTMrPIP
zl14`(-|Fv39tt{VTZ=qW3eP0-RN^L6Jqil*i0xb!OnIT*Y?Vxlgkm|veUp|OCli%G
zW{^UjJ?taHx+4XMHT*=BpcLC$09BskDJAs=IRiPa$%0Qv+n@K7JYdgNIz&lDEEJKI
z5r>5*5-F!S!Cqg(u@^r_z9@4zN{`UW@liUF+)Ud@;2&tMh~?_p@IrQ9M%N=p>@_$c
zIF=(lq^<A{_(V2E<R4PJ(%qtq#WRdy{%~9d>&s#N>*e%YBvsTC$JCAiM2g91){0nJ
zh)5-7H>e-eG{qc{iN!KEuE^7zD%wicMA^iEh=PbiIGaC-Tt7#Ux!!n5x>$MuwkzSD
zpNR*&L*8<Do=SY8&Y*#R@4et|0e-6un;>i@kdQeKU%T(wSj14}MNGZ=VI(ZE<5nFb
z6{CTYLqa0GXk5f&G2Sk904jDebfS*c{H<;hfy;`Z%}sr2{+#TJ-10w~YRlszzZ%xv
zTSQjS{fSRCBci^QaRy8N%~hlZ7hp#)0c~!zO6<2FZaoDjHrf9^@>yOIGQ1s|qy@<L
zVhC7o)A(ZFP(qm~i5k^|7F#0WTx2e6aFBETmZ-)z{ANoI5V|dxxO9w?=dm2GzyJy<
z1x*nv(*mauNjeXfaUI6mVE*Up^fk~u0h~N~kqG%zNw9emQH@;g8yb7m@gAB<>Sa)8
z$e)5bC0|j-miZ?Aw~S=I(EA+XG;6(z`f|E=FY<UxHB8h*1$X$~RCXI(KrHuUll+t7
zDUb*2{*wlniWnAQ$Oi_HO^m?TG&7*IQ~`x%Kv7JlDNUl`3ARBfxXZHiaN=C-RUEX1
zlow|OyG*EKwD+boYN;5~=xc_ilqTGUO}evK>|P22Cg7!67$S2;MQGI(!r&AyaAc@*
z8A|ewQ1&BqhK2$tv`Mk4JqSuEFJDO(mY>)4HI9Zrm<(yspOA024LIg3yHu)>{f`ts
z)$NZ;6Bk(xt>s^nU(nG+QIMtPZy`1A)4S#DX({C&R^dL9FFglm!}&i($vKl=XN!Y7
zGn#<TgOAwX^UG!|w~j!LsLV*oyU=AZUWqnb>V@R9xPQ@<Ma>9@?}1^^unof|_Z}Q%
zyh;jMVosedg0bANOzZC<NVcmN^+54jfto1HW?^;?meWBFP!L|-e%W9lo@=~9Xz)5(
ztGg0BD(uAy%zH6qI9l|9p@A%dlb@-QVb0`5<UBl6mxfE+eSr0NC~D<Ha0&ZvltQF=
zQZ^KV&gXBlJwa?#8>88-UmxjTP0k}ZX>P>ZG}%a)%APZnEMADeAY+itI|s3`kA$#j
zMeT9VUP&*ZcP~UkOFB`UiceS9NhRN?jb|~O29yuu9J2mmCGx0RAx==p^sCi?R5@~O
z)B~%e_K+5$WL0$V*maw0YuMU^vang(piwgUN0xmI-Jo362ruO~_o*9t0#YP}-H{hs
zMX~mRl7f(Vr>g`Ou5_CahQ?Q#?R->UAz^xwPEg3}IepWKlCy<~>l6t%uV)|oOVmmU
zz>m}aDnnfC%r{_G`-c>9Q8_Bf8cO?lI3X(^M9aArA{}{UFDO}zNLPooq?pj`F8Obo
z5iy|Jig)OygDS21P(*OAqD6#Q{l1#uVZ2&T)Gz*;km<|b0M**wxGeuXp;2E|(sI>W
z-7WZlbDG3x77e>!Tm#1SfdPJn)42tNQ~h})NEJ*kf|Yy3>;jaLv!0;XcL;fG4J3zD
zj*^XUgN9_L1el<r`pApeSE4eAAI%|O>{ucHn#5eHlGjg9EF*e7a9o=ZjG`a<3d28T
z!XEe)pk7Erm?b=x{uD&r{50rm0>M#46TZ@?^p2zzlViYXs(Pb(RXCBWJ}#@R#Z|RS
z@gUh<j45{2>iVWwk5Hx)l3O5EJ`JV{FM<CwvJ@3li0sz#h%6NyEl~=gvi=2(Wbt{6
zl$t+dKUIJ=h0x_>ShZ{dIK^I@1~aDWKL$4lU94@^c|eY=ythV+T)Tgf91dq})6WCW
zbJ<C&)8}v2)<psvNuL7h`08cXE-{qOQ9BT*eVUZ#B)L7HKY@>A8HIsfi+A6C{XH%T
zV;1K&EjAtjmH;>o9t~g$ZnbVFa(NS*K2%f6n~P;f#V6k7gc_OjBU)}XNfpF*(6N&9
zp_%uJ+y`Lk7lV90bKL767hbpA<~Rm1T?%HIvLCZm%7pVwC==Q<VOO_4VVP$5bTB6>
z!v6CkLOlE+@gvnXB=ln#B;WY={hx-7JXd>v+{I6_>Za_yKjq7;?CO_wBQv;+TBa_`
z+rB7@$nGlX)C|e~@xznZvomL}xzOL6^<Ce)m%C<m^7rQ$E_^wp>#Gg@MkU*=UBhIA
z_+(Yf+Q0aoMA6DEA=kGZzud;}j;IDjZ?CQtWkkLDdR3h;+p1dk%Z8pjnPyALsN31a
z@A~S7_^!UZJJ|+Ck(UG41Bwvb8Q=r_wLr(95VGugpd%wBq_d-ENXW%NzYu9zAkbL`
zVu5j;fsVkqKtxDLS-UB?CcwA12Riv!kPZwD5qDnifGIxE9#99@XM}VQF1XIOgMt9x
z2@A>2j?U|{kg(3Oc9;M~odH=;5v+qZ{X)98^MP?7&IdX{duLQgSbLzO{URS8l#B|Y
z!H%FnX9s^V0Oqv^;KemQ5E-KE1pVWJM#3||cYxTa>m8jPfw+(!*`OXa7zIWI-53=h
zMLZJpK8ysB;|~+Un9YZ~QSmp1hDZh>RuD0KC`-z6=dqztQxCIY>N&_R)P6M7j`bVn
z*+sEC4%@}1?~#LwJ3X|4ioY<vfllOaZ*GtbYP-?UeW*aw819VpH%e1tsv9GQ$KP!1
zk?zzqMP_CBn;74u>Lyw4%$rT}@ryLgib-qz&C0?p)y+{;_uOoL<K0Hhv7R$8_>ZaH
zzg>MyJ*VyFv0n28+T*<!MNT-bSr)S(Mf?A^<^7JPM6Vpw%^kC5xSe<FDsvaO^`A{W
z>V9+6oNlRoYCf{38n$j&kQ!UJrRHSpjy<<d_TAN}J=Jf|g$bvO2X5D#GJW56>s0^4
zg6Pxc#>k1MEysH<93FSFU&HVLX9tCN;?ECvc&wLl7kUzYo!a0T`1_oYw8UE<Inr!*
zHY`j_y1%0#?X8yYLq-g0J?$7Vn16P4;fNtGA2y75yX#d*`p|B)Go1}pElRhGjE(6I
z$zXxk8R2nyIa%H!uPds!(VMI;6J(@lE1Vf_{l-NZsj>Bq8N*D61ewF*&NwqY3D*{7
zrX@XU%p5VKQ;?Nzr@1VzOSL#FBh}cHm6<k}%+AX2aM{@-^A=~199_&eWse$LMvnAN
zsNhECOy0P7<mf5&O(VxlJ4BAkopFX6mG|DY#iPc4@Th6jxVfFAZ~Ow<<?}C5E%8lQ
zZfy2VTsb&2XVMyvD<{7)Z%NMN&x)IK3O1F6jxMaJaE&h7x^c<qDRuSDqu<$iD0Ix!
zf1PoSDc*N&$(U*1K58EGj~_ZibNP3V(#g5gn^jA5XPh)1%Pl!OI4p1Gc~5fQtV?-I
z^WOWl_*mZT-^;?rzJIGCd2DIPosCP!esI73*w_zS4uy@I(|RU(T-md0OUKQ9`RLd<
zzN<5A{Jd_Gl=1UJ)yu{&5SfmTUnm(O^e>7?OYtw3ja}wn5;g6(f2n$|aKbX}%9IJ^
zynfTN3Cm-59-pwn^n-BXM{#FUCRQZ;zHH*kq?Y3oR}JYBPWsp`aZg(9QkPF!lWICK
z>65e}IDc(Mnmd2p$g$=5m7}Mf$gdhZ7f=3l!b<n#^^-T1PyTGm&J&aWIqe5ruwlko
zcfrQ@elIWB^g+vsg3sr6;lj-eB&mhfOVrB?YnGe%lZ9Wb93m>(vL-FH=*!Bn%Zs*t
zHtl55woP+IQ@*NMnL4F*>!#&X>b}}qcfW4OzWevL?`n>Huw&1qDG%xo+^Ku8^ZRG_
zAAEf{wC}@Rjk0$h?mn*H{_tO?6COPL=A5hVqdgZ!zVm4BFO#=F+IRK62aopOSkkxU
z!0pO+S`PlTb$iRV5BEK2;lF#_-1qPA+b+HH_o3%^w*URZt7i}X{t<=sdwf_RpZfTS
z@XZ~Mk5U64K5ht4?)RiIa@5o(O^SjYPnvtqe)!~A@1^}(kH=I^Z9UOv+m6<g{q{d>
zJ!L-D@9F9I%Tu48NxZw`>DfUY51;-tG|bp`&M7Z$`#I&!`nL1K2R>^1cY3n1{X!N$
zs<{24ub{sDQts?W?U%<dH9q@gQdRM@D}~$YpZz*@|D$KWy?e~qadqb9;*M+Y->vWX
zeNM-tj_dQnOwVsDl23bnbJ?3apWpguV9WDAK2A2hxV?7Nv=@JVTCnrQoei^FUfkWh
z)b#SNEmhN!fUe<>5il)6W=rUBCg$~T;QIv&SG~1=)my|ES>#r!?C?=Sc4v&f<rSg7
z^DO~YsjAaUxWhi)*iC=BvfC$?!2_!1Wf0b|Enj!jw^etm`aXlG2z_|9n|{aMsu7t)
zX4vWbVftSmbo*rWV_DUYnZ$sw^UJV)&0<{jB9oZVqp<?(7gXS$39kfwx)m2Fx_Ppz
z!ZQeY)#5DTjj%0iu>R62T=iiTVXV?;5$dYeEP@HUREhO#D{+-1n;0JU`!13G*H3Yk
zKbz>Ix$~1$b}LLTl)d^x6p4_spMsd7=y;124G_g842X}5-(Qzal&V9#rD^;1Gl?*x
mAkFDES6Qlwvtc%q*<?{Ztm<AvXsXmT1jZ;Q6QOiA!}7mA_>Hvy
delta 2988
zcmW+&dsr0L6+hRV3v<~W+y!O?l;~i0o7G)1v#=~%<6~xbc3pK6z>o|+P(;&`1T+sd
z8^5|i@j)t4t9A?8R7^=~3>Cg;Q$#@%pG{5cBTY5fYU8KI7>LF+Q9jvT{NtW`=ggeP
zJ&)g+FaMR)c{Hj0&w1AOpXRsPXYkjOc}N5J&G;=R@<zupr%7^Hl?stLW2Pi4iU+$g
zg7l!tSQvU2P^1DRA~RDeVV_l@Z&V^=Dw0p33yBa$Dyd?pNuI1IQn7)n7}<|pM1NFf
z0idMVE2{=6M@6h572*+i7UTC|3;rYHmxv|9E62jBU*bYcSmpm}2`I83=aQd+m&;`W
z8hI~+IuKH1T!b6IW4i*S++nnpQ6$^%nP7<QCjxfa{UF&4#xRJ^mP#I(!v^Hr$BHXp
zI`3k`s%&3@bXJp!_+~;qpE%aO1nF5WCODPo))`Vv4hD$JO6_Qhvq)UQgk-K+yvx;E
z3KTUT-$7O09pYxrg|2h$tVc1tP9~`G%}g+mBV_qN<?HFQO+{udihR78GVV}DWIRlx
zu9Xop)nJBz*U1Khvi1xTAZY7F0`CKjN|q{FF&%<gT@cAKAo!4zqmwf*Q#k<n?mCM{
zQDk`+HCAqgKv^{t4CV-VQE*SQ$iZMCZ)O5A4f%1tovQcp0t84s64`*{(~cku6ZGfg
zQkOLU)6_;e-B&@-KZVLv%WT*ySH8{9f|wSKAdB8eoz5zzpFInaoY^^M@bZ`G$L{E_
zEY$G=ehCC~=vvxIT_`tGcdsxJZ<!f_6T6|XOs9s|+CKnKi3p|Ty;PU;chzn9U29O5
zln^;r=>*05BB*USSSR)Lc3?BJ`HB+pt%=?4$YBbVnq@Fe@ezZjsJ3+yK8|WTp98(^
zISWmU&Z)@fK8K@`W|)biS-oXvXynSODDm!vP~(1bT^o<0G#jC9pB!PZIFwCV4_$R5
zX_RY0;S7Ao`2{-D_%bpeM6M$rXKr1>w}P>4WQ-|Lc(X+|6satY)fK;U97~<vUyQb6
zfo$(sM|mFi09&9;uYN(i=ziO|%61mQ?g8;>M)BBGCJ;LP3;V0!w>O=#aOEv?uz>H<
zT3sVwBMIyxiH-@N7oLNf2>O2WE(lzh#VAVNV!%(Jgj>a%V&o(~1hV@9y31{%R&?S!
zGK&pL`HSXRY40e8&CSZe2+4JB;)>9_O@EKZ8C8kKk)<)2+9sFr{~{Z&Y}0|3mR8MD
zYLE}a^3DrPNQpdfp0w|X^y2eWp<g~^Ev4OSkRAB@vU)IT(#6GK#GLw2wG-9$Z!oxK
ztb*(m>`&wZ3%cWFmeG|{6OkJ<+QJ8GmXn3}owOyaQ%A0v401vnU;Vax19VOlM>l$y
zptP-m2=?#L+0XW*jwQAe5cuqsE9-3apfy$;vBJ~~9%ibSi!vVN!bAwS9Y(cWOhB~|
zvguGDA62G+?p!V&Z7a4H5SKRDCRUblcT&fsU^A)G%5YV~8|+lc<EUa&(@Aa@VM8=s
zO{q7DBaa<Q(~Hw-b$VxjaY%0L7gvK8i8IrrmRmL-y$0Eg4n?Pdp_kdeAm@mR4~a8q
z*~ShvOu~XimAnCO6H<lx6da(*?5g|LeH{g0s<(?G#rNE$*%0s~nQR>pIK6Job1&MM
zLRG(L*Q-616SE&<p*XF^yl5(^ui2wGX-De2WwEQq=4{pG69eB6@3d`;e2RO;(V%R*
z2O)hKHg>OU*i#ZOiCq<!d(-Roa8;F7Y(~cE+0}Dfw^skCeM|+9qh4CCg18J+eR3op
zKS4%l%kg%b8GM^doX7A&ve@Q>aCT>ku*Ynlj<$0*?1WsZ{v3-9Cj1?CIf?k&>{?2|
zhzt;c27>m554G!0A(iuKA2~<Ih`D+sy{OT!Pdt`Ah82&U&J>SvW>St9lXA|SdLYIA
z3@&#P`yaduEEJBs$NV@z7Ngg=T(r<n>nJ-p1%1`VDU%&{QfNhb7l7_wU~j7aTwLv5
zfDHG7>R0eP=wSAoROAA~%d^3$UM<~8unV^f8)Gas?|xD#=sXFEqn?F8(_;|uzY2Qx
zzEtFEoc(a{xHBwXITX5m0=XBBLb>iYiCL@D9w8m%9o!*KZ@i2zkq&Ks#2J~-87<v;
z8AN-b<t;h@7BZo*vlqPvn)eI@z8QmDjdnW^a*is@9xe_-xFLp}Rd|JE2F3r*#~_@0
zi%acdYx0qK&Esex=q3M1t!HxtcQX=j!k$8^NG%o+&4!c5J}1xXWs|{oyN0ORMReTX
z4odk&&>KI&qHSZ{O5vWR;c;)u5UR)rL8)04`NHnA1Y}9o-?U%y*3(N0F&jErP9T&$
zowY~3&0shJ!y%OAg3=s=6YS&V8b%H;y&%r8-G#u!2V8BPl?h0~HS5EXRU)g5tlc{a
zS~MNB@&|N{1I@h=sZl50>%~_67!v(epgB+~XxYPtTY^%d>W@;!IS#b8A7Z<=Xl2Aj
zJIt^@AhovdKs$X1iP<}b(-{ASn0a++5*=(}cAt&Z>UF4BTSn9zbBT@i^hn~v&B*2W
zX9~4zV*;goJp{5Rq*U&NFz=&%!&iZEDc3zvXKy-8FQrmMUyJmbzlq;ctO^SyDY!Y-
z@+4n-<yHKkbwzY#c}2$x@p*mEqLt)9!xn6u^2zCRqPC-|ML(%Df!?%_F-p9h5UBYP
z9fVS{sr6=LXXVd9>3BAET{`%4=Mf5f!VN1r51~h9S&pp0zefJD4HV<c>maPh@p-an
z(Hp`sijy?k+R_Ro7B6`oLT<pmduxX9WdBwOjT_5lS@2=}R`szVu=@<pLBFJ6?+&$G
zb>%11znX{hMe^{#4_f&3oQuCjcq^a8CygpxJM7WqnG&6CQc-5|!@nh|fJ*cv-JN7A
zr-$M5FEb`)6!R3AOydBXVy|0)ulvs_WJ<4JHB8C?vvc97=t;UCDH=0oSQ?BNK6>r2
zA4iO7M@hpaFb(&B=}8xGXv%sML(v}JMrlA+Ge@D7YBzt~(~}tNPaH_>6->Bqa4?Z+
z!rgms-pn-F`nvlE?<e}Y6JIB~1`>&ZG?VH6fHh_^4JNWF>9d+l-Gf6U@rViEAL#EF
zOx*oMPog`~-!-r|(Qh@0g9APNgNel6o}PZHfZFNr`TFKSA3gW=_Z;X?q*1{{e}XC*
zGE50&4BqVP8D--BL^bu?ry_$l$CDTgV>74he7(-ZZW+O^{2<|c7n#2NBzbj<_F;>L
zUJ}x85n<OtVQao)$7STWb^y`9#(z2oMUuPkBFFu2(3V-@{P=rwkT?14+F_1e_fY)W
z9MqW9yl<G};)Zy1E}EHi|46c9{m1dMbJ4Wq*Dte<!@X>LLN0R0iz}$uovW;){VE&Z
zP=O{TpZ$t;)L&=gXDZNqbA2D{_~;vURAD=gZ>m6}<2&afHeNLkiOCz*r#RMs%f^)%
zh>!1_htkE9x2?i|lO3$^URO#6K$a^Ly_EUG1SKUu#Z#Cs`=k%g&qL8iOj^GFVev|o
h>}K?*s+PxR??Ip9qC7cIis!wL+^jJZpjauD{||Q&XTSge
diff --git a/data-raw/datasets/antimicrobials.rds b/data-raw/datasets/antimicrobials.rds
index 3de6a4e872ab757830a1445d702f02b22b7f0101..23e0988fd6711fed96b676f30e014c4378360b42 100644
GIT binary patch
literal 45316
zcmV(tK<vN$H+ooF0004LBHlIv03iVu0001VFXf}-yVkJ9T>vZsd>Q$l_#H{J{aE-D
zU-zEWZV*G$F6Kdj>BY@etZ4gtq>{LszR<^&OXZxCQ<?7A@#Wr3FUA&j7wfCtv2ylr
z+It%dn8W!K`K!VMxZ+ikCDE$<*$FZRPVzs3f{wMgG+S8cm5xVh<t7>sOtkv+A7Q@@
zK^W0FMB!RkRYeY-yrOl6$v7|MYm>JW!<#x3zn;PPEJ(U(<)0)Rf~Q7B)yHyjmMmr1
zw`+T)QVoy&>^!uQp+9l{c+gtp52QrFH@?k4Qcn?#nhj~R;pbx<mb54oB;=~`*}0e%
zPZq*-y4UkP5VeV1>C=Za_k%*@*e*skJ;4ghD@^0+$ZJWQ9e7Y&(EYDc@$H=%3X1VU
zXgB1e_ICM3`w6n{&a)Q%l<(_2&nJ`kax{Xv(-o@qm8Y4oJ+@gA1?vUk`MkER%+cfK
zQy0F4P9gz`r2=%BLkFaFGM2WxkG`!iBOWe$nrh#*B&9ZyO$%0YMhg9(wCHS?O`<_G
zlXl}Hi1Zu0gV&DyZ-H7jZ4hYFG4(hGy7-nvLyG{J>pA-S59(^8+H05Jrz3!Vq86wO
z<95;YOoUzB{VE#VSfmE;3qHjOEtXjWg4CO$*aEaSyf&6STs-lx3=)@s8S7#cC(WDa
z2wsx+huH0~$i`%2#J<urx$K#L>x4}OJO^J6rj>(u<MF15&i-UcVrqDNpHN3bqU|L$
z#SVTPd6GN?-%io%OVYQNNuEUA4N#l@F$%EMTXJ(Yd$iuz77!c^A;-K1*B={=AdK7;
z+~$wDaw_C25Qe!bm~TK9!4xSL^ucTa{V$M4rei%U;K<6aLvNri6+}~m`;qJbm)vuP
z%+y<1{n>>V93?_7Y;?#?o-Jv##It0w*hhfFpSe$PkTwCMmtg%fHjh(kNanp0eV$=J
z;@&eBQ|+1kw>PYm-!o7P1Z}-~#PEU|HsX%3=yGbg4&{s1Ez1WZ!(eUz5x6QCWlFN1
z35ZrvoVXO3Q)ZDsD>2`LAB|2IZD-k+t(KiqtwuER$T_?)?7}=gKgTV;Q6mT%Q-zVo
z4!8ixN3UCTR^F$v#LO8-t)KoO;bn?Ji&VnqsF`XY3U|}cu0P)xdp+ZDh8aISRa~08
z>s>+@DdhVQ4(-+6dj0wdE2bVZ2k#K9#}fYZ+?2BbLH1DgT%DQLA$NNUQg)+`0M!D)
z21hh9n~+~EeFpkqYAvlxgXFF>QV_2<r!ZiOaP2G-1YDv~GuPjJtY({fZ3dj^pg4PN
zpwNp=!5tdcf*kUI&PykJjtdlt={B#_gd1O)z>qE2dGo&0PPtcKz#lhXf|+Yu-{b-Q
zCB7lD7RZBp(2N;fbRv>UUW%0U<+7-%rvHM2#KQ3({V(WojhGZT7P#*;B4Hb`9n>B=
z>~pmF9>|mMAZRFZaT8-Ees1ilvP~5UO0?1ygP!j{8dx7(OfGHiethR+DJlo5zJNW@
zcPjba%Ko0MJUX+t%qDMif=q$FUYJ*S8uV>$=8BK4iN9$bKkNV;PeeJ7{VE*H1C{H(
zqAmLe_0$-{^y)ccc-fU58l6h9J-rPAn|}6`-#1CzUM&uYKV+_`)ZY)2e<{vrg!iH<
zwuTO0bUT&w#q9@S^L>KQ2G;Y_fj^hi^ggF8?C>5Y+GnhJSuC2<z#T80(>Y7p0)B!{
z)LP<p`&g*SfRvrjHFl}<_S_7YIt~enx)$PFoJNJ6c02@E6iNYYkM%DP%_wBu%v4d^
z^XkN3O3c|>?A3^dIv3Mitk>24Jp0TK!U<Su6e7;M2I?g)b8*@on*wdud+r@|cWEWU
z&`9<t%8y3TO#OE8bglZD?;n$&$N`$s+4mMc{TATdh{ml{NqLFoQw{UIcF_AKW4xJ^
z-pk$}{`e|vhhksO0<=CSs@O8XGNCYhMPn~5Ms%KM2Do*PyZDav<m^n@{E5I5IMxp*
zhv-lDqW6<cKAYRPoV5sV)kE;k-mOb0i#D#Mid2H9YI7*mox+M4aOB6Sxeh{gS$Gpy
z*5*2lbxvv)sD3Wod1Y_2okOdVs0Dc-SH5MpTl4!GuVX()4IfG9Uk7E{lyQD}c$+PF
zf3;l-jB7V&bx9Xb)DY_*|3NLQY72(q<F)Eu@!K35uthy1B?CZiuYaeQj&%}`-nTuG
zfQsD<!|R+Mi9dqY%%MG%qOE=>7J4~2+um}*BN(o5{Ed6W1x1cKHVf(^`NtEe$Hw9!
z56qr^lc~`R)FXsS=W94rqF-mU1qE$JDM@pfx8k~<p7X0#nHGG0wT1-tY6c7^7~%Pn
zWjr-NhK%o^J2WP%Et)=Xqw)s*3a!qDShE(TZKdXZush{A`37(FOvE&~VFQ4UrC7`V
zx+NGe*-Uq&dy0)<La0@Yjvv6bkg!osBvEOy&f#L#6id&7!bjBwzzXy}kOVbNjL^Kn
zrnPQ!pm4xQ&Q`NML;dS=)Kz3M56Odz{gcIxiPWYxrTulfV?}XQ`oAQdetyb6NJbxD
z*cd3~?!lGh`gNcyxxcGgU?iDtWU_1RS$-h5ZIkGvuJZr?NTQeLQFV-0m(roIk^M#4
zDqh0fJP6hiG#Ez`j1WALmKreMABPteNMz1TLol7Yl8~#rJ;3g1r0}9_s=W~&?Hp+U
zerElp)<VIE5xYH$0^cts47|N<^2#Qe?A3Ilu>?Y0)k~=F{5Go7{zu;Z@TV^@Esr8v
z!N0qvR%k$DLQO%spLDCUg>Mb|^2pYgU;rW2>YP~%5*0xxBTudji1yAId6glkfFCI0
zpQk1%^5CF*vH&SbzK0e1IA2+fR8!oB2ERy_bX9#H6+l_&g|OfC$}0a?8Y;b=%knHP
z#$kX<ZT*Td=wk}`Twz6TUIr9rL;PzE<ZHh*naFY+<sHkoZ3@XC);T4Oy3bpn*y3w~
z65nt+q{xWJ*O1v5{suO02zs9-*V}5o=KP=RosW1MoF$hXng#nPQbr&k(U{^GR=_{O
zfTE!X^qXoRnv>M_R{!xJ3lU9T0_*nIh$M`6$zx3YmY`2Is!RE1z<VTvuf@rTuu-OR
zL6$9ts%T1IN8AsDlvDAKnYm)sEG#`g_35S;M(0dhrcewYc=y=ioO+q*R~P6+dQ_&T
z?Rup_iMR@3i0!yxq?<CLBdsz(XLD#)dw^=xiErbTmHji`MprL7nO=CuQo;YlSZppd
zS+ght8gLOG1t+=d1|sRVACCWvFPiR_F{A%ZpSt@i`VfNT7~|(nJ%aJIHYi&!z~W>n
zXjF*ip9pzS)?4KQqE!VC`$+x<36nStNI?O*vM(4McJA}JX_v1ZEL@^5gKqq=3L@0n
zt7vR~!_E5AL(xhIIZj}^J}OhwtPW;kz03SA5!_6t24pYiQdwt&e`d6kLI{Bp7CoZp
zAaeK4h;iPPWa33<W4FMlqS#RwldOAzj7<z~SIPIl#TMeO#~erqN}3huFJqHgG>|L^
zrC>V3gKtYsv(6_3`90A^!#Q`!)?w0y)An(PuS8+Vs;FARDZCt4@anPBc0;;&#?njL
zqlwmAloM8N<Vus^SzGbHyr+<!;~RvXfU#c}bekm}+|)O`AEP_O>WZwI{uoY;gD!MS
z@<x`EUR-pdp1m9R(@$~L`^Z8YK=!n4f&cBE@@e21j8cZ6XRWg(h9U^`FasWxP&0kS
zhxs65tWv1L^XMwpzlz5Py;>O*#=gx*f9h=n=YRfE0J$ooaP^$JAH2_Ejez36n=EeL
z^GV2eZNV^X@yfdt4V<2mxNcV?Otf=>zo`J|Uc8<hq%(Px^pBAUavJ)2!Q0rS?BAc&
z8Fiz2hxLkUvfV5chkd%wO0z!m*^@{ea~zx-<^>e356@Q2ax2Gt=TIPwah%|DmPRhh
z$}oHu)ulkcvjI=C-a!JAUqjboFw&;R_$U^97qJX*oswszt@JX#Qq*d#=$@_~Jkgl`
zVi|t6Zk|&yj7qHbt_e(?GldQ{n~`}Bn$@GDE~8!r_3g37c0nSMTAE>0H=6tPYX}0G
z7NoL>j5V|WnuG*5<p~J>FrQXe>~g^Zq$U*=W00Z?*z5*?{Ew6*WlIdu32a$D<DQYT
z&DE;|*b~ry37<a0+fK5=W{9B-(@8maph)R06{W<%Hu35j9PwijM3673!$*h|MG|-z
z&5i<-JEz=N&?-Rl2a^!Ie3Oah^D~(;X9xXjg945tZ6BpY@&1TD4Rb_Jjkqt#=7>iH
zGMypvthy@z&Bh-odio4}#5fjSyXQWj0mKUu@={*OBLHsn5zHX4()Fc_oJ5ybT}EMw
zo;y^{);u9*1uud9nU50;odVnG<M_X6Ym6@cqPRR!W=8kn6SZ{hEot!!DcQp>;q7iB
z1ugxXX8L-9N|Bu(1Bgp0_yk+NaB(rjoN6#Ridn2I%aoaiL|8@`_wL)=<pn_j%Bp26
zg$sV>1P8?1*t@~XuD;Ej<<5fc=VxB_0x+~3eLFtIJL}S91jPyQ3}3rGPygWx5g_@$
zo9;_=y-(=QMPa42P$cVxWxY<T{aC6SoO;Kxe-^^oDEKnNn3RNexU_x^TLU2C0}%M`
z>#hQK_h@1x#3Fq=fHf;~uOG7Ku(!5+NmOB-oPAchl5fIIYfYm9DuYtV^IE_;If|>^
zqcqI*Ko6w*=vB9AFGj1y49VJ{#R-W0w8U-iAL)~*tSvxT7H%_G1xMG|xh+kXFkhha
zxR_+fsVQ>{t3Uc-2M2Ohny&2WUJQDS%xrfm<iA5d-2?#}FSDH25FhOvPj{7Cm}Bn^
zD;W8noM@+VW#&V^5XoXWUW>dloBvdNdWChAq|sd^h}^JC`shVx^gb;#n<&O`ZEGzz
z;QX1Mg#ecM)Jv!~*1%<}x_nR{ZI&;a8wXFV^xiXZTEUAfiJ~Tv#gyFrUDQ5iI2Z0M
zJq<zi0vqImpHJ>RnQaB0oMUGDNQj#Ku;kCG4i#avfmzb*b$@YHp|n!d%KhF)wsN_K
z)V}ka2Q{f-vCoHxxA(9?{lnAat=wki*dlb755sTTU^6LcTw<~|!Zl=9j~D#u3fFmr
zWbb}>Z(nzffiIRajvM|@pudYG2aI!58$VR#djP#A1$kYaxbBN^*!iD!*({%*2`|AI
zKe!s$wQ+^R<`&Td;EsHU8VrY2RQnv;L~aMBRD(oH$k_(rQsc)N?I8^I9(idMvhsBi
z(-AI6Yrck$NaG11@bpc5A*zk_a3V-1DRMQDnvvPx#?sC@E9x<hd<9{HJScLFYhcR1
zb87tSP|W=N9lEtKEs<YG#NB4Q2A2Ev$nq%pG4I;1L^QT-#AWRuVmQqdBRIyDU>%>A
z*<l-e?=b#6lsIYcXN3Ho&GQNsK>eWBlNq7_jnn+B6_@*z@5{CvX!y9#un<d~Y-#51
zx(z!-ch?k#Aam3EL)OM`U$w7<aVG{w`^hbso8t4IwLi5wyLSbMCPAp~X6ei0RV%=W
z`H4QYp=i>uU;%OFM@gghstlnP81l2tv%mrTxMuITi)zMK7r_%ET(11yh@|tioOKje
zb$1XeW92qZd2qKQKZavmbVMSpmZnbMb~!TBx`k{*z{dR$!Z6IXG7tY<xaA|QA4y=Q
zr&6=vKMsFL%**g<rdidpe|Juw&ss)<cPW*eYrxPvT|4{I*yjIel+yASo?J+sRCX`x
zD653Eq<!Z5l)D%On}QX9Y`zjK8$jptLAM=27dhV~Y;g=<9q*eGOgbkhu9<o}aD<bq
z0Z69@4v+~#t~_yOT3or=ke6kH+0@Gl1IAy);603|y8?^MpExZh?uCu_+&2`zd2!}6
z6gKfVZh$p}>HqXlw*%|V<vc_xZQb!c_`qmclf5j%i*OuElhZIXZ~kE5@hU|@EhME!
z=Mic!)sz1kb1Afp<5sL&yX-#T^`LHCFub@_$pckW$xar|ltPo8@sp>wh~P*9xm<zb
z68{H(bw-^MezQN`@W+hI!Hq@;wY;SVSf~vcX2Uf#k@gnMS#tYtmmo8vcV!uhDYI03
z1y0rPN+)%Jkp_}@nd5@vkmJ|X(-pf-OQ1+>%5u}GX@<4&^nm(JP{a6?=D`94@sC)d
z--KrK76T}{g%5Q#pJBQcV>Dt>Gng9-8=fIdj`9rtbu*Ing^mfA(ar>`5aS{gTQ*|n
zzi;-s3TqnF>nk$Xmr?YfWSK}K<8N=IppEagauSWRj7H);FnC68ONi|W$#6U++#18y
zlZX!H>~FZMSTrq}8%^ilE2iFHZF@rY+rT)hQ^nu`2j_ajL{J%k<aP2IH*U(m5*9pC
zM{g_9a^ICw@YjO7s_@<AVj>LKO1X3ayp;Ghyx*H|uPw>)56A~S3^M+le?8bi$7XJN
zpv&X8?m8Wt_W$4+7HgPa<qMUZuD~O})^|lp=?`GeJs;=aBTuiM`U{_U5j!HxOwKr%
z0Xf{$-~^Pt&U`tt^5Q{GXwS0ZsO(ldik!V?tYE4KP)cg`G4b1%c1{pw{9#tgYt-GO
z>yleC>sr3sO{<3Bs!=p{c`3WK7vv6i8RF&;9y#@TVgbE3CG}nk8mB5#8G)K_nFBAA
ztSzAusBAI%&tFOq<9VF_cts`L(q<ok1|FDXY!UDb0;|Jl3lKxLYj^I0j%TKGGS!4s
z_n)y=KpvVI!oyK@PT-vb#Lf4CP*g)`^gR$xn13BAC{505^U|KqdyD4sdbjF|KIiD%
zK5><1%K}0wiy1exUok57L9VX`T7M@`zfWw)GTfQrHY!b2Jl?pm9qFr(Fv_3{5g%{K
z)Cw>>ef=cr0&6zy!}S{kbZ1ZVD-Lnm;vZ{rr9!_G5pI07EHgE`svU`8S<_nDJOckm
z@{#HftpG?%#2M-VDmFBOAAZ3s)x%ea!K<aH=qE6p76{{MMGK*C>eJ!yfBGc5tkYEd
z!2cDo2CN=x{0RbZ0${k}$82n-va;VX#%z1Hq~0K@KFQE5eO<N}Jsx#zY$|#g&>zIx
z)dPF+9<4@mPM#Enr^hLCWc18%tuS(sAS(mb6w1D!x`@m2d2D>?9FzKvL8JCa+h_iM
zi3O&<A;G40L>{f2TN#e#up#I(I@9g{Fv${CmBi;+eMj0-*fWS)4T>sMJEQmiHD54I
z^wJ?xiXP<^>exvHRobt*xS*P00}g)<YRpQe)t!e*E17<xz0r=W_#Si<c<PwGL)nU%
zy{(Foo#VGUIWjpvS!BiheYJK!wfov$>vwga=z)xIDLktWTxOU6@?H_d-okAs<Q_xX
zL4Wv~2AE4BeL->56)u$o?VBtY>NR`@Z#Y?M6;_{PcBCqTu}}+K^4EjFUs43-(|V3R
zhotKMVXCPq3_QKckeiyWL;EU)kF6*XUw_q43Q)<4y=+3((Ay8PBE&}{!$1qIN}{XA
zUawY(7X9u#j=>Y`b2QL$kE!jL4L3CsWlXT$Mym+FSrWN9$TLx&B!}gW;dP^La@n>C
zphOGSgdMB;-r_rw^9u1nM9fu)=5Jhk<_Cn>oZo`n8W&z9k@SW%ThhQOoYNP1fp|<H
zL!MSG{!c$UR}JCmX4Q5+)lZ9E*zVR0suwlcUMTC(nR1qGArE&>&0P#}4bV(!ab?un
zSx0>0=PBIy+0kEbdpoq^G{l!x(fs_!wC)_%R(IcWRH!%5-3Fy|wYA<z@y*c%&N9=S
z&?jN8G$8}E4al!R|EHHMvs1jsqYynb=Tl-i^r`zxy0S#@`e9o&LoEQ?ce*E8&ydyG
zNJ2vNSq>w}?^5bdM-ssGFDSWHxe;Vq(|`D%pM+zC0P>TQg2Y}kSOC)rf7xPu=X@rS
z#tX$A*tf`~R$lpTx-aynN_X`w%-<dtJh?j#v<fO&AT-}SxW=`;+X{=p3`^?eWg86r
zo|)T`M17E?RHChRW5}H|U<wT$p_&ZpWK{dW0X_Tf#kTnhm`g|f$naU6LuF%$9P1eB
zFggf&#)L6g04?F+qkKFiFrY@$$L!khpPmQj(lZd6BkU<?WZv#QG~#GA*`m7!#uyT0
zAQ+P=waLdsxzZrw+wYbj$?$do1`%oRl1est1l+7UR=B1eRpEq&Yf;sLE+_rkFr5f|
ztu`0IGT~~%Si<~ikb{xlD!Ox=E?Dn&`8*&Pbq}nVh#+S}gZb-Bd84J%?ln8P<9@!B
zt>@t^^%^esv{~wA>NynKIs2XORzixzW1C+rtE+2lE2`=vNh%y3^kngVL5~2a1|nA_
z@t`B?d&`YC?L@Fmyy-Fw__8q^5|G9;YG41-figD@`6?Ox0hER0Y|`k=k4!%X8~a&I
zk%CisNzeKB_Cr!z{;g0P?K?ksJ#Sue9{AE1zKyLkW~TJ?Nk8O#DDMCF?)p&;wjdld
zrtm~u2<wnn(RjzQq6E;2Krns%5*PK%*^0Z^0aSrK0I1SiSW!ZL8N~}X32VOKd~VHN
ztmXcsA=>qwn62Iqv@m;_bh&wtI7q{t`-W#o1{i2uz5O4dQ7BXxseusWB|d69`z)Wy
zROk9R-oTvJbZ>osP#I}T7$9jv1Ef77)cjfYPbJ-|U}3;I0L#7N>f}?G%*c}DhP>_n
z1A>IyS|r!ywgC}-3)1yGoqmK!;8;^H5_XI077zCkwe;D%z}WjazXCU-xp=p1a3Hn+
zanuQ6xP%XB+`CYE%b?Ruc6;u3V~6=U(iO*kCH16%(G);*!Hp|VXHKOLxIo6?qQ!oh
z!C^gp0TUK+Turf+B%!;cXW}Gth&@7+{^~7cUTyNJ=dnm1mYdOkFZMz(Xiktpq!Ry@
zUWBmU*=P4F0NbilpBv62P_ZN9)I}9KqHAA>4Vw29As0}cyFXb^VU0?H0{_|3mRS8A
znH3zbFyjAZbr%tFFDi5($tBmG8B5tVt!NV##KV053MfIN4~6O<*ZEP|S1~ACNfe{k
z{($FeIo<g+R2yv#7GV~rfg3<z-JeshDGg}R)D_3XZm-W_i5#=CJMy4}h-l?DiQcbw
zlmDS7sBNhdh~=sajei`BcXZ}sYrF;b%+XB3vwvfnu3A!dcwzn{OCvb-)M8bRZ&lT^
zB4)9_VI2Y(y<`JLHCQkJ#OCk0utQ)oK%^EpG(Y3jml{mKm_^k0IP|z~vP@i6<w~qb
z#d!xPzCZEZvCbAwZv-|3A-q2Xjd|O#tR?+HFw3*+Im7xQ+%u5#gnE;L$c3G4OnVUz
z&N?NIL2($dWkcecE#X-2*O7vi>FFyEQAp`Gh~<e0u~D@>9Oisf0@G<y7ecB+IsH_0
zz|Cz{C!p9aNjtQZ6VZC^LP6PjL<?H8?_4&4n-+E%Pzx^3DXfiQEP>cdH5l1K+p^<N
z3R>esQ%ZeBiGl%XlcN-QI{+^JbXD>#{+;}WV}$9s`ZjD+9fk-+B-bLw?Dsp2#txXZ
zwY3Nxm4DcevckIH&0d~BuOCaO88Y&|d!IYSw@&vAbW!08GANg0Sys~|CZVm&b_-o@
z{{G_U>(00MZ74w+%2V--3RqV8#B>VO74yRECxPpVNRhU<dfkatzfL?zSkibKXwA*w
ztfr54u=_kDw%S*x!<=*9J76500#~5$9%qDckc&PL{!NQOCF^e;7TSl?Md45jfkV@O
zGOrR0Bpk#yC9QSQ5FIo@@?fOkQp%_6;E><CSVq1}><h`2*v-Y!pJo1&Z+wD`oGpX&
zCzzK8G7h;n|H~UK$bn;-ktg79fFwkWv-Y>#xaYXTCtMGbx;sI?dt-j?u-#X$sPm@j
zj$OQvCR!PlCL~q#vK|x}0!^8gO%!GH5+|slW}n_vNh<bdFNG@lRb&>aKg>^38P(DN
z2YuX_<QqCUi3O)38?fdE-BV^}YMQ`Qis~_V<Z)k<73y2uf*5FuGr`DdQu<D5n{wF|
zGpVyXnr^by<!o?m){a;(*6P%^mimkLq2@uEGF}mOe?!jpo`eF6SW*zmhf?TRp>H53
zvqvhi3+@5avNB2Vv>XqlHCkKC3Gf~sQ*o0NW<A#8^>dG+6aCuB;Uagfr_^*1F%iy{
z#Z93ynLkF6Qz#B2lej^f1~a!AdlG^r?_(pXA-{xIvgXi1LfFq4A+Y@mU9@gq#QOiR
zaN(_PV@tWMki#CkB->wE7y0ioT3dcbjTP_UtwN^zq`$pM&!Z2jb>;Y-ufxmys%n8b
z`U+-TzrfOl4$N1nIuSs_))oJ{MJ;M7Q!`EBW*j4GQDwem8WjFYDJ9q6^oA;}E5u4g
zdam*+S*+uD5m0+5zHjrgx&-lG=)!_V*FCiW5dfTV1<2`|iO#YeDsFp^4<aeWgpw<4
z1{X2zInp@#*d0XbDF_Reb%ertbg&L_IOi$viQcwDm{;VELV-r93(3)3CAS!(Q|4IA
z3R_|7Xdb)<EG0wvzZ+Bg)$QPw(wB33HEcqMtMnQHefrRFq1S!(#)&84jpeGSSmdjT
zkp}?aNPjTZ3$!j%HEobh<|sL-!?WBU@cZZ65!P*lrEnkn|Fk|jem`I(WA$QYd=gcE
zJhz32L?V4pY6$IU{vBWi`xy}BsL1gq3wN86P7p{EE=m<=2J(^OM0=w0{hiR-vXzmt
z2~I7;S|J{_!?gli;y)HYE16}`BhPt$8-ZZ-sJ6s{zAsP?c%7n=g?8{*lls$T_HP=u
zo2&P1XiMcl4Cck*oRCn<8nX|6E4_759nQF+#XoPqIdNv`ITZywsWw6rhE~n*p)N)q
zSv2|Z0%0wM?W}UTs(|!QmJtSA3CwC{lqHA5V%c#p5EDgKCI4lb@ta#u32nHBsz?@2
zg}`9qcu`*7Lw=Cmb(L4YLJGu3c*4|8`z6eXq=-4zTOjzV5qZ7+08-^5EdN|WCXV^h
zlY%+e>%ur0RVhS4!+mgbme93+9;r9boG*YPN)EDM3w~&!!An~hRpCO?1^CQyjRaci
zNgSP7)Jykleg+H(KE(B|_6dKNZ$B{%hzQs+OGLbG>IPm^=W^{XHqu#~Hw-nqJL85U
zmFFe~u3uL1>bb12U9Q=`p(#89_gC+97d(4dT-4N-9%g#?DC<|B-DD`6rzvs-BjD*5
zMnUxJNeJ^ZR=v^$V6TM<Wx_)>xN}%}D!jhFyec50hJQyQ<`Uo4Hr`)42Z;XA$TxWr
z2Yw`C!?G|%!k*OFET}n+EUk`(lpaZ=`~;?+V&Cp0mWH;|h_bquU(Y;G+8fgnrQ|%#
z-Q-kfK_jtJ;_0u5ZI_|oQflKMt~Me+>hy_D3))p?gq5QDnu#U_W{&2=YcCQwSt#N4
zsmkSGwPj%0aOV5+BjU(|4P||qoipn27v(x(tbNoa+A83`CCSc}V&6S_^I8+-=hrNw
zFLJ>dOnqX&5=ZFVkV^#8bmTTp?7aTlM5M|fnV50RqE_zW6y?bFwj7IS*_Xj7pYTUl
z=%r28ADOCO$+-Ys$+y!EEbC0!7;^DFj}%aXs5~Hmf6=|fJvu6>b&nqOQ*TjH$Mt6}
zSEsrxLd>R*4wZ&(S4*DvvTf~I(w2DXJHmqDn{GqA{D5uS&on%O6SFJQO+Z*(qnRjJ
z(nsYFRne7iFa@Hgt4@bf!G4?mqt|O?!sR)y_o^H-B5j>8leEE5mwnX+Pk3TrHbKNw
z9yqs84J!fn&3d<dIy6Bch5O*gA^~SU;C#@S%!>sqj8PnqpeO-xz?v>G2JaGw&s_nV
z9lhlx_Gm(s5HK+Z)h7y5F7%{jC2)n#vI|;I_!8edN+S1yEPH{`jbyvj$n{hS{=Lb8
zGtwYP(h$#GimzVgYGbb`FFb;OO6lk(0L;s5b=2Yl3OI-|_rRDM#FhsiC`i&EdL2e0
zLK|B_0Bk(zJ%cxGy_e5OW|M2?zZJ30Es59t%=7NS>wpol=+kl|C0jO}bbR?jK0tgf
zlOf9}t4_8zewNRxrR`R3ylCIFD6$ow5?rP(dx}_a<X793<4R0@x(7gqa7)Xtm7XKd
z0={$<2p^+zfx0f27{dQ{A1|4$%T*x3e>siBwKNkIwm$<C>{Y2{Wsve}+xc^Wnm5e)
zgNe%nB=@k?nz23yZqZ7fuID=QSAFe6E!OqxtSk=bhbQ|=Y@cSy5_B-}O!yYUec~`}
zh1E$TOa5PyYeYV>muTN8xrcb;%KvDTrHGh7gahiO8+=DdeyLl(<J_hyA|<ns(exAs
z<jxR`fTTbTg<ZNlJEz#<sU>$NcM^HFtEtvtZJ1gRv(xx6)PGT_^}GS{FGx@;tL-+p
zeH<O;r!0?}VIlDCgqj$3%Q}pdBnppFQCLLAs$m4to>lj?YJH9woEfsSyB+?mVDg?L
z0-;d@Wu1G~%j=VWDPASh$I^TD9LJv+R|*BT`c{`Ng0~8SayQaoh-MU}iYC2nBlftN
z9Xw83ZGCR3y|TieYJ~!#E+Ux6GhCH;QxU#Nro$!4by`O#`iDU~K>^RFLa_$v(hXs#
zMsFQesf6wD>uo$n)2+=q8Ptof#Hbul&SPlxek94-vL}_B0bzc-?m^0kdF0tha-hL)
zCLy5?1r-n1g%Rktfx}<xRDxEp1QeWFNlFWz*isfXBF!X`Y`R#QCn7ki!S)NCPG&u5
zo#eBt4}I>>q#R#8-NTyyx10sqxB0yQUU_r%{I+*}E?*WK96X70W=b857^95&9gj^z
zT<}N6{;tQN7W*KS6}AF&EbJNY(1tz^l7BqqT!rt<F+V)eO^`f0e!t%M$t^n@*O;y=
zqt&F?O0mxEr`jhlt)In5&yiE5b<p&g0)snuuRl2uVc+yjrbFUZ-2K=gFnH*Uch+ud
zt_iXvOj9qviu|Hw`_4%Eu^i?5Qjh<8TUvCl+|h`+zy_AG`$ysM)uQwuu5PYq#*MPv
zCvEmwovZ?IW^QY-g8G}lW82mivm6+2;XIK@auYhpBCl8&fU~Lpv2j3MLsUuv>0EA5
ze>#-Rry0FWGNe^#0yoNW+iDgO>g-poxJHxC3o?@~bDYjgW5A>ZUyWmv5k)rwamLrg
zT?(pQlm@T(^5~f%PMQJ_mYVm&<d^}PfdNfdiZQwyU<TpM`v!fa&=D!)lipmAdR$ck
zuG-Klu5!4a=a9G371G!P-D=L|1zDZM7k6c77G65)T{CF$Zefo11tanl>0svCKRF~k
z41U?2TjksE*W{xtETlDl1GKp4s-TN#Hhvi;r8YOZey|8NC#r^<2H#I^Wu`wymZmjj
z$i%BQ@d#8xxuPy-#r|LNyfo(;J^Ec34~&j#i5}L+LgTYo(t-5KfJJ(xdZoP8hsdi%
zT@L#t#nHg-+{m}b?OSwzP<yQ0?6_eiy<y<<-%Ym4aowo~_z#mQM1tb}*M%BrOE36s
zqRmN$F1k5|C^d$m1_VYo22D(^xQ^&wa~ab3;%5{xKN{E%(r4T8t+X%$JwgbKYWM5b
zbKo!f{I!F@Ipbd!TMctypxFBDV*sAI>3QYXDqUsDDyOCU`JYE|=Zv9%x5R$A08hbX
z!r;U3bDoGS$SYM=1qR{UsojKhCPf%;O|Lq#bhqPrPEsarS@>;$rxu<xh~z-0OhDZt
zFMq|NRxwHaE86JOaXeBu1=6o!vN)>ir46bX5xL&o4V}n-Wy$ea{(TOO=2nQQS?YDQ
zCKJp!7gaRlA;ISihkRs*%U!zZ<Dp))OiigkKNyh}`=2%RtUpYk`#tHF4q^`?er>QV
zMgjbJI2QYoi*#+cSId?M3Mw=|$1R!baI3K4-<6=eRFxB=Ls|bn-(}5+&#Dgmve-j<
zTQigc&QOTJC4orTpQlD`^FB|hz&b*=M03=Mk^HTA3NmH{!ELNfMIW@TfwcBWEhZB&
zSpsv_Y_;jN$#BlhyWO~4x{wLE!I!ZSymLQgjleuSvqhNXsPphS!{!7So+02ky7dn!
z?vln{P`f_<_%JBEj9MskZ{au!azAT{kl4*2XK9Uw6Iwf6#8BVIgt8BIutS-L#_Mbv
zO>02TX5{s}(*t2aKdvQ$U2F{Jo&;QZtN@Z<2ntniE8<fm@q!JbEnX<M?~gwti4dD@
z7VKNr#XYdrW|&CS(RfR$gy}U~?EDHr*otfBfidb!=iJM)GxyT%rt5NH+Cjhf?djb0
zGUKji@eAUAYd!?CP8Os%OEOg2YPyw?+Ay^WoJ^~!LzLHZv}Tu?m5|5Y)1WSY>&YI_
z`#sc?cTHJVYAo-4r(j}Dw5mvxJ1ZvjAWX3WLF&ss>f~nvc@vUKX^=V&8pt+_Ht~cw
zX&gw`JjqNAGiuVIk%o?TILFj)@!9w(N%hSd*rz;JhCVT|%@~xE(cfCLBzghxQ2TmR
zFGT&)7YKj#t1(h@YujJeukPG0iKX`M_Y{DLb&*VNN#iasbTC9{`!G<kWIY3{@3u<o
zpJ{IU5nfC^nSGNWNF3QXYtA?>8^}HaqhC63?>nx$QSY6RgdPM``;IW$CNO+<#=Ib_
zbc%n7hmtu80*(U>TU5_~Olaqkim`68s;!gxw<ViYfqIk<3{dlZu==Hmp8)s<nMxjV
zbs?Jsml?m`zsbRVFMfkSygm!C8GjUC5aMkttHy@3=M|hF%U|tGGXduJ@J#>i>qptH
zCY#8-qXcA-P&PGd9)n)%9=Q9@_W9JXr(tmXx5^qDe3YQ9;58ri=27rpx&#Bt4n>(#
zL_uRQ7!flm21~(<QKne5Y>QX|I{y?=A=xrxgr><_At4%~tJ!;8wT-fcWkF%dy#o%s
z*ub9E;m7jTNO#F4snM};2I7=e^WNs0(Vk9|J9_0tVHgph1ieV}UR%^qk}w;AzuzAi
zHeXIxj}f3f*l_T$rgcX~6)##G?0-8pL5Z-|zknyCJdq_3UAp0rlKXijC--wEs}!ZR
zCAr?>@dFQFBQ|?|F|alcT**HZiUrui5nSz&?kK$6-kcC|4IMy~@!RkKdSFDw)(x1b
zA(ZT#!w^6*7OdE!w6?1J{w#s-T{40~Alen9w}ExDhW0nSlJAO4{A$&(b{_SQ#>2mP
zuoaKyBrD0^BF5Mb+H;=S9+qNcE_l_C3uQ>+N^|{$@s4!`fW<cDIzb3kkC$8WUQcD;
z?qdt&Iv2HVgeGJ}p>`>q@8-(g(2T%T5+n@Gv7T0B;SG(KlNh><`JF6pg~}aDkc(c?
z&VSdI$USKR)mLjCuu$L|J{w-G+~?QL>sAC^Rh?V~aQ!@dAV~f1R^2xVU=>wTx1)!i
z4@uv^M)bpWwT;osICfOI1Fo0@zbG-9^^p~Yvqanvd}GvU({<~Rs9LBTVz6kU6c{2H
zc$!Qg!u$UE0nS_&4zcqkUB1Y7eeULZ1!V%yX;93ac?=CLk>HDWmQ6N{i$oYldk7Wx
z_l~YEECE{GQhp_w_=PJFy=4Ly8<emfGzW-!BFR!(N~yU7rQi>u^C{A{qJ{&~q9^$0
zW>lPtORirgng~vJo_a<ULjjyX>wh|2c<%YAsn%Gqa_n{z2KzSSLVc|UpW)Mk`S&Ay
z5T;9NlLp7!g`F6XOnBcT<v6JHMO66fTyx8Xoo1D-7U)a`8WURxKp3n9i+TT|sC=2k
zf3NM%a=T4D>;2W7IdKipWOw{h2d9^F_`etE$@3_T6bqmG&M!pjqbDb{@F9Vkr67yb
zzv{j}KOv_6ki9B?GiJ)_6^~P&@bEBp^^~iVF{0ki{74^9u{63nUkFEH5{wY^ts8<K
zMLQ0Fs`aG!m_=qT(Pr<C&5&AuBJuW^l7k!v6{qM4Sbhs*CEBLR_VqUI{HZit?O*!g
zc@Ie-y+gW9nV4Z*jDjgFxQAQv&h*XOBQ_PtwUp4sL@c6<TVw>Szw5=yl}3NZ4!YUi
zS<-aFV<`VLv<$V5yLaw0iXYRohU2AiV5BFW04cs0@bCT*H1;oK8aBRZ@4mGXLS{@R
zSbzHFRahe^HWJuZkH?P&=ymQWjJ#Fnpr`dqXGH>BYkEP{%~qNmXp!9*z?2<^6l8_v
zSy3`g?li%u{0}2*(*sQ|n}?PpO#$hCK<B6pFQZj+7Ep4p6awL^V3zrvw5XI~yF)K$
z_u=48eN+a(c<U7?eX2Zm82Et!O!*}^02keHM|9?1HWEHW<?<l!<=y@Pt4!Bg?4v<P
zW^r!7(A-?yRZryu2337m^cqXeaxi0%oI9|TrG8CUxYX5W=LLt}+Z=SOtu-b>KR|Hg
zPcu?Lz0%I{O~8>0q7c+w_T~@HiGLzB-uFZ^e7KY7$8#2h^Lljmmy$RzT*Iwh5bg4d
zw$-QdsfFSxTT_Ng=eq*xzgPR;g>#e$Gr;}Qp}vo>kN4spALoV(E~{GY@F2lbjC%8(
z3n1Q&C><bd_>~fh5$ylC2_HTa9H*%EdFJZW%+D7Mrx1)pPHM07exhdNN}qefZQmtY
zatOB=0$D$kB@oc*poLrr<y^Iw9dK6uTG%`iC7SKWs;#m!r{j9iguc;#`IJafN|!fB
zKhW6-uMG(Nkva49RzgJXE-3KrCPVZ7-rT(7Jv1I%&8BTOdO_{U^nSongwT#a_zH5D
z{(01x|6h_>ZRc`7fh!@yV_Ob7)bMc@p4ZXXm39t979>uwn67X%^l>|BIJDwk*enNi
z>=`y`X5>`qCKm>A9!4f}EX6O++UXt%tz3YKURzOpZR4|7ngK=ZC$?iwF>Ay6etI=_
zgiUU{oy$5J@`wttzlilFIQbNy?|KW|i_Pfu`AgY&NVl2PU8syaVIh>*q_if4LH$o2
zi^hc3XHy`gX8#>z!Z_eUX|BsSX8noFj^o8B9HhNRFy5+P4Po;&#gLJ75kOkgzj{JR
zC5K`w^Wj9IMu*=UZ}Vvb&#$ka^RFz<I%3(h<@Qz7jyn0dJx#warW?vS6)AqRcoyRy
zd_$TOKp1jb?r}jm1G6~}CPzd-OV~#es~9s$#adaONArcHxTdZ&rG+t6JtKBwz+x2C
z0GG907Z`IZnC#!o@?z`u&+U8~C*65M`}Swc-u|Ldz<k(glk~8G_&Q5|4YlL}EpZ4&
z7713rYH{##S_qZ$TB>wr?IO0o7Osm<=mE#L+BN-hI}lBnksuSLz<=2Hamy?o`^Vr2
zb0=OKRg4)*z$yLk??vyh{%`@{9`3rtI-G+tR;uebemT#8GTF@T!C`=O--w3AZ(x53
z@k#Ga<`>LWU0?hDRq8Ce<l2HNq8mQrbpETEg`ATSB~Op9*e}=NDE6=z0cp+vZ@gQ-
zGaPHoo-2Fg*09&(vPkJ8pZk0iB|wxnvv60jMaf*e8UyP46m1zmjW+s!p&>f{@l2q2
zpSD`)CI`y;O$+=>^ut(TujmV7k&}M6?B0!oA<Z_Zp+<vqAiOSK%BZBFauv>bEebYo
zdQfO!ZlEa^FXzg;DGsYU1m}1HTCk=nE0+mu{MRZ<Obc-(GW4uW!~eh3?fOyrB3hl_
z`A^69k>CvXu<Q73JM}0Ei1gfaVc<&V%61WH#<+5o1KX;#uczb8ZTY{1s!wKU(>b<C
zlf$Wx9`}~>MBoR(zASZ6(8#*m#R<AM4$|5E_d0<$vNx*<&|OXdHMRm_*_f{J2dpG#
zwnn^YZvG@HIqiWyER5b<4MXMnCHwcT&Yt{fGVWa+qF2@`#s4dBjLoc|D<E$v!suUv
zG56rj7e8`*;YWZFHtrQj%57cg6}qNac6k5Pi5oo(i&`GN+dy{Djpryc!<nPO;;c<B
zl?NjnpPSt3A-NP74+y-kp+xRk--jJ|_BU4fv+mPz4bheJ!eETXT`b#GmI;un*!@Q}
zD7>49B6GbDr*spM%kT*RmS+Yp18o~P)=rTGplA9108*?@b_KmWz#AkFW2QoilqM?+
zURju26rTkR^a9q1`nQQgn)<>5Im_xVC8*t(bhMvpO!qz_&dUPUgO8E5)m|Q^m7%Yn
zG(6jpe2$wO;Y0M@a6DaI#|#5cQ}`50b>3!!TNWB%?Bm{6!1M~xei(*^1>y@iqA_kH
z=7{32z#(2&1Ir?+JGa|iuTvY=ekVlO8wfU0f>^7oPd6Hj(9+JG4-lk>answ0S{p{c
zrBYVnf=Ye6&w{sy=05CSXPk8q!(|wqo0Y!mtXE!akyU}5gLfD6F`aPKOGVvgw5m%y
ztTpn$n}wChPuLY?Yuq2krjmOzAB~cQ=H?$i_B19|mj14*`WLGfQ_3HXJD9HCWC~q_
z(Wy8b*+c#^smx3%gnQafi9TASYYCq#36`bb{cn6e)Dc~WSSvNW`#5dbA`0D)K0yu>
zM;o27spxh7wE>UP#w7?q3r$}XwK|CnrLiGLrDPX>Hk;jSnsk97d&<QWlU?iW0d<WS
z`2<3z*aG7cZ3ib`kp7s$C#cD}PZd(I1+|#u4c*NCYHW+}nu}f*pw&KRbOYQM@$sRi
z%MUwM@UOd`@@KXe%et7Y^FHlo|D=!awa>%&)*`d@Er(YydDl8TYFVtYO1kwNQ8@Fg
zaZ%c7IQ$7CuG<?`^Chm2TsO$7+#;G^a0tTE#Sz-J*s6-){4%Ph#PGo8FR*P~m$=O&
z@T%%nS;r71RsSC{lWq>?YGef{(oTTn+xasyKi;qa2~xitA`9A4YTNo<v_p1xcWCWT
z_e>uOB0ugv7Ubbug>W!4EXPbQB+Q?S;3o0o^tP`X^;n)~-Zsxq3a@&ImR~0Xw!iv`
zE*FiAB>aYPhXl2LqGRkax(jCgK(=Ji4i&s+kn~1oPe;b~rZajFI;wEp?sfcV@ot2v
z)F8dfE}W+CW^vIFYybfCL~j_8vKA4dp-tOGuxdt@Y$~5)FH<0xqBI@R`r}3$hhGdt
z7DSCJY<$Q)kgUz+he_2z_mdU2l(KQ>h`Gy#G9mB9IK~;_IO|3Md0RTo`(6?mvV3eC
z@4KO$q7AX<$bZ|G=~)s#wpfU_UuhMi2%*ECckgIr7<zVt1wi{{k#V}u1kI<jE4Vdk
zt2{uJrwLjEeS=i_ZSVf@Vyda;N;NfHvEgeykU08?tXSR_WqH;DA;kvWZdOebOCR0U
zDXTImJV6F_kzQ|dp#0tx0%JM&6eyn$+Uj}!4C6M5$p~lH&(KGj|0Rn8??Oc3m85mk
zH(#&PEIBaIw~M;jfa?`fKKFgsOe60QcBnNz@tN$xk9Pj@1t=jRwb+i)0E^{tPyI7e
z|8$^;o3dRP=7o-}r%j^2ZTj%ZOV>Xq(yeX2GYaheER=g{4GTa*DpDC2y~Z(!MaFG)
zeR>G~nkj23#i0kH@W%{ol%RM<+dgS7PrqQ&*@u<Oxw6!b$-bt5m^KWV7d#Do$p{+^
zYb+%Y93-$5#w5cJ5(WiDO9cR@B3_F3(%^u<>Q>ZSWl~ix<Il%ni2Ox(C6WTvUC39-
zDnS|T3z;*-j*-sOzV%EQvykE-g&j+stbMs)v)1*tue*<`MmNtIWHA^c9sptB;kSm2
zx&zFE@rp)!N6eo^doufe(Lt(Nb7&xZvgNSuI^85AYFw#=VTTa-DRpM#Cx=Z*Y#%fB
zfFsjTY1X&|vBh))KIKE!ziWP~mJMN?AgK(4mzr9w0K#U??e6LFu@Sm?^lK8-#J0Mv
zqa<(dhGuS-TeUYfYbFlvJ`eJ(nPb!VJ7`)D*~+Y%$Ly8`Ll#5iWv3*?__NPlQbyVZ
zUxle~dO!nc7@<a(I8DDC@Rb2L3Uys%A;3ameW%M<O3v12YF9g8wnU<TJJkUdjG2=m
zP~+bBseXfsyzI0nd-k3UhbU4I60xBu*P66@VL}bZ4v7K&Q*VyWT;qd+OMf9gpO_u}
zX(9lA7U#tJT0TAm`tpRYLf@}hmUcW%o4xF`3^G>wTH>EXl74VVKO8F8V{)G;>I;#;
zw%12ogK^a~$k8_5y}QZ?vR>O>9yzD%2ym+4m)SV%8U!w|o_>v>d}xL$sZ!W4=j8~y
zt>G*}TXAILykOd};1^rJsR?kquS8rxa2p7mzjA_5mJ*H)x+4w4xM4W?WJ8&z8jl*O
zO#@oCH5_{VEALK@1BJKIZ2oE@qn8sR9n|<PgO06~=zvOKuM$Xid|=HC4YDh=Vi1n=
zO=d07Z)DK$WpBfU$LnXIE98#gARq3?YLQhevJev6nuhwp-rsNBg)Y+MPaW(8@^uj|
znhK!<#aeOhBrX*U<;{@Nbsev4-8y)!S61tkV_sYaD8HQs?hU{YxL4Sb$-`W|-(l95
z6vbj46R>wXM-hHHd2s>;-FsH+3^;UO;VkL|!VRW-mk9p<;MLA+Kw^WvW~u65Dos?S
z7i#MCK`dY7F~1)wu1Zu0i&3^mxOzbvF3#1psY+U0EGS1EqNsbg5@kNaEq|^d;9D;H
zfQGxPgYEwt7XzifPmEyDDXlDcLZB#iJE{DO!sflg8BUaV7-x0~>V0z-=x6kt<VTsv
z?5kd=Z;<UP<C|x&t6<!x(`><@BKHA>l_Zv9tv+c@_w_%M5UT`K*l1Nf-qan(N93+c
z1k<&ttG~Qw`v>`ykl3{+Rz27@-A+s)@MpPk>7RktlPn-WbkppfX$UmSBbC)_Of1oc
zv3!bxdNAU-ncTUA@@Q4?OHWKCtoM|dU18DyxE=;c&bYsud}abnoD-PPereMgt<Bp>
z$hXGF*8gy4#hHAWu;-x7rQ3MPN5sxn5vR3gUsWGmjnd3E5s=JnzOCLlHhIwj9q5TN
zm?Hj3br-dov`-shOp!e53w+qMDcyNHkztemDGt|3)KZ>N&nYD%`l^+FqIC!${=WXB
z34h`eyv!1C{P04sW}ZAHIb|<i)B5SAGA9G@NtLc?IN^^?>As8o4m(hDeDT?>!Ip)u
z48PqqWWNP8YWo*Yc%_-VSV27q>cjz;;}N^Ztpi<G0NA{w?eY8T`uWuQZJ}2acjTJs
z%*w--AM8V|%3quy8O~#u&wEi}yES8elv9p<=rf5nIp4m>3)aRKAiB*`9X(_baQulr
zhSqsU4%v6l6pz>=zDBT@kL9sk_|-aoo-xM-&+cS<I!n9pd_AZjL%<IMY)zFSi49J;
ztMm)@?spj&(?~>MB}!YV+1d9nR~C}iSY{*CxvcMLz@MQM4)x(pN@vMs#Wo`bGc4<@
za5|RAN3urAs78YylE~Po?XC0OI(3#4>K#qhQ)6MPI>(VVhodToKB*`k<+X_UrF%CS
z5{co(4hnhI331e%$rU3H_7g%}3U~TmJUzXv!CHr&8F#im;c?6HjmqpLB+CHbx+p<A
zI^^68$m(QR7)T>+QE0!#fYWgIQ~G-YWu9A>VFQ!RN;lGWw~}6z@vN1?xQ46%jIJ2T
z^e~xbl-YL$jHEysbQajnu}(9)0wH9~?88?SIa|kY#7o&uBT!0Yq&vl7rwQ^OATeOW
z`%p9wk6;1LSjL^SQqi`Ri2|~P^SL7$LuFUQ*JWJDsah7x*fl#m!tMJJT>1J=w4QG=
z0|NlLD#=y7<}<4q=!3t&He$_v*<1qmVd@r1)}PFP;8hU{j?CJ_G^^BxmIX-^KuK1G
zVr37!qbq4(l+)LO9%(y+)r)7M-%ogX)9wO2qZ{5K1MGUyfL=Ve7GdSML4^KlYWtHt
z-*f!bUC)E`G6p;r@TpT+8A^^XAmNMS!aL5yiF7QEhfw^Ur<SnL)oACvv(oVRXK8F5
z*<k!Wjk*rr9L7i6x3)x8JmmP~>^6kG0Qdr9wFnO}ysxDh>d0c}ARl@di7!%(l85RD
zbHrhN2qq_h6)JW5-xqwB4tr{Skb<c?eE2S|Lo)y|K+eCco^eZD<qFOo?g5XDuroo?
z0{&bq<P;F4I3U$k>4n=eq)QkZ0KK?T5<{sMrH=$|l*$iU8+NZdPdj4KvhZF)uzB02
z!VS&AEWZ=-=-M`i_?M|Yh3S=ddu1LYoVo*QGJ=J%1zZ=+Vu#~tnIN5OaWx^eN}Pd{
zBu-)KKakr7W_|nMH`ptQTc%%x%?SbW0q}A?Wx*Ad>1Rz6eci#08sA0;yMrB{Y5!J5
z0>ltoKf1#)q3(vkEgmBq^J%U-MKX18{Hfa!THXyuTz)Ka>JK=OSb@-bJ^PWmUeDF(
z5{gZJ-?i@AZ0hj5rScm0nb=&<O2@Gf!Kb-dS!qRwkn~9~J*0xY@j3wX9mOkQ&jHsm
zhk8;6{D+n-F8=G`Q@Xuac`tdd&sJ*WCf-8Nse_5^&P~sOt;D$21-#bfsa8=<GdnGc
z)w4?Kiw79QK^Y@d6n$XeDuGWcRf?0M6_^3P^XXDACd&A_lLf4QxGLP-o3>TN)x?A2
zwKi}w|9?{WqWKG-c!KK{G_%LVH<uBN4si@EJ@SY;)pldL40W$xgnAu&y*KArsX8i;
z*Cpq#!qNp8-0~_#ewlLrk`@W+BK<|e@v*DT5YbWN5DW5?8%6gnST+sFP4238GDXdQ
zU6+1SFrN<0HB|K(mbZyS+ePTY6#DRd!VE5GKn-L?&=s86#eVMPTy~aNJnHCG?JnMY
zDHl>jy|rl4pSfm$K3JFG9<Lw;_jOq<(b(t+E!UJ3S$psjTr7ADjaxv_`4-Y@<{+}{
z^={p^`MZ@o*}-JUiaRy5tPusZz-@PM5P+}@Pz|g<6eZV(D3B|78$^_R6tLW1GCp*V
zJ8DWKFOx+h6vqwV1fG;Yw~qR$`dji~pd1^!l=m0Em7Ub4!*eIPw$?}@-dl6;K#+^B
z@>K<8?VmuujCpE=D}3jn*;vEyaIqpTtXX{ND_s~f43-#C;)cs(cAynG5^jH&$ccC@
zpmir3ru8^{B!PeEG2PWQFysa#e?9iN+>0tsO~-j&&XY*VW0xEcS`tdYsH}Ebjz=bQ
zLZY3S<~e`jtNW9HHG~Hj=WFoO2QDmdd6=d>0TH=vo~N&OXN^E14ZP*6GE!b+%W}<!
zm!pxQ;@wHq$T$GW_5ty)hiLRe@gu=A_jej5I=tlP(UT-oxy){?^|mbLOjD1~`hmdt
zFpiC6&t+jY=qpXiqfhU~g0I}7x^d+YIg2JwU+1b`8kw<(YePCyw~>bXydW>Y+*sGZ
zN<LRsi8z=fQY}%1As2w)9MVOUmP{Z*_R)P|FqE{y3*-`$WN}p8y2jJFg)LUbB!Lho
zLJ*+TMm!u*R2bsOKfK|x-H|WgbLqGf_WfUL!O)f}Hx=wSifevrDLGmz<ehzRr?8<M
zHJL(OtQw9K>R5E4{oIL7LfGhUTFtV+V%QJX6}N44H?E^s=6=NyycYuT*{r~`q0XL3
z)wbQ45e}q|%K78CJC^pQ?g<))iJKZQsBlZi5d&HvcO5AnTDvh9crQqH3(*QWNb$cR
z7Df=yFcx&qE6-BX>Q7g^qVVj3$7Ac$%!FU@X_|qkX7?Tq*z~$Th=-#K1BFLg3GvSb
zJn-4MBg?-rgRe$Awul?gyB~H(W2?8PNH9zZ9o_fDux@xrUD!{<U0|-3nNmlVL_Vdi
zm<&{99tm)dvXi#^#06iZ)f9q`Z~|=DOf<BaBEo=rk{6|gA^AwEqf0wT5A-eYF2<BI
z1EMHARoEP!3kmbvxn>h4lAEuu31OR2>9UHkWUl9TW#q;#q_u@VbV&aP^fMFWvqopg
zLw%DQtuwIC34r?jWI!d;kVzFTlZ)P%VyZn6=a#`3xpaWdmc^?cH+o)bP|%9z72IiI
zg*BW*y!RaSh!9NduHMAzjd@Tje-Gp>s}Y7X2({b>j7=zUCCJ9+Yb;}&1p9zT9bsXG
zC!Vd~J)Y-?FDkHZrLYMC=Za?)=)V)5tDjv!eZk!&Fi?&+y->1cMw8e^saiZ67&J8s
zPVqU2Vn}SSe5qh@*eJ=tW6^u0zYYZB3!D_?FXn<KsPHsi{&f8^)D5+tX!dw?rK`@$
zzV$7D^bq3A-W6k{_t~)@&sALIR~OWRf0%XEmzxj28>LF{c!vNcekppPzmvks2-#`>
z<S1n*9X^|5k66{f{6&&Dk%5s`<VVDdwO_-Bc*Ip5mjHfU7e4KgE(<=r2fD545zB(c
zZ8iBxBe+@^qAZC%A;Q!ri0Ike!Du2Q^O`yb7<ky4&0cgfe3dH6W5I06y#s(3gAVCc
zE6wmzHPvJ8Mc6tC<<OT)(RKS{t<|x{0IK$ALb)b)a`B?8X#6QAtMxoBm-yzB$gXk4
zt48EO*q96X#qV@Ncvz7A7m4e&e@8$W8?n}qI{C@?2Gpf5DNYI^=;JWIew}dPJ3DA7
z(%|t4s{4(hxx=)un~v+f_C#G2j)lS>0xYO{yskSlCgd#s*~t6vgaO{}>(WYE#ZQo9
zIg{brdW7E{)bc04)6-(Ngy%`%nUJ4EmA*J~6u>k~)qV!a(q_f1%sre9v*4YLn)Fo!
zxKL)&RVi8uO{s?^S${VK)oas^c~2QVkh&xjG=WRKwR}9wu|K2R8V;-1naiW`6@8n7
zTmTWP=yD!Uwd3j+GrNFgg;FWjKT3MI%$!wvrqOL;9s(dyi5P%df+L20)1*uDa~jlX
z&)v@s*(-%>$sc(vN%3o*8r;+6Y+B30(4HllYdAeFTN#x>qJhmx4Hl`9)`z^Vx<mcw
z%fWx_6Z0C4_qB%Kj7*|d^=o{%W0W={#D(86c=I<c85&sa89imwp#*g-9g0V{_%SIz
zkLAP3sSQZR1i>4q#9pKoxV_eU!3&dRaw%IspuQJk#7Z<0tT=jAci2(trMA!i*y&me
zy`92&{tlKMWI+KE*Jpdq=z+V?-ADm?5;`o@JVjI}yyh^t^%m*B&l}ItUdpxvaA2YY
zimsM3bnbY<X7nY=XDrlXMi_q*t}UhxVor=5%aVQoUV9RN;N{#*bKP+*_CT^R$Qxw9
zt#lu{*))Za(mZ#hw59j&ybNh^LZBhPH{c1lCubLhUteLjEL($gzlHIRcFZM{oa05#
zF*z!%TbBE4BgXqjR0zjdCZNaCCeLznIbG<HRnRXk%S^s0K~<DiejaYzh!m^*&M(&Z
zNGB@!-VU6M8+mOIhD~433&@g50?GPw+{=wIIKUgWkR%XLc62N#HW!(LlhDn+q~RXO
zbEI*Pd$lj)NC&~A%Wjc=Y*isKJxA4iW{sDE$Fg7paN}ev9ky*i^s8QUt+B(J(YxI!
zBPq)09}_%}QwKexQUiT#D@Hs`Tx`%-JQKEDG`n35uPxg@iEDT0#y8sesCS-fvr}l!
zb#n?@+5j4R<O*n5fs+tlL>y?IdVLjz|0kMugg3!z6-&LoUU(a$pR5GOwLw9k`_8U|
zi8|uWh>-uZwOw>F58gx4R*2Nk><9GB)t#2^B}AqtWsK^DtZUgg>V>!LR&7fCpGnEj
zUH@cH#Dc`Z4#!qkbo^Hwq&7(LK!v8|TVgQ6<FwWd-chsNUhbN)M826>$<KR8@%q;T
zf6%G5f~ot{yed!2c5FD`$g{uIUdVvn%L)b!llu~8H_n`tyWA12O$8s$4Us{=>ycp6
zh>Khwg*x%n40gPLiZC_rrf<C|EYGQHc6&W(>#^5YNs$lxsrBosL=RTG#qlU2W2G6s
z%lvDOCLfYnW3s!OSp%3b(EoWv{bU>SofPSy<Ld$`wJ<lrv+s5gJdWu4v?(f>M@tH#
zq^wJ{F|~4=D*3-UT1@Gd)+<a~#m0*0syA(BBx6Qx{KyTIrb|!8k=4P9R9?1vA_b{O
zNYI*uGHggddyBdzgC~|03N(~w&4L0KRXS>fw;fG#jsgk{Gp>vsu*^*%>Z1Y^r63G%
z*jC76md4bm*^NXN^*-Trv_;^``U+PK_`}1`xQuM+Mt^cd2#Q4zU^Hf+ekR~b)M|vb
z(SJ%*G>;{}ShtC|c&E~}e425&e|LDS#X|2*Q5eaPx@1afSr}E#<`GI1vx${;8~sbZ
zR?dNw>M}RPT1ttB!*3eLP+Z|4fYLU4t6#FP`*0izF?Nzlq5JFWLXB3Ez^^I{bq6cv
zV$!;SYF1qyPl5ZWNeOoezBH`*l|$O)7iT_%x095mnFSC8$b#1fGix&Rv5O!1V}v#l
zPrb(AP7<8jBOHZ?b-p1pR@oCW^ziZ{#Y^w7IvEyJeHrWO!5EE}lK6671wx{C|KJAv
zM&_HG$8=#X4As%7+_DOVr{}H=O67cMri>r>PXbyIp_73K($Fk&g`5xdXQHaT*NTF5
zQYu1nxn6&V&B$fygS%1+D^)_Yt&(;M!B?Y>E(I~nZqlkM$TRT(A`nwTaGMF8Xnrfx
zUbXI=V|JHE^jf+FJ6Hg!cPpfU?jFY#Rj{0PLSc=jw%1VKPu_ukMt}J{VR*_wa8a(a
zr~{gCDbFx*c|K|Mdm_yGA?kSkOR^AUXXY`vJ~aXlQjwh>q-w(B;slUIDXBQoT;)Ir
zpz(t+c_m<lREr`GzIEw6_{EGn?l?QPC3_0vd1%M@k0@-zy&;S5W%<28|3vci#<8uj
z1l(pKg<EwgItN|P9L7=%g)MjFru~C|jQSxNLUaFCPVw8dY%dCYHa2z!^s2aUnv~<$
z5B3uiyMB8|BvH$Ixl<?fQdV6Su(L!-Qih4yz!anV*7XrRqaNmb20HwqE^o)6yrnX=
zc|Z}`Fq!V!ccdqX9tuAGiV-{Fle*=mLB^ma2#t)b(i5kQO?o!Si{iTCA{}C0Lm;F)
z?In_HQdpywy!`A+SN2Ht#eRH9`Onx-`|xJ!p8k$UwJcwTJZJrfQqv^L9FBQQOzPuj
z%>$iWivoa6`!*$?7sp^*CN|4Poj7`Hh<(mr%!r!B%W5~r_(x`!5E@Orm%t?+L&HzK
zzHG|unbb*!w{fuHU1$w8V&GaO=m_*WKGuETy4DD8@D_!f|EqoL@@&~pQe1wk-c6qO
zQxt@p8Fyr*vbWhIlGG%4u~JWX*GJXEAm*gQcZ995{%ySF$_lwtshbHzG|vmPQqBz}
z#=fWkd<Y-Ou_e7G05#pVIK`p_eN{8c?gJf1x~YUvkRx9_R$k7DK6y!nck}olUbHE{
zf<JHV{2I%=J;uve2DKSYjO!C74?OE4vzuVz2i+N;o8s5Ugns<9FV1G~9OgEPW?<a*
zq7`_sIJVs?hgjncoxmfVyZ)<iVTuXuY0+Zf)AyryEliLK3hQYQiT(uNG|Gi3@_Ti{
zq*~uCTBS5Cm5_=Cn3n7Wg04?Lt4XBBeQowI`@9AQml7%dw;%;%+m-0*^_{%D^VdMd
z<77c4<*v*Q;FSULStX1wbQY3t4VIL}v;NYuVl;>>lc;ZT_1)B2R=1ZV2aNZ_O^-`p
z6;TwvXnUIUNReC4q{}X^kZFJV;E@fGfl2;r7V|NhpGl%!<Nq`4Kv9vHF+Hoq{Iw4i
z3ix*7wge%F;zy4h)%1Cfk&1;nB(eagUQ!5i%x#<URNBjP`@>-3<S})dPb=+J<>e`S
zbc;JA_d*{5@^zxGD~F^^K9JB!->I}NPMy9jsr^pT)u3W-SJod`JxpAPhumx1Mdrm)
zHICSfpZ2MrGls1DntJV|m#6q{6rKS}c?C^!*NHn7PN99i#>|;5!PJvgk4kfyxaSXQ
zxkDsv6d=e;XX*>NjrKPzE}+P7mH~CN286>K-=@5`T+7}?rPNQ)2@uTYvY-^8D8=F>
zc{hi9v!(?=eN8zizbFguE0>0)poC~t8m_2#8UXk_A&9-BMUV(U%%S5LMD1WK3vIIg
z=v`X_dRRm&x-a;hgI>&rKp{!a8-irokE;0J`r5WyW?k&;YE+@QVC^yokHX5m<nAAF
zd<?5Do1nlAL+x|e0uwV`Lh8N2$5cUb3D;;pe)c>;joy?88Uc3kOOjkm)ThTQ-DVDY
z!Rn)`Cn{v&hYf@6?r-gTlIxkewHi-z`U*}b`i3K6C5D;T6rnKCbL(yhW%ru}XWUGE
z4nodM?TGULk9UX@I*m4*8I^}jocEt%bW;8=az+0N3hYL2fL^#-PJhw{&H>Xgs@9Ci
z%7fTn>J$L*{H*8c;SA&FCoBW&91tES#yD(RtwF18%j$cH&#xZe8{YvcGcNA@)C7iz
zPw7ho)ltr}8lhHPinDCT9`ZNp%8SPxm*>E3X{u>ePHDQQG9g2_o?TR4uOcuzf`;C4
zoQuRyUxw}|DS6P*25C0N=-cX}^o5Iq*=+c*lsX_H1SzsjyehQ}E@<LUo5fqfFZ6&?
zQX0p!6@<+c%bmMaDv5847We=CqphyT$YKQucE{U2<fvC!lKk&l=L-HMlpt-B(dEJt
zf?rE-0`QHjZ_6@?Wyh%Jp`Fsh2sK`2D!4*+4T-WX`v&ec2+Vi?V0vc~3}88_Vv+1z
zke=vI1z@~U=UBT-Aox|_$Eo6v?z_gw)tE=%MdlP?du-%mOtmXi%mnWI{G!$p4qq=h
z6CiG+w@fkb)Qd-;$WPnip&+ew32xSSLuU{*lhAp3f+rFH;i9*8!ncsx$y|^>cCH6r
z1lNeK7_`YNSC9;1Pb0GW!9fp#S|sz!aISTv@3~bH4<>-q9FhTwnYU8{-xt|<RZVq4
zHty6QMivh$?Ny6p$`x+to`{%Dy9Wc*>PV#0$&AgZ@DJvfee5|MuQ9l$;@cruMnfyf
zpP3U{>N;MUCnQTXoXsltqd%@>ulv&|*d$%UZl#7h?Q39v@_;3OTZwG9f33D*IA07^
zK%5^yzjV6C1uFZqklUCjVVav+fvNz3c;Yj#aKQp7B?=>Aw32A}wF1T@J!n#euei+l
zMaUF)k#lH2{mIjx|Pc@G^y9<^hOf~QnCVQrgL!jl2cofbOK{5?K_#dOve8J;Cj
zQ%d#E43osR9Z>9hw<vSLDkCjR!}9iRyW^KFPr+KPhyH9L$16>LcaJfwI|34h39vJm
zEou!cw>L;dGd(L?)<+`XZVR0Nz^9ekb30b<mjp7_0gjq?PIhH30+pls3{rCEgd%Xp
zP*c=0E_1QB<t~U*O9f&+mrSu^hW;w>kf-?!&ZSwtE>dDy9l2^|!;JjUW^=#4<C$Ut
zew-exT{z9u`}ArUpcdHi#-dDew_V5Yu&q?Y6@K4?Yb0OKkZq5da9IHm{y}drtpg(3
z=PhUS*3b?GBUHc*C=LSYF3e0(k6y#5R6qS3c@)RW?TMw8Y8S8NR<Dk1t5)Gno$uu<
zqMOsdL657htN+TZn`gl%EGOQps0{ngYsn%@BsjWCX#z__EK92oZ*w39H3XTML%ptH
z!i!(YqEv!Z6Qq{@8g_9P=Q$f!R6y5?7(AZ3;^3p&;K`cf7t*v-1#3ioAnAP?^8*uu
z=}jo}<hA}{Qf$QEL{NGrE$6g9l3ibv5{<O^ddL`FsPMb3K27a&VAq0sg;pm2KytZE
z^XWV=cpH6c!K2*$^BeCudiNT%LBB~&zFsH0DN{&q_!a{d3CkIMHPJSLSD-YwCc3P2
zeuod%EgWm_4SoBAYD+uPwJz+2n}D53U#r4Vw4t?@=9{ka4f0o>XnQ0t#yyJ=?U|V#
z$>WcGZTO=(x!g-f7)s#PQN@y#4kx6O`bY}vJ^vZ%|B9P_Fg02mM6f%Cn8;AO0X_7#
ztY=?**~}Q49;IElvkA~!2d4dROCYIxd8y~rWAckde38qa1NU(XnG>y-(29do{X^Q7
zRqunr39&Y4K3x%qu(H-fj)h4VR|>SXKUVYthD|UXbDn0&ND3d0S+46J1v?GznxkIM
zzWaO^%AcE*ff+<}Z$o)d9rJ62u~qn?K};S~iQy!rxY<|5&wDjkbkNp_J9kgh2-307
zMQyfTbQw$+c$$9tTXnnVluY7Sc<yVrJ>08@$wf<A+_aK0(BM?8G(f&_Sfw`04Hv}~
ztWtA_C4A$%`3ahLqvL#to$^EYYO{lo1kZ`{WM?YDP`TY>(=@=nzQ(+^ZQv~dt3%lr
zy8Z+tfO1BFF7<bmQqL5Va6;l}O=}GPXBzh+^H1<FC4%Z5HC^|*n2x*#y25Y2?vs<^
z7S%qB9Yw2KMTf#ZHN<8U5pkdzAQ2jj8<0C4&E&TKgXBnxvjO09pqPjZDPaG3#<aG5
znYzG;M`AXFnH~^NY$*lcnX8pCCM@s;?I~$|x)WS4gJutpX<h|twk~<vYqJH&uTL$i
z6{j>(Rd}Z(g<FPV3>Vk&s-9|G)B3#VV{FMS`(*_;@Q0j%lJZJxk!iBZ0&JJT3fFm=
zKjJ04@(-Y&ivLWG#Fir~=t16__s_ST5T_ep9FXzsYleMXUfHAz98}L)7jt09&G^PG
z%<&}{E5svajahv)b!6esf7Sry;L)&eWF0_0PY@U~cFNjxh1H;IcppGDbeq&&^5Lc2
zzH=XWLn1MQKe(Hq?+!$XAL<S@eZf=hz3wmuFX382eM|g~<btnEgTcD8Wme!bHu81)
zJEv{r7qpVgXtf9!@GQ_gCAZ$$tl`2{z7iASc1CUkQ?!_VA}W)q(q38K%EcW~kW=!y
z%h6y_TUY2=fon<nd-mn^PXe|?_aGlhZV#vMLgAcs&Q>RQo7IILo#*sutWi;%6P`|i
zgq{VlSCs$9GN2aq#L*C8Eo}jz`Ba4*Wkb}tLXq+F5x0pys<{bHv6@D#dRid8hl*OF
zCr3bJvTjJ7<r`!oHY;)l;}g@XVP`Zex&HGmj}x%ot9kcN4<Uh8jUt-&OByhIhgi0t
z-R!~oQ-1b9s{t610n?q!)fL0_+EP|wytgcysS~Ka?1jSKY^!0Xnrw0_@ku9q<GubL
zz*9p7l#J*OK%+<(uL7TnX%oOQ$_tfW4y%4c2nWnvS8uRQAoQP52^tON^E{I9NQeKy
z7&DwiA(?7zyRh?+lmWS-{FB*Cy`a%w9UK1Ea1%arW>~b<+=A`RkUfnHp_B}B(PRHS
zauG#|r(jc##Y#+$%<)SAh#~{i*bQ}Dn0aRtk1M|H@Cfbyrz>TH$G21Ox3*V0Q4|8b
zXb$H<0PTvDOi^f0*r7!{a?ou;iIU$kLlf%7e`Bh3sFLJHcgPSy@d(Pm*mLGB3@TZC
zgH6^6^m-s0qWl*~3A6Hax0NuytijmJ4Uwc3bs-RpDH*bRhZ#kVxkO#fyYWl8?QzvS
zq?ujH46S^3H3^b<Jji7Anj08sbQfqW<~##zUQ4(x8^9Y<SV?_p@g{Frq#~Vi^e*-D
zP3kxK$YKKPpMyYyC}qD*mS-#;)S$S&_0XMwyVhw9>!FE?cA~h)Poh3Jlhr)1#!3Xu
zVl~dmG+n3_k6F6Q9z+~qcMK-Gglo3{`Y(%lew6Hw3UB4WlwR^)DOLWabfNC6Hja<M
z)ab0?qXXu=N_7RFM#JU(2WyM?%-by`|43v(=xPBMed}qdmd=jjD6|bM7>^^u!w&M=
z6Ap5r9Z!eee*ufN*@L`eo0L2%cM$SKJ#da3<%B6}0Obpr0S8G<io{hF(N<m`8-d{G
zgIR|V+P_!qBOCW?wf9`GK93sO8VoXpCzh!#h@D7Wdz5iYv4B~DneAo{P?oYbD6F0K
z8PoHZUH7qPD;DFR4yH#8+NZ~h`vG7HXR5-d7&X64R8nXDf*540X%jOyl(Lp$Sv+oQ
z=4Bu-++9R5NOkw~CbN{=MZ#yA815@5w{X0|K(0mI7T9;0^#KBson+K@pJUqCTQ-e@
z|2)&?!<zwLf^Eqj{kC6FB`!!q2Qw%@S>8u4$zu1A!q9!2Gw<Qc>$GS~V3yl5E=LH=
z>i+(fNmlq)V2iPoLblkfNqeNLRw{zs1AbaZ)z#Ic9#)H<mViUie72yMtYJU+%R3Mt
z8PKn!+UU=2n-t?>&w}g}4Z*yRN8>D!=*DW$Oef{c%0*%vE$T^cLQ_$6prb!oB;?7P
zb2X<>4Soo~1L{#OM8j@FU4r5s7Q+QwNlXaq)vfRlNnt!kqQ0Y=FbH}rrnA%a`nq^L
zjROgDiW%UCM6r9InuK6QoKiWz4zrsc#CR1j={-_B3wYw|nKZ>d!!mh<_wB)F^q}Vr
zvymYie79k*Fs~-!ZjtC#n>J$XZk7<*ew8_~;!Qrt;}F!Gpfd|N;v1dZZo66hx%2e}
zjb~uD;sEL$1r^;6MBRz~n>&9W47nY-B^#sFv1r-+GM<j14AZ4t$ZjxoG`t4V9W#lJ
zFF6941Q0xBq+L>HVdIg8cbJaeyWY0<*xNaTYqV>>F7WtH+e;`owNx5ib7N;1As48o
z1(?*#_PD8*!ND-i#JJ3?gBFLAT29lX>wmY#$q+!0et7O93%z~;Oalk$J{j`9KGfgD
zefPo+{$@$DVl+hRB3kK6)4=oFXE#5;+Jxb$f4txuLg4$g%eZ8<$K$4GU3g(ZpVs)h
z;OdCsbaw6>;MuvJPQ2UJpQL5SA=m}!ew$yqq}7Xs5d)!e^iEm}yu1&3QW~7`QnR+S
z@lAAxwqhhRm7%)#M^q0^K5Awc62ghFo+S|j^6WIkxs<S4?)ez^mGkW41Jl7du`u71
zFTmQM9TavLfrI5E=9H8}9$4vH!g`xgAIrRJ;o5sq>Ah#=J_00or{+$9$9@h+{I;y%
zkP*7ruL{fPx>UG9nFO2BTiGliFzTr>N%%&D9lyy(x58~0nTZ>4l*hbCX@jj*<uN3@
z{-Mb{Mprzd#FB0pn|+W@R=qEtuME}L%i*K4`*pRSAS*&1hTWN3XkR@HmbMnEmg|M<
z--R-7Mt!S#E+m7hAC?@)tg79a8aHt3a#VcFcEH(had}>Fk43Kvl>AJ<zwH9u*pgj%
z>=d;or_sfy+fC!f?l*fzclE0;c&d=DAms1ZjAJI6B;|MK1ehJ4Pa-lBH&5wsa<wC^
z=J8Ydcwfs`@f<|7_zB@sN@N2NkOdpD|2Ap&<vPwj%YRcga0k88QVoZYsBp819I@`P
zuxK%zg^*(W|3uq2l_>qxRbhk|mtM|w^Mcnpkf!|xapjSR3xnb<7?lvnlWjZWs1iI6
zS5$^OCedT3*~++X5{sFZxRgcsAT#Qj^V&GY-&aqxg<Y6b2*>)u2A8pQ*PM;zbBK3I
z8}|Mg!^7>)y2fs_30itT9EufZHRuc2=LF^;(NH?e+Y|hHi~!kWjVr~nQ)9fAY<KEl
z*@f4x%(U>qAa;F_eJz4RGs*n=nNLU={X~CG8wlS2U&UwkW-V8%4c$B=Z+7j-`^RFb
z8YbS_MBLX}fGkhY$PLzg`Tw@kZWY_d@y~}}2~=iAyH))i(|g`Mwcmv5ld}+EBu%Ms
zSb&&hf@X=liNE;8^gkt*`#;P)>QQ#=F<kcWrlyVAMHFu{Z`#u-gC>A07KMkD9+6*n
zB0>6(67}RfHGmZr^Z3<uI3{Ei62Aw0c`wx0ryX(tg1^aogt~)IN?&Q9&h**SZtE`I
z<n4tNlDQFY!y5URtFSdi`DCB4)3#Pvdtm(qr-g}UO#|R3y)}*S>=R4TJ_6UWkK7JZ
z1=Rd2F%5#i<9++GcdY=uAlw;hQ3E0QPUC2+w;zsviIvtae4X}XZO~~~1Dv1d9ls`d
z*Nyl-5;Z_#+^1s2rng1C(Gr;ydZD%m65Fh$a^MK|W;bpE!yomtT;f})564y>3*YP|
zR5NE$M^jhdD@mGmBYr1E_CwNdf&xA)zpN+ug(;oPC+kvnxF&UM^Ek+GA#cv<O#qli
z0b96sP|Ed;IYZIyg=5(BR$fd;aR8ffIVEKo#oAy1RUjnM6hj<oF7|ZUkLUHde^Vpy
z5>x^#SZuD#qp?kmz4qcPJtRW#+AFd^{xZBg%!I}R$b?Z^*%RjtSA~e@ykJsUr|%0O
zYg|;0D8rnwmHwMxvnNyY8xixC=PA)Z9(J@BONx`ig*y=b<r(en2NFU|X@*)sEaW2-
z7eFfp)XblOAMizNnG<H|PPD78e$4KG6$HP2;@FZ+Zjin#{>7eZzEEk{1?4#i6Ra71
zZBz0Q5{8hAFF^Blo7w&K=FEsmXY;sH^o(EhLe?C{fJY#?%#cBK=ad^Ma2#4gBhj?U
z4eHvJm#V;(U<XBSc?vY#$s}%#ouuHtmZpT=lg;Wy{baS_*ZwEU3*L|#MdQ5`cqX^f
z0uu}#v4r{;93zER>T#moRk&)rduk$Bgp^Hvp`^$yK?49zqElK_7@Lyga_qqS<plp+
zfQ)HkHmAWQ55L4dVwh%3X0>ei5!toYE+p}@C(-o<3Osjqv}DWSzXb}+_}(P{h{^yw
zya~*|Z;sxEmgf1=&UubW5|-ZKwP%rhwEi(wVTLGdgk?yPbjq41_b<i_Bjz2oWuRL#
zY1)CM7g$#`F)u#=WX$HUX+$u^LW=NGJ0Uw^qObz;H$`j>sTwXvv89QX7?^%Erj1Q6
z<KI3}GMTT^Yw8<!v`LWh!FPhzRp$I}mGL(bZ1ssj#B>~3$^Pi7s?6vkar5Jiqt!-R
z395ZyQbCOo8~du^rY_SD<=%s8`v5BG4JKx-XlUgFDkX@Pu?GRp6q$KA9gGZo?-4UP
zzy8+<lpXU9V=l9mpT{O>wY3!N;gu+5?9kvQbpgl;h0Y~8g03UEw~y~CgQMu>xrdNH
znh?UK_JYPkZ37J|_EK0WACTZ$6D325pa49GKDC#Vmmc?D5XftcTA=d!G(-k4$Gc~7
z#uBzycN8K9=40K?3$R?eF-Nx8O>-lfZVcH2P~ei4gO_EftzY{d{!W*jU(cxN<j^0R
zl-+V8?+FyEQe$8?*-od$Zf~9o0{z3<R`8#{qlh)lXVEy&{~}^G^fEWL(U{3Ge6;dU
zG;x`$BFU5=p#p8idrZ2qaTS-J3FC41)N^1|tbqrA-^5V|%&l*6ooUo~!IfQ2%nYPW
z@{ob(Y<6`tP?T#?>>!q98?=C0f&8FshUl$}X($q?lx{P-ts!l;HS3ej{gU=KTsq-n
z@>dZnG+&njK6{pMGO!@)&6nCrHDXln{O(cRuCfp*gL(|YeHUV3-&+c)R2K&U8@TZ3
z=E?8-tb~f3Y&Wp0`Bs9iIrwt;5BRjLZ*Ype6<E_1_j+A27d%L1aXhlc40zF}KNecM
zkS~-50EcX-jM3@E%LG|D4LU<eY<)G_b+|q9$!3l$fS&|+TNMLbQz1q=Fm~--*F7Q4
zcs=VLHnI(<tTo~M9qpUjFR-VBZ~YF=r|e7E9fbe<O#?Q>^v&n7X(5!od;M7E8eTGc
zN>r=@f9|d|LMAn$O=gc7hZ`Fg8{z^I#ayUAmD%B>Dy59LBapOd1TTWJXt+fJ2M2#~
z{Kf)wiD5|_0%-1+tNjs0rnlajw{P6AGF#>*=KU87e86V6i4Z}bxZmU~&P0G<y%fq<
zFq*A(xP178AkGGyi1qhAbj(q!UM!>h9FYJWw9cqO1qNZroX010pEmjDuJWab(!UKT
zB-s|BV@?En8^jezI!63~vJ%PGbc8GHAyBoP2+Ry4_&WrdN0mc<VMxE3ko~Dv;@fgW
z=&x`tEY45kTT%_kheZXPa@Y!4X9!8sQ#6B0Ezc$y>l}@k^NWO<KYo$tKWna>;SiR3
zu5Wz!dhQEr6_}$p@Syq@**GytTlST;*=0%U@LjnZxe8lMxTM?D5IPUqlkA%9%|d9S
zk$Fq-t~<|W?pRWNSgxrK!|=4Fz_`hOgivn1W?#V8ViB}7zaj9OO>LoYx$pMV82<l{
z3l2Jo)+P?oi7EL_=)X1MQ8Gp9HY4PKwGe+8jb)nYYhgTxt42Rn!ooZ=pYG_7-#gm#
z5iR8<dp`WXIFJeqgR9~^=uF=$oxrLKUuppVhb@9cmyvM2;3+Qlnwuhfkr9PVxURfo
z{Af>Hpk{LdMH#f8T`$r#Mt?2vEBk}TrnV)esXBTLov!BmZ`!Ml%#qneHq4GCpymRS
zCCU`(_AGEVkbI1U7%obb%?j__@lGY!tzpz~bJ)bQq)4ZO!y>L1uhv{ZEAVQ?jA-gJ
zvo`7Jn5iLgSmMLPNT?WS@VFTVV>ZAXKDlxAT(ke!L<4{ekEJcj-S|2R`7j1QxlxOH
z{*dO-arPFP+6&MAvS9$IP{P7jvMwf&g@jO{$m&6{@ZJk?j-{E8<v2iXQ&y0bgat73
z^+F4p=C~go?`q4aK*S`~2ekKxS0S*xMr5A8ca1vgW!+YY4DhuIsmu7Wwu^SM%NHG5
zH?x4LiCgUx0O5{8tC<}n0+&J4I2LoFub3MKH26o@aIoQxNcuA21-=``PzopV?09S%
zfi@Rf1(|Rotvy@CuTIMLj848|XPt9OA8wbnx4EcCuG$nLJ1;>W=uVZ;74RqN0mrn&
zC9@`{&_N7q24>tMKr4pD>x!)|ydgyEwetN)cdUY%Qug73Wxw7MIS)P8q)pZ?-8ZuX
zJO!g};|?O)0{f~hIs^CUqlfGO%0@^A=vs!5t3k&tHxO-p7Y@;>ZEfk;DNfxeU=vd*
zIS=SrtCEwN;iK~{?3`!O;U3{}15n?yIDnKmMfx(3QqQ0KyF@z~bk-fxV~tXvNj1TS
zN_xM9n$QhyWxNKVW&RL$ooq_)a~T`p(94S}Y5hHIWo<t<9LA+`UwCEYM0IFQ{|RJV
zW9m2+%Y}?(%VaqmN^Wb^nfHv=dGk)lWfjb1eKhA_vPwn}u?Q-4qpiqEPxe>6L)lvx
z<T;Dc+nP|Ow5K^?Pt4x3GEL?3+E^O7i82&Pxis`PdBo({XWTq9T;B#B>z123U#ZaI
zU4_BVF(#ZNQB!hx19GfAhfi!|xZS$knC5PuabDo_7&jxrTQCAoN7tTKg|)>+$|4_Q
ztZgW)RT%WGVXtuvK=E~GTJVwsVt{sGP?SF9Fpc&R%KRz10Hj{v;N^_hyq8G#29RWV
zSK800G&X`Jt(J_48mRVNn~FJ(GSJ9)q3?Z4co^3&%=>yK?AAc_$SfPsMT$B2`Vl9w
zi=`)DdiMObd;WMbmf$UA3NC?X_0c6ffJ=?zGTvsNG*RD-oWV%`V{@b9_x0F!U{jz~
z+(D^v@qnb1g?ZNY_RAT+Out&_-jZ&w{jo$BFBD5nQI7&{TXvCUWfg>vv)?D;>^P{u
z>*|ZU)E!>4NubZIr$hZ~rm$DAQ>wim03|nugi^jr6rz-J-nx*Qmd=Faa-Y)vi5eDk
z;<i1ZE{F|@*XMeX?#WT1ZM~b?<fr?sV1qJjr}jcUu!^BqO<2e!*DvQBvf0!B_$0Az
z59Tmp;yF9ox0GTjnYkH7sNxvj|1{Mrn2U2bXO2t#fL+O{C{bRsfUa%1xB~;$V{HhA
zMSt0<e`uOQxGkkLhNo91<VMm+ov<l|Qeq(OGy`thy%K#!P1YpuBY%eu(X+9xi~K5W
z6trTV#n-uK*yjuE-_GC|zNG95=)}sd3st<0vnPjKdnc#rYc^lY)-pWc5;EYQ&`yqr
zwnB)Nuk9Cxvr?rtwjNkYY)nShu<)nzehv1sbSgA7y9NTbPe+-p7h3<y;PNw8bFVt2
zE5O_kSfb%L^1To81666nx1>fam9?be(vzS)dk~$VBJj^wX{%g!MbzsZ9l1lA;o?KX
zh$9`4%zcf{flKPj#hk4~|9ONDs+5IBRzJzqp8n#&dN%n<=Db2=m9u629ki#p;t++l
zw$yOCm}H>kyIlW~*TWn~eZ&(pO$U**z`0ff1V9_YfAo(?*I<=cAMx5FH>UtcWKGhx
zCY=b`@<+t=TH?9rCUZ*QsI~$~z)h2th@<3@`eV|(qEq_d|B~kv(L<1K)Xoc%pwk<T
zF`n@7_L;IP-g(=smKmh>nYNGiSGfCy%7@NrF<;614YIUcb?Ju47DZp*liNWtVWDem
zUq!C|qqQU!f%OAdmG#<@EL`SIy@Z7Z3!$p7r!H*y7Vm6=yHf8+E+(r)Zno$a(p-mU
z752O2b(q5%T%=@F7bs9^rwIpavwp6Qg45BWiXPX)bW=gtbAsn~QG0eH7kBckuLf9I
z!9N3OraIjZ<dMV$-LD8w6RZ!)?v*=@f8%GPHUXJ*u!nNHCI!eW^ngJqhYrBrls1lU
zgcq=*%@gpkG(d~QLtpGQeP>?9SGj(36IiXwbc0GGLU=F?TQzInh{Nk|gim%Ve)+;5
zB6&XRH0XFL=ipgskJZF`*p_RIA1J)Tw=3bUr3TIOkP>2;&x$Oj^bw;Fz5dG)Pg@c?
zs+(Yw;t9{&Mk~f>x3<wrmP5)9vq&}U(>lOSKRXxc{#W|cX8AL1%i_g_B&}a&6Wsl!
zZE>B?2s$NRnsM+>yYr{t2-Y<!k;?8RXZ6bXYq#lI2qoO^mZSUn<`x46TP0~k&IGu`
z9gnH!{jlcsrp8Oe0P=_o6)5GKvr8q?e<l5VHPBMhqqflG)$c#xjz0z=#QVX0Ux@w1
zfM#(O(7B-~dinbN&~}200S{%6>{MBWNFnDq=bkRT`p)1@cfz%XB17X(+A=QqS-8EI
zK1-71qtY8Lg<|f|9Teq-T~!3)zepZ#H`g=Tr=;|gy<|#6fe3W*ZXQ{tyeb0GiPr%A
zxAD)0$#wHyHAfc^I!2@DamqS`mnPmT_T*C{eSR8qLs4`5WhHVi)4NDP-VV@O>)9~K
zda9WO0IR-uFpd{Vw*ZD|PS<cPW#b&!D>x04g2}3Px3{Sz7!2}AanM9#(`ik|{IRI(
zSlJ`bRgKIsf@CQnmP2e~NE#mTcr{{MQ8Qbkt^u~8Hel@t8fDTIbV!@SH>`b!a6=Tl
z**Lu9kj$WWT8@n_j2wE}mTpFP3&7RH2f3kiG=%dGaq6QnR*_EIN6A=AQ6~yz)3<oz
zlK@F5n<+cp{8j5Q-eOX7N(b)Uab$Zi{P2D2!Qg)SFBqr@=4axKCzit^`63L}pK7bS
zI;Q2hcSUD6n2R^my&F&&D5O#o{#Js=r?+QSJ+?-^CaZxZU-o%qcSzwUGqjUut6|Wh
zJ;mU0hKU%}{b&*1rNrG~^iB3I&5{#GK--h2ozqQ9P?){TyHFj!@7w=ewAH8SAb|wx
zm>=&CMR9QZ8(LkZIcfa$Uf53{)-WwU@s2xq&mzpO$$a3tKGG!{0GiC6%)wdMfnUo-
zN5JT_&Yj@4eweKa`*_*p3_xb>bp;>0Ay3HG_VZHTl!JSiS#{@Z5YNDvE7*Td<agxg
zayq?6b^&m%s?-Jw6g`QicP47kr2md0B4L1PH!m6VO4&o%H2a0JLECt8d6IQX?ZIyj
zYW345vY&kfaGJy~8+$m9!Mhr7FPt8I7Bc@ysu$R)IYn3hAI>->nIbXy3;h~~H3^(*
z4GI*=e&|l2dAznC9ECDS3y%y7{>z1Uh&R6HfQG_1x?e70FktZ#(FDJf0I4JA_Veum
zYuAd^Hzvyxq_Sz9QU9D2d|4!LEVCT<8CNmd7cAboAk|JzLMAPBIvjkplg!$ylBIOR
zl68+H(Mi$~?!A=o?K-*X0|JST7n(mjM3)iU%{rC-JsQ*6zOYU7LNo<Vmcp9;`!IC;
zm8xotOKy4&i2rzja1LhN{q8;gtiuz~54<t0#?w_EcPFF^*%2XZc@Ok0I)K+zyKXY{
zgW-}%NWAHSxiiUz8xj!pqIP#yW#HJ7cDkZHrVN@>LD&56kpntIRlZu-ixx=<tMJIG
zW2LcOJY=NE*Cn;IkkAxXk?k|miP7yibFv(4gL&4bEhswyV~F8EL9Ed*^XnjgC=u*6
ze<n-P?=5WPE>e2Uc*o^ZX7tL?8H8w*59##1G+<o0sWUfW)8q8Vgqe4d-@uY~A9e2H
zW0j85O{DkyzC6%qo%Tv@)F<u;PMSyM7z$pKpe3v%`axjW>W7*AI_|w`s^P<4D3?9D
zxN&{ITnNDqMiy_(y5&0FyyD%$0x)PueYq7H^C35?!JWXBG=}Sy8@X`wCpE^wpg&NC
z<O(nZsNa1RD0;!meH$f+lG4Fzy65G${%vIThVL<d;fb<zAmJ!zh3WvW%vkeX?u^~&
zqgv*pno*{f6HZS5-{Bqh8=2RvQS>2MJxq5%4i9q0h9G61ktsk_*U92{P<t|{;CTEj
ziKcYoeFi?HYr9hl{>jT7@}|MvdC6>@Z(ElI>}Dg+K5&<<S8a{R?(qwLds6?=0$};T
z0x~W-hEf?PzRPQEeG^g6c&P~R6Gdi38`y=$Z1JN!S6z7b?u_0)f)p-#nzMm&hpytB
z;>Lo*FPrY!v_y_p&Wmm_9dCLl<lq?(GCxUF1&}B=esd!5j9OvzCIOdFFn>FN{jG<x
zImxIQPd$t|ZETICJy>s&e~2!Nm_WHbar*(Cw=P&f^B_|N<#c5mnij#wQg7(Jz^K`6
zkV2}SHyt6-G}??25$tg>Gm2<fG-JGSh{hXiK!L{bvEr!7W)l#yoUQ6k@9_nDqcla=
zrs$KwI|6>nK4VWw7ncSkK#s4q=t#+;L0R>32=pfd$mV3R!OKBJSAh(-b1#tC%O@hP
zMJ~P}{d(+(K@b`lJ7nDI;2|-srT&B0^8BJlny<z64>EzTre5cTBH+LR(0Ie>x{-1}
zp#5zSx4g>Y;a64i-%H5u#h)I`LmJ_!Etbv+O3$=lqJjsk51z_edTsC2*|Z1;3qZ#)
zCCj(%Z>7tL<;jdT#>1w839(=DGHiKGVuhY;wBLKB)X~a(^T~u>46Of5JN?e(e$$`Q
zULnJW0(?DR&|*N2lKCe1dpID+PQnfWBnM<&Gik?~uSC6~mURQ{7`G1WVO>0AAdw=>
z^o!~L1*TDifqL`8M>v=prKLb4y4fZ{Rn|@*8n3t&y@$aEU!O-DuveFU^o=jTEf$B=
z{~Ty9b8wgfc$eKC@}6rPF;~or@O33&hw}I`@Z|JDyR-9a{BUs>RA3<XE3)I*C+B0y
zmU*y!*r#<-Pr=V=zmLC4xDLS%HkB@e0D_VUX%2wxd_5|%M7l?R#JpOHIc72!ha`2-
zg#$2sQLA2H@f2s!%}{KqN7M*dwSx@cvz4S1^^~@#2cYx~I*D(9z(3nn#m}c8D6Ebz
z9<_~PT>^%Y=u^K;fKrc$D^}#rP-z&@MlIb7{3`is7a5|c<fP00&y91Nv>KSBB{+NE
zZ;9ptFv==5ElD5oWkDdEqaKlyLfN$7<1DXcg+m@#b8y!F{%Ia%MqZ0PgC-2T5Sr<+
zSSmP>XdI5)tIE&8HG;pM{ECvNS8Bp<*xP8ttd8W~JhIRI@=04qoDWs_n&a|+He%_&
zq_4bdT<vy>iz%50Y<$S<9&5qEy{DBH)WXf_9oi;G9l^;POa#+DIG(R<JZ_zXsu9&O
zlls45V}5k{11ummZXPpu7O=ccGD|aCpua(N@DZ)__1>p3dNd`X-ZjV){GX*?ssh&z
z|1#UKV-@O8l<xe!@aH;45!NPs7gEhM&FA>8Wdoyd*7C?IMSegnrf?(4QIbRp8j<kJ
zKa6RMx1(M<M?cF#a}!12%(_08HBqaKf?f*<!O}4i88%TnL9;ZE5>VadI0Ls@;`n2y
zknlJ3q~3T;w=XZ7T~bhzq9PH26uxVh+Ff1+UCtk45kal?01O(+V`pu`3T{L?1pK*B
zM%T4IfRamU41~QmFA06d?gUa9QOuR9>DZ?3iY1w@vog+bvD+(aNllV&(@zil2%{>(
z$@%jVYvmQjuMlw!@#-$yL4aeGP++^=huW;bt*di^`mPtcQ0m#eza|`*W<^^_rKkoF
znpde<2I*=B^9dlmv&&lWA395au{~<tZ(@A#Jr_SnWDPRc;-?+&!tt@0=t+65m%wYu
zLX;`%!r0GvA34$#%l*%ffV@Q`==Qraok==iG4M_qpJz_#fe$Z|6bW2~IjWsb<XYEA
z_qxcNE&{_<!U>61R&kEIg5wG&<&((2QaeA@L0SRx5?Qt&tWL%Y<QaKVK^Xa>C$UiG
zYL)RKi=v;7F1N9<W8`rG1uY0+??ZL9LK6B$I7n|bAVK1tY6EjshMuXEEk>8@w_YO$
zwrH@Cwmlrjrwlc1cy90&=$Hb|rDNdUAhT=O9zE7`dGJm7tKz<FwN|jOy}<=^op(*;
zNrh~z8J)Ts_5o2C&(W#amvY(-Kl2o54F-C43`Kw352jDKyw9<H6AusAMl?eAlfGg7
z0q^bGktRkLQX=thPM|30CR95)KbF2%e5;n0->tfB)-ByGvC-*tX|CWIv&5kFBmgtU
zg)VjorMow}Q-K8=Rb<hPU;l)}Kx>(a&_UG-8ku~Z>yI3+g^1pt7(E7-44b-f-9Xt^
zg=qw}B4Oth8*k1<D7$tRQ$Mt5IfR>nyD%V~rh~*MaE?^q+p{|_7hQE+bOKy>I}Qu}
zu=JcGL6_H5KVlZB*735lXz|0pslB?n9TrJC=t&sm77=Y%7A5ApYyca5O5b=P@ST=1
zPM`olOBPP`NPl=vCy2>6r$a0a2=p@aiv>2|+yAtQ3$cotPx5$roDRD6R9r{;@O5lh
z-tGK26BY&22_XsMe|9@p+61>)<PSq4wxXxisHZ-4#0tK<C$S#J?~B~u2Zp7Yq%=Tl
zUMAljlSk+0){j<+I?`+i{HTnNg&GB;;d}!NN{pZ^s!1l{DVLZUb9>8!`ZcBJwa0R#
zMp-Tig7@`{b;4FF1Ec|={kV=5bb#DE7Amr<$B(RyGh6OR*Zr3`Q)hv&)Vp7m{ISd7
z4TImthOB5muc8&IhoY1Me-YG#^8dK8WB4N$$+I;)WC@i~Qx`E~+tNW$u30)g{YdqX
zD~Hm$9UJ8DNSkc>P_K8{OyR=zVXb+D>N@^-O7_xZyYBdBCDpMJzsK{`FqycNaFfa=
z0**lFEGb8%%)u#{2KB1O;5&abuWK#34O97OPM*@}-3QVb&gRykMTXm$!0W;*bi`A*
zDPByIyhpiJSTJT#YoK;qla(@0n&(CRvW~-xIG`_MygIGYSaf?0VC7`e-dda}7cGDK
z;yAw1ye!+>=f<(h?>j=O2bel-?5+=p*|=*b|43?(B9Q;Cg$hgnlq-r~j{!{;`N7oM
zlDCV`b9E9xF>YOA>L33c48KY7+<HY21J0peCe#BUUQzxF7J9w$ICg|PfpNvnY9aj&
z`OW)OUhAw8P@Df-3jfOTaOcw8+Z&(LRTYItzZ)qI`@srD2U_Xe#(N4{%u}2*O%V!-
z6(QVgbysp^k(e<wE?3W3D`~X+@(VI=fK`my9S1^ALBii)WAH*sph9$#v-l8)^?xa^
zYYe{8SHhVB7LB)QLnqCKrws>XdP0E&MJ;Hlmto0Eh!MEdA_d;OY0QU!PVN*=!|^8*
zI0=%^W>ALCfa-cVTW=Adx1<A)Kfdd<SvUq>G0JdGZ*?35bL;z1IWcbUxz>ug!Q;cC
zy0ixzx(|<8X=>Jj7zIWYR9Rn}t{SFT?~!D^FP7wqH?+Qy_CL_TWP%_|9idCh<_jG6
zq!A0C#Raa&C*KSdiYeObev~qUbh`sdRd(=n1g9{_KE*QfJ59stD^a^UhZnPd@D-y{
z9~I>x;1ND_Mm!gZ>j!iBMPhK9@q~(fr^Was*yixsq8mla=<+RTZN#px4~y^daW~{3
z4Is@hm4$nhlH>f_kER69Fs2I2{CdwJMN4U{j2_-mpVqoHAe{;w{x|I=Sn)sTO(h5s
z3V@bT^d{tCynCePQZ;#}(EdfnW}*USz*AQN|CmgnU$1M`0l+Xn&#g$}lR3mO+1@i*
zZ*HHu5R7#QK@&mg>32hXhL<iw*1oslzXKJongi=FCo=<sx;DZnFwlpR(Ba_T5AvQR
zRXA^?RL359Ahbc?q-(KvqRGL9kb()F>$SgQc^>s^!Dm09)`vbDT3w#gn=ZTr?!<~;
zaD5<Cq{DuHd5IhRWjHF=;*yWu=z01P-c2V8txSejFX}1bfxMFWT7d_w*DQ_{<fcW~
z&#>72j{WXie*KQ^G;|9I>n+oUZon!CyW|$`PC$bi^qfxV)&?T*gWx{Mk`PJVS4{zO
zZj2lBa2M4#>PW-vNT(v4zbaGSFNv$>P&12&)e0@`$&WzGsl&;==6Cn%+vK5|9Kkx9
z>#{yTE68ZLlM&!8+MbG(kMp{V<PWmpZh8|k*LXlC4h7fUJ?4<x=&Hk%RA(NmxR-wO
zABtwNj|Sw6{wzUjlpN(ez22)UxRQG9Qxa}!=Qh8`9%sX0`2};{72#!S!Fq`uC~8Z-
z-5Zk{8r3t{Vz1#k=qp*yLaPk^p4BR?iZ!y)+BvrkfTJp+sGR}+6{|B{Af1&`THXRP
zN}(nzGqepY>7>G&eU)HA`0tK8ks!<T!jI0G59H0}OK%}F3Y-Cl*m}B<(Oxrr$}XMm
z<FF{TGaQq5|D5(jlN=<Dq{clj6F<z|lE<k+`_J@S?B7LP^Qjn-f4ad=$%FL!ar$xV
zPaRXJ1wV#R7k2Y&5pkX{TYmsie~ArBpLj}4gHASiJyVX~-P?(sJ<diJQDpk;95PJB
zYfG5E9&v-Lh!G{F6;f+sJ4GVla#MD?v`YcU$>zN8v$g^l!&{lpihLL26@nz45L!+Y
z6I^P53FdK|O4E3s>;{%o)OzS`b;j=KSG)qFg*SB(IpP%HnqgqF{Z8GL^Y<Z%(6yj8
zE5FT;38Wa0>8+Uih{K{#Va1hewR@hNpt^1{Qf7CF35w8e8e#!^9Kp>@XF&O?=L+qD
z4Xfj^upTR@%HjXFzTa9ZvwQAw7&4F%tgSUwmR<IPW%)(hq#z&7Lpk5+WW17jROL9%
zlZ5i5r>5kb7%@5tOYH<kHBz`Y6K=c-T3!sd+{Vi1J(*jx9TP8doP?-@JXSjj4M!?Q
z@GQ0CmZp}9Sbzm!*&4`1{Wd=a%$7!V7c{}I+p2+kY=lWt7<NUrZK%}WKB0%XA}X#@
z22o|gJqf`4+La)nghI)@WFe+l|CU%;us#jzKY$eNyEWm;8?65$c$!Ztm_-0O*E)Br
zif4BVc#Z^l$)tSFGg!oU12`)58SoyNWz(^Wo3#{I@Re1HaFhJz`BVRkdNGLi@|Rzk
z3zhV{1(>s9{I?k<Is1&PuF5}%1s)V!@r8}Y`b=&zf%oL@26gv;U=ng5(Cd#@f(qJj
z;RYwpZF1bJtPwX}_2v=|ELfdGMvbjJPpN-UD96!uNByJ;dCHL6IIsYy(!K_Sgm&=y
zxsT_BC83Q~GogS+iHwtqG2meRFT7eNEz8U2iVX2r*BHgl+f`8ajocLX=TSQ)<}K^>
ztzLsJe57&$EA+ufi-bSQQI)$Y$1|!=?%8dQu{ZgsmoLPkMB!!F-QIWzW*fPh;jb2V
z7Y$;#lX^pKPwUq2$DAITe#@Ic@j7UT{=Q_0>REeh!l7ZBQotuWWSK?%&!AHG)F@}*
z$7yS}7`Bd*DwSim#7OKoG~%h+UIs0g2zsF;O_g|BWSb3-m4oDjG7V5djl;qKf^&g<
zZ@*8c@9-zv=$Z;1-j@d9*X{6}A8b7RT3OyZlbN~!@%~)hikEkus)ef<@t}>_Lm$>P
zK=xC1ER|hfRBoOK(GI0h`B|a~&5`LU7bR=B!6UmThYmD}_NloWmxyzi?r{UtDw+Ra
z$Nj45#z=b~Z(U$T2GtkA$Ki=FmORflZ!IaHlEJNnqKmy&F~tMJ!Y&XmAf<{@j=+%x
zVVVzyr>KAe7~AJx>Y(nOM0agki)q+@zB~~r1s3?5dnDv)8Kycgf2fGSnK-!P1z%w2
znb8e|TF+Y8F8f*ADDgWgD10=3EWlkm`;g){DdiF;->VF`=`QxuEyP;(M`-q6kWHg3
zB*l<C3v<frcz+Lyx;cph&FV)n$f*q1kNu0y6R^S)M(;-qHN&~%u})gApP8wl?`DNy
z7)&ISzqqqMhbT&Xfot~nk_m)5X)uq>)+p?*u)Ly&J_LT!DD6PTK0wB6R*R--z9a7a
zMnaDaj@O-~*Y&X~B$#QyiaI{c3d`cIaj>#Bh=G59V&)0#U0eOB_YjULaI#VBMf$e*
zdre0M6+_UX?xE5i{DLJ)ZttU0>7ENr1r17H@2SWC9c~%wJRe*E`iBa<w4r(&Vj#kf
z3#Oeq0>M&m!n+$M{UDFFsqUMD9eWG<r0%q7CxnS#8}JlrHpAzSkcfTO4MfYm<)Nn9
zcE$eU$NPP9=~fnhZYrCjmR^4-ULiO@@n#HCYkY#}2-~-y(tKeZgL?!p<(Mwthyd(c
zJE#8O;YxKsP{Xz2*@mc$tE^CUdg4$%Z7(vGn!^{^Ee#0yEh?JCyT(t%eO_zd5sLb-
zP1a8cumKAFKBws9koF5Flfp;qx4aI*%Wxzz4uqDn{D<X;D9KVw0cl~&Yo^&<&3XDM
zDfGMh;+mJcjVYkUuJb}52;2w(ZF!h&mID^}b2a?A?T}%#5ngPA+&tL6&br?qDcuQQ
z1`;EEldg<cWlhKIn5^gM1MTR0r)1+Bw$j<xfAxiK3pm@Zrrc#z_ZerI!>zQ<p|Yf|
zNzM4E2d1TMOl;MBf8@o1B!P4h{F9mlZ+_VrgM8O%|246gqEyn{6n1zRIPE7E8N76y
z=!{*cXOri@rDRPt*7hIqzit(!jMc0Dr)dO0bL5sfRG*xhx=`PfqrH4n3XWf!VJ8Hn
z)XxR^l=DJoBZRZPIvu@_lvJ@`q-G~3W~BT3PL^@m?<w%DU|gBjH&CZ>$KL1#1rcsu
zwK@4mpZQ~6AFAxEg{cUSuKhZ?*aB1z9(j6h6ycr>snxeuSC1~9#`>Z*nb@Ae{`UsZ
z5yJuTF^=~Fu#20H!`$5B>2ppAp=M~Pxsv6L1qW5)?Ss&!&fXS2Qw3(5_3nx^qYl_I
zE(Wed8GVHCVC_=@-D1`SjW0&mXij7>3v>kybdeR@HvtO3%*#zW?;&IS+oddA_;Qh-
z2e$m|5jx@NRJwI5`+z+2xTC#$FIR%#*R2v|0Aq_(pgIPz)(_3Gywm?Fz$iJgNuz*o
z6$O$ZRM6^tsMD-?>x2ZA@PsvijWsdszrX71{ZBU*iek=7S%JZ6rnx|#bp8uQRu*-d
zRc|PbirKl#k(xdh2eQS)ij^FjyCS`LlIQ}xhhi#^S0bP%kMSOIB*m|bQXJ-r;>27H
zUX8|?m4GD~XI4e<3g!_DfEfuS-k>FF=aNfH+*FR&lZd;7QER@17PWDnm_^j^sxOpA
z6`$EoF?fS*nLCl1A&A&AZ8leE$l*wNmu9cK6AO2mLS6%6Cr-oC^*goHGZ`^6Lwgp2
zVo_iT4OGg4QxJvP(RQUX2Z+a}CCB0b>7iST3;KRwzdp2^OxT6>dg>E1{LVBX2&Ecu
zd@Np1h|BS7aa(l0GA5WjI~=nUDOJHr4O7Fj=@Q{|ar`w%7icL>toL<MXn0L&>+3y9
zaUcl6lsSv)I7*Go1bWvu=~5QPeJXCXE(@vGNi_0TF5*MUXa|wng6~2z(sifNTqzof
zd?#pTyGsc%94bk}r0wZV=D+>__jZ|Sl})?80<jd0+e|Gts%ASu7W0C`!7+?qr~i{D
z+K`d@{AE7uH6rAH(7HRRuGG|RJYh3?Iu-6xtzKY&qvXOpQkW7saNB!;HS<NzobJar
z!ygvAbUx$s@&rL~mq6B_mJPfU>lj?$466qkOTt5jg*`{a=ZP4$K=7f$!R|##b*G?u
z@)U^Z8?FJ=MwYE>mVSq-&9iTU^i4H!cnK6~TbO&;TX*yd0rgJk^C=}Pk4E*wk15Pf
z{Sph0*;Z?U-mKL+X!fWa(19Qunp0OZqz6DnNwz6@NIHZYnV5VF%4f4fqS!#11@7e7
zth)6w2fcQ~#P|P4ahES11e6vP??^rzvQf1CvC%fc!{eu)tf9?ALkeb6F`rD0>G0QO
z@C-8X+dJl~FQKMBP6C<C|9UN28{LA*T)uG=kRdBEI@;QA0Zu)t_Wz>9X^k9BU1H-Y
zgBY0)9uY-rYFhg@nE?Xh2QQd}(ESq}e=n?b9}Vr{^C$l_j?udSZNSL~9)J`rc{jiE
z5gL`Jk&(ol$Zp~AM}tqHk>Fbe-^ZuyA6W0nm+o~O^~P0~DKOjHMlHB5-wQAnN8>jQ
z6E2^&XZ&9}-2o(dh9>a$ko>mILiijUxb5h;jok{V20hpOaQOmlh0TuR+K8V=#Y;xc
zZP9%sz*UJ7B4r1S9Z8V`H<}uZW!m+nNOF3-!;|K;ee26uMM1S>fyVyLq_?dgiYW)r
zcVPw+PtZ%<^4JEZSj9D0Szc@nBZG8Ao@8JTJ!pI7j7vldyETdd(}JNE*7Fz-Z}K-{
zfl_?R0$LBz|Ba?n!%UOQL|e8NzE{QB%;hPBVM_X~3+z>`CoeZOdN@-b@n_BwLP>u2
zx{n{LnUGv9Igd&)PX&&@9qYz(yT#EAcU9ys5#K<x&e*Vp)+Qt{;UH-GJppo+wRKj0
z+gbr<zmKB=go{&WpyDz;L=e=ABvjOUG%rjYMbaJi2FW=TiULnb-qJN#Q}COfgVi+u
z-ANop1F(CW6UOCDE5W41TqzVtjRSZpDbp;Gk)$Xqe{=n+cV?#Pf197&kj@a`y!(60
z=j^ZGvm{}A2X509{%JOIaCdwhDm|$VXEKGQVpT6$=q%qz64#I!EmbulJV}hb@T`4F
z?*!-ZVyWZHq1|ZX^6_Eipa=6cu8aaPwz`L>)_#W74DV!i`v3o+#q+BP)%4zY<k58Z
zpOhr$hvIZ0Fwibz+W;Jm$wrdzLw>BdQfUTL+$&1X9;exmTq47$5Jfi%htxl{+!fbJ
z93=;Y;u#Y;g@*r>t?{2!tulK3S2Vb!%**uPn`vJq???X`JA?ljJ9*oo!-+Q>DAX)C
z`D!1?1Y)96KquY3Y3VvvY3)1aP%wmpHXHq~Sm_|o7G6u^!`ArJ^J!;mM=H4x<pB)}
z$N*F&0)3vo@qe`EPVg8+0x8DQMpW(Yj8<bNjdVUKF&MDAhDh1&o{C<m@Zo5b&+^7H
zRJQLepv}}s>0Th;!mgp!5hP=h*dcSa&v`eOeU89VJ@6HC@ptH9;;~(COoqF#9z1Jr
z^AG{qe5)yA&m%rvDFF6w`_VQrH=`{GmR|Cfxdyfw!%ja<8*{XC(Z6i(X>o~8%222s
z&YTzS4C#Gsxf1>Si9EZBNFsM%#fsz5bJ7gdyNdHjPEDz2r~)(FTqeImJ>(I5u}eT#
zQCy5uZJbX$WPKc{32&DEYK(aKcTM3uo(5i?h~`-V^Bn}tbn#WrAZdl-S?>s>lu@=G
z*waij;b&0j*BTs+s<|D}9-dB=Od33LZ^C2#n*a{0PhcPtdq`d*R`l=_jIO+%>9riV
zz7&;O0=p36y6`_H4N1Q{%o|$;UnMEsUN}(dY952nA~N+1ECL%YV0w0%jfzcoN_ci=
z?xIIvJN5i|K9WaW#ervnPszct0SzsSfnRI)m@ez<4uMBzK#TciN59h3Y>^w9qy9+1
zU*4Wr+q>C~vlcQx7f(^yfRSEfv#K0c`bbmCX*cyJ8SQxL?I@m~jZuym;5*crCP5
zK}sBZh#XN-qiY~IaAhIVN~t5$q+7%maI{t5p@*{*XWFBjbre2CI5=w|kJ-V<LR@p^
zO#5cZ9UJVwnyu)Qe_;{U&z*>G+DOayzIR#hVU&buPpDm70_@)$VtQ?4s_ha9t%**o
z6eSd&5>$WR`XOVlO-Zdpg=1bHvsfTGz{o;!r0si7Dhoz^5n0%tMg18B8m7%Jk#)6K
z;-d*xX`(`quqgCdTxkqCo;i|QzwY)QeX05Bi#?|O^%OMRyJON9X(}*;&w^F%Cq&?|
z_D0{zZ5EzHQKOXU@99?Ne=H4mGy^3M7DbP}&~MvyP|xHIenI|Ul|RSuKa-{#248a4
z09Ca<%Y=?XV5>b0olZM+(S@#y>EmJ^oIE5uG(h3#8*_ytbGnMy%})rrk%HCC@92Te
z>m_zEnJ`$Fv>j@M0UC2dx&&@0PTH@V0>pUP$l;M0*=NprRWsw=WhZ)^T>afs%-bMf
zrwSwK(UGHR@baOXLTbe;*!-2kc-aa$;Vf_X+zX354y-X#yq6=K1>4?ePM71`sR&xm
z!93@hRD+mFX)4*v$NUsn{ditwbDR&%QztTlh+b0@lj>7$kyGt^y>Gcd)!fI2ZQ0NO
zEDrA%rFC&%2L#wDR+eZ{W%KD{s9d=Bd>xDdOv+3?Ty%#u%Le(l9nYBC>9D}wM-nR1
z0U~7=PQtm~{ns%4MAy$6UI*bj41AcjK=KubP&5?DLyvC?;@^)9f<DUOx7&BF^2QCu
z37j!+;l^&AOJ=Q}7dw)OE($<Z@*tUl4&txbQ1n!9AE5!*^Jq?f42St!;Doq`lKLs?
zhex_<?~=mX*A(fk28_=4M=TmRM%grkL0)_oeFQbpyh0fd0hE{4xjN#?@!SuJ+WtCi
zW~}cUe;G7vsz|Z@`pWimpJtgEZZz!cv%!T#iNaxeIwZ&hf!`ja1)MgHZa;?Zz}t=1
zJY>*mMxkSU4Wl2?Hxg=Y>fPNG&6dsw*LQR9qJZFZNqM5qG~u+EH|c5I#A1HoL0j5n
ziWo^qzGjJzzmp2v;7{r+y0q8}?^3jrp=SI_?UnBsjb+2iiHL%HN=GH8hsq}Q&^ljZ
z(<1`zi^oe$4_L<Elt8qUqc^;%bBFfBBjOqH1yW<6`_Fzs$g}v|?SGg?nJ@+unRNfQ
zz$hPUPvUS&mCOrwccgPwrZf#{*WoOmyDZhzv)k_%cbOBRAo9uTmDnTdoqdLq@XLfN
z9}`<i*E471Q({iI9rCKc?~##`RZEm_J63!6;<+{*Va^QHb%K{v0lbKFB!?z2fMH8(
zrPN%9L&)z5Bb&7jLYlxoII+G9p=vuiM6*R07yI`JEa%4)gu$jnBF(pT<qEkT3L$3Y
zQ}yVMd@0%_ZI*|nWY~cs<*0EP`b|D~Uji~6D>g$qM1sZmoV2mIN!u-4l?P~TkrsK^
zb9Xv%*_IXse1Q#2Ui>LZ$3OR9j&^?O@Ld@;sF~OIS*?2$c2-!&WzrxyaGCgePg%B$
zTN4F(4$-of?;=%kJR6SPEEE1_Ib$L#FhRsfA+PzH&`Y@u(sXQ^=?EXg2kd97%PjH?
z792|wEsIYas7Q^AKBstb7i!){dvwHD;wRXLOarLhTW-6~36?!8ab0OWG)p^k?3r0e
zoq|4AxF=Zh0a2aGvXr4V;hTsb1t@n}6QHq{8^14goSN}8jX=OGoIW?|r8KS?qNT?M
zH3p%i90<ZiJmNHl!^&#QscVuOqj$k)FP=nu#DB;^<sls?jow6<RrY4G56Ffthugnb
zPjV3bn7*#9(g<;0zuRA6=BgV^O2+HM@jCWdTnmIaUNL-o2HDXRE_lwGOS(l1IEU2x
zsNu=@$NYtHzGE6cQv6V)Ne!`|ed&pz+BgBW2cnp7WG$=cQ4!h*G;iutDXD0<t$VVO
zd!EMVPlgal5;Gu_%2?jQt9%@a%dQ2*m(5nD6vn}s7Sbn6ANuq<l|K}ZnY4WinujG)
zE*Lc~>a57_;=Ne<v$s#FL|sUqzXw2wv?2{uKXf{iPyB<r165>T>b6!SHCi%yJ3U4j
z-5y|lkSljI5K`)*;D|$GaEzynVT*wLY0(1@1~YWS_3#BK6}>BMQCw3r@=8T<pewK<
ze27kh`z@RKP!n@;0>FgLaIHZ^rB}y05MfM}qj~exAn(4o`PI&fiR1}&E(2Ln)3_Q7
z${G&s$A0zm9WD&|l-MFDNo#rlfLb)|+reA;%$+G7#i5?)sHB_{C=%7=dbjYU0y|8Q
z*Do87Z>2#%Q7I`}h79wO)OsP_$QR3)x%$oUu@W84uo@}!f0RoSDM{`6P`W|{xiA%w
zrh=abHvN>rU>2c8cj1AsM1T5%_|olhC7#kErDft8N$Z%3?bKTKdvTQ6Mmt^-r5SAd
z6Tz;3veR3|q)L|_#_meN`lfQ%C3=5e>&2k(Jp>^-Zct)x!r+V_-b~gz0qB8IFRZ?a
zQ62;9(k;q~IWwnhKLLNh1gaIZi^w^8lnI~!ZO4%6!F0gp_B|yjQZKFFT$sH#Ku1)R
z>(7}Cukc-yB??bFYP{Vq0m_eQ%b3jee75D<;4JFkL9?@GtQlq=H_0B4os#^N=5{9y
zvq0I{bvBn#Pbo>arQP@R%(vQ$v3bU1Sl72f@9+J2Ix$#KMss1jtVl*Nr#NZZPNs!+
zZ1QPK5Ub8L22(`YD1PE>=Bk4=c+gvr&vJAfL+5X!RNXDR$7gBfaR~;{c{p4$3noqX
z6A={M0;=VwwrX<`pwwFB5=)tMh>o>8=5!EC=Q0IU^tJzJ!hh9^bjz!BVeZ=Gchiu@
zRWeLWdw8`=-fT^>hpj=1Y+8<?_V(ihq+3Tt?jb1RJ`?vq_f9wdI8l|WbhRqsFCGgm
z#|Vo~JSy}|>P!)6fvYWB%Mik|lj|_T7QN^Ui)5wXE&aqsKXdDs0h<B&?u&{<h*tNx
zQa{ZA{*1k%%A@budg?QBTag}|)DHrX&5R_8*P8`Yf?$w95LXBp^}Ob_U#fV(M$u~z
z>k;MlhDmAWVjp7!WX&UU!4Z2vI|uRdoyDhzQXeFQj43OhNwF)1USiH8EZHNlDT&?t
zL*G?lGIG^ZOR?FvSf<MfhS2(=!^+l-vo5I?oB{N0MZz$u<S^l{!dUuKMt^dD8fnVX
z{s4{H+g@29&#Ccs75Y&Rdn+-YKONDJ9azWi8aF6^_u^v1E>t1n=bqX_{B%5`=V1u@
z?Gn$r&0RQ}`lYXPD+_M(!4t5Q^x6L=-q!zo?zQYG`tuT&^lTp?o~@z3+mtMsr#f?G
zREZ^x;Aw-BqC=)#G6+>PQ598{nh1S$5LY^-c}73*uniTr&_g`MAr2YQA&ytui;g*f
zgvgzp><$IeB4UX{cC3+XA)sPBZ-8;+%&=X`sG!Aqc9A5NWS~VxMQ&PYKqf4`g@ki+
zAe^t9dp+VBvQzh0gF47-)`}!%Y7i^fjoch?I_vOm$H=Act7MW%>ht<q0&97C4u;g?
zzil36)tJIJvz_14<Vvj3w!Q>Opqi}wn)f&s$Oglk5A_VPJ=3&|v1zht6e*{o3w*3K
z;1T(99rZShGA!xuJKbUk9*?w4$v<OAg+Io0fT?zpC5|fH<r{lrh)&A)3_*S)45ttL
zBWclrV1-DCgEysK8M?^-DF=fiLTEtp!cv72G&?>UJ~9tnV~0l5YnK^~NSm8yiN^!t
zi7ZDiKz-rMn2AAEJXL*n1|s~HO%QoeX;Tw&wJ2cFxY7R}^D`^Xti&-RvnxUeo2uF0
zq1k`&hnbgEBsJ>h?NP=BSlONLDw2M^h2qrGjVs5R!Cfb{Q(GMGv98~xvBWFGDVwSt
z$urP8*+*PcHDO;f;9=(~<**GN?uH;L@0)B_^eEK{mH-F~EBt#b7YmKopM!;rY&g`e
zmF7v^nQ@>y<-aRSNRzO%G+1xcEsULdNn&lBE~zSj#U<4&Z82oErtCN{g;*Qd3KdX)
zUN6bRSz)psngBAKUR}hEB4u>=f(;3vA*3Zrs528Uh1C>}O_<))D;^^MD}^5{LaD0(
z_(7q9nI8NBQ#-xYG7A$*hnd|qYA1>VC=-rwJClrHtN=9JuB#j&p0EZuG+WU)jh^p1
z8jKq=yp*N~;^CD`?TY%tuXWz&KounVU6w1G^ZJBSISx<f(xG{f0hkLW<f%-*sbql7
zMo|E&1xx^*C+5r^*?)jP(JBs9+%Brzz*7DY!J+%Gink>CNl!OdQW;`0G7L26e|Fmo
zq6T0qYyW7pw*-Zqy8~m019Yp>+e&*gIkEs4aO3wx&7W1<Ohd{OSi^fN-yDJprCN>&
zY<0-mH1W`696VtM;5}VI{r%6IS<DqzsEOz|13j?iB2XlC=r52d?i74toW0fsh}hk_
zc-J6-aiI#rf)#M@nqJK*nbRcTg#m+^6g}{yJgaesD>jJ!$yTRWMMA$zXS>oSZovM#
zY2zW^!v~p1?2-W!PDoSP^!C^zlE9P=3LbGjaUWdUZ{;^)+C?w?<)b~muD=frETSsV
zN6xV2xj&dmk>JbmO*4DAMCQ?JG^)sqB`*sb%X>h(-u3sIo{_)OE}{I~g)xRysmNMx
z9JnYGvmLr3fXEx7&7UZvl*H0mt9=0MM<GRs#)g@<-M<&P1G|C7A>nIrDqY_g(>84U
zvTi9<ZF?tR1`I?mqMI}V&F2~sL=Rik=^uQD#^o!sCH?$FaM5+r81tM?$6<pmbK)3U
zceG4<^lljr_H}XqG4+lVkR1XmRs=~#RXWKH^~;f_0`c~d$L;hXvRjt0=^Q>i75PLp
zVy6D+v%&M0cf~@>K36$M%}5L_{-+sww%HZO5f~T~@b+7~S2ETv6YGe$N?NwYriD}9
zN<+{nTD|M3p+z-cs3}%2Ok#5*Cp*tBt1x5WmIb)bI_jG)WX0klDs)zd)UKMm*R_Yj
zzff$Lr@6iE%YBC0=u#|r;vS+0wn~g6MBVM(a`FFU!?MCy_4(hn*X9u!b!e=Tmf1-a
zvr+ns|Je*FsOu-?nEP{u>#LqH^jKX`0=RFcxaPl}v-b`mEjMoN0a8)xXJ-mPTBhRt
zgOzh4&AH13Eu7`0-5wEfS=l$<{{+jYX>wW=t|{!pO%_kso7^XH-T21Ihy@qBMF}xM
z5Pc>9h6f8j;2#o7Yb-GDW~eU+`gPhHE7FvBi#HdnlzbyGWXbK9?Cbz9mDTs^e9|%C
z(hQF{4Kjo5;ePYw&8;B1b+W<8+}|w=5?E3Rp8VKGw{k0aFKR=f4nZy7k2%Q<%x%t^
z`x!T*GPa<?43&7_j&Q}Ib}yv_B0QlN&5V#KJyPLEPPXy<Wu_Q(zEs-E7$1Y$CFL4+
zGg4aju33PSBOl&kaa{eZgca2Ij!%G|VP&8<c`xcTq}zyKb)?#R09Het3C^27N6TRK
zE(a*v*e>>1jS<{v<5DvCcrL|@*I$^>7?mN~y5;F~c*g{@4B{+&sybOYtgJR#H6tXU
zlTycMqFqD9kmGZ=ga;X#ZCal_WjVD!A6JF_7#PZ0K}WSwW#UMMsJ81)B_EKDr{}n{
zsG$(?VV*qPyJ_Sb#MTbqk171_5(o1=&wsf^*LGu0xqA7CPPBwb4257!<3;}s?Cr-F
z7DL;ktYD6r$TW*hK<)(bLvVY)*o-I4q~6`;lm_Z#dXgaeeF~^q0^!1<b#5&e`ob?`
za!9;8*o$+gY2($n%pu?d!kiK|jFt^{dQIatbL%u_DQ-HJBaNPRxGR{Wg)s;wIp4YR
zVw4H+Si?nhJyc|AcO5kT%l}ZLJ)BDlP)xU7eh5?SOM(wdc_&t+B~b6Lf8QQL)%$Oy
zk}Z+T;zP0QcqAwwbx{KIpn0N8;`2DR$?`A80d(VDoW=UZH&aKWKYTLca@7`ob<6d&
zy88((mJ4JTXY+QgEzw1kyAGVM5Z^Sf`)DtxB$-!joHS1XPb#LKG<&KTmiL;!P1OXL
zb)(W}EaH<YuC_zhtdgC-aQJ?9^P;Hf%C?2D;KERDO4>&p>K~G&CT|e(nc+Y*#&29x
zEqR)+R<1K@Y+{b@l^YQ0;3i1+eWXNh!cWHItXU%2Y|jWAwzCk&+dBh8+*>AE92m8;
zFU27W1h59+J&w_qBo!)njz_C~^GyBGyQ~gl+6;HlWf<O}5p5tBJp%4X-Wrej%ww7A
zz1ax^yamOLoQ{gjM50jFQ?1O&S`cbT1WT^)F3>R==?sUfy7<_`Rq|0`NJ#4Vm@P^O
zP?*Y5HQY3MfUAvmayGOPZAW*<&lm#WBgPbeWz`^Sp|WGU1Jt;5qO@84|DR%lx}!{z
z#zP$HQ0XUQe1*6Rgc%wdsz};?iDn#6^{z*G20|pg49lmf%B8#Yk(;<R+K3dRB?<{+
z$0_TVc0?h>e?-9bw%6oj0ZaXp{Pyk!n)2^;r^Z4IA4EHGy|uG>N$x+>X6F291R|L4
z7YjogTJj2Ff8Tx}McuFiz1O1)+6bjVChG+QdR*&H9Rs6`D{;ANLfit@eVauDQ>ynQ
zuZ<Eser?dLTGSxi>#W_1brlFJ1D7vTi|0<j2$pi<9<jKMY*Zi=@wO8ncfTNahgEsH
z(x(RUF332L0VoXd(`uZsxT0BGxf_sk5Gvd>1~qvD7v|PmQ}6jHztMS9%Hl2~Y>`4W
zks+0$%YN7RuL8N;`^~wh!4T}3nB+(gQ3jo3ibZAP#k)f=k?z}gwc<eJ$mv3f8~bG%
z?MQ(gBku6CuVz?s@7fK%Tf1B>jAlhvw4)SC@8+K!oV~p9Qv40t4*>qh1E|y$j)=*u
z9YAM+HmEQ-?ABVen4U5)asRa1odT%ulbqU%I6dko`zgWj$x`w@9m-h7cudUiQT2HZ
zn;kG-R$5)9DPsl5XyOsfx79MOU|WdJd3%JsMM-qILbueNKNZnvtgM*?eWX-t7o;9N
zKPc*0#<5v6rh=vk@?@J>gn;QS4Tjpq;-JqO!Oa`=W)dS^gS5?ra;t5Pm*r28Sy%l1
zlvEiF$icOd)H`Ga&~3mwDd|&1Vm{|zqHC>iBMbK5SOz6tqr<l%H5W`?hT~B8y)(-f
zNglpcc&_SgaJgo@{@7CLf4%{ni;WChwh?DHGzKWbm6K~<qs!;M_Lr*D>>-(<$K&YF
z@Bgv(e5qZ?0?7En(afSIH(1o^6DK~TyBwvZvaQIT)ux^BP(j8H7)xxXnc-sf-)a*}
zi8#s?`-%fyg3%Vp4E{yi2@dOIa&O?3{ZCC)juD^8w{b%ME@LT-I2<PX0TudfbqkRR
z_x&^krsCn8II{7R41pX@)RoQ5&ty`e!R{R9C{N)-7@!1n{tj@)z6%cD=O}60sl?(#
zx#09OVUcZ+&E1(yw5<53Bq+B(f_NZE5&z$v(#14f%bH+_vAn7y5?d}|3a%My?{W3j
zsn!A)?)(bF#(wsiVW=8}gH*%j><j8d(%9APg4gU^9mSqz6$BUCbPh=Woobmlu4m&T
zeUTp(Y3+>8>GrTs(is38Bfj`A^AI80IixoM2`|FxQ6FQ1ipi}s%<tKE>69pgKTsOU
zTGMn*oY$FYEt$J;%mlHl6sIR?Eg6H7U&geE?x*4*`1T|OciP<q5xRf$CdN>ytEbqz
zGP~&Xa_CDXoOw}FQnxS6%+>hl;pQ&0`I-QBu-uOZ78u`tq}=HXNKgLnpbdi1=iG+~
z)vBe1>(wj(Wkq^8NrM%(1wj~JYh|O}P&7lEB;M<~BR1PQA`CA&<Oifp_YWMZ7b3NJ
zx3FjGK~~C~B@A}l0kN@k)#RZ_)-<m84!#)l+!wIaqG`XwUarJ^qC~ODLGH*J+h3is
z4APJSG-w@1|Cg}F&5M{DocfKlOHYBVBL53u5HSo5`JDj4F_)FsDMX0>eHTxg>se1(
z$)nL%oR$$7lPX;vdfYy)=?Ye@R72W04<qQI;3jY7$hA7@PJkf?g8_QHhytM#HS6h7
zE2hJuqE@v#<Y9IVXt-}1PO6MO1r5pUQl@IBwBd>Ly=R$ATd$2pJlvyy&Yx$&ha`fw
zrx#+090P}K<6TrjIWv4(TUNB$BDeH~qkmK<tj4uM$DH0sjjqF62h+=`IJZ-#lo{y=
zb^c6mPn4K9676sq*M6?xdntxOtosd{EmSdSD>&#{2{C=|BXEBci;{1QaLLN+F=0dy
zmqOAOGy6i&jh^CkqiWO@!P~o{=_l77pWoXz1YvCQ^0p@sYe>L?MuT3QfHKZQI@3F2
z-pRoB#|qx4oF0xJj_V)Y)cobTjgx?<@tgP&_$fC$0G0#-CYSKRR7&HvRqMt16}Jy*
zhPHnBW==wEc?<SeBz#KqY16loX!^7jWyh+U{X>p~ex7iD&JUjecZx!!IHKDKxp7%&
zk8bH@NU4}*C76^4!t$_6D0Mbv5!);$O|ZBgJ3^ARa%_+wa5QH$Sh|jsVg!V@6?(%S
z9S;^s0DCjj!^I*p-@8(qOw{{|L(*MOwcSdhi(O)uiySKBl6t`9<mNfC01W~7K*{ht
z^;fj9d{TN#KO-$(AzrmUin=9-@x!V^H3~B7p;4Vv@T@Jfa0`Ll$t4w1XG)tsegZ*4
zC>MGS(loDR^4QAT&fBN-HZPtp!PAQ1xz{#j>c20D4)SNYG(2aWbCL)GNv1zl(Z1eM
zyr1aUM{<ugUpUUr_T9NW^qohaA(%{a{$hB~yQV^$V_LF)pc@K-ZN0?bvj>k`VPwLe
zG4i4j`vU^_dBV1n#GiH5V*{&a2=w=oWnh@TwU~*qPJfBEH2TX`J^A0YC&_{ome_zx
zmnu0hB9__D1_0YeqeJRu6nR-6xYsqfo4%@CZ+?aut@@U(s)RuGP4VZjH?LD0u%6`{
zb-3sqoCp*)I9Q2bY-~vs_STmN7ND!v<>zeP_^VG)xIMmo<pHRsd`AO^TNEgZuDy%W
z?cQ?^;L?GB(uqESzKk}5G0%mZPt0}N1bQ5rZ@H0N5bC`yqDb0kG9n-n*KM<MmTU#w
z(!6bZ^YzE<Pj}Gc@vsNXSg2m8B>a>A?xDz9fP%<YiYEhYj6eeH_Aq*t(O*F7Jp>dh
zo}({_zB>spo2{m>_TK$2vIvw!t2q$6b<QBfU7X8iIrx)YC1F5GHB-iYd*lxpM*rNK
zvhD|(7(KS{_+;dc^+K!}D>VnLpfV|&a!Yh0hBs@3M^z@>$>(RdL|P)RcyM_5AR+MY
z@M&Q;j;VS-dHzlT27bJ7-BSTkmpCHez+Z4?PUaBY8)GOSY85_JWtWm9-xk;QQa2L=
z?f+3u&lhF3{5A|~lO9(VU;=vjFQ1{+sGcp&<tPD4JPt8lN{?wcn-Y9#M#k2U%QUbn
zewkD9PTbdIdwe8P>Ys%Py)ABwGVA25Eb)MRAK!HTL{=BthzE)bu3OJuQ)&+<-4{w0
zqY>)?dSvqwX?4(JC9fmU`-qiIPk4ldSb{m`17+X42di==gv9G-^ivwA^oL%5iB1~1
z#q=aR4n{JP7!=vSsdfs7iBkYWJH~C`0yA9do`5KNHJ!2nu1H(I`YKpJ&QA=k*+s8)
z>W7Yra2!QLvqeZLdotaom2%ES4eZQnBWpi<8Z8ek1>ygb7f8+L1!FNwHZEGNgVA_O
zKd%GuHKtBqyn|~Y<1!-ArQmfbifR9r!DGibgRhDbx4c!OHC!N$Mn?%;>;7G*x~Ugt
za}JJ!qG%5l5F@@wzH>g^oB60M8;Wq*YgRj3V|Lq@`}QKsB`8iC25Eq|@NOzFi!Upe
z8{jV1SYsXt`of2|ef)N=;}JhuJ}PyWocOp=C^c{CK+~5eK+osx)>V#FQBURbT+1*g
zuGFl+>w-X3$ip51*^+)Ii1E>c6q5B8`CbqG*8V!f`xc>;rrcq2uwM(xR%kfmh{D*v
zEp%-t316_DJ<i&4FFBTb4VNkHthR|_q$qm^^~<iXh*ybro%4L$Bgt_|QhM5@z^Iw?
zGtm_{>|-o!$2ZCKiENnE$*gBR^*8R#>WuQ~(3^`=RD#B!)Bb+_WGGh|JSmF+f##z-
zdLxuIlYX+BFm-sEg1c}f3c2GFD}ZAj&#|;wbM}0{tTbJnf9Or;5Gg~^vE6<N=TMC4
zP`*?V;b*DZ9!iu1CPfDBMkAff#t;j^1GMgCQQ|0^Pv$AiuKm{yH_)cLiVF(<=inp`
zj@*~n5P3rAkE{Qc5A!vEH?C8#`c?#=k5n610XmLNDBP&{@4AmAH&)mB@ZZSuqolu=
zsw;sNry5%}bz*{!YRvGM5_;I=F1@C+kV$=-9bO7|Evssl68bGAHcBYuaGbxh0%}&O
zfbMJ-Rg7_{62K{%!Y*DIq5_4GJNH0Eg;B$mNMp92R<i-Y971d&0qFg>F0pLZhe!r7
zVv$^wGvB4vih|t+AGp0vUPFGwIh~xQ{Mf2VL1~(JQ?ys0&_M4rl9lgc7T&~dwbW6U
z7#o%*?D=`?2KZ#Wk9jn<hhS3a2~)};g<Mv&UV*D*E@Y$IV9hsehSvm(gt)ck_)GI!
z843C&Jzr2taddAsH-?CxMRXc8yb&|Cb9JFqRso#IT4po$zTBSY$6s5%st1R-vPxA=
zd)=`Ab6DW=K|uI2Va)=WiszdL|BTg`d81&JYy&e~zg3kY7K&z~rU}Fi&EK<!^tisc
so=f8nj*1f-w*UYD0Mh<4rT_um;R4t94giG9<~}eDivj=u00045S~fQ?jsO4v
literal 44504
zcmV(lK=i-;H+ooF0004LBHlIv03iVu0001VFXf}-qgt(-T>vZsd>Q$l_#!w{t0WW~
z`<PgfXrKb@lpPY-9GOizCIBn<l!cIy_g*O3*K(q)lYmdqXh!afgjRV)!4uG{FszGG
zY1LY<%z>4%D=@FG&D0g{n6n<pwak<MSGKDx{XYdQ^>qR2BgC5ilV<hhDByYlYmzaY
z=P>KPfZ<^D9_$sfV{^K*jIC%G-&K}eF1*aN-)=87{k*liqea$EgwRphd{msI580XI
zwAfj3_*8`X58Z2pfyq}X>T}Ot(#3RAPUFkA;J-G9Aj#k9VfpqLt1t%m>3Qr}GzS0{
zLxiu&&D5))AODv?DCHB|34BeyBTz;6*5k^uB;o^nNJ~&FjS{K~AO~P^Ydd0ZM^a}@
zt>=HWMbx4jVh*sGz@X-t)7!ls!;3^&(Uk>~<in@p3iUSv&Q`Ig8k?AUrzJ&Zp3&69
ziOk54f6e&c#O>*5o$kzA=4KIckm*)_879DEbB=DlgC#jeogthHZ_5}q4F3Ur2C5<R
zr5c~xq{FsW9s-EH03Qth=~){%?fxCBGx<Uu{HqSeu>D@C+wwbOBcDzVmgC^BPjr$S
z4IG(1o1%ISco5pA4?4HiN#PG?^>@k*a_X3AICFSBlv?EI-Lj>k(nxc!vX2cIH9?Uw
zw}RUYksJr23D^c`#G9!OoFbKpdK)s@wUs|yMRe8N9&56Yn;1ii-X(LLhBs5LzX87_
z<Js5P?(aYl`ayqqepF0K(ph{3_|KSAd8o$86l|FuQH*>uc~_VLs-JNE%~dja8UvXM
zZpLDOIf_^+Qa`+HLDA5up6!Dp`YzQQe@}YxmnYwZ>_CHi$eR6tL2#E)SvZHF27~iN
z>_l~2yz1C?s@{1hov$K%nysbN2GL?K3&CY-Yk~e|EF@{upR(jO=*qS*x4oe_pN|M!
zh1HsKD`l5_qE0J;MC$j(TW&9bqr5||3gt%wLZ+wqwF55fM&7_SB-m%6)nKHC!4qte
zt=1%iOXwvl=MICKg__iibjpk=WaQuo#H;CST4^9<{j2zF^#VdOtXo<jpAnBt@jjRS
zVD5Vc@Z1U=ByUIDZ#}(auK*3V-EUki7(*A#TNbjSUR}~_h){OPvz9`)HceCidTJx?
ztv-_L8o0wZUSi^0MG&Q~x%8ZpzE9-}MV9lv*)=C_qSVIiPU24Eg!Zopomo2^XG|Jh
zrvInqMn+OdUm#^frwWySlT#?QSt~LeE`-96wu@fz!nlp_)y${kzHGuXiG#7R{=zUe
zd~m-7VvUkg73A;}^Ws*L9}@ZgtF0_2ETQocOZ20Ja)}?+M7nZqNd#6_6s8u5H`(Ph
zrYcnyNk6FX?zKQ;^Os*hPz09|(l(mhVdv}Ur=I#$AZ!M*?;l|=bNFZ;FbnM}s8U8D
zz)SYXBNq=NlIfA#Y*#ZQhk^0#H8?GGs*CwrKr%PhA<A=h#@0j^{yq*6dMedPWK%^T
zaorjbEOV?AgY>W%to@%O4J+O8(XP0Hy#N{2=MN@x(zm>u(I3y+y{14aqOuG!y6K-z
zKRKp8>`z<_SYOzre>$#}GQa<Ls~O>X$mj+d@FmzMw6g@<?c7{-GPju@LKD#$(hv(5
zw*qi()oO+AXMATPovSkzC#y~*Fs_m?tRuvbZ`F*316b->>05yWGg%(P)0&gk&Nkj&
zTs~0jQv{~C^V*vBHur7@3&T^SPYMt0N0K!MA0s_4cx~QvfuFv&vkkI~t4Ca=uD39?
zf@niQxra1ibl3h}pc|0QZ~*q(wd_9Oituvr*!uh5?O?giqE5M^31`TNu3rF$UV%@&
zor7zf{_N`{G%k%O0Wf7tft&*~QlFiP;Oj{N<vKzDmm5e@P88Vjj?OVL%wZu~^;rSb
z2d=~5IVP$p84hA#`I{_9G8Wv0lvvMLyP_JcQ(#w2mbQ2s5m!}Zc0}Yr#Hb3WR$-Fs
zhZ*GuHD~kmCvzF)@<GJQ%OI_l8@~?15LMrt9}Vf?VO^xQ5r-;}ZFZR8nGM<vo63;&
zi~4>0JV)b0jxL>TrHJ{ogpw5nP~B@Nyf2Ay1M2VkayD`5X^@nF6ONSd-cQp#H~`(I
z#JkNLNeip!ni?$8<V2`-5%yJJk}APV3%&B9F;~OrbwqY<eb7|Djm<Y{!;}A&EDqs~
z1${ZC^d-2_+0wfYR0OJf7CATfP4OBJHC?wX4vp`maWy|j776^#9)=ZjVu7~Zq3!^c
z&m@*pZDC^7=WnivVqVBpP<Hq!_KMV&Gkwa(hUf*OfmH*U5CiVIhNA;aPg#L!<Hy<3
z$-6F*+}>**t<76#r}vNpnNaDwr%Me5joX9hnZ^2*eGEtzk<dx;r3}aAi-svmC5IJ8
zM-51r<K_r|x>_&pdUh<`S*K!AlV8m2$6AUxa%SXtk~ybB4M!4D(4op&=@{M)L%2{z
zf5Cg)`GHk)=w!Y0%hdW@LLzNhO@fKZ=mt>O1Ko<ZX)ZSewmeZj<$PzcO;y2al#y{g
zmA`sF&@pno%endI#FPIr9Vz7yv9AV`$%}`eYSV{<T01-{*-ZR1mCD2%^9`lN%lCC>
zsgKsd8=d29E@3zL{RTymS)5npT?Y}xoje;?#6fJ1no-f#x1QrIRTn|1jpOtKin`@0
zK>r`5Yb6=qIosdhLz?}7VbB=&k|FSZ9Fp7lV<e8#)HXb$x>9QLG8ueHj^mZm%G=UC
zRHVn%2P~T7IE|vvjoedQ9r^hTj4l-;fnj3a6WHoRiFCm4ORiWez+J4?zgvG8CUh+X
zS}NIGRc;Nr7K&&+rTtOm<3BvKxQ1Im9594mE$61emFlGxun7>gvgq=NNA07B5HwV!
zHc-)&mN=}*9?mJHW+T45<u^xS4?cHTwtiy8l#;q%A+d7^{tz8s!YMpE)T|zLKkW1Y
zB5HNwL26E!$;mhX)TTA%KRzm3p$_)wUQ4O)<4m)a4%w*XW^XX?26h2OqNwzCAA(`P
zo(u9PYJXuyBfx~>WTF~x8W%9~0~4FooqG<{_l*i6cJ4d+cWk}YFfr8q9F7$n-O*gu
zMG|?YngHlJmWLXyn;Fp9P=_HJ`&i6w1DN+NK!h@k+Xww~YDEzww><U^CI*n95V<wY
z5t_nnW!PuBep;sAzCE}yA;f&yjvq}Ho{}s?--9#RU34bgf^NAY4=E2IDSyJvCH4!F
zB!8Cul@z-o8=KGz@Y{%x_?E9KRCGD?0N)|buAi(1=>A%_fs0cThD~&zzF=$<zg9x!
z-3&U5{Ys<UIvBr5CM3n~kdkP4#wE^e&7&uCN=d=caU*F6!~X5_a5hs!NlI=bOlN92
zxI8RiC|dZ*rb!9<9L*b}nOPgIb8$SkzzQO7588pyh|;TDt2xro^B0QCoSP*oqMX^k
zlRqs23+vj9aZxRI?2<@vDN)%!?`<%7Q$0vR*4^iEr~*X@qh6F7U~gOB!S5Exaf{{4
zq`gZLN2E1UqyyWlJH_?YKoRIJ@Cep&E%<Y3-06mzEG`lwHHqepOYoi@wQ^RS4%|NM
z`k)mZkN#`~7g8Eb%f^>(uWNA|`V)NUa-%SPsxCQA+NU!wa)7cj3`$6&z^+v$pZL6x
zE70vND33$^=u07zP1~ar;mGZ*epr+ob(k`SB64<g-Eh*vfT`N8-&J(MKI^Y3A{s{l
ziK#*9btD+;Lrmq;88k_Y!X~WCx_hh(0ylTm=e--fqA7smcdj*|h^M+=;*jZ_Y?H}f
zCg!8JzXE)QGLbQ>MWS*3oGnE>(@-aqFqsEJ&YU4cqX81`8(E$7%55g_?Zg^Aziu{Y
zYIrTlV@46qs`pfX7lg?LYdIAUc4Qn$HxzWl>ZN#OtP;s6nO{1g!8fwSUL(njvW9m-
zB8q~kGhp)fuZq^(01CVJzQ86^HFtS7a`s{Mc|X5tL;x>*s{_F<z-84qZAXGY4V);b
zUP)v*2TjpmuSC6%-A!sC$_drI7Yd3}WPjs$t>TP8jJ&`<4o6o7kk+15FJB1EQt$iZ
zONPFyz37{NN_(|j$NkX)FuwWHS3>LMqB0|rws<2iS?46m19)-%3EjZ*iiQ}w_GRU0
zy#^8r8namqc+e{rDUzk8HDtyuaGr#qY4B1Z8vo*)MO2FNor!Zr8R5INELHI{=0Wz3
ziI2Z!fst-y>ll-K@uGxk=#{2E6_nG;eHj4CwWMh;Wr*i&h9wq?RN!0kLFxh>2alz?
z;T(E7<7P$ZisPRI80|+iL9Z~?%%v7;5TRqEcAL)u7|uU5F)N{nmWe?rc0`20L8+#v
znm>|rWpp25-0q%B1Fmo~XvZLtsU4+T4|xH%^ykg{aN2qz_V;s$$jWsQKN?H{_x+>T
z8MtJm@{s^(F`McUesTn^7(%2WN@r6QNt<MZgIgJUmG{@@e0-;R2Qa_pxo@D0YY;WL
zmk-8i)JVb&IiP&9t|*I_g;oF`SP(~<;;U4W8=%&SD(#_Hnis}{(>mQ>h@{P?GH=VZ
z8C49;sjBH4yN_ar=7RqFHH*&8JC1-HE0wAtx%(i&?m{G`oa;OoXmWFG*d-Lha_}pc
zhB&c@DZJ*(q2E_~ynH|QyQfga6aQ9^uWa)7t8^l0oitSy`DH7Fuxk!VLpK)Ipn3;~
zM&20zeLpw&2HHP*+?2mrq@vgUA15nD&lV@B1N)O8#P@vx_JZ2fw$lKh@M|%z_}+oV
zklsQc{m3)yxoSR{00%ZL3u#;Kpj=B>a*|%yf<yb(lb4+N-9pIb^5}O~REQy`_@0K>
z*)w`&CLu%1swmSzu;j6JDK+nDNO8cOi``oBA7s#q<J&sz8xO8DRmq}S;E?QGT!cus
zd-<Cc@U-jx<Nz#N4%(U@`!$Yrbks>RV*duS0K4`<aU@PGE2l|wI5NV0RE$QTflvJ+
z%?B*oc0vTSPG%}$+_-kqSG74huBC`_i>>69ms7$TgZ@cf_xJ0pz?5=#660V3TY7p*
zEfwdB><U&fQ2%jHzH^<!6SV!kjI^_QeE$JC{xG1AR?HKV*A!_hZw9l!H>!T2CN&{S
zJ<cmo6{k1&x|z`JmAgMyY5RYX{KHsOk}+6=6Olk>TXmpFibH9RBNBZcIRn<4!mJ<{
zlDW|{YkS}U=q(FnDwBT1_FDHa>etTd5vju<C?wUtH_*<D#&=l+0>ali*889Rkt@>)
z=tZFuX0cY}U{DHR@w_JBDsYo)F1}>@b|`#1Ig(bH2(q?e-8*~o!UdX&0S~|z>WE5J
zk-O;Bs_nrM&<D>1Xm~8q;q*;yMpHg3Q)F@p<fRY&8fUUx6$b;!<4WU;Ue(Loa^$hX
z3DG;!@Qk69t^2{ZD?0#Xn^VGVfRYI%Q*@xdiUpG=z<(F~U^fm%OY#M;Jt1I?Oez!9
zL-JaQfp)ku%G=p{8H=cPM;Z_|c2qEaNjL|xOf@v*at6xL)~z`y!>%o_Sr43Ums5X8
zQWyujiv()N0f@uE@zt)~aVc5t!WcY{5&Fj7fa2P&or7Y`>D?8{uc{v~0f=blF`EUf
z(awp`6fF69yrx8l5PY<fy#?qv?VteqJ!uVP6zwverZn8+@6dApeXsbqtNGKpP%nyP
z-pq9~m}qi5sKv+2D-k$NWIj+bJAQscY_zIfvWf1waX}twJd7strklfHF~l)ff&O+`
zv(7ouAopCkFyG(ZT^Qri{I3?|x$>3W4BLCK-SC}EH<)F3H_49lV0K7?g%miYV|!Nx
z6$Xj^xxGlGz{^(FaKqE4qtY;_J#5?P<yd;LITJcw7HHjd>3nD?Df?o?0?GVq)ia=A
zaW?{xx*5F}DhrMf-u#8D<6nY;NDuu0`YPkBOxn^2b__MduDqIpCelk>CEHZ1UEj#7
z{Kk%JL-T8$=CcY@LHw_!!@q_jHh3>}9YcHDjMhi$NdtS+cQmuX6%*Mf1l<_3WS~BG
zLS(2-KV9S_as*T2V#lEaB}1VmNeW9(4GSO~G%!6m&YM77k)Mq~Wi%glN8G&m$o*8;
zCt}6~%a*9j$5>9&>Xt(;Dlp-W<yg8h;U<q1%mp{_l!S-{L;F)cp5X1uIMJ!*yi{UX
ze8&`BM+;(bko;@p_?U(*YV+g_N;!<*+vf2Qp)<5Lkt(gKh}D`@9@wu*ig(ntu*<7f
z*T@J|(lyulJgDLJdSWEWHK*j*bZPe5+A3rty3ZpJLUO6(f#-x3DIYMAV}}|f*3V|C
z$nKD-yDCtu1;Rfgc&0Z|czas)4PaYEm7!V)w+D03+T{1E2~|H>IRI(?eD>LbiUE8r
zjIS56<x!>1zr)q)PEl>@k`GQ~NuqX3Sqd+-pLR6(j;pp$sV&bwyzR+Yyk*`Nl|SSc
zRV@7GoRQtNr*5A?s!ILSoan+Oyo)D@X4|ruL^8A4qTj88%F$HRuu@HM`^hg;;z-W4
zXit}RYgL4eO-NrE%U|Q~44gf5CBMQ6DROHA)FO6CrMI~BozH)nh~cT^BYyMJgpO7U
za&h)R<*OUp-6U1L*iTx9>|S(n*)QgyNQurI<hnB<5l*Vm!sVwxoLBqI2KgJaN9K_|
zbC3YjRL-lmtjfQsk_7=&N9)WlH^~H09de_?(CR4#+|R1r-!gkBW#h9xQfqSJXnSdg
z#q9-0Rl8KBr>;=0d4SMBdp`eL^cz*7v8zIk3<Fv&8HXdd2oCut3qS!g2u18c>vpxj
zfRdFR0aRZHpG}g)t`aVd8H+c%gX+?iBwtMP=~oaQ@ZKzl{m7du%!R%a4h~Y=2$1fk
z2W2YJ6fFQxRH$p|YQZW|Q0_1IL21jO;BXsadZcQzP9rMwd!{g`si(2+To2CjBs_4<
zQ8eeJ{yki{k!uG_Vz-{FA5>y`Cf_9n$HQF>gWLOK8c8qa{C<}Axxm}IWcL{`*8a&Y
z>exF706Dc#jTmK`ZBUlMB8-l^2gN5=s+7(2@8ITvIvZ88s<o!kxSTm+xKwi*^Ab+M
zfy^4ab95s4Pd2K?3+#)OU%j(`=4aOV=Bs_mkW*(`celRW?@G@r-5+}cR5GJ4_aDq<
z=Wej;%L86b@4K2NX{FMAc$P1B&(M-ciqF818T6V_K<;V`oEa9yo+$PSZpz)(kKr!5
z?6RWGIL{e1zahWs{<qf_;Q`%Mc$=jjX%xJpGj`!a8GTKM=_69IX|ifBHCg9b$sbgl
zL1u7s6CZP>cRoRMZ`zeIBQ+Y~(&%l-;erk{*3LR(Ia-lz_Xne6(2~95&zrNr_j{H-
z?~jO>-<lwjXg<Xbs*ExoFy3bB2<)r&9S)Vnt9GqJSqdet4A23*eEZgR6r3;i{Hb1r
zu&0cj#CW!4vDsOL+eFtNX-{q$;AJZ}{wvWy3@9sk+Bb1!b;P05nycP;Nkmv_w7;55
z0rHT!oRRZ;)z8O`pI9cDZI>;JRojmmidjINaFE%NyACZ|>N6DpXoZD=Yw}B9R_GyZ
z#iu8AdDSWW$NfjJ?6Uc=Z3MSHMHUT~BDJqo*Ek^HG(GzfZ`?=RFBk@0`4}YT!SU~#
z=F1F`xnutQ%*RrKti*c)4Ejl@F;F4HezzG^Z0YGMDeCkoBlp@<s_|C{`FNt_`gz4V
z6Ief1<?g(YqfOj>F=-G3$PL;2D!G)&hI^8xTLB{r2JhstC}%MbkKRoBF|v)ZD2@Za
zwGwc(*7#n>e#7Vz00p1^D(v(`3&L3aasy^^^cjoQZE^3vs?!MNt@kXD2%<|O!FPg`
zBvnwmP)+$%=G!j<!`lN<m<0kiT@7V0GFxoP8~i&xc>0}=ai-!+CQ}2U6K_?y92C*o
z=1=xb`LXy&z!@h)A+^?;DNt(=;0NlY9s@0(^jDB}t>7;&L&?Sm6rrF?y3VP-YS~_{
z7p!mIYnbq7HJkve;yCqJk;f-SdLP|Fd6nuuU%*dfJ)b=dx#aqvY$McGVaKRsfcN=2
z0rujd(MnyMX`Sxoh+A&mFeK6rdr6%Vg@&?ohg=Yt1g;6$tV&H3VC_UnIT<V#`=%jT
z8{y2w>M>uzAC{S{`>b~6I1N3m#>L}lSh^Sg>)wT3>jIOW>ab@Kr|W?nM#xj*X5?Kr
zwq64TyJUbR`1E+_w$wyIEoXEFzsf%!$`hi)L2GbGH!m2uV=C~xQ$yEdXARC+Kut?V
zBbrgj!tJLH5d+*2&rvaS&TC^hOIesP)phdab#${p7a!bQU(^rlMiAmo>=53H;(jJ^
zM$9XiF!U#I7gT24uM3veg#qJyFH32l*Y?eBz0QG5dQzUqZdO`rNDHD}K+G&X#{!KG
zQeqqo&?~qkU=c9E%%q(Hn-G#&?CiTcB@gdU5`Mz8yM|=M@mlO08I3i-D;el$>ZJ$$
z8T0W{i_fZ&$D0N|(7iky@*d@=Q86t$SaHxN;%xX7?8p@B@-xNTRNSh39yw|JRE67#
zT<_$WEHer}t`zQ5qKY1sGf1e8$XiQSPXePiKg%YML4PrkM2a;G7b+4=_b7!<=5=ws
zFEIho(9OWR=QEFZkn2XhZ#TNkQ)Fx1{K7De{2u_eY$oekn^d;9LMnfdgtK)&;f?uT
z_(1^{PTqSWk<QoM#eHC#BmUPE=2p}%m8h>&jwnq%orP+B2u3le%Bw$k7>?{S0r^Ka
z(ZnS4JqV1S%zC-5{+x4*wu9g#e@>;^Q#!6iBJ5d^qHeu0Dpf3g)M&${EXe!`h_@n7
zv%A`xNnr>LMt|{qALi>=DgyI9I#uAfCjwIreeC5}BUcEq{u0rl5-V~81?HJ?TOrq)
zbd!2!ydhOOQG91(1iY}Vy)as8=W%GFW{7U9%i*0Ry=RDE0~&QZnIe;xSrcnp9V*<F
z_!^4n=V@H<P?Dj!IIbDW)8W;2_RTu?tQ^uFwoMpFsRBQkW0cYiP&H&XzfMMeeBAkX
zo?N7gLz=z1G+k({M3+MUIK1bu+omX2Wpun2{T)|PUs9@@;Cr7};n%~!&p?@KT0o%~
zkrGA|7l>+7rV#t626rbYG8X3N$2$HRL^>lQ5(4Lb38|3>t@Y7J0=+v-M2uX&n_ln{
z2G5wE$-`@UT-MDjl}3(u?4^(;+LBsNwtk3RIKo(nd!v2}umbpe9hGZ}#%uQh6l+2r
z`%$m*J%j_=_Dgqv?-LOZePclyP{cCcZPN#aXWRt=bYt3~lBSKC%hX8m<gR^_$PL!V
z5Ek;wMHjNXCV99UDICIG8Ozk%a%%}=MQGSPcSBldxVhIst9?r^xCMXtl->ig`2Amn
z=TDrD<k#7p32k{{WFZ2fN>4{corFP8E{Ow{oGlvm&YdL>cReH57amQR`6Vm*LfRS<
z(w{G6NX463DgP9da9s84FYnOIw+-!Gc+PzdG4gV}6hr}Vj^ke}$x?3)Ij!koH<*)K
z!(*Wa!M#U%a#iaV!VTZMFCg~sx_8>iYI<GA$Pf>l;)WmNOtX{*ZL6pb8gL`}l^Lgo
z0@lp3rz@0BE8PH0?y3+m#4fp+(5FLRly>Icy1qXG4L4_J39K@x20*oglv&yx%E-E)
zm&XC2IXTF)EjS_1+rr5FoSN>YZ_u&rpziUsZ3L7!<O`D?4a#6*Aw!|Ih?w>%EJdq0
zFi=<!z&}wRz4zmHk|m4>U_T5?5K_#ins@8*P-2khaBcv0H1y<)l3jZQ6|Znul=Fc@
zv4QVN4@bSbUw*mAd+WTSt1+9}`$BbMn^vxxj53zeOdFwvBPnyx1T^DJuv-68Di~2q
zZXv1-$a^z_izoXrNV}M=>O7FRov!8RVweiQ+hXCuQWwoMXQWzq;B8v^`=CH5Q4~7>
zGc*6Sg}wK7cv*^4poi`+x)j@;YNKeXoi$mQihFx}_y7UUkWPw_v!kUfU!zg`2x$nD
zk<${3(gosadag-k`>~ECB*nQIz}h3*tk1dVDNAS`&&DDF@j>^d5Zad=?E%kN1h1hs
zZNcfPR^I$q{7f3I%dve^s+qrs8fNL*DJMB8#U+HjI$go7C*WW<hq^Zmju#8=a(I2*
zVtLGoC7n2dh`<kh<5Y2BF;d7tnmNG5ERLXt{xCg$E@so(5M&CtM>IA8H^ex33mwg=
zd&T(PIb!guI6x2lj^_WPwpGe(p~F5;mn6TgVhMPwr+R#0!4bT|;8g&@s#Nb&>ohyv
zeV0~(Y9oep$KP!mlEqR%vvV+qeHgjTU>}F^t|^hW4sF%m>&B|R$M6E-h!U0^+ZYP3
zj{9_OxjjQt2|ME^;K=nX4gEc3SHqB8VtHAVH#qgGmfbi9hth_~;%$=5vFoi=dDwq@
zY%d)(Y5Z5>SC3)P3T6vD+{x;=pxAleid0rhhaotJCpwIp@``D$s~)tny7bQ9<@e1!
zNIw`)-g(V%?EC$|QH+<a2}ikH*+TJh2h!^G=E<cYE*}?brb1}^G%FN`d(>n>V8FjJ
zZeA#Evg98Js}=YeBTx+Os0g6m+d@t+ZR@D78-QCy*B0JfRv@$wwmx8eb@FKH1TkK*
zTthsAbQ>uBMuiCvnCn2>EUGvi&ZeeBCf2|OS=Qm=?yb64ZENl#@=fU-e&k!8ZH?op
z?DWSrR$L=JN}sNGAeMG_lU)2_^Ke^Bmz(sBkt)f{*Lu?AJ9X`|4wPrp7109BKt=^L
zwP{QC8Nw4>-o_I9SMr}M{CoUtQg8Pb%(q5{WhwxO;p144<j~QJY&DV<M(x~HYRj@1
zvrkbQz>(9e9=tXTBrj5E`%u66^Pjl|%jG)0hU%$d_!!PYEjR55@KCY>@q6k=C5Xk5
zjaR+__YpuOFBD?_IB1)wca^tWxJ#`gpM@+wMoM$tlGcAiq+1fdLGG{aMJ_Ua3k;od
zR;+=+qBq|7ckW%dKH1`YUFg4fS}DL!h1YGPb<t!|aSf06@Dh;owfb3lRd(aV-=4TN
z86RH*@NIz!4F6U`XUE_-FBY_M$wJsjXHg4|_d5B(S$Y=fces3y7j`X!^++ZvC196K
z`?q2dhAPoQ1q&6I-dZPsmg^qdKG@Q5HqxI12mU=^HHj)m0G~d8xV@-NXqaDXKv}t>
z`|z_5)o2MrH?&$7?oLqT)<fx#lpr*wUk^n7JuKZKT$GL_l(X|8vVq}qosIIh>JhfP
z9?x?b|MEin3?LKjw&I^y4}~AD4#)@5=TJo6I>54<JM5o39f`k8li~hCQ}=N|Hh!j1
zE`la;egn)%GzB6%bIkwLD=cQ6yt!8>Fag4DmWW<*4GPd0WV*u48J)soM8&RA-D5M<
z*fZqS))3{awCPV=Ovrg<ZKJ&ye1re)uQB@87gBz*UNSUZKc34aiU7zpFZ%@b$m!-p
z=vWL;G;!f$0J|oAbBAq8C5&r_Rg#hS<mj>+mScHclGB@$*FuX0OsXPDkQI!x)6-De
z{-hr?Tie#Di0;HF4~~qa^%sb`fx%r>2VmxCotsoaRIGo+Aipye3OBp~7pCEbv{yi7
zU#h*Ntv-A|TB}>KJ4(3CfDF7oM=e1S??Ojv3*#A7+gUTOfmDAR(2mKM+Y@?Sl3=2B
z5&SQ`#^MYhbhc07FS52Ve_JOQ<6<-&PCIFCPsGJkT6I0yiM{F~u8!8ja)Dv$KJY2Z
zsQO5wd<Ed>`lhHv4KTjhT8h!S45wKR5=q|`48^jh-bXZd<;3A$CK#iT*&<r04Q%HU
zTFyOvJ^D<OTKbAPba3kG<obz6(7&K=NMRm#b-m`<-TCk9F38Vkc+{`BC|2uV*;-Io
z^bEoplN_dZHAt#Lzn>?lP_UjGWzb<jo_f0|$Nw>%kvvRPHBiHObU>hC(n~dx(WD2H
zxjmDhfTw|C;8|q&LI<h(o;$;(`T=&_{9S&7jA~)z9%<f`TR*5mVXE9?Sn_X%zU_qp
z$M$nfs)s64sw>0C42+}(#7?pg^<%ED5A_vO^tuIzFwGu^(zyS5SG;iqCQ+w+2tkyO
zj2+wbNAE76p@)5Ob9f4mT7E|@Y^0jP1=7RMPa0wu4KtC=WxUWz-sIAdGK}~@clo$I
zChT$LoyHv;+glfd+*W4Vatovw6p|tJ0bZ)Zn{wwtQMO62vo)U5PfqL=NaBC%qUC5`
zlZ888!Ge*8-BA$5Z66D@!|Vw4&aB+k)gV=H@g89zQW{IYsdI%di1AH}X*_Yv$RtFs
zhzmX;kB)}*M^41j+55ZAS<YA1Vc1QIaPys@thbgHgwy(0W?tILAxUiF<igKTUD*WL
zUOjhyG0Lk}fOpBUnW}KWQG`+xGGYfm&A%TuO||t$+q`V}j9Zqj$TVnsg}q^XnnY(-
zC$>A6J^i(UY!wuM4jl@}r6#91!hLvrIokuKbsjG3=n5=0rIn-|0-`m{uiRJ-G(8fz
zIa;;u?uVr#F(~wr&#^ZST@B!{n4H?5(}NPg%AAJ=o4>LP7fq=eE^z@N6<C~aERM<T
z|FLq>*C-nF9rVX4js=C66b><6q0JV&3{~QbxO|bfzUhh-(g`Uw639LwS6?z+;}Yvn
zxJqNfVW5jXY-Npv*7r3?>6v&)J=dhKrB=EtaWB>bDdxmqu4#NN*Z-05b&Lu1IUe-3
zoI8_nj7ItFL)<E3)7NKx&oN4|nnjE_n$fkuzK}XnflRMnR>A6~8p?tx)a8+CokTc;
zgbEotS??>O)x8W<DMeml>rlXNoH2(J&FxPp2p}gSdA65tYV$fj*QAd|+jn)bHP~I}
z3Xj#fYdnH-aZOrOYfU#zRYF^0`XF{}qFTNq(&7&fO5)>&qb~RZu&3D0w-*gKw>3gv
zi7>9_%L8H$rF+Uyq41e{;in+T8kWYZ{Z&!TbD!w&D~16f6NI~4beH_R@+tpiicdfm
zYnCcI?QJi5?$xsZ0Vzf<zX+MGH%BKgyS=*q4It&6c!x#mC)nJ6wF`Eu`2mq!s0xWL
zX<}ZNi&3?K-??@|z}xsw$jP}`&6z*~=}4Dk!a={ES*5VB>)JPqYRarxT2O8{-7^a>
z<E2pWc60|tr#XsIn-Qd1G94)5(L7VK@*1ES#?m^~kd|8;1R>l7%&$8#q%G;PIMk)q
zg-WR9dd`zi-FG@r@&xzze{;1#>(FuWrw6SL^DRgijFR1JnfQM_-YaduE5<Eu@i4=D
zWAxWvB>xFjiC74Q%y;_)0zPZSv}0rGn7}kzB@Ja|=_y_vPAX|`4Rv)!*uplfMHlg2
zSN#2CbLo4T{mS{c$^sS`y3%8ZRJ_sKf-5gS!)SBz;57#tN~_-bJU3h(lK=i%rV_NP
zzVOwX=)x~RRO_L(<h}T{b`xCv?%`?A>R%_NJ~hCUP~a|TF6nV#N9)LTxuwT|K&tOY
zw0a0gHSD))h?ksnw~tOZJ#&sg2$!P%Jtmr;v1C<6BY+lX(fS?)Fg?g_oW9j#l3i<=
zpGR4B%ai|J<|i6+P6erF10G^OyBl0JJ(it4$w9U_5IhQv9Y=tGW2zLmfurLxssZw2
z#|N$~ODsZ-Ps(G;c(D?Q;})0ddj=re6U`X7G24-ikVoYRYlB>Vb+@W6ljy)|cMnQW
zkum1}ouF9ln56}NW&cExV}wtg+h}0uThs(}@TcFI>lX+JJ~WM#5scit&+BsQGol6`
zj~ABM#*EMbVaf-sJf!YF3cw(gO$32OkBMHOCS{IDrINSkNasAgnRWSOTebU<bHo0y
zH7QCMhO*z8HY`*LeX_EKEj6Kiy58q0UnQzk5*gS8TocK%UDZqHVF}-dG1{{dj0%$j
za>o5Bx@4UuBue#L<XVh>PjHt?D@Q71dHgT|VFxxf^{QGAcEkP+oD^Yby-lp-AT!vS
zP#};vH7qPB>qte@t<Wc{C2}mn&~l*q)CE}kF1%OVUDug4O3&2btmHK5v)?pTtcXdJ
zn0+3c>sfmS7gxrRp+=DR1PI}RSqnou&?isB#4a&Ni)tVq>VfchPzU!U_GAo@AV2Or
zv9MVAiSA7<ftT6mEzmusIB}g*4{s=kyt!?9+pJ-ld?+_k3HRZH@E;FrI2VJ`S|uFp
zR0Mnyf|ii50UPv-@%hJe2_E6bYm;BY%-tO$pYxCjz5JiB9unUT97-dh{+!K<E<6GS
z-RL{<Zn|tmb~(=X$e%H*6zobTJO}R7^U^E6m5+f1AL=rtsyg$9*Xi}P(m|tohM;31
z@{PIU)Cc}<oeER;rVa6=<aMh1p0JtREixzK<JML}tWfOq%x-XEC@MU-atm0wk8onc
zV@gTpNRwuk#Oa`l<M1yf)3O}oj?Cq_6vB1pFWCG~$6qIkzq}lr+wx9KSX$$jP);YG
zou%bID7R&n#{Mk_*_=CrUMfqaM4y|T^#kcZHJJ-H<Mg$y^~SYq_pEB|{JC@njvv7v
zCk4qd@$G@<tgVO~C&*dO7#6Gc)V@$t&sogD62EG;Ricti>zZN=*zY*50fRSVaLd>=
zZwB9kMM93ji8cOm_M2`8?gEPItH!s?8PHd)*@p(fX+9&*a0vc)IbrYeQ#kT!P7#UY
zYo0{r`QcDoHXggcW$(A83r<r%*2yV8{|GNtH@51rWhMU^qHp%bye?z88IU`hEb$pO
z__?!UDUw{NwY}@J0dD>wQwPrS14+lT8h8y(MlK4`<j<K_L7`Q}jaHS&!<*h2L_=Ck
z^3<D3@5xIAQgx006m>=NY<?RS$1I?F81Wg}mo^Zj+!C_@33W!%!Io2&R>M^`9wb~l
z7l4B33$nJn9$(p}uxX^MuP$$>Y754}jmP;IsyniMdG<PGUqgFG;isEEc>$v&Vb-nr
zU|}=&1nO0+;up@A0SXMQx7e)vFmbJpr|){LZ7~j7z<x%gy%7N;UbEeV!4GRYx8f5t
zGyzBZ6M#3)y{snKM<a;<#?sF^pM}UTw&mfS$h5RW_sp6n_<)b)^0GBd-KzsSw0nLT
zF?`SfSN5|VpWAZ%YnNzA*WHvJb-oop+!jXY4YPF}6`g0P)3p%D6ZeQ>IQ}x_?(?#8
zxsDkDOf#7q=F|&+`<sD(;?QiD&;8VVs^*Y_>yO9cCc~TTm&3eY`Z&x6UJUV-yt|Y$
zAuCA~X^pC%R;u<@JVQ7zH@U@mS#5#4v$$2EeyZ+#mQbQO<e~pD`_~WW!lE<qE+roo
z4`W4^40NVXw;&=?s*RJ2)1`T~4cl)HDR#x{7Cn;ViVL*0IQ9^qXA&|ba=u==D?gI)
zuE6YFLlf=s)gdgH_C1(cfR;O)c5m+znL+LPw)$hf{nA<Z2|-7So%0Y<lX$xMg^0<h
z{^&w)NP;$<&IxWZmrvZdN&2BWecO~w+#_!X==vjF#`%I1Pk|+lVQekycnXMf{6}b9
z$MXqXdK9}UwM58Hw0j^~#5J${I(_41jta_aEo9Y-ktgP=+6jP!t^Lo)b75Iz>^PMs
z55}E*nkCj*%F)UPtT%;hd&b{YbUq^Yp3Q|ZRXbA&5=rRZczKcgN^pf)+Fzj?*dt9i
zo7~JRqW0y>2}f~aknnznGtF^D!5Be63Hv{|m0DL;=mnuxhjzy0L7x_xWE;C$rG*D>
zVIw2NG@*Cq0uGNtEU|f3z{}=5Mdq3jAlTGHDL*|1Xxc$KU96;Xe}onlO3C3XXK;IV
z!oxf5?F+ki)<~PE>bAhQ%t(hj)ZmtJQ@Y#g<@)p$2Ni9pZZiNSn+=+4wS7~AjG7EU
zO*QZA>z6yKQZzS~&2VPiS6FIVPp*^+i?XQP7eK%X50_-?zF0?xZ$>m4gF;X_N`dNd
zPUbyS2Y}WI3k~*H)@8)3^=rJ#YuWMl%N$6k{eM;YW`}|QY;hBP&kOM9M$h+~4vELC
zg&xo)q3eGaQ&=WX(`ctFAAv%V`7BZlGVvXGsFv=feY8*Q^!C@@XXdz&e2WTZ+8n&5
zQm_wx=;KmQRuadI0*UcC!Hu^@37Wg268|c}04wVC`Uo0Yor#EO7#PVqSVt%+p5vv}
zy}C~StyQprz+?6)m>|8q5b440b}^HWX=fW+Abcu8(<|LR8}`!@-sv$qn=Z%~X819&
zzsU5ku5Gh}Y#H36T`j~sR{NI5xgQQ%XS9`BX)#x=i6r6+nGfcm)AYSc!RmxKH_Uw!
zgzXrh_EA!eq1b%oTN7H>Y0%fVecg@#JqByl)L|PzTOcb^QEjDQ_cfp(`EP@g7d5+p
zRSn_@hsb0rK1beH50utU3elL+GB^*q!|?$%G~ZPA$2c|0=nx^YxHZUr-1!p!>VqpI
z_@8K*`(hG?v;&2Fj=S)jtT$K)n_4%Buze+tU;S~a#I?3@3XazsrUu{y>#jAqrJAvX
zU~Dc;0`og7gp{8Con*FT|M`(kTzhf=rjSGHUzqCk%mUSTsDnfXqz+3e)()S&%Y17^
zbTTVhiM@Scll<P+AiAc{Wix^S)_!Wz)yz5?!Zef}<?9EG(-*FWWMufCi(<KA6f|)E
z*E35!HnZt}SL=lD!Rs0ATf<6~O}QmsLr~kNwx={*dD>D==o{JpB^6MRx|zp+oaNDL
z&0C7Z=3+BAjZHH_eLRj!4EhhB`|`Z34=;Nx;qRD~oXjJW@Er&i1EUDk6IJCkD1Qq_
zn_ICTNS4}ne-~Xu0Got=8!Y3&n&_-WU8&<p8A<CdUdAE!G*#|sE}KU5xoG+r&aJ`E
zXFJ7&H(6P%)02WH(~|eU7#?T%!_!G<U*n$^O^okG`0J5sYPirQ;dRSac!~x<5myb<
zvSJ@bU6-m;TUrB|sl%+Wtu|o-QxA7^9yucYD`a*$&mfK@O}a_P7O{sVH+64Wkt*xM
zP-jXm0hq9lLlPE`Sn~zGca3VtXmm6kC1dzprCj#sM!K?m0Tk*WaQA<OH$dFm#!!mJ
z<llhgV8wO-YGI2qF*@^I^}$$NLi}hJO(+tFU)`Tc0f88-Faoz$@XSW3g^8{)>KfEG
zWGR$qovXPTizwr&*+q`QCsWY^t+p1qc?^XT5U2Ef@1{xfmxSvFx_OMq%3|0qYKf|K
zjzAQGp50hon)(mDo4qif%!#n=A1e?uutDAJqP0xY83Im@=&xpyUaS20`_?)l3&$HV
zaG_U^&ys2I^57NL3ph=sQ*uNnnRiKWMifILto1M0&Vj@Tz}T{?om5H2@8nsTs8c~U
z_Fh=X6z2mmSH>Ad!#3Y4jQUvjU**pH`wsF7p&dub6YagfnDd~!&{XAQ7DCo@#;~|e
z63zN41v5N<g(IK^dlvA}2_kyGELyk<<Hu7nTpVIbmSCV9nXGm&TOgU2^;TbBj`Fn~
zV3uc(25v<AM@XWc{&!hFc1J{+L`pQW=W%IC=|-*;R5F$6Wnc7K7#$}Dd`(?ZE*SJO
z3sd*(A<Q(vF^IG}KN)YYm*R)+0N7CvbFEuga~0SGl!K&x?t{M8G+{|c9bDwF_hY#|
z^wkO4JaCpj+vA35h8O5o2Y~+EQ%I{$Q|XUR$1FTAW%nV7*(?k2$#H-=89cX-td9ry
zhjG7ET-EzYmpL@JDB!b`loTzP@bw$P`zhohgjPh8LwJ9j$5nkOS?-!-G=|Id*5c-D
zN<?hmJ}WPw;pXqS6u|-l?zz*3toeK939XQ8J{*`4OIcMo=zdN{OUXW+1tfdq=vFW@
z@3nqIw&NM-gLnyjr2ep*$*z2K9||Y|3yXXm4a3~F0^2y%LGY^MVIb7IfiBF6YT1La
z7KOR)VPKM2^zu(FU9F`{Pz_Fbb7I6%vqM@NZ-8!h@Fl%dsSD|&8G!4Iwz}k|3j%Em
zd#O|<lYpOy#D~vN3H<1B2w<l4u-=;s0QlMeo@~?B7~1{fPbs^7JX)vnS1sYtXee=a
zG&SsXT7vW&!IckBEQMl%=?|Z->t5;bMa1l?N+6Havh<}BpHgl#Jcq>525L)TfoyMH
zC#9p8<23FoQ4|e<;hx9`GG7i{;UGa@D;c6y^<Uuke<0u}G~4*W7;PtR)Go5!QZPa3
zOOUkud+;PrVM}rHeD{f7HKOlla9h~jde}q}AUoY`(jX`BSk3eWdp=s!_7e0=EVg!}
z?IS;E${A3yXT28|iekEkqKq9)KHP6Y0@5OZ@qoUVS%GoD15CF;{5P+66Tt~<g6c{A
zHSf-?j}k;07iA4OHfKYL&3)lafkZc?;U9et&E4K|hu#}hLlzBQz?D~7=6PQRiaI<8
zyAm&9=L(C{jg*uSM0m~f>Ny~K2E(D&@#<Ws01ddR&`xFR=ezjk<0yovcR>&Y9bdYF
zGqsvcY;9obDLnn^C;IU9hPQV;bps0P6?Wiwdpu(nOx2<lj@aB+I<;V8KKS&u5eu@d
zDF~qCy67MQL3>WCh^|D@2j63TApUcV$A#~J@9leu$`Kr*K1M>1l8O34amq31f<@rG
zI^V5cM+_KO(&jjs%9|n}PZ=}pE$+CsEVeoO>}^hbJ-kN|pUKriOjo+>r366w`fEc7
z0WjqLs>QzLWH^j&+Dj$}13Ek^4_Yns4*(-PdI6B1^yEj~BjdFb6<)MuWb*!Gf?%>Z
zxdrv5STqiGSP@y;8Go)RKKVC9SbRDg#-rEmN5liR$d9E<8m`oZYm2|X^$DjNUSq#n
zSN(I7(a==P#jotQ)diQgr}|t9>tNnHwN+LkT4hJSB0?JW<DHBrG&8v%7D#!Ha+X?}
zay{wk&wpyH580T$oSPsqGBFd<tJ4;)xyuMPY<IR^-ry1zg7SZc4^`W^6BzG0nVLC3
zFV$&-9V8SoLkENrJ$tx)kuu+ju!~~6U!=8`)`5)T8}<nBqVh6be7t#%D?toX1{m8n
zZYK&y6!;?qTYQW75Isca^WQQC@Gg-bRDdISznOt8iS)J24DWfyFdPwGnFh-I^3Odv
z*H;f%<gvgs00VPr*{lb#2d_OW2nfX4*d%UKi^L<PRO&+Rvk^9gU=%@Ve;Jk}KwGhn
zm$QJ7Pd@VKswZo)#CC+HkSC^E1%!P<n~ga0&+|NIfgiCNsCsr&s%Zr*WRf}q>}tfY
z^8a;FHi%1;+2R;7%&8b_{Z+qTsq??PIp)Phb{H+xwu(Z(HOY1C+(;?g4q9Y-iEZ6|
zX((adPGepZD(=tdd>70icK|&6Uu#EYd5N<SYtz7RsPOv5fWt$?rR7vU2DsFS>2I
zq??{b<|sVc-}-W$WQXA__`h64@o0jH)_NG0uJ_2svTvcXXf28@W{!ViZVPb3g+P_I
z`jv1l8O|<=Hl@2T+g4o3)o6tcPK0$S@)|HlLH?RE9jxbHO@OudRE)uE9K)M}^#fWF
zRLoFCsi|Y~xZ4UFUTa2O+}J*YSmRfv?#Qdm=U|LR+~f#XvRN>M(-4uX4coi)!aZ2p
zvLq^Bch;bDW0KOs0h;id;u^NYUN&@u3b$pEO&kQ*GJ$S1FPjX^TD{CA<c#RkKGPPd
z>?>}Z72P^-War}OJf0Ypn*P;an7t({z?JjPP7zuC26K}RHW>p^u`KFd<5(JMh4l5+
zu*|rJt^4x!LHC7!t_SQykhZWq7c0B}!xkqZYkaaVTwv2_*$9ep?YQ3at$9wKOd;I*
za8wgwhvuVPVx8dmy0E@!40Ipq=xTgRb5V7U<lNeJw=FY}_{(+4rW_R0WbxdvQxFAH
zuKrXO$071>6Z&tCwc05mgcJ&a3OKgIJ&_foI&hnXmV{cwaapNeec4F$V5FNImrP2a
z1KspP;@^s4+;`LDgD)58cqEvyo^J*LPDu8SgaSwEq(5Z8bc?)w$jHWgj+mQvhv*LK
zdUvLUbcKe9mW~3Jk+gCNwMqn)S?is8K8C7&3rIn}D(pe<|5t!4&FCcAqlC@S3cT9B
zpV4=T%XgGmU2c1lint`Xi;&`~P0sTlyvC9X;i;V`jyF4WqP`+0?2~)SiIjYue;FA|
z;CO?o=8xQlAX+v><T+dg8vKiAubK5AdvktZaDcE(fQPv!@*JcMWb-6e32UQJ-Ha{V
zvt*!x)&~|es@3JGsR#Oc#)bS!Xz*#yz?@<WLkjNDXLnB>6jCU!&e^9^!&umRnzm{q
z!L~P3FjzS81))S})%er_PHnoHkg^9^RZ1AZ?|^S5)tE`Q?_N5Bu!6)I)1BPW=T=zj
zoGjvL8?z;NRpVdO7eh(bb?u*HMTJyPnF$8BCI^sxvc-rdY(1eH4v_lGsJ3#)f}@9D
z$D`>N6nqnMx{>8*_k^nN_UFUaTG(m+RWkf1auI%3=mvIQzN?R@v=Y0M>SnDW`nunh
zB7rk0VAx0EXs~IuznzVnfMg8zY|#ryObp%UkjhsX+ZTn+v&>wNIVvIFd{06DLN>Cw
zZ+GVR=TWJ(=m_D`=tA2v1;H)@Izgo5P6fOOS1y1a?A`fU_9^X2RY|;tW{HFWQT51J
zBVANO#~%!Q$EAm5J(6EZX=uns21Xt+4&^r#)_B$1sIzj~&j)aMjG0*@1%V5K{uZ*6
zWOJ%@BZDpH=(IwesKcR{rq@PsGo8d_a^~pF9nqt)swE%PE;LKtfIal+716^A2d19N
zI+W{pu&aer@w07wl>GHl=C(Ym<K6*g|G4(9LW-Y2WE%*7G^bh0-)QPOK$*y<<Z9g?
zea}im<Se#aA2wKKrBm<ycnpI~ZraXE{4A{XtSGwhRnKbT4iSC_ctQyic-g?5aFob$
zjze@sOvi^>nyX1UNOMV$459Nx65O4R#dEB<XN0C<M+RQR{UZ7ltzu)*%dkocwX@Na
zZoaIk7SK`ZG(ZAX$C@cQw=cSTn}s7`B6ZbWRtFKI5fYL*775q(Z^e3+%5Z!v3+KU<
zGwT<`QGH-&8VOPf4aHpz_AV&3b#2&5UIXSFC%Ydo7w=N7u31>opqsUbJUxRT2t`g*
z8mLQFaD?9nu+7m6W9Hx{fDDrurbiYvD}-!-WTMN?JbZEj-Ye_VRQAY~T=%isylzhn
z;gg6WG9aj4HQzi#;6kPx?S63#&&_vGvlL?R)KV^Zmmu7YW#l=pic6cf2xzv)s(8?9
ziwV<FO2`9ty8h~}GR=h<iC6-s&Pg~Z@M<yzIx<wDPv;LRGx=hf6nTygJrie{gkhV4
z=nQXlXe>{>DDb$&m_~52j{6Kc7AVR6i4fl#J%|L3y)Om&+iOpIcMUEf?AFnPsjaML
zw6grTBC@zbJ%M}K2u8AAE<%5`M9MGF!B%>>d3P1IV4Ux!Ltte=D9Q^j|72XMW34e=
zq^T`Z!p=#DsiJLf0Yj}$D`8Sv?@f)t*C41kwFbdIs&(T2#R7K_Q0~Ve4>y%4{{9I?
z<4f{QbO#Z}9G3P>6l!vW4MBe!<uC<YFDvpe299Po-@i8{upn%fvGIY3F*jQRFA%%b
ziVGg`Fx-ZfKsTuwZG-4ag0J8Yp*fKiiHSiA74%OlCFdJinXw3lx4k@I9ujEurkj-T
z)7QntqEyO46<5}+SA9N$k;@jxjpMl+3QM|+Rs2YeZV>zw$|@_K(mS}&%{&9=H7`&l
z9%I;>TrIcns74&dA*+j1p}~=P2mBPqhhwA|%<II&F*6b{jHOtz%hBxMg}3-r^9l{H
zypXG*B1v-Q3!9yZzamS4>e@?)zYb2GznWs0KB6Cp;8%=-s3$oMV<XZbvd9}^+FUuZ
z(OMPHhL->ywv;O^kC+L%idFBZlS83{Uy~}Zs64XZ4O(sQqPYa{ukYMD%BX6NiCW>^
zdfx{LFWk~|WF`pHRKTIl4IngUjH>`7K-<5=zeTxpE>(H{aB<icCOFrr-o)2vLAG+5
z6#tF>DH3L_tv@t3n?Alld!Ai2jbIJXiUYmH+{9Jyuc&-#dDZ_5AYOE^VcyJf!LcJ#
z#T`|-d@j&11{4op3w&I;uq|`HloY2BS1y%Q`!w3YaZHJsF8Lu!1zn2`#<rJd6|N|T
zA>>$#yVwJH4yjC-vIUH`@E^Lnq2KMKTxp%2bv%i7&nGCdeLp!z^_}?ze7f#MBQc#u
z*_3$`2?iY2%cMjzD><T4ve6Ov<yWAGUyUjeAYZ|4ZaNtQI7nmv8Om4V+C87;1)y<z
z@Tp_v?n3{DKQ0Y?oHNBHd;27R^62hPB$1{_HhsX^IQ>sidTB|R1}2x;^R@*MYxW9C
z)FEI1&X@04f8l4laXNnt@!tB3u%&No-jaO7rHMZnfKyBo_WU{+Djwc8Xh4NkhJukT
zy>C;@8`Su-(C8azB|y(p*&#GIpB`N5E!b#A1SvZKKL`-^Y13s1^6wr8k_DRAV*!K0
z7syI^^o_Sryw~%DKJvuo|As3-&pGVfrP}ZPVCesYmE4i+!;YJ7C*0nzxT{ytLr?18
z`<~hzlf&FN7IM|hsod6jY6mcdVZmQ(#Mc1b86LeTA`kPTD{$hPxrXKu!bU_GT%@Jl
zSJy*gfN1z<=arNw3modDy>@^BqLSJrfhj<W#@m+zPw#%@MNIfZNZzN-fNeG7HT*9_
zw98YZyvJxWNDZ)*>@wfC-1%JJE^lZgvOhy3(9z}xdHF#WfYCy&9Y_vv9OnFdVw-b^
zNtV_&n<-fuwZ;akAf<a^cgM|qi3e-~QE_gKvN2jU$gurBT&!KuAF$m(r#o4ob)j#>
zk2Q5D{&N&uMD(E95`TXG#L{g5xeRf6EyHNA@v&RPMP){w$ik;!+Lrt2QJ#`3fI=_y
zZ+5P%UJwED6ytt1>zwvDsIix^0w|z4&ZooAWl_n1C9za{X_2d6Sga(-*2G!SF;I~K
z^_vS#;pvX%Hk_Fx*R2JD@kUG_+(YccFZsECqidQu0JWfr3Al!?j*tx2##jo*e^twl
z$alhTkRa&}meK~%0?P=a%Q4aDO9rW>ItgR`68A2!xd6HPAEkRqi7{X2Mg!WQgk<%1
zl=WZiX7?-jSYcH&a0_9+s^{BznbE?y8|RRFD0zAD$?m<EO?HgGTTI@o-?I63AaGTD
zioW1pAD1iOvYhw}@@(Og#9~tN8H*}NT44N%JX^(=U1d{(3Ud7;0G-=gL`xT-t93!{
z>N^#VCH6rt@*xb-Mo=HK4&@2PLp1SRT;@v6{xbTwyKAv^-0@Hvt9$&~zZNuCX>H$i
z%OiFezSe>;sl`a3Gj>sn-sU#502TRL1kKQ;)MLGj;>HJk3gjNYAy_oM`zSGPAq@>$
z+5&B#q$dj#3T3rrKsDVcEsA}t4Ix>QqGxnlQhI89KG=NkpuQpUj{H=VoLeNUmb;ZL
zeLW|K*SHB=R)uY_3bqq=YLqV!T0IeAkA%N^4I|6jrc*sI6}C4KHUYz{tNAvaq|fKa
zvGg>p&Diwa=<t@M{-Fdpkv7FycFByyuv%Ep4vCsvM%n!;jT|tWRZc1e=}=&fldHeA
z^sH_-2PXxSYwrsmcAiQs8M@b1uWnM+w((|H-SNem;6cdd0&hOc>BNaEKXz9@p$<9Q
z#+$ZY>=mQRPokKgkGl=%*R=BY$yZ<4lKck!lkWaycocIGjNN|)9GTEAt-4KoWl8CA
z2w?C`<0w3}ye^bg#%5P{QO7EKaJ`3^-GZ9OahM~}+)cZyBneyqt81<vLa%D{-5&UL
z%zNj?By#e=9rFU^ob=tKJs{Ssu9(oIr%_7?`&<=DkRNrbB(?RW60b;5lt7gBy*30y
zQK0;}kooN7#fY#`N@33fnqtB=k+yqV80i}UpVu#?PLVo$Ed^&^0@rWhTX0n@IK>32
zeir^wMjBD3u?L->bG?`^C~xXafhR<V#P{lhK>pUlM>M|XRXXtay6}-OI5$~^mbQv9
zOtG@<>+1||e*$ijr5v>(gXxk^V=bmV+|=4p&18Y>CIePH^j(mLLx;UyAyxHuvkp14
zqjLj>scmI(b#Od&UCr=g;(Mj|)3Oie7^WhY0WLp5&Y;yefkz_A#Ou+8nVrMPZZy1u
zcD%yU0E9F`ccr8Iq7wTWhnv!bO+<d`hoMb|ZsY^^{qrM-0piv92W@I*kA%Q7?d$E7
z!IE7k%;FYv-RDlnU|xPj5H)`KK1@<+%o#BVCeRJsd@PJm!rhMDACWIjK`NRJvrE4~
zJ7x_CE527C%9a(gWPx@-zsTY7<sad#7l$~<*e=O_iW(<PQ>IsmyjuAU@4~2A0mWhy
zlUSqTNe!a;?oN&vzuo1|irMU4Fb}@0*iaaIlft95x+<U(x-~|9+PzcQSO^dJ2^Fsg
zhDML#pMd#9a9i7*`q#B4_$}iVt}Lp!xZ4)4ufAp;@Inb}W`(gMQwLgd^Uaz;zv_Zu
z{0acG6Q58ht0(g4eB}gBqn!B`$Sqq3vDuK&6SC;-^ym8|Pnu$=(n{ZQY)DN)jPT1g
z&=vIqZk=gPKADhJ<8%+qI#AAPytG%DC$(qRF^Gy;9UJu(B?oOk2${vKWdbs$Tw)6p
zZ@7PL{^U@pa5-m74-<ZZtIA4^WpuI2wCZ--3k;G`VC^h8r}?%Q5mYV*%{8)E@!^%e
z3o2ju0-XqW;;D2LL5O9;BBZ);fKgJ?#ipRXxO-=*==gK@bATk(_4fUk`T4Es=7$y&
z_McuBV^B{GK9E#TCp<ZAYeQhSKk198UvyL$zl+en90{D2dD~DCSFi+!TkJiAh)cvM
z(tbwItR362#U2&m!NP0T(Vm<^B0!FHcv1BbzIEv-zmhex3qOIeD2KfxPhW-4SIL3z
zG_Z#R2<Jm<X_;v38x0oXVhJklrl>$j2B6H>!{^N!HM<hjBy}yEF9*hd5Bp&XwU_$%
zn3Bh}gT*GekE(R%YywX{Y*7p`;;!pM-02NI{cph)7Nl}{eolTS8NnqnM25x<$XfDC
zSmSlWS~*Va*443W03Bw#d{L|OrCyx$VM>E2m?1rfU}lS`L<jW=sG;g>)DKx=bi=?O
zlENE4pw^e&7?D%USi8%}A=vR85_n#HA}3czyt~l$fHM>_{zg>?s3$P5b4K{u;!=mD
z2;YL$h@WBJdZF+aPfU`DJz)X*m>8`1y{r=Q+(~&4=S`-6i7H}R=Wh|MInqriLgUrl
zB;kA1<P*DeN&}mwAN^`beDq4BTt{;29kbqSwV|5?IZo`lniv_zw0UW0lT8D=eH%Q`
z&PNu*HDfwC@zv6MWsxT*5Dkt@(yvv$yArB%OjfxN2d3|>Y^kH2de&jgp{4D>$BaNK
zF=Vmp0HBTaSu@u7#m>?|{&sH#y&0OSwKRY6$jMOfny>@PD#mc3chK<nq4XldOql6H
zW<*^aq&AC_{-XZyKXjMiRQEb1RJUJ-AN(TVlcd03I(XqX_U*EqF^x>$KXX$c*Cpb0
zy_;*0Kw;!5FfeJzL?z&lSlIMu-t7+?BIBK*E8LLKs0tG5@kGVJJ8smpD`_2+IKT6r
z)Q``)Jy&MpHmxAsZ67Ss56`J%8yOiMe%i6`d8->$;Ze*-6!v+|y%XHe62AxYs?uMF
zFbzue&V$9K;7P|C{4!jT{_cBu;~nB?!LIBJJj1|xe0*}WX&*~RMKUtFFm)h5;Q1Ch
zF8=LdcNw44GkW1Idk=b4VA=E16}fyww!eZioN}|gzjyr%>&oDBOI6G8-BR*J!>B_|
z??--u{pCq^R412JOe=5`QjxJ4)q=7>X=g9;5$|SXVtNke1(^6s9cW7euS!?W^)Pm0
z29CFTnEJrTyChnd(qGGFXsczpH|IV_qWVv`kNiU=j?c*I3Y-deeWVOu6*uAj_UDXO
zXv>CV{(i^>ljw^!4H;Ra*)NR9^v0_t(`u+BOj9Po{5mHiU+Qd3rU$Fm7^WNbG_)Mc
z;=yA><&HOLb=E99#h$&@ekMrmVEnj2#t~zK)Nz?FM&DO&#wd@dl(%p%2GG^{5G(a^
zch7*@aQ`m}wt<4~`@`beE(3r{u2cj@CSR|&X>S{{P)jJe--h64qHpFOg3%Hn6v8dp
zg?#SwFsxf!bg3airALqb)IqHVEYXq~4Kn@O!(Nr(&_m!N10~*!=!s^Jfi8Oby7Jvd
zQ@_b58O^@Ivz-QYwLyfvkhYN4@d2v$ls_%tKDJ>bl%PE%5ke^X{0*<!KPEPgabO-%
zlkouHXU?E@w)NVpUZyRJ0rS=Xmk31wdIv`;tI^8$tJ^~VwA;7t5b?d%zssOpwXe*S
zookt(*%_liIWFQ=fgRLq-qXiZVmpUp2|LC%J!GdWa`~If(-k?5M%s(z*+RTR;68NS
zi3GtwD{+G4&Z}~V7V*ZRyxo2W1!n<Na4y(4=Kj=6b-x({_c1rgViNmU5Bu85g7pOY
z@D<29x3a3$K+Zc5(j((#QsH7$>*nGriaTqjMzW~;23eun6jk^HmAz#;=fN4HFo5Uk
zYh(-IcDv=!gBv&QCtPi5&KF@1ANw;CaNftYo<4oQF>joGyJw)RMC{pdE&n;Iv<KO;
ziR0rou<p1E!UdO8EkkUUpCZVJX^Xyi9u!c1<BhjBo{)I*Fe&~1GD{b_xc9X%1+MY1
z8mT)7R`|H?UgQz-^T505e;+iw3z1(nU13pYkC)0{G!M>qdWDqZ;_;HsMv`+g9+owl
zD>=KBD0WLA!PXai_Wu&UBP!z=Dmv4^=OJxLNP2Z&J&Iri+U*5aq0ktLogoe@>Qx%m
zr4S^)7t0~J-Vxzlo*M}(3M=ooNiZ|qMV~ia%7YJ<_1yyFe?E_Ak6li7pEN;`D5CQy
zR1g)JH|qEgsTfAzWFysso*7uRP<WmPAkp>uScjWzJS-$p`1*%1?4qXlu~j{RAw>2n
z3-wtTFi?w@|9BFc9?uz4oIDBd11q~LM-Qzo-EVL6gO7Gx6kzd5{%A_V#ZOSqsY4^A
zSnVcB!H|Sc9rH+ZB*-REQSC7<Ob<fVyqzmer(8&vB|<w3x3BX#*P+~Z@(8XK=Qk)m
z4<pfY-*^3|7aI`1+(L}|06oX0n%~^gN!tlMG?j#u{$%@cCtHPGj(3nDaxVdj*<mTS
zl0Z>(Pm?A*%Nvi}iE9tbbaCEolB0>Gix5#&s9AGu<rxSiSBh3I`H~^R7P;L!U1nWq
z%<L5}?Q%ogvZc6;=WRf#WWU1juN7_zT)y_QUR+~uLp#WYj&@Lc?sFKe$#MA%jnzDM
zxEogzCz2pA2mkQR3J`<bq)L~~XvGmTq=Va<s%(}R(nh<&5H<wfFYr+E59(0TlXaI~
zhjXk9y(%>Xz{&L;?I2H<i_N+LZZaDHc@@9X2;4vbIGkMO5W|IGH}PC|TAA!4?nUm(
z9@KHVkU=-w6}*?sCnbztGDdyGzVLBj()1T`9?GJXipFd}h_!se<%2AjqYB@a>#M_N
zC^LDDFZa3Lt{|6U^xRO!b>ad|y5Ru~DN#p+Xytxx+bm((5;d*9wE4{3raD<6Gcf;P
zf4AB@P)o5VLFxBB9|*$s?W97PgYQHzad%D;eG+)N*(FJ98>DbN>-wE2g1{7wp}{E=
zDT3`C6NwCP3sa2N751sQe8<wGwA>y(8a=mn%TChc<--<04p}*PFm0Fk2qfg?0^#GU
zn_6crA`U}l8FjSR64$Tv0sqe^FBOWp5)#P`kjl}<O;p$Os4mggp+iOGl7ltoeS9yt
zzA_XC(<_NHtpmVNEa$j~S1}0cuv<ad++uB#;Wa02kvTM&Fe208q62?zbm+$ea;(9S
zw7=~0Sch&4o_+GdAwyw~JzTD?O>kVL9%V!JhrqD=3`oYtyc^GwT><QyrhA{A=X^0$
zQN;Qt`ka(A&GlC!^)Y=z<^~e5{VQsQUXURIZgxWHqw0D}<vKMTaT6201rT!vg=N>h
zSVniWuXjYN=yVxHJX{nbT|Zc)Fqfet1D1!5#74~1)aF55bA=A0o5o5WkoFf<rhtp^
z=!=b|ykq~(hh{kLoXHf0Pli8ee3E)_Gx^7j4{~zar)k3-B-ujFJrL(D$VCSYrJ?&B
z7zOXST_M>VVclu)#fCRhAN_~>v`7MX@+KN4BZhFSG;f9ccmO(-)p3H1y-Gx%+6x)<
z1P?idx#*L%i8#O19cpqwR+Sp!*FFr1ELZy^Fk&~=<EZnN8ZVvWkeiS0*c>g0xUCi1
zymdlI2*X<EBTn3663%gE{c%LW7o7w>4kgl6gYLD=^NJd{27qcejH_KGnPXA&fCs?n
z6>6R1T`@?cPZPD5sI$?GO6@efE?SX@B26fWFifHL-Z9|(jnr;9EK_aLe^_6xI7Q#K
zJJtp6aj7C2%nU@)%q{2bU3bys!fgx(iPlgI&#~c5Fm4$M<o&k5|EuW(&i=V8=<X>R
zF#Szj=#?4hTv4ca$@!hnv>uE$>hgl!zeq^>*H03Rs2nhKD#ygP3BPtfQt|}(o@ur7
z6;??A1J@@_`avdjF}jZz%2?ar+*X;Vc)s(NIft7l_A)0chaTy-NH!VDQS)7^htjpa
zq7^B~2%pDmO*Mx!u(*>hFO4u4UHba+schH04^z}a`?m6H)CBPE+-%fq<r3Dt#C~$l
zOep$~WCeF@GHq;3?P+-Dbj>DE?3_)lAnWxiW#FM6^uj9MSn|n<j$z8u;Ko`V`f7kd
zd4DEOB}q%ndIst$wdKImp~_so$T(OHrk7}nahZSgs#Pr7mn6&wV#}C;9#gXu?znq$
zF$d%;>c634d5?={a*gvRc#WopY3BwQ+cybc_8sQ}dpV~~EDmD__ELK!nSjx+55k3o
zOqx#vair|YwfWfwmLW#)%p-ZVuadq&akk^hAB0m@rlKe?dG@^!thqa~t4;=5Di#?}
zZM7D(EIdA6sp!d+yyNeU(@3C$eij~BG@6MtvAo!zL-C%A%pY)EMPr;;RSCpbo6RVR
zo@Q*ChwRU4cyuOAc0ra#IS{cDM4e%S7pv?q7D=iXE=VK*wE6d$dp_tavzlo}3lSW)
zTtzJ<rPd}mu{L2h96I)Y$Qk!(P!5j2v(9cZV{r*~!gW+$d7nU}4i>Rhes)Ltx>$X?
z5t9iYXkeUk3vQP^2$y2)uoouK0ySD@&9Ej~XkO?|1GIo;rax?MYRxe`)t>~aO*p=y
zr(4Fk`40=b(Zzq}{8B5oVJLpjvtJUE)~F5w8f|2-iQGR?ne{!A(=?+|xvy+7dw7K>
z7SQvN3h!T9o0<SNJ#v^qMdEEVi{j6u%x9m`D*&%yqTs9GeGdnE|Ivy^9$m5sf#sq0
zs58#Jl`|YjDTv~IHR`FMiz`NrenqNmti@$yvB}cj1Q*%v1woP7T98eoXfJ3-qjd-$
z?h>Ye3?W$Lk)syR1T|kgQO|oYBwDr9VP+L8obHk%5a$wVYCr2Dd|k2$iLvUv`}m&y
zzl&af03JmfNkAqx3aK=v*(Zhfuft(gF<%u*ciL8F%f`tr@+pKiE;il9(x)>BqF+u0
z5sSO-jcnF4o(4ui`Au3#@pBRGpmN7w^Md#c6OQ7%|82T&Xr*@qt(R0Ihm;N+hOBsb
z+h%~@%azMk+#Yjaly&Dv=rF(r=f{6ZzM$3rtD8#MRs+7(-h47Qy7b4KKdebqBIPM&
zT#w(>D$ry}#NO*jIY7W`4a>yi6&Pt0oz;lr+q6dqSg9?bsl+nYkb+WzjS0fHlKWly
zMrG^$?+1(L@JJ34G*@Rs84m~RI=TChnBPh^-lue*;OwxJ$le71=x@iTTe*@dtTe}I
zTr?xkz{QD?;jkFyOS)2GoXCiYX6=94g!vKz#u})eXei|tVP_xOE{U`>cNdS?i_A7l
zNueqUk7%Rj!djM0B$l>&S~axGovU0RkAh!kJ}j1ukX=2$<zIshcCrEXfG&M1*L2sC
z2lF$$oXYTh6n)PRhA19Y0!3aW^WJ8Htew~ebMP_oqv6g2bt;Y(r!Deu;ooZ&AZJm2
zADWlRZS3^1bl$+&@pg5KghtVzhRY8}FQlaycdZ5w4)ovAIdP=)atM7ys|=b4Xd@l#
zmfzB4uQ5>p6#{gpc3|y&Qdc5xQ+O6(mxeBGg~<d6GoTv73JQyrnDfP_5m8i(9$-`b
z21`$%8hQv{Z{p?8Z@S{3B1NIS_J`rMtG`7^Qq&Qy54WPNwa`_83VHq)k4q7O79Jud
z*RrY`bF<GLyBK)tmdZq?zySuSoaxj4rpy{-QmVH=CBrO-04znz--B8n$*SaCApA<Y
zE?AD7Bs8{t014lCxe9dD1S|4dp0^sdZg~5Y#!1fo1P%@SFp5QKM67-W%9Y`W?f=cr
zW<htrlaz4uwEDv}>?)BgGL08J`p5jYz23Ltwj%4_2tKr!qY!)Y?ElKQY-@cDkFV|H
zb^hL%Q@`CU&BSY7dMAyE-ANLiRzpJUK$-eHAK@LA%%mA(EzgZ5i1$rt&CTRa%cYqJ
zcQiNpVqqSS7ck}y$xdh|>$4v@{}6vL+a<RzXgA$asVIS;5e(8j1aa2l8B>`|D=^IQ
zaUdPhO0yI0H~FDzqvh-`W}+5cv^oprJnQ?V<#II7r?@D(bQ$j)barKIPtS!tW(0=x
z>u9?h`WZzlo;<A#M2NDk)A9qOxVPx7?-r{gQf}iJw>y?7mVmR!S5oW%h(+!ktRC9b
zUz;zP!TI=<a2sdvKZ4e|$WZ4XR395=aEzf+r_~`{W*IxaOqS7B_=TtoN-MZmCM>hH
z+;?EO93FTT*fqieiq+8w%AhCaH=b%7%?9eeU%w349RhlQ8_J!AoFI+o(K`d)S+K=k
zXJ#jWemLEG`CD@0`m@-+8%&_81QVj%=d1p`{HduGPtCFUR4G7zU>TYtwHhox*C@AB
z?Yy$a`4xrBuO@>d=6FM8RcMp*K~FtkDs8Xd15ug!pFv4GOG;79f!VF(y&7^>uHe=t
zZ{~a^45R<qSsXi5{h%78CaAkf1X_vm3mKbwElQjC9i?PZlqborT~ZJr>nGe7<;LQ>
zGLnY!2$E4sXu<8>ag9syJ&n4K*|rxw3jWUZO#}`<4Y9R|l#HQnWdcN6<9r1ltc~Xw
zvRm&TyPoyro5Wi?xgf$F-|#8uxgv}vCj$u0nx(e9H1pu|b}ky(Wsw$n`{1P{rr7$k
zbu5P<BLW~_poAhR1ogNY;GJ&R)OQrlnZm|d&z-`Fnq@Ohi^L2O703||YHbgIYr>C#
zpNhtQxJYnQfVtW8#Dkfp0&#sZ1Qk#iNUbA}ZX3*#yevCF_kCwUv771$7+yC{sJ2>c
z_jojVee&kT-JA_@+BAmp6|=Y>&bV5~wH;N}W^W22?FT4Khz*D6m(>_tfIrTvHOvpP
zT5J`-{6gP2hXoR31ZO5!K2-42WvzLva_4N^iXnwZ1*RQnQG`r*34cL!d?~}aF!?g%
zg^{&Wlj1Y!SjWCfJazxoi5n=}vr&TX5ZM!+Y2d#c!>}(53@E;teE%{g4ge;TnZo`C
znFlaA59(T>mbp;tY(4v1o&iT5PNkaEAM`=g&cF-3v-x@<+Nc*}p(v#%I!3YG_m3Z{
zPm<=g=TPJiul8hRc+ACCgwyrn(v)YNUjSl;zNN_l-olVDnac1!yA5kgMsJos%qWz3
z=~5kgsdu+s)=2ij`}njVzDH2X?=w1FL8v05prF^r{W(?yti7g7ZrM_~{&~(zb8m0S
zHjA?*n%$`%&}ETwj!)9zwx?(Ey`|()IhcS66*n(<Ag$F^3{d`PT;$T87&qgtqD<1d
zP_?RUPSY?GfnuG}8zsWR(Jvcu5jtdQen$+x;(jYoB4_Uileq!TR`o0Wl?uGl9S=I*
zs}90G_v0**YM@)%4`bvi*`qz&D0U*o^kFv{I1dWPa#y4)Xpa%kYh#3O?;j3&2Dp82
zbNy5ZIqaRc+~Jeh;*cYn)C;Xv^a*nu<;X>f7TtmMvsP0ud)BM(6v?GrJ19;|7j#nS
z;tkct<p)4nuUk}GIWHf7sLpL!t1N}9+{J8b($m9SP#)iB>ZSAKL;l#d;t!M4pguS_
z6}1NdQB-HF5nm<C?ynDwtjH=Ud#4mRC3Y19g6aG<uQ_c5UxK`<bv$lE@gk=B(UiW0
z1Ty2ay<=E+;3($Mu|&En9Q@v3Pn24fLtBHhat-{^A7FzCMZ9a@kn8=W>(*X_#~1OJ
z?O=Ac8^;}**(UaQ>`cwJO_diw?TG~?q6cYt`OEt(L=nvbeM0d;4m~ICc!rd#a^7XB
zrdYf^oDR)ttA(co71*0bJbs)w=1J7Lwxwu*a(P^e8t`Wh)-hR62gqQ4HwZ)h5&$^M
z2R;o3^L2G5(Cc?7E*JHW;ltRss2Y4LZa6DJo5rDW2={Tu=Vn5ZeRt>+(?Z|HUkj!^
z1ZYXm{N|R9H&)RcNb_qO?oVZt>py<FZAIzWL1rqgVeM*C3EZj~&+3mRO_OT4eXsoM
z(b%1}&DxX=B_cY@_Wo-AyF~t<ks%KyCZSUcd6!onS4e5ut~D$;qyqp9$kv;q_gui=
zSebkGzXdk~9}KLperWqLSY-0M+x}6~(|&OrrR92{wU$9wz-EM8t73{e=~ZW>#WEl5
zWko|PhX((Dl8aNVeeWWlE?L>*ceW6@mt=y=!ZdLD+-RPRaYpjd;cjLQYGDBg<j(gb
zq=ax-vT#>`UxnHA8+5-4yr?H@QL=~qK~<e*{bk%W`~tQ%`Z{$3xohxZg@%|`gV=o4
zmWF4KQm(vQA|Fk`_P)<wy!+R$L47TWFi2vx-!Zg=i!2Qmo{sqwy_r=S=500oH+L*f
z)AZ+7$}cajEOMIs-M8xv0#3Zo={sk5{k@LcpMc>fB2|fLEo^Z!a|+QoX)VmxX3#2l
z1vd%eg`z}S%2Wx9Mluh7J-J|P^A!>cQZm(|cS&hB5jgUFMYaQMC!<ca`&F0=xC~Qf
zi$E7Wz~1~45&~N>K+a&4KHz~YYvyDkxw`C4(BA6n<FGnOxy!qZ@f@S7#|j#nsd6;|
zmV*ILrug+Zlj+-#=nS1uM6=e}QvwejWbC&Cw`{7Bz-n6yD%ZPiGiPY`SMXJ~0ayD9
z>j$`hr|JPhn`3km@aTs&>hb<{k&AmNw#T`cpSi4%+m1{|OeE^e)TbOb{@lST68~Og
zV4qCzF+6-sPe-xM9K?U!K?1ey2k_u04H&>dwT?WTmAx-&hd}70#XIVT81Qtu9!S8u
z+%?lOms|iw>&ZW^M%3z5fZ{JCghvnVoi1S7YXsY12o`Ha+>vdsL?5Rurv~ALbWZGK
zAs=n*b8GTH{pxAHJCqo#t5=RO&)+2R6lH3OhUiqR`rUl@Oy~K>F8#P^8@1;K5EI|#
zmYC5<)nM=hOJN4W_vQ9LN~h?9<pLWtPA$ds=U8~Gu{WeJY5#wBPKV^&-?-@2_;0qe
zaIjR@b+noLxIxW^kWwQ>q}<4o<gJo*AL50Jq<V`KnZSvv{$j&h`%FI!OjgT%&UGyx
zoT@`~ob)b_sVwicVP`}Oq$lwyuNEEZo@xY?2O%Lxdbua`eXfztdp?bd&Jj$<z%d(9
z#lOOW^MK7pgnmu5l}+4nd->8?Z&uQV@Sbr-fbvHe*dJoK6Hi<r?M+&v1b7EZ#wYU3
zPW^gAC>+bc#SxvvD0aX2a>z9%>lkwa0Q84v0I3RKbDI6@jBvXUEQ+GBocB`51sKhW
z6xkCP#hd6#a!x^^!~I)uaKNx+fHLL{K7Cy|Yas%Lf|Iw4dIvA~&MPReJpTK&F_7bO
zkNp*8xVe;YN&USO$47t{M1&!34yYAIhe&iRdT)V_*Qj6AnY&8?0W~@RO%+WoL)$r;
zQG3U1)cc}Azm}LK-Ic;9LNh?}v5p`bX>Ow-Qh%e6z^N>vQYB#BDhy2z&Z?p9P(M4K
zZb~PGf-d=$o!)t{pnJJ|8g;NmyF?CzYBK`9LTx=yYQAD-bsLr|1c_YteW<zmj<K?b
z*A!7l%tfEj6YPXoO6ciQmOy#VVDwj$-jtha<*FH8%oqrbLw+FcEauSKV#EnW!sJY#
zzdi@A?TjS{fv>PVlgu<N#7kkr1=3i9MlE5wIGs^Y5{cJ#hC>^1OIxBY+JZq-t6`hK
zzN|SNjV?<ztAL<-vckXdQb+qjjgb3(XzoAnVy~n~z&afVQ9j^@Wqwjg73ZH#smiLf
zO%iVpJr%}HCuJi+TsaaZj+u@j0yXv(fJMZ6ApHy!I0Ftn38BB6<=Nu3rUS9jd@NjX
zyfOG*FAVe1{1;iUY-OeyNb9cm-I?8Xog;ia1}I|BTsg1pR|^7kqcRH-M8}(iYPhU6
zd3Lq^9yLPnz3ws7B?61X_tvfG?ZPTpYx#iqM~yhA;nZFG>~#gW`=zPLAhnqcE0I)9
z5RwsaMcgMJDWHEFB>s2n#8c<F9dI;}Z%FV7|7XhIz`vaxI-0-{i`UFi0PvUE#D;y!
zm*7sNM#q&gpi_Myp0K6oBqyj%AkYcMAy-)Gio@M&-Ag%52U`JZW|jdKu|whu2;$5Q
zjA0$_;K1q}fMPIIpfsmM#F?ZVb;&R^P2vp7dL4vAVi?rea+&V?9LsC#d1#Zy@r>Ac
z>fq3bokP75BP%3_e7NV~%Q>OtIK5y7A(L;zD+6sF7<j$u&#$=$eUt@ZCZSM8K2TN*
z<!<H&>lZmr#l>|rLGxbzFN7-NTkym~<DZ2=5?f>q+fzw(T<s~8uMO!vCF{~H{CkR~
zkVG)s`|GG#INsbB0+7#lXwQ2yi3ddpp$=n7k<9*<0<OA+A`H4+;Qph|){76P)Qq})
z_A`1zcnL_t!NFqAq<;LhH;oX@qt!<-u#+fc$3u@X)!F}>-!g2;NKMR<CKz}_Kb8J;
z3`SycfH&kOB+<2gd;31SS7%WGtJyQ&EWa#r)0*R;oala^YWnu}Ag)U$xJ+x7E{#7R
z%F7kQ2_$;f8oTKK5z{xa=7c6cocA8Q)j9ZRShV~YZt+Vxl`<@=@wzmqL}4V5_4SAZ
z29(m88AP;U8sOCbE5{z*Hd*vAiAYq3_kX|`iMcZ=Fom0%Tci<My-9gLv5O}fnP3=^
zqn_KW+Upq_rVs?$6e}s61hjR7|A-hsD}+oEC9d)mAf4k#MvL6Hk(c?*3SBW0o3x>@
zr=?CUa~6CQA}c*nc_X1VD$&Mtaf&&TryH_t`*^J8Bj5nuRWr?wgp8d~2WzwURyN#{
zI6t+2pEw`;BOLD;+4ofe?*t~>eDiaCSEov8g{^fV{+dwPB31yhKReg>yDE%0LXnM9
z%Yus1&pGga3=<`8(zvDbX!OuccGP}h)n#AbXL6Y9!w|Epy38!@pcsbP!k*<f$pGp@
zt@_VyoU;`7CMKUKgb;POct~aqG4(jqy2wvkd}CMjr8IHSoJVetJQ-aaw8EyaB(ipa
zbP_Sb_3pQsxXK-qXil{g3m6hZX@x^l4*R*@4(55*zPwNa2c+zFa<KFXZ?Wid(?;Cn
z_}g1bA~B+z1AfySf_i<NhF($bBRN|@Tty9MKztoi$gX288b1UsPf?M8hE1BbaV~qc
zF6@WPt0N+)azs<%hnmMhnIaLk$gPJm3Wb$me@LztgBaVy{OUk|q9(}5ISP>j2^}?D
zaQW|N^ob$Cr<g0c7aY<7=Fzq4Q`N6r=6Jv{mTVeO_sm(oQgWm)O<xo(xh>XDO@Z1R
zea1BbV?VdM#iX^E0^CQDz@g*HiK8Verk(dJV=g{KpAy<!5SVP@PGK*4OZ6!SoJ2td
zqyrjpeYm;k%@TsGrBy&2+NpMGZT5qtY1pozY?<Bo{%P=~CQT!&NqZc4@_Ondl28mq
zABR!uv*YabeNp&p?M@kaj;2MVM?HNjc=M@rd-`KtwSlM!!yvmXzdN$lsKYpZ3Sr%+
zx$m6Ze|&XA<E76`!U7P&ZlhZ`V~5a>`#VC*XMK~(!U7h7Lv>TcOe~-Mh&~p$Nj5lR
z#a|Rb&e8dy2xxt;!kaB=D=s3NAgXdN?Z>687Hv?=sX7!wIcLoT@_AxK`590G7%opV
z<XT52u94z&9W6oBffGlrJ0TNMK*>FKz6Ub>M@?jVDH*0}Wczo^s^L_tDp<Pn*tWBP
zYu>RUDtIt|Qss`$DL+7jU99Isl83SQ6wAHbYG^pLPr3hsKeHNItDYm$z=%wi;!})a
zD<I7NjS9?@AYSehV&3gOY+wa28uTFj>gL%mr`*vlBoWuqP&j4U*g}oex@Gy2WOfE@
zp6}bMKt@Yi=cx$(ZlN?3$_?;K!yJ+{tz~B!^C|IWt~5V2Vzc0DsflI+KJi(K5%{RK
zZBE&5Syu2|Am?gNX~10DS6;Wei^mt`!P{1OOdG{I*E*|G#u53<lmNFzliBdeF!vD@
z^Ar2Afgv`qeUaAo>NK11XhUDFwHyg0$K?xe%t`R*Bd}X@Ix{FH@f<EXFhq=t+3*XI
z82(D3NLZi+)8A!x%Z+bDbQ$Xno3^S6-_AB5^UE%Kir$_wj8wksANq8YMK^}cW2d?J
z@`}e)b9kdO$4c-j?m*|rqW~O>LI`dn1i*V*X8k@AK-?5hK-o*<&0Damcco7@INQW@
zb()Lkr{CFK7|ih7ZHwXaj~X$dyadQrE7#%nG<+6rPEp!e(Y_^;m#7LWTZVtvWC`j4
zit?525yMPt!`d9|P7Yczg;b!O1_IM3NiT(!6=mDQOC$eE?7LVx#TNLq#}cCW+L^^i
z(etOMIkQq}INCu=S*HW)Y+^4;e9dvbVPb0N9n}gEr(#3F&z*nYMShB@=!}5|UMUcQ
zUr5VaaZ7-K?&hbv3^09L`@@B%R$su<4UZE`3cMv=3xg8*V-OSS)2zISe6gyGpIq}Y
z!jV_^0l>1-PEG#wQm->MQm%Nd<N3k1qohKwbqe}j@N3%y1NDW9_+6YaOpX8}Fdn&4
z3OD1$%Q^(|%&k`74vTV!vC(5=GX`SW=ACrf!7%RQE!M3D^j9_k?+4o9l%F-0bmRBF
z-mo{Du_9M}?y=qPZS}+LOTcg%Y60w3mHTF;>92)%V}wNx_BX{i1H34zi6uPU|2a$k
zeWMBT?a0zM@W1Xn)(#%dX;RKTL!S;if}Jh)kZFS!?L=gAI!^CqSZ^`yU!qD_mrOSf
zA-&VSQEgzx_ja7+A<F09R^D3!eeS->NqUgPHkjB+>M5MYUr`ZlruJTK)Ff5YQ+>{N
z6hV~N6TFzgUrfo$&Fk8yHa20-a_*fu1utTdX#!u?j4v4NF`mor2%_&zjOaJ*Rbg{R
z0BJ}=&#g(=;GIzD@Ml_ozdc7UgHay2^K;nxFjQ@S@l}rsb6(3;=)M0O#QSvOLL}5C
zB?M>+^v{{N+mg0jRI&4p#JO}h*X%<Xe#FX(@PEyW6!Qcnu*|YiuemroRdeB_Cp49}
zEDi&$G$0%2Q=nrAGiqirv#;=zbkU&qmU=kZ7Q5Z7Uc-E?HHREw-R?bb)DAkx52qDP
zMudS5A%(0p^qKu~gmUm{HVkhH?$ogef5Fas9p3e9JD{gK<V(*VHmT53T>@KPh`R?3
z^cTVwsFIUH(eI3}HLJ!<d3~=oVD_Qk4+O!T!4ay2pE&xG;V#Bb<1u+_5>#*!nO4p}
zXmcwCLc6398A0fycQlj=NvuaXQc`)-7gFIW5S+VFG~cN?Di(JrG%5<o8}ICcn4PxJ
zQLS8kb+^K1m-JAC`nJDV8WD;#V35FeW#K;;zchwxuw56F!0;87O5y{jBlJsl570TN
zgSVL&Sh|oxuQ7TpRv{=!4i<THVdXyTH*2((IW<vNg3CAR)e+MbWo&#v5pnJzzz!5$
znO^3|nK`GNgTnGw>waX<@yk<Au>!Ngm`nP%bZ->H;~`f7&||$ydQJ@7+|9|S5Qx<J
zqb~mUA>T}VAh1T``&0Bea5YK!pTnRqpK)8)Fimnzptn6+BG&0$A=o5wTM4Z?6;1ij
zPJ5TR@IK8K0)aV@S=n~uHVli%gw(anv2#~DJ=i5%1`%F13`U5UIes$%QqycA8{Bf{
z?R2^0tEvi$E3aD2Q?wY1E)*}dc}k|V#Vvm|GR)kXfL-sz&}I};Z5ycQuijlXpWX~(
zbTP%QF4=nn@JzcCTw#B119iznuZLai-zA~+Sj*Q!K`x0!;T5HRT1C=z&ml4`c!KQf
zw=W>cLI9hq4Uk{BUs+|V#zjJ$5Khd-4R2fmg)AZ_e`q!H5c^!>QtbEEEr<%;@W1P8
zTgO&Yx13g+`9F0OrF+OQ4t2orTwox<tPTMk;bWL2<C|BRn7I_TK<shiM7Dk8r|iVU
zJ9Zf3`3qMN!O?u=Uo{tfDAGaQNA-W9UIveNXXyJ$?zGca@A~>_pMEX-7kG8$Ri#51
zRj9XhD^H$m*b?biNx!haNCXI!jaJfeVNfncLwD_d(i!Q`!x*8gharZG_Yp+>;5W=b
z^2v+^p72SInlk8uMWYnFHZ{t&c~i|S13ffu4HzVQk45MUPRlKMbDW9R8;wiuw0|O3
zKjDgOdc4R7`QSd*Y>%sxfLAT9VoxZOuyJ=IS`TQR4z#0n_@*{iF<_eWwTuP!Hz0OC
z_(A0b*|-K=klY60s%~44!L5=k+!MyqO`6A}g9XS5r+VbjksxE<LcL|I(4%R=J4PsP
zwmCNSfFKFIhNJ7KD^)Hx)3%|Ok%|pCMZyQT=9kuSK5}&PVjVlp72#yiO{O^my@1(O
z3luUkQ;Uc>e}USO2v7K#;&J8_BVVYjIzSdCcBT9ZX#?Yx_0DEiW>&HdUs$50nl=D0
zfa+iUegMZ^iGEJ0Vl?IjuU2~r;F>9&y`MPto7x@)rZ702{bo^1R)ZFOZojywaP>Ek
zNA<dfzz;^i1@6D;`u5me<Wzg@516*@2*F!|Br~g<hV?R;&wGKxeEnYVt)PEy;AD|K
z6&wE%kR=h8iXao9iY%%k4YR9M4s{^0F&ak2^1TUdafRzY>0os@FWA-WE2pL-fK-S)
zVy8@w%RASL&=b#B9Jr+TJHU!RL1zvVETQfqAyGmvWG%gay17%anap<ATHvknTL76_
zmqGY0mdM^`f56RH-d;U*2(4Sz%3!F;#IjT}8=9$xk`%=Y6tCS|L7!yJ>kjRfUkYh>
z(-~8L$U2soqZfBExk%L2IcnkN#QL3#z!>kfXv#4*SwJ$=p`QSkC4~!9hiSe;;#F3p
z68me_2eM<U2hT#M_q9z?Z*@+m;3@j5O%al7`Xd)M#-=kNDb@#7TD(^%YHwQGt{D{f
z_;MMwJRpjjzy!J9priHn$AKH`HFa|?`fcvU8T!d3f$3`3?*gOyCTXDE#l4&VTfQ5B
z5hbd5N)m#^*_Gle`!azW1m0qiph4~mS~|}Z-B$0D0mNMe%71`HZqN<XanoVT!m34g
zMW0lg71i@o9@QHtz;tE}o5%^`=t<Tq!ptyTEoJ`-qj0|cFL8F+4m<2l(Te>qIEh<s
z7enC@3myls9{?T$_5OvrR?<+`8>xa$29@MNWGeK0Ob-FL7taGD{+w>CCsjqrj-X6B
zGC6?9LJ!4uKm;-Ui;%wa?QkoNShW7+jQQHiy((S}=+!=zW3aJ>rdgEO=1u}1a`?pw
zRqtKO$@em>O<yyQt{;UB&g<~<z$%ExpHtcTQ5s92Pg0u}iQ;b2ljU#tw%HLF<Ggvv
z28MAclp20`ygvle3o<?AQ$evBjR_gg{8uf;VY%mHv*H$&o-TD6(A^x6rTV{c+-0Jl
z;<KAi#@t>44RQb4BGtMuaw(5lET8uI)cMxcF;8AzdVmXz*0|Jwy}s)^h9x2zk7=xN
zCZ)03IhYF2w8ot&=@@B7U`qIA1TD?yt%T`-<$moO6_m}$bnqoSo5(n$f(V6{G=vQv
zTO@m}S&RD~d}K_~VzH*QUcWgC$&xM&X+}t_z_$OxZ0QmRQJcpg3fRkv=7cXrso1pu
zEcQvXE9RUQE~OQvrBqBiNJLS9+&33kxO{fo#xS}pG>$jZHNL%?y`VKd9plI5-i@$6
zhrzoRFEt<Go=ka=yckmlJ`@{p8G{M~EST$H-jkF!H?zrV#o?-gQbOB+D}IAooOO-o
zO{{s+ZCysZxI@FjvGmgMi|IBS9$Fd}oUPk->uIB{6`lMgOVE%#?u#tC5rD3!3_gXz
zP(gSHyU3J=+E@If)h&Ri9~zT2zoHG8TLnp*vPi$R7{Kf`dqndc*B!N?eMLr}oL=?p
zOCXBq)9Z~RAV!_|xDT1WaOPtCl)gf=){`dzxKd|bx%Cw>f(ksp0jZR|p%xR9MXvf&
z<ROR^p<WIt$eN!m{Q!B&bUE$WIzwG&YiMdg$Wa(6Zh@tbL>kwhIQi%7@mreySYGi<
z6wdos$gf~w%YtWWOrgT4x38}XA@@2%Ur(O?7j+2c$)iB<AQ=Cna3TFf8tjE>9R*!V
z?HR46Ol5`GF~awSMij7i?{}YvysP|_bH7>rPn@jOm9C()L@{-(F)CT=E56l;H6+))
zLxa1Pj?q_kA36N+lR1O~>NU<s>a(b)Y5T?ym>hyrTLNze`Z>Pn*Le8hh_Vk^>LN@h
zogJ0Yr9v8y**^9W>gX?JohtkiT}~+8I=o?GH_el>LXW*ChU_o(nJlheX@S__PJy^x
zohl2ja7jfFVLmYo&hU8Pa-;f};GFj{6i4CXIU!$kG!fwlD87nI>t4{0un}==U|(<n
zRv;_J&qpKi#_QSP*#-SA*@?;p8ts1}<|22k{J|&Al(X(dhbvUDsD|J726XW_QZhGl
z+&&+k-Q*)~PFxyvOx!^64E|a4G|_>e`guUE_%6-#SDd(NhMDx1&9GI_0C{~MsO+9+
zc)go%$B;V;`~wguMQ_+C4ER*M4B)!M88CYMe$Xn0T&&G#vat#)S+gLFGpJ5>lUKbY
z(iE28=WtCK(6zLBGuMAvU9&=!h&ytf@2$%gh3D(yMo?qKo>*A8ytOvLPIOX7Zrj*6
zK(){WK!Uv46tOB^!2LhmKqU6kpI2tAR}~P%$%lfL!|KLBKK>Qx@PV7dExvM<)oIAH
z@SgXYQzdNj{nOyGJR6US8iKm!LUsN>wD^q_-D=J`G)v4_&{d)yi0_!=Kk#4t5I7It
zY`qYnp(WpxyJJM%h<Y!Ys*74j6rzu$i21;o`<KnM%yEm>-fbpjrT)%x-Ba>o#|eQ~
z%K1kovMoDx*b&3gEiNW8fu9EA!V0qUy9Y3$QIbNaf(D<mL%5(6_nckyMQ&1Bu8(|q
z&Oq%KOok}z0BZX@gF507l)s6`8QBoYA*Z<i(G?*btGXA1J+~C}-Y4U^Kc;wi`jfOC
zxaz3$tT}-&+UdPrOIW2dD`HDgyddCf0(Nj*kr6pL7$m&L{isL+&xtJ(;+QQ|85J(G
zh}8!KRqpr%xE}c$D_k3ks59!XyN7g*N;!u_c3pak(_HD@Cs=^>Yi+Pzf(Ub}3#uT@
zW}Y-`H)m|1hx)!hXwg3&4e&DxDW!z~%=g7WAOPeps;ovL&+xY@TPqRPGHlM+-mH5P
zJHjej<Yap^bd>Fgk(j;fvEsq{!!ceG&`W}|9`+OeQt5?`2v6X=2KF%Qj}Cx{qdxM^
z7^1u^uod0aQN6c$Lm0Xb0_4fM7(}048j~svMM4dj%8=1Zx~W>p`z)`~L>(B~1}()+
z014c3ZuUTYvw#tFI~u<R8Hy;x!Ai?xx(U#(8Kwg-;Z>)W4t&HiD&Mj{y$u`R&VP$Z
z9XiWdb9Q|AW>dWE7NAm_hoRB^rY&;esQC!En=AciRv6_yqwYcgFagh~w6DfjJ<nB7
zaMA|wQPZy?0n5eL1f?(h2t>%mEPTu<inW%9ejkWpwI<Y}U^|Xl0FR0lrf|3)uig4d
z0B^-*vd{S}?ny*G2F<02ks*8nO5-KTSF|#DjDlT4@8jP=>76i^IlnV6VKD$c`#H>?
zEDV!`^PclyArFRQfq8@6w(D_6Ql8Fbl+h9na7Qo3K;dkg1A7xlsq`w$YC3><GTxSf
zyejCv7J~K1xtMlz0ZqhDa{38KL%5!=UU29jb5YZ_fYuyp48QhZC-ZAjHO8?ic5tAC
zQoE`a9@J1v<`)x|3xzo@2}rgMzjLlIG8q;dM}Y=fW)P<}TeQF<y8MyLX|e!OyF?{1
zNtwv>4xIJ3Yv@}cXkxILCSetkdOOTNR0$pAAGqYO@<`7W<Axf9?P&&gG_gt-N5G!%
zNP3Q<>_sd@<=3S8l~j`iJ-@~6jTBSD5xR+YcM5%f4)XvzBta1<7#kcifL7Z<t(COM
zn+<WROz)?Q*I2ki#=*|~nJosg;NFfmoYeN|3fu+6`aHNQV~@S|;41*0_cRE93S*a>
zFhCu~a(P8)2nnevK!ukeXXxarn~0R2VQN-x0I=${)RLL!#bM8pr`C;{4ihLFv5L}W
zHx6CxW4jbM%E|co-rTZSa;ZT>l2>>i#_w2Tl#dKA{46?&{4F>;H4f@KkE1B3F1R*M
z{?Zt|4sXmQq0b<cMX1tu2@@=z1kcx^GHM&rjQA%Zp)QuSY_npzAgBGpVhM(LS3)L1
zBU8iOf2|#ugM2R3Opk_i_suxpvzAM4X}Z}D+nhgDW<$su$M|<)54t*I7spmVB|x1b
z)Qvu>Q;?1ZfrI{cO?LxV)Ez2lv!z6~C{gIe-*<q9{<LRab5=%nTBFKt2(rh_9G8E2
zQxt)K=&@dJ)FztWC@Pvk4um_(=o`K%Al-{G@3=<$v75z&c2o&6OX`qQwcAx%Up3&_
z*87pE(W0s*%q1rP+Pi#rrz51gfs!vJF`<*gK`Jl6N6y_YS{Jpe5e0R6c+MS~Sj@zh
zy*^;|{O3vSG9{TsXIszkTFQ9T<*90K&3v1Ji^4PA<+>8rXjB`NJgAC)h`?-w0_*}L
zFCOL7J}bkA#IpB9QIx;@SGsQ4ZO8fKsNUeMujclhp=sU9$EyH=kg*5xf@(|P^vaZi
zmpxJauf7*X{gbWbM4zerZ(HdKqvLbdsNRl*8qI6y;D}#N-xkB~$ngiqO+qx3v3tFO
zQ)Y+P8HLo$AONau83uU4HMcXi%Vu3NQ=&S!KQ%Ld=$Yw|3v$VY%Vc?S^TEQTRO_q*
zL~Hfh*CQ_b2!=!=!LoDya+E;Wk$Fb{jXY4`lN^lG>JqZ+9$i}VT%v~AM^)(Uc#+l}
zC<8y)zL>D#?mRObNC~)GL&pS}R)qS)R169yV2@hSQWK2_N?1dfYzg*h=uwpI80PKo
zy>iG%&iqS&0Ud<N>7BQ<Yr7(@g_$Q-`h(G80d}C*{5BEC)w0uesg?rn=8Vo(_`s>4
zR>WQp57&O}t&N+zE)E-9D#42naCVmqpJ9qeEs%Qg+<Y@tpmc)5O!)Qu0iD1ln~i_r
z;#T##X+jwT@1Y>=!-)q>CE<307*yTB-h^8R*XzHY-(MZ>W(F!!TBH+4ToOO_{(C4U
z!tR=mWjiBqY3<zGE*S(H{I@-(&F;?@T651(R8)8u2{&2=KG#Y()S{6wA@Zyh#Y2xn
zhBL>SNc$zLY^KY-DTT99Rk`ejvY0Xu_J9XrRbT94I#1}&K9Xw{X`5p-%NF#Dz+36<
zjXljbHqJHSb*sC`Epzk%sV!F0lfhaiK?eu*JDg?0$1E<J0%W8o(O5+~W1f7K3dzDO
zr5EkB5lwHrJS@5deQ;7xGkC40KFVxT<FTgnVqImSWo-DpbQE1|)u(>r9|ov<@mN~R
z(M}Jf>z6C{8bsWH8u|0q1SQ#UlT*Rm;!Ful^h=d3+Ild<_IisrAqls%WkjhQeg_e{
zR+SC1&+wk|sA9+vyPs?YnLHO?Oanv<632a+bpMs|!;xkDQ}2HXvAh83cBVf@D=Oth
zO6hZ3hMd2>C;);YuBAY8zcyBF4f%eqFv%_dRHNUk04``fOMOg=KkcJlBMM|*)#c21
z=!LPO040=1;V?g51nc^k0hAa_O-&m#qw>MnDDLwJJK_2{*xkciVsJlF(phzzGHg{<
zj4m-5IcUM_tH<4TW;oEa2Gmk)Ng?~~Hl|(#QS+HU;X@iMl3dMVgHia1wL7bkxbT6=
zx3$g9md5&lrRma{22ggXywLXR6+9cz_)9BQpD{VY_%QEn)47#13Q>wTQPT`y)o|~;
z%9UmVeH=`L(|F1JuhlKT323qM{itb$+9#)dX3cp05lipWjBvts%#9)>WI;Bp(*q`X
z;@FUbXC2rkj;5L^Kp^xVl1rbdK(~)=H<d-5ozX*}9FzYAQX=95EcD$(Hnu+jnxE9Z
zms_Xp$X!?IcCDuO(oc(mzInc@P*4SjvH&!UwK%B<Vx5W<0%9c_r$-ksllvH+hmE7H
zrKWa@DA_+J>=V@k)#09a1dlGs&M8pIvx&!5Q|nQrFqRZfWxIeuf9ubkon7QtQw4l5
ze#oCWj_Sl){%#Bq_J~iJlu6L2lc_;CYW?BiFBzieuk!HODkN7mRr;f9^O7g-_tGbG
zeu)h0rPAHtr}Vu$$?KdV?|7zEmz21cfAnx~IS5dS%}W1K1gkNR?`c4rYFvqq3&ML^
z?S`dvZJ`7&*m?~#9SYD-ILOawW?clC&E~?Ks0_gzY{vl6m;ZQK(iG?FE9&*<a_>*d
zvvDSEj?{NxDBlKym7Wbu{~7r&jXAnf3^iw$6yOcBbl;HDjuh}Xm4plq3R;-wR`Beb
z=+Hif^?#*L9HIp8;mPm&ydJC($a;O_oRyqS3|%AEOw26O3usIrdpC~Dl=GCaA)bzp
zBb$O+7!`L!ec47WRQ>eJS^qhA#xgXJW^a6SX^XRrY6Zu&#Wkg)WG#aEjAAw_ux3Kq
z-wM^*5?)9l`yIIGK}|@?Ft7ElzF67tWgL%w78#jmWz=Rr^np)j!UQ^H51(7(O*;cH
z<rN<lf&~c9)T?<F5j&Or+A)1cwXfN6!cBD>#C<=*6)sV!)Aiq{yLzCNw<-1qswl-`
zMi=Q((b^W+Ql?NXxt;OYiE$JoIY)K~$rOh6SmuFK(<L+RlOshUC2s%7eSk`(RjVDP
z-K%?vmw1z2x~7I?ZQw)Fm}E)Gq2-gwjA5bATLDf;cFn0?X@S6%Wf!_%(&=>tbXOO3
zO^xK?uwV=(3(F+9V?OBHCHepKJ1j(7ynqXi@}<7mYsLnV5DSzEg!`=wzbcO{{9`*w
zn?Fv(q=#DE>?hH&#t=Z@E{=JDFSz*mOwKq@j_T`O7d>YSD8bb*$SkEhoTx$>4~$lo
z821)|IqpCoz1jPeDtebpNuEY&&f6@;Y>^;4Anx%JrOH+VXDHhwmJJcI=x4UKqf&iB
zU?64?CbtEE^Du~;+jwure@=MF>llaf98A@Y#<~g=arZiJLR+)yw?a47T$5946)413
zkH;Sd^JWlh01ZkjEGsLwK`|g~fKJh>%Dsi7@Q!tvO}m7!!7wgXyc(h#v@HFA^|x2W
zm$1@v6iIfNxNpI#Yjsj}fP}UfiAEEEW9#HU^a`6s$k;?dQC}9Xzo^c*@2r?s3gOYj
z6wxdrKQZOh2P?*sLa{lzZYn9KjrS5fC<7RsSwtuZeyG;emYk5WGZ&@vgdw2+@Td9(
z4q0*6fSm~RVY%&HAQB#SQ+cSvS@nz6$N*VPX)gzfVNK`1#UEJ2B_@+nXG&o-56XBv
z^exu|(qsnRbmY&tq8i@u0XAgU`5kG$b&%@!>q<2OV8%I_j};K@n3owcRbVtwCQ}NL
z<nF826JM9TIuEOp%Ot3I{+u-=pRn$3o?i-<`EQ`TkEcoN=yw{CPgVGUVqOR*gd)f@
zD>?|5qtyqKEIuZ%y`RC2I1hxI8R6D`IGQU*_^o~;T$c^#f36*Cs3xr2fUIJ}p-p@#
z71{uaWPd{Cyssc3IhSr-Wq5J2ra~JLS1rfb6JYdP^r5w~;cfTQ%3NcO4FxNby0}nE
zC}t7H+{JIMBT-)-wA}0G5`PK8>7(K(auv*E*0gB;WAX$7@R2n+O_BW$bC264vuh)p
zwOi_d4N1f(d&eZ9W&j-3%;>L1hUDfIu3}tlZItvxfF-b61Bl>tZ;d=B{4GCmECl~o
zlN;x%+FC@)wjh~uPSk}tv!>5i8-Jvq2@uj085s8DVdXIPht3yYW!MIh*#&kok@;Jl
zeJg_6{L#%6zybzg8lc6~aFHSjEAT;Ye?2xKpd(CFD4HVnWzu69^6dHIE9Of6@N)oq
zKz(YPtO|KsQ86<~11`f#Bh4s<@|0Um`W(amKy0aF5?u~6MgRG*_w`pt4^?499~+8b
zwQyk&+R0XxO&YmPz?nWKjFKGsj0j-GXKMMX4jpiC^JYUO@lSzOz8OUkZ0Wk9JIx8?
zQhmXwi(ujmeHm;J`cVYmfl}yqEW|l_pU>qD=((x_zu<P_i3cg5*g<YP`;*l>8hv?M
zSQUDI0LSqWW#B6;VydvyYRf*AO@jyy0&|q<_Q?@g&FuDJv2?Mg6K-;dYAZ4;E$f`W
z9ml(1HFx^g_FDyx4@oys81PtPmFeGp(63r88N+6ikJUOAo2J&?9Sb?kq8Ww<V!`b?
z8IMwoPf}qjc-N!LZt)1K(R2u1P9+MghnpyDEc20KHchmc4VqNpL^Hz@44j$=cut(h
z<54eBPE6hRYxMktv7rglX&B8|K6#r=Pr&nNvN5}mQ?^@$Yg8QNGt|@6v6)JFRG7X~
z6xi~2woo4ent5&pn|bryS3<|kc9NP#{VR!Om%iTu0r80T$+Q90_1-5YPXB&rg;<?<
zO%L1p>ule#Uje111=JN-oBdfjrIcg!H-7!kgIo~l=ojy^&4KLoWXuMcpo^NyDA}&C
zJRTy*OJ|lVsWCuHk_Fft76XV~t)fO|8a)d)Xzsf6LYVLS@V4bJ!6WgOm}RZtFB7el
z*3gk8cV~gd<|pekW7{f*Oh-|$35Y&gdOi-PhO?6lG2{T0x3G3)BOHza4xKIF3Gr+J
zsGCK_5OakTv`|9u3E75c#R-kMXDteA=^HPJYXvF?nVj!2#sPj+-%r90A^=z|N0wvg
z@a)ba{TcLoq(7Q-*Ee`vL-ass0;2dgwN8Zxj$I>81gur}t$W_-4XNy$BX3WJaN~gw
zvjV+mnjmPeGz;O}nY;}=i|V7|4=CRqjlGg|@u?kUVV$D{Le}ZRK7~=J`asp3jqXjL
z+lNhy;Ix^2R<Hwc9401jL~X4Cus6WS*Y0_yi7H*lID@M_w|gmvGv2;Q#(pW9V)%hk
zY<^DVjbXkK&rsT_K4m@M2;N?qv$9a$At^Re*A`|!0ORw_*^BJP);#Xi1B+#;Y`Ihm
z20#F1vDbZ`bv1D=A95LrDN-@Q%|ig44x4%NqM3hGQ?=2rFVIFxRL9n0Cy9Bj1vtEu
zjM4ZHM_`t<Skd3q$qT0>Fc`TMlK;hs3ZeY=qb?crkyXPg2oOSv^n?{m*jdEgz>J1L
zbbA&@8I2slYq-%*<IQYxlVG%M)B;Q#zyQ2ohT120G&aN8?O(q^i%g*&Cs2R08(TK0
z1921Xm6q2?5UxO)C?R(_-J`vEzsSQ4X)^i#FDmX4hg83^Vmi0XgHg4urE7#O#RLS}
zf&Lnye{9;f7+V0lA#nJp%)N?lu^~EyHb}57(&<o2`A=3zd(l5YbVfV>z@nk6RW@i8
zp;Lq$S>Jy{x$J|9TuYydzm$F4F9>6EC4`VoF`+^QdNC;PXmr^xw;z98RH6Aip!vj~
zfJNGRxDNO+oR*y_5It&MmWL<r9WW0ol(?XVy85F1aXE#xd7GDC_$f-Xt36S(Oxq24
zb!XQFO$uIG9@T=zS!%9W7|&{;T&!>J%bc@;34^&rcU$juJgk9Qr`}(W2D<1(w7^Ss
zUhzfGK+%*oYyvwVkz0{YdJ8Z*l32jEdYSHpT5)p)@k~8_q9|T#iQ@UTKdYuqlEWAU
zoQ*LN2_NGr{ecZ2YLw6h4Vnt|%C=eYNTaJ}q=GD*{y^YHAqDX_70Q$P9&9nZxNN0w
zRgdtgzzSnSZZD<(IDliwb;($o5ojiOPv4Rj-;ifqhtfCndoyAV)wVDY9<Q6$2{mhO
z0hdfP>?UYgW=;7rD3c*C&IPDPG1x@QsRokwW+ap7QxJ7zA!pRGBbA{Q904P(<;PH!
z;}G2{j?~GRk$#UR>pS(?HU=;L8j&$5tH6teM``<yq29W`*7(X-zY0*0=BKM>z4&uq
zmPL`_Q(VK4)Ei{rm7f$i-vZNJ@M@+1t7(UkkF1`sk0cQYhlwB7z%feYkBP4em@SrC
zWV&M0igIxPmOO}GuK=A@r*<XD7K&c6D&Y;$;8|ab94rF@em!CJ`odm%9|AS1tbG>5
zuNx74a2Fw&Tmnn<hh5(#+ODqSrjYTsnJrYj3A9@r>$ln9zHB8;3aj5>%~!LgLP`mU
zzx3Dq&cT7Il8*I<mZ+bwzUmeo&w0Lb5&TYVsv`9v?;*w!Z1-XKDAMHC?vI8);oKSo
z)Gtw$p1v{JdtB&PPON3a4(>9-XK%%i?u*5hS4TBCW_~@-%zGe`-ZmmGp9J8meDfBr
zZ*3M{w9{5hZjQpahuVS+GQSn4{wy-!bB@P3+OoX<`*8m%0>2@(42Ks57GG(!G{z-t
zN9IsqeFDsOxv+<&h{WqQeS}urEW5X)(;)cln$^xdo%Aq#CZV!xA*zCclLqRKHiLCE
zv^bA`wa{YJv^!GaM%TU1|A?8thaWvf-D7OJ!`^MITtJ*f0?^8`P|2_VlN;F5vv_Y7
zYdL8z<}+!4nT4*bIy<t%4nizNDbkmn0|5v~L%zFFnCLH}+PI-6AozPPpxoS*KZe5i
zolgA5jp_)_hnXb&p;+}hBM_PdgzGs<1ibzxgnPl1=LkGWnx)Xc0`XsX(yxBXW;BQx
z+E#x?l~O?04C_d`;xcq33K#BL%uXbs$QKZF-!&5!P2hjYdV|{rME>ASc;t{(C87Vo
zHn2P1W7P=Su|#b_aUJ=31_?ra!$l)pj$RwN0+f^6sB&|*$N{O^OIQzuxrj&WSQfbJ
z?g9oIEL~*|nnnEXl*>)=6ugrw=eDlD>T96&!0h;4&ij8{`&Ln_yk8EmkNwG5ipX@M
zjgAEGEmv&3fR{&%lM8Kx!u1fq@z~E_LrYw=_ES5CPm%f5v?MFXI=`~!*ZI@Np4g51
zXpm75`CFW-6Q%hklELY5bfQUQNwV6A_q*!7PTA(ur2#h>vlSRYb2H{d-@p}(mK|~_
z;rg3t^)Le7Dt7~Coh_b3n*o8kS*!I(c0h#7J?hN7tznCOH@_kxS}>y$s#EO5)6JIa
zZa_hie}^HM<wh_;efUwURns50u@tbDiYwX{v_xxhy>H{}OccwOBR0r<@MR=Y+LTT{
z&sMoaZNdWH6e*S`or4kA6UkEs47z}jbAXAL?!P<2?~Cl<?r6-m;qSYIZjG{CmfFU=
zoXg|SH9}v7dyoWF@Z_Fv{BXIXW}+t-&5C!ZF{#>JRu!ZDWAr7L6_06F0Ihi7MBjiZ
zMHCQ>_7TZs3>7c$-WdstOWjz@+suPnGaB`Pk2zlh)@7vl-8Q^gDHS}9<tEkNu*QH}
zw1KVVejUBU1INXQ*SH&g$8=(;`0u9g;Vk#oR+MR&4T%S0croc(B4}H?dPO*nx~yov
z%bzKNk5XLzhtpejOR$gX6xp&{JcMI#a99Ods{NNk_%3%rb!&;sR=%{J@cJj4do7w7
zCXAzP!m)VSgz%-Jxbav5M_TJ3#-CE5QwdA)OV-(m0O$Oc!!=GkPf<X0Q!}B-tiE?=
zD|6MF=CF^UAADb!aHL@S!L^2nUt{S@#PGt1q2VSL<$*t%zygNBk{T)<{EhM4-7`Rg
zx+Ak1xp(9_eu>o1ZZ>YMRqa;A`Cm1nUBUL%7KKJN>!B8L|AUcxTb&<c-fAKo(ajsC
zb&{%ywz~86q^2aAl&oIEOJV4`n)r7TZZrDD-vH62!FOUhl{&t^{v2JneFV*4x6Hwe
ze)=cTeTczU8UmV4WUU9U!ULvSEb)Jn5ql9=MkSr(e3A8HUWt-_Y81Z1KvSpreu^4R
zMMZu3X76`ThuXm=e_@Oq6>rhESW~U>v&Dfu<`6VZz^PUN;_y*r9%rd<8xP!O+h)G(
zD|sUGL+K@x-P9}w+&+EU=iTW~GlvJBk$$8>B?!5~fqu<5Zj_6rTWB1R|1-rwPJ%k1
zY0N|R___8B)7$=yjL?WHsAIXA7nIjjK>a{oV9G%ka~59-uPZB>E~v8q3sv1$*^<pu
zkyQ=nz<ubWQf*=tGnG}B%aYhO?7H-B8szt<6_A=M-Gua;Yw=c1_;j~`JJ$jk#IOC#
zj=n^&_P^RKSgjPxa4X<-a9r-ysZDKhflUe;fb6d0pQRtyV@ZqV8<Va)xFE2IINQo-
zaRK(mf#lZS#QA$G0O!`YSp^VAYZgaV`1xLz+_;`gm$KYD@3(JBG;x^lJ@ypeRtewx
z?l+7H<S_0j*(#r8X?<tkY!#-Bv!dPAF=zsx`Kz*n#!L}b)x&;VHo>9o4+47z<LEQM
z6jn(YPczARsb$^}cc^KVmx#DkJWC=6hD{gL1^X_5D+WMHW=1z|Y`j>+1D&8G*vrP0
zX@Cf(8xppvwC^b_gx#3!pp%1}zQ;=Az>3TfI=FCNYHWBuJ?2f7s!Ir_;<O+$D&dZr
zyNK>bD9<%Y0`uvA)lcY1tsr4`z6$5yov*ifbjEO#ZbJ)>fN80~1rFuTmhLJ^Um*O0
zu8JhV)YZYRj45!cnQO$=GiQwK;zy4D^fP3C8}T;^l0X5fv~@AgaWKUS*N(~}CCF{*
zE`0mH&AtH-kiQ&(SJ_6fZaJ{(;}`CQAd;4cstS|N8owk#jRcZsp*&>CRR?rc^7gOV
zd-&#RMQ=*_fH^wE5AOSg<d<wm=zrN~d5uhET~<VKAof!u>&Oul1Gny<Qi8l&^4Ib)
zEVhHK0%*U>{2k&c#XLqLa^7k<mw(vQ{jh?KVq(k!Edm0982y`6;dD6CMt)||Eim-@
zpGH6X>=iC^BWYEdk6FhWunx3;#vbhBd-+V(-<^T2aQ8Nc0eeR}Rkjep715&2>tL58
zq!A6uLdPe<QkXc;C$cD#eV39!lgy=0$SRE#KC~iYbM#WG;S4CMy<hTne9AJncv17{
zWB<C!>uq^=x^)1=Z#S#(5q1yntaIY3Xta}4<UqE`0?&7%9Ko{JSc=EWjrMIYp)cK5
zZ7mFL7hFa><S7<mOjOyHb{^Ufe1>dgReuzOKY36jo^jZQBh+^_>XbOcxc``9UD<@s
zR9rI0iQC*WBHnIb4Tv76s!B^zoo`1-C{_n<n*W=vjCp`&2vlv3wg5l1NmGdtx}Lap
zdDR^tSq>ifQ+XkqVs+x)?^4m~2j0F}2=d@_56rb|YWR8ipX6XSk%m-FKhC}s?hBq`
z%;0ri&lsQ6X>AVyfg!P$<qljQFoiq?P^zCEL-j-P_KTz;f#jxm@0_6k+ea34IeGQ`
zE@<3p*~!mIKk*q*^!-!IkN=%{!p|n>;oOX#Muz6{n(jj4uMS)2i)9t$9bPE_Oc~AI
zuYR;R;BV9*U6D#O|3nlw)AGZyfN|VY84C1zDN}jQ*d{BczV+S&vHW^-5O`-I5})S?
z6$=>=w^ea8%(JN60*X0`-@KEB>5@x1k&gr4JYV?{D&*Dcdx(o3SAiz-Of_?v!ma1t
zix$p6|IqjqHdT`FqwL!91WP(k?(j5r@go0m!Uh+B(Eh6c^nyvxD7vLmbKpag&<YmU
z8gd_7OY1g8K1NGg;Zb@=pFr(w9UnB%F^efY^JZ{WMuhTxRchTnY3%Pm88EPx?P-?0
z0Q`K!wA<w2Xn0WNtX-CT=)$?$wbL^A^`*XuUVM@}@Jj2a_iEL*@m&AkFS=q}#;>M;
z{a4)$Y_%)%r|F1v%X^}yh!u`(2k6`&@4CKeon-oW7SlKmx=wWK1IxFOLJl=fXsrFM
zt}Uo&4NEpMZydF{(Du_A%BiZ1cJ6}Gn2V_7LwL<okWFA|6%ls0rPecrwVGN+EP)|9
zK&YxIiGtL4rM(1D(mcJ&mANMseDNqoBdecF^gXI4WKLRv|B*fbEv%c-RqA(eXQTEO
z0?B*1i=4Hf{Y&~3M7uwdazK0_Q7!JBGU2pftXFsj05N0EA2zndF?zuU<jbLTV_zVP
zJOH853>8uG%0+VOMQ&{Hj(}gMx3Obngk(OM2kdY=E8-&<o?n0b<_RUmSBHg(xssiw
zwQM?+OZMW+t>OyGUe%HvrUNk|YdL(35^Zoi3R1k~GjyQd{M%ps$6XIYFEpq<ou0Y+
zP_~Om8h==`zNY#=&+;R6zPjDvM*50ugME;koKlLkE){Xcs`Cud5-YIIxEa&4iTFxt
zJkpP?2DI$QUAm!0EG=xdAmkMT)8bptn|i^wV?5E*mV9rebH92<&Plz>ofoLvCsxkS
z89G$?V<A^b%vsV6!nRsEg;g;lwRM4zY7X5t&^CbFlHc_13(Q#47wx|<Nvlb6$7BQJ
zga?8NNa^ZCu18AjCRA#hbR2u=j^4bx`#q3zMnXq$D1k;hWwtL&ZRsfEa_h@Ri^;33
z%W%*?rp_V>9_>7WsX(IZryV~~*y-Fv)o6-y${I>7f^gXgbxL*1fRdjc$zAo&lk$I^
zEE5RsC$KL5>r$StR>2J?Sqz(e@;+R=2TD0c31yC^w`*07i369iM<o608&7+WTbt+N
zcgcY&%drz&*agdg#Hd6km>}WLOJ>yipT0gKl%VfA#fd;9YInCVW*<Buhu-Iku7@5S
z)V(~dKV_SCS0Pzjr2=)mb3e-!mUY|OSpL-GsocKr0cfs0JlP7%=28pmQSUld3N}Vr
zonDkM2tmkmwYtikzgNfun7tY}Z$Q3b=rTh<O1$2&*~_xgC?Ykd4{@vAq_XIW%1H;V
zxIF1DN}s7Y5&G#weU7uiHq?b<fP(6vkoPfwr)1Jjz#&2vL8$@oR}k$L%3J8CK1iF(
zuBbm_=G9qKPgs{WXH;0^1eZCI-TH)O#n!p>z;l$3HkCCZ&Y?hyDoqNSRV9hk`xz4R
zPE>svzr*6V+rA5TT;npTSwyG-?lPn~E--1RJyf^Y38Zy=Gx5n-JsgZHP)+~ajnQ)!
zG;sg++decN^!_VLw^4tIUeWF<1|u~t*8ZJkQnjc{02P{I(vSFaeX3zkE|)b6Qh`8L
zbM;P4siv%Q`%0ZYgPLxPMFgXR?_Os?N|I+$ftDU2ZMeAle<1BMve~Dxy8SV?&mfJ4
z?y1$wu}0T<5bH38#tV@T;%W`Z*q#jZw!EIk!O%^eFP;+PqwY#WXH~$5-vx@5Cs8`^
zUGd&jdPk7rk~s({k4IaNk{eFBlN5C5o6PUYQtlo#rXQ;{4qaR^LGMAIn>PAy_ghjn
z@u|!>PU!^D-Y{L7I0aTahR$XTfPvqOUrxUsMx(3lc|K*HNs&Wsg{rY}KBqPoF=B*_
zWs|y0^StRlHh7*k8Ue>6`J&fwK@ww#Pn7p;&UrMB8V4ykLVw)Fx*B(2%8LTp8$oNn
zI#u8K^A&|x22-aaToM?l@K`6QIauZ0Lk!d2-kN^0Q)!meCScG=f4{L~eRJd4%Bmje
zevLP6+@KU_E<EoSYt|=K)8upXGeI2t&BEX|x>UxfkqUXZAS!QON0YKw<qfhuNFNZO
zpYU`EzsNI_Th1!A=$Ptf|E5xizWc{rnW#Y1HSg?SFB3o81#%_(d6u?5*K<aR-m)KO
z4SL$jFW};o)_=`Bp)cFOzf^?5e#!o3z(Z`6qtIELI?#0f{CsHMR)A926#3!LrMjCB
zVE=QE_LX4`&8iRRGFr+r6PY*Ej2Jc3hlHX9l?51(u-hZwI{)7Zx0NP9Eq3qOYi2fQ
zux8wlELkniW;*^>ik}0VGMn3YKgPE4DPm78;UDR%q!N{t;nOv|SknYK8+h%p)yAOr
z#9NB@FO(ySATq1kgZ-V~K)OY6Vb|*bXAuZevaN|ZGvHWNUy^4SEC~yxf+x&_P^c3Y
zhIb;0)rv{xvVriB`A!mjmHlrxVHvnMFP@A>G;JYZ0s-Te_{hb8n6)#SG9k!qIL)zY
z8e<q&*EM!h`_|IDj`tOiWpE>gkQ*}<G<;sumx{K@ZH16ZR(61GG_+@UfH|HZ<D$aM
zvs_{iJ|;HHG;zFX!AT9lel{r<V&_aBzXWj=P73;f(?8BpRY@aR!nFJUD!dp`3Th<&
zL(LDp?AR`NfV$~ck*q11qr#ytr)L^Ao%|#;hG(>9j*f%Mji*9tHq6ig`rJKX)k`W8
z3xpKR88x^)Pvq}5fWu&luQjfcH>Ek(>!lHsi1{wBtUjlvy+WOk{-cR#8Mj30Z=BJ3
z5DLV3dQ~F%dcd942++<F^tmqARi2E5!T|ah&-Q2`Yrhsn+?mVI7p1T2#MPNK)bah`
zP%K~Z^fIAe+{`@S=)z)pQYY=@Argv#DK$O@Wd#exCMqpcUs8G#NwHX#8C9Nz0Us}`
zI@-oGq~0RptWTord#Ui565`xx0{h$uo}uQqCdtu%8rWXCQ={e~bW52jPTG{W9phid
zjE>=X_OtQ5R{E*RT@;5CM}jG#zpCwJa5uXSSKR*__{QX!kxcfihb40lzVFz~R{+ME
zo8cC1u;A)CnfBt(=x{F-zat`QnUEEr;;nIdl7jdQ8imGW^BQ8Y=;5M}l$`^XF@W_~
zHqYne1-1xj#A_+5H%jk2UJot!ghUYB{~76C;d-+30m*Pf@7eK_E{Y{(CQfUfrtDX~
zYa&TANVA`mot(@QDmuC7lr0c5c#i^~2TFCy4F(>Cf`?%YLN3&g1Tkmg<HvA2)<1Fd
z%hlsd>s7rb7UGyOB#Pf;hV;6O4kzx$lb&=N(()&Y{JA!>Z@T|_<cjnPC@*779y6<1
z_)X(F{6chM4~q&p=XR`P2LcF=Xg|J*sie@sRG-_EgekFv!G~1wgVX$dW@0VBCx>i8
z&ozv(rmW-_(Md8Kl;`~-wS+FE>==P|ZeX|{=R~k08LQZ>LlgsU@R(8F$`e5+m0IR?
zs&DQ+Qb``Gwv$;#=z^5g-~1YKUWw%VikK|j;?0Hjrp|wGcup-}EuKdG=Xc`M#$20d
zQo;{(K+~~({W)}-QmQL`{;mrQc<`6TQNH+utux1?S`&gx&3gkYnjhSi{qZYcr2Aw<
zn<!twkh!p>^Vh80hw|LH80(5>2pa4E<|grDU*|R-ym$u%+&I2jke3<Oon|cK3-<0D
z-56|_Q~gTBMn%mZ!(Ia0<qjq3*Hbals33puTMc@PO6?^&sdbvO-w09B^Ka_d0eXZ%
zwoOE6>ezez(60Nl^Ak0IN<iHsqYq4`0Sy9ycw2)B5-<L2D+=P5SwBKE4!dCr&LG7`
zY7e4+i+~xMnr=7G|0wD>T}o>nVM4z{7@<c^A=^*6y{ZX<+FCZW`m5`i(KbP`X@d$x
zDWfpcj4)A1NiXZ(o$$r^VnMEE)^`|~=B!WtF2JuQ%w;n2E*o}pW6?9L{vHGkZcr31
zHs0qCk<?TmKfEy%!gVt?G?qfqc;hYaV*}wv6(+60gBM&6yjZ_{2byX3pfdD5u&uw%
z#6CQ^?b7su>%5DZLnO+&MgtHs<Lj!s%nS%L6s$~j<_mqcPqHyU5237O)~7;Xqs<v0
z#oi;y*pss&?K#$W2vrhWt@kb0D>_%vdH~Klkm`KXS|UIZK^(HZi`0d5@Z^Ox11Eif
zqE-#zO6BQ&<K$$MUeJWmkGzH+TvE2}03gOSt}PF@1@V!V^XuW@8$yut+!GY`Ij&w~
z``wpL6;9BiaxDVyjVrS7AB_cbL|nL~O7WX{-z!q7{!4?AR0gtsV=Bfvdq^sMLVQ8I
z#RBO)kR+4@I&r`8+6KC8()dwtmqH+WegJ|kzJ$EEz^JRZ{Tnp9r>TXVFC^`H3@ik|
z3yPxdtH0cgf<zwS4r*QFzP6^;n{su5sJT9$*>KC7?GmXa{2V!TbYd9vV7#hvK&4*|
zOPAYvag|gSBWeqmYd>0iL&0W`Jkzu;A}9{O+=)$fFdDTHarI=q;-aEq+loJll{fd6
zempNDEQn;b?W_~|DZ;?7RqJkqy>%1Lb`xs~?cNtRiF+2TJ?LJI!wd8WYhM!J+y3yz
z4B$(z3VTFQt~w&9U^Rx^AMk&S0AA94sP7b>vZWQgrXJY53vj_W{R2trJ}NVkw$)ma
zYKzXDImEWx0~!?MfU@W8+mL;mSR@i<gr-S_9}XZJwrLa=aWdR6#0!G|q>OL|wGUvt
zIAu)yA#RdvkL{dG?BeBiM{Q%*6{M=zriVvU!CCX5C_Tr6H7EXeI9wnF5_*y|T%Snf
zy|qS)vsVHUiAB|>F{X`5!xbkV@%Rb;QD>*E5V-3m>eyMR97n7U1Z}i>PA)YKnm-Jj
zdTHEyAC9U@jX;z#*D)ZSP&cXfgQ^xwP)ZFLfaZtiJjX%~ino)HQm9mP7b+l#o;HZo
z|D7Pq0IJ-}z3!3=qI<{PWm-Cdh?do?mS-W%W$<T4r5gp6rpm}jEgigo{z*ROw9ESt
z=i}wf2I!8AmOY8Ef)Tc+h_a6GJ4|4f-e<?4znz@Ap8i8}s6(aHOX?obYmnvmOOY97
zzhWz{kJu84dawqP?QiOjrIV=;FqS>r0S3=&ixJ#m7&#nwCY-JI&9Z4#>XKFR(IL;L
z$s>Igl!)$_f*fr6?9EBI*a<=NnGxJbJH;|?_zA?XAHAQSne>@mz8c1!#F(C^EG@TR
zza+Z=Lq);}4bLpWn8s)7zA|9v?JyPv+ECopgvk`ihO&fuYu5#L#?VffKD)qe;m|ac
z@h$y+D^F`&>>dX8-9*T44cN2u4{|9TMIiX~RPBPwEVH}tKw&B2AY)_H%ZMh^OV&zX
z*rh>D^tBYBzT+}9qkM5zk1`xX(5+<J?PsqIWOV7sS;6`n0*W#j3ow7VLX+&iiSlmB
z=nEnI3+ej5D+A7c_H^krmNua_=k>O%(JD&r>js6|9t^A(s!OwOcU@2UGHcWAWrIz1
zlbn9iev|nSXVW9lUyR9CYTMFect^&6^cnZ-vb35Ix|3Q_T}@EM3ISXW(y>W{_c7|{
zwX6D=`8Pe!joMhCOP(qM2Hu}14D&4E04BUmzdv09>|2wm1KZ%93oNr6$c!nUFTdP7
zXE_;&<ZXOO{C|d+X|=8<^({N;ZZE0~nxW|drJm|)U+`hrywh1@2iT{GZ7>biPc}eD
zasn2JjW7tAB7@82F82iWlk{!l+G48_$%f5@F^O_T7`wnJU#f|~s*0X*XxzDf&4r}{
z=mMO4;;7b@gScADN@815+QgLXgcsLE?=KheEsI*lJJUcA)!sE~(WKJ!qGi=VcQrJ9
z`_R}iQru<9*bDRrM>cv^sfczOq))H)+Ko}`9}8l)DXr<~Am3Tnf(SYf!-HCy=Ll%O
zcY48F@`Z#{r(jI~)XS4bqtln87|eeL5>j}?_~aIsHA3~OMXPB<|I+HsiB?OImZHoW
zQVj4T3EffKJkv_|F)+r?m7kj{8asBPI!#fH&WuQx;4<akj9t!+F7^jQB(?u|i_UuH
zZ&GL@qyBi>BfhvL61`*2K>|-su2)4kCm;?qv{#NgvweL$R$J40o}kC$OUKpXO8@nl
zhoV%np~0U;!;e`z-hxa;;+medU8l-;htk@|P+yrK#Np)!B{v?*6S7&tw4|~S;&96g
zL|G&Pj&JAexwuR2^c7TG;#VpO$>8XPD$j{J;_CgLP={1g=X7}P@69DFc3{N_@WRLe
zw3ek?WaT?D><F=QRR785Lmv~;8S;l+QQzX06^pn_vpXwP-s|=|z}6nowDD<F_9_-;
z@R&Uotx2X`W)K*5s>^zd>olpmMa0LEk8y^5OQmM@&5Gb#hN=Bd{CcKh8Gxz2aHJnS
z(mmXYJ=Zzm85C3J!$veH26B!mFHz)p(d8_ItYLltkTIgytstvZ)je){u<eGPt@Msl
zgsiofLy0btCpQFMLc9p*3Re+b{Vhz5-EGMd0%DrjF|momeq*k7&P5(2JzQ4tSu2_K
z%L_aJ)^&;mm|NiMr=yC&gPogfgryKOXy?5A<mJ?0K~NNsHX<{`exb?*MFw3dRdEEV
zA;;dKM;49pW6ld-F83U40VM3nQ;B|Mr!|?r{VACd&ENQ;J7D51`w6Z#PA0a;Qb1x<
z5HgnP=X?AjtLYE8ZgL_cs4<HV@+>-3WwH_?{6|%rZp5w(3+mexq5Q8nHN6bVrZ;S#
zDPiwuPBe=N_W|HmlPK6sTG*6rb}2kuQ&K2XRzkp<6hXj!qrG|AVX_ceDviQT9!NOq
z$iavr2lJmb<tjhBFCAyY%<}x{G(~lEz!egWiqiV~o~5rDwsvQ(Y+Yf!_m#aCi;1do
zV=5c{b|6UPSL`BiF~wLsDOMyuS!WlEiRt^S!SM)1EVi7%<Xc*#l@S_man^k!PU~3~
ze~(2SwPlTnyrN4Kznq~K`H_Fa;l&cHlvTLkRI%*3u(*@neuY@kMxy@n(}4;QXk#IO
z5qJWnQhC`d>xe~7;gKBTma`EVyhQkjO0|R37Q*7s_@k6m=xd-9qWG{mCxF)->y@~O
z&_reJ+z<h7<;hERbttT-TwtSh@O(oZo}p8@k{~zx<Ogw<I#Ol6IQ36=>DyK(V8P1%
z$`hM_ZJMQ!%nbxTHBfCt@wJWcK!V7)kSaDX+fQQa$e?tO0q`xN1W5+jFF%|J8h2t|
zmfEhLzcxrHe^yyhX<A6P)j(B{$Mw5OaEFfFfa`dq3dv*1wf%h>L!)V?%jAD&Rq5{d
zi1~GenY14!0)r)~`4*+G6PywBVQ#eGvr!`W&NqOD3XOSp^Epr7Qkns;)Awe}kU<le
zqCF!ofi>yr<^7nC@Z9ayM=)N`5_qBIC?FbJCdCD*H#mEKM~ABsFt=9i9231J=usPV
z*xiyclJJOuO|!^CpNbGy`7Vsc5+fvz9)J@tMirm{05XUl)&K#s+XCCh4%@Wj@IEjN
Mivj=u00045T0j$0q5uE@
diff --git a/data-raw/datasets/antimicrobials.sav b/data-raw/datasets/antimicrobials.sav
index c126ff2834e94d40899d69140a4934bd6956fbd6..7c0907950b7fcab9b7d46206ed201527aa1dd6a7 100644
GIT binary patch
literal 370416
zcmeFad5mO9dLLG#MTj$&1X&;qnwJtKikJm=w)3d0gVuUGJF9!Phja8y_pXKm!`xSy
zFRR{EUXw>nRlz35q6itZMUxaQm<#?f25guDWJ3^a?^3qRks%16AOaLg!?Iu-15w11
zA_?w-f<YL}9RGgb5%1;8%&x41M^{y1rYj;|ym)bZ@x^z?cRqNfeD{UF@QK3XM~@#D
zc56>+g$EB`xnFp(a4;J6hu?GO&VDjF81H?m(d*p#%gJdpXucXX?z|aC&Bvo?RQUR}
zwY9(Ub!%(*PkvwX#M<}WEtU$eMkj@GwN(0^jqUHLRtlH=;S2oUH|VGI-*3PN@qg`}
zw$10+-`9WRH>~mh`omqRz~|*`g)-j9|F6|vz0V4K{xN=D<?Fuv>(=-`pYiuBJYV<D
z^Y1#whyP!C^Yza?`eV}nU(ELJ7tufbUwcx2X6E-<hmYI-Kim8JyR-Y}yRm=pKlab}
zbB{j@_~~x8|98=U{Qvo_@2@>8`1P{;=cVlUU&8qDf9>AAH}8M`VeMI1zsrvQ%=feN
z^D*WJ|3Ch|*Is|^`(Ax~J3r4peRAgdqk@CLvq*p4j_;D|=Znw3+5KO7Ht6r$^}po$
z-|qjLjsKSI|MKnrzoma}>7Q$VzAW4S5Fp;d|1JDqd-%WU^v|;Wzj3?&Z}HzP{=4@0
zZ`uB@-tPa~{eQdvZ|wfxyxsq|`~P<T-`M@Xb-Vv>_y6twzwZ102eS144?zEq|3&}5
zeY^i}!v4=LzuRxV{$}l!@88|s<@ou3_<cR#1OLnO&%O3=<{2va`wu_Qw-tV7>e%~u
zj<=tveMx8>3DZBn^7_NqXrah=ulxSH9pA0~+PA<>w7+@J2hYFn0l(mX+5flpC(k_o
z`;%DGe*^#j3H<+!`2U;mzyFB$u-f9wKs^5&leIP0_qu$Kbw2+1cl6K4zw?7r%d_6U
zX?5@8FWX`J{P8`ey=^bg*7@U{Ue^C*<;%vxIr`H!5C0f{Yxh1K?L7z2j88X`=5zGG
z_;few#LtPZ!l(BKy>b6J*foDT8a4P=?3<bSetA@SjyA(-zWkiq(4y77L41@%qomgz
zKIf*RpB|ocd)<@H@Hr<YKHVEc?eA|kn_2<_KugBmWHfwENrq1+M^eKH1m^X*poCAi
zdr7y!k^LDP*|*?t_++`XQC@paYgV>OYtOOfpT+-#0m2yPia+<8`3ff$zX^ZS>9qE0
zP5dIH@DqRc?#7EzC+YTvQ9Egz;QvB|xkHVqRG&<1-BHpxY4rA@#wZ>nQF|z_7hW!I
z)M{|ZL6ZxA`n}0ycQD=`7FxYQVKj)NQ77(>3cXfgG~SB`jd8m-OtisTt{2+d>6E>R
zy3IlpA3wqZ9K~ASK00Z<u+9NQ@;&^6L9BnWAZ5LNGze)7F!SVC%KI3r)NaO6KN?Ef
z+gV3PV-&LDKGz?uX=V_0$Cf^b+etrZYQxB6a^6li?nJ|$e5IT8?LADl^|K#!GRb79
zO`+o$)G+F<f7072tV`iZBSE2NFr-W}v9YikSF_vfu_mhyqh{>w=o_dYPvzktvcg7h
zu$MF}(@e%4OU5BFSoe0M55rE}v^rhy%&^;QCf;JN9eI006gPTO`yd*0yq)OKIwBJ+
z?+xP9#3l;;JW6ERF&UWZfzG641_?80M?j&l&JXw^4f}CpG{68pu@E?)-NOFlW9|ID
zZo{SfZ+?if<5N6Pe>LEN|Kp2q)oP7+bkgo5&A1U^zb9R9UnY1mfs-C4ACHH309y?}
zFzXHr4J@Xhh8K#T;4Aary)8M%417Gb^<Dj)bY1yQ?J>Rb3I&vY;jjMvzh>(?#MaSe
zHN5@@wVr~Hab)cI{!V%$MJciN0cc7PSSBl*9w$T(s4!_7ejD_Tq{H5hyd;HeLGgrD
zNgokzW1^U0+y(;Z2_S1;+nG+^9qT+uX_ys#DP)N_WEO8MJYNb9h0b{8vBTlo+JE#9
z?$+AC7UOoS*NqFr)Z>m$u+tf@j}GDiPI`dO45a}&<6f;;S&CP<u2VF!gwANk{XxVp
z<)7QJF*SN5)U$mjaLgV%{7KIVG*P=5^@kXSWqeebZ2!O>;~)f<6o~eA)=`GHSzA-m
zjwMNR45B@Ic<R-fNhcm1L|uML+Ce8<*aRbax7$1FjRy8bnc`z+41jGsH|@{l&;Rgm
zzVYSn_}@Qs1?Q#AUG3HHP2u_7e{r|gNe+Rox&S>qpG=VN_V(MLl!tmQzOcSq+^oG-
zDsweoF53D}OE29kZnEf&%;Ps+E~e#=i=|qvTw)zhVlDFv$oA&HJHLT!UxnVWw|q}~
zStyWxKIFFmsr)0&q5`s3tbe)&P)ctfru23Ks#n07Z*WEgH+x2Ri9Jz*QXU<}BmJn&
z%Op8WTj`x9_H^u}1GX)V?G2KKeQ|F*0!27Xx}Xrfox=JdKG2PX!f%fcBRf#og`-6H
zfqrj<jn<PI{Xsk&y_Yl&Z}@)scxoJi)0J4~Qn9qLQ+ct<g({U^+>*a#%U52kNZ#kY
zQr+0JDjP2f@Rq8@ooy@H+Cs7@FKlmb7PYiotZY>*S@Cu@%Ntq|Q69E7Ufke2Ojfl~
zCO2Q)@zO1O9i`jaF>i+zceIa{QgLTX-(k}F#N>{?Q>m18wE0S<T-2K04oYn3mFniE
zRof^RHaE&zabvrLVws$3al2T4ahsiEvhpG}y0?R(&CT+*ex|xpL4RdFHjCBGjTZ$;
zFj>_`H+L{#X>%KWFJl}N$d33!+uJ)E+ngl9@RN`61?=eB_dXE(RI|Nyr_~#_lmL?Q
zrFiO=eiw{*MgLriZeky5uf876nfHI-U*VhqVcf=PA4{>zWhRu%w8q_i2xRV%YNCt=
zl=cw&b{7Z8{gNFritndWE1Tno37>L~r0uD+rq@pzQM)i6>W5SMOuwp7H<_AjCs(^r
zh|q8L*ydH`G#CoM#~+7eCxs1APlvtu5I9{96pABa5pgue5V}Mvt7*mEK4b;j%48Db
zJN*N0IeU;SE|9YWOop|HLF|b<$J<$N_Zsm)#V<^bRCd%!+Ra`ok+T94nGxiB{FZzJ
z?66XSy=L5HI~=Qave!w_XV&c7cy1^^aRvL~t*{?HNIv3zIHsrzb1&t<YXZObuwpMl
z+BAwf!#n-BYjwCEKwQ;pML9{{c*&M&S_P3+lp~D9mpqpxGI$MtxULg?B-4J5$oga<
z^SQ#K^wWj+5a~$2H<=XTV^AH<xLI)7lyqO{FA<Sp!w|}BzfM4p9TUTo-fE0{Bk2eJ
z0rle>r`@u5z>~C+rqf;I1qgX~*l5R|Y{mk^fo|*c4u>{JRymMyJ&ec7II?3W%zAyC
z74~4@{h^FfzI80*BYOnA(HEJWW)d{)JKdMg$U@Zhc63RdLd1in?lfrw`zw4!_Meot
z+lUwC<=#&ATgIcYOX-k~Awo9lvUd!DK}x<#*4tq*q>pLML+vx<x!m{iS*&DN_j@$r
zbXqwm)L~dJ_LP+yc+Y0Ck?gg5GLeloA1l&nN|IHZQ5RLMU*4bfW(?@|QsiU-Wipxx
zIx?{D#4TAfwDbIWJnk2C=32@(qOr6at+u9RTsTK!=t{J&`;<O6bz}z++II0>cI+VO
zg!Sq|S|bBHz+ii6$C5qpyxL4cd5%wSa@uQ;w3$Ot-vNGl5QN*j>16Oj?P##?P>3`R
zHW4#-qER%An**JG@We?g!1JIZFs8F&6?(_yN7x{G<cJ#yL)$DYjG}#35d6)#j=>xN
z%Xjf1DTj;+>p5~vKZL+uM+fCW%z;b$EY(R0>qR+ybHIgUJCJ8*YNt~zA}4DQ0x+-s
zZjd`*%6%pVvR=|0WZ$F6V0r-EjP+?4y_cEtVX_~Ead{)dq|=v)X0O0HjlzSmHG&eX
zzX2<tXf(hy2YJ2r6=hZ%s;hL7!H-$-5ui0BF`t%x??mTkI<<mRJW1bAb29m-(wd%}
z0U`g<B#iq0z0XYcbp*~Q`CsRkwv}ZmRbSlZ43{>^1n_S~X?uqc6m416Z6*Ip;EYPf
zT_H)LpD*qxp8&o@8U!~Y4SGA}vhzq~uuH;6l&j!vw6s#$*ieq5THP$!b0&??s8*#N
z%;_e2Dhvl$k4^0bQd`=I?P94?LE~78`RP}_MEgVfl~zq6e}448{`gU?hJ`i=xdU`}
zG;TwY6SRzI4=<Ab%$%=_&hIyiGPE~dw(}A6Y@KBb>Dlv~*Y#d!4`+sGcBz>3c_kKA
zz#M+E0EI{UQ-!^h#K3Mw;Q^4{s5cOWB+uzPc91u)M`c(T7|%x8ve8%&&2d}#HrD3>
z?cehg5_9Bd9jA*RfO<Tu)7<eeIn3lv_{iIl7tmd8Z@f>1tF@>ZMOf$!pBP$;#t_a!
z`HPoBJ7_{{utjEi7_6lsnom=T5!eT`re|HIKaN!zJ+uHwuzr)Gmp0-t@wmNs7!OVB
zSU6;DU~28pbjt53<-~R*chZIaSdvi9d&BmLIk=dI+iOvh#Y-|E$4CBm^-*T_F<z>@
zmCEn`>cO|o>|+R-DWs1m!oTYMyLx|bbWQSAvNeE5mZ5e<>3V!Fz}w5_FNFivsJ*Iz
zP*Hlf^cSB14xrtjB?u^=0v`GLKSdq^Gm+Xo<-ck!2cK+#{gU(MC5pS16MMN>rcDVq
z_Zyj)kPfxq@aoEKPp7Qw?{TO;Do&2eHC#3#f{o$Ha1?_*H^~P3y(db_tX&E0NQj?X
z><a!sBjbD-^N=@ug3lpKXefRH-Kd-biek`(`re+>ei2TXVXve71E<f3Mm7YJ59}If
zQ*TE;C{t{QNjlxyDDxCm7#?REP!vhyl+1WLIAxvAWwG-nlJ?G6CVd%1x@HcXuAa78
z#xHj<Z#X9Pxo4DL1319uM4sy5mRSd1k8A$-Kl6F-7~+*(boZURo(H^u2HY~~GHJbv
zNwi5=VSY{S?d?G5ZL)2n#wwL+MM*)VHk26LC~g(E^mQbwCJo=%*{<&R{?Ml&<tTby
zNWb~Y*uHmp@~fZ4Di#W}`~Ag(WdA_Q&)oMHk}LbZ>lOA2{FKYjr&I2`10|#g^5MDe
z$AFRKr7Rxs(cSRBS0INAb|q_T$(JFAgM3)HdjW@V4xB;9J9>Xv;hb`5$les?zg$hz
zqWLU|p2w4Vkmc7=+5s?TzI)~JIU!Vmt+`G896&bVe&RXM1PAW>Hf3g`wlV0y|Fm;7
zvL3=QMdYlhsa7hUO6A&C9g-bCMKIy8G1OON@`J3)m%^9`X1zZYuK3Ag3l^txEq`&o
z#3gawP9H*mflowonD)a=068D9L<l_~|HL84{!E7HIT;23>scSmk&2SoMi9<HN`V<l
zhlnJrdw)<D)|PQsg=dn(v1SdnlaWae#}wJyI_yO!v54Kk@C7}DRoufN?32MpDD&a>
znQp-RLiw6xMEeXa6lrK?p0#_86CCz@3F5jG6llC^ooHf&gYe{eRO}t{OFk|ahBc`|
z2-36W7_!$iO934xSbDNQMnwo@RLJV>gi=}jcG8MDyYfOON;^PJMr>W{f)wGnamYK~
zh1`0*J3jIm>~&y-sS-tKQrJKHDhfsFspgrQlV(zWQVM%ev}1CRh9xoBOV3cFFCFC*
z4BX343qA!tF1~A!gA{CvWo0ZW!?Uzm(y|W4chVxL8*c}Fmm<ttI<I}np#eUEStI0h
z>BB(`16HS_Qu!qeApwcndl)06^@pS~z5B388ysb`;|^?GA${}y@QcH-eHsHqN;^G@
zkJDBlW=>Lh8Dw*XUK=DNhT`oM)<+NxX5RpWH^gK@_9ma&SFkg%r%C+s<09tEz@e=y
zEGVq{xQ!Q3TP8;{rfGmU!0KR#_G$KqxEd`VCC#+Y>+hY&K664bkI(;*@~z1`I%Cc!
z`(M&&uzP^yYn!to>1~tYfoL;nT4~$odmCas5y;V+VM7IH<x+9e<bLJKX36AxWfP{k
z5kPr|k~wduuwF5<h>8gTD<%Pi<W0^;kbPCRSExcfDCPr|$_^xiARsgCSRXek+uIeR
z6Or7|Zh{h&?-tfKced?|+gqDOc6~A3l=6dI(8smZZurNFlMEejCo2|Ml^%H0&we{s
zRjvn0H4g_ezH^-OS1Q+2ZI;;Ou^;Fg?4wM@H5?O8pz)Hwzy=E0m<-v4J}x(?&X4Pc
z=0Be1_Mh*&%wAitu_~Ji=hLb0s-?Tdc7Z|p96Zg>dkW`#R(thLA#7Rti(mN~;hgsG
zZno<1Jx%Q*X6;trcvLOjd#hNU|ISlORPKOJ={R90A<(5C7w-w+T9`pQQ3vToqX(QT
z`Y}ndn|ue>6D+lMz&~~3{>i|dI`9?_EzhAGW^$Gr9YC6@Z2}=YwYS&*;pO?J*B%Bq
z`ryf*sMWej6R1H%FSKAdlaHqTLb>*q8I7j;4=tO6Yp(Yya<3F_RXQfGO()Za8ua9(
zWU%K!zc~<Fa)DD0#o%k=LsAAHJ4od|vL$Belh`Z}T1l5l)37-jNgE)vkKy{mGl{?J
z4{A>xp-FoulP~@he?R+~482mVRyORQuWl80sw(oSZf`(mD3rt2R%z4Ep)$yT#pitf
z`#F60=oMK9l-~WRJKtBU^+{HeTan@b#~D6+R*!cfc~Iz+z#Bj5@D^APc<xz86wpF8
z@U)>s;jRsp)F|@#Z~zNmx|xZ~<GDxSynO$^{wps5KER{S`jKH~7uw0Ie1At3yp9LN
zB7R3`+&3T?dg&h0tHG@-pq`_9CvArp(}AK_u3%*c!I7D5l6TjD$T|;*F$8oo!D4RI
zS-lf@o9d2o6<bIeN5Ukr(Yfa>hi~2tdZ)Dy{^3{e)?m3Q?gff&h;Np`lYox;U1aSA
zUb=^}x$|;vgjyi*!%rIgOhL>Wq<BXZQaq=)<p4S%$PK``+wgDtx#iQFJHLKDdwx~Q
z^aBuUmuh7jguNVE)r}HL&C2~e=YI~49;No9KlbCG<A?oVkU~&$`fKUAW%i>gi_XGR
zy@s-L!4p62_((-bN-c#h8IlTlr}8re3TMrppI;|!b@lRzzM+3Vo*w9oI9;^*Jmlcz
z@e{!?q;vk(3($8%fGncel+HoZ3(m1Cpl|l}QafK&A%~9}pm<*t_k^bk6tHfG{T+`q
zP}GDo&cQm&GgFV(kO_qK>hp9hYhIr2`FuF13itoFy;|)^99YFRW+nV`Nw|U4mDu7K
z`!wye262oNNSHO^x7#0Q;0o6Hq2q<M4}K8m$Wa2DxRk)Pb7Z+ZNQ_u^s^?q|p+op7
zKR4u)iVZ>!6dQ!BVgs1=!uL5DoshkT?_&g!z2F7y0hA3enHCoV8P_@cb=|6G>Do$l
z3kDV{b4SuFd0A>geHvW(`Ad&L(t2l4Nba2ZeDL%7=turx7kGo=YJj_CHH0oflat9y
zbSdt~eVD*Y<eN*z+aNr(lEG1cr|!Fi4_LuNMI%B)I6lp$;VCRtV)TQ?yGjO+EbDM-
zq>2|OU4_C?45f7%hk@DIRy?omOsA?y%hU_)9NLT08A?5c%07GEuVszP<FmIByb?b^
z<p;m}KXhuf)1al3@)hag`{q}b$|Xy6md(+{vc70ELuWtLP9sx~#@0i;FAE9nFVwk5
z@r=_IdTgsK_>x0$xP*+#8MkzVia*o5BG5Dsn7ifQX7){LXM6?mhuCuM?NpEWryhPQ
z;cs*RO50CVhrgw9hlDSCP%D{;i0jREi=|Me(Gx^D>&Z_zoUp3=98S{je6j$DNdp`)
z_!tOnVBntkMRnCqG_5b&#oAT-wNs*~=+xpV=x2~slKxa-i*`deol`r4j4Wy}KFvTa
z0+VT=kLc7*KG0YT2AB33b}QJ$=$AXup{arR-2;<mIhb>zl}lhR!?ep|pO5SVMZqkY
zd5-~m#QH*?WCnnm-i|R(;nU2E1p!`qFHQ9{%ET${SU9Xgbb10?o1njf9m)aRp9DPk
z9Ij;p4-)~uT+lYQ%R9-j7z0Wx@VPP*1>z6+jXQ8_&;tz)4WcQ73kOgP)>m`vp$rS}
zo^qZ9TOgWP8xC!Oe`hC-W$yIE!rF{Li>q}6mPd!7lP|5=L~A^>(_rr-v#-<0`Ax)x
zi7B64NsnTgAIu5&2&xyJHw0y1d|m!bD)Rf~&-i*dKd;o&M_IX1saPyR@gYWnCB$PW
zs^Wvml3GW=%+}k1LB<Bxj0PDN!=hX*!?r@qJSwJZu2`*#S=ClNN(1a^_59g3>kI~A
zpi9=-=Y-LHw5vrMwFl}SRWo=XzPr<EkKtt*!9_B@GmIP1l}VbI#qnUOubb5~uSyTf
z$I)2cE`qTGvMuJH+pwqkde;Tuu6P_*K$itQ+lN2%CB)@BMKpr*=-J%gUAD!nyt24J
zUa3&II$ib%XOQ-1xUzq{ori*6jc=Mn7#BAW&%sk1xY7^&!#&DpS-Q<<zzz}51_fW3
zA{<l>uV@B4X^cn_u;#;eu6UiFwdOvanq{%$Q`*}AQChef`Xe~Xt88u?Qry8`g%7dg
z+bF8CXQQO3bfdHhhgG4!5DZ7WLsyw+!-r^?lURF_(t&^J*FOh%2dxEMNZ&I4fU-~v
z@h5v-i9rjyD=A0+q379sFmFF5WefQawxf7-FLmY2aUuEd=t3)9rv%qXj%e#X;8=~0
zPmLNI4fIG5xQ3IQ%pd+yZ%2@DHavxM4pdV(*k#z3V<wYK{jZf4YeewI(HhN@F0C>x
z%3?PbX`nO;=}#xk4c{FndwXubK0W)~(ve@&f2l8!Uv@t*-qn`EIQNFcZ-NOZ_J)xG
zpcs5TD`rnwsUZ53@EF_<ww;)?x0$psR#0fc22}9!hQ_<X<l6pmhaR)=L@X`QhrxP{
zR-jMCUm5xW?bY7a_|9P;-Ej%A?x?f&Q&r?%*>hv}0m|m~(=~;Qs~*<H=>hk{l3POH
zhvj(j4s6oLx~*5ikGJc2rAvD8^#tNzPwr*xr+?+E-%`65A>Oikp6GdpdNcIctR0op
zcY<@W`xJguFzw2ZR`Atqd$|*DmH0*QzgrT&$i63Xw>F$q96x60Hx?_&C?^`vBn;Wp
z78HktsKiov?(N9b7!R&58u=;2;7o}gjiE^Sa&HHA8AeC*6Y%U9jooFY86WlB_!WUz
z;SZuLKmN!l_(F((0;5C(8e<U%%l&q5Px=ABCHTfl@B2MOUbm5Wx}6mCm7deNQ+J6F
z;R52Bi@%OL|7f5C$R|WlfmkXS6k6w*onPN;nm0MX?=pU?EMfMX#(_-I6l<`trFxo;
zZ97*(Bu3{0)MEk~8wu<<FaMjLzghb9UM<8k`Msb1?|*{(6~Y<(liCBweqG9+TO8P;
zgwYIfU?-)w-ZIgpDhB1a*O;(cm0`(39fUe@7y36umMQcD`z}^<naBFni1DTHGMN&h
z<owVH(EW=--!Gh9nBuB26VoTH1XkxP=Bq6PobvSk7`w?cD!`iYhfF|uh8F?i+3dU7
zclB$sBlr!;dVh2`hhkGN(c~d?k;1_=2W=XCzqnHDo412qo2f*xpNjVoz%Z?h5J=3K
z&n9GX{enMrxI&YsV|(KU?Mt42GL_^XizJL?ACg?Q0IVRF;pHx;)8=-0i<JptO6P)}
zHE$;R95MJS=Pm<>3XKc@&F#zGH{?B(zW>D^eNwv@HzNQRBncX?lD$m%y}a~F<PN;T
z<a>RyNhk4LE1Nq<7k25kFh2u-&+&C8?!k5ufe%zROW3HW^nghVNVT&;IMJqz5!%@-
zA+iC)tN9Pi=W}pzKaJD<)-Qs-g4HOPY*#A<c>?0(=Hqp%-KZksj6M@~qu{{izq_zR
z@F<&>O@e=#F#`OBE(n&y4IAhY?X(otX%F*x_87E<Z6EmW(Eim%0!nA~eY3Ei*QJoy
zNXDXigI^8$fz=0S@FVhh(C4qIJ=eXsdm6zN3g~1H$rC#B8|A6^%J54@PrZmvzh4ym
zI76qiY!03TUND$Udrzg)Gxg4+A76c1Zbr=jKfmx#`1@0Loz7f+_$mG&NZflZjg#@g
z7k}q&29Ej%F#>y@@Ggfra0+^!%(^awr=ah)4kCWWeU$xC!4vVF1Ojk8g#%cST!PVp
zXJJ-Q)#~$kt!uWf;64gLc#rPC=JXFPfcuibSr)3C{y7Vtg8W<&5dE+3dl}-fcv{$s
zl4wvpsV7i=wb%^luDl*GPl4s1D;kHKJg1K&d?7#uVTzg@_h*GY01>hkCk2VEn4)Me
zR|vGH`-DVk4=lb67yme34~KF0lqw@b^#aN{^sj;kFZ6co1sBh|M28Kq6EHEzBt=kw
zVvoIwqu$$r2>`4aq;7B62^APp*aI;%1`Nd|vw`p-U`}kG;Zt$2bD*z`ixXP#d9vzY
zm@I{ezrB`T{jr~h7A~NX1H||Ub}4AZrsm)T7uO8L2_E>1<__#7g9uxT<m@tEm257a
zO$S<>v|r5GyCBfe8|5i^p-ox|6%d<vCcY(#W~Q5YgbCJoGRz?K2K$DjMGn@~5QRR^
z>-|=88vA50vNcRf!i>Qi3?Wxk&ND<{eLTUt&#w;)V_4g;p0}guZs^5n(C87gGKLJt
zgQ1TT;cXnW7Vn?@etJgoS9gvY9R~dNA|p`p{LJFD!mt4YcUYnB7e=_c<?M6wLiY8O
z2^QZzC201h$lcBhZkLyb-{&fe9ctmvz0&}{HcVOw>xxY#5;mppCzA*5F~Sp3bcBdE
zxCsk*TqI#eU_UnY5$9KJA$`4MV3R$3?+7wqf8VazxLt3Zu&lfXo}ERrfJYMY9#Q?%
z-?QY}|MSSFb9~n;HQVpu9tYuTW_LU70oXCu<KsNP;QkgmAoD53=hLa3?g*MB5pK~3
zo+Nv1Lk5}|d2SVX@)F3qp2e5J2Qnk~9;Wvb|DAWfcK2RF(k1RV9;hQ?m6pudfqZsO
zj#t`c*&JWAWZIRFLBoIpsnU%H!pI<Q>ppRj3tX1Gf76Oh3OosV8t0p_uW0gM*L5*z
z*L5-J0ZL&A;rN!fagh=_djeBFn|1Hi-}ZB3?W=$GtALXR;-Jslk1y5BTo7-7+3n$)
zf>fTU9T&M@aykxrLRJuD5j9$|8XQA;0h4C6+OcLp3z`rxZC2hA{)A13uPGi%tC<W?
zKYwHYy$rq)5WM$Fus^%|_Xp4;wBr<r2$zBn7WiSku>K0{&+5i2zvA$0W#_^>yn4m?
z2{WnRLm7x5(|Vy#4o>VIp+*lP%cvY#dhYF@ik)0G9x^{T$1G>M@^<Xs=!QqU`z5}$
z6VokqdHC8*<$>@2Jn+;2m*0YAhHakUFNd!uD1cy49`IxX9)&*Qer^8V3n`m}FRnZ3
zqQ`Q_uB_n@0_0|aJ_X(|+Rc84&+WLI78s+HMhr*dX6X1>&P8_F;Yz!%0GAF$K`qT2
zc)?e}2TSNXIO#*KpcAWlV%#3X{^10;u^3DTZgHJ{{wnUPRlN4O5XWF`?NeX5dvA=W
z@#bSdzyqiVywo5fVKA}<_Xsl7{)3X(E#TfXTOcc&gTE!~C-5^yKvILBsdYh+QQD<k
zR>5cgq}!u{e?|IWNe`}9@ul%meK*ie2Y>sUf4EkU#MdN^7a$uH{M9jCP#6}F-1bHJ
ztm`%TS2&uBucO(8)?ZORsm|zUh)M~J-|fL80%S0*#fxY5H-)Q8d?M<yvQ2uvZ1~L^
z8U3V|&Fyd5zd#!Kd(<If<+VwpF%0Y)xQ}O;=m%<<{_wshK{uE{MyBAglsj&2I{se<
zTEnZ-7u9Ql4*ACK_{0a;_qh5xL+NJEgQvjDy^8zWT908b!?Mf63-vzp_pnS6E<byZ
z?6P^fspSjr?cS_zm_H+pvFMru;tP(Cu&9yK9BvFHJC7%3s>LF6>tWK~*(h(q!BVd2
z!8O+~>yp<I5knM#G^$iT2AmldziU%JhO0;fPO4@fwpn8EYI%!}lXjP!&>>4#ZkFG#
zXX3%Feg0SOQVtZ<KpA@G41H&~^EIVsU^l(MzQ^%hroE@yV>}9-S=ldcPj6FgU?k9M
z>O4TN+1Mk&1NtA<J{dd8kp{G9Z79}-|C6++!c2;g7P!(bl=ym6Cn(f<c)}7TxDeky
zJFA46Cgc6P#tQkCw=<?x%oU9LvFo??<)Q=a-oXh<;ld5;=>*=|Y4tv?wDfk&mih#b
zd1Vo6_mQ!S-H=3-d@DpxLaKm4hyraX_*~Bi3;p=8$r&jRQ-?sX?nwl3n^|N^kVeio
zrv#NY?Q%#s?+Ip*Sn{fkJii>S{$|Dw;luxz`!eY^4K~iRFO|>8*xg}YE|A{}+~Baf
z+`e4Np8=a8)yvC}(ruQG(Kl0C;(n>}zE6e0`_xz)3Uqw;@J-xf!o7ze+-W(SS3$KY
znBR2z=-}$;pfpbHCx7=X&_M&l1BP8C4<q~lTG%B|@i&z%lcAUCgL<C0qV_#Me>xUX
z{(7RTbC2rdDNY!^<@$tbX>$iC?Hur*qZ?|EWnEeNJ3n?G>y2QVA^Q4CauAKbF2qY_
z-5Gy<Nt`3X59KPPqhao`Frs>@m(W^@o|ng8Z=l}-pE{+KtH6v{?3kpa8Hs?G)oggt
zt=vTCivNB*{hNw`Gj{2WJ8O5dFxafQ-ZE+4w@4y>h&JLh@Ad}nTUkIarl0au9u9*a
z(b@-Z<D86Jyg(e6d!_ygytlX>!xjl_bRX9@Ak@$cCD^#^$K6l)`K)r`-Fv|f)H(>g
zLny0idLezpSxEKgdrSS`A0&g}=tX=P@r-#nvd=@IG21~Kt-vFPq_fQXFzw#5Mi{7E
zUy)|@By7YwSW++2v`vbCkL56$f{>U2k8Zr2m~tbTV!#3UFN;&iq{S&@GL2Ih^sKyW
zoB-j_x%_W{Td7jNpTg}&zxnG5w=idvUMzsuGGsdo;I%#<Cl0!^r{K@C;xs%){K0NB
z1yF^T$)uYDP~u76$4%%;@3)>#)*EuUYXcxF4_p36>$Ze%;X~VaXa{D9-N66YHE>Z|
zwlSMv(tJSiDNK=m6weQ`8KepMzE9XM+|8EOr?afr?{)gUaaWu`n=}CR2Zu3Cq@;b1
zPd<rTu#3{7xMiI~HCQ3C8%(J)X&Ypxgan20sSX_s7BCU}!v&XFK@kjAWhMsT%H*>)
z56j`^T0V*0pULSFz(HxVijWQ>6`_2^7%s?9Hg=Q?gO{7$Q-moop@&6-z%5)V1Tp)F
zZ5l@`#MAS$8TO^DQ~g1pW7j@7{EF;L*aG9ubRl;{{(GMDWP$z6y=DB@#m^7iCzv}w
zxIbIXW8H&*UpsCg2Wdr3ObwpH4Z4?}E4G*M6qe6Q^WcQhp@$Pjvwp&0KWG8I;`@%<
z4pH`Wk7Cb-3hPZ=O^=6sf@ESz>>!z477r0b&bG_c9?N}rOxreD0ng5_@HHr*e}hbM
zZoe4$#QoxQ7S1W7z7Q)#;<R!6oL}rN^&hQT6qHR1vU|SsOF-$B`)U0D4}amG%RYhC
zgS&5^f1h}K6eCbbccuOkl3uu<IVqReH`BR&(`p~*_<^X|h@j8cpNT4<9Rj_k@;K;z
zgsS8e<4#(;Ar-e*>K&Spb|9vZSMhdG^)%X}78Y+&i9|`C9yGY?Jkjt)5Zv27fDi*}
zsPGv*SJ+l7+OvySP!s!0+GDb5_o*^zVogn|!vxap_%J^4{;(T-4Ta{Ot+^p`nKzF2
z5t*SI&_f&HEA)A2M_)s!3UH)J<O0rsDour~d;-gefOp!se?518!%jyr80ylcJblxP
zTbU{rZ%;?!{b{u|2qe1YM=z5{8Z{JDG6$fq^g#)m=op?cR_yI44IN}lifviRhDq*%
zSs$lx8+$S3sdR8i@hl#6@gbGDN;7E(44_bIcg-PTH?gt|$zU(yeU?J+1S{ABN$NVm
zVN9Z2B0{uv5?%6f;hx;i7&F2tXo5HDs92cD8iCGbaX?4GbV-1K!9L(=A>RPBA-uJ>
z6Agr%YNZp}^3Fj2WLqKG3q4G_(wTxR<Y5&2Vp!E64o8D<Y_SXjxwb;Lr1U*fXWC&D
z%KCbLFr35qkfBIq42L-DtP{9VjRHtnH+Z)sHf1ynvw2__ydBk@$pP5zCD;u5UayPZ
zNFPA&X`eZR%5&)_J5du=yd9l0#E%^&SV-1Iz*Gep%kZl*v52F}zDfq5!))3g{eCy@
zVZeM5DXA;V0}mf$r5L_G-Ue<O##*qn*AH>ie5{x>8#NXmzJ*$kN3!&VS6?XFkq-a`
zS;u@_>$n9Bwnq9M=vz*wOi@2>IIGI*f16eV&Q6HR!p@LI&yS1X)yM7hc-q^K5qY0U
z)JJp}d1n|6fJz}&l=8USC<xb#hu$C7Pj|204y-dJX^utSg~s0J8;d#$PL<hqP|itI
z|0kIRn<`1$h;XN{@<Ec2p(B;vhb%)FMWA=W2XTRb4+tNI9KfbeZXph}cr|r9v||&1
zNVvKj@}Z;N@v$0wA>=P!<j8QUoLGa;ub&oRR4c%4^xsv-r@J!0%Qqi}xan(afBk<_
zdV*JN0-WSL=E5xCi<il9=I#4HLoARdOS5SAEWUWL+-5RQKLBav=?7e>9^w`dBXOA!
zsi~bvglS{|R={*JSU$^SrEVr4?u8UbJb!Siy8~IaB0B~9Xtqhs`ZJ5t2ft9W?G||A
z=F7bm@^cmRr1SkE=aX)1NrqmqL;5b<_JE@~z-HP}@*}(f+}qLFk#QK=vX2uyog3^)
z1dzcl)(`M3fEA?-OVZxXAX^w_7FGBz`vBk3uFM}ZLo^9HO~o--4E19r-7H18TE5rb
z*T>j_M^LHa5EM-*>s-U%$J2eq7|w63KE@nBeLvX8tgZbgU$T9T+2ba`Pq>=%?CT2G
zE2A$UpRhn~e93*in4dOcwS^mB44+P%FQpudVB+v+8;$##(Jt6&-K`S)Vm2ETn}P-~
zH`w*wPI%3Ck=L1f$th0?bp3<<>^@KXA-kN}w2@Hc&1gYr$ooTlfaWtVl7a};K!Cu9
zREF2{GmiVRpoQ%)KiGz-%8FvdU_BnjEsO9jrzyY0Du^V{^HYrVZNgWF$7j0cmEFJg
zYAv-V`2BzOt+hJf2(&&a&8P0erE=%_eOSNDK0J@y89f&WYjr^P>GEdxA@^C}*D*e+
z8-_cZ%RoD)f)4?%HZ#lt?&S+8^$M6ae8MDB&op#hzVi$3n};yUG<}r~1hp1Op_>{N
ze3(*bQYsscPt2YTMO793^691<#4*5?yaN|E3GfTs8xatrEir7_vh|-9QIDu$`H*JM
zrO&2zn`<BbfB(0fOZ@~Sfb50~oJ-pr8tnNEV5%k90GsWN$g=b~uH40WwIoi_#pPJA
zyD{2LNu#091NDcHNu}o!Ar~FpgHQ_hRT(kLTp+2Kflq_hlf7gXa@ZH?eQ7FDU{UWK
zaC&T$b!7?z(JHyH|0L%Jhp&Hl$#){!FhY!voHg>acLk@DG?(T3WCpUI^h*9sslXOf
z`E)_PfL3jr(~b*nJveU0gX>J+<+sU|oip_(!4Km7|9AvDAX&r&9Lm$rnWcQ3Z1)_!
z2iMm80CeA7l#hGr{=tUG$XgxKK|awNEJKz7YJ>w<Smls|-UN@3C5SuRbGraO@c<Y0
z7=uI!XTv3bU~^250>1;_jtJGD8&&-pF$wGrN(r${4&$f~`!=PT<fCe?;`ksxZPz`&
zP|t|-$>Q7cu-Va*WviqiZ(-NXlg9DEI!r(X1fh?F+2jiIID5|2)BE7o-v6Pm$vJZh
ziJonT^YcG*@u_j1EQwG32XvkgzE2&FITYU#GOmF9b(AUY#Y?QLczytJEg{+ETgqpL
zQr!@qRVE<KNt-u|4_LNOuZ~ZDJKUSO_R(MZNZ}NYY8R%5L>~{lZ5v5wAS)9ZNX=&E
z_S5C?_!2$1T$IyjokA9??N8|spr!D}Bm4q7`RDM|=z7vkB=a54`4DC(Mw;vaYjbh}
zutQC7s*+gl4me|F^;&c+_jb}(AlEle8E<rAoC0AVIemgoWxgR_^mf9Rr8Ll3lAGCc
z?55LJIB?`csP669ImGuucTi2*(f)W&z7e-i<+{ECpMii3aTy|vn`IPfW*C38!%|%7
z+xIgJN<Ub>*tnp+z#vh{`a}8)zS^-2ZxCCfqaJK@w0(9glcena47z{W)_JDNxzFY2
z@;JaJ?Pbg_i28pE)ebi!uu{S_f%^*gs_5Z{61&(9{22U>MClI8fif2fOq)g?Vt`=g
zx7A!=ySTH7c67en&W2YUaSJb>#oRggAl&D@)?fda_+<}~;6UW)QAjypdR|e!I_p`9
z@$z1xI${Q+Ycup9%jW38CH*pc%Do^*w=Vd0O8b=AM4{04k#_wwLf3Uwln!gegHTm=
z%VErre;gt^Jwk*D9C;9u<Lp|}znfA_dvqDA!}IC`&%sqa$d^B?{&nFu;MxfD+B5k0
z%3z^A<!))7-(cCw@C9{5rw0p?)yH!qYECo`@c(7^PNaSa#ACc~(hUE$HcR3ex$1ml
z@=|ypMAhrTF6sUM>bsth|1@~OT_UL&-%`4J4lXVf&nT>^;hP5dH7)DFiJZs)S5q=1
z%{j&y+Psd5i~H@{#MXCHyUl+dz0Gw8J(Dc8r=DA9JzsV$E=R^+ZkJ_q>qNYto>$B5
z{hu5pgN!+~+50c1Q^kU&(UikNn#TtkP0?1umXlCJ5=|K&>>H3l8NF#D=FcL9LoJt+
zp~e8Sz;{s{>J&8+K-vzaUI%u_Agv5Mui8G~S%p=LzxJz(?#Y42x8G;Wq~GsY-GX<v
za5xnteLiW5`E<FoPf?1;ShD*t#F_cR&;9bA!ZY+>2%jpyWqQ-4a6K<K*ezW`Zm<Nd
z=j6};XYH>J)9|6dt(3@+L{6rcGYOr4OCRZMVgG;er}+Cn7r`OH%q-)Pg!i#f?M#-G
zaA(rtP^tA*=#mr;`R?w+aGu_s{HV}Z%|zjF=0IH;9<Ss)HN1!Zp)1Nbcj5#Fi9~d~
zG_2h_fvdaS32;kqJ2=71>En=IF%jTF>OV;BIqrVjSA@Qb`-p_LZ2dPz2aEicJpO(5
zoMqXC&)EmP@nCeYn%`0@?#qGL>L)69z&_&vsp0S&ebFvkCCwb;PdInUoTm1?sE6UR
zz37-pJ8GG9rjlu89Vr^|>iv@etcvWMpHljQctd;}I3CI^w7J^3vEnj5o7I-wCtEG@
z`c}*p1s`@dT?LLpR*EF)GycF$h>(N0kl|7APGuXXwjxVhMq4ea{GZ8^iu#$XX!})d
zWir8COQs;G!d2Doqs0}p);v-hrlH<MkQmibZ{oUHQ31noiS2L+{KBR(^bAr9cX?Gr
zvtZ}?+&bC*^Y~N`EIt*ivI!)2poHR`1ZT-<m+iv^_n6*abT6&;|DyL#OmFYGpIg_3
z1((6k0$}w=!LRhApZSc?jS44?c62m`u{?u@K|Xz6e7!21%#KR#_ijMk%Y6qV3OTP;
zP;9yiJu=(kHP2mo{U1EKFNg$K<L*EH(IfH=y8dw&b`20kQml%o9Dg|Lf6Z6x;={Z6
zI@>w$!0xXO>pOdW_3ipzd~L4c&5N(E5eg3;1^)lT89biZ!`$e%`}iuB>%whZe4TwC
zKT><Cu#Zm>CERfI?fPDLU9RfIi?6TI`}JDb$7{R4qx>??-*_aa^z!|?RE{Sq+8O=l
z?y`FdFD{>csy!UU#j*Jjg09C<lx=My+D1Hr&;`$-uZLrrS`1L}4|Tus&sViD&v-kF
z?9v!FDU~3@SzkjBf^khvqc@y>E`obpO+FChH^v`46v#vA`#<&DS$Lcg=Pf-~=HT*5
z<aq{9SX9E3^@KbFU`bUO`|aMISdbXw@QknjRdxUJ_^JMi!$YC{@BFy%3nRn;vT!F$
z;b2ala3MGVe@Oi-tb6=}S2Z!$tewlR^V?ya*9!mLpVW1Rf$)s~56-N*x`4VH!3$$}
zH^XH+X(jQD!NkSx2Mephb*GvAspGRA^x;D9geo^Waq0Dbup8t+zqj?D{{+_?geCmz
zZKDa_aGv#6{rJNL@y1v-C%0d+dK0WVVivy>EqQ)Zix>G(?cn6Mc;7oa<?W)<13Np_
zVn$%R`h*2KKwhaoNbhHAj)V?C=!WHboVjz~>?P*!Vc*@ojDOP-z4BszTp=(UExKJ8
z+f2LO*0HEjnvIq!a?~pW|B`f2yNM)?%i#(ej@}hEOb1)P1m5Stns;bnv+2Ac#r!UR
zq*V|H!{c=~<L;5hlIh|wwFujI;ZS{E;jv+<;TU(~YX4<jU?xa+6S1YmEj~g;uSVys
z4hhdt&8O+VY5!{b18N}b57D*I{*`g9sOX{on?DTLG%-*XiHQbki!Nxpq`PXH8lBbV
z+4hm^WA3ZnJn<_R>rM~$Hgfe#>hF~DVN2~=cdMejpXKXNHiuVrIJbJ3KVTTX^!ZzV
zHP}sjuw4^9Oovy`0Yrq}UM9C&if7H2RNxs94O{44^DmW)<0~3J?QyYOtCa+nGR0mB
z0ME~x!_!&uPZs0lr^*R%1@Oq?I!$pum9cX+3yx|ntJqep{J9P1`kC+d4arN~ZmyBr
zN#p#YoWO(9BB-*($*gXag)RWzgI8OS6O>H1eD-_=`anqX`m4c@b8YR1{w3}8ReyBR
zcmd+RJ%iusMa1aL_iI&nTpTX|@mdPvR~aHbTl;2r)^UHc3B~B5mBd+V19NXp%LW2K
z^8&w2B3=zZSq>F6zJ5w?I5+~_%C|Vx3+**ZFjP}}3!c*!5CG>iTu20KZR7r0U3c}P
z*tQEcwk=@54joklE3ASS0vyZI*Ix^Gc<s@DApV!ULF<_KcZGAgUJ^247H&~C2e<OE
z`F{v^Q5yljI6nSpt`=|~J92Q+L<BIUWC4mSQpkfrn+i^`qY*BUG~ojLJ^#rYQ6g~0
zkvd+iZtN7{0d<aZBfyE^yWNKY-+fq7eh6`;;L~T0B<DV_=keX{W$@hv&R;-GFT_FN
zP#o@bU;)1|tFroL0yjiWf<19Iq=O1agk8?JM!W9D9y1cRF^HF*ZO?PeKU=$YzeVRY
zk)B~X7=mpZ8(&g$u^lr5^Ydhfyghb2F6WSdCTGvkEF9M}arEv!{5782J*;H*9!h*_
zUe32P&d<Evc>OZ|<`+A+c~64=I21>gIxs)BHJ5SQ(*i@LJ&W$?^NcVbECM(y<eojx
z*Sf~S`|bd@<}FI5+9L44h17htNM@>kDW*ovC3mU@-J5#e?`)|h`p&jEi>^f1=ivE4
z@b6pu!rxGM&bW;()lV$rqr!P^fIvRV%ix#Jv;ahYwF!MGy>K=DJ}oyxhU>YuFMjD-
z+82NHR!?#mvB4?m3HX}#10Aalw8mTY<Wd6SeZ+PTWy#Q!-FV-VY!PTCW5<j}8FIw=
zG|z_3X0x7YfOM~)DY`pB-&nOcyAiD{>{QFACy+TK!6n|>nYy=l=LE*qDh}&MxW`*a
zZFHPXSULP^qdldLR-q5`EBj367t-5Ba|J0C%@L#ob7>KK@hH;W>+6N9?O?C$ZcC7-
zspmK(XWL4g<FX!jnM(yG&3>6lImv`5z!c)d+M%n{^4YX~?Q*lns*mFN<REirIBvV?
z%X#Uo&3QU~7iDw((S3GyoS<{kTg!)iGoLJiONwL91S*Fo0v8eS+0&OhFJ4RI2!G+<
z)ANFNtu)V|<CoDtC6%jX{Z#5GyD(f`kp2-l8s~yT33yZnrdSj)Gl&l7`gQjFUCSDa
z;I9Pvm|%%g(QIo<MYF6a6-_@tzY&=bAWFZQ3}g<yJXWO>bMW~1KE;^@lz#MQJ`_1{
zZwPxRyDoew{c<(-6=7{B2oR3os;lg$@Xk$0Twc!qB*>TUe$%gij(T=8ev@Tiy1vWk
zQ@``X@u0~0FM)3spJR*t&(U+C?ppYx^nuW$tr7H-AQknYW~?gA{P^e?&vbj}{mL``
zaT!}cU?}FCgcKvenT%7D_6}%Br&ILfKDk-qQd)6R5?a|ztDXZ5>+N71xBx<;u%P3J
z>e?HrOFSImVTUAr11^PIDLV$mFRt^FB(4HD!7VI~ANW*?v?8PIA0-GLbrUvCW{ivR
zY-z*wtRO)*T-RE{J?ZMS2T7f;ha9h^q6OhAm1x(9sU@Mhso0vlr$v2*Umue43X^=v
z+rc}aWbGAF8rC9`h;t-uGD&p^s*;d30ZbL1eF*vI?eHltYPZ-&pmTTZI%g)!%HA?*
z9)#6u31Vt#l>D&7wdMSnGvE#$ZnI4WQ35qy@O_fbp`90`i?QkJPu_ZwH>+mw$gnYp
z8C83~FoH%+(aP$0<)U_ZqvL{p*zj1|;oDR?1D85KbiIR}R^h$6(g%XU;yXEyy^EbE
z3;gzW7x{OlLt;w(_KwYOuQ9sy+nb%Ax!mR80L|5(g!_~WpPYq*3|9>LP0+-={B{{V
zak2HE8{ch#&H&e0jta=(RyZ3{Jv_a`FT~G2N&QC(|ME9Po<D*X`YeC%W&EtiB+t;7
z^~>BxxtO0_d|zy9q*NS5jC$JfzF5<Jj#TidRWQDxo|M#|;zCuCcXA2DFb*Xnl?e((
z$>{(AC=}=|pvnv^q{~W1{ge>DKnbyug)czp1SMEP+yu~HW?M)4%P1UBSXM{^$~0F@
zn$n6%>a9TU2r+}Mz(A#JZ*T5Ek&lo=a*!=wr@%i;mHLwhQlF*o|7Dfuj1YNy86I2;
z_d){B>hX&U;`%9Eo-H3-4EIm9KfxVCN#JKVM*_SUi!(2{PF2mMc*zPa@L354r)rEp
zlfiz_8DuHig%!#z{9{HeZrAUAW@0zrxP5^C1wNtul-=)5mcV0%AZfcn?570FPo`B>
zU{$MIP=E>N!KB4nWzwRLAh|&cRAYnBFSq<`kQ1$a;b*6c=K&i9T*-$U7u(C=eeT@9
z5WOFEBkfg2uu_J9pO&Eu1TiqlumWh`IQ}+FOfE4)2dn}c;k-2%$+fp28}OjK`r!4?
zJ0AStx%<i|9K~~SU#5BgojiQJ!6>@BJEa95d|Hv&&-G{rBK7#`Acg65dF_+jH1M=W
zZqPG>kLeWqi7`zrq%tlZfDD0_=Bv*|9u9)MaqWNk?Qaoz<8gw(j>;Y`<qwvgiwpD{
zmx;r*_*`5<5B5|P*uoz@cU9hatYo4*Y-t@-QOt_@r1CwZw<dbxNg8f-VG<J(WQmds
zYHY~`$PIdQd&!StWc~872F$iQCw9ddj6V_H*CWpHC9?~)<6<i9*oAK$>6P7K)`<sJ
zc|hM0>BhO>V0DOj25K(yccQG&&7n#qJ9tYaQ$CkUqI%YOhWvWHR5DX4$_lqt%0{Eo
z)DHv)ve2UCY6U86F=PS-t5vO?sfYs2YK7#h8LlvCwkx1uE7lMw*b-FXgv8}@Z2Q&Y
zJG`FC^JL9Us^;RnW#{_be!bASu5z5#Q0|5SXqIl{FD+j<KDm?}hYh^_dTOr}sow`|
zR^a1h2zuFi&*}TrzwSQn)B}E-;aga?s-A)8Hm+$H271o$Si&2<PkSr3!=YX0pYhA7
zJu&7@;*z@(xUvnzvVdP)J}I;3cKt!HFJ61}b6+KWkMMmt|7!rpS@heb{jMQTc?T9%
zjz>kFg5%RVV~44CEj=f_f*z0vQJL`K_4Cj%%V+8uJh?R9s6Pt+xNHCF@Gp?A!&P>?
zVN4BImf?*&eGj-53V(s!%I;<CRu=1#pX&c5P~~tYLvfPKM>YdqQo~JKtcF4xE_CO8
zX96a;zE3EwAp#S?^9CHL628{}hAuONtGiF*QMd={LyPZ=wdlDU#8UoZ>G>rVH@Wlc
z5_Wk@;{49}eKlJB0U^UCmFFOC!A$uEw<id(@nw`50PO{_Tnob|Uc_xK@WWvW1<udA
z^TTBp?;5<jP~Hr(d`HP{gva%ZTsJ|03(tu%=;#9-j%nT8L@-_<(?MvLRr`<dxF%6X
z%II{YNT$oqKYQ+S=kTLoANc-%_}voEyx(hr9lM}k?t=S>b{E}8#BpA|{kR%=xB5Mo
zw`&}0DaNn}t9|910sq9udjB>iO@<u6U1vbCZQSQ<+~U<4$a-oVf|A*Ilt3a1_?F6K
z6EXQExHt*|%;;611d(UpRdG48Yz1<g^pL<COwy2AlOFVgJgC<7b8sD7q+-q%#ck{)
zGf<rA^-Lz+2gF_VN2wgC_iMBJpg-t|%vtcK0PY_OUAh-_qu}Sm2>`$nFg?j`SsJh%
z4?J>*?O*S;R$;gKV@;`uhE!#UJ2Y@L0Bhma)L0cRY@!1}yHLZ!q|*<V%sHMvV(11C
zyfagJb21mFZ{4oR;t|z}gcRQ{G;ldDox3T!W`@4lMcEnaG?_NyhJ-k~IZJr1kzRbg
zvFG@u`lE0k)BFGKUzGSl*r2%4SjqLJbmW}eOZk~PVq9X!&a5-b=GK{eewB0fJaX#3
zC}JDpk!AQ`vJU4h5+FENqXC>|`Ca}rr~vO!&qNK<kq6#J=D{S*xU1P+oluK>xvrC9
zA_VN>CD8cLxmNG`RbCV?vsAVNuvE4f7^QMmO)*R5O|x*olE`d;6g4|e9GtAaGT)e<
zn{23l{|$j)lz#Zxe<pDK?ifz{&LAzrUkmu7H(siiYBd-k5U{<UWZv)Z7_h@3k!f~y
z#U(X8-MfCj<&<4>GEX~dfTw}rg`JUdglOgcBQ`Coes9HYJ+sw_2W4rn&qW?+7RJ!&
zfmd0;$1Wdf4vyXoe8}Cu{er*|$eReaz&u^vQ-THXe%$?(uM_%3kh!-&-ovsB<HrXS
z8mHIk*u8aU$$JLMUtrJ4P?Qt{|13Gjf0k7^1eO#_7az~^`MXh1?7qykyA!*w$?aEG
zpM@N}JqY%tYd`SZcT&CxyHeP6oS~OkCSP2jm)KpTm%!#(={#O6UtHp+GStXD7=i1v
zCJsN!=R!VXKLi2rFh4kHJ0W9(ceSu(XM?e@(A&X8Is95(h2Q=#9yh}YE*S(C(9iTw
z_&{R^T02v`JQJXZTZ9HTC|6Z7Y<)VB*?x`N&^O28TeJGQU#pr6<w|9<#G;pmgjp%U
z#8BNvps5vK4CS{m6=0jy)DZ-Ld2f*MhQ|kIo|axzE3cx*$nB@cpL053?W2Dr`kdi7
zNb7N4+k)ryIe%dBbVa^1)N>!>Zlf=Tex+Y2@Z!PkIiKGoSHSNCJME9Y^ez7>@#`qU
z{cdNS=hgiEco)<2Pa8O836M50qXS3On+O3s=%FWqY~ofM9b*!~9^eTFC2;y)eqL@`
z-mLp4!H(3=U7Rahl}$Jfi@=Ua3u%TVm<^FaFe%#}vu1G;Pz2eW2nCS@$*2_}&lBn~
ztk+ZK+3=3XO?VXUe{=Y{6CEWUHeo4WeKm0Qly2VaN5&_Jy$u#R11A~a5J)gWW%cRG
zojbK)M{xIl{B_|Q5Xum@M_y2WQJmM$?V{|$e8YL@xJW|WfJ7QaGxu;Z5A@V%jids`
zCx}b_Jw_R)Q0Y9yZ`^Yb!Gyq2eR~7Q4Ogx3T}jFNOey8I-`08K^Fz0Xm?D^?-r<R;
zXS`OCPZ7RZBa<S{$wrT*LlPd&IOf&Y^IFziNT<>F*WxRSAF$n;Dd~!7N(5ixANb%3
zW-V1L<W#9*VWvtIv%!I#pL^YwVISz19B;_B@^-L9H0n2Z7ADP*kV(VSyx+5|bRr2r
zGb3bjC-^0AbA?gl8c8NisZ-tF0`eC!6S5>ranswKp-7hf-q2~l{bqM4j=;qi3(`K!
zfiX%E_8@v8KBYclnR6V#lJ0*V<n^}||D*J$dq4eOD4n7Ef2DI^89!HDfCo@EhX-b%
z7jpDgbd>2Y>5k|Kj`AjUo64p;#R;X`{EYTyTffG+?0J#h4|y;O-~;%U=?GwCpyPb+
z*>jbFBQ#a72Y-S!^E>u)<Vy51tHKla?JDy6^PDTE=C?dLz4co@11@NXEmfS(J)?f+
zaeyZ&tKSdyYadp>D*EIRLbNUQ(_4mzG<Nxno@W<jtKtpkd-Oa<&(H;z@koF4>?bn9
z^)q~SZh9;;1=lZ`vvZiYhc*9C`m}7|3|w_xFjE0u1mNnA!hJ;V_ch+GtWUu%|5~O;
znS+}P@ylW1vhX5>fQiiYV+bt><F{Ko*Dzm~my<jR>%R7P{<O%=Msc`>%H(EP{Jh+3
zsorCrZn?K8KKH8U%mwrwaMn%Z$_v9F=p~IWuLH~&yGnse<Rs&0$^3(HU&7Gj!7yKm
zM+Ya68Z*wk6+)<tZw_gYLgEX*utGO8@$q#3(&w1sr6>1fK7p;??|+x_*U8=(hM!Wr
zRK7BYm)s6}fqhD8fqlxV@Od6ONTb2F_Qv34jC^Fg1t}gSdnq5?jKY0LWP1dB-MR`D
zIr?yjYBm6`W*vN6b}#5;%5vqNq3#$YEjYliX_!Tzb*5lV+tF}ah)Xwujg~_4%>>^t
z>fHG|d+!H0SQ9IfnKibRNwYr$H@d02K;kjWgoc)vCT7p&Cl7=D_uVJosdQY@YmLR2
zns`P4bsj%2fPZr}R$B(=2VZ88WwUAEj#}ES*#~}3C%R97AJHX+y7(9#nz1PPx)IXq
z5-|Jvjm>5GOoTn~IBNhJn3k$XB$6)JfQ-Z8hjyz3ptEOg7Jlk)2fNa{Klob)Kc^SB
zuQv0TZ2Z;T%f#(C5B_YOs=X=2kOp_WUrt0C4ShC3%s(JA4AAhG$|Z5HrTv1*>PWAl
zBW{J)7c8vZD#x<ffZ0|=`1XBMSchHqFvjg6`k}Me<yzNRC~w5QZ$b^05UNA44x<H%
zppCHt)iT@H1+v5qEyA@)z@_pOH^;$XTTW~$i7OU2aKrUBK(JIjpLbtyPu1TJexV<H
zlg4lGg)c<yC|th0GJd@r-*c^j;{t=bG+%QswRe5x2fp(Ik;@_qKWsYn!mMTMdaIYa
zz-q1jO7{HQsFV>ER1gD_P{0amVA50xOgg?bGytJIR0Rv}DVy&?dJf8dfADIF^bJZM
z&A|iiIp`slERCU8h708<9xjLv%(6K-jGk9#$Fb6T|5B4AA3qM7VIk@^3s8Q=ouShK
zlhgQ!avIOiPs7bDq1}LtT%q9iK643qs<c#pJJ^%F@Jm1OlZsE;z0;^0-+`cBt#@%_
z_Icr_I?s<jMA;R?&t#g1pGKT;J2>0`js|<t@hu$XwhQGL@^knBJt_L3jbLJeyF5hq
zNHwFWIg!Lm(v%12qiT`C?S%<U=RNniY&OMTEUmv8_`vtS<tr)&86?p$ZaUO;6a=#p
zA1MCl3+@fyU371_Gz*}<*nOl6?M2aPk!pyvK_(XpCt4Q_q*!gC8k%bjgyct%bDKEK
zKknP{drT*j=x`XWGQ~~JoDgXRWWDABS+ChtGJ-rVuaWQLACaff;iIKe5+?hI`<Knl
zrtOVB0>Ytl*_FG2>4o>K(cYkHW(0`+BbcrPA4_ElVDpKy-{&8`nV|2LIRGzE^+-Ww
zQEPyuW6+>2Z3D5!(VWH*M^d6_rtMTVU>G2ufbS+)X{9QVEGtvN(uy`jH%_-aMc8rj
z7t#(E5MM+narlOcwJI15Gi^oO@G85pd>`As6+gQP{8LnZSq}gi-^tuo6%FG;(mhD_
zl2K3n<Jkf1x4gW4fjmd{@#cIynq8D#`21MRk1zEzxPhSl)FEG8+=sV<{`Rin`!O6f
z+^lRVow3YcFW8kCfWt?n?qv`GdRi{2F3Z;Pq(XXr)B>g}oD1ji>oa8EfGAP-AvOZ`
zVT1AL@W&jCkJW+<bx?>Y;UAQx=L6i9`!4sMBybdF4ICPcq+#eB8GNI6I6RTIkj=<{
zdbl`Vz8AN~9kJKtSVPf3ucyF4F$Tln6|Emq%EmI~Dp`_g$3GP2+d^g(P+DRZ!J&o=
z_4TQqT;2{(Cu>K)H6nCqf1s6W^@ebpmM2=vk_8{Bx3k{Jv?88C(uVd?lDLzDRoDRB
zB9iV%QzKOzcsqr4eAMfapR!39LN1~&5Bo6=b?VGy<;HF4vGfs!&qgjy5n5W*5h%j_
zAM<!D4~Nfaexj$uN1vJG=*w9;vkDtFHN(R(r~)(G4yO(jxLgB|()njlOZC3M`6<tE
zXcjj%Y1oXlqX4a{Nt}@8dO^9fMnv#-Xsw6iQMmFdVnti94<up3x6OuVdFK_7v{Iaq
z;`1TxU{MO|TN^0ThPI2FxMD=QjU)mGu5f;`A+%F}E7;eq-TQWtUmL&{q7W2;^t9BU
zKR4&_;f3UMVpn%eLfhbt`VXLuLBJ0Nw)hj&Y}gLrZXNBj_L!3hwTN7HD#<=<SY_Vu
zk1O^@2T4F9qwLP^&2DY`E}Emsc@`cHBkHL6G3fOWfKxWJ>`d8nU0}v$Pqt#WmrbVo
znqx&&28=>c3HBtmBpN(L%!Zp8-}>TmN%t3c@M@WGR1e3%9oQ4VrbXiawPV6@YJbNd
z7hG598KSmaQ3kjp-B({=&&RT*bYH#K+2ishJ;;%IEr^n4Th2cZ_&8V3;Q#i|><nBS
zE@ZtKr}8y|MFHo+-KoYw8uL0=h?L}aCR|(yuZ2OFK6h+-GU#*hX}2-Zjs(tGx~0#0
z!%k1FUP4PZJ8@|^sNWBM=xZN+@n0Y=W&Z&85V+gg(sORk9&1H-;JK6Hn+#`~!w`$@
zuolX9;QD6%B7^24e_**lf#2m%4j`OUGDbZaHSKa69ennQ1L7gQrL`5%)q0ZZTrm?j
z<jMw%I~@-Xow9_JT^zzh?|UiRA?U*R#mM?29?^P$GKmM|F>WY$w<ax}X{S&9FXf@Q
zMOK}Bq0Uj-6v`YWTm4oy`v1z*ZSO!{D*Pq=JLmwin7^E#XOpW~L-i*?9=i5H_iNZE
zU`S5L;01XonwU(U(5%=V@BqDnc&!b7N@fFJIN=u+_(r(85JE@G9uRz@0YFqnI6s~n
zS#o*&_}SE6b?v1u-K`(AL7;XZh3zJdUYqz)*8Pzc2+_oKe_?&MxLJEkWgfdB{#&v3
zKtm_IRAlfMfnyL@_iCot%e?f)ZYk7$!>jAAm{3kZ`>OCB?5aXqBq`S3<6;?~k<IbO
z<6;GAVX7Xp9YTckLLO&odPQs%tu>j{!jN@@`Mg4x#v2##JW$zyZNmwsO^Q8WE9NI^
zw~{oD|L8>ICQ)av*U~7PoMp~2--|j!1ng4w0rD1X2^Ee<?~Wq`=jVMT`m^HkklRps
zkVrEYnF(?ke;EvwucP!0)N0$?Q7KO2Anw3($yuzB)58K|>ge|xOrBU@nUVXN*%qi8
z73Hun>R@Qeq4q?op(HUc!;q)YsKDc8wjJ-P?tX2~%j}5K!eOL0mTH4T{hE(U3Ndh8
z(Q3=o8~7y4vu*<JAl!E#MZFZ>O-?58r_UNue;8T{JSKa>OxjuGR8yjlyg!+_=(Qq?
z#wu0JI#j<RYb*^sFY{86KE|VP9-pLr=$zPbtFLlE*-!VgL+>4p+cEp^{aHt+6+*P@
zNx!WCW=;4i%I7>2CNPZ`VrvbMFu0f14{I%NW?n;e`0(1D6@2LZ0r4P+#=nQPu#(U&
z&LN#yya#|B3g`lSm>qgMkfRwOa&ZGhpR^r>_<?3TWLA?5ju_ye>Fwaev0|B@W_(OH
z8owSxve^${F5!a9Vat|@!+vMjGcGf~6?edMdY5SKZZV$Wc8dULneI|&jP)4K$Q|MV
zwyk!Ww{z%rm9OnXND*f5`E_Imy|Do6excnv!WSDMzKdWP=-)y=cn4SJ(+BVy&MXC{
zQ-<xm4)T;?iY}62wllDN&QA3^<D)EG9Y&q#D8_8~JX83YeLdu4+7B_58DzqOMBS#_
zQGArfztOc;{Lqfa_>Qj?a~Po_I?LD|g~`&9?N{&5dYi3gCRg*Lq0fNiQ^;c0mI|WU
znD++BPuMrCIiGU{1lYJR4!G-<(I*`&cH%JEiB9&sok7yvm#Kh+33pWKheJW*K=BGX
zjOP3^$SKf)X7Y9je^Sl~R3Jr`+F10BQ1tvd8V7MD6*+g(GF}4lhdJ_gWE?2-53oAq
zT$%-8*7pMIs%IT0yd9SJ8e=b(Ed1dC;35fwHCYxadwo9?dwtM<Gw=g&8y%#Z%(4Ju
zX%i2#&*13faDfZ78wcV1QuTIkB*4ozaUb0XD>v{MM-jz!GJ0{7x8W6}Y6d_160!W<
z@eF9==Ir$A00bGk%s0eTp7Hs?ZFey-xUTOo!SU%UwN7P$!zjO#%?m=nS?KMIF*kyI
zhPXU3JEg;uE*@o8X{JCRj3wTVR5co$<zXbx<Ic1rfP>DBq$#;Tw?@#G6nwh99VwMU
z`NW7Z*VEl3NH;Um(Md}`B$dZqjXwz*Y(ITR@te#ey{|{&##VTm{J#oI6BFrg25<Hf
zk{0y@;`!houi=*b;>VH)=`MMUZrq9uU4oFe)CAc5SLK~DZkpV{Ea<qW)AjOBMc6V-
z43qBQuu(O=!&VWUvf##`tCh}N^l!?qk+7{lxi4}olz!vOf9^+Wbsje2^O@z^M2?Tz
z3;4Dd)<HJc?v;f$-Yxn%ZGwU>a}_~+BPs0X8=0DKkbt);7T{3`ZW8OPFYVxqY~l?N
z?V$}N+NEhvl2i4OIvt+pFY|e?Z+|Igi-67oorIer`Dq}O;{dAb(OAz}h0kb=BOa_|
z=R|-<v!ctyCh~be6H?7^re>5MmiGD3VO*<rP7V=+$R37sw-pH;8jX)L^+BI@l96o}
zW*j#O$uL70dVjJ@%Wp`{OrcZAgOeeeJ9MrYbO7m8xnDw>k`5B7>bpK{C8t=XLuis4
z3Eh$$5DAV9?+^RXjQ4?CWD@Dc=ct<Lep?9<@$Mt1LP>()C@b-HT!q}kr#&8tq>mDz
zWSYr1)iXE8X`kXY&ia(Uveps%DfBu4v6trBF+*xQrS?1yXyyw(^WGmVW~smtxErE4
zN%OeF{DhI<Jm>}*uOAPjpWcoR7Nz)Ncmt8jqL6_KD|8j-O_-xq<u|#V@W(5=FrKYn
zJ_g;VDPKJ*e92?NiyVPN0eW>+DU_lXgk*bbvq%dfOwrlHP4Ok`)*ps@=+{2{(O<e-
z$Esk;+W<?!qplCQhs*a~#1l~U!#h}EEFbF(uRzYV2U;)i2hyr+<f!dOH6ew4GFbL3
z@&bRE{5ZsalqP&Eh6G^yG=%lFZgt=+8>dud7Q<q?+uLgg`p#qty+JE{zaN9ShmMkU
zar8s98#+y6gG}})5<ZOcJW4AaC4J5wUw`l92-G`eBdl|SewUZeJq-S4YipnS%3Z>3
zk9WC<_FT?)kOPokL9f^vW0Bg!JJdx2wNM5!6ggd~b{{^uScjM7oag+PYHz`f97Q<L
z!()-cv3!1=h}Ux8DInHV0fckXh}wlQ4Da|;yH@r<dn2z+C)44=+K?kA{j43p4FZjo
zhI$3?6ZD{KYd`tl0DiiNR*WM}Rx70s-(ZmMHmsjbzzetmMfd8xqFBjf<CRF+BE2{U
zG?|2Ua{4ZX3ys9hujuGip6a1z(X&PREp)aQ_+lleqzFjbaGa0H(4>t}1xWtPaHE{h
z_&AWN&I9)VlF2><4ou@%?)G3Br^oP3!&iBrTzHQAtt}<D1}?cRaLFx!v-&B!)rfXZ
zj9R}ceUm@GgMZ=L+J8wnhU-}i7o8X^1M~#`9<;}xcvCntIChTZWm$jx1K9R5vLk*E
zr6>tX!q%BOA=qwO6{}%#f8ldfouIx5K7oe!mhOjqKlMG^4}?P?M*gwyOpq0JzM<DL
z$h{106#977${%t@8M;*6i#R`QWG_a{W$YOt!1o~AkeQROL?$-%cHnDnn~Gr#oE0H)
zeyo9>8wqG^B`uJ0aTiOmiMliLb6laQAsQ0v2dDuon7!POG=MK8(8?=th;d`AgZKWR
z2m)>`Lx-FaVp2H|zGXWdiM>b#<pq{<#NLjOAySvPBh58Um%#cyT~dviFlVV8%&PH;
zVVg`z+7Ex*DKb_P3tR6G*LTp{S0+c&hY-~GI6V%EJOEY><$+`HcBDqvMBi*O#cJ}X
zpBby}3bgh7I?vrf@4Z=mPRi2tp#g0AWuygsv{D#7y+GKzv_Ev8v-t&afO*o+d%L~C
zkdr5cV;lsQ%=2N56ZFqllWBXunG9PIz?|>5;&yUup*vbhC#)YPKc%w?DN<S26D?VG
z+>KOL4k`M$A&Z%G$y2iPh~&{1koIx036ii-Z!vioBh0YR56%*Lw!F&+`W1m}Cgodg
z^xxYN5b1z%=IeYxq_N<mneM_yQ4_r**slrLlk4Qd@i|PXy&XIHdXSyUu9C;#cfDB<
ze;B!Z4W*nvZKBV0#|XV02s|Ns?X^$jV|WH}g!BtZY;=E%#@z|N@%%c<(Vc?y2Wf9d
z_6j>8K<2$rh|@^jOv5R|>flwT5H<y<11WE39s519YSIH^Krnz4au9e20#aZpOM%8U
zEga>hGwUuN7;?P(V;LPa6h6blK33D<5V}+y^KdL{&ZfOT!!dYxmvSOA2r~?Gb;OO4
zh7k$|ic*<2n6@xJenHAl!Kc}Qps&r-)qY-F@!uf-ce|1={uF<|5&SlBE<zew1v{;h
z&W$1>$*Z|Dl4eo@w;-Q~>h_DmE}*DtR>-C84J(6Jl37Y`T65c5X2JqKUalPXc4$Lg
z0sp_vNoG6(^Gz;SOCT#m7|Epdg-N?Oj!9e`=k3Vr5WHGs1ISnr9YJ2NY@lBvx7;Xi
zy0;U3j~LGlABDgbK1#kW^K_ok9e%IZL-iY}6OIVh1e#eBQ=z1n(jVuv8_U~`l9K|u
z3l^*S=T3*@>s>KCU6<xA&QH0$vBeLXg@+#0MZ9lZ?2R#3lS!VwTUCBU_~!fhb<VGE
z{`oB&oC`#+01niDeHIRID&NAvxfbG&xbnr}K=vu*%CCfb0M~x;hyL~5Ixe3`Mh7O_
zPvvv3QcKkasWQ9+auK$)G>Cz)MfuYQwW1uLSviZ8Et0dy5tz33$-+#7jA;RahQts>
z8Vqy6Us_+XCf87Y^MJ=9<ih-8!<rzg{AOFd-r!^=j63=p?d|n~ept<{qzIIl@<fnx
zWBf{@?SVf~%5#rq2bckVh4%+S!VaQe27`Zup2J5Qv9eVZS}T9Zl<`_n?qp26&_liY
zlzsJf;Q8yXQT1X5T3i(8^q4jYIA6qK+3;oEydBlecwaJ0Y8;)siBWRU$`_%eHw53Q
zt$909fCVWZB+dt&K&_xXWvVMla86h`p(Du{&C=<-rW>+(sR%J|n<8GFSy*o<D}w}8
z0kUw1V7`?#Ln@tTd0k5Sv8QFC*gceEo<d62<gkYiOR5uL34L6`M9>uq-=j?~-j=j{
z8@4{$Oeco4L0Ahg4m4!R*#$sP{BF_=137{YQKfM2ourz(Q<fU|T^D&=>aS>&y3^_Y
zSLpL%(Ziv`N&&YpE0MjqiF=rpYTw@W^)N$mkjO#=(>%eIY;d~Q7jZ+RyhaM#To*xs
zqg{9>dOLJ%q?<m9G-(e1EH#IJ*gL>sQRKoTySKH`jmi#)e#94&pUA~fgqEZ~Od3rO
z`r87JZ5ONHC4>_|v@$Re5TVVV2RS+5D>aWhv{vQ4tL+FTjuG^91!4^G=OF!*>LIe!
z^Oe}EM_}-RTxsMeLV5vd8s`o0>e&n$lcHf1!*n36q_Z`h!ij@62I&LiNaF#5mtudJ
zIQqK4|NJtqR&oXBb*fMM=<#pkyaxVuz79v@W%;<(hH>L-aUBKpf#)g++_`D^q*4a+
zu53K~rcLcn7i#Bk?A}`-5ed(}!hXo(kB344vGkkoeJk(>&R#uhq@2AX{z&PiIeJaq
z7NnD^Pvt8xbkZxFp*4H(z?~h$!9i-OgM;7lY;~}y^N=8uf`8KQuSVa!k|in$$MRG9
zPA%c(T<7`CCzCd%c|cTpbT@>^YewszAbkgsL!hT%VJsD4UWU5C-cRgaW(r`qY2*kS
z#gr;#<m0iA*;E^z3sdhz71*ah46qq9?nlzvnc}9RJv9tMR7occ4?zs^bL=V7__`#A
z=sa?QJ9R#8+`r+TH(v**FMi>l@b~*O@<0$468i_SgODr-k^->?HaNAU0K6R$rIm1B
zkx1GoToW)aA<~eF_8^<v(bpi56A@rxeWSbu(na0~?LaGN*IiOUXi<Tfv@0)>M92mC
z+-8Z=K%r%@|4G3-O`dA|-s1+n^6<sS*cWvLPLj?D6x4)q*&eLHhmAo@#n*me6ypM7
z?jLmUsd!*Tx!x?q>3&2P!nbuErqj%h2+uNQvMVwV7SKtvU%FwrE1(M=aM=q2HNOJ=
zavSbCymT$~e-wDAnQhH1RVn^(FBdn0i&`4bS<B|ui|bDK+8vDd%{FEbM<Z~}BZd=b
zL;D)BKl$f|zNh(munKCizOB3Xp95!`mnr<TbS#SWeQ3tGde*RT54ZBBwZV{42kUUk
z2CPWHllJSVtqeL8#^74hq6O#M4TDRIcmK1W!9CY9g^qv8-vP;5I2v+fo5piNCsIt+
zBRcPs$(Eu`a#@>-0+}>NVJ6L0nCQ~31ZL81olE29mw?PSSHYVCpOkMs2>jOC|D*c?
zK2Pur)t}?ZrTmuI5xw=+{C(O|wrF1fM3(b!`R@odgEu^$M;878{;r>#vdf|n<VKMJ
zD6~^X<^~8Xh7VMLYsg>b`gg<N*N1xr_%*~|Tl?x?gMT^9%jx&+7Pt;aOYLt3j_UX4
z<K;`)+&am=L8F=Wau#WyWawW|jbh$g$kbyDLE5v**yHXHv3`!?nacBcHrV6hE*l$^
zp<0X*bSgiR797l%_)EUug<ke43L-`?Kx;-EWJ*H(Gfu6JANIJ`utIw}VtJj?NQy#l
zE}o`+oBSLvJHVg)*XT<Fl=>?n9`-l?D*bV=2-yG%07W#p&<{sEXG+Q?rgQ@t%7t;S
z*|Yg}o{0a1I;c?MpX<NS1MHH+1&zrwU}arZD4}@@(4>f5bM4&J?A5`^lT=@{_Iq-k
z!l$Gox?`TGSX!YANoOvx=N4})y+<(h+bY%SDs*5Vg$L@wrG8s>;~>qvt%}GZyw1xA
zpm1-e=;x>~%k%JK>yEf>?Vj>SS|a{e@O2IHP`edukIpx7S3Rs62<knAt&AW*ODp=4
zjN>v0aa&`7PyDkll|jLV*>UtqFC<ILGrI9)^V$P%hi>BDM4)fIKsy2J9VnwjJkk_j
z+><tt_5u2aW<xu12k{nFs{t=^=z7E!sTFs4Pno8By-^z`eWJhNJ<O116okayKM8(Q
z`V@4snhUVw?@$ql$&w+%(RrqK?TA4lr4?-7z5F~&8SM_(kY{w9){yi@(>iaEUc<1?
z$92-+?N@voEGG0wQeBd&he8sTi_$eFhkd#cYxP6syd5j;M(sTvB3x?CdK8KupCamj
zhEa>XeSRIU>=)jntu?-G?M&eg9m{TDAx&RwwK*v#4n)WtMf<pB2II!r#oskSOj)^T
zsmQ>PDtSRN7+dY&mLsvnsv_R9ktx$uhO)^ErswFP`T5D8UupcGwO>LU7&Ubw-J<i0
z1>(7rp_69)qm(`iScU7!Zx&1SP*zRT;sVNRvhw{BIGFv;dFVFEEz#s;3W%fU^C(ZZ
z0Uc!hO$2{+591*3L{L9Mp2k!`3w_ZJL+i{J^%<4du0W>Ot=NP)fhYaPKRjQ}Dwl5b
zf*{bukjAg9>#R5J$?{p|y`ApCNz<b`unYFOVy-lwq5ZsyVgYYQ-t}H1W+6wW*cp0p
z`V`5=Zzdwx<x?1iQkM%aPd*KLUmb~*`G?p;Q+zdPKPf8UW`b}O2%w9xNMD;Lh$0L`
z<Nd)L$A?E5I(R>Bhv{YjP3tSYG!W#1YtkDq+Jz)je^w>8`512lMayFyU1};o$MtC7
z4?QDu=KBW?jN*Mn8BlTYb-^dTy`CO#Y_n{a?Llo^GTm<pF>f_OF7AZduyvC-?j^)-
z7yMK5c(l|ATUcBQ9eA<5q2(3kG2kKTYyI^QkLvxuaS!@ks2y-7bb%7MuP2XSsw@F;
zQa`0yaVu56D15=c?X7#JgvmUnlX@tJbGoFpr#?~s7wyRR^700kGvxcB@0om;;D`tg
zRIz9~ypKV&77fOB!9zr17PLzHAJz=~quX?_5aV{0O2{eR(5xX5%P30l{bhxL<mv5E
zym+9MAPT`@u3PCa>h9xE7PkvTZUSW@j_KA8<MvCbSBDjBC)iN;_7N3OHAx88Mlm2X
zNIEW`#~b#yGqII?^>aE8{#WIFh#0NsIrf=bQ$UfqO_(S{qfyQ7vob8FMORXWDTlC!
z<(&;^T%?5xe<I0Sb-rz%xgG24>Q7ZSK)C})5rhsv0HTpNa$>7t11y)rt!mGD!`A<z
z!@azG?fX*y_O-Xae76o!fZnG#8^7`OW3rlz#ihQUfJ^8tYK|;Z`Gb}%rO)zu3DZZ6
z#xVG5jOiDq2%3DX9>kj02?8I9{t<F*!bCnnLc{TwTm|Vw5^Ui#$w3*X!3ONYNFvmb
zQ;e7DJrMIDZ3~<#2{V09nq*0MSFqzuN#I9?Nr93%^D3`SPn))!hAN}ej$USozJY@2
zxc(Y+p$>(Gj#E)H#m6I<%%xU^??ppt2Ylq>bLyf1_l&$}c5=VISbwqwPY%^T1D_gy
zR0d*IWLY93<nTlUiz;gWRx&gU>o<?14-y7gR>&GAjUHlBE!5Z!=ZtaxaUYJD$5mhx
zr!*3&9^T2hf<D^X*{uaS=cA1ej%vGLoFm+=LA|u>3!^_?YJ=<UGb9wPg-y>`daE{n
z-;|Us+OO#Kay*`GpNy7{lJ{F@oKEoFCi*A+Qo!MUWs&hI)2Vh{wiL>llg)H|BDHwF
z;buK2uF;S-bL0Ott>DDqJiS*B^UI5s?3M>6&9W0oH|XSbO9GUbMzw}oWnKflEwAp@
z()a-VcfNLa7ZH6j=5THgH_iLAkd%J4wo^Xm3JSm7MA$gnms2G|VXzavDsYo65Vc*l
z04RPA&d=G8>ry={FTyQ(2qh*Mj(6voY8gqyAET*^{8k@$fD?IT_t9f{UrPV&{}yo4
z$3<~*kXJ9`lK{uGmwU@20XrV0S%hF)i2`ho0aRK(k4N>ri`q-Tz9wf^Ve=sH*vQ{o
z2P=GpvsA%FbOdr?+-|82e3}z5wQT>uD(?lq%kC-cBIx2l)CakRX0=HO$F)U$D7nxC
zoFq>0)b_^&-<4Wc9I7>C{@J*u4D)hPlmco-kj~D=frS0N3gy%B<cj1|*|GvZ$gg;R
zvJcbFh}b;xDWeqKx=qfKb7u_?13kr1Bhq_TNUM+c;B25m=;j!#sMW&V;O110aF`r<
zm>;%5YAZAWa*4jvoCrSS=i#7W?PzCYt~7b#<7#7I2>EEzD(TbAYi$2yrV;`mMuP&R
z(jwbKI|5SUW)F6W{PMV~$!kTo{Y|xFnNB;VFvb3^;zTmDyqzrsI27T}1@MfWM<LF~
z7ykS|>VhtUBa=|dhQDN@m(w%o4~0B$&HGbH+1$CI>$beTJYLgPo=jX0gzo{^1d`Fy
za4so7gSdGPUwY0p#&DtWBhO<a;C%_}X`F#($s6bf(Ft()Lb2^{dUz=dK?qxYzOQA?
zKu7)78(;p8AO6jMnzd`C`M3#Cm^4sj(o9TAQt7%vZfLU0vu7!sj|#UBQon+K{rA4T
zwhLX_0y=8mFIeF9)mmBjn5_Swl+D5Gl7121;O^B7b|31^*Ua=n!RFmDO`M>jJ2ySB
z<jdEic%t^uzx5g4uWk<_a<<B^X5ncYKMQz(Aca79B9PmuY=JKK>o?A^A9HZ@O0bi9
z|0lovmcUU5CsR|=U!b=rSHbR=TguYgtlSQ@_Puj)yEde34xVJZ;15@o=O{jG2CG%R
zPkkHw7E|lhIVlkMM?fNnVBj)Aesr>Tdp~w=`<T7x&zrmh0gr9nvA=gJ+mJjcux*wg
zmmsj^-hWCq2WR&Koc$Q>m3B3ND`jCgc(6_;f5_Vvp&uFnSY#|OXW|L^EgYH078ID#
zjq@EdIm6t2GWqZ2-Xor41X(#(`HafdV96v;P$GjMml)tJ*UXK}njgroE|jAccM!kL
z97=Z}8xs$Ua*13c=-4vumn<s%k7<*FZPQq|_=|c86TiVRgNDp=cxHaabMW}RdapA}
z|NWo)w%Ts87vqX4lZK`6SfhpcK80dKk%$2vK<~YDFVK5}k7#!g%EZ>7EQ9joB6t)$
zhI?SL?dMDnuosOU47HqY(B1@iQ#jpA=|2uds6-!^GHjkRUdYC*NA+RU@5B6sZ&BZ^
zGf1YAP1*51x3A{s`C6Cc=)QlDJ*O#@P35z=LQ7C5N^yynKsJ-Ue!ReSH99&6x0$%Y
zcYpVv-rc2o!7U?r-s$;xw%v@|f7(Ke-Herq-He5Z&#xxWU*2z?vCGK;?NjZX&$O4J
zr3a57`>wz>jYQ<T_$O!nB8DNeMlQitglJl~fKL(f-VT5~R75@79bR!^iR~G!BkiD*
zVsT;|k}ZWEY5X!H6ma*zYAipGHzfa5I}n@$7CEc5xrMDGn}jAI7S*c^#}r>L*-K^k
z3+fpGZ$XV10I{QLv!Ny_YZCsw2<;`M+>$&z=JD_R{O9*s>Yw%DyT6HjmgTO(`LIk*
zy)obZQ%ela$6^=8ni_ge?3=i|l{fE?+puP&?bJ<$r~D*l<<a1<!4Zk)CX?os#3VIz
z=jK22@DS{%Km4x03qC2y#AwOj-PDiz4v@%v+?~=K-~FJ5vbptixKG>r<R#+nglSVa
zL)X21j~rykEi))bYADLaooOZrtqw)>P*AJLGue9AgJi;t4|p&V%zK18pX>s~(1V+q
zNaL@}`{fZrsXE4i!K5jTnKZRAXxu<I2r^60$EVC@4t`$`@VnOkHR#>2OfWu-J3MUh
zbN;Iy@lG&4Q2Pm`cXvNKum6>@g>akdfA`Yc4RTaM{yRF5$rM+bC(<7)ApeD;J;E!C
zOjd85=bW`*_Rh#dy216e8~<;hQxytk^t@HvMPyNSs@q#7!;_oEYQ=)|Y?Zfze3Dwd
z3(={s2l?bT|Ihyx_<h7v4a|N9-tzo6)?07?k#l~Q-<Kl097xk(#pH6J`SV?&WmUf=
zv7>C_TqRkEo(6nOe92&AIk`GwK?G|WUYThl<LfX!g1RVk0~f84;*mZY279Ay4O|Zf
zQ#fbX5ZO1h4P%C+o91G4&941%{4E_G;+8xhT_<B<2c63z%&sDMJc1TUeNT`+3i?BH
zd*I+L*sUb(qBcnzH60d`Ln_D<P`uuspe{f)bjT;v0&B1~CIfeQq(m}9X7DmCv<9CP
zZzm3;7K3!H&pHW=uEWhecoRpA*~ur}Be?zOH{S{E;Br&>7T-n8WUQ5qsf~loy*)sv
z_h2#3I=D+H!W2mo5#+p`9=a}NJ*e4^Pm~^`YfC5}?Bk|Ose}9GG=;d=y~B8q1_j;@
ztjZB{PS_2(ZdgA`4lbP$wbe2s^kW!E3iR}jaS=zb)0YmSBY>`%H&2>6m3Z_{46|R1
z2+8!WC}iN(l3g#W6277fBuYk9=4$DbGQ)-QC%6wSJ1(}0Ro1!^xHz46M3Wsv-W|#K
z>cR@1%NGUsVQ+Z<n%k<uh6fG<wl|KFJ-APYM<FM$eS~Z8aG!%Q*l30-@S|Q+4~9SH
zCqnACZ-C-*SdF9nvspO<M6n*=gv^pfKBh~*1wesGTGipLs0L%@@`fku9=LMZ;un|8
zTPA@MBMw2V;HAJ=kt9JoGIi@^m;ss84)lmR^%IXT{ms%J_v;ydpWpwPyZ0N=yVIeH
zhdq8Sx1gS3i65eR6bk*Ey;tUentI5+GIewNSEs}(mOkG-&I{?2%y$;v6!XwM=0LYJ
z3!@;nNVL;%0)$H#9krEAD!?#Z4C(B9JU3uk&<XqX)Le4tzypyQMovf<oXuNSnSu6}
zQbu_oX?urFr|tCGN|>V*ZYPHB;zOHFwgYur+h#YH#XfPk&}zL*y%z35z+RKjgU1|1
zdhzXgYXEP-eLFNXGfv}Q%26T<#&`HV$ynFnXo{=GbgY`Tg8+66(J2l$+4r0?zS)WP
z5sO_mGaR09C054aF29b~G@s>X%ZOHJcbSx{n-xmMF-dg7OQRMAzJOwobJ1xZ>%PAK
zK;<0wTdnpOo@!97;pg@V7mZ&ynZzw^us`nfWq)7O1-s<1E@Ou;pT7TEptIN3zUOb<
zy>HhHIX{=TqXb?OOUikE4)@bQ!IvM8;{WCMEaltR_u&tTeq`2N>1Y%>{t-ecYQyA8
z5gyHdVMZk+n5HcXYy%hA;+htvE6{+6;k+Fs#87@1Zcau9C{|IQh{jdAi{ez0=9$o+
zY;{AhsIN2_D~InN8<qnajs|i!2f5{u?xyLK;dEEqhxwU)rt?O>{Ki6k-{v+Xx}sYk
zy<#TDW%vN9b$ofp{g5yPz;NY?#cV5sO_kRwRS5Q^GEHa7s6Gd$^Rt(uKVD1aA9tg#
zVV|VeD;WKOCML_|xyAYRpIRd4e*}Wr;Z&hKwy!F*r9F@{&mU6UD>lg40&mA*Q}3Me
zb`UcrGyx}A7UNRrHr(rN<G|-0e*U1{v-C0Up*g;xejdJfGv{q(3%(peUsCvH>S!kI
z=w;IPxoQ=jM*sRJ@^JWhf?ENl-&Xj<2etd%BfF1Rif8Cxa5~HEZRYREqyH2FZTVLh
z|D8<4R7P&HQ)51>M|h3d6^FCbB}j^e=@PCr%^Jjc{}nR5eV-@bO%cp3?$3=W{dgMd
zj5uGn`p6A_;77@K?mxOOfO4PL1c_(eEZpSnM}ytyh2lr9-pd<S^D=astz*W2vWxRb
z?yiOSM3*z*fsCGgQTz)yn-ke*?KtZ!o5KULuR#=M+RI7gXZ7}vGO^0u!<_|qUzWHK
zALA@(#<=u>EZSgf3Itn!;*n+yI?M4$h(y**M39G=2@p<t^om$ACb!fKra%#k*7NVW
zTu~WAYXO+$hQVEaxYVypnd24zo3FS$pF5u(1$+3lyTANZ!sVcco82;cB7D&KLpbo|
z9QQ8ir!D6YKdJCKo$}Lq?s!KWI<#9jb#Bj>ba5|_m);EY$@}kq^N-Z-58x$g5@w<%
z=PRFNr1+_yDB@zw>9?h90X|}<SJux=A@e_y@9S76$1H$_Z#wkb6lNgk{nRgE#y+i7
zL=by3P}{C<K)@@qUKo<Ym)ITlR-eTj-guJYjUU_ldccju^jTfMJO?+>FE6o+Nb%3P
z^~-`^&^2M4M*VP3dO7d6{r}l}+t^66>^zLIB*)k!@FrRaiPm<Ajv~w^vucvXPv?hN
zJ^eAg(_how+Vl=AWs78ytm$GEr;5cTTR<`a;@DWnup}6k0@%SK`4J;dl$DS~iW4Lg
zJB}<wGGwe`NQeQiA_bNr8J>lpSV>g1d7kH-bKhHURW*xEjx<enVWxTSeeZkU`*H5M
z=bleZfh6FyrUWPuEY(`iUg4PxHb~Fv7v~MmeZ+U9=k=t>;GkAnT1C`Hff|xAzpxy2
zoAy<R6^wV8?eFYU<zxx&9)5wZ&8qaz{_XV}2>%m0Eox66%;Ou3=;c^^1$EHm%^cV~
z!eN;@WcHZ)<*6M0d{SC^zVjl*JZVq_zP3)M0#C7R{?13QM{;XB5RKsleuL(#e=G=R
zEF|jy)~6Il%Q#xK4G1YV>n=yAZMG0U$p|o}om*df3Vo0eyCH*DZ4~`Jh)-IZ7E(D%
zM)vBG1TeYp@{IODybn7|vLc)@5$)9X;E+pw-s>GYvn_oR1ZNv<g(R|G@B@?GY_xNQ
z^|CNodX2Jm+wvu4Cb)9+jzAvLImVEq9h+1YITH|F&Qb@?aM3`VDbqO)-;jlWHx=1*
z-~%zn&hajYWE*ei*!>pbIjl{6-P~(onrA#jB#Ky6KzNoczAD&<i)oXl+g8}=!4^5S
zgY{xl+#(2@mNf!-SDxdva1K6U)o0yfNV2DOa63lG<#>%@YeVN2fwwnd6U#?PhM_K!
zaxsOqh<VoY1RIEu;NCTx2+9j6QJ<P{=-AnJSCMsu7mh`Pus+(Mh*(R^2*rDlD<0_M
z`=C(U(WYfwoUKg3<%o9BIyS&gXk&={^r>Jd;(dtQLm9IJ0Y0YE+CymJ`T-tAI~+N*
zE($?5q-pTQ$70w?dk}O9@bHpK>4>tiY5D+N*Uy7~ak23jVLAGRh{aGrp>DAT{Uy9=
zg6=Z5{Fvpp`=xVZ==?yC4cD5VpI?d?J@X3-F!wdraLXzF7?{S3oHjVB0J~Voo6O}R
z92s<nbrL}?4sBpnSU{X%E2~suoty_<@nF3Rp#ue1Ev{i)S%%{)9R-LRgp&#%g@Un5
z)4iR+AVlvFoQKz!r3FMi^V1M4M0Ek8^GSA8rE~4^o5i`-`Cr#>z(MTZMlU(S2kESP
z80Fa54wLwVZ@JTh+|Lrr#?a$z@T0fOqoZ4$%LbUFyJ{?p^{_D-LfwKzyoSs<hrPT#
zV+Lx4V=_Z}Hf%I+Y!4CsQe*qQ4v<2G_wF2Kk8q*oEKfSWKW6*sqwdbccs^#Q`rE^L
zDcHZRppR|281cPV*Pym<qMo_5?+|g@6!@WZ!a#i7Rg1At@v1#sbd~;vMGpYTsN9M(
z81RDE6l&WxIFeybwnQ<KP{hL0qJnqf6YyB#$}Wu6O?Ag;2M<}~n;zl2;r~{9mqt6T
zI|Ic@^i@4unS<X-eG`!cp=!P~8D5Hg%{n(8-%k5_|L=dgTI}nqbO8eO5;MI$aeq(A
z&(-)&v9CwtJfj8lyRg80zUA#l4UjKs`)B9NJiZ-qQQrTJPu?Khz{v<mfUV?j56fhF
zP0u+Gu8+h;S*)_`%;&*lbZ3*g<LVLp0&u1JgOZxmEYNae4E|64>TFDg|8X!leZ$nD
zC>^#>$Dc$Pkru5^Rj47ll3!wH?7Z0ZmRMRi%3&`5qUCYYr2eG$q0QQDqq+v@Z5~7a
zv-kwRW)Datx-LWD7Yx8Y6gAWd4JkeHuA-v8!kU;bX18)YWko&*DN{7ni10|;prM<o
zDHyD5mGzia<}KOqG_g$TJv9my4UR{>LjV&zf{JO33w>;<x?XHSvCXfNoyLwt2$~W&
z$w9GcrqbbHrzh$h(;4m1<p2lF8Aehc<Km?0W(Kw->48l)?k9ZEO6_df9Sz-&1|eSc
zrg3e=jCAyw4y=8PbQcejUmbM`SPq3i#`ZzDnJl12GEP|Jsv$a{Z2Je4rX!$Hy~CFb
zZ#~}+;v5_?2lb6pR3{>+Zy4pt`idlXtZN+Li2Lh~D|m!gyduu)u=PVSG(&K7I~lP!
z@9hkhBlI6nX(z*(bV3~GvC|A|h}y@axx{xFo&Vxo=Cd1*GyT*b`6<%d(6$cmwBmac
zzYZqJSKofHG+%u(zcTur=a%$=ar7ObOH@^`3n0knzIAyXzWBKr^71DxFF&e7t&E|T
z>}OL5{@Ijt)a9A-GmZ4c*9#k+U%pu_^t8VC9UrdWMC6l_of`My<apcCZ@hkcgwB~)
z*;qQKXm7GS!S?+oxliC{F%F5%6SzNJsffGHoX;Nbwb1KsCqL^vD_EdvSp<Vr77-P;
zy^dZ`TEtL%59-xXK^V@zcUk{D@0_B4N@oJmKc%a7(LW{aDo;Eg%2PUgUfjH%^loRn
z|H@|dCJ4SG<2wt%#Qkm3c>(yaKmoc$zFiIcuh;@(_%r3+c%E<uBk@L|Zy_p5Ma_mt
z9j3)86hsx>6m8c8gC6DwWF+#j#XV-*Dh?*S)pB0BP27b3T$W<jcm3sY`mQTbSM}(a
zggXy$Ot{MeRZKroCAhnt{O8Vo&nLG5cSGUilYG9cmwm=_u73n#x&4YRDK8t(JCUf^
zhg^3Lkjiy;jb*O8A|&N>N4c4C`O>=Isj2~#zV;jU{{8CBCT!az2k~}wem>`1JR6-u
zJcGM^;cwP(hH!|=4LRttl;!Onzs<gGx4YZ8jUw!W@Q~5<@TY}G@O6slZN<Z#TB8L~
z2kRj|aprXL75tr@zPe-du%PQt{%7kqo4CHpE+WAZfU!T(Z{(Z=Ai2IF>_#BIFGH}A
zbEmf(*+zfZ6K_v+6uW5f((e~09IR<Q7o-%~06IR7gN-33>AKD2b7<Uvi-pEgunGwL
zzz6U3z^s5P;g|m&UtX5e=8JRA7a-(yW|#WQIsYGg_PB(@1<#5z1E~JtN+GzUF9e+v
zDjz3zDB(d>y?Lj&r@#Lx+z$|12zEN#Q_x#b-njn8y!aM5{HkmOekb(H;4$KwVleo$
zgP-*yk@4QI07hC10l239&V<ijnBs2^6ftGU-z4?Z;KNDWq@~KL2=-IVSAr9P*v&h|
zJ@Tvn^zRW)I&?&f_)$W1fEP?A;(H+wCJWt+m+`Tv<#VlyV1d8{Z^yk0+CD1tYeV3t
zlNN;VLI)8kK8&#^5nE$3MEO*g{*vLH`nLMQ4{yVZjvbY|$DLq!16c(g+%!HWba&`t
zJ?cWI1AK7TaA?(Wbh=w|n8f+$*?6m$`r}5sbV`sngeKqtUPm=KvU}c_US}H&+0Z)R
zO*Hni1z&yX`JN}OXZd+f{{iPgf+_q$q({f(m}@4TDqLMzO7=r^1x;8gH#nLv!*yXd
z@WJ2xMZk40b6S`9l)0Y&IJ<!`n*W@g(;hcd+}pPS>WHC9<M}cD6Z~P{OlwDw)g$vQ
z?CARw<7FZ~9UYu;3&0@xio;hw_MPa^&4WY_fS<y;HV5VyJ)4h=(ZbSWukALZv_gpe
zWFHhgp>Uab986WuUq!mW^PK-eUKBl#PPo_!V~LV5a2PI%b0Yeq>V_3i5qB>I%1r%Z
zcR{?cXI6>&Qm~4kk1#%q`59OY%WNK~PtVs_OK~d^sSlC=Y_C64bJM})D5SoGCFgEG
zar2G^;?u7E9O>(x`&by2(>~A7#k}@n;s0nM1=E%r410`|%F0LaF5!shTj&Qt@2)FH
z7hU>)0S=$-i5LF3GwjjA_8a02xMvIOHv+0{kKVJi9|1kvP3T1Pd;=IJy}-@(GuEv&
z5$DnTHy}qbiolZIY7lxy=L*vD@4)AlBqbj3k1Y+IYpc20Io^k#AGS+}h-g-gG2KHg
zE2q#~NjUy~)=qY}-f@WXtS!C*K`brj;*n)z1LCnO2B~WFhpKx1!qa-umRj<13P06J
zyy#uro^5xmhtUrBxBR}<>$P^^YlyEm+mN!V`+L0u>k76a0%2Q=P(#EFviWES?_ec;
z^w2@fQqeq0iwSy0Jwkp7jlfe6+OgfL686Ut>`S<Zr|GiaW8ml9f5Z2fpUv+v^sgfw
zBWV}HkFT!0ly5G&9w4NS(T)i`VOAmg1%{<HRY531nW`cDk}g>pu0O8Dv<hEq<V<7E
zPwsr_{D0%I=vS5AG5i80TwGjFg<ozgsGB){c@p~W@TumHg<n|yeEi~gY^)!hg8yx`
zFmD)gzi-G0+QWd{rsE<G4ESVeyJ`4lvqyZO8S0B1@S9c-{@H|gp!OK+V0#~7;GhYq
zeWYYj>TV`j>XLpOf*@cwee$9m-^-g&B9ADL+(cF@9$K!z7|c5#!P^<&rPQ{+22|i5
zO9e%hpl?owhYMMw)o<BC$G(ie(~q{aPl~t}aPY2uvR5Zx#|6LuK{TE5r~Cp4xT1fQ
zYom6xDjT_v20Xt_mJyjrC97J4e=(H!v|AdF?uXDu4SKC_+^B7+t%nD9K$7)b2Sv)o
zUa)5g76bnF8XylH&i3H;&df0QHneq$2O<Muukl_F>Mxgw?kg=r$`<;rqkdYc3F^+%
zm~@vWOu9}flLp0u0iBynH=kv=eHeOvGauByLHZGAe__!Cki{o*`=P5K`N#Mf9^rGr
z&+vHvJ_4EZu}3QAk@y*YGn1cTf+94fhJ6X6ps?2R8byH#6TFJUbzdTn1nt?>s5am`
zE6S@u6feGowPXBWs~wgtvS?A!vxd$ecxi(lNJq?RWS1+E%hxsXGvno(DGu$-SN^q6
zRBu8olt^;m=74YBTgKjx&MwEIBr5rxi`xL9Pv$k-p2F>dYk#?xd*W!%E_b^BDABF2
zzxipc`>EuYI+qbs&x|t3w-TyV>^&=cgv)R>j4&-ZmTtu$C(B6-des6F8$KV3zqc(A
z**1LP{pj0q+_pz;X}1#20)3FKl?2rA5A@E0F+{Ow(!WrZg28IpFvYV5905i<gjQ7x
zIVtju7JNB^w1!w!z-;2x%!Jbgu6)I(ao`Fd@YV<hFBGXA?Oj&*-{}iO^!tJD;xE>b
zei@hTQV73{OO=Ap>$gC#eCLA>;C=9g=zzP|(|(!x`oFt=v)zRnbFpIrPnO~Joc#Sr
z&c#m#oZ-`n?+<uOeKDdmE3k7oD=<!Jz?q;my^Rz4a-Xk(aL<lkAEx+fGc(`+!TL=(
zN``fSI}`%E2=7%>B&ih7>iXOooTwWPy&mhGmEk^g>)M(<e+cHl6W0NdrMumevSKd{
z_<#QT_6OVOCjs3jLiZtfg7n=7yla<v7P<02u0{<o3=eRrF$xikKOsfpI+!}wJ8V;U
zu~XZM@wk(<DE6#Vh{Soafj4MoHXPw14ZH7yv=97#7R4SMm0t{HIi+Fy;GaTZdgtuD
zTkjNpd?EE?1z07*<X7Y1cU*GEw$KbiXP^$`cpES-wpNq{vp>eAS1IYM3D+~_sGP~P
zWtEB6)K!1c+Zost+I+OY{7u8@w)4RiIm9%|)-B-pqW#U~d*lEvyWQ`SGYA)!R>R29
z;um2)H3#sQJ?Elq+zRR8(h%Lr6I8kneqWMfzyDX3-l^W~Q5p=$(CJXn%M;H5qnmDw
z>O((a*+hQEr1tLd1_vGFS_>gIVcZq_JbYpM__U9o;w~0&+BR6`n>#~E--0NI`)BQ$
z7@;5(k}GWZb|bzMk?2mI#|vG<`4nHH{;7UJpG-gM5}ZAJM-YY5_dmS%*x(F85`+^F
z$LvIU<FzYvy8guDz}|{|kd@&ad2$146{o=)grf~y1d}|+IJ%J0z{<@)2kGNT!$=%;
zT@J*fppEbXmL=phhvX+Lp-e?%49LrBBPkGMJyr7qNcjZUdOhCu*6bLG*V=JNSV01K
zem9rrpxr&110B^k>E2}fFzpIFaIq2f-mJzfUeXAoKR7SED7BFHeFxg!TgD4y5<VpO
z9R|7gS&MdB^=&`4q+DXhSqm#sOc!(RYQ&QHT&8wZ$)CjW;wS_`GHh*HfmHGqtT5Us
zPiDLlO|&5)#M>NA8~&XviTE4ft?C?&cJLfpD^cM}7on;UVuFyOcMlp*4ZE=+T%pjA
zO*BPpyLc4s_;j(DFW5MgE7DpBHUt-`oT?o-_i%DI=$+}e>&L66pNoS5_UH225-jA+
z7=DHEt7u#?eRoTE==%yj!QcJWo4`Y$Qz5MeH(Vj9r@%uD2<&`<>xvi5H6w|uE)om9
z5!7x`6X7FL6)J$GI_A#_ehX|wTuv|2TE;l>2_z@;6&?}9Fa%Mr@V{%#!B0Nq?^He`
zf56d3w^7WW?qT4MCHm88LP(K8qM8pPrGuTo@`R@##e%sKs6h65n==`HHU{ykW|xzj
zs>JEcCl33yrx1S|=*D<2>0jrE{x0Rnnu0iY4T_66Thq_aF#O-D7WcUS>fV1)y@k6-
z#{Lif=%C=&5A**CyEm(AOVfW}HT%y1lO*a+`QAmZK1BahKh<4<tggaqqDlCfq=MhH
z^nFZOY26<tyPla}cx$kJtJaAa1)|I1{(e)+V1+ypcmpebw>mFvgIup!Wh3-`e7*FS
zcxDGQg=^(9&bc)0i4_q0rQVVb9B-C>fR*0Atl2_8epFsaHlS;PFzLaQn56mpspqi-
zFV##B<Xir0zzgIhzG%9a`*}1GUgS^<@ZyL}Fl1#s-fkEjAIZ`4JkGmGa_{nY4M6$>
zC_FXPKQ92>A@*7)&ZT~gfq(}GuSJLi7Hq&=Bd?&msWNWVp5f>lqNg{&GIB2s8*tR|
zp22eC;MfwHuPj+umavbU7ykG;XQ;5)6(^bG9*oz!@FvIfQz!xKiSRy<vVrTfVXUAg
z;oVOLna|+xFC~ub<V6`C0wylmMk@A?O?TqAkFhVQ%+J9on<-Tz>E0qx3ax8lKPH1t
zbL*4E`9%<<C&oqKte5uJjdTuwajUvfy#<}g0KKX9m+MkH**MVt!mcl`FNTexOb;bd
zh(;NX-$$tx(T5D@;M3PX6iBkOjSPclofmZOWCfC3rGn@$U>>)%(S4u3d^r;RAN<sh
z-};qjzc`KFAThhgGiTEMqA=;wA_lLC`K2=y9sws$V;L?BI$`EJ{@VI2Twck&4u)XR
z3Dt3Ye%_0;e=<L}x2`#BQ0C~)=C>=9s=iIOPSwkA!O023L;=;2(8Rj|cT#_(=|F1F
zZb`Xl*4}$GS3w&(YO*S}4+aAh;;Lp;)Je(jaGwm1tF&1#pU$^Tqqq5nz9BsMP{j-9
z&8DGkV`(_P=!0Q@psnK)Db_<#+E;!C;G$Fr8$cM@)aylNLI%Lr=r!G#3e3ek*$cYq
zsgjn?_hhW3IQhj><C<7r@wV9(`jb`TcZ+IaS=5B(Q0fu_WHk=DP>x1$P4rjO3E;cZ
zt?wVuRTIa+v|he+`#$+i|LH&Rr+@S9pZ+_;`oKCw1mW|QrR8~dMvCNuG5_b6!cS2j
zwvI_%c-5F9lpCy>EC8`K;bKsH2qrzQ(86*!L4y96|J*^+a`;4AcF(3b<KS*kEimck
za!fJ;Al4AQ;!Dwv6|KVgl6G8WdD-2*BeiIqLdrcbR@UZL-A%^g3Yx^|q8+rnG`Ad)
zxt8EGeofz-y#lr7!oJguo=_GxPjhQ4^nieNgzC`FD#&7Y)&%E?a0H3t8F<j~ocry$
zb;JCh-r`QuCi(1cV`n${HyFkP-PsrOZy^8KJM~@J0^qOnhtX5?Q#)>!U*#m){u82A
zk+9M<`1@oGe}QTY-Ioiv=OO422++uZB+kRQ5S=_1<?}Gb9hlwx@Jpc6;9VJft~d~J
zWa!+OB+mk#C%5m(Xxs{wjnHco`ltIdKh6EZI@Sfp^QlWNG@a_)pYWxNRZMs}<*&5<
z50f9BnXmlBH`Z@;5WhPk)Po)>)6ur>;E@=CQus$EF9j+)<xbhMo|aC>eHZ<~atEC!
zIAIqFC;UZMjReR$FS@)*6QM4yl|(_E+L2ux50wxGD);k}=8JpeC?95FzJe3V40Yhl
zd)1F(B<%>JiEh%@qB#GB=<<iRxy-YK&R_Vg@2uW}QDq%cpC*DCusrb4M7`G6uF$ZL
zzBI7XCb!^P!s<K;E7D`ex>otrbQ<BVw%1Gif44K(syFw%lR{Mp!L^fhoL#{Xoc6Vp
z0JV^VVSL5oLlD_gYq4>=JcCo<<_DY(IlUJ=Q@_`C0qqT)o6@P%@J1&tTySpJEg}MX
z<)1+ctw#-}^=7n#gBk-+fJ1Ae0ZaR+WDo0l-!~jr2^IZGJK4pv+4PaLl7`Q-8OmC*
zk2n>c<kf6{uc1k?nJtE|ybD>GE_Jg#W?bzr8KI8q&jPw^n8)3QUF2cb+3~rAbQiL5
z$u$dos;517k=krLMZ9loZx4q3K9Nv^Znrk=tuAA3p?%0vl|&uPvrvqG;;2_^z1wK*
zXwL}FF9rf~InUR}`S+TKqjD$w5k(0u=5&NG>D*o>gRUXh_eJo@o7HQaPT`Zk`h(wA
zeY3U!kF`P72%li4%lF|IrGwL=8J=i7EzYN&Sd}2bVbDuZLkhle1<>$l^0Wr6H5P9)
zp8BSQZXU=li(|3LxPkiB;i<y*({^nG&Ux)-yc?rB>h_v&SFEN0m{E7XA$?@s4^kg5
zW8%zo(wlFjcoOgbrC;6#JZ-`~Hu(kuv+2(#U4w50-)F!xNjFQHqPvKl#}m@3Y3w7{
z3W_?|5amTAkO-bVp2Z}4b)KKn{)9O@f2DQ^zncKC<ad+DhOqXo23*Q={DL`qTCh<}
z-2?NZZs8-rU$F-*7=v?Hk9@z>oeQ5mJ6zr<<XFG;M?YPC6QMmUx~HZ$!DZ%0WSl>f
z>b&TtT>kk6%f`|10JQ1-mpqUYbGiiS&Ym(3szxH@hkxW$gotw21{hG8hHGG$vPMS$
z&U`kk9kW}bqn;WB_9=`itTwtecTl3VFth;l!b9Nm2e=LWNKIYnX#hWf9|!;9LR#R#
z+3C$tJ%XSG4?7g+_mu@$cj8L${Lk<yDgT)nevG*{zi>+cjG|v(`&a*5_08iQH#AIe
zjanbg`3)3VoV(4$0R{sck<maX>KxxahAPr7=zk+lch$cveFzgGAV(jL{N<_6A=TMm
z@iDl@_`Nv(b3W(oYsSC04Hf?*D6h755bBKQionSHx40do07ra_g^=T9_|D3vfK%)E
ztAB@P;KkR`w)^1r8--o#kNs1hsNRNRDTBum`*5E>pZ|CxsHKb#rLt+)lXMS)@6}TL
zQU+n<aRar2F7$Vf;(|6b>dTwqdJ|Q1-srbCSkeenv1ZBy^xM1O#(Uh4Q~z`f@Ep(^
zw;v=uf|)P=*#EPBd#{0mx=y&j^M3yg#>`QP(X-RaG1&J4t|t4fFSl>Q(6}406e5T~
zNhbHRg6zH(BRnqUr7TEs7GW7BxKbg;VRVY;bg(F7qI)G{#FY;Gi-|RX0Ee=FQWvCm
zt`a++jG8{pJljYv*uU-<v#>kG{41`m1L!=&CvI0nGRD~uND?0SL##p*F9MP);go0r
zPRMl|TYxtrZ)str0xHO99+y-utfY3FNs7>kRz+eu0Luadgp$rLAc%{7Y1QS33#%bU
zBtO-EW)+3NYpbiauizvWE|o-mF*$FoF}YyvVT5i+%OKTkhHLEKz>qO$DJHBf!^i9_
zx>ureegDPz`rwAn&D*~3uHLx*n4YxHy8kX1+<jET$?+`N><$i-fxxilU_fBt!k*l*
zV!iq9?Ym|#m)5&eZ!+==gvf$}SL=TAjGjY{ad?c|dBQf1T|CWtNAJ=(E0DSU=<`}%
zl&*i@);rbP-P&RJ_Mib9)*bbR=;^Dp#lYzUdGTf!c-EXLmi6}NU~!DzUi8BL_6LwT
z9I^vmPP&3|vE|o^WwcjnG<9@#vYrK57Vr7%m-bJ|Pha65+Vnw({PeBDNwllNtm3yK
zrRwQtt_(kRPN4MtfA;lTfFB5Hr_-yGBHXAP`PQ`wa%6+Uq@hO5v}yI&27}OJ^Kpvq
zXIK5WrCykbH<pp-WW-t;j98(NN%`1HPr-!u<92{JN5+jWDudLUTHZMQGQ3<hlb+Z(
z{bYoNcD@phI>i5w2XQ8y&VqliRUs>kc@6~Gsm?cFnA?vE|MxRr{4dsTciS)IUluqG
z)SU70xdijoo9^;X{$=g4nD;CnU3bD;;M2gNg#*aKq2uGR{$;^WcmJ}!{07Gu3ftuz
zCC93ei~0cVssSsd!#4F5?Z)8mU-myaokcL4ccCPb9`l@~?y4q-L&iOSAvnC3<ViC#
zEx}<Cyts7U5<bkEQh2A49`5Jn7L!xsg70BvBYY2oi|ON&zj?eRM+s8;P3JPs>DDff
z={Ro*ceRbJ#xu2#fBbq2cldA<3fQwj2~XBq-XwPp!;5xmcrJ`8N<y-wXvgXtG!!fJ
zX%8{u415u63ygcaLo*Fu4ytNN`_2JKl4u9QF2mulZ-E&W>u%QF2y_!#{Inrw*)G!2
zm@@t#+QA+I-<E*{^bMHY3}-#3wiv>dL1dAE$7KY#Xbt;Ghm}2z!rhOmVzk?-1D|Oy
z%vXod#oA_(Zbv%$v&EUQs`U-bhjoiF*=;}w7~6ACuJzslJS(f!`e8hecDCyW(C1*c
z5#_Ab^mcZ+I2?nNAC%)#rd+RSZkLPrvxsl4FYE$VeNE&voh>Vo3jOgXQ2gw8R;!1v
zMSn2E`if@I9_|-$WT}jT$z`JroaC4vKad3oT$yMG&)XYGT1g~mfMO{hCNo8Q?dWH@
z9akSi?WT$4k!r!bL<;XpA6btG?ZtNl`q7^)?`Xau_^N=;nLy0uV?}m0nu~T+N9-WI
zjqaOTLF9b)tQw{&#uOclb_jnkwu;9BYPI3)DK^0QjrX8a;47$FNgu{E8B|u(ZTaR=
zaW+qI3S3k|bC{Fp4;K`lL}7G=YRf@>wHfr-yTYV(<r7yLvy8Odg0@YxBghB{M3Y&A
z&yEF8)ZmY?FddcmYR3rB747ugqyOIV24aG!*YE+vZ%5i$bgeo<)3h9;wCb+clj0&Y
zYB7uX+9C}}r2rjC;tGKW(rpd~gJ6=9`shzlfu%MtRwsIg7h<qjI)pP|N7<0DZnUE*
zXu(T^O(7odW7FFg59m0<leqKe$yQf3@U3J&VW?b{;YK}L+o$t*+i3gsj?>cny9j~O
zwU6vmL$j0F2igbsj|;fpKkn31BgfQR^U1{nx-u}BWCmX<=7(MB)VLPbq@7+WtskVB
zf$|&Za;oHf;tE*&X@4dBgEHW2y@n(l{n=Er?g2249ssex5XAb?u}sRvJj40CjTp<*
z76Oe$?$&zfL5$FHK4;KvYk60r9oRhr<{S$M{LC8xlMaDM!md(%M$&v19@NRS!G?-<
z{4sa2B^$8#^vwo{;z`J{5xDa5S>R#q$Y@73uv4Ql^bsSOHP>^XJOGyVs?e_^%tSld
z{QO>e3&)jD15d83xV~xZZ$t;jo?wh{Oh>e%kFyMCs;9Y$BH0XaEl<m$c^H{$mmMT{
zhUz8X>2XhO9vc!;23SLw=MWkL+{(;+;>uwi-kb25S-gX0Ej|&6XuyfKGFRJo6V6^6
zPDUpd{)c=ZAz!cP_q8GW88E7YMGUh|_kq7qS%dwHY2_|0B!2OV%i~ex3}f)D!8R1j
z7ZJwbSKlP}@WmWfGpnK93m!nstFgPmbe3}7!m3Mk79jdxa%<6LNPTogTb!$a53MgS
zq_|?6M?14uPz103Vs$g=mMe?smHYLF2@77=2brYM2(wBed+D>}U+ZqdqLn#Z3iXh7
zFYH==uX26__}2X0eq?$vw|S~?`mahu&K(57y-ocp7)r`g;Br;S1tBB&F7IXG=bZXd
zW9jcH{phki>dRd3^mg25KhWC&;xZo0wzp>uoJrm`On&u7dk^Rx2(k@@8C0<M2LsSo
zQ@wxLFLD#ce-`<)0PyzX<VS91=0C=L4fkl^89GWD^6y1>8S8gB_@mkgLwW~qz_HHQ
z``TFkz;y9v5`O?}(^~1ihEONPxk+_u?kyFfuFxU`;ahF^9pwWKhK(E<joZq`&BuaI
z{KG0fA1uzYMywW(o!GU4XEn@UxgCDe^jq0Xv;NduWPBJ^ZnmG{pcF;YZaFIN*7rbi
zBt9NrL6~tEaMqg|pfattM!_^Z8Yt}@v*VyM+o<s&?rRQ6&L)Zb?ga3<FvTVQaUn+?
z!#{?BBaQ{Z^E^%?7b{Xk>b8qKZUR0+>bWup-imn}zzIcPS6HYDl71Le;P=txt`u_l
z!L>qtSxqu{fqI)EV0h*j7c222#w^4zpZar!AMN$;|L(`t&jHSX-$RWz$vGzZ2a=ov
z9)g_NSMXh|Z0tVf92D)n&KP4wzyWN=*)H@AVL7}*b7-J_{)+m_mf??lmv^Cz=J%Ds
z!04HGIhu6qRW7OMrW`h4er}GLvddF6PQQ`<sgrwB&>T*?!1;iS`Ex%6G)&Iuy64Q?
zFdV*B&HNDj&`+(ug>YXbI7C}x^cy|yz1cY>KLi8%4bWbCTYd=K#jyDpuyQ#ISWr5W
z=y<uqgw@gSPAgv-@)NMz6ymmj)GQh{DxJa2xbdI5w*c`oSvab9uF?d=DW_XU%GsHM
zY?xL&4g3w^HS~N(&)4#}FL-{Z?;1#P&xpUkBUFTO%@Zc$GEiBD0lQKEmDN?k1%Gi5
zSegf8+%FX{5Oj4H5cP|YMPp?b);xau0?h60mVy(alIR6hsaX3J?kv59)SBH-Dl0Gy
zN|%NOd%U<(S@YY6^`_rngvtG!eE?h4yMz>7MBy7qxl57N)j4csyFIL~%y~0Oo`eep
zkEjfP7xxLm##>e6*S{6})XeFV9!zye9{HknMA9pJ`ftf#{%H;7^jUu{IE0>Vcp<N$
z|I7?%M;87R^H;1lamQO#ixZpH`zizcf*1wUg(oslGir^&&r{wDPdD64Tl>uSwzo3-
znD6?fPgmapGw_u6HWTOyKP9`ZKIFZovhe2I!W*uAOa+*0<|S1oTyOX(Ob<X_`|YUi
z<ShMUC`usT%jpQ>H^En?V<Y)+>Hc?{uJ&~al{@j8oqPTMfeVPSKb~U9I&2R%6FwpR
z2)$C%ui>}+<_G`DWT5JnRX+l2UB|R8w6G>VU^BX%d37}Hw?4MPpIy-SN!%#aF@3t2
z^-|VPZajyday+wE`hE2pLz12=n`?BP4a`hj1fL>Ym9Bx!`e9oi^(%RP&M>a1_ZMNj
z_ptmO4Fo>tiks#>bacs-b$0J8SdAStnzz#hOEo?W4(>71&fKhbiZms4B2JEQS=|9y
zZa0)mvV)zk`Kx2?e&^Oe6o_NU`=X!F#NI2${o~a!);|J*!uy==dkZ-Djd6+CF(P6Y
zK%|R6Se~OxA3bE!Zkn;bNCD83n61Jny<4nHf&W?d)@|b-zSTH@{HLJIf%3U8Px2pI
zDcXHriu(mxc180e^!W4MzC_Q?d=A{HKGH=RtNg)dx{s@Ou&PZ8h3$GB_x`~oJCnB`
zEX`j7l0M~}OF!ZeBBy|BVXF;zr8n&`OBo7_9vO=(azfqB$aMvN=tRx9TIqo<^`uKK
z_fK>or(ktu373ksQ_P3&f1ltxkBt6f>EHV2ewgsG*$Zbg8T~iOFV2Fl9~qw)esNGX
zLXX<#PU{yZEpi_K01qOUe%;fAc;df|xE_0c(Jfb)oG-z_<IMhO{vWR2fkp9N`>4L1
z;SI`n-q7u!ZOr5D>}!?I)-1H_z9-Hd&|6@}T!&*w5<odzsB9cui2gHtG}%7s@ouBD
z^;vug)C+}1cJB52vvyrc9m4m~ZGIbnK-Bs9h`7+qH>KduLlX56-=c_*WP{~<+o1oL
zGn$9KQQ+|xC47b#tfG-~aGTQE?Fq#R?_sj@?^r}LE79xSUBr`uHw-8xPF|Nw@#LF>
zU8CTGKQsNPOK^Ml`vjpV{p3%6>rwSieH;FZK(J<T%lpNo^UmNEKHNlN<?yPqY1fJ8
zUz4AXbBkS|a-g4oNA*?{nM=R!vCPibP+Sn&dpKWiZEXQ!6Pjv8#gqS*;NeEWZ~pop
z{&4*cYzg-eJYGH!>^u{`ndm3tY<vxagN(ncPy6)}3P?p?jQYt-45u8_=+%ZQ`9wH}
z#4DTwqOPJ8szsg)ynFIIUFaHTr<*@t_y=6C{2}0x!{kDqs01hk6WH%hqJt9t@b!`(
zZ^J2+LfkM#`ACk!x4m{+`bd0Kmlfj@4}gjDj*J4GSchiP4g6GtCeM3>C;r?i{U)^J
zO}`T!*%)pqi|4R)+^U81dKkwsDWIiC`y*=w{0p9nP`8bW{O)!GE(%<KO?hwBLB5z+
z^f1~{E9vvL74Vt`%2oMhG}+!h;OBJ6^RwMrqvQMw`D5iXXILOI02H0rN9Z`2J0NBd
z$qAkjWg2jycg5)73V&rj@p1kd7XA8=KGxj)5?qy;P-Cu=V%g3u!%eY38v>D7zvUGZ
zU7!eVg+=^TAi7>Ck`-fTQ1z)|ypAQPQ@L)I`7=g;=MXwkEXb8*`s+9029mBg#Zp<@
zj}9$L{5+t36pHTLFgut#*?zv-?oe}-Jg&+6ddhQv<0oDy>oZZ)KeuHlKlgn)DA$Wo
zy!tyd182wY_fnkX5B}26ZV10ab1}tgI0?U-Ksl!manBu+qYd@<Rp$9K@Z#&~_WE}o
znLp<{)G_&NcVAwJGWu>Jy+7r?9_~K)m;8?Smsj;M5oM^vKrWQp57)o+xffqwL)(Kp
zw+lMH^=mh)TIZa9?0C1(9~zEtX7{?AH(gA{_(fV2L_JGoOO_T1U0yNN*RN=QI(;Vf
zlgddJM#Aqg{Q==ebfkSq{L&^UlK2j6%SoB=$jE{*h{)Hd`H-QWp}-DkleFsHMiG5E
z*{KjrgY;s0rzR&Y0$)1l)ti=U)myH$uDmrI{o(h#ScI0PlYUB(byCf?NAYR4!=a)J
z?gbRD#AA+#1|*pI^1NU0eE;Wvj=$gg-k9g0zoI<yfL}_CLN6UWUI~;Ipf@7&r~<VS
ziicvJuT(&)i72Dr6nC6L<}elIr<&)|J^EgX^E>lvAATqIU!B6gOpbu10$=5bbQDcj
zAWelzpY6LR5&J#U8&uf{KgGagGJmFw$88rw4_DDJ^*sQV-7H$qa(-VEIl%C<Ee>D&
zKDdca`=kfWSiY#vJFp{T))DD}0r#`UA=rVkn|OANB&)}~t3aE|QsVO|i5I4t_X`d2
zE+_r%5qLNIkKfMk8w+btqzy2Ka-yqUq11N)--&(Wno<?GP)>@AOMrXrlGVAS(*=JI
z2(=;wuC-;0Cqi(T0`HXW5jV~61NK21h7{d{&*G}AMADN1XikRXY5jFwXlOXU!JVDH
zxL?RSW`60%*YChoDwrRF4;^2V`8`Q5+7OuHwt1N`c_h1!<oWV@_O^wv+Qc=64+s4#
zO$HQ{AGQtn@k?}txQNa6jxIX>n*1C^ItFbhG@AuuAH{yl9vD*G0|zCTK9N=%Fi}nq
z+Q~z=Pt$-UW?T%8jNaFFoMJzoAMkvPT6$hQ3ZDP2hFSrV6K1QxXu!{Zi!dAWit~TT
zZOiEUjVhi5<0<B~bnf3z_CM=?{Wa(hK&6Pj`9cr~6o;KLDhFJEdjA+XV5o*=bij3%
zjiUoH{5e?;_y`J1txOPTRAztBDhUFc=yx`L(%T$HvYRng1XO}k0ow{O&fq<EYTI=a
z`n5THuLLgQt8=~BK+n~Kg7u;+M^|tLOC`B7x8hbYbE`U)Gx%Lgs?4-XFz`J+{C*+f
z^*8_J@Az`{4g#hkz#b_&+YgS{AJ=IRWe;eHVstCK(F<?qd>)mJfmcpKzh7>roG+$I
zDc$=zd&h|mC0K3l0$LA>4yg=YTEnP#6KS|)a6`4o8P&_}$lsOvHZF!7r-;!;Ya8tH
zltqAB*j8s*T>J`lcoTDEtw5fjDRC4ZDqHMOE9;=}yz=Oyna^47IMdtVONTJoW{c|k
zlyp~V#$N7hu|Ir*<9=uK@2}?cFYrCs+~Rm6PM;z33L@ay#z9<YDhT>{Ke$qXF#^oO
zPM)4&{C@Wyy;@qlkeRu^xPBLQS+McnoCUb>Zb$t7Tsro(E7#_hpb0D%zuD!m4+xFs
zDj(Tn#{N|KWcsIkzl(caxje=l&wbq5PkYBZ$xa?}Qqwr2vx<7NTdTtz4ndLb7_7`I
z&^!KdbEnDZn?(_qiEZN%eTKA;jx#BK53bp3L?zSAyZ7*7{@D+`qk!k>hgsaK_|Dy1
zCU*rK!dusV<4DjcIK<N-Ka6_v>K--yOixks%=f6f)kH7OeDSaRBjA(HMiS#1KH)kJ
z%5rm}hP&0ZDfNfbNVwmjLA8<YHy(jXWkXk)p%UF?hDzcR<J*0JCgV2q452*I%_M#K
zawZ5LM2Vbt`ah2duJ9V|Od0w=r*L*^dMzfhbS~W}^iXI2n_pSK3wlMdP|O`~I+rHu
z?MUwsv0QXo=JcD&M$SnM3Pa1<D;a;jJ_~p2t~k`4eUPP#_%6^tgxW+MCk>37DTC_t
zyuY<QvP5kRL|i^<JFoCa-^V{*g(uWz8_a)GT-cQYMJNH0b|Yc8XJDLWhA?cW74;6`
zss~0}G#=qn#4KOZzl2&1z07Bvem=_Znc_Blb!Fy<t9LQmz0=5}UP$gZeQz&W&9k3d
zH_|<E=C2|S=UpgADZBzVD}Dw)W8yBDelyJ5xMg!ZbDd>l@k~KaPv&bpC;q~ou^|wl
zgY>__b)Nw{3>`?mx7T412K;zF(qoh1H~32s3xh=%9lPwwh{%9!2X#jJeaYY{hWpKd
zM;Z;f7W0X?3Jb8f7TZlR7ToQJ(r&+%{8Hf#=hohf^NZkmh--(y=^noTDHm5D<<{g#
zxiL9xxcpogxP}#VW8F}lNjD&a7i*Y*>87{_=OmN_`tkc5ykF4W#Ef_E*?D_6;QlJq
zmEn&p9N<rc|5tb{VC6jizBnFp{kFR|%%6R+j)%1kFf3ys&$^C;#}~(6=P^YWvW=<m
zOcvfGZG0^UreqQVIC-|pbWO4socZdHejCm~^B)KO6&@#v?k@9Vf)8`X`?&6N{G{+6
zIu8>HcbT}Cdg5enbPQzgC_m}sabL(9FOEMPknTQC_pUcT_b+@I>kmu!)9}l63gvVV
z_~m2m|2Y3I#4m@Z&SsL^xEo+NG|c(i%I2JF+V|TqjOIyM!5RKBQDsrh`2i?6rgLbY
z0=~Sz%b3|B_4N{ntF88)-7W?LYDDqyy^zp#@}LU-_BX9^&`l@58Z}DzD6>QSk-z)}
z!Q-jycY+TvBF6zAV2r-5;hnSc0dW7Gzz6VA63=ZwM4$LpPK|HCJ)b8x>1wyo?t_P6
z_?8e4L}0fK-?y$ww^!Rq`~yaba}bAD=bFTt+zoINSd`~RNcPbA8nxW-!_br1ABDkE
zvSw84-hgkL2IC*=2d0M^p0qU{38UbEVuwR9-o`#%3B%{Jx{9bv$8CfcorNn<eKOkV
zz?plfD>9wD3fHmuwCS)l5yGBP!lSWn?=Yq#*-hab>-bc_^)1rYiNi)4{-9wR6Hs_T
z|GK@$?^6FtLyY}tyY6?B{Av2}m-lNH-{IT73cejy6RfIC-kQ;mWow6!yFy4ba*n8M
zWPNNLll831bV}gqpjUjH#)kv22D~94fo{s|d7GJ9bE^&skbttbx2H00G^XK9y<8>Q
z;RxkyUXC`Qa$xYbc}%0?B5m&ES*jQ%Xm_jE!1hl4(d%_65+jT*4kU?J@xJzxzRekC
zf0(g$;a0IrCLj!?+sV&2t00s#{6-5Mkg>=&tQZE-(0G&=7e2tZaQfNWMTHobJ@b`~
zhf!G9JLS^ov&y3#e#U#QPe#0SX55)Jl8t6Goob_iUypWtD!kNN<V$>kUyO7hGKb1|
z6z$lE(&;bHlzOFAqd)ibd3bzp!U+$XhDY@}{qcjPQt)xvZclG}%H`rHga2h)D!h--
z3ig~K0`wio6u0WBok5gY>sHr4rAG*d!$s2&wPNhk%TIsooLQcT1?AqpoB6?-`I(<0
zKJueV*O_#m$@u=`;>6#alb>$TwT?IE=HEzVOO_VPrHnTPSD<sV_Ma<P$m-R)^;zy)
zG}#~2;V2ul?!k}{0z&{;H*_zv4~wp-H@6dgY!n0G2Int=I2fcLy<d<LI9Ew@SO|@+
z20TS2%i^R5f{$<O$Tp1AtZiTeI2<>j7sB^rpMerDL=^|S%4r_(Pt@7<RbbD!H9cEX
z;Er}rI4CO@3MEAl?F_w@ks{Gh+QA6SlJ#a*s}E!m?fCcO^TS!~FwU?wk$uKXdI|sV
zMa)4B+6C5mWR87zbMBz_qM;+bZ!==qW1J6cJ)KJ?uDPi9hja7uaQCs<dy)G1`v35u
z_BHjdUEG%Tb@}{{bN^iU6aZU?qk+C1(4&kt3V}zt1WL*QI)yDR?LD!KCeO~dcw&Cb
z01of}*!nHr6B}^Ua$sDmLVi=$J2)RWklmKXgiktq%Dx{fT^{fy&7Xap^LPYzb-w@u
zCakxo;7`(z^nCT&yi7o@)4#fY%h#UFNmW2jD=kTFH8{cKu71FGED1-`>3z7n^cU3#
z78NqUtOY5&c@y-c20b}hUlscv@8PY<_m?UBTmr{X5_n|~_D*p>(tTzV>S;DQ=oQ#i
z0lq1B8nq5w9q|p^M*I>^qV&)rFd@E<#gT!MY3qR1;Gr_`Tp#vPDuQtY^bd4~A>2#L
z+*{LP0`b#W0rz;XipvTE7^tu~FO670BRh386GX*M-H%K@us$+n9Yf07*={DfBt652
z@l<GbyWQ;`+ZQodj0_rm{QM5+6*O`P_YjO<v(q@NxpWWqW2)gQexQLcrw&wn)5}?!
zfQ{uC*wZGwPvvxp7r@DP%-<ejKY2eXZ6&noYx+oVXkdO;+sWI}$C@^DrNIcdapc_y
zWRv>kgiowHdo0cddaL&i+9n{zrE0^Q!~940kTe@m+-h35SPc2~V8^{89E!q0q_Jqo
z;qe{FIcfE9C+TWM+a1iX&202%A69k+hX%Z#gEmMaff;T_yO?;X-*@29AMpy=9+O>5
z;zAhhXjyk<@^YoC4C}&K4wufx#f9GukWt2N*-Az`?F~%4US(}izIMY`9kA!JM~I7C
z)SJaPl#6x<WN_~kHLPQ3g$6IF$)~Yp_+YmkZ6K5G`R}GrB2-yQ@714*BF1}&$7IEt
zT4U-l3FzR*qd#zTVjeA6c!;Qop_u(8)P<_MHYp-I#pEMW5S%lH*VY0*eaz0O?HJ!A
zzLn(jYw(L|;(3VQ-EArYY`CQXq~<HhUK6uZS#SY<1%6C)&0Cp6j1797nr0qK{I45@
zo$TO`d>81DXLPs8`;ac2K=nZQL-)aP_s#0O6a{iQ3i#D<=UQG5&Bt(i&%IwhIHlg2
z^hablyN8hgKUoLpKM$vk_;njKT(M$ZaP1+)q0Cc!EpCQ36^T`oX2ywQ=B*w0QQ(Xf
z7p_#*(HjDB#x2zd>GHf>vivs(@7m18zTiFp@Vl$vO2q?+RRGxXD_nsq9+E(@Zdaff
z=e7n6L9N|G%W>CEK};HWB$kdplWtnZBn^461Sik8?~~9|cw~P1vi-qGWx1Zh^Y_Us
zy_1uteEJ%s%LNL6n-kYM<2Oz5g%W<eeN%XlrTgFY$E$Y{`IX+t!$D)<$112sxnFN~
zuabuj84txeUG$Ic=11iNRyGzt65q1DXk(l|`GQYiwJ;eNTYs==!Rt!i=fQVFzq5HD
zy{+!Xe(LBnW>F91Hc=wqu#p;PAY~JlLoiVB!lyfTrkMJdzluX;-|b@m+a#YNoK{w0
z1SPrd(&{4g&m}T~8Xc?*rH#3|G`HyI)qvK8)6HuMUf(Fr^O^6*eUni(b<+?SCqC12
z;8pj<Ibq#ux^J#T2y=_Fp#Iv$Q3JA&3Z}cBy{{lgZ}1)(aEAM4)`H(X)r5yvur?lH
z&s66{+(dHt++=&x?2`%i(Luyr0F<{&`=Z8MVf5GB^wr?%CMZwZWp%LsMK&N*xodP_
zn&CLmZWvqCUNd1!v~z`x8p+Fzh25<N_<1dl?>NiYB`F?>gh=i1jkq{s_vtob^oXys
zTEYbf{mqi1^l|4@JJ@H34P4$pY4@NTVzf2T4MHfZsb@qzAi1YHCtv<en~k7|tLHcN
zpikm2_Ax@AuB;m2y|A<lgJ6N_!qN(qY()j*KtdcQYt>x<GD<3yX-DvV_H9p=_j6&N
z^v}EwK4Ak~68P)_6J7*5jtaatCce#USKg-ghU$X0>Z8CbUNl8N)E%A^_*N&~_w->0
zR<LVAlR<U7TX9^Zej0dM#{>S<juFS*+78YU>LCFjab-Smw@}*fqw{mAO3u!Iyq)|8
zuKxhyDBi{G9>+G<O$S2IFNL45tGLJ%VGptXU@IbyqJTWV->GZ_jsi~=?Y(|paTNDz
z863uK4IahhSk<p&@Gn+?q((}>a)?YLN9E`z>6}#Vmo*kRdbW*bjUR(QFU12!r-^1`
zpI_-9aJ7B=GQ(}*FR5-AC-7$coqqS0@Zjxazcll~_x~TDYuqWXku{`i(DWF8H)p$d
z8U72tBEA6jnCU(2MF;$__U-_LF7x`Am-p=W>z?_)1vIQmzZWFWl={7*Ll=a%u7`cg
zV6J-8+#CU`LDN@!1Cx+g&9|@5rz(_&sLmKV$oBoT`oOY3-80s?f(A;?L4a-8S?a`K
z%Yeyp$jBd3Z4++Z0$;H@{3CUpeuSySal&|Xc<qR*$+-9U&#b37XYM^C+R+8CaA?RH
z!25nu#}s?te8K}e@@e90M-{kGO38$QkM#jHil|+U;uDaXw9#9<f&K_)!1IOmsbSqC
zFo!jG?Cml@UGRL86Gc3faq*nNCkuCqOA81+pzBkm;sG=(2ogG%`07~a3PObn&MOGu
zWuC1UmtopvudRY=Rcdi<WyzgjFD=b4`SYL~!D6N_?2+@nSdS9EextBY+!Wn`KywAz
zk?x@doiLv67`2DKNgL^regs?>?VTIl0m05@(!WWYP1J~otJ?!;L;KJ-aSYTq6Fi0$
zFBu(;N$Z-JY44b|gZSNV)1#?V)jCEl8~hjGWT}FlaL!855xj?CAA~niI2!d`;D(1}
zs_-(F@Jj_&{@Mk+iV@DIo!=5%-%oyh=f3+#4y$*e2FXQ(LgiKi#`8f>7yLQ0h=KgV
z-{;xsk<Io-Ay*{Qg{nO$b`%N&qeI9?GF;?BXsvz*Pe2(!sP7xa{jnO3=5fh9H2EN|
zdCAi*`~z6pX7AGB=Q4broxXXP;A!TI-}8<2yWkR0{oKvh5<CSzco>>o|9r9f)`;IP
zD;tj|0i@SEy&Yo}BNTV-0IPa1+uoi%=xx+Ho4sZm>YJjh4UV@`ZNdvD;rVYRxDfr^
zhLwZES)X<g9G$@@9;hHM*|DOcj=kZ48}0Zk1+aDy^Vgg9mWu+TKN?_yZqsG18rt_^
z3|NdpzO?UYL^(?RFR%AS&z~KhZx(TAe(10LA>hZO6r+FuHSwM%KEqwwIAJNIw=6iL
zmmM!NXQa}DisYyrrLF4=#i2o<G=rTZ5amwyP;Pv*9d!6XBk_d=MZoOPkLODW)Pf73
zrRpgK{T`LU`p3)gjrudb5pc|~ZfSyiR}=-h4zzK8z&3)7AJ)Mtv+sa`%cPUf13m@Y
zR$<?Wn=d+`P8eU|kJKkP=mn#re>s=Oz)2klVhLfGTnk5a4AvqjL+N6yQ^mNviwG&>
zF<}-fEAWb-ii;q_Bal4;ym)vR#(G(_3M<Rr&R}lQ>GjpQC6FkhNa*9)JF->*8E!;6
z-96K5!%1{Xi9Y$hLeKb<*FIgn+uLt+aQicEpY|U>d$Rr>=ql(4LS8BP&)e78Z_agA
z_7JyXca|5)(S10)K6d}@nI;!{l<0S!4?NNme>v`~EQFz*5i*;SvK$k}_hLNS4=HCm
z2hTLm__)Swr^7yCZ}LW|I@qv^uJnq2(FzgYYs#<=3v-oKS1771@mgqiMI=4+(K0|b
z;KBWgu&81caYJN1pV;B`AD0`3+k4ey$Nk~I{_p&7_1=&-j{<Hpdy`>3q_ff0<2rbm
z%g#&(+^Z(J!_3T|{E78@S*)TH=m6uunLXuoKZgh6%8jwhpRh>8D}bOPK5D}__gOE5
z4)PF6I&AX-Lmw<T0{v=VA`U{yWj|+Q+Rp(_3jLayKleWYPH46Tikv`#AF&h9tBL#G
z?B#Ec#_NT>+jIF<F$Dc3ytMdfAw&ElZCRE0?I6-RcPzupL~j3;N&#BY4xz<Ilx)JX
zGF;2s<H|$FCh=LLk$}l<=tUdD32M*Hl+10l%mNg=B~E7!zwlho7lf&YX5r#z#`~>V
zTk{hRET!;twXn1Rj;G}L73k#JdJYCg7(!3c=teMNC13#AX5=Gv5a|tTdirAc9DL{B
zd`obT(%1jrKk}Dx4nnD9*Cp-Qekk~yCBEsabMQQ&_#E(CA-9~l!E=zohK`cMYM?gs
zH@mMI+r|C4-@P{Kr%z?$_&USwl(edik3+Yx5WOJMkxi25a^r{qjqq&qW3G=ZsC4m{
zYJ1!6j}M!GPCg2!)El*@Z~y?aalX0%#~KJ+Dg?Q?i$Gs)Z+>O-7}`^;fq@5JY{0hH
zi{u+L(%y}FZxaekR>jiBqiM8Skix?eNwlLzqEwl8p>+w>6E^s?*KLId0}g0QIw*W%
zImA$nc7_U_G|)<g(TJ@ZaziK|em`tIqaDfkqEMYknJ$fO<2whvO?MZ-=i(9|(M$XV
z8!mgl6HkvYpLQ&f9boiK9c%!kZMg9EO0O&WM)U_>sl6_&H|kce+t`E$e^0~fYh&9c
znjT;q+xF!i3~TD09{u6#$9{v?(R9T(bj24Csm*3h23<(v+_IYBhBJsQ?3O-(_loth
z3mr;Ybt#}R#SP(a!PN>=Uuv`tAO`V1GRGAqPCd`f{Ri0A?wS1sP%j;u^<MSPXXyd$
zp2ML#!tZW&>a=j*nLU84*v^e%{1ABNh0Y7u#n+m%_7ODB_Fw(R&A?gC54CqM^H2W%
z@BCw&AMla_>e%Vx!6Z2otv9b-n_C>$sppg#zaA=hw(I)?=fD6F@w1M;l=kbA(nghb
zpF;BAy_9t2q$%b4>qtc?!xgamPO(ph>B4)3zu))Y{`z+H9?ej36b5H6=!g+}apS9B
zb4`~ljuGexkg4U43#sJv$W(Mhxs_LWpMkUQe~<qyX!!mQ*6-C#Js{S*N>v#J0qH_w
z)+OC&`uE~2=lc67=Fw{5O~l<bMy~`e&~&<mC#+!FP)Rdt1sYJp`ukZ6v?m8I*kv|Z
z8xNtsANJ=`Lw5bqM~+we)bCI6<|_7$*(=#=*;}#zu*#3-tnO#n4(aCM@t1%V=aS>c
zG)qR`_Mv}a0d8BE&sXQy#QoanKSvLKZViTYf+XIX-5WIS&C6!0cclWq(6-))uS3wP
zASkBbvI6xY=Ps|f_7U#QOSn|O=)L(~<~M2gAAcwCBm9m@v4*QFJ`x65h8OJ@gMD4>
zbGak-gOv#qO*=4>qw<dPgU1p7NG%S<=23CHIg=_&O2}E(PUtjvXBRPV{(PbxHefPE
zq(Glj1u5QjZi9b^j!Nw!lh;!_m{G*l%BoX|FRDMIpG9dlT_C!B;zpV9puer(-=qIR
z{X!lY<&g*8<|cAS>fA(O-iqk4GT}h<l9FEEvda$<%*1!oD)>>_kd;+1q>NVut1@F&
zEv{5nsTv6ISz1$P(CMY+C2M|ZZE4xvy))^WfDr0%i;u#4G2RlLay!X!X5Rndzp;J~
z#!m3&4c&~i4~4fU(XHp;-v-y<TDnJX2#T!}AYii`x?}*)hkJg>hH(|It=wVY6`<Rk
zCyq5Qi}(24*{G+W>x!AXK&i9PIhx;lnVs!de&`#3n{BWL$gfI%yfIxLiGDvku<nI^
z(jb^lt@M3k_@}I4RCWv=HrwdrtNTs{$7hFwo5|kogCD4FR0RhIa2VNc#yS3c{Gt2K
zlN+OaQ<Y7;?@Yo+_uzblt6Xc%LN%drC}72aYi>a5W9PlOS%(u7;Z^+O`uPGQL=-j`
zC`HaO4;t1(yGs+slm(1MJHkXLw<##<S>AxL2Q@mzO+sBys(GcOzc~FxT4if>nUeh<
z{M3)%`juz@^Y@;a@8;*hy~l-}_51Jq8t~NtRv8Rs+$)^kB%Ds<&(J~Flll46o*R;D
zg9V@Dl)_G6#Xd_~m2e)_+jc|V&Cc;Y`bEgts=1r2Ek@Zgy|mqWqATgomDQfYuTINs
zIa(N!F{YVlKjYZ!WK3BHV|*guwVmGJY=mAXoATL-7Ch_NH9d}YoN%S<pO{v@xnJ9a
z+aEB8)mg>Fw38d^o`-PBJv;sV;X;9b9dNCw%jikQyIV4;B!b+{yPY!Q-H{;liJE>E
z%5+}xUpVvb{1<?y15Xk&6>|GYcop~(_b%XMv-i*VQYt$qJl*dHp2qhS0(<+a1Sj&#
zgt7O{?ZtsXrNgHG(aDbYYE9tZfJ>84V8cB{VPrZZ8N<f#2o{wj5W_(d?fAQta@q01
zk8U0(#{hJ#-B7pS%?|!pL1&=Cb`NGI>T<NhUU&#_Ch-{wV3_8M){i2m4I5dyVUBjx
zINovB%&LNPQ6FL&?Kyjbj2_KKHri>~#`WUt`)-rK2XxwPqrof?T!aMpq|gIQAFE>+
zUb(0U#XyD{jQ85bP<P<4jxDAB@ZAR0bkz#1c7Q@yCi@+qIi-s>vTSN6y~4($DSgU%
z+G^;-tfo^QcFC+ow{$$#Q#&Yjq{&j`iX)x5Kzn+aE-3n@&1H<snynwWj1&mgR}Lu;
zv%r+*q8M2!D(IA${^Ai^@;>H!+PenldFl>F8vZ2EsiF)H+HGWN1BZYf#ki^MoIRdJ
zfMVriTs}R(?0St~VW4A(7B%Vcw-I}x3;qRUuO_;rhd9kZw1fA0bQ<rD=<xot`o8uP
zt`&(`Du#kme9%6EbexL=NHp087PVU@u{^}Frp|l`j;rIHXKjD~)OdAz415kX3;!0Q
z=LPu>WWiy$6|nHc)UALGVcdu1#jvLmNr@^;!C(L%LY2WRSVq~DbY}THN%YkFhd=YU
zI8UBIQf&M?(o_A3=gAAnG1H8SuG;Js_(xcjH@sxK$78@bVE_OuJSS?S27iq3n5Z<&
z1PQe4agJBvK9a?FSD<9sy3#xq3K-nnmCPK?!Z#zE0+?m+Ox8p=p`n_zUQ|D~j(Kgc
zO-m!-NY@bq!ml3D&NlF=kAkj6Q`K#CP+QhI3nG()^2}_+IY{kjMAR%RYURnSB`_Er
zOR2H;Cg&^KiBGgU+MKFk;hUn}&<N+F9VmiFc~c(BqaEuh)+=>_YA#Wio<vPEfvr#>
zJT=n=T7c8iXvh20eOe6c0JfS%4yGKA9@!KbKvZ$iIfzWc^YP_p$9vI><SQ1)q-$|4
zw|j?JjhMw87@|LN<;u?hxDeyHAgSq<lsymt>>;X$k@R~QS^-f-ydI&=Sb2yJ1*w$Q
zV!)InvZ>(n*0(p)sT5_=9|C?{1GakrG&YdV4t1u;#c6iXfo&N+fXdNM_EPDv!98QB
zO?;zhht23N9qrh+1K{DEmETb}Jgvs)hLjJyzsSOwsh&hTP{#2dGAs`adNI?Ob~98%
zNW!$s4{KW~eGEsgw5<TjOPJ*2m5}_I98A!$)bDqvW2-AGP<e!U>?!(P!q=H!>-XRL
z8t=cI_7P3#PT<!W-T%a8D>>cIvQyLj<?}#?6V@Q?ZGAb2-*-SRB)X^llt9)1OW0B^
z?k5Ldn44(N3XqTRl5n-<!dTGZW>A!tDh0U&x5d$LQX1!ZcDaA!?yGdB<w4o$OsnFe
z!iCCec+JcFYB6Lx7Ldl=s|4her?UjV_Y<FSX6C<xUM7rG-Gxi=8PVhzezWOQRFl3r
z0D<48ouZdfNa*~>NRI9^do9!ZEQzkmdK@-B)7NZ^^ne#4+-U9V1K26HjPr72j6T3S
z?ns3`ySwn-fF6${SWp|lYA)?a83DfMY(H%GnouDOJgM9B4i1ctp9~Dzj+{_7Hb<Nn
zxEf^1kf{`Y^)T7?N}6`ta>X)~pT~wWj2r#o>C;Zb@MJV4^%#DpTc=sG*?`~xIjYTi
z=Xf92)Z%t!gLvkxeZ1*-1Bdhb*Y5?tLH?+wHsd4lUa;(H?hq0B1;N=#m1WzqdI|l(
zy<jawkPsqD7)hhaMY~4eia^!*(fu$w6yL9*=Xn32={Xhv;`)b~lB3-d(A1cH`$G2v
z=sC7Kuk;*87pGkE;&Pu@-@7-2ckdPJdo_<6U{pn+$5F<Q)5?trr-Y9;+It%~*b(%k
z)urPD^2*3m3Qry7=Z+=@<$C3bc$L=-oDCk(#J$J2N8kZCIt5O_5~9|N@AFr1@cRO(
zFAfLVr+|acR|N++4Zis9KiI4SKS2JoX>6Gc-`{G&;r2f6^0=~5wS8KA@cS|gFaJl*
zzK-`lAM5zHZzE3kJ@AonF#;K;;*<5+DJ^=kwlv*T_6H2|!j`?h$xSzETio~jb&g3F
z*5JV3RezKW&voe80qI)S0pDe--b`#j&sr<}KHmsq%}oS^5j#L{A)Q{rNn?XGnm2}y
zD`T`nGB%2xe2r{0UsNzs814}?fx37`JK&0ErCspOGxa=(l;FskUDP{WNDB5LN^KlA
zf*wxxKE<PKfQP-Ndn?oXmW??>E<BxqcAjpXUiw<x7n*w9x8_$W@Cz+@CQ0TM_a_3i
ze^bO;nFr;|${aO7q_VQ$RP{=wFdikPJ=OfB`>ZDM-WO;EG&{@EfBVZ%s`nVM7Y8PL
z$8)j@`es6W0_b5w|5{xB6klvW$CnxkoxFQe-rT*Wytqes)H$)=*q7)R`{^sseF=yx
z{6j&jihE?M0X`=C&kSG~5sRJ6zK8pnSHkvcv%RRtycPrh<fTvLBprNl?Y>5n&n#Kg
zlD~9(&*~gUJMeSm>_~n`y|FJwYb-|mD0(PSlgNV+JI(#ZXW(M}DdKhezPM{)Q)rhk
zKer6uHnu;IbWK%ml~7uRtC66y{k};4&KkXnoIFiwKWKm5&-_r${KKDEzdyv?dCol|
z_&cGOU;t(O9V;`YPNW&9K&tFnv4t!kdo|!Zbzj>N`|<6t#4X)C%J&+3QGB1a6d2mu
z+8{npePqQbX>SwiWUq^Ocm>}_AgdCWhBPTVw|&JaF^f{AR8_J7#5FS4f9({%Dl2j}
znRW_4FD{GDtd#RE`7<6@u`eMs)+>Iv;^n4GV;M04A?~@04#Ag&q?buBt8}DtZ2YB(
zyj+RX__gAWa^-Kb{1;6)yHKImSTRkhT^{QZPGeUVoolnQ<htZ5;URV<f-*sBU_9By
z`9*MQ1@+#}fJNM>STZE%J)+6t0>YbEMR0!n^D7JUU>doLgvrb3`<eU!RJ!l{+WP@;
zSKBxgEM%PELbYDq2Pe<x$KuJE?-BR!7@vsH@e4osjrIFY805Q@-r+#>&Rqrzpn6F6
zDg-!V;u)B&TPA-(JcBX*g<_u+?Y(|p@eFYD*gKB)9VJ6cDpNVwqkJ)4B4EF-r{u94
z^3BH1cDTZZhqDK9SD+~l!X<tzpx_U#6XWDgz?aZqF}5}ccysx(5}t)u=Y+p}dcogb
zoi{WG(qxTj&Q7M2hg70Z?j}2#-QWDwm#g>pps$xXwg-uTCP)3tgO0*Y7&ONS{Hko)
z_3cBtt?vnF@TCyko;;3AQN#UCe{IBW%lt?V#r2||tsk<~vvmmxl5i>M+EAyVTN0dT
zqVGQ_^laZh_?`9pxUfS!m+p0C`FF^@&&dB0zht}Fdm8x3C`NcNY0&hA$NYv;?rwx#
zf*TJ#h_q0VGGOFKJFW?&;-a?Ernt>z<&m*w+AV&!kl(8m%6|v#cTMAUtD&IB@p1Oh
zi}WJ;X0KSa_o6>)R8Q>np|3`feY&XiUJv?E9PW^w7gUB~3ZStf+a>m*?JK6&nPF?n
z>_aR5*wfLU_j<KvjWzfx|JHVzJ#*=zUXcCduPE=D{FcUpXeVB8Bn@O$X$`$>-LMD4
zer+^A1VHovqTFcBUDkB!&-l`~`^`&^9h{#deVO^Wxj86Aie$!amZ9Xd_!ZNT_OVdx
z{fE~`p3JiJD?j>=*6)K&7o@DyEqJFtDBu4WgXC^?TE1tR{eBxpmq%zgmAp!D26BEK
zot(P;I+Ijg#hzo*MATfCQ_Np^y>IJ%mcH{dt?GToAE)HP8QyWekH{@dKZ>*{I+MrS
zdNPSV#jqyp#pdmk)nHU&e=sEML{AwX{dD8KQ~;I34PE>>AB#z6UNPynZX_!~S1IV<
zRB+_*<MQzP4~?IDzauI5ey6d=c*EPU|A1iO2%3ydiNvw=_|)X}KO-G*sTO&P!RBy4
zx-Xa;p!-}Mo^&5U!WmXmwCPpK_~Tx}AL~2+JI;%o+X1|E(z?HP#lo|SOY^yi<2sms
za@}09&;aq8du7RL^1O*E^dSY_|5$m1KK~rJ8y|NSaU&YwmKXbhbSCU(3%#%yC9xl_
zDD|eX0gc%s&S&EL*v%Gd8+B^@o_fBgUzwM%X2FM_?7xK<*m=9|GU*<@nRKXTGVmBL
zIGo~>=b{A1j}yP<PyPH4{7Cga{L$4t<}DFe!0~hBQ;aSAM$)(R4tUuJJx2PM_>k>U
z9>f^j<KkyOMnoRrP+4`uPqeq|;2Gm2e1g<%QZA|*sqX~PLolr0ZC~biA!Tql4*Tke
zUskR#IbVXCCrR&PW@hoH*Y8ux@FISp#gdj^AANdm9)6*{Y{}BX9OZryj{1P3%<ptb
zQuF#OoG6p22G&V;Hme8Q>si{1qDlBmMIapr4iAPZ1MUG=W-5)doS<a&2YqB^o`}DO
z?T*Z$9_mv)E##7YewXiUz~^Ri1ub)Lh)cqt1U$bE-9+1Mvfb_a9O8={9)Gx>9@RGN
z3T>%SH(*baYgWrp6+U-(jZ$j`@+p1P?zpj3nPcnp{&4GP(6D$K7b%-!0C+93c4J2H
zse{`7uH;MmFr#4xjnL2N73I|*%sk7@;}L=-W>dsBV07tTJEp;BWyp9b^V@xw<b_^u
z`~_T*|LN-Vlnl9xAZp!9C!n%Q&t5UFm}iQV%!?P?2^rgT6_r&4DGwcCPb2@%=v_?d
z{U=rF_udcSDQWk{Ig#zNbBO=Y=YD&o-+MAhlkPp`uZ+)A9M_qdPyHnDIW1|D8*I`6
zXg`ySlSni?Ne)Q(Cd}kDDjRqH54Tgo+Qu&>_bT^;orWg9CwXvz*VsqmSsCi@n?H;#
zT8Fv72JxmLsWvG(JuQblFxo$YSz(4}N!f-$e*0+`L0rY-gW=;YUozC$?KVuy1h!Ng
zZ3TxltE$u=^=7|8k8bQ2kRF0j*jZs|v)TZj>$K`J%Q%1|ZaQye_2hq`3A)*Y?fkeM
zMMy#2#h8t-lE~9oExkT#uT8VR)0|#}1m#Bh1>T%~Q00B_1;I5+|3$_#zJGLlK;zU9
z{lq?aoE35_08c~Ps(Nif2si0z^_O))!^)ZtmRML45IMn|y(DLy5y(BN2V9|rw{PjX
z=ZY^<`_kp{?a!&)($sRP8UYo_A^OS4<Wad*c|4{0)4tn8oP+33l6un7L$_f-36WJ%
z4wpzNgDc=uWNb%4pRAkY4W{WODk<hz+Zmj=!pxY-He3$y$rdy<vq#Y%D5Rm(x9Jwx
z`&Nf<)b}<z$5Jt4ZX27t-f>R?Fgfgk+CbN$9ovRG?!}caAdS6j<-2Sq`?>@Wgpk<)
zk!Z*1CR~pr95&m6=L!aARuYEZX@2(V@Q+jU7)FcHjuW9zK_eYM^<IEb#Dw#U9yA&)
zLsMvMQM42NGn^Kciz!a;tH_DIqat>7v;(ZUZ@%r3;zS0b&9Y8q`r~7vPS{|pMzo{e
zOPNT;rS9c>&ib-nYhrwyIKTmvU!xrv)q!Gk6p3JJwawbT%%*{E(LpqC()jlpTiycB
zkFD6z(T@6z2jQHf0~_OFK{|DR70&dFIYY$ky#}n$Ij7Oi6@Xe=R)o=hnlBP`4{1-X
zHK49<v3@Xt>p|7I42Rub(N=FC$5$xxc6$KCl*3sPV8tYR6#c=39n`l2eh(NPLPJFg
z2Z-6EW0v5YNt3G;r5<Wji*~ruX|QOL*|gsTd5AS(o7r-9cv-qx$QQYSDvVXKOnYzN
z&s*i6))b0PX^7Vv?OD#*C-7$U2LQ82etl}s{qE?MRNBT0s78A~UpNFZk9LOk9Rlz8
z>hwC@41*Lo%^l+I0#a=DgD>Iit>8<P(C0^<tv}BX@JeOP?E`t0STGe&UL_*#_-e$@
z=?^4Ls~`Zgju{%HyT4NBos;L}LFnKz9saA_Q`N~MEbbGmd;cBdpWc543@K_&$F9$x
z^eN@L+GC5RIAio@jj|EC^5pNos(~3e(>;N({-A1d53S~BescZ6XMq-4ZLkfn!SMeq
z@Y@!aGVX)H=gV#PxYDoW9_I>=XIfYG<UzHNXMFe<zp?%R-UM;1*5!QN))Td0mq~BI
zdSDm8Gp-})N~lb17+%L0oEL^TGxm8u{c(ju5uCF80pnRt)yL`g&4GK$i+d0GMbwK}
zHUz!|HW7_iPJu6n??Vr=_$FUm{?_UP&=-3~;cy$LeLhjoiT5Jfuh{jZigQ=<mzCi<
zbnDuhE9y--xw?-K@x(cfcmYON!P5@$QDhNk2mIGWDGg<IY8&vd;ODqE1o8yMQHtDd
z4_cnqG?GDoIpLr3RLfT;`a`M%lqy0$r8>xR>XLe>=Mxo`<$H>s#ksI{;Mgi_CUV#t
zr&!l1XZGV=ZD)-CgQfYEc_&E-?ye}mgm^A<M!YcTU^noH&@5UY?Q-&P%ljeuL7RE-
zogV^EKI@Iq6Y7`sgs?BkC#%kj4V&wYsBEMkwofvCTZvCrZof1R?vH(T&EOIGqef(j
ze$@jnFiw3o2m%%N^{XFe;G2WG;j6%}(@#qYZf+EDRA;~O>+28dIn)S`qUkaA5n=Bn
z!h9HRDETk<=f&WrKiEfqgwL%(!cVid(N27k@aS9LcD5v6$YCmF8*yaEbAedEVewk3
zCi@|x%Q~Fg>FTzR%c+@5U3NGu{Jz)(_5%)0&-pjLH}X99ak=x*_EeIK$fr<(HzCm4
z98{kJ5As|=BvfL^A^u<)o{GG~v+F-SxN%eRpa*H)O9CMR6Mn%jE#s>fqZ|8u0Ld$P
zP_ZbJQfI#p+`Fsw!>Z3-`}3RC2XO4Vhwzgj;*a~?M0ua^)*ClQ^g`xUHV$tAG+$Vr
zU+90dz#D~<NLilm6GglRPvo_I-%fpFNe4Lx-8~A0h>Lu<ZpxGL;Gan!APU$H+vdF3
z;TmtEz|T_cgGnoOIm-J#|8x9(cy|B(Zg2SDp2;f#m#*V+weY`Scn9k;1W)H6kG>p>
z^#Y?LzR{M#{=(q{&k4pqM6x)NV8i<2_BOHZkIY~_TX(44lDky1IC0vKuh#tq*6>AM
zIgfK@p7;^x%#*+H?O*0O(||NAxb=yCcswd^l^Ati=72d}3_H8Iada_<_d;^dO{j1s
zxdWA-ctC7H0N@y(0z%4#M7ruE$z()0C#>gwI%t!iCo#-If`^*f$m8gEkwv*c@0=aJ
zZYMfs<|~NL3;2S(+PE+}mvwxPi97g0{s_~|lg`-d0Vip_@lObrR2W<&EP3ioP!*{l
zs0k~uTPW<FoT^A)x}1r#!$lDv=>2z}2=5#;;7{7T*-ydOJUe`7^>tif4fW{)29zZZ
zxSY#7GU~Ih_l+mq?mTC{^6h`Cg>&Ypu~UP(tV(}h)_e2#KyfQHxbOzw+NnW>&4YiT
zFC!zroCRlJ?>CcO!_2q-r=P4oK#&sX<fRKNsnzG+590nhV&{kZ>lnVV@ci(7qr|a&
zu0FcoU;Cg7#@}DJ(S3rdg9FbO1iYvv{#?>2hn`H5Fi@Y-{K=7IsdY9XoE7!Lq-z|)
zj~8`#)PMXFs_BTJ1RWU<3Iz47LX1II`-r%}7UiE>DTPl0Ld*3|Hk;7Na%u@5v=qmo
zW$=4+%Hz7sCL^EsM`$q~q>DBRf^&!g^V@hGN4u6-`Xb0>_k5U1tE*4p4-B>Kb9=R;
zconAKDT%7o%V&#ttu(H77X|fgd3)NgZ^cU}Wc&-hgCsm)hDHl(?;ZMa9^-;Mv)MB>
zC5+=RFn_n97&dt2u<_KjMg_UM1YPSh<LxAR^gs{tC#l34tU2Jb6Q5wfp4r$8(VtNC
zry-+e&;|k(Cythbf?g3lc>2U421CpcbdmN`e^j*#l`DS>$)Y)A>YbvA<JQ5hvy}J&
zJU!Tr{&=}&O%J$ctOZg#bqSGv+IYy~!#cofOB1T)4SFdA#xEHfJr{je&cTB>3%UNx
z|Mu6{i3gz)M=RCiCYQoiC&_V7<mbueAir+`A3}Cpo?orw+3_LxbK~(L@ZUB-f=ka)
zNdFFf=pROjkIV8c`*V2ZGsK(wfZTvH0ncU)s(21xKr6&r2^%F~+XE8hr}T#0=Mxo0
zJN#@aRJV|Wf}PhktYn$kP~69<Jler<SWIbe!gMMr){38^lYQ?a6ak?T8~ES2k&qi7
z!lk~KUP5`^_Ic@pKe(IXP<-&CuRX3lKrCWh_QNf1+Bej58tcFFh3*OPYhQEy&Y(|i
zgYn#l(d}W<dvLFtD)ZA?>HW5FA>gRJzk4j*&b?!3#4=J50f_CBWf5@aMJa?9pTBF+
ztF8c+Jp?y9=5a@v<XqtNigv8!q^yvJkv^(Nel%e&(+BrCu^Bz1y`n;X!8W?)-a<O@
zv}o@bO#z=Z2)_jU4?D9<svmTAdig<S&-o9a*9Uxv=&(tl52&2zweX8sw*PUP%{X^u
z6EsFo6L2!zPKin$Z~r5G(EY}~BIWKkp7pNyclxp3+7}zmWbX*2A3@MoyNQ6igm@@H
zgVL40_|saa2OR6s!LIDp_vold+X6N=svYnQy>q9!Fd^{B#Y*T1=O#<KQI0<_izLfL
zJD5ovEAbBWg8Xe-_b^E!98oZtglP|FUd2dT#Ph)GdVC1V&<Ad4;nMtD$ivUc-si#X
z2g0!63(U+s`acEtybtm4)qP6<`y6?K-4m<xqjV9=&P*3QNF-W!_Dc=X$J#%$^&_CY
zt@_q1$cfE^PR|uJu@ClTmIm-6Fxh?^^pQ=lE703F2x9$uYcK7afOc$%L{p%~K1>Ai
zJadkr{gL120^SMz@rqq;vI58EMGbPzvps|ttsTS(<3hx7ffuq)G++>ctagvgkUz$8
z-ahIL`ptnyK+g3+=H?fn{2@WyJk#^04o5waHFNqpzZ&bc1~=$J;j{}_wPa-tay(hA
zEyAIWCp<zOy~#=?iN0j<iD-xJW&Jyg^YQk4#Z*w>dDdQ9TAYWgX;~I9xoV9wsdg}1
zYxV~9^cHOhNL1X}*W4n@gaJn<Ry%p7AM(Q6rmy}W13x<I35g+&G#n)-?(c`A{+`}o
z*~tDL?a!-{F*87VMN19*GZ`2%APBl57Jf{dr6Pv|eg#h+zf<7(Prd%fK*tx@=PIMy
zJ3yQ_JZO-^@KvIChWUb{agEdh^q%6X-hCa;4L6(LGrLhgsC~96$v0hEG+GE4hcMF}
zQD(&JS4H*%6JvbVO204MuM*SzG_x;yI@A+;<G_xJ1Cd(?&v;bmTtP$D4&)U+VS#<2
zF2kf1+tKh$yqU{Mr<7nZWhdh40yhUD9>$}bcecVwUL3)vz>U5!(w8PCihaQ<4<05z
zw=-Y)5!ih+5I)w~2~*KOFLb}1*tyI8;OzIfhj$V^`{weu0MB)rW;>wb;8zR^f7!$S
zw`oj%^XA&zDHno#3E18?Lyj=eHQx!p=z)`ckqxS@)9uycIur7ZQ-1!!RnN~yD)Z85
z3wAz|6*p>NlEw_D#;>LQe>?HFW@i2g@BMcB3`0H~U6|bG-1|iY=KNsz{dfVr^zrxp
zw626Np3qL^_TeAf6g6>A0bf>^fE|jmaA8&k)?&CE_<b8bI9!%uqr+9h&qLwUP96H@
zy3H`yc*Lj1&74_II~oOW>wK%V_v*ZTr=DHT#QE`8KVRtQeDLJ!fIkRzp#BvX@G0rB
zh<cRypLv62BkQDfKLtHD{{B4}OuBzNI2b+zpT^;=-#%^@<02&Or-6n>aVo%#*HL9L
z7eW7qPVwagyEN)tpIB3z-+Ncr5XwvZ7(});2a1bu`!35X_<pr`0p1jdDc*KR;3R!1
zB}#bH<Ds(jtAG6W2)CggFGbX;;daCx3~-CsE9tYI_<e-i%{CBiz-?{A<OucVu`3J+
zaKWBTqAS6&1`kNy^J_)S2HMdG@WjshE?kBl0WqKY+$zt=g~)pxgI_(nUc68AgFDGS
z@soe&?SHTOpozP!gfxl%!^DlzcN8D<);0IHkl|64jlkoC+3!EA?`?G&Nl#@$wM$o=
z({uDo9Paqwmw3@I6#Wvr*NwG>xh&3_xMXXKv~eACo{i3A2~XWge(h(!^MCv^)d%e+
zocbWT*Q}KT6wpM!pUMllj@fNX|0($=?$1BDW}yf@*r2ON!6|W+;{uV=azW)LuNHL8
z@XBBya`x><bCvLql~uKxsu2|u{27=}_NQGQhs}@4k2ZAf8hvQ}fIV5e8O4e?iv00x
zDnaZ~XLEDfn87n)t{SM$?mqk?`vQbOcyv83Wywy=Z^Rd@==V2=>=joQVH_g;eXyj#
zYF3i`XF|H)b^=~#tc@aYi2Y<=nDdi;Vct*ng$11KeymJ!kMw;K_Kf$9KbYWW_S#j#
zLbnZn7x3@3Iya0zQ@z+PulOM63Fv3%gWNa1KUewZ{zLG4;i4vUYaM)$=fzz$zt$3p
zWcOS8x*kI>5>9olLJx#W7pL=Ujd%~{c6}Cl8#O|jPbTjX^pE6TJ}3|4Ht0g%5`tst
z3U;BgSA%fdK>s`!;U#WsVtgpWLto4B&{AauoD}&dfhYpLu!MY=Trm{Gq^<8@z`%%D
z02a9nZFO#Gk+B5~^PD_qrSth=(z|&7hkkOS`k+(WN?|$)2X;PBiaWD%^7n>n=w8~x
z7X+?&<Tm^q(;)=5wAt54hTgio8K>J6Z)gRynn%@KU0IcLk<<8DEw6jBN0|BWJ@DP(
za8R>P!FsXoqkcrrcFt)1`Kf^CaMEB5hrAQ*S8!0keVKmuxC|iLA&U{dApP#K!880_
zv@kJMf{VM?`T8tN|JW~m8u*|N_eJoAMW<@`0Ur#VGh~Y5D1aYRdyezsb90N;x4=Wd
zmd?&CD@$~Abcb+2yZh^%-i`%gfYNI1fC^Ew?d{ov9(4aVdrdf0vJV)ab}QA^>uBux
zZ>94rKKtsg&4BAO{VebQx=I8eYpt@ngvgdb2TU<v3650v!NbH?{ot!V`UG%fQlNmJ
zN%Ef;^UIOCNBqJNf3BZ87=So&O`)wi-0+6h5PHLM6A*dVBm_z=UGBu$>EDO9g%AK0
zU$6c0HrF2>XTgQz5@dK}A{>YxbQ5l<OL$~nW#jP(kU`Pj>r=(yeFVgTn2U7H&M+Mg
z@9;;2{&D~g286467Zx$ZH~iVP96*#bkl|e!CNmlzyPPsQ*;3A!kZsyq>4(qb;|Ug_
zZK;9))I6_-@&dLM?SKgyGn^VrC2Y+P*lZPC{wdegg&mhwgi=3@yEqP}j%A{ip1hl$
zK()ImTLH6oLfz=k{xSHo>5YyzcG&3b6rSXYoI0m$t6>uw?P!OlCowHU1*26kvgz;P
zFZD*J986OccpGq9Szt(x#KCZ-HOgyUlTH5UeAsKaVsNfbo`r<p@jdEoB);Cv%pd(J
z(2wm+Sd!ME71Vk*WZA=Ag!c8;iF$4~=EQCU-JpBNV1Rf$sSNRWnAXyk`>RR7M>6}N
z=ju6S^{Bjb8vi}DZI~bGd-%uoRS}Yvx}bidcrJS;8#Re|YlkrHllcsHSF!KlyO#5(
z!p<>pWua-hRo~Bq9SB*zpM7f!I~w1M{zMyFJ$ROe(iYoeh}WVu^C2JhI#;CnT0D(*
zp2DbyI$vs_Sw|GCqRt*)&a&{k>tAZk)-|{sFSXkHX=HFQ3Dd;%ZCEJ6QGS*M47J*D
zrO#etk}`a<k!pb;WsF<u<+55A7m}h0xW*3iCU_LDZNUG%Wbj{da2f!E=*<g`ABYvS
zMU3C@tBK!G-Zzu;#eQd<2M-JV#Sj1U|C{?glailee~;*EU{8<N*T4vVU-t7x4M5>=
zFF#rieHve)5z}z}AWeBYY$ng+rF!CW@!vW>dE#4%KlQ~w`-|jHVd5FoK-Lk0J52Bx
zdE$BSDex)51-_t9243<W6p)~&0)$Jo+LH%+_WQ%*H$^uP3vGS=ySVNM!+`rkW6S&y
zU}188_XIw~^^yC-VwGj%?+<{ZY55S3cN;jYAe&K#wxG|&$><L{(4vVLrW^oHu{>_F
z?h#K9>Kk#+x_A%qJ$3`SU_kE!bwrd3oMN}Bu!qr3nw@yZ+enRiey9mJoUtpg>7#K3
z8};pWN2=7gh#WQ`O*mqU;={ma$jH3$olEfZc&WdBet7Mn`H>@hfAwF2ALmZ5nFoBg
z^Lw&C-g%kBWc)Syc7_n3ycXIfXzcBXXjY<%%YIQy?;F3icSwCjJ(Bnb;nBJ+*I4{g
zyF+D~(tDRRo9okP%CdWz{NlT*5qbGbxTB4%*W`&Kq|D54zq8JRchb2C&viev{@}Pn
zbJEk|$G67dN0yEBi{CvvpSFJ@pLQSPAl~$OApF&u(Du^z@ec<`grq`^mbp4i@!T$Z
zyVluDcn$7Y_G?lgqmL858tvev{rWRpCA>Z8*IJXppU6A|hj7cVr*fLw;$gI-;&L@3
z4D7W!PYFm+(V7)wfZG<Rh+~a*;BYHF);exAhVu;s71QT!q3hP5;+h_J8p*!KL4Y+o
zjqTcY+iZGicyAxT*~7tU65-k{#*ffL>`u#eIpU+LzZZUA7jdvh`6%<)u=A$&LH&@5
zNnRJ`77-2AR7D_iiS=7B)4+u#3UDR+fFcRh<|Woe5>_>OXA$8rB+_3*paAh`78jOa
zi5Tr*-4+*?-Pmzqt>RJR!Los!qltcz3~}-D9O|lcZDC=N=8my`lkc|$9w8=q`+CA7
z>yN;v<vD>!Ut$wph1U8u?(@oUQ{soC1aIYh)?xdNY5Dgt-gDyD5>LE$RY3iob}icn
z4(VS(*fnj>_j>lXv(LRjuRWR~B*@y>a(wgZkIg_XZ(OJ>!%w>bGLrLdoD0qZgT7-j
z$y(HG<J~0(($y7M-;Oy)Mkly{M?QO4E$qSG|AF6Je+c;^a5#OP4#D5VcrRza_igmx
zgD2qA31pQydu{`)wcw0JTDUqghNuxYuHMet;Y=YAYy;}4#^!5*Z^n#Ohx;$c-|I&r
zxA$wu&AP`TfP4axC!;@T1k6025&?FRwT2L+wasSjp=Z=TK2bZEXV&mY36$^Zt35W`
zVLy*OdExPY863}iZ+%!za?kZY0Y8rqp^?51$2etv#jPei<3RL;W0``cY4K*c!>{sV
zXCTL4FuB0l>FS$2JH>)zse1`WvJ&U!3h);XhOw;<6_)VUJ89j&_%r`x3+w)@2d4N(
z9lva-N3Sx9FDMiTdVqTFb4fV{i><?odNL_$<TUFXvszm3$B7^Q{{5|Yst<9Mz%hkO
zyfG$&PMUa5y>`XoOBz3XIKJcret7V^;8HWGcLHTYaMYabL5Rg)_C3|YWMBaOf$P?k
zYR}F>nxgl7ly={O;Ka@w+yitnz^P}gvm?`*P95?0Y@j?TD2?%KjT<Ls>yrO{@pA<F
z;GDaM?^wL1hxKRhQO0<<TBgv)%=L!#;MMtYt`PU)>t`Eo@bFrqW7q$UH~)0?VFSUe
z=xl!@ts~YMa*IiR`(C?pXKwz+O*eMA6X%ncjpffoduP%A?x3ISq0eUjX`}ldT#!Zn
zTqpS@Zp`IefB)S0!4Drj7GUs{S-<l2b;1k8-=Qv5?0ZI++#&IZ5R;%Ban31z<!BrV
z*v*ZNLqYsfmY0>7!sv;gBk5}afA-Y^KJfkeQLUNu58UJEE{=uPPEv*fRKYl&w>X^{
zKDMN&M4<D*+PTvo*cB;z;Mb%>syn21kDz{pJUuTu!{a4}sq^Uixy1{7c>8+9Mfu9R
z|4SSA3ryGsjX9e`^0$oM7}5kj<9XDl7Z`po;11u_{y2|Gx&UpQ{d~He^tXQe6W{d}
ztnYSh1Cj2X%t(B`iSe^d&-)r|kw67za;U{B%f_Bhr;#7<yFur2;cd+*U)|OT>T789
zYVL>LqysH7wxJ}z&efQq=AZ-t%)!xm@kkl*M{3=!@#E2Ws)9G$ni#`eK1*P=7{a*#
zuymFoxV-CcN`IWVdsyDJytZci!1-k`(~Sc@zgz)}T-R|V9pCq1>!h2|{2Cku+D&a?
zjuoX32o@y#&Pe3BusBz7V@xpH(Y_RfVXthzr3HM)DkACZdvMg3maHO^-Y9LTJUH0e
z@;vM)XuUakGD`Qq+bN#ve-!&ienSd6-OgFJ$D5#^kc^hmdwm+V6RB*;(gL({zcgB$
z<J0OZJZC?R$lErs$$UB?Z_^g)K&gJqJl)qi+i7QYLaGF<Pq?J@4F{jMZG^oRJ2Kk2
zQirae%e}U1aPhCLNoVIaYq7h4^|Pe2Ew^jQp4T)QDcWjog~+eSrTP>ZMmrh->+H3M
z`KT<Sl2@=wBb!>Wr@>a`V|cl<W@B6^?6zGMk>A*d{&IX6x*tV1e8i}O@9lb(w%@ZM
z*Oam~p0=~DD;>RoKX(b=VXc6Z)|kVQt`G5tt%A$=tO`R5**EERSV_3ksCTebEQWdq
z)wQ1s|78e#sq%$f-uGGHsq@f}WRnkX+!lQTEb)K+C*N)7se#W`ggU70;RtCruR<OT
z1$QjK$>-~oa*WgBfwBG_v6O{H74&|dV}IqV&U2T8Np^gI+yHyTs}Gokr*=XcFxX24
zEgxNHUz~1pf3gp68k{{$$SVUX(n$b_oDVQ^?tHxA>Z6<am$T)w!3$vF;R8cV8N5)>
zBUFXPBd1qz^m0PW<X)c@js_1OjNqLiI4Vvy9fPm%(B!pv8K1m3{OCLaeRMO)M`t!>
zpNQX}OSyr|$?)>p75Rgj*Ddk-oai3>vs`^Lue&6z&guD++=#5^+a_gGmACUcpVRHi
z@1N$^81A6v5xrNME=VsREe)-#I7$<LL;X1OJuHEQ_!;%R%@kj!X<<QN@Q|3E2pXB?
z+6V1zSM|VM1YB0!#1bXeDD2C!OAdJ<MIGkS6-T!KOd&5K9#NQggHFS4r-MN-T2qfN
zSE7jj@e$l3IF%1?Cb{xE3(l8=9swA0!}?Dr^5q=jW8Jhn#>5LaANZAjGr){=>pE~+
z8~cOs3<bjNu&?TqRS)=LnJ1B=q2fp`0ku7Jj@#t|w~3?ef96m9g}?DTul@JVcN+}i
zK8yL5p1FrESXo|PV4#awkBJQy4@!Klo5@ei`lCN@c>4&d(PcjIL^(j<ZL#SR-X0Kd
zn`yrxYfBrlw)CwfAmceh#`Nj;glg#{_ejDo?>o2Qhgl8=nv!KTTHA<96Hcvg#*F8G
zrBM@3!JX<PysI%1QsJPc<rXpEYQc3O3!6PSDDfa<C^Q=x0<y<?0>1PgaB}$Y<8yc(
z4Gt1Bn8yU>$|ba{9AG}$F`SH7od1OAX~w$gQghvlkN5@S3@O<~8h3C0(nv2?qTu_C
z>UTpw2tKqzDJXQRsUNiHN?@m&x6;13UC47k`G-G*JXg_OKWcq2$j$6Kf%o^i(A_!J
zI4(4RoSlxno%H2rzWD!r3+UKbS8T|mMiZzA6WH&+LEAtn0Gi*Tv&uu&RBiLJ?&C>7
zdG__Z{}$2XEOze)yWjn|`mp^Jegle|36@glOJS!_vUe~)HDlth-JBeM4Q&?fP3Nbk
zsITsp;lSvuuvbR=ZD^M_>pg^lCVg)g0{E&)84T0I6Ld6U6D`=_DH74SgITxZshAWy
zpo+YcW##@%TCa;*Ufc`LDK6l{JL&xRh0lEZmjRc}#zCEac#fe&)~W}dd7PC=k6iEw
z!YTZy_>A*rOW!Hw1+Z&Ozh7>roG-mcc!QX*Tli^rC<9eeM0|e=`(e0`6ZF;L-q8WE
zei*4Vs6;Pua1L`r1GXC~L~Vze!;mgitYN&vclZs4WEI@vAJ{-3{BRW0MO~4GghNyu
z>Z5!9gegR3kDRqL7{Da1>r>889M%!=N*~llP}Ua239ZsRUG%I|RsH_9et$3d8R0zy
zMsv$9b%)CJD(7zzJ_<$BFT&Y4Nw1(&@MLv5d)N}4mHFA7`!oMM_DL7UmRNa1ljJL5
z4Kn*@JC0p%4zXhFvXS|lSJ{|-QfjB9GH3T67)G}s{BG5|rG@8yscpieO~9vhl2f8E
zmBx=j5+PpA#jd9XwM>U_9c}R4XeT&1F>Kpxk+WUX!3$d!uI5YVpQeXjMy40@-+?(d
zuL`ApUzV)j6TUW9j|Fh-!6Fwc^p{0AhDDqKH0<FB&{z-66`r`E0ZlgPhRZHsCr_lq
zb?ARTG5r4!MCHLQVj}V6=KAPEIsGu69*K){tnb|XO<tzQ!L>lCpfAosk3c^Q{pHp>
zdAygh#z}DI?g17NYSfH_5m(Ov&Mbj5ICCW`#NH!Lo%)_%!k;&bcx~&Q-&%jz3y-{9
zMZp^u>N$QW)VoaokA5h|>m93|Gx(v{10yEkPj13a>Z?(uDQieDWep3;@ZA|Dy%aa$
z|8MVWV<XM7vn&Nc7(hgUNPH<Onh0&Aopjl*@`r?!c6ZOr_A-;{9(zWe5rUNMvR&&c
zm$yDV?N*QmM4|u!qKH2rkXDfpKafC33EKUEG)MuoK$hi8BvB+bfIzT>WRW5wM0t6h
z=bUrjTW?jh%XarLZBPBM@4fGR?|VPaJ?GqW&xd?nWAbh!G!}!-{lKa;<cUR<^HSq*
zwYgEi)ldETH#RmI$2?)NgvZWi$qgSptS{aLbw2N_rRSuxJclPZft-w>0#z&&lP_Qn
zG7)wrseXB$C{~b^<pY0ydd|^I^Smv3fqACcw{vq$8b7B}a&nmFwblB1%pU`7%*S7p
z;V6p_*!$+4&4xLN4;Bx-LB~e3{L`<M;N!e3;b)hAcr-}-5zGjms90IUCzdZj2K@@?
zazFNjG;ilD>$ZbfF%C7~&uRp)5&z!oUk-1S*Si0E`aO3BjPlw5t_#gq3C@Z*v|sw|
zIBx^anttvh8BFJh^0^rB0{a`>6qohjt!xUv#Ra|8c^eSYB;PNH&>2(*<$m*&uroKG
zc_RSI>DgDFn|;>iJLw+m8*l!vZNf(fbjG}i8hl`3#{5<GZ$oJ7H4rcbYeZN1pQ(yd
zyWlDiFJYBCj+f5PAZiXtiOMY>sD)kQ^8%4v@O#&_`jzFyo3ACi&V}Qj_|~1x<_=;b
zB(tbEpUvcJ9s*h1t*%}auXFwP+Kv5)8#_80*nz%p-<SB-(=e4X3Z=X~X&vo$`vx75
zPvAk&<@wJI*A*l*uB*qBb^YAUx6CeNv(-7F$s^PnZo|r<yVru-EyVF6_e4A~Q-5Pl
zJR!aU?aXWcVSIL><<0lWH$7Y1yHe?69HM{MdigIsxU1un2b-MU3b~PQ{PeHf*@Pmc
z4kjus_>PTai92rhI}vAP@r}E);<pO!#@Z<fG4V}5kEL3MC*VKA{nQ{1%b0yQ@DidI
z940?@$p{E%D0<v8VLso=j$4s4gcLa;Ex|QF^On70$2Hc7n=6!iTRO?L5M5M{=9Yh4
zdaYlE7n3~x%isHB-+c7tua)KTt`=0Qxw%~p5v3#nufgh$S4Kh$80oDV!oSFlj&e*2
zp=^TBpM(-$o#{dRiSPeI8=JUY%_U4gVQ6x;d}(P?KEHvo3BGzpzeWh`u>(K0gBj0n
zYVmXBkGX=Ig&)C%@BHfhjZK)o4LcQL07Mi-xB$c-2l+dn{+V6zWIXj6?k}hKOBKGj
z038$_^$xXmD#TlY0bGUy8SYjP=wQr)vjYhEFPhSv+V>E*&eW{haL(2@n?#By-Px$T
zC7bfqO$D&hxO*d)xQ1LY{+H@KBU{2NZx`~#uYC6tz#FcMFL6)e+TPjyAM`e++>^}c
z*oelT0|dh~D1yF3(Cry7+_2)Z{D$t;AQpqrrs_9ol;13+YqATRi%RhDFrCjA7JmF!
z?`*=8;YH}oq`t&kGxQ~lUR~@SL;BGO+ai{QJ{E(15w9?wOHX(Of1=Nl38K7fnhHpz
zm!pbtPk0gqWS|_KomFl<ZS2Do+1a8C%<Hv;(ENTwQyusR^AA4*>#L@f06zneD~8K~
zCFhMO-Hv$;sI7v7f}4vu=Cur`Nv~(&!}q@iIHjI)aWeu^1^}BKUmX2~yb;RK6Y@rt
z1ze>?RCCX0uYCVvcntB)Jfb7M*S9!e$AUMXhY_Oecrldyf%8xg<gxJ6jo{=M7^U=r
z+s1CZ0BH9Sr|TD7&csuDOK_}Z8bO3UQ9qRw7dBCcC5mWdCdmC`Yh^UbX4!=!e5JdO
zP(s?2FsN^ttqlv)X#*PJ+wA8YewEXdU&q9^&)fq;wr`-{vsN{)9oQjBA)+2mH|q3>
zZSZ$?2BcrBFZ)@eUZY8ZDCPN+Ro*`j^d3q-Jo?j*H#VvM9?B7T68opnXPBWMp&P0^
z&KUF~ysS=L30K@G_b=e7X#Z;Z5>(&kfc!fnM&H1$*$sXo+5MC|ax?S$Q{vqb4i^Km
z>aJb}CojT~wfd?qBLfZrg=?l!!E@~;;%0}O@1fZ<7Vvkw0}VpBcQ9daz+oA`CcJt9
zIUngk*>6LG{*iQ{U@exP2fZrSyP05f?x-&>$8&wH%`Lm9_IRSZLt0WAKElV#{`QjJ
zzJzmPzgHLEn0d~fY-dt_=ie7bq^je&Bfr@do}0fstbh2+TewsGH+S-N5PsK&oC*gr
zfHQvX^RjE^k`N3`^p!n^0kf4)@|~nhmxm8KpBN(~_eIcK5MYc3JuB@gI<oP3`*2Ag
zba24O4Mea_EYr>b96h<k98B^QUbm3_?l=8NbJT={s2TbZ_zuJH9yhk*bH_U-R+(ra
z3JT_r@7nm`x6Q=C&g1#lPZ=9#UVh_RZV1A;ekJ~G$qqXtq08<z4eEqTc1p)-DEU=$
zWkbd{sT=)7P?M@tTPB^}k`wgkByiN`=5=to7VrY<E6Zg1VOw`k>`0g{?TUw)V1yN;
z-sp;$vf9e(qFlXsJ2>Cg))t|bEA_*bb*O+ytsKgbu6%@)pVjExjgcw@0F$fh{AJK}
zk2{y|-&YS>`v=^__yLupi7ESdPI^B6ecN}4?`BYc&^CKdRHE*XL2rd$PrJh5+X^wF
z@%C<fE|)iDK%GJ57_6+nn&|G__@N9hb{@&$CHKe#P%*qb%Mak3a3i=!WAonkPV$55
z$VL5p-FSd1O~B>(M4SGz&36mA^-q5N+jlmHZL;x=j-i)ye$C=jkLwXh{&Vk*NxK!5
zO_Tos0LS!_N=)NtE18;7CHpSpV#6-WX5i=m?pO!io}14E-qF1Xqp11t&KgfmEE&TB
zA)bMEOEY^jveW1=Bay5)nM2ZP8cWxlE@tsbNKrYV=TBEjZc_N8|L6xR{SCrh(oQqF
zCOnm`|1`J@?>O0g$-SxfC4sN9_MQoM4^wCQl@D;E67W=MK7mJ@-R5pZQokPV6!r7*
z6aEgHFq+c$@F&FuS81jsm&O|^38?^jatUTroXb$$b4GI5K5n93lG~p@{nxX`x6k^9
z5Q2}Kf0!kBe7De}TlgnGLp-<xcaq^=JmEp=NiqHf#L>4Y%fK;1!B4R6h~v9)&+l!D
z_$gL4fd^;wlkn5$rvu*91#w%cLqcIQ-oI(ZSE7G}oXvNWe<OHG{R-C|UQ-U>S_SUp
zC_8h3r}IrS^(c81e(llX(ghcQ>%G$+7XDe>iweRiAaswe0+@7<F1y2C1Lg8;deq#*
zHN{Zslt(P&g@NdvP>)B~gkPhhr?CGN1a&zyj;!S)vnxEv2;1gLS<SFU*U!^uXX8~h
zITJ0MG!eK{-JO&JTyQ>K*6LS+Lk@cLzVYqCN`FfDXAefUIsBm(^z<RwfCFDf!R(Ot
z0sIj1?!{e!vqxuw#_4u%qN|%&N{{N@m!b*m&Qrr^m;Q@-ohEuPXub-DF!-+4(SC(s
z67Twg363E^NqTqOHw3yJxY=g;SRMyS`M%$6g65kS>D?wmI-!z45=t*YKk2YnN_Qwz
zTCK7{*){VM%0Q)x>1O{hW{ugscC;hUzt*LFew9z#tuGGq+K>uqOJQ()eAG<6K1zDd
zUCdLA<+uSIB4pJiZK_tkCHWLH9UB<YNT*TJKE>yvKfBGrKy$z@;Kr!yPOuwC`E2!D
z;EH;K*uX9L7{}#0I~VPs#z|w>ee5X{y<?_n(lVu>`eYGz`)&B43YP=X4snAmlOcs;
zc=1C_#?%;~A<c%NiEd}xRz}%qhiyb}h%Ky5_E^>OPZW>AM4`qjtP<_eb2%n1+*9dg
zP380wLvU<y(32v1v}2!5!yx1$sAcr0djx%%lyQZ0@Ky&2ETSC@08;?SFg16o*rYmq
zhCIO2M-HHf4Z_Be4f*9+Q{v1)Z-@ZM0LOXx0^er;-~T<!e--5$HIt?-tuEmRVTzn9
zw1&bg)K=)m%I8z}uPcmurza~Wd8@ClDrhjuR@SS2@K~)v^V5PL0xz9E0|j3v`d;`g
zS@`IeMn>Na3Y)j-W25^-xD==rO;5qE7m$bW{Y^rcg*~5&SEtHB@M!}0%=bPEH~%~B
zAIOyfeIAH+fgzH8;Mq>vmf%Y@ytHkPQP77}+d;AuJNnb}Z~;_TqT>Xi%{RBwy~~F`
z^J^t|8>g{6IKISihvQG9xG#aaDFF*MCZ-v-+XC7XvQr8?A|C_Hi49Fz6{-DpcU!od
zc!A5nmyE0o;4F$<4qsz5cqVTwe;E*ZCHQ0`oA2Hy*j0oj|9Rpw#rnY+LE*;<(>;aH
z#2J_Ck?X0v_Q=n?w2<c|;Z%HL>w7+ae6xGBPkuA_OaTS@9k|gaf_Sg7O}!NV3HEU9
zx9woqjzkao-sB4eofK`7gA>hXrq^}AjCOXL$8o9xmC&1P+S5k-cR4jgtH!KSqujWN
z-EQJrc_8A8dqYH{W1`*YN9Q`^th|3p?;G={G~&avdh~~7FrHNJBdraC7}-NGc-mE+
z=8mxwc(Fro%}+rvtX8xGw^#7>8H_E0)ZvcOI);l+yV>!q%@)s+G_irVMs_FJpLdR;
z=Wun!svZERfwrxeJscVk4To>_x(uje0|IBwlWg?I4zc|m=(vMvR&7io`9;iaw~t^j
z#)l5!pEQ`eU3xC{OwmrmXHxyv>jyDmrJ@)O7|jYnf|a8k9I4QFlCDkZNa~!gM$tIm
zjCQ=&dFAN7+GO3LppPqNP88cxSnjm$QRqQ-P(e&-+Nb_j>I;~0GuuD46#K)yVytNc
z^ZeAd01>d@8nA$!>ig+s`8P7|?i<tm46m)OBK(#-uCJ}GRhN;x2)!uyMoz}&{lY)|
z!oMu=B#$5Td_9wH+j%@ZzklABLFaMz1`j;B!TXXc;mOT|Zf}qwN?Yx-vx12fnveAr
zzQmE4_agck0wWY{cTcdTwF42jc@N6pLN+?M6WkL2D6U!ckcxJmw%WcC46IqHz>-fJ
zxJ$MNaJ|P9lVuL!w$5;9v}5JqN%={33#acu0(KDB&O+zdA6CHmFbM~a3%r}k0-bQh
zY**rC3^Xw!w#V&Q%k!spVf07H0Ue0)$QOIpP|YdAW2G5NDB)@HA2{AXehyWOC>X~%
zW5-*3BKlK|!Z8;MCSM)q-?KSYr&2o^;j#xTI6XQ|<K+CO5$Q+{m(k5itYq}Zr;9`)
zLuim)beh?$DW44*jr)h99m8sQBPd}XxcV{KQIxf$B6KR+2{6N;_-MSrQa4Dsa1L^+
zL!XU((E;xJW4B|6gaiSyY%83AaA1_$u&nbE{SKg?s^6vWN2rHl=b9yAl+6tMaDdLZ
zM8`KmL@(Vr`XyS@kEN?uKWDs|;!(no-09~Y?l1gC?Ogg9@gf9$XGTA*jNwl_CS@ci
z>AXSh`R9%4baXU9NBevIr-X2yebLjMo#9h{hd<C2Vzvgc4~M7>&=8z_iDc?rOqsPF
zJk^<m(p6@85V2NZ7ecITg_x^`+Mxzxci7lxF?eV+8DGGGLs(qRAZEodoyXm2CyVSL
zvJXyMWDp5#TSw9<qYrrwXRVwMwNme^GO(c47hwng1h`gd5^2~Tdb(nrr2UuuK+wA<
ztf2`&8f_Hg-~|>YPB&O_bH%7KItm^079!e-kt42mcCN#H0_1p_XbSXv$V_@EK8A_I
z7@{4Gw-3S)4T@cG05wiJPIWd&mz{%u*I_T(0oQ<{L1SCOeD;FJCax5mZ5$P((AaaQ
zr+dSSHUg?eJ0_?0?`L!!^R32+cK2Nam1#|V>U%CXZ^N9ApJ%OOkgy`Bj{6f1Dtmpe
z!C{~v`eQ?28@}*tFQCTK0F%50^$4G^H=`ZB6~JKMj;<G@jE$gn(I)!uRm=N}HM)UD
zVwh=>hwbi@VvqnR)l{{jKT&Mpf(DC%7<5sR`iLU+JKD)cetZxk@(vXRMT6x|M?0K$
ztuVPR2Ny`YI8L^Po8hSO3NvZv@(~QfjzT_Sr-_80J{BVJjE@|Q4y<Rvcf|i^yi<Bq
zI*+~idXlRy{0FBem>V#h;`N-KoNZ+s3GYXFISRLpfwxQFpv0aG%Vp`rv(H;tyM))t
zl5#;CEM!KYp<H+0Zr^viorb{zQZ3u}O{jthDgs_`#c4%)zu7*-W8pnZ3Y0u)HF{7`
zQ7I-1P!;V6x;jnDXY@L@4YoItSDcmrfjXi<6c=DDv_lrZSK#Bxr)(na8@*yn<hz5Y
zrc((9J^CYj6&;A0kxxREC`cWO0?L)Nwq`A$P3@yGLxG8fzg`6|V!w&s=Pvy4@BAaX
z$7thz)7bp;<RAB^>LX0`_dnnMyMSDHx6wXLd{9&JwLQ411CegG1WAxS>;=h*^w<M|
z7icHEgamw|Q9&hTlsKLuvV{Z(2{Id)n*dv;jfLPILI%4b+6l_cBW~9tRwiiH!MFS5
zbXvJrj&`y=$?oVKQ&;j{fM9XCikx~~u~@5$&#fJR{y>Oa%z}hc1)qDpcFE*uo~z#(
zHoy7)+u9-AH(&bZZ>3%<!yr-zOXbg^Q}?UuSEf@J*eB#M43DGV>S6)S$`(i*R6<&0
zljp3-DZLRTE{Fcj=jYG!&DWO+AcUKRpLhNyuIN$ja5GK+3qk5|?<RAj%wF%c`&GHi
zV!+XO>`IEOQ{>{rEA#L{7l1EGkON=EP>7FA`YZe?{M2dU1Z?aPq=$q`)*^;HZJYX(
z+aaN`^g#9eY+_ZT#M^{?PbDUw^%j#{)}HzMjM~!OK^OEYv2WY^gFpw(H~>Lph;AAg
zNcToC66~A2n;aAnct#fJ_Y!AUqYIHSjI8^ooR2~^dm?;ctvK#3wVG8ZHmLJs*vFc+
zahWtoK|cLZCuOg01Ybn^eElwc{wU<1+Mk=*^nWV<ytcUh>hjNbr`#WMbLz54_+0q*
zs{R<R?Fu~KfpI-`Kx7O6*znHevnD?)io9U-k@{V)*AkundZN>i-cTa+OgeqHTEDkp
zcJ(Rl?1;3vMnrFdiX|o=Wi_3AtBR3tKUtaRd(n@*XME3##_p-C-<OqdOp}9mCgk9R
z>Y($O1*1xhQ>Y~lonA^s@%X@wNc(LlbHQka(nEHeI$)?M@rZl%8I7z=q*KqI`t$ZF
z-{lQuyqpz?g6^wI^vA1OpX`yXm6f1}AwUW3Z*~daI5f#=v~vprXR1x`DdN1i@DL};
zjwd+@yUrc>ArT-^F?n}C>CZr6W`J7(FD5a;ix7r{+%%PVvsqrFi~fkU(W^1xUc$!N
zNo9#}2$&NENe?IFB|6oPRXsj!woP)xrsz64T7eugF)Ps@@EG2kU}MB}*ymL=fNQH3
z**U%Y3e>5g5K!@TPjWKO#m-PNYrJdMB<g<Xt*{dieeRt4i5zKgJ5Z6g2k4KsFlHsK
zEUIt_V8mYf^9%2DHRZw2Ko4%Ey0~h=n3QzS2rQ*jT|dxI;<Z^NC4Bc*=Ev|~W%$nT
z51w%@F}sw|7xd4`E@g_pTn=iU^T%|%6xdmo>{2i<{k=|7^bdb&qmXa#IT-q+H{#bU
zEOLe&_B9I1W9)mD3=vSjPbB1m9xV#~=nMc<(B`w)3ff#yFk@N9vvYUatxHic+A%&J
z;?2@E4a!TmDft~1p&Vk*=2PJtPI>BsE+zQHO0Xxk8;38Q{lP4towuBR^)<!W{#mRp
zM~uA1#X2^Ph%K!d>ShHEcOt8?E{kRY4G)d0?yCf@K*G{t&AgY?R@TjTNo}=i77q3G
z_0`4j`^BctZn0>|-Gx+_;V(p_e|2eP)om!&s&)5)eQT`>!w7RxH+!JPz9j|(pHfeJ
z%D*1lw-hfX%f@r|@BM1r!~2J|f9sQQqd}puO@LtN>Q1vOyMX)vs;ABD{*U;5=M;#X
ziQNV+ko~d*8oSWe!QHVQ0I;>|5$m;is7qO<p2YgG&fzHvm}oa)Rfe3Uq0TNBl5O3-
z8Lt8gxNo1~nR%y~?oap%uQgB<Nr*L+JPkepLSkNQvylE$QC&&Uy&@i%Kc<<b;}XT}
zByKXXLJtaB{w9-7$SP=4*%%jZJc24CpoTTumlap0o(35Q44Bvk74z5|rC|{j?W8iA
zU&;KnC`n)wMYKl^=?K>yGD3p`kJF6C2Q4s8LT@LqVS(A-h3V03i2npW$@Np!y}&c`
z_qEu^d<Xk@CGF!s0zY0{I}!oAQwzD^)O*kS)#aJz99yU7x?ceeVK+P)fkTUZ10u(p
zMC~$>Jn0k|$qQPl(PZN1BwzD^2E-LZ&ntT+BdvpGyU7h>fHwcUU(1?Tl4Cd>SxxZw
zwStb|#>s_@e45U^GvKiHal+wt<FuFH$5elL{)F3H;osc`QIfz15Q~(~HD4H>geC^*
zh1Wey@?yfXUO#LxG%+wINrTWaGlFZogmb%J7YECh0W%f&73gvda@|7LcQrIo-QYra
zS*>P=E$sYg$5_X73=0m^7bV{=U@>E<P#g!tv3Bs>xLogsy)xeTc#U+!AMFHM8t*Oe
z6bi;!UQDw=&e%LeJ9;|)<<$SwPCH(;GiI7YWYrF~vM-3ksLjW5qQN>$J|T*@X1o6R
z(Vs%@EqPbaogU5)Q`CNg4o%)qeJu8~hzA4!oXK}iv7a6E`tsa!&DQ^U4d+U9gPj21
zvPQZfZszt^oo}J0-ud_7_nrgaGF?spe<me4flnCqd7(dB_?_rN2qi4@g`xDd#Kq&}
zExasrLe^z}2!9PB;v-`Q%QedfJ~IZJI#ayOET87>{e-P8TL=S?k9P2xg#P%Q&}$Xm
zWiES~DW9CQ_PY|MMLX<2nJtaSHce7h85VeVnA#wU?LMiv*no06O&NrFaV()=&otVu
zA3k;PnE2NmHEkY(zmNYDHD?w$pC5ic-`vu9eKRfSIGUY#PXAc&>!tk@%pCm<eegW+
z>UzSf|IYdG(3>y#@JTvM|75&uk~}BZ6S-@uBYx53;vR~5P(CRyCmxwcPCMPM;@SGL
z@O6{q5GIdpz>FIlF%e{=vkl8KSDS_7HM3dP6HB`EgN7F1)dSy&XQzP$R4RBXL`%w{
zDW>6WtDQ9VkpV_*9G%)%;C^6`+5z`3ybP1*B$~l>hMxtRJsbs4?tN(XPWvslqjZ<k
z(H|ZoL|2+HNWdGg`fW)Twbvc?U_&uvui%s#VqCH0`|#%h{0jWb2M2{dBE(!2h6U5Z
zr>&zs7<Jp>Waw(aP=!RKdCGm%eHeQ)cRD7=>W=rGgMzN4d-qZ9)D1h3VW(|Hl!<Yr
zv3nKk@A3H8VKx$rpk@TO?77+Bu`Raas+OD`pB$elcifXr8w@H)hmR_5uRf+{iTfpA
zazTjED1ME`?{30ku+!N0J2JUAX2lqndKaa3NU|KhTRe-yp|!@G5%J=Ffqh1?Q)xBP
z-GNVlsHf*$yN$D_*~j3AJo=NDhTXi?hh#tNP;&aFhrLSlDcbS-!Pc%TFNy3pkPxh}
zQfkeTIO|$RmE}vR9nPnf+UGsZIm}wH<-yGau10JKUN72V{hWoNT7UW^J71hXEmu5*
zM6);-7jJ=a3B2edDN6Ju8RHxu=+pq$I;>Rq`2@Ov0<g-uZAghfVRFmoK}Qy=&YwU0
zx4&-uIrQKZB%+`rGvqldGtbRj&w1#>MeYG`@t*F78!}vI^mbr$LlEK$MGot$><L1$
zngE=ZbFD7?3A20`R&+@(T;P{V&H7APTHF|j0tM?6x$c~m;X?tp`9tIJ^^VCM*x*E=
z04<e9J7_YKRmeWhh5%=bYEeUg%MN&jw5>q#f3M;$J<>g<%?d(5nmrnasZ}lZqOxiC
z*wbR?MStK&t=UR#P~F`PZ8#=$2y;4!Hqm!A8jqM27=XzGK$WZEW0QQvHQ@)JpZvuq
z5a;Mc8b0Z?@b8`9qb7~+my_Ie8o$T;_xqFan8Db=n_79kx$e(--_n&%;Rjjl7K;W1
zXBX8FVw!s(^TzD#$)$rIr~x<~JEmeoCipg-j9upjQjjmAJ+@;hp@(DmoJn`{oGicd
z!o?@Y$zQsj2me*<FJ5Qab`va<wV;I*NNYMIH@3w&S}UWG5kIfw8(_*yv0_o9((saK
zCqKXYqk>M_5RSo829ejk*1)K(jM8W)KA`rcKAlEt^PbAQCO2<@6N>zJk9gO_i4JDh
zcfU5TtRIYt=U(DIrNNZ;=`X}S<&7zrs)C-*+NXCX<0oRD!nOKk_vvNMUpUVsII<1N
zvqHh9?$QF;Xk&A@9oDLzG!g<}BA+{^ukSa>wsVi+>^Pv9dI;qE2#KzfV3m4J1R>CC
z>HK9>gz?O5TYz6~9S_^?bxwx>d%?*K1Y%it3;sc2eZV;DdpW;5_O`Z{EuL+Y3h5{d
zVxQ%=8bOh{!L;7l*2){9rEz?h?Qm^bRf=vHkez#=9RQ)Cc^kQQ_Y-As=Kj-6g!~M0
z*u`2E`fRdisn_cW=?Ha`nfzwC!Lu{%z(Qa5hc>YLY+ru#R}qJoOWPmvKupl1zdO;r
z7o>+xxiY~b_(j}P#HSrd^4<iel$VKHy7q7|xs20Gu72)$w}^MU@XL;;u>nOTpN*$Y
zekL`oars$pXQjuksC^YXtIOc;r`<0my<TwZhD$Lp6WNI6-=SrZJ@BLz)58d>5h!;M
z$g!k%wL64{?I9oTQa~m+g_^|>z6phnb#;Qsv_SnPD1g+fv4;S*iJtIXMqxAVDkhwz
z;eXIiT}STH#N{iICBEd(J0Hc!Y5-Z@2+=XRnFM>s(8F$Vc&)Mi;ES0Wx@1h=yy%H(
zs2k%4a$<cBv4r(zG;)a#C`vviZTXHXVTqVzPN%7Q6^k%-9*q{pbO5~2Mx}NO&3R?v
z`5d?``okGzaTm*L>x>-ePPFaMeVi<nbg-gjgHpD)bA|_M#zY|Ou+Sx6$4lKJ_kkR{
zX&tC>Gkx2>bfv^InhM}=nv8h-H@X;HF(pqXSE1%<YDO0rcZoiMZ=_)vN<aKF|M_*Z
z7v>B@HKkGDqp5P3yVbRs-(~0LInP}J&ul|dk?a{<Si9YTA3WSq5<YOaD?D5PmZ7PM
zt(O@|4s3J+MTa-|Pl8cJ{vLM?<aaR@4!6=<?Cvyr+rc<$4@hpOrhtO{VIksR8&R6?
zBcJ85?PmRfA7Xo$HIj8Yc9a&$AmF8g@T+zB3(xJ`^mb-n;C{j&WHYUIgZ~%FpIvPh
zuHV}^-lH<S2d|_u{E8{7Lm7T4qJu%FUHb*|u*?lwgGReK{a;;nRe0#Fi#=LjtrCY$
zoM$Jeu!J8sHvt94zkk>7`VH~#E<95Ci{am)PqcSL^g9#3PWJmom5jm3Ds2`70E<X^
zI97tpsvAon25aE?C9|%mRclqVctC2=14L9|hOuUFRQGDD3Di6q1lrL=*8rNTyINmC
ze2As<>2L|I-b`_yKKyh4XPb1F_XJH3=SF?D7m0U9-5z2toiq+^6x5tQ*c`6v^`$lU
z=Zxff)ldtQi)IURvHe+I|E;7~{|mqW4|4s<v_N!)t8VUlU;iv#;I#OI?@Y?=?y+nF
z&k6p~Xx82{;}6b?69O3ZPWD5qaT^ywuePD$06#MfkvSF`)2Ezr2!#ewKk&!(AHY5N
zu#0<|VjhC~DN2le8sfa+4dZ53Tkrg(z1B6Jzdx9F-ywKc0JRVQ>HQxEe8TM6Vu`Cf
z;PZvbt?)_03s(+jX^PB@4NqM$A0q6~wO-x%2S@yM!QVJu+S(}M@g9HiTX(i#N!mHS
zFkaeNoUq$NT+|tMdl!kv`>?=27mbSw<doe963-Hvjt^)p8+s^^f%|YB*op$w7e2BQ
z;W5m#&y3+EJOX}XtEa$)hRdBXxZt8(x9U^vUcsTQnVh}0y6y>x+hzWWX!hdI0?#A7
zJ*`zI=-T8&mEgJHvlbrz+IMVhHQLa9P+*^r1CLF1?`D@g2mJKD){U$DjUPAzetHT+
z@*-e((4~yenZ`H0G3g%?@xsBymzT%(`TTrS_FXYUM!iO7V@wf7fT#yu4#dAF{r@N1
z?YM6|gC-^M2&>ufLP}JW1kSM<$Xz4(XL%Ven$P)oMh*}3vbeew2nI<*F}F~m7I-F(
za_4`rglF!i^W2>~e}8*ptGV4Oo#)WxXmpR#K|SaTj(6tNpFh7ppVr_6|Bpvs{@x$^
z=C3?AzldA!r+8(RAL%r)u5#Jl+STgmoThbsTM|RwzC%?NON;Xk^q(F-UYzhhqOxgt
z#@b;d&(g_^pDOd&2Ct*D76O6u`2hXme}{q*3?J!hqZM$S`s)>L_&@i%`qdv4e#f7<
z|NrZMjlZw{VC1omtIPEeKCUjWR9z&A<gz4+ob@#Cb4+UqZ@iY`zW>O7|G6W;R||Uo
zxIA=4SfC8FIU2puh9B)?ULnE)0N-=?+L)wck6CtM_{!TS_&MDg;Vzc83jt>Q?w~0*
z6@w-nIB@<rXq2|B*yz@=UECet5IvGP)_tss-|meZ4u3I+H%czojSF6?*O%#d1)Knr
zu9dP}TTcF9)=YNEqIDNuR%^?_OfP#8;^Io5r3RNWCMgF*3p4rhogvEYqSb-3mz6a<
zw2Q^DUXNuQj@^E2>z?@=%;5J`9D(S+6#f@>lYMRuXM*ET>EGC_UNLiZ{`$@LgwMFT
z5B}^Mz(?)I2}7Y!D2d;>_(<S|_?$iv(7+AEoqJyR=&X#7;B6znCm|mV4$J-Ipbv(W
zAn87W`0*6O5LXS|5gU|4`9<*e6<6q!{d&$fuR{Fo$cMzP>gb_POd;H{hF`4nimM`=
zKfDtC%i?4I?f?2Z;jJ||0NUVM8NA^WqtRQ$B@ojz`?n#8fonafgY=yazCK0Xq_Syn
zN0ODb_gU!XWDO!rQN@*N_G!O$B=)LOd|%tZ`K-|y;BSoY0{k5|2hBsHil$!)U^{6w
z<nAH(v-79vde?Be_uo8@X2E}9{=ja5f=Q8$$(mC*B;Cs(&TC5ncM=K_PR{+6;4bqk
z_@y8E)jM0wPGgVu@s8;N&%NFr!U9G<v1o+WNB_XrzvXtUIi6G5G<ZYLMx#eVs;AHk
zKbWfwiIv;8VGyo5WxUo!?Atv7FaDsbhRKR<OE}K=VjL!}%nGDSW;FsnZNx4-m}?%-
zo#>aj!n5EKd>JkQ1(!8kEsHCwL4qm$f*M#hio63ZZ`DwD3f-HWoDy8VR`_i`{@=d^
z_^?BLcAzN7J6L<dQzmDcCg0jvG^Nmt4nzJ9ZL#wA1yAGcl_2!96^JY1&ad(?OMd`N
zt?t0Jai#fW&^+300(l-c5!ZU?7ukTevYhLvx!>5<ck##6`B@9244HcxbAYr@K>)O8
z3AN?%+|c~D&$tr!W#?AHYp6CLVTv(uK5c-zzAV7SE1ELEtNVSd*A@Y~xIz}doj;!?
z_<iTD-ec+4e|i=0+k+uDba9LLBZA)zV8Oj1JXp2+w}}x!@1YC3L;Q*u?;Ee#{gL^p
zW*->Z-E^C?$M6|o<&*mPoD1%g>^l|c|5o~^eE?f)r!vG<HGbviHXYEvDb>Rnc$@Wo
zKE!A4Apjb`!=L!dZ7>Y5;L_2TX$1LEdZ(*NP#X73uw02`#2!z6wT3X9cKdV0=Rv?V
zhj}$%7(XV|H%DYm9BjRT{-EYPd)aK)RqUUC+5n#%4Dk8ud@XDEz4_Ot@ga*<3X8RE
zn55DN&f(luR1>o85%4g_<dpYGlKU+DjbHx*+$V^WMz!qZpQsGK<$Zz}-iYIEo8k@I
z#f(#`vU%|$;h5Vn?j4{{ZvN=t#{rHhPF>QIl=cBX-c5%^&l&LHX}}*i^y6;ND!~sz
z=zBwu6vO1Rry4Nla*heS&Q)~o;sERQMQC_eFEAfvxGL_)KKvcO4!*VrECefU1FNK0
zM7&3wTN3Ztd8)SY$30ej!9Q5p1YBvofoJdchWmYCSQu_M1|3*rRJwbW!4R$wcc9zW
zZ`nD@<k-8ZHs9yCpZ!*X55g;;taW1Fg`d}CkIrI^H1MM3oVDdQKK(&E<f{51_kNgU
zutKQ&{CEEa;4SR#ozorgZh|m?0;U=9x3hAWS8p(G@}lHJS^SBOBK`!D#<gZO=@uxe
zJR-*1Sg#UuJbI&!bahE^fIlk3$t<<;c|EuG7?@(CD)jwmv$}+|R5y`cW*dB$?GQe)
zs#(pb`2B95JUPDdcn#J@f>%eP{EW-h&qfxAo-qiFk^rt7WEo;SA*w<lq5x`o`F>*`
zqLHKt1)oIZGH_%S%v;vpjCSB|2*w9R1KS8!Kn|Ua?KJn&+F2eR=-dPgU&M<?xj!4+
zKR{TEs|nSG-8<B2TI`uVPVW{wXwD>TkkjlOv~hAqBNF9AfB0?_B%lz+9dto+tcQFE
zL#2QxW#PFF4=JM&GZXE!TVEVD)G}+)9zPo-rlc4#T@DpF$fNi9UbJJ~r8aC<3B)fo
zeGJ7nd!%9Zx+j?LH0oqO)rFafkDZI!*fzs7rL+2$x9%LA?)DnN-$j4YZVHO30+(7M
zy$jc{MGhuz7(UFVD*PtAkS99sx=Jj5dU}Z2<1`KWtwXw->LW2$5P7uVD`>j`@+(AV
z^z{%XHMo9h|I%-sesNBU|JZ+v)x~<%1)k*c{1%1Y_m}+oq?+`|>v5iPAN@5_ZO(BG
zR#~P*zV6CRxLR?ob6Rpyj5-&;<8<Bqpl;p!;a4|-cel8r4yu(tLfqjz4wsSx7(5Cu
z&&0o%x@Q@U20N$z88v?azT~Bak;`=aN_3TbZR_o%cUi6f-f_Bm8;1gjrISpYD}i;!
zTcc4~FCZ>z=hZ9WW?(yIeQ%!0bKbE0Jn%!g-eo552E216_~86(y;j(b-}#MS178m}
zgHJv-Jx1~|kVbSedMAQX^uoFB)GHS~q`cEJv~f&PM8FS-5{qb_tP}MOfQ4rb@#=8$
zxeXy|Qjf|V=%LZV8YG<l_#AKG`@kDzeWgp$hcpzzhrT1?ia#)&bys+e!$Av|tppb^
zs5AseUn~d9amMUWhWLhwZJZoo`x@=A-(LK*%Lh*z<pOH}=gdQnl9hK5YujIpc3^!1
z<`#|fIXs=YwLfFtADY>43mzx!^)~t&-|e(c)Zb_aZ+A{rq;7$^M88d(chsb-W(@-V
z)1q1Ml5kQ`QEfzFiFVQl`mmGVwQlv@OgO%c{x;k*6}t|P(7vg*o9Ud;a2X4Xa4<O<
z9qTHSYWuXHkZa^KYPsmofD2(S9JGRYRVoU*0Y{ucwjX)z>}bcHJaveRs<M7|VJKha
znT2k5z`3&55XYJqp4^VwLe>;rhZ9PPREuuHt{V+ep|Y2C-b$lCe40Px<OK7JPc!Qg
zWY`mA(`gEMycq4+ETp}pfnnhzRGb}_I5A3j?d=wz)v882F}0jyuazd!YNo7VRLt`L
zqG|y&DnvW@5YAR{@<RsmP_)>`5zAbLnE-}Upw@@mEr{INj&I#tsDQJ;gj^@>>`z95
zcu_+Ko>^X6hCY*+ZQNBLsY8Cfwgl$=%JJs5KKCHu&xN1-r8`^LGaWi2gIZqO_%6)I
zX!OvFOsW<7c<GYj^XRN*&Mznc8IK^5(DSKu&Z^_SB7MwSF6T?jA-vn`G}5_`tGtW5
zIP=<wZhJV!RHm_bVG9}#el*0Pq6sf@sU3`#O+|5lQ<gV^&H~5<iVtDiaKZvkZQ`8x
zV~6dWLLtl#pUB3{3OMm1yWpROn-OGV9#yRS>tPT6=PBfn@mFa+u6wqy^YaOg^Q)Z}
ze>2x3q?$x103sPGfJnL$Aa>76-~lQR5-`u7KtGrI!fb66e5vyr34xK};I8F<Ial6X
zzOSad`5E`sACtWK{OPz^H7?JehMwr>9?+d=1$ec9liTz*4i`Vrsy`QA=HyegJ<!;^
za58zmH2^PeDxQ5qakIc+?$KTzUYvezJt)pIKl(erZ(|EoVF;S#aB?<F{y`ULj~`VR
z=kBRhBs~Q;-bitv;rm{+iBxR}|6NYHycf=*S(k!ERR2KnrqcNf_UF1(ALHMk$>%|W
zso%#S!QeEQq}n->5R)do(o55&2gUt*<+uIEJ6k*`WQtUQXU^55n$Ty49@P}RuD~~0
zdzaCp8qLz90$dL49!X&{(>;<KU0`$uZ>-0msz3N+jFpW&)T@fAaF9(?<9r(KTyPwh
z>Be;dz$=d9+h;EM3VsXo%sYab*=aE8Hv+gWsC#J*5p-i6-0Y%SclR{4bvN;-SF5I2
zQip>gJIPd+JZf)s*<Qo7L~2Jn1UlGu$xyGZ*wsY6zPjj}ib>y8O!}r`a{bkHw4<pY
zT;O6N!v3PCI8gy(P0mxn@A1{Gdud;NRQt=1fsYgL+(tZ!6S`-_aUQowW^p#>K6__E
z-(V4bOrFC&n@ZO)37JmgTz*WruWs80+~Gf;#}Rj%PD)Ux&|YirXd^a;`~1Yw<b2-f
z67C~SK<uOWXQO~azO(g40f&F<_u#&ywa<HE&}UP00o<Y1<UKvsQCb3vrZ-jSw?IPx
zWfO7`+b)ys<o9qqsoOa0zJK2l^*-Um9{^7Fd0-WOMpt7$7gx!wU?UJ5rCc+=CvNSx
z+CEIxI`#I?_Oaur%x9mwv42Z;bzjNP!?@oi*44t-mX?9>OeGdc$EGOdx^VXDj#pXH
zBeFv^t4?#fIr%z=SDbs;-qu?`#A8o|a0;j4jm*y%p28jlDiOSIYjjNRGw=N!+y3--
z?hIVz9AfKt_mS3*tNP)0K(DUVhANHOh46vno3pY#$3v+e)i1g)M>uMz{n+2M9-&VC
zxg)(96|TOX4+?(`Pk#0T&<{9}g%5rxD$3FV>xro!ofURp<925}U%tMvzH-6o9z7i%
z_nIf&PuFpL;_~z1VzpXbq45llf@{lg=xC=xBnyYf<F7v}SK=EUBt45e|KN{8df95@
z4k=b$`*@ypzl>ag-@&=fes*Q32ol)pM)9L3E>(!EAJQUgXEdWK(3?g7yU@`xs&wP=
zLk>rjDB#4yxkVCAI(52Ya?#FLxtt*g`?Da)o|WOr=(<Yxe-?BBS1!12b2a`X&zvQv
z0zXKt*4LK=<L1|&sAuu<eN#*&0l6Dm{zXm6x4g=uho%cl7%2CjZIQp2_5BBMC~w_G
zkU89Y8@+-3Ve3SGCLjiAiN0CGx^L>>lGDL>Bv{48dH<j#|NICY0UlMCjY^&>xsPk?
zeM=rRVDsW>h<&3Se#bh(^@2W#?+S!-<khrxNS}%#-GN=H_Pf0=4sp$__WLO=WmW@C
zA}%oOZqcC9ToupQw_Mx--O(=0a`Y(n6_irIr6D|`xV_1FEzk2c%O^Y2IHwuZkKHfT
zYwJsH{RrU#Ol3@Zfu!#*mKr>roh<>Mb1KiDr_%nqm;6vJe9wP@eYkGAsary*M0*18
zbMKd8rxfSC+6K#}ocGw^{PzaD$AAPx?%<n<;#k1XNh9`<`kCz?dc+90KXgZ^4HiB*
z^%#^;>V9Gl>vtOfaU&4B*e?2%K%P0&iFOFQYQnW{pyq+Pm?wMS8SU2eNSncP(N09c
zL~(QtH@g11@1Cq>Q#`<DoMvHMHc<O`NWte>_wym+C8}}wJp9vhD!1+@IY;Fm|HU1`
zKa6==I0{I=eqtZY!t+-=PvSgc-;Mp8&aW@gqP)PaUgbQZZf!kI>%8#M@8<c^Ec1bi
z@O(5XpDVAro{~f16WaIqg7hgwDDAuED!@BYY~wlb_Y0imPfpWUS#NEjtp|mj-r&1`
zANKWAOgwm?5?y;i`}vbIlb?*9<mU$ZdvmJ}`g?QfACgOP8A-ll?q7+YdAqQW|LDuV
za%Zbc6E1glWBd$SrXCn1KKpd~#-Q`z=jM&ORh<*ycLYCnp}LsLWV&W@?MP0_gYCU?
z`=zT&^uysU^}_JJ{I-Yxxg+r*gW#K0V`O-vD=pXo#uofD@C_7!yXo9OwuEY`hZf`)
z+ze|Q6TS}~A4dw@tgzN0lzF$U)=_iYt)B|LOesOK9v=EkG6!cA$kW8t4kOGL8H!r1
zT=)-v^!2FAo<Lzv?I?}jc{9v<EG_GB<B6U`JGZQqnwjZ!YP*_|oIiv@XWkzA1^cbB
z{+wA&Q*+~RG&#)rnT7d&({vM%4)ys9z~$Tk{7I~s<oxvZ`RL1En~?Lb*!}1tg#eyh
zU4!pNol$UI8|xL}w3e1uAt8|KX(rt>ER*ywgcV@i8IJ+7grJaKSN8>MYq5&EVENcv
zM$#4Rm~=mT%k`yY4<@l(Us?4#U)&I{+FQ{dl&o1dkn+oldf=dXIG?On*Ifa&x{h8+
zR90WCVxZQ}*%^9_Kou(<(4@Y;49D8+o^E~Jj}kro@y>YsT;}*H?k(Q_9FH%RtptFt
z9<=rkLf$=zr{>hp8V4%7H{&NNY#sgNI9Mlx{CI?-gPZQRVto3F+|~J#*Ryz7e+lv|
z1WXKnQiOw<{HXiIT8evBUqAZF@-h;o*USn#l9TkQ7|N%qXUxFp=l=zNzwCZX&dx$k
z13D}Dx%>NBU0H;#)m(n_<7*{;<*js2vas;a01u$4lrzv6EQg1@oHv;02X07SgC#$a
zr}!0pATO)ib4l3Z>+#?A|7e7`I1#M94=!c5LUXaK1NnFP+_1)I1W^pdnMnl0^A3A5
z=p5^xgXhT1XL_bog{JxN17Jk*D{$1E^r-9!7<7K0m0<XYl*AsE?22CiW3g*8NwOHb
z=E?_2j)y-N&m{f>2|BJw^}zJNDG%D`gBCm%MOrgXyE*$=1scSN&wybQWSElAkgGz+
zt(TO{BE*i_7l9w@;|fBLigtDwdliLh2aVt$VhzD!Dw?sktYf=PlvXqcyWM0Dh-I=C
zc89Qo-!;)vAGS6YgtTd1!K_Mi2nS)-zvdIKQuJr9344Zp<GwKdsJRF2OLehzm`2w+
z+Jmn#jmZ2Kv=UzkODu#W;^ZB6JM=)M)oC~O8_{690XL7<i#EI!bOjy|`r1TCf6xHS
zqGqJ6D=_o2k88!c9e1Ad%B^F7B4z=tXYD|gjTm44Ny@c-&f#GIc3$ji57Xq&dtF30
zSO1k7lk+jAWf}%pNxY+(!PRBzDA;LOp0QDPW{JS(ePp9Q2-3Qr<`Ihon+h`}V;U#X
z=m(+a!285BIZZYi?VR>f)j_KX+fF{^Yyk>k-r;Y0f%2-6wsEw>nn@fV8@y|03$<2i
zOIZ^-^6`^s$8HMrJ-;<z8jiX&!Ac+58HL3@MJSG*Mms3NaD6aH?WDdSgUL!ya2#M7
zws~yak~m&OI|<T<bp2rKbON8Xz9m0sw$ZeI{FPfNThY=zkv}D&#Ha(8Nu6!WOvRgl
zKR@RG$&Yo6JLr-5Qy=$lO+B25(g$MYUac2bSD_0$!JijJ@TZ`lLQB<UxL;JorDf1J
zyB<ao{@ASoJT@#F6P@_;rR5aduL@7u=Bl9zrg)7@R;wc1j75B3ObK_|P+z2yWQ+@y
z>-eNupDj8gT~Df)N%68!yW{~xorSvPN{Uyhj-tew_cbVn@`|K__Q95;`|g0dSjU1c
zlg4d6F6?f8?mvCc#uj&h)8*R+qRi%TOwknd*s^+}({u9c96#URBzmyW^;7BbEPYFM
zY36&Oftk^4&|gQ%Mtf}j&!o@Xe`2KkHW3;qy8Y|*hsyT)!cc?0&NW8IcamM3_7y05
z+Lw*}w6z-8*s+Nl#~vx%H?`5}#uy$JiEcY>CAo(C6n25-W^bufuel3?7Z1F>fG5^~
z-zq~}%D^~QowUqxWDW<0pF!!LLY5Kp8SMmL(d@NJfAuvwaER_J{J4E(2g=<&qYaQd
zkd49jq8%7dgC9s-PA~^TY&)%Ew|@XOG<HXegDwfFGZXC?DzvpbfJ+}CNy{2gvWIy-
zwE!mrg9i9G`w7LXo=@&BMit0<w|D9t+8x4`jzF93HbJLajU(QmMLQ@2jgJ?b{Wcf}
zn_75IAxEPT!h$;*f8`c=i;6!e>_On*(fOl&@O_Bju8}Dntwcu4$V@cS>mEmcyy&3W
zK1p9E9kYJG>og4AeQaNVJqo6q-{s&A!LF70(!(a;#2&X{B^@6`0}aqIzJ+`6C<UHC
zYig^L_659ar{}FhszC{cI`EftG_aPz8QDc-7uLmIxpE6!4?PCPxKL0KQ+y`o1e6vW
ziI4giuN(ZZBuyxUZs}gs?>rf~yC)b>%4P>9^9VZcZ9$nJeZ<q8_vnv;(WeQ~u1Rka
zB{5@gfM=bw6v$X-qa8-I$HdVGxgezvJubL1Bx}j(W!4_RThg$jd4h3!v(ok^i+12K
zoMn1VSE~SB%k%)+hyI|~f+;LpMhEx10%fJ6oetu?#Pg1@fmcpcfMYEfq(OJzkP`=t
z{pjtSWlR#|#b_6@3OVnTF;vJ8z!{bp$%%XOf=<2AR4%8NK5y_5Fu<6~9>jc2;|+42
zprHTLX*$}`z%U2(pzTh+&*8%gy3Gc*-bwmr3qSGqz7upClb$*E0f`lzouzjOdM3?7
z_h47(Ge8>=WfSWX<1gC#>=pdor?r(H5L}_9^Om7+DBu@P*_tOjo`&eVgH4#ZuJcjD
z9fg5$^fNCv_-h`*VOhX>vr9F&kfvk9Ks7<$u>;amJE>(rGqihruf$|$ZA4KaYv+=v
z9Sk=ujU7(l$G`ag2d8Y?BHW~zxfzKj^cyrq!RG@mX#^GVl4)v0d{IwoL9P^Jy9jb!
zh|{SObpCXe_s`oDJ5^Zv(SvW^!TynGA)I5y{&_+7ri6RIaX-;<u@QwcLp`HRqJWa3
zD2K4<bj*j{?A&;H=+))d?-lmK-}s0Blkjnp0wMrz03QIkDf$#Hzc&A*<8d8k*n6s-
z3&(Xpe+a)0_YP0cyL3P>JT>e=Mo_w!Ie({I;~Fksm@8fzBmp?<>mGv1Wjn0%Qr{&F
zpxep5c=DV*YZgm*=-ouezx1mg!Os>9AE(5vInREeHtTCM%0+hpLP_6M@B%-gPwX1{
z7DCxTME6AGu)~-+eN(#~z-YdCViXn0J}K(>z2A&4-i%`BE1?I4cz=*7xpD5=>Z;hv
zi{Rx1Cz`pfA5L(x@OQrt_6Dc)g?*ItRtvst+`a_;a1#@WnjQsyfD<8@owyNNfk)0;
zCBhAy{qCmo9-LkoFtpSkW1migPeLa_kgS4rI8T!mivCn?oxp+A07q@H!GYJ#>(6z4
zo}W*MaaLRmiR7xGB$j&6zTEzRPv_f@3BE)z0AKQ_g3=HF@K3=W`xJKr24W;L0cYpo
zp{4m21a<)@7Kp~{j~cBLeQmz?Z%nNmpU|)H(u%D<mz*#$2j3fWRjfDn+{1U?jrCsm
zuC22>@3vd%dj2yHdqC}x_5BDgo&3%V;)kP?pZ>QQxHA9x-bP_h^x+@-`8)5Wz=hh*
ziGQ7lqxqRz@SY!D?sGe$xPs3f%Xlctr7O6kYmi6+bjk}VFnR_Y<^7>Hq0tB2cT<e5
z3vRb-{>-ft5gT_2>TK_b;TVYkL8q8ZazKzFo+DM(Hhnjxi}RIb)7h%Xf=pe6ZkI=V
zt@3*#x9ExUdi=+HQ%7#abjX-owfi&#feOzgOSq=eVIP0on+Px7+-RPPacg#s27R|h
z*Em~Vhh~~ny!BOR!3n^YliuAb+@xDb+A1QaNmfv+!a2Hb%8>G_JftWlpd_IR9X7vr
zgIl}kkJL-*aBk<~250e!aBF%EZ!t_WS^(ScUs_*Us(Cn{;A7TTS3sd7>TM4Hj(^>M
z*?SvrX(PUu_T^ZZ+u8eb&U?0N1$8fOFjv8|>eYJ>k{s!KU-`Z-ZM^4kDuCidFE?hz
z$GO@%iVsIzjKqg0on(-0k9sP6NAGyJT@u@ULLsN2L35p(rMV9{AQy?Es#=Wqlp!K~
zaZB-1w4C$h#BA<riD)bwC_#@_GJ`s>S(W$w8kl659$CAt7`V<?ojdG;Z)4T>9wa-)
zZ!~^!5AfE5nJlEqB3y}2|CCQVcV3@Mg{$BX0mgf8r}bP|_|b3Oc@KL!BAaFBt~~x=
zIey#c5sB#Dgx@PGo7k_m&kH+O=m}c5tx}-EEnIx_9xwDC4T`~snK`%kD|A&jrU#D8
zXOnp81UHW9-dz=nF_p4@8Dh`l+VBL~L+E%YZ{IyTv)z)@)912&FIyuQ(T{?E>(Edl
zXBJ!(k|D~3Ck(;^e^uj-YKx1wdl55KTU-L;CO)bTF3i~{m@loa7?VU@BkC6cwXIcS
zomOD-Knv~J6Pxgvsyx1%!T;a<)}6<2Xx@VgLeS5d=S|7kA3t`F2HE|k$^sr!H!wt`
zXP;lo--+==929Se@XeD*y7vz87EBJH55u`QY8;`4OTC`>aHJ|2nNR6xT9zy0&-WkP
z7at9%`k6oZSAJ^aeJC(#f!wh8TsXQS9|m8;`d+{b{BAYc2%(flc(W6iUthNydjEA>
k-}j*~1J-tzJ4<v?^9p;PtF7P7UY*I&Ut+!fuMqnG1Gn9yLI3~&
literal 353040
zcmeFadu(J`dLLF&ELbzK4aE=wMK2fHvakzntLsft@y4uXvuAsEdZuT(cilS(qP?uT
zMc!e(rXC!UNTf+*!G;nmD_JojL4Qnu1d#zJFpMO-a^h$l7)Ip8fGjD9V>rRUvapgR
zLAzKZ5CT<Ae!uT=?yV{oStNV3(<BQs&2!E@@AIASeCK<e@4NqUY4c-$_T%}-j~+kH
z->W~V=kGswc{_hQzc(87hd*@Z&TcZ=8}IyJqu06f7n9>?(0mv*?z|pH&Bvo?l>g>j
zE;s(BTn_)q?`s~&eSWi4%h&sZe5qQj{ZL`;hpMIgC4Xpv?R|?jrT=~l8pQwgyIMED
zXMf-Pt>2R4|6334Nd|r|Wiyme9{;~mf4I#I{Qd!cp5>dq=bLi;pWpa<9=_l5&hzgr
zj1T|6^!lrxee@COe>2;^Ci;i}>rb|xoB4g-;p43S|3G$qegNx(|FJ$lOc;6|;D0mQ
z|4sBC|9@`nhwIPF{yl4b&iejRcKk14{P@3q_wMW4pL<Y$9@g)y@m>0Rc78s<{NVq`
zpMT}mS3dvn@y+}^|L5PO;R6*oh&+$y|IPT%SU+D}{>|?H;`2e@-K_5!>wB|*Z}6Ax
z@e}d)vi*+>>dpCobN=7p*DH=+m+k-Z&Hlf^e>eE=%HzLf`@eFt|8MsH&Hlf(`@ed#
z|8MsH&Hlf(`@eRx|8MsH&Hlf(`+x0b|KIHYoBe;)_y3P%@Bcpn`9J;_`TzRO{=W|U
zKfC;{ANcC)^_PG6-o1MqKmQNEZw7qefBF8|S02oKLnbf(;Bzdk@H3Og%HumqKT-XX
zP&oo7e}4JZ2d_{Aj%Ba<{<|696_>AIfgQw8l)ql{?{E9$@bBBeFZf^f|Be31bC3W2
zIF|HZ!~cH_|9>m~|91TEKjJ;Cw&=<e&;Rx$mt%g<%W}-~!3V#ue?IvAADvp9`Tljw
zyN$oBhxPNvatwRjo}SI~Q4TNb|FZODW8obANt=g%h`;r_pNw{1fad=v8%gs8YWRP$
z8+GCrL>K;(yMx}i{{r-yKN*c0{44s+jQp^CD!xFS;WS=)!F6a+>&_rPNTN~F>keOV
z)zME5kGj3?QD^vq6BD284WjlBH=9jO0Rf;X<8Cq<zMv$-CzAuo;RFKX`dv`MC)>TG
z+u+Fll#T2=@i#PCDppFl7c^&it(bd(Ilm4669x!loGbp^F5@elRQx9VO{dfP!@B6*
zOXA1>_GaaF)JeL%Vbo3<NBBP<VeXJ)D%mH~dUup`jvBq4s4<EMNz@)n@%*O?m3qBU
z%%e*GNfY-5<K1Dt)f?nTgE$&>;_fKlYvo7dop{g~w|m1xD`5TXQ2m6~qi!?bL}Le-
z@PpX$dn;OS()iddc059-Z+#*!;a)!)gfIq_`Eqzmn!`WL+s7ECR5M0+s9|(8MuZjY
za=lTTMg~!LY~j7Q?e!%6q^S)cv7N@caVHw~r1oyow{n<X>t{deXwd7)-$GI{)T%H5
zMxrizA(5j-5+WFqr^|9lzr7yG&g5>h#}X_*jGD2Qzz0c{#6e_<jox4<X=udj88(w~
z$G*oQAoGd}J8{##b-gpgZm*emjlD2Gk<~jK;&Y=XrS_shC)&4;$OKEdL42IpM4_Jt
ziA=lpXFA1XU~&gKqY@b;7D2_nNW*^I7!A<zj|VWhGJ*c&1B_)?w_SF>ojt<rzTbKn
z_Wl3)b5HB_Mm#!dcamn@h_JttuGf!=XT>o3!ldK#@D5<A0SIQ^;rZG>yNA~x#|Klc
z-?@IaZY)!OOe?N@9!X#LOMmw-+qw<0C3M*oPhV!ebf*!Y0@d#%y^*4XSldVp0cE1H
zX&qkx)AxYVlBVIQLGM62#vLya)}Z@*;S=D_>*)%n8pdsG<emT|D;UOajnnGVQETQf
z3E21ow3x4tI~<>D!mmQ+i^G}F1us8#ILqb!gTJ>~Z)3NQ+pS(V&J%@?J36sW7rZ*!
ziwAiDnHkCebiv(vp`67NT;k~xx}Y8R2N7$QV;#$IX1=gg3OR(^&{Kj;)NV%oA-Zi5
zAB9C7-k99qvurrPfZY^=5k_g|){xX=LDC3=XonxY9(+0W?9HSTkM^RjGzp*|N!f1i
zpf?&=OERU0j2NJX;at1GM9#H8^W(qs+Lyog|M&}+INxOE>JLAY!tY!Ee6!w3_JNkV
zfGd2TOc3w(cH5w2hjNYqZtfLo^{2%WSM$>a!YF^mm+ls7OnO`>*6XEWW}Ud?O0R}`
z7B_(IkLlF*$6Tuh=V*#>yU%t2dG^Pm`lo9Rv+w*dzYYo1rhunK6}Ngsp&l8v)MUar
zP=Zdf9K<7UEv=<@oLK63-%<yhJyz!R+}ar=4QqL4JOV{FOu9m;?W5vubjWJk<Ne6C
z5&L?ODBai_#a+}R^E>KE&i)`Cj^0ih`<eNb@7L#_52i6D#o-?7TPzeS8|B+o&ScT&
zy?A>~;w4Kj-!4nMT&>jXQ{{G1lB$J`bxT@XL$JWqP|x~$t)O2^h4Nb2g5_GNq8VYe
zzgD?jVHpOiS}B9I+Z(q&;q~a(H7ky<>)J79+|a(2i-nCfmdW2@(E7yS#_g)tBVWtK
z4Q-}eE)}dqxnx5wS8Fx<Tq)&im6B$ttQV2ImaV5+STB@rud_-9%eQ3%qj+gutFLa9
z(NCF=TA^C2+?Gwxp!NsEl~!Kcz`$j~*D;2Yj%R(Nvd&2oj6L}PEdxmFpSdsirfzuV
zPOCR;Dd8gNig)aO8}P*q{e1rYeQ~;mZPg#X8qS4xe&k=`TmZq^ZY3aVe4VhI%I9c}
zySrd;+#yv%o(Cx5;XND!+r`=fJwv{T<yUS;ub(ucc78n6iWO~#bKs2JJQs9kBJ__P
zo5B0mWuc;(K?a~$eJ9=rE|vp<*Lk88`3b9_F$VJ@QvOCO?)Gu#j#0e7$E{)s$;k;`
zj~pl<@^@mX5kuZlzDT>*hzH8HU~r_omrl}d_F9SHcyKaC1FL7M>;h>E*Gi?%dd;}2
zo$GZH^p(Bp+jws1_;c)(?0xa!Q-NzF<=#!+C%hlx21cS`2Hx*t#csDjx<{Sioj%q<
z^9(;-C~nmYm3erdWb)4uJ)g*DiYpxtSbmgNnSUD|W%BVMsDNhN%sa0}x?_AsrH6!N
z1o#%{i8_bGxY>Qs7=w@w*U6~e3VE@io3=X=(%RYc3Yi-1*hnUToYmgjAKI7+cE}XS
zDr^$Z-4FYzn;bg9)a!$hWreW6EOcmO9H$!>kdTUb<^9+9leXncV&qy_BB#`l(9|8n
zA%b8Ht$01UZ{%yc4Zl30J*Njz%<e#}Asx~oSgN4*ydD|)Aui%6S=sX_xN$}oB57ay
z3jSu8DXb*vI{8_DMx0igNl=VKfR`?31LbT68_7<)CllCc^Rplkujf`%k~o}Z)I|~R
zS2G5*W?~&_N%AG=$iUk1dg2y3CwS<^Tk*J`*BNZJ({6ZJ#s$0|Lsp=D-34#O>%p~9
z5Z@k{m|e8b2KN$@^&O>o_b|v_+A(lYyqbi35wFLGksSBhBdum1*U3Q-jA5HEoeVb6
zjt099g$UyyYI;5V+=)ifFm4VMAaUnRTI8(Cr_B6gG^GAD`Opxs*Mo0pR>sbJ`BAjX
zjNKT-`iQ5-P`=^v8ettrj<JW}R?8%LJ>Vz<`C|g49e%Y*BKx{I-~zH<@OLx0(y8uy
zJ>+NU?BkR|NQ=ES##H-E3}o%3I`Du;k-_u;vWZU5>yh0(jNZ<`$}rglBw6lZ(&@`Y
zvsbvnjKYVpwD0xgZ{dsdNk*1`@fJ`|KsX3nZy~x#7a#W`OFr;=0JWaPdA0D{M;16n
zN?JaR$>blSHX{qBf((T&ILEp0Ota#yf<f_I$>sha+}G#tFY9`R2=|xj?RCy{v8F_M
zu~x2CmDVn<S=MzW$BVe36z!ISpb_6bkGLra{f>KrRES%GQ2C{j-&snyz6f1ks^YGp
zspWE|qOEy7)oQJ1`53gmFlg5)Tmfp@3xw9}22d!L%cxw=qZ1|-GotmA-lSHK@M|Ca
z&p&lguVbMNLhb<F9gN!$Xap&n@&ibJX3p1z^Z4~b>5}L1WU|%k?2siz2_^+{#EuGh
z!%yVF;BWt6ekUafuv?M12V~~s8ubPuh$A23jvdqu*^5y}|BMBJ9JckIls&h306Xo9
zke_9o4#Ebu0MBBL`8qN6aG30;d2lLu1l`s8#=8_ST8$b}L=<^Fo+ukC8iR!lAtzf!
z6)daS8R_jP7lf@uBKcy->tT1S*a47X2rJe=bv@?rQQRWsEp^0W;^%IlBc$MdJTxg=
zexIf608q-vTY_{M@>0nU(KGwP_5(i9rmmp8Ykq$b?@XtHc22-M^SMur`#wdc`qPx(
z{g?K>duE@4NlS5eM3%Sn^Oo(;Q`@`wc)|?uJ}>;t8B~mYCV3Z7vRwpEsAw_C)|VgZ
z57j{=k~WKf?g`cx+<s~>fKtihlddcH!s*R?=H3rH2la;f-GXq$>f{eg2iKtWAPl0H
z$R92UGw#!c5_KU2@u6wS%6grLAPj=x(Qp*wnrj>a<dXg~p9<Yf&%xRees4?BV@o6s
z5k^4yHmg^DFz)1_y(ABUv4?@^4KeQ|!(K-*pO%_TI1NUuu|kkqxGwosL#D`(dpcd(
z3C3~H_j-)@lsX^)kw%0cf*ZXNi;OyIldyM&5w8b5ObdfJ*2o@+QxmInF>g4wG~FY5
zPr`D7zaY~%jWm}YKHRt0=J%h-RCbII6Fj;3=BCHVSFV-UjJsM~_jzBhm5swo!UhLR
z$_F;yu2Dhda<#0a7eW;!zA6RfzhaIHYg!yhRpSa*HrA^fnhFw%EZAjqldlo?t@BkM
zev0H%es;g!-b;4(BwhC{_V<!~>s2oNwSnut>g9LxtWrUH&$bIdd?r2J0{J}yvndM^
zB`wr{Z4)lbpAGsAxm@yP@T<T_P1#iePcJ)vv7XAZ5*f(jg0B;hb8!PJg=LYI&y@er
z_*X*k0V5j1Ocd@F@CbKJYS9H2M%1<|Y19Ef1Xocl2Idh1zE7hLOX#Oo%Ek#r!TE4(
zkBNgWnm3MO3w$S^S|i3iswYI4_&DYJc#dJ9r=26@Uz}sr7aoK+zMuBPRK_qZ;F%nR
zdORoZAsjic0sUmyNDG4g^-KrKYGDo+VEX*<Hg7}4tRaWd(h@@D%AuARjvuSAos8_r
z8+$!qRXamrCpwCSJ%tMs*bFkGJ2)hL$gG4s5w^>417iO}uSXL`)DzH;!Yz~@%BLfo
z&J2K^g+%Ktl^tzGy`CmUItV#lM1kJEwCF|1GEXZQgD06r!NBr*I-FqX$?g~hz_?Hb
zVTj4%x06=P*_Di)C~Y{vA?SqIy4VHD!13GNsXIRKnd^0+tf!ndNDSCNYc0b^6|SIa
z@FA=6mN+32=|Lc@VQ8A-dgc*Io~5IKUxZO%0{r`NK1>DbF~~s(I;e7ivY-r4!#+RC
zePrvH8XHj`R0#Smm1DlrdF@LKdHHDo##cAYbDC)oL*dcs9*D^mCZ+d?rTK=W21B>K
zKf`!%kVzhnJJ5{;mx?V8$JR6kh>&88QGA%zG75aK{Uqfpfp?YfwL$91kVb&%YzaVk
zLqz+675J5{cz@6=b_V#1BvRQ4VS}N(tt=$|)~RtD8IemSM<XCDt)3~1;#zHaF~qbB
z2T3#S>#etsWS_|)`wcy3Ta!1@dFOBWU(!>M(}Od#&LIUp7t_{_#|7?{ah=H1sv4sT
zQum6<%8P}X@xw~xT2c64KHnh3jOpaU>(YjDu*xRBFB_ArY#cIhrsV7cc~+g5uUElF
z6Si5oya5iH5PD_nTcy0dUN(9T!HRYh6q~e%{s={rzg62<x0ct}Y6T8qf&Q_37fU>@
zr+TJeEKD-z`JL>w+Rybf_+E?p<>x!cFU$9uOlSCBD%G*un2C6XW5NL>KJpj4T_Klb
z2PY7Nw%sP=>kZu~P{n^fm}d8v?<?O!z8_BBK)!3JVWN9#VK+G6*V;2EKAm4?aLgk0
zhp)?m@jmq{U-=s0nEKGJ1{vUYnI7b8kE+GHPYWe${**sDQqqUggg}!vCP-gW$#Rqr
zxb-x8z@0PlAW32Om<3t@i74rJ;{MUVmHAN$7~5k=hnkke{QeBYz6UO&)U9;uDP6wO
zpDuZydF4TXn|Gi5v3k9mG=Tzy|3L}7-d~sNn~<0Ev~aS%$r=14LD?xho|c>a&_#qa
zg62NJODP;?yR27*Y>EM*4NFT+r(pG%o*@LFI$A;_tP9#BsRIP@Axt}XcJOzlL1?AH
zkqbJR{M^s-_lrTE20T!$mMeBJSB1~Q>IxfGJ-(~!70AHk#9v!0;(V_yp2y4D&*Ha7
zFUvY0Y4d0Ae7;`qlMLjAM3N0or%TW0Wlf~%DLiS_MlizS${JEY3Q@gvvJ~s!k?I-s
zj@gE&1)yXAl(utSLzl!;kHY!(&VTtIy@d6Lz-rbG2ormv-t=qWfY<9ALQKA9%QXcP
z=B2wELTkSE>8geo=){?&O5vlkbL3J%^db}F1<CYTynEiB0grVW5OM<-HoHN-g1ZIy
zup%X2EBn0Fs&*q-!&hRN^UPZof4m;#E4g?7{#Q5a&=3@bdqp3_AB3Mdefc5mMgbee
z8F}^$RHTs<KD=r@i#(<f;4#G!d$^Bl4KOza-R)ZRH|GuMZO*8kH@}=cZ^|X=gNr1q
z8sKCd*HSrTs+A(Xn)dUG^O%K`N2xyI7k>(L^spZkA_yw%6yYRuuUpW604H|^dLe}u
zZ^Chh#~rhTIH+otBE$%Fo%x{f)a)I#)l?^i%j+8YU`io~^Fhuv3t4!0{6sJW>5jkg
zG00`XcokM=N_R-r(5s)Z*Ezerbp3aBdLtE!hRPLngs9>UMzz#rDo2ejI<%c3yXDbC
zpb#BK9*i@QK**lmudANpl61)D!a0)P{$F<L^@AknUZnWpl5{AR0LDmKZ)*_8I2q*9
zL;Q2|vl+PTIzI4yoqP93f#(kr=v1WyrQ`YZe#+&5+`~Ld7*Sb0dpXj59-7eI9iqCs
zLsWLPltSgVpz;Zu(`0nS{R|tm2&`%bhhwPFx|Zb)T##NcJ)LrO4T68=F^jzv*JusQ
zX5oPIt1+{w&_j!@)9L=q3TMxS&jmZ3_kZH=cYz1!&I4#ypi1ZjDfkjiIQwxQD$(K@
zBvadxV1SoaGB}93Z*j4q?F^BFu*qP!G8=|{D6-hOFu65~(H<xVBPP<QKv^2qvttxP
z2%FlkkAl7o7;rPSgt%1`;-Q{>D<J(%jI5o4Lnl=2lEGf#<V)hGH{h%fKY-l3U;pnq
z_4;v;I!U_Yr_<=r?Pp*Ylc}FdwnIoOA$B~7vkJNFP`Z!-ek1F$leOsx6#u1hz!XYJ
z72u<!>3}V}?q%vvTe@B$wLb?u;Fs#NpKA_KlB>fq^*2(v*PnRsU4*aE9w=Ks0S&$;
z%lxW<?}w}L{d!SYC^LF2C35)CgaATX{u6mH>r%%obeaT$7MQVT_A4?J7-<W9r{yFn
z_bzsva))E07=VfWQPTNXVa1vi`*WO{MyuORe0&__z|k=rDXGJQ=oqqT=`8*cnFQ)?
zK|#;zXZI`!cR(h#Ko-oGQVe>2>jZi|Mu2NJoz`qNnP)|v%mT9-CD=8BgWc=#G0qG`
zN(jXt>g0DJ`BB5$X~^#j6SdMmralF$%tyyZpk^4{gPDqShY^?n4cxpQ_K=`8Z1;M9
zI?17^rAjTZkuh6N$o-+7t_Ktp(@k(c0LsAnYK%Rc@oR;$#~imT4!j|?VSpss4~GJZ
zDnY{9j6e&klpf2X-9HZN#YK=pI{oNBhv5<b0`nJ3MlV8s7%K6+6S$N4!JKdpAVdDe
z^YEFZhL8F`x`Ji-{aWCs2s+8VAL7_w#X_L~hQ1iY2Ymt9vlo=1UqrB|QhKTj)Xbg*
zB2KgUFI7vB@f)$F{Je5aTc1wN&c(Da%Wmbqv2Jov8n4r2W+l8&d`3M?tYQ7W+OgDa
z>50egwAy1>!NK84JH9iF8;}Y~Sk5aJ0v~4?eGlaJI{3!fb4S{lw@ZPpi(J(FW*}G(
zpm1isk2<(~!}@nwx+%zs-us0w!Ee|xti2cHL}&2t3N!pWuKOQ}J+Yl@b_BJ1+yvS4
z>=*|q(O9Ho3Url^&<+EMN~f`gC=%2o!&K<OgB>xZg}pGHzhTS$k!kpYDV6n{Ur0O%
zL}zX~vU=!_y2`b6LvkDXw^C4KS1Brzs}yT65ES|d&OpQ(FH0w%GVm;&_9Ug#{`_x!
z7Vr$32{?_mK8D9o(Pa9t*A<_aFprmX;IDi47yVrtzS~Jn=jODFfxo0<^Ytk;r}UQ+
zMk6DN?2l1Pqk*FC8MqbWB!yg14AOm#aUdGP!7J$kxA@0WnV1Pi9R=M+1S<>u(md)?
zi_g5kbz|k4i9R3)g6#tCNykzV8^T6+XJ@tZMP}lv{zLxwEWFd7&ziz;_S`rBG(7C>
zxaJ9O`gi3ryxWM(j^J+Fg+VLj>&YZ@*8>3!bOwdI0GXlt!wof{5y<6+uON}{Knsdm
zgMtT7SqG;Bkfr{H`il+w<WAtEX7&sG56<nEQ)<8Ybm9zL@SJwL8F@_rb~BF8?!Y(h
zShs14*KXG7#Hl}5;sw_U8<)-8&FIJe`d7cRem8>uRktj_Lh)SS`IF%jEy_a|^}{|q
zdMeC~Vjl7f;5d;wtxhjl)QKsc4H%M~GMydAS5W?vgNGkcmR~g=mEEnTGyy3>e5EN~
z55DM;6+T(cn0J0RsDNhvXzZpA&G?|_s*gc$GKrwquUBRKkv_0bxU0exLV5~9Znxdr
zk$%AL1U87$YZwPmT|M-Nr7R7t=e4NjVQ=Iz4!^}>Z{gijLvP&cn>bf>f>FysOtWLO
z!n<0S_A478|7|kS`}5al?#nnBodgVahAMxktlK#U4{)6LYC+F8NFKz2obbucp0Nx)
zc()$>HT=QP|F=KQ{Rs9E{z>K0+>euG_gd@+@grG~b5{IF%8C}BK2=s8oHw`?vAC2h
zE8)7(NrMAIfZ%H-5QXnXu;6H+N~uaM3?H=;XazHwMOtuxBVmV2r0tHe3p|4|Y?!s3
zfMN>;0g~D1TVBTNVF_(jAUTct{<N>UDJeP+T_h81<n@G9NOfpygKB-3Sq<zd*;~rK
zf;+V|6I`)KJ(x76nyno8UHyC}*YVg&T#x<Z5XAFH?7@o#5|qLxDjI)iGOfUjL_ibd
zCai#kvaGFxUKBbJ^q^Uf(6)n4Avt#ne_sD7f3y4O-fL10N$>pJPd=&Njhhhwi-=t7
z!vgYLTegq*p1@}c)oXzFPMOaOefm3sM>F=`>jfBmD{paK?Y&X&8dkT$Ek-af2RIuQ
z`pgl4*{Bs^$qhE)N?pjV`*!Mg_vx>Io`Du1E}<^=I71I`#!vK;rWJ#b?x0FgGo~*x
zZ$hvebj;CWP!**fqTA(7Rj)@;SK2ehU1=Q1>s)ZZq^DOSnb>4H)pPkb!nu5|u@OFm
zj|_VE71i+VT*n3w<^>>zkV<7bk7KoB$d;WWB;yRe?c4+0pO{BxX_ll>BA@~<d=
zJ=e&uL1u-IfAqie_a`=;zjv;I8~)&taQBte{{P*d`~A%fob>l%H~>7NPxS?GS?Qj%
zT`YV9;Dul*d_6IM27C*WN-!D)cSSYlny)LJxpnFHO*lP|wqJ4j0}mp7N#H08H6*7=
z$7lBc%)J`t3s}5c+i>H9Lvlv`UaVlr(1a}PnQ|yy{<Gy(%!eP^-GN~}8#UW#B1VfQ
zdGV>1qDoKC+&_sxHP<d7OX{P^x)t)PHE=FP6NYkGkD_7i#blCxv%_%~M?0I?ITfsc
z;EV^aH0bq6l3bMW*?lX5)`y@R(r?Mz8+O76aS@8P<--6>Xs^eu%Hcw?Z~F#K#zWc|
z_%*r(TM;XZi-(2a$+Oprg8zF~yqmfX%_F)89|iPqU{kYqga;o6V$=&fL-9Dv&`~IB
z^!_jjH>FJL617G<;C`n4V$454TaC^+v-R*nh%_@Y!uP27c0<tCN2i-{xc^i?7>vMW
zfcJ-eL=x2C(vVmr_gl$v?2|!HwGiQl8G{u~Q=JHSJ-Bnh(KT|Qnip>k^J8ddr1^(w
z)TLe{NCyn5jR!;OLkM<4U)T}2=Wq~Hib_5{*Z(}D^UmlY;Hlg6JjZh`i=Xnt1{9N_
zWw@Ik;b{ar-!7o{oUVseDQGc!4nEhb@$5Q(Nj~m2S5fo{^MCry2JSt>qy=}4*gQhe
z3K5O_?)~-{?o!BNfd>w}3_~8!938u4NV<?as25tR4Rcq2vyNf50^b9cYz5Om&e*wu
z?;$J>+PM{7TD&4(HG6+~xo-P4_)C|2!|ZM)-(EYW{EbuEF~lq9bhb)j&mD-7)h9dJ
zkc75vVvUUQLu+O#?JHdpX5@MYF1(**+U`C`-^Kh}Z+>m_ZbH%`?)X05f(IN;N%a9f
zwGzLI3vTxTsbC-nCHyk(5?APL;1qbdc8kjM_C&b=Mc(!-O-1DCoSGUG=2Y~JukL^l
z0&%`NLkeW2>C5u7w%%~Op8M*zeHC!ffZySHJ>KlQ9$<-Q>{ynzXXi35g*~|WPWfXp
zTJ`6d9FK$IC~9rRssO4DsCI@GPa2#f{H9Ldr_~CoNTZ5J(zx-umiF`7e7G>a5EOj(
z<)BBj`F984cempdNC<bb-jnIPy~@kbBifqPBU&=!y1+aq<Y@xcvSk=VhRHn9rioFI
zu2z&<O7(q0qVhkzhjy}9f9293ISG?`@jz673qA9;x*-c#t$0@UhF^L~__>$zz25m{
z;F$p)S;UnSx>bUI9Dbf40Sqwtz>^0|itYNMKltfmd8<*@W(Y=T6VETF1r;6zBD3{L
zzPX2%Q(#QtFYTHFQW{rKO5<a_pP~}MLeTy8K{38}#Njc-2d^1iQC^#N>I#O`4rSgh
z|6Bvjo?o90_SL!E4}N9y?igO1O=p{c#p8x@xMlux>DKywaTPgS3Lj%Q6tpH}+0!QH
zqQEW!gcuxvU>DD)Q((OMIeo54dEPQ#4xen@3v|og-~5gruWv=7o1fY_+r+<mNR@rM
z|Ke?QMf&J@o5~NhzZYC5)6?5}S??KJbZ!K1aw60OZw+K7o^gt2_9uuz(Lr`w2<~6X
z$xnD+ce3Q&+|d}0P#SngVwmW?MafO*byApW?fQEpJT~TzgVpHg4|Tpjs+A9)iQHnV
z9_WB?{oaqii+ziyQ8Sce7GE!ehr8uPIoCPhK_-~z!R$K(I`42tZSN6&RM+7f)vv|(
zTWi&dIeX36H{caf@stH`Owh0pRUD{$<AEYk#bMCQ8yK{_l~N6w+@j&8r|e{cXHTKN
zBgJ8PFPa=wdUL-$HEjeg_=V|JH9eqOkxpTm+t1xwGzhb|jD#LIY5Fqs#8$@7Q|@!W
zzDYhv5L0C6iDhy%3e`@+SDE}P$?YG7Mu)4uC%B`p^fl09(jg5oQcy9T-nU`sfV;bT
z2xl$`XjKpu#%Q-|eDrll2d{#!kQFi!p@yZRSvd~;L5FN!kBLy4^q1`t6LhjQCRfM>
zT)VN$k#@yFxOQ*v2&rC=n4CiSC9D0~4^O7`k8nYR?*i3aMZ_KyLOQ%kb5>A~Kmb!z
zgd?Fm1|wIzlfdI@rY+hlK~>7^DasX_?<wpwL}7}|DATNSCu?|LS@tE2lw`+?@8xsd
zlV|o_MxOoN|I2-sbejenEAP7*I$nnGq3yc>6gpGjTL9>-%jq^s$KadAQfz)F*cUEo
zOv@ut857tL>F!`j`1j}Df-_r7cRUBshA|%Yw{a>$_pV)F?-|i4slUiieElitlmYy4
zu4*^8n!i6T4OUa@HBZaeZn>5Y_=9N+!0q~0RlI@@RCGT2Jd0oIk9qv(k(B%WFK%N!
z;ruRmDL$J|pni%M-U$}I0_jw~oxSAUD{S>F|NOMv?1xTB1N~!vO$~>BE1>oXA3pjT
zH9uST)kW;mX}oqHKA8S>%y>pWnEoE^&CRNwYnYQF9==!V66S<vEeO|->rQK~SK!(S
zmV+xz-wd1u`-<GVZ{Qq@TYNAUkJhAm;S((KRt#MgTvPjSUk;ZgA1gu!VmI#opr4<#
zzrDMt&$o*GtsDvWlfiIw8#Tf&C?CPhH)b15$CaL6p{qhZhM2fzZ-l6xOi~J!-~k&M
zgchNpln$10D93>5Nk=F*e9w%3G2Ua$zgRW+7ps-bzZk!!{>5OpKyADg`Bn;tvb0;<
zDIC84JHMrH2=z7LhnxU^CGbM#;csiv|I^Cw_ZV)(y3OSPsC*f@mo)TU)kZ8vKMi>V
zuz_78Al33es!P`r`X3*$hvaAE4)p-}q;<=lA>w1{{yrdrX3K^q{3UKJJ(&=!_dJmi
zgcZU8@o=0NJ`uD%((Ckl<F06;c|A?~&GZcWF;ruurwBn0#)H;5Btol<!(&J_+N>V<
zTWGh%RUecIbqa8C!BAvY5QGAv%mkjS#v?YU*$_s$pRY?O7CR8953v5lS`{YZ!bQmP
zBkTeLzC*>{RE8Chd7S}gK-dy^4MvScOx}*~d`#_p`%X^ot^0v)%)Pt+71?+CEI4aZ
zI%8%0KdWy+5LtQuor(Wh8GfWITFpb<Yqq(X7<z_p0JBXzgsJ-vJA@jlB1GkpphF8M
zL^JRW_{wkCN7<LrQ3_tPq&=QUS^=X?JRxjwj-c)b*uPm4c1n0$oz9{xS>9b@*w4-D
z0{x5Qq+a=~KL+dvBWJ>Xn63x92j`4YMewyCcYN#~wU?`!_k@}`w<O%I^2^XcFK?%Q
zu;2Sf|5WxtJBCrT?1J;|gN1jIp5Z>wfi+s~L)o8puJAl*HX_K4gzp9E1)x>=QSjg@
zR2zX7Zy72+R(PFEU<r<4$|vf28-XYB<7kJ{Ka?UHj_fBr81R;DqHavUkoI~EzHvQ-
z*djEC)M&@tdNXWC9D_}Je~&@*)9XQN^3_=q_}q^7V>x2@0TDAV)z}a*<@CwN;74v3
zmf_v7?b~@SWj3F41GSX%FQiVHHSdq~rVSO(fKS?ZXP1-0y#CNQf;5fQ`Q`^jP;m=a
zLj7g3n*S`TqaE`4QHk=s1AFTn&jzbuzSo0h`=C&bbqdP_v)dPPIpw`5^~{gT#}Q(h
zQLo2wolx~VG5Lv9Fqd*&G+-+KESG7)2iOnm?wAqJ589Zq_?b>=#5$4rAVI8;_XqO{
z103;62T!cHYIq&ZUT2IM;cPW=_vk2Fl*kv3f~9rPJ)L0h-;_nBvjINq&QgFnxRZ?r
zLjJVEgx+d-3y`bW7D#r&c@RE!r89XM+&(yF(lKcSC|+(vv49z3ZGG%nLOw1nN2*FY
zj*q_1`|&<qAjlZ@ab{U3@E8#pb24S^@P6SSv1Oowk<ACYqB0=?$aXKmX3%oIE_x$v
zgDzvAy+1l9dI!>`J5iGr$y~wT<1oPja^B$JFkJ;iG?UlE46*cCN&<8kMK#iXH|}Ae
ztOX${C^H7j3PdH@>w&FBXuUhen(%86P84m7n5+<@jh24r(JCDda0r+1igu(SpdcR-
zUa5gDi<SdD%4w7?_TvU`xoi$vFJWIaEhmgl;1z;jZONq&!3wW@GqtxH!-F-0$me?`
zeTQ`bR0{T+e2=@0ylg=2GcbjBPG6JMnUXNaAZ2`h;D0-0hLuh*Qe(S_bMn;wL`H8@
zC1D+j*K-SRQtG`$0x}weaKT`6qX=|MXb29teL!ds_i;>LsE4_Gc)c>@=F_Gj0?(DY
z4AQ_s@9<C+ir}IXdC(N=;R$vNr^}J8%Zs;;^H91Jpnvvs(X+8%d;LN1Pn^sB)&D{1
z13u*jaFTOa2DT!f<OKaN)k~*>`EAuOpOd=DF^_pWn@%?R0LW>cK4^1m+cC&<KXFg5
z02^R384RI;QD1LM7C_Eq^W#Iy9V=ktJG0BK!9I~Hy&j(NQne;~gghlM7;R7Lsg>;r
zVN2p(k8a*<M(+y7rW+O?GreF?fDwmd(n|3Kd(%ui%yWV-!|IlmaafmkaYCnEqNN;p
zncg28E^$5-1Z7wf9?V1tCTtL&xIGwzAs(zooIaQ;E*_$4Xp>0ZAy&Zzo_K1w*Tw^G
zEQcL-0FfaMH<1A9YG1{FKbY<UQ}})PTqDfT^;_FPe<PRsD_^pGi`lynT|eUwfgtb<
z>H5t5)`-m(UOq_ip+X$#e1e0(f^JA!?GrN6n8LekYKK#13W7WNf;q_SYJsP;l7-A(
zPf971QR)rLHck5xqG^ks<n@@q&^Gd1McLN5tzGVqjeS5HJdD=s!F!s1R&n3uwMRnV
zAS<Uugzwe>_LO;4mQxT?5Y!`}C0X&9EYCqv+O~;57u-FUnV-$OK@aPxJp2#;$#>Pa
z0ArxlNg>Kk)AMWbd_0+td+~j?3LlrtBzz>j#Wq@<VCIwMBXK{m|Gu|$IJ2>E_$WM1
zr{EA-5rCu30E-~zA5agfww?W4g3L4R^x`|i(CaV>SJ3O2z{zZx^GLl83c3)4<N?|q
zs!xSrRavP_t+^r=9qmY7@wdcon<Gx>h6v*ob%|6Bx?AFQ^K`yZ=3Mzysu!4h@BjP1
z<y`3}IJz%%uFS}Z2};lITnTHX5X$qTv%`CgT+epE^ufC;b`&rcXeUO}_v$Ub><QDz
z;wcj8jh(^Xo48T=?vSYn#|vWG`efq77)nT<^n|bk-%*GfA;dQQ2IqEFl!GwMyMp6I
zs?+v8W?R>zX<L1|f)&g!wWR#re5O{|b>KJ{53V?!6#&En&*nVXdJ^>A-}w(m&_|I4
zOK?*-{X95Pu6%-D`e$}u3d2_j#r^=`XP_Na4Xt)Ea0{pqE`-3PmYPfk99rNDA`7Ap
z%78y4;Gv3edEqPJa`C4086VnN{wMUzeS5+*T{om`CBz7kgz;e<^`SqdREsobFYkuo
zT)V)cd=2Nwn);<wxiu-hT6sh5QP+z43HrZcp9)n%IT7G-tt#@Q6(%rq9&DxW7v<jh
zv9HN_a14%^fxFlZtS(1ed|&)Sgm=QRbk&i!L;~{GQ8?~&cn^gX$Om9+5>l1qPGf?B
zJ*u?1#*FNq@_H_HUmJRR8C*T1`|cazownTjfBt=iLl_iYj4oN!AA4qSsDPw&xI6^W
zXdNp`)EKOw2#)|w{@Fhc^m4${N=D-&)Fq5mz}xn;o=PvaV2>XQ2h!nIZpl<jGxSTs
zCG|~6s0JU~ueFQ-YlnR?i>GA^WZIf-Sz_VtATi%VEa?4_51E5P8cgXHeh%HiIU?D$
zKN|CT>}-kK$MU>XUgj>Lb0H=4$m+{nlu-|J;0egSo;6+%-6$PEQ^Upu_B~cWGsDI;
z7OXIct<n)5e77Jw#-Q(ORL&&wsAc7rLH+Ze&V9Qe$2NP9Ajh7pL#0p78NMZ8^6GL0
z?_}t^jTL`@2=^P@MI;fD?-CaYm!X2v2be6z=?Ij6*G(CuumM$e(+A-b9@M}(bzZaQ
z*8T9lYp#Fm1LBJvc%TANqDL3+?X*YLeNVolx;yZ9L8<q*Rh+r6FKJpKjQ8$L6Mo91
zZDuwJ6CEz4L%vV6i^mbV$cbpggS0#o_G7vb;}94dVT1RT%QMA!112%fnkAjQ2FcV@
zeg=Hit-x1(uliSozK1Cq)Hlz#|CR@fdVBYZGw)6<Sp!``u-Q93Xg(~-bPbc$PrLg2
z{Aa-*EcThaYi0^&YYzXlqFAn-OHY_(x3+?Q%sc<Z_dnr%&ej{g_o+NJv+l?*0#CcW
zKwo%%-OpYqK|Dequ&EA=Z@HQA#2MeKTdn_RH*y7XT+rUx4(hFYss7(Tjo#q8g5F4$
z>fO$-Bk}*eS$_mX*(>v}p6n%qQ`Bzt-UI;Txgi=Hji%CLO_8EO7m!dv5=k!*89hLp
zGcuHLY9QwPB77NOlq`#EkPb+v0SzktN17cTy$<wN1Gn}D?{I#pw>R&98tVfKT5w*4
z4k?v=K7*@szC%sraLhP^RORD}t+W9%^vb;l!GFdVe(BeC6kZ{>iS2^3OwMpJ++O^i
zeKy?c$N;W_85J%SjtQ62W#Jd;V<SRGUu(K#9ugGJ)bGmwl|9!8KBgI64)zFm9zm&M
ze1(Ch=!G(<)bRP>jOX3G2jRTiocyHFH@0Z`nFCMZ?HQeS*fdHXOH+FB?8FHa*tl)@
z$W6O<1QTKNxqZFq*m-!l+&OqZ)f3qK?ym@a6ZhevX&FALjP@4nPvD$7i_ZiFuFNm#
zjR&K>)$C7NabFIuR$m-ZH`G0Kqc5(T?4w2w@n_*&<RuPAnhcNiM28GYjhgD0GA45n
zBo*`!B@2PGBH(y5fL02*6Y!J51mIu@VeoNfygt8#S1NwedxO;ipZCLDh4%)*qqet_
z$}sq_uMFC|FT`PV2Z1u>bsVr}-3}f?LHG%}KJX`3K~hm!*bKVk3A{C8jP5E-1ns>-
zJWXiTBUH)OGrffrlcXYKf>aow_=6=S@XLiyjyGz`!YNn6|HP%^x$S;+?wem71H3yB
zs?b;XS$xS8_8HzOUOcy-ncw#l2Xd3B_JHS{2cz5M{`e@^_r3oMe?jOrK|psJ?dV_(
z<!EzqwCp^chl8a(5p1P&7TB2FH$Z~=W*Z@OX}N3r;lk&p+#v5i+7<+WrQZC9KY2iU
zT-P=3LVgYw9NC3<z4y}VdTrO|tbt!}{R}VPw|7ayy3IaIdb4h4P5*_zUvS-&9Gl*M
z6z;+A&EV6_o)dg$`RDm@E927(kMF7%yx{uzzI&wlF=5{w!)veM%A0ljFk$C{>t=Mt
zRz2*y+`Zq|dm_%acqFGF=nL6zi+Zjn^Pd*{0zNywX_!KG$oUF5k<nGXt~KE;ARd94
zfV&{%xG>a_YaMi~p#q(dX5%mAt7`oE{=1-GL_aNoqscku+^oSUSyWPaaZ6QFD+Sz|
zR=yX{(9I8=zIx|pe=iGfGi<1(=kz?>oxOe>$t=8BOQfX%E6PIW)61ecpzMVkx;jkk
zCGpGF%f8<E_P_O0LQjw2o8&C{+REp-f+_sqK&VE)&{lEi{!PGU;F9b3Mp(yO{=fO-
zx{grPoUw-h#+awe#<0?a>1onR;u%5t*~_8}i*=>iGTKoGZD*IeE;%l@p7-ws{>2}x
z{ii?8^#s8NJ$l<fa_(aZR$WiZO&`qqD_XJ;dJ<z*;Y0MzXi27Pn7m*&vVjxV{OfLP
z;0TjBDXkauJl@!-;)!Ld_R4Ri3Da{}vTof^-xFz$<Q#@6`EvQd{JAS~^2PUYpB=p?
zr}jkkDOD?~WoqiJLt)Q1Vdumn+>-H8=@BicawiVSj(G-M5WsMdq9?G1joMmD-!TEs
z8JfG=2Gl<ISt^0uy*sUK#@z$;Spk!CPeew02NH63k?KRkeP2VvG2TKHHG8VOs}3Vx
zrQnpWPDib@$j@7*rE*dFlQQ_v=p6$7-KjOC^Qvu#jbfaA2p?2&u%I%A^`h>UbxH~p
zK313??i1(pZ>#<>@go=OP7it(^3*|U_i=_k;p_Di^hs{``zx%&rLtV^eB62%<mK<K
z*M+~|;ZsNe0mZjO7&s*7&&PQ@2|T2zQh*lk{2CrF*6U?^`nOcC7Zo^BGlncRuPSFf
zQ*R^8A*+>p5T1AhB6BTp8<nF*iz;>mJ*}q>@R=EShU%_uK>XrP+>RgX%X_msj}-r=
zoSGu+ZbYlOS}DmnjgtzdoG|;;BYUOkvwJi1Zaob4XSv*u{R`?ft32XD_Q)IA`z^s@
z<#YQ?d*m=MR_pg}>#7~a7IW(|iz>)TA=H5*Qqu)a8H7IzmOrL-4;7`A@CnUb+rXk+
zz6gaP1-@`@PS<e~iliR;`cSDC)B_>7ioVUU{JI$;Z%|?XqIBge0dM9W{d;0J#+P3X
ziPg?HC!u%0n%{1NtEdgfKD4(AxQh+#9W~+MM=3_Y5R(X5(mY^<Zk|AY!5)Ob1h-(M
z#W2=u3qE1s0!P6=Nwu<3fQ85T<|Tu#?mY<j>b<hwFW^rGwo9f^uczGN{c`^N)WdV8
zA6)*G@zn*+M?i#j)!|BG;ljYE@|K&4+jC4gGC~x{eJAfb$atXMWxKKad>bL3f!yl%
zwy;K5F|cr+7T4E7t_y~$@!l&G)4DycyiruMqYYEr+29=*^A6|q;_zUl8Op%vR>lw3
z=7Znlx!S`DX5TSG`-^aTvY(GdJ)TwRxQm^u+Eqt(8uMdSV{U%r^GM*9@hLdtNd>pf
zmLS0O=3G@6T6}K_a9MVvH<?fT1KLlMVEksbDJ1hu@ol4O%$k~>#~W*^$-A*GMr}&(
zpAE8Ec)cI&lyYDAYYML!^R{!!>t@bd4(Zw9Rh=N^-?)0GTEc3qFOgPHVi-YyJ1q#h
z8n&)JGVX9fu0E{9fZ|n2ONRKYrNF-t0FQUQ1Z%d!QdzKm)w+WV19U_z?7SYo9(fnS
zS>Rprjm7pXE$lqRy&lr4>B(V67<4U(a_m^=NR(F@>_>QaRY+S#&>LnE<Oc{r672q>
zo$GfGTcmFbrW#)?6mR=Hi-LR+>Zrp0;SplH5&P1dFjInQ?sFJi*CPgxPJnq7?rmHM
zCYgRHgMRXC(8S}^&B}f1e51!IFWE}LBfc{nw_PRTT=Y-vL)@pQ4(K|6T!6b7pds9G
zb_95q01Z#lm1Z!D-(N}na(?08QT)!g2AXHk%_q_$#f$6jpOYRjyGB|g!}BlagLqM5
ziv3_~Pjq(r{#j|Vu1cl__$q==B#QCHLdEdfbSk<R#e!*G6br`ZCW7;)azJiS`~4hr
zTNd6PZ_7OdN$>xu_k_>c8{&GbueZAX&!Sv+W%+zqF6AV`aW0$|uDCBk*{dA5B%k_8
z;J0jk`)_@ga$Hk>l4U&~J$MOwpEK{-c2H9;haL)sX!##?Kc%seL@W!`xR~>>F(R*>
zKLc}lZ$|BYGP+*GIab7iLHwtsClk#bs5#XW%hGa^vXI~;T;J>2(~1<+K}M(*NfZvx
ziTN0Ym&D#kO>kj&3;h%s4shW}>!JS!=7WS0&&@~>F0haA>Ht$Es2S)@`XGVRn5(=K
zP9EC{c(Pb=IbX0lDikY_3>x}0Dz69*maq|u1#^;B#5=gc@+AH=pC)u*vL5J2`3id_
zBuP;QtuQD_D?&=Z6RT_RZ=$6T4E<5A1PMuFSX5!TWUjgR@UHnf0euOMhIE_3l3o`P
zG&q}rzp+kOs8)+$&kC!9_e(W$x&=d~4gJ0jrztQK&HMhCnM<cjfr7W5JiX1A_%e86
z*cin0Lc5zEK{BLh<MR4<c5!Kp4)fZ8;iH+3-9#>Bha~G6^my`bZ|V81xM<!I=>q3L
zb%uVNT`T}76Nt|b%`T}iy0J@|ouq8+;^#akdh1DeKQsS{*>%p`Dwor1^L+Je&u+r2
z%mCL<<e4)#n|PX~v$#9O*@~zybPs%z>gDJE#cvB=dITxxS@xwT-UBc3j@g;_Ks~6G
z&o@#MPI+f0gBw{)KB50ZJ)u<1LG-&KJhZ3GFoZ@L67r411>q$Zn^jimdgNK8hl*4x
z0F6+DJ+v+d{F!KinMK3?TDjDudrYT_bdOOKplmFW1dB*kY*`^MWs(V57^Iv9ZQ<3{
zl9jG)Kww-m!sFC6(0iw3*?Mwc4kRSy-ua8l=NQ2=?J~aD$#6a6XNz54nSXsIT!(?^
zOyHcuTNdtE8B{&`>X!mMuczuXeB8s{!;n&_16<v1>VrB&L}Y{dpv`at-#XQk37uH0
zAD*uV|0r{MHui3-`bps&uK`>IAVHG@Ooe7Afm~HVOSQTN0ga`ufv6Xsg-kUs1xBV$
zkp!ETpiX-_-%jCJ@c!1P0{<lUg<qU1o(62>@w5|O>}o4KFY-^$e;#A7m?*&EDB4HO
z>gykuOGuePb_H;~_JQ=A&aORSg;R493}n}SrRmG8|NU1#=XmVh7q*rDK8Vlu12Mn;
zuZg0=M)B<SbtI&_!Ca800=J^q<#Qt9Is5E-u1k&p5AdUeV@__<>%o8E8t&XwzFcWG
zX4XCM-E#la?|rB6-3}8tUejyVQoh^C=h)0WOBVQ<=?$<pfIi`+)f4tpqvd~;T$7l6
z!zbq>YeAIbBVI<J5#-<-kpzGSG2p;Uli_PAyz4xZCqSr_M<G8tQ5}v_6Sj8s=`5D?
zccdoK0PZo}a}*nwydAB_9tyIUe;Qb(0d@Cf(_?X^bE~fNO2F{EWLmH*f!MU->NCz~
zniTE8EEdh>U9o5)&|=X9prjqwb^lO_FxA7y!72Xnxb|GUQnd_`s=6$zRICVTN7II2
z&=evVG@S@gl;r~GSDjZm(?MAlO;O^++2($9`}0>*zLxI8S+>@)b9jC~p4bi(F*g2@
zeKeFe3jmESb-9seaBgOQ7w31do;O}i^;{y=zlUxFY-kL@F1shp%cXd%ZWmVc=Zto-
zzIZ=oII<_Y5<Haw6^<MFDqY*f`)8q0a2<=P<J<B&5Clxb({iVTGUw{n{h&9Rd-O|R
zB|QxvY;$&|sOl`ci&I*&PkK^ey`wi>V-shZHD;%mH=Ukeh6bjdQ4cb>ic9z)?uvB8
z*`0fib6jrUZ#@cjiMfBd|7S^8;UOfxSfdIM%l7>|JuT$)CG;Q8lxKz&3UDOQBVBcp
z$a|iGj}OM)+XR0=Nh!;z(1Ztd`D~L=Izt#x!{Q+@)<d(`Ht>x6y*~=?io9q3F|h_c
zS5IF`zn^@*TwFiv{+WI<b)g%r{(x5t<D1g2DqcM^PpW{B;QLudkpVzFH%=2+LMdw^
z-Hu@r?C`39J&Vq9Bb}uGwFRp%@Wt~DWbcNOvo(2lk8_Eeq>`vL5V*o$f_q7m3D;_H
zW+~(^2-uQJci~>rIHw4K4t6@13xO1p!)Nokv*+ZapeOduzyAZ`&$r*>gXOdKiD#aZ
ziYI62BLS6F@1JMlN!A9)6S}#t9?x5S)ezGty3I-G>&-I*-+)LPQUGTip<+qc{$R8^
zYd3Hkz!wK3<y0s5nJyMhSD*;eOqK=zsNQUe*DNeT5vF0PLjjO4Xd3Q%uv!!l=WUIe
z>&VF<6=Jm>(N9K_J15{>&dOj5luZe~u#O#KSEjVTCxi^niLkaFrF@p&Z_dJbf6x;i
ztKda;g!!MvI}NCc_%-VK1KcnOGTsRo4{VlGpzs+F1exkQpj-f2@114^B*&5w6{&~|
zKHlN_nqTn>UaSHHeTSPf(gaGjjKhR)n-f1H?}0p(y&_%Bimu%6g7hW%1OSjN^Lw%t
z)+s(wQ9|j=OTZI>5x+*<5RXI}yZJYrfeWsqtRnG3c<1AtfBVmg{}OCCygYdk{%i5#
ze(TPZBU*oX{`EzxuVI!ieL1=^=Up^_5urX!#<yyrL+FfF9hs|DON`J=5QAGJK`=1r
zcasu)H)Jt{LmxiIc|+G>rWX9&6-#z76-%kU^*U#>SgM*ty<`tJgZJrrdN|N%+OKT#
z)#&9c-M0OjKq!*l`_w-XxP5C3BW1sM*!_0Fuf+Vl1Mu|POI3K0D2VRiYX)Xh;dgC_
z*7$3mu7dZ4FuR)WyZMknlD*TQU2$?tV+LUA_*m|wOc&roRq&WE{_<@)PHAVp-K!cW
zUK9F3-m5Z=(I9WC6>&E>%Z|vWCJQ&O2YP?=Z+=YR24qNt*9uPOi=6oW@Fn;n_sJYx
z{;Wf0{j+doT@_5l`=@l=@tH*x&H`Kwpl;D~tH9IX*C*?$|0P{No$9-2xlPxLIM=AN
z@N_@u6Xt&8h3_Mu4SIyoB{+k>ej=Z3mcP!0Us(@lmHQ*dDEG&q9*F3vqhG*V7S8aN
z9vHC(W;hW$A!37bvE)!oO(r_#S*H<}*WuHm3ZMO9JPyX2h=h7TuzTD6BObtddZRFX
zh?!!LiYTeTfpm)`?M_6xUsqB{gmD|rPGWgz^jzzEB{DDaUrMIIL#=tAZ_(o^LIq9L
z`5`$}6*ycwg)hSc+qCI<fpyJ$Xa-TNxgwuFyI&rE*3a$S`~N`X62o!eN&`Ph#}@Ak
zm+^neDhc<pHPM#AwX~Z8Cq4i)Z_eL&;J@tsBIw_~|E2HzkBJ{g5#I+o<Gih&@Q%`h
z!VG_SwxfPe#HmOCGkhlaPMb6nbtuNR(E-8$o^XbR5rmSb(si@VT>TiSu0{Pp?4PxA
z4F;9Mz*-A>3N@Hi3ayW?Ao7K$#h@uYAP8QSFvk!C$)*{=*AnV&MS6tz!|lNzh4+FS
zj_yPU^7t^61r2{-k>>eV^YC=_*YR18Fwo;z$Qd}0hO&z<D{hE%rCwyuhkB4(Z~phc
zCG<I7uE1+z7vaax;tPWHGo`0kA<q?kiXO+yNN;@UU-8X>{uA4b<ljU5QGCPFelBr{
zJOuS*>RSmQC-~)OnuMghmYPhMqLkEbTjz)QU?<6%7=+g(KBL7To?i}{XKV>Qo$-eu
z?xgJGTWP(nWTr)WiMEjD_cZ8tG0k2}qy85h*(m29Hi?26i)C|dQ!Ja~j3S<OSD^q%
zsem^XX_ksbJkBOHz;?h8B{i_k%z!~tC}Ys@E8lT*I4CK-MpbQ7FJsUI6bQNmjX@Jm
zRM*#lw1vzwzfh<Q9(E*!o7>)qLlFEM$K9@fMgz&h?Y!Xpb*PHlvj$Fg!`m5}+?b`K
zY=85J-g-mvH<Et7_w)am(gV7`SHk1-_ok(w80dlMAkYKIjQtuNz%W=g(=kpC-L|Xg
z*DP)9Dt!oeJ`3M#3UAZtnc!g{aV|RA;R9>7wH5Thb7qH0ltui1ihN<wuh=}Ch<vs>
zLqBpz&-6SX6!1JaHapJIaZoqO@N=#btXyU+)Tf;WKZ)n6N#R9`Y;6ZUr}wH~6}jdJ
zE}xd#Kb;5{#q|}|M|S|%7Y99?a2|+6^emQ7Bl&h7`sZAOe_k^$m#0(j(d_0j{9V}Q
z!;EO9(Hj0>-mORBeT{ee>Mv8)$6sfb%MJ5onMuR^$L8VU>~;lx`2CXbka-RVF2<k)
zb)(0aoyAM?5uSu~&Hb%EDSV?*99~WFd*9+Ya5CTi;^)8x`1asg!W%dVaX}C0bT%Ak
zlo~N2#WL`((ss_24AapI>>`cd2{nj#w08uqDE&BFBABIUYY4L6$e-!C&f)BGU77F)
z)7{IRGcuK1PwtY8%mdZD)Bk?GmnJ)7DE>+EQa#6cyrOzymF#&Vh~$~-iDB({PN|p2
z*3MYqZ6wiAva@*qY^pyU0Z$c!<A~GIg+orGrf(bG_pn?Jo?1$8onY4wl9oB}ffydO
zvmelw#B1T%`zQQZjiA$`ka}gn?%V@edOq^zXY4e+_p$0VD3FPCnqTd@2Z=hx>@txn
zHJ>>*pF9Y9yqizHPwA+n*BXnmEI?e(&6VD1FcVCbo%_9zGW2^UL+6fJ-ao;Bey&Ov
z6uRQWM%;}BcXlI$m9}19&vp9}?rm_T>wcOt@B)=W<ug>*z|;_i1bG6~QzXEwG+P;X
z*?J@B6K?+K?;5-uUr=whaB=?wtH?b8Q36k`V^I@qC?~EVEP#fljo=du$O!`oct}rT
zrT1YsqeY1q(~ykUwLDM-hOf{&o#GURUwuF5<&*h2fW9sCiGU+l-=`}r&hwgSk?)50
zh*WtNE(dfKCKL7F2*(4$c%m;c<-38WR?#4y2LVo$)Dk#X=E0Ui%QA$UgaQ7r$mNR5
zA%HL`5<L_C4enXP)*Hc|?%i)!J9S-n@Ta486dvDvcJ~bF_RT+G1}=AxxSQ%bzWgKK
z_pb0C;RPGIe)<5+vUR(WAB6?DU?7}Nm2wGQ|71f~lpl^7OArXk*2Y)3`jc(UplxF?
zm2p&ot-Mm>+5LL|VUhF(k{&IrxA+f-M@T5U8hx|C7nomn((ey0;ono~{25i2VLs|M
z^AOU+onhu2R(y3FACP~MNndFOu5c#Gr>9e_Cw_kr{M(#sz$oeG^wt|eKjCA)`qMw7
z_@Lc8j=J$3FrHOg6N2S)!AJGt_q#LUL%{<2@Cm^haN%$=*oh8r;3S0u-uoxn_r*k>
zQ85h!r7J|9VInk&yG-ncpfe;X;-b@NA=YHR(-xM748Hh%>-BK2dgnX8qI`ov5*^~@
zEnPo$<b-!oPUIWRz6&cQpDEt}HG<wn=Y(!Gra)_?>h`KL)6iIJAXG4%4BNzH^at_Y
z1X$qv!|*g7Uh3q4ofy`bk<A<ge`rNArJMxB{SgOI#8<8YgH!{|#u!EwvK;UMEICZu
z2M>+HffPEqbgi!ZhsAe+D7UVfxLPJ3|G@W%3aMeEro=aN{gmhi{j5YcXzi+M1(K>J
zdmhv@os{6Ud#{H{@bxS2+FQ`P>VfRGs%hX>w9_8JlAZPlmIJ*nouT=gYaGJuFX?#H
z2^YSwsdL9B=86nr=_<P6;CS+Sb6<-668Oa1%Fo-vjZPsizC#B+x7)A<jylmW&L`cy
zWG5N*)LxhaTy>w;K14gvD-W+19pE#vXMY;xiJOM6$55<y^&_VP7VJvq{oeqOl2qI(
z$Y#QOr8X>Bnv{5&ASw{GD*j%@K8h8RUt!3(0q&jPT=P?<29^zd_1V5*Xv}ihInghC
z)E^}<lw=Md^+wV#w2KJJ_x6WJ!YxMhkZtpqJ`UaUcc$akm>geJ0v7Oipl;kH7_`bc
z#hO8D!Fiyw9!hZuoYP_pl3}oDis5{z+UsFCm!xPeKVkZNR*$xUr(E457o;hz-Vo-Z
z_~P~4YG`iB46bO}pG+-cks%yP?Y;z|lZ7l^j|>xP>q%FbL-0W8jBzx|s@MSUCA7&#
zaJUC$RY@H7V;sIx4}ga<A6eaTTY4^;q0s6c#t?*`{1xv@7u|B-&~l*dFd0DU_`M(Q
z0dCKMeE@ooPrIvHmd`(qEoB_R(~c^*!x_D10m-M@@HpoztyHK$*-5rAkG$&blGnqv
z!HH&PB$)6x#v~tuW)D||Z&!0xfM9sY7F^f#oRcG#j97c-7Az^##b2u+tVi&Ap#~TH
z(p?1MP;7;BjvdANY&{M7R=K<1BYau|*nAX>zDd`5{yDk$JYHM6<c8oHt>}=1?JPa0
zZ*VCF2yW^C?isWo8|pCFfxzXbY&F<+;}Jm(_Mr%b2WzF8(H@@>w{Ujn_H^rJ*NIyf
zNP(GA9bb-Oa6h8#lp$azcpQ}WWamk>U0}Xu&)**t|1#a4B(VsBUM1{HttZ@mQuQ%x
z(yy&Q+6(gMT)+GN!xG_VORy#;HogNnH*_iNv3SBM@4R|$(ukky34VIimZx@b=)PV*
z!H(+Yo%p3Y_ZfY-;JPcCf}grqxa@f#^UbOHVHxB4Cp!I1*L9yRUH7vGp%{Vm5kO0-
zcG<SZoGxf(zV(Jqw{?2ds<_VgNT1=$t@GA)u)oc{|8xHwe(Cyq@cRwC&Q<nvXhl7q
z!o}Y+K2wj!;8N*n)9WAjtFANWn>r@vsQ}25v1G$ewCW(u&&y<z$?br*PpeTaYIDL!
z+z?mj<{vg5?kk0-&^&=(c^EOp!JX@_(|=H^0AHIG9PkL$gN{Lb;3e5t^ZNa5P3RQY
z=|uladJ!*F3QMC1@r2GV_=B86S}Q4y=&umr5h1*hY3zs^NJyv1R+>*BIo8j-TTcRi
zF!yek@4VweaKwvN;15cbPjCoE_JIf8+3n~E1mCer)~LWW!c$t{d02Fh;1LZ7dSvCD
zUGH_taY;P)sZ?Jv_tKX(xAxi~6g%KX;??M0o97uOax!^j2|~PJ{;^*73bp!E<r~~f
z?M~|V3j&KT73i!&;1smZ-FiU)^Rc8_u!Ia2EF&mBHl#89Qx9Fx7PTKIrb`bAKLR#;
zN{?e05_Qe?44ogfTd<}W9SIJLIy=3VYCUq)95c&Bogp0g^afcx2=`DZrl>D^YaDfs
z(&%_duvbJDX~aCcfFHp^3gxPg20nz(uk<kjQE#57_TmovX81M46ggu|9k0i8AnC~Z
z+|Z>nzJ*3Gv}E5DIV}Z`ohu(&s={I5>13MZF?LJvF6wU7OrB;(0TR7GfSF;W&)8}C
zVWw3K7_T1N^7IBi$&#^~fNJg>c|B$dCZBpK9EP&M0sUbnW_K=jj~B3TFUw}p!%DMc
zdev)1=0#CHIqyd!-k-3>FUq{+*;g!3_b6?kb7aSwcA5i9SI6rCgFib3y@PQ()^Xtd
zR9SJI=cM1x0v2H~>R=VU9%<GS!$f8i4DO|zt~HiaGBEpMJ+N6ZpYF_rLs~Yzw}UmX
zlu$2_H1u}uM|eRw=#dWvge^+GkpZGkn9ayh+d+s8G~?ixfytUg=V+K?EzraXU{RT$
zW_(Dqh4eF`(t!8JwhrbL+;I+Hwho9BxJ%;7vW>WdyO?h>swbQ8RhS<J__1}?Uc``D
zVqJ!EX^scjuG(36ZLsYst?c5`?z89p$-j6D$%Ecl7JE0}#uE+z1O-FLheAK-GD1L0
zo7{ulBq!eMu@ab88NT;E8K&qW8D={JP1fvGdp&QC53=yJ4-vwFKAFDns7J;UVlwUf
z1PuWMug8!IKO|~S+K%D_AA#bBc05M?zE+IkyCS*(hni@s4b>K~D|7<dtW5_e9n$z{
z=p&c-QN#O_O%6-NJiHEJ%^Bp(Ya|1(x41f;Fwd49f|XI?FxiQY;GnCyD^mf^3*KT;
zv=9;+d%B=$J=_%D9EPF5XS9sOIdKY{h?4JvzHy*0;)(diUVua8_HYiR1wJ5;s%?%C
z_KG=1VfHARi~5$}^W!Vy`LeLlYm8^2unPu&3$R1mNK1M>I)S}D$H%&Qeb8kV+QWPH
zVUq#+7zG$>wmlGc=$qGLMPPv9@PQ{)8+$ZHVXY$pUIy`m(g-UzFh4JNH5F{E8T=z=
z!>EQcn3p2J&%Q*Azcro#ZM>|Swi^1=Q-VY08@-STkqEpqhYdSSgmkclBa(9%^?KM|
zHeFyBXW<x=A!8omk+bY#43E0_WZf6}uvCRwvL6J}LW;o=<6$H(-WtUR00&(ldv6x+
zav;rMdIV`fK1?@b5|OG$^o1PGx?6&DW%Jp%rV6T~qimsZH_4RA;5AySj>N18bo#FF
zzy1E=e|e9og7a;x?BHiNSoPweb+_IJds?qB5VP9N$DQjI{f!A;bokNN0n0#6xV`^U
z+9=^gv<erev{9C8kOf^~y;3zk`&t2=Dz0XiV)r9b$XidgK@|&M=vzPir+=cp#eK;8
zi(iK1EAA~uPtV_zFdra>>vu~+5Z{BpV7+(MKp2<UZxGQ43TdrGbkK*EjPvz5y}Xc)
zzUohB3hhQfKV7^`##XTL4+BWuipFp#7$7EsOf2kQT*W#^N-8s1Wo`oOk_}*(iRe91
z>St!w=<6igU5a#$_InDvh=Mi~dNCRwW~c$sk)32@;LJ#h|FxuGpBX|fy9Dfj<j5pC
zCF}he91T(JzTY}=UX!i_5|YAUO+~~gBP1eZecFMh*TdUGn7Jln*!WJI#Jj)&GI_L)
za#YH2zpaEqS`Wz++$?z0miEM+3Mr)4F&+{~?mt1o2Z>M`&15Wvyg!<Goc1Yh<7^HD
z5`4{s-X=pRu7p@SZo=hlST9@H7jd96J@43Cqm0?1ct}(vVIE7EA02`B2VDo=?#gm-
z9Q}BZ86;xpS{O4tAjyDb0stJk?gGX-3pgLb9I2v@L;3UfchPU9Kb`~Goa>!TRXFJ0
znTz6^8PiBK=%PFb>&#ig`dY0(O_WvnX<5F{gYe#P?!BM<)y*xe3Z}XZ@Dq#%JR|&}
zyQxmf@D5fM%f~#!v*%wS0(fW#G?$i=y#})cJ2D9gY}0mtL>-Q_fWVn&Lq6Np-dB%~
zdP8W@>Q)9$Vx3+O3Q4O>M)w)+_IBWgS?~0{K`XT1k6}{{85;B82nH(?L$!LQnoME0
z%@T7R%#7?H>3g+rA02>tCXeFmdAe#jF3Gog5bSz#xgY$>CgHNjw-7|CE9WfWax$qy
z^41z-k=nyMl)?dZkQXroyxqfzx?L2a;H8Y-%hRIyi{p|`Gv)K}Ws?VCnlz$zehkGc
z{s{lv0jZqNT01c}^Xod|OfmWMRa@7~j_0y)5#)2Z+|T@1fQv4?kK!nj)e7|2^ffx+
zZ9}`&7@8oj9^Ng~vinfhHROZxdsc?)^p&o=c+QpD93KL{(5UiE&;#LF3%n@6i2f74
zgApNUM}tNmu%PtW&>CX`X80#m>Uj*e0e@*3#axHUE-vg0<GAehpi-sBVs?C&U8v`@
z{NnlQuNV}e?WyxTovw54imvlngsO}n3ZAd_svVVKf*I>-^Ez{`2K%gB?ms7-!nCJ_
z2LcRM6}~2u`|U9(&=kG^R|HkN6hL1OKQ07NnO_dTRxb+Q{c(Y8b=3(+7Rh-QJkPf$
z;EKWm&kCx-S^)l%>uf{anq&MrbI1p#76-%30B`BKWZj84K1q(@0~L@AdQMACCdi9B
zzRZBMf``E+D{N`)WTu(6llCNf56xYA0@`(kAJ9OG-+3kM>{)Qx)zmz(e&FE7gzLc%
z8lUPr-XH8<r^Pv%xG|P)F$e~)hy9v>Wb8ko=xyv?4{jWsjGags#(73K@-#1ZbQ)_K
z51siqU0#p37+^#%AD)e~Y1qOFGDXpk<nekqV0>|kh?!0MlG%3k@*rK_2csgi>f}+l
z2Ou->UHBfZ3sSUeYsV^6tR$cMHdgNsvnX_<t`~3RCDYrs<ouYf55n1Wr3Sqoon~aP
zS)i`8_Ks#rHorK$F?LP%dV7N*CnVGZsBMgKELc9j-!zWU7hgq&t$Z^Xwj#sgt+*ZL
z=MZL6Y^VjbP6vDZ<?ys-CZb`~BpqtC$K6PI#NZ;2Q@$oENxHnNaS#ai3Ena`l8zAX
zFvorjccDH%SS(r|yu}YbE^SQ|)EJaD+Z+cob#Ni|N`)JV`zh1A&|T9&xc47Gze&KK
zw>mBy^Ff8yj;<bfhq9|A8TUx97DN|D-V6OfDSYKTY88FXge+4ZyvJVqNE$&JuK6-p
z1hLUQx9hu2pxm3Ftru_MJGzsX{va$+&Q1t$c`p>wRA$8RD2z)m6p~Psr633a>X1+j
zWjSTtNe_(hM+--!+>sXy!bafNO8d$(G(U-q$hu3#L$<IxmeG+z?=y_I;W=|Na0r>A
zj(s=|Yd##~ZcGd!Esya)rjKn5M!a!t$0LD5o(r9%E7J#+3i_+gOT)*wPfM{s%6o@S
zk@Nrby`tX^`mi`RL=TpaNMcTdJh@VUhi6rHMbP<xl|ps>wy?!u!BI8s)8cx?(qJ`W
z8nS_}Xw|N-83PgLxIIZrdu(SD!nDe4I!o0e$O2);F&O%z6*I{mMq-c;Bcan|IGSZQ
zc#N<Pm*V9L`Xzk3N~tFHCtMe^N}-L21;Ka}%TXm%nJ4^6H~4!t4^;1ei*Up>B+$&N
z9!dp9KTPM(a}W=&*H3u=<VNo>%=U*AxZu6U^-az1$?UrKAQs_!we9%y^<MNNb+g_d
z(lUo?FT37q?>oERIAvE_@5T4!Z`M03%!d@X;Ch2VV~4h04)0s#e&xsh)#etQzb7Ne
zLxr*q{H*CiN^9C6ErxeM=0Ub6Pvs8t!0Y$xi+ZM$H2){^GX-eN4+4Y430Vc!4e&3O
zA(ED}^GFCuy$9~`umhje{s`&RXseL}jD3XDki8G??6~?*q(P(7!4<{$l-aridYwd#
z)2p=P(vh+izK;ccjzElqbsH<8PbRLKT`*+SKZF@xPe%0!GpbMWq3Z)!OnNbj8qB3N
zKllxd;r=XLCk017{LK1zUouI~m*FyEl-?h-rE(nB)f?hIXtNmBTH=Gm?<YrKqiatY
z3iP2Q;bwys6#9-A7Nwv0+$(t1k^yYbHd&rZE<%M;uNVlV{Xsw2<UTIPdSyb$=2Sxc
zSgJx;Cd%?+o+RY;@T<_I`#p3(LY+vLkoj=kZ&Q0Zgr!aBo@h0lFwfuu2<Z=ko{AQ!
zy!x%A83u9ynVE98-abm9;+Uz%UY!~kuEv-7kTAltsTMMPOfpD7{Fc~{!7r&h9P;(3
z)$sbK62Y~aJk5?(Akiw6C`nc!PRY+&GfOiVD{BF~d}e->RbP=5GEB<2cJNq)dc_zF
zgfB{jpczUt)eNOU4p&n@;v%pjS-h^Kc%{4nVqA!Q1W}Xphe4zFK@XcD^?IQSKjJ!@
z=0XnMltARqzc-H=;`o_!>*c!pQ^{5NUSK<d%3TDxRG!c+e0%0g`S!TPXY6zM?ew3{
zH2Gb)Sb<%|=>Y&rD~nOzQocT(a~Q=CiD%0WDGg5(>;@PQ;QSE#$Jn@60IpA;-Lt=5
z_PkByNAExWJ)F0|%YL82k*D<Zbm9JVcE4_N%+3JUN$kDLaQIhKTvJZ{DdBRg*JRkE
znz)*#srC*dkbt;XUJc%7_WuJRT!=Nl<L-B1|0mt1o)vyS2A-H?=%ZPB3j6wAu>fUu
z=^W&PhJc`iQxu#>f{R~Mxr%J<lx{j7z4daIm{a(ZCee?EiiqUAg-V2?20cm}LUc7F
z+D|KHAwGhj3VbugAy7lY$b(*(=v!nHv=r6{ihf2WQ0)R!m7!F^)EQn1aVK(8x+JAG
zSdA-zBRGn7R51nK=bTX62XVq?I3$G8D(D-99wrSj2&Bps&%)Goi0R6d<@fc#C)4);
z|1iX{-q4f-*UBt{d_Cz{(2si9WLG$!Jef5cp6J$(U_L1w0FNo_%tId52C{oSNCE@P
zSY;LXIWvzYlz!PWZ48=s69&yJ96^|*^ZgH5EY@8sk^m7J1N)j3#S;D__p$pwdHKQZ
z$Jh_q{R=>Wa?=j9g@=tnOaakueiRQ!+}PX(Y%tx2v-^4}<k*0@-vD!Ps$y-h<GLeG
zO4HjJG8@=VwPRP=pTW`@T=L<v=k$FpYo2&K_v?_8wxJrxM~G6pGfcheX<#wLYCg5H
z&f{KOq3u!j{NPGY?+wPgL)Fn3#L)=1&{4kE%C{k9jM$!_Q;g{Bd^&7spR}Z0iie47
zy{`&I9<`gZM~OuZ{2&K~rhm2+E;^JsvH}YV5~hA~a5DhGC~kj}<Zvh+2yiwnS(Iy#
zob^-vi}U!>+-;OZe$KfkX`*)-$N&n43lUs1);(@3HAP*#xR?PZgBzNGb#PLN_UuVY
z2JN+_jam^%xV8-6`Dy^fy`HU??}z(K?*CD^hfNDC^7N;8?o|H*PoFOM7dYj<WBot-
zKExiX{~mz1bV<d`9#fitJS7*PGm{+yQ`ocw_yxaWH9wg?KUebaW$|P11C{&gUxr;S
z)Q)MI>l&I4C(HCRLB?)vFZ#8fWb)5xK7E2NKtZ*MdZ*$^Kz=4aeUc61?hrEJgLo!0
z@oM;`a0EPwKEqf<>NHe|6wrxmBu&_hf?Rz5%R*r$1Xf#SPK<=r*71HtI$Oa{Q+5g!
zn$r<WadPLVBzmp!EA^-@^)8a&%dMA#-`nr_4cbj$^0S8JfM2vSna<lW0B&&;n>*K$
zb3UJzKOy}DIFzQLN16c}>xx1F)g*Av3u`eHzxIJ=1P4!2`A6;#<h+B;Ku2VoLRVqK
z@{XI)$DP;b75kZ@++xIjMpmX+-|{Pb5x03>IpnvnYyyptZ?t=Qk09d2kN0WV4zeG_
zLpwB%h`Va}(tz{bA#^STL0MQ!foGd0x>N$p$JTgP(t+{9=p+H4=hh+Y!64`nbt0Ns
zSROAk7ggv4-RR%7acF@IgB_SCx7})rP2*9U=oTGjJ#h#A+LQ|)4`E$rLWH=(_jzQ@
ztzK^w<ONU>6L|yQ^@K1oFQn}55j2HZ86O9gC1d1GN~theGGrKvO7DDrD6?j!Hs3~1
zq!!G<j?c4)HIIGJacV_gkBTfbO^*t2W2vas;F~vW0k;CkJ*0aQRCx*S3S14ZM>CoW
z6D_u%i9um+M~4X0MAJfqfWoIJl@mc9ENZdWFW!PcWH<jdb#GBQ%t>Q`W=5z;YzkAH
zlp_ZsM4V1Kh<5Q91LkNMye<InM?E3%0gDAXmQ#*|(%<Mh9m|P?ff5PRr>VlPYRY4%
z@xjv7=*1a2I`vzU`&Ib2P?Z_d6^aJ{06bqZ^vjI>3h5)DjSStQh#`~zBJ|M!kV8w*
z(E@#x;vusSPzV*i-aZV`70A`c1ZwDuG!jxypbb-wqp-B^aBbKL2uF3|0zrjy&a^bC
zl_(n>RSc;N$vl2V^?Imhlu4E-<K4ZZrdzkO3szkAZ6+S<{Qa?!G^=4RCYa$3jP+$?
zie({>rEQ07;AX&!!pLMUC<{`S2unETvXMyG`@$ZYK&DAOIuSkkxS9#f^WjhvW05{L
zkGkHCc>f?nf$qlbFx}97^h{n4weMm4&)wY{&<lVB`;n5hiUDvV(i}RvR5T4MBB=-a
z0FQ-xCRq1M#OcyeybEh<69IkHcl-JKcZ$EGTFD-fDz5u{Zxl`TScDHuHHO0*DaPh>
z-9YzCNlB!+$K<7)4<6e#TkYLB#V0bPtyhD;oOk}(UC0%|UI%XPDxC>GIZ#~{hahHG
zf_)1W{8VV*?G~Tj72yFY#gI<DmrJ|z^(q!peGJ{a=m^2AAzb!``l^5j$#8z?%#pu|
zoH+jMVx|3Gi0S@M{e{RNJy9aM#clY31nKRNowny6gT1M*8{AoTcX3FHIz607fMRfi
zUWs|XpxxLBy0N`oIPlQn`S}RvP-K5W^09=TJ3jzEXC*olDwRC^td8IRVtpYGfCpIJ
z3Yq=lQh5l})(I#je_Xo+O<0izl%NVA(ty%N1rh?OLBtQ(U=Fu7-P!YSao)IJTyODJ
zwR7=(at8(gFtLV1m5~_GDfFKL|BJQXq?|efm*gjXKDGDFz47JEExH?#cff+ZBU%UF
z@sOlCeFv!x9r)~ZV6-e;$d+HiKOc>u=+hX}PDc@?;!pVZqLrPvi}G|GEM3YG(gj_j
zX5uj(_|i2eR-gl=L3Y~okysG99RJLwBBq#2Jo%(`;l?*tJ5yMb*P~OyedJ#xMQejl
zGt)6Xv71(HF|S9xkkObzvamu>5~=W&5yy$h5%4LzeeBSy3F?svvXQ?X4W%C3%XFun
z3MyCXqw@QKdhq+LS$_W-H0w<m>hrz<e;}&SR5TuasmKck5hFf{UQ(%OXcSsc?$;Wm
z1h8bu?~Qz?jY&qIFlZV|q&bQzQYb?wN@)~QAACW2iQLoI10!HR8NF8z^v3&@cMt0K
za1o8*>mCQTAb#C9lj%!sTxk1rRf9_@zTn>Sw7&2T%PDx)8qC%+cd@bdw3AKrg9(}a
z$Rz8U>_WuZQ6U8mkK`+-7cWJDh&|VN;`4H)|58iF_59NJqJZc442kLORm2X3(@=8_
zK74h>Jw8LC+A>)_`zez)181q-bpOq-ZQg^2l8ic(=|fEx^r85O>cjd*>6BLN6Gx}~
zv}SPf1%;2$ieA4m2_jZ<dM}$3NOm<oz}cO8j&lTl3SNPN%Ob&8Yt*ZfG1W>Y;^Z4q
ze5dj}bh5&Q)N}9AW7+pe%H{se{~B=7$Ad|+=~+xB%jAWCTk20ebq}Dv-zkkZy$^!J
z3i5Rw(Gof$mDh)rWVH%s4S$yjTGDWbrx*O_0OY{9-BKOp5YtkV$xNpHo)yA{{uuIh
za5n`?LsWBvDXcZ(qt_#>Vx)#Dpv-<0a^ae$(eSw`^Gf`vA+N_UDJNZNi)J+JTd$xW
zt<30jJab90pHuYXoc)$(!_r!&j<hqvCXRf{$Tjx<gr+lN;dPGA541jn(~8DBPzG1#
zYjcdNUZ9^eH{O^v<6OAa;|$1Emef$F0^|&BPB{UrpUpy%e6AktjLek=kJ=b5T*et!
zNBYEK+N?x-;Nm+!3GbAI%y6U@4f41lOJBy#9`x1N^0=$Pt43G-b;$81la3i?V&7JA
zqL`Z2##-37)YZn&!!|oDp!h?I-m3>c2VeLz|DX%{1qLTV(F$5|JhD^|n{>?61-q8h
z=@@ox8D8>x2F3}X5{N~Qc%CSPBc0YD&JP*Ggh3f4$eo77?Vpg`T51aa=Ez_pvy;rD
zwr^=^qoh0`=(Op(9^aJS`Q6vP{JlT^JO4OKuT%Zk7!lcb!3`w&)l>{g`taaec|Nmn
zc|X<v{#SqJd+PTfBU**t5pt(A^KROb<qGfwvzjJq7g)=*qG0jXnC_<`T2i!f0~cX7
zb^cV}^>+h&s6Om(ggEx=I(}yGy%F@ZD{%cN46Kdv8t7wpd%xQJX5r-JpkMRO&wTl*
zz)1&(MN`pNz+dEBV0WLSe^~#_f?uJ@WC=ZU5?_Q9Vfd_hvex24Dc~1F+=M)Kl{_2%
z5FZ`w+`PXUzzlewm`ME*{BjnqHp=U`!7C8e{2VOeeotUZ%bya;!qIksqc2j=<(@iz
zBu`0HS@m3+Oy>1h0N?bpZ;tXmo$*t~B<Y7x{PX3szBBb+=-0=5P?F(gTqIAC&hfT&
zb6%yZtnhLI9s+2<UzED9$nf0_HI<6Ig@KMN;axP<G%cFZUdh=*<hvVN3JUU6NL}ro
zn}xH_=zF0^%Kf{)^xgG)$xe)?SmynoP3qJb-X+s$C>$fe0gkqp?iPdvHv0}F#O{Q5
z!9%m<7CA)B#kn&2Yp#_n9I-mNr!~RJY_N-RLVADoy!4peEq0WTi~40udW7yreaKlw
z_ys?$$~z^<%8z}y-oGrJ_4l&)jm*fvm*iS-o@#hPMo=EU;t?5vSO)ok;DzX{jQ`Nh
zum9uCdm_s>xjN4!Y4<Gsi$%G@hpm4>4FUpC=3aoL1vLs$G?-PIkfh+Z3nL|3RnUg~
z!1O5Q;|A@XAt2&Z-@%IVw3sc76uV*A)asGKOtiY@{RLV?*LM#r*DC<NHqSi8;3sGe
zTS9;ydPu<7DhGf;fb5A9?5q@r!@5dwIM{3|O$EEZgrIFB$^~HW2p2-~m0OL-{tUVy
zi^m_Nb}#R}^*h)%+1rWi8!YKker)CJ_2!PB$oZe(;YoF6CHgT0Q3bO8xD9PK>fT&q
z_?e%{z<0$>6gLYosFQoDWL(3IR76euO3BiB?sYTkAM|10`~JU;dq<M-Es?>S%k126
znBT7#XYQ%8;A#F(T+Sazm=>v)^4Mm!i-x2!opvNO;}2s>^km2nu8<)p74;QrVVP4s
zsCNOcMS?*O@J5O~02Z3Rwt=j?GxZCBbs*%KC^N%90bwb~j9*Qx2^y1*&jdnOn#L@A
zz8c^&*Z)n(i?B>kPK!G{H1X5>2i`}F_;wCIs5~EVdGAvTa!J46?xbGC=SWMf4}Kly
z>I?T=v@h+FpfJ3KBy(xfw9fHRY(Z_A$+|ID8uzuxq;w*d7{3|$V-;_5n0Jq=+-o=;
zYemCzwL-OQ&Oz2n>i|4Oc`HpBT9U;==6kOOe%yEbkN*bl$MCNhF2^Z6ope7Iz5kM&
z%d_|6AZJ4TE8mZm43={d=N{k%Pn;jk@Q3Nd$ZjjJWe?gJd=k!j%wkYtfjHwppb`J1
ziW}5!iAS1+Inpn9{syX1RyE}1sg_<d_<shq7g}t_=vw-0Mw4&BXK(S)Yn_Xx@4Kse
z06yOiX@|HLU^u*x#6iRLu8$uN5{WcKl7*V}amn=Pu$eh8Ih=1`vxh!=MJC~4E=&S^
z<a<3S(MpqlJ|2U@upNlQXhqRDZ7G2=ZFu=2^*;cgoEV3cPPzv$&(QFjklv+b;Tsie
zWn*e52Z?Lrcfve3dN_mF2fWD<VTvS3k5uTognJMN9Udv2M3aM%KG?;JZh`)1Uc9fQ
zU*X@jw;%6_U>kz3Ml2_vJaegy@p_QX1a*JX`O(!tnn6$R5DxFPW9SH=YNq5-Q>PH0
z-i)CJ>h-WYS)f4#)(3t?K`hj+3na^~$)Y;t^++{bKoyfA2VjSTWo=kxopyLDWfrd<
z{&fbCbSEPxl|)}<*hX;qlp59dg|sH<j6f0G_QpZ71M^Z*i<16ef1~9zRfvxRJo6+=
zMak_!&z{6x2`_y^GwBQ~KQgsjo{!_4C%?%YGi3Fm&BH03Hj!0{i76GS{wzw;rBcNM
z_TEvcWPVCZuyx)rIFb2;))Q_wdf%y*5LE3bsGAs<3-p5;H4{Id_RHY;?X8SG#vlH|
z<~Ef5#bStuH-5$sIL*$B?>21tBcp*Y3*)Y;-mf@;E5F<Dz%7<QZ#47J6VT4U=qfn?
zRsaU^e(3=DlA!cc=?v1n5OKq@$4n^5Api@?%*6=!5p@f>43H`|g526{t0c|JvTC-j
zgfe0<6EO4@@7pY~9*B$D0dH!0NS@1v_t&IKes95tIrfljXx!-rkv!O_&_@63E!d>&
z?b>0Wk+H}4fCkG*J&ahFVW5YncPO>Ddic(>q#2@z96dV5NhYm!qFr~CHH6U_6u46Z
zr_;daYJCg$$5OQlN?h3p^pm3ex3Y1EY5bIWRl&n&N~o_i7u;_j=+4-_uY82<7Cel@
zqR8oG<<Fk7Z;cL$TUxL`?(`MzSL(qv%5-6UYnh|%R|4Ie%l**b*xa^fJoLV^$lnq9
z^TPdUn!abU<lZ#z2ioBP=2L(Q!h!B!;4|7W>B$+jp|YcUm)`N9h9e}AhSkfX?fVI=
zO6aG=4ro;1>?%2n5#J9lcOn85sVGbMp=1DfJw$Js=mmuxB_xx7F$9TxN)s_%sRVr|
zmlNANG;9TQ8V$rpK5wDoE|WLEYXqP+)U2Fy*6(_49h^>e1C^0mnaXJiwpYdl-B4y%
zscb%=O1KtEv2qoRFv&!f3_6)wjbE6h3tmb237gT^un$uA<^rFBj~4fX>7N$PUe5sE
zFb>8!FDFuLttc?2EgI}0!QoQb@A{&Kmm;6kVNqYP@Ot3;B2)q6LL^H)=p-K_ZNnVd
zHVSN%VHd45^fBIjIJ|y(`|~T8o{!}<=;j+UmGj4(YcTf{l9YTbJ1QAe?)r-RdIs)3
zNASuc>AUkEf49EfJ&<=LU0`bTsL+$Rah#~%G52oN?11bX6%`HQP<i|n_JS$Cjit%J
z2-PSrH*z~nqXJPr4{5SOU|Rn<_<6HEy<)KsrZFJK-<vqs;0PbEUt^i=NBXYoHlN)P
zizfjWyQc&>_srX1%yF*vZZcyAE=)(+I%VwEx;Q`NjYV9)bh-Rqd8(a140W^XCMf&7
za^^=F-$-x6fqNbg)`N8s!`V8oJcF?@$kQd4W<-7xi*VRjC(T3{Ua%PlW^k+hSR%v>
zT1xKenuub0<amC?3wqJA8bJ7@?OxXq<-sXlxG;Xe0&oVm9|is9+~%)+m2fxc@ujjE
zxVsFV2=IY*)~fYf@R+Z<e#5GZVB@;3?&7#FiC10^^uarCeaBDKw+AqBGfu1Ec>#lE
z{;B5Vujt$p;d(2Nm#ihd=be<UBLR>5K-#ej+aVL6(YZLz>zcAuzo}S&^Jr6W;=M*D
zs9JHJCKQ8Vi|K|@E6rY(ZhVsN`!DW%GvGpek*p~HoP!JWP5Chwk$>vAaBq*%1-XEX
z@Ft_um*O9S=_-LW=PMA5MBU>XJTbfGq!%X>KM#bzUZm$^;d<LU2Jr8>2B#wWmO*tL
zk80apWE~cG!pSQmm3lxbU0!jYX5s4f&&$byq+IT={I8qacn%|d1xD}%7JLQ2<<c?8
zLk;fvI*i=aAB*EWHJTv)v5Uwv(+lBog-QvJ0*uP&85~K3Z+qy>WbQxVQ5a^4cEC(;
z#K!lI8eO~xqJ#~@!@xh6>wB~hy#lw6M?{%GU|$`lVp($XJF#%C8SLxDzsYX$*Bg0x
z*r)L-?i{QR9RBD4#s|h+3Qd8a>!B`i5yE>cI=sODO6?7q53WqYbxzb@W@G%Sy@CCq
zZsCEq1%BAzh(oveV^C$I=xQc3GKPcKBLgw!#Nfz%$e}I<bvh97F%FLQKz!<W2S@a8
z=JinCfE0ZL1|joq#zc5@w@wj4Gr>%2!T%g`z$L8roCS8r_F5sUB8cNTpiCu@%VcBT
zAFdDQ;zjAfUfw(+gpuNjPcO!25?%6$hh7`7A<Xg_k>m!B2;xm}yKpn&Pyol?=6$b?
zM<4+m(x)~Yzj=QKeRC}r<2g%TGzg6;s+6VVi<lkAIYy$`1O??$&+BBw>*+y7MP^5G
zr0{}Tu>p2nD}a<`s-6du4`N@L5U&T%Y7QV!#*}J(c*-&!Aqyu3j{>AB1(5#0*B6sv
zPil|tLg3`}$b86GI<89^DxVfFc0M_L(bM~d7c!v=5$5o1UcKeVW#o>x=tuBROWxOU
zyzhSn|HDbWX?}+HAB$Cg!=hL!f$OBMr)ujZleNNDAM8;<zSJO1pV@&9DNhogU%20)
zcBo`5;ay9Wt(NV@o08b^V{J;VTLWRNiHgcK<O==a65(A9oH!D&4wcF-`i0=uy;)RC
zc*RFgvnp6;(sZ!zESzN5l0BE6d@4Pc2LIdUHXKNHcE-UW^(uU_&z#^#?~lq3iViP1
zfb6-$G#!JYk0vaHWk{S$*bnPBM&htfXA&)<xNokq4qm1TmG#F1Y<ePCu0J;cwjB(c
zGg;vFhO_B}!$)wV{1J6YcZk~8r0-tL$9;dALUz~>we^a>7rVXzb!`=0V6Pc{Mx_Qm
z9L3#I@%@J)Du%6;e1F=8s+3J#0<XN<J6U|;%6-Qm=;l3DibYi2qFO0bLOrS<T!W^i
zY(2gKYwB_g+NQ=cu<(B=8E9-_IvP;Clm2kxO;Eg6fZsdWxp)B!s>W1#kl)PW*uEv8
zZ9jP+-$_pP|Jird(|vn~E)k&apr(wg?B9nA{^ZYX$2ggPhjLYm#+mWmL^3mQN&d!@
z2ma2$JHP#H+k_8zNx)Iw4F0|VMyI~7QNMRtxWH(hpxFj>d!=O{%USiCptk^=oe-es
z@VNC^@p#1RgAiW~9cT#k(qW+QOCkWa#WbO<scNINH(FpP6z}h4Qd0*Y>3QI@Wdx|q
z9!`$5{1N;^_K-Z227N)x68eLlB1s!1QD?GtB<phc7wLp`)K?1Mvh{FVTU~i6pVr$=
zFy2rVBWYEP1-h1bTA+E`p(<$iH=W#*u+^l)lS&zs{LY`A(C-LT2sj>@P&^!fEUKE=
zmF!Xw-9oYwsmZRe&}Awze%tU_i_!7fU@X)$rxm8y?5hQ(5iUZQZbo1;;PVqQ=mg;&
z!3?NG?^5W#R|qknRSmTUe*!+x0fYaay?2j|Jj>3*7)x@LNdj-Ig^)<HLUa^CN@mnm
zd^7nYte)xa>79OX*u6^cK$5pe7Rj0}R&lCW9Fjtk2@u)N+J;vP!%_e{SU7*gh!bTc
zIFaN8$;64R2#^FBQVb~x;8mo+awNgC2^8m{s?GO(=bZbyRb-JxvNzsgv4C#gdw=(R
z&pr3tbI$`>l^}Z6Gz6!R!5(oTV1Njasx<^NcLmhwjSd=-EQJ1O4=b(Z4bdnbFC{?g
z*#`fZ1#`WGAv<g(@J@6@7W!68I1P37f?9@Bl}<~N#^j-3ns8i0UDl7)^3tqlz`5(X
zS+TA>l|y0yN3oLy6i0AZS3GT<OlHstWt^vW_WN@5Z^2cIj@Z-A)mVuEx;T?({K8L@
zE{0TYShob8(n1G+4;Mb@9^`%|-(H<BSDu#_qw3Lrt%tyWR=-a5ujhN!=#hMFzFhJg
zjCbDW{?2<?!vfKTiT%DdeVv3_FS#C$81GdId7#gJ>qjg1;F&;7>{yp`_7(Mv9-O30
z#^JMTqZvPbgIpc(iD0IRj<G2sY@GBAKN|+ZeFSp8Epa;;P`1qScuI3?-YNw!fY`0&
zCAPD$krG?o_#jL)2@rGk7)PEfw14NWi*x&TE;>Z}chq+~3!e`+oZ<I-ZzTE5>CV5f
zQMm`g?9lkRg2eOiyBYr;@E<VTn#U6yK?xU(G*LAQHtHfX7#4?3kP_XnQa$)>7a`XG
zgB#-JWW+I>M}uQ$QRgk&gpBCS1SRKkk-whXM_7bdqkDJD;mTcY60XQuyDVHiNcJ|T
zzwZ-UfU5!b!|7f4gxv1AD`Rx!A&Ao!AoSeq6O)1Gk?f6dUEP6SzOF98%5{~ekqeyv
zIlg#UQ9&eq&)<LiCo1>g5&WdRyO$ylg1a*A3kB2N<MBdrD~orN9+{8_`?S^SY~gkX
zbL=SzHW%UDs7Tzd)|+7Q^E>=w+9(XVaBf`$?yn_`U6H<dX!IuF1aklX(aOCBu6`1A
zceoQ3a#G&e<o}oQeT^gF^78*%XqPQ!{1hf-BKSpAkWfTLr}+8PyJhKd@X%Eny|L&N
zvWT%+EDS^KgsS(txYWaX=*RlL`?7%BX43ThigRc<4mxuNszD)bkod#1u+ZbCD3)M3
zN~~mDZj&g&SiJ-&3Yd`j-oxTv`@ttcf73bMVQuR?dWUrP>*cu|K1Vcd<0akfRXccD
zJK^*uJ~~m{2>e5>4gk@3dIlqUa6OX0+NYAj@Vlkkr<srW0!M`e@p$uPaG;|19v1ho
zFa6_xKsadAU?u#q2vGqZFpcng14nO6balyTtSePB?o^h=-FaKtkn>aXmgdLD8E}%|
zgNpTNk_ZE~?UO6}O-L-fZ+N7(rM8*FO7(hMuo_}V+s;v&OkRG3k>U;G+2IkLrjsKN
zWDmgq^%wYN4M$zn<7S7UvgD&?J<Tq_QbakGxbuoo1$4x9q>>}KD?LrZnWc5xTVPBA
zEs9v@4bPkjew_Jz9NlGpi5|oAHD2Px<16fyEaAaSuXGfsa%yd9kp%hW?7iN5SjdNe
z__u!*aNNy|Z54dFOy2txKXCIoyb46J{6m^|WBJKF!w;P880;hVlTb$m&LF$;^O_7r
z@(`HE#$<+#v+)&-h=6P5Jn~Y2=3MkViw^jAQ@R(4dLpgB*PK_lZt@;SCmiH4hDb4i
z^{7X~%RU9ZS9aUID2qGINgHgSG`1R1PiO*CUI$X|v~k3qw9F@4F%R(0xLalC`Bnbd
z;JFHZtpZQkemz!o#8sDp@Q+uSmn#>4@1Z%SB6&OYDblyy0Zo6WBhJ<HFN>%t?7Gaz
zpKE51((Ud-Ua2z;r=-&z+Oq(To$iW<Ywh5DafD`nd>0+kl{^&S?AV|eGO`(6OfbVB
z^sU-}A2ZWm2mFxTFEFDO4tTI|IS<0548cgxo%!liA#xAs$cP9V+Gro`!EOnIG{A;x
zRT;zGfNSKo?~pOG&oJzJY=;oL#lBdlW1eLYQ$1!!qaL>|pmaC-rZ8;{c=;E#qOQVv
zKm*n|kRJ7TUhnGGbgS(>+*1427g`E1ndC+buYelCZg-!1JL;hw5xT{--b1_%GwID^
zCB06_vSlH>hpKv{`o70T!wjhUV+w?_bEpKCNG!wx*Z#h0GivvR!jAE99B@v%Auh|3
zy~Dxor(WFn4mW3Ny)$?vvj;hd(Mu1Lc0|lW94sU2jzKp^^GHMMLU)*XTsvH9W(l^T
z$eG35pNR`|dh_*XqAP_r9va>_+J})^_#EMHOuTV-M%~Qu#`D5nGWtq;-CKlDP^?57
zI6(np4aXYR4u@p#0DQMQE4SyzAThu5TMfe_8(rTeezWNg*^z2Moz(U++$2G>Q~<1C
zk?QLANiGu^{iPX)7YN7=pB!H#7P1&#aKzQ#wyV&5TCal|s0yT(AF;X1Lk2OHrj
z9Oq<wIiH?C69PWQADg`<;3V!}@%KUl%HhATHxC2Og8$tb`6T`z3HV3Vy~5suU%1E@
zx^qH*@qE6J!M7MObm7t|`fZQ`c&<WvF`xq*f#SywP}VcuWdJvd1$>#Ne54kzwp+)R
zi{dcDW#ahE2WgPv1MFv6PnZ?*`|oujUNISTSg`_wA$zAdMGle@gKo@ezOW+$F=e4Z
zes$SH25HP;?0Fo3%e9aboBFW!71DD!t0}fmesjXh{X&oAHb`&SFp?lnhyLhbk92@9
zBv2{xzxuN6kxH+G@B=P6O^X&6ZzL32HI^gbHv1q6o`I|hV`f8FF2JuRMLnFAJbT`}
z<@Tw|G9A}-Zoqm}we8?P!F+bYd%rI_AoJ%qxF^nu<?wqi`B9wu;=lAt<sP0t@+(Q)
z12VecHcx$$+q_$x(-J;w<$3<|WhGTj=#rYmmWM#qpGyy&-`F+Eam9C(Cr=Z-`0AVA
zu5}HZl+%j^9XBX{h4lhzf{Q6vj*ERa1DD;zl(w)r9XMD%;AT|)1{Sijy(JLXG7%9Y
z30s!bk~AaXMz~r1_JR&id`hu%md|#=WP~R@;uUxe(ZD~*lpX>tSB8;Thrj2smU<Jm
z;XnZ6`A<N~XF#i`-=_yW)s(&<#p-4XtiJ)lqid5(|HW3^?(uRQ^k4kN`q9pt+i9FB
z&gXeo^&x-LZ&wIH^zd@_bMHNRBkhB!FaO&s_gWo@uNFJuTsVzkjQnd5VeqJ`6CWG!
zmD&m*jf8+Bd;QCECXQiN8i%0+(#UR1%!e!D#kJ&bXlm*QKU}#dgQ<`PcY`Q^2h3#e
zG(RwJl$OKa&|0BC3|F4w4@iHwG+OS(5$G1$8^U9>e&p;}4~ll;DNCEkxC|J@g%h`U
zfAPx(R7GoT)=8v;zi{Q4uu>LvVv0CPI>ZBV=qwJgDZ6AK4E<S5htY2-TGT*%>8<S^
zZ5tf-ddBBNRd8(V9Ibb2?Pe9PQOpdjFQ`hYPS)=)O6;n73BSkwLteZytwTA}YEcwS
zYZc`SR8_c`A@2u+Y0DMz>_}8M`8i?yh}dYFFk`B3>|v+Hd5FQ`ys!<GQsFDa*6q4(
zwDj&oPS--HcLknGN?uDLb?*K^W)?~&sLopyE#VoW8f%tvI`q@&J@tdXH2+TJ9$arg
zTOhV&@V7F)(;&S;V&(1$xz_XPlgGRPL8i3YoE}iFDf(|S0Q_EkfxAr0fgdHd2ZFvq
zkPdUMxjrK+*GL4ycxl1LW-S+(r=m00Fl6@`yTAWRk~6%}Kyx@+dneBO4?cSQ%-{&3
zTQK`APLZAWqxBB%!wkgpLBE6}x{}~x9V}2Y`Uzv7ZD<P_C?I?kVJOXd9!GO{{}AeK
z!K}A2H3=pS!@&rV*RMVc(;^|uh2VhyVgVSl2ht|MS@9_CQ6oZ%&**6MhsTF~NPx`t
zy@Fk;R~%M3iJsCrAe5^RJ~W2vL6YU1=CF&tGni^nr@YVGkj~vC&nx;feTzxZoo6F-
zg6uQgtZn)6A|VAkcA8j$V!9Y>M?J<oR#Hrg9VN^ZDK_M0paK}Bw~-?y>M<mduS&}9
ziG!6y6)n7AAwxbtE!dr55{)%XgNKMiTk{O5hxl--1J^Dv?T*9Un1B2A7lx&xKb#g^
zO;C|dD4&9Mn8kX|=uoWq!d$3FaIMoBrX4vO+c0L}WaioL5+ioR*GF<X#}=07p)qVq
z!AYNg5jx73@l$#4)5U%IZ~x{!;1&1>#A_<JzH)i$c;!sL@9<aY_vtrCKWYI;QmTtQ
zz+R8rb{V&92qgiNVNR9vta~)){V72OT@lroX;PuImWB5d-~OFCYIeR1?dy>#L*!xG
z89}GE@M6hiFQxDh-odL1)IdOeSy9YLDyrGx<fKp00KZV5Qr+qcj;k;5%xa)#sgwA>
zL4@)33O_T$@e9pNb}rtp6!)IL_V~|K?t|vf*wl%>D)`Q~2l&(!TDw<So<F~RTi9d3
zAc?B;^G`~SgqLW44OR_gAtl*gTY}X!dpTZ0knhVEpbztPUQ7BDQ@{LHf8~C)9p=GB
z7a2YnAwOMS9%H=-r{ddf<BXS>lV8N(Bcawz34V}F%Icm!&XM{wWN*3DK;bWM2_niN
z=LfNY0EaQw2R+H*p_0iBe8YbRc)*Lj8|~J8R*1OQyC)&C;=L2+0(ShPN?Bl<`@Owe
zTG07n=hE90Rp$%o(8&|$&Tze9UmpT6b+ylG@Z<do6thIn;w2RZ9ShUrJSf&7JMW#h
zQm_k_(oJM-y?Tse%TmEraV7x730m(lCsa4~k1U{h$mue6DW*m=Vk9K^2A{@S;TO(T
z)D(Q-UeD;w7c^(BI`;KQ&3yZ?7AD!)V;B-kfkQhXk%o`hGv~w6b<1HZIV{gV90z>N
zmP;`9WShe5+F&Z65^o|n_zG!R$=)#NQvY*hdX5Ibjx}rfzA5~Ye|EF7Ubzq1xd4uA
z-}Hy!+cwRxJnZ@M2E+9f{k8caoks59fk2L(sY^E1Krri^L9Xmou#TeFdRc+rurv%@
zSSC@vx|mrD+5G<SCx7DpZyf(>;y;`sA4WXwesME-?6TWw;8%ampmhZrXW$Vy+}f$}
z0k|v9@2PM7t1I_$2_)Ax7-4>XpU$7={X+Xg_AQ0k>AGAZYG&WkU-S5iC&BWkrCD4+
zY=3Yf`W0Zz!vFaYQs;P>2|vG&4CJQBjnFy1170^AHsg=vD7TXxW}A2B!w@+@LN+c8
z1p^xdg$>=%tk|<ws@HSe%h`d|VY?*5K#I?m?kq*r_e6Xp2RZ7wRphb@yv4}}7Nfa{
z7N0|Zs{suPs|WimILC14Qs3`D2(?)k@1j%N+o$Okj)7qnp2U4;_K1JxJAdSN-u{_i
zO8X4!UoHtr3rdr{vf25CvXRJT1ZRxtT%IpOhbxI=F4^Ut{OV;lR5r5+(_y?%r}c&V
zHrO{YGiD3nxEcnIO@I^Lr`7HZ+*@mJ;Ov0;Fx|)*EbN}C1}3><YxF7#bL%^Qe0E{M
zUBe+XXU!rs|626Nj<4ks47sS`xkXfIqnj@+ga?^<7-3%4KqWR>=&daVyxBPjk<!os
zDJ{b-y#}=ea?<tSU<?fg-ke@Dy3p-<+`nsf3-6~r^V&{*dx!g1C~6Q7bVlPb9~jng
zyS5|QYWx)+Q(I@6wQB#ShAipkexP|i`CoBQEZ{mnZyeIF^sWiyKwuMkvc6MN2F{yg
zuX}pqqxV7Q!0IXZIC0<%;d{PGX56K5&Nl%F&x7rvYRAv1DSuoW_q;r1NY^ikaB#t2
zzOHM@KF8D-fAT9U_uKH-nh~(J&qwhA%K3iB0$zfCH8j%SM!Q&6)Mto-aFBP!j^;c?
zbSktewyPanqtrO2fhYv8Aa-#&P(T2G!5O-S*+=pfX3DdmNbQ`Hopug>0rw?43}G+V
zju<#bU&1kRNqTkd0hf0gpf~l)zx!>K`%o6E;WeQF<KRp;`~i6iU=G(57?2+XJkW1x
z#e^up7xxu{Hf-o6j99Y-Pu1Nn-c$uho3+NSH!c(d*C5+jhjO|AU38k$LMpF*7s&@O
zSEmOO8;^6sIkaS#++XaFMol53N;ytAPd2)@U8CZGPCzI%Zq>|UIC^Ex*eH5E><T?%
zc}|8?4Rsi#_NqA=KJ4TlYlx=)*gV*v(I_|`#rUHe#R?f7E^-XoIn0W>%&w)l7NbRq
zVJjZ}jB%mvq3*V_akbtz!Wc!518QuljyiQAf~aR3YHMvTiC00qt!m~Q^%q??QOF?7
zl4}BYp-`OWXb;-WuD9Ipt5k<RV$crW-xMtJ9(JqEck9h<-Q5JgBcSi&muz@~`*dpR
z%LDW`4E{QSJumyb9NP>`M~NVYV-Wao5MPBsawUm)#~MFc;`%Y~o0U79&S|#(SAO`L
zDsRG@=8HsS2v4ZWvFXm#0fP|W5!@AD@R^+eq_98%Avw2XVjCGCeZ&j_SL^i`E_(%8
zE08^A&mBI{p$YH1xw;PHmv+P4iC!Oex(%2C)q9wFf+_)kQD(0$`Ok^wuUw6OdGqyT
zSN(&(@atQEmkpSo<t1BSH2%4wTh{$dUXSb!tk$PWV1nT3)yQVTvp|*S6q=E2`v|>R
zgHuw%l+J^CEq@6d3p!^5fKy1O?Pvf=P|czokHB%q;IZFN!!&k-J?m@Sc>>%;d&i4*
zCpC0MIJ;ZCkNoZ*`S!}2H7at^uiOBfo$Vj5JZyKU*So0wgH;*#WxJi}3;M@PJ=STy
zV^M#%_ZX@*FiUofW0VF}fF~a{w+4-Gz&m;2UJugj9lA>5M}_y39uDZE38%xippR3?
zx8ocFKMHnsg=A*Lui?%N)nRC)iGMW{?lNYeg$B}ltlgWRr=Phm07cSoFaL{wy7K1H
zcG5W$KDsC$Cv~7WPl4igKu`x~6Gmp>u?K{i;9%znq9*)oCM^Pg?WiA?rtkq&C<6NU
z?ZAYK9qnd#Gj(9X0++;J&c}Oj$L{$LAToUj>ZiF~YxBYlki<L=>T?q=c<kYk;AY-0
z3}u&GC*Ow;UN7|Qe*7PMrSbp*eso$ya)IkKO1=y4iFYf5a?K-p&K;<C7dUrP)x!9A
zR_;J9BN@mUQFsEAxt_`HWw27oC(&Fiz(tWRJ+yl{<H|?eSL6H)Pb=qx)k5y-vp@cS
zuRPeT;~=eZ-SNHGf1SP^lwx!w*87b&=ZE=k0Uzr)++S;e8vrGeK}kQWuYaOG!WUb@
zxm1V71W#}frT%Bn{=zLH#>I@94}9OlGqG9fR|NevI>BQ)0OWED`sn=iVP}_h(IY?`
z_JVYEhl4EG_-C?(bdKEM{Q#g-?9;)oq61=j2Lp58^(#nL#5)**{>(&20B*@2CP(1d
z$DXrbeZ*?A^#OlrW^oo&iPIkbayElUCSwM|<(7TYa}kzo1`kwvA)bMA0X&CAJ^bSD
zS~E-TFo^s^*9MtgSXv5ZK^dk~L<PYvBi^P|oAmq$Fi4uQXEuz`_57B=VDP#zR18*+
zWy=e&;W&-%ouo6l&*B_(f8-B*f8D<O#xq)+9l0-J8E*cLIRgn_X3Jghi%wl^Ut})a
zSdI945??)dWcom9J=?VgJrEG{@n`Eg3V$w)*WOs2nv_f@@X^3_6q3hO3~tNVl^0lF
zujs+k<Ue}l)0^*99(1Y)VWEqPIy{bs=+}XF1Jbdtmj>jl1{aDzgdce4;U^k3N^X^Y
zP~q7Itd)jHBsh*vEjw3b%<)(g*ZhA@Tdy}P4>cSIeX%r8Z*mfySX%Pw?=Rs*qwwlj
zlVo(0iavOHSNj}EAN*6V-Uoc({qm$7)R4TA?5W(pQ$9&QRR$!LhKQ#GZ)eCgr2*J{
zke*_foJp)Oxi^9+#R}FRqgD$1JtYt20y7!@G)%{}C<~Hn%y~<FyN&^q8#+xMbcXOI
z3L}$`fIm?a)tO%cH6)@2nyH{~l0MD(lQaN_g}vvg&;BPX4?3+&*=sE69Tt3OZ@pZ(
zCuMO&2^zAyHo$k5;k9IT&GF$G_8QZuGWd+Hip)<P4@NSK-BT{jDDqT%;sc4!A=s4t
z5v;IJ0lL^8!|>HjRWRe6u-usEMh;(((>ur1R8#O(IG;>-seq3`=^OHM=4kmd$FBl_
z3;2)KiobcZDK+JqT|)tH1_<@$j_`1HKdi2ALdn&xhjd9UPkz>E;Wc;zvZ@Gn291=9
zuOk)K^u(m*-L=4vjLF~Ii!OW$8F<233vjD9f^gJ>hFL8?r#|fSxn|vQFXaEBhQd4>
zHCJle;BD6QB4u})b>V?eK0cL^k;u?OXTbgT+Mtp!81+~h7u!MW;Xjb3xM4%aZo|;}
zrIM=KC6o`{_yE(27L0LG(Qd=j5N;J=%#3BNtz$myfT7P^8&Iu{?@&63deEO*cOMo>
zH3hYU$hTG7hnxUM3vW5qu(i6wMPc9dEY4We!=)-xyA3l}${bzQyn{C~Uke!zX3YwC
zV$`#9<k?=q=i{SktsYzTHZ^mWxL5cGq>uw96_rLkIBikNUp4BTV)Y?ku%2Gk5OI}5
z3;A>*67@vAsIL|M_0zZoaU%``UmErdj8Ky{(mb^ZHd@qU`2h7rd$t7x-z+HbimEN<
zOcZ{Mdh#(Nc{;CdLu?e)g>IW>NyKbz>dCGV%4%pars%Szo){_}JEkn0*XU15e8K&d
zVhxjnQR^{DfO6k7O161Q^(bxMz))dSSIi9}(LP1CgKUDs^>s^+df+(|N!FEDZq=vh
zNwaCPAE>qHVpid?d!q+nSC69}8w;hfqtI?O_e8yWv<_SM8XAm*u+0b`4#Hux1{VuW
z$1Kg7i=?2ba8!?lNT>;6aO||X5Tql~=#Qp?YvzMtP)IC&C{UVxi{2q41{?Kgwy>Ho
z>&*_sT#9WjEnO2@<32^r`W`kt*Aq7%D)M_U)#GMX@fFwXX0s!m-lm@l$_%r^QQIDk
zEZdas)!L+iqaHM{w*wRZ9cyfll6`FmMp=V<N5$Oi9kpwzk|WAPaZ>YokO&oP+my)7
zL&qZRD%ZfOERGu3jA8#YBMFbyDWyS?kXLBgJnb)rfu}hx24UjMK#-ArU>bb@VoCd}
z2HHL))=24F3`Ux5q*$Jo&?y#KYuKrF(Q=G1#$~BKcaWWGrY;laeD@3dOskqfgTPw|
z)@e#hKkGY^S{-&|zeeT=kbt_i578QT?EolZ7c?md^Pp4ys0Zg}{(TzwIA!LxRc2&@
zd|L#w>bhxuZ0qa;OM4N>Zy6b&$-s#e_2Rhl;q&B*<meCS0K<D0;{O0J>omhSQ`Hfi
zif-^5S?Y~=mdxs5lb#jIc-n;fM-b^_8jN<sVaAaSRS{qfP0|5gzOj|Pp1#216})=G
zIt*rG8f8&!l`iKrFs`=mCY-r8oI!q<)iiA1WH|2c#=%;ZeE^o61(9h_$+OGQV=!sX
z`5DN5OF9cYUx;psAZ3tVAkag2!hs!X74vcQW?&07v>%p2Din8fV;6&IYt=3JtH%tU
zu-$|EER~s3e^~uoX%_rkwM3V(uD*aEtYGW<&!B4{%%NAbgUw>ll5oCuzi$mQiH|Gz
zN+Q}Fz%Q0?iBlr=7udC-dobx|@O}Av@YLit9>j@zTasCBumol{YPZ4YQIroBw~0q!
z-$Uz5{!-Wvu8<-HO>-K3{it+OzT*P)wfcGE-~DA@EHC{YYy72W$==k|)L+KE3)Twq
zi~V@~#{vJ9T<4Sb_zU}8@Ou~f!;4pT?}8<N_ylu*1d1S!&>9|mH(^m&VF@2YKF5F6
z!$a<_dNUiJ5{mdx)QHab9QCx^K?2yOoTuX|c2*Q*lO`X@uZ`LZ|3JS8%G78jIt&M%
zD2rCpQF5oY3lhRkOt_P+B3bk{eaj-Vde1O4xEW@DI77F*gND}I)Ag!3qjh#hejk3>
zfcJG)pRLd^KXy3I^9BA5{F$zt^x9^Z{h5sp3&O1dj*oc#TP%SGqVr`ICk<`q0Gb$d
zq;9SE`?IhE=kJhw?(>5PnA}U#<pIwO<2IecC&~CDpDOIwuKeJ4KdXF-ma_{n(DY6)
z%5DkX)9=C8Yz`0Va*_Ylmu+ABT?k378@=(a?0kcS6?`j}L_RGR{6OTn;rD81osg%a
zo!Df4kc-D`fGnpqplt2W+0?t{gZ3c(b;fqh;OwnRrg#1MpI&(jZfu6&3>BSf7gVl{
zO@Bpt*J_Y@*V-%6yPh%S8sT&2_g?iqLQpKZj-7@OuKj1!F`e*mqrS-O#;O4AZ17{j
zd{Zm|Wr~T~M=a*sCc_vQNDh(u7kHF~oamVHi)Spw$N$rIkHWQK-#Gp{UGI_-W!n4E
zZyBa6Ts3O}3cyBv&n_kUd%g@tvlH`B<Z>|$5Yuz^rV;hbEW3Z+8K^B=g}~@W)k9TT
z^@4(5vQh{w`-{mU6g&pxI!LtBEhfNbZgF<mssA~sDwnKcY&q`|LNrN(oCujo1onq(
zcx!2?gso}R`_f{`t05uJBV|y|)#-Sad#hr6@V8>$nL0A@J3pUz=TqWo|9O7G`5%|!
z@rx?dkq6s7t=z<=rFRYr7CA63;+|&{F|@$r&0pNhP{msn^DCIv^EMqqf;a>-Lv-y$
z*LC97XWRi_?H=@2rvLC=zxM5wx4=X@<sNjN{^sj;{z=b95QO*5vXH==rJ2_uz)EC6
znT<QHa)Z$cWyHPvJU?|0z__B-%-W!t-h>~x-_dm)dixvP?}j0f4tYd4gtOZb?3m(G
z;g2YXe9U19USJ?3+rh=dO3^=^ZZ%#ERj1pbn&2z}Q^f^`P5Z3*=cp%={p3VG=&D8)
z;3-KylEv#CXKpf*>g`57;E%FYqju2B8q@8H{^z`(aL2lf7TdZ(?Nyt_%`EEKgKQ_6
zlFsg&2D7b=N?CUYEW~ISoXaDGgPqt;VbmkQ#CW0F$zq3Clx>i^lk$#idX&b$`^^D8
z%F;3pV+kMR_bWdsiDiS`hO1UMj)Qe7<KE%GH9jAFB8YID0ns~S{BX=TCVHVn(<I8o
zpx@AN0@DJ~*!L=zmwfAi@y*`CYe0UZ;<mxw8R@Uc?Lf|s#7+($jT&UCG6H&J{)zo?
zHN5?>@|4HuG>+U4zqj+O@(`;?$MP~pi}YB>QF;Y$ufpLpkn#D`Z<qsk6z2HcbL2X#
zKby3Yg$y-C4}_Gg6!fhlRj4_|!pTKS(B+r?p7@{WvOaw}gRy_H`5^tJ{oC(9d|LQ*
z{+s{wj}ksM=$)JXj7fk2J}}cG?0?J*$W^Mw3)^{2>uBc%7Wx3@k}o!%RL6A;{HOBc
zwd)tf3ym;e=VzIIN%`-sJcK6aZtJkNg*E0+WDwT*by44NU_`-_&h+=pwl}9C{q=ou
zZcy*!jX}Hj0wu#AXX>2@lAi6<+ncYUMo<@g?VUDqKQ(Cm5WfQ5Bi(>MBEI<7R9bk5
zWpo?t!N*{je+%>(hh{VhZ9o8)k-~3{Bp>9XH*yPRBHBA$M^!~Tfqa-^HrjUJHU-uJ
zAPje*b-0$9zuMoymJR;Jg@%~J<)h^1`V&9(jfa(owJq3b0YPbCdG7fHczpi6Jn+6U
zqAP~+a6UDn2@0k8q94|p4Mc9%wV1qg@27mf^QD%T4NF75AMAdr+7$WE2<7X2x8R?C
z`44}z@{qb;a2*_~^hS^LN9xg^(TacKI!iwdax7l8U*C!Zz?VHZr7Tve*T)yb3Hw!A
z=?DQ1$j1%D@VI5)0xzE5uj`)UigfDt7k0>2X8#cIz(JUB&iFuQ*q@d_!Jz$V*C)Wz
zUdAq&icufZ-zM$y%Zs&6k^@tf&Ca1JBtOE~^9GbfOdb%Hq3AitDJmA-JZe_ob9n2y
zacC$lv8aHO7Nd3Yp{;6E$ac5tP~CPpC&f`|)WdWK>0;unr`b#zXrq`pPE@xxRAtnI
z{<XID*{r(2<~!AToBd{*U-UuZLokMkkclz#CXB!nN#F-qUX#f9b%*+5d^UqXb@&x_
zlZNAfC)hEahp8lE!pFRqW|NP@(gMts3Y@{vhXqox+8JDOmOP$FXNusg*Z@(Fq-SPb
z^c><hF3W@4zZ*ndT%i4HW6C4wil9uD_Hr?vQ$iSw<Z1Bf;a$^rc$h)g?N*x-hU5*M
zb#GX!4C-UC>-}N57s`6)GB!aMo}2HKZr>zv2Cj&oA1D8qAO3}(Ul)FcL|ZZvj`cws
zqwa|VeyeYmW2_mt<a#;Z?%`9j*ZPo7#9!;|$-0W)^Vs|-e$U9Rag*W)`pEfpx4ly1
z-i<6bu^%qEem>6+9~5+Q^SAC*w2nESRQX2pUn$RWuQYHkLWy4QvhplyKb+AEj%;BG
z54@`7bWo$92#CUEkKG6d5zQI}$pyOfRHyJC1dc($=%W8_z3{dva0`-$ptoI>F$$&A
zFsDi&7WKfyd$ZPb>0;$7D)y++Rtb)cYKo}W)Aw6|6*)?l+?kD5QqX&Rie!$60{-Gl
zOd7!3jQ!#-@b?Glontsox(6>CAwRqv^Bh)YA#Wf$XBOfHde)c)i6kNjQesHca|W56
z6lflIo=LCZ#}#?_IQe^=`mK+?jr*y_$Eu7Ej$E*xa!C4x3IurlgN~c{3n%1y&%mGF
z-bnoF9pb$rDE8*D;K~2r<nZ$S1bbRr^18zU>YRfgA||DtK6H0kJ$|x-d|W>O8%%QS
z$43aVm;%}~77|}eL1Y|vUavKX+XULX-T#r`c{q;sn^}hZybIg}Jog}k=HfW`>d?-z
zE-^DJ)2I&D^MGqT11^=4Y!BCtKj_25g@FWnmKV%UKf&T`eoIcD-!r{<z<CP-?VbJC
za0OK$$yKPKk#Ksg*Z6BOxGSFbPYVA0)UW--%0sB41k*t4F1Q%Y|1f_pgZvK)6Jn$S
zskd>FznK3m14QDf-7O)Uma)+3u!{BCKEd~Oh(wqIP@}c23xQ{s9hM0DV5}7UaoMq(
zjnbGES%UNC!AT$&g7xfr7-g-VexHfQDMKq+)@8_)Gr^%yd2OGw_s`b?EWU2)9BKcZ
z=d!Ew%)0&#_`8OgW+ANY=dybuoQ0^Kq;z;L(^}I7<~2W$pCrACmB0Qyc$bD~3T=YL
zgOuI(PrgUZG*7-qL8vHSSAvG$Z_a;@dJ4go<{1xCAPMwqpnryc4e|i@>~7VbwDA#2
z*9Ph_j^MSyS6xm1lT{B1#}<d_nZZ4~Id?TPqvd5F6zamO1$-{J$ZBcPwGK*4c3RFt
zN;X7JDGhGmnZt)I=xP7w@cEg9kKg>~zx8vKhj6?H2U4W82nLD2^{hq(6Z=4u2%r~X
zE_#69Aw)Wy&-f*<(=k-O=vIO=*f20f=8YYI&VEsVAhZE1j-gD+u$AidpqlQAK1^lI
zsm<CJE?OLih`@Ri-r|ZV93eutlwYGBzh9wraj9#hxo{L6B0TI6d{GxOlH+Nmqpv1l
zXR+wx0aR8wiHe_3=M<B4jY2l#MrRiCV#9IZ9pG!QZ3W}A(v##Q&~6Q8e-<8{OqLsd
zK}{V8Lg7%S8Ec|4_<!`6R`JXZ|5WMEuRMZM8FZVIBWt57dT05uzEhfqM5iup(0A|-
z;I($ZFX%}66Vt&WBfqBs*}P$1pn9;qiFZ1aIHK}>t<kC0VCI7}L-le?QwE1`&=0g?
zebm@)&^w%$wIrHIXdND9uf*_&4x1R<NaM|C>f?0`>`5-=((nJyr+jqZ-u(byurjn)
zKNQpjeuX?g-T@?b+c1MO*KsDlwqv^5z2s3P(P>kk{Y$?GJkVZGubEgYJI7A){VD(X
zsIoj-{xc0a?O#aNtV7pcnwkp7{YU$EAf@H@A0+QO@Fgw{s48v^$1s_nZUCv-i471Q
zl0D<_7?{~JcBTdG8S`=QlJwJ~yM<ig^nd;vD~~`|P?*BaawfT+%>O~>HtZX_BuEF~
z^Lpi^eZH@qzXUsOV0VwKKkF+|QFhPGKZ*2efw^rL(;Yp`hp-4~C_yz~OheYymZ>%a
z2BYx(2_+W_^K*(P797*S36;<f*012ZrO)F8a{A?NvZMZ`#i<{yJi=^uPrRS>N6N2{
z)7(v-d<L#~&J=#Mr~V53!##p9jm({M6XF-=%&B(JPrh@FbN^T8hwDQ-_?i4EuI(Tk
z-5Wdp*f!St({7u_(Ah65Kz&)}fCY3f!`^4Xu#ApOZREM39~0<&wZDxS4?2?fn^JiO
z8l+-7CHv;^{R;~(y7bTwF!Wz_-{D=zwO8T79UOD<)8R<h?T8~}`rles{C5i}t|g0*
zE6GAS#wBhj>*zX;47wuD67+4|QM?}${bd+Q;7gSskEi2r;v?Fh!B`(Xw)5~&!1Zm|
z@q=BXFjQ^ueTrTFG*35y@n+zXcqrECuGyO|*6E<S4u)MU)R}l_{=|Fx<?+yXgPp)!
z<KPSMLkb*m`bHkwz++A10DY14s;0j5W8Z}H%IrzOdKr%er*FsMUyN$mFqY1hs9Map
z-PDqkmGKp1<(Tr=qnf-{>6gR<hOYaMo~8TCo1gllpTqh>vv+L%?~q;;=Ji>|6(uJl
z@coJOv<7MYVR?@VE>2C*0b63<!d{v8%J02}-!?c7RCkRAfjYDIekdO0_IHjT9v>`j
z<J+<;<d4zEsz_&D#6je2T9k)h>h8n^_+AnBm4aV;p=rqRNv5Cmg}?Y2!P`l_h~7xO
z2)i#2y*mJevitRrG5c4iv+K6-6$zEq;tGCI|AOm{)^1R}>oCLR1n>q;VirPJum}pB
z@UWZM<BeEgwN=OChDlcKR<~h>G{|RYYWXu8p&drR(njF?*e>by>bz(>Y!?b8CsT}<
zq>6&oP^BTUsE71ETk(&+JrHZQOz^*@@u*@b&To@dU_5}mHtc{V`@yhNz}~<c$x#dL
z@2257(RL4vE{E7!n+BM@+nri$DwKi?WA9IY3lEDh_^Qe}-Gi7GdYo?iR9M(LaZqo;
zek)WHE(C`k%gmgieji&1zyB-A=?up&G&B^pT0yTr%j~Ux)0e=%!Ya}pQt|$W*5jRd
zSXw>g#)i%Tlo<J*q0yZ2Jq?6C6#tH$X~96aZk#DnZEV)?av@-=?!wEtWw27X|1b^4
zjhQ@<6?}Htgckc1Pum7h8%I>8EW+u0kuVv*$~ORDcC%Z@_BHc<H3*8reIpJOJ@cWw
z_KVu&3}R=b{xH$%--g|HGR2@6+LFQvoRY$htF}8CY(A1(3^yS8CaV%r4-?TQPBB{}
zZoVSTS8h15ro2jxdQvq--%}~aRH`=A#29gl%Lo>Bcdaj3yGXED;H1HCJ2A^Fh;a1B
zkRuZ<KRZ*z(&>%2E$>~kO1sJ_8uh>ubE9jM2@A(H+Q$Zi#U{6_(ySRFf1gDN_E4>L
zluPz|ZGn*jJJNzNyoqhrQpSN=J)&#}fC(%b-jxlI*_u|2efn6_5!+XL2g3q!MjmDM
zb*6sqr-^U;2-0=J?-OUA|Mv#{KWgbOdj4nmtDV|3jNQ<bXmfvnSP=bc>j+q^vxgZU
z3^olZR1n;7oR=_?ZjgrXo<0aBc&HZe>23rz>#$6d3R9PROGm6>kOmy9Cz7E7xdWVm
zsygb?@m-YXRvC=>tj0d_Xtk-=-oj4x(08Fme^^G9UJ4*B3p#AYlVV3ke}Iwl_NTR~
z1*sCvdvhMu>~LlW>7=Z=fz~hwRlIU{g%A-rf@1<!$hm`9g%BwF!xcl?UN$40BjA1S
zpjcV9s@L)Vm!q%#=$Yx&kk0t>fAx{}DdlR-+uTdO_XDa_cR+_CaemmR0F}V2mI^4;
zYEJU~EMWMGe1PZ4@B0TozH*=UvO3H`>>HOy>#c_FNkX5`%#yP0MC+sf+Kv=|$EtL8
zjzwYxN0*<pFIQa0+>ZAn(eq$rgtltz+cV{vDiH0vQ<g~n8zv`<C0Mxgyd;6E`}lg#
zg1C!6f5U>SEQ28LW5U4a(f?!EufxG0@^}||BdC{fWcPs$h$kh-N!9IowGGoK#2ujK
z{gO(e?tmf|R*LrP;5Wjgw;?9j)NuyOb2Q1#lJHVQ3o1H7;J%<~TqsJW!{|0ML_N6Y
zdJz!LQ5r9<cJ8B+?OOCr5kI0BRv)9DTTC$-5QMzSEm)3=G&GD<p}nnEr*mZe#9%Qp
zNN}Zk(6?=nrKscp>g)8!uw6g!#^iwrqFtahFqaMl9F2&8Lx?x-M?D3Q@H+<fqTxPD
zvVhOqE_|4HKlK)fiU<0m#&nZs2-0TTtkc3S_QG`fn9}6yi^FL2Cy+$yR}dT|=iU2`
z%E2$3)qYrC_v!!}d}`Cr+e4D+%E9kR69l@hb!^hd0YiZ>{APp?IUwGf9DbTz(Dogj
zO09O9;XNo(6`Tw3M)q4EJp^93S?plqB`zI&jvfqP!w(mG+(r=G5C(Cv(z5QD>On^l
zet>ZfE}e~w3%?WN3XoBvv6B>Rtz*Jfl(|7+y7v;rc8gC@&rWO41yz+}8smx5-~eeH
ztk*h*5ETznl`pEHht;#K!wje~)$yYBZWeYZN2cA{3lVV$!oLW!M1Nphfxv6bF9zK~
z3k)%s#yxv?054x5VEaDuKoD1(6rM^@j}DAj1UM&wakj9=`1MF9Y-#B6E<DWF(L3=n
z>>S!Nao9`lFVDGIL>QWP0a(1^3Te;I_yh7RUVHU=yjYT}Ym!Q1ou)Z|=x(7;*#GA5
z0$p%SvwFOn@H#ZseXUY1<?U*`+5PL~@@pLcL~lsba2Gu$(Cp$A;rP`&<rvnhxUx8J
z5n&H8yCHLijO~d{Z>4ySL^5(YQJQ9?xVWSwM_X_hXS3#PfxbyYjkz9UE!xK|(^vcN
zVp0R{3FnY;povec)hy-o^mE5I^wn-+-r)uv@>4Dwz69?$+8xx?aVz-nxd2O|kjX|R
znix3LL6WQVFi6D;!NVEz#(fa)<xkCi*P{ad=~*X#FIPhuTo1_kozcq8r&DKubg<~X
zw3b}MSkKeeQuyf9x`q;S{Py6U@EGy#-go`6$|HEIqa1b^W;1Hm{MfjB_6fh+&rh-Q
zLV0eyCGtt5GYyXJ^eKLC2$}_*d{%DaSsMc$n1=PU)UCD%2?o0$hlTIbNbDwU(U?CB
zFkve=p%Yhi?DJu0I<HqW_pki3>AeN`iSE4J$nd<*VUBwa?#3jo1#v5AZwY%X&6nn=
zr8V|^=J5D>ao$e-AntGU>ZY53z%<U=v+R%S{#FvUtc0Jk{vy5N5-f0GLs0#+tK1w@
z%@nyZJcU*AN;w3gF+}3wvHduWzSkL)0DfDxPg$+q=XlF9Gh9`e)CkIrdM#~$DZ950
z7q%uDV5RWBgK2@GFr(NvDYfJ;D5@-N0PI3lz-Bd#zB3X(R*81mh%A0&BN`Vl><&@&
zcHaAXsHUPG_S=%0X$ZK(9n^LCIp{*Rz-UyU1-RB!RmVgTAYIQphivMu+5fPGg2f#6
z%aqdti!+N$M!?R<-!xI+0u&)d)6UE<LU>YQkT@X1CkMUeQ8;qEcj1A3SLlEIldppR
zRR@=$i90Ho_kvf^5!eTW1u0R%D<%wQm^+&RdAJelWROd`lvS%@2S&u`a3;mPS%Fi)
zy9)US1H-I?2C<#$Ht@Jtge&E~o0lOP%IWVB{k!hTSLCZbNOr+ieh7ZI9%1!yY;xT=
zy@8iU%GrZg2ESXg`8sH6FKef$D5vJLdJ8y%1MLt_*{!m>=&WB^HVe~3xM1T`250eV
zQ;g67E{!-aBoZ8K4W5xt^#GJ`PdW;7!t}yGxD-IQ;hogLeZt|A_%GzD3O$g(e;3+~
zIUakE^g*UR{K5YP^n+XEG%z8Ys_M(}@pWGBMwJd0-hdyX9s`I>`1%g7;1%)DW3xkv
zrCySpCXS&~<TQK3a+Wx6L=VpB(0qe>2I^P|Onh;RfS91jPZP)b;iGa4*AsAaN;<bZ
z?Z@sK%U4dOcI$SU`JvV{;IJ4X19nxa8!-38>~cBd1YfItlnzB2l66GW5Prdb^gkT#
zVt6Fy!lH_%mMKK)kQ!5l#-bja#*rFWjqy|(rdWI=*&%(z_N-E?r{9McnR+WV1+IS!
zy=KV+SR{1P^bpKU4IVQ+3?0`$ZX#7--+!3y1N@Nx6K2wk-oxb1z$CYBD6_NXSPi@(
z`gg(1&caKV_&&36BqR0v*|`O%##r_xP=^R{eK@yp;<mgv??z_l=gV;ZtbAaN(#GuB
z^kR-*Ur+WjrZz+e!0}N*28>4soTBepoae8;Z2y~haPTe)l1UY~d!$`}ETqXC*fkJ?
zXW;p?X<%U}?Zn+y$6nfSxT9ncn|m!<A}oZZClbDgcW`d!r8wUm&ch0z^EqJ$Euh>L
zw8%^_D2H~kpqy75!mlCf;nq%#=WzQZ+1V_8_ZJQ-k092@MT3CcX1%-XaGUd^$l9cP
zc{50GYW)L=200iXorVjfAOa0Dk{-dUDB}V_Z=2zOH-2V+;ts8dp>6--=oy!?1ACXk
zwJBM^#QU0crt4{boJ}B}jYYX4y|I?yW$Lrv_m!1L^pk=e?`l5@&jp`z5Lze~JXd*Z
z*gg;z`+|Proj<zS?rs|!6^>S``&i@s>DJctes{gr-sm=fmCR~Jey%2Xgx8ZTdU#Xs
z4gMm5<B61Q<w@{Ze6f-am_7>ujBWUE^s2ocPq2FW{b*sY4kq3fJ;<pdMg5&A!tlzG
z_dnKgQvO~MUhfrt6+Zu0{}AxoVY1mx!q({5(RKyPq6P--3X+41*~d~|&aVPjj&yO$
zNJ#WZFmkvxO#klJ&EY#RF65D!362L`NTGUAOCiXE1bnJWXjS+(v{5^D5G@Aouw5jG
z3~vFin|uWNXU!edz&f&Sf?*j!uqWkSh`5wvnarQfxY4V>p56n7<5=g}atVZJX0M7R
z;qM>}RnZB7J<yj+Q0CT!Yz{6G+{eM(>>{+el>zSN!{2PIHyszay8{O2EF*(XAH$(M
zNCr^~w5jSHS)K*iYww`8degUPW|dm!XV4Kj-SFu`4)hauzP<9OyH{`X_QOqupY4t_
z<;mbitMc65Bi0K0SV*GLx)U(v2RZjm*Ccz;;(+`Yj~dA0n?495P)IVuVneS4N7`lH
z&zL_aETZ?eGa_c#d=Ea^ctg`SY(#khxuGLsg@~WU|CuSxhFOByxTp1b-LgB_{1RYS
z*mMCP>Glm6oV5(Naq+uPY}9_{-wYlfyB}pFee^H?TR&QPJYZcQ;PEPcmCo$R1b)2Q
zx%{}2_~uhn|H@CUJkES+IR3z#p0um=MwuL{0ll&jb8kBw_yUjsS9{VD%RP2zJLd^H
z1XT((<{u0VFvUFaA#`*8rCGl!929aEQ-Auu0US`>1r)GOk=VEA>HRF6JTFrJB9P#r
zsU~<BSjaew5f-sz5fbI;oN)b^q8Pq92zie)9hp=f*VmTPqaGI}jZucIMJf=mwgvfB
zW57TxwUL5*0iT%;i)p-p=Mox6u=vaZ!lW_!$@zPVeT?O0KY7X_C)ryL3pq3MGvM?&
zOT{hD&qChJ=ru4NMUR18GIEWwWVD*&Y=!<<bU=1az4NcXCCEn7tN+h8|3#cr5LVdn
zm)=A--Pq-NdGLBw{8YS~P2J@=MduiY$q=mHANy}7%@;#lcs_Xqx6wIX!qz?izG!k^
znI4Tw>Aq;BD$s%9pa!U4-oFg9@SNM-A}@^sTw(Nez4`(Q%201*k##8c!-1U;T(TRm
z1IIJ27kg{t2vRo8$pJ!VF@nT{5%%WcwH(qc$YQPcdMIUShE40uCSG}A5J8nhOp$jX
z`34aRR`{aZX}Ww))I%wJOfZEkn8RZ9rI$w>?`kDNIN#PK;p_ccQfXvS*dOq9%PI=Q
zZ(lHNZYq~~qd)uI4Oeews&3Z^#Eh}`+mU*RR9l-`OnEci%W-|iGWekC&;yNrr{#fk
zyt@(T)Hh)9+VaxLRDBD61^vhFTblL03k8N++f*OHBWSo_6uROIh|or(Duo#YlOD4{
z5tWy9oq>MHE6{$1d0)*mLd}{4lo%qwvt5K?@`0iEIX~K>&3&-<y|3@ro49k?!SnL=
z??0-VcCMz^O!;6;(c{X)*Jvr}alqd+6(y!S8|@l3cekhaq2g<JUjrS+BO^y2^IvUv
zWrlY~=AYOPm&X5^vB#PH-w%HO9{~TuL;$E$=Wk?kx`UkVw^!%OckYzt&YyPM*yL+K
zjS4P99M!2AM|2A7dIE&Q=IQ6iY8F0t0db?wq|$rCGtBkw_2DXO5p1vg{2k7CGM>?C
zj|+R8AH4nLt;%Dn@8L)b4p*G}!}2nA?hmvpJdpPFkXDP;6Yp!;xqq^EHz}HdEAD6a
z+lr;0n)<;HS02~wdD_>rSD`3ICdY|=X>!xzpeDKL-Xer!Bo=K}{v}my3{A1P00#H*
zg}ZYNa?@0SMNmSaC0!_N*Z2C8st)Hxv#L~Aiot#i0gas(!T_!(Fw|?_n+;r=7#~lD
z8{iq9fx6_3L#{6VV!g|yWhew`Mf3ZjTTR7%abd>!^{}6+b)ALNGr`9!#7CUlxoEsj
z-WTU_ne^qj@O|-dW*24WAAB3|5bO#`z{1aa9R$78;MQPJ4+r`CRRtnn@qRTdw|o^i
zJ7EW<$*$t=K*(3P5cVvhcET0<#y&V_gRlk@mtqNflR^k|Dn(49tlys1j_<2pZJ&k$
zt?j}5jD=V=g|H&qG3}m7a)ldk7+NMLZZo*0-``2^TElVflcnV_AnbDZC_1wc>UZ$|
zXF7ZH%g$a|@OP-$g|hFGCGc0Y(Po#xU?Hf+`rVp^wu~`h<`xmQD(08x7v`;62Ho5-
zgD$~^M+9!&Q{IpA1<cR+2g%Om)CWKMH&z})9SYWN@phl~SB__)H!?`)<<*`Zwh>{z
zVA~&63rejK5OP@zO&UP+W9U!!{c;JV6ZbujT3`Vnl~mZvS-NqgPVdVkrCyp&(0V`4
z^#8v2`L6&jws8F=eU|LoYBGoEzw>7}!2>KC?pDP_A%aZx8v{B;4HLc>^gcQOvvn<W
z=7!$4xxV5$-%I*EAO28fy`pvAhoQDsLkQr!dmawi=XX!x^A-A=L-+#A&wf9KaRRPl
zwK<I^YgjwjufvQ)e(oeVY1Clk!1dJxCh+)Z))R`DV}Px$mFo3i-4L1V&PZ5N)K68$
zZHUEpi(7^+#GqIY`$_*C08b_%sAd$#sVqdpJd^n|`?o**$)C9Y8^`}$IwvnQ7x_8#
ztkCcL;GN$BzS+kDg7N8+b?3n$4edN1lph|^l>}GdNHy!iHeeMVCn-1>k?C%^BH~8-
zXb=6!&*jako6Fgx_ZG7-vIDL&>>(0RUcjzK(`4hD7=kfO8E74IEIGee-!0j}S3|ZV
z(MBIqa?I+p;hzJ}BiXTL$`+sw6Cg2-EV)<RfY}c)E!A20L~}5Q-y1t=A*Oc#YqQgK
zist)q#B^Sp<Qn*$19le{XF*um1!s}+$QtQF+4U^xABhB-Pt;h`ki+|fWLIqJ-STIE
zcLN_16Jg%f;Mw+N@0Q9rovsp>#=9uZ3P7jHHR;xEy_sy8`ux5@ox`60(FvTtzchr;
z`4t=LMHXqFh@|%g!67XF@FZZ#4L-=&!JsH!S+dwsItXZbwvKLDw`qR_R;ys|5Oe`*
z+3G@k-!=b}YgTp$)$56ZVHPm#j#$*=soIc{2@7JCqRddZ$cJYF=8AgI1?EPgvP`F_
zZA_0A?Zd=-YJ|pZQ#~3DCWm05P0pf>c$aDzh6jrb5d5NRD&&uPI45}QNJHL+9}?E2
zvUQ4ADzsbO0E%FJ2+^RmX^dCXds$wGvRIYsnc}I^h*?jYbu~DM|Co1E?`$+b#bcRK
zM}{6Nj%a=hv}VSEFgO-T7YDVSQwq2R+cO>zs81O}Zf2aJq^GXd((LGy)fUq}nB;vd
z_H4{^*afDsELFg{gkDJzh9To@oH*k2DaIZ3;JTA%n})TrJPypQVyvCsD)F?X^@BYC
z+XGP#UdzBYzzd(v11&<uOmt~n*$qyi{Bdnh+niuxl_8YRvl?JpG=?z!xv~!owwm^0
zc7U@)dEbX2*vRYXvwz(3@)yCIV<Fd<mC5u|PS?W%pUdPT7JPo;CtLi^SzP<=w!bhJ
zxBYqNk}cuhuS~d{Q@~<;x^dvVNc7PM2S4|$I4_RzQb~RdI>Z?miT}@?9vczxKjg*S
zvKnt%iC0v`Vme0&3yg*3x~~VERbgKZ4|__3S`~qlJyYE9Im!xDU=<EuYYG$F+ct@M
zSYTsEZ?X(Qn<{}2SpZ=KgJP~KC~UrYMDkv(rFy6w89k`MCc0l4wtz2v6f_N(vTWgO
za6H1kCwv!%6O~wROvnEAxU=^xCZPAAMvidwN3{nwQl8d^&zHs8+I$L|n-R_gqbAWC
z^;p_A1bX9p!?iM*7weTef&Cbrz+s4uuc?Z9n45yVshSS9zuQ>Er_Kx8!pyc0-L@hI
z(R$8P)Z?8rhRiFsbj~57)n(yh7*q6~*23l^kVVJ*q!stI158jbOA}DAprpsh8zS=v
z*fL0BS{KxinQ1r4J?!p=4~d*`z}uBT(pSESO5B4lTday-vvI+A<VHGuyrd2(19Jue
zU~E2}4JQ6De6BR&)Y@-DI|mI77P4hZb>N<m)fxTKb}H&&HE{>VArycPD~oAPJgmyv
ziQYPht;sfU?}kxA<$#b!>KPV?Hg2(}T-gUMuwr+kKf)w1M+oo84#7t-%t+aHptf_-
z%>VBh^d3sPc9hR{qeM%KHi~|K5u$OY%G;mT&m13T_GCYJ?^k$VZMWe50Du~N6Vz~0
zewX}`=cUDbo;0N+@wQL+$nUA21}PZlHZQiV7hGU^hPP0Y`^CW%>Hyl41UV}OfANPX
zq+KgO)JPH-DmL`dVG%f4703C`-5^%&*X{Y9ChTh*IB}nxnO`WmbKSyj&mxop?CES~
zb}6iA!EO&-?_w^g+`2>n9jmiBd_GBhy{W1H0&;s$_Hz>yIehkp`L}={faoLl+n&Fh
zfy-z6TM&8Pd;V~}q))i#P(RF`2(r*4{WTuRVaQDxL?R#VFu*T%Y^_7?!x1B>17IV6
z4M-6y1^WlA(o+rIx4MlGN81LXZ#yQZ^WD@FIJUPFF3FjJWRD~S<LyC{7@ha&w5?Q3
zuN@iDpCUarjA2UclQax;gd>WoBxb>8Ixaug?^B`EWcY#j53AGOId~BAK^$8Z7ve{Z
z1yo<}nR0sl?<YPa;D_&X3ogDK^m@;od(Ps)OdD)=!MEh>!g4&t;hP@isDw6WWIafC
zibRijzHuLh{M(Z?lYc7!;iT}J(eIk*6Z>Y=^gF`E>fgw}jhZ8+U-Eq<*6-0>;mgOx
z`rXd$a@%RI`xja}^}JuJlu!6&>%ZRGUB`h7WB<(#Rkq1`$X`kVU!I%q%&|}M$1AKm
zrtR^w2Pf7YxYljOpSRv8?3vxH_tzX0FS*`Emh>Nge?{vJ)cx6a|L#Tw`yKBju<!1c
z?64m-g8K~^uie948CN6u@%);P>$){?#dUgO{+Y2(|NR5_Wqk}jD=r`)hqQd>zMH(Q
z3)u4f$XWG^A^Eqgao~Mp9e3U%(q&Z`xb_D#1w)<+J=rH+ne*Mjx7e&T5*saxhVt76
z93trYOwyI%l$rk0>_<0{i6D(3+m$TMfRm5$HLB-O5}!`B7%58jKI>F1;1cIC@RTz#
zF+8=v0Il*ye?*;vlfH+i#QH%!=+RD*gqouV2i=BSMN(Ugq8=?lVM7V2VNnTp$C2xE
zZ9Z@xNN>EnI178O5~NJ>mi=Ye<TBYxh;f^BgvGKmpBHDGc3qscJQT7dr91At**#G+
z`S>%`&X}G?($v5Cx#yL~bohvaj`Rm%zXH1CH2dD5uPY@A0gLM`e>kd-M)TBf8c}9&
z6dxe=8QNp}***iLZB-%VLlE1ngGI^yFanr_=St@}!Fmmtddcn`zhm39;QTD*XFQL+
zPz-!wW`?^tezRaF`Fn}B%vf=-MBu|UxOS{xy|I>}HYP)W1#oQu>I_<DqC3_Jfal?j
zY4<Y175%e5GB*L!yqA?0V0**hz3`*7?2?eYwS`b5OeXmKi+qq}T1Oae<<vM@B%b28
zCz<`5slWG=D^CWvAc>9}%?D9G!3Xh$Em!dBPM|S!;A9=@ho+R}3Ve~4*deVg0Y3hS
zk<i*A^bG6|_-pc$z(PX%$d2oS?Gp~sH1W35{s@MNc-?T{VWz^^N){B~LA!$=6jSAh
zaX$I8RPUPSvE#&wIHv^J8vcq%3*>N7%sD%d{+*T#&SJHTz|_%bd>SWmpKxA>?dA-}
zou6Ss!eC{y41W+Dw#UVpSz3t{PlF=*VH9$4&bb<k^Dc9|7?vOx=~TpOk^buJ5>mvA
zoGZ_PQz=1y2D$ODdI*-?lK<Qc%=%jfa7Nf{;63D9oGF8;;)Zmz*u(#Ef4cvWC(fsQ
z5&(C*1tf1SjkvL}tGKoL!+a5tach;*at<#X%FR7%c&=Z1{A%?3lZVDn;i>S;KlPQB
zCk-en`zy1rHx|5ij=k^!`zHe7M-*3~m_z5)mu@F?*9~(6wjrgHJ&Et~-7696&|j_w
zz1~MI@{|pkW@9vbnk57+&g^i<_0pH?V^`sccN0(qkf1QRi$%j%v<qq`D;C3IC_EjQ
z<`JGwgswm`EE8SX$uib7<aEQMq!+RCJD>bq<q0gsS2M%XftQBuJ_9eoOUM9xj%eC2
zCSF+w>m8AM@{(<(;m!)bUrBs@I~NE1&rnX&55Zhc(>eW+(}bxxm%1SxHO9~2KpCH`
z7IK;&?En7C6I^)lyyW+zmm_bp)#$po1uQVssbj(8c3mMilfWinhG0NGA<~3W6aiz}
z<=qrjH5Rfwt!7HM*)@MLgIU<VKSe=kY`^ucNlb3mWdTTeow8$6)B|Av6~rgC<=L~!
ztax-mnIZ|fqMm44pWf?2-iE_gZp@LU0CNL5KsCpCYWa#NPm<?DBHLEt9;By_Jp5i4
zl9v3!qWoLkZgkBk5o6RnQhU)K&xM0U&y>m&9kNKsb12pv_=e`ao_^HR9JI^9LU><{
z&bX<KcI}uSh`Ppr){j}1g6~l(l^{?jk~PU=%q~d5ZM<_Z$Jc9jNIpy>Y3hqV_IoQ&
zz|IPi(&-A!(@8p#{J=+*Gx&jNcI{%{f^ys;Don`}A4uyti|e}U4a@$aW@ZU)IE{UU
zul9t><rr`N2G;k1%5i<)`MGB03H{QNL+^~=IFE<<^JMo{2JPixOP+zZxna@syq*(}
zbL_u?L!bU}#~#l_!AgP)awnbNGe<ugnz=<>F#VBz5f@B>2r@!I7EY=z0w4ZP`((}d
zm`~bzo!x^kUHYNiqUhrexDj+&rgif6&zGl~sKvU%VADF24hyD0rZ3}S(4@n-<VKEP
zV*fwp@=bI9uWbKM!0$Pifcuefb*8;tbL*!|!lw#;9z3<{1Ts(U;ogt^Q;j3x#NlY9
zU%xb?$cP{KH_&4&cpE(N>3qsPI@<^1{Apw;q8b3Vc0+`CK#elI7n#4*hwB(HKY4@)
z@|VMYMf}Bl^8#45YvR1@@p2Xxmfi9$zdE!s$P2`U@QyFglV^#a@dLm3Ltm&ofjz5Q
z=9<#sQhp*&dq<&z$=6E*_B#nKWBZkS22T{iZ39}g`T45qD0c^vvQhMn0C)h#?7OWA
zx353EH;!cYEd22de?2n}NVM4oeepcW6HHCb{mjY}a?>wt*Y$+lP%rbNJVchfIt`<z
zWFkS3w<CN=6q4nKPV02L2A2?cz}g?k47^G>Wq!a(OE(>ynFJC1kvbUu8g@D~Lt8?R
zD1rPGTLKTiq3`Rkv6oD@N_|$J?7jsamzu$U^1x@Qtxm`1CR$v#D<|4SC?1j76Y3sV
zrl=>Tb->!8Wkp`Q6Gk51Dg8d3azs6Yt)QqsYLIfUIrZ6ysNF2#Xl1{;x6_Jy9_>Kx
zLA`;AsN@#x3Kns*<YG$@)@_-yhAZIY;q|Q^mCFKO$6vq``F$?_oZD3i?^ckKHchJ~
zw@Ab%5ItMaOp37ymyk(Gc%7i(+A-f>xqstb;(0}Kn@<9GhNLzPuMh06@%)<mxefrl
zk=r~InUb!&;BNr`Ccl7FQ=j}P;9u%yB(t@|cc{EK!fx#V{}xbs3A?qa>xN+f*I+xz
z<bd!g&Bwx;s8H=DwQb@_clQV{qxJOON~}Zi_0XdPyXer=v`GJk0(0v{2TlUT(`vQ%
zcbM5wU$S@FshiXSbX3+`^0#8zD$w;OimKDnltR${L~pXNNzo@fiRavAO#=M;Fq}(c
zj4ak|fIhWHUN&w=2tp8>Fy<Ph))m%dVs2CjlI&J{ciM`NxlhyFew+h*=jitX?_Fpl
z191MCxEKAi^ndx}@MxdPe(_Y{a6a1qr4Xj%ceEoGAhe_Vkjd}pUamI{cqPF)n*~3U
z!%+U=_YZ5Y-#?L_23YKejj;R8nyIkfalhqw5=pOWRhVi)B;e1$4OgKTNHmCtybw-N
zN%DyLh_SO)coFxRP^_q@fz2l<-h^abmIVSwi23%}1e@8uv2<;By?qo-MSpHVR0;0j
zT>ToVR~?+@sq@=zU6I8R#vZf&@30!x9QD|K71x_9IGvWz=nz~J!>uXnf^L0s#tDVi
z6Z5lMgB_2e=TPZ#qV5IAzoQr43lLtIaJB>!$xc{Be;_Y1{3#_#Kb74WOmSk%%0)fa
zi6Ev5-=)A}duEm!Ax>Z*z%0rNqaL*7*^V?-Fc_c|^<KgyDVlY!*b7ll5O#aj2FAxh
z01m<;04Om>U2x`8-Kg$$lmVy<(vXJ|^@@7%cu?Q;8i3b9SlUQ62}p=4+t8&f7NTAA
zB1!Kqhdp>o-K|60Ru~namcR&#voG>Rf=n6pWtlJfbBi*X#X3TDs0$I*kW1}!v)~?%
zli~vak+G;pZ3D*#croZb+OKT|{O;4tx`v7n5W78&V3v{|?g5Q+OyAPV^4^=WW2K8h
z>a#lIm0>wyvmKi``lC9SYKMzpa=l?Ir%0@lMOwRiehw=BBK1culaz+%o_cGV<9r3(
zL)E+FBU@(~GrJ-Bl2Tjg9JTWbM|Zw(aAZ5M-{644kMnN3lVK3VI4+{Xd^f{yBOu1s
z#MwLJ@y8NQeVKvUNV}kmv&*hemE=@=%P<Bic{mCkh2PnwP`iR-PJN`}t=l<tUN3nr
z%Y$-5Fj)+HJ8n_u%n>=A&OA@vF}~oFV_-;8Q92HN{(61cq#e}1IkW1Uk1+$6r@sl{
ztCd2oc<Ot9YGw5`Z2M*l*KBMY{4+D~!ME)vepjvo#g&ZS-25GP1}?vDY+<!h@Yz55
z^Iut6h1D_~i!~Wh=6VQyLC%g=LiK@KF!XC$e&fygfqT=44jX32eF#tOuoGpc9sDX-
zGe#+(;yRLGB;p@EJ{&QOe`LvD?dN<G@=N%RzF>%UUWW_%24!+82VD3aeKoW9|Jj9a
ztgPbv-!)1^>x}hB6Qk{tnNq+2KYPSXB{(p|5TYH`UEzs{!cPP)%86b{{zUS`?dm!-
z!c!hZv)E1-QhH8x7gW%WwchK2B?!tcm8E!eihweN%aT0GsYqgd_}of%YAu_n7^Pd>
zp}7jfIaxIk!`JcFXT%JCJd?MF?d;8$7t16CK<dr&-B1{YlK-L@=HbVnR0Q1<C{t%h
zD~vS<*?oDnlI$o=t$y1_z;DOhapXiKCQ`n*UxQ(}<)Xg^f!M!$Sr;6DiatrwKFbmN
zoBZjq->Zs7uVLt`{Te3as(h5yyM-UV>973u%4#i#isIZGUQfYAX;|O)e173@Jt0rB
zhjxi*v-g!obsesW-C}2L%Wp!=Xaujpj7JTsdOh$u<0y@M21=<|`YinmUW98ff~70Z
zUab*u2EKug;A;ptV-Cq?)Z|VJ`x3)(p2K*za970c{}nAP&4dR%2qW9$#4>dC6oMx`
zVz%+;*Y7<<kbqacPh@a<!l#npNZ7Q0LVsf9;5|Qp;pTl}<RtOK73u89k3>&lNvH4p
z*^SC73^(q=)mc0d2c4C@-wwPl0q?wi_oUpwRo{ofy#!AXrnpbM52v|E=N2pl^9I0k
z+xeE1wX(+vq}y<ut+?lSsUPXVZ%i43p_C{18E5z~bznjRW^el!e}TV`lDx}>CL{0%
z3avi2_p#L^GjLma;?nZw`GW;x-J{^|LhasU#taZ&NL~VRve4i*z8K|_G&@Vs<u(o(
zzS4`mUwp@!x_n)qnxbvCt`LJHSEXuxkZ#s>tSKEo)0NMGGVvRh@cEznme27VsN?k}
zxXX#(@+^DQBgX~!A9_ZmoIfT=8qNoh(@;*NrvVyfCO-zEJ2eWs5TkE`A?-YSK3u_x
zrb({|)8j$IO7(gf+O{6rvjDKT4WoEjN=bU33DlmtF|mOw!q0<5M@)SY{uu#3ct<rZ
z1>q{zze27`=GX1~=}vI5+YQH1fD1+9^$1Iv8k1Pop7=AYyZGSOlOjP&e}4PdJ;xQ-
zz3`Xu!Mo3eH}>nW*J{?Fi}QP={PMZe%k`H$pjKH``x;{@73D&nTg}8|xZ--=ea`L5
zbKr~L@;93}2M+7ou!7=djS@Zf64rC$2<E-RN^*0%3RZzTvmw5?`S}c7aXsHma^X|o
z_#b|vvI-;pkg-Y^Jfp9BBk60q-wnK{2q9<m_+{jON8j&^Oz6Yaw&}^RgZP0ifZ=xt
z8-#Ig$W0^;IOWgGE)+?IYI`HMn;uCnJpemCl<|ma@bUwh33qw{ah`(BPE*sJB#+=i
z#gH^nNbW&^kXSinR#>5^6|`+3_FvOHB+ru4L9nny9v5266Le%DAvj|gu+2uV=WXMN
z)mS7)05i)-h8m~(@&a~%5VdA@VLH}}Ku;CHs7IY(kq`t%I5M)f+Lo-r?A11-JQAz0
z`_9fI81=wHT}V8z)b2qXxAnb-c|}JuT>f~mPF+44kakdi!Tv@)s8kTTLlCvTX9=gK
z0R6Ks2G~)LW<@mMEBrKF0KI32VwUAmVTinNv<ySe1eW!po|r(`B99sBbR%mAqBvd(
z!J;}uYHfT#|DzsMjMV)dXRWZIJg(WY1g{XJZt4;|S+E`=gcdTf@IejWwJEtEE%Sx$
zX<t{k_3HA6oS4-&i}&KG|KYE%tO6YPpe9Zbm%>)Z&#&|F-AsP|XbHb|_)gW!-x0Q}
zfDyf&K8TR_+u}|8b3l4W<%Ada0x~zM5WRBv0oou|N?68$$x6{r(Jqjk!6?89yS@P5
z6j65&gJ6~83Bxvs6!j!1<qk~WZ9@v164lzkn4wq;j?m=K2-m5v5CnrHWJ1sfwe{FD
zlljiH^-|<>S05!i>>vKv_dKht!sjI}(_yYM(RCFZrKjnKjYJuKuZIa?lN=NENct_o
zCzJ~hu)GqERM<~jh4)&*VR)5p?d=>5$lL86L4$=JHwY-K->?1*CKoV_ylc>@E&x{L
zKrY}@1#$XC9mTV`vd0ZFMN(sWC-26)dQaOCbCw$3;{;;UXk#eC*)%xU+?p#AV)@p#
z<mfeptOvF+;6?=a8+tj;Ud!>#$f>>_AFfExu4ejde;4vxz;|%Pk_5Q`c9^D7`V_-@
zZ0Em^+C4|+G3dyqL$KyL@V&ggM~{s7d)$rVcM$H^>Da~|OgCE%ICNxo2(N+y6+phI
zw!4t?pc~-?ugI}m+oi!1W~M_em4cjbfEs8q(}hC^ICkrUg4JX{(gD#YC(8oMBEA<<
z9C9W8iP{njk~oGJHltfGP9#BPf-|ho2#2R!1P?&DU4%c(iMuvGdj}bQf4$J~aLMMn
zv&`y)RbfsfO-()hUj^53Ci8>A-Pv?YrF?a|Wi^pXo$2@M`#aOML!hh8+U7Kf-i`fs
z*9Gtlz570J81g@^$>YS#o<T@<9)JSaP0$QLFV1?{vxew)9#8V=1*Y{Z@t}u25Jl{A
zktL)}P{@N@<(UR1H&ImJR|BSGo!~Y>RJ)_9#lm_~{qpP6&(MV+@DiE7+UKH#oD1a*
zO655S73d*Jb~OmoOe@<<66Fz=%_tgzFe5CpXq3}lvf%78-l5F$1`KpqfOYT(^Bj^<
zp!G+IX3_Senwl$n{d46gU3Q=Mun_5TTys`SuUCetSCiwKE5pRA8kt9M*{Y`;*PPXh
zz^s)<h-t!br%n|2uj^^9J}^1s)eM|y_#<At;@rsY5d-h&r`CUyc*YEnju2mn%a|6I
z>&-%EE%Mm+2(GVJ`0SkmKY#Mo?*RQ=ppDz~cI*p14xU~+VF##pL3xQ@Z`dD4ajk;k
z$$E36@qN?lwf*XA4ZXNh<-Xp8!=l7L+HbWbFikq<w&@?$-NiHs8;;1(xqsU?<Z7|~
zjhwHsw=Xhi|Cp%W=%Qjm3~RzKoKYG!Pew}|la~?rbaLs4VGutZzXmQ9JOacEL^=*0
zEHK${Yp2E??)hzXE!m%(`r;QLhhJ}#+8&Y*x{=Q~bsjI3c*XnC+QURgzPa!Xz*Fsp
z$$Tq0(UFCn+S|BTz&<^m+388-?N7~@@7-H2o!@nXMD6!z!U?d5I{6h*QCEhYp?3|<
z#!j~u+kS%XzoTY0ooBRPM`IDVdS&+OW?lFkUuP+Nevx}uzMmf?KG4+EKji({Zg-&w
zh4Tv?9Cd%bxP0-6`*Rw8f*+ooxQLp-9_|C+ON!Xu=2H!BnSTEzJ9Bg3+(FmfEgyi1
zcU0H$Z`Ys<s_QD9$-+2*YQPPbQBEr=4LC$erW{vWyEWcsQ}-q=@RIn9-(SdqeE9s!
zfG<2=K#V93jB)5AIP=KyfdD0=o5y-@9Qz)d);YoB9=hCU9W{!66GE7314%beCa@H%
z@DV!7i>yGcz<OiTo2f6?F<^c;hUG?ie*`U4Hd{J{T}HREGgo$9Uf5&|M*zGvj<-*9
zyyyP&kTmtBKlTTN%Mf#xK;n3CIjnbcQMw)U)VTbW1Of>zH(I3S*NtCZYaIE5wg40C
zx%}y+eqg2geGL*2yX)k9HfrN`bYS}L5Qz06=Sk|@bqp9^&+L8w=H=y^9WSgtOnP3Q
z_@%f1oyuwhH!D3tBzg>!2s?X2a&eHmxPNCXeQ~=%9oKd@+w~i{nF1mcJw<z<VTLQ|
z^(}x!B+LD@2kO=VmS;+#?YBHfT|gM^FX}rZl;fF)$^P^7xBb_Dva;H0K&unpXr?XQ
z>8oB!H??Knn@wd^+%DM#)xlDJe#cx}$>L2}#>C9!j|jx4rCAxuVLt_NBjvK3;2Cb0
zrT8Nqzpiu6>8(~HqDP*5G@Vl5bI$JY>HOm`nTR~XBvnvxojq73cEPbTW^ckiZEL>6
z50&AW|2E+no`;Kb5W*L5X7(+>B2^Okri4u04wh!Ae2O4gV19zmlq}!eOxaA&&CSf<
z<P1KGqxqb^IywJ@XSZj(`o#EN32vtE+}^`tcUsW9hkc->QjW)Pz6HEHT%WA`CgtoI
zxZ?f)iSeOH=lsII2R<ck_L&*jbpIdq&Tn>Lhu=wGf*n`~K)m-?2{Ha2#CKHMOTnWk
z!MFptI-m^6hIL>&Tj>JXv*&D*z6yQx3~v<vNQUE>*ZJ8+a0+BDZ9d*X`eoR}5%K`n
z99D6JQW&J8EGz(n{#LV8nxCW1Y{M91&2WAWuBCVS4?h1>>y_1Zbu&40<NE778tDgN
z@%;8U5BC1pEo$Z%4)C5wUE`a3*T5te^blwt_o}v({9P=`xWSlq4+qvc$%{{Y^d9)b
zFf^vw=Ywrp=L_ilralYKC1;UWX&3A~rFFB;Y0elZ)){oK+a1sS5zX5EC*AA5S`8l$
zRC0PGU-w6Eu-G(`roQ9Xz8(9!2J<Mep0lasfpdn!U1ahBwZkr<eg9NxuJTst<bC>$
zc6Yloz13>N@?fpHPeB;ErQh#DHhZJnfDJgS!0Fb$(Yu>tmb$qgoxZS46@R90@+?1}
z=+R{uGloaAv+2d*N)1kwy1JJ5fggV9$DRXD>@|Yx#|)$1A%?3w85e%wy@jrzS|Ao&
z7H_i#^Ozo{`wgbs!vvcSIv9z1d^lO}q@`Su-dua24UHxLa`o4@xW2Fe34Rlo0AFmK
z&-SAT6R$aZX<-Yvc=bYl6rTcZz~>fC71R7Y+PC!tBnWXh-ATBqb)b1**H{1v@&};o
zLM1`{CpF;_gErbT(Fv5Y7!wUbaqSu!O;tof0Ah+qJ%T?}pFSYL>S9kdgQ>EV!rJ@*
zjC!)!_Tn-P8yO)?4W${8)(9O*^~I{dmv`|c>OohK0ukJXWVTJ8gegZ9bW)>;wY{=~
zdV9ODB*j?NW2wroOwD>Wu_+~{WgtPD6!mDq2EJfqW8GUn)?1hFF9UK_voo_WE$=sd
z&M$|zH0#1id<S%iB?>PsgOukSjWq>^pH<^(=C5q(kNh;~x7G$U@oJDBX&xUn3b7J9
zw$pyj-eU&jm`q>ngg@L1%C`*26Hs_%w7ysxFlWg0#I`y~dw{mi@%H2=fX95(GnVYB
zCY_$@0aT$d33ef6S<MHx5Zp*$XWCO1<D0d;#B{gTsaJtl^u4UjP3%y%<eO--3k$87
zRh7rnWKo;hVvc&!2qdal<az<+2rh~$Xw=|srTDhXLLQBJ&`rFovItvjPS-Rzg<E@R
zWH1$1%k-C^$pwSc>O$1R5}X#e$%biak6~o%siPnO>9a5t>pDBqh4Z<#_Xw<2Z9kN!
zV41fH3%X6oFTW3rppw^rpL3VPE~0)f;eBDPkW2gMKmI?tf3w%t;`}{(zYf3aU;JGw
ztN)_=b-fykZ!o6*Cz>q{#|}O}9{R;F?QlqFU}6LIZe{PQznkdy3r&Zg3oNtxR^s1$
z_D}sP`8QYy8vhP{zAwb^yVd#a8Abv91$5$720rnqlQ{8J3w(aPlak|#^!l?mgI=H7
z{QmFay21=O=ygbc@k7w-<PVR!x4&@;y?&v4JC^F%4lF#;cCQ*9avG+7*m?p;+^=PV
zo7#*0+PXhK!H)e-K+is^w1N2X#DqA%^uZ})8**gwLPOD1sekr*`U6$K{DfUC(V-f6
z7E-3cP2ix8*^`Ek_!h8nFy1@jwFF_qOF%97{r1)I(wf<oVr^gg=U_Lr-EHI!c6GSo
z(l>0^5_IXKN_jD-kFliZ>wgW`Q!Ei7!uZea?twW9gPK^U>5^yfx7rk{DDqEwNc<&#
zw<zcyoCC5O?J60G9}OP$JnlZ@?Hj;?tp?7mchb29OIDv>Sv_h~z3xKz?X9cgHvq<k
z`I5Tb_4|A1ukbJtF@BhzY6H?e8~{;Nis+E6K{d(sOt-4-UEm`t)$18vf_aF&ssx5;
zd%>&Ns~v+>j|d!$sD9x;M2^8R+pOk%0f<P(6c(A(Aw!bIXFIqpUL$sI9Y%k&04k0F
zZkd-Hjui%ctW>PiW_>VThw~ehi+XNZA-FF`H*4nC?x-z9tOQI^yS`Q3YC(sQVJHw=
z13=MijrDLRYBFIoD&_&MGFY<#%0%p2+mFPfx!+RmM{LNli52AX2ebA<I8&N~S3DC%
zz!SoZsY=bv^I=g>h!9YK__CfI5rn#z^2Ykj!5sV?S7r{PHsWo}g|qItaM3+CvpnnG
zdcoR&zLz~sB3OPc*3X_b7fL9jugfztb5sL6^ZtmDT0emI-$;03<tg}<Z^O@h*BNcM
zAyvFZjxzah+>H1IT~zQThvnu=<$L!_GZ~gwQ$_x(@-bB%-^1R!E#Q3*yA<;X_doWx
zYk%8&Or@0&O$GR!>Jk#jD%i~WH{rqbPBt^U0Q<)Vu!VfsT-lWqaZ#sJUQ8-kZu1U|
zON-Dtyo6tawMwB+^T7}O&dM6z#ekz}<1mA>GyKAzyJ`mEfRptuY=Ag{>S3YQb+Dj<
zgB0Op4~XN8M5A@#r>NF)h7%kD)*)tS{NN_|N{m=Gm=(giZ>r}|<nLbfs8MrU-r&od
zr!z3Ue8>XaB5D=ESzl{2>HT{DEzui}h+7utyQ5m`vRa}2BM(j@{dKkb;aVlV*R6af
z?7yu+a(E90I|30JeckWhZ_r`~o?39c@?qs%u)N7IGy@6$K(rlaoQv^s_c9~TI@fnL
zOoM%ij1W~_5@H{!?DVLgcl@~aPFmN`{@g#@#JV1L!4w|yr_(>-Pv`WCZ&F9kKw4MI
z9hXAb!k4wbfMY|43FR-6m$5PTPrjbd65scOC!6n7)<DwZ7{O)OD3+jCM#%%4Ke7{i
zU-`d+DLp)MxD*EYuhqtM7mqOf*|lWgd^#gH^V>|}b->D71$M8&1At*}81t*Px22-c
zuEC#^4TNVAUlkbjYWjN00cA6K{wL+jCGkAudO1UD@0g#Fwc0Uk8qqJJmWS)B3C!d}
zecdKyUSHNYFS$OBDAw*II&tM+ee*{uYjrqZp%Lr#v`$zklgmBLUf07?`R=`wdUVOZ
zUE1IsylK)msPAyY8{p4ER_hq%S*M3svuQu0KkP}|FJ9C;??Ia4W?v@o$=_rC=PUC)
z*PcGp!s7^-TDkS*6~Y6aUqj5s_w6V>q9Ob2*yEJ}eWM|jO0KKJp`RZExd-VzWW*2m
zjT+o_cimFp4$yXUI|<RW>+4YF<t;}z9euY_y`EC>s$^GzY*4zYpj;ZI-3|`;oSy1E
zJaTl^hh!jpFQa~E0HkG@xWLQtL$&tcjqnHX#drT!3-||2$U2qRfD=x_2MzEJNO+z<
z?Y45XCgJr8zRxc=DLJlqemqEeXg~4FcYP7-w^dz-$Khdq)>-d-cS<MpKzbK==hH&5
z{-7rfZfyO)q}555$>W)QXXA1=$(RLNAiAhBLWwakvKfN`<G>$979=`<pxRLu`-GA$
z4cst~&jOH%A&N<XrqScf-(?2%&`KrxMizTD+4WigbJ#e#<%L<We06PQaM7--<z*QD
zvK!7!i5X;c3oJI+ub|PbShrg<bEQyT1M?W|NS_fLW7IF}TnsuJ8l2(zdCR~cD@8pT
z65xY6EAF&rd7%s&U<+8=Q^%X%pB^MXd;fmy52^PTba0}t1VRJYjebw&D$vZ#+tJWo
z;{G`C4z$jf4ZSf#v}&imX_lZNl$mx)J6=21W1e}%kI%3{*@7EWJ4kDg@$z>VRO(xe
zMuTk@Vz)#+z|xU~pdZd#VF;WZYi#nBC^A_r<!hW$k4B;)wd}2iqoeRo5CaiSwcu;i
zgIvKbWHwm0ik5fbrM`&mLH;zpK$aj4BkI}mk)t1IcgM3*T_J*e9m~Vf8`wpL&RW#N
zXQy4jh%q}O?0NM8OJmhAM#mKqQxNqCWWl<}^tQ27{0#8{Q2p1_&LC&*q#WGKkc(rz
zYj+=rp1_v>-~NN|w)4+`>o!b+S9ftFv>LbZJ_-S4EP&Iyg`VReHDmkzQE6Cypm&k;
zP@pnww{2X_l>(os8omRu^RVG8`~2EQVg82uh=bx0SCpId&?V_9x9_-i&){h-A*l>_
z5<Pq#{9Nh0cuDXx>2NSS{wu%*R%C6}5KRUbE};MdcC&UmvKbp*2K279{uiJxZs28j
zsb5O`O7PNOTRnkC2H>SQk#u~Gc`lvw&vOGOFJ-Z>P{}3X1iO}vuH8%TbyMrp&vk#-
zCD_0s;G#F`{to&;_GHR>M0}$pWPo}XD$mPqVulwOeKpfE5`Zw%GA4I-QGBDhI&t4u
zD*sb;diSaA!W6!lw}(KvMnz&5PR6oWYrnMxrl6IgUX77Bv_2mcxUmSFa|oJ;Jc8mI
zW9f<@ej|HPkozrnCqWt;QVbK%58zDqUH`Z6Fa9#<anAeNz4TuB&W!V;@cs;jRPnAD
z?-`@-+gHMK?8d<RCbv?&cVWK(z$81>hLK3fohEpNAlMdsQR@=Oum=f`HUhiISxl3N
zcCt&XWpa*_Ix*4z8Nca!f8fvkjo<&C|1!OcVE!cs?Dp6TIpBpE+V;M%9Prw`WS3&)
z>7O<Hc?i+gA^vA?)cbhCpJGb^fBKpcf6^p8qS`PIV6Rl_x(&Ud)SFxIk^sNuQZ~-u
zYYe;yZcH2g<@}KZ7EIvEO}q<mZD2x-P}b<eAcCIE4LW;0SkHmnuRanW-Ny)n$wn6=
zu<)0-7>J+^N1IU(vmiC0PsI}Y#7F0WzzdJDCOQ-g_T<C*R=|Dr&^RDSsvdR_#vPQu
z$piVEuR0*_4!IE6*l{6{m^UykO$3p0A#*O|Gw!?%@HLBf!cY9+kMK@NZ+|aC&d2By
z$lh6f9ms5q+rNoe{43IX50X6c)Mx+SZved)>xK;nr;~9`y-uAeEvR9b^QYD@mx@$3
zCU75)nxQMM*ORx1)~2!bKHT~4XO*?q3+OW!6gp1_(ldqp_n^Eu^pWnJ=C7y7e=&LS
zqMW*wt+QcxoM+OvY(Z+bQR~88C+TCOTwwbmMKBDxhq6+lyEQVgquVyff<<2p+76B)
z?&MC^k5TJz-P27D<YoDZT6>uA`!9d*w|ow8*QoEC$9o6|HEV_^di`fv8Zian4TeI8
z>@r~Lhw}xVIgy^0DZvw-qabtPPz0)=@WA^5`j0RNCFrWb92)>F;0Z(w^dp(VQ0hD-
zo17#`X-7;m5(G~=bRh@}0a1_2cOb$Fr3U6>b#%1{*>Sjwj3`Y`6=7&*icmtn!cQ9f
z1u6$R+=j>8h(Q&ov!NacvZ3IIk!pt7lA`(=bYXZhNYixf1GHn%>uu@xcLwNq*z;cS
z*IMaQa4KAHVh%RP#Auj<B(v!O%`RO=&u=ZWb6NV6{|xp)2WBL(@`nEWUN_2*!LYrd
z^YuXOo{;$gOzUe93H(~!fXQ3y1Yty8#f+dv5H9=7qKJnF;FxLgNSo?#jOsPoW{Ucq
zFh^sohh5n;_X+RA6qcreJwODW4vYj(-JQ5VPKOuvGI`$woVwqrIn(>WOwx`Hrfv=z
zK@xnJgC39pEY!;cuvAH-SsuICj5VF4&qMC^x#90M5Ow=I?rt0~I~KiAI{6+@ocmX#
z7aWoC2Ffio*0?4r)0uGO>dSL(XBF?-Cip)G4{{DruF*I*=Rz~^$wXXuk^6Ce&%0On
z`B`cI?#f!1CQl0l7<9m}{<`VG56gp|kN<}2DV9Frzg;jaB%;+$eK8!CqK3p24ZOu3
z8#a@It}_&Xw%mei(axlXa{95b%Xp#L$l&H_rGT3+{JZxnPiX?rE(1C_0}qYji@m)%
zU%qpvR6f7`1Q)!&l29aG#T^7uE;?i2A+YgupFlj|B041q@_f$G*N!>A{p+5C_gBeX
zQ!Ul0D*1~NCSMBrieE`#VY-(V=a*?%o)b9M><qw7<~OSSJ1bA&{5r=tqwvk!LO9Dy
z=eL*OWi#3H5WXm)h9@iz2oh*mDaettKLJ&4|5*@LbkjkpNKo}E*hv1M1e<8c(eiln
zbpGHzhB*>^kzeWdqH{aKP9TwA89;RzxGMY$e(|5ceHL(4^Ltm|Bh1~1`|O~96cNHF
z?yW{1pS<U$6)}thdJvF+t7E!|c4|k2jf>EEsm|*h$j_snP4~VFjX1|EYw4Zl%Mbte
zb*}#|&I_{!NO;2Xu<p#h+<?8w^V>~$1*^%bX=YH5A6Yz5LwxV<Iyu}AL~wpP*FDG8
z_@z(pCVjT4y+8Gpm8Z20*a}bTB<cP$itbni|LV@5{N;!VPwTzapm_4WU5q={p4gZk
zhANAlD2y8xz`L#Gs5duT9fJypDj>rR9K>{A(NCbuQ$BrU^7l{cy9ZPa!=w6bNT0X1
z>M+v-zcN9Gj*@SAy<ECexte~8mfYZNTq#`QBb$c~`pp9>X65E@%)k}#g!@s)5i#}U
zzx*33PazPe3xcQtod;-WSbwoY{`UPlC;bUrUC%MCcPI2+g<wE0z}h$Lga_XacNALK
z@}nhsZ3hivhLw6f<u}9<c^nBTYS$tL<3$Dz4}1o6V{&q)UxybtWw{9dAeQJ_{WU)H
z&wS^P{Lb4y^Gk^yasHl*lN5XzS5umU2NX$m%t2d8DoS&3b0EDV^7qKJv56gPs&abf
zL3*E=`hoBLj>=QK3XXG6(lu#jfG<6wX#+?YxZi-C$^8+TCNTNs(WRW>r-gm6sc-)I
zH!4q|I@H~r<_?DkE121ae^?w-=bls46FbeH?ZxDCA-9$_3}t<AP&OfOv^lJvpPfgB
zaj*}l%7WeswKQOa3AWUUO31Er<AAbKYQj1b2sk5#-0rmj2-|+{#NQE_PfyPA!jppU
z_OpNV5b%U|+l%u5%LDxX)7vygOrJ_{`*5ZvCBhpzC7Y`Oz6Q-HVJ~ES4S7;f5{(<i
zGf%d!vZ{uI`FgLWd+pTJpZL9%r?5;m_Bk;8P7gSweL~zsAT3)R(6#sFK4I@R(#hA@
zGb)6((Q>&~`YA|#5-$w#mc5W8lnSZa!X_AR@ZIvVM!+0bx1nlz!#4|{u=k>2e@a*n
z=tVEPGwYec-XKhXg{t(7(<Wry`g<fEi}+qXLa#ZRjK2eLSkNOMyz@(dL&~QX9RIjy
zjk<S(E_wd^#64@k{?mYFwAFX^cb>0=OY=*!XVftIB?6bi*TPrn{Gz%n4qbMf4+nzF
z>L%kX04Vkm=@}vDY<|LHL*%m3lBONZZ*69C;=PG_vM=()v7dUIX3^<)cB8co7Z|D%
ziokX1IItcr3v_w$F;Vr9^j+7@VRHA&SNn7t6z3}70q^lkC9@)6?--o9rSuR#AI1RY
z-RA7v{H)XP^K%pt*GU~);LN`R`{RMiA?btWzwx~Clw!?VCM75Ou6Sp^4gTQ<Xh5p>
z>E3zoH2SW{|8m~tDQ?XkQS6*!qqTVwfk}Vj%mGi*$L(Q1N`$L&K#J{a$|IRn2aHLW
z7}ETrzu3<&*^52zftT=q8vLzQ)88uK>Gm!p%%E;=OwTd!?%FB*t^Tn7_#ic4_Ynff
zx%nmuBrY`8OY*N=zUS#Pdna{2bemn;Z{WVwwmqG1bqf9%hi|1(c{{>bgLb(tH0TM)
z{BrDKVSU3c*3?SrS61@*7k;*N?&-e1O(VG-ofA0Uq>ot=w)s@jCo12slyZHd!E!^y
zeu5+LC(O@bvF=W2kghTU#E6}JnO5l_w;hl?Klnqw>NZ^^GBZMj8YWzD?}jfEs5Z%+
z;%<_=4FYVt=2wMg4V;n4w^v=a#!+g+*bJ!#D`~CwKo7+Saxsml%7)}LRix0c%mvQ(
zYYEMS-xKuGj9nTsJN+<)Wag6~UN&R5TUcL$nS5#e(oX-poo}?S<fkBmeh&Kj^l<k`
zl8?Br_#p}7OG|F47{O(?P>g`dN-nq=b$AGfdb}XIA`z6ig~hU)dYW4*L;O<0aSO{3
zA<%h@dyWgMAjG?mQ9J!Upp?d)Xo+2bFtEg==i=OT|3*&(bO2qi?bNq-xH<82@@WXa
zc1GXteIVRd@F!%@y<?Ar*2FYxPf!nI<OFC-L{A6$c@x15B>oHOG6&X7ZYiK{04Bn_
z<(Tt101rmr=kSnQZV5VU)H@^jw~wyw52iOvkB$4{cmpz{X5f-^8ul}5eER8vAN%=V
z{_4upZi9UC>aL-QbnhD_cLKi1>!<lG&hif(-mgwW2hRmtfNzLb(2p!X{U+9%J202H
z-)blQ;WT_J06er#?>*IHJ2Ru(I51D*#Z-0@11HW)+Sy<5V@T%{XJxVMXAr+G`8ftV
z`#kYDp<~Tl&QB=pHh=i9O?N7UtF-KP{$SaA`MM9tGZC&TgM5B2{DuAJuBJvi)9>RY
zV7hh)%Nd)s&1vz!+IY*-uNa@2Azk>QCS?_{Ie4lSF=Gg)@fau0O7;7<I_U!nCfH29
zaDuK2kHV~YJbnJ6bJsBR)qV$%5d5zT4KRndPZx4kQ-ABP5sz)aEL@oBO?Zsw+i7;f
z;mfh|`rv!Rh^}y@jc=Qp5Y>}nLO~-6Phj%p&nKP>Pd}aPrNDyW&vIR1-C+l&AYd+v
zJS1oQ1^qILe^2@AyKk3szf>dEBJKYTSn;mAl?Pm3;Zi~@Z3f-a#3me9Bb}B9trYE0
z)V9EG?}{>R@*^4GVv-U{U^k_CjMpncOp8O|Na{WkV3w!{_d@W<8fMy5)i5WVP!w5_
zMUyd91GO^u>zq6OkVOU%EjCI2Umor_OHbc0dKoBYYU+;*pKL)nF^4zgf;=`j1~8;a
zFKN53UwrrVllE}?Pq9?)m9-;*1?bzRf_@%y&1grZy<0;|`?c5f;<G)?Wsb7!oBawn
zr6+Rk0|M0sU6v2WaX}L^WV4pp!==?$dTEEt5fs*;1|J7Bn5pwF!m5=O>eW?67zsFq
z=nd0qofk1Xj6&p86{+wxoWh#WMIHX%v%WzFEcv(Mmcbxd7(NYSG+?S=o+7qag{%pp
zs#QCo-l>bPQ`p1BtlGec9(JqK8YG*o?eA+27{<#+%QiEFJ@VP=B>oPlmG*vY)H<yA
z;`NuE>(n9Mw&}LF6p7w3QZp_SLNPy(JP3b`od)dTgz7c-zD<RZ6ML}o1t(&uGC+Z5
zA?i`v+U~7gclyg2QytNph}#0D&syB5$B~9L4dMs&zG8TU6N;{8g*AmkDN&E-)l#UX
z{k97jvlnR?h`><3y`?kUggl0Z67?|A1&l!x?d0HrDL?_MRU#Z2=rB&&U-HV_H|hw0
zBQ^>fL9|m7`)|M9g#%3NkdGm~W$)+1_Qyb<l5a5Q?5xF@&l!;RCeXJ)Z4}JH+yc$$
zC_q0;3M?4MYJPc9&LWYvuw2pwAoxs>1t~!i(41@$Kb`e+I!xzvVV7a*!~d~o=d~}~
zZQ2%S9ST<(|LJu6dH1A#?|AqVlQ7I*FtnmQcoOfvihJfp<NGK)7UyOC03z5hTb1#L
zfe9MW){AYo(XwGAApif``?}cJlk6@_L4XDjQ6Lf@Qq){lh=(0+x9xV@5)aq+YvwL9
zJ0I6`b$1?6+IHLSb=&Rj508D7hXDaXAU+iF0s?7;gm^##AtllBfHX)!C?p#K0+FCd
zYyg2^3A_6cfe_u{_xqi5s;b*xZTrq{u6_H#u7CaOUv;YL)H$b4opb5{8GY9vBc6f{
z6xN5Y;Me<68<DH?V~*+5ch=H*!>2#>ohiKHXgd?O?VRg3&%&=0@rQqq_=TfOSpLHd
zk!uqvvpCvpgM5j2DFvC1ulv5v$HNY(n;A1AwcY8i2ML6QB#RCZ+=fyK)4bJ}$r<ft
z&RgrR{JX2;A-n$cqldyU$%Q|k<U*kzoVIh^nF1w4F2o+Qq@$e5nedM7zSG^`o>3lb
zt}Akp9cQgOT6H4Pg9#B?v~XlyaWe=AY<7S~;?30m^}3F5o2`S`&47yQOCpq~jX7^(
z^|22A3SpAQO2+Ls5m*$T^24nmZbxFG)9m9?BSEo8$;Z=H3;Y9^w{1e2(zxH3pD_*R
zwe%g+LVVnPI)nhGRkGLGh<c3e^Fu~keF1`Rr4g0~u>eEh#HC5RmQ{d3=G4<bk5SK^
z$-Nv*pVd-#Z$BVM2p$fPiMj}65_iS+Ak1&2aaI%X>PPrO>ku}J+FUApeSZVC%n)i-
z3WG=a4ye`b<1z%369b+hEnYYvXmhh2gP{5GkyKir@5F!=Sy7M1&wB$wutL<xA0=(o
zNkF_{)T8m#tmH;mw?Un1RdWuu>Wqx2$7InyZm^9~x^^`^=&}j*TEb#lcU~awSx4Ma
z%K_Imx&1g&5+yOtFKh{rkP5GX3s7`&t-V@5lMh9Y=Dt<>eJnQ`xK3t)<FK6Kh%Q$b
zkToM8aJi1-@$_Mi!#ww|GTjTytMlYJgjX)dl~X+v-IF}I)9npTBYeT<(_|S2K`!Q2
z6?j4UjD2749%6}VMd1R^Eg0-7TN~wqZtWy_PSUE%TgnmImK(D&)qByzS*Ttl{6)ww
zMlrI|y9k%%pg7sV-hQA{QtWbLQQL-BD<$3M)P(NR;K#l!ZOX~SBR|LkXTbN6&3$y#
zNMOK|R-<hvx!<!T#zhVQrk{hR1Qm#SjzMM82&GCL#PWHv0u(SB67@vUiESld$-Qt|
z!Hh}rqnxOx1UwN!1bel4&s0Yl$NR^rpB#VmB<it=@-6UQtCDBbhDm^>K0#M7F>2k-
zRL@=ueT{->#2Yj!MbP6NatH%wzsQPu^s1;yr6+-6)?|eO%RcgYXjj6ZaNL(TH;G5X
zUT7k4@rx}5Y<GyU+Nh-E^vWc5VCQ&^^8?yT*#2UkB;{#=eyzI{!6!Es=h3-G)e~{K
zXQOj~;N|UGUzv&fJ^^}7dH<bsKN=iyo$qZy@9!r|jt`@?0#hjOgAeh<;eJ&bm#5jz
zjkl#4{}tj9-$J*0o?iIrMSRfp4*jkE3*vF1zi4i33<)hMQj<Ei^Z+t~AVgwy+IQjw
zf#Od>6H1a^Q!B}jxiP@CX*%z~1ID1KN@*$A9X7XF2C^)w%=%$#78?M5XXFO42!<}=
zDrp;oZAiW%+el#9IcuV6ynd0X2E7QzjZNB<!>9*Xr3+yA4<CV6G9C3uy9}Q&y@wZ(
zfYk`>cMmx->NwJ<gZ(i0Dg0yLa3B-)B&{yQ3EyrVP-`Dw;QrTQp9TFp^j>O)3NX|b
z^{@lX^0#Od1DNPP2zyj0cJGL160LSuQ4gxI&Tbl0fn4pIFJ!~_cHOKY(GDivioi7^
z3jk4%iObFpw}urVI)T*udHV%l#(1Z<h%!;eH`N!Kg474%KnLzuQQrYrP<{%4St{UR
zrzSpUcP27?;@MhYjirGe(|G7Fj+$u720>qCBuE9&MD8UPK){oFOCZn>8<+`*x<MYI
zn`v@~jIU(Bquf~_mcH=f@o4A*fO1BFjGU-vdPeYSddLrUA}6&F8Lg@LI@p;8p2Mv^
zQ)+T_fi{Wb#M*E|Y9$B{2|AAxkeOC6i@@P0%vQ^N!1sy%pViFHXa^97-9h|6tMsY)
z<^JfM$4Ngq_aB{4U~F8pJy$P;FmmO%XeggzfL{t<NPrv0aDRk3gXNT|AJT(xOHbWx
zJ9Xad?lmXz9yx8N;jpf7Y-m|h-?uuu$QGTmq)>-RYaQ{)T<UH0U=psk7^J|ay%zN%
z`W(vx%bCO~b~hLhNU2c|#Ih_uZxQDyn%gEP)}7~S-(XhYtix)Jddf=BT%{DO697@+
z34q$Jj~$N<(paGB%S1!4F1<HqfS#u1#wK3+`jUK3J;$g2;GdcPzk`!c3Oo3nCzn6G
z;(0u$<`R0>&1UBq`z<2N7D8-+>2}%@P@n}!GE}4k|0W6ueZUhDRRNU=>!<?+uG8>?
z+iw-;a%rOPED-fXo{0utAYq^CfRV!S)B@4w=I9vtQP1QaUoD^VQCHuX`He3QAULPP
z>VX}cv3TUFj!IDpl(aDl5moM0)Vp1E;l8~19E9NM$L|UMxh}r`?cYv2OH4KdpM0Mb
zN}YZV_HfePjZ-(%ewFQBVqFL|1yaUdJ!bR-)t6P&jCx4|aN~c5C!E*0x&M>&x|ixU
zzSN}Rqo?mYULc~dwz+S*d=d;Z)6diPu@9?D2r(wNl)_)@(Zg!vlKWV~ehIvB4Q(b_
zrcKSydoAop{aDE8&S<3lsql=n?YLuRK%%9VA#C(L!(@)AZ`6ZV?T*Tt-jnn!=lS=%
zb)mZf5R7nx#&sN?L{GcY3yK;-6$fyQtRvm+n<kEu4v1ty-nsR_UUHJYN2ZAwI;Y`B
zg<>();<PtCb2y@3uGO^W@&c4fa$3hL;+=;ZW{<5+S2N&z<)+Iq^q<cA1LE$?KP)l%
zVPUXfx1e=rblC;eOY0R++_yawo#vds)+^3DYnLo|O}*krr<|ve9!UU`JgcR4mOb+&
zfqh-v{O!h!{S6<?a=(4?*l<1L$AaLai;0i^QsSe~j!-F;_93V7QRspnAd~^Av)x0>
z`p8<9W!mC-zU4i%&<VtOjG89>cq#e-C*b|9y%Tz3VPELIn#VAE8#=#|3EaVsZ8^3(
zFeV~U{B;M?c@k{eAmIa<X?R*JOz9Vqe~f4}I)O9&mem4(-cIpCJZ>V#I919@+BraI
z3Wul%TpCuz)F==nw6*IRMkr)?%+Flh%izj2?9lc+$<A+P{VvNnXC7c`D{lP@UJb!u
z)78YNZ>xz9p)@G;iOLChP*hc=lG6oIpkTvRdHSL}pLT^~FmS`T;!{c|rjxWH2gj|B
zX;=tmz{3!;Q9bl@<q@PhlEJgBo8dLT7$BriJDpF%x?119aYq+MReatx78^t9bdi>3
z$3&j6vtU(F2^u``qluj^@*ru!<k}0QnN@Li0RquY*dOq`a>9Rosak9Jr6^0hpPFQ0
zT*K8-Iy&N82J4hp<Ba>{l3u-A#9#Z@1-){;`gwYj2iMR`Ug*c*9fdv;q$nAPM>os!
zE1qHF8Zu!mlO`A=@Gx|VP`lZSNCuwg)eGY(o*-n!h`4Nrc_vG9X)@17#8*_*lV6I!
z3y8=&?m!_pbv%KJCQcK)p7B<@Jj)?ALmk*EV33wR=U_RkH+Nq}dv&4jHU2QJ_Qd+A
zRTtvUsalGsP{*PW-=r0M-Mm>5zM)YwTX#g3Yj{iugjxuT_+<}qyR`CV%&%fZEH<jP
z*y<}Qs6kAa$$1aUP=)oq<u>M*8g6sHT&*KAgD=;yV%9BJVNh=&xK14aUzc3rkR$3z
zj`%kd>yqlY<k@!K`h0jrdjrCDiG4Us9f_z!{f%R1p_@${klNCtg($2^a5l;kF|Kfp
z>uOcw4#d{34j-AatYc4fTClv|wbKSD5B+W&tg3uI>h_f2WZTvpcg7nnwZ+4MA_?^X
zA=o<(J`bg-`G)`~hnw*n{p8~S&In<ZDrX|65xU!sG{?5*J$jk9lbsJ+V3sqaN`Axw
zc5aG5`6g)e<<(QDR5y}cY8#F%tb+z*tW)X2Q>H19_-T5Z(E?dPSM(wM5Q~ys=+Z*f
zHfTfe5uH1PuLIn`F2hGoMdIJ;nWf$=+e2Oo>XLuH^LQz((?5zhM^60xyyt>*hpX8=
z64pzsPcAjyCl%`hoQx-BLLBk6!XGQ0!x_(;K3^mE(ve$2x|9<LC0^Ox1O919^WoZ{
z)oF2Q8G>DEyl+(DtLp`vFEkRq{bJ?|IB{_UOukL~%v1eOAD)O)`nl-!*PF-OR1sCU
zKSW3mZT&WzBst0kW+J8iM(~BN4iCekfc(I}*=-Yl^*NJ5U6Oo}SvDX%=Al#6Lqk}R
z``Dz>M&3qf0#n^1(^oAFBHeI5>Ji;l?Zsv&<iQ~5{xu{-pM<<Tq8`bQF-3Uo6y4$W
z)tDP&MQQKF=As^)YUj$aqbqG-xfZ9PWJb9OjCv@Bo;DuJooE>a9qv?5r<wS;u_oIK
zrm^&`VfxVJ=!3*twb?r&DY#KfTb+4H{3Y9+N}m*b1y@0zW_EfmpLuju`+6YDmG#3$
z{>R}jIq3BjN#*9v_jP-8b$-B>u}@egy@yCLH+T2vT>hX%nOQ!Zw?BArRlGpE7w+HF
zuo%U`J{|%*f+0frBLe)@p^S_~qp>3v=@Vt+ao6@R=oI|#vuX`)`MBhz*s9Z}ho^Yc
zyX@^DzhiY#kLtJVysNk8MAkrO3sXFQI%U7VpLGR??d@(dP^4sJJO>N`w?+h^9%g##
z{Th$cThhwzQN@)FRHDTOB+@!aOT&5N6RlATv?J{8;{T<(jir#{9KN%reYDX}t&54%
zwe!};qbtfu#JMZeP48&X%}e$BRusNAy<AE3^541q91(c3+<e;kjM+Iz=~~)3+=uCd
z^v<02+0I=tPZ!$jr@3Uc7KauwM~+O-*@U|;Bvlfa=H5E|w9LW)M({A*RJ2<AYBXXA
z%W`>=Pa#XoU_S|EX1;GyHo_WpxYJ8=C!0bh$Y^u_*jj`8_<%ya=qX~nCzS|}0bE9J
z^&p}nKkHdk7{;Cbw)@#dNL*ATzR-e!JHCKdXIsjkt?sY~2e=^tKrr3t7u2H?gtrlQ
z0W=fzlLdJ70HjV5dp`_gZhL<V&bzj02+xA32PS!l-2fX6qtS5g<&&v)x(Rwg%}&8)
z&!em8={VWxn^=xa0&g?p4_>oB8Jq``t->84;0fZdYJ`{UfsLVWXgE4PI6hJyK!q=&
z9v?m!>XV=DSBe-@K!DVW+?qMhYK2ek8WHsv?liXzZhzu7o=^$ZP?v2<><R7VcipVd
zD!w54<pu|QbS|qZx*PEQo_OEgOME;v>ql4ih0m@56c)z*<f=)3ihiXaTdJT}$uMa%
z*WPsF8+*zO9DbMTUev?)FiDO`Kzf|`*!7;0Kb+3w4d{NdS5^oxX#8=?m^XM{z7SCM
z=?Q6LgQf_y4}JlU<>o@rByzqZ0|JNFdol<2x#}nTOgVYL;(s4sBLoV&E#GJupeo(%
zKs)<ePhWU#{!pvBJpKN^{jSN=u;Ws2`ph5B(5p<`JH?Tli64;EUqYV;e1qsL_ljn3
z1I`;nI?hNuVTSd1h$|6oK1U-{IMWlW-9>y=zTbpbmZ4?wMC{NbJvS@~Qrl1RIGPHp
zKo-+GdZ3h<CX=h`3F9~j>IFR1K_=CA`UF)K+48e8&=K4&1ACDCTX0LUF9B-Zdle7a
zAkF<2uW&QJCJvEiF|R#6PVhI?uk2#Qfj+cT9g44qwUl);7|Q|cv~jlhp6G*W;Q*n|
zc#Njw8I9b8^Xeq1OeJ2D9)ybsKkRdBbfDojckbW2+(wHNozq^V?_4hROq{CEV_ou~
z3j|rK2gw1^sgOciTVUJ9wYJ(xj-jEmZD?V<zh~P=EIg=rSPxc}JJjR|DVEamKgj+!
zx-CUJP7aEn9pOYM9b-cv$m@s4LAIQPqYx1ce@CMxJ!}FbeX#D#o=eDII%22iw9{=S
z`wyR)C|PO7Top^pvogOk&<`LQCjWbvCbWLlG4E4Uta@d}n|f;F?s@7L@F&&7)fZ^v
zmE`A}ydGQEvsdM!@pVW?8?D1%j&;ZbY0$(A_~ZSn?x)%AMgGkMPCvtB`mtdj;tP&4
zeHJS>dEdG5w$^anycPrh5vtO%3{Qb9luxx7{lwKU=>WlBiE%_B9=uY*Vmj*a!&ocO
zYawX5K6eit-fv`R51GAvFzk4AFA3`^81;lp53Ilnu(P16b}~BxmtzFj_^LQ3Z+c0?
z`3m`=&01cN!AZG*CU_i1!QmO(H)-KSB`zI;sHE)=PS2r)3&+lwotyig>ub_3Ww8po
zE%`;%>#hzT*Ku`QeOA7YMaFUGm_7aSDpr@RyU+dx?#U!Y><_tdm2i)yRqpEcz&69Q
zx0<Zl=eleyBpKvctK)HkL{iO7JlDA_=3a9j@=?Bza_(21&cYT%TrShuv-MOmQkv9L
zUDh9m2z3>@`=SdQ8SFDe909P=1d)ghdN|k%OB&XVMrLcLND(Yfq}yn(N7>CGEI)Ud
zxk&|-@DJt$Luh+MMm^3eD&r9YVibfv2im3P7A}|+D7>x7q@EZ^))?{JY_}8e+}Zb#
z6t2&RM+d%mRKJR6qo+~N0l<|ajZGbNE0DrS@&ylCEX<>s56c{TL#2%@r=y;92r@L-
z(}vy@AaJTK`=lkj=SD`7ol-qH*e*?rVu1BQ)DUOjWoB@RRFA`F;Iausdd_SIstHU)
zyoAgZb#oX{@05JUx6;B@q-lZCFrx{eR;xlEi_GzJJau2hQ_!C~pD3^v#_y*19g%)W
z?@O12ni(@9PMdeQv9e^wij3mcz*Sb4vD+&73iefWKtk51f9AhDHvdqLFibOeC-!;g
zBloLU+gDwYuB=0#!+uIgwcbR$F+bwNCQBxGT8O}1SRS@QUKzQSo&>9b^-3rRd1~@I
zqA>Jg(RIhuyf5O5jb?8>1ie@sDbt!~HD%G$){T$u^fKd+7nKyiN{3*OiOGX5x7;=Q
zvRvuaE&tV*vwwN7uy^-(O;BQ)mA2vgHRY&RcZ5G5$P*o_)#?quw645|Z^?|PVVsT2
z_awC}!p3@m3vdw@))uV1vEZiJu%DJm_DZ8lnmAj$_LAN`eTrE&Ir@ix&u>VMb|sDS
zuPjIV!t8JDlWdmyrq5?sU%6T{9yDkpuL-WDxb#cdDk&U2?e!aOq>sB5=Z*0#R&l?z
zAx9NA-&x@LD&8&|p43e)8IQd<yki`d;@T>pp2{}rONd*~5NkHy=Z#~DH}9l-W<LFM
z|972yl6v%(Uk^n-c}==u2-NN2PM5>x&Us+nu6GG<>h<|$k5`NRw97&BD^(*Acnc{h
zt~Z};{Y}j8TC(H*<v;j`IlmMtp!z{9IId?kc>aB4AD+~2UGhG%lXfG(vA7E_ZX@8m
zc5ilc317Yn&&kgi7NC71b`jrigI5#4M8HKF?^c%8b3Y+{a2*l9B&Fv!CdLf+6;FXn
z=XT-XX}vAaH(o;gjgRa;Y@p=(|Kj0a0RF)Z*6&EweEPgxQ@=Boen(XUt^6!IH)VS#
z!=Kaod>ivfe=hke=*rq^zCZKeYu~%KhWLhi2bZHOtF;qxV=qZp#^d)h9l7j1hafUk
zfqP8MgB_SC;Lz3VBVg*{-Em|h{opUZz<1i!Oyn3nK^Ev6>C!P`5_ucOm@hfvH?a6g
zKSxML%cf6Wl-$HluXqO3%5rzaZP70IEYmyj((>_ImUHHwf9Ho**P4u#u8TrQ7G8p!
za|5U9T3xy>efe1P0+KWLtv@jaeR%=L;Cw;vEON_RC*$8;j=rG(7v9h70t&+JcZEj;
z3_se1AFX%Vu+SqN;A;avv?Do3G{eQdaVm-2*YXGvFv-chp*P4vzQ1=q2t=(hA0(pI
z(5`Cc@hkb-{j?vtckdssudcP$+f(}?z%&{^pvp`yB$ieX#^mAKllONK_}9M+N5JIG
z|M|f;e(cYG``4}=?``elbWc&`$M;&8KZTNRZ;G0T&I6*+_&sUHcp3~7M@%8+@A-3B
z;uPRw6_3Yf%B6aH-g~QQfcAqfFbDe>I+bU5iUx0Yl2mgv`dfdKzn@EZF#Qa=+E}PB
zyK=3ufKN1ROI26FH5Qf@q(QR@pJ`0X_5Uc{r~Kpp<7fAQKe!5)hh1(c3G$9AN8`6T
zh~s;}BQIEpqbcIg>Ir^x9)1|)Wj#|D#;XI)PPo4rv^K;_T5_Bp05Cloe>u?c!QkNb
z*d@#~vqd4EIt70HO2RLUD>ZYx?j3A;-t}#xQGI~{EtFMXaBGK!#RX{Fq@!bU#g%l`
z#f1=77d&fuk!=xG;!WK(zrb8+esRlW&E6q+#?mq}XV@PQPw792UadW_IBErczKN|y
zPo~!0O+VinpTN^%Kwc+j8i8xdvF|+7I>yw^J^8b5fu3}lhrBw0$~XMZrzg{K6kY~B
zu}&juf$Q^ysFYVB(X`;rPNavXb|31sV}L0d1DgZ`I@HT0pPXqFZ*HL^pEjVzb)q4@
zB*wI~Q1xYA=Ze?bU&e3AkG5wTmy$mf_sstN|Mr;p)E?|$*>kQ8pV01T{4Qw$#Ee$|
zE)*3A7AM1kKKaz+)ATO6{1;)%QG9^wNh)rZw+;UqqdsHAK{dHIe<ySXJ}3N2au2hB
zU%RbAOSUdRro(nqZt}13C?Npl;NVaHz2r|2cfetE?6V;L#7~wN7o8K~tw&MA25DZ(
z5#qrtzY?#Ccxhk%@~_`pYwhvs?;~ihM5%&KJ?;$Qv7lH%bPnnRpWa<P5szs+{$NNm
z21eti^PV~6wVR#3)iWMX*OT!EmzN9vM3;EiBtbDsl);j<)S!Tq>NtIczC&8dC1uB5
zX87iM)^VC;EMM6&XW|{?A{;{5apN+_m0fK3c{Mb47D5c7lUzp^Q5MnqW*UYP?;hoN
zum}J9w}GDRxl)!`5PG@u&!<*vC*lNOPS1m$&8$aG^lfii-?QJ^Zmyg8HE@l+aNV&#
zO+5N=j-`J#J#y+fv2&(zywQbzbG(B=3O{+1({U1NN8~HSM`EP2)I|ihmAJmRvfzjb
zUM$3{FV=vXFsU$nnq|yN{QU5~zC+gBFa6yH@UsU;S=e6Ydj<f-XtW9{w>3oMo=*QR
zDIWMSY#=xKfE(8zuRf{?7R0~x_G^fLTi%COd|!b*XQhAK2imkZD#N}4UZ4prz>CXS
z1F#oe*ZR?i=4ZX73yC1!t%H%nQ^qXL=rrr;jjlS!d^X1)?knDdCxMF6-O`hLxLGZ3
ztik;nxcJC%SQQwhR?=!2jWA$NuVehA_5_*cbMdj+aVp!}deMYj8sioM=q%HCv&tBq
zCLRJ4OZlKyZ9oYs$+DK>s8SiK1wkrKa}q=U%gY5HCVj}<-~R3&BL3t4BAVBxI4s2f
zae<c;`2QA=e@YL3#<UowV7+h|@unsjOTz;i4*SQh`AA0Azz+i>@Jk4qay_)Lo)L_&
zX9x-ZaJNII4@Y!^?_M+mzrxV=3?Oeow)QjQdc6iq-0E!j5~Bjl<b3dP?ZbS2^Xc#U
zF67A`s0_SV4Q>3q&G3e_GE0aex7epFuKuZ$aePJ(d&BL%C?pKTn}a>LsaCpMmBA39
z*fwCh)Nk9q#L1rPZ#QTBs+5}(J_3snwIuoD@=-krdS*|r&uan;{QoueCJ(-n`0kf}
z<S&8lVD)YsZ$O9&eu#EPqcWc}5BjmnF!D9o;aR+SqU6$QjyI2_WLL(UU#*HtKCR9p
zDMPxa)deKOkWP)@&vZLzTKzmFUvB`%z=@U<pP)fTi3vM@DAy!A4pj>ta0`~Y$q$;_
z*xDzH7Q{rcuSO$sZEVeigUBvwpqEIlU>)Jb`v;~u-e_&5F^qcH$Oa==xoZkqMg`LP
zK)=1y>_PRdGVna7xdb6oqx7=h=p}!3*AzkDu(8v@4iS~4KD9t<^V3cjwA~<N#fbgN
zr+|m^t87HTLN;{~{`|FJ9wqt@7oEgVM318$`M;#x${pxMxAXV3Ml4=}$s}M8U^RqS
zQBQQYhuhSP-ox(x5ToJRF`(wUjTy!fL!3ux5cL%3%U~|eke3oxhd88+T<<1AMe-@?
zv9R-S{XrhwNh+)tQHYZWg~u1iyMUU5IOw-`8SbW!glDK8V6MH0eAK{=KEJ^&Wj;Hi
zXhQN=`VZr7<$XlCpQzUARae-h_}Y+`T$|6R+VifyuR_IQ2HPthb9<58k>j-pFBLP^
zU7-;Rn$l?D4OIMY<x5W&ssSN`oja7|pB^7^?ZH>xd<uG2(w9mfS3|+xX@9$d`-lgk
zk7v@Mvl?>v1{=p-ovJw>uCwa8(fL>BUmW7K_mX{Fwf_4j`PW?t&rqu-oh@g8?0|Cg
zS?A5rvwa8#Rn8Na@_0HP8~2{2EG0IBdAhLNjh@TvbnfbSz*g5DWq;RuzwsT&!3a}!
z^fK+vhz61)unXUFuTHWdZ^fn5^z2)0eFXSYzVjc{ao}5UCK;JsJICvc;LZ5<nt1T`
zst7H2@0EM7E23v8SS{mq`TEx|P1~hhJa(E%$&suNu6`a8tGPSCwnaQ00wSIF&=xrs
zB*#ID&&8Pe$|T)jVjaRD9Z><7KfdTHqdA?S53P0RiLn3LWpDV=2JV233LyIpTBwxy
zh=Am=mw3nWt~tTB5qYkg;>5972XM#dd+o!3d+%6Dfd%Jgz-wx${T4&63i$mLC+;w+
zhinID>WaSNEeKI@AAY=>23FraAmbI_O>(UV+F%zD;nf$<I?fhcrvRq~jFx)GGI~g*
zP+=M$^b0RJ=RUIWlv>?shY+ch)q=`}Cs7YdbBNeZ;E%6d=Dcu>iXw9CbmbmD*-P_o
z0e$3<jF=r8xc@o6v8y7Ac2Y)ysNeE<YNJtGP4tRRz)KbKIL+hAOb$*6p#X%By160x
zWnDsc+SLHwR6$xR0umD+S1qN@O4LKFhyh0Oh3n(f&@y5D$OCAVo)~ANoG3Pc3RVd1
z1q&F3Il0C@wmRm~PI$O>O)<ft(8t5|HdMrsgt5-W>-z^?f^<*(Wnq3{*$*A-v~Lk$
zHDqZsU0<AsFn#6wn%3TalIY{yU;hvH*05Ig7{CbTR~?g&(B5eLzGs=1M|M}#q)*C4
zD7l(GPWm9hdm>-C{9_oz{df=ezjKN<TSs7zbchBRexX^)6KtD_-e^wSI3f3~7xq)U
z)Sb|?s^U?Hk;StuUu&KF`i&O$-MK+5gFFy<sc#&^eBC#7SWhuh9;atKCXK*{1qj8X
zKp6HA@{VeUTNZ~oCfr7x{J6Ylc={Rmz+?3=>?-Vz7kzJtw{F~plP27-WUBUP<=p>h
zj8L%5+G>^)T|P(zo&rMb52$Cytev4RJ$VlL{nMA8+tXY4@{00e*!R8tgkb?Ipo19?
z?lL+sgG<W3Py5C5@ZsH4{5CI%4=3V%&#Fnkg%dtwm#>Hy&TrSA<bA|X{O&KTu7Su8
z!E=H>oTWebfCkDRRBIOlX><{E57KdS8!@OQt&j^15#PsIj<@O}5?(nO8>4`WR|Xe2
z*6aPF20hDBu-NiTE=zkZUUmttO=~Zj10xBwA*^ez$WNZ+bKA=A_)quND3T|y@61mM
z|EB(3__IL#rbi_0x*n_|f=+=iLX4vPlx5c!E5+yHS47#_?P?5zfOmdwVpi^M<PPWq
zj}m^uyux>3-nTF@$X#_*M7h9E>z>O|IAZ`imC1b3&s&=O%`t-*m-=z&!WYdhzKClA
z1-OtC>hZe2UBr!$Zr)z4d$^0m6*sA`SF2`-P)A^sMv5Z|^sZOu-9o3jV4qVRugYO7
zYfANcb;-o6dc9HeMZ=`W*MNP!77ep}(J;AUEkXew*H;okc#WQ+e|I^I_`3EWt((sl
z|LSwl*R*c#B7XZJ!?a<$jMEbHC<?k;tcw%t=)+Uav5WFEtfOnhPtbCa-;p*#TwizX
zU~<F$;jl^+zP+b^oeeEC?zQ-94!60i_iyQ<IHlWMC;1+iQwp4&Rm%HsWjy<PzYpgF
z?QNcSl6_L_BmG1@qZ8-Opv$YPwUhhZ@|=hhZQlc*i-Skc*TfPJwjBYsZT`2p5iIt>
z1A<f>WhMxtxWlXSOrjY(?&q5A?RKX)U>zK9W5sk-|JlQHJKmIjNdIKgj;lthX$H4i
zwiwd+1yC+KdPLHx;v$kx7n$@Mfnl;!r+d=u@)q$C`wfo!+PhyC-VqNGw6|Hr|IxI(
ziz9q@U{<-?F;_3MmsghiZGP^5pmE2P&3*bqu&09BJnZoKBIw1mUH$vAahZs-aYm<n
z{TB5Ofdpq1zJ=M>oWCd8ul(qzKLNc*phv{C=55kGf0*a9{dTy2d%U``bn(CoUB)kl
z2ffx|_x1dx0ZaR@TD4kTqO$_GSkAV_%L@q9X1gvVbKueR`FV+wuRlrW{`Y?7k3p-~
z?%*^eW?AcWmU+I+KArVrXU^^@;<~5t&s+9gx*o+>&=;VcZ;ql=?1>Pw9X3G5MP9G}
zBK`z-=DxEi_U#C|r}GcIg@2!{{JC!rMtmOHq<0heV|<u&es24xLFaMwfa4=Kx7NOz
zGTK>s9>{exxqdt^Tt=L1BkSYZ^M|l$1d5O$+)w6>qz@``R(<vs_hKS2vw?xjk>V0R
z@g3_0w$W|TF@As_;ArmA6oqZ#NUp!rmhT@zt3x)_VVIJ~N^Yn7#&G$uW$iTKYv5_9
zJz2j2AUyBj@WU{kF~8iZyAOi}YaMa7yEqGH(SEo0wIL72^>7T6hIoT2aVI7G5K&5L
z*?!xDos*(#YSWhnY!18dflzrEM?gx#bzYLTZsR(!5W=A^5WddkcyXBjI-GLcOH6SM
z#hB=-VCRK(x+s{34wCbr#~jMECeBNsG0roKtUXBa<>r3$zrr6@C$hAGAU0-td!C*g
zE2C^zD0C@3IpKhw9-0D$QEuT@v2u+Fj?^E+P_7SH3v_oqfT136A+@0zOf-%x5ZPu^
zHXWtjWE0ClO$nv><YieOF25FChnWG&U>u08>0#o2>y$hBfkA+m0UAyqy)Ne%d{Qsa
zCvO2EsI9p;G`A<zb!*qh?zQ7O6T#OWCOtvrpa10z;y0Wq+7QiUXFY}I=fnp{_;*$!
z<o~E&%cooyXMK1}@~<raYkbz8r+J+F?Dum2X1>*6mwG?FZ@YL<6CJ_Ylbd#|PCb~*
zv%ks9@b!GAfxYs48sB-6{hJ0q@&~XkUtks>qfGFf>#WBF=<9?=Ano56|H-ZJ%lJ>O
z1w;I&`8YHq|DWYo$`kKpf8Wo(@oV?iy5U>n^ib;+{=T>!w!6(BP`sqLProDV(BHaW
zmE8R_`}tB^3nmCKxL{$IRDL(5`X{_BgrCdf6Qx6c%MxgBU;KYy@~Ex%uB;#jfI0Ks
zL?>VnYVX$}DD2whkB}Z%+JxF|NX8J=ajs_ZlKExj&Mu5O5oeil#C~hty+n|rp`K?J
z-bVw(4u=a<a;LG@d4COJiieXEnhbXnweB@34Ff9)*o2DEStH4hhS@YqrkF0kn@3(k
zPXUy@%eI8}5{7&Up7JaB86{&Xl{B-c)CM0-EK<Gw)+XdJLo6>7X413an|=C<{x$tI
zqxF68jbA*Wzh1I)yW~&9O|xe;mJy>(vOj&2{hF8g`382-7JLgykKo8$Mlvb<o_LRf
z$Go4%Wn=!$LamB3O5H`qq#I%}>2bCe>hlW>t{(G_`GW4e;b)RKxoo%@R~5Q*fq^_%
z!q=;zS&!gyb?&G2TQTpSdUXX**%@T5>SvboD@z{0zrM170Ja2A?m!-=g%Q6Tea1Y~
zO#2?vq0q;__qGVmTEfRSciP)K>0D=$j`YvQI|Eno<5*RNwdB=9%r3HactoS$D~g<-
zBiPrJ7akY)v-}n4bzoO|N_?Hsv>a%B<=xeJDQ`-?@(7-*H~C)AmpzphKjE9dz~8S<
z(k<wNJ&s5tt;-s0bgmL-`rV}GpPT!am}l@p?#t<%!-Zw?KF)QEeDZY&50BuuT&`oT
z+?nq4CCp`gkSaE(RS=RsP!RYePv61bfvAAFG4#yX1~4)66XBH+4wOew8$!=F5O5JX
z!IMmByAPi;B)ekD_SI+v2ES=KH?sQ8xZMg#ZBr8eM}iLZ={<yx78QF@&m9(MBO(f$
zXIdi}5A=eT5CR7i=;o|y40i%}J?hc5zz{<8C48BoGWU+?ZazHd6)J%s@0a#<_oLq%
z$<CW!2|$>~;cZ1@u_+^Qt6_5pzhKwF^x^Yhm({iCgUv<)9>UQYGD|feR&*5IYQg?|
z+e94nJ4$T9`c5FWciFqBM_;%1w@|x!WPaQ*;9^*Mo$v4Rnv8u@b9P|R7ZrAJ+xk>J
z9e8hdg&t6Drh#TUK8mz~!fVX=1_KiCpj+KN58m;{odcjEM#K7efPi$VQas>GbqF5U
zxb}<#(rcxA)MMm(U0hqMeki44ybCRLqu&~!tSZ8pMglb8fp`lKAXe@{>~O)YWZC|3
zJ7Eb;{GkaJjxmj$T(qC+!M!OvK3OP&;1fdkK5n9pqJwq|zH@9!V?woAdX?_Q&eT99
zD_&G3UBu*o8pY^pcCCol74SqO$~L7NzdQ1a1(|lOI6p_=AB~*S``jx;J%Tlc2(L55
zyjI&ggA}4c<_8Q`JVZUXHCUzLBgIDe8jkc_u<=BnM4P8W#Gdq}_(`jSs?n&`GamEH
zH}0hDil*)ezFGkoZb)3W2T3X~n@e21KI?(SE6(v{r=LMjYgO2J#H~;<emIo$D6_Rj
zW0B{N7(vR(MRM8H<@41A+$5y}^9xHgGY^S+?jQ^CkEK_q2m68vwea0Zmr7L;xz=3Q
zs}N3?+0bGY*DFYhj(X}fejiM?KPW4bz;)c3GAF)-@MG_MxIaMY8{^0*NY&@jt$
zOFpE${4xv&c?3`aFc6Ocwg<$Wm=E8lbMN)^dG?q1+5h~bt82t~=d*XYhMRgU@4rJ;
zr}N!MSLM6t<g{Nko2L1Ulmg_##Qy*+ZaTv8K#Wfur2#LT^k&Y~KQdN*R|IRYXa9Qr
zA*XE6>yrYFjIoap>p`Ns@oV2ugL9|#*W6A^sL8t=eOU$^%>(hUl+P~_6hdp7>2}9?
zC({TQK@ga4er?%b5;?urCKy{3@OBImCrNsMGolu^JskK$f@gPN^cbA|1#}0+xT@w>
zuR}hoG#%cf8C^pQA{g}mOolh<84tidpR$VDCEridOb7uYTpPGw-OD7t@8XRn2Ox=f
z=b5t94nmn|!0ZuR#QTfqfCq3|eo+J1<)%ouzVpG|M6ZJ8ZT5~Gpv|ZU^wuzoBhUgr
z!lmSPVniMuAGZ1(2nN;{M2w)sq8_$rudiP}8hPUmWr&IwK&%v<_OkYE$alEWS3OfY
zYT-lF!)i3F%#2Dh)!u1!4pZyoQw9g*6kK`BzC}G~@2l`T@IhkpyRb)#7I#~~6N97!
zU*2d46*M8!v2@gfbKQ80<%b~`_%Mi&+@V3(YwyzhMmV&G_%Qnes~M6{JDo?f&Mv$<
zy)sER7MZM@nPnj_K-kD4>OnE@CLXgRX<(t?!cmR@<0Z*G;eb*$I&e|O<-<0Z(XTr=
z6pty3w8mXDFS@MNa^is#6!qvHw7oPX_#no(Kg57BcCZGi4?7}+N}~wLq2QxlL_N5#
zWMjCePQaPCRq3QE5n-BXeWoKspsYRgfZDtMBI@bkrj&TQ-E~xE4{(1%<nM_J5DdL=
zYOju`c~399+eV~RG_6EEg@DfoO4wS8d;kdyy&gy;8-ffYf$<06r<?TMr^*YE3{DjX
zF5>-@e11GWkB0~Eb~b&nyjAMaKTLK|bARz4{Z8=b$)G2u=RVusP3CSV<DHChyy-7q
zFHUt5EDQt5Hxc5=2|En2bFiq^A-9=esltdoP@M@sddv3S!M)$mwR|@GYV9(5rsHy}
zOS3Cf8Tjv54fVTusHiRAB<>pz6*wL|7#EkPMUY8gMLqdd)?ug8S&xnQ+qp}h9J3+2
zIU)_qtx2>LcRTD@D4%0(#eJN~-`5Sl>dAa18Lyb>%1pyGu|D3Do)uYhpFR2ZJ**F@
z2qGwut&emLG!@lnmUFFy*FXtX4bGWQU{Z4lgRB_8VqYM~sj$<=5;&bE&(z-=UFe$n
z;Ah#7^IQM)e{uc~%Yf^ce~jMfM4WWc#dlBo<y|A*I@*<9(h&~$4@B^|F@s?bdv)zA
zZuC@Ms&lrkrtc-1e#SUrCyqV$JSqD;?<vx{T0$s)ZJv3E?K^((*K`5QOrVr><fFuA
zzy9l=A+8V{)Gl)$gxi%bUfizrn|u=ZVK$nGV|e7puedS-DzPJHk&v?cR>ZrFI4GTV
z>(HnPl6`W*bnbO=<2SfOlJgqS<+#)2ayo}-NX(n@oX7A&W3~2`gco!F@C&d*KW1#)
z{bWC!<*3Q~K`_6L62j6CLLUB7o$d$jT*PyXGk*zB5Ns58uVp)Pwr^t1amX<M3PKRE
zLSLcII|BpMFvZfQ7d=Gm9K00PoY(%DfZebc32#VAmR!x3?+1ZqO{9l!{n9Ghr89Tt
zbyw1vue_sp6v+DYkNhP3VvnJNH<XebbCEpnNHu@vB#1h~fACQ5Fu*U%Xtod4%9-EY
zx)*8Qu`jI8FWD?F`|yo1#l(f#_NzX>T;uP5_)*O7+z+pf?|p=;OXK>NKmL9XBs(6p
z4V<=9x`KRq>n84k4qs26e72hXMn3(M-@NxMUErnV8RyQU^1eZyJA>XM8g_)iF8xJt
z8coqfL9*w|`vb(%&+``{E|%?_v~trqxKI}DABris$ccY)KsR$a`H?V-Y=Y1z-GTj8
zr1LITuhRWgY4>Z{zVn@tk6tiSulDP$5j{6zzZ?HC4>hogC9`F!NnRySCdUvS;1ZRH
z<S>t88;`cY11NV&rh(S79Vfy53a3UoSz;ahEv&#&$~n?X1J+r3yMSaez(TAOyTYZ4
zV97cuTCC#27ae6W-kg4{Wr4E~%c}+FYcTOL80+&M&Ka>O>^O@Aa#6)mn%9D=5=<a!
zfY|LVuFTIb`gIvAjU{l-xQ%g2&LF+?_)O1M?cSniX`M}6zv%02avjKi^VLS49{}`M
zri+60*^{Ja`LQ>?@b%Sa9+y7!E30S3Q@gmMhL2b`V2scmlfn?u_>}c5hm78Z(-Voa
zc!;?2xIa%Mj3GILw0YX7p@SLUsd_42E{5x-m&o!DC=x@;V9;%UO*v)>N6|XS#@V-#
zn>whH9aqaPoTNi{GP)cy%WxHP@Uth$-|Sn>U)cga_2AA3ZK@bf=4)s2$64BYU8Wd;
zE3bda7th{H^EEg36W_b{3~M!R{-I<P`xerH)9&y35-tXLa58?6?mNPq(^%fFqnWy}
zE9lD_4rY1Ybc#Km`bhZ)Ac+|CAo-MX4^G5P(8(~XTz>SOF)~PvSRwir$6Ks-*Y9fb
zUGo$_D@OVDB#mxQ+vQ9@V_sl06P7aO@69ilVcH%0>ZMTSA!0z)q>{y24QB@um=<gE
z5ST=s>X3e1Y+)T7Yq+U2+ytJsFD}3=SC?P{Pfyr$=fmiciaftx;P>D8-o57taNNTY
zdEoU~bO?In=g&|0y`FR4;BcQ+Uxt@Gl-y3k4!U`Whr#q5b{It8{pLR2c=nNl3p)#|
zfh8jIHNWGST#x>J{N$lFfIyj_`qO{yCs#j)VUi}s1N;P?x_Dmm3{R$P<`9$A>xFeD
tt|pl*bDN*8IDhU3^6_JvzmH*%0nu`kD@T0mHV^5w`hJD^_<wVA{~xcHLFNDe
diff --git a/data-raw/datasets/antimicrobials.txt b/data-raw/datasets/antimicrobials.txt
index 8db2ffc09..108e65898 100644
--- a/data-raw/datasets/antimicrobials.txt
+++ b/data-raw/datasets/antimicrobials.txt
@@ -1,498 +1,498 @@
"ab" "cid" "name" "group" "atc" "atc_group1" "atc_group2" "abbreviations" "synonyms" "oral_ddd" "oral_units" "iv_ddd" "iv_units" "loinc"
"AMA" 4649 "4-aminosalicylic acid" "Antimycobacterials" "J04AA01" "Drugs for treatment of tuberculosis" "Aminosalicylic acid and derivatives" "NA" "aminacyl,aminopar,aminosalyl,aminox,apacil,deapasil,entepas,gabbropas,granupas,helipidyl,hellipidyl,nemasol,nippas,osacyl,pamacyl,pamisyl,paramisan,paramycin,parasal,parasalicil,parasalindon,pasade,pasalon,pasara,pascorbic,pasdium,pasem,paser,pasmed,pasnal,pasnodia,pasolac,passodico,pharmakon,propasa,rezipas,salvis,sanipirol,sanipriol,sodiopas,spectrum" 12 "g" "NA"
-"ACM" 6450012 "Acetylmidecamycin" "Macrolides/lincosamides" "NA" "NA" "NA" "NA"
-"ASP" 49787020 "Acetylspiramycin" "Macrolides/lincosamides" "NA" "NA" "antibiotic,espiramicin,espiramicina,foromacidin,provamycin,rovamicina,rovamycin,rovamycine,selectomycin,sequamycin,spiramycine,spiramycinum" "NA"
+"ACM" 6450012 "Acetylmidecamycin" "Macrolides/lincosamides" "" "NA" "NA" "NA"
+"ASP" 49787020 "Acetylspiramycin" "Macrolides/lincosamides" "" "NA" "antibiotic,espiramicin,espiramicina,foromacidin,provamycin,rovamicina,rovamycin,rovamycine,selectomycin,sequamycin,spiramycine,spiramycinum" "NA"
"ALS" 8954 "Aldesulfone sodium" "Other antibacterials" "J04BA03" "Drugs for treatment of lepra" "Drugs for treatment of lepra" "NA" "adesulfone,aldapsone,aldesulfone,aldesulphone,diamidin,diason,diasone,diasoneenterab,diazon,didimethanesulfinate,novotrone,sulfoxone" 0.33 "g" "NA"
-"AMK" 37768 "Amikacin" "Aminoglycosides" "D06AX12,J01GB06,S01AA21" "Aminoglycoside antibacterials" "Other aminoglycosides" "ak,ami,amik,amk,an" "amikacillin,amikacina,amikacine,amikacinum,amikavet,amikin,amikozit,amukin,arikace,briclin,butirosins,kaminax,lukadin,mikavir,potentox,prestwick" 1 "g" "101493-5,11-7,12-5,13-3,13546-7,14-1,15098-7,17798-0,18860-7,20373-7,23624-0,25174-4,25175-1,25176-9,25177-7,25178-5,25179-3,31097-9,31098-7,31099-5,3319-1,3320-9,3321-7,35669-1,42642-9,48169-7,50802-8,50803-6,56628-1,59378-0,60564-2,60565-9,6975-7,80972-3,89484-0"
-"AKF" "Amikacin/fosfomycin" "Aminoglycosides" "NA" "NA" "NA" "NA"
-"AMO" 54260 "Amorolfine" "Antifungals/antimycotics" "D01AE16" "Antifungals for topical use" "Other antifungals for topical use" "amor" "amorolfina,amorolfinum,bekiron,corbel,curanail,fenpropemorph,fenpropimorph,fenpropimorphe,forbel,funbas,loceryl,locetar,mildofix,mistral,morpholine,odenil,omicur,pekiron" "NA"
-"AMX" 33613 "Amoxicillin" "Beta-lactams/penicillins" "J01CA04" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "ac,amox,amx" "acuotricina,alfamox,alfida,amitron,amoclen,amodex,amoksicillin,amolin,amopen,amopenixin,amophar,amoran,amoxi,amoxicaps,amoxicilina,amoxicilline,amoxicillinum,amoxidal,amoxiden,amoxil,amoxillat,amoxina,amoxine,amoxipen,amoxivet,amoxycillin,amoxycillinsalt,amoxyke,anemolin,aspenil,atoksilin,bristamox,cemoxin,ciblor,clamoxyl,damoxy,danoxillin,delacillin,demoksil,dispermox,efpenix,eupen,flemoxin,flemoxine,galenamox,gramidil,hiconcil,himinomax,histocillin,ibiamox,imacillin,izoltil,kentrocyllin,lamoxy,largopen,larotid,matasedrin,metifarma,moksilin,moxacin,moxal,moxaline,moxatag,neotetranase,novabritine,ospamox,pacetocin,pamocil,paradroxil,pasetocin,penamox,piramox,promoxil,quimiopen,remoxil,riotapen,robamox,sawacillin,siganopen,simplamox,sintopen,sumox,topramoxin,trifamox,trimox,unicillin,utimox,velamox,vetramox,wymox,zamocillin,zamocilline,zimox" 1.5 "g" 3 "g" "101498-4,15-8,16-6,16365-9,17-4,18-2,18861-5,18862-3,19-0,20-8,21-6,22-4,25274-2,25310-4,3344-9,55614-2,55615-9,55616-7,6976-5,6977-3,80133-2"
-"AMC" 23665637 "Amoxicillin/clavulanic acid" "Beta-lactams/penicillins" "J01CR02" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "a/c,amcl,aml,aug,xl" "amocla,amoclan,amoclav,amoksiclav,amoxsiklav,amoxyclav,ancla,augmentan,augmentin,augmentine,auspilic,clamentin,clamobit,clavam,clavamox,clavinex,clavumox,coamoxiclav,curam,eumetinex,kesium,kmoxilin,spectramox,synulox,viaclav,xiclav" 1.5 "g" 3 "g" "NA"
-"AXS" 465441 "Amoxicillin/sulbactam" "Beta-lactams/penicillins" "NA" "NA" "NA" "55614-2,55615-9,55616-7"
-"AMB" 5280965 "Amphotericin B" "Antifungals/antimycotics" "A01AB04,A07AA07,G01AA03,J02AA01" "Antimycotics for systemic use" "Antibiotics" "amf,amfb,amph" "abelcet,abelecet,ambil,ambisome,amphocin,amphomoronal,amphotec,amphotericin,amphotocerin,amphozone,funganiline,fungilin,fungisome,fungisone,fungizone,halizon,nystatine,nystatinum,terrastatin" 40 "mg" 210 "mg" "16370-9,18863-1,23-2,24-0,25-7,26-5,3353-0,3354-8,40707-2,40757-7,49859-2,6978-1"
-"AMH" "Amphotericin B-high" "Antifungals/antimycotics" "NA" "amfo b high,amhl,ampho b high,amphotericin high" "NA" "NA"
-"AMP" 6249 "Ampicillin" "Beta-lactams/penicillins" "J01CA01,S01AA19" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "am,amp,ampi" "adobacillin,alpen,amblosin,amcap,amcill,amfipen,ampen,amperil,ampichel,ampicilina,ampicillina,ampicilline,ampicillinesalt,ampicillinsalt,ampicillinum,ampifarm,ampikel,ampimed,ampinova,ampipenin,ampiscel,ampisyn,ampivax,ampivet,amplacilina,amplin,amplipenyl,amplisom,amplital,austrapen,bayer,binotal,bonapicillin,britacil,cimex,citteral,copharcilin,cymbi,delcillin,deripen,divercillin,doktacillin,domicillin,duphacillin,grampenil,guicitrina,guicitrine,lifeampil,marcillin,morepen,norobrittin,nuvapen,omnipen,orbicilina,penbristol,penbritin,penbrock,penialmen,penicline,penimic,penizillin,pensyn,pentrex,pentrexl,pentrexyl,pentritin,ponecil,princillin,principen,racenacillin,redicilin,rosampline,roscillin,semicillin,servicillin,sumipanto,supen,synpenin,texcillin,tokiocillin,tolomol,totacillin,totalciclina,totapen,trafarbiot,trifacilina,ukapen,ultrabion,ultrabron,vampen,viccillin,vidocillin,wypicil" 2 "g" 6 "g" "101477-8,101478-6,18864-9,18865-6,20374-5,21066-6,23618-2,27-3,28-1,29-9,30-7,31-5,32-3,33-1,3355-5,33562-0,33919-2,34-9,43883-8,43884-6,6979-9,6980-7,87604-5"
-"SAM" 119561 "Ampicillin/sulbactam" "Beta-lactams/penicillins" "J01CR01" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "a/s,ab,ams,amsu,apsu,sam" "sulacillin" 6 "g" "101478-6,18865-6,20374-5,23618-2,31-5,32-3,33-1,34-9,6980-7"
+"AMK" 37768 "Amikacin" "Aminoglycosides" "D06AX12,J01GB06,QD06AX12,QJ01GB06,QS01AA21,S01AA21" "Aminoglycoside antibacterials" "Other aminoglycosides" "ak,ami,amik,amk,an" "amikacillin,amikacina,amikacine,amikacinum,amikavet,amikin,amikozit,amukin,arikace,briclin,butirosins,kaminax,lukadin,mikavir,potentox,prestwick" 1 "g" "101493-5,11-7,12-5,13-3,13546-7,14-1,15098-7,17798-0,18860-7,20373-7,23624-0,25174-4,25175-1,25176-9,25177-7,25178-5,25179-3,31097-9,31098-7,31099-5,3319-1,3320-9,3321-7,35669-1,42642-9,48169-7,50802-8,50803-6,56628-1,59378-0,60564-2,60565-9,6975-7,80972-3,89484-0"
+"AKF" "Amikacin/fosfomycin" "Aminoglycosides" "" "NA" "NA" "NA"
+"AMO" 54260 "Amorolfine" "Antifungals/antimycotics" "D01AE16,QD01AE16" "Antifungals for topical use" "Other antifungals for topical use" "amor" "amorolfina,amorolfinum,bekiron,corbel,curanail,fenpropemorph,fenpropimorph,fenpropimorphe,forbel,funbas,loceryl,locetar,mildofix,mistral,morpholine,odenil,omicur,pekiron" "NA"
+"AMX" 33613 "Amoxicillin" "Beta-lactams/penicillins" "J01CA04,QG51AA03,QJ01CA04" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "ac,amox,amx" "acuotricina,alfamox,alfida,amitron,amoclen,amodex,amoksicillin,amolin,amopen,amopenixin,amophar,amoran,amoxi,amoxicaps,amoxicilina,amoxicilline,amoxicillinum,amoxidal,amoxiden,amoxil,amoxillat,amoxina,amoxine,amoxipen,amoxivet,amoxycillin,amoxycillinsalt,amoxyke,anemolin,aspenil,atoksilin,bristamox,cemoxin,ciblor,clamoxyl,damoxy,danoxillin,delacillin,demoksil,dispermox,efpenix,eupen,flemoxin,flemoxine,galenamox,gramidil,hiconcil,himinomax,histocillin,ibiamox,imacillin,izoltil,kentrocyllin,lamoxy,largopen,larotid,matasedrin,metifarma,moksilin,moxacin,moxal,moxaline,moxatag,neotetranase,novabritine,ospamox,pacetocin,pamocil,paradroxil,pasetocin,penamox,piramox,promoxil,quimiopen,remoxil,riotapen,robamox,sawacillin,siganopen,simplamox,sintopen,sumox,topramoxin,trifamox,trimox,unicillin,utimox,velamox,vetramox,wymox,zamocillin,zamocilline,zimox" 1.5 "g" 3 "g" "101498-4,15-8,16-6,16365-9,17-4,18-2,18861-5,18862-3,19-0,20-8,21-6,22-4,25274-2,25310-4,3344-9,55614-2,55615-9,55616-7,6976-5,6977-3,80133-2"
+"AMC" 23665637 "Amoxicillin/clavulanic acid" "Beta-lactams/penicillins" "J01CR02,QJ01CR02" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "a/c,amcl,aml,aug,xl" "amocla,amoclan,amoclav,amoksiclav,amoxsiklav,amoxyclav,ancla,augmentan,augmentin,augmentine,auspilic,clamentin,clamobit,clavam,clavamox,clavinex,clavumox,coamoxiclav,curam,eumetinex,kesium,kmoxilin,spectramox,synulox,viaclav,xiclav" 1.5 "g" 3 "g" "NA"
+"AXS" 465441 "Amoxicillin/sulbactam" "Beta-lactams/penicillins" "J01CR02,QJ01CR02" "NA" "NA" "55614-2,55615-9,55616-7"
+"AMB" 5280965 "Amphotericin B" "Antifungals/antimycotics" "A01AB04,A07AA07,G01AA03,J02AA01,QA01AB04,QA07AA07,QG01AA03,QJ02AA01" "Antimycotics for systemic use" "Antibiotics" "amf,amfb,amph" "abelcet,abelecet,ambil,ambisome,amphocin,amphomoronal,amphotec,amphotericin,amphotocerin,amphozone,funganiline,fungilin,fungisome,fungisone,fungizone,halizon,nystatine,nystatinum,terrastatin" 40 "mg" 210 "mg" "16370-9,18863-1,23-2,24-0,25-7,26-5,3353-0,3354-8,40707-2,40757-7,49859-2,6978-1"
+"AMH" "Amphotericin B-high" "Antifungals/antimycotics" "" "amfo b high,amhl,ampho b high,amphotericin high" "NA" "NA"
+"AMP" 6249 "Ampicillin" "Beta-lactams/penicillins" "J01CA01,QJ01CA01,QJ51CA01,QS01AA19,S01AA19" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "am,amp,ampi" "adobacillin,alpen,amblosin,amcap,amcill,amfipen,ampen,amperil,ampichel,ampicilina,ampicillina,ampicilline,ampicillinesalt,ampicillinsalt,ampicillinum,ampifarm,ampikel,ampimed,ampinova,ampipenin,ampiscel,ampisyn,ampivax,ampivet,amplacilina,amplin,amplipenyl,amplisom,amplital,austrapen,bayer,binotal,bonapicillin,britacil,cimex,citteral,copharcilin,cymbi,delcillin,deripen,divercillin,doktacillin,domicillin,duphacillin,grampenil,guicitrina,guicitrine,lifeampil,marcillin,morepen,norobrittin,nuvapen,omnipen,orbicilina,penbristol,penbritin,penbrock,penialmen,penicline,penimic,penizillin,pensyn,pentrex,pentrexl,pentrexyl,pentritin,ponecil,princillin,principen,racenacillin,redicilin,rosampline,roscillin,semicillin,servicillin,sumipanto,supen,synpenin,texcillin,tokiocillin,tolomol,totacillin,totalciclina,totapen,trafarbiot,trifacilina,ukapen,ultrabion,ultrabron,vampen,viccillin,vidocillin,wypicil" 2 "g" 6 "g" "101477-8,101478-6,18864-9,18865-6,20374-5,21066-6,23618-2,27-3,28-1,29-9,30-7,31-5,32-3,33-1,3355-5,33562-0,33919-2,34-9,43883-8,43884-6,6979-9,6980-7,87604-5"
+"SAM" 119561 "Ampicillin/sulbactam" "Beta-lactams/penicillins" "J01CR01,QJ01CR01" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "a/s,ab,ams,amsu,apsu,sam" "sulacillin" 6 "g" "101478-6,18865-6,20374-5,23618-2,31-5,32-3,33-1,34-9,6980-7"
"AMR" 73341 "Amprolium" "Other antibacterials" "QP51BX02" "NA" "amprol,amprolio,amprovine,anticoccid,cocciprol,corid,mepyrium,picolinium,pyridinium,thiacoccid" "NA"
-"ANI" 166548 "Anidulafungin" "Antifungals/antimycotics" "J02AX06" "Antimycotics for systemic use" "Other antimycotics for systemic use" "anid" "anidulafungina,anidulafungine,anidulafunginum,biafungin,ecalta,eraxis" 0.1 "g" "55343-8,57095-2,58420-1,77162-6"
-"APL" 6602341 "Apalcillin" "Beta-lactams/penicillins" "NA" "NA" "apalcilina,apalcilline,apalcillinsalt,apalcillinum,lumota" "NA"
+"ANI" 166548 "Anidulafungin" "Antifungals/antimycotics" "J02AX06,QJ02AX06" "Antimycotics for systemic use" "Other antimycotics for systemic use" "anid" "anidulafungina,anidulafungine,anidulafunginum,biafungin,ecalta,eraxis" 0.1 "g" "55343-8,57095-2,58420-1,77162-6"
+"APL" 6602341 "Apalcillin" "Beta-lactams/penicillins" "" "NA" "apalcilina,apalcilline,apalcillinsalt,apalcillinum,lumota" "NA"
"APR" 3081545 "Apramycin" "Aminoglycosides" "QA07AA92,QJ01GB90,QJ51GB90" "NA" "ambylan,apralan,apramicina,apramycine,apramycinum" "23659-6,73652-0,73653-8"
-"ARB" 68682 "Arbekacin" "Aminoglycosides" "J01GB12" "NA" "arbekacina,arbekacine,arbekacinum,haberacin" 0.2 "g" "32373-3,53818-1,54173-0"
-"APX" 71961 "Aspoxicillin" "Beta-lactams/penicillins" "J01CA19" "NA" "aspoxicilina,aspoxicillan,aspoxicilline,aspoxicillinum,doyle" 4 "g" "NA"
-"AST" 5284517 "Astromicin" "Aminoglycosides" "NA" "NA" "abbott,astromicina,astromicine,astromicinum,fortimicin,istamycin,istamycins" "NA"
-"AVB" 9835049 "Avibactam" "Beta-lactams/penicillins" "NA" "NA" "avibactamfreeacid" "NA"
+"ARB" 68682 "Arbekacin" "Aminoglycosides" "J01GB12,QJ01GB12" "NA" "arbekacina,arbekacine,arbekacinum,haberacin" 0.2 "g" "32373-3,53818-1,54173-0"
+"APX" 71961 "Aspoxicillin" "Beta-lactams/penicillins" "J01CA19,QJ01CA19" "NA" "aspoxicilina,aspoxicillan,aspoxicilline,aspoxicillinum,doyle" 4 "g" "NA"
+"AST" 5284517 "Astromicin" "Aminoglycosides" "" "NA" "abbott,astromicina,astromicine,astromicinum,fortimicin,istamycin,istamycins" "NA"
+"AVB" 9835049 "Avibactam" "Beta-lactams/penicillins" "" "NA" "avibactamfreeacid" "NA"
"AVI" 71674 "Avilamycin" "Other antibacterials" "QA07AA95" "NA" "avilamycina,avilamycine,avilamycinum,inteprity,kavault,surmax" "35754-1,35755-8,35756-6,55619-1"
-"AVO" 16131159 "Avoparcin" "Glycopeptides" "NA" "NA" "firvanq,tagocid,targocid,targosid,tecoplanina,tecoplanine,tecoplaninum,teichomycin,teicoplanina,teicoplanine,teicoplaninum,teikoplanin,ticocin" "NA"
-"AZD" 15574941 "Azidocillin" "Beta-lactams/penicillins" "J01CE04" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "azidocilina,azidocillina,azidocilline,azidocillinum" 1.5 "g" "NA"
-"AZM" 447043 "Azithromycin" "Macrolides/lincosamides" "J01FA10,S01AA26" "Macrolides, lincosamides and streptogramins" "Macrolides" "az,azi,azit,azm" "aritromicina,aruzilina,azasite,azenil,azifast,azigram,azimakrol,azithramycine,azithrocin,azithromycine,azithromycinum,azitrocin,azitromax,azitromicina,azitromicine,azitromin,aziwin,aziwok,aztrin,azyter,hemomycin,macrozit,misultina,mixoterin,setron,sumamed,tobil,toraseptol,tromix,trozocina,trulimax,xithrone,zentavion,zifin,zithrax,zithromac,zithromax,zitrim,zitromax,zitrotek,zythromax" 0.3 "g" 0.5 "g" "100043-9,16420-2,16421-0,18866-4,23612-5,25233-8,35-6,36-4,37-2,38-0,6981-5,89480-8"
-"AFC" "Azithromycin/fluconazole/secnidazole" "Other antibacterials" "J01RA07" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
-"AZL" 6479523 "Azlocillin" "Beta-lactams/penicillins" "J01CA09" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "az,azl,azlo" "azlin,azlocilina,azlocilline,azlocillinsalt,azlocillinum,securopen" 12 "g" "16422-8,18867-2,3368-8,39-8,40-6,41-4,41661-0,42-2"
-"ATM" 5742832 "Aztreonam" "Monobactams" "J01DF01" "Other beta-lactam antibacterials" "Monobactams" "at,atm,azm,azt,aztr" "azactam,azetreonam,azonam,azthreonam,aztreon,aztreonamum,cayston,dynabiotic,nebactam,primbactam,squibb" 4 "g" "101497-6,16423-6,18868-0,25234-6,3369-6,41662-8,41663-6,41664-4,41727-9,43-0,44-8,45-5,46-3,6982-3"
-"AZA" "Aztreonam/avibactam" "Monobactams" "NA" "NA" "NA" "NA"
-"ANC" "Aztreonam/nacubactam" "Monobactams" "NA" "NA" "NA" "NA"
-"BAM" 441397 "Bacampicillin" "Beta-lactams/penicillins" "J01CA06" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "alphacilina,alphacillin,ambacamp,ambaxin,bacacil,bacampicilina,bacampicilline,bacampicillinum,bacampicine,berocillin,centurina,devonium,diancina,inacilin,maxifen,penglobe,pivatil,pondocil,pondocillin,pondocillina,sanguicillin,spectrobid,velbacil" 1.2 "g" "18869-8,47-1,48-9,49-7,50-5,55620-9"
-"BAC" 78358334 "Bacitracin" "Other antibacterials" "D06AX05,J01XX10,R02AB04,S01AA32" "baci" "albac,altracin,ayfivin,baciferm,baciguent,baciim,baciliquin,bacilliquin,baciquent,bacitracina,bacitracine,bacitracinum,fortracin,mycitracin,parentracin,penitracin,septa,topitracin,topitrasin,tropitracin,zutracin" "10868-8,16428-5,18870-6,6827-0,6983-1,87603-7"
-"BDQ" 5388906 "Bedaquiline" "Other antibacterials" "J04AK05" "NA" "NA" 86 "mg" "80637-2,88703-4,88704-2,94274-8,96107-8"
-"BEK" 439318 "Bekanamycin" "Aminoglycosides" "J01GB13" "NA" "aminodeoxykanamycin,becanamicina,bekanamicina,bekanamycine,bekanamycinum" 0.6 "g" "NA"
-"BNB" "Benzathine benzylpenicillin" "Beta-lactams/penicillins" "J01CE08" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "NA" 3.6 "g" "NA"
-"BNP" 64725 "Benzathine phenoxymethylpenicillin" "Beta-lactams/penicillins" "J01CE10" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "bicillin,biphecillin" 2 "g" "NA"
-"PEN" 5904 "Benzylpenicillin" "Beta-lactams/penicillins" "J01CE01,S01AA14" "Combinations of antibacterials" "Combinations of antibacterials" "bepe,pen,peni,peni g,penicillin,penicillin g,pg" "bencilpenicilina,benzopenicillin,benzylpenicilline,benzylpenicillinum,capicillin,cillora,cilloral,cilopen,cintrisul,cosmopen,cristapen,crystapen,dropcillin,eskacillin,falapen,forpen,galofak,gelacillin,hipercilina,hyasorb,hylenta,lemopen,liquacillin,liquapen,monocillin,monopen,mycofarm,novocillin,penalev,penicillinum,penilaryn,penisem,pentid,pentids,pfizerpen,pharmacillin,pradupen,scotcil,sugracillin,sugracillinsalt,tabilin,ursopen,veticillin" 3.6 "g" "NA"
-"PEN-S" "Benzylpenicillin screening test" "Beta-lactams/penicillins" "NA" "pen screen" "NA" "NA"
-"BES" 10178705 "Besifloxacin" "Fluoroquinolones" "S01AE08" "NA" "besivance" "73606-6,73628-0,73651-2"
-"BLA-S" "Beta-lactamase screening test" "Other" "NA" "beta-lactamase,betalactamase,bl screen,blt screen" "NA" "NA"
-"BIA" 71339 "Biapenem" "Carbapenems" "J01DH05" "NA" "biapenern,omegacin" 1.2 "g" "41665-1,41666-9,41667-7,41728-7"
-"BCZ" 65807 "Bicyclomycin" "Other antibacterials" "NA" "bicozamycin" "aizumycin,bacfeed,bacteron,bicozamicina,bicozamycin,bicozamycine,bicozamycinum" "NA"
-"BLM" 5360373 "Bleomycin" "Glycopeptides" "L01DC01" "NA" "blenamax,blenoxane,bleocin,bleomicin,bleomicina,bleomycine,bleomycins,bleomycinum,blexane,nbleomycinamide" "NA"
-"BDP" 68760 "Brodimoprim" "Trimethoprims" "J01EA02" "Sulfonamides and trimethoprim" "Trimethoprim and derivatives" "NA" "brodimoprima,brodimoprime,brodimoprimum,bromdimoprim,hyprim,unitrim" 0.2 "g" "NA"
-"BUT" 47472 "Butoconazole" "Antifungals/antimycotics" "G01AF15" "NA" "butaconazole,butoconazol,butoconazolum,gynofort" "NA"
-"CDZ" 44242317 "Cadazolid" "Oxazolidinones" "NA" "NA" "NA" "NA"
-"CLA" "Calcium aminosalicylate" "Antimycobacterials" "J04AA03" "Drugs for treatment of tuberculosis" "Aminosalicylic acid and derivatives" "NA" "NA" 15 "g" "NA"
-"CAP" 135565060 "Capreomycin" "Antimycobacterials" "J04AB30" "Drugs for treatment of tuberculosis" "Antibiotics" "capr" "NA" 1 "g" "16545-6,18872-2,23607-5,25210-6,25211-4,25212-2,42643-7,48170-5,55-4,55623-3,56-2,57-0,58-8,61355-4,89483-2"
-"CRB" 20824 "Carbenicillin" "Beta-lactams/penicillins" "J01CA03" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "bar,carb,cb" "anabactyl,carbecin,carbenicilina,carbenicillina,carbenicilline,carbenicillinum,dicarbenicillin,dipenicillin,fugacillin,geopen,gripenin,hyoper,microcillin,piopen,pyocianil,pyoclox,pyopan,pyopen,pyopene" 12 "g" "18873-0,3434-8,41668-5,59-6,60-4,61-2,62-0"
-"CRN" 93184 "Carindacillin" "Beta-lactams/penicillins" "J01CA05" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "carindacilina,carindacilline,carindacillinsalt,carindacillinum,geocillin,indanylcarbinicillin,urobac" 4 "g" "NA"
-"CAR" 6540466 "Carumonam" "Monobactams" "J01DF02" "NA" "carumonamum" 2 "g" "51694-8"
-"CAS" 2826718 "Caspofungin" "Antifungals/antimycotics" "J02AX04" "Antimycotics for systemic use" "Other antimycotics for systemic use" "casp" "cancidas,caspofungina" 50 "mg" "32378-2,54175-5,54176-3,54185-4,58419-3"
-"CAC" 91562 "Cefacetrile" "Cephalosporins (1st gen.)" "J01DB10" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "cefacetril,cefacetrilo,cefacetrilum,celospor,cephacetrile,vetrimast" "55624-1,55625-8,55626-6,55627-4"
-"CEC" 51039 "Cefaclor" "Cephalosporins (2nd gen.)" "J01DC04" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "ccl,cec,cf,cfac,cfc,cfcl,cfr,fac" "alenfral,alfacet,alfatil,ceclor,cefachlor,cefaclorum,cefeaclor,cephaclor,compound,distaclor,keflor,kefolor,kefral,keftab,keftid,lilly,lopac,panacef,panoral,raniclor" 1 "g" "16564-7,18874-8,21149-0,6986-4,83-6,84-4,85-1,86-9"
-"CFR" 47965 "Cefadroxil" "Cephalosporins (1st gen.)" "J01DB05" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cfdx,cfr,fad" "bidocel,cefadrops,cefadroxilo,cefadroxilum,cefradroxil,cefzil,cephadroxil,duracef,duricef,kefroxil,sumacef,ultracef" 2 "g" "16565-4,18875-5,55628-2,63-8,64-6,65-3,66-1"
-"LEX" 27447 "Cefalexin" "Cephalosporins (1st gen.)" "J01DB01" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cflx" "adcadina,alcephin,alsporin,ambal,amplex,aristosporin,azabort,bactopenor,beliam,biocef,carnosporin,cefablan,cefacet,cefadal,cefadin,cefadina,cefalekey,cefaleksin,cefalessina,cefalexgobens,cefalexina,cefalexine,cefalexinum,cefalin,cefalival,cefaloto,cefanex,cefaseptin,cefax,ceffanex,cefibacter,ceflax,ceforal,cefovit,celexin,cepastar,cepexin,cephacillin,cephalexine,cephalexinum,cephalobene,cephanasten,cephaxin,cephin,cepol,ceporex,ceporexin,ceporexine,cerexin,cerexins,check,cophalexin,domucef,doriman,durantel,efemida,erocetin,factagard,felexin,fexin,ibilex,ibrexin,inphalex,karilexina,kefalospes,keflet,keflex,kefolan,keforal,kekrinal,kidolex,lafarine,larixin,lenocef,lexibiotico,loisine,lonflex,lopilexin,losporal,madlexin,maksipor,mamalexin,mamlexin,medolexin,medoxine,neokef,neolexina,noveol,novolexin,nufex,optocef,oracef,oriphex,oroxin,ortisporina,ospexin,palitrex,panixine,pectril,prindex,pyassan,rilexine,roceph,rogevil,sanaxin,sartosona,sencephalin,sepexin,servicef,servispor,sialexin,sinthecillin,sintolexyn,sporicef,sporidex,syncl,syncle,synecl,taicelexin,tepaxin,theratrex,tokiolexin,uphalexin,viosporine,voxxim,winlex,zabytrex,zozarine" 2 "g" "NA"
-"RID" 5773 "Cefaloridine" "Cephalosporins (1st gen.)" "J01DB02" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefa" "aliporina,ampligram,cefaloridin,cefaloridina,cefaloridinum,cefalorizin,ceflorin,cepaloridin,cepalorin,cephalomycine,cephaloridin,cephaloridine,cephaloridinum,ceporan,ceporin,ceporine,cilifor,deflorin,faredina,floridin,glaxoridin,intrasporin,keflodin,keflordin,kefloridin,kefspor,lloncefal,sasperin,sefacin,verolgin,vioviantine" 3 "g" "NA"
-"CEP" 6024 "Cefalotin" "Cephalosporins (1st gen.)" "J01DB03" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cfal,cflt" "averon,cefalothin,cefalothine,cefalothinsalt,cefalotina,cefalotine,cefalotinsalt,cefalotinum,cemastin,cephalothin,cephalothinsalt,cephalothinum,cephalotin,cephalotinsalt,ceporacin,cepovenin,coaxin,keflin,lospoven,microtin,seffin,synclotin,toricelocin" 4 "g" "NA"
-"MAN" 456255 "Cefamandole" "Cephalosporins (2nd gen.)" "J01DC03" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cfam,cfmn" "cefadole,cefamandol,cefamandolum,cephadole,kefamandol,kefdole,mancef" 6 "g" "18876-3,3441-3,41669-3,55634-0,55635-7,55636-5,55637-3,67-9,68-7,69-5,70-3"
-"HAP" 30699 "Cefapirin" "Cephalosporins (1st gen.)" "J01DB08" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "ambrocef,brisfirina,brisporin,bristocef,cefadyl,cefalak,cefaloject,cefapirina,cefapirine,cefapirinsalt,cefapirinum,cefaprin,cefatrex,cefatrexyl,cephapirin,cephapirine,cephapirinsalt,cephatrexil,cephatrexyl,metricure" 4 "g" "NA"
-"CTZ" 6410758 "Cefatrizine" "Cephalosporins (1st gen.)" "J01DB07" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "bricef,cefathiamidine,cefatrix,cefatrizino,cefatrizinum,cephatriazine,cepticol,cetrazil,latocef,orosporina,orotric,seapuron,trizina" 1 "g" "18877-1,55639-9,71-1,72-9,73-7,74-5"
-"CZD" 71736 "Cefazedone" "Cephalosporins (1st gen.)" "J01DB06" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "cefazedon,cefazedona,cefazedonesalt,cefazedonum,refosporen,refosporene,refosporin,refosporinsalt" 3 "g" "NA"
-"CZO" 33255 "Cefazolin" "Cephalosporins (1st gen.)" "J01DB04" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cfz,cfzl,cz,czol,faz,kz" "ancef,atirin,biazolina,cefabiozim,cefacidal,cefalomicina,cefamedin,cefamezin,cefazil,cefazina,cefazolina,cefazoline,cefazolinsalt,cefazolinum,cephamezine,cephazolidin,cephazolin,cephazoline,elzogram,firmacef,gramaxin,kefzol,lampocef,liviclina,neofazol,oprea,recef,totacef,zolicef,zolisint" 3 "g" "16566-2,18878-9,25235-3,3442-1,3443-9,41670-1,75-2,76-0,77-8,78-6,80962-4,85422-4"
-"CFB" 127527 "Cefbuperazone" "Other antibacterials" "J01DC13" "NA" "cefbuperazona,cefbuperazonesalt,cefbuperazonum,cefbuperzaone,cerbuperazone,keiperazon,tomiporan" 2 "g" "NA"
-"CCP" 6436055 "Cefcapene" "Cephalosporins (3rd gen.)" "J01DD17" "NA" "flomox" 0.45 "g" "100044-7,76143-7"
-"CCX" 5282438 "Cefcapene pivoxil" "Cephalosporins (3rd gen.)" "NA" "NA" "cefcamate,flumax" "NA"
-"CDR" 6915944 "Cefdinir" "Cephalosporins (3rd gen.)" "J01DD15" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cd,cdn,cdr,cfd,din" "cefdinirum,cefdinyl,cefdirnir,ceftinex,cefzon,omnicef" 0.6 "g" "23636-4,23637-2,35757-4,35758-2"
-"DIT" 9870843 "Cefditoren" "Cephalosporins (3rd gen.)" "J01DD16" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cdn" "cefditoreno,spectracef" 0.4 "g" "35759-0,35760-8,35761-6,35762-4"
-"DIX" 6437877 "Cefditoren pivoxil" "Cephalosporins (3rd gen.)" "NA" "NA" "cefditorin,meiact,pivaloyloxymethyl" "NA"
-"FEP" 5479537 "Cefepime" "Cephalosporins (4th gen.)" "J01DE01" "Other beta-lactam antibacterials" "Fourth-generation cephalosporins" "cfep,cfpi,cpe,cpm,fep,pm,xpm" "anticefepime,axepim,cefepima,cefepimum,maxipime,pyrrolidinium,renapime" 4 "g" "101502-3,18879-7,31142-3,31143-1,35763-2,38363-8,42350-9,42351-7,42353-3,50631-1,58412-8,6643-1,6644-9,6645-7,6646-5,6987-2,8272-7,8273-5"
-"CFA" "Cefepime/amikacin" "Cephalosporins (4th gen.)" "J01RA06" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
-"CPC" 9567559 "Cefepime/clavulanic acid" "Cephalosporins (4th gen.)" "NA" "cicl,xpml" "NA" "NA"
-"FPE" 23653540 "Cefepime/enmetazobactam" "Cephalosporins (4th gen.)" "NA" "NA" "NA" "NA"
-"FNC" "Cefepime/nacubactam" "Cephalosporins (4th gen.)" "NA" "NA" "NA" "NA"
-"FPT" 9567558 "Cefepime/tazobactam" "Cephalosporins (4th gen.)" "NA" "NA" "NA" "NA"
-"FPZ" "Cefepime/zidebactam" "Cephalosporins (4th gen.)" "NA" "NA" "NA" "NA"
-"CAT" 5487888 "Cefetamet" "Cephalosporins (3rd gen.)" "J01DD10" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "cefetametum,deacetoxycefotaxime,epocelin" 1 "g" "32377-4,35764-0,35765-7,55640-7"
-"CPI" 5486182 "Cefetamet pivoxil" "Cephalosporins (3rd gen.)" "NA" "NA" "cefetametpivoxil,cefyl,globocef" "NA"
-"CCL" 71719688 "Cefetecol" "Cephalosporins (4th gen.)" "NA" "cefcatacol" "NA" "NA"
-"CZL" 193956 "Cefetrizole" "Cephalosporins (unclassified gen.)" "NA" "NA" "cefetrizolum" "NA"
-"FDC" 77843966 "Cefiderocol" "Cephalosporins (unclassified gen.)" "J01DI04" "NA" "fetcroja" 6 "g" "95767-0,99280-0,99503-5"
-"CFM" 5362065 "Cefixime" "Cephalosporins (3rd gen.)" "J01DD08" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfe,cfix,cfxm,dcfm,fix,ix" "cefixim,cefixima,cefiximum,cefixoral,cefspan,cephoral,citropen,denvar,necopen,oraken,oroken,suprax,tricef,unixime" 0.4 "g" "16567-0,18880-5,25236-1,35766-5,79-4,80-2,81-0,82-8"
-"CEO" "Cefixime/ornidazole" "Other antibacterials" "J01RA15" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
-"CMX" 9570757 "Cefmenoxime" "Cephalosporins (3rd gen.)" "J01DD05,S01AA31,S02AA18" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "bestron,cefmenoxima,cefmenoximum,tacef" 2 "g" "32375-8,54174-8,54203-5,55641-5"
-"CMZ" 42008 "Cefmetazole" "Cephalosporins (2nd gen.)" "J01DC09" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "NA" "cefmetazol,cefmetazolo,cefmetazolum,cefmetazon,metafar,zefazone" 4 "g" "11575-8,18881-3,25222-1,87-7,88-5,89-3,90-1"
-"CNX" 71141 "Cefminox" "Other antibacterials" "J01DC12" "NA" "alteporina,cefminoxhydrate,cefminoxum,meicelin,tencef" 4 "g" "54908-9"
-"DIZ" 5361871 "Cefodizime" "Cephalosporins (3rd gen.)" "J01DD09" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "cefodizima,cefodizimum,cefodizme,diezime,kenicef,modivid,neucef,timecef" 2 "g" "18882-1,6988-0,91-9,92-7,93-5,94-3"
-"CID" 43594 "Cefonicid" "Cephalosporins (2nd gen.)" "J01DC06" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "NA" "cefonicide,cefonicido,cefonicidsalt,cefonicidum,monocef,monocid" 1 "g" "18883-9,25237-9,3444-7,55642-3,95-0,96-8,97-6,98-4"
-"CFP" 44187 "Cefoperazone" "Cephalosporins (3rd gen.)" "J01DD12" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfp,cfpz,cp,cpz,fop,per" "bioperazone,cefob,cefobid,cefobis,cefoneg,cefoper,cefoperazin,cefoperazine,cefoperazon,cefoperazona,cefoperazonesalt,cefoperazono,cefoperazonum,cefozon,medocef,myticef,pathozone,peracef,tomabef" 4 "g" "100-8,101-6,102-4,18884-7,3445-4,35767-3,35768-1,54166-4,54167-2,54168-0,99-2"
-"CSL" "Cefoperazone/sulbactam" "Cephalosporins (3rd gen.)" "J01DD62" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "NA" 4 "g" "35768-1,54166-4,54167-2,54168-0"
-"CND" 43507 "Ceforanide" "Cephalosporins (2nd gen.)" "J01DC11" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "NA" "ceforanido,ceforanidum,precef" 4 "g" "103-2,104-0,105-7,106-5,18885-4,55643-1"
-"CSE" 9830519 "Cefoselis" "Cephalosporins (4th gen.)" "NA" "NA" "winsef" "NA"
-"CTX" 5742673 "Cefotaxime" "Cephalosporins (3rd gen.)" "J01DD01" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfot,cft,cftx,ct,ctx,fot,tax,xct" "anticefotaxime,cefotax,cefotaxim,cefotaxima,cefotaximesalt,cefotaximsalt,cefotaximum,cephotaxim,cephotaxime,claforan,kefotex,omnatax,pretor,ralopar,tolycar,tolycor,zariviz" 4 "g" "101479-4,101480-2,107-3,108-1,109-9,110-7,18886-2,25238-7,31138-1,31139-9,3446-2,35769-9,35770-7,35771-5,41671-9,50632-9,52128-6,54191-2,54192-0,54193-8,55189-5,55644-9,6989-8,80961-6"
-"CTX-S" "Cefotaxime screening test" "Cephalosporins (3rd gen.)" "NA" "ctx screen" "NA" "NA"
-"CTC" 9575353 "Cefotaxime/clavulanic acid" "Cephalosporins (3rd gen.)" "J01DD51" "cxcl,xctl" "NA" "NA"
-"CTS" 9574753 "Cefotaxime/sulbactam" "Cephalosporins (3rd gen.)" "NA" "NA" "NA" "54191-2,54192-0,54193-8,55644-9"
-"CTT" 53025 "Cefotetan" "Cephalosporins (2nd gen.)" "J01DC05" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cftt,cn,cte,ctn,ctt,tans" "apacef,apatef,cefotetanum" 4 "g" "111-5,112-3,113-1,114-9,18887-0,25239-5,3447-0,41672-7,41673-5,41674-3,41729-5,6990-6"
-"CTF" 43708 "Cefotiam" "Cephalosporins (2nd gen.)" "J01DC07" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "NA" "aspil,cefotiamum,ceradon,halospor,pansporin,pansporine,spizef" 1.2 "g" 4 "g" "32374-1,35772-3,35773-1,55645-6,55737-1,55738-9,55739-7,55740-5"
-"CHE" 125846 "Cefotiam hexetil" "Cephalosporins (3rd gen.)" "NA" "NA" "taketiam,texodil" "55737-1,55738-9,55739-7,55740-5"
+"AVO" 16131159 "Avoparcin" "Glycopeptides" "" "NA" "firvanq,tagocid,targocid,targosid,tecoplanina,tecoplanine,tecoplaninum,teichomycin,teicoplanina,teicoplanine,teicoplaninum,teikoplanin,ticocin" "NA"
+"AZD" 15574941 "Azidocillin" "Beta-lactams/penicillins" "J01CE04,QJ01CE04" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "azidocilina,azidocillina,azidocilline,azidocillinum" 1.5 "g" "NA"
+"AZM" 447043 "Azithromycin" "Macrolides/lincosamides" "J01FA10,QJ01FA10,QS01AA26,S01AA26" "Macrolides, lincosamides and streptogramins" "Macrolides" "az,azi,azit,azm" "aritromicina,aruzilina,azasite,azenil,azifast,azigram,azimakrol,azithramycine,azithrocin,azithromycine,azithromycinum,azitrocin,azitromax,azitromicina,azitromicine,azitromin,aziwin,aziwok,aztrin,azyter,hemomycin,macrozit,misultina,mixoterin,setron,sumamed,tobil,toraseptol,tromix,trozocina,trulimax,xithrone,zentavion,zifin,zithrax,zithromac,zithromax,zitrim,zitromax,zitrotek,zythromax" 0.3 "g" 0.5 "g" "100043-9,16420-2,16421-0,18866-4,23612-5,25233-8,35-6,36-4,37-2,38-0,6981-5,89480-8"
+"AFC" "Azithromycin/fluconazole/secnidazole" "Other antibacterials" "" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
+"AZL" 6479523 "Azlocillin" "Beta-lactams/penicillins" "J01CA09,QJ01CA09" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "az,azl,azlo" "azlin,azlocilina,azlocilline,azlocillinsalt,azlocillinum,securopen" 12 "g" "16422-8,18867-2,3368-8,39-8,40-6,41-4,41661-0,42-2"
+"ATM" 5742832 "Aztreonam" "Monobactams" "J01DF01,QJ01DF01" "Other beta-lactam antibacterials" "Monobactams" "at,atm,azm,azt,aztr" "azactam,azetreonam,azonam,azthreonam,aztreon,aztreonamum,cayston,dynabiotic,nebactam,primbactam,squibb" 4 "g" "101497-6,16423-6,18868-0,25234-6,3369-6,41662-8,41663-6,41664-4,41727-9,43-0,44-8,45-5,46-3,6982-3"
+"AZA" "Aztreonam/avibactam" "Monobactams" "J01DF51,QJ01DF51" "NA" "NA" "NA"
+"ANC" "Aztreonam/nacubactam" "Monobactams" "J01DF51,QJ01DF51" "NA" "NA" "NA"
+"BAM" 441397 "Bacampicillin" "Beta-lactams/penicillins" "J01CA06,QJ01CA06" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "alphacilina,alphacillin,ambacamp,ambaxin,bacacil,bacampicilina,bacampicilline,bacampicillinum,bacampicine,berocillin,centurina,devonium,diancina,inacilin,maxifen,penglobe,pivatil,pondocil,pondocillin,pondocillina,sanguicillin,spectrobid,velbacil" 1.2 "g" "18869-8,47-1,48-9,49-7,50-5,55620-9"
+"BAC" 78358334 "Bacitracin" "Other antibacterials" "D06AX05,J01XX10,QA07AA93,QD06AX05,QJ01XX10,QR02AB04,QS01AA32,R02AB04,S01AA32" "baci" "albac,altracin,ayfivin,baciferm,baciguent,baciim,baciliquin,bacilliquin,baciquent,bacitracina,bacitracine,bacitracinum,fortracin,mycitracin,parentracin,penitracin,septa,topitracin,topitrasin,tropitracin,zutracin" "10868-8,16428-5,18870-6,6827-0,6983-1,87603-7"
+"BDQ" 5388906 "Bedaquiline" "Other antibacterials" "J04AK05,QJ04AK05" "NA" "NA" 86 "mg" "80637-2,88703-4,88704-2,94274-8,96107-8"
+"BEK" 439318 "Bekanamycin" "Aminoglycosides" "J01GB13,QJ01GB13" "NA" "aminodeoxykanamycin,becanamicina,bekanamicina,bekanamycine,bekanamycinum" 0.6 "g" "NA"
+"BNB" "Benzathine benzylpenicillin" "Beta-lactams/penicillins" "J01CE08,QJ01CE08" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "NA" 3.6 "g" "NA"
+"BNP" 64725 "Benzathine phenoxymethylpenicillin" "Beta-lactams/penicillins" "J01CE10,QJ01CE10" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "bicillin,biphecillin" 2 "g" "NA"
+"PEN" 5904 "Benzylpenicillin" "Beta-lactams/penicillins" "J01CE01,QJ01CE01,QJ51CE01,QS01AA14,S01AA14" "Combinations of antibacterials" "Combinations of antibacterials" "bepe,pen,peni,peni g,penicillin,penicillin g,pg" "bencilpenicilina,benzopenicillin,benzylpenicilline,benzylpenicillinum,capicillin,cillora,cilloral,cilopen,cintrisul,cosmopen,cristapen,crystapen,dropcillin,eskacillin,falapen,forpen,galofak,gelacillin,hipercilina,hyasorb,hylenta,lemopen,liquacillin,liquapen,monocillin,monopen,mycofarm,novocillin,penalev,penicillinum,penilaryn,penisem,pentid,pentids,pfizerpen,pharmacillin,pradupen,scotcil,sugracillin,sugracillinsalt,tabilin,ursopen,veticillin" 3.6 "g" "NA"
+"PEN-S" "Benzylpenicillin screening test" "Beta-lactams/penicillins" "" "pen screen" "NA" "NA"
+"BES" 10178705 "Besifloxacin" "Fluoroquinolones" "QS01AE08,S01AE08" "NA" "besivance" "73606-6,73628-0,73651-2"
+"BLA-S" "Beta-lactamase screening test" "Other" "" "beta-lactamase,betalactamase,bl screen,blt screen" "NA" "NA"
+"BIA" 71339 "Biapenem" "Carbapenems" "J01DH05,QJ01DH05" "NA" "biapenern,omegacin" 1.2 "g" "41665-1,41666-9,41667-7,41728-7"
+"BCZ" 65807 "Bicyclomycin" "Other antibacterials" "" "bicozamycin" "aizumycin,bacfeed,bacteron,bicozamicina,bicozamycin,bicozamycine,bicozamycinum" "NA"
+"BLM" 5360373 "Bleomycin" "Glycopeptides" "L01DC01,QL01DC01" "NA" "blenamax,blenoxane,bleocin,bleomicin,bleomicina,bleomycine,bleomycins,bleomycinum,blexane,nbleomycinamide" "NA"
+"BDP" 68760 "Brodimoprim" "Trimethoprims" "J01EA02,QJ01EA02" "Sulfonamides and trimethoprim" "Trimethoprim and derivatives" "NA" "brodimoprima,brodimoprime,brodimoprimum,bromdimoprim,hyprim,unitrim" 0.2 "g" "NA"
+"BUT" 47472 "Butoconazole" "Antifungals/antimycotics" "G01AF15,QG01AF15" "NA" "butaconazole,butoconazol,butoconazolum,gynofort" "NA"
+"CDZ" 44242317 "Cadazolid" "Oxazolidinones" "" "NA" "NA" "NA"
+"CLA" "Calcium aminosalicylate" "Antimycobacterials" "J04AA03,QJ04AA03" "Drugs for treatment of tuberculosis" "Aminosalicylic acid and derivatives" "NA" "NA" 15 "g" "NA"
+"CAP" 135565060 "Capreomycin" "Antimycobacterials" "J04AB30,QJ04AB30" "Drugs for treatment of tuberculosis" "Antibiotics" "capr" "NA" 1 "g" "16545-6,18872-2,23607-5,25210-6,25211-4,25212-2,42643-7,48170-5,55-4,55623-3,56-2,57-0,58-8,61355-4,89483-2"
+"CRB" 20824 "Carbenicillin" "Beta-lactams/penicillins" "J01CA03,QJ01CA03" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "bar,carb,cb" "anabactyl,carbecin,carbenicilina,carbenicillina,carbenicilline,carbenicillinum,dicarbenicillin,dipenicillin,fugacillin,geopen,gripenin,hyoper,microcillin,piopen,pyocianil,pyoclox,pyopan,pyopen,pyopene" 12 "g" "18873-0,3434-8,41668-5,59-6,60-4,61-2,62-0"
+"CRN" 93184 "Carindacillin" "Beta-lactams/penicillins" "J01CA05,QJ01CA05" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "carindacilina,carindacilline,carindacillinsalt,carindacillinum,geocillin,indanylcarbinicillin,urobac" 4 "g" "NA"
+"CAR" 6540466 "Carumonam" "Monobactams" "J01DF02,QJ01DF02" "NA" "carumonamum" 2 "g" "51694-8"
+"CAS" 2826718 "Caspofungin" "Antifungals/antimycotics" "J02AX04,QJ02AX04" "Antimycotics for systemic use" "Other antimycotics for systemic use" "casp" "cancidas,caspofungina" 50 "mg" "32378-2,54175-5,54176-3,54185-4,58419-3"
+"CAC" 91562 "Cefacetrile" "Cephalosporins (1st gen.)" "J01DB10,QJ01DB10,QJ51DB10" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "cefacetril,cefacetrilo,cefacetrilum,celospor,cephacetrile,vetrimast" "55624-1,55625-8,55626-6,55627-4"
+"CEC" 51039 "Cefaclor" "Cephalosporins (2nd gen.)" "J01DC04,QJ01DC04" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "ccl,cec,cf,cfac,cfc,cfcl,cfr,fac" "alenfral,alfacet,alfatil,ceclor,cefachlor,cefaclorum,cefeaclor,cephaclor,compound,distaclor,keflor,kefolor,kefral,keftab,keftid,lilly,lopac,panacef,panoral,raniclor" 1 "g" "16564-7,18874-8,21149-0,6986-4,83-6,84-4,85-1,86-9"
+"CFR" 47965 "Cefadroxil" "Cephalosporins (1st gen.)" "J01DB05,QJ01DB05" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cfdx,cfr,fad" "bidocel,cefadrops,cefadroxilo,cefadroxilum,cefradroxil,cefzil,cephadroxil,duracef,duricef,kefroxil,sumacef,ultracef" 2 "g" "16565-4,18875-5,55628-2,63-8,64-6,65-3,66-1"
+"LEX" 27447 "Cefalexin" "Cephalosporins (1st gen.)" "J01DB01,QJ01DB01,QJ51DB01" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cflx" "adcadina,alcephin,alsporin,ambal,amplex,aristosporin,azabort,bactopenor,beliam,biocef,carnosporin,cefablan,cefacet,cefadal,cefadin,cefadina,cefalekey,cefaleksin,cefalessina,cefalexgobens,cefalexina,cefalexine,cefalexinum,cefalin,cefalival,cefaloto,cefanex,cefaseptin,cefax,ceffanex,cefibacter,ceflax,ceforal,cefovit,celexin,cepastar,cepexin,cephacillin,cephalexine,cephalexinum,cephalobene,cephanasten,cephaxin,cephin,cepol,ceporex,ceporexin,ceporexine,cerexin,cerexins,check,cophalexin,domucef,doriman,durantel,efemida,erocetin,factagard,felexin,fexin,ibilex,ibrexin,inphalex,karilexina,kefalospes,keflet,keflex,kefolan,keforal,kekrinal,kidolex,lafarine,larixin,lenocef,lexibiotico,loisine,lonflex,lopilexin,losporal,madlexin,maksipor,mamalexin,mamlexin,medolexin,medoxine,neokef,neolexina,noveol,novolexin,nufex,optocef,oracef,oriphex,oroxin,ortisporina,ospexin,palitrex,panixine,pectril,prindex,pyassan,rilexine,roceph,rogevil,sanaxin,sartosona,sencephalin,sepexin,servicef,servispor,sialexin,sinthecillin,sintolexyn,sporicef,sporidex,syncl,syncle,synecl,taicelexin,tepaxin,theratrex,tokiolexin,uphalexin,viosporine,voxxim,winlex,zabytrex,zozarine" 2 "g" "NA"
+"RID" 5773 "Cefaloridine" "Cephalosporins (1st gen.)" "J01DB02,QJ01DB02" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cefa" "aliporina,ampligram,cefaloridin,cefaloridina,cefaloridinum,cefalorizin,ceflorin,cepaloridin,cepalorin,cephalomycine,cephaloridin,cephaloridine,cephaloridinum,ceporan,ceporin,ceporine,cilifor,deflorin,faredina,floridin,glaxoridin,intrasporin,keflodin,keflordin,kefloridin,kefspor,lloncefal,sasperin,sefacin,verolgin,vioviantine" 3 "g" "NA"
+"CEP" 6024 "Cefalotin" "Cephalosporins (1st gen.)" "J01DB03,QJ01DB03" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cfal,cflt" "averon,cefalothin,cefalothine,cefalothinsalt,cefalotina,cefalotine,cefalotinsalt,cefalotinum,cemastin,cephalothin,cephalothinsalt,cephalothinum,cephalotin,cephalotinsalt,ceporacin,cepovenin,coaxin,keflin,lospoven,microtin,seffin,synclotin,toricelocin" 4 "g" "NA"
+"MAN" 456255 "Cefamandole" "Cephalosporins (2nd gen.)" "J01DC03,QJ01DC03" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cfam,cfmn" "cefadole,cefamandol,cefamandolum,cephadole,kefamandol,kefdole,mancef" 6 "g" "18876-3,3441-3,41669-3,55634-0,55635-7,55636-5,55637-3,67-9,68-7,69-5,70-3"
+"HAP" 30699 "Cefapirin" "Cephalosporins (1st gen.)" "J01DB08,QG51AA05,QJ01DB08,QJ51DB08" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "ambrocef,brisfirina,brisporin,bristocef,cefadyl,cefalak,cefaloject,cefapirina,cefapirine,cefapirinsalt,cefapirinum,cefaprin,cefatrex,cefatrexyl,cephapirin,cephapirine,cephapirinsalt,cephatrexil,cephatrexyl,metricure" 4 "g" "NA"
+"CTZ" 6410758 "Cefatrizine" "Cephalosporins (1st gen.)" "J01DB07,QJ01DB07" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "bricef,cefathiamidine,cefatrix,cefatrizino,cefatrizinum,cephatriazine,cepticol,cetrazil,latocef,orosporina,orotric,seapuron,trizina" 1 "g" "18877-1,55639-9,71-1,72-9,73-7,74-5"
+"CZD" 71736 "Cefazedone" "Cephalosporins (1st gen.)" "J01DB06,QJ01DB06" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "cefazedon,cefazedona,cefazedonesalt,cefazedonum,refosporen,refosporene,refosporin,refosporinsalt" 3 "g" "NA"
+"CZO" 33255 "Cefazolin" "Cephalosporins (1st gen.)" "J01DB04,QJ01DB04,QJ51DB04" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cfz,cfzl,cz,czol,faz,kz" "ancef,atirin,biazolina,cefabiozim,cefacidal,cefalomicina,cefamedin,cefamezin,cefazil,cefazina,cefazolina,cefazoline,cefazolinsalt,cefazolinum,cephamezine,cephazolidin,cephazolin,cephazoline,elzogram,firmacef,gramaxin,kefzol,lampocef,liviclina,neofazol,oprea,recef,totacef,zolicef,zolisint" 3 "g" "16566-2,18878-9,25235-3,3442-1,3443-9,41670-1,75-2,76-0,77-8,78-6,80962-4,85422-4"
+"CFB" 127527 "Cefbuperazone" "Other antibacterials" "J01DC13,QJ01DC13" "NA" "cefbuperazona,cefbuperazonesalt,cefbuperazonum,cefbuperzaone,cerbuperazone,keiperazon,tomiporan" 2 "g" "NA"
+"CCP" 6436055 "Cefcapene" "Cephalosporins (3rd gen.)" "J01DD17,QJ01DD17" "NA" "flomox" 0.45 "g" "100044-7,76143-7"
+"CCX" 5282438 "Cefcapene pivoxil" "Cephalosporins (3rd gen.)" "" "NA" "cefcamate,flumax" "NA"
+"CDR" 6915944 "Cefdinir" "Cephalosporins (3rd gen.)" "J01DD15,QJ01DD15" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cd,cdn,cdr,cfd,din" "cefdinirum,cefdinyl,cefdirnir,ceftinex,cefzon,omnicef" 0.6 "g" "23636-4,23637-2,35757-4,35758-2"
+"DIT" 9870843 "Cefditoren" "Cephalosporins (3rd gen.)" "J01DD16,QJ01DD16" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cdn" "cefditoreno,spectracef" 0.4 "g" "35759-0,35760-8,35761-6,35762-4"
+"DIX" 6437877 "Cefditoren pivoxil" "Cephalosporins (3rd gen.)" "" "NA" "cefditorin,meiact,pivaloyloxymethyl" "NA"
+"FEP" 5479537 "Cefepime" "Cephalosporins (4th gen.)" "J01DE01,QJ01DE01" "Other beta-lactam antibacterials" "Fourth-generation cephalosporins" "cfep,cfpi,cpe,cpm,fep,pm,xpm" "anticefepime,axepim,cefepima,cefepimum,maxipime,pyrrolidinium,renapime" 4 "g" "101502-3,18879-7,31142-3,31143-1,35763-2,38363-8,42350-9,42351-7,42353-3,50631-1,58412-8,6643-1,6644-9,6645-7,6646-5,6987-2,8272-7,8273-5"
+"CFA" "Cefepime/amikacin" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
+"CPC" 9567559 "Cefepime/clavulanic acid" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "cicl,xpml" "NA" "NA"
+"FPE" 23653540 "Cefepime/enmetazobactam" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "NA" "NA" "NA"
+"FNC" "Cefepime/nacubactam" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "NA" "NA" "NA"
+"FPT" 9567558 "Cefepime/tazobactam" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "NA" "NA" "NA"
+"FPZ" "Cefepime/zidebactam" "Cephalosporins (4th gen.)" "J01DE51,QJ01DE51" "NA" "NA" "NA"
+"CAT" 5487888 "Cefetamet" "Cephalosporins (3rd gen.)" "J01DD10,QJ01DD10" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "cefetametum,deacetoxycefotaxime,epocelin" 1 "g" "32377-4,35764-0,35765-7,55640-7"
+"CPI" 5486182 "Cefetamet pivoxil" "Cephalosporins (3rd gen.)" "" "NA" "cefetametpivoxil,cefyl,globocef" "NA"
+"CCL" 71719688 "Cefetecol" "Cephalosporins (4th gen.)" "" "cefcatacol" "NA" "NA"
+"CZL" 193956 "Cefetrizole" "Cephalosporins (unclassified gen.)" "" "NA" "cefetrizolum" "NA"
+"FDC" 77843966 "Cefiderocol" "Cephalosporins (unclassified gen.)" "J01DI04,QJ01DI04" "NA" "fetcroja" 6 "g" "95767-0,99280-0,99503-5"
+"CFM" 5362065 "Cefixime" "Cephalosporins (3rd gen.)" "J01DD08,QJ01DD08" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfe,cfix,cfxm,dcfm,fix,ix" "cefixim,cefixima,cefiximum,cefixoral,cefspan,cephoral,citropen,denvar,necopen,oraken,oroken,suprax,tricef,unixime" 0.4 "g" "16567-0,18880-5,25236-1,35766-5,79-4,80-2,81-0,82-8"
+"CEO" "Cefixime/ornidazole" "Other antibacterials" "J01DD58,QJ01DD58" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
+"CMX" 9570757 "Cefmenoxime" "Cephalosporins (3rd gen.)" "J01DD05,QJ01DD05,QS01AA31,QS02AA18,S01AA31,S02AA18" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "bestron,cefmenoxima,cefmenoximum,tacef" 2 "g" "32375-8,54174-8,54203-5,55641-5"
+"CMZ" 42008 "Cefmetazole" "Cephalosporins (2nd gen.)" "J01DC09,QJ01DC09" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "NA" "cefmetazol,cefmetazolo,cefmetazolum,cefmetazon,metafar,zefazone" 4 "g" "11575-8,18881-3,25222-1,87-7,88-5,89-3,90-1"
+"CNX" 71141 "Cefminox" "Other antibacterials" "J01DC12,QJ01DC12" "NA" "alteporina,cefminoxhydrate,cefminoxum,meicelin,tencef" 4 "g" "54908-9"
+"DIZ" 5361871 "Cefodizime" "Cephalosporins (3rd gen.)" "J01DD09,QJ01DD09" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "cefodizima,cefodizimum,cefodizme,diezime,kenicef,modivid,neucef,timecef" 2 "g" "18882-1,6988-0,91-9,92-7,93-5,94-3"
+"CID" 43594 "Cefonicid" "Cephalosporins (2nd gen.)" "J01DC06,QJ01DC06" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "NA" "cefonicide,cefonicido,cefonicidsalt,cefonicidum,monocef,monocid" 1 "g" "18883-9,25237-9,3444-7,55642-3,95-0,96-8,97-6,98-4"
+"CFP" 44187 "Cefoperazone" "Cephalosporins (3rd gen.)" "J01DD12,QJ01DD12,QJ51DD12" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfp,cfpz,cp,cpz,fop,per" "bioperazone,cefob,cefobid,cefobis,cefoneg,cefoper,cefoperazin,cefoperazine,cefoperazon,cefoperazona,cefoperazonesalt,cefoperazono,cefoperazonum,cefozon,medocef,myticef,pathozone,peracef,tomabef" 4 "g" "100-8,101-6,102-4,18884-7,3445-4,35767-3,35768-1,54166-4,54167-2,54168-0,99-2"
+"CSL" "Cefoperazone/sulbactam" "Cephalosporins (3rd gen.)" "J01DD62,QJ01DD62" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "NA" 4 "g" "35768-1,54166-4,54167-2,54168-0"
+"CND" 43507 "Ceforanide" "Cephalosporins (2nd gen.)" "J01DC11,QJ01DC11" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "NA" "ceforanido,ceforanidum,precef" 4 "g" "103-2,104-0,105-7,106-5,18885-4,55643-1"
+"CSE" 9830519 "Cefoselis" "Cephalosporins (4th gen.)" "" "NA" "winsef" "NA"
+"CTX" 5742673 "Cefotaxime" "Cephalosporins (3rd gen.)" "J01DD01,QJ01DD01" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfot,cft,cftx,ct,ctx,fot,tax,xct" "anticefotaxime,cefotax,cefotaxim,cefotaxima,cefotaximesalt,cefotaximsalt,cefotaximum,cephotaxim,cephotaxime,claforan,kefotex,omnatax,pretor,ralopar,tolycar,tolycor,zariviz" 4 "g" "101479-4,101480-2,107-3,108-1,109-9,110-7,18886-2,25238-7,31138-1,31139-9,3446-2,35769-9,35770-7,35771-5,41671-9,50632-9,52128-6,54191-2,54192-0,54193-8,55189-5,55644-9,6989-8,80961-6"
+"CTX-S" "Cefotaxime screening test" "Cephalosporins (3rd gen.)" "" "ctx screen" "NA" "NA"
+"CTC" 9575353 "Cefotaxime/clavulanic acid" "Cephalosporins (3rd gen.)" "J01DD51,QJ01DD51" "cxcl,xctl" "NA" "NA"
+"CTS" 9574753 "Cefotaxime/sulbactam" "Cephalosporins (3rd gen.)" "J01DD51,QJ01DD51" "NA" "NA" "54191-2,54192-0,54193-8,55644-9"
+"CTT" 53025 "Cefotetan" "Cephalosporins (2nd gen.)" "J01DC05,QJ01DC05" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cftt,cn,cte,ctn,ctt,tans" "apacef,apatef,cefotetanum" 4 "g" "111-5,112-3,113-1,114-9,18887-0,25239-5,3447-0,41672-7,41673-5,41674-3,41729-5,6990-6"
+"CTF" 43708 "Cefotiam" "Cephalosporins (2nd gen.)" "J01DC07,QJ01DC07" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "NA" "aspil,cefotiamum,ceradon,halospor,pansporin,pansporine,spizef" 1.2 "g" 4 "g" "32374-1,35772-3,35773-1,55645-6,55737-1,55738-9,55739-7,55740-5"
+"CHE" 125846 "Cefotiam hexetil" "Cephalosporins (3rd gen.)" "" "NA" "taketiam,texodil" "55737-1,55738-9,55739-7,55740-5"
"FOV" 9578573 "Cefovecin" "Cephalosporins (3rd gen.)" "QJ01DD91" "NA" "cefovecinsalt,convenia" "76147-8,87792-8"
-"FOX" 441199 "Cefoxitin" "Cephalosporins (2nd gen.)" "J01DC01" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cfox,cfx,cfxt,cx,fox,fx" "betacef,cefoxil,cefoxitina,cefoxitine,cefoxitinsalt,cefoxitinum,cefoxotin,cenomycin,farmoxin,mefoxin,mefoxithin,mefoxitin,merxin,rephoxitin" 6 "g" "101492-7,115-6,116-4,117-2,118-0,18888-8,25220-5,25240-3,25366-6,3448-8,41675-0,41676-8,41677-6,41730-3,6991-4"
-"FOX-S" "Cefoxitin screening test" "Cephalosporins (2nd gen.)" "NA" "cfsc,fox1" "NA" "NA"
-"ZOP" 9571080 "Cefozopran" "Cephalosporins (4th gen.)" "J01DE03" "NA" "firstcin,imidazo" 4 "g" "100045-4,53820-7"
-"CFZ" 68597 "Cefpimizole" "Cephalosporins (3rd gen.)" "NA" "NA" "ajicef,cefpimizol,cefpimizolesalt,cefpimizolum,renilan" "NA"
-"CPM" 636405 "Cefpiramide" "Cephalosporins (3rd gen.)" "J01DD11" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "cefpiramida,cefpiramidesalt,cefpiramido,cefpiramidum,sepatren,suncefal" 2 "g" "NA"
-"CPO" 5479539 "Cefpirome" "Cephalosporins (4th gen.)" "J01DE02" "Other beta-lactam antibacterials" "Fourth-generation cephalosporins" "cfpr" "broact,cefir,cefpiroma,cefpiromum,cefrom,keiten,romecef" 4 "g" "18889-6,6647-3,6648-1,6649-9,6650-6,6992-2,8274-3,8275-0,8276-8"
-"CPD" 6335986 "Cefpodoxime" "Cephalosporins (3rd gen.)" "J01DD13" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfpd,cfpo,cpd,pod,px" "cefpodoxima,cefpodoximum,epoxim" 0.4 "g" "119-8,120-6,121-4,122-2,18890-4,25241-1,41678-4,41679-2,41680-0,41731-1,6993-0,90849-1"
-"CPX" 6526396 "Cefpodoxime proxetil" "Cephalosporins (3rd gen.)" "NA" "NA" "banan,cefodox,cefoprox,cefpoderm,cefpodoximproxetil,cepodem,doxef,orelox,otreon,podomexef,simplicef,vantin" "NA"
-"CDC" "Cefpodoxime/clavulanic acid" "Cephalosporins (3rd gen.)" "NA" "cecl" "NA" "NA"
-"CPR" 5281006 "Cefprozil" "Cephalosporins (2nd gen.)" "J01DC10" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cpr,cpz,fp" "arzimol,brisoral,cefprozilo,cefprozilum,cronocef,procef,serozil" 1 "g" "123-0,124-8,125-5,126-3,18891-2,6994-8"
+"FOX" 441199 "Cefoxitin" "Cephalosporins (2nd gen.)" "J01DC01,QJ01DC01" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cfox,cfx,cfxt,cx,fox,fx" "betacef,cefoxil,cefoxitina,cefoxitine,cefoxitinsalt,cefoxitinum,cefoxotin,cenomycin,farmoxin,mefoxin,mefoxithin,mefoxitin,merxin,rephoxitin" 6 "g" "101492-7,115-6,116-4,117-2,118-0,18888-8,25220-5,25240-3,25366-6,3448-8,41675-0,41676-8,41677-6,41730-3,6991-4"
+"FOX-S" "Cefoxitin screening test" "Cephalosporins (2nd gen.)" "" "cfsc,fox1" "NA" "NA"
+"ZOP" 9571080 "Cefozopran" "Cephalosporins (4th gen.)" "J01DE03,QJ01DE03" "NA" "firstcin,imidazo" 4 "g" "100045-4,53820-7"
+"CFZ" 68597 "Cefpimizole" "Cephalosporins (3rd gen.)" "" "NA" "ajicef,cefpimizol,cefpimizolesalt,cefpimizolum,renilan" "NA"
+"CPM" 636405 "Cefpiramide" "Cephalosporins (3rd gen.)" "J01DD11,QJ01DD11" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "cefpiramida,cefpiramidesalt,cefpiramido,cefpiramidum,sepatren,suncefal" 2 "g" "NA"
+"CPO" 5479539 "Cefpirome" "Cephalosporins (4th gen.)" "J01DE02,QJ01DE02" "Other beta-lactam antibacterials" "Fourth-generation cephalosporins" "cfpr" "broact,cefir,cefpiroma,cefpiromum,cefrom,keiten,romecef" 4 "g" "18889-6,6647-3,6648-1,6649-9,6650-6,6992-2,8274-3,8275-0,8276-8"
+"CPD" 6335986 "Cefpodoxime" "Cephalosporins (3rd gen.)" "J01DD13,QJ01DD13" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfpd,cfpo,cpd,pod,px" "cefpodoxima,cefpodoximum,epoxim" 0.4 "g" "119-8,120-6,121-4,122-2,18890-4,25241-1,41678-4,41679-2,41680-0,41731-1,6993-0,90849-1"
+"CPX" 6526396 "Cefpodoxime proxetil" "Cephalosporins (3rd gen.)" "" "NA" "banan,cefodox,cefoprox,cefpoderm,cefpodoximproxetil,cepodem,doxef,orelox,otreon,podomexef,simplicef,vantin" "NA"
+"CDC" "Cefpodoxime/clavulanic acid" "Cephalosporins (3rd gen.)" "J01DD64,QJ01DD64" "cecl" "NA" "NA"
+"CPR" 5281006 "Cefprozil" "Cephalosporins (2nd gen.)" "J01DC10,QJ01DC10" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cpr,cpz,fp" "arzimol,brisoral,cefprozilo,cefprozilum,cronocef,procef,serozil" 1 "g" "123-0,124-8,125-5,126-3,18891-2,6994-8"
"CEQ" 5464355 "Cefquinome" "Cephalosporins (4th gen.)" "QG51AA07,QJ01DE90,QJ51DE90" "NA" "cefquinoma,cefquinomum,cobactan,quinolinium" "100046-2,76150-2"
-"CRD" 5284529 "Cefroxadine" "Cephalosporins (1st gen.)" "J01DB11" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "cefroxadin,cefroxadino,cefroxadinum,oraspor" 2.1 "g" "NA"
-"CFS" 656575 "Cefsulodin" "Cephalosporins (3rd gen.)" "J01DD03" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfsl,cfsu" "cefomonil,cefonomil,cefsulodine,cefsulodinhydrate,cefsulodino,cefsulodinum,pseudocef,pseudomonil,pyocefal,sulcephalosporin,takesulin,tilmapor,ulfaret" 4 "g" "127-1,128-9,129-7,130-5,131-3,18892-0,25242-9,55647-2"
-"CSU" 68718 "Cefsumide" "Cephalosporins (unclassified gen.)" "NA" "NA" "cefsulmid,cefsumido,cefsumidum" "NA"
-"CPT" 56841980 "Ceftaroline" "Cephalosporins (5th gen.)" "J01DI02" "cfro" "ceftaroine,teflaro,zinforo" 1.2 "g" "73604-1,73605-8,73626-4,73627-2,73649-6,73650-4,74170-2"
-"CPA" "Ceftaroline/avibactam" "Cephalosporins (5th gen.)" "NA" "NA" "NA" "73604-1,73626-4,73649-6"
-"CAZ" 5481173 "Ceftazidime" "Cephalosporins (3rd gen.)" "J01DD02" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "caz,cefta,cfta,cftz,taz,tz,xtz" "ceftazimide,ceptaz,fortam,fortaz,fortum,glazidim,kefazim,modacin,pentacef,tazicef,tizime" 4 "g" "101481-0,101482-8,101483-6,132-1,133-9,134-7,135-4,18893-8,21151-6,3449-6,35774-9,35775-6,35776-4,42352-5,55648-0,55649-8,55650-6,55651-4,58705-5,6995-5,73603-3,73625-6,73648-8,80960-8,87734-0,90850-9"
-"CZA" 90643431 "Ceftazidime/avibactam" "Cephalosporins (3rd gen.)" "NA" "cfav" "avycaz,zavicefta" "101483-6,73603-3,73625-6,73648-8,87734-0"
-"CCV" 9575352 "Ceftazidime/clavulanic acid" "Cephalosporins (3rd gen.)" "J01DD52" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "czcl,xtzl" "NA" 6 "g" "NA"
-"CEM" 6537431 "Cefteram" "Cephalosporins (3rd gen.)" "J01DD18" "NA" "cefterame,cefteramum,ceftetrame" 0.4 "g" "100047-0,76144-5"
-"CPL" 5362114 "Cefteram pivoxil" "Cephalosporins (3rd gen.)" "NA" "NA" "cefterampivoxil,tomiron" "NA"
-"CTL" 65755 "Ceftezole" "Cephalosporins (1st gen.)" "J01DB12" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "alomen,ceftezol,ceftezolesalt,ceftezolo,ceftezolum,celoslin,demethylcefazolin,falomesin" 3 "g" "NA"
-"CTB" 5282242 "Ceftibuten" "Cephalosporins (3rd gen.)" "J01DD14" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cb,cfbu,ctb,tib" "cedax,ceftem,ceftibutene,ceftibuteno,ceftibutenum,ceftibutin,ceprifran,isocef,keimax,seftem" 0.4 "g" "35777-2,35778-0,35779-8,6996-3"
+"CRD" 5284529 "Cefroxadine" "Cephalosporins (1st gen.)" "J01DB11,QJ01DB11" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "cefroxadin,cefroxadino,cefroxadinum,oraspor" 2.1 "g" "NA"
+"CFS" 656575 "Cefsulodin" "Cephalosporins (3rd gen.)" "J01DD03,QJ01DD03" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfsl,cfsu" "cefomonil,cefonomil,cefsulodine,cefsulodinhydrate,cefsulodino,cefsulodinum,pseudocef,pseudomonil,pyocefal,sulcephalosporin,takesulin,tilmapor,ulfaret" 4 "g" "127-1,128-9,129-7,130-5,131-3,18892-0,25242-9,55647-2"
+"CSU" 68718 "Cefsumide" "Cephalosporins (unclassified gen.)" "" "NA" "cefsulmid,cefsumido,cefsumidum" "NA"
+"CPT" 56841980 "Ceftaroline" "Cephalosporins (5th gen.)" "" "cfro" "ceftaroine,teflaro,zinforo" 1.2 "g" "73604-1,73605-8,73626-4,73627-2,73649-6,73650-4,74170-2"
+"CPA" "Ceftaroline/avibactam" "Cephalosporins (5th gen.)" "" "NA" "NA" "73604-1,73626-4,73649-6"
+"CAZ" 5481173 "Ceftazidime" "Cephalosporins (3rd gen.)" "J01DD02,QJ01DD02" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "caz,cefta,cfta,cftz,taz,tz,xtz" "ceftazimide,ceptaz,fortam,fortaz,fortum,glazidim,kefazim,modacin,pentacef,tazicef,tizime" 4 "g" "101481-0,101482-8,101483-6,132-1,133-9,134-7,135-4,18893-8,21151-6,3449-6,35774-9,35775-6,35776-4,42352-5,55648-0,55649-8,55650-6,55651-4,58705-5,6995-5,73603-3,73625-6,73648-8,80960-8,87734-0,90850-9"
+"CZA" 90643431 "Ceftazidime/avibactam" "Cephalosporins (3rd gen.)" "J01DD52,QJ01DD52" "cfav" "avycaz,zavicefta" "101483-6,73603-3,73625-6,73648-8,87734-0"
+"CCV" 9575352 "Ceftazidime/clavulanic acid" "Cephalosporins (3rd gen.)" "J01DD52,QJ01DD52" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "czcl,xtzl" "NA" 6 "g" "NA"
+"CEM" 6537431 "Cefteram" "Cephalosporins (3rd gen.)" "J01DD18,QJ01DD18" "NA" "cefterame,cefteramum,ceftetrame" 0.4 "g" "100047-0,76144-5"
+"CPL" 5362114 "Cefteram pivoxil" "Cephalosporins (3rd gen.)" "" "NA" "cefterampivoxil,tomiron" "NA"
+"CTL" 65755 "Ceftezole" "Cephalosporins (1st gen.)" "J01DB12,QJ01DB12" "Other beta-lactam antibacterials" "First-generation cephalosporins" "NA" "alomen,ceftezol,ceftezolesalt,ceftezolo,ceftezolum,celoslin,demethylcefazolin,falomesin" 3 "g" "NA"
+"CTB" 5282242 "Ceftibuten" "Cephalosporins (3rd gen.)" "J01DD14,QJ01DD14" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cb,cfbu,ctb,tib" "cedax,ceftem,ceftibutene,ceftibuteno,ceftibutenum,ceftibutin,ceprifran,isocef,keimax,seftem" 0.4 "g" "35777-2,35778-0,35779-8,6996-3"
"TIO" 6328657 "Ceftiofur" "Cephalosporins (3rd gen.)" "QJ01DD90,QJ51DD90" "NA" "ceftiofurum,excenel,naxcel" "23709-9,35780-6,35781-4,55652-2"
-"CZX" 6533629 "Ceftizoxime" "Cephalosporins (3rd gen.)" "J01DD07" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfzx,ctz,cz,czx,tiz,zox" "cefizox,ceftix,ceftizoxima,ceftizoximesalt,ceftizoximum,eposerin" 4 "g" "136-2,137-0,138-8,139-6,18894-6,20378-6,23622-4,25243-7,3450-4,6997-1"
-"CZP" 9578661 "Ceftizoxime alapivoxil" "Cephalosporins (3rd gen.)" "NA" "NA" "NA" "NA"
-"BPR" 135413542 "Ceftobiprole" "Cephalosporins (5th gen.)" "NA" "NA" "NA" "43269-0,43270-8,43271-6,43272-4,85052-9"
-"CFM1" 135413544 "Ceftobiprole medocaril" "Cephalosporins (5th gen.)" "J01DI01" "Other beta-lactam antibacterials" "Other cephalosporins and penems" "NA" "zevtera" 1.5 "g" "NA"
-"CZT" 86291594 "Ceftolozane/tazobactam" "Cephalosporins (5th gen.)" "J01DI54" "Other beta-lactam antibacterials" "Other cephalosporins and penems" "cei" "zerbaxa" 3 "g" "101484-4,73602-5,73624-9,73647-0,87735-7"
-"CRO" 5479530 "Ceftriaxone" "Cephalosporins (3rd gen.)" "J01DD04" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "axo,cax,cftr,cro,ctr,frx,tx" "biotrakson,ceftriaxon,ceftriaxona,ceftriaxonum,ceftriazone,rocefin,rocephalin,rocephin,rocephine,rophex" 2 "g" "101485-1,140-4,141-2,142-0,143-8,18895-3,25244-5,25367-4,31140-7,31141-5,3451-2,41681-8,41682-6,41683-4,41732-9,50633-7,55190-3,6998-9,80957-4"
-"CEB" "Ceftriaxone/beta-lactamase inhibitor" "Cephalosporins (3rd gen.)" "J01DD63" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "NA" 2 "g" "NA"
-"CXM" 5479529 "Cefuroxime" "Cephalosporins (2nd gen.)" "J01DC02,S01AA27" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cfrx,cfur,cfx,crm,cxm,fur,rox,xm" "anaptivan,biociclin,biofuroksym,bioxima,cefofix,cefumax,cefurex,cefuril,cefurox,cefuroxim,cefuroxima,cefuroximesalt,cefuroximine,cefuroximo,cefuroximum,cephuroxime,cetroxil,colifossim,curoxim,curoxima,curoxime,froxal,furoxil,kefurox,kesint,ketocef,lifurox,medoxim,sharox,spectrazolr,ultroxim,zinacef,zinnat" 0.5 "g" 3 "g" "101503-1,144-6,145-3,146-1,147-9,18896-1,20460-2,25245-2,3452-0,35782-2,35783-0,51724-3,51774-8,55653-0,55654-8,6999-7,74699-0,80608-3,80617-4"
-"CXA" 6321416 "Cefuroxime axetil" "Cephalosporins (2nd gen.)" "NA" "cfax" "bioracef,ceftin,cefurax,cefuroximaxetil,celocid,cepazine,cethixim,cetoxil,coliofossim,curocef,elobact,kalcef,maxitil,medoxm,nivador,novador,novocef,oraxim,zinat,zoref" "NA"
-"CFM2" "Cefuroxime/metronidazole" "Other antibacterials" "J01RA03" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
-"ZON" 6336505 "Cefuzonam" "Other antibacterials" "NA" "NA" "cefuzoname,cefuzonamum,cefzoname,cosmosin" "NA"
-"CED" 38103 "Cephradine" "Cephalosporins (1st gen.)" "J01DB09" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cfra,cfrd" "anspor,cefradin,cefradina,cefradine,cefradinum,cekodin,cephradin,ecosporina,eskacef,infexin,megacef,sefril,velocef,velosef" 2 "g" 2 "g" "168-5,169-3,170-1,171-9,18902-7,55646-4"
-"CTO" 71402 "Cetocycline" "Tetracyclines" "NA" "NA" "cetocyline,cetotetrine,chelocardin" "NA"
-"CHL" 5959 "Chloramphenicol" "Phenicols" "D06AX02,D10AF03,G01AA05,J01BA01,S01AA01,S02AA01,S03AA08" "Amphenicols" "Amphenicols" "c,chl,chlo,cl" "alficetyn,ambofen,amphicol,amseclor,anacetin,aquamycetin,austracil,austracol,biocetin,biophenicol,catilan,chemicetin,chemicetina,chlomin,chlomycol,chloramex,chloramfenikol,chloramficin,chloramfilin,chloramphenicole,chloramphenicolum,chloramsaar,chlorasol,chlorbiotic,chloricol,chlornitromycin,chloroamphenicol,chlorocaps,chlorocid,chlorocide,chlorocin,chlorocol,chlorofair,chloromax,chloromycetin,chloromycetny,chloromyxin,chloronitrin,chloroptic,chlorovules,cidocetine,ciplamycetin,cloramfen,cloramfenicol,cloramfenicolo,cloramficin,cloramicol,cloramidina,cloranfenicol,cloroamfenicolo,clorocyn,cloromisan,clorosintex,comycetin,cylphenicol,desphen,detreomycin,detreomycine,dextramycin,dextromycetin,doctamicina,econochlor,embacetin,emetren,enteromycetin,erbaplast,ertilen,farmicetina,globenicol,glorous,gloveticol,halcetin,halomycetin,hortfenicol,intramycetin,isicetin,ismicetina,isophenicol,juvamycetin,kamaver,kemicetina,kemicetine,kloramfenikol,klorita,laevomycetinum,leukamycin,leukomyan,leukomycin,levocin,levomicetina,levomitsetin,levomycetin,levoplast,levosin,levovetin,loromisan,loromisin,mastiphen,maybridge,mediamycetine,medichol,micloretin,micochlorine,micoclorina,microcetina,mychel,mycinol,myclocin,mycochlorin,novochlorocap,novomycetin,novophenicol,ocuphenicol,oftalent,oleomycetin,opclor,opelor,ophthochlor,ophthocort,ophtochlor,optomycin,otachron,otophen,pantovernil,paraxin,pentamycetin,petnamycetin,quemicetina,rivomycin,romphenil,ronphenil,septicol,sificetina,sintomicetin,sintomicetina,soluthor,stanomycetin,synthomycetin,synthomycetine,synthomycine,syntomycin,tevcocin,tevcosin,tifomycin,tifomycine,tiromycetin,treomicetina,tyfomycine,unimycetin,veticol,viceton" 3 "g" 3 "g" "15101-9,16603-3,16604-1,172-7,173-5,174-3,175-0,18903-5,25247-8,29214-4,29346-4,29347-2,3455-3,7001-1"
-"CTE" 54675777 "Chlortetracycline" "Tetracyclines" "A01AB21,D06AA02,J01AA03,S01AA02" "Tetracyclines" "Tetracyclines" "NA" "acronize,alexomycin,aueromycin,aureocarmyl,aureociclina,aureocina,aureocycline,aureomycin,aureomykoin,aurofac,auxeomycin,biomitsin,biomycin,chlormax,chlorotetracycline,chlortetracyclinum,chrysomykine,clorocipan,clortetraciclina,clortetrin,declomycin,declostatin,deganol,demeclor,demeplus,demetraciclina,demetraclin,detracin,detravis,diuciclin,duomycin,elkamicina,flamycin,isphamycin,ledermicina,ledermycin,ledermycine,mexocine,novotriclina,pennchlor,perciclina,periciclina,sumaclina,uromycin,veraciclina" 1 "g" "176-8,177-6,178-4,179-2,18904-3,55655-5,87600-3"
-"CIC" 19003 "Ciclacillin" "Beta-lactams/penicillins" "NA" "NA" "bastcillin,calthor,ciclacilina,ciclacilline,ciclacillinum,ciclacillum,citosarin,cyclacillin,cyclapen,noblicil,orfilina,peamezin,syngacillin,ultracillin,vastcillin,vipicil,wyvital" "NA"
-"CIX" 47472 "Ciclopirox" "Antifungals/antimycotics" "D01AE14,G01AX12" "Antifungals for topical use" "Other antifungals for topical use" "cipx" "NA" "NA"
-"CIN" 2762 "Cinoxacin" "Quinolones" "J01MB06" "Quinolone antibacterials" "Other quinolones" "cino,cnox" "cinobac,cinobactin,cinoxacine,cinoxacino,cinoxacinum,clinoxacin,noxigram,uronorm" 1 "g" "180-0,181-8,182-6,183-4,18905-0,55656-3"
-"CIP" 2764 "Ciprofloxacin" "Fluoroquinolones" "J01MA02,S01AE03,S02AA15,S03AA07" "Quinolone antibacterials" "Fluoroquinolones" "ci,cip,cipr,cp" "alcipro,bacquinor,baflox,belmacina,bernoflox,catex,cenin,ceprimax,cetraxal,ciflan,ciflosin,cifloxin,cilab,cilox,ciloxan,cipad,ciplus,ciprecu,ciprenit,ciprine,ciprinol,cipro,ciprobay,ciprocinal,ciprocinol,ciprodar,ciproflox,ciprofloxacina,ciprofloxacine,ciprofloxacino,ciprofloxacinum,ciprofur,ciprogis,ciproktan,ciprolin,ciprolon,cipromycin,cipronex,ciprooxacin,cipropol,ciproquinol,ciprowin,ciproxan,ciproxin,ciproxina,ciproxine,ciriax,citeral,citopcin,cixan,corsacin,cunesin,cycin,cyprobay,cyproxan,disfabac,felixene,fimoflox,flociprin,floxacipron,flunas,globuce,inkamil,ipiflox,italnik,keefloxin,linhaliq,loxacid,loxan,lypro,megaflox,microgan,nixin,novidat,novoquin,ofitin,oftacilox,ophaflox,otiprio,phaproxin,piprol,plenolyt,probiox,proflaxin,proksi,proquin,proxacin,quinoflox,quinolid,quintor,quipro,rancif,renator,roflazin,roxytal,sepcen,septicide,septocipro,siprogut,sophixin,spitacin,strox,suiflox,superocin,supraflox,uritent,utiminx,velmonit,zumaflox" 1 "g" 0.8 "g" "101500-7,14031-9,14032-7,14058-2,14059-0,184-2,185-9,186-7,187-5,18906-8,20377-8,23621-6,25180-1,25181-9,25188-4,25189-2,25248-6,34636-1,3484-3,42644-5,55194-5,7002-9"
-"CIM" "Ciprofloxacin/metronidazole" "Fluoroquinolones" "J01RA10" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
-"CIO" "Ciprofloxacin/ornidazole" "Fluoroquinolones" "J01RA12" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
-"CIT" "Ciprofloxacin/tinidazole" "Fluoroquinolones" "J01RA11" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
-"CLR" 84029 "Clarithromycin" "Macrolides/lincosamides" "J01FA09" "Macrolides, lincosamides and streptogramins" "Macrolides" "ch,cla,clar,clm,clr" "abbotic,abboticine,astromen,biaxin,bicrolid,bristamycin,clacee,clacid,clacine,clambiotic,clarem,claribid,claricide,claridar,claripen,clarith,clarithromycine,clarithromycinum,claritromicina,clarosip,clathromycin,crixan,cyllid,cyllind,eratrex,esinol,fromilid,gallimycin,helas,heliclar,klabax,klacid,klaciped,klaricid,klarid,klarin,kofron,mabicrol,macladin,maclar,mavid,meberyt,pediamycin,qidmycin,veclam,wyamycin,zeclar" 0.5 "g" 1 "g" "100048-8,16619-9,16620-7,188-3,189-1,18907-6,190-9,191-7,20375-2,23619-0,25190-0,25191-8,25192-6,25253-6,34638-7,43987-7,43990-1,43991-9,7003-7,80559-8,89485-7"
-"CLA1" 5280980 "Clavulanic acid" "Other antibacterials" "NA" "NA" "amonate,clavulanate,clavulanateacid,clavulansaeure,clavulansaure,clavulox,serdaxin" "NA"
-"CLX" 60063 "Clinafloxacin" "Fluoroquinolones" "NA" "NA" "NA" "32376-6,33284-1,35785-5,35786-3,7004-5"
-"CLI" 446598 "Clindamycin" "Macrolides/lincosamides" "D10AF01,G01AA10,J01FF01" "Macrolides, lincosamides and streptogramins" "Lincosamides" "cc,cd,cli,clin,cm,da" "antirobe,chlolincocin,chlorlincocin,cleocin,clindamicina,clindamycine,clindamycinum,clinimycin,clinsol,clintabs,dalacine,klimicin,klindan,sobelin" 1.2 "g" 1.8 "g" "16621-5,16622-3,18908-4,192-5,193-3,194-1,195-8,25249-4,3486-8,42720-3,55657-1,55658-9,55659-7,55660-5,61188-9,7005-2"
-"CLI-S" "Clindamycin inducible screening test" "Macrolides/lincosamides" "NA" "clin inducible,clinda inducible,clindamycin inducible" "NA" "NA"
-"CLF" 2794 "Clofazimine" "Antimycobacterials" "J04BA01" "Drugs for treatment of lepra" "Drugs for treatment of lepra" "clof" "chlofazimine,clofazimina,clofaziminum,colfazimine,lampren,lamprene,phenazine,riminophenazine" 0.1 "g" "16623-1,20376-0,23620-8,23627-3,43986-9,43988-5,43989-3,55661-3,55662-1,96108-6"
-"CLF1" 2799 "Clofoctol" "Other antibacterials" "J01XX03" "Other antibacterials" "Other antibacterials" "NA" "clofoctolo,clofoctolum,gramplus,octofene,phenol" "NA"
-"CLM" 71807 "Clometocillin" "Beta-lactams/penicillins" "J01CE07" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "chlomethocillin,clometacillin,clomethacillin,clomethocillin,clometocilina,clometocilline,clometocillinsalt,clometocillinum,penicilline,rixapen" 1 "g" "NA"
-"CLM1" 54680675 "Clomocycline" "Tetracyclines" "J01AA11" "Tetracyclines" "Tetracyclines" "NA" "clomociclina,clomocyclinum,megaclor" 1 "g" "NA"
-"CTR" 2812 "Clotrimazole" "Antifungals/antimycotics" "A01AB18,D01AC01,G01AF02" "clot" "alevazol,bisphenyl,canesten,canestene,canestine,canifug,chlotrimazole,clomatin,clotrimaderm,clotrimazol,clotrimazolum,coltrimazole,cutistad,diphenylmethane,empecid,esparol,femmesil,footlogix,fortinia,gynix,imidazole,jidesheng,klotrimazole,lakesia,lombazol,lombazole,lombazolum,lotrimax,lotrimin,monobaycuten,mycelax,mycelex,mycofug,mycosporin,mykosporin,nalbix,otomax,pedesil,pedisafe,ringworm,stiemazol,tibatin,trimysten,trivagizole" "10653-4,10654-2,18909-2,54177-1,55663-9"
-"CLO" 6098 "Cloxacillin" "Beta-lactams/penicillins" "J01CF02" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "clox" "ankerbin,austrastaph,biocloxin,brispen,chloroxacillin,ciclex,clocil,clossacillina,cloxacilina,cloxacillinanhydrous,cloxacilline,cloxacillinsalt,cloxacillinum,cloxapen,constaphyl,dariclox,dichlorstapenor,diclocil,dicloxacillinhydrate,diflor,digloxilline,dynapen,ekvacillin,gelstaph,novapen,noxaben,orbenin,pathocil,stampen,staphybiotic,syntarpen,syntarpensalt,tegopen" 2 "g" 2 "g" "16628-0,18910-0,196-6,197-4,198-2,199-0,25250-2,55664-7"
-"COL" 5311054 "Colistin" "Polymyxins" "A07AA10,J01XB01" "Other antibacterials" "Polymyxins" "cl,coli,cs,cst,ct" "colimycin,colisticin,colisticina,colistina,colistine,colistinum,colobreathe,colomycin,kangdisu,kolimitsin,kolimycin,promixin,sogecoli,totazina" 9 "MU" 9 "MU" "16645-4,18912-6,204-8,205-5,206-3,207-1,29493-4,33333-6"
-"COP" "Colistin/polysorbate" "Other antibacterials" "NA" "NA" "NA" "NA"
-"CYC" 6234 "Cycloserine" "Oxazolidinones" "J04AB01" "Drugs for treatment of tuberculosis" "Antibiotics" "cycl" "cicloserina,closina,cyclorin,cycloserin,cycloserinum,farmiserina,levcicloserina,levcycloserine,levcycloserinum,micoserina,miroserina,miroseryn,novoserin,oxamicina,oxamycin,seromycin,tebemicina,wasserina" 0.75 "g" "16702-3,18914-2,212-1,213-9,214-7,215-4,23608-3,25207-2,25208-0,25209-8,25251-0,3519-6,55667-0"
-"DAL" 23724878 "Dalbavancin" "Glycopeptides" "J01XA04" "Other antibacterials" "Glycopeptide antibacterials" "dalb" "dalbavancina,dalvance,xydalba,zeven" 1.5 "g" "41688-3,41689-1,41690-9,41734-5"
+"CZX" 6533629 "Ceftizoxime" "Cephalosporins (3rd gen.)" "J01DD07,QJ01DD07" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "cfzx,ctz,cz,czx,tiz,zox" "cefizox,ceftix,ceftizoxima,ceftizoximesalt,ceftizoximum,eposerin" 4 "g" "136-2,137-0,138-8,139-6,18894-6,20378-6,23622-4,25243-7,3450-4,6997-1"
+"CZP" 9578661 "Ceftizoxime alapivoxil" "Cephalosporins (3rd gen.)" "" "NA" "NA" "NA"
+"BPR" 135413542 "Ceftobiprole" "Cephalosporins (5th gen.)" "" "NA" "NA" "43269-0,43270-8,43271-6,43272-4,85052-9"
+"CFM1" 135413544 "Ceftobiprole medocaril" "Cephalosporins (5th gen.)" "J01DI01,QJ01DI01" "Other beta-lactam antibacterials" "Other cephalosporins and penems" "NA" "zevtera" 1.5 "g" "NA"
+"CZT" 86291594 "Ceftolozane/tazobactam" "Cephalosporins (5th gen.)" "J01DI54,QJ01DI54" "Other beta-lactam antibacterials" "Other cephalosporins and penems" "cei" "zerbaxa" 3 "g" "101484-4,73602-5,73624-9,73647-0,87735-7"
+"CRO" 5479530 "Ceftriaxone" "Cephalosporins (3rd gen.)" "J01DD04,QJ01DD04" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "axo,cax,cftr,cro,ctr,frx,tx" "biotrakson,ceftriaxon,ceftriaxona,ceftriaxonum,ceftriazone,rocefin,rocephalin,rocephin,rocephine,rophex" 2 "g" "101485-1,140-4,141-2,142-0,143-8,18895-3,25244-5,25367-4,31140-7,31141-5,3451-2,41681-8,41682-6,41683-4,41732-9,50633-7,55190-3,6998-9,80957-4"
+"CEB" "Ceftriaxone/beta-lactamase inhibitor" "Cephalosporins (3rd gen.)" "J01DD63,QJ01DD63" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "NA" "NA" 2 "g" "NA"
+"CXM" 5479529 "Cefuroxime" "Cephalosporins (2nd gen.)" "J01DC02,QJ01DC02,QJ51DC02,QS01AA27,S01AA27" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "cfrx,cfur,cfx,crm,cxm,fur,rox,xm" "anaptivan,biociclin,biofuroksym,bioxima,cefofix,cefumax,cefurex,cefuril,cefurox,cefuroxim,cefuroxima,cefuroximesalt,cefuroximine,cefuroximo,cefuroximum,cephuroxime,cetroxil,colifossim,curoxim,curoxima,curoxime,froxal,furoxil,kefurox,kesint,ketocef,lifurox,medoxim,sharox,spectrazolr,ultroxim,zinacef,zinnat" 0.5 "g" 3 "g" "101503-1,144-6,145-3,146-1,147-9,18896-1,20460-2,25245-2,3452-0,35782-2,35783-0,51724-3,51774-8,55653-0,55654-8,6999-7,74699-0,80608-3,80617-4"
+"CXA" 6321416 "Cefuroxime axetil" "Cephalosporins (2nd gen.)" "" "cfax" "bioracef,ceftin,cefurax,cefuroximaxetil,celocid,cepazine,cethixim,cetoxil,coliofossim,curocef,elobact,kalcef,maxitil,medoxm,nivador,novador,novocef,oraxim,zinat,zoref" "NA"
+"CFM2" "Cefuroxime/metronidazole" "Other antibacterials" "J01DC52,QJ01DC52" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
+"ZON" 6336505 "Cefuzonam" "Other antibacterials" "" "NA" "cefuzoname,cefuzonamum,cefzoname,cosmosin" "NA"
+"CED" 38103 "Cephradine" "Cephalosporins (1st gen.)" "" "Other beta-lactam antibacterials" "First-generation cephalosporins" "cfra,cfrd" "anspor,cefradin,cefradina,cefradine,cefradinum,cekodin,cephradin,ecosporina,eskacef,infexin,megacef,sefril,velocef,velosef" 2 "g" 2 "g" "168-5,169-3,170-1,171-9,18902-7,55646-4"
+"CTO" 71402 "Cetocycline" "Tetracyclines" "" "NA" "cetocyline,cetotetrine,chelocardin" "NA"
+"CHL" 5959 "Chloramphenicol" "Phenicols" "D06AX02,D10AF03,G01AA05,J01BA01,QD06AX02,QD10AF03,QG01AA05,QJ01BA01,QJ51BA01,QS01AA01,QS02AA01,QS03AA08,S01AA01,S02AA01,S03AA08" "Amphenicols" "Amphenicols" "c,chl,chlo,cl" "alficetyn,ambofen,amphicol,amseclor,anacetin,aquamycetin,austracil,austracol,biocetin,biophenicol,catilan,chemicetin,chemicetina,chlomin,chlomycol,chloramex,chloramfenikol,chloramficin,chloramfilin,chloramphenicole,chloramphenicolum,chloramsaar,chlorasol,chlorbiotic,chloricol,chlornitromycin,chloroamphenicol,chlorocaps,chlorocid,chlorocide,chlorocin,chlorocol,chlorofair,chloromax,chloromycetin,chloromycetny,chloromyxin,chloronitrin,chloroptic,chlorovules,cidocetine,ciplamycetin,cloramfen,cloramfenicol,cloramfenicolo,cloramficin,cloramicol,cloramidina,cloranfenicol,cloroamfenicolo,clorocyn,cloromisan,clorosintex,comycetin,cylphenicol,desphen,detreomycin,detreomycine,dextramycin,dextromycetin,doctamicina,econochlor,embacetin,emetren,enteromycetin,erbaplast,ertilen,farmicetina,globenicol,glorous,gloveticol,halcetin,halomycetin,hortfenicol,intramycetin,isicetin,ismicetina,isophenicol,juvamycetin,kamaver,kemicetina,kemicetine,kloramfenikol,klorita,laevomycetinum,leukamycin,leukomyan,leukomycin,levocin,levomicetina,levomitsetin,levomycetin,levoplast,levosin,levovetin,loromisan,loromisin,mastiphen,maybridge,mediamycetine,medichol,micloretin,micochlorine,micoclorina,microcetina,mychel,mycinol,myclocin,mycochlorin,novochlorocap,novomycetin,novophenicol,ocuphenicol,oftalent,oleomycetin,opclor,opelor,ophthochlor,ophthocort,ophtochlor,optomycin,otachron,otophen,pantovernil,paraxin,pentamycetin,petnamycetin,quemicetina,rivomycin,romphenil,ronphenil,septicol,sificetina,sintomicetin,sintomicetina,soluthor,stanomycetin,synthomycetin,synthomycetine,synthomycine,syntomycin,tevcocin,tevcosin,tifomycin,tifomycine,tiromycetin,treomicetina,tyfomycine,unimycetin,veticol,viceton" 3 "g" 3 "g" "15101-9,16603-3,16604-1,172-7,173-5,174-3,175-0,18903-5,25247-8,29214-4,29346-4,29347-2,3455-3,7001-1"
+"CTE" 54675777 "Chlortetracycline" "Tetracyclines" "A01AB21,D06AA02,J01AA03,QA01AB21,QD06AA02,QG51AA08,QJ01AA03,QJ51AA03,QS01AA02,S01AA02" "Tetracyclines" "Tetracyclines" "NA" "acronize,alexomycin,aueromycin,aureocarmyl,aureociclina,aureocina,aureocycline,aureomycin,aureomykoin,aurofac,auxeomycin,biomitsin,biomycin,chlormax,chlorotetracycline,chlortetracyclinum,chrysomykine,clorocipan,clortetraciclina,clortetrin,declomycin,declostatin,deganol,demeclor,demeplus,demetraciclina,demetraclin,detracin,detravis,diuciclin,duomycin,elkamicina,flamycin,isphamycin,ledermicina,ledermycin,ledermycine,mexocine,novotriclina,pennchlor,perciclina,periciclina,sumaclina,uromycin,veraciclina" 1 "g" "176-8,177-6,178-4,179-2,18904-3,55655-5,87600-3"
+"CIC" 19003 "Ciclacillin" "Beta-lactams/penicillins" "" "NA" "bastcillin,calthor,ciclacilina,ciclacilline,ciclacillinum,ciclacillum,citosarin,cyclacillin,cyclapen,noblicil,orfilina,peamezin,syngacillin,ultracillin,vastcillin,vipicil,wyvital" "NA"
+"CIX" 47472 "Ciclopirox" "Antifungals/antimycotics" "D01AE14,G01AX12,QD01AE14,QG01AX12" "Antifungals for topical use" "Other antifungals for topical use" "cipx" "NA" "NA"
+"CIN" 2762 "Cinoxacin" "Quinolones" "J01MB06,QJ01MB06" "Quinolone antibacterials" "Other quinolones" "cino,cnox" "cinobac,cinobactin,cinoxacine,cinoxacino,cinoxacinum,clinoxacin,noxigram,uronorm" 1 "g" "180-0,181-8,182-6,183-4,18905-0,55656-3"
+"CIP" 2764 "Ciprofloxacin" "Fluoroquinolones" "J01MA02,QJ01MA02,QS01AE03,QS02AA15,QS03AA07,S01AE03,S02AA15,S03AA07" "Quinolone antibacterials" "Fluoroquinolones" "ci,cip,cipr,cp" "alcipro,bacquinor,baflox,belmacina,bernoflox,catex,cenin,ceprimax,cetraxal,ciflan,ciflosin,cifloxin,cilab,cilox,ciloxan,cipad,ciplus,ciprecu,ciprenit,ciprine,ciprinol,cipro,ciprobay,ciprocinal,ciprocinol,ciprodar,ciproflox,ciprofloxacina,ciprofloxacine,ciprofloxacino,ciprofloxacinum,ciprofur,ciprogis,ciproktan,ciprolin,ciprolon,cipromycin,cipronex,ciprooxacin,cipropol,ciproquinol,ciprowin,ciproxan,ciproxin,ciproxina,ciproxine,ciriax,citeral,citopcin,cixan,corsacin,cunesin,cycin,cyprobay,cyproxan,disfabac,felixene,fimoflox,flociprin,floxacipron,flunas,globuce,inkamil,ipiflox,italnik,keefloxin,linhaliq,loxacid,loxan,lypro,megaflox,microgan,nixin,novidat,novoquin,ofitin,oftacilox,ophaflox,otiprio,phaproxin,piprol,plenolyt,probiox,proflaxin,proksi,proquin,proxacin,quinoflox,quinolid,quintor,quipro,rancif,renator,roflazin,roxytal,sepcen,septicide,septocipro,siprogut,sophixin,spitacin,strox,suiflox,superocin,supraflox,uritent,utiminx,velmonit,zumaflox" 1 "g" 0.8 "g" "101500-7,14031-9,14032-7,14058-2,14059-0,184-2,185-9,186-7,187-5,18906-8,20377-8,23621-6,25180-1,25181-9,25188-4,25189-2,25248-6,34636-1,3484-3,42644-5,55194-5,7002-9"
+"CIM" "Ciprofloxacin/metronidazole" "Fluoroquinolones" "" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
+"CIO" "Ciprofloxacin/ornidazole" "Fluoroquinolones" "" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
+"CIT" "Ciprofloxacin/tinidazole" "Fluoroquinolones" "" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
+"CLR" 84029 "Clarithromycin" "Macrolides/lincosamides" "J01FA09,QJ01FA09" "Macrolides, lincosamides and streptogramins" "Macrolides" "ch,cla,clar,clm,clr" "abbotic,abboticine,astromen,biaxin,bicrolid,bristamycin,clacee,clacid,clacine,clambiotic,clarem,claribid,claricide,claridar,claripen,clarith,clarithromycine,clarithromycinum,claritromicina,clarosip,clathromycin,crixan,cyllid,cyllind,eratrex,esinol,fromilid,gallimycin,helas,heliclar,klabax,klacid,klaciped,klaricid,klarid,klarin,kofron,mabicrol,macladin,maclar,mavid,meberyt,pediamycin,qidmycin,veclam,wyamycin,zeclar" 0.5 "g" 1 "g" "100048-8,16619-9,16620-7,188-3,189-1,18907-6,190-9,191-7,20375-2,23619-0,25190-0,25191-8,25192-6,25253-6,34638-7,43987-7,43990-1,43991-9,7003-7,80559-8,89485-7"
+"CLA1" 5280980 "Clavulanic acid" "Other antibacterials" "" "NA" "amonate,clavulanate,clavulanateacid,clavulansaeure,clavulansaure,clavulox,serdaxin" "NA"
+"CLX" 60063 "Clinafloxacin" "Fluoroquinolones" "" "NA" "NA" "32376-6,33284-1,35785-5,35786-3,7004-5"
+"CLI" 446598 "Clindamycin" "Macrolides/lincosamides" "D10AF01,G01AA10,J01FF01,QD10AF01,QG01AA10,QJ01FF01" "Macrolides, lincosamides and streptogramins" "Lincosamides" "cc,cd,cli,clin,cm,da" "antirobe,chlolincocin,chlorlincocin,cleocin,clindamicina,clindamycine,clindamycinum,clinimycin,clinsol,clintabs,dalacine,klimicin,klindan,sobelin" 1.2 "g" 1.8 "g" "16621-5,16622-3,18908-4,192-5,193-3,194-1,195-8,25249-4,3486-8,42720-3,55657-1,55658-9,55659-7,55660-5,61188-9,7005-2"
+"CLI-S" "Clindamycin inducible screening test" "Macrolides/lincosamides" "" "clin inducible,clinda inducible,clindamycin inducible" "NA" "NA"
+"CLF" 2794 "Clofazimine" "Antimycobacterials" "J04BA01,QJ04BA01" "Drugs for treatment of lepra" "Drugs for treatment of lepra" "clof" "chlofazimine,clofazimina,clofaziminum,colfazimine,lampren,lamprene,phenazine,riminophenazine" 0.1 "g" "16623-1,20376-0,23620-8,23627-3,43986-9,43988-5,43989-3,55661-3,55662-1,96108-6"
+"CLF1" 2799 "Clofoctol" "Other antibacterials" "J01XX03,QJ01XX03" "Other antibacterials" "Other antibacterials" "NA" "clofoctolo,clofoctolum,gramplus,octofene,phenol" "NA"
+"CLM" 71807 "Clometocillin" "Beta-lactams/penicillins" "J01CE07,QJ01CE07" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "chlomethocillin,clometacillin,clomethacillin,clomethocillin,clometocilina,clometocilline,clometocillinsalt,clometocillinum,penicilline,rixapen" 1 "g" "NA"
+"CLM1" 54680675 "Clomocycline" "Tetracyclines" "J01AA11,QJ01AA11" "Tetracyclines" "Tetracyclines" "NA" "clomociclina,clomocyclinum,megaclor" 1 "g" "NA"
+"CTR" 2812 "Clotrimazole" "Antifungals/antimycotics" "A01AB18,D01AC01,G01AF02,QA01AB18,QD01AC01,QG01AF02,QJ02AB90" "clot" "alevazol,bisphenyl,canesten,canestene,canestine,canifug,chlotrimazole,clomatin,clotrimaderm,clotrimazol,clotrimazolum,coltrimazole,cutistad,diphenylmethane,empecid,esparol,femmesil,footlogix,fortinia,gynix,imidazole,jidesheng,klotrimazole,lakesia,lombazol,lombazole,lombazolum,lotrimax,lotrimin,monobaycuten,mycelax,mycelex,mycofug,mycosporin,mykosporin,nalbix,otomax,pedesil,pedisafe,ringworm,stiemazol,tibatin,trimysten,trivagizole" "10653-4,10654-2,18909-2,54177-1,55663-9"
+"CLO" 6098 "Cloxacillin" "Beta-lactams/penicillins" "J01CF02,QJ01CF02,QJ51CF02,QS01AA90" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "clox" "ankerbin,austrastaph,biocloxin,brispen,chloroxacillin,ciclex,clocil,clossacillina,cloxacilina,cloxacillinanhydrous,cloxacilline,cloxacillinsalt,cloxacillinum,cloxapen,constaphyl,dariclox,dichlorstapenor,diclocil,dicloxacillinhydrate,diflor,digloxilline,dynapen,ekvacillin,gelstaph,novapen,noxaben,orbenin,pathocil,stampen,staphybiotic,syntarpen,syntarpensalt,tegopen" 2 "g" 2 "g" "16628-0,18910-0,196-6,197-4,198-2,199-0,25250-2,55664-7"
+"COL" 5311054 "Colistin" "Polymyxins" "A07AA10,J01XB01,QA07AA10,QJ01XB01,QJ51XB01" "Other antibacterials" "Polymyxins" "cl,coli,cs,cst,ct" "colimycin,colisticin,colisticina,colistina,colistine,colistinum,colobreathe,colomycin,kangdisu,kolimitsin,kolimycin,promixin,sogecoli,totazina" 9 "MU" 9 "MU" "16645-4,18912-6,204-8,205-5,206-3,207-1,29493-4,33333-6"
+"COP" "Colistin/polysorbate" "Other antibacterials" "" "NA" "NA" "NA"
+"CYC" 6234 "Cycloserine" "Oxazolidinones" "J04AB01,QJ04AB01" "Drugs for treatment of tuberculosis" "Antibiotics" "cycl" "cicloserina,closina,cyclorin,cycloserin,cycloserinum,farmiserina,levcicloserina,levcycloserine,levcycloserinum,micoserina,miroserina,miroseryn,novoserin,oxamicina,oxamycin,seromycin,tebemicina,wasserina" 0.75 "g" "16702-3,18914-2,212-1,213-9,214-7,215-4,23608-3,25207-2,25208-0,25209-8,25251-0,3519-6,55667-0"
+"DAL" 23724878 "Dalbavancin" "Glycopeptides" "J01XA04,QJ01XA04" "Other antibacterials" "Glycopeptide antibacterials" "dalb" "dalbavancina,dalvance,xydalba,zeven" 1.5 "g" "41688-3,41689-1,41690-9,41734-5"
"DAN" 71335 "Danofloxacin" "Fluoroquinolones" "QJ01MA92" "NA" "advocin,danofloxacine,danofloxacino,danofloxacinum" "73601-7,73623-1,73646-2"
-"DPS" 2955 "Dapsone" "Other antibacterials" "D10AX05,J04BA02" "Drugs for treatment of lepra" "Drugs for treatment of lepra" "NA" "aczone,atrisone,avlosulfon,avlosulfone,avlosulphone,benzenamide,benzenamine,bissulfone,bissulphone,croysulfone,croysulphone,dapson,dapsona,dapsonum,daspone,diaphenylsulfon,diaphenylsulfone,diaphenylsulphon,diaphenylsulphone,diphenasone,diphone,disulfone,disulone,disulphone,dubronax,dumitone,eporal,medapsol,novophone,servidapson,sulfadione,sulfona,sulfonyldianiline,sulphadione,sulphonyldianiline,tarimyl,udolac,undolac" 50 "mg" "51698-9,9747-7"
-"DAP" 16134395 "Daptomycin" "Other antibacterials" "J01XX09" "Other antibacterials" "Other antibacterials" "dap,dapt" "cidecin,cubicin,dapcin,daptomicina,daptomycine,daptomycinum,deptomycin" 0.28 "g" "35787-1,35788-9,35789-7,41691-7"
-"DFX" 487101 "Delafloxacin" "Fluoroquinolones" "J01MA23" "NA" "baxdela,delafloxacinum,quofenix" 0.9 "g" 0.6 "g" "88885-9,90447-4,93790-4"
-"DLM" 6480466 "Delamanid" "Antimycobacterials" "J04AK06" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "dela" "deltyba" 0.2 "g" "93851-4,96109-4"
-"DEM" 54680690 "Demeclocycline" "Tetracyclines" "D06AA01,J01AA01" "Tetracyclines" "Tetracyclines" "NA" "demeclociclina,demeclocyclinum" 0.6 "g" "10982-7,18915-9,216-2,217-0,218-8,219-6,29494-2,7006-0"
-"DKB" 470999 "Dibekacin" "Aminoglycosides" "J01GB09,S01AA29" "Aminoglycoside antibacterials" "Other aminoglycosides" "NA" "debecacin,dibekacina,dibekacine,dibekacinum,kappati,panamicin" 0.14 "g" "55669-6,55670-4,55671-2,55672-0"
-"DIC" 18381 "Dicloxacillin" "Beta-lactams/penicillins" "J01CF01" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "dicl" "dichloroxacillin,diclossacillina,dicloxaciclin,dicloxacilin,dicloxacilina,dicloxacillina,dicloxacilline,dicloxacillinum,dicloxacycline,maclicine" 2 "g" 2 "g" "10984-3,16769-2,18916-7,220-4,221-2,222-0,223-8,25252-8,32380-8,55668-8"
+"DPS" 2955 "Dapsone" "Other antibacterials" "D10AX05,J04BA02,QD10AX05,QJ04BA02" "Drugs for treatment of lepra" "Drugs for treatment of lepra" "NA" "aczone,atrisone,avlosulfon,avlosulfone,avlosulphone,benzenamide,benzenamine,bissulfone,bissulphone,croysulfone,croysulphone,dapson,dapsona,dapsonum,daspone,diaphenylsulfon,diaphenylsulfone,diaphenylsulphon,diaphenylsulphone,diphenasone,diphone,disulfone,disulone,disulphone,dubronax,dumitone,eporal,medapsol,novophone,servidapson,sulfadione,sulfona,sulfonyldianiline,sulphadione,sulphonyldianiline,tarimyl,udolac,undolac" 50 "mg" "51698-9,9747-7"
+"DAP" 16134395 "Daptomycin" "Other antibacterials" "J01XX09,QJ01XX09" "Other antibacterials" "Other antibacterials" "dap,dapt" "cidecin,cubicin,dapcin,daptomicina,daptomycine,daptomycinum,deptomycin" 0.28 "g" "35787-1,35788-9,35789-7,41691-7"
+"DFX" 487101 "Delafloxacin" "Fluoroquinolones" "J01MA23,QJ01MA23" "NA" "baxdela,delafloxacinum,quofenix" 0.9 "g" 0.6 "g" "88885-9,90447-4,93790-4"
+"DLM" 6480466 "Delamanid" "Antimycobacterials" "J04AK06,QJ04AK06" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "dela" "deltyba" 0.2 "g" "93851-4,96109-4"
+"DEM" 54680690 "Demeclocycline" "Tetracyclines" "D06AA01,J01AA01,QD06AA01,QJ01AA01" "Tetracyclines" "Tetracyclines" "NA" "demeclociclina,demeclocyclinum" 0.6 "g" "10982-7,18915-9,216-2,217-0,218-8,219-6,29494-2,7006-0"
+"DKB" 470999 "Dibekacin" "Aminoglycosides" "J01GB09,QJ01GB09,QS01AA29,S01AA29" "Aminoglycoside antibacterials" "Other aminoglycosides" "NA" "debecacin,dibekacina,dibekacine,dibekacinum,kappati,panamicin" 0.14 "g" "55669-6,55670-4,55671-2,55672-0"
+"DIC" 18381 "Dicloxacillin" "Beta-lactams/penicillins" "J01CF01,QJ01CF01,QJ51CF01" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "dicl" "dichloroxacillin,diclossacillina,dicloxaciclin,dicloxacilin,dicloxacilina,dicloxacillina,dicloxacilline,dicloxacillinum,dicloxacycline,maclicine" 2 "g" 2 "g" "10984-3,16769-2,18916-7,220-4,221-2,222-0,223-8,25252-8,32380-8,55668-8"
"DIF" 56206 "Difloxacin" "Fluoroquinolones" "QJ01MA94" "NA" "dicural,difloxacine,pulsaflox" "35790-5,35791-3,35792-1"
-"DIR" 6473883 "Dirithromycin" "Macrolides/lincosamides" "J01FA13" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "dirithromycine,dirithromycinum,diritromicina,divitross,dynabac,noriclan,valodin" 0.5 "g" "35793-9,35794-7,35795-4,7007-8"
-"DOR" 73303 "Doripenem" "Carbapenems" "J01DH04" "Other beta-lactam antibacterials" "Carbapenems" "dori" "doribax,dripenem,finibax" 1.5 "g" "56031-8,58711-3,60535-2,72893-1"
-"DOX" 54671203 "Doxycycline" "Tetracyclines" "A01AB22,J01AA02" "Tetracyclines" "Tetracyclines" "dox,doxy" "abbocin,alamycin,aquacycline,biosolvomycin,biotet,bisolvomycin,chrysocin,dalimycin,dalinmycin,deoxymykoin,dossiciclina,doxiciclina,doxirobe,doxitard,doxivetin,doxycen,doxychel,doxycin,doxycyclin,doxycyclinum,doxylin,doxysol,doxytetracycline,elinton,engemycin,hydrocyclin,imperacin,intaloxin,investin,jenacyclin,liquachel,liviatin,macodyn,mepatar,microdox,mondoxyne,monodox,morgidox,ocudox,okebo,oracea,otetryn,oxacycline,oxamycen,oxatet,oxlopar,oxybiocycline,oxydon,oxyject,oxymykoin,oxysteclin,oxytet,oxytetral,oxytetrin,oxytracyl,oxyvet,stecsolin,supracyclin,terraject,terramycin,toxinal,unimycin,vendarcin,vibramycin,vibramycine,vivox,zenavod" 0.1 "g" 0.1 "g" "10986-8,18917-5,20379-4,21250-6,224-6,225-3,226-1,227-9,23623-2,25223-9,26902-7,7008-6"
-"ECO" 3198 "Econazole" "Antifungals/antimycotics" "D01AC03,G01AF05" "Antifungals for topical use" "Imidazole and triazole derivatives" "econ" "bromazil,chloramizol,clinafarm,deccosil,deccozil,econazolum,ecostatin,ekonazole,enilconazol,enilconazole,eniloconazol,fecundal,florasan,freshgard,freshguard,fungaflor,fungazil,imaverol,imaversol,imazalil,magnate,spectazole" "25595-0,25637-0,54178-9,55673-8"
-"EFF" "Efflux" "Other" "NA" "effflux pump" "NA" "NA"
-"ENX" 3229 "Enoxacin" "Fluoroquinolones" "J01MA04" "Quinolone antibacterials" "Fluoroquinolones" "enox" "abenox,almitil,bactidan,bactidron,comprecin,enofloxacine,enoksetin,enoram,enoxacina,enoxacine,enoxacino,enoxacinum,enoxen,enoxin,enoxor,flumark,penetrex" 0.8 "g" "16816-1,18918-3,228-7,229-5,230-3,231-1,3590-7,41692-5"
+"DIR" 6473883 "Dirithromycin" "Macrolides/lincosamides" "J01FA13,QJ01FA13" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "dirithromycine,dirithromycinum,diritromicina,divitross,dynabac,noriclan,valodin" 0.5 "g" "35793-9,35794-7,35795-4,7007-8"
+"DOR" 73303 "Doripenem" "Carbapenems" "J01DH04,QJ01DH04" "Other beta-lactam antibacterials" "Carbapenems" "dori" "doribax,dripenem,finibax" 1.5 "g" "56031-8,58711-3,60535-2,72893-1"
+"DOX" 54671203 "Doxycycline" "Tetracyclines" "A01AB22,J01AA02,QA01AB22,QJ01AA02" "Tetracyclines" "Tetracyclines" "dox,doxy" "abbocin,alamycin,aquacycline,biosolvomycin,biotet,bisolvomycin,chrysocin,dalimycin,dalinmycin,deoxymykoin,dossiciclina,doxiciclina,doxirobe,doxitard,doxivetin,doxycen,doxychel,doxycin,doxycyclin,doxycyclinum,doxylin,doxysol,doxytetracycline,elinton,engemycin,hydrocyclin,imperacin,intaloxin,investin,jenacyclin,liquachel,liviatin,macodyn,mepatar,microdox,mondoxyne,monodox,morgidox,ocudox,okebo,oracea,otetryn,oxacycline,oxamycen,oxatet,oxlopar,oxybiocycline,oxydon,oxyject,oxymykoin,oxysteclin,oxytet,oxytetral,oxytetrin,oxytracyl,oxyvet,stecsolin,supracyclin,terraject,terramycin,toxinal,unimycin,vendarcin,vibramycin,vibramycine,vivox,zenavod" 0.1 "g" 0.1 "g" "10986-8,18917-5,20379-4,21250-6,224-6,225-3,226-1,227-9,23623-2,25223-9,26902-7,7008-6"
+"ECO" 3198 "Econazole" "Antifungals/antimycotics" "D01AC03,G01AF05,QD01AC03,QG01AF05" "Antifungals for topical use" "Imidazole and triazole derivatives" "econ" "bromazil,chloramizol,clinafarm,deccosil,deccozil,econazolum,ecostatin,ekonazole,enilconazol,enilconazole,eniloconazol,fecundal,florasan,freshgard,freshguard,fungaflor,fungazil,imaverol,imaversol,imazalil,magnate,spectazole" "25595-0,25637-0,54178-9,55673-8"
+"EFF" "Efflux" "Other" "" "effflux pump" "NA" "NA"
+"ENX" 3229 "Enoxacin" "Fluoroquinolones" "J01MA04,QJ01MA04" "Quinolone antibacterials" "Fluoroquinolones" "enox" "abenox,almitil,bactidan,bactidron,comprecin,enofloxacine,enoksetin,enoram,enoxacina,enoxacine,enoxacino,enoxacinum,enoxen,enoxin,enoxor,flumark,penetrex" 0.8 "g" "16816-1,18918-3,228-7,229-5,230-3,231-1,3590-7,41692-5"
"ENR" 71188 "Enrofloxacin" "Fluoroquinolones" "QJ01MA90" "NA" "baytril,enroflox,enrofloxacine,enrofloxacino,enrofloxacinum,enroquin,enrosite,enroxil,quellaxcin,tenotryl,zobuxa" "23712-3,35796-2,35797-0,35798-8"
-"ENV" 135565326 "Enviomycin" "Antimycobacterials" "J04AB06" "tuberactinomycin" "enviomicina,enviomycina,enviomycine,enviomycinum,tuberactin" 1 "g" "NA"
-"EPE" "Eperozolid" "Other antibacterials" "NA" "NA" "NA" "NA"
-"EPC" 71392 "Epicillin" "Beta-lactams/penicillins" "J01CA07" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "dexacillin,dihydroampicillin,epicilina,epicilline,epicillinum,spectacillin" 2 "g" 2 "g" "NA"
-"EPP" 68916 "Epiroprim" "Other antibacterials" "NA" "NA" "epiroprima,epiroprime,epiroprimum" "NA"
-"ERV" 54726192 "Eravacycline" "Tetracyclines" "J01AA13" "Tetracyclines" "Tetracyclines" "erav" "xerava" 0.14 "g" "100049-6,85423-2,93767-2"
-"ETP" 150610 "Ertapenem" "Carbapenems" "J01DH03" "Other beta-lactam antibacterials" "Carbapenems" "erta,etp" "ertapenemsalt,invanz" 1 "g" "101486-9,35799-6,35800-2,35801-0,35802-8"
-"ERY" 12560 "Erythromycin" "Macrolides/lincosamides" "D10AF02,J01FA01,S01AA17" "Macrolides, lincosamides and streptogramins" "Macrolides" "e,em,ery,eryt" "abboticin,abomacetin,acneryne,acnesol,aknemycin,aknin,benzamycin,derimer,deripil,dotycin,dumotrycin,emgel,emuvin,emycin,endoeritrin,erecin,erisone,eritomicina,eritrocina,eritromicina,ermycin,eryacne,eryacnen,erycen,erycette,erycinum,eryderm,erydermer,erygel,eryhexal,erymax,erymed,erysafe,erytab,erythro,erythroderm,erythrogran,erythroguent,erythromast,erythromid,erythromycine,erythromycinum,erytop,erytrociclin,ilocaps,ilosone,iloticina,ilotycin,inderm,latotryd,lederpax,mephamycin,mercina,oftamolets,pantoderm,pantodrin,pantomicina,pharyngocin,primacine,propiocine,proterytrin,retcin,robimycin,sansac,spotex,staticin,stiemicyn,stiemycin,tiprocin,torlamicina,wemid" 2 "g" 1 "g" "100050-4,11576-6,12298-6,16829-4,16830-2,18919-1,18920-9,20380-2,232-9,233-7,234-5,235-2,236-0,23633-1,237-8,238-6,239-4,25224-7,25275-9,3597-2,7009-4"
-"ETH" 14052 "Ethambutol" "Antimycobacterials" "J04AK02" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "etha" "aethambutolum,dadibutol,diambutol,etambutol,etambutolo,ethambutolum,myambutol,purderal,servambutol,tibutol" 1.2 "g" 1.2 "g" "100051-2,16841-9,18921-7,20381-0,23625-7,240-2,241-0,242-8,243-6,25187-6,25194-2,25195-9,25230-4,25404-5,3607-9,42645-2,42646-0,55154-9,55674-6,56025-0,7010-2,89491-5"
-"ETI" 456476 "Ethambutol/isoniazid" "Antimycobacterials" "J04AM03" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA"
-"ETI1" 2761171 "Ethionamide" "Antimycobacterials" "J04AD03" "Drugs for treatment of tuberculosis" "Thiocarbamide derivatives" "ethi" "aethionamidum,aetina,aetiva,amidazin,amidazine,atina,ethimide,ethina,ethinamide,ethionamidum,ethioniamide,ethylisothiamide,ethyonomide,etimid,etiocidan,etionamid,etionamida,etionamide,etioniamid,etionid,etionizin,etionizina,etionizine,fatoliamid,iridocin,iridozin,isothin,isotiamida,itiocide,nicotion,nisotin,nizotin,rigenicid,sertinon,teberus,thianid,thianide,thioamide,thiodine,thiomid,thioniden,tianid,tiomid,trecator,trekator,trescatyl,trescazide,tubenamide,tubermin,tuberoid,tuberoson" 0.75 "g" "16099-4,16845-0,18922-5,20382-8,23617-4,25183-5,25196-7,25198-3,25231-2,41693-3,42647-8,42648-6,7011-0,96110-2"
+"ENV" 135565326 "Enviomycin" "Antimycobacterials" "J04AB06,QJ04AB06" "tuberactinomycin" "enviomicina,enviomycina,enviomycine,enviomycinum,tuberactin" 1 "g" "NA"
+"EPE" "Eperozolid" "Other antibacterials" "" "NA" "NA" "NA"
+"EPC" 71392 "Epicillin" "Beta-lactams/penicillins" "J01CA07,QJ01CA07" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "dexacillin,dihydroampicillin,epicilina,epicilline,epicillinum,spectacillin" 2 "g" 2 "g" "NA"
+"EPP" 68916 "Epiroprim" "Other antibacterials" "" "NA" "epiroprima,epiroprime,epiroprimum" "NA"
+"ERV" 54726192 "Eravacycline" "Tetracyclines" "J01AA13,QJ01AA13" "Tetracyclines" "Tetracyclines" "erav" "xerava" 0.14 "g" "100049-6,85423-2,93767-2"
+"ETP" 150610 "Ertapenem" "Carbapenems" "J01DH03,QJ01DH03" "Other beta-lactam antibacterials" "Carbapenems" "erta,etp" "ertapenemsalt,invanz" 1 "g" "101486-9,35799-6,35800-2,35801-0,35802-8"
+"ERY" 12560 "Erythromycin" "Macrolides/lincosamides" "D10AF02,J01FA01,QD10AF02,QJ01FA01,QJ51FA01,QS01AA17,S01AA17" "Macrolides, lincosamides and streptogramins" "Macrolides" "e,em,ery,eryt" "abboticin,abomacetin,acneryne,acnesol,aknemycin,aknin,benzamycin,derimer,deripil,dotycin,dumotrycin,emgel,emuvin,emycin,endoeritrin,erecin,erisone,eritomicina,eritrocina,eritromicina,ermycin,eryacne,eryacnen,erycen,erycette,erycinum,eryderm,erydermer,erygel,eryhexal,erymax,erymed,erysafe,erytab,erythro,erythroderm,erythrogran,erythroguent,erythromast,erythromid,erythromycine,erythromycinum,erytop,erytrociclin,ilocaps,ilosone,iloticina,ilotycin,inderm,latotryd,lederpax,mephamycin,mercina,oftamolets,pantoderm,pantodrin,pantomicina,pharyngocin,primacine,propiocine,proterytrin,retcin,robimycin,sansac,spotex,staticin,stiemicyn,stiemycin,tiprocin,torlamicina,wemid" 2 "g" 1 "g" "100050-4,11576-6,12298-6,16829-4,16830-2,18919-1,18920-9,20380-2,232-9,233-7,234-5,235-2,236-0,23633-1,237-8,238-6,239-4,25224-7,25275-9,3597-2,7009-4"
+"ETH" 14052 "Ethambutol" "Antimycobacterials" "J04AK02,QJ04AK02" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "etha" "aethambutolum,dadibutol,diambutol,etambutol,etambutolo,ethambutolum,myambutol,purderal,servambutol,tibutol" 1.2 "g" 1.2 "g" "100051-2,16841-9,18921-7,20381-0,23625-7,240-2,241-0,242-8,243-6,25187-6,25194-2,25195-9,25230-4,25404-5,3607-9,42645-2,42646-0,55154-9,55674-6,56025-0,7010-2,89491-5"
+"ETI" 456476 "Ethambutol/isoniazid" "Antimycobacterials" "" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA"
+"ETI1" 2761171 "Ethionamide" "Antimycobacterials" "J04AD03,QJ04AD03" "Drugs for treatment of tuberculosis" "Thiocarbamide derivatives" "ethi" "aethionamidum,aetina,aetiva,amidazin,amidazine,atina,ethimide,ethina,ethinamide,ethionamidum,ethioniamide,ethylisothiamide,ethyonomide,etimid,etiocidan,etionamid,etionamida,etionamide,etioniamid,etionid,etionizin,etionizina,etionizine,fatoliamid,iridocin,iridozin,isothin,isotiamida,itiocide,nicotion,nisotin,nizotin,rigenicid,sertinon,teberus,thianid,thianide,thioamide,thiodine,thiomid,thioniden,tianid,tiomid,trecator,trekator,trescatyl,trescazide,tubenamide,tubermin,tuberoid,tuberoson" 0.75 "g" "16099-4,16845-0,18922-5,20382-8,23617-4,25183-5,25196-7,25198-3,25231-2,41693-3,42647-8,42648-6,7011-0,96110-2"
"ETO" 6034 "Ethopabate" "Other antibacterials" "QP51AX17" "NA" "ethopabat" "NA"
-"EXE" "Exebacase" "NA" "NA" "NA" "NA"
-"FAR" 65894 "Faropenem" "Other antibacterials" "J01DI03" "Other beta-lactam antibacterials" "Other cephalosporins and penems" "NA" "farom,faropenemhydrate,faropenemsalt,fropenem,fropenum,furopenem" 0.75 "g" "73600-9,73622-3,73645-4"
-"FDX" 10034073 "Fidaxomicin" "Other antibacterials" "A07AA12" "NA" "dificid,dificlir,difimicin,fidaxomicina,lipiarmicin,lipiarmycin,lipiarrmycin" 0.4 "g" "73599-3,73621-5,73644-7"
-"FIN" 11567473 "Finafloxacin" "Fluoroquinolones" "NA" "NA" "xtoro" "73598-5,73620-7,73643-9"
-"FLA" 46783781 "Flavomycin" "Other antibacterials" "NA" "NA" "bambermicina,bambermycine,bambermycinum,flavofosfolipol,flavophospholipol,gainpro,menomycin" "NA"
-"FLE" 3357 "Fleroxacin" "Fluoroquinolones" "J01MA08" "Quinolone antibacterials" "Fluoroquinolones" "fler" "fleroxacine,fleroxacino,fleroxacinum,fleroxicin,megalocin,megalone,megalosin,quinodis" 0.4 "g" 0.4 "g" "25411-0,32372-5,35806-9,7012-8"
-"FLO" 65864 "Flomoxef" "Other antibacterials" "J01DC14" "NA" "flomoxefo,flomoxefsalt,flomoxefum,flumarin" 2 "g" "100052-0,53822-3"
+"EXE" "Exebacase" "" "NA" "NA" "NA"
+"FAR" 65894 "Faropenem" "Other antibacterials" "J01DI03,QJ01DI03" "Other beta-lactam antibacterials" "Other cephalosporins and penems" "NA" "farom,faropenemhydrate,faropenemsalt,fropenem,fropenum,furopenem" 0.75 "g" "73600-9,73622-3,73645-4"
+"FDX" 10034073 "Fidaxomicin" "Other antibacterials" "A07AA12,QA07AA12" "NA" "dificid,dificlir,difimicin,fidaxomicina,lipiarmicin,lipiarmycin,lipiarrmycin" 0.4 "g" "73599-3,73621-5,73644-7"
+"FIN" 11567473 "Finafloxacin" "Fluoroquinolones" "" "NA" "xtoro" "73598-5,73620-7,73643-9"
+"FLA" 46783781 "Flavomycin" "Other antibacterials" "" "NA" "bambermicina,bambermycine,bambermycinum,flavofosfolipol,flavophospholipol,gainpro,menomycin" "NA"
+"FLE" 3357 "Fleroxacin" "Fluoroquinolones" "J01MA08,QJ01MA08" "Quinolone antibacterials" "Fluoroquinolones" "fler" "fleroxacine,fleroxacino,fleroxacinum,fleroxicin,megalocin,megalone,megalosin,quinodis" 0.4 "g" 0.4 "g" "25411-0,32372-5,35806-9,7012-8"
+"FLO" 65864 "Flomoxef" "Other antibacterials" "J01DC14,QJ01DC14" "NA" "flomoxefo,flomoxefsalt,flomoxefum,flumarin" 2 "g" "100052-0,53822-3"
"FLR" 114811 "Florfenicol" "Phenicols" "QJ01BA90,QJ51BA90" "NA" "aquafen,descocin,dexawin,efnicol,fricol,hyrazin,loncor,macphenicol,masatirin,neomyson,norfenicol,nuflor,racephenicol,rincrol,thiamcol,urfamicina,urophenyl" "23740-4,35807-7,35808-5,87599-7"
-"FLC" 21319 "Flucloxacillin" "Beta-lactams/penicillins" "J01CF05" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "clox,flux" "bactopen,cloxacap,cloxacillinhydrate,cloxypen,floxacillin,floxacillinanhydrous,floxapen,floxapensalt,fluclomix,flucloxacilina,flucloxacilline,flucloxacillinum,flucloxin,fluorochloroxacillin,galfloxin,latocillin,orbeninhydrate,rimaflox,staphobristol,zoxin" 2 "g" 2 "g" "NA"
-"FLU" 3365 "Fluconazole" "Antifungals/antimycotics" "D01AC15,J02AC01" "Antimycotics for systemic use" "Triazole derivatives" "fluc,fluz,flz" "alflucoz,alkanazole,baten,biocanol,biozole,biozolene,canzol,cryptal,diflazon,diflucan,dimycon,elazor,flucazol,fluconazoli,fluconazolum,flucoral,flucostat,flukezol,flunazol,flunizol,fluzon,forcan,fuconal,fungata,loitin,mutum,oxifugol,pritenzol,syscan,trican,triconal,triflucan,zemyc,zoltec,zonal" 0.2 "g" 0.2 "g" "10987-6,16870-8,18924-1,248-5,249-3,250-1,251-9,25255-1,7013-6,80530-9"
-"FCT" 3366 "Flucytosine" "Antifungals/antimycotics" "D01AE21,J02AX01" "Antifungals for topical use" "Other antifungals for topical use" "5flc,fcu,fluo,fluy" "alcobon,ancoban,ancobon,ancotil,ancotyl,flourocytosine,flucitosina,flucytosin,flucytosinum,flucytosone,fluocytosine,fluorcytosine,fluorocytosine" 10 "g" 10 "g" "NA"
-"FLM" 3374 "Flumequine" "Quinolones" "J01MB07" "Quinolone antibacterials" "Other quinolones" "NA" "apurone,fantacin,flumequina,flumequino,flumequinum,flumigal,flumiquil,flumisol,flumix,imequyl" 1.2 "g" "55675-3,55676-1,55677-9,55678-7"
-"FLR1" 71260 "Flurithromycin" "Macrolides/lincosamides" "J01FA14" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "abbot,beritromicina,berythromycin,berythromycine,berythromycinum,flurithromycine,flurithromycinum,fluritromicina,fluritromycinum,flurizic,mizar" 0.75 "g" "NA"
-"FFL" 214356 "Fosfluconazole" "Antifungals/antimycotics" "NA" "NA" "fosfluconazol,procif,prodif" "NA"
-"FOS" 446987 "Fosfomycin" "Other antibacterials" "J01XX01,S02AA17" "Other antibacterials" "Other antibacterials" "ff,fm,fo,fof,fos,fosf" "fosfocina,fosfomicin,fosfomicina,fosfomycine,fosfomycinum,fosfonomycin,infectophos,phosphonemycin,phosphonomycin,veramina" 3 "g" 8 "g" "25596-8,25653-7,35809-3,35810-1"
-"FMD" 572 "Fosmidomycin" "Other antibacterials" "NA" "NA" "fosmidomicina,fosmidomycina,fosmidomycine,fosmidomycinsalt,fosmidomycinum" "NA"
-"FRM" 8378 "Framycetin" "Aminoglycosides" "D09AA01,R01AX08,S01AA07" "fram" "actilin,actiline,antibiotique,bycomycin,enterfram,fradiomycin,fradiomycinum,framicetina,framidal,framycetine,framycetinum,framycin,framygen,francetin,jernadex,myacyne,mycerin,mycifradin,neobrettin,neolate,neomas,neomcin,neomicina,neomin,neomycine,neomycinum,nivemycin,soframycin,soframycine" "18926-6,257-6,258-4,259-2,260-0,55679-5"
-"FUR" 6870646 "Furazidin" "Other antibacterials" "J01XE03" "Other antibacterials" "Nitrofuran derivatives" "NA" "akritoin,furagin,furaginum,furamag,furazidine,hydantoin" 0.3 "g" "NA"
-"FRZ" 5323714 "Furazolidone" "Other antibacterials" "G01AX06" "NA" "bifuron,corizium,coryzium,diafuron,enterotoxon,furall,furanzolidone,furaxon,furaxone,furazolidine,furazolidon,furazolidona,furazolidonum,furazolum,furidon,furmethoxadone,furovag,furoxal,furoxane,furoxon,furoxone,furozolidine,giardil,giarlam,medaron,neftin,nicolen,nifulidone,nifuran,nifurazolidone,nifurazolidonum,nitrofuradoxon,nitrofurazolidone,nitrofurazolidonum,nitrofuroxon,optazol,ortazol,puradin,roptazol,sclaventerol,tikofuran,topazone,trichofuron,tricofuron,tricoron,trifurox,viofuragyn" "69574-2,87794-4"
-"FUS" 3000226 "Fusidic acid" "Other antibacterials" "D06AX01,D09AA02,J01XC01,S01AA13" "Other antibacterials" "Steroid antibacterials" "fa,fusi" "flucidin,fucidate,fucidina,fucidine,fucithalmic,fusidate,fusidicacid,fusidin,fusidine,taksta" 1.5 "g" 1.5 "g" "NA"
+"FLC" 21319 "Flucloxacillin" "Beta-lactams/penicillins" "J01CF05,QJ01CF05,QJ51CF05" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "clox,flux" "bactopen,cloxacap,cloxacillinhydrate,cloxypen,floxacillin,floxacillinanhydrous,floxapen,floxapensalt,fluclomix,flucloxacilina,flucloxacilline,flucloxacillinum,flucloxin,fluorochloroxacillin,galfloxin,latocillin,orbeninhydrate,rimaflox,staphobristol,zoxin" 2 "g" 2 "g" "NA"
+"FLU" 3365 "Fluconazole" "Antifungals/antimycotics" "D01AC15,J02AC01,QD01AC15,QJ02AC01" "Antimycotics for systemic use" "Triazole derivatives" "fluc,fluz,flz" "alflucoz,alkanazole,baten,biocanol,biozole,biozolene,canzol,cryptal,diflazon,diflucan,dimycon,elazor,flucazol,fluconazoli,fluconazolum,flucoral,flucostat,flukezol,flunazol,flunizol,fluzon,forcan,fuconal,fungata,loitin,mutum,oxifugol,pritenzol,syscan,trican,triconal,triflucan,zemyc,zoltec,zonal" 0.2 "g" 0.2 "g" "10987-6,16870-8,18924-1,248-5,249-3,250-1,251-9,25255-1,7013-6,80530-9"
+"FCT" 3366 "Flucytosine" "Antifungals/antimycotics" "D01AE21,J02AX01,QD01AE21,QJ02AX01" "Antifungals for topical use" "Other antifungals for topical use" "5flc,fcu,fluo,fluy" "alcobon,ancoban,ancobon,ancotil,ancotyl,flourocytosine,flucitosina,flucytosin,flucytosinum,flucytosone,fluocytosine,fluorcytosine,fluorocytosine" 10 "g" 10 "g" "NA"
+"FLM" 3374 "Flumequine" "Quinolones" "J01MB07,QJ01MB07" "Quinolone antibacterials" "Other quinolones" "NA" "apurone,fantacin,flumequina,flumequino,flumequinum,flumigal,flumiquil,flumisol,flumix,imequyl" 1.2 "g" "55675-3,55676-1,55677-9,55678-7"
+"FLR1" 71260 "Flurithromycin" "Macrolides/lincosamides" "J01FA14,QJ01FA14" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "abbot,beritromicina,berythromycin,berythromycine,berythromycinum,flurithromycine,flurithromycinum,fluritromicina,fluritromycinum,flurizic,mizar" 0.75 "g" "NA"
+"FFL" 214356 "Fosfluconazole" "Antifungals/antimycotics" "" "NA" "fosfluconazol,procif,prodif" "NA"
+"FOS" 446987 "Fosfomycin" "Other antibacterials" "J01XX01,QJ01XX01,QS02AA17,S02AA17" "Other antibacterials" "Other antibacterials" "ff,fm,fo,fof,fos,fosf" "fosfocina,fosfomicin,fosfomicina,fosfomycine,fosfomycinum,fosfonomycin,infectophos,phosphonemycin,phosphonomycin,veramina" 3 "g" 8 "g" "25596-8,25653-7,35809-3,35810-1"
+"FMD" 572 "Fosmidomycin" "Other antibacterials" "" "NA" "fosmidomicina,fosmidomycina,fosmidomycine,fosmidomycinsalt,fosmidomycinum" "NA"
+"FRM" 8378 "Framycetin" "Aminoglycosides" "D09AA01,QD09AA01,QJ01GB91,QR01AX08,QS01AA07,R01AX08,S01AA07" "fram" "actilin,actiline,antibiotique,bycomycin,enterfram,fradiomycin,fradiomycinum,framicetina,framidal,framycetine,framycetinum,framycin,framygen,francetin,jernadex,myacyne,mycerin,mycifradin,neobrettin,neolate,neomas,neomcin,neomicina,neomin,neomycine,neomycinum,nivemycin,soframycin,soframycine" "18926-6,257-6,258-4,259-2,260-0,55679-5"
+"FUR" 6870646 "Furazidin" "Other antibacterials" "J01XE03,QJ01XE03" "Other antibacterials" "Nitrofuran derivatives" "NA" "akritoin,furagin,furaginum,furamag,furazidine,hydantoin" 0.3 "g" "NA"
+"FRZ" 5323714 "Furazolidone" "Other antibacterials" "G01AX06,QG01AX06,QJ01XE90" "NA" "bifuron,corizium,coryzium,diafuron,enterotoxon,furall,furanzolidone,furaxon,furaxone,furazolidine,furazolidon,furazolidona,furazolidonum,furazolum,furidon,furmethoxadone,furovag,furoxal,furoxane,furoxon,furoxone,furozolidine,giardil,giarlam,medaron,neftin,nicolen,nifulidone,nifuran,nifurazolidone,nifurazolidonum,nitrofuradoxon,nitrofurazolidone,nitrofurazolidonum,nitrofuroxon,optazol,ortazol,puradin,roptazol,sclaventerol,tikofuran,topazone,trichofuron,tricofuron,tricoron,trifurox,viofuragyn" "69574-2,87794-4"
+"FUS" 3000226 "Fusidic acid" "Other antibacterials" "D06AX01,D09AA02,J01XC01,QD06AX01,QD09AA02,QJ01XC01,QS01AA13,S01AA13" "Other antibacterials" "Steroid antibacterials" "fa,fusi" "flucidin,fucidate,fucidina,fucidine,fucithalmic,fusidate,fusidicacid,fusidin,fusidine,taksta" 1.5 "g" 1.5 "g" "NA"
"GAM" 59364992 "Gamithromycin" "Macrolides/lincosamides" "QJ01FA95" "NA" "zactran" "100054-6,88376-9,88378-5"
-"GRN" 124093 "Garenoxacin" "Fluoroquinolones" "J01MA19" "NA" "ganefloxacin,garenfloxacin" 0.4 "g" "35811-9,35812-7,35813-5"
-"GAT" 5379 "Gatifloxacin" "Fluoroquinolones" "J01MA16,S01AE06" "Quinolone antibacterials" "Fluoroquinolones" "gati" "acorafloxacin,avarofloxacin,balofloxacin,balofox,bazucin,bilimin,bonoq,gaity,gatiflo,gatifloxacine,gatifloxcin,gatilox,gatiquin,gatispan,kinome,tequin,tymer,zymar,zymaxid,zymer" 0.4 "g" 0.4 "g" "31036-7,31038-3,31040-9,31042-5,41494-6"
-"GEM" 9571107 "Gemifloxacin" "Fluoroquinolones" "J01MA15" "Quinolone antibacterials" "Fluoroquinolones" "NA" "factiv,gemifioxacin,gemifloxacine,gemifloxacino,gemifloxacinum" 0.32 "g" 0.2 "g" "35814-3,35815-0,35816-8,41697-4"
-"GEN" 3467 "Gentamicin" "Aminoglycosides" "D06AX07,J01GB03,S01AA11,S02AA14,S03AA06" "Aminoglycoside antibacterials" "Other aminoglycosides" "cn,gen,gent,gm" "centicin,cidomycin,garamicin,garamycin,gentacycol,gentamicina,gentamicine,gentamicins,gentamicinum,gentamycins,gentamycinum,gentocin,lyramycin,oksitselanim,septigen,septocin" 0.24 "g" "101494-3,13561-6,13562-4,15106-8,18928-2,18929-0,22746-2,22747-0,266-7,267-5,268-3,269-1,31091-2,31092-0,31093-8,35668-3,35817-6,3663-2,3664-0,3665-7,39082-3,47109-4,50630-3,59379-8,7016-9,7017-7,7018-5,80971-5,88111-0,89481-6"
-"GEH" "Gentamicin-high" "Aminoglycosides" "NA" "gehi,gehl,genta high,gentamicin high" "NA" "18929-0,35817-6,7017-7,7018-5"
-"GEP" 25101874 "Gepotidacin" "Other antibacterials" "NA" "NA" "gepotidacina,gepotidacine" "NA"
-"GRX" 72474 "Grepafloxacin" "Fluoroquinolones" "J01MA11" "Quinolone antibacterials" "Fluoroquinolones" "grep" "grepafloxacine,grepafloxacino,lungaskin,raxar,vaxar" 0.4 "g" "21316-5,23638-0,23639-8,35818-4"
-"GRI" 441140 "Griseofulvin" "Antifungals/antimycotics" "D01AA08,D01BA01" "NA" "amudane,delmofulvina,epigriseofulvin,fulcin,fulcine,fulvicin,fulvidex,fulvina,fulvinil,fulvistatin,fungivin,greosin,gresfeed,gricin,grifulin,grifulvin,grisactin,griscofulvin,grisefuline,griseo,griseofulviin,griseofulvina,griseofulvine,griseofulvinum,griseomix,griseostatin,grisetin,grisofulvin,grisovin,grisowen,grizeofulvin,grysio,guservin,lamoryl,likuden,likunden,murfulvin,poncyl,spiro,spirofulvin,xuanjing" 0.5 "g" "12402-4,54200-1,54201-9,54202-7"
-"HAB" 175989 "Habekacin" "Aminoglycosides" "NA" "NA" "amikafur,amikan,amitrex,arikayce,biklin,biodacyn,chemacin,fabianol,habekacinxsulfate,likacin,pierami" "NA"
-"HCH" 11979956 "Hachimycin" "Antifungals/antimycotics" "D01AA03,G01AA06,J02AA02" "Antimycotics for systemic use" "Antibiotics" "NA" "cabimicina,hachimicina,hachimycine,hachimycinum,trichomycinum,trichonat" "NA"
-"HET" 443387 "Hetacillin" "Beta-lactams/penicillins" "J01CA18" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "etacillina,hetacilina,hetacilline,hetacillinum,natacillin,phenazacillin,versapen,versatrex" 2 "g" "18931-6,274-1,275-8,276-6,277-4"
-"HYG" 56928061 "Hygromycin" "Aminoglycosides" "NA" "NA" "antihelmycin,destomysin,hyanthelmix,hygromix,hygrovectine,hygrovetine" "NA"
-"IBX" "Ibrexafungerp" "Antifungals" "J02AX07" "NA" "NA" "NA"
-"ICL" 213043 "Iclaprim" "Other antibacterials" "J01EA03" "NA" "iclaprime,mersarex" "73597-7,73619-9,73642-1"
-"IPM" 104838 "Imipenem" "Carbapenems" "J01DH51" "Other beta-lactam antibacterials" "Carbapenems" "imci,imi,imip,imp" "imipemide,imipenemum,imipenen,primaxin,recarbrio,tienam,tienamycin" 2 "g" "101487-7,17010-0,18932-4,18933-2,23613-3,25221-3,25257-7,27331-8,278-2,279-0,280-8,281-6,282-4,283-2,284-0,285-7,35819-2,3688-9,54170-6,54171-4,54172-2,7019-3,85424-0,93232-7,96372-8"
-"IPE" "Imipenem/EDTA" "Carbapenems" "NA" "NA" "NA" "35819-2,54170-6,54171-4,54172-2"
-"IMR" "Imipenem/relebactam" "Carbapenems" "J01DH56" "NA" "NA" 2 "g" "85424-0,93232-7,96372-8"
-"ISV" 6918485 "Isavuconazole" "Antifungals/antimycotics" "J02AC05" "isav" "benzonitrile,ravuconazole" 0.2 "g" 0.2 "g" "85381-2,88887-5"
-"ISE" 3037209 "Isepamicin" "Aminoglycosides" "J01GB11" "Aminoglycoside antibacterials" "Other aminoglycosides" "NA" "isepacin,isepalline,isepamicina,isepamicine,isepamicinsulphate,isepamicinum" 0.4 "g" "32381-6,35820-0,35821-8,55680-3"
-"ISO" 3760 "Isoconazole" "Antifungals/antimycotics" "D01AC05,G01AF07" "Antimycotics for topic use" "Triazole derivatives" "NA" "isoconazol,isoconazolum,travogen" "55681-1,55682-9,55683-7,55684-5"
-"INH" 3767 "Isoniazid" "Antimycobacterials" "J04AC01" "Drugs for treatment of tuberculosis" "Hydrazides" "inh" "abdizide,acetylisoniazide,andrazide,anidrasona,antimicina,antituberkulosum,armacide,armazid,armazide,atcotibine,azuren,cedin,cemidon,chemiazid,chemidon,continazine,cortinazine,cotinazin,cotinizin,defonin,dianicotyl,dibutin,diforin,dinacrin,dinocrin,ditubin,ebidene,eralon,ertuban,eutizon,evalon,fetefu,fimalene,hidranizil,hidrasonil,hidrulta,hidrun,hycozid,hydra,hydrazid,hyozid,hyzyd,idrazil,inizid,ipcazide,iscotin,isidrina,ismazide,isobicina,isocid,isocidene,isocotin,isohydrazide,isokin,isolyn,isonerit,isonex,isoniacid,isoniazida,isoniazide,isoniazidum,isonicazide,isonicid,isonico,isonicotan,isonicotil,isonicotinhydrazid,isonicotinohydrazide,isonide,isonidrin,isonikazid,isonilex,isonin,isonindon,isonirit,isoniton,isonizida,isonizide,isotamine,isotebe,isotebezid,isotinyl,isozid,isozide,isozyd,laniazid,laniozid,mayambutol,mybasan,neoteben,neoxin,neumandin,nevin,niadrin,nicazide,nicetal,nicizina,niconyl,nicotibina,nicotibine,nicotisan,nicozide,nidaton,nidrazid,nikozid,niplen,nitadon,niteban,nitebannsc,nydrazid,nyscozid,pelazid,percin,phthisen,preparation,pycazide,pyreazid,pyricidin,pyridicin,pyrizidin,raumanon,razide,retozide,rifater,rimicid,rimifon,rimiphone,rimitsid,robiselin,robisellin,roxifen,sanohidrazina,sauterazid,sauterzid,stanozide,tebecid,tebenic,tebexin,tebilon,tebos,teebaconin,tekazin,tibazide,tibemid,tibiazide,tibinide,tibison,tibivis,tibizide,tibusan,tisin,tisiodrazida,tizide,tubazid,tubazide,tubeco,tubecotubercid,tuberian,tubicon,tubilysin,tubizid,tubomel,tyvid,unicocyde,unicozyde,vazadrine,vederon,zidafimia,zinadon,zonazide" 0.3 "g" 0.3 "g" "18934-0,20383-6,23947-5,25217-1,25218-9,25219-7,25451-6,26756-7,286-5,287-3,288-1,289-9,29315-9,3697-0,40371-7,42649-4,42650-2,42651-0,45215-1,48171-3,48172-1,55685-2,7020-1,89488-1"
-"IST" "Isoniazid/sulfamethoxazole/trimethoprim/pyridoxine" "Antimycobacterials" "J04AM08" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA"
-"ITR" 3793 "Itraconazole" "Antifungals/antimycotics" "J02AC02" "Antimycotics for systemic use" "Triazole derivatives" "itra" "candistat,canditral,cladosal,fungitraxx,intraconazole,itraconazol,itraconazolo,itraconazolum,itraconzaole,itrafungol,itralek,itrizole,lozanoc,onmel,sempera,sporamelt,sporanox,sporonox,traconal,triasporin" 0.2 "g" 0.2 "g" "10989-2,12392-7,25258-5,25452-4,27081-9,32184-4,32185-1,32603-3,54179-7,7021-9,80531-7"
-"JOS" 5282165 "Josamycin" "Macrolides/lincosamides" "J01FA07" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "jomybel,josamicina,josamycine,josamycinum" 2 "g" "25597-6,25702-2,41698-2,41699-0"
-"KAN" 6032 "Kanamycin" "Aminoglycosides" "A07AA08,J01GB04,S01AA24" "Aminoglycoside antibacterials" "Other aminoglycosides" "hlk,k,kan,kana,km" "kanamicina,kanamycine,kanamycins,kanamycinum,kantrex,klebcil" 3 "g" 1 "g" "18935-7,18936-5,23609-1,23889-9,25182-7,25213-0,25214-8,290-7,291-5,292-3,293-1,3698-8,3699-6,3700-2,42652-8,47395-9,49080-5,7022-7,7023-5,7024-3,88002-1,88705-9,89482-4"
-"KAH" "Kanamycin-high" "Aminoglycosides" "NA" "k_h,kahl" "NA" "18936-5,7023-5,7024-3"
-"KAC" "Kanamycin/cephalexin" "Aminoglycosides" "NA" "NA" "NA" "NA"
-"KET" 456201 "Ketoconazole" "Antifungals/antimycotics" "D01AC08,G01AF11,H02CA03,J02AB02" "Antimycotics for systemic use" "Imidazole derivatives" "keto,ktc" "brizoral,ethanone,extina,fungarest,fungoral,ketaconazole,ketocanazole,ketoconazol,ketoconazolum,ketodan,ketoderm,ketoisdin,ketozole,kuric,levoketoconazole,nizoral,normocort,panfungol,piperazine,recorlev,sebazole,teryzolin,terzolin,tocris,xolegel" 0.6 "g" "10990-0,12393-5,18937-3,25259-3,294-9,295-6,296-4,297-2,60091-6,60092-4,7025-0"
+"GRN" 124093 "Garenoxacin" "Fluoroquinolones" "J01MA19,QJ01MA19" "NA" "ganefloxacin,garenfloxacin" 0.4 "g" "35811-9,35812-7,35813-5"
+"GAT" 5379 "Gatifloxacin" "Fluoroquinolones" "J01MA16,QJ01MA16,QS01AE06,S01AE06" "Quinolone antibacterials" "Fluoroquinolones" "gati" "acorafloxacin,avarofloxacin,balofloxacin,balofox,bazucin,bilimin,bonoq,gaity,gatiflo,gatifloxacine,gatifloxcin,gatilox,gatiquin,gatispan,kinome,tequin,tymer,zymar,zymaxid,zymer" 0.4 "g" 0.4 "g" "31036-7,31038-3,31040-9,31042-5,41494-6"
+"GEM" 9571107 "Gemifloxacin" "Fluoroquinolones" "J01MA15,QJ01MA15" "Quinolone antibacterials" "Fluoroquinolones" "NA" "factiv,gemifioxacin,gemifloxacine,gemifloxacino,gemifloxacinum" 0.32 "g" 0.2 "g" "35814-3,35815-0,35816-8,41697-4"
+"GEN" 3467 "Gentamicin" "Aminoglycosides" "D06AX07,J01GB03,QA07AA91,QD06AX07,QG01AA91,QG51AA04,QJ01GB03,QJ51GB03,QS01AA11,QS02AA14,QS03AA06,S01AA11,S02AA14,S03AA06" "Aminoglycoside antibacterials" "Other aminoglycosides" "cn,gen,gent,gm" "centicin,cidomycin,garamicin,garamycin,gentacycol,gentamicina,gentamicine,gentamicins,gentamicinum,gentamycins,gentamycinum,gentocin,lyramycin,oksitselanim,septigen,septocin" 0.24 "g" "101494-3,13561-6,13562-4,15106-8,18928-2,18929-0,22746-2,22747-0,266-7,267-5,268-3,269-1,31091-2,31092-0,31093-8,35668-3,35817-6,3663-2,3664-0,3665-7,39082-3,47109-4,50630-3,59379-8,7016-9,7017-7,7018-5,80971-5,88111-0,89481-6"
+"GEH" "Gentamicin-high" "Aminoglycosides" "" "gehi,gehl,genta high,gentamicin high" "NA" "18929-0,35817-6,7017-7,7018-5"
+"GEP" 25101874 "Gepotidacin" "Other antibacterials" "J01XX13,QJ01XX13" "NA" "gepotidacina,gepotidacine" "NA"
+"GRX" 72474 "Grepafloxacin" "Fluoroquinolones" "J01MA11,QJ01MA11" "Quinolone antibacterials" "Fluoroquinolones" "grep" "grepafloxacine,grepafloxacino,lungaskin,raxar,vaxar" 0.4 "g" "21316-5,23638-0,23639-8,35818-4"
+"GRI" 441140 "Griseofulvin" "Antifungals/antimycotics" "D01AA08,D01BA01,QD01AA08,QD01BA01" "NA" "amudane,delmofulvina,epigriseofulvin,fulcin,fulcine,fulvicin,fulvidex,fulvina,fulvinil,fulvistatin,fungivin,greosin,gresfeed,gricin,grifulin,grifulvin,grisactin,griscofulvin,grisefuline,griseo,griseofulviin,griseofulvina,griseofulvine,griseofulvinum,griseomix,griseostatin,grisetin,grisofulvin,grisovin,grisowen,grizeofulvin,grysio,guservin,lamoryl,likuden,likunden,murfulvin,poncyl,spiro,spirofulvin,xuanjing" 0.5 "g" "12402-4,54200-1,54201-9,54202-7"
+"HAB" 175989 "Habekacin" "Aminoglycosides" "" "NA" "amikafur,amikan,amitrex,arikayce,biklin,biodacyn,chemacin,fabianol,habekacinxsulfate,likacin,pierami" "NA"
+"HCH" 11979956 "Hachimycin" "Antifungals/antimycotics" "D01AA03,G01AA06,J02AA02,QD01AA03,QG01AA06,QJ02AA02" "Antimycotics for systemic use" "Antibiotics" "NA" "cabimicina,hachimicina,hachimycine,hachimycinum,trichomycinum,trichonat" "NA"
+"HET" 443387 "Hetacillin" "Beta-lactams/penicillins" "J01CA18,QJ01CA18" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "etacillina,hetacilina,hetacilline,hetacillinum,natacillin,phenazacillin,versapen,versatrex" 2 "g" "18931-6,274-1,275-8,276-6,277-4"
+"HYG" 56928061 "Hygromycin" "Aminoglycosides" "" "NA" "antihelmycin,destomysin,hyanthelmix,hygromix,hygrovectine,hygrovetine" "NA"
+"IBX" "Ibrexafungerp" "Antifungals" "J02AX07,QJ02AX07" "NA" "NA" "NA"
+"ICL" 213043 "Iclaprim" "Other antibacterials" "J01EA03,QJ01EA03" "NA" "iclaprime,mersarex" "73597-7,73619-9,73642-1"
+"IPM" 104838 "Imipenem" "Carbapenems" "" "Other beta-lactam antibacterials" "Carbapenems" "imci,imi,imip,imp" "imipemide,imipenemum,imipenen,primaxin,recarbrio,tienam,tienamycin" 2 "g" "101487-7,17010-0,18932-4,18933-2,23613-3,25221-3,25257-7,27331-8,278-2,279-0,280-8,281-6,282-4,283-2,284-0,285-7,35819-2,3688-9,54170-6,54171-4,54172-2,7019-3,85424-0,93232-7,96372-8"
+"IPE" "Imipenem/EDTA" "Carbapenems" "" "NA" "NA" "35819-2,54170-6,54171-4,54172-2"
+"IMR" "Imipenem/relebactam" "Carbapenems" "" "NA" "NA" 2 "g" "85424-0,93232-7,96372-8"
+"ISV" 6918485 "Isavuconazole" "Antifungals/antimycotics" "J02AC05,QJ02AC05" "isav" "benzonitrile,ravuconazole" 0.2 "g" 0.2 "g" "85381-2,88887-5"
+"ISE" 3037209 "Isepamicin" "Aminoglycosides" "J01GB11,QJ01GB11" "Aminoglycoside antibacterials" "Other aminoglycosides" "NA" "isepacin,isepalline,isepamicina,isepamicine,isepamicinsulphate,isepamicinum" 0.4 "g" "32381-6,35820-0,35821-8,55680-3"
+"ISO" 3760 "Isoconazole" "Antifungals/antimycotics" "D01AC05,G01AF07,QD01AC05,QG01AF07" "Antimycotics for topic use" "Triazole derivatives" "NA" "isoconazol,isoconazolum,travogen" "55681-1,55682-9,55683-7,55684-5"
+"INH" 3767 "Isoniazid" "Antimycobacterials" "J04AC01,QJ04AC01" "Drugs for treatment of tuberculosis" "Hydrazides" "inh" "abdizide,acetylisoniazide,andrazide,anidrasona,antimicina,antituberkulosum,armacide,armazid,armazide,atcotibine,azuren,cedin,cemidon,chemiazid,chemidon,continazine,cortinazine,cotinazin,cotinizin,defonin,dianicotyl,dibutin,diforin,dinacrin,dinocrin,ditubin,ebidene,eralon,ertuban,eutizon,evalon,fetefu,fimalene,hidranizil,hidrasonil,hidrulta,hidrun,hycozid,hydra,hydrazid,hyozid,hyzyd,idrazil,inizid,ipcazide,iscotin,isidrina,ismazide,isobicina,isocid,isocidene,isocotin,isohydrazide,isokin,isolyn,isonerit,isonex,isoniacid,isoniazida,isoniazide,isoniazidum,isonicazide,isonicid,isonico,isonicotan,isonicotil,isonicotinhydrazid,isonicotinohydrazide,isonide,isonidrin,isonikazid,isonilex,isonin,isonindon,isonirit,isoniton,isonizida,isonizide,isotamine,isotebe,isotebezid,isotinyl,isozid,isozide,isozyd,laniazid,laniozid,mayambutol,mybasan,neoteben,neoxin,neumandin,nevin,niadrin,nicazide,nicetal,nicizina,niconyl,nicotibina,nicotibine,nicotisan,nicozide,nidaton,nidrazid,nikozid,niplen,nitadon,niteban,nitebannsc,nydrazid,nyscozid,pelazid,percin,phthisen,preparation,pycazide,pyreazid,pyricidin,pyridicin,pyrizidin,raumanon,razide,retozide,rifater,rimicid,rimifon,rimiphone,rimitsid,robiselin,robisellin,roxifen,sanohidrazina,sauterazid,sauterzid,stanozide,tebecid,tebenic,tebexin,tebilon,tebos,teebaconin,tekazin,tibazide,tibemid,tibiazide,tibinide,tibison,tibivis,tibizide,tibusan,tisin,tisiodrazida,tizide,tubazid,tubazide,tubeco,tubecotubercid,tuberian,tubicon,tubilysin,tubizid,tubomel,tyvid,unicocyde,unicozyde,vazadrine,vederon,zidafimia,zinadon,zonazide" 0.3 "g" 0.3 "g" "18934-0,20383-6,23947-5,25217-1,25218-9,25219-7,25451-6,26756-7,286-5,287-3,288-1,289-9,29315-9,3697-0,40371-7,42649-4,42650-2,42651-0,45215-1,48171-3,48172-1,55685-2,7020-1,89488-1"
+"IST" "Isoniazid/sulfamethoxazole/trimethoprim/pyridoxine" "Antimycobacterials" "" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA"
+"ITR" 3793 "Itraconazole" "Antifungals/antimycotics" "J02AC02,QJ02AC02" "Antimycotics for systemic use" "Triazole derivatives" "itra" "candistat,canditral,cladosal,fungitraxx,intraconazole,itraconazol,itraconazolo,itraconazolum,itraconzaole,itrafungol,itralek,itrizole,lozanoc,onmel,sempera,sporamelt,sporanox,sporonox,traconal,triasporin" 0.2 "g" 0.2 "g" "10989-2,12392-7,25258-5,25452-4,27081-9,32184-4,32185-1,32603-3,54179-7,7021-9,80531-7"
+"JOS" 5282165 "Josamycin" "Macrolides/lincosamides" "J01FA07,QJ01FA07" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "jomybel,josamicina,josamycine,josamycinum" 2 "g" "25597-6,25702-2,41698-2,41699-0"
+"KAN" 6032 "Kanamycin" "Aminoglycosides" "A07AA08,J01GB04,QA07AA08,QJ01GB04,QS01AA24,S01AA24" "Aminoglycoside antibacterials" "Other aminoglycosides" "hlk,k,kan,kana,km" "kanamicina,kanamycine,kanamycins,kanamycinum,kantrex,klebcil" 3 "g" 1 "g" "18935-7,18936-5,23609-1,23889-9,25182-7,25213-0,25214-8,290-7,291-5,292-3,293-1,3698-8,3699-6,3700-2,42652-8,47395-9,49080-5,7022-7,7023-5,7024-3,88002-1,88705-9,89482-4"
+"KAH" "Kanamycin-high" "Aminoglycosides" "" "k_h,kahl" "NA" "18936-5,7023-5,7024-3"
+"KAC" "Kanamycin/cephalexin" "Aminoglycosides" "" "NA" "NA" "NA"
+"KET" 456201 "Ketoconazole" "Antifungals/antimycotics" "D01AC08,G01AF11,H02CA03,J02AB02,QD01AC08,QG01AF11,QH02CA03,QJ02AB02" "Antimycotics for systemic use" "Imidazole derivatives" "keto,ktc" "brizoral,ethanone,extina,fungarest,fungoral,ketaconazole,ketocanazole,ketoconazol,ketoconazolum,ketodan,ketoderm,ketoisdin,ketozole,kuric,levoketoconazole,nizoral,normocort,panfungol,piperazine,recorlev,sebazole,teryzolin,terzolin,tocris,xolegel" 0.6 "g" "10990-0,12393-5,18937-3,25259-3,294-9,295-6,296-4,297-2,60091-6,60092-4,7025-0"
"KIT" "Kitasamycin" "Macrolides/lincosamides" "QJ01FA93" "leucomycin" "NA" "NA"
"LAS" 5360807 "Lasalocid" "Other antibacterials" "QP51BB02" "NA" "avatec,bovate,bovatec,lasalocide,lasalocido,lasalocidsalt,lasalocidum" "87598-9"
-"LSC" 71528768 "Lascufloxacin" "Fluoroquinolones" "J01MA25" "Quinolone antibacterials" "Fluoroquinolones" "NA" "lasvic" 75 "mg" "NA"
-"LTM" 47499 "Latamoxef" "Cephalosporins (3rd gen.)" "J01DD06" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "mox,moxa,moxalactam" "dilatamoxef,festamoxin,lamoxactam,latamoxefum,morrhuate,moxalactamsalt,moxam,shiomarin" 4 "g" "NA"
-"LMU" 25185057 "Lefamulin" "Other antibacterials" "J01XX12" "NA" "lefamulinacetate,xenleta" "85425-7,99281-8"
-"LEN" 65646 "Lenampicillin" "Beta-lactams/penicillins" "NA" "NA" "lenampicilina,lenampicilline,lenampicillinum,takacillin,valacillin,varacillin" "NA"
-"LVX" 149096 "Levofloxacin" "Fluoroquinolones" "J01MA12,S01AE05" "Quinolone antibacterials" "Fluoroquinolones" "le,lev,levo,lvx" "aeroquin,cravit,dextrofloxacin,dynaquin,elequine,iquix,levaquin,levofiexacin,levofloxacine,levofloxacino,levofloxacinum,loxof,ofloxcacin,oftaquix,quinsair,quixin,tavanic,unibiotic,venaxan" 0.5 "g" 0.5 "g" "101501-5,20396-8,20629-2,21367-8,21368-6,30532-6,30533-4,48173-9,53716-7,7026-8,76040-5,76041-3,76042-1"
-"LEO" "Levofloxacin/ornidazole" "Fluoroquinolones" "J01RA05" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
-"LND" 9850038 "Levonadifloxacin" "Fluoroquinolones" "J01MA24" "NA" "NA" "NA"
-"LSP" "Linco-spectin" "Other antibacterials" "NA" "lincomycin/spectinomycin" "NA" "NA"
-"LIN" 3000540 "Lincomycin" "Macrolides/lincosamides" "J01FF02" "Macrolides, lincosamides and streptogramins" "Lincosamides" "linc" "albiotic,bactramycin,cillimycin,frademicina,jiemycin,lincocin,lincogap,lincolcina,lincolnensin,lincomicina,lincomix,lincomycine,lincomycinum,lincomyocin,lincorex,linocin,mycivin" 1.8 "g" 1.8 "g" "18938-1,298-0,299-8,300-4,301-2,41700-6,87597-1"
-"LNZ" 441401 "Linezolid" "Oxazolidinones" "J01XX08" "Other antibacterials" "Other antibacterials" "line,lnz,lz,lzd" "desfluorolinezolid,linezoid,linezolidum,zivoxid,zyvox,zyvoxa,zyvoxam,zyvoxid" 1.2 "g" 1.2 "g" "29254-0,29255-7,29258-1,33332-8,34202-2,41500-0,80609-1,88706-7,96111-0"
-"LFE" "Linoprist-flopristin" "Other antibacterials" "NA" "NA" "NA" "NA"
-"LOM" 3948 "Lomefloxacin" "Fluoroquinolones" "J01MA07,S01AE04" "Quinolone antibacterials" "Fluoroquinolones" "lmf,lom,lome" "bareon,logiflox,lomebact,lomefloxacine,lomefloxacino,lomefloxacinum,maxaquin,maxaquine,mazaquin,okacin,okacyn,uniquin" 0.4 "g" "18939-9,302-0,303-8,304-6,305-3,41701-4"
-"LOR" 5284585 "Loracarbef" "Cephalosporins (2nd gen.)" "J01DC08" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "lora" "carbac,lorabid,loracarbefum,lorafem,lorbef,loribid" 0.6 "g" "18940-7,306-1,307-9,308-7,309-5,7027-6"
-"LYM" 54707177 "Lymecycline" "Tetracyclines" "J01AA04" "Tetracyclines" "Tetracyclines" "NA" "armyl,chlortetracyclin,ciclisin,ciclolysal,ciclolysine,eficiclina,infaciclina,limeciclina,lisinbiotic,lymecyclinum,mucomycin,ntetracycline,tetralisal,tetralysal,vebicyclysal" 0.6 "g" 0.6 "g" "18941-5,310-3,311-1,312-9,313-7"
-"MNA" 1292 "Mandelic acid" "Other antibacterials" "B05CA06,J01XX06" "Other antibacterials" "Other antibacterials" "NA" "amygdalate,mandelsaeure,paramandelate,phenylglycolate,phenylhydroxyacetate,uromaline" 12 "g" "NA"
-"MGX" "Manogepix" "Antifungals" "NA" "NA" "NA" "NA"
+"LSC" 71528768 "Lascufloxacin" "Fluoroquinolones" "J01MA25,QJ01MA25" "Quinolone antibacterials" "Fluoroquinolones" "NA" "lasvic" 75 "mg" "NA"
+"LTM" 47499 "Latamoxef" "Cephalosporins (3rd gen.)" "J01DD06,QJ01DD06" "Other beta-lactam antibacterials" "Third-generation cephalosporins" "mox,moxa,moxalactam" "dilatamoxef,festamoxin,lamoxactam,latamoxefum,morrhuate,moxalactamsalt,moxam,shiomarin" 4 "g" "NA"
+"LMU" 25185057 "Lefamulin" "Other antibacterials" "J01XX12,QJ01XX12" "NA" "lefamulinacetate,xenleta" "85425-7,99281-8"
+"LEN" 65646 "Lenampicillin" "Beta-lactams/penicillins" "" "NA" "lenampicilina,lenampicilline,lenampicillinum,takacillin,valacillin,varacillin" "NA"
+"LVX" 149096 "Levofloxacin" "Fluoroquinolones" "J01MA12,QJ01MA12,QS01AE05,S01AE05" "Quinolone antibacterials" "Fluoroquinolones" "le,lev,levo,lvx" "aeroquin,cravit,dextrofloxacin,dynaquin,elequine,iquix,levaquin,levofiexacin,levofloxacine,levofloxacino,levofloxacinum,loxof,ofloxcacin,oftaquix,quinsair,quixin,tavanic,unibiotic,venaxan" 0.5 "g" 0.5 "g" "101501-5,20396-8,20629-2,21367-8,21368-6,30532-6,30533-4,48173-9,53716-7,7026-8,76040-5,76041-3,76042-1"
+"LEO" "Levofloxacin/ornidazole" "Fluoroquinolones" "" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
+"LND" 9850038 "Levonadifloxacin" "Fluoroquinolones" "J01MA24,QJ01MA24" "NA" "NA" "NA"
+"LSP" "Linco-spectin" "Other antibacterials" "" "lincomycin/spectinomycin" "NA" "NA"
+"LIN" 3000540 "Lincomycin" "Macrolides/lincosamides" "J01FF02,QJ01FF02,QJ51FF02" "Macrolides, lincosamides and streptogramins" "Lincosamides" "linc" "albiotic,bactramycin,cillimycin,frademicina,jiemycin,lincocin,lincogap,lincolcina,lincolnensin,lincomicina,lincomix,lincomycine,lincomycinum,lincomyocin,lincorex,linocin,mycivin" 1.8 "g" 1.8 "g" "18938-1,298-0,299-8,300-4,301-2,41700-6,87597-1"
+"LNZ" 441401 "Linezolid" "Oxazolidinones" "J01XX08,QJ01XX08" "Other antibacterials" "Other antibacterials" "line,lnz,lz,lzd" "desfluorolinezolid,linezoid,linezolidum,zivoxid,zyvox,zyvoxa,zyvoxam,zyvoxid" 1.2 "g" 1.2 "g" "29254-0,29255-7,29258-1,33332-8,34202-2,41500-0,80609-1,88706-7,96111-0"
+"LFE" "Linoprist-flopristin" "Other antibacterials" "" "NA" "NA" "NA"
+"LOM" 3948 "Lomefloxacin" "Fluoroquinolones" "J01MA07,QJ01MA07,QS01AE04,S01AE04" "Quinolone antibacterials" "Fluoroquinolones" "lmf,lom,lome" "bareon,logiflox,lomebact,lomefloxacine,lomefloxacino,lomefloxacinum,maxaquin,maxaquine,mazaquin,okacin,okacyn,uniquin" 0.4 "g" "18939-9,302-0,303-8,304-6,305-3,41701-4"
+"LOR" 5284585 "Loracarbef" "Cephalosporins (2nd gen.)" "J01DC08,QJ01DC08" "Other beta-lactam antibacterials" "Second-generation cephalosporins" "lora" "carbac,lorabid,loracarbefum,lorafem,lorbef,loribid" 0.6 "g" "18940-7,306-1,307-9,308-7,309-5,7027-6"
+"LYM" 54707177 "Lymecycline" "Tetracyclines" "J01AA04,QJ01AA04" "Tetracyclines" "Tetracyclines" "NA" "armyl,chlortetracyclin,ciclisin,ciclolysal,ciclolysine,eficiclina,infaciclina,limeciclina,lisinbiotic,lymecyclinum,mucomycin,ntetracycline,tetralisal,tetralysal,vebicyclysal" 0.6 "g" 0.6 "g" "18941-5,310-3,311-1,312-9,313-7"
+"MNA" 1292 "Mandelic acid" "Other antibacterials" "B05CA06,J01XX06,QB05CA06,QJ01XX06" "Other antibacterials" "Other antibacterials" "NA" "amygdalate,mandelsaeure,paramandelate,phenylglycolate,phenylhydroxyacetate,uromaline" 12 "g" "NA"
+"MGX" "Manogepix" "Antifungals" "" "NA" "NA" "NA"
"MAR" 60651 "Marbofloxacin" "Fluoroquinolones" "QJ01MA93" "NA" "marbocyl,marbofloxacine,marbofloxacino,marbofloxacinum,marboquin,zeniquin" "73596-9,73618-1,73641-3"
-"MEC" 36273 "Mecillinam" "Beta-lactams/penicillins" "J01CA11" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "amdinocillin" "amdinocillin,coactin,hexacillin,mecilinamo,mecillinamum,selexidin" 1.2 "g" "NA"
-"MEL" 71306732 "Meleumycin" "Macrolides/lincosamides" "NA" "NA" "NA" "NA"
-"MEM" 441130 "Meropenem" "Carbapenems" "J01DH02" "Other beta-lactam antibacterials" "Carbapenems" "mem,mer,mero,mp,mrp" "meronem,meropen,meropenemum,merrem" 3 "g" "101222-8,101488-5,101489-3,18943-1,41406-0,6651-4,6652-2,6653-0,6654-8,7029-2,85426-5,85427-3,88892-5,90980-4"
-"MNC" "Meropenem/nacubactam" "Carbapenems" "NA" "NA" "NA" "NA"
-"MEV" "Meropenem/vaborbactam" "Carbapenems" "J01DH52" "Other beta-lactam antibacterials" "Carbapenems" "NA" "NA" 3 "g" "101222-8,101489-3,85427-3,88892-5,90980-4"
-"MES" 176886 "Mesulfamide" "Other antibacterials" "NA" "NA" "mesulfamida,mesulfamido,mesulfamidum" "NA"
-"MTC" 54675785 "Metacycline" "Tetracyclines" "J01AA05" "Tetracyclines" "Tetracyclines" "NA" "bialatan,metaciclina,metacyclinum,methacyclin,methacycline,methacyclinum,methylenecycline,physiomycine,rondomycin" 0.6 "g" "NA"
-"MTM" 6713928 "Metampicillin" "Beta-lactams/penicillins" "J01CA14" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "blomopen,bonopen,celinmicina,elatocilline,filorex,magnipen,metambac,metampen,metampicilina,metampicillina,metampicilline,metampicillinsalt,metampicillinum,micinovo,ocelina,pangocilin,probiotic,relyothenate,ruticina,rutizina,sedomycin,serfabiotic,suvipen,viderpen,viderpin,vioplex" 1.5 "g" 1.5 "g" "NA"
-"MTH" 4101 "Methenamine" "Other antibacterials" "J01XX05" "Other antibacterials" "Other antibacterials" "NA" "aminoform,aminoformaldehyde,ammoform,ammonioformaldehyde,antihydral,carin,cystamin,cystex,cystogen,duirexol,esametilentetramina,formamine,formin,grasselerator,heterin,hexaform,hexaloids,hexamethylamine,hexamethylenamine,hexamethyleneamine,hexamethylentetramin,hexamine,hexaminum,hexasan,hexilmethylenamine,metenamina,metenamine,methamin,methamine,methenamin,methenaminum,metramine,naphthamine,pellurin,resotropin,uramin,urasal,uratrine,urisol,uritone,urodeine,urotropin,urotropine,vesaloin,xametrin" 3 "g" "NA"
-"MET" 6087 "Meticillin" "Beta-lactams/penicillins" "J01CF03" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "meti" "belfacillin,celbenin,celpilline,cinopenil,dimocillin,estafcilina,flabelline,lucopenin,metacillin,methcillin,methicillin,methicillinanhydrous,methicillinhydrate,methicillinsalt,methicillinum,methycillin,meticilina,meticillina,meticilline,meticillinsalt,meticillinum,penaureus,penysol,staficyn,staphcillin,synticillin" 4 "g" "NA"
-"MTP" 68590 "Metioprim" "Other antibacterials" "NA" "NA" "methioprim,metioprima,metioprime,metioprimum" "NA"
-"MXT" 3047729 "Metioxate" "Fluoroquinolones" "NA" "NA" "metioxato,metioxatum" "NA"
-"MTR" 4173 "Metronidazole" "Other antibacterials" "A01AB17,D06BX01,G01AF01,J01XD01,P01AB01" "Other antibacterials" "Imidazole derivatives" "metr,mnz" "acromona,anagiardil,arilin,atrivyl,bexon,clont,danizol,deflamon,donnan,efloran,elyzol,entizol,eumin,flagemona,flagesol,flagil,flagyl,flazol,flegyl,florazole,fossyol,giatricol,gineflavir,givagil,hydroxydimetridazole,hydroxymetronidazole,izoklion,klion,klont,mepagyl,meronidal,metric,metrolag,metrolyl,metromidol,metronidazolo,metronidazolum,metroplex,metrotop,mexibol,monagyl,monasin,nalox,nidagyl,noritate,novonidazol,nuvessa,orvagil,polibiotic,protostat,rathimed,rosaced,rosased,sanatrichom,satric,takimetol,trichazol,trichex,trichobrol,trichocide,trichomol,trichopal,trichopol,tricocet,tricom,trikacide,trikamon,trikhopol,trikojol,trikozol,trimeks,trivazol,vagilen,vagimid,vandazole,vertisal,wagitran,zadstat,zidoval" 2 "g" 1.5 "g" "10991-8,18946-4,326-9,327-7,328-5,329-3,7031-8"
-"MEZ" 656511 "Mezlocillin" "Beta-lactams/penicillins" "J01CA10" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "mez,mezl,mz" "baycipen,baypen,mezlin,mezlocilina,mezlocilline,mezlocillinsalt,mezlocillinum,multocillin" 6 "g" "18947-2,330-1,331-9,332-7,333-5,3820-8,41702-2,54194-6,54195-3,54196-1"
-"MSU" "Mezlocillin/sulbactam" "Beta-lactams/penicillins" "NA" "NA" "NA" "54194-6,54195-3,54196-1"
-"MIF" 477468 "Micafungin" "Antifungals/antimycotics" "J02AX05" "Antimycotics for systemic use" "Other antimycotics for systemic use" "mica" "fungard,funguard,micafungina,micafunginsalt,mycamine" 0.1 "g" "53812-4,58418-5,65340-2,85048-7"
-"MCZ" 4189 "Miconazole" "Antifungals/antimycotics" "A01AB09,A07AC01,D01AC02,G01AF04,J02AB01,S02AA13" "Antimycotics for systemic use" "Imidazole derivatives" "mico" "aflorix,albistat,andergin,brentan,conofite,dactarin,florid,micantin,miconazol,miconazolo,miconazolum,micozole,minostate,monazole,monista,monistat,oravig,vusion,zimybase,zimycan" 0.2 "g" 1 "g" "17278-3,25607-3,25722-0,54180-5,55686-0"
-"MCR" 3037206 "Micronomicin" "Aminoglycosides" "S01AA22" "NA" "micromicin,micromycin,micronomicina,micronomicine,micronomicinum,sagamicin,santemycin" "NA"
-"MID" 5282169 "Midecamycin" "Macrolides/lincosamides" "J01FA03" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "macropen,madecacine,medemycin,midecamicina,midecamycine,midecamycinum,midecin,momicine,myoxam,normicina,rubimycin" 1.2 "g" 1 "g" "NA"
-"MIL" 37614 "Miloxacin" "Fluoroquinolones" "NA" "NA" "miloxacine,miloxacino,miloxacinum" "NA"
-"MNO" 54675783 "Minocycline" "Tetracyclines" "A01AB23,D10AF07,J01AA08" "Tetracyclines" "Tetracyclines" "mc,mh,mi,min,mino,mn,mno" "acnez,arestin,borymycin,dynacin,lederderm,minociclina,minocin,minocline,minocyclin,minocyclinum,minocyn,minomax,minomycin,mynocine,periocline,solodyn,vectrin,ximino" 1 "mg" 0.2 "g" "18948-0,25225-4,334-3,335-0,336-8,337-6,34606-4,3822-4,49757-8,55156-4,7032-6"
-"MCM" 5282188 "Miocamycin" "Macrolides/lincosamides" "J01FA11" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "acecamycin,macroral,miocamen,miocamycine,miokamycin,mosil,myocamicin,ponsinomycin" 1.2 "g" "18949-8,338-4,339-2,340-0,341-8,55687-8"
-"MON" 23667299 "Monensin sodium" "Other antibacterials" "NA" "NA" "coban,elancoban,monelan,monensin,monensina,monensine,monensinum,monovet,romensin,rumensin" "NA"
-"MRN" 70374 "Morinamide" "Antimycobacterials" "J04AK04" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "NA" "morfazinamide,morfazinammide,morfgazinamide,morinamida,morinamidum,morphazinamid,morphazinamide,piazofolina,piazolin,piazolina" "NA"
-"MFX" 152946 "Moxifloxacin" "Fluoroquinolones" "J01MA14,S01AE07" "Quinolone antibacterials" "Fluoroquinolones" "mox,moxi,mxf" "actira,actura,avalox,avelox,avolex,izilox,moxeza,moxifloxacine,moxifloxacino,octegra,vegamox,vigamox,zimoxin" 0.4 "g" 0.4 "g" "31037-5,31039-1,31041-7,31043-3,41502-6,43751-7,45223-5,76043-9,76044-7,76045-4,80540-8,88707-5,93497-6,96112-8"
-"MUP" 446596 "Mupirocin" "Other antibacterials" "D06AX09,R01AX06" "mup,mupi" "bactoderm,bactroban,centany,mupirocina,mupirocine,mupirocinum,plasimine,turixin" "20389-3,35822-6,35823-4,60542-8,60543-6,7033-4"
-"NAC" 73386748 "Nacubactam" "Beta-lactams/penicillins" "NA" "NA" "NA" "NA"
-"NAD" 4410 "Nadifloxacin" "Fluoroquinolones" "D10AF05" "NA" "acuatim,nadifloxacine,nadifloxacino,nadifloxacinum,nadixa,nadoxin" "NA"
-"NAF" 8982 "Nafcillin" "Beta-lactams/penicillins" "J01CF06" "NA" "nafcil,nafcilin,nafcilina,nafcillinanhydrous,nafcilline,nafcillinhydrate,nafcillinmonohydrate,nafcillinsalt,nafcillinum,naftopen,nallpen,naphcillin,naphthicillin,unipen" 3 "g" "10993-4,18951-4,25232-0,346-7,347-5,348-3,349-1,41704-8"
-"ZWK" 117587595 "Nafithromycin" "Macrolides/lincosamides" "NA" "NA" "NA" "NA"
-"NAL" 4421 "Nalidixic acid" "Quinolones" "J01MB02" "Quinolone antibacterials" "Other quinolones" "na,nal,nali" "amfonelinsaeure,baktogram,betaxina,chemiurin,cybis,dixiben,dixilina,dixinal,eucisten,eucistin,innoxalomn,innoxalon,jicsron,kusnarin,nalidicron,nalidixan,nalidixane,nalidixate,nalidixateanhydrous,nalidixic,nalidixin,nalidixinsaure,nalitucsan,nalix,nalurin,narigix,naxuril,negram,nevigramon,nicelate,nogram,poleon,sicmylon,specifen,specifin,unaserus,uralgin,uriben,uriclar,urisal,urodixin,uroman,uroneg,uronidix,uropan,wintomylon,wintron" 4 "g" "NA"
-"NAL-S" "Nalidixic acid screening test" "Quinolones" "NA" "nal screen" "NA" "NA"
+"MEC" 36273 "Mecillinam" "Beta-lactams/penicillins" "J01CA11,QJ01CA11" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "amdinocillin" "amdinocillin,coactin,hexacillin,mecilinamo,mecillinamum,selexidin" 1.2 "g" "NA"
+"MEL" 71306732 "Meleumycin" "Macrolides/lincosamides" "" "NA" "NA" "NA"
+"MEM" 441130 "Meropenem" "Carbapenems" "J01DH02,QJ01DH02" "Other beta-lactam antibacterials" "Carbapenems" "mem,mer,mero,mp,mrp" "meronem,meropen,meropenemum,merrem" 3 "g" "101222-8,101488-5,101489-3,18943-1,41406-0,6651-4,6652-2,6653-0,6654-8,7029-2,85426-5,85427-3,88892-5,90980-4"
+"MNC" "Meropenem/nacubactam" "Carbapenems" "" "NA" "NA" "NA"
+"MEV" "Meropenem/vaborbactam" "Carbapenems" "" "Other beta-lactam antibacterials" "Carbapenems" "NA" "NA" 3 "g" "101222-8,101489-3,85427-3,88892-5,90980-4"
+"MES" 176886 "Mesulfamide" "Other antibacterials" "" "NA" "mesulfamida,mesulfamido,mesulfamidum" "NA"
+"MTC" 54675785 "Metacycline" "Tetracyclines" "J01AA05,QJ01AA05" "Tetracyclines" "Tetracyclines" "NA" "bialatan,metaciclina,metacyclinum,methacyclin,methacycline,methacyclinum,methylenecycline,physiomycine,rondomycin" 0.6 "g" "NA"
+"MTM" 6713928 "Metampicillin" "Beta-lactams/penicillins" "J01CA14,QJ01CA14" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "blomopen,bonopen,celinmicina,elatocilline,filorex,magnipen,metambac,metampen,metampicilina,metampicillina,metampicilline,metampicillinsalt,metampicillinum,micinovo,ocelina,pangocilin,probiotic,relyothenate,ruticina,rutizina,sedomycin,serfabiotic,suvipen,viderpen,viderpin,vioplex" 1.5 "g" 1.5 "g" "NA"
+"MTH" 4101 "Methenamine" "Other antibacterials" "J01XX05,QJ01XX05" "Other antibacterials" "Other antibacterials" "NA" "aminoform,aminoformaldehyde,ammoform,ammonioformaldehyde,antihydral,carin,cystamin,cystex,cystogen,duirexol,esametilentetramina,formamine,formin,grasselerator,heterin,hexaform,hexaloids,hexamethylamine,hexamethylenamine,hexamethyleneamine,hexamethylentetramin,hexamine,hexaminum,hexasan,hexilmethylenamine,metenamina,metenamine,methamin,methamine,methenamin,methenaminum,metramine,naphthamine,pellurin,resotropin,uramin,urasal,uratrine,urisol,uritone,urodeine,urotropin,urotropine,vesaloin,xametrin" 3 "g" "NA"
+"MET" 6087 "Meticillin" "Beta-lactams/penicillins" "J01CF03,QJ01CF03,QJ51CF03" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "meti" "belfacillin,celbenin,celpilline,cinopenil,dimocillin,estafcilina,flabelline,lucopenin,metacillin,methcillin,methicillin,methicillinanhydrous,methicillinhydrate,methicillinsalt,methicillinum,methycillin,meticilina,meticillina,meticilline,meticillinsalt,meticillinum,penaureus,penysol,staficyn,staphcillin,synticillin" 4 "g" "NA"
+"MTP" 68590 "Metioprim" "Other antibacterials" "" "NA" "methioprim,metioprima,metioprime,metioprimum" "NA"
+"MXT" 3047729 "Metioxate" "Fluoroquinolones" "" "NA" "metioxato,metioxatum" "NA"
+"MTR" 4173 "Metronidazole" "Other antibacterials" "A01AB17,D06BX01,G01AF01,J01XD01,P01AB01,QA01AB17,QD06BX01,QG01AF01,QJ01XD01,QP51CA01" "Other antibacterials" "Imidazole derivatives" "metr,mnz" "acromona,anagiardil,arilin,atrivyl,bexon,clont,danizol,deflamon,donnan,efloran,elyzol,entizol,eumin,flagemona,flagesol,flagil,flagyl,flazol,flegyl,florazole,fossyol,giatricol,gineflavir,givagil,hydroxydimetridazole,hydroxymetronidazole,izoklion,klion,klont,mepagyl,meronidal,metric,metrolag,metrolyl,metromidol,metronidazolo,metronidazolum,metroplex,metrotop,mexibol,monagyl,monasin,nalox,nidagyl,noritate,novonidazol,nuvessa,orvagil,polibiotic,protostat,rathimed,rosaced,rosased,sanatrichom,satric,takimetol,trichazol,trichex,trichobrol,trichocide,trichomol,trichopal,trichopol,tricocet,tricom,trikacide,trikamon,trikhopol,trikojol,trikozol,trimeks,trivazol,vagilen,vagimid,vandazole,vertisal,wagitran,zadstat,zidoval" 2 "g" 1.5 "g" "10991-8,18946-4,326-9,327-7,328-5,329-3,7031-8"
+"MEZ" 656511 "Mezlocillin" "Beta-lactams/penicillins" "J01CA10,QJ01CA10" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "mez,mezl,mz" "baycipen,baypen,mezlin,mezlocilina,mezlocilline,mezlocillinsalt,mezlocillinum,multocillin" 6 "g" "18947-2,330-1,331-9,332-7,333-5,3820-8,41702-2,54194-6,54195-3,54196-1"
+"MSU" "Mezlocillin/sulbactam" "Beta-lactams/penicillins" "" "NA" "NA" "54194-6,54195-3,54196-1"
+"MIF" 477468 "Micafungin" "Antifungals/antimycotics" "J02AX05,QJ02AX05" "Antimycotics for systemic use" "Other antimycotics for systemic use" "mica" "fungard,funguard,micafungina,micafunginsalt,mycamine" 0.1 "g" "53812-4,58418-5,65340-2,85048-7"
+"MCZ" 4189 "Miconazole" "Antifungals/antimycotics" "A01AB09,A07AC01,D01AC02,G01AF04,J02AB01,QA01AB09,QA07AC01,QD01AC02,QG01AF04,QJ02AB01,QS02AA13,S02AA13" "Antimycotics for systemic use" "Imidazole derivatives" "mico" "aflorix,albistat,andergin,brentan,conofite,dactarin,florid,micantin,miconazol,miconazolo,miconazolum,micozole,minostate,monazole,monista,monistat,oravig,vusion,zimybase,zimycan" 0.2 "g" 1 "g" "17278-3,25607-3,25722-0,54180-5,55686-0"
+"MCR" 3037206 "Micronomicin" "Aminoglycosides" "QS01AA22,S01AA22" "NA" "micromicin,micromycin,micronomicina,micronomicine,micronomicinum,sagamicin,santemycin" "NA"
+"MID" 5282169 "Midecamycin" "Macrolides/lincosamides" "J01FA03,QJ01FA03" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "macropen,madecacine,medemycin,midecamicina,midecamycine,midecamycinum,midecin,momicine,myoxam,normicina,rubimycin" 1.2 "g" 1 "g" "NA"
+"MIL" 37614 "Miloxacin" "Fluoroquinolones" "" "NA" "miloxacine,miloxacino,miloxacinum" "NA"
+"MNO" 54675783 "Minocycline" "Tetracyclines" "A01AB23,D10AF07,J01AA08,QA01AB23,QD10AF07,QJ01AA08" "Tetracyclines" "Tetracyclines" "mc,mh,mi,min,mino,mn,mno" "acnez,arestin,borymycin,dynacin,lederderm,minociclina,minocin,minocline,minocyclin,minocyclinum,minocyn,minomax,minomycin,mynocine,periocline,solodyn,vectrin,ximino" 1 "mg" 0.2 "g" "18948-0,25225-4,334-3,335-0,336-8,337-6,34606-4,3822-4,49757-8,55156-4,7032-6"
+"MCM" 5282188 "Miocamycin" "Macrolides/lincosamides" "J01FA11,QJ01FA11" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "acecamycin,macroral,miocamen,miocamycine,miokamycin,mosil,myocamicin,ponsinomycin" 1.2 "g" "18949-8,338-4,339-2,340-0,341-8,55687-8"
+"MON" 23667299 "Monensin sodium" "Other antibacterials" "" "NA" "coban,elancoban,monelan,monensin,monensina,monensine,monensinum,monovet,romensin,rumensin" "NA"
+"MRN" 70374 "Morinamide" "Antimycobacterials" "J04AK04,QJ04AK04" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "NA" "morfazinamide,morfazinammide,morfgazinamide,morinamida,morinamidum,morphazinamid,morphazinamide,piazofolina,piazolin,piazolina" "NA"
+"MFX" 152946 "Moxifloxacin" "Fluoroquinolones" "J01MA14,QJ01MA14,QS01AE07,S01AE07" "Quinolone antibacterials" "Fluoroquinolones" "mox,moxi,mxf" "actira,actura,avalox,avelox,avolex,izilox,moxeza,moxifloxacine,moxifloxacino,octegra,vegamox,vigamox,zimoxin" 0.4 "g" 0.4 "g" "31037-5,31039-1,31041-7,31043-3,41502-6,43751-7,45223-5,76043-9,76044-7,76045-4,80540-8,88707-5,93497-6,96112-8"
+"MUP" 446596 "Mupirocin" "Other antibacterials" "D06AX09,QD06AX09,QR01AX06,R01AX06" "mup,mupi" "bactoderm,bactroban,centany,mupirocina,mupirocine,mupirocinum,plasimine,turixin" "20389-3,35822-6,35823-4,60542-8,60543-6,7033-4"
+"NAC" 73386748 "Nacubactam" "Beta-lactams/penicillins" "" "NA" "NA" "NA"
+"NAD" 4410 "Nadifloxacin" "Fluoroquinolones" "D10AF05,QD10AF05" "NA" "acuatim,nadifloxacine,nadifloxacino,nadifloxacinum,nadixa,nadoxin" "NA"
+"NAF" 8982 "Nafcillin" "Beta-lactams/penicillins" "J01CF06,QJ01CF06" "NA" "nafcil,nafcilin,nafcilina,nafcillinanhydrous,nafcilline,nafcillinhydrate,nafcillinmonohydrate,nafcillinsalt,nafcillinum,naftopen,nallpen,naphcillin,naphthicillin,unipen" 3 "g" "10993-4,18951-4,25232-0,346-7,347-5,348-3,349-1,41704-8"
+"ZWK" 117587595 "Nafithromycin" "Macrolides/lincosamides" "" "NA" "NA" "NA"
+"NAL" 4421 "Nalidixic acid" "Quinolones" "J01MB02,QJ01MB02" "Quinolone antibacterials" "Other quinolones" "na,nal,nali" "amfonelinsaeure,baktogram,betaxina,chemiurin,cybis,dixiben,dixilina,dixinal,eucisten,eucistin,innoxalomn,innoxalon,jicsron,kusnarin,nalidicron,nalidixan,nalidixane,nalidixate,nalidixateanhydrous,nalidixic,nalidixin,nalidixinsaure,nalitucsan,nalix,nalurin,narigix,naxuril,negram,nevigramon,nicelate,nogram,poleon,sicmylon,specifen,specifin,unaserus,uralgin,uriben,uriclar,urisal,urodixin,uroman,uroneg,uronidix,uropan,wintomylon,wintron" 4 "g" "NA"
+"NAL-S" "Nalidixic acid screening test" "Quinolones" "" "nal screen" "NA" "NA"
"NAR" 65452 "Narasin" "Other antibacterials" "QP51BB04" "NA" "monteban,narasine,narasino,narasinum,skycis" "87570-8"
-"NEM" 11993740 "Nemonoxacin" "Fluoroquinolones" "J01MB08" "Quinolone antibacterials" "Other quinolones" "NA" "NA" "NA"
-"NEO" 8378 "Neomycin" "Aminoglycosides" "A01AB08,A07AA01,B05CA09,D06AX04,J01GB05,R02AB01,S01AA03,S02AA07,S03AA01" "Aminoglycoside antibacterials" "Other aminoglycosides" "neom" "NA" 5 "g" 1 "g" "10995-9,18953-0,25262-7,354-1,355-8,356-6,357-4,41705-5"
-"NET" 441306 "Netilmicin" "Aminoglycosides" "J01GB07,S01AA23" "Aminoglycoside antibacterials" "Other aminoglycosides" "neti" "netillin,netilmicina,netilmicine,netilmicinum,netilyn,netira,netromicine,netromycin,nettacin,ntromicine,ntromycin,vectacin,zetamicin" 0.35 "g" 0.35 "g" "18954-8,25263-5,358-2,359-0,360-8,361-6,3848-9,3849-7,3850-5,47385-0,59565-2,59566-0,59567-8,7035-9"
-"NIC" 9507 "Nicarbazin" "Other antibacterials" "NA" "NA" "nicarb,nicarbasin,nicarbazine,nicarmix,nicoxin,nicrazin,nicrazine,nirazin" "NA"
-"NIF" 71946 "Nifuroquine" "Fluoroquinolones" "NA" "NA" "abimasten,nifuroquina,nifuroquinum,quinaldofur" "NA"
-"NFR" 9571062 "Nifurtoinol" "Other antibacterials" "J01XE02" "Other antibacterials" "Nitrofuran derivatives" "NA" "levantin,nifurmazol,nifurmazole,nifurmazolo,nifurmazolum,nifurtoinolo,nifurtoinolum,urfadin,urfadine,urfadyn" 0.16 "g" "NA"
+"NEM" 11993740 "Nemonoxacin" "Fluoroquinolones" "J01MB08,QJ01MB08" "Quinolone antibacterials" "Other quinolones" "NA" "NA" "NA"
+"NEO" 8378 "Neomycin" "Aminoglycosides" "A01AB08,A07AA01,B05CA09,D06AX04,J01GB05,QA01AB08,QA07AA01,QB05CA09,QD06AX04,QJ01GB05,QR02AB01,QS01AA03,QS02AA07,QS03AA01,R02AB01,S01AA03,S02AA07,S03AA01" "Aminoglycoside antibacterials" "Other aminoglycosides" "neom" "NA" 5 "g" 1 "g" "10995-9,18953-0,25262-7,354-1,355-8,356-6,357-4,41705-5"
+"NET" 441306 "Netilmicin" "Aminoglycosides" "J01GB07,QJ01GB07,QS01AA23,S01AA23" "Aminoglycoside antibacterials" "Other aminoglycosides" "neti" "netillin,netilmicina,netilmicine,netilmicinum,netilyn,netira,netromicine,netromycin,nettacin,ntromicine,ntromycin,vectacin,zetamicin" 0.35 "g" 0.35 "g" "18954-8,25263-5,358-2,359-0,360-8,361-6,3848-9,3849-7,3850-5,47385-0,59565-2,59566-0,59567-8,7035-9"
+"NIC" 9507 "Nicarbazin" "Other antibacterials" "" "NA" "nicarb,nicarbasin,nicarbazine,nicarmix,nicoxin,nicrazin,nicrazine,nirazin" "NA"
+"NIF" 71946 "Nifuroquine" "Fluoroquinolones" "" "NA" "abimasten,nifuroquina,nifuroquinum,quinaldofur" "NA"
+"NFR" 9571062 "Nifurtoinol" "Other antibacterials" "J01XE02,QJ01XE02" "Other antibacterials" "Nitrofuran derivatives" "NA" "levantin,nifurmazol,nifurmazole,nifurmazolo,nifurmazolum,nifurtoinolo,nifurtoinolum,urfadin,urfadine,urfadyn" 0.16 "g" "NA"
"NTZ" 41684 "Nitazoxanide" "Other antibacterials" "P01AX11" "NA" "alinia,benzamide,colufase,cryptaz,daxon,dexidex,heliton,kidonax,nitax,nitaxozanid,nitaxozanide,nitazox,nitazoxamide,nitazoxanid,nitazoxanida,nitazoxanidum,nitrazoxanide,pacovanton,paramix,phavic" 1 "g" "73595-1,73617-3,73640-5"
-"NIT" 6604200 "Nitrofurantoin" "Other antibacterials" "J01XE01" "Other antibacterials" "Nitrofuran derivatives" "f,f/m,fd,ft,ni,nit,nitr" "alfuran,benkfuran,berkfuran,berkfurin,ceduran,chemiofuran,cistofuran,cyantin,cystit,dantafur,fuamed,furabid,furachel,furadantin,furadantine,furadantoin,furadoin,furadoine,furadonin,furadonine,furadoninum,furadontin,furalan,furaloid,furantoina,furatoin,furedan,furina,furobactina,furodantin,gerofuran,ituran,macpac,macrobid,macrodantin,macrodantina,macrofuran,macrofurin,nierofu,nifuraden,nifuradene,nifuradeno,nifuradenum,nifuradine,nifurantin,nifuretten,nitoin,nitrex,nitrofuradantin,nitrofurantoina,nitrofurantoine,nitrofurantoinum,novofuran,orafuran,oxafuradene,oxafurandene,oxifuradene,oxyfuradene,parfuran,phenurin,renafur,siraliden,trantoin,uerineks,urizept,urodin,urofuran,urofurin,urolisa,urolong,uvamin,welfurin,zoofurin" 0.2 "g" "18955-5,362-4,363-2,364-0,365-7,3860-4,7036-7"
-"NIZ" 5447130 "Nitrofurazone" "Other antibacterials" "NA" "NA" "acutol,aldomycin,alfucin,amifur,babrocid,becafurazone,biofuracina,biofurea,chemofuran,chixin,cocafurin,coxistat,dermofural,dymazone,dynazone,eldezol,fedacin,flavazone,fracine,furacilin,furacilinum,furacillin,furacin,furacine,furacinetten,furacoccid,furacort,furacycline,furaderm,furagent,furalcyn,furaldon,furalone,furametral,furaplast,furaseptyl,furaskin,furatsilin,furaziline,furazin,furazina,furazyme,furesol,furosem,fuvacillin,hemofuran,hydrazinecarboxamide,ibiofural,mammex,mastofuran,monafuracin,monafuracis,monofuracin,nefco,nifucin,nifurid,nifuzon,nitrofural,nitrofuralum,nitrofuran,nitrofurane,nitrofurazan,nitrofurazonum,nitrofurol,nitrozone,otofural,otofuran,rivafurazon,rivopon,sanfuran,semioxamazide,vabrocid,vadrocid,yatrocin" "20388-5,87793-6"
-"NTR" 19910 "Nitroxoline" "Fluoroquinolones" "J01XX07" "Other antibacterials" "Other antibacterials" "NA" "galinok,isinok,nibiol,nicene,nitroxlina,nitroxolin,nitroxolina,nitroxolinum,noxibiol,noxin" 1 "g" "25608-1,25723-8,32382-4,54181-3,55688-6"
-"NOR" 4539 "Norfloxacin" "Fluoroquinolones" "J01MA06,S01AE02" "Quinolone antibacterials" "Fluoroquinolones" "nor,norf,nx,nxn" "baccidal,barazan,chibroxin,chibroxine,chibroxol,fulgram,gonorcin,lexinor,nolicin,noracin,noraxin,norflo,norfloxacine,norfloxacino,norfloxacinum,norocin,noroxin,noroxine,norxacin,sebercim,uroxacin,utinor,zoroxin" 0.8 "g" "18956-3,366-5,367-3,368-1,369-9,3867-9,41504-2,7037-5"
-"NOR-S" "Norfloxacin screening test" "Fluoroquinolones" "NA" "nor screen" "NA" "NA"
-"NME" "Norfloxacin/metronidazole" "Fluoroquinolones" "J01RA14" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
-"NTI" "Norfloxacin/tinidazole" "Fluoroquinolones" "J01RA13" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
-"NVA" 10419027 "Norvancomycin" "Glycopeptides" "NA" "NA" "NA" "NA"
+"NIT" 6604200 "Nitrofurantoin" "Other antibacterials" "J01XE01,QJ01XE01" "Other antibacterials" "Nitrofuran derivatives" "f,f/m,fd,ft,ni,nit,nitr" "alfuran,benkfuran,berkfuran,berkfurin,ceduran,chemiofuran,cistofuran,cyantin,cystit,dantafur,fuamed,furabid,furachel,furadantin,furadantine,furadantoin,furadoin,furadoine,furadonin,furadonine,furadoninum,furadontin,furalan,furaloid,furantoina,furatoin,furedan,furina,furobactina,furodantin,gerofuran,ituran,macpac,macrobid,macrodantin,macrodantina,macrofuran,macrofurin,nierofu,nifuraden,nifuradene,nifuradeno,nifuradenum,nifuradine,nifurantin,nifuretten,nitoin,nitrex,nitrofuradantin,nitrofurantoina,nitrofurantoine,nitrofurantoinum,novofuran,orafuran,oxafuradene,oxafurandene,oxifuradene,oxyfuradene,parfuran,phenurin,renafur,siraliden,trantoin,uerineks,urizept,urodin,urofuran,urofurin,urolisa,urolong,uvamin,welfurin,zoofurin" 0.2 "g" "18955-5,362-4,363-2,364-0,365-7,3860-4,7036-7"
+"NIZ" 5447130 "Nitrofurazone" "Other antibacterials" "" "NA" "acutol,aldomycin,alfucin,amifur,babrocid,becafurazone,biofuracina,biofurea,chemofuran,chixin,cocafurin,coxistat,dermofural,dymazone,dynazone,eldezol,fedacin,flavazone,fracine,furacilin,furacilinum,furacillin,furacin,furacine,furacinetten,furacoccid,furacort,furacycline,furaderm,furagent,furalcyn,furaldon,furalone,furametral,furaplast,furaseptyl,furaskin,furatsilin,furaziline,furazin,furazina,furazyme,furesol,furosem,fuvacillin,hemofuran,hydrazinecarboxamide,ibiofural,mammex,mastofuran,monafuracin,monafuracis,monofuracin,nefco,nifucin,nifurid,nifuzon,nitrofural,nitrofuralum,nitrofuran,nitrofurane,nitrofurazan,nitrofurazonum,nitrofurol,nitrozone,otofural,otofuran,rivafurazon,rivopon,sanfuran,semioxamazide,vabrocid,vadrocid,yatrocin" "20388-5,87793-6"
+"NTR" 19910 "Nitroxoline" "Fluoroquinolones" "J01XX07,QJ01XX07" "Other antibacterials" "Other antibacterials" "NA" "galinok,isinok,nibiol,nicene,nitroxlina,nitroxolin,nitroxolina,nitroxolinum,noxibiol,noxin" 1 "g" "25608-1,25723-8,32382-4,54181-3,55688-6"
+"NOR" 4539 "Norfloxacin" "Fluoroquinolones" "J01MA06,QJ01MA06,QS01AE02,S01AE02" "Quinolone antibacterials" "Fluoroquinolones" "nor,norf,nx,nxn" "baccidal,barazan,chibroxin,chibroxine,chibroxol,fulgram,gonorcin,lexinor,nolicin,noracin,noraxin,norflo,norfloxacine,norfloxacino,norfloxacinum,norocin,noroxin,noroxine,norxacin,sebercim,uroxacin,utinor,zoroxin" 0.8 "g" "18956-3,366-5,367-3,368-1,369-9,3867-9,41504-2,7037-5"
+"NOR-S" "Norfloxacin screening test" "Fluoroquinolones" "" "nor screen" "NA" "NA"
+"NME" "Norfloxacin/metronidazole" "Fluoroquinolones" "" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
+"NTI" "Norfloxacin/tinidazole" "Fluoroquinolones" "" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
+"NVA" 10419027 "Norvancomycin" "Glycopeptides" "" "NA" "NA" "NA"
"NOV" 54675769 "Novobiocin" "Other antibacterials" "QJ01XX95" "novo" "albadry,albamix,albamycin,biotexin,cardelmycin,cardelmycinsalt,cathocin,cathomycin,inabiocin,novobiocina,novobiocine,novobiocinsalt,novobiocinum,robiocina,sirbiocina,spheromycin,stilbiocina,streptonivicin,streptonivicinsalt,vulcamicina,vulcamycin,vulkamycin" "17378-1,18957-1,370-7,371-5,372-3,373-1,41706-3"
-"NYS" 6433272 "Nystatin" "Antifungals/antimycotics" "A07AA02,D01AA01,G01AA01" "nyst" "biofanal,diastatin,herniocid,moronal,myconystatin,mycostatin,mykostatyna,nilstat,nistatin,nistatina,nyotran,nystan,nystatyna,nystavescent,nystex" 1.5 "MU" "10697-1,10698-9,18958-9,35824-2,55689-4"
-"OFX" 4583 "Ofloxacin" "Fluoroquinolones" "J01MA01,S01AE01,S02AA16" "Quinolone antibacterials" "Fluoroquinolones" "of,ofl,oflo,ofx" "exocin,exocine,flobacin,floxil,floxin,monoflocet,oflocet,ofloxacina,ofloxacine,ofloxacino,ofloxacinum,ofloxaxin,oxaldin,tarivid,visiren,zanocin" 0.4 "g" 0.4 "g" "18959-7,20384-4,23948-3,25264-3,374-9,375-6,376-4,377-2,3877-8,41408-6,41409-4,41410-2,42653-6,7038-3,72168-8"
-"OOR" "Ofloxacin/ornidazole" "Fluoroquinolones" "J01RA09" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
-"OLE" 72493 "Oleandomycin" "Macrolides/lincosamides" "J01FA05" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "amimycin,landomycin,matromycin,oleandomicina,oleandomycine,oleandomycinum,romicil" 1 "g" "18960-5,378-0,379-8,380-6,381-4,55690-2"
-"OMC" 54697325 "Omadacycline" "Tetracyclines" "J01AA15" "NA" "amadacycline" 0.3 "g" 0.1 "g" "73594-4,73616-5,73639-7"
-"OPT" 87880 "Optochin" "Other antibacterials" "NA" "NA" "aflukin,auriquin,biquinate,chinidin,chinidine,chinimetten,chinin,chinine,conchinin,conchinine,conquinine,dentojel,dihydrochinidin,dihydroquinidine,dihydroquinine,hydroconchinine,hydroconquinine,hydroquinidine,kinidin,numoquin,optochine,optoquine,pitayine,qualaquin,quinaglute,quinicardine,quinidex,quinidine,quiniduran,quinindine,quinine,quinineanhydrous,quinora,quinsan,rezquin" "100055-3,73665-2"
+"NYS" 6433272 "Nystatin" "Antifungals/antimycotics" "A07AA02,D01AA01,G01AA01,QA07AA02,QD01AA01,QG01AA01" "nyst" "biofanal,diastatin,herniocid,moronal,myconystatin,mycostatin,mykostatyna,nilstat,nistatin,nistatina,nyotran,nystan,nystatyna,nystavescent,nystex" 1.5 "MU" "10697-1,10698-9,18958-9,35824-2,55689-4"
+"OFX" 4583 "Ofloxacin" "Fluoroquinolones" "J01MA01,QJ01MA01,QS01AE01,QS02AA16,S01AE01,S02AA16" "Quinolone antibacterials" "Fluoroquinolones" "of,ofl,oflo,ofx" "exocin,exocine,flobacin,floxil,floxin,monoflocet,oflocet,ofloxacina,ofloxacine,ofloxacino,ofloxacinum,ofloxaxin,oxaldin,tarivid,visiren,zanocin" 0.4 "g" 0.4 "g" "18959-7,20384-4,23948-3,25264-3,374-9,375-6,376-4,377-2,3877-8,41408-6,41409-4,41410-2,42653-6,7038-3,72168-8"
+"OOR" "Ofloxacin/ornidazole" "Fluoroquinolones" "" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
+"OLE" 72493 "Oleandomycin" "Macrolides/lincosamides" "J01FA05,QJ01FA05" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "amimycin,landomycin,matromycin,oleandomicina,oleandomycine,oleandomycinum,romicil" 1 "g" "18960-5,378-0,379-8,380-6,381-4,55690-2"
+"OMC" 54697325 "Omadacycline" "Tetracyclines" "J01AA15,QJ01AA15" "NA" "amadacycline" 0.3 "g" 0.1 "g" "73594-4,73616-5,73639-7"
+"OPT" 87880 "Optochin" "Other antibacterials" "" "NA" "aflukin,auriquin,biquinate,chinidin,chinidine,chinimetten,chinin,chinine,conchinin,conchinine,conquinine,dentojel,dihydrochinidin,dihydroquinidine,dihydroquinine,hydroconchinine,hydroconquinine,hydroquinidine,kinidin,numoquin,optochine,optoquine,pitayine,qualaquin,quinaglute,quinicardine,quinidex,quinidine,quiniduran,quinindine,quinine,quinineanhydrous,quinora,quinsan,rezquin" "100055-3,73665-2"
"ORB" 60605 "Orbifloxacin" "Fluoroquinolones" "QJ01MA95" "NA" "orbax" "35825-9,35826-7,35827-5"
-"ORI" 16136912 "Oritavancin" "Glycopeptides" "J01XA05" "Other antibacterials" "Glycopeptide antibacterials" "orit" "NA" "41707-1,41708-9,41709-7,41736-0"
-"ORS" "Ormetroprim/sulfamethoxazole" "Other antibacterials" "NA" "NA" "NA" "73593-6,73615-7,73638-9"
-"ORN" 28061 "Ornidazole" "Other antibacterials" "G01AF06,J01XD03,P01AB03" "Other antibacterials" "Imidazole derivatives" "NA" "levornidazole,madelen,ornidal,ornidazolum,tiberal" 1.5 "g" 1 "g" "55691-0,55692-8,55693-6,55694-4"
-"OTE" 77050711 "Oteseconazole" "Antifungals/antimycotics" "J02AC06" "Antimycotics for systemic use" "Triazole derivatives" "NA" "quilseconazole,vivijoa" 21 "mg" "NA"
-"OXA" 6196 "Oxacillin" "Beta-lactams/penicillins" "J01CF04" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "ox,oxa,oxac,oxal,oxs" "bactocill,bristopen,cryptocillin,micropenin,ossacillina,oxabel,oxabelsalt,oxacilina,oxacillinanhydrous,oxacilline,oxacillinhydrate,oxacillinsalt,oxacillinum,oxazocillin,oxazocilline,penstapho,prostaphlin,prostaphlyn,resistopen,stapenor" 2 "g" 2 "g" "18961-3,25265-0,382-2,383-0,384-8,385-5,3882-8,7039-1"
-"OXA-S" "Oxacillin screening test" "Beta-lactams/penicillins" "NA" "oxa screen" "NA" "NA"
-"OXO" 4628 "Oxolinic acid" "Quinolones" "J01MB05" "Quinolone antibacterials" "Other quinolones" "NA" "aqualinic,cistopax,dioxacin,emyrenil,gramurin,inoxyl,nidantin,oksaren,orthurine,ossian,oxoboi,oxolinic,pietil,prodoxal,prodoxol,starner,tiurasin,ultibid,urinox,uritrate,urotrate,uroxol,utibid" 1 "g" "NA"
-"OXY" 54675779 "Oxytetracycline" "Tetracyclines" "A01AB25,D06AA03,G01AA07,J01AA06,S01AA04" "Tetracyclines" "Tetracyclines" "NA" "achromycin,actisite,adamycin,artomycin,berkmycen,biostat,bristacycline,cancycline,cyclopar,dabicycline,diacycine,dumocyclin,embryostat,fanterrin,galsenomycin,geomycin,geotilin,hostacycline,hydroxytetracyclinum,lenocycline,macocyn,medamycin,mephacyclin,nitox,oksisyklin,ossitetraciclina,oxitetraciclina,oxitetracyclin,oxitetracycline,oxitetracyclinum,oxymycin,oxypam,oxyterracin,oxyterracine,oxyterracyne,oxytetracid,oxytetracyclin,oxytetracyclinum,paltet,partrex,pennox,piracaps,proteroxyna,qidtet,quadracycline,quatrex,remicyclin,retet,ricycline,riomitsin,ryomycin,solkaciclina,stevacin,stilciclina,subamycin,sumycin,supramycin,sustamycin,tarocyn,tarosin,tefilin,teline,telotrex,teravit,terrafungine,terramitsin,terramycine,tetrabakat,tetrabid,tetrablet,tetracaps,tetracompren,tetrakap,tetralution,tetramavan,tetramed,tetran,tetrosol,topicycline,triphacyclin,unicin,ursocyclin,ursocycline,vetquamycin" 1 "g" 1 "g" "17396-3,18962-1,25266-8,386-3,387-1,388-9,389-7,55699-3,87595-5"
-"OZN" "Ozenoxacin" "D06AX14" "NA" "NA" "NA"
-"PAS" 4649 "P-aminosalicylic acid" "Antimycobacterials" "NA" "NA" "NA" "NA"
-"PAN" 72015 "Panipenem" "Carbapenems" "J01DH55" "NA" "carbenin,panipenemum,penipanem" 2 "g" "100056-1,53823-1"
-"PAR" 165580 "Paromomycin" "Other antibacterials" "A07AA06" "NA" "aminosidin,amminosidin,crestomycin,estomycin,gabbromycin,gabromycin,humatin,humycin,hydroxymycin,monomycin,paramomycin,paromomicina,paromomycine,paromomycinum,paucimycin,paucimycinum" 3 "g" "51719-3,53824-9,55700-9,55701-7,55702-5"
-"PAZ" 65957 "Pazufloxacin" "Fluoroquinolones" "J01MA18" "Quinolone antibacterials" "Fluoroquinolones" "NA" "pazufloxacine,pazufloxacino,pazufloxacinum" 1 "g" "NA"
-"PEF" 51081 "Pefloxacin" "Fluoroquinolones" "J01MA03" "Quinolone antibacterials" "Fluoroquinolones" "pefl" "labocton,pefbid,pefloxacine,pefloxacinium,pefloxacino,pefloxacinum,pefocin,pefran,pelox" 0.8 "g" 0.8 "g" "18963-9,35828-3,390-5,3906-5,7040-9"
-"PEF-S" "Pefloxacin screening test" "Fluoroquinolones" "NA" "pef screen" "NA" "NA"
-"PNM" 10250769 "Penamecillin" "Beta-lactams/penicillins" "J01CE06" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "havapen,hydroxymethyl,penamecilina,penamecillina,penamecilline,penamecillinum" 1.05 "g" "NA"
-"PNO" "Penicillin/novobiocin" "Beta-lactams/penicillins" "NA" "NA" "NA" "35872-1,35873-9,35874-7"
-"PSU" "Penicillin/sulbactam" "Beta-lactams/penicillins" "NA" "NA" "NA" "NA"
-"PNM1" 54686187 "Penimepicycline" "Tetracyclines" "J01AA10" "Tetracyclines" "Tetracyclines" "NA" "criseocil,duamine,geotricyn,hydrocycline,penetracyne,penimepiciclina,penimepicyclinum" "NA"
-"PIM" 65453 "Pentisomicin" "Aminoglycosides" "NA" "NA" "mutamicin,mutamycin,pentisomicina,pentisomicine,pentisomicinum" "NA"
-"PTZ" 55250256 "Pentizidone" "Other antibacterials" "NA" "NA" "pentizidona,pentizidonum" "NA"
-"PEX" 16132253 "Pexiganan" "Other antibacterials" "NA" "NA" "cytolex,mangainin" "NA"
-"PHE" 272833 "Pheneticillin" "Beta-lactams/penicillins" "J01CE05" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "fene" "alfacillin,alticina,antibiocin,arcacil,arcasin,astracillin,bendralan,beromycin,brocsil,broxil,chemipen,cliacil,darcil,feneticilina,feneticillin,feneticillina,feneticilline,fenocin,icipen,isocillin,ispenoral,kavepenin,maxipen,optipen,oralopen,orapen,ospeneff,pedipen,penagen,pencompren,penemve,peniplus,penova,pensig,penvikal,phenethicilin,phenethicillin,phenethicillinum,pheneticilline,pheneticillinum,primcillin,priospen,roscopenin,semopen,suspen,synapen,syncillin,synerpenin,synthecillin,synthecilline,synthepen,triospen,vamosyn,veetids,vepen" 1 "g" "NA"
-"PHN" 6869 "Phenoxymethylpenicillin" "Beta-lactams/penicillins" "J01CE02" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "fepe,peni v,penicillin v,pnv,pv" "apopen,calcipen,fenacilin,fenospen,meropenin,oracillin,oracilline,oratren,orocillin,ospen,phenocillin,phenomycilline,phenopenicillin,rocilin,stabicillin,vebecillin" 2 "g" "NA"
-"PMR" 5284447 "Pimaricin" "Antifungals/antimycotics" "NA" "natamycin" "delvocid,delvolan,delvopos,mycophyt,myprozine,natacyn,natafucin,natajen,natamatrix,natamax,natamicina,natamycin,natamycine,natamycinum,pimafucin,pimaracin,pimaricine,pimarizin,synogil,tennecetin" "NA"
-"PPA" 4831 "Pipemidic acid" "Quinolones" "J01MB04" "Quinolone antibacterials" "Other quinolones" "pipz,pizu" "deblaston,dolcol,filtrax,karunomazin,memento,nuril,palin,pipedac,pipemid,pipemidate,pipemidic,pipemidicacid,pipram,pipurin,tractur,uromidin,urosten,uroval" 0.8 "g" "NA"
-"PIP" 43672 "Piperacillin" "Beta-lactams/penicillins" "J01CA12" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "pi,pip,pipc,pipe,pp" "penmalin,pentcillin,peperacillin,peracin,piperacilina,piperacillina,piperacilline,piperacillinhydrate,piperacillinum,pipercillin,pipracil,tazocin" 14 "g" "101490-1,101491-9,18969-6,18970-4,25268-4,3972-7,407-7,408-5,409-3,410-1,411-9,412-7,413-5,414-3,54197-9,54198-7,54199-5,55704-1,7043-3,7044-1"
-"PIS" "Piperacillin/sulbactam" "Beta-lactams/penicillins" "NA" "NA" "NA" "54197-9,54198-7,54199-5,55704-1"
-"TZP" 461573 "Piperacillin/tazobactam" "Beta-lactams/penicillins" "J01CR05" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "p/t,piptaz,piptazo,pit,pita,pt,ptc,ptz,tzp" "piptazobactam,tazonam,zobactin,zosyn" 14 "g" "101491-9,18970-4,411-9,412-7,413-5,414-3,7044-1"
-"PRC" 71978 "Piridicillin" "Beta-lactams/penicillins" "NA" "NA" "NA" "NA"
+"ORI" 16136912 "Oritavancin" "Glycopeptides" "J01XA05,QJ01XA05" "Other antibacterials" "Glycopeptide antibacterials" "orit" "NA" "41707-1,41708-9,41709-7,41736-0"
+"ORS" "Ormetroprim/sulfamethoxazole" "Other antibacterials" "" "NA" "NA" "73593-6,73615-7,73638-9"
+"ORN" 28061 "Ornidazole" "Other antibacterials" "G01AF06,J01XD03,P01AB03,QG01AF06,QJ01XD03,QP51AA03" "Other antibacterials" "Imidazole derivatives" "NA" "levornidazole,madelen,ornidal,ornidazolum,tiberal" 1.5 "g" 1 "g" "55691-0,55692-8,55693-6,55694-4"
+"OTE" 77050711 "Oteseconazole" "Antifungals/antimycotics" "J02AC06,QJ02AC06" "Antimycotics for systemic use" "Triazole derivatives" "NA" "quilseconazole,vivijoa" 21 "mg" "NA"
+"OXA" 6196 "Oxacillin" "Beta-lactams/penicillins" "J01CF04,QJ01CF04,QJ51CF04" "Beta-lactam antibacterials, penicillins" "Beta-lactamase resistant penicillins" "ox,oxa,oxac,oxal,oxs" "bactocill,bristopen,cryptocillin,micropenin,ossacillina,oxabel,oxabelsalt,oxacilina,oxacillinanhydrous,oxacilline,oxacillinhydrate,oxacillinsalt,oxacillinum,oxazocillin,oxazocilline,penstapho,prostaphlin,prostaphlyn,resistopen,stapenor" 2 "g" 2 "g" "18961-3,25265-0,382-2,383-0,384-8,385-5,3882-8,7039-1"
+"OXA-S" "Oxacillin screening test" "Beta-lactams/penicillins" "" "oxa screen" "NA" "NA"
+"OXO" 4628 "Oxolinic acid" "Quinolones" "J01MB05,QJ01MB05" "Quinolone antibacterials" "Other quinolones" "NA" "aqualinic,cistopax,dioxacin,emyrenil,gramurin,inoxyl,nidantin,oksaren,orthurine,ossian,oxoboi,oxolinic,pietil,prodoxal,prodoxol,starner,tiurasin,ultibid,urinox,uritrate,urotrate,uroxol,utibid" 1 "g" "NA"
+"OXY" 54675779 "Oxytetracycline" "Tetracyclines" "A01AB25,D06AA03,G01AA07,J01AA06,QA01AB25,QD06AA03,QG01AA07,QG51AA01,QJ01AA06,QJ51AA06,QS01AA04,S01AA04" "Tetracyclines" "Tetracyclines" "NA" "achromycin,actisite,adamycin,artomycin,berkmycen,biostat,bristacycline,cancycline,cyclopar,dabicycline,diacycine,dumocyclin,embryostat,fanterrin,galsenomycin,geomycin,geotilin,hostacycline,hydroxytetracyclinum,lenocycline,macocyn,medamycin,mephacyclin,nitox,oksisyklin,ossitetraciclina,oxitetraciclina,oxitetracyclin,oxitetracycline,oxitetracyclinum,oxymycin,oxypam,oxyterracin,oxyterracine,oxyterracyne,oxytetracid,oxytetracyclin,oxytetracyclinum,paltet,partrex,pennox,piracaps,proteroxyna,qidtet,quadracycline,quatrex,remicyclin,retet,ricycline,riomitsin,ryomycin,solkaciclina,stevacin,stilciclina,subamycin,sumycin,supramycin,sustamycin,tarocyn,tarosin,tefilin,teline,telotrex,teravit,terrafungine,terramitsin,terramycine,tetrabakat,tetrabid,tetrablet,tetracaps,tetracompren,tetrakap,tetralution,tetramavan,tetramed,tetran,tetrosol,topicycline,triphacyclin,unicin,ursocyclin,ursocycline,vetquamycin" 1 "g" 1 "g" "17396-3,18962-1,25266-8,386-3,387-1,388-9,389-7,55699-3,87595-5"
+"OZN" "Ozenoxacin" "D06AX14,QD06AX14" "NA" "NA" "NA"
+"PAS" 4649 "P-aminosalicylic acid" "Antimycobacterials" "" "NA" "NA" "NA"
+"PAN" 72015 "Panipenem" "Carbapenems" "" "NA" "carbenin,panipenemum,penipanem" 2 "g" "100056-1,53823-1"
+"PAR" 165580 "Paromomycin" "Other antibacterials" "A07AA06,QA07AA06,QJ01GB92" "NA" "aminosidin,amminosidin,crestomycin,estomycin,gabbromycin,gabromycin,humatin,humycin,hydroxymycin,monomycin,paramomycin,paromomicina,paromomycine,paromomycinum,paucimycin,paucimycinum" 3 "g" "51719-3,53824-9,55700-9,55701-7,55702-5"
+"PAZ" 65957 "Pazufloxacin" "Fluoroquinolones" "J01MA18,QJ01MA18" "Quinolone antibacterials" "Fluoroquinolones" "NA" "pazufloxacine,pazufloxacino,pazufloxacinum" 1 "g" "NA"
+"PEF" 51081 "Pefloxacin" "Fluoroquinolones" "J01MA03,QJ01MA03" "Quinolone antibacterials" "Fluoroquinolones" "pefl" "labocton,pefbid,pefloxacine,pefloxacinium,pefloxacino,pefloxacinum,pefocin,pefran,pelox" 0.8 "g" 0.8 "g" "18963-9,35828-3,390-5,3906-5,7040-9"
+"PEF-S" "Pefloxacin screening test" "Fluoroquinolones" "" "pef screen" "NA" "NA"
+"PNM" 10250769 "Penamecillin" "Beta-lactams/penicillins" "J01CE06,QJ01CE06" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "havapen,hydroxymethyl,penamecilina,penamecillina,penamecilline,penamecillinum" 1.05 "g" "NA"
+"PNO" "Penicillin/novobiocin" "Beta-lactams/penicillins" "" "NA" "NA" "35872-1,35873-9,35874-7"
+"PSU" "Penicillin/sulbactam" "Beta-lactams/penicillins" "" "NA" "NA" "NA"
+"PNM1" 54686187 "Penimepicycline" "Tetracyclines" "J01AA10,QJ01AA10" "Tetracyclines" "Tetracyclines" "NA" "criseocil,duamine,geotricyn,hydrocycline,penetracyne,penimepiciclina,penimepicyclinum" "NA"
+"PIM" 65453 "Pentisomicin" "Aminoglycosides" "" "NA" "mutamicin,mutamycin,pentisomicina,pentisomicine,pentisomicinum" "NA"
+"PTZ" 55250256 "Pentizidone" "Other antibacterials" "" "NA" "pentizidona,pentizidonum" "NA"
+"PEX" 16132253 "Pexiganan" "Other antibacterials" "" "NA" "cytolex,mangainin" "NA"
+"PHE" 272833 "Pheneticillin" "Beta-lactams/penicillins" "J01CE05,QJ01CE05" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "fene" "alfacillin,alticina,antibiocin,arcacil,arcasin,astracillin,bendralan,beromycin,brocsil,broxil,chemipen,cliacil,darcil,feneticilina,feneticillin,feneticillina,feneticilline,fenocin,icipen,isocillin,ispenoral,kavepenin,maxipen,optipen,oralopen,orapen,ospeneff,pedipen,penagen,pencompren,penemve,peniplus,penova,pensig,penvikal,phenethicilin,phenethicillin,phenethicillinum,pheneticilline,pheneticillinum,primcillin,priospen,roscopenin,semopen,suspen,synapen,syncillin,synerpenin,synthecillin,synthecilline,synthepen,triospen,vamosyn,veetids,vepen" 1 "g" "NA"
+"PHN" 6869 "Phenoxymethylpenicillin" "Beta-lactams/penicillins" "J01CE02,QJ01CE02" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "fepe,peni v,penicillin v,pnv,pv" "apopen,calcipen,fenacilin,fenospen,meropenin,oracillin,oracilline,oratren,orocillin,ospen,phenocillin,phenomycilline,phenopenicillin,rocilin,stabicillin,vebecillin" 2 "g" "NA"
+"PMR" 5284447 "Pimaricin" "Antifungals/antimycotics" "" "natamycin" "delvocid,delvolan,delvopos,mycophyt,myprozine,natacyn,natafucin,natajen,natamatrix,natamax,natamicina,natamycin,natamycine,natamycinum,pimafucin,pimaracin,pimaricine,pimarizin,synogil,tennecetin" "NA"
+"PPA" 4831 "Pipemidic acid" "Quinolones" "J01MB04,QJ01MB04" "Quinolone antibacterials" "Other quinolones" "pipz,pizu" "deblaston,dolcol,filtrax,karunomazin,memento,nuril,palin,pipedac,pipemid,pipemidate,pipemidic,pipemidicacid,pipram,pipurin,tractur,uromidin,urosten,uroval" 0.8 "g" "NA"
+"PIP" 43672 "Piperacillin" "Beta-lactams/penicillins" "J01CA12,QJ01CA12" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "pi,pip,pipc,pipe,pp" "penmalin,pentcillin,peperacillin,peracin,piperacilina,piperacillina,piperacilline,piperacillinhydrate,piperacillinum,pipercillin,pipracil,tazocin" 14 "g" "101490-1,101491-9,18969-6,18970-4,25268-4,3972-7,407-7,408-5,409-3,410-1,411-9,412-7,413-5,414-3,54197-9,54198-7,54199-5,55704-1,7043-3,7044-1"
+"PIS" "Piperacillin/sulbactam" "Beta-lactams/penicillins" "J01CR05,QJ01CR05" "NA" "NA" "54197-9,54198-7,54199-5,55704-1"
+"TZP" 461573 "Piperacillin/tazobactam" "Beta-lactams/penicillins" "J01CR05,QJ01CR05" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "p/t,piptaz,piptazo,pit,pita,pt,ptc,ptz,tzp" "piptazobactam,tazonam,zobactin,zosyn" 14 "g" "101491-9,18970-4,411-9,412-7,413-5,414-3,7044-1"
+"PRC" 71978 "Piridicillin" "Beta-lactams/penicillins" "" "NA" "NA" "NA"
"PRL" 157385 "Pirlimycin" "Macrolides/lincosamides" "QJ51FF90" "NA" "pirlimycina,pirlimycine,pirlimycinum,pirsue" "35829-1,35830-9,35831-7"
-"PIR" 4855 "Piromidic acid" "Quinolones" "J01MB03" "Quinolone antibacterials" "Other quinolones" "NA" "bactramyl,enterol,gastrurol,panacid,pirodal,piromidate,reelon,septural,urisept,uropir,zaomeal" 2 "g" "NA"
-"PVM" 33478 "Pivampicillin" "Beta-lactams/penicillins" "J01CA02" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "pivaloylampicillin,pivampicilina,pivampicilline,pivampicillinum" 1.05 "g" "18971-2,415-0,416-8,417-6,418-4"
-"PME" 115163 "Pivmecillinam" "Beta-lactams/penicillins" "J01CA08" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "coactabs,melysin,pivamdinocillin,pivmecilinamo,pivmecillinamum,selexid" 0.6 "g" "NA"
-"PLZ" 42613186 "Plazomicin" "Aminoglycosides" "J01GB14" "NA" "zemdri" "73592-8,73614-0,73637-1,92024-9,94719-2"
-"PLB" 49800004 "Polymyxin B" "Polymyxins" "A07AA05,J01XB02,S01AA18,S02AA11,S03AA03" "Other antibacterials" "Polymyxins" "pb,pol,polb,poly,poly b,polymixin,polymixin b" "aerosporin" 3 "MU" 0.15 "g" "17473-0,18972-0,25269-2,35832-5,419-2,420-0,421-8,422-6"
-"POP" "Polymyxin B/polysorbate 80" "Polymyxins" "NA" "NA" "NA" "NA"
-"POS" 468595 "Posaconazole" "Antifungals/antimycotics" "J02AC04" "Antimycotics for systemic use" "Triazole derivatives" "posa" "noxafil,schering,spriafil" 0.3 "g" 0.3 "g" "53731-6,54186-2,54187-0,54188-8,54189-6,80545-7"
+"PIR" 4855 "Piromidic acid" "Quinolones" "J01MB03,QJ01MB03" "Quinolone antibacterials" "Other quinolones" "NA" "bactramyl,enterol,gastrurol,panacid,pirodal,piromidate,reelon,septural,urisept,uropir,zaomeal" 2 "g" "NA"
+"PVM" 33478 "Pivampicillin" "Beta-lactams/penicillins" "J01CA02,QJ01CA02" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "pivaloylampicillin,pivampicilina,pivampicilline,pivampicillinum" 1.05 "g" "18971-2,415-0,416-8,417-6,418-4"
+"PME" 115163 "Pivmecillinam" "Beta-lactams/penicillins" "J01CA08,QJ01CA08" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "coactabs,melysin,pivamdinocillin,pivmecilinamo,pivmecillinamum,selexid" 0.6 "g" "NA"
+"PLZ" 42613186 "Plazomicin" "Aminoglycosides" "J01GB14,QJ01GB14" "NA" "zemdri" "73592-8,73614-0,73637-1,92024-9,94719-2"
+"PLB" 49800004 "Polymyxin B" "Polymyxins" "A07AA05,J01XB02,QA07AA05,QJ01XB02,QJ51XB02,QS01AA18,QS02AA11,QS03AA03,S01AA18,S02AA11,S03AA03" "Other antibacterials" "Polymyxins" "pb,pol,polb,poly,poly b,polymixin,polymixin b" "aerosporin" 3 "MU" 0.15 "g" "17473-0,18972-0,25269-2,35832-5,419-2,420-0,421-8,422-6"
+"POP" "Polymyxin B/polysorbate 80" "Polymyxins" "" "NA" "NA" "NA"
+"POS" 468595 "Posaconazole" "Antifungals/antimycotics" "J02AC04,QJ02AC04" "Antimycotics for systemic use" "Triazole derivatives" "posa" "noxafil,schering,spriafil" 0.3 "g" 0.3 "g" "53731-6,54186-2,54187-0,54188-8,54189-6,80545-7"
"PRA" 9802884 "Pradofloxacin" "Fluoroquinolones" "QJ01MA97" "NA" "pudofloxacin,veraflox" "76148-6,87800-9"
-"PRX" 71455 "Premafloxacin" "Fluoroquinolones" "NA" "NA" "premafloxacine,premafloxacino" "73591-0,73613-2,73636-3"
-"PMD" 456199 "Pretomanid" "Antimycobacterials" "J04AK08" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "NA" "NA" 0.2 "g" "93850-6"
-"PRM" 6446787 "Primycin" "Macrolides/lincosamides" "NA" "NA" "chinopricin,debrycin,primicina,primycine" "NA"
-"PRI" 11979535 "Pristinamycin" "Macrolides/lincosamides" "J01FG01" "Macrolides, lincosamides and streptogramins" "Streptogramins" "pris" "eskalin,micamicina,mikamycin,mikamycine,mikamycinum,ostreogricina,ostreogrycin,ostreogrycine,ostreogrycinum,pristinamicina,pristinamycine,pristinamycinum,pyostacine,stafac,stafytracine,stajac,staphylomycin,stapyocine,starfac,virgimycin,virgimycine,virginiamicina,virginiamycin,virginiamycina,virginiamycinum" 2 "g" "32383-2,35833-3,35834-1,55709-0"
-"PRB" 5903 "Procaine benzylpenicillin" "Beta-lactams/penicillins" "J01CE09" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "afsillin,aquacilina,aquacillin,aquasuspen,avloprocil,cilicaine,crysticillin,depocillin,despacilina,distaquaine,duphapen,duracillin,hostacillin,hydracillin,kabipenin,ledercillin,millicillin,mylipen,neoproc,nopcaine,parencillin,premocillin,procanodia,prostabillin,retardillin,sharcillin,vetspen,vitablend,wycillin" 0.6 "g" "NA"
-"PRP" 92879 "Propicillin" "Beta-lactams/penicillins" "J01CE03" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "baycillin,propicilina,propicilline,propicillinum" 0.9 "g" "NA"
-"PKA" 9872451 "Propikacin" "Aminoglycosides" "NA" "NA" "propikacina,propikacine,propikacinum" "NA"
-"PTH" 666418 "Protionamide" "Antimycobacterials" "J04AD01" "Drugs for treatment of tuberculosis" "Thiocarbamide derivatives" "prot" "ektebin,peteha,prothionamide,prothionamidum,protion,protionamid,protionamida,protionamidum,protionizina,tebeform,trevintix,tuberex" 0.75 "g" "NA"
-"PRU" 65947 "Prulifloxacin" "Fluoroquinolones" "J01MA17" "Quinolone antibacterials" "Fluoroquinolones" "NA" "pruvel,quisnon,sword" 0.6 "g" "100058-7,76145-2"
-"PZA" 1046 "Pyrazinamide" "Antimycobacterials" "J04AK01" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "pyra" "aldinamid,aldinamide,eprazin,farmizina,isopas,novamid,pezetamid,piraldina,pirazimida,pirazinamid,pirazinamida,pirazinamide,pirazinecarboxamide,pyrafat,pyrazide,pyrazinamdie,pyrazinamidum,pyrazineamide,pyrizinamide,rifafour,rozide,tebrazid,tisamid,unipyranamide" 1.5 "g" "11001-5,18973-8,20461-0,23632-3,25186-8,25229-6,25270-0,423-4,424-2,425-9,426-7,42935-7,55710-8,55711-6,56026-8,92242-7"
-"QDA" 11979418 "Quinupristin/dalfopristin" "Macrolides/lincosamides" "QJ01FG02" "Macrolides, lincosamides and streptogramins" "Streptogramins" "q/d,qda,qida,quda,rp,syn" "synercid" "23640-6,23641-4,33334-4,35835-8,58712-1"
-"RAC" 56052 "Ractopamine" "Other antibacterials" "NA" "NA" "bufenina,bufenine,buphenin,buphenine,bupheninum,luteonin,nilidrine,nylidrinum,optaflexx,paylean,prepar,ractopamina,ractopaminum,ritodrina,ritodrine,ritodrinium,tomax,utopar,yutopar" "NA"
-"RAM" 16132338 "Ramoplanin" "Glycopeptides" "NA" "NA" "NA" "41710-5,41711-3,41712-1,41737-8"
-"RZM" 10993211 "Razupenem" "Carbapenems" "NA" "NA" "NA" "73590-2,73612-4,73635-5"
-"RTP" 6918462 "Retapamulin" "Other antibacterials" "D06AX13" "Antibiotics for topical use" "Other antibiotics for topical use" "ret" "altabax,altargo,rebapamulin,retapamulina" "NA"
-"RZF" "Rezafungin" "Antifungals" "NA" "NA" "NA" "NA"
-"RBC" 44631912 "Ribociclib" "Antifungals/antimycotics" "L01EF02" "Antimycotics for systemic use" "Triazole derivatives" "ribo" "kisqali" 0.45 "g" "NA"
-"RST" 33042 "Ribostamycin" "Aminoglycosides" "J01GB10" "Aminoglycoside antibacterials" "Other aminoglycosides" "NA" "exaluren,hetangmycin,ribastamin,ribostamicina,ribostamycine,ribostamycinum,vistamycin,xylostatin" 1 "g" "NA"
-"RID1" 16659285 "Ridinilazole" "Other antibacterials" "NA" "NA" "ridinilazol" "NA"
-"RIB" 135398743 "Rifabutin" "Antimycobacterials" "J04AB04" "Drugs for treatment of tuberculosis" "Antibiotics" "rifb" "alfacid,ansamicin,ansamycins,ansatipin,ansatipine,assatipin,mycobutin,rifabutinum" 0.15 "g" "100699-8,16100-0,16386-5,16387-3,19149-4,20386-9,23630-7,24032-5,25199-1,25200-7,25201-5,42655-1,42656-9,54183-9,96113-6"
-"RIF" 135398735 "Rifampicin" "Antimycobacterials" "J04AB02" "Drugs for treatment of tuberculosis" "Antibiotics" "rifa" "abrifam,archidyn,arficin,arzide,benemicin,doloresum,eremfat,famcin,fenampicin,rifadin,rifadine,rifagen,rifaldazin,rifaldazine,rifaldin,rifam,rifamor,rifampicina,rifampicine,rifampicinum,rifampin,rifamsolin,rifapiam,rifaprodin,rifcin,rifinah,rifobac,rifoldin,rifoldine,riforal,rimactan,rimactane,rimactazid,rimactizid,rimazid,sinerdol,tubocin" 0.6 "g" 0.6 "g" "NA"
-"REI" 135483893 "Rifampicin/ethambutol/isoniazid" "Antimycobacterials" "J04AM07" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "isonarif,rifamate,rifamazid" "NA"
-"RFI" "Rifampicin/isoniazid" "Antimycobacterials" "J04AM02" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA"
-"RPEI" "Rifampicin/pyrazinamide/ethambutol/isoniazid" "Antimycobacterials" "J04AM06" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA"
-"RPI" "Rifampicin/pyrazinamide/isoniazid" "Antimycobacterials" "J04AM05" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA"
-"RFM" 6324616 "Rifamycin" "Antimycobacterials" "A07AA13,D06AX15,J04AB03,S01AA16,S02AA12" "Drugs for treatment of tuberculosis" "Antibiotics" "NA" "aemcolo,nacimycin,nancimycin,otofa,rifamastene,rifamicina,rifamycine,rifamycinum,rifocin,rifocyn,tuborin" 0.8 "g" 0.6 "g" "NA"
-"RFP" 135403821 "Rifapentine" "Antimycobacterials" "J04AB05" "Drugs for treatment of tuberculosis" "Antibiotics" "rifp,rpt" "prifitin,priftin,rifapentin,rifapentina,rifapentinum" 0.11 "g" "100059-5,76627-9"
-"RFX" 6436173 "Rifaximin" "Other antibacterials" "A07AA11,D06AX11" "Intestinal antiinfectives" "Antibiotics" "NA" "fatroximin,flonorm,lormyx,lumenax,normix,rifacol,rifamixin,rifaxidin,rifaximina,rifaximine,rifaximinum,rifaxin,ritacol,spiraxin,xifaxan,xifaxsan" 0.6 "g" "73589-4,73611-6,73634-8"
-"RIT" 65633 "Ritipenem" "Carbapenems" "NA" "NA" "ritipenemsalt" "NA"
-"RIA" 163692 "Ritipenem acoxil" "Carbapenems" "NA" "NA" "penemac" "NA"
-"ROK" 5282211 "Rokitamycin" "Macrolides/lincosamides" "J01FA12" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "propionylleucomycin,ricamycin,rokicid,rokital,rokitamicina,rokitamycine,rokitamycinum" 0.8 "g" "NA"
-"RLT" 54682938 "Rolitetracycline" "Tetracyclines" "J01AA09" "Tetracyclines" "Tetracyclines" "NA" "bristacin,colbiocin,kinteto,reverin,revrin,rolitetraciclina,rolitetracyclinum,solvocillin,superciclin,synotodecin,synterin,syntetrex,syntetrin,tetraverin,transcycline,velacicline,velacycline" 0.35 "g" "18976-1,435-8,436-6,437-4,438-2"
-"ROS" 287180 "Rosoxacin" "Quinolones" "J01MB01" "Quinolone antibacterials" "Other quinolones" "NA" "acrosoxacin,eracine,eradacil,eradacin,eradicin,rosoxacine,rosoxacino,rosoxacinum,roxadyl,winoxacin,winuron" 0.3 "g" "18977-9,439-0,440-8,441-6,442-4,55713-2"
-"RXT" "Roxithromycin" "Macrolides/lincosamides" "J01FA06" "Macrolides, lincosamides and streptogramins" "Macrolides" "roxi" "NA" 0.3 "g" "18978-7,443-2,444-0,445-7,446-5,7046-6"
-"RFL" 58258 "Rufloxacin" "Fluoroquinolones" "J01MA10" "Quinolone antibacterials" "Fluoroquinolones" "NA" "monos,rufloxacine,rufloxacino,rufloxacinum,tebraxin,uroflox" 0.2 "g" "NA"
+"PRX" 71455 "Premafloxacin" "Fluoroquinolones" "" "NA" "premafloxacine,premafloxacino" "73591-0,73613-2,73636-3"
+"PMD" 456199 "Pretomanid" "Antimycobacterials" "J04AK08,QJ04AK08" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "NA" "NA" 0.2 "g" "93850-6"
+"PRM" 6446787 "Primycin" "Macrolides/lincosamides" "" "NA" "chinopricin,debrycin,primicina,primycine" "NA"
+"PRI" 11979535 "Pristinamycin" "Macrolides/lincosamides" "J01FG01,QJ01FG01" "Macrolides, lincosamides and streptogramins" "Streptogramins" "pris" "eskalin,micamicina,mikamycin,mikamycine,mikamycinum,ostreogricina,ostreogrycin,ostreogrycine,ostreogrycinum,pristinamicina,pristinamycine,pristinamycinum,pyostacine,stafac,stafytracine,stajac,staphylomycin,stapyocine,starfac,virgimycin,virgimycine,virginiamicina,virginiamycin,virginiamycina,virginiamycinum" 2 "g" "32383-2,35833-3,35834-1,55709-0"
+"PRB" 5903 "Procaine benzylpenicillin" "Beta-lactams/penicillins" "J01CE09,QJ01CE09,QJ51CE09" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "afsillin,aquacilina,aquacillin,aquasuspen,avloprocil,cilicaine,crysticillin,depocillin,despacilina,distaquaine,duphapen,duracillin,hostacillin,hydracillin,kabipenin,ledercillin,millicillin,mylipen,neoproc,nopcaine,parencillin,premocillin,procanodia,prostabillin,retardillin,sharcillin,vetspen,vitablend,wycillin" 0.6 "g" "NA"
+"PRP" 92879 "Propicillin" "Beta-lactams/penicillins" "J01CE03,QJ01CE03" "Beta-lactam antibacterials, penicillins" "Beta-lactamase sensitive penicillins" "NA" "baycillin,propicilina,propicilline,propicillinum" 0.9 "g" "NA"
+"PKA" 9872451 "Propikacin" "Aminoglycosides" "" "NA" "propikacina,propikacine,propikacinum" "NA"
+"PTH" 666418 "Protionamide" "Antimycobacterials" "J04AD01,QJ04AD01" "Drugs for treatment of tuberculosis" "Thiocarbamide derivatives" "prot" "ektebin,peteha,prothionamide,prothionamidum,protion,protionamid,protionamida,protionamidum,protionizina,tebeform,trevintix,tuberex" 0.75 "g" "NA"
+"PRU" 65947 "Prulifloxacin" "Fluoroquinolones" "J01MA17,QJ01MA17" "Quinolone antibacterials" "Fluoroquinolones" "NA" "pruvel,quisnon,sword" 0.6 "g" "100058-7,76145-2"
+"PZA" 1046 "Pyrazinamide" "Antimycobacterials" "J04AK01,QJ04AK01" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "pyra" "aldinamid,aldinamide,eprazin,farmizina,isopas,novamid,pezetamid,piraldina,pirazimida,pirazinamid,pirazinamida,pirazinamide,pirazinecarboxamide,pyrafat,pyrazide,pyrazinamdie,pyrazinamidum,pyrazineamide,pyrizinamide,rifafour,rozide,tebrazid,tisamid,unipyranamide" 1.5 "g" "11001-5,18973-8,20461-0,23632-3,25186-8,25229-6,25270-0,423-4,424-2,425-9,426-7,42935-7,55710-8,55711-6,56026-8,92242-7"
+"QDA" 11979418 "Quinupristin/dalfopristin" "Macrolides/lincosamides" "" "Macrolides, lincosamides and streptogramins" "Streptogramins" "q/d,qda,qida,quda,rp,syn" "synercid" "23640-6,23641-4,33334-4,35835-8,58712-1"
+"RAC" 56052 "Ractopamine" "Other antibacterials" "" "NA" "bufenina,bufenine,buphenin,buphenine,bupheninum,luteonin,nilidrine,nylidrinum,optaflexx,paylean,prepar,ractopamina,ractopaminum,ritodrina,ritodrine,ritodrinium,tomax,utopar,yutopar" "NA"
+"RAM" 16132338 "Ramoplanin" "Glycopeptides" "" "NA" "NA" "41710-5,41711-3,41712-1,41737-8"
+"RZM" 10993211 "Razupenem" "Carbapenems" "" "NA" "NA" "73590-2,73612-4,73635-5"
+"RTP" 6918462 "Retapamulin" "Other antibacterials" "D06AX13,QD06AX13" "Antibiotics for topical use" "Other antibiotics for topical use" "ret" "altabax,altargo,rebapamulin,retapamulina" "NA"
+"RZF" "Rezafungin" "Antifungals" "" "NA" "NA" "NA"
+"RBC" 44631912 "Ribociclib" "Antifungals/antimycotics" "L01EF02,QL01EF02" "Antimycotics for systemic use" "Triazole derivatives" "ribo" "kisqali" 0.45 "g" "NA"
+"RST" 33042 "Ribostamycin" "Aminoglycosides" "J01GB10,QJ01GB10" "Aminoglycoside antibacterials" "Other aminoglycosides" "NA" "exaluren,hetangmycin,ribastamin,ribostamicina,ribostamycine,ribostamycinum,vistamycin,xylostatin" 1 "g" "NA"
+"RID1" 16659285 "Ridinilazole" "Other antibacterials" "" "NA" "ridinilazol" "NA"
+"RIB" 135398743 "Rifabutin" "Antimycobacterials" "J04AB04,QJ04AB04" "Drugs for treatment of tuberculosis" "Antibiotics" "rifb" "alfacid,ansamicin,ansamycins,ansatipin,ansatipine,assatipin,mycobutin,rifabutinum" 0.15 "g" "100699-8,16100-0,16386-5,16387-3,19149-4,20386-9,23630-7,24032-5,25199-1,25200-7,25201-5,42655-1,42656-9,54183-9,96113-6"
+"RIF" 135398735 "Rifampicin" "Antimycobacterials" "J04AB02,QJ04AB02,QJ54AB02" "Drugs for treatment of tuberculosis" "Antibiotics" "rifa" "abrifam,archidyn,arficin,arzide,benemicin,doloresum,eremfat,famcin,fenampicin,rifadin,rifadine,rifagen,rifaldazin,rifaldazine,rifaldin,rifam,rifamor,rifampicina,rifampicine,rifampicinum,rifampin,rifamsolin,rifapiam,rifaprodin,rifcin,rifinah,rifobac,rifoldin,rifoldine,riforal,rimactan,rimactane,rimactazid,rimactizid,rimazid,sinerdol,tubocin" 0.6 "g" 0.6 "g" "NA"
+"REI" 135483893 "Rifampicin/ethambutol/isoniazid" "Antimycobacterials" "" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "isonarif,rifamate,rifamazid" "NA"
+"RFI" "Rifampicin/isoniazid" "Antimycobacterials" "" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA"
+"RPEI" "Rifampicin/pyrazinamide/ethambutol/isoniazid" "Antimycobacterials" "" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA"
+"RPI" "Rifampicin/pyrazinamide/isoniazid" "Antimycobacterials" "" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA"
+"RFM" 6324616 "Rifamycin" "Antimycobacterials" "A07AA13,D06AX15,J04AB03,QA07AA13,QD06AX15,QJ04AB03,QJ54AB03,QS01AA16,QS02AA12,S01AA16,S02AA12" "Drugs for treatment of tuberculosis" "Antibiotics" "NA" "aemcolo,nacimycin,nancimycin,otofa,rifamastene,rifamicina,rifamycine,rifamycinum,rifocin,rifocyn,tuborin" 0.8 "g" 0.6 "g" "NA"
+"RFP" 135403821 "Rifapentine" "Antimycobacterials" "J04AB05,QJ04AB05" "Drugs for treatment of tuberculosis" "Antibiotics" "rifp,rpt" "prifitin,priftin,rifapentin,rifapentina,rifapentinum" 0.11 "g" "100059-5,76627-9"
+"RFX" 6436173 "Rifaximin" "Other antibacterials" "A07AA11,D06AX11,QA07AA11,QD06AX11,QG51AA06,QJ51XX01" "Intestinal antiinfectives" "Antibiotics" "NA" "fatroximin,flonorm,lormyx,lumenax,normix,rifacol,rifamixin,rifaxidin,rifaximina,rifaximine,rifaximinum,rifaxin,ritacol,spiraxin,xifaxan,xifaxsan" 0.6 "g" "73589-4,73611-6,73634-8"
+"RIT" 65633 "Ritipenem" "Carbapenems" "" "NA" "ritipenemsalt" "NA"
+"RIA" 163692 "Ritipenem acoxil" "Carbapenems" "" "NA" "penemac" "NA"
+"ROK" 5282211 "Rokitamycin" "Macrolides/lincosamides" "J01FA12,QJ01FA12" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "propionylleucomycin,ricamycin,rokicid,rokital,rokitamicina,rokitamycine,rokitamycinum" 0.8 "g" "NA"
+"RLT" 54682938 "Rolitetracycline" "Tetracyclines" "J01AA09,QJ01AA09" "Tetracyclines" "Tetracyclines" "NA" "bristacin,colbiocin,kinteto,reverin,revrin,rolitetraciclina,rolitetracyclinum,solvocillin,superciclin,synotodecin,synterin,syntetrex,syntetrin,tetraverin,transcycline,velacicline,velacycline" 0.35 "g" "18976-1,435-8,436-6,437-4,438-2"
+"ROS" 287180 "Rosoxacin" "Quinolones" "J01MB01,QJ01MB01" "Quinolone antibacterials" "Other quinolones" "NA" "acrosoxacin,eracine,eradacil,eradacin,eradicin,rosoxacine,rosoxacino,rosoxacinum,roxadyl,winoxacin,winuron" 0.3 "g" "18977-9,439-0,440-8,441-6,442-4,55713-2"
+"RXT" "Roxithromycin" "Macrolides/lincosamides" "J01FA06,QJ01FA06" "Macrolides, lincosamides and streptogramins" "Macrolides" "roxi" "NA" 0.3 "g" "18978-7,443-2,444-0,445-7,446-5,7046-6"
+"RFL" 58258 "Rufloxacin" "Fluoroquinolones" "J01MA10,QJ01MA10" "Quinolone antibacterials" "Fluoroquinolones" "NA" "monos,rufloxacine,rufloxacino,rufloxacinum,tebraxin,uroflox" 0.2 "g" "NA"
"SAL" 3085092 "Salinomycin" "Other antibacterials" "QP51BB01" "NA" "coxistac,procoxacin,salinomicina,salinomycine,salinomycinum" "35836-6,35837-4,35838-2,87593-0"
"SAR" 56208 "Sarafloxacin" "Fluoroquinolones" "QJ01MA98" "NA" "difloxacino,difloxacinum,difloxcine,sarafin,saraflox,sarafloxacine,sarafloxacino,sarafloxacinum" "73588-6,73610-8,73633-0"
-"SRC" 54681908 "Sarecycline" "Tetracyclines" "J01AA14" "Tetracyclines" "Tetracyclines" "NA" "sareciclina,seysara" 0.1 "g" "NA"
-"SRX" 9933415 "Sarmoxicillin" "Beta-lactams/penicillins" "NA" "NA" "sarmoxillina,sarmoxilline,sarmoxillinum" "NA"
+"SRC" 54681908 "Sarecycline" "Tetracyclines" "J01AA14,QJ01AA14" "Tetracyclines" "Tetracyclines" "NA" "sareciclina,seysara" 0.1 "g" "NA"
+"SRX" 9933415 "Sarmoxicillin" "Beta-lactams/penicillins" "" "NA" "sarmoxillina,sarmoxilline,sarmoxillinum" "NA"
"SEC" 71815 "Secnidazole" "Other antibacterials" "P01AB07" "NA" "flagentyl,secnidal,secnidazolum,secnil,sindose,solosec" 2 "g" "NA"
-"SMF" "Simvastatin/fenofibrate" "Antimycobacterials" "C10BA04" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "simv" "NA" "NA"
-"SIS" 36119 "Sisomicin" "Aminoglycosides" "J01GB08" "Aminoglycoside antibacterials" "Other aminoglycosides" "siso" "rickamicin,salvamina,sisomicina,sisomicine,sisomicinum,sisomin,sisomycin,sissomicin,sizomycin" 0.24 "g" "18979-5,447-3,448-1,449-9,450-7,55714-0"
-"SIT" 461399 "Sitafloxacin" "Fluoroquinolones" "J01MA21" "NA" "gracevit" 0.1 "g" "NA"
-"SDA" 2724368 "Sodium aminosalicylate" "Antimycobacterials" "J04AA02" "Drugs for treatment of tuberculosis" "Aminosalicylic acid and derivatives" "NA" "bactylan,lepasen,monopas,tubersan" 14 "g" 14 "g" "NA"
-"SOL" 25242512 "Solithromycin" "Macrolides/lincosamides" "J01FA16" "NA" "solithera" "73587-8,73609-0,73632-2"
-"SPX" 60464 "Sparfloxacin" "Fluoroquinolones" "J01MA09" "Quinolone antibacterials" "Fluoroquinolones" "spa,spar" "esparfloxacino,parox,spara,sparfloxacine,sparfloxacinum,zagam" 0.2 "g" "20397-6,23610-9,23628-1,35839-0,7047-4"
-"SPT" 15541 "Spectinomycin" "Other antibacterials" "J01XX04" "Other antibacterials" "Other antibacterials" "sc,spe,spec,spt" "actinospectacina,adspec,espectinomicina,prospec,spectam,spectinomicina,spectinomycine,spectinomycinhydrate,spectinomycinum,spectogard,stanilo,togamycin,trobicin" 3 "g" "18980-3,35840-8,451-5,452-3,453-1,454-9"
-"SPI" 6419898 "Spiramycin" "Macrolides/lincosamides" "J01FA02" "Macrolides, lincosamides and streptogramins" "Macrolides" "spir" "formacidine" 3 "g" "18981-1,455-6,456-4,457-2,458-0,55715-7"
-"SPM" "Spiramycin/metronidazole" "Other antibacterials" "J01RA04" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
-"STR" "Streptoduocin" "Aminoglycosides" "J01GA02" "Aminoglycoside antibacterials" "Streptomycins" "NA" "NA" 1 "g" "NA"
-"STR1" 19649 "Streptomycin" "Aminoglycosides" "A07AA04,J01GA01" "Aminoglycoside antibacterials" "Streptomycins" "s,stm,str,stre" "agrept,agrimycin,chemform,estreptomicina,gerox,neodiestreptopab,strepcen,streptomicina,streptomycine,streptomycinum,streptomyzin" 1 "g" "18982-9,18983-7,20462-8,23626-5,25185-0,25205-6,25206-4,35841-6,4039-4,42658-5,42659-3,459-8,460-6,461-4,462-2,46719-1,48177-0,6933-6,7048-2,7049-0,96114-4"
-"STH" "Streptomycin-high" "Aminoglycosides" "NA" "sthi,sthl,strepto high,streptomycin high" "NA" "18983-7,35841-6,6933-6,7049-0"
-"STI" "Streptomycin/isoniazid" "Antimycobacterials" "J04AM01" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA"
-"SUL" 130313 "Sulbactam" "Beta-lactams/penicillins" "J01CG01" "Beta-lactam antibacterials, penicillins" "Beta-lactamase inhibitors" "NA" "betamaze,sulbactamum" 1 "g" "41716-2,41717-0,41718-8,41739-4"
-"SBC" 20055036 "Sulbenicillin" "Beta-lactams/penicillins" "J01CA16" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "kedacillin,kedacillina,sulbenicilina,sulbenicilline,sulbenicillinum,sulpelin" 15 "g" "NA"
-"SUC" 5318 "Sulconazole" "Antifungals/antimycotics" "D01AC09" "NA" "sulconazol,sulconazolum" "NA"
+"SMF" "Simvastatin/fenofibrate" "Antimycobacterials" "" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "simv" "NA" "NA"
+"SIS" 36119 "Sisomicin" "Aminoglycosides" "J01GB08,QJ01GB08" "Aminoglycoside antibacterials" "Other aminoglycosides" "siso" "rickamicin,salvamina,sisomicina,sisomicine,sisomicinum,sisomin,sisomycin,sissomicin,sizomycin" 0.24 "g" "18979-5,447-3,448-1,449-9,450-7,55714-0"
+"SIT" 461399 "Sitafloxacin" "Fluoroquinolones" "J01MA21,QJ01MA21" "NA" "gracevit" 0.1 "g" "NA"
+"SDA" 2724368 "Sodium aminosalicylate" "Antimycobacterials" "J04AA02,QJ04AA02" "Drugs for treatment of tuberculosis" "Aminosalicylic acid and derivatives" "NA" "bactylan,lepasen,monopas,tubersan" 14 "g" 14 "g" "NA"
+"SOL" 25242512 "Solithromycin" "Macrolides/lincosamides" "J01FA16,QJ01FA16" "NA" "solithera" "73587-8,73609-0,73632-2"
+"SPX" 60464 "Sparfloxacin" "Fluoroquinolones" "J01MA09,QJ01MA09" "Quinolone antibacterials" "Fluoroquinolones" "spa,spar" "esparfloxacino,parox,spara,sparfloxacine,sparfloxacinum,zagam" 0.2 "g" "20397-6,23610-9,23628-1,35839-0,7047-4"
+"SPT" 15541 "Spectinomycin" "Other antibacterials" "J01XX04,QJ01XX04" "Other antibacterials" "Other antibacterials" "sc,spe,spec,spt" "actinospectacina,adspec,espectinomicina,prospec,spectam,spectinomicina,spectinomycine,spectinomycinhydrate,spectinomycinum,spectogard,stanilo,togamycin,trobicin" 3 "g" "18980-3,35840-8,451-5,452-3,453-1,454-9"
+"SPI" 6419898 "Spiramycin" "Macrolides/lincosamides" "J01FA02,QJ01FA02,QJ51FA02" "Macrolides, lincosamides and streptogramins" "Macrolides" "spir" "formacidine" 3 "g" "18981-1,455-6,456-4,457-2,458-0,55715-7"
+"SPM" "Spiramycin/metronidazole" "Other antibacterials" "" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
+"STR" "Streptoduocin" "Aminoglycosides" "J01GA02,QJ01GA02" "Aminoglycoside antibacterials" "Streptomycins" "NA" "NA" 1 "g" "NA"
+"STR1" 19649 "Streptomycin" "Aminoglycosides" "A07AA04,J01GA01,QA07AA04,QJ01GA01" "Aminoglycoside antibacterials" "Streptomycins" "s,stm,str,stre" "agrept,agrimycin,chemform,estreptomicina,gerox,neodiestreptopab,strepcen,streptomicina,streptomycine,streptomycinum,streptomyzin" 1 "g" "18982-9,18983-7,20462-8,23626-5,25185-0,25205-6,25206-4,35841-6,4039-4,42658-5,42659-3,459-8,460-6,461-4,462-2,46719-1,48177-0,6933-6,7048-2,7049-0,96114-4"
+"STH" "Streptomycin-high" "Aminoglycosides" "" "sthi,sthl,strepto high,streptomycin high" "NA" "18983-7,35841-6,6933-6,7049-0"
+"STI" "Streptomycin/isoniazid" "Antimycobacterials" "" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA"
+"SUL" 130313 "Sulbactam" "Beta-lactams/penicillins" "J01CG01,QJ01CG01" "Beta-lactam antibacterials, penicillins" "Beta-lactamase inhibitors" "NA" "betamaze,sulbactamum" 1 "g" "41716-2,41717-0,41718-8,41739-4"
+"SBC" 20055036 "Sulbenicillin" "Beta-lactams/penicillins" "J01CA16,QJ01CA16" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "kedacillin,kedacillina,sulbenicilina,sulbenicilline,sulbenicillinum,sulpelin" 15 "g" "NA"
+"SUC" 5318 "Sulconazole" "Antifungals/antimycotics" "D01AC09,QD01AC09" "NA" "sulconazol,sulconazolum" "NA"
"SUP" 6634 "Sulfachlorpyridazine" "Other antibacterials" "QJ01EQ12" "NA" "cluricol,cosulid,cosumix,durasulf,nefrosul,nsulfanilamide,prinzone,solfaclorpiridazina,sonilyn,sulfacloropiridazina,sulfaclorpiridazina,vetisulid" "NA"
-"SDI" 5215 "Sulfadiazine" "Trimethoprims" "J01EC02" "Sulfonamides and trimethoprim" "Intermediate-acting sulfonamides" "NA" "codiazine,cremodiazine,cremotres,debenal,deltazina,dermazin,dermazine,diazolone,diazovit,eskadiazine,flamazine,geben,liquadiazine,microsulfon,neazine,neotrizine,palatrize,piridisir,pirimal,pyrimal,quadetts,quadramoid,sanodiazine,silbertone,sildaflo,silvadene,silvazine,silver,silveramide,sliverex,solfadiazina,spofadrizine,sterazine,sulfacombin,sulfadiazene,sulfadiazin,sulfadiazina,sulfadiazinum,sulfapirimidin,sulfapyrimidin,sulfapyrimidine,sulfatryl,sulfazine,sulfolex,sulfonsol,sulfose,sulphadiazine,terfonyl,theradiazine,thermazene,trifonamide,trisem,truozine" 0.6 "g" "18984-5,27216-1,463-0,464-8,465-5,466-3,59742-7,6907-0,7050-8"
-"SLT" 122284 "Sulfadiazine/tetroxoprim" "Trimethoprims" "J01EE06" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "berlocombin,cotetroxazine,potesept,trimerazine" "NA"
-"SLT1" 64932 "Sulfadiazine/trimethoprim" "Trimethoprims" "J01EE02" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "antastmon,astra,ditrim,ditrivet,sultrisan,triglobe,trimin,tucoprim,uniprim" "NA"
-"SUD" 5323 "Sulfadimethoxine" "Trimethoprims" "J01ED01" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "abcid,agribon,albon,arnosulfan,bactotril,bactrovet,deposul,diasulfa,diasulfyl,dimetazina,dinosol,dorisul,fuxal,lasibon,madribon,madrigid,madriqid,madroxin,madroxine,maxulvet,mecozine,memcozine,metoxidon,neostrepal,neostreptal,nsulfanilamidesalt,omnibon,persulfen,radonin,redifal,rofenaid,roscosulf,scandisil,solfadimetossina,sudine,suldixine,sulfabon,sulfadimethoxin,sulfadimethoxinesalt,sulfadimethoxinum,sulfadimetossina,sulfadimetoxin,sulfadimetoxina,sulfadimetoxine,sulfadimoxine,sulfastop,sulfoplan,sulforal,sulphadimethoxine,sulxin,sumbio,symbio,theracanzan,ultrasulfon" 0.5 "g" "87799-3,87803-3"
-"SDM" 5327 "Sulfadimidine" "Trimethoprims" "J01EB03" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "azolmetazin,bovibol,calfspan,cremomethazine,diazil,diazilsulfadine,diazyl,dimezathine,intradine,kelametazine,mermeth,neasina,neazina,panazin,pirmazin,primazin,solfadimidina,spanbolet,sulfadimerazine,sulfadimesin,sulfadimesine,sulfadimethyldiazine,sulfadimezin,sulfadimezine,sulfadimezinum,sulfadimidin,sulfadimidina,sulfadimidinum,sulfadimidinun,sulfadine,sulfametazina,sulfametazyny,sulfamethiazine,sulfamezathine,sulfamidine,sulfodimesin,sulfodimezine,sulmet,sulphadimidine,sulphamethasine,sulphamethazine,sulphamezathine,sulphamidine,sulphodimezine,superseptil,superseptyl,vertolan,vesadin" 4 "g" "NA"
-"SLT2" "Sulfadimidine/trimethoprim" "Trimethoprims" "J01EE05" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "NA" "NA"
-"SLF" 5344 "Sulfafurazole" "Trimethoprims" "J01EB05,S01AB02" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "sfsz" "accuzole,alphazole,amidoxal,astrazolo,azosulfizin,bactesulf,barazae,chemouag,cosoxazole,dorsulfan,entusil,entusul,ganda,gantrisin,gantrisine,gantrisona,gantrizin,gantrosan,isoxamin,neazolin,neoxazol,novazolo,novosaxazole,nsulphanilamide,pancid,pediazole,renosulfan,resoxol,roxosul,roxoxol,saxosozine,sodizole,solfafurazolo,sosol,soxamide,soxisol,soxitabs,soxomide,stansin,sulbio,sulfafurazol,sulfafurazolum,sulfagan,sulfagen,sulfaisoxazole,sulfalar,sulfapolar,sulfasol,sulfasoxazole,sulfasoxizole,sulfazin,sulfisin,sulfisonazole,sulfisoxasole,sulfisoxazol,sulfisoxazolum,sulfizin,sulfizol,sulfizole,sulfofurazole,sulfoxol,suloxsol,sulphafuraz,sulphafurazol,sulphafurazole,sulphafurazolum,sulphaisoxazole,sulphisoxazol,sulphisoxazole,sulphofurazole,sulsoxin,thiasin,unisulf,urisoxin,uritrisin,urogan" 4 "g" 4 "g" "NA"
+"SDI" 5215 "Sulfadiazine" "Trimethoprims" "J01EC02,QJ01EQ10" "Sulfonamides and trimethoprim" "Intermediate-acting sulfonamides" "NA" "codiazine,cremodiazine,cremotres,debenal,deltazina,dermazin,dermazine,diazolone,diazovit,eskadiazine,flamazine,geben,liquadiazine,microsulfon,neazine,neotrizine,palatrize,piridisir,pirimal,pyrimal,quadetts,quadramoid,sanodiazine,silbertone,sildaflo,silvadene,silvazine,silver,silveramide,sliverex,solfadiazina,spofadrizine,sterazine,sulfacombin,sulfadiazene,sulfadiazin,sulfadiazina,sulfadiazinum,sulfapirimidin,sulfapyrimidin,sulfapyrimidine,sulfatryl,sulfazine,sulfolex,sulfonsol,sulfose,sulphadiazine,terfonyl,theradiazine,thermazene,trifonamide,trisem,truozine" 0.6 "g" "18984-5,27216-1,463-0,464-8,465-5,466-3,59742-7,6907-0,7050-8"
+"SLT" 122284 "Sulfadiazine/tetroxoprim" "Trimethoprims" "" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "berlocombin,cotetroxazine,potesept,trimerazine" "NA"
+"SLT1" 64932 "Sulfadiazine/trimethoprim" "Trimethoprims" "" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "antastmon,astra,ditrim,ditrivet,sultrisan,triglobe,trimin,tucoprim,uniprim" "NA"
+"SUD" 5323 "Sulfadimethoxine" "Trimethoprims" "J01ED01,QJ01EQ09,QP51BA01" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "abcid,agribon,albon,arnosulfan,bactotril,bactrovet,deposul,diasulfa,diasulfyl,dimetazina,dinosol,dorisul,fuxal,lasibon,madribon,madrigid,madriqid,madroxin,madroxine,maxulvet,mecozine,memcozine,metoxidon,neostrepal,neostreptal,nsulfanilamidesalt,omnibon,persulfen,radonin,redifal,rofenaid,roscosulf,scandisil,solfadimetossina,sudine,suldixine,sulfabon,sulfadimethoxin,sulfadimethoxinesalt,sulfadimethoxinum,sulfadimetossina,sulfadimetoxin,sulfadimetoxina,sulfadimetoxine,sulfadimoxine,sulfastop,sulfoplan,sulforal,sulphadimethoxine,sulxin,sumbio,symbio,theracanzan,ultrasulfon" 0.5 "g" "87799-3,87803-3"
+"SDM" 5327 "Sulfadimidine" "Trimethoprims" "J01EB03,QJ01EQ03,QP51AG01" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "azolmetazin,bovibol,calfspan,cremomethazine,diazil,diazilsulfadine,diazyl,dimezathine,intradine,kelametazine,mermeth,neasina,neazina,panazin,pirmazin,primazin,solfadimidina,spanbolet,sulfadimerazine,sulfadimesin,sulfadimesine,sulfadimethyldiazine,sulfadimezin,sulfadimezine,sulfadimezinum,sulfadimidin,sulfadimidina,sulfadimidinum,sulfadimidinun,sulfadine,sulfametazina,sulfametazyny,sulfamethiazine,sulfamezathine,sulfamidine,sulfodimesin,sulfodimezine,sulmet,sulphadimidine,sulphamethasine,sulphamethazine,sulphamezathine,sulphamidine,sulphodimezine,superseptil,superseptyl,vertolan,vesadin" 4 "g" "NA"
+"SLT2" "Sulfadimidine/trimethoprim" "Trimethoprims" "" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "NA" "NA"
+"SLF" 5344 "Sulfafurazole" "Trimethoprims" "J01EB05,QJ01EQ05,QS01AB02,S01AB02" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "sfsz" "accuzole,alphazole,amidoxal,astrazolo,azosulfizin,bactesulf,barazae,chemouag,cosoxazole,dorsulfan,entusil,entusul,ganda,gantrisin,gantrisine,gantrisona,gantrizin,gantrosan,isoxamin,neazolin,neoxazol,novazolo,novosaxazole,nsulphanilamide,pancid,pediazole,renosulfan,resoxol,roxosul,roxoxol,saxosozine,sodizole,solfafurazolo,sosol,soxamide,soxisol,soxitabs,soxomide,stansin,sulbio,sulfafurazol,sulfafurazolum,sulfagan,sulfagen,sulfaisoxazole,sulfalar,sulfapolar,sulfasol,sulfasoxazole,sulfasoxizole,sulfazin,sulfisin,sulfisonazole,sulfisoxasole,sulfisoxazol,sulfisoxazolum,sulfizin,sulfizol,sulfizole,sulfofurazole,sulfoxol,suloxsol,sulphafuraz,sulphafurazol,sulphafurazole,sulphafurazolum,sulphaisoxazole,sulphisoxazol,sulphisoxazole,sulphofurazole,sulsoxin,thiasin,unisulf,urisoxin,uritrisin,urogan" 4 "g" 4 "g" "NA"
"SLF1" 5343 "Sulfaisodimidine" "Trimethoprims" "J01EB01" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "aristamid,aristamide,aristogyn,domain,domian,elcosin,elcosine,elkosil,elkosin,elkosine,erycon,isosulf,mefenal,solfisomidina,sulfadimetine,sulfaisodimerazine,sulfaisodimidinum,sulfaisomidine,sulfasomidine,sulfisomidin,sulfisomidina,sulfisomidine,sulfisomidinum,sulphasomidine" 4 "g" 4 "g" "NA"
-"SLF2" 9047 "Sulfalene" "Trimethoprims" "J01ED02" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "dalysep,farmitalia,kelfizin,kelfizina,kelfizine,policydal,solfametopirazina,sulfalen,sulfaleno,sulfalenum,sulfamethopyrazine,sulfamethoxypyrazine,sulfametopyrazine,sulfametoxypyridazin,sulphalene,sulphametopyrazine,vetkelfizina" 0.1 "g" "NA"
+"SLF2" 9047 "Sulfalene" "Trimethoprims" "J01ED02,QJ01EQ19" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "dalysep,farmitalia,kelfizin,kelfizina,kelfizine,policydal,solfametopirazina,sulfalen,sulfaleno,sulfalenum,sulfamethopyrazine,sulfamethoxypyrazine,sulfametopyrazine,sulfametoxypyridazin,sulphalene,sulphametopyrazine,vetkelfizina" 0.1 "g" "NA"
"SZO" 187764 "Sulfamazone" "Trimethoprims" "J01ED09" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "sulfamazona,sulfamazonum,sulfenazone" 1.5 "g" "NA"
-"SLF3" 5325 "Sulfamerazine" "Trimethoprims" "D06BA06,J01ED07" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "cremomerazine,kelamerazine,mebacid,mesulfa,methylpyrimal,methylsulfazin,methylsulfazine,metilsulfadiazin,metilsulfazin,percoccide,pyralcid,romezin,septacil,septosyl,solfamerazina,solumedin,solumedine,sulfameradine,sulfamerazin,sulfamerazina,sulfamerazinum,sulfamethyldiazine,sulphamerazine,sumedine" 3 "g" "NA"
-"SLT3" "Sulfamerazine/trimethoprim" "Trimethoprims" "J01EE07" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "NA" "NA"
-"SUM" 5327 "Sulfamethazine" "Other antibacterials" "NA" "NA" "NA" "87592-2"
-"SLF4" 5328 "Sulfamethizole" "Trimethoprims" "B05CA04,D06BA04,J01EB02,S01AB01" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "sfmz" "aethazolum,ayerlucil,berlophen,gliprotiazol,globucid,globucin,globuzid,glyprothiazol,glyprothiazole,glyprothiazolum,glyprothizolum,lucosil,microsul,proklar,renasul,rufol,salimol,sethadil,solfametizolo,solfetidolo,sulfaethidiole,sulfaethidol,sulfaethidole,sulfaethidolum,sulfaetidol,sulfamethizol,sulfamethizolum,sulfametizol,sulfapyelon,sulfstat,sulfurine,sulphaethidole,sulphamethizole,tardipyrine,tetracid,thidicur,thiosulfil,ultrasul,urocydal,urodiaton,urolucosil,urosulfin" 4 "g" "60175-7,60176-5,60177-3"
-"SMX" 5329 "Sulfamethoxazole" "Trimethoprims" "J01EC01" "Sulfonamides and trimethoprim" "Intermediate-acting sulfonamides" "sfmx,sulf" "septran,septrin,simsinomin,sinomin,solfametossazolo,sulfamethalazole,sulfamethoxazolum,sulfamethoxizole,sulfamethylisoxazole,sulfametoxazol,sulfiodizole,sulfisomezole,sulphisomezole,urobak" 2 "g" "10342-4,11577-4,18985-2,25271-8,39772-9,467-1,468-9,469-7,470-5,59971-2,59972-0,60333-2,72674-5,80549-9,80974-9"
-"SLF5" 5330 "Sulfamethoxypyridazine" "Trimethoprims" "J01ED05" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "altezol,cysul,davosin,depovernil,durox,kineks,kinex,kynex,lederkyn,lentac,lisulfen,longin,medicel,midicel,midikel,myasul,opinsul,paramid,petrisul,piridolo,quinoseptyl,retamid,retasulfin,retasulphine,slosul,spofadazine,succinylsulfathi,sulfalex,sulfapiridazin,sulfapyridazine,sulfdurazin,sulfozona,sultirene,vinces" 0.5 "g" "NA"
+"SLF3" 5325 "Sulfamerazine" "Trimethoprims" "D06BA06,J01ED07,QD06BA06,QJ01EQ17" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "cremomerazine,kelamerazine,mebacid,mesulfa,methylpyrimal,methylsulfazin,methylsulfazine,metilsulfadiazin,metilsulfazin,percoccide,pyralcid,romezin,septacil,septosyl,solfamerazina,solumedin,solumedine,sulfameradine,sulfamerazin,sulfamerazina,sulfamerazinum,sulfamethyldiazine,sulphamerazine,sumedine" 3 "g" "NA"
+"SLT3" "Sulfamerazine/trimethoprim" "Trimethoprims" "" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "NA" "NA"
+"SUM" 5327 "Sulfamethazine" "Other antibacterials" "" "NA" "NA" "87592-2"
+"SLF4" 5328 "Sulfamethizole" "Trimethoprims" "B05CA04,D06BA04,J01EB02,QB05CA04,QD06BA04,QJ01EQ02,QS01AB01,S01AB01" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "sfmz" "aethazolum,ayerlucil,berlophen,gliprotiazol,globucid,globucin,globuzid,glyprothiazol,glyprothiazole,glyprothiazolum,glyprothizolum,lucosil,microsul,proklar,renasul,rufol,salimol,sethadil,solfametizolo,solfetidolo,sulfaethidiole,sulfaethidol,sulfaethidole,sulfaethidolum,sulfaetidol,sulfamethizol,sulfamethizolum,sulfametizol,sulfapyelon,sulfstat,sulfurine,sulphaethidole,sulphamethizole,tardipyrine,tetracid,thidicur,thiosulfil,ultrasul,urocydal,urodiaton,urolucosil,urosulfin" 4 "g" "60175-7,60176-5,60177-3"
+"SMX" 5329 "Sulfamethoxazole" "Trimethoprims" "J01EC01,QJ01EQ11" "Sulfonamides and trimethoprim" "Intermediate-acting sulfonamides" "sfmx,sulf" "septran,septrin,simsinomin,sinomin,solfametossazolo,sulfamethalazole,sulfamethoxazolum,sulfamethoxizole,sulfamethylisoxazole,sulfametoxazol,sulfiodizole,sulfisomezole,sulphisomezole,urobak" 2 "g" "10342-4,11577-4,18985-2,25271-8,39772-9,467-1,468-9,469-7,470-5,59971-2,59972-0,60333-2,72674-5,80549-9,80974-9"
+"SLF5" 5330 "Sulfamethoxypyridazine" "Trimethoprims" "J01ED05,QJ01EQ15" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "altezol,cysul,davosin,depovernil,durox,kineks,kinex,kynex,lederkyn,lentac,lisulfen,longin,medicel,midicel,midikel,myasul,opinsul,paramid,petrisul,piridolo,quinoseptyl,retamid,retasulfin,retasulphine,slosul,spofadazine,succinylsulfathi,sulfalex,sulfapiridazin,sulfapyridazine,sulfdurazin,sulfozona,sultirene,vinces" 0.5 "g" "NA"
"SLF6" 19596 "Sulfametomidine" "Trimethoprims" "J01ED03" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "duroprocin,methofadin,methofazine,solfametomidina,sulfametomidin,sulfametomidina,sulfametomidinum,telemid" "NA"
"SLF7" 5326 "Sulfametoxydiazine" "Trimethoprims" "J01ED04" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "bayrena,berlicid,dairena,durenat,juvoxin,kinecid,kirocid,kiron,longasulf,methoxypyrimal,solfametossidiazina,sulfameter,sulfametersalt,sulfamethorine,sulfamethoxine,sulfamethoxydiazin,sulfamethoxydiazine,sulfamethoxydin,sulfamethoxydine,sulfametin,sulfametinum,sulfametorine,sulfametorinum,sulfametoxidiazina,sulfametoxidine,sulfametoxydiazinum,sulla,sulphameter,sulphamethoxydiazine,supramid,ultrax" 0.5 "g" "NA"
-"SLT4" "Sulfametrole/trimethoprim" "Trimethoprims" "J01EE03" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "trsm" "NA" "NA"
+"SLT4" "Sulfametrole/trimethoprim" "Trimethoprims" "" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "trsm" "NA" "NA"
"SLF8" 12894 "Sulfamoxole" "Trimethoprims" "J01EC03" "Sulfonamides and trimethoprim" "Intermediate-acting sulfonamides" "NA" "enterocura,justamil,oxasulfa,solfaguanolo,solfamossolo,sulfadimethyloxazole,sulfaguanol,sulfaguanole,sulfaguanolum,sulfamoxol,sulfamoxolum,sulfano,sulfavigor,sulfmidil,sulfono,sulfune,sulfuno,sulphamoxole,tardamid,tardamide" 1 "g" 1 "g" "NA"
-"SLT5" "Sulfamoxole/trimethoprim" "Trimethoprims" "J01EE04" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "NA" "NA"
-"SLF9" 5333 "Sulfanilamide" "Trimethoprims" "D06BA05,J01EB06" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "albexan,albosal,ambeside,antistrept,astreptine,astrocid,bacteramid,bactesid,collomide,colsulanyde,copticide,deseptyl,dipron,ergaseptine,erysipan,estreptocida,exoseptoplix,fourneau,gerison,gombardol,hydroxysulfonamide,infepan,lusil,lysococcine,neococcyl,orgaseptine,prontalbin,prontylin,proseptal,proseptine,proseptol,pysococcine,sanamid,septanilam,septinal,septolix,septoplex,septoplix,solfanilamide,stramid,strepamide,strepsan,streptagol,streptamid,streptamin,streptasol,streptocid,streptocide,streptocidum,streptoclase,streptocom,strepton,streptopan,streptosil,streptozol,streptozone,streptrocide,sulfamidyl,sulfamine,sulfana,sulfanalone,sulfanidyl,sulfanil,sulfanilamida,sulfanilamidomethan,sulfanilamidum,sulfanimide,sulfocidin,sulfocidine,sulfonylamide,sulphanilamide,sulphanilamidum,sulphonamide,therapol,tolder" "NA"
+"SLT5" "Sulfamoxole/trimethoprim" "Trimethoprims" "" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "NA" "NA" "NA"
+"SLF9" 5333 "Sulfanilamide" "Trimethoprims" "D06BA05,J01EB06,QD06BA05,QJ01EQ06" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "albexan,albosal,ambeside,antistrept,astreptine,astrocid,bacteramid,bactesid,collomide,colsulanyde,copticide,deseptyl,dipron,ergaseptine,erysipan,estreptocida,exoseptoplix,fourneau,gerison,gombardol,hydroxysulfonamide,infepan,lusil,lysococcine,neococcyl,orgaseptine,prontalbin,prontylin,proseptal,proseptine,proseptol,pysococcine,sanamid,septanilam,septinal,septolix,septoplex,septoplix,solfanilamide,stramid,strepamide,strepsan,streptagol,streptamid,streptamin,streptasol,streptocid,streptocide,streptocidum,streptoclase,streptocom,strepton,streptopan,streptosil,streptozol,streptozone,streptrocide,sulfamidyl,sulfamine,sulfana,sulfanalone,sulfanidyl,sulfanil,sulfanilamida,sulfanilamidomethan,sulfanilamidum,sulfanimide,sulfocidin,sulfocidine,sulfonylamide,sulphanilamide,sulphanilamidum,sulphonamide,therapol,tolder" "NA"
"SLF10" 68933 "Sulfaperin" "Trimethoprims" "J01ED06" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "anastaf,archisulfa,archisulpha,avissul,chemiopen,demosulfan,demosulphan,durisan,isosulfamerazine,isosulphamerazine,methylsulfadiazin,methylsulfadiazine,methylsulphadiazine,novosul,orosulfan,pallidin,retardon,risulfasens,sulfaperina,sulfaperine,sulfaperinum,sulfatreis,sulfopirimidine,sulpenta,sulphaperin,sulphaperina,sulphaperinum" 0.5 "g" "NA"
-"SLF11" 5335 "Sulfaphenazole" "Trimethoprims" "J01ED08" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "depocid,depotsulfonamide,eftolon,firmazolo,inamil,isarol,merian,orisul,orisulf,paidazolo,phenylsulfapyrazole,plisulfan,raziosulfa,solfafenazolo,sulfabid,sulfafenazol,sulfafenazolo,sulfaphenazol,sulfaphenazolum,sulfaphenazon,sulfaphenylpipazol,sulfaphenylpyrazol,sulfaphenylpyrazole,sulfonylpyrazol,sulphaphenazole,sulphenazole" 1 "g" "NA"
-"SLF12" 5336 "Sulfapyridine" "Trimethoprims" "J01EB04" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "adiplon,coccoclase,dagenan,eubasin,eubasinum,haptocil,piridazol,plurazol,pyriamid,pyridazol,relbapiridina,ronin,septipulmon,solfapiridina,soludagenan,streptosilpyridine,sulfapiridina,sulfapyridin,sulfapyridinum,sulfidin,sulfidine,sulphapyridin,sulphapyridine,thioseptal,trianon" 1 "g" "14075-6,55580-5"
-"SNA" 60582 "Sulfasuccinamide" "Other antibacterials" "NA" "NA" "sulfasuccinamid,sulfasuccinamida,sulfasuccinamidum" "NA"
-"SUT" 5340 "Sulfathiazole" "Trimethoprims" "D06BA02,J01EB07" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "azoquimiol,azoseptale,cerazol,cerazole,chemosept,cibazol,duatok,dulana,eleudron,enterobiocine,estafilol,formosulfathiazole,neostrepsan,norsulfasol,norsulfazol,norsulfazole,norsulfazolum,planomide,poliseptil,sanotiazol,septozol,solfatiazolo,soluthiazomide,streptosilthiazole,sulfamul,sulfaplex,sulfathiazol,sulfathiazolesalt,sulfathiazolum,sulfatiazol,sulfavitina,sulfocerol,sulphathiazole,sulzol,thiacoccine,thiasulfol,thiazamide,thiozamide,wintrazole" "87591-4,87796-9,87797-7"
+"SLF11" 5335 "Sulfaphenazole" "Trimethoprims" "J01ED08,QJ01EQ08" "Sulfonamides and trimethoprim" "Long-acting sulfonamides" "NA" "depocid,depotsulfonamide,eftolon,firmazolo,inamil,isarol,merian,orisul,orisulf,paidazolo,phenylsulfapyrazole,plisulfan,raziosulfa,solfafenazolo,sulfabid,sulfafenazol,sulfafenazolo,sulfaphenazol,sulfaphenazolum,sulfaphenazon,sulfaphenylpipazol,sulfaphenylpyrazol,sulfaphenylpyrazole,sulfonylpyrazol,sulphaphenazole,sulphenazole" 1 "g" "NA"
+"SLF12" 5336 "Sulfapyridine" "Trimethoprims" "J01EB04,QJ01EQ04" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "adiplon,coccoclase,dagenan,eubasin,eubasinum,haptocil,piridazol,plurazol,pyriamid,pyridazol,relbapiridina,ronin,septipulmon,solfapiridina,soludagenan,streptosilpyridine,sulfapiridina,sulfapyridin,sulfapyridinum,sulfidin,sulfidine,sulphapyridin,sulphapyridine,thioseptal,trianon" 1 "g" "14075-6,55580-5"
+"SNA" 60582 "Sulfasuccinamide" "Other antibacterials" "" "NA" "sulfasuccinamid,sulfasuccinamida,sulfasuccinamidum" "NA"
+"SUT" 5340 "Sulfathiazole" "Trimethoprims" "D06BA02,J01EB07,QD06BA02,QJ01EQ07" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "azoquimiol,azoseptale,cerazol,cerazole,chemosept,cibazol,duatok,dulana,eleudron,enterobiocine,estafilol,formosulfathiazole,neostrepsan,norsulfasol,norsulfazol,norsulfazole,norsulfazolum,planomide,poliseptil,sanotiazol,septozol,solfatiazolo,soluthiazomide,streptosilthiazole,sulfamul,sulfaplex,sulfathiazol,sulfathiazolesalt,sulfathiazolum,sulfatiazol,sulfavitina,sulfocerol,sulphathiazole,sulzol,thiacoccine,thiasulfol,thiazamide,thiozamide,wintrazole" "87591-4,87796-9,87797-7"
"SLF13" 3000579 "Sulfathiourea" "Trimethoprims" "J01EB08" "Sulfonamides and trimethoprim" "Short-acting sulfonamides" "NA" "badional,baldinol,fontamide,salvoseptyl,solfatiourea,solufontamide,sulfanilthiourea,sulfathiocarbamid,sulfathiocarbamide,sulfathiocarbamidum,sulfathioureasalt,sulfathiouree,sulfatiourea,sulphathiourea" 6 "g" "NA"
-"SOX" 5344 "Sulfisoxazole" "Other antibacterials" "NA" "NA" "NA" "11578-2,18986-0,25226-2,471-3,472-1,473-9,474-7,9701-4"
-"SSS" 86225 "Sulfonamide" "Other antibacterials" "NA" "sfna" "NA" "17674-3,17675-0,18987-8,35842-4,4040-2,4041-0,4042-8,475-4,476-2,477-0,478-8,75650-2"
-"SLP" 9950244 "Sulopenem" "Other antibacterials" "NA" "NA" "orlynvah" "55289-3,55290-1,55291-9"
-"SLT6" 444022 "Sultamicillin" "Beta-lactams/penicillins" "J01CR04" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "NA" "combisid,sultamicilina,sultamicilline,sultamicillinum,unacid" 1.5 "g" "NA"
-"SUR" 46700778 "Surotomycin" "Other antibacterials" "NA" "NA" "surotomicina,surotomycine" "NA"
-"TAL" 71447 "Talampicillin" "Beta-lactams/penicillins" "J01CA15" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "aseocillin,phthalidyl,talampicilina,talampicilline,talampicillinum,talpen,yamacillin" 2 "g" "18988-6,479-6,480-4,481-2,482-0"
-"TLP" 163307 "Talmetoprim" "Other antibacterials" "NA" "NA" "NA" "NA"
-"TAZ" 123630 "Tazobactam" "Beta-lactams/penicillins" "J01CG02" "Beta-lactam antibacterials, penicillins" "Beta-lactamase inhibitors" "tazo" "exblifep,tazobactamsalt,tazobactamum,tazobactum" "41719-6,41720-4,41721-2,41740-2"
-"TBP" 9800194 "Tebipenem" "Carbapenems" "J01DH06" "NA" "NA" 0.56 "g" "NA"
-"TZD" 11234049 "Tedizolid" "Oxazolidinones" "J01XX11" "Other antibacterials" "Other antibacterials" "tedi" "torezolid" 0.2 "g" 0.2 "g" "73586-0,73608-2,73631-4"
-"TEC" 16131923 "Teicoplanin" "Glycopeptides" "J01XA02" "Other antibacterials" "Glycopeptide antibacterials" "tec,tei,teic,tp,tpl,tpn" "NA" 0.4 "g" "18989-4,25534-9,25535-6,34378-0,34379-8,4043-6,483-8,484-6,485-3,486-1,7051-6,80968-1"
-"TCM" "Teicoplanin-macromethod" "Glycopeptides" "NA" "NA" "NA" "NA"
-"TLV" 3081362 "Telavancin" "Glycopeptides" "J01XA03" "Other antibacterials" "Glycopeptide antibacterials" "tela" "arbelic,nvancomycin,televancin" "72894-9,73630-6,85051-1,88886-7"
-"TLT" 3002190 "Telithromycin" "Macrolides/lincosamides" "J01FA15" "Macrolides, lincosamides and streptogramins" "Macrolides" "teli" "ketek,levviax" 0.8 "g" "35843-2,35844-0,35845-7,41722-0"
-"TMX" 60021 "Temafloxacin" "Fluoroquinolones" "J01MA05" "Quinolone antibacterials" "Fluoroquinolones" "tema" "omniflox,temafloxacina,temafloxacine,temafloxacino,temafloxacinum" 0.8 "g" "18990-2,487-9,488-7,489-5,490-3"
-"TEM" 171758 "Temocillin" "Beta-lactams/penicillins" "J01CA17" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "temo" "negaban,temocilina,temocillina,temocilline,temocillinum" 4 "g" "18991-0,491-1,492-9,493-7,494-5,54190-4"
-"TRB" 1549008 "Terbinafine" "Antifungals/antimycotics" "D01AE15,D01BA02" "Antifungals for systemic use" "Antifungals for systemic use" "terb" "afogan,bramazil,bramizil,corbinal,lamasil,lamisil,muzonal,shoprite,terbina,terbinafina,terbinafinum,terbine,terbinex,terbisil,zabel" 0.25 "g" "10720-1,10721-9,18992-8"
-"TRC" 441383 "Terconazole" "Antifungals/antimycotics" "G01AG02" "NA" "fungistat,panlomyc,terazol,terconazol,terconazolum,tercospor,tetrazol,triaconazole,zazole" "55196-0"
-"TRZ" 65720 "Terizidone" "Antimycobacterials" "J04AK03" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "NA" "terivalidin,terizidona,terizidonum" "NA"
-"TCY" 54675776 "Tetracycline" "Tetracyclines" "A01AB13,D06AA04,J01AA07,S01AA09,S02AA08,S03AA02" "Tetracyclines" "Tetracyclines" "tc,te,tet,tetr" "abramycin,abricycline,agromicina,ambramicina,ambramycin,biocycline,brodspec,cefracycline,centet,ciclibion,copharlan,criseociclina,democracin,deschlorobiomycin,economycin,hostacyclin,lexacycline,limecycline,liquamycin,mericycline,micycline,neocycline,omegamycin,orlycycline,panmycin,purocyclina,roviciclina,solvocin,tetrabon,tetraciclina,tetracyclinehydrate,tetracyclinum,tetracyn,tetradecin,tetrafil,tetraverine,tetrazyklin,tsiklomistsin,tsiklomitsin,veracin,vetacyclinum" 1 "g" 1 "g" "101504-9,18993-6,25272-6,4045-1,495-2,496-0,497-8,498-6,7052-4,87590-6"
-"TCY-S" "Tetracycline screening test" "Tetracyclines" "NA" "tcy screen" "NA" "NA"
-"TOL" 54691494 "Tetracycline/oleandomycin" "Other antibacterials" "J01RA08" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
-"TET" 65450 "Tetroxoprim" "Other antibacterials" "NA" "NA" "primsol,tetroxoprima,tetroxoprime,tetroxoprimum,trimpex,trimplex" "NA"
-"THA" 9568512 "Thiacetazone" "Oxazolidinones" "NA" "NA" "acetanilide,aktivan,ambathizon,amitiozon,antib,benthiozone,benzothiozane,benzothiozon,berkazon,citazone,conteben,diasan,domakol,ilbion,livazone,mivizon,myvizone,neotibil,neustab,novakol,panrone,parazone,seroden,siocarbazone,tebalon,tebecure,tebemar,tebethion,tebethione,tebezon,thiacetone,thiacetozone,thibon,thibone,thioacetazon,thioacetazonum,thioazetazone,thiocarbazil,thiomicid,thionicid,thioparamizon,thioparamizone,thiosemicarbarzone,thiosemicarbazone,thiotebesin,thiotebezin,thiotebicina,thizone,tiacetazon,tibicur,tibion,tibione,tibizan,tibon,tibone,tioacetazon,tioacetazona,tioatsetazon,tiobicina,tiocarone,tiosecolo,tubercazon,tubigal,tubin" "32384-0,54184-7,54204-3"
-"THI" 27200 "Thiamphenicol" "Phenicols" "J01BA02" "Amphenicols" "Amphenicols" "NA" "armai,dextrosulfenidol,dextrosulphenidol,igralin,racefenicol,racefenicolo,racefenicolum,raceophenidol,thiamphenicolum,thiocymetin,thiophenicol,tiamfenicol,tiamfenicolo,urfamycine" 1.5 "g" 1.5 "g" "41723-8,41724-6,41725-3,54169-8"
-"TAT" 9568512 "Thioacetazone" "Antimycobacterials" "J04AK07" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "NA" "NA" "NA"
-"THI1" "Thioacetazone/isoniazid" "Antimycobacterials" "J04AM04" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA"
+"SOX" 5344 "Sulfisoxazole" "Other antibacterials" "" "NA" "NA" "11578-2,18986-0,25226-2,471-3,472-1,473-9,474-7,9701-4"
+"SSS" 86225 "Sulfonamide" "Other antibacterials" "" "sfna" "NA" "17674-3,17675-0,18987-8,35842-4,4040-2,4041-0,4042-8,475-4,476-2,477-0,478-8,75650-2"
+"SLP" 9950244 "Sulopenem" "Other antibacterials" "" "NA" "orlynvah" "55289-3,55290-1,55291-9"
+"SLT6" 444022 "Sultamicillin" "Beta-lactams/penicillins" "J01CR04,QJ01CR04" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "NA" "combisid,sultamicilina,sultamicilline,sultamicillinum,unacid" 1.5 "g" "NA"
+"SUR" 46700778 "Surotomycin" "Other antibacterials" "" "NA" "surotomicina,surotomycine" "NA"
+"TAL" 71447 "Talampicillin" "Beta-lactams/penicillins" "J01CA15,QJ01CA15" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "NA" "aseocillin,phthalidyl,talampicilina,talampicilline,talampicillinum,talpen,yamacillin" 2 "g" "18988-6,479-6,480-4,481-2,482-0"
+"TLP" 163307 "Talmetoprim" "Other antibacterials" "" "NA" "NA" "NA"
+"TAZ" 123630 "Tazobactam" "Beta-lactams/penicillins" "J01CG02,QJ01CG02" "Beta-lactam antibacterials, penicillins" "Beta-lactamase inhibitors" "tazo" "exblifep,tazobactamsalt,tazobactamum,tazobactum" "41719-6,41720-4,41721-2,41740-2"
+"TBP" 9800194 "Tebipenem" "Carbapenems" "" "NA" "NA" 0.56 "g" "NA"
+"TZD" 11234049 "Tedizolid" "Oxazolidinones" "J01XX11,QJ01XX11" "Other antibacterials" "Other antibacterials" "tedi" "torezolid" 0.2 "g" 0.2 "g" "73586-0,73608-2,73631-4"
+"TEC" 16131923 "Teicoplanin" "Glycopeptides" "J01XA02,QJ01XA02" "Other antibacterials" "Glycopeptide antibacterials" "tec,tei,teic,tp,tpl,tpn" "NA" 0.4 "g" "18989-4,25534-9,25535-6,34378-0,34379-8,4043-6,483-8,484-6,485-3,486-1,7051-6,80968-1"
+"TCM" "Teicoplanin-macromethod" "Glycopeptides" "" "NA" "NA" "NA"
+"TLV" 3081362 "Telavancin" "Glycopeptides" "J01XA03,QJ01XA03" "Other antibacterials" "Glycopeptide antibacterials" "tela" "arbelic,nvancomycin,televancin" "72894-9,73630-6,85051-1,88886-7"
+"TLT" 3002190 "Telithromycin" "Macrolides/lincosamides" "J01FA15,QJ01FA15" "Macrolides, lincosamides and streptogramins" "Macrolides" "teli" "ketek,levviax" 0.8 "g" "35843-2,35844-0,35845-7,41722-0"
+"TMX" 60021 "Temafloxacin" "Fluoroquinolones" "J01MA05,QJ01MA05" "Quinolone antibacterials" "Fluoroquinolones" "tema" "omniflox,temafloxacina,temafloxacine,temafloxacino,temafloxacinum" 0.8 "g" "18990-2,487-9,488-7,489-5,490-3"
+"TEM" 171758 "Temocillin" "Beta-lactams/penicillins" "J01CA17,QJ01CA17" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "temo" "negaban,temocilina,temocillina,temocilline,temocillinum" 4 "g" "18991-0,491-1,492-9,493-7,494-5,54190-4"
+"TRB" 1549008 "Terbinafine" "Antifungals/antimycotics" "D01AE15,D01BA02,QD01AE15,QD01BA02" "Antifungals for systemic use" "Antifungals for systemic use" "terb" "afogan,bramazil,bramizil,corbinal,lamasil,lamisil,muzonal,shoprite,terbina,terbinafina,terbinafinum,terbine,terbinex,terbisil,zabel" 0.25 "g" "10720-1,10721-9,18992-8"
+"TRC" 441383 "Terconazole" "Antifungals/antimycotics" "G01AG02,QG01AG02" "NA" "fungistat,panlomyc,terazol,terconazol,terconazolum,tercospor,tetrazol,triaconazole,zazole" "55196-0"
+"TRZ" 65720 "Terizidone" "Antimycobacterials" "J04AK03,QJ04AK03" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "NA" "terivalidin,terizidona,terizidonum" "NA"
+"TCY" 54675776 "Tetracycline" "Tetracyclines" "A01AB13,D06AA04,J01AA07,QA01AB13,QD06AA04,QG01AA90,QG51AA02,QJ01AA07,QJ51AA07,QS01AA09,QS02AA08,QS03AA02,S01AA09,S02AA08,S03AA02" "Tetracyclines" "Tetracyclines" "tc,te,tet,tetr" "abramycin,abricycline,agromicina,ambramicina,ambramycin,biocycline,brodspec,cefracycline,centet,ciclibion,copharlan,criseociclina,democracin,deschlorobiomycin,economycin,hostacyclin,lexacycline,limecycline,liquamycin,mericycline,micycline,neocycline,omegamycin,orlycycline,panmycin,purocyclina,roviciclina,solvocin,tetrabon,tetraciclina,tetracyclinehydrate,tetracyclinum,tetracyn,tetradecin,tetrafil,tetraverine,tetrazyklin,tsiklomistsin,tsiklomitsin,veracin,vetacyclinum" 1 "g" 1 "g" "101504-9,18993-6,25272-6,4045-1,495-2,496-0,497-8,498-6,7052-4,87590-6"
+"TCY-S" "Tetracycline screening test" "Tetracyclines" "" "tcy screen" "NA" "NA"
+"TOL" 54691494 "Tetracycline/oleandomycin" "Other antibacterials" "" "Combinations of antibacterials" "Combinations of antibacterials" "NA" "NA" "NA"
+"TET" 65450 "Tetroxoprim" "Other antibacterials" "" "NA" "primsol,tetroxoprima,tetroxoprime,tetroxoprimum,trimpex,trimplex" "NA"
+"THA" 9568512 "Thiacetazone" "Oxazolidinones" "" "NA" "acetanilide,aktivan,ambathizon,amitiozon,antib,benthiozone,benzothiozane,benzothiozon,berkazon,citazone,conteben,diasan,domakol,ilbion,livazone,mivizon,myvizone,neotibil,neustab,novakol,panrone,parazone,seroden,siocarbazone,tebalon,tebecure,tebemar,tebethion,tebethione,tebezon,thiacetone,thiacetozone,thibon,thibone,thioacetazon,thioacetazonum,thioazetazone,thiocarbazil,thiomicid,thionicid,thioparamizon,thioparamizone,thiosemicarbarzone,thiosemicarbazone,thiotebesin,thiotebezin,thiotebicina,thizone,tiacetazon,tibicur,tibion,tibione,tibizan,tibon,tibone,tioacetazon,tioacetazona,tioatsetazon,tiobicina,tiocarone,tiosecolo,tubercazon,tubigal,tubin" "32384-0,54184-7,54204-3"
+"THI" 27200 "Thiamphenicol" "Phenicols" "J01BA02,QJ01BA02,QJ51BA02" "Amphenicols" "Amphenicols" "NA" "armai,dextrosulfenidol,dextrosulphenidol,igralin,racefenicol,racefenicolo,racefenicolum,raceophenidol,thiamphenicolum,thiocymetin,thiophenicol,tiamfenicol,tiamfenicolo,urfamycine" 1.5 "g" 1.5 "g" "41723-8,41724-6,41725-3,54169-8"
+"TAT" 9568512 "Thioacetazone" "Antimycobacterials" "J04AK07,QJ04AK07" "Drugs for treatment of tuberculosis" "Other drugs for treatment of tuberculosis" "NA" "NA" "NA"
+"THI1" "Thioacetazone/isoniazid" "Antimycobacterials" "" "Drugs for treatment of tuberculosis" "Combinations of drugs for treatment of tuberculosis" "NA" "NA" "NA"
"TIA" 656958 "Tiamulin" "Other antibacterials" "QJ01XQ01" "NA" "denagard,thiamutilin,tiamulina,tiamuline,tiamulinum" "35846-5,35847-3,35848-1,87589-8"
-"TIC" 36921 "Ticarcillin" "Beta-lactams/penicillins" "J01CA13" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "tc,ti,tic,tica" "ticar,ticarcilina,ticarcilline,ticarcillinum,timentin" 15 "g" "18994-4,18995-1,25254-4,4054-3,4055-0,499-4,500-9,501-7,502-5,503-3,504-1,505-8,506-6,55716-5,55717-3,55718-1,55719-9,7053-2,7054-0"
-"TCC" 6437075 "Ticarcillin/clavulanic acid" "Beta-lactams/penicillins" "J01CR03" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "t/c,tcc,ticl,tim,tlc" "augpenin" 15 "g" "NA"
-"TGC" 54686904 "Tigecycline" "Tetracyclines" "J01AA12" "Tetracyclines" "Tetracyclines" "tgc,tig,tige" "tigeciclina,tigecyclin,tigecyclinehydrate,tigilcycline,tygacil" 0.1 "g" "101499-2,42354-1,42355-8,42356-6,42357-4,55158-0"
-"TMN" "Tigemonam" "Monobactams" "NA" "NA" "NA" "NA"
+"TIC" 36921 "Ticarcillin" "Beta-lactams/penicillins" "J01CA13,QJ01CA13" "Beta-lactam antibacterials, penicillins" "Penicillins with extended spectrum" "tc,ti,tic,tica" "ticar,ticarcilina,ticarcilline,ticarcillinum,timentin" 15 "g" "18994-4,18995-1,25254-4,4054-3,4055-0,499-4,500-9,501-7,502-5,503-3,504-1,505-8,506-6,55716-5,55717-3,55718-1,55719-9,7053-2,7054-0"
+"TCC" 6437075 "Ticarcillin/clavulanic acid" "Beta-lactams/penicillins" "J01CR03,QJ01CR03" "Beta-lactam antibacterials, penicillins" "Combinations of penicillins, incl. beta-lactamase inhibitors" "t/c,tcc,ticl,tim,tlc" "augpenin" 15 "g" "NA"
+"TGC" 54686904 "Tigecycline" "Tetracyclines" "J01AA12,QJ01AA12" "Tetracyclines" "Tetracyclines" "tgc,tig,tige" "tigeciclina,tigecyclin,tigecyclinehydrate,tigilcycline,tygacil" 0.1 "g" "101499-2,42354-1,42355-8,42356-6,42357-4,55158-0"
+"TMN" "Tigemonam" "Monobactams" "" "NA" "NA" "NA"
"TBQ" 65592 "Tilbroquinol" "Fluoroquinolones" "P01AA05" "NA" "tilbroquinolum" "NA"
"TIP" 24860548 "Tildipirosin" "Macrolides/lincosamides" "QJ01FA96" "NA" "zuprevo" "100060-3,88375-1,88377-7"
"TIL" 5282521 "Tilmicosin" "Macrolides/lincosamides" "QJ01FA91" "NA" "micotil,pulmotil,tilmicosina,tilmicosine,tilmicosinum,tilmovet" "35849-9,35850-7,35851-5,87588-0"
-"TIN" 5479 "Tinidazole" "Other antibacterials" "G01AF21,J01XD02,P01AB02" "Other antibacterials" "Imidazole derivatives" "tini" "amtiba,bioshik,fasigin,fasigyn,glongyn,haisigyn,isotinidazole,pletil,protozol,simplotan,sorquetan,symplotan,tindamax,tindazole,tinidazolum,tricolam,trimonase" 2 "g" 1.5 "g" "54928-7,55720-7,55721-5,55722-3"
-"TCR" 3001386 "Tiocarlide" "Antimycobacterials" "J04AD02" "Drugs for treatment of tuberculosis" "Thiocarbamide derivatives" "NA" "aethoksid,aethoxydum,amixyl,datanil,disocarban,disoxyl,ethoxide,etocarlid,etocarlida,etocarlide,etocarlidum,etoksid,thiocarlide,tiocarlid,tiocarlida,tiocarlidum" 7 "g" "NA"
-"TDC" 10247721 "Tiodonium chloride" "Other antibacterials" "NA" "NA" "tiodonium" "NA"
-"TXC" 65788 "Tioxacin" "Fluoroquinolones" "NA" "NA" "tioxacine,tioxacino,tioxacinum" "NA"
-"TIZ" 394397 "Tizoxanide" "Other antibacterials" "NA" "NA" "NA" "73585-2,73607-4,73629-8"
-"TOB" 36294 "Tobramycin" "Aminoglycosides" "J01GB01,S01AA12" "Aminoglycoside antibacterials" "Other aminoglycosides" "nn,tm,to,tob,tobr" "aktob,bethkis,distobram,gotabiotic,kitabis,nebcin,nebicin,nebramycin,tenebrimycin,tenemycin,tobacin,tobracin,tobradex,tobradistin,tobralex,tobramaxin,tobramicin,tobramicina,tobramitsetin,tobramycetin,tobramycine,tobramycinum,tobrased,tobrex" 0.24 "g" "101496-8,13584-8,17808-7,18996-9,22750-4,22751-2,22752-0,25227-0,25800-4,31094-6,31095-3,31096-1,35239-3,35670-9,4057-6,4058-4,4059-2,507-4,508-2,509-0,50927-3,510-8,52962-8,59380-6,7055-7,80966-5"
-"TOH" "Tobramycin-high" "Aminoglycosides" "NA" "tobra high,tobramycin high,tohl" "NA" "NA"
-"TFX" 5517 "Tosufloxacin" "Fluoroquinolones" "J01MA22,S01AE09" "NA" "NA" 0.45 "g" "100061-1,76146-0"
-"TMP" 5578 "Trimethoprim" "Trimethoprims" "J01EA01" "Sulfonamides and trimethoprim" "Trimethoprim and derivatives" "t,tmp,tr,tri,trim,w" "abaprim,anitrim,antrima,antrimox,bacdan,bacidal,bacide,bacin,bacterial,bacticel,bactifor,bactoprim,bactramin,bencole,bethaprim,biosulten,briscotrim,chemotrin,colizole,conprim,cotrimel,deprim,dosulfin,duocide,esbesul,espectrin,euctrim,exbesul,fermagex,fortrim,futin,ikaprim,infectotrimet,instalac,kombinax,lagatrim,lastrim,lescot,monoprim,monotrim,monotrimin,novotrimel,omstat,pancidim,proloprim,protrin,purbal,resprim,roubac,roubal,salvatrim,setprin,sinotrim,stopan,streptoplus,sugaprim,sulfamar,sulfoxaprim,sulthrim,sultrex,syraprim,tiempe,trimethioprim,trimethoprime,trimethoprimum,trimethopriom,trimetoprim,trimetoprima,trimexol,trimezol,trimogal,trimono,trimopan,triprim,trisul,trisulcom,trisulfam,trisural,uretrim,urobactrim,utetrin,velaten,wellcoprim,wellcoprin,xeroprim,zamboprim" 0.4 "g" 0.4 "g" "101495-0,11005-6,17747-7,18997-7,18998-5,20387-7,23614-1,23631-5,25273-4,32342-8,4079-0,4080-8,4081-6,511-6,512-4,513-2,514-0,515-7,516-5,517-3,518-1,55584-7,7056-5,7057-3,80552-3,80973-1"
-"SXT" 358641 "Trimethoprim/sulfamethoxazole" "Trimethoprims" "J01EE01" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "cot,cotrim,sxt,t/s,tms,trsu,trsx,ts" "abacin,abactrim,agoprim,alfatrim,aposulfatrim,bacteral,bactilen,bactiver,bacton,bactoreduct,bactrim,bactrizol,bactromin,bactropin,baktar,benzenesulfonamide,berlocid,bibacrim,biseptol,centran,centrin,chemitrim,chemotrim,ciplin,comox,cotribene,cotrim,cotrimhexal,cotrimoxazol,cotrimoxazole,cotrimstada,cotriver,dibaprim,drylin,duratrimet,eltrianyl,escoprim,eslectin,esteprim,eusaprim,fectrim,gamazole,gantanol,gantaprim,gantaprin,gantrim,groprim,helveprim,imexim,insozalin,jenamoxazol,kemoprim,kepinol,laratrim,linaris,maxtrim,metoxal,microtrim,mikrosid,momentol,nopil,oecotrim,omsat,oriprim,oxaprim,pantoprim,potrox,primazole,radonil,septra,septrim,servitrim,sigaprim,sigaprin,sulfatrim,sulfotrim,sulfotrimin,sulmeprim,sulprim,sumetrolim,supracombin,suprim,tacumil,teleprim,teleprin,thiocuran,tribakin,trifen,trigonyl,trimedin,trimesulf,trimethoprimsulfa,trimetoger,trimexazol,trimezole,trimforte,trimosulfa,uroplus" "101495-0,18998-5,20387-7,23631-5,25273-4,32342-8,4081-6,515-7,516-5,517-3,518-1,7057-3"
-"TRL" 202225 "Troleandomycin" "Macrolides/lincosamides" "J01FA08" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "aovine,cyclamycin,evramicina,matromicina,oleandocetin,oleandocetine,tekmisin,treolmicina,tribiocillina,triocetin,triolan,troleandomicina,troleandomycine,troleandomycinum,viamicina,wytrion" 1 "g" "18999-3,519-9,520-7,521-5,522-3"
-"TRO" 55886 "Trospectomycin" "Other antibacterials" "NA" "NA" "trospectinomycin,trospectomicina,trospectomycine,trospectomycinum" "NA"
-"TVA" 62959 "Trovafloxacin" "Fluoroquinolones" "J01MA13" "Quinolone antibacterials" "Fluoroquinolones" "trov" "trovan,turvel" 0.2 "g" 0.2 "g" "23642-2,23643-0,35855-6,7058-1"
+"TIN" 5479 "Tinidazole" "Other antibacterials" "G01AF21,J01XD02,P01AB02,QG01AF21,QJ01XD02,QP51AA02" "Other antibacterials" "Imidazole derivatives" "tini" "amtiba,bioshik,fasigin,fasigyn,glongyn,haisigyn,isotinidazole,pletil,protozol,simplotan,sorquetan,symplotan,tindamax,tindazole,tinidazolum,tricolam,trimonase" 2 "g" 1.5 "g" "54928-7,55720-7,55721-5,55722-3"
+"TCR" 3001386 "Tiocarlide" "Antimycobacterials" "J04AD02,QJ04AD02" "Drugs for treatment of tuberculosis" "Thiocarbamide derivatives" "NA" "aethoksid,aethoxydum,amixyl,datanil,disocarban,disoxyl,ethoxide,etocarlid,etocarlida,etocarlide,etocarlidum,etoksid,thiocarlide,tiocarlid,tiocarlida,tiocarlidum" 7 "g" "NA"
+"TDC" 10247721 "Tiodonium chloride" "Other antibacterials" "" "NA" "tiodonium" "NA"
+"TXC" 65788 "Tioxacin" "Fluoroquinolones" "" "NA" "tioxacine,tioxacino,tioxacinum" "NA"
+"TIZ" 394397 "Tizoxanide" "Other antibacterials" "" "NA" "NA" "73585-2,73607-4,73629-8"
+"TOB" 36294 "Tobramycin" "Aminoglycosides" "J01GB01,QJ01GB01,QS01AA12,S01AA12" "Aminoglycoside antibacterials" "Other aminoglycosides" "nn,tm,to,tob,tobr" "aktob,bethkis,distobram,gotabiotic,kitabis,nebcin,nebicin,nebramycin,tenebrimycin,tenemycin,tobacin,tobracin,tobradex,tobradistin,tobralex,tobramaxin,tobramicin,tobramicina,tobramitsetin,tobramycetin,tobramycine,tobramycinum,tobrased,tobrex" 0.24 "g" "101496-8,13584-8,17808-7,18996-9,22750-4,22751-2,22752-0,25227-0,25800-4,31094-6,31095-3,31096-1,35239-3,35670-9,4057-6,4058-4,4059-2,507-4,508-2,509-0,50927-3,510-8,52962-8,59380-6,7055-7,80966-5"
+"TOH" "Tobramycin-high" "Aminoglycosides" "" "tobra high,tobramycin high,tohl" "NA" "NA"
+"TFX" 5517 "Tosufloxacin" "Fluoroquinolones" "J01MA22,QJ01MA22,QS01AE09,S01AE09" "NA" "NA" 0.45 "g" "100061-1,76146-0"
+"TMP" 5578 "Trimethoprim" "Trimethoprims" "J01EA01,QJ01EA01,QJ51EA01" "Sulfonamides and trimethoprim" "Trimethoprim and derivatives" "t,tmp,tr,tri,trim,w" "abaprim,anitrim,antrima,antrimox,bacdan,bacidal,bacide,bacin,bacterial,bacticel,bactifor,bactoprim,bactramin,bencole,bethaprim,biosulten,briscotrim,chemotrin,colizole,conprim,cotrimel,deprim,dosulfin,duocide,esbesul,espectrin,euctrim,exbesul,fermagex,fortrim,futin,ikaprim,infectotrimet,instalac,kombinax,lagatrim,lastrim,lescot,monoprim,monotrim,monotrimin,novotrimel,omstat,pancidim,proloprim,protrin,purbal,resprim,roubac,roubal,salvatrim,setprin,sinotrim,stopan,streptoplus,sugaprim,sulfamar,sulfoxaprim,sulthrim,sultrex,syraprim,tiempe,trimethioprim,trimethoprime,trimethoprimum,trimethopriom,trimetoprim,trimetoprima,trimexol,trimezol,trimogal,trimono,trimopan,triprim,trisul,trisulcom,trisulfam,trisural,uretrim,urobactrim,utetrin,velaten,wellcoprim,wellcoprin,xeroprim,zamboprim" 0.4 "g" 0.4 "g" "101495-0,11005-6,17747-7,18997-7,18998-5,20387-7,23614-1,23631-5,25273-4,32342-8,4079-0,4080-8,4081-6,511-6,512-4,513-2,514-0,515-7,516-5,517-3,518-1,55584-7,7056-5,7057-3,80552-3,80973-1"
+"SXT" 358641 "Trimethoprim/sulfamethoxazole" "Trimethoprims" "" "Sulfonamides and trimethoprim" "Combinations of sulfonamides and trimethoprim, incl. derivatives" "cot,cotrim,sxt,t/s,tms,trsu,trsx,ts" "abacin,abactrim,agoprim,alfatrim,aposulfatrim,bacteral,bactilen,bactiver,bacton,bactoreduct,bactrim,bactrizol,bactromin,bactropin,baktar,benzenesulfonamide,berlocid,bibacrim,biseptol,centran,centrin,chemitrim,chemotrim,ciplin,comox,cotribene,cotrim,cotrimhexal,cotrimoxazol,cotrimoxazole,cotrimstada,cotriver,dibaprim,drylin,duratrimet,eltrianyl,escoprim,eslectin,esteprim,eusaprim,fectrim,gamazole,gantanol,gantaprim,gantaprin,gantrim,groprim,helveprim,imexim,insozalin,jenamoxazol,kemoprim,kepinol,laratrim,linaris,maxtrim,metoxal,microtrim,mikrosid,momentol,nopil,oecotrim,omsat,oriprim,oxaprim,pantoprim,potrox,primazole,radonil,septra,septrim,servitrim,sigaprim,sigaprin,sulfatrim,sulfotrim,sulfotrimin,sulmeprim,sulprim,sumetrolim,supracombin,suprim,tacumil,teleprim,teleprin,thiocuran,tribakin,trifen,trigonyl,trimedin,trimesulf,trimethoprimsulfa,trimetoger,trimexazol,trimezole,trimforte,trimosulfa,uroplus" "101495-0,18998-5,20387-7,23631-5,25273-4,32342-8,4081-6,515-7,516-5,517-3,518-1,7057-3"
+"TRL" 202225 "Troleandomycin" "Macrolides/lincosamides" "J01FA08,QJ01FA08" "Macrolides, lincosamides and streptogramins" "Macrolides" "NA" "aovine,cyclamycin,evramicina,matromicina,oleandocetin,oleandocetine,tekmisin,treolmicina,tribiocillina,triocetin,triolan,troleandomicina,troleandomycine,troleandomycinum,viamicina,wytrion" 1 "g" "18999-3,519-9,520-7,521-5,522-3"
+"TRO" 55886 "Trospectomycin" "Other antibacterials" "" "NA" "trospectinomycin,trospectomicina,trospectomycine,trospectomycinum" "NA"
+"TVA" 62959 "Trovafloxacin" "Fluoroquinolones" "J01MA13,QJ01MA13" "Quinolone antibacterials" "Fluoroquinolones" "trov" "trovan,turvel" 0.2 "g" 0.2 "g" "23642-2,23643-0,35855-6,7058-1"
"TUL" 9832301 "Tulathromycin" "Macrolides/lincosamides" "QJ01FA94" "NA" "arovyn,draxxin,increxxa,macrosyn,tulieve,tulissin" "76149-4,87798-5"
"TYL" 5280440 "Tylosin" "Macrolides/lincosamides" "QJ01FA90,QJ51FA90" "NA" "fradizine,tilosina,tylan,tylocine,tylosine,tylosinum,vubityl" "35856-4,35857-2,35858-0,87587-2"
"TYL1" 6441094 "Tylvalosin" "Macrolides/lincosamides" "QJ01FA92" "tvn" "aivlosin" "101526-2,87586-4"
-"PRU1" 124225 "Ulifloxacin (Prulifloxacin)" "Other antibacterials" "NA" "NA" "NA" "NA"
-"VAN" 14969 "Vancomycin" "Glycopeptides" "A07AA09,J01XA01,S01AA28" "Other antibacterials" "Glycopeptide antibacterials" "va,van,vanc" "vancocin,vancoled,vancomicina,vancomycine,vancomycinum" 2 "g" 2 "g" "13586-3,13587-1,19000-9,20578-1,23615-8,25228-8,31012-8,39092-2,39796-8,39797-6,4089-9,4090-7,4091-5,4092-3,50938-0,523-1,524-9,525-6,526-4,59381-4,7059-9,92241-9,97657-1"
-"VAM" "Vancomycin-macromethod" "Glycopeptides" "NA" "NA" "NA" "NA"
-"VIO" 135398671 "Viomycin" "Antimycobacterials" "NA" "NA" "florimycin,floromycin,vioactane,viocin,viomicin,viomicina,viomycine,viomycinum" "19001-7,23616-6,527-2,528-0,529-8,530-6"
-"VIR" 11979535 "Virginiamycine" "Other antibacterials" "NA" "NA" "NA" "NA"
-"VOR" 71616 "Voriconazole" "Antifungals/antimycotics" "J02AC03" "Antimycotics for systemic use" "Triazole derivatives" "vori,vrc" "vfend,voriconazol,voriconazolum,voriconzole,vorikonazole" 0.4 "g" 0.4 "g" "32379-0,35862-2,35863-0,38370-3,41199-1,41200-7,53902-3,73676-9,80553-1,80651-3"
-"XBR" 72144 "Xibornol" "Other antibacterials" "J01XX02" "Other antibacterials" "Other antibacterials" "NA" "bactacine,bracen,nanbacine,xibornolo,xibornolum" "NA"
-"ZID" 77846445 "Zidebactam" "Other antibacterials" "NA" "NA" "zidebactamsalt" "NA"
-"ZFD" "Zoliflodacin" "NA" "NA" "NA" "NA"
+"PRU1" 124225 "Ulifloxacin (Prulifloxacin)" "Other antibacterials" "" "NA" "NA" "NA"
+"VAN" 14969 "Vancomycin" "Glycopeptides" "A07AA09,J01XA01,QA07AA09,QJ01XA01,QS01AA28,S01AA28" "Other antibacterials" "Glycopeptide antibacterials" "va,van,vanc" "vancocin,vancoled,vancomicina,vancomycine,vancomycinum" 2 "g" 2 "g" "13586-3,13587-1,19000-9,20578-1,23615-8,25228-8,31012-8,39092-2,39796-8,39797-6,4089-9,4090-7,4091-5,4092-3,50938-0,523-1,524-9,525-6,526-4,59381-4,7059-9,92241-9,97657-1"
+"VAM" "Vancomycin-macromethod" "Glycopeptides" "" "NA" "NA" "NA"
+"VIO" 135398671 "Viomycin" "Antimycobacterials" "" "NA" "florimycin,floromycin,vioactane,viocin,viomicin,viomicina,viomycine,viomycinum" "19001-7,23616-6,527-2,528-0,529-8,530-6"
+"VIR" 11979535 "Virginiamycine" "Other antibacterials" "" "NA" "NA" "NA"
+"VOR" 71616 "Voriconazole" "Antifungals/antimycotics" "J02AC03,QJ02AC03" "Antimycotics for systemic use" "Triazole derivatives" "vori,vrc" "vfend,voriconazol,voriconazolum,voriconzole,vorikonazole" 0.4 "g" 0.4 "g" "32379-0,35862-2,35863-0,38370-3,41199-1,41200-7,53902-3,73676-9,80553-1,80651-3"
+"XBR" 72144 "Xibornol" "Other antibacterials" "J01XX02,QJ01XX02" "Other antibacterials" "Other antibacterials" "NA" "bactacine,bracen,nanbacine,xibornolo,xibornolum" "NA"
+"ZID" 77846445 "Zidebactam" "Other antibacterials" "" "NA" "zidebactamsalt" "NA"
+"ZFD" "Zoliflodacin" "" "NA" "NA" "NA"
diff --git a/data-raw/datasets/antimicrobials.xlsx b/data-raw/datasets/antimicrobials.xlsx
index bb3afdd1d9d3c837ea38d708b9ede465c2850b94..931c6afe52f55040e01d984ce121b2cf6ed968a7 100644
GIT binary patch
delta 74964
zcmZ6yWmH^IlP-)C++Bl9;~L!EEx5Z|a5%V2aCZVhgS)%Cy9Nku!Qmq_cjmqK`_bKJ
zoz-ify{c<h)gyhi0`-0Xg`^}4355yv>C-1LeEs|yBvNq5kIy=0aF74GNGyjq`gbES
z1(FFM2=6f`h``UGU_mRqs%*ru)O{~%;(7R+0&XI<Dfcw%q5yO>H67TNXYRxD(b>?c
zn0}G&{zRXw^>zQ-7sV2ap6;0a7!IX)BGUAQAC7XGC{vp}m%`vw@h0ElzQ)UcidBv@
zhRiU*#-PfeKjA=eI$4@`x*Av#lJxYG<$z)YJhxp@<n$CNB#SWlXMLZGA*F=#!I7v)
z8EOM_>cHCv%VBvezR%O066(g}j0<##FTk!fPOLiN#N6TB`d;16He}G%0kq&nj6V!}
zAyF2W@CAE<;x%Ujw25W;KanPSK=Wd{I&Ti5#EpF^m3*{J`0a!>_7b}xw_^HIW1*MD
zD+u|Ga8u?r$OFPv)t)<aK)HDfDf7|BZS|n(CjhP_3;PK}^I?M)91P3|0u1c`32faP
z6!w2d76%3n;=e*n{^=6tzb>#*8vZ-hlc)^9-e7_tJdlhm=x`q6zp<Pek=~N8zfd_~
zzs9!YviSl@Aq*!;+6@`VTB`VNYOWrDs;nihl;s_(lMGe{Px@U;_Rab6{@tRfY?B}7
ztl0L?`@_id!0WM|@>Hg{mf*{f;``lUYVKU_rd?~h{=T{@&imC|=km+#`^#b1`$j#W
zm^oB%v?=`TbweV^@3!%@wb`{bP7<Zw`S?Q%heKD3^Nj9dyV}>IORGt|Gf$%YPsc^;
z)w8<(qF@B^TP6RGIP(_J;XsLbrykZfY96bok8dAy#T|GRdaW@i{BfB14fHXoPqBIQ
zEAGl{<>JIX=_KDYuCR}tr+U^U#Bl;|$t%yN3m3W*ik{W#n*w%Af}%q<4^DNpbZz|n
zdx{qtH^B2>B`!OG@@?<#po1ItHte^X9Rp^MZJ)PL$;m@s#WT+hkIz0Chv;}G)5(Cj
zf$~-=a0KG6t82ahJsb;ey*?K}nfDgD+ts|p<yN%=Z76lOCHIaI_^<9-FF?oR6y&S@
z&GO4@0|QQznI71Qx8O|rR%VwV=K{w%d{M-t+v90m0o`xCnmiNC46QjnBkHYf%;8np
zxr(>6!v{+Kr4aA8=jR^&14y6GgAbLyTw`3&>wE7EI2(Jw3sgc2P0C~ApY6pZ@yE+$
zVW#fSw`cEmHScP+ze%Ya3ju?dzNyC~_ebE(d+p`5YM|t43dkjQ3YmH)5yWzQdC7h6
zdcObq{`Q7PY|h98pr($s25!AbE{QatZ%W_i-Z)=fT=4#k2=l#*)4k&{z{+^aZGJ+r
ztJAZ=_xX*#zoD!88kPU_p6~6Ep<z&2=_6lm)3{(8>O&1fFW={&3-nEN+W&c#S^CYp
z1Tz@+=N*LI8s}nSTUR-z;9jCrrT#d+emFTD*fz$$RBS!^bTrlpOMH&Ea)GyE;nm#Q
zHoJZqq)13IX!JK@Ptf@_Sn#mC)}GT-ee(YDLa!<{K=CwaUaw_!DpL!YTvX?G^0~Or
zZ*9Q6ublqtP?bS56_C4n*7uu8j_HC27mhcJXNzOZeZx(o{>E;>R%Qdk$1E3kx!LN0
z0Ea1T^np3|V|3lnbJ^H95g6mD;_Q4Tv_GAe)I6*#><r~;a=GT<Q#}B|lX41mUoiMP
z6DvUw6s)#yl3i)49kl8S>EvN*?di@6X;sxAyT)?q9@49)00eY8Mc3L&&z`h29+>JW
z54e$4I7k}H-7iAolqhS2QJ!;?qhC~_oZEV9Q30KoHacw0`T4uz&;vXU>$0p2+wJ~#
zr^UE0a+r$COt0hXR#B<w0K_^H6(7wubuz;Xd%-F?t)=XRX<cY~*+!LXVKgfG6u>~n
zwJzy39YfLyI0d$_8FUIJd+Q^?3k%Xf5i$Yob4c*u{1Su`Ro*X!g0*@RQT7Ivqv9+$
z>v;qi&4cb=K)Q66ZJsEpzq_56<J}AmTRjBvks<a7UadQQh~&_hq#L?29ehnXeQY{?
zEINHivihWqrldaK-@QM`4@u>x>D5xm>u&My7EKQW(gfeta^icN*i<~|$V1E}SPeRn
zsaep!^8Runn0IBCz}}rm;@(C+S`Wah(%NxVoBi|vf;B4;iz!T$!kP?SJc{A&qJ3*f
zR!1hu!<~KtpM62LA5V3dNWB<Oz36k{=K1r5XSezCFA9;Q<Snihc8KKq_+M4<cRM3@
z9h?hCpmwISTT%DKplztYSJGgsSvT_GU^a}NYnmaoz-sJAnPyXqeYR`9Usa)WVDG}@
zbJN-W0-1pW1qWZ$?GqY`;pZAMPjCq9(E=sPsw|-y|1c(3tozXo6Ma<&Qf0lJ`3aY~
zhUM_{YDgLC&w&o>27%jBoCUN|;lm)>-(&YPz?TH{`vmkl-YA0XqW)W4;e`I<_@DhR
zqffLJFfYsX_`pv?!I~Wyuc~8euFj{io9v6K`@0|lUcvbYlGk)W-HSh?_k>!1`j6^i
z>!L1~mieGGfkTcZ;kRI3$d@pvm${B@2bQkA?l_3Hpw)Qxaf(PfFL;eJF##MRv|6v5
zuPVD&DX}^g+T3-GStjmvcCh7F@>&jA)T_&<S=P@<g?uWCl%Tgv<X}`zj=cU=S0MF<
zI@@vJ_wkU=qXu)CJB92OR7?9Iop&D0cwjF1(2bu0;glp@qBsr+IIE5ZCV$FR6DQHG
zgO4HFqkGt=bbkZY03fzzVkmu>iJ)%xE9>pOI%s9Wy_M-WQ4)o)QrMvgjF!@q_be5>
z7eZd83B`Q<BxpDR+fxarhdM<wsIy(f90n(q<_46h@8(AEQ}(z934T7(+|sR&1q24@
zdtYDEG-1;3$IR;h+hu5T=QoeUtk!Dw_rPDj$CgHl9-URrE`IB5r7>+~Fm0tXZBZYN
zt5{8m)AGu`mhBZJ5tBnS3U2096IB{!$JBLcBxd5*>yO#Jf(5-l>sogka{MyOOUkZp
zFP|coR}(ubF2p!zS~Q(#g&KHnJCnF)>nvWpJ37wRD><D9X6t$MITlK|;%?$7j8@aJ
z6q#e@k^g*;98Gr+Zc7gOZKXB;^Ala(pC@Ia<cvayCWU28KMX@eg@y4bY&Bg?w>)E=
z<b?vQ6kbwJBAN&y>xJ#TFB1hncl41?s~eg1A|z)b)U2^-Zw_>B4tQ@4o^J``N4?@l
zHRGRTsa4W7fd}Xs_xi=xv@5a(`T=}VYE|7jl*?~^Fhqu_zc??z#gg<a&FD<Hq&A1>
zxm^8xVhke=Vd@|H*m!n$c7$WGy(W2YTzn5&U(TjaH@3{~AF7snWGt0In|PSXOS%qu
z)X)*&3zya<7~GvJ*nc@i+`oU7oq?9x2*mbpKIySP1k{BO3c3l{6*FrM7&&V-amr}i
zugA%ctH53I`}AnvCXI%uXu*6#^5_?7LSgIIgUP{uQz{R~?mIzOH|MD_l?64F(WaD5
z*aIH=;z5I&`rd&Wd1yFYrgc<SQ@k(9^}%*VQhE2ROh?3%?OE#bC*$<iNY);7`9F{I
z9e=@v1FyRAx1D(!aC%M4iZw+|`<OaDlV+4{>SEy5J|0`HV__+7zw+8)@7(#RAyTR7
zHKhc5T{x~8^S%^39ms4n`B;@9{}JrjZM74sjH4dF5S<a2hJ}PE{uu(fO;59n!@xL(
zfcv04c3v@0;Lq8dRZxo#T+zlKUBiN57(#FD0O9TV9nQ!O6@>vVb;V&2)dk(u;_QYC
zH2sD%v#DZGLi$Nv>6ps(B$oX{Z%f#IZ2S&7;cR(J7tTE3xEPBY`#?EKCoRdg==Oko
zi}u%DXE<I&o`wO@Je?jU<jYP&FVgB|x^!2=!$9gBgqZ=hH!+I0&Alz0E7|JZ08kbV
zU|X0;&>w#MicTaCzk<2pPv{nB9!jgXZc%I}2d{&|6j<qx(<jg!1*v`E4VR-}1na+s
zjl#vPv^z_}iC1mmln-vpY&>*tb+Sv{taC}e9Nq1N8vNN6UA!i&q$YZw#XioE4NWvo
ziK02xv4iwsg-cE=XKhML$T@LQa-&Ebkk5U`_^a)N2|F^=KXC7c8^0MeEa*Tll;R<m
zbY?NCHs}_}wscW7Z9tme0OiOe7*^x!XRE<BpYVA%uC+^8aFSPP>T6efCXqctEiyHU
zQT?9`jq)8shor6{IQv*p!Iw1w?lu`4qwQ;Y*#|FU*0F=46v6Tpxr8?P$D-j5fLlwo
z{0x$gt0p^d6dby42)q8!KV&wEv}$%AOb`QZx^E1E8jUnBhSZWhgUfifZ*6DP4H^S7
zwpa7GbeUB1Nvx09>eR`Mbg<qRX_ymH&P+jG97P)eJ{8YrIrRsTuPN71-&B#p`O4~G
zNEui4?#?N7)!VG~O(|`LpqSASKs46w9ylH}=`Jx|p6qskK6~CFzB*wpZ@{qhYbEm}
z8F8)*Xj*?AbbeiQew}oF&GFSW7ht{01Ga@XAr6C5U_-tM?*~nSVq??4H;Dug(I8J(
zb9>zjkNLhqtD*T&=LJ51Jr~n+1=y+X`g|Msd)#(X=o@<@s{W8~{i37}_zm-Dhc;*-
z?F1!E8r5yNLZ7yNK?<#*2LJKr5O?#|98UDz83tI4(>}M*3A8tg^^U<4sjNRvo8dIm
zu+LBzCYmKn{WNboUtgZj#P=1-*V@w`9{$^9;4+5qRBMqL)hs&+s<8X_q*f_;Vx#=n
zpBhL^tR?9(%FHF*XREq|fEDG}jF^@o^s$b>WWQO|jfWg>P)p)di$!@K9fvR_SCurR
zS~_g=1LmmfeA-YEavTIVxcDcVg=zV9C^})hd=;X_4&~6NGsO9g94jbp%{7mTnDLDU
zHz?*cTc7=BZ;nqdFPZ{;){=qS=;S>kp<F4sHw(_M8NRyTJAZGS0z_|ehOd&eWMOPU
zsXgtH4x8+<L}P`UnpIocRa;tBTizDwCmyigL~$IoEpzy%9=*n}U?nErN}VMOt9flE
zney6@ArfcVB}r~lVhN<fi(`aZ*3_98Id<3jH0?h{;?5W)UzhOTleGmb))=NQHU6~G
z<-=#@BZ1KKeEYf_0W1riQW{l2C!=;-M-V$f37_ZgHO!Tz=m)1f5eZQOorAm=C0UN?
zyX9R3rFBer_gBR!75m?{$fqtpeJ0%tidMeK!*f0giPXVDvs066ks7IBiiKgExk0v3
zy`<Oq7}O)%Y7y`W23cwHlhZx%u$E`{x%4zvoKCYtAxkGp1MV)rz0+otJC<zjwY|a+
zJSsG@ZE{-mpTm9zP&7@)6e(9y-$tY8G$XfCKYZrb;#O|~T{Z<aGJM_WEy(ZIS*Z5t
zmK@MC@9-@)Sg5e}LS(JM`UQ<F?Xsela2gzG2Q%7DP2s;}^h;(wtCLEFzJ5C7T6`Tt
z%IDQ){&O#VJYe=CyrW2Lt9qAogZKsFaX65IpXeu;&E3hG@#h@$d3S=VM|g^4h+jur
zE5(+%-d=5VOQdB;N=2h<OMyDA#?<Bhla01st%2V(pv~S{z6YalmE6xsBavM~S5sDD
zhcGI2cAjDAZD=?WG19@`?M#UnZugjWO&y4A++Fb3Bm!;)XnW^1AuRNRPX|ea?QzuU
zwAt%*4a#tzytt>|KgSm!qiU$<>*|UB+;xGRJ{Qlsa50%j3uKL94-&Ax7`E=7n%?cE
zG=b9f%Fki`G>rQ>vR@m~HLMwTj8FF)^s+B*k(IwJ8;$4@c8W2c7JkvPaz;Pn`aC-k
zar7(SBoy!`j=u79J@t4aA5##~_Ej*h7PVNE7inw%JTBe>WR42Tk-N^!doL93EARu+
zR32;#GB|jRT`Yl92bS~)gCQ9G8Q;h^2m?louN+$)!?ldjpp#xHrqUS-=@_|$GN{{R
zLzw_R?9OT&>O@>35IFxP=B0ZjE*wTV)ch+s?JjV3xM(?2$(4F%T<#mVqMvfMJ>(F7
zzr!SviLJxQSz~5`p*UB3MdkTmO{km{Lz-hX0WIjW**#z9_%qMzrdS;Fm*$1eb!7nl
zG<m$E`RCztH1>gcm9YzK1m3Ybow2)*_vgf|b(>iJ<rL2f{-swgh9N5BZCG|1K2C#!
zXP|5h8j+yLc*Y?#LDse(!>#}R*PBSWy0oPhcT1WdLrvs%(p%Nan^0xLbYxhm@H?I%
z0y7^-pQPYUiPowlt*?{9-B7EG{%*1uyN>(gi6d&~Ohb*ur;0Oi&v509$RfHl;t`qR
zKRXpfyAAlMrTH|~2dJdKEKhk>K(9D70ou}N*se~ePZ=}WXSUg2VSWgEMI<YG)%Mag
zM4yzJ=_;1QoK*N`deHXQzdqB#)Gu@2hjn*g`3LJ&nQ27zq#rz09z10qJaxFI%%r<l
z^W13K)NI{GAzFd$6zgNgI$}1~HS~-{JD4>=n6JSLQK;I(q|3_CQ`AGcneR-D1HG9m
z?3<?YJsNfV!h4sUYP21r*WWIv7Zbg>SjPJPQ-|uhkg*5z4&t(*WYz&=IP%f}<=3Fn
zh$;NAmn!HNAMoTMt1M#PrE9&0y1=`b9i5exc`n>UpVw*LK95!C8ryN!l7pv)3k73^
zMz5+(WadJ$C`h=yeSqB1f#K$@Q-}EGqs3_WDc$3|FPC~J+(GK_Ue2IVI2MrJ4d0X9
zZZGev?U2Zk`7B27a8=$_G0BmkGZ9$vJydbp6oUT(;6y)dnSKh$cq2)eb}k!0?R9=#
z%{BkjqcOFRNv3~hpren19PSP)+1(jsZeX<m&oJd{(&9(o1-N;PH*Zo5^4}e_|5kqQ
zE(B@359MkTpUG484)ZoH?D4L-GFYwO@%`yCLcLSevwrFfLGeW(Q9vZ`&7>I5KweCE
zr5}NHWyuS8G`wF-?%m3Y&c6RebEYtI&1Mf;a`4ruN7QMKuG=+xfc>;(@%iR`aq5`N
zR3Zf?o)`H?AK>;^_xg`f<3f?}jp_VmQ{LZ{lcl%%a6H>P-Ht>v9n5H=GxxE+_5bY$
z&lWq^Z{Vr-TI{b~4No+JNp;Rygs{ZhZC;G@ehz({yy_vNZlqk?@ovP8P;=F~U4KhL
z<_yaZU)ur#ew9RlBS9KO1SEoWt@A2AvcY5kkd8Ha2ih2ZV?kU0`;59S_V9#H9nm#n
zC%z!GEYZxtam$%~5=XY&fz~&j6ZK=+b<kgksVIrP&ueRJq4m4CDK>XlhrhqooG%}L
z;qgR`2A$$*ExTx=A~ZhL+UDLo87QO*vi}^vn5HhF=9I#`%$!*PoB5N&2m`QdT_xX0
z;;ld*3r9IG7x`@bmL~oJMaAq*g#cmR;%C$1XVKz!k&89nD`==GfWY^<mzeUyEX|)r
zrq{OUXy4oW_zGZ99ZF5xH|d)^Vq4vo5#c4vy@XO_*;aiL^LGylkYq8=`O#+s;5!d$
zOdTxc8NFYc=@Vi0K~fQC?E@k4Q^A6i*8P<Z!ULeCi`P0OmUsWiM-cukO68YeCa`E`
zx%JECrqqj*AE(4R0<#cnjv^qY+@bz<rms1&=%k;}Mk!N1>(!I4z$xyx69}LW0Kp6x
z<HAT^%vg<$F20VvfTr&PD<a<wsqYIK9JbdQ4-8M1><yBX_DSPuAb{SPyC1r}`lzxm
zdYV<&)DXGH<$uShu3|=nd@oy~zDnv?ZxNL>?3dEfK2n4Q6$s|70%HZ9fd%9z_o@7d
zQj;b%399Sx2IQU5>Ma2a_<x(|+)Xi}7mfFSwXak;vx83Y*?TTBum|%wR(oc$r|0TC
zt&Wsi-E@*4{CS_?j)1NRef=rR3+P|azP!g+r-Y9LH=c?!EseTgUVl*((B}|(SSpM2
zR?`Gua?2#;%HeCOam`$Xv%*=L+IUwXK!R!e4TLj4sd=%w%18U<2+Q@@zYL>5XuI}C
zvUSsg<1fKtexZ_`L4+pnZ#Gwd2G6?H;=77kET7{FQX_eMg8_V={j}^3<+Hok)vx?i
z$H9fDw0YB3AT2cA)Ts+oPAg-PDo^uE7?&0r1d$N3HD22ey#G^_o-IC3Jox;rme>`E
zw(AB?o;e{EUid7_eQkD!S~15V<*wDkZ-0Clf{Q;5SMLY`>@Q;yvxaSj(m01*Wizbo
zTU9{8mvWv8!SbF+)ftH03lyWtU^I&;Biq|GW`qLkj|%ZPM)3J-;x0^egOh&ukr6l3
zbT>&qtpY5br*=;ksuweLus-45DcY07#oIPm3k+!Yu|y!RM(D`!<abFAO##aqUIiOG
z?nA>Lt;PjCRW6aB(l`TKFkM04c$hY+BPbxu4pf|qM=!t=@#O|bx9*I2TP7@u?`3I*
zRi2v6=NYG!mQmm!%ANU~3X7SboXu4}`4L{sH0Oeg2<B*gsU<o=2WJ;2FSAD`Arr70
zTalxd2!IA})a^=s`G!~sop@=`$QiOFMRO!^1Up;BMM*6oC=}&^S{@xt8>_rpjR@>J
zNnIyDz~RjneveNj$6pI$F&wRizX6ctRNVa&AhF+Hhmtk^jBoErb_(9vZ5>ht2irMd
z2v1Q2#-sO0F$H2%tT?~&q=ix_mcMN{-xK_A)7=Kqa9^VE4fa;wuVVRa>v)VeU2A4f
zHNjBbOqsI2Gsu|-L@+D?zk;louj>D7F}Qct=yo;ecGc;2p-hUn2MO~)VQVk6fkOw(
zdwUAI+1hvCCr`N)+Soe6`KO+Vfx1i@keBFM6+8n=PaGSkZWecX`o$1I6}oV+vS_2{
z+qUU@yFwnblg`nPAz??Q+$Vx0oasn{=2uUsF~bWi`t;fdmtn_1N#lNJ3r!Beb)9CC
zr~IEEwb*fx+U0sJn4Kvo>TL8`96#bqr!Aa6Llj6CpvNY`R^Czl8evjv7Mj(8YFLEm
zONdYWrQrct+9vRq!_**KV*qn`R%!WK$<e*90m%*pJz64bw^qFWb0`*qVG3^DGQ~b@
zIKN>>+pk-;h~VWpfK(=E8`td6du)a&m2CoXGqSdhNU7SHtM}*tcnyiP3uuL9jsBwh
zIAid%aVHMKR`G)EEL0daIa@Xq{__u`!AeffM>0k&kh29%M>d`AKbt**ps@CfDR<~e
z8cD6il6S?_dyNg$%3yB0p1ca0e1vcywKMo5cnh$V62Jh(LPZxwQS`F8pP~}Kb{cp-
zOS_g|to9wJGK|q}F)-c!FYpuCCIVDf8}`o0vB2NZ*V~3@PwAxMq7;IU!U%AQJ_QBw
z3wQJ6_&wz(%Nr@8LR)3DT-8`!>sLe(cJk#cj{eq3w1*0<Ao$890ueDinmRDw{V#6-
zb8F_xC-=wRxra2k7W-RpKak+=KbYB}_h&Gef|MSndSC#Z+|BGWOqyIa=<j-eI2{zM
zs=t3oxu6Z34iv;2QV{4eHXHJ>GqR+e({#{FG%%{${~dVUh8_(SoW9N<DE)w2JZUf!
zu%Uby-|A?XcdNV<tCKRw8S;A4J%E5;$bX#&7D$e+yv7`wKT<H6Wc~GE*@!nSiIR*P
z;TH<Bhi^ByGs$^_Mri=0B*d11a@YO_c@}iG@oVib<S0Le8>-ah5nSdE;bcQitENbs
zQD6s->cUjv$Rz<wmYKn<?_YM4Jbwg|6E)9?+5B2M?`lNxHDd$?*P$EW0XA(!HK1p~
zIpkhUehGG#Lju1@qVQpe#!pPmZe*K()Mlf)%c^2g)Z6B~F;#ndS#jpVfY&Wp_@4ei
z7eFV87G>?W6wFjuoznhp^fBvhgG{-(N&CQ~4E#EmYCD9^3&x4;)Y%}HbUa_sw;jLZ
zg*huC9kA-J9g4Pdwon3h^~I64O>+#yA0?J!ZJ|O_bse-yGn?y<GPyH>B*pihmyFcu
zfLKWBjfzn4^aIb;kIxRLkS#d#?rNgia#c4O_pqWM@1gqVAMN@QXG3T@)-U6<#{qeN
z6STV-zq+a0J_Q?%wHK6Erw;CZ{*__&w$De%O3IgVQjpxW<CF_HWVpeYg`{X87xU$b
zK~>v*y^9!3q*v;?@0k*l0;0KumG_ycw{|EG)vr$5pEfY{7#zeeYZFwEObpLMK%A3a
zTAi4;!(^q7B()%e@Jr*HV$q3p^XKWmrO?Ri0S`n%@g9C__D9D#QB~}S#@M7=A5$hW
zY{rT=dIE{*AtGS11D=ke=ZE|Jh_WGsol&z8m+!sn_}8Az0Ri#p?`0J|XSTg70uvgL
zdm@(jWpS6puElRcfRQi%rJ+@sJZoR$b>kY7E9Imq<-|SZ<epma+$M*2d-n5*{)^U>
zQ|~dB;kR*FpLWZAZ+gyyTJ&Ru`tbpd7ZtnAMqwgTRStk7F(%DM4ujktFfGl*6-A)>
zSf5CtuW02Dn}_I>zk{V-G6Ra!$E^C_lhBmFH}rmcP@v#LDdO8U9z(pyd$%_s_T$dq
zNW2SBILFrBjMuur>LV3&NeY6Zn`z@q<gbs3^0cla7W`;?XZvS@Ai>W`b_fN?dIl74
zlNR9rtV@yuZ5akD#A_O`?w~!ErR47)fde%(>FM*8vZ@WfG9GH}$YgU;jP3QOh0rfS
zJy}EqxU-)YSDGK42DwCd%=RwbgM~q2m4TSsW9XXwUpzhst!;*=I<9#)a^goBX=s61
z%0VfZU|X_=YV04}Ew~GkR?_VrAXx81L%t|c>TUbA$NfVRyNSG~hTnp3aVD~a5k`>s
zXu%T#bUy_$aIirSgN<Wjsg-Kkhc{-*Ai^tE0<{9AR25&pBR~qL53+-9<2v!*$jz{H
z@iEEuT~_2@gYk!gv^~ljUg5BAaZPxBn^2kYmcv7a<(!R-H@1fuT?6E0$`tuTObp?L
z2T$L)k(^A+r)U79PM7cg2kf;(?TowPK6VH6bT~z(isJUj6d7A;(BD+=sYjR;$GWh)
z%>K9CU4ps}F2OWHLER71<-{n^Zdl|3z<7u4SGzhI;rrQ?r<EL=dunztejbkbn_u9i
zFFursTA%ZQ1B0q7k~Qm<dC0Hh_Lqb_XIs*O{$9PPZ<aB4748#=B>}m%cPl#~kX<Cm
zkvrh5UTYQepMQ@0TwdI_{%PhGqC<Q#*eC5bnm?fU(TD~35bhCCnk|OOoZf%LpkT=e
z9zZeYo8(xut-8frU(d0=QW}2@M~3zlO!^cFrr;mX2V^@v#_moW@n42Da_!o5J7_K3
zJnTgAJ?@MQxGY6~n8_h%Sp84>eWZy>DC~DuQ+_JJW1LoqLU>WZ+aTp(*3PCZUHQ8a
zu@#N3b20L1E~nMv#11)8SzF!zS{s-9qsWhKIQ-|=sZ;8@^nVHgK*-<9x0)@m575>~
zV30O@i$cvg{S~{Z%0_u#rBd-EcnCK@Yt+Oq2<mTwWc4P5OAo4TzNi8HZH>dcaz&As
zx=q>OKJ^1o653fz>=KvB7s6Dh{8qiW*b462cNh7$gM7&J=n67Wc02L^sDMilA`OqB
z5Lzb6gG`%Pj41%WN*cL4OvIr2cz*rOX4$;vOkr<tnB(#)tQ*S*F*r7EWzgcf=Bf#|
zR;%_5>}i3=LSnAEa5#|YgPSW;1o{hRD2AjP8*wC!C|)QrNHEZPs07fAX!+_52WK&?
zM)=!_pPX>>Ch70ccO1ZQW{&*}E(UQ`NEmX+>qBGX^?;dcb_7)yjq4+SHE}|iD`gTo
z9(1YXi{iJMWY{gNL4MA353$tnK?1zOt4QUXPnE7&AJ}FhZCL=|9lHoWvrlQ7B-F2A
z%e6WPi+RyGe6ab8)xfAU#B$MvS@z|3--Vm2X1f4|V8K_5Z4bkjnstHOk$rep0S`;F
zzwJZ(gg_JWPYo}oAK#?a7rnUyzL-Yz?(Zm7xwMl0D$LN~h1bmE|3_;4E~J5)DPr!o
zwZjBtuJB><UE?GKVIm)h+erIr!tnHcO{C6-1*K}HWNH@GqA~>DskNixik1(5G*{rX
z2uHrkO4T?d?Mg}4xCwfVV#uW!zt^hpO`xPy0s<FZp_mhWO|<$X3CC0AY|U7VNfkTC
zUIzK6DILxBI=YdT(6WvS9w5cHq&q`XVd{_5U063ga^$Zd0pjuaF|m&Z_Y;B2fh#($
z!<P(lzFE&{hG$s=o9TQQO35!CUY4RB!Wf+9V^S)#0;AONt=fzxo~_{<jQJo=UUUnA
z9&dEUk;T|{ZiJW|z8P>JS|nwzz7aQGt}Xq^iPiaFhqv$O#V3WSaRXD{sK117a9=-v
z^!f)!5{E!f5y&8(NG?0+AnMEk`9f`M-X{qE@9E=UI!UKQm6-#A@yEHL_oU#NRGtz@
z7m(!FA*%B>RFN3}6JVrO-9HRcDy|3Kr9_$7LM<bZkIehcx8`~IB_TG(`Ih$y>jc--
zYsL?u4UxUXTk<!aSi*?TTdkb1-@Dr7@6Ypp0*_q{FAl>tPsc&7iQmP<f;CXb8FS`#
zDQmKQY1icMZy;CwzwbP>J(e4kC4bPbbUMD90K%aVCnSDlJHizWGJnd8vn3E4ZJD^}
zeCll~EY0vgrE_H~D$^<2JeE>|ZAe9e?LIMAH1Rtj>3n!!p@82aLWKVe*%XnM?3LaQ
z&d&@D`p;Jp=(|B838|=%DNo0R(NEFA8qB-0@GuDD*kG^>R5CD2D?YJ&0`9+MADD&`
z-g-vNPCyMOhYq$Do`CwitgFi~eF7#OZvxqiwTM5lH~c5`BD46hF&b$xj`DAHl{nSl
zTduqFsx?XC<g)E(n0f+*1-jf=6)*P+(9b6=klwZ)!IUZco-@DGT=m9ywkYYnhOW8c
zreZ)IRR>S}-dxj71D}tk9Q$H;?WU_j(m$d3*BGcG%A^>J)dH9d6Wdv|Ns_MJ06B8i
z^MiO-fYO5lHi?e=jb4wte*J_30mngN{z{TG1B<-%==v38-G%}qZS4s3A#2sIN9UTv
z+0u#aQO+!*mpc(Tt0T>N<#`2p`#@~gl~M8{gP;D?DJ9rzDW(Xc=(3m+t^Q7VSN$oy
zk(jcT)s(F<6M#HBEw+nkK-ouHue9Y??>wP~FeLOiITGQSbRXdMLG&JUN0^u-#2xut
zNfM@cK5J#tGA8(?O5+kkuG)U3F;lNG;Z!&l4+e3-r<VkeC(=uH)aWMZtE|o<$mop9
z=rqj9;APsou}tBR5o2#+i=L?M4q_rkp-1;MIXk=F12*%?sXmMKm?9;jzRYrtbp>=T
zaz*QTLIJh;8p+Bk7HR7WRgxh`zg4QupuK{>Tn(t!e4UrjuZ*1dtz>jR?LX;V7z=|V
zg;pZP!nmLO2NG4!X{zkF|3SI$q8A<VepuVJpo^@FCLy_*qMa<?hw&<GI>xagfYMcg
z9^zX;9Kb*&Q0&DiKG!$%H8huuX?|MzGr>=Nv6*R)#rj({wb7f(KVP#8(Df%wSb#vY
zh}P^nOAQ@-2m;-UC3cEMqUfsX46PpI)gBKsamme$?kN<{Hpi6fLx$rI>Sh@BKyJOP
zLVRmdHI^6d310EmSs1G={{Y3un$FD_3(DO$0bsf;_2~7t6zax}!z%NMSe=CkZ|pyx
zp~1|>@x~rDheY_{Ecz`Y!z&~tvAK@i6#7Z$0Kv&T8S-Y^%_8}i^EYeCh(LQfTCad_
zGu?GYp8=T-K1g|iq5|uVkfm+*lUU+%Gz|Fm@jLRI!Q&z~X7L=ur}dtt>OxIr^_88l
zARt6f`kqXl0|NAuco5;)r!F9s+`wdKJ5^Iq<VuNej{-V6fZy&K8>+e|+(DcnO%f`*
z;Mq3vZ#oqhnPo{6?EzC*(<1GbCr|fQ{g9zkOd4uLx5dh-ji&6}76gJOEU%tEoy3Lz
zOsP+QK0Khl#Fu=HWan+}&G_TA52kMA3>Zzm;X>q7A_$G)=kT`DKk~Mr*6pAM*hdlt
zYnN|7C_zb!m0K~`%$)GL+=tgp&N?Lu{>Q|4&o65j@`VpOw@lZG`8!GJ>}-=oof*=1
zqZg+M7?y55aO`YHD)ksN1hXA<KZf_@XjzNKQ4Gwb4*P=6@>ipNYK$B^^IOte0vu5^
z2p*pEU;m)!8=xm5Myos5(mdA+O}(MRm{{bWBS1O|Pc^F%33g{uOS`^L9r!5lu7!}T
zLaNIoz~sV9SUveN+xIBZB>V!=zHP9Lb1VemQs>CNoR13`UWGP&z&SE3!l*Y2gNGv!
z@6QKASgg8G+1v&<r5ZWJ^Vn#9;322KK%y&$vp$0vzQ4)|^V2*{Uc+rT6JB-B*=e-0
z|Cvo}G=hy)w*D=_8XZ7IP2V!;0}3-`$%E#r5YYA`je>k^MV4m$V})|f_<Uitk|!uo
z!5kKYe20$~jb3WO3ZKr!-c$%Gr(9qgoD(9CR|seN&08=4o_%C_r{pvOfSW|AryV@m
zRiKoRDAvM9O~KQnl0-KcbGE-EFOHL^wA3qe_*S?XKZ}5esy_x^@i5nC=F!FS7nX4=
zl^J(@@=nDxx(F;YZe;szgc@)lbHX>$)H^}*#6JG)z)G5|q#RQsibQ%m55Grjxgb?D
zz%%**fUXyu3{yQ4oYZUq)>x5dmQSK6@a(apsJ_v=q+&XfH004;h-RRAIpIKSN;w*|
z5=ZDVNrhc}w9#cjDJ%<l=SnW**bq3m?ZFk6hhDc3kp@N`bB$XjR{EzwEtYQ|E{*o`
z@*o8+^*>a0P;tv$Mc*HBvZzb6lxh})3+HFwJYiOg%%scBDF%80X9+qg6_R|^^B;{=
zK*G(opwXV(zIOfT$ga@eIVz$Nj=$Qa`K=n(KHryRDOnZ>zYq8e$dxUNlqQ><U<H=k
z*p=(G52je6e;|&UU%9U@(${_|Ga5e3tC3o~<$?{w3N`Gj@cdj6vGP_AlSfh8oKk|X
z&^Yl6-8AJ9=rdvfeR>ZiC0lczsX`sHN%>STS-9z5jTn<QrN*UE()c!xHB5a5(hdy}
z9~hLugNd=sM24t(AY-(6o57-~(7R#CpZ=?<Ssy#wYQl{|kcd3{st5#KLn#|@@Z@Vd
ztn!_r7y0wBA(b2-x0FxObO6}&)G&oPY*a%U2kTr(eykag0>K0q%Rv5EwO!ZY-<cR+
zb4kXEjc*3hU@e{yMGs3&s<{kg#a2kHnXaxcV%ok{`$##zKLw)SE3xYj9yF`rc)yD)
zrr!DY4{C$gE_ZxPr7{Y<i}}@E%7RGQSXJZ#xb*`S94mr;3!`DomIx3N#N(#Zp~!Vl
z2fO0qE5<<KmrT}0G^k4S1`XaT%88X-gp9fx--%SFYBcWvD{z@xv@otSz7ETfu#+H8
z4P-v}N=(_S(%=U$fm@ZxWMcdvy6=iG$oUgG`Rq02B6K=8I93ez1$0PW6t&#nVQ2cu
zInI;~oEvELDp6oXYaJv1gg6KCRv%$e!Fm+kGCTk>bkoEL{pC=EVL4FKG_B-$3U={9
z)q4k3$3OYqDrACP>w6towm(Qgbz@i1%M8U%9AYuTk$hMkjrl_lUugVt&=Yf<2wM0j
zwd%@XD~`ajYRPXzY0j#!+WiWD%xe@w#nKGtP496?PT!0d&(EV4pBYmIHT=*Yhp>@r
zdM*KnM(9c|^Q!r&Ci6L7Z=bSd%ZEc+yI6q@QCsPI!w)R380FEck&B{_A-%ctgEszT
zD!hY`sB=FCtOI31I9f(JD7->OgukBEXavIOW87QWS)TfwlLSd7K#wisQymheC0ifo
z^(swvZzg;iTOt<3vCe0){wgp~g5L*SDGktCv4%eHkLayXD|XS>^^1HkP_ZQgB1Ywq
z4-M9C+V&V18?Tgne}BhOuf%EjjeID59|O(Qw++-vj>KhziS*3f54-mGs-^Ede#8L8
zY~0H{N>IEuX+zCc+qcK@71P0E@#V{XC7K#a%*YRf%g2BTuj3obWRdI+z1^Ur2}oPE
zOrhfr{ExjuKwvDKOaNE8zXH0Cx^lz;gu2CjQvf3DDS`O_1Fgy0^sn4)pS;Zml^InE
zvljQcI*X8?*H&`l%y_XpjqGT!Cw;&Xw#5;~{MaLxM44eQ5TA&R2Vqq#198j{sN+S7
zl3Z1|*SN}C_nA}WVmpTbxba=-d^KZP8mzH9@4xnb{*E%?XtXqOTBwxD5JQ^9gO=zc
zJ)NXRLD4>Qq2jVo6&XJwGDC+NB_eDR;*qgXd1$5AWu>Hd@qbWgs1z&^Q>NCl81nLp
z$}D#ZiMbm0EL{i+lh3s~Q=MF6^p)*}UnJ5lKiV0?9Xqu6O>H6pj|BW8dC_{y<3`6u
zFy1s1&&~T_<J81s_p2OIyQP$l5ZY@do%a<!4%)#Ko8k{!yx-6gG(}!@stl;-L|&<L
zLMTU)8lmC~>Ic;8em$9LYroYS?)--idVg7JKP2&p8_>Ap)QbSSDPSHcFzok+0c+Dt
zr9V5T2fko+A-73F4y9k(Bp1NJorQZ#*Jl8Q6OCuY)W|KiP$(Yx)f8H(lRilB!5l|>
z+fbNocQRuSpzlb6mW+aNi5Jzb`%YD#G&}P`<H{=T?daKqDQW+nWIa}IVIbJsw)kZp
zIqjLE+mA2))n#(_RhrG8MP_q`&B57aNl6341;Q@DQdzBp7^OZR-Ri3C2_G9NG0@P)
zrVzk}r{o*7#Z}3$aD<VGB_?o-xnR&tuTq3Iz?*yCfoscFe~NC_cJ}{;f&JyJ0I4D^
zExtQW+7NBw-akvgsnjT8n~c?_w?<G>#+<xkyf%*ci|6V=YpX(W!16y!k<a{pNd>@v
z3-l!S95^J?JHZ3yz?@eZHALN50e3`!iAyO(ea&V2Xl@f$D~YO*90PS2&d&ZNLzeAG
z>&Mxg*z`d@LYRb2PPyx~s<06L@GSiw@+Yy*e`z1AoeISFux7z<0@weEvtAiBWQc_?
zad^;M9I0GFX*bGHPJ0oEV(j&r(b1er5b61#iPN$Fntad(DQ*7|Lvvr6e|esRO;Zwb
zUmxfTt`DS0^ENu^{ZlexqnLV~u5`F31DCY^<-=vG)k2rfx!?b?b-7s~#gwq@3`TpT
zFU4Q;DTCnt;!aAT6SQf;H1Ct0rnH9u8=&Tlk8{b2^fmLJxOM*jQi*Q7c@}U4pSHOw
zmF*I=VVdU$otO>^m>qS!&|+n`dY!P<CjRX@v`qg0r@rii2pPU?Tf#*d>m9>#A4d}w
zOJ~Hwa6`tzL~&_$Tcw|p327U{%<2NrXqJ23l&Mg&2?!8YBlSKI5#ZbyBw(VVIJh>D
z^VPT&1(5uhmih4Y%;mS6Ue}2vI@;8U-)s8=lRjEaoqOM9I67XGXau2DSkW|xHbW6?
z5y(urY^(FQi1b@BX1~4{Auh`|I~79+#Mvk?^W%{(KUHOstv^U1R}~R|hf=_1PwCNK
z=_~xvx#+?;KFoM6-|9bT{$HL3U#}EcD=)Az6>P#Mk8(3!a5YN(U9&68TX`fY^%<-i
zi7AH?2(>|40e-wZ83wTAk2qQjW&QqQo-<o!F)Q7?=su?UALYEnVn?YIFl4}nehSNJ
zfa2aZ13%RRV)4eHMDwGN_p-8bBE{@%ra|@}JS|AhWOZbuL{;|M>fcr~RLMWka~FxP
zsoj{%|GnZD@M2g@O0(Am0V^!l(sBCiBBSpyB26VQh|rC+c6~@jJ!X&NP=!9Kow!@K
zjJTzg#cdy(<UzVLEQj2iSo@s|w4|JYs>A+~5s^d4hsQ<!=eB2v*p6x9)MGF6KUke7
zs`b6V#8j~T9ttKlGe@^KgiqTFHS<crQEA-~UvhHb{nM5lsKE9yzC<C2j0L5-rke2b
znsD{~g+Ai-zc`X_UGIT0>lAZO%T~39#4d(m;&}nZf?ULH4`{LS9qIsVqd4M$h*}%k
zfDhMh?#*Ip)EA=O0ctvY5a-&r%!}#ISb8>%9QUtXva$F&nm<$t_v}>>IzKY}qj>t-
zD7AwXE9%9c(1la-#eL^7yw8XH3Z{Oar~QY(g}w+@h{kLubxK>YeLfo7M~*z|w!>ky
zRks>WOSO(IYa@<|<1-+fOGX(KuMe|Ql8abkP*r~7ir>lpk1WLbz_I^F4^*7$O`V18
zOse&m%wBY4#v&GEHffP|wQWzv@BV>B#d%2e{ecWa$~H?VN$(3f(7d^zzWsT}K+m)E
zpHjx)ZNMtPx3=;{b)20qs#4&C(T`rH6x0yNGm<z4xG~n|13f=-x!8-V)-{0uPlsT^
zED87XEe(`6=2LSk*|&5HeKR7Znk49g^Ll1+y1mNhDqa<B3M$&;hnZJ3&^Yb`9fy$-
z$%Y(s=V(2v<B0!>t;Hc!r%Xw{t?ixXJ5m<p3Zi9AEjp~_(V9`U{$a>^{#`tQDuURD
zv7sE$Jl5n%ke=;%YWGBwhGmRpUc~~%`rL9WV6Zdw7x~k|bdBnojNjgZ9sL0LyZy>l
zRw>=N5xLM*LDVFsqTjR{pzu8*8xG#^z4bYetBASE(60XAIX|N4Hl#6CUiJO6`R{8p
z{&O6L*5OhU_7Mh|UZJe2ZIK2o;)j2R8^CW9?Y=m%IklW9Bs~+~#k>f1o5_sL3Yd%A
zNnfS)wqo6thrC<@jpEpsx}fbdagYJlsPFxVyQyMtvj}9sG5g0oQeYPW^#VZ!aZL*H
zwuuJeMPO1@c++_jeo`<MVHs9c^8vZaY1S~J_d~;=*RrmkO~(vLt&B0@j@<y9U?91E
z#<%CPQH!!&AujQ1St3fM5mom@L+{`2w6fu4v4_{12+ocBBXXvltJ<h!W=DR)PvuFs
z(f!kJU0V1pe~j^1WXR2JQiVDbM$jDQLD>g9108CGPzuXMgmA}nCL9E%X5F=RKMtYz
z;ixo!T0dMVqG|ddGUJ2>HF^NeY+<R%w`LTfUojw&^avw{Buc>{g%teki(1Iy^cs&{
zoJvSFs>0n+=1Rh-DDY`pxzB2~QQRA5#Xp;K=Vv8R(a^MKT1-838|&Dp(xT&HWpk96
zCJAL|w)J=~8yj}}&4rnsQN)bdFaRTMv;&Dxs#ih>+7v2i@?xk|;y6H9P%-iB<7HkP
zT%iJcALN&f2!>IS@Uxuu`mAr8{G7K*nqS3~wGY@{eNwfAJ_J6Ufj>hK{Ip6;I%_U7
zMvE>pdW$Z;@sG6P=`b^~MInfxzXw>wVd<j}qTs|>z9&dA<Il;Z;}MOsy_24Rx}U?a
zO((}a_J_s=g}1jH8nFO}nzTn8G~dMgy%Nm`zlzicSuerb>}>L@Im5Gm-Av&8qa54)
zKKWsi;7z8p)_Y6kC)mA#hrqsdk{TGG4c}VWGU5Nt#Gg(x+;Zhv?dMuMHez(9m!jRD
z2AGx=O32NR#Tu})LbK}@4*y_;YXwWCi7qlUp^bw4TR*BEu$ySIm<#o@u7MwC!=4|f
zlAIsM?&B3NkVQ-r;3`JkNQK4?c8Z7K@Sgwed9-NA2){Yr{nRN95A3fwWNTWC1`Ok_
z@$emMBh@JAE%-y~TB#?kvAyfskz{$XaH6XJpBgeX=}a|_yzDe6k_A{V6s0>-MJG(h
zNdj6mtdNeNv+M@jZ)MMUo(G0dG3x8VicigOE0lXpADgdp-rj5CtUlMD?aB@ke#q~3
zxy;Gl(9NWv-h*tJEzn&llAS$PB>MRxM4a;G`tT$*XmXZGkIwVU8GnWL$}lYANyERW
zZ^JO@B4g3YMXqzb*DY^#N*(Ty<;#Z4BT$emg7EU8`O&9)u_MSumX0ol#t2I_5=njc
z4LjVm?{;z0+Hb-Av3{c)pZ#UvsQf3MlsIV^*ok2}oV+kdL}kDgmlBS%4;@tuek`(;
zGkVV-e2RSQhJ}K@qFxAAlAckiuSE?esbE8vEkZ~oI1CY4HF6tX2XF4d3GBQs4ImNp
zdlTgi)YKKNTjmLGUmIV8xFP3nKLKM{jHSitxo**CS4|!unEz*4)<?B@bZJ26pP--r
zzctSlE&coz@b^j0%SXk^6`SIAkwltsi8*!SgL+j6CQ}@^)(pI$D!Q*7ie6tk#&-$-
zX?mMJoqgR1Hwu8wO0N73S_5DIf4aU~N}Q#ee-axu?3=3K?2pLDUej@(((K3ar<5ot
zt%=#D>TGDU58-jLIDh>A=S~;cn=!T*DE3_LkNz+onV_u;Hk=oxi^S`_FR${j84VMG
zd>i5uYgIp+)`?KC1)9VI5JUCKnsu@w!?qR{v|^e{9xFX`c(=!v;4?-M^lo<4TgwX9
z9JJ&4M`C`YSIM_kjOozy|Lir<Y}$m1y^$-cIbrl)rwSj;h(if(_;jOoRd8c|IMGJi
zsA)d!er9w+lOAOKF1z_XVUN;J!f1qbso51;&zDI=%7yh-oLUqpU@5~&jQ^6I&-Nnl
z!w;3KA%j%hhfBl@ol;`;`<c&)%YOL98KLm5_uLek&#O-zBmHO4C5t7n`aA7Gk{{eW
zDD{hvSD9npLX`e}VRO&(0XGBBJF0eEP)=p6n5{O~z0Wsxex#5R;avnmIykXdP<M%8
z5H4lFaC$OS+8rb?7EO9g;Tlt1TK$7490TD^A6Se^^grMel<D)JP|Oj}+2qG=E0}wB
z&eT@aB&ykHU-}e3(6OkolL45=F0?%9y{T;zI16>mg6bWP+RmKpZL#d_u+D9<&L0gf
zv14yx2}dNDU+=o^2#?Dtz42q_Gkx5L6Q-asjA!R<(U}0}jc`h@kAG^pZ4IV$#xT4_
z*jhP`VmV0vg#YM9x`$rBZ|%m9*V5*iSV|mB6wciZwUNi&lc=Q4-DV-cEW4vC#?F5M
z$LY#}s`-a8tf$u<pP9}_WA_H4y3>5PjMMWS<x+P>WFgXh91bhFAoO<>^b;OXnsJiP
zE*(m6z&U{*7N1!|CXUI~Yt`Tmp|uEy^-B~aXEV&H6Ni>2tm9U8Q$5?P-7wF+ztGU)
zyvj5{mu)D!iA?vqoL=eiHw&LbWUe3UB|U!atuTWK`j{-F`B73CbHX^GbHcEpb5dpQ
zM=^^q_&*h8Qp({SDWmqYz|^CNwny`ZNuARedqx9)-KrBmRr8!u@D&~qb+<yUAbYMX
zmiMS*XrN5qugE^Yc{!>wB|^QKPA~rL>s+PNy_w=Ou>Vcto}>S#7&@?le<-H1x3aP~
zyR!H7c*>{Wd&d8sd;6HA>#g{(U5ddOEYMlf)&j!GAfrJbY>isA4Q>$Jhl}iwZ(i>f
z>{B{GS$m~#y4PV9+v@X5Np;eH)uJ2!t3C&soB%<B6FWMs!-U<g{a{9RiIRMfM#|Sk
zlW8gjR(GVt^(8EaKIGmkOG1lvR~nM4IrM()kuC#YLECGnB+joU2GWE8b`ays_ww9#
z)dQ5&3rnHD+Z}w^c&MXv7K_j|F^VPxxr2>BK5HXV@|CBk8LOcTcG>fp!c-EgqzP)6
zJ^Suxe}6Iqm90fHYYXDnj2m{k(?JvLomAI?18?5G-ys*#iC{qll`p6*E_tx+ibE6r
zFkhB2^S(OJUVri;{~i5AQ6nv8ocO6n=S>PV!HV47IY+Yyvc@pKf6H$nDrB5Uy2WJ>
z(3zX3!I_ARkBka#KWIZcfiYkp_32P6!byhbEW5<RbA8zSJ@%~}2eE3P!j72@6Xwv0
z@}8@_y`*0O<CEOZno-qr=$*J47mJjLbz*RmR$tK^ML>D1PA}qLHz&e^9W2b!VVgu{
z{mkJ38@y9G+I*y4X(chtAlUm*36@b9z__2Rpv!kQDqb!I4@x;D7Hb<u(`^H^%uH1r
znplkEqPry|&onN>*Y=atEHz8t!_lon2o{uv>hJG<T7mZ(+jIEU5C5}VAdC~;qSVoW
zq**_rWFQ;u^sh2|O=Gi0N^F$50<*ls!Xl5(Fglzq9M4^FM<nTyz|umcsDxe?AO%lX
zk_08S9t8Iz1%eh~dS*mk_^({(MGjZD6~BN~wZ6+AI3b4E7w%z+z=IaI9<L^Q0%E;u
zMs&KgGl{y&OHfas9ahz&g*mpm?W>mlVee<hnNI{pK3@|yqTDzPeeTd_z;LT73Aqt?
z6N(w=EN8mu5H7z~w9#F@z-X)00~VfxEW%w_H80ZyIw3kbA-p;v&vRP`Xo@J^Dsj*>
zci?>LkopEko^Fi-135GEGZg2XURQ(p&IfZ6H}$XUzZ&6}US1Ce+Gp!t>Xil>C7Wy1
zn;X=d>(rYCU(@3>XGp5aq7>i$w&h?!%iurKT80hwm4j1;fbWD5s49v}0~3+fQ~N?s
z%4XybKc^(Rn*?kYdjGm%vkv^_{QsDG%cwkl@J$$p;_mM5eSqTbUfkWaP@KV~Kyh~|
z?ogz-ySux)JG{L6-~H`=$mAp+=1g+VBzNvhV$j&F=Us7N4Kgx+QK=MS;ItWu`ZY->
zp!9>(iD7a$2Eh>~LcYtV@8Z|j)>uk8C+aq}IV5KzQHLc0Pk~AyKEVQL`Jj0VU&dOC
zI5lcUWs#e-4FbP^#1Tcl@43mDLiU+EtU#CqJ=KKY@w<)A{ObBrixj?Wdpd~$#l^AA
zQmoIoE}928TpKQQLl<u~()tXa%+vFayKPHhW~p7P*t3$KhjQXPhIfc|qGJ36<klsQ
z7G;hTAKWVA`LasrUeytIQM$Z-4E)%buX-J-cOqZ6Lt_P19^GLI(AE8(^2+fV_yMep
zTTo`WojhB*Ag%ZztOVL|Fb>g;7A5XgPKl^5w=z5;c-mg5BeE$+jxePme5b{ftpDTt
zJIjtge+H;}1yyw-B*pW9tZ*HS?M}1!I)b?DfxJ08GT)TXoB(WQtic*PlJ2(~TBAlg
z!Pa@{EGMGju{e&|JA!BXb>>(y0iapd*)lgG)H@<nXKiie3OVDKvr9t{b4x0g%Qu7g
zc^IgsYaq{v$`NZk@ey?g2ZNm}+c?M(rp^#6Em!BkCvYe;TeqHZ_R$dRVm(+?GKv-s
zZnG+8)mgil`iAit^gKo+rRw|jgY-9t{v@zOK8QMtMJZibXJx`n)(iwR0KjXqJ|C7#
zhC4-_Hw#Fb24Tvh2x6eftikYQro_`0uGT^{rY#(fUB`g+O$I7DuW{}cvr)g6tS<|R
z?%r0a#zOR0+f9tIgCC|BpUP`d7A$lcPM_7GnMoP`gddihM+AdX2%2KwFN&LC0iMhc
zbb=2m(7VZ%rl$QN&!pcbuzk{X)y$BD6*DfY#geY>pt!T7q%{#TJbc0JeB88?9gD}?
zd@POHav0@L6~Y%XElDB4I2DODj5<Y6OEFtPlf&0oaRzHxIS|;a;W_@dfc@*O`{vri
z(~qH-(zJgmy?sYVx*5w&+<%>%zByrL?q^wh`Th5&dA$RvuyUm-7^%~PL6EewJMrnq
z6&<YtEp%|>gIC=na)gg6%-poIEr^)MsgOiv#V(QZ{%*>j9h8{EKS2`)g!o=;?TBw4
z{%VY`UQR#PBC<X>W^msF%ww7g^i8-}{dy*_g1H0K?nJ2ss3bzVo^ermBoT&Pl@aPZ
zP9=gQ%mD};Kts_ergW5A4X^I!cwy8BW701pLq7N~FhMLLk|9=plh%Gt@oiu|J)Xi+
zBgay`@sub|B<j0a)kXt&5O0qncyQEl1GMG2Bx3D|rvcPgn&#bI8MZ{#Vu)Na7+mQ3
zb(%S&u+`p@snNYqVujbZsQp;)%)+#jI*0wcMF6tUl@a5mR`o5(^Oqr<L%aQeUz~`)
zDY6Kjc@bffjs`mreNWO`?FGfHHN$Ru0vrNed<Y6g)`9lX?7!^84TISawAU<`>r%RZ
zYxh=iG&W$`o<WCmjlxx@EQi5iW+q+j5)DLP^#a-C>KD9+2oCCKHvJ?{6>bm<SpnnE
z$$+qh&xL%e*U;kdXM`eWWovPR6KOWnc35Kokl&xIR2yuByvg|DdB{A)=b>l6Z%US*
zqiALZ>kFQY<@p#Kiw25u2@!x98baF3wMQnGJ0OytmaIBG?`oI+HIi%a7<tBMGxG^-
zWNc$p5k;peXK%^tsq-wv+z>aB*;ni_0DK7Ek5?`=?n8pKj2KZ|@{z{cSKq;`?zF;g
z8g=;NWeTtg!NHIuK8gP+vkCO;v!3X6Ff<nypObLBLaGLk7aYT4kAHvK=2iOB7`3iF
z(%4nhjwEnrcUj^PsHph9B{|9kCg+1){2Fi6uJk)*2zU2E6yv0(UGCkiQ)L4YNP326
zG^2ix2>A0()ujTEYYxwczLfvcj{G}qBjb&|$0Z^uuQ=6&I1%zVo~Mbmw$q-bO5N~l
zwXUWG$z<$s#aqcI9i?=)-jEVo)o<x@>sXJCK{Qm$j;4AQW}#$Hsm^`|!;I?f^(%w0
zuxk;CE_+VyQuCpxJf^!5S9E9x4h=9h?pVUhYBR?yat>1MGCjB;kw)ZLIQjnlLq!X0
z5n)vA#i56B;mBzWl`)O4wjZH_foA4{Digrkga5ap<mTBGzW8SxGxA1Vjcb%8*3Ng!
zKI}O~4C+)~2_=x~*hpvtogm)O;~fn7Zi%vD<91!EJxCN%FiLXB>FHbwC{NpKn3J6|
z<Fi__H$^3|(!396W4y6jEOzLTcnklmIwkr}L@s`>5o)$M9}~j085KD6i2D#QAFntn
zZ-hkDcJ!g3Ye*z0=;cbu@yF(XVTMZ_4w3j33Ph;Ai(V9M(O8pwiMWl`N_FU#8^Kuz
zAMS_*DjaUB)cRwxQ*r>$ckwryH`(WfXFh?KfSO(5yXcQIrHS)aPEQir4X~x{0koYK
zMt#p@+PkgizX{yf%qj%#kfYy*U{0Swh6@V^ReJzzoq{pPB8+9&5p>hvzUs4_c@!n-
z=zlM$G8;(fk^Se8WiQia^f`peLD$_GF)93cui%3xb?(Q4w`_pms{pnW{(wo8ymfND
zn@1u+WABk!(78+4LZfhNJJR+YjY#Xe*ncfM)GCKScSYZQ3VVW_W&v0;A45VhZ}41j
zcdYG>tLgQi15lmwT5bBKD!5)98Tdlf?-6!_WHS)+2(_~oD0aj)rpO_X&nNw$*x`oI
zESm>FeB~BJne0?V73)POlVfzkg`!1E!j)iU!}SXXk686-zNv4;ZK`s2Du6>=#c;nO
z`ol7+V}6RT8sTVW*p1OqQtY{rQta6!p8u%r>D4yuhm3Op_J>9N8CsHc>LH=xLxnH@
zSeXIFA1M>j_OQS>(IC&{9i>ow8)^Io1qlYYH0kX2{+J{ng@I6zF(NyQ!XPDh76nzM
zCATuKL!vI>8s2oaAf~71e99tc%fWIjZX!gYlh&zgc`lr^kDpdeo?0{acta-a22Bh_
ziK)sWzlU^j?y_xS<UwGPz?ZQt;3QEA;FpqOMxU4jZBzVUtmz~fgg`)guUznhf`A1u
zuB;>)n*6_HL#Z#Z4MoW#6)`$NQivVVkL8VAeu(RR4@5BM+2ak=I388zhr7U8lQxQ8
z`Zj_MN_lRhTA3=h1$*;e4vXx)HbENn7LvuHAXG{-y4LH1D~|f~{ox_4o`0@cJlY$_
zj_0oKqfD~psbxfdwQ@d4-(?m-__T{@OwbQ|FV_#N#MKYGH)+C&qQx$ao@D3~lV=sK
z31y<)(mYgd2p)`|;^jjl_<BbNvd)0PT%$ny(!a_LM@!$BJd{#$h#L2=dW>^G0STtl
zzO!ZW*eI|Q@zIC#)*bco0aAE~tFNWjm(jv(;qY&Em)YfdCno4gwcPu!aa$Fj?l@IF
zWb0rd{Vrzfq5XEzpy+E-=E%UUK;t#DjShQYG}Hwqi>yibz|!_t9+lX<t|p0-HD_og
zNh1y>`3oXp%I0qLFsC+ZEakgnTN#6(lWB>?eFVhV=PSjH;T|7*nG~E?)S=)9G`T<R
zGzM_VEE=arAR<H;p8hdpgJS`KRu1~(PQz(vyOVr&_Y4Iukr}eNR%?||aE*2dT1knt
z>6!H6-xP)SU~3l!fAy#cxozk0#IV;C*+RN3{F2%S`^l0%2IHmSc65<z9pC7*7gkAM
ze^UtSCF0&1m`8Dm@-1(s>7d^i6wO0yKM&1FfT|{WF{H4%^QU}>op2cVw&0~IbLAB6
z=F0V&zCaNS9#{`M6Z5m-o7_gMEM1JqcU&(rg*koPnN%@K@!`usx1L2T50Tv8(KCNp
zHv49A98G?)F_W`gv850tNYjpWKpG(v2SbF2O^i`OLE!A!pBCc2j7RaW-0};(L1No~
z$U3YONm(3shW7Q-ddi^!TA_7rJS3?MVayz*;xs3)kUE1$o!HLbHi<HSnEMc3o$RPn
z;i7haYpwSteQy3Wpw<-@V4r#NDjw$fp!q8|_hhdb503LEe3WB`YnF4pgHui&Ixhu}
z9?w@qwTMF3<3g4aEWX&dS>(xrq%RbBiy2vv=`%kJMXw<V;z+~}fU$GPdV$Ry{f#G2
zkFZYx)gnFmg$6hB0;XlgR7PD}*q6C);lBG`Ie7Z1k$|aO|C7N~x%nUg>y!QZ*OB<b
zn}|Etv4=h;y`n#>e|^^fi>zK|vY*1LU>AKmx3WGS@AN0;>0LnoYJS_2LP9ol1iyVN
z@|Rm5?JWX$MPNaahn@RyL~@9xM7XT3SL(faky5!EN*3v3rCX7RkOc0;i=97Y|L0_6
z(1(VAEOg-~o+5aXj|~lRi>xw1)SLiA-Slry6dSszd)1s_b<-t<x5-k<x}ouhoIRuf
zxod<%{+Y<cK3&UBu2>{)QgO6ekl4DaxFXsMAow*e?bQ_dbiemzU!le$FHuR01tAve
zhzw`yB&mtcvmXmp0$+SY&t5w2*ae2`^@igmBte;94#8ne9kzlnL?1i_s{sM5w)-bI
zsro9jX{F+EGcE{iANmdK4CQgOJF-D9=k3cOs-%?Q2A=)>eN&OyZlvoEi4UBmIJ|8|
z0QLcrpowI$^UaXFiR4m$`cZ_w8FwJEJppie4~tA|{KT*u{XhJXUQui}0Yk_SMPJye
zRA$1>XR?SKgA*b~5&t;}Ezaq%D<6J!q~{7gY}YR@1WX$>Q9yjfE#Cm>Ww&1g@Si@3
zKhXDaf;?b2Ze1Pp|8pJ65Ok{+Oi~K;qp0mk8o+W|1dv9hl6s3n2^IYQm&ZJKv;2qq
zrCQ^yWlE9Q0@S)sFz(;Q@Cr*$-DX0)!daC>B{kgs^Lnma3tJN+3~~ajw=kur@u%}F
z@|Fbm#{$UUjH+#I6BQ!fuYeVX-g5Df9QC*e%yiC3f-s>=jgFaQFeA%T{D2;i>stuh
z@E`Z!74K3_R18J9?5q_a`W_1DI<fr-rSM~WlzKu(+TnY0SZLx8;p8`rSt?r?ac7}#
z_Q-2P7&qQ+%9N$xm}<8L)}EGiqp}_!A@z{~%ViJKBy%tCmJ0@5lE*0XZya0`E2Vxk
zbU530J#Qnfb3jS6XE?0PYuFZ`oR8c$LglGchIs;8aANebUkr)sEpGEzn64XFoZMUG
z@tFBi3M57t2XZFh4(hgEfa`U3A^UvY3)XXU*Sq||>n)>QJj&L}+>TVFIY!x$M}W4U
zL$~=JYHo=IR%I~*4qdJlwj2G6ghYs+g5(UG#J8pE8jpFqMDqKxAx#rdtV$#RvMbVu
zf1ParZuSbli){eSJYoHUjT1g=G(wYE5!knlK66=&8ATcaev)R%ylVP<Wkq1vRlm;S
zy_Kc96F*ZiLkALxZ}Ppujk%%4$Zu#&`WPw%9{XClCxX=lj#hALvd;-+-hwtGeWLy{
z6)JBcPMko{L1?-t?=kQtRSu3=y)#gzoX_8$;3;wvQf?FZ?N`X~FJHLdIJGrO33N3D
z6nCOA=LQ}e8^niZ$vp=bpP2UZ@>p7btGQm-c8ynpH<i`nqS(C!?~`XbbGBeW421AQ
z57Z%1YjsjL{(f<1yt3wO+dS#PTUSRzD9c9DM6IfO%WW%`(qEte)Tix80W%uUq|`qv
z>EjBPZ1@@o>yRm*yzq9hdTPU6!cUJJdMqR$ufaEwp0%h%+yCcZVKKyDV0|oQndH&E
zPo|w-DZNY+tF^>HQ|EA^jAJV+LJ?K?g4++Sigd5`e>mXpek~!IK@*+q1#M7fI`R;!
zCQ8nP(at-Y=j1@llNuXAZMMGv$=Pxpm>a=&YKROWLJFr`w|pNj?rL8IE!jH3yOLc|
zMdJde00oVFs$2_g^q+xD!M@6enQeGR>D}aK$AK3-P46uMcN=cnon6<8dXKr4gPSYl
zF8;+g{Bc2=_fO7GMGLK2Z?^^$4xVFNW*`aMH^QBXWELP8l44y!#<rblISYy{7-`zt
zKsqgET9@cH!Cljd)$-r6;Maf<tZ~BO%zuax3>o^Au9^x&>Vl&EXhkp<mV5K(T<);{
zn6cGunj28R?$woI)GMWEyct7C;XYgTfgMMrVG}Xb)QcPIbrC8u4}@0E8c}IbG;1gA
zPEdVkZbS#9^=<d`ejQ6Qi6<py1j%YH-QKWKyP_>X^K&!7h-qGe#5TR51x5JaMsfb8
zSk8;{UMO~(Njrd5V9%=i$fY>XqD)2q5gC<KE*5oI*0h#wL0g`-ujaa?O|O@1F5n*y
z-c_ciBxL>)34MtbX!l3@^q)D+<Rl4VSozTwm(M>SMQJh3Bb9gF=Q^{iY#>UxFR0v{
zz?YkrjO${dNh((%g=|VtOAupuyC$f?opGzzo$)ix_WQ`2VYzM(t3qb~+BFu6L|>1M
zuTxow2yN|adPalDOZ)Gft-t<YWAxr`3Ny^Ibgb3c-e@Nouxcb@B$#jB?v)45@=+h_
zf<5?v&P6ExayhPOI+lrL1QN!waZkpp{O?^OLr&aU7>|wH%EH|05BPXiJUY6kamT;W
zcxY~(PMgbm{=~k`!53<F>-h@A8ZXsKroCi_YLe?%y3~nN2DmArnU7=>hZZjw#K&v3
zRvTR^9Z(9sjcb_C&4Sg&c13P(V{WjjdF#UfS%xJg?s6oQXnL%nWyIId4;TwNSb`0K
zeCdq&I{H#5sV$nCK^8ucF?J8VGDXCUbQ?ML^+k9|1^;J_4J%CR%VvLlfVjv+^L$Gd
zgk!LIPZyBt+x2zBQ$ZTcx*u<O5s`Q?mZ~IXwu}YY^fPf6S3C<Y2iI~9eoNCNR%!$s
zl~}ySXkp3MIUv|I^N8r!Bj1M*oB7`krma%wI7c%MIjLbv$8*X`MLHV(z^+x--?%-W
zFe(r;-No&D2(AQ1hAF9aXISR2=bt}n;UdU7N7oYTGq9k}&jljRh%F!5q)Og`zcA@5
z<Lr90d5h!3R&l)^+O*%bip{aS_m~3ao@5c4lwj#!k@<Mm+M(eEGdLJZ)f9M>@eXSb
zP4ZN-ZB1;j+$2&)y940mRS)*!INz0G;=<rmOd!!&dpZ`O-~VWzcnjm7oP}hyrZ|Xy
zIkqP+kZ7UW%XXJ~<{fzm=nO6MR8iB;DKx0r@JAQin=`t4uJ-VeLQvpaAASdjWv+6@
zRB5uZ^BQIIVuMzX$+d8<@142HJu8S+y={a)Dk{&v542nh?eYhsL^9(xp)=DS5tfH7
z<T+R`*AqCE+3DH#E~mVgHZ~+bXeOka{T4l`EgmM4z}HS<xav+SHt9<~AH?zRfI76x
zjF<6l$iz|5+G)U<UAKAeMXm%=ge8$mPegp3-8l|vZdoK<Y8`tusxH3_X80|~HsIXv
zE9jjE4L9iS64?b`z4?_kQ0_5W+Co40g{ajBQIYYP?sV38>)AXbkK=!Dk^g(ax<!od
z!FwwmjE-&BAuHML9lGAvnqW0rtdTltD=Y?E3q~ct+DXzmihODQ+oA**z)_hwzt>YJ
zUE-l`qd{UK7nb@OV8PYPyD}~e<>$L^uJ_YrM_#gFN#_ckOJ{L2J`Jl_{dLqXg07d>
zVkKAY37LtR)j;8(wey|C=J23CEOn+(+znnWrPzftRbDo@N1dk3&Ls<C&RPimJFSls
z;h$Z<Jqf%qU$P@`a`rJGtVSX&M+IwNXco`V4^^eWxKjoZ6Md`vNICq?I8|j6)sn2D
zLlqu|7}gStIA_9aGssu2UGFd<n2J`P>HTi2)BCF_6GO*Qrm9H#9sS0RW5KsBzr?e{
z`lb6@D84OdCbb>}?a~m8&pJG*G<QtpYrR%!2uOBr(!2ye%K|9DM`lzLov%*_PsXMO
zVJj#Y8$qqhzoxf_1B#70dn6Bt@AAxp9T*ixMROnaFTc4O;2Rs@-5TH@iUe=aK9EOs
zMd!P3(*>?YEoC=*9v*)IMybZT8@KYWUjMonKAJ2p9Xy5KGjW;dGd@ebcm%xNRGx@V
zeeonV6Fnabp#7b@ngmHJenQ8mzF287x-ggb-hPj_OekWVe|YUzmQizq8ysCXdh=py
zsO%4=K@)rY5C^0Zpk22a?`%4D(xLe*dh^qF12P!b|LfPvHsy=_0j2h=>6)xit(zH1
zC0;VraGeQwSEY)ql4j)VrAXT;Q)wjzdt}yx>+*szV5A&#LIQ7qH=KnWUIp`e4wW{Q
z+h0F1`W=uvWh7k$i8pm=y>X}r=2>E_W_&8HQ!u@bS?$%cJA+qG5k@C9aknoJC1x;|
z+Gs5Muj(?lq!<Tzc_815>0H66uAx`q@|$IMnF^;jBmJUP_eR|M0Y)*h;lK-}FFDpp
z0NgVf5D+7N#`jfrwX)Lr>K`GL^iWe~7&iQ(QTIE>cl;*tgr71^u#7nH;(ZIStTC;Z
z0Rzvy?JD=2<273eE|QI<6b_u*awBP&*IMzq$<s~lPN!zw3VlU(8fhxSQ;2qIh797J
zHv7g=qk$()6(TfRi|QVDR8)Osd19`VNdk6_z$<OcN(tt2urSOD2R+AXh*9_o>!PC3
zXvAz3dE{QYIj(aL?l3j}B9COb-St_bfUg!MQs&$2+-~CT3olvXCs!YhID!jnA<$es
z+V<!-xz4|QOJhv724Cc7*x?I?jVZJW81irHyL}BzFrlFovu>DY5TT$7Tk!@z(^w`_
zK+9A%8FOixO8h{aJOZXc6U~O#wJcPdB6YFfbtm=+d;>3UO~Q_M<+k9CW<h(PBr8gl
zpP)#g-X~4{qvZ_z|ACt=kY7o|ok)>hF_GZd2*I^m4e=0Ug=CkL2T2@BY|5Np<R^T(
zFR2iBXbH>$_q}>b_zxE10NWlq8|em&t>>*T2dER`I-M*AgFIsTp8?EkOmcnM7zXim
z>m2pURmBsH!41<vb#;$&17-b8YE_1KWik?|STm~sABT~<WJhV^Brl;_FyqlpX`lW_
zMZ}iBn7-^^=HN!*c8DB_2@3*ufo70TfEn=<KA*DAq-&4r_f<;LPyf-+<Sv@Tj0*c5
zQ55IWRQ;uqt*frG$F6i3TB()%UL3ei2-|CGWO)Eb?U!+KZJsBikg1+-%)5o$?8nM_
z$DY$m%|h}QuY@mLy|_Pm2Z))MEXlA^O-3Xk1G8y22mG@?CZnMmxQ)ECVGG@1XMgIC
zmu|0_uVcdz2(+I30_2NGr~_mXF^VjLf7xo~lIy6`-iOCtpa|*@4;}VS@lMNLit%O*
znh#(sow}2!6DgY3?Szki7MP!WXf|FyUc@J=hJRZSwk2MaS<`CR4{27`AypM<rP=vU
z=-dWPb19=fe+jpFD_Ikes;l`F?M|Y(6bF@oMNiyuOa^-b|MtDoddg;RSXQ>LF7Ky;
zbf%yD`g#78Jj+xwNuGeIVIx2Hg~9PL&09X3w3!wwsZ(fjrkNjOEXnzhr<b63iDvLa
zz^eq02qkaIX>_N3*^aNS`fc<$fc`dLGum5^=2hFvIH+~nb!sxoO^hTLkQbH=GB>HP
z4XBNskG((y1Z+7ja5uJSJ#T!M4KZ#P3@YJJ!-Mo!*WEv=9L~4WF8o)X#bBHYG~~}y
z19~a94hbUeLGH#SV#QMgypjzmDzQw3-%TUvu$GKv#1Hxse!=8;_XZ3$dMXK^<K>{U
zxJp(kd0V6uAu|bR-T)0pls6xPs1nCJ7OCp6U-+Ye>`O#R@8ebu!RdwgZ+)aS>3Qo3
zdQZBVo~`>{yS=2KQMMG7YUN4@mz0igo_ycD^%|9l;d?H0S_Lp`NJ1@yW|2G4EQ*M}
z(SGs+-=%Fzd)}$d6>9NN#6Ua#hkQH!mWF(&RISBqGhtyru!5bA`-f;Ju{OwB?M$FB
z8~&^TN386ol@MP8X!yVIo6r3`kLt+UxJ`2ymX_;QBrG%E)GS(OcjW8?E5+x>Bp2LG
ziHf(fwXGuyvjss-d3=`65YkVZBf&ddTS^nmKkI{`eivmT79Cg)Y@H1myCgji0l#bY
zk8^ZJB}@2U0`{kmyHQ;CB!N#GNCO|kI0QhV!TWOxvoT+aJ6$rfB9@di)vh8Pu!U5A
zvDXYZQj+o#<z>XtQmVnj>mNZLbv##zoMw+m;k#gGf?fh~(BMU<jH}o!ThCAn^|&Kc
z_`v1AI#wC~Wk#i-1Dz0}4V%?;BQ^?g%4>W@*+VYI9+P%HFf!;NJGBck3%^nP?ga=r
zpy0x9J66#TkajjhPVnX*sEAFe;!=y$FG@qOO~Jg;-~Sk;`z4G8=DrqQn^W867VrlS
zVLzv_it?m2EzvSqc1sRS@=vy(`!Th_cBF>j>sseZz=KYhTW|zC8ZH=jQahB=#FOZd
zRHqxk!0ICX>N5T668-88<9;(P3NCQ##oP~x&0K1!i64B}E(71n&6@sO0<tAKtnp=X
zWlcP_H=NVcbNw_BmE1QxP0uvkn)UgSb^uNM)9n$(+uoFCtE7-cTk#MRr-JG7YyZUI
zX~cXaN&Bs@qHRR0Fa5GsNdQyV+d?#^sdUPGJ~-TxO$@<Xr9nq`dDLe}(E%um&X`lM
zOv$y6pvY>?QCE>XApCOW;MPJ!nO*+Lbvf8a@efd)$?rP+CuD-y>%umTz=xH^GMQ|u
zJbXYVau?txzUuBDa-n$y4x~0c85^ix^v%>go1utPt%FNQVrR9tc*B^@j1OX&Wk$I2
zhJ4d9g1*w7hJk@h-DS#D#{}NWE8Q&@&6-iG*v?tUszo=(*6QugpN@-JWW@Q<qBDAH
zQy96?MTiIe1TcOQ_y!42IDLm7gTcA#+$1+gqV%1EO^W!_Ccf!m&#BUTz2^Uu#KQQj
zxVPcCqU0WvT2>Ib=B#p63_KX{>4g6M?J8do5)uP_`HI#ze`{cY0|2JJZrC%6{O0|E
zx{EYe=G)xM<&bbTr|TWIU|M+yuJ*~leB|W#PAWKUWd(Mhuz*rcxcE(Ru`LYxdUoTB
z-k%^2xf`X)9yj^W;T2tm=(w6%6Ax2hW(}}{R@s<X>-9Z<dM1rEqRimnuZ?sTbygHc
z-Ec$ee$dk;dDKeTdIrckKT^N`z3R-OG?y3ho#S=r&w?J<@k$_he8X>Yh7@IrT=WFL
zTQ6;nQfy=ix4WmR8EdD^vNS+ftpBgsu$0^jdWnnwOgYZHf)~}y6My8Rq@g235`jft
zbxzy|ldaJ@eeKb<ZEqm5r)T9Ov#H0tN!{))LqP|8T8t$<0DSX#I}35%jl3NOj>DIb
zw^q#()_egQ=vs?B-)knByMI=AO}Wl2A{So*n31J$*XU&OY@uF`jY!<x9|NjTluf>m
ztBt8G5yyI=<tnbC&i|NhhoVa(1^L93R;FNGA8$NK+~y_o8IXGq4U%$YnX{m;bl3Mb
zurdK`4zzJi(?Y#HQTZ2Sh6i5Yo^;)*Q19DN5HTcX3I2c5)8V4Uxv*q;xG-QSV<p3F
z_(l_cGqmhlEYPk&M#Q8<r91bPpPIr~lV0_3;+^q4y$dPF2<E>q*8SVT_pK1Rs+I`V
z9-pNEQ3k!7$P@;MiLh*Tt(aF-74bjQRg(ZKQxN)D`rYzOyC>sQhwww)OJ_%|H!6G_
zFPV$xAoP_{3Ccjr>yQ4K+TNNuwm@<js3gm3WUACs6AAGMWm7&@rf@BrFb1En6z&8+
zL)1uA`1ZP1&_IWwPL^rxNCUPL3%iedK6gD+mdMIBT}G3;@l73*n9_3JCO=ly?=;}k
z;mzk3djxXh|E>%jXdI7uIMC*o;$_IAn*`|<_uKwz5~Kbb*}gL?r+w436cPR2!}p0*
zT)M;Sk7Lw$uXg+o$1J~gf5RxT`@I;D+w*2l-8gXCDfg#~>6I4Qw9_b%FA6dKkolV)
zsO>G<%TZp?FjrdwYYKP*Z(*=G@1Atl?4f*<?(M6^&jFZo2X=KD2UJYVjA00$V{ncz
z@5{LuI5A^ZLVOaE9H?S2OwPv$h7!4s$`kiE1S`&p(P*s0CWfv5r87ygnF=u(nh{sH
zg`v*g&!O*cM%Is<o9*wj9}%aZ`q0eyfW@b-7nc=#?pz$)hR6a0W>xnV7q5szE*o0t
zsFsif1}%!8Tb^zS-2KvWT|PB4PH#i>8i3oEsV5kZW34&-fN9`x8dXS)Y!KGw=+#Gs
zS#rnx^`u<P!JXglpwNL$aBBYkEbEy^o=f8P-yRO0LJXZW^;A>H#%dZSC0wU6+GC^T
zGF<gz3IGy}g?5USaNFnITorpVY!QOVmImMYNS00pR8NgR7otO@cqv!{Ohm@1Nn)JD
zEO8MSY8EyN`^%$<^$rH?5cKNMYh4FQ5?cqbu{4c%hhNcX1akW4m9Ih)syBB@@ik0y
zI<~TR*ovG6Mkf>3YY_U0b-1l8hKqpR)N;)%04p13(EDaquA61vI_-uTodQbjuh+f9
zd=Ev7Vdp|b+a3yl`YF`E`~9l3nrgrER56mylo3&9o7J_)J;5&N0(t!%o?4}C$JUnJ
zmZz&U%P#u3l>m(<9*)1RFnRtYm1C4?{P;fY0$WRm1v3PD&9}dJRORdR?-W2gt6|X`
zutr;vV_GCI7lu!(jEP+4Kxjmfqc=w8e7jBE`UyS{Z_;bK%QXH#lQ*0`ineouQG3<+
z2N5=F)Mv7YPw759L;q!!=E>7{#-^Q)tJ8v!CBltAY+<9rQ$alDD0GkDof$D=#ksAo
zLDzweB!^6v?v#i&m_h|=pa5S%Y3sxY*oDciZw<rGo91=`m*J%MiU*I(u6~-c7qFxv
zL!-4yX<AzB2)wAsz*0Pgr`npy?podjS1Tk?pBn+esDC^QGjBi(7mE4r52`Rg(Flyt
zA-wb&BN@IqEqLQZI#%D|fF+EI55wQlT|;USN@=3=@13}=C#IB339)D|N!uy|xac~V
zFheruEc)(@%tQ6Nytb}E0+dj3oz`J8inuM5?cy>plb+p1h1n^LXyKzpu`oxLR1<EX
z`oL)f_yw0ZEaH_2*7lnOtgNE)%iEbgIuwqj$MXb*BD{?n{=B7B{V+r({gt`cz2(lN
z%0|=l2aP{=Yh{72e}`74J~J@@D%ae#CUtM_Df3O-m03bLmv%kXj7sxiOLO}C7{38g
z(N`HyESj3poo%C2^$kg$JD&uVjR&VVNa*HHP9IuGL8+-TG%5mW!F;F}$S>w>FAknX
zTVi1S%AYc!HKYwKtJUzjGlk{wx(cew`~h|hox<eaq$8@-l%wDZ6x&un9P2EPFX!8d
z-QTT1ESiP_`f#Qa8Dr5C3<B+mcS0ouv&yiJxZFUdq;?)G9d^GZ3~cO=LN_XDh~^!I
z08S!ku<aHGyQ|kYStt!D#IToS29}tsSH8Ba!yrj+mhRy%L?;$ehU7DK#a>VJhU;ab
z_{*VN*Vua;#C9Ol<49p((PmUIBK9WxrgY0$O?G?|DqS|fDzKfYUDP<@qH`Vf4+ZM*
zEFzOuwU`d}VkKpgkvG^R4P)Uu0|h5~4oZO2Kj!wjkUU~+hPI|^HVWrYk<l408k?!p
zlM7RnO3Y+L7|+LWq@K&s-gYaA(-@a-r|e8bNC|YmgYIDC8RH0muXyOO8nRCV;xwoY
z=!d6DMc>`Zsv_>gEg_z#&gmM!Bm0>TCQ3=|3*YLHg$J|g+YK?<aqJ&Rsj^(sd-K(M
z{C?r|o_Y>*WwJ8OIQ<u620c@eGySd4pS0=x7Yo6mg`0H!8+n|=aR?U0i3`SGg6Xk(
zvX!;M#@8-?i?b5}q@4MQP|Q@lDKa5|n<h>lo>C!om_n_rAn8(w{b(PeFh+oglJAfq
z&De_!oclf?%p#SSpeZ+oidutOL~k*INnUY#6&m)KlKfn=eRwszs|76G?bmZ|47l!8
zk<`6f<$Um9Ubuf}(1(haVEo3Pn~A)nHEy-=sxKtP0Y|X_A+!<fY$xIuLqS@4Ru={d
zm%iv)Yin=#Rm!h_`DO$Xq&RPwuoU~so$#BSVtErRT@*ou$Em@wR>B9D7@RGoT0KlT
z8ZLFmHfJ~~^B#>K7Hk7D$74HXhwz^ES0KVW6?*X@*~hd)!d4&H6<b;}#Jz`@4nmkq
zP!RztmApPccOgqvN2U6G*)z6LERjR)L<n0*um?pFGUmWMmqb?$6dfD?lbwkPZeePz
z{`cp4+~iOoms4#ZH|PZ6$GpnsdDstStt42`kwUQazy^d~&=iBHL>X!m?}oClXCI5z
zgYQDA@D<prJ*BuuA8#bvSj@>ck2?uojIVvh($fI9ck^_4=XY~2w8}Mqm*?LJRc<-n
zZ4_^h-rb^^352m{hw0ZYg^7YvvD})Nhjfv-qA6q<CsipnGrxcxol(Qotd4|4$I2k4
zfrv=slzcosYAgwPdn&kcjll~zQK}gB4aX}=!OFn!6|*QZCT7m#;o1}j;dTbO=GlFM
z#V-J(@Wb7spGjj*gV;7Nb+mNe<^3K#z&shHi%KBe)*0zvQ$<4i?ZO->Uv~VT77ge}
zRIhnu>|#JPWy2=L>BD6{ZN%U)KQbz!@PjoT4%-(-onQW`65V9S*&VEDWIEay?E`zY
z%g3r&wRV=SRXAHS9Lba*j>ul~kS+m(ngW32&c03WsBVM`qb`cF!ImPNX+_F70yA!r
zJecx899|j*2I~u~7SL{ieFb5U^6FFz)6Sw=JGCqCA&$PD01;0ULLWh1r?sc8C=>pe
zWZ*c~$lPR`Z;NnC8%p(EzhW3!LQ#hM7q~UFzZUd95)5%c{e@`0E4Tad<T1Y9`VD}E
z&Aw)+j6yG6cE24{hB*|Fb|!X0^!to8dG`!MB8Hw-BS7CTVNK#&T!z(8g77hWikc<6
zPkd#2HbUGOJen`{HNoWruksKg^5;p90>1nuyN34qlR4LKQ^WOG)ACa`ZE_>n7(=MF
z*vp#Cxg^d)+mRV4R*tflJ2bYqQ4la~(GcsK#}A_eB=u0kCJSHl-vw<y8+ndxp*eNP
z^@jBpo{HTO-QHK(DXTpxaDU7p*>2Du{7JQQ^Q532nP~fuZhWv2L*myiK@Mv<>u)CF
z>m_a8)iCXkBzatW`o5w4QxW>|92!^T+oj|q_J+}$F1{aB!&>-0;6>*!?7!Yr<2*8#
ze(|S447Y>{4aN&#AIfK(Ij#EWZ)85KNOYdnaB!5ufy8h6aO7oDECP*0%$j@T;%=rS
z&RCh_9C=8yPWzjQ4{!Bk125$VdODL3?UHi2GFe-m`#wL418#4Xpi7v(3tJ<o#V8>D
zPgxehDrisw{_D@eDJ8vwech{j{nNNA?bD12SF7AB&|c?iRlRJKE?>JW{geXzc?%2H
zdg6$(?=XiPXx@nT?QHULZNty4o#7{|77M(et@75S^%z^#(>r&TITO+^|8V4^jGM$~
zF$G~vq|OroWE;iqONIpUQ`omkcT-d2ct9b7GUsC7{!^$@)bW>s4sVgX0Gxr!)1vbG
zGI`F_xReZpzRWTVM$gF~O81*bFHhgl*`y7!zk6;{H284UcL;atVI-fj4XJ)-p1(YM
zMWCYB*^s*;Q2EEMhGVZgB%k13&g?`7hpYzpwuI64K$dxs`HRiX!D^6eEz_B%1z_EI
zSCw!yf@SgSeE+|5AMgkh7W|Mun0_vbb-c*f<@i`bp3Mkw^bAUHXND}-&Cx-U<9{hq
zmO@p=rgSpC?^A?z^cfab%l<HhQ3Q|kh$Zl%&_Hi*Y#8y#$81O)qow+4D)H#T#6dxt
zYoY(+lUF7|XYn3p({2RLG6v9nYcpS7lvzbG5r&}7Tww8hZ`c!-vhzU2WQk1i!q-i^
zb}YeB(MFx6BaMeuKK@r=Bc+E%K?_YdTW*63mP3c2{r)cKX`XDq;Wr)Wk$G0WmM)LI
zl%y($y`&)ale<>=$=Ov3=b$X3x0_WTbys$q>Nn$^iZQT!Q%<0Gs0pyJFw!4m=6KsY
zJStv%9S5D=VDLU6`c3m#wcU6`ZMDLaqxz3#TU)_HVB-J7ypyd&)O6hY3{WHp{~q-|
zox#s}7w8!9W9BI7+GQUJWt8E_`%5H9$zru4#`_m}^&u>2ArHQ{o))g{aFoU=jH*q!
zx(FXrukee%BvJ9PDFL^-XYXhrVll%*8%Fq1o7SSvg-4kiJgm-@((ig?NZJ3+kL;A)
zjtvtXkX@P&rAv763BwN{6Ec6Pd-m|a(H@*2CEc3mBwX>vE+bG7dM40cT-vc@l=|&_
zm3U*GkG{s}ipGjvOk&N0v|P2DlrF{)6j5U8TdjC`K(_M-CkF7*7BSSDyH5$Q8_n_u
ze`jHRViciw%jVQ}I-nH1pUAxI#dSa6M2co`zqMvuP*I&44}bMBD6(0W366XrC_R$b
z-)-Vt?~#|SjO`zN<Y&SL*CE28LGu)I*B4t7<Oh>hVceOOY{8+0)Oc1L{5~ci(SEIW
z8{c_5DxlS2Xb+f?m>6{#q&8?##=_H<V3HoD$iREuL)I3BPsUMqv4>l}52A1BSzgu2
z!!CLblWzg~Cl&~)4CF5PSIb#v<&f_gcFm{Cwk@iEr^AIAd??JJ$!|>r2^zQLimqoZ
z=^PtWc~+SAsV66(bR$|11>yR>XeWr7tdclktD925!vMWTWpny-nhrX+`i9^8SOtzv
zHJmqIye33VI__MwCt)h{TdauIZsw%_P0f5M;O?b7q-|qw_B<Y<bU-5xr5qv4M3_Pu
zMuC*6M9z$e%K&O9X|~{$zb9;?#zXK5pXQ<I9-2TIXUkxI&|c>$rH$q+5tdJRbCyW!
zqFf}K8v*;NMhh;6*D<x`@W8Pud=W$maz3|QzjeVZ{rQDc8p{oiLjK3635c#&rohp3
zF2y3UAgBy))K+iF&mPP3o6h=7_;Z=`T}Rn-NJT7@sH8QApp@M{EX^l4rHCT;WjgY}
z%4fawd;guH@r10zc!xKzM&YfZ{eF_l<3+(?0fcCs#xEXV<YxEP%HD7hutMnf5H`L%
zQkU;%+H$d`9=0hjVsqOJv4Gtu>MO~4F=pkG?x?QTOF@`iO`U@;D+TdW?$$&$Ka}!1
zDcx(_V<GA}o;&815J)H2cV9SqM1mxwl(}H(1!ICqM?{0$dk@Y^UWKs7(dQo%Ema!!
zfB^L|F++?i!#u{mHJK~cV8~*Hz%?*`jT-OVS|$>>YpqSjDAs1Uu~mC6<aZfwS}klT
z&h4pK?M+Cs8g$o7SVIWXC8?}XA0oaV5xw!`AjeMv#c}X6WM#ZVFfJ+v9@>;4iI^=u
z%(QZ>Q2$l#j8(3XN_v}=bsdiMQv$I)K)vv4M5*HS*k0|g=o1S+FKamuyT+Fl&3Ys$
z@+T69Xww>Utc3N5n;8;)n3XuR={nSk1P2!{Qnym;BNb^>k$ql!SFugro4Opu*o_b=
z>!QrdcAh8Qg4D}oJ8HrkMbI~*wX6eoOu@X4XUG;rv(yVmV*4i2M#cnKfYM`uQF9LC
z|D{_2o)!7G|N1ve_2av}{^7zIvfU^5j&6a_q~2gfv^am@SgA6<N?D2&W>0660!`sk
zrduM${qLqZ2h5OdKk1T3KWVDqCNb!}J8_+v69dkN@XyZdmA8e*%B2v}%IR(Fup!*_
zQM!n2I~xPf$Qung2uNDrFaB0;YAlpH2g>1I61zcZct>vsqbfq(5dMRCqKH~vmjD~r
zX^XA%-s7XunxjKzI&&((t|Rwr6gxhk?bFv=@{Hv3F`|OVK%9E#y3~nGxr6$~l6|Xy
zkQ#Y<(XD$<O)+88E~u$~j?dgQOVhq}q|$vy%I^6@|2J75ut{Dz6=hHN`5ck}<qo72
zqm_}onOcL`WcrV!(8d&AEI;a$-)0KTbz&DNE+YfGW8ZJX9D5gL@+3_`5pkpD%H8X%
z;CDZ$AMtKY(60VcY3YGjIffR4;5TkPh}iKMIz{_ZLaLVDCkZBZF=E>2{z5KjHx^g#
z{TQ@;BCHJuo(LD8c^9j{dd}A^g_?q1Vn&nl$m;%B4vIid{0Ug_)+n%sW3tkz^VgE<
z7rr*Iue#-<kpu7MmJT!}1pU6K8qP*i^0?oZL()b0RvBTdi?h^ZZ#)jwAYd6I1uYbq
z&xh)Mv<YV6<L&c#+Z|NmAU=`(mHQi9M3SV(J{gM*(1{KHR*sZA#*xk>WnKq8WXtx>
zp%eKLZ?KNGf{e&ln_{M89!kZ(8c2&*!?>cMR$nO0?mI(j6?Oo)?G+CHV4ItG)jg5U
zig0*>UhqCK`*R2VZf>8;SBd;d*_Vd8%)x~F5Y_(*3r}H%>QDFWs0K$n>fEgl_McfV
zr&Q(%aA>bB`Kgf=>XVwnG8|_AwVCwKk^=gfC4%ld2&|C<R4EXj%qu%<&rW<n{Y3gU
zR=R{G+m=J=K)iyq^(N?ZYbsY7owYv3Rri!=0qVH6HFgIY-c{OZOznij^|JU#nI#Xj
z>~9-9GA%$=Kb~AAHJw064C9fSZ2divLQ4pM7cWIRveHtdYhJrq0&$7%OGpWqe()vp
zl6*us=6)m=%*th><kYV%#rasm$Lk)o{W!XH*l{9|tQ}(7GOi1`!tnfnp`t8e6_jIe
z*!K6+>khPht?3I`ekiQym!uqOT(1K#m-6c;?RK&pE->EQ-0ymwGEg^ob8k9s$4q^|
zN9Uk~4?=N7h#ypY`DJf|9{mdK>`x_p>NcUp%azfP4Rg>dsBWwAv?a)iSL_Ccun7a6
zI^|!}cSVd<>a@mSNJlOcqI!qBaii4UpKYB4&{l(p>+20o<F+f(#Kw3iSH_qJQhlz!
zzw27~FlMU~o7a{t(q$?{oQ&Rwv8)&Y5Eb4#>04F8ci9vI>g_*a4CG5tuV#rEm{1l%
zTok?%`0*c^8eqWj5RtKz4`&uU`%R8$$f*z#MJ(Ac8y7HHeeu8y$4|19b;3j9-Ww`}
z=DWSTwDghw{dgH*^n=4@OP=eHzhj5G@06w@$`pizHuryMaZW#WT40L-bSs5T*XC8h
zu>Pjz@Mw%AyypNGGq}w@t_<|fh>PHDSC15dsg7q_XCMqia2GFgGMz+*A8yIRmbH^e
zj!YMhrM*m05plWi!B52R^#cNMA;#NyETkp5)YH#s^&B?KVG4?;o8RUOJ;O!cuBT-~
zGuBs)sruP*Zn|l0sf7X51V;#Mw)pc9PN;e(HHR(F-3amI{J~Yt5+R?=!7C{e0hOwq
z{7ZmZN7m<Ex0QbTPTs8ni@#A=U>LT7{0)Xo-=1Vrzm{oB!^q}QWwAWaHJGuO2le{M
zVA2JDx8oR|aWl^zS4o6b0jjsd?o6ojrwdm_zE}G<30S!xSC?(z7p=c<*!>t8Gs-I~
z1p^$;gjiN}d?dMC$FZlSLh3)|O?)-)_7kKK4CJ`i>np`K$L*3WN@66MEF<nEx26yC
z5R41*o^T6X1%a2(UZ7+PO7S(u;<jh#3yP}@pHO>#5Awt9dF9i2o*6X7h_`GV!~4=n
zC{8qy{{9%^Obsw^8BQbX5lNO`ysC=X!6YGsMUo)lA7@zug?a#6K*)ZXgLY@|HN<~w
zPT9mT@#5Fp?@VNe$Lzkrn)d7#tGCsgIVO&Of~dmS!3zf!7*Wbl@s5-MA-9NS5Qzqn
zP|u)5GKwECq#x&jk%xXk`n~0D{KCpZ59GTe<;A-?CtSe5r>GuDMK~$kRg%m<`8e?a
zww5PGB~w)(EY(G=TUy!<U-~oyo#7%?TK>|%D0TMLs@qWb=2PMRM3AQ?&|lMsp8v-v
zRqDsvY}44?njt9#coq2dtq3{kR_~3ZLVC!0X$92`)W*+%73z&}DOR*nIgDI=+xKL4
z`Hblr{SY7^oV|CB23F4Eez?U6bc^Ke^ZgUrMZcrh=sVeI7uoOtxLaRU#xvEP;u<|m
zR2yI@DDdCi*o<)&dzq`l^&HnvF_0-E#BVxQkD(b7;0sv8`elV0xP)lz(uXg}%R1xF
z5WcIa*IAc2jtR04JnFvfUEXo;LjUW9_-W-yT@Ppy{Rcc`zwbn+u;8<j*q~mXka+IL
z!@w9JrWc^yh{No2ARRe;W!dyXwOZg$1Tr(ue2#1{evIEc_~!f%Om5WdlEkXiEmH_y
zy0qExCu@ZQvJpY>XI=r7ref)gGu(w0VfK|!8Y{P18>7<J6C4Uz1yO=UJMhi+yDxa!
zopT%Gmn?V*a!h%GF>$UVso&JWU7KYl<(Db7gMG@R;DM3k4ux4Zqodm`S3<j*njh!!
z`nym`L{#rm>&E))hHFM~O^;*fIN1WD0}Vz34M;avy+#82c-i`L6MJtqo}aV&4c+>o
z>x+*N)5^vF6$t}^Z)!wNmh78K^S?LU%mo<@Z8&)dYG_w*{$SI6`z@>$>gDy#p#6%5
zOSQSYP9XVi0R<1WBT(j;h4VC*l(E`Loo2VjH|x`TD07iJ{ja#+L;iu?yqWL1a*~o3
zHnOzS7lyxpol!2bgB&z3cys?bIMX-|yYXqv`ZQJy+Exc3#c39OD5%AjV`euuWc{Ip
zsvL31^uf6N4K@Y8?dl-mJ8T-+Yb4WQVUXCwa^4A)7TI{vrb~OSF>{SIS)G{lWg3*4
z@+INd9B}r1$r-^Je^X5DaCu9N^hs(^uDq?t2)?b~IS=)Q_f~FpoCWdzw_v@mJR1Yj
z=C_p(Yc8a~Qu$sV@K%{@Yc$}WcF9fX09rh6umq|%O?iE8c1@%hFBdG1+5>|0tv5ay
z5#A^dP04!QRaIwTYTuj`Ork`xSjEs}NLC-Vl;9mO{d!4?3oeum?-?V@^CfNO9)1FN
zEdA7dZyIw*?6J$H<opigBQU4qX{xX9DEuu52|R#EzJNpd%9z~g@8i^vnR9c8efP@H
zDo*)6^1sst<n27w?dwU>t|lqf>?=Wu@}@fT>Um-YbfcdB@Fa%nr1xTs!@9b8sijA0
zdK4-DN{fr<S_&y#or)AD=bYV1ZKS@D5KEE8b{;pVC2AbPw~Wl`rCE@PkNvJzW!!`I
zc##0s+K(JQl=jacIEOXWSyw85iT~~>Wlrio^Z5<NmM~KB$|Gg`$gF(daXm*S|HC;(
zYjW+SM>uf70>-Xbyspq&USZ~!a~sx;V;QsUzS=wEx<LPs2fAn)qz->jB|^793Bgq?
z90qYrT#gsd1l3ocMUEbM^K>tcmDTj6{?t(bH13FqZ=oD;<v0yhH<tFg;q72ZvRwlr
z`uL+!;yx|V>#7GNNOn!GVPkjhy%Gr#El+;+9*Kt~if%*+|1yX*VhQj3m|Tw$j@8Xj
z`FhCmMh3a`-ZfC;b3*~_c|GRmqaqhs>Msf;al6>ovk4<cp=Rk#)<<@6PlkTa7{mg|
z#$BRQ@GTYGV&)DZcODX5Dr90hU#(`2=IG+GC3vhI9xY}kwsa-kX1@J9C`&JLb}*#g
za$>z$V0g=##dvg1fOblW3g9Dn4jlW9=VzR*0G_j`0Ckxl?)g;h{<QMxSMgw0=+N+v
zFo-((#S^){>3QWp3IvJ*2)M*8W`y>E_OvxjO?yzv65JF+wt9PhY0JW(k~s~v$BulA
zIb(7_5H$z2Z_&NWd)qkMT(ci-?3#IkZtZLjR~8+~4=3gUKi3rJBv<0gOgvqSjxq<f
zpRDYw!h)b>RIiDU#X2rApIXT&cGU?SPji;)%LA~I2Z)~qvjhnqfdA?(<x&{$QoEsv
z&9(BrPF8=Ge=NUAUsjE#x_5|OG~?atuq)Tl=pK{cQJTXWSe44e4Wm@_d^Z2g!Ne2U
zSt`d!Sw5s@@Wgd;#UPx1VliJjIP(pQi}cz3c;I7PX@b4)v6K|nAx16^BV9H=divK>
z*eup$ta9<ejQ*p00C(WgtYf%ugQ#3b|1v`#9a0^=$p7*G%r|Tnfgv0tBO4TU0vXI;
zC%WE;2ul!>h%M$M_~wOE_1VJ2sEP#Gdo|G&pBvP_>oqKfh{zC!xT#6n{Ma~Ub1Dpd
zG0GmU@LjPT@Xuq7+WEvdWc#Jcn0R2LLF+ebeIhnMDXz#_9g1Rwoh5^sq_ilu>$c$k
z&$4q12cyG9iG2e@@mE1aOV$L9L+U`W81DsWX-cnhM-GT|-T!}FomEs^-L|c9cXxMp
z3GVI?T!Iq{3GNGbcPB`2w*Ucxy9S5g?(TN^_c?pteeXj(%(hxv^-$HuoO6uczYeVz
zlO2QK`%?hg&6F_8@Y@#JV(_vJ0%6ka^RA@z`N7x%+-9*Vg+|dxEET!iL<hV?xFlGL
znT+ATq|iG#cbF;|B0y9^&~1+4wc(gr@PYBZ;6VagCo>mCQfMm#=$j3l@UQQE{5v6!
zB!&c}Ud==Q<m~Z665QBqnTWL1iWrbBjD4*+n-R1dvDeV_G_1~6sykzwqDDvlr5pni
zC>?4JicDUN+wZr5LC>XUl?@F%hgLhuAB0L49!QNA<W0@R1j@o0&#mxWmsP~a)FP?(
z=x)s-neb^3w9z$OhViy1d;2oKM9VQv>*J4tJq4YW;h?aEhe3afZgu+(SNEC7Ed7|w
zSp!KQn}#Gb!<~Y+*u3jIJXk4{6fg2&Nt{uhYWz$|7BwCwUC0k!uiFycbgxu;Uz3^5
z{*x)!D$=$wHsDQ0B2EbR?VpU;BbmAf=EB9pP~zP2+TI3yw_24aRl!s;g*bJt^-Tw2
z*$sicpTM^FY#4Q;(AIyjFGBBQ@{U-&zfJWhol(a4+k-78)^En>3(-E11c!_L0p~S3
zyy-L9IR@(lHi72>mCxp>TvRuldE<J$4Z47>#|(wi#VsjH4FYZUo2Wy<#*!kIU{*w+
z6{p$-hz5c7{f1JSNQcyezJmW*VKN*dM)^gxHw0v5S2r>KoO`46oIBfcemUDIb3QxJ
zoZEcv*~{9pr!Ue~F>_s4CMCSMhlEO4BA#_Qj!6;qh|&l#`Jg?yNne4SZt1?UbON9V
zX03vIOGGcCX`E%@&4N*!D@j)*VuhMr^H`ZAZ`8@Yov+`hlSO0nOkMXR&?2wv>)RuM
z8CO^-BPb4oDL3C)c|S^8I@5~=uZ1!0Udtsk?BI8JES_KrX88v4P74QA<<&GJLOtS2
zH6@-W)K>^288K~qn`>u9s}E|p>I0l3K0B1>(~ZibB?p(&(4JuY0&gYHQ=;P?EzkiY
zzhhv=houwOWadqt&nflf<TF%V6`zXX^ib8xe<$uO+?qqT|8jtqvkpa_mx_YL-tI7i
z3E)b$V}*@AE5XOr_xA~4>6p$nK97`*lrV=L4Ax7VHrZJuxoS-255OcXL;}CBdhD|n
z-kFYJU%?7Y&*Q`<LCavKoOBl;80ZsZbnu>2HLNF=wm7qhNIxdu2F6?wHnt0XuG^=h
zAUCi}>ewtv-B0S5*B!eJTM;=DOO_=d_LhN6=1>RtSciYkeDs`TwYOjPFM~tnP|%YH
z3vI>vu5nQAoueNwG!s%g0Nw9p6`TOm=N@$Kyc8_rEwzrBRZD$l^c`66?+nL@f>e#|
zc8?MNrTYHePuWQ<`XC%OWCYAQB>EmwoLR`F#u%<Xyj?w-4R7DSNd*!=<bM0$P5n6t
zut$*~il>flyO1z^Bxkj;65rNPMl3cxiA3t#e+nrO0j72Qt3+VI<CmLcp7<p6(!Y^f
zrw0W4E*%%@<)w(P&XN)Hm_e>vf;Lv7kzcL@(H`DJKk@NBJT;Is-}<&PAqCdalC0}b
z;|GRco)$x)Z+mwye$mbi&y5Vuy;kuEEvxH&PzD6JeD2+sgg&MehTsZ`{lCWB(%q|Y
z@>=(vfo;j4igf@L4OR?QR&RpXx^a7KE+8o2{tDOi#-Ncf5?dNdS<%Y|-GCD!<;7+X
zwR8NX`)7toEiY7#w*QFv6uMb>4wZPCfV}<@Ee_W(X}Z`0QKt8+i1F<e)i{~yl<u!O
z-bA|Q->*T#deL_7f5hqeeDkpuapVK+^10Z<0Wf`1i)(Z@B@W8#;$FTaQQ@;q1S9{P
ze##DRDM4K4D~3c^;u5%qm(c&RmKx8XJD@Ou`Jl+X-ig(~T}vPublvj>C6EnjDNR@3
zB6$Ta{Lba~gakA8&-{SgUGb~~>wC}VD#7RfX!!q&|M5Hnd}zj&U~1bYyWQ7?kG2&a
zAo!tN(+Fcvupig<v|?LZZw2oxVS)9HjrT`+FCX%JtLC8rP(sX7LB!a=9P6%kPx=9y
zTElfCGT5CRSnZF0I8;LKgc$NWN=r=bislFiz74SLBBBbuC}&T1S!-Y;Y4Cqm*^s44
z27DYU5|x1b{-00bo)Sw?8hJ~hZS+eg<|52W^Q|gA<Gf7T*M9;!@ZR)$NjuKgr-;^A
zsYjT0vqEpnsBDqQBWV1;Ke4i5+al_9Rrig3<X1bHls@D0t-}n-yWuYhJSK_1U(ZdS
zkxRYZ(+zU(P9Y7QeJD(1yNEIahEfi_3!-Z~^Pqs*#{OL<J*fxyCCMT@vp*^}!&#=R
ze)7IW<c2Xt(2mlfC^qs>ABcR*<<LKrz6EIyj`+DS+iFGMRr;DQ6v3BKt=KK;WMlsD
z`$xS7r%X(G9V&vNlKLp}&qaWzYkAh<;a1bkY?fjkoyDKsJ#Uga9{-rkVgG#t0km57
z^K{v1dsC#F3H^J8VSoAln)y}yTo!YxPPoz}74pdcD?5Yok8=jAP|l+|;q?!my{rQn
z;i@<H707?oq>+=AgmE)A+w9t}+29UfLr+9T*Qass^Uk?lnOkEDy)IZYS?BgiB3Y2N
zkGKKmuVb~W&j)v6?YE&zoyY;VfE^r@Hvq<xcgr;V6mEw0)y0sdqQ_>u=KR+aOD5jT
z8y8ai@&EM5Zn+TD8yyulfrzDKMm$j<V6?v6&mJY&fn7FOpy%!3jHiFugqpY=`o)Ye
zsk@=X^os3{lXmSX8QRt48;@|e7k_#<bN#J?&nA{SGJO6$^K)E0DsZsr35LE97fwN<
z%zg$HfGmy#LNoooRUJ1L5o9yb1#-pfu)#(`L|Dg`juWm<Eu;(Ob}~s$03XBisEmFo
zPeaF76~Z4Z+kIZ<8b}aqfg8X}XOkuxMwfdD%;a(13KJ|$%Sj@aLI{}HiU5hw(ptgM
zKtzFF>)%l(0;q=A0KlFE;T46mmOL~7nH>of{>4NBX~{VF?^y)jcr9TO-#EQAVIN21
z7}lF80-wk3N(TuD)rT6Ik}cuf7BYzw2ItSHzrz>as1eo;wLVpI>V)9jrPlep<<p>@
ztLC9!T59g+nY+L21sInfagwk&W}p$vOuuI1`o(T6r!=hv0y%c^lQ`6CgTwn$KWpS~
z@7Vuj`9OV_C*#H24GqO*_a&1Pxqt`AhGf<XED+{lAqdJblwJ5x#vBWVjhmVGI2hQj
z`iQiIV%Was|3ZjV=H`Zp^zP=lE+(Ez#L|2ecbvk=B}mHM!2^Sx!Dkv-YA)1JP`o@d
zv5sz~B9QCq1<ZEZ@CC_T3>wq5FcA21B;d!{`{gbbOVXsYnSM@S+^8h`@1n26t#x2f
zb@GVWSFqqh1!`Qw0NB)@Fo6Di!RLBoKI)v{d>HSb-dlrq&c@zj>#I-#(>9|r#&N~*
z4P=-rG%2wek3v1}BR7{jx$KHN%~`xCeKY|XAE%`_;NhW_b0a8MQi<r#b@yZEQoEW(
z+JcboXW05P;C*xUIII%YLVrX#7loPOw)RRr#z#E)iQA%Ng2*rUh$u&}kMJl`*LY-N
zQ|<1i^h$@j2Q`@G^9`D;YKT_nq;{8a`lG$bC@+5qO5a)dq8eTIDFRe@sTIOl@{GgL
zx=~C5fOd_bu(O#h&buiQ&daG$QnUz{c&0f)xYSE=PN$jVQ*}{KpjIt~REi>@^hI~<
zs<V>Ux#Y8P!I}e9ST(yET1r)T<BCwv6DoIgEga~}d`RrP_v6X25R#LocO1=+2gU@w
zcu#tDEF6@(&kraBRHeH5E?dJZ7~`{gW6x4ZK=3Zcaee`A?<>Zf-33PNQ*kL>ES6f}
z-<0$^G$Wa7IzOTIDy7a4<-=AeIV{J*7J5IDc6{GrCuM3sdOC$<N4hNJ7pYz3OC4>&
zX}%y^ziA2n-fsBOdJ&EJ$gavT9pN-W2CW!oKkf&&9}g?x+IhVJrFB2fwB%?J;%U^v
z0ene=0h=mm2>y_fNHWJFbJX$j(ro*8BpH44<VTWER7cQd`!6AjXr&OT8dHeE@JL@R
z&Nc)j-MU>A9*CZ_V&5?_M_AJ>kGoy}x3PFMF1K<DLtm_V6~si9*EMvHG19Q(T{hGR
zRW3bMDDy?~>54C6D2R>vm(QYH5Kv95xidu}WiT=c@qv5ty^(OsL38US(L{aalbjT#
zqr~Oe)G3%ThFdkGC}ERAwiNxrnr4cAxZumRBDLN%8|?-SDUnQOa!={iTTNC=$MZ-s
zck!M(reJ|2V36?p9L*_MBG_VW2F~A%w80a8t;JDb^=nAS+)@Qsb#L4_0s#A!h?sYA
zW~-9W;F@=%nI-86`04xlUz_d626+ri!vby_e^p|XLmKS#&K{f4cMrWHc+K-dfzKQ`
zRjPWMBChoj#pM%f6WR{aE^%mYB@rFWJbp~GWgq0mq$Z^*?+p&VM%eoiqsSUw;#P}P
z32Qt|{}G7M2H=xyY-tg7?35$B(Pe4&W2REyYIC#JeoYrpikUeq*6A*Xo5wva4%w_Z
zg3>bU{KG9>3?;r6=7hKBk=mUf6hA`)I|Jbe1p<pT(E~$i{$$A{2{#cGF;nu0PAMhB
zrGinA-9j&w9B9MUmprJtC5ih`7sbad?u!42{j7t`3E+8I0?8&OCRnw_{E8?EqIh^x
zVD8@A*`+@2c&c$t4dz)&5hJ*GmC>CB!=SImE!G#bf<2x#`N{`6tf!bUsf$nVAd_pT
zt6LQ>r{&2v4d0k8QKymp1KO(bZ*0uJWlT7&5kN3X0rX8_aJ48D{*2<R6Y9E_BEO{N
z@bGw`f$aXF@f6`eB{C*0Q3M%qhR4pUWhxj4_}4Dp0S|6_2FS%=4*!^}ayssOB<1a}
z5Agzo({gVP)LNedtV0V6Nd+zJTO9br2W?s9>3|dD45A9zk@KzC68#8kRCEzd!d%kO
z8r%CJJpO$r@lu#2mqz4Iq&*eS%vb@0L~SG(P?b`f?DvO7+8JC&=460^HKid5cf%fa
z1kEmw19#FA59ps{b3r^=adZ>MSF9UC!<IK_(!OSI*2FMxX+q@0?aGHMVKE*v3E=B#
z;j%euYYBjip6efJalRgBf$HwUV35`MX6bUkqd?aw(~se!nzq4=uNF8no)3}5uW7;w
zgqh~u9KH)e^oo4;^31fx!d{FnfXGt&coc~Ml2!{KcYq!4V)Wy>TJ6GOkk##cF5MT%
zqQ_b<-1>EY4e@;kVGiVV_7Mf(Te2bn&Es9#Wr>Qd*cgUDv;3dsqNyfSGamLoBk?5U
z%3O#EuHDc}UL<q8NV+><HNhQgosceZT>mC&Q4l%<on8f6{mgTs=@^i72mf0Ks2a8E
zY=)IzN@zWjA0MP~EbY48R(9hR8-B9WpLD&1s#*6u+Vh&Q8n1SAj(PT+!lPgS3tv$#
z3hX(b#>tAME58a}i}>mu_Y=~tYeUrj7M6>}Yr{HVl#wawb2c5o3nxiNt>*w<<5<4c
zir*+jB_*i4+E@Y8Ep3&vpw3^*vH-<EMhE`%fI|=@Z9+rPW9k%l$cDybO&xHsHL%pZ
z8y2YRMXylnLA5)hI0B)s6VZk9`C~47^2S*&9>&18wDC7dw&FVavj+KL59QwtbM_-h
zlZI`9x+t|fQwB9a0W3+=eC;?GQll}RbG!Aim{df3fkW<62;!6F@>2tH3Fvi6*<94G
z!%WQ@Q3ZXuN2B(>D)Kb@mhpAqr&)2;lqERMGE<khK3c>SjwFR3Yq%s|?HL09uZ$JO
zj(YlJPcjqE#MmI(>s9bUE#x%45IeVe5yF+;xOIwiNZw;0xcLP&pZQ&aZ~7{-DzDc^
zb1X+U=m(QY`{$Y}zWDKgBFW5G^g<Q{yFK0faY4q$466{HYo<G^5<JQM{js6yH-AI^
zq3b);S9M`56Wgr-H?9bo340&l(Xx|Ux&v`NnT>*rCi+6F(ZSe3bD}vH>-LQK_eQ3}
z_%~r~(uaGXHTzgs+pj|njiI?A#jh1@d5bZ)`QhW*|Ce%)m~4R@7IN*a?0yDG3NC~V
zz9FHCe_eNNx584J>DFL$tF_VC4$8m5^B#ac-CC7Ud%psXmlonxw`OQFxKZJSo?!+y
z{R${)S5`g(Vtzf~`$>{ldaR8bze)>fJLhyWx^4i*$^gT}@FC%PcR}TB+PBo&9T|0L
z#}zeqWq>&KrlQ!6^d}!S(V0x45J`3RxY<&r6UtXayL5N!-gfN$m_BnogzyW&4FMvs
zb#mB0t81@mM%GY*;mgxQF$0WP&A&}EYS=dNjO=@OYd+iy#BWcd*IJc^mOo4p&(W59
z1cCv~UV++M#@m7^5DveK_N-Pnl?tMr7^%4aRM-^G4S6H9uL%JEsVzTLXmrYW@n8c7
z1#CG!sKY*^4<R4yWJ@;bI_(^(qix{_c?;Hxi@GCyHEs+Cdt-<%oZT1Fo(MPw{ohCH
zC`W4Lo4**0NDJ=8-)6&Hd+Ib3m`U4?f1Lt9|F0!1@2xF1-PJ!ol&Ib1dHrdTFF&{m
z41Q$b@5miYB=xluzu$}#KM!--?gl+vLJLD8d}aErvroe9HKE@h?sbAHN70$k@=qmR
zYlpjmw%NE_0~77zd7~4${>9(oC%)FzIJX&SCYzT#vO&+GIM7UN8>U&117Ed+;`IL2
z3k(PcpJO8a#97ijUO!r9d*YUq#*AU^f+S$bCB8P#@wwm{X{*glomAd_wl5#KB){q3
zO-k=-+*YWzHnGsdPd>bN^iA!!eefg_85B21(gCcaV5gQEtngFZ^s?<b{?&_u5$w#L
zC8;wfO>H6&Fj0W1dA2WB^d0L)))M-UB(Uuloi?^*mJ4x^!&w6XGvBoDqz6+gN@Sn<
zpW61Gw~D(W`0TBFzey0r5-vOboeJH~eHoKE5dgE3KuP@7@m^$QjE+qnr1e`M_G_Oz
zY`gwGqO;}C3nhFMakEfJ5zRJ|jsz8J2}cRSKtg3n$KD74&i;Rw%V;03+X&q!Z`lOv
zM&|tdvvl$p!?GDX=@flBDUY6vVes2h)_vB}p~MenX({U{wQgaSP01b#@izlZm?R~0
zLH)Mpsnj#!#_sTZWNE?23}a3sF8?<Ql!4aQ;&m12Fr@owz7Xhj!*}LJCR{^^yC|e-
zx=z3+0se#<9X+4;M%g3vS`ip$4STm(@KNwVViss%zLKx@u}Z$thjRN-RZ5m-*GZRb
z=%^c>bYttiMQ)5(P@orB8Rb>TFtnGr#t$pT1jAMRx4%2zmMgDvN()cf<cF1I5K)=S
z-C^CLlm>;)-+JOzrQ?I#npia9);f!1YZ{=Ci?cea__<ofZP*$aUm#qXdXL(T3rvL)
z=d}Gj%*YYigCNw1ulaG)JIJiDcFL>-)L=ZUg}kb^lmfq!s+sVI1RuU5z7xIa^=Xf!
z`jI4<qSWsj!;3>cu4*-VG`ND^lGf3jK;ThCq)(6W$i8%uMX37AxJ4btkGn!&?Py>l
zCg;ndm8p5y;r}WzM6M~FXhJwBdQDwIFSEhk!cu#|E%e3k14DR=y<9>vI0)bev4o=4
zMF}iMNQbbZhWw_(%p-k98KTe8smxYWv(Bt^UNF1Iqu=y#%?wa8`_p&teLjf5d!%W)
z=PDKNt9M}k)y)DvHpLR;jm2;&RbZ~SE&;4Rkcr5S^|3Qk>&sugdS;bnJ?Q`&TYBP3
zDDs>9{Mo3Z`%I8~(oKQGquhtw<ZBZYH)T12c1UhqYidI~Gl9-37i!~p3CRU78oR0^
zN^GXK4BSv)WFl8lB$zo5fL=n7;0zb#8xyG{Sb>|fK?~T;))2mJW_(-UOD0;%PFy0~
zGKGItfJk$K{*_F>h#b;`vHHNSShI9YNdVS@j@a^6es2&9<xlu%gBQ~)cD2e4w!d>4
z&F*8eLQE+9&@_BO&hfn^Pk00y6T|C~qi_flnRIdOjc!j#XznWDwCXFK_FlNVh5hC<
zF^I1hTLXBvfTOd%wh*Jv?t(A@vrH%=@|79rndXYy9D*U2;epHOAcs>3Kl=<`>1v|1
zLqo+!pEDd>B5yk3O^h7B8x9@x9+r_<bnKAc5|I`iP5kh7S7F+jw{6qW=!pEzG_|hZ
zXkJVeG<iOk!q}K2dqBPOmk<#8eaO9@tk3@K_8M?&s>yz&taWv7VLUm_Uz9B<yF2((
zBbzN3X(6Y@R;|@BhK>B>za=W6RK`>KR1=1o#9`}p)Xh9CO6vQp(4IneSUuTa*+<~<
z9k(qUyUpgT|KDY)@PvE~$0I#X_(D+LHBRgef|c!gMFuiha0{$M;B?`gjG#9c5pWZy
z3^03!c-2%(xpwEbf+X&DSTlDN@^LJTqi`j$-!t0}`$Ycp-ixv0r|{GQ@4e&reHT1U
zR8-9!YE(N#(5EM?toFs`kRbHVKKS-v`mQ@{&voQjc2)g`6-MV0yOl~O%bgcLlh}j@
z#omg-MINjEX8z+@cXuiRNF@F(N1**zjn{U<P$>De(4OnHYUOB-5uc8gp@RC41D7to
zdj2D69+_2Zibg`EU^hy_M#81<t3xoS(md9@pHP=$V5aQ*zPP$;kHw0L{;DICF{`3q
z!LQ^Sr;(e^QZ;ODT6E$>QBFV}j{#ZRbD@u09M@bxfBAYaccFw`gPOGv)(D`7nl0aT
zVio69BV)yazB`&jhENjHjlH=jwqQj`Dv%s;ux}<>xzWYJ$bRel;^&@sYebje=#6A5
zf-kkbCBSG-q2SAd+`LNl5sar|?~gAfl%l6eiuI6em7cAae0noBTY#RIkV~=UMDu-J
z+4gXZFhS%kp>pp4i)H0-lp6@7A~3hoFp>0!rsd$_6R7WAN}P1D?rN0$05O-k35qtE
z;q<&#PA1_Z;;~(tu;xTVK3u$ZE397Cy7|EC2nY-HdV!q3#MrS^UiLA;T}m#@E$+1u
ztQcsUWgUM7IUB}IetcjLY)|TtinUYwgg$VyJf^J8KMU+0+TB5%fWC6!B3OrCTWTnV
ztTpV~;;$l#%dvksg#tnyv>G2!L%W(9zTOUBAQ3m#UKJ=`oK_?{ZGo@ico{D&?i~}X
z_!v?rMVnp^%xq{jx9xj%#<kE}bo7=6N}8B}&sv#$r)fk97rP}f!&^l|?9<MN>ytye
zg7T8$VwOh5iH-t-EX2_>|BQugkBzG@R2Ig)2GBiLB1r!J9%1*LalP;<{`}adliM88
z%)3^8{!qsj)T?JkI8UI`r?(yPpVdn3{9<U+!2Xx2OEB9QNVm%QeW)lqv8+cDZy4_h
zD<#{l+6@B~0U<JHA2sa-&b)_AhoQQ|KDyC5V0@da*)w|pobycin$M!*H;KEJ(PWv~
z9@s*(MCy<CsfI@XhIT6DnFKTJb$xQvxZ~bGz!qU{CC{GM)VGFlMDAwK`~l1k)upG3
zw~n2O0DBlNOccsy&!PdIxY<P*+5sNE%blN&eSVOoY?fw=Z^Md92n^9lbokpxJ^)@k
zFam}>urCo(htCj=rCI8}6*U=#uzj81<3XW0G@q9OC$rPic<R;XF!vjzx9=8*AVxIR
ze<AvL#mth#)$<juw4nYr#Nwu4vq55z=`XHI(6eb)gDuF}?c;ZMi-A=&8tZXT435!(
zL4x@qu@_g__Heernc>^8RGif4{0%e<OoYe_lnnk+@eCba=5L<iY;wMo434W3smR2(
z`-nPK+9h({m*w;bz9-lv>11N$a5COSb*1M?yP%me4GDi!JU8kj@H;E)-MY;WpJo>f
z!iYqj7UWfym`pZ{?g$J0<UXJNH%#@lx%3WMahW?X`m`BSB{q2IQbU#>rrdB3sGqic
zRutL9pNBmS5WT;v*9~e`W4*;FBJ!Ram{FDgANh6O1dL3N2pFRoj^2v~sZlyXknj-U
z%GR|n_D#s=6Ht1)Cx7Y%2da*5k*K$&y3h9O@6OgR+fG>JBFxX@D5edd<&+r>&n7w&
z_B@SFy)uQ0VwO0T9tm}?CSWAPESbovb6pjKi$e6KuFEHN!c@OUbxKpYuKPupdaTf#
zxuM`9dy)2svIK&jNaG`n>jQH%4Kv-#B{N*Vh!6sXmIe!tWQ3<~qX?10o~LUuUY<HC
zx$>R14WAeSrmdLn=Nj)2O0hjy^=jPDU$Lk2Fw$U)bQBv4q;t$@xB#)5sPg446}u><
zneI1&p(+nyx~Xco$k=*Yu_mRU!SwjpXlk4gKERreUa>zU|9FGw)sZDTA$dlv-7VE2
zy>2AbcaY~qKp6Eo7Ix8ntY=O!eM9HV`r%Mp+<C=8v~AK2g)L@~_Vpku#aayo1;q{I
z=cnIwvi$ioJ{s+iZoojYfUDKvW#&0LEb?pVKvO#QoH}?&ElF3hk7VVp7sLX>17G^E
z^AAyJB)sP2(FBW>Nd){uOM#NMuefSu9X<X`gD%SO^jW8t9*Hnx)p)t;6&ZuwdN6}o
z5^+J)e;j?e42XztT@MgQ1lOCP1)){FiMTIhQmrLW`}AHz$AM0s+H3dQ0%St3tRDf%
zb!v^AcbFWu>DN9}+W{70V+4>dW%pun&|8EhYCNHh9K8>s8OJxhy;+8n+cSofA4Sd+
z<SZ1|5K$2mowg%$sTcmyu0b{bM#ev$i2OUw?!g!2EE8vUc5vz0<;wwfhKa-Wt{@^s
zJwhy`hyh@g0*U7+#``GJM9jGL<H{Tp^2&oB)=#6n#fv9%iVte3@i6ZnzDQF(<~s6+
z2;^=R5S*W>#6{9I+KajW1})Rx1QoX;Rp5Edc<Do@$(JR(55~Adtnm1qBlOcKs?nB@
z(>5y5nk$<HMs2?-EcQrfG&p-)zJ;oF9ajD%G1o5(%#+rn-<%9*`PMCwD63?}Us(Gs
ze5!boVnqSTo_HcM5X=9}6-oB|<xh=%vgfGepB1z3yE|rb4iiO-2lvS;KyLU8dL3OV
zo+kF4o06f~r)%mbqAx?7iaHxzYmw#H`hPn`=fVQ*#j#k#<LRX8O146jakk*v3SMA8
z^vFxS0JI02M=HM>_u6ACD8Q#!xM=sGplCJ5BkE}9>rfhs;2({UjN&=t7pV$UrAg5N
zG}VTJQ(ZZ)^5%g3q&_19Yc#NgqLUU+SE_sWB3um3h01`%6iyJVL%<mf^;7vQ|C79_
zhM+!gZDH>&IYYfUpxgodd2#1MG_?N9o&kFnu#3sj_@tntDcpnD6+EBi!=f-{`31$+
z%l)G{Y5nxY@GbbfJRg*JEz<_C)~}pAUa3_gspGOF1~}#1Ckw*L|5Qd}WSY{}X!NFF
z5i6*9nSIefznZVuvI*Md6heGeoUIp&c&yF4*7NJyFE|}q+B?tYaGjq}=={F^4q?0t
zWL!2UKrRpIl4amPlU?$08*q$+s5i$y*N;iuaE<q*s~Zg@gK>(f@RE+}K#+>f^&vAQ
zXkr3v;I*GA@@~PoO4+5<W7-q`#GY4qlo9lXrrYt^NMt`qTXa+;-&Xs9eUvtu^PnZ=
zNzM6&*Q!WdJQ*XC3zGql>P@DwaVi_&^twZ}{daiIj|WpzfhC~B)PsyS`IY^#N6XM`
zk%5NCHnY!CsSwYR%4$aaCvE8LDLG9NJVcr)NHuc_Oyd$7oTd<7eZAksH&?b2Kg1|B
zcS%Q@;u?gL1-VEC*^nK~UGOMDY9LUTv3nszB8+9J!JEEYYp9qsFk|P!Byt2)RP}Jb
z5B)_kDezP><*bnd?Qusi8;P1m;dTjM^9%CT7Ru?2ra2hj2-2Ncn>66ZVtQS4q&Ula
zjVpnFcocHeIkFT^Lg8Mq99zfsB32o!<--<y!lvjJuK5<ksf6@ZM;e$hD&A&xAoY;W
zpZUX@e6`)#WJAUiY1PnSq~!pEB%89nr6aX?uXH3Pc?nc)xo=p(Ecj<_U%uX{DZ|VQ
z!`tRuC+N~iIhAC`VsoIgQWTE`f_~XhU}Q9p*zcJz?8McsVn;yvwpyTAgo-t3g+_{K
zj+2%jp=#aB7(b$tRkwE~{4hEz7#%jexl?lKQ_w3+<KiIzx7Qxc3AzMeY#0M$Czyv)
zIc>iXW*44gbd^(|9O3X)H8+xn(umX8-h9=gFXmGn55O8grsyRTZ_H9IVoF$oM$ZV*
zC_gbNgnQnG-S_;}ZFq**zKRcmj!5T3@4~dm=USsuYEVrij*;@!<AZ2!OM8%$_k=Lh
z-a%CKiT)0GP5whOwtx?a84s9B3}DviA^1qwOg7`FY9gfS6yRXn{lzFYt{&x);MEE!
zAh<NwDLS5wLhXC;rcpIljhU{DfC@a(^?{I@2%|*GAzzhwhQ+;$QV-YQPT(;})-2X5
zu6jf1is|>^z~{}6w5o~En{PJ@ZhgNYoj?8)`H#h@8#!?4B3FRMdemS8&I<9x+TZx`
zL<hd^cUE@1U7v(uyNIcVx>xjxC`)hg!6$ypf)JFCue;Cp^^P?byYQ`}OLmzmQR|ro
zN=!XOHQ<Q8yc)UOVToZT{b68i(Y1+B-=VEqIYxfp7{f|n(~#t_i{zVBrovy0psKVR
z<n6czQLvqmMF1U+R01HYAN0cFSH%x-!-sMsnEI;0eK=U;8F*L$RlgZfzoCstAO+XQ
z0pG1ev*5)|ImKi_-6$CPwLv?A$3f;MzVWp%koQl?<Po*P@xst%im|7t9s9__&>)Fl
zD&Q;0&B%TmK34{dlvJ^f%(A<F5G*gM+C>Wi!olkw^S8U(m*NGV8Ek*CxUM`D-7EAO
zaa~SAXrA2e_K%zc3yQ&Uv6-`eu-L;uNeZ$>URBFW?0%v62?PdNzEp966<`6pHRS_P
zvcs?*p{|JTeFUk5w4#0oL1qBy4kK$3%M&nB-S_0xJ?a8^7qjWh4ha;moBzEOVwV6c
zRZr9}fXktKN+{Jpw4hXI^npbrwsjRWDm*jJXhR4cb<$gyFEEMFxP?Pert%E2WkHG%
zIVg(!>hpJ7g=?e~uBf)PE=300zk*b(bOL{*!F9)Hav+w<QX99(QvWlhP^iWHG%xS+
zY1%rt3N^mm=N_eMVCukAY8^7o;x$Zc6O^k7NG*Oict;W|IKk}Mo&CF2=v-T=KYwCg
z1io?#%Grg|mXVJDvI(z2$xukdJ8CO15I9~`65le@yN6v&auVxtsDB^LI2B=xA#d?r
z4&r-1z7Zs}Y_1mTChH5)C3Y@Jha8JFkSN&MOl#=t-ME<Qxir7EXCxd-8zCZa$$5wZ
z)YQLJ|Ha}~BUx?pWcdWkb5bBInk9MA`WHu-qA4U!)~@W2hJN`?lJP3~{uAVcMZm>6
z{seX@jUvmi^>vqfXkD=9pm}r7pYr90l(3oJ3c~yyYH^V@=PHq=71;c-kUF7rfBa91
zfB%Q@^O=o}W4oOnwri`>zUI*$;1~OX{!nbV$9fgS7gqRou{o#p&sl9J+eoBbuO`mK
z_j91U`_fcToVCFYJ;j1T60)6&owfJZD8qzhQ|+St{%ToRGS3n5W#bz$HVyQVuBaDK
z_IcWQ)lx>%)DMRdtat)WXb%Q>VhjoiQ3_6IDzC>j*<$~nFGaSUO=EKaN>;(DI;#};
zuk@o49{2Byrk9E|j*rgdkuaxwBe<F{Chz@-7D24A`IxXW2d7KewJyQFV~~5U?qHAK
zF{V%yKcvg}JYu4sn8m>UO$Z2poe6>aO=OPcg@2t)^AUbXOXkErZi7dKo{RcrA9Kj3
zIQ<N36m2F)JVF2{z)H&K=0L_AH2JLymPKkE2XF2(T5o5f5?_x4_Wr{?U-pNP7@o{_
z@Su;wit7?jWo0Kn1MEsKEpO)&;^t)T1Mv=4@2639)|%!a;xc9@*k{p-)8zobi<Pb!
z`|TxE6CoKY2FKkQg8F`zuw&)J`v;3*7*_71k!VW+_jMRRNE#O<Yr=>7@M4peG0(z2
zL-_E1XX6qJ7I;mUAA=zZ!ZXPxV1ndBjjHb=N}(afLn!h=gZ9;l*Zf`p56av!&t42Y
zpCsyF?2xs8y1Ds#Q^w5e`*l<)PdWO8{XZ&^|6z{hy^YBb@pS#rAR(CD_Of9b)OG-N
z@(1oMMu)OG>2m~E^h*6He<04U*!<wp{M3~H=TK5JvkFx_z1MyO-;#~Rh?u)3wz=Sl
zWiZe<coFSjHdM5P2kKK3`P88&oXaQC?;0ebGx|8i5N`?%E?B;)=TU#17-N-^qL6}M
zZXUOBGX}xog?=q>EtfR6+#O1`q*oaOGowyl4@drDwicD=+d2W|eDNbPts((WIn#0+
z#3ym#`)S18v#v&31t+UfQrVEZR2@IU*}TeXrPfvKrtdZE$btmkeAyYDsy}_Q*}#Cn
z%E#izstxsb@(4)}XNR+CA}NT$V5*{@vfc_!O}Pb2Qsxi7Bz-@RG0KIaIrWqSf-|&a
z*asI;#7alb>bR*Gm1h)05lSRx%a99{?a*95p%>)-f1pVfV2_f9&}54KysMJeN0zg-
z{Xzys%*U92uYWb;&t<J0pp%Ld>i^_UYHnafbz|0aTTNT0HAeEn(<DC-yT<3YC1P1K
z7&dBLuuK9ASjx9?j(!B7?wP#I5XZh>51MM(OO@v8wtl-f9%B<mP396K3vg#`zIK}F
z#ugI|s;?%D{?+g)zUg|>sncdU!Rc4oaCK9$N-U0N;@@4!@`GV}Srl5zVRj)c(o*Em
zy6?UA0_#J5?ho#a_N%F=F6}{P9s$s=cWq!HstUs40NZO6lw^|!v+WdD_n{KM@#*El
zca6`jOju&qnw|7|9&A$@TBulBVQaWp*9;EyNT?yZHhm51e<&C>&NMd)DeFRKfHc>I
zaD8%k?OTaxtfuK94rt2XA4zE2(aa-aUPj45Ag~xK!8fnxYtrQe8cxb2Qe@vw0*5ub
zJ-YxgK%ZpIwZC`<MFgasx=AY_bRlMm=o7yLL0XFnpUnysxqTm^p<x;VZK81Kw*-xa
zezM}3<riT6E5-ws%t^8|qwit`p&Co6niK00bIRm!jok2cWG$MaLCC}<5S0{<i=_d4
zBm-G>f(Bv)<cnwj%T(HotD{65J%(cH^D{gSkV`1Ux=gk;27_+J6VBHl)^`#Yq~*4i
ziF=bFVj_z}WX54_-f1w^D@+M5b41iBf>dWRwO5O*@@LPy^V@JrId$6F_c%Kto8gp4
z2VEx%OtlT0f6T}*#ZBaO8ORaiAX$(b2}Txj{9?3g)@$WYm2oJzRG4Aey77B0yyhGL
zRH5PX<zZlFIyLc_a4J@IGJ_vtQ*43v{1|ptzWo0=%iRZ|5@j~P{J~e=2}CVzEid?5
zig49tWTfm3O$#5x&o6H8Tk?TD;`Wj5I8nUmNEPIYOwLm3HM8KQTnGda5M)8atg1kj
zG939qe6b?XSoEip1OYseQ*11e@YeEEwOB49(~}8mH!!7N2c#>lwmw@TX!W}oQEr-f
z_o7v{GZL(vQC)Ht*~3Q2B_B|!o4$xX6(8n!Df^@*?U4EWA_}e~V!Nb|VGg!ze8+qA
zXMy1=|NPOiWB93AV~28^oJSOI$l|0)%5twgJ(X46X|i#W*Z_!)C;xO~!x^xF-(1Q)
zE53D^)Ry7zlT@M$!)l?FpC;lSQ6(iT%#lFzri-DcGv{RDNS@~s*PdnrhcJ|Bpo?W2
zgH5gzRHl2@0IRo8UInMguKT{uD@2nGugDkmS8YtUv&Jcw-`a?8IA*Q=nvWQ90;J<;
z*&Empp~I&CyBJv53KtKaJ2KWJKfo>z9r0|y#MN(~#ndUWSUYn6Z>P{dMj`eCF!c$Y
z$~buNM0i>LOD-5UAFEv_#ybqJpt%#Jc#aQ1Z7$CXU&H3$lH^NzRo>)?mh#bT8zAuL
z9}1qUtQ7^LeCRm^gJZ>0%hwRlpMlH-OiVyVHGu16*WvBsO7kZTiE&*1^{C91Q#4rQ
z9#ZgP@o|O-7)uu2Xpkg}pJKIL%NFgrnE5ggW}LS$PlmT7*_Tmej6F#a3w?PbFUfo|
zY%2O8kYC^qJD){D-T2dNxQF<sOhXsWbP{Pg!r-e%A(Frn*Z$5J&Trv{{+h`N;96k<
z2G4PT!Us5loHplZZpJO4T!83os1KS1YeCvK=xP=;ly4znqdGQ@#?`fy2;d|{$X1dJ
zSbFlOo3%gz(|e^ry4ml_Qa~!^aJaYi@SUI-Tr5RY<TE_Umg!pm1l2bp1u2SE>r(Q@
z!}?GV<{}2mI<B0ug>$>vfOO~sc!(CvG`;RS&p)<{;Rk!yIJ*?B@E;Gpe9Wc$sbA%e
zr!s!bnD@h2Sn<#aaPG#&Nltj6_O_dxc`Vc?kZi2rBO3ae@%-WF@jeOd6!_d~Ip2*l
z$lQU}!9V4lieEyYqQo7|W#N$fwH{HC+kjNT>d|kP33s9%GF7^oW@0`Hphxu8zQLj^
zQHlI&tdacsMa&8g8h7%PtgULOBfXc+R!J@(_7_n#->6;eH`ls9l~~j_s_1oSN+{;j
zGclh;sCIUX&nD+;lmiVE^jxFtJv4c))@GfRi`r!B&{B3huO8JKeR{&g{pd?hN_BRx
zx%aljB}iU$C5J{JKjFeE0CS<TnFnPO>{k1TO^s3?+uwMAW>QD`D72>zhyPY!+jryO
z_21vc)c$(pGoV;7i+o~<jlJ|6Z}7P&9;dDweJ)9MVMZP44)Im#HDS=JCf(!>-x1`l
z>xXfRwgwNWi`m^@GcBNqHb=rXj&!9(f*c|db*a~?afq7N$jTlm2K*eGCzJQ~&kHaX
zj0x1#M7%idZ+P4N*|vX<OOiEYz?s9y_^5^kiqlBHKYdi(@2L?I>Z6iHf#9b|{L6y_
z4?Y3jwKSrcgmX=!6w`Q=R>8x3_#OEI{c@}^ez>E&LawS--gxKcT3T*G<`s^14?mV~
z(Tqj%9N0m8XPP1E0J@A3gEpPW1XEuA^$>*gs%Q1ucTUVg<}yBLLpXgZ?knNM+p+e1
z9?4TlDghV6eEF1y#TrQmJeHvF0zE7&ZjyoDt>GN+Ow~;KUkaGd^oH}3>G*r(B{Uy(
z%9*?Z2Pi*T?>TcH@!HYCWk6^~V^ken=9l)*A(%O$f%mo$0lzFPMxLoHQEsZxZ+Y3&
zPx^<)lYCO`XGCrlme!Adh)~n|r@cm2hlfA0rGpTB(yeZ<QEJjF-PLA7zOpy{VcHEV
zGch-=qSO9>ZkW1=-MXRNgc@|rJ+|pg^rMMrL-JSYrmdt|vKeVZs<RmEDxvI{Jow=o
z`NzU25iDW*0z1V?9lS>w-{2_-$yX~05g=(<>>dAvk)k+&`#m+7&hGn=hx@L5%e7p$
z!*KgZrn0U0SI8$K^%LKh*%>am`Yya?D#wm)>k$I)gX_TXfm+)k4hO+hui`qFu(Q!I
z*`p3I(xIO?ON5vy18T=cqd$dRZC*Y`waBco_?b(9CS;4YU2e9Mgj7tAVZwMJMz!G_
zYt}&!($J=j9{;Ji^Mv;gtIz~8#gVe_<%E4b4H3}p647XxJvbPY!7$-ak7Dv-ffB5@
zY=LfAL5u1A{iNZDwz`*$lq@~bw9$beDrS(elC9Iw$IO6+nFceL@o<v@ZZqXf;oQZT
zRX7c(J@lMWY1`9ZP>M=GPE$q}h%l^5qZT%XP<~=-8gpVN?M8s!L)0sxD_5mb>cG~;
z66xAmj8rvJ4a)sqFeD<nU;a13DS}|Kcb_E`wx&8>@XxH|?wP7OVL4<2VQ3efnjM24
z|4MA`hLq;qXe}!*#-VKFtBv}}O3~s^xjJ${O9HEq6<M^QB}X<~x)o(Bn#_<dC4tZf
z&O7=e5IBZ|7|Hz8hJ~I(Ze?ce-f*ZeYTgahig{<=jO6Q1A5ydN&D=jx*s}zMo((u7
zq1vuL_7}RE5fDKYwOs?H0WoSSzI&9_h_D8O%e#Ml=dTT{w_B$soX@qJvFv<!OX>gv
zk58lDc%K$4Eo%u5M~c@>%=0w%;yzNP>^$PeOqsHWy7FTJBnTnHcwkWMkce^zyQcjE
zbj^ZAejnoV)w4UgKtT2eTkfnKDE%eOndq2?ZslzwyO+jn<;@)GNQm*KB)pgAIg0^(
zJRR(~^!L`~41MqX<6Ki4)ZHbJaSYH>uElt+`3{78RpxW9-!LwdSBtUtE$P-PxxNsr
z&^#>ibPr<kGv*HI*2OfK5?b~1OhnpcW9JR(4*NIg?7T00NX=7`22>Jqwl8@SPEq5L
z7xNlGx1W!3I$`rwhACb{+3MK!OwG7>iost@g(|3-X!s!K)<|aR(TJ3(4}nT{cS|wv
z)^<az6h8j%^tIiB=Ol#Rz~R(j2h1+#;q@@gg}+CEGZ#?agw;maKI4E9-%@SJkBH)$
z43>+qnr_YSHpp6D9>qWTt$p^L1;h{;*X?fmVBp{EpCSJ5od1RPI+3h9hxqIf<L@Rl
zi?~!on85G8!5m`%V<;S<mX<5h;uD&}Ji!i-E|kj_7v4*DfeBEhfZV<NnD{bw^pu8=
z%@0Bhw0uVPU8pt4j3We<xBdZHhqV`_ZOqbimnj9d(pKIt$DHwYLKk52dlj;d7_{qx
zaV@t|xxON#x_BTPYcm@Q65s4#CV2m``y5OYaU)ywfCWGqEb}Hyr?$n1SO?8I*L7Rl
zxTv1oKu{~$#3uEuUHm>i`+XyyJWHcfrc~P^;ANkkFZv}z{vNwNEKZ%YiKY}`JbH5y
zf|n2u%T~Q0ZjPRykijLnqiZTn7d^AXrY;X3J3m)F*h?OLd7m$e*j1e5xc>kHoM!EY
zu;y`o{10H0iv4E0F{#X&WUy^2bDc+rFlNS+w8&_U&!{#FK~+gdeN+1v9<GJ|Krl;;
zXfmKvV`>o-CQ}p>K{4wt+L5@6&@R9x&z7W8;|_gOmWp;sruN?&lfZBidbrIHJO#QT
z@r2c}IC^I>jDmC;^ru>?<T|qaz9#=$H6U;qjVv~OB>L~TIO;V?s2|aAY3QQ<miKpd
zZhj`%wXU%qvlv3WqTYsJ5Zle7!&%mRORJSPpWIr<Ow0$jG^eihw}J73kMS4|=pSQ+
zgU5erB=E#ZdU*ymd#59M_qj&@7AiL5;R{b@*26?OMGbD~M<$(<_y)k#iJ1V+tbRCk
zlU0XFvRP?BRN_*(zY!tJt4~UzbmCh6M#)#ve(wz08AR7Fw7e*b)Rt+a?$t{%BE$1v
z$%1k8=J8)?0RMY}{N*a#aGBuCNETUsB~h8eSu9>U%4b*nF&OFTOW1;5810tlQe0wV
z8`gTNi^7DP+SjTpDSJRxvHxcyP4QNidNVz1qD_gQw58AJ-Jtqr=5LX~9pTZPfwUXL
z4&VDUlfL|!u9Z$ohrUdWf2_EL>>}0nQ|Y8?26RDVpu0n4RlPW5lZ%x+uYqK6`a~{b
ze1^-M?poMzVa{Awhq+SE63F^o<oH{Ve<iNsjyR9{d;M~O5@6bCr(j?fa273yEl}^*
zbzteLGNi%yML@2RValQSvlW&UZ5=NaZtb}Jo9>2DUSRia$EaDk3@?7Jzl7TJRLLhl
z*Vm~hIXA>YksMco$0fvqA%{8LG{a7rE#sB;kurkUqp+_l*pdY@m*TTsC{a1iEg|2B
z_EZJ?Hc#>e`+)YsAGTQ<5o)K)ThMYHV=G{elQ90?JYattz&A)p342`&Wgm{di*%^9
z!#cJM4p=<A1{t+W83ZiGtX>xNy1_7L7fN?~V?K;G<77ffe>n@`kwdjh6h^PJJmx)R
zTCi;qB(y$V61AO#(evh+%Jc=znn<Z9No~64H{yYLLIPAPW{@;5)iU)$8Eb-ffqd7}
zZC^Tn;|yR)Lh_$QO-Ms56~oPy+VvQp@NCAAQ+DRw9nji+qfF&h=r~%;3ODiQfm&%G
zU(7}Bz5~JWJdcHcrNUU19WG-2rp60pVKQM&>H+Do5~Z6uUr1~OnpvwAYBtwsv>%;&
z9&gqw0DxXfq`Gz-TEA<KBbUXMhVHdo<hwhXp0zc}|Exf@Kdpi~maGP(1P;-@OvjSw
zw^*yhY&t?X_=k8i!BkDg(h`Wgm*ln8@otGWb4JZyjEnNEKo(f1V}T9MtJrV6NQ-Sl
zfY+3Pz+Irt+>F@ej@Ms;jUP!mt9F2jI{y7DLq{L`aL8{{+v?3v<)Y`KnbBp>3g0~g
z^0XTH3q92$_GIESdFfLn)~99ZXe=N$DhdPpd;Qf^pD1qWBal+_@s+P(9vTNjbsv(Z
zbrHtc<^B#Swby+_SrA4lfqPR1bs0eYu=IXJNnes7CzL#p>bXHW>P&`m3aSN|tS{E=
zctebMTB_ebqnJ{ZIdlXDzKbH7VQHv*^UjZxGz-_iAKKq^ZiieuO&``n>AZO)A9wPA
zzE#NDMKkcV-#2@1xk&vRF;{)~Ps_VLet4Zr$uDd^tQ5?OrB}UVAKE&rb4-#w>%Z=6
z8F{D2ayffhTZa0eshj*WCLzG+T8Kvg%Hnc8drJ4AVLA$80h0PhueU%0PA{uTIUYjE
zAK9OC*p_Hru)(cn4GG4n_WX<ty79<ZcKdTp+haVhWm}@<R6MT{V!SE-x!)cc^2|ho
z)Jsb@$E!#QtyXy?zog`@74BIU`k~}9idGe-IdpHl$+nl|&pg?m6}tk?ANO64?j#+q
zP&vtSe#u<O0tpDhp?(o1Uvy^n=OxY<gf}p=J3~KB6F~<b!jZB2vd(jQKVA@P5)9(I
zOW)GZ*869kd%wGcfB>a8-Z#nU#h+jLI*}>w?C|Owdc$9@*-Qa{^k=5Z=Y<-t2~1TJ
zyywI4{l(6qwE6hwPzT_vvT*lL%*zEz>~O=H^SbrhWTh~NJMZRnnn%n8lV-nI1TUXa
zirC3d>)?W9ucT3PozUb}M1A%2<xqk%_HiuJ9N!hM8;A9m^IYO|^1GIbi|E+LE9rBj
z{lvQ<*<M&;ZxJ&up{6zY#(ug^_t;x1$RTIjLDy6pn1JE6;Nt+q<Gd@)hwz}5A78!5
z%^a-&g0l~?z14cCK;BDAEY&!vECC|;`>lwV+%fqsm3(4?nBe-l{W@~(myY(FIEDr#
zdd+rHH6%}@Qx=fz`+G-+t@CzsJ<pSN@m+~?ITt)D7^{}mdAZ!4@U|SsuwIJ0Zz1*a
z9uGAG)$ZckZ3#e#i@-4rQg>U^9Dt$&Yv;Cq6<p1!#u|zyB-Y>H)!*XP-}#C92hAz0
zC+~-xwaR6WNA!IS<)mLW>b~}?toDyKmI#L$yB+>$NF!Hl7ZlO<@r-8P-}(0}vMG^G
zHL~qr$N5@Jbc5tqX*S^`M1L(~rKJe9merQZgKw2g_DlheOTq{9)h2Xw`b5NzwulNm
zAJ*5a^n(<})U1Klay`@BaH2{gvAO9*2>lyENQE9d8&VtnGY3W8-Tfnyu)K2bma1EZ
zpMPSsY#Xwvui64;K#x>4pX*RVk(}RaSv5&W8`w%fZGx60AZbI_hEKlja|br}wT>*_
zH*r6*UAqA<IM{YyXsJlwFbS$g#HNkC_i`Q`tbwEP%T)3bhL2?6g#~K`rg@b0>Z(k;
zx$Rm6<I!|kuG`ZKb(3pATc<Z-bEiAg(*@T1@6TTPhwxAEls})uJ^B=Gc2k}ve9Nkl
z!=zV91*N`ee~7G8RUr!iy9Bbi<H#x-lF44iHYUJ6YK>}B>PXTsQ{(9LK(k?W`=*fN
zXTK3Gm}xbEvr|-ff?R4bb&kW-CaR)G@2{hkBRb=-91a5h#+;M~GYm~s3slxT9&~oI
z3l9iAX~s)l=eo)a2bXW6Qcf;N{wv9{t&ib}l6LaRzx);P<IR_k1$yX8lY3=17^L^O
z#PI<BouqJczn8(9!B{?6aF?jKUC9TM>P>f-UWTu7bczp&@#!jj^KyN4$^{{nN!Iy~
zKwljxMeHlux0A4NGZD%CjCUE7b@GDR6XSI>LSxJwO7v}L^rd-Q>`91OLN>|Sq!qO8
zQhoejs!WGF(r+$d;e`T{h=(ZC;*hW5+n)eQq6PA;78LYB*YF9>sW>7%2`V{sN*HD(
zTiHS~BDJpv0|?jyt$&|(BO5`3T}b65<f_-qmz2Zs$vaSAKO6zNB(F#GF}rJ>*alSH
z_(R_7Q&wktosQ6*%ac6n;EC>XV|AL}qz>gxC{n(^MB$(2_KJmLsK347P$jU}sTBPm
zvfeT%kD%KYPH=bU!QCOayCq0)2n2U`hr!)l9^Bm_xVvkR5InfMU*2=hcfP87t9I8^
z&yTL@X{qkL_F5YNsc;=G>7O=d>2FC-7Zb)YnKz6LtZGnGS1O&|Ct*9N289)nOCXlP
z8G8sa(V`gF2^NdWF0TmwW^?(equV^(DE}AKyh<=%Sv%=EV(m=O9<CfS5^M3InvvKo
z?AtOoS!y$A@N<Qp%Y*bO7AFJ!J>A>YFmKF(mOMsWRQEd&Vi9Jga3W+rLS;e#^$)L{
z(}F-^;>W_4ss!Ci)ytb51+pJa?KV+sRW2a|F>0cmZ2dpRVq*?;o}F!Z^KBWizKz5=
zTqQlB9eAO+rm`-X<PCm10{%X>-{4)^$9?NZim4P~ayX3HF98E5xK|R5L?{vxFcI$e
ze_2)uC{qo9xM(;uXQRDFeY0td6YH<FO1EYhzP(er615Fx@LXzMsOOU`tE$m$zpR(&
z2_!v&f5iD5!ac=RFA$8PKh3d0ghbVIh7>sVpb+2-i>`zP3`ZLzF=fJsg)paZ-b6FU
zj72QZB+q`~o=X0#K}_3_CIU4N)jqPNCc(RIL<_|U?5kq(t~r>BmQH_}DzSWCdgpDa
z9&2?`Q;2+_bk1P;qxtWTW|otY%M_D}qiuRZ4yW8OiZzMK!Ewz-M_r|h$xRmaXwS}8
zm~G7;|0$<{dCYD&ImPAx)oeFYtyuW;G{Jph92Jj$91*I-pBO%Il%9P}8N+1ZAfg%H
z@Dn0f0hnAn_3pU+O3qG8l)riHw`ctuO9a&w)@@&jvu^t)xb2aQ8^u_lImrb+2o#H+
zup)2AoiO_ri-NvTaI9~WLJ6N0cLv7GGamD9ohW5^l%neR$KEihV1Sqjv(gD4`mi6y
zuzzhLco&@GFCkbI=6^FQ)8a2QT=nFN0pS;Z0+RHA_f$O?3I!MnU6^)ppEAl(mVnvF
zFnta^DBk|FH1?AiT!@YFG2ox=CZfhBgT`h6!-dV8pm01FEOVrhr$5@$;G~2vu53!s
zij2G{w`P9TrJvu^UR3#niqJ^;Dj=dy1P}F=+}n!#X79Tg>#X)ws_g2x`RJ>0S2Y(b
zpo*6g0qZ}~k^aJz5*2aww-)y9E)b8>7r62-h0p1~F+`b<<dtLj$J+TIAjjg$+L<=6
zC4_!#Xw=Ub3~J5FBV;gOTH#bZxodHr<hHhdb~85Fupj&E!3MiKi0Cg+|8l1vuu`M?
z)hZ_IUKPCi@pGvXL2!6Zr1}&7er&J+#L&LKUmYaG5T)%tDtQG%zYL>64bEu%CG<LR
z*PL{e``4(x>FBSD&6}9=C>T+^GOW6A@CkeO{a$QhrE^I$4*DMr`Lmg2fSig)8**O4
zXLv{S<P2TTU#iKBB42_Xusnvu>N~Hx+L&FT+0cXtA0zh(35G#!xK0PU9cUkFsN*#x
zPsQr~e_Ve<^ATK*6PUSyoLq<5LemF9rd-eQIU^a6p@WnGx3hNK_=K1{9An#ch4EGE
zo8%=KbCN|Y^;xnsE=qGp`7a%By!W*_xSR#E!ELnVgB5f9Uf%guShva1P9N!SvyT@c
zEpgW++lO)%(LFLGf1?_Zu#5xiQlU$opbk4Dfu3ryOpd)#RcLti6bqN4)fEwOY?w@r
zzFb3Az66H^-q*4La2p+uzfB*+fND9P361(f#oBiD0+-#|wr;ZJU8j&Clx*U6*h&@M
zpS^|kO3>fyT&rSJRLk*b-8_}LYEX%&Gx#}CT^2cs&&stqOuqN|6p#QTlhF-uqkq5x
zi?TR?ZADeps`?R^hRu9cG?Si&ZIi<v(bqY_69gxYWKy-};*)-qkKA34WGWedbfN!p
z;<hq0BZGC<lkNF4ZHxXE0teUR*?Q)56pfK!%$qc)0OFj`^dS^ef<)GRY2k4OF5gM^
zSaP9EyjPf?=XGw+!@a<X<WR4*BPi;G=b&VDqBV4HNB?enM_(!?&}-dFZ@nreTHh4*
z{p>}Ya#6GH_fV5$)i4oWh_!&uLwWhJ^?2`sD;{yEYWS$`nhdg3T{(g4>kvNm0;wkm
zJ7cG+Mpb@rPP!e*=d8M;us3U3{kt?y{pA+{?tdp6MpJKsLes#TpsW3A+JGv{i_S02
zwc9aTOtGk217oMfW^;?lPii*tMxpLP9E46Y))S%)yG-X1*&KQg5*lksw^;~8xfnc;
z6$4#|s(<`mC&f|2eb)5TcCmG#7Js^PTt<`Kb{7fdx33)irJPi%5edoUFCH_(ppku0
zXcLvQNCbDjx)uSlLPuIPtseradS|YCZ6{@2ePrWop^U?zdXUqIqc?FqBgj}QPUfP<
zmm6J7JeWLE`h}#82@kqu(KG@@aml38aS$rO`!ewo#UK8>a!}6&<yl%zy2xx<*!a|^
z34m(#7I1$i)Ur|0HH^B3dD2p;Vf$*S){pT*tloC|nHoUCp7PeVoxR?-bTb!SxDU=y
z++?tcXyUVt=P!&k7iw=Ixkyu9vW)A0sIdQ@()DZZ9F^(Enk{xGws=8-hBD7zbluP>
z0S`?HL;Nd7o?R{bkp>=A4;+*$Mj7zKe9haLvGt!FW6))YEs~HJ|DK0r2iy`PHRE5v
z7c&EUD-)RMCI>sAMrs5F3~#k-02;586<5Sib}F{Iy=@ljExNZG(rukS!OGF^jT1F@
zUH~_e1=Fs&8^eLQ>!3Pu_u5w)mlmrk;pEP16Gf*z*(p9%hv_m|+t{rztNE-&mI_@D
zmCI?v0P#)e&>q6iDAIL&0~q~}cFvcqaFWEOv;bcmoC{tSC6KkrhRo_28kK-#<h=W7
zxr70|@W}4&M>VUEbVuI-=wOpg^^8a@opnf09O;fsGR=t5NWgRiCDaI|oBW%Oh~NWZ
zf!Df7n1u=wIxpmB_$A;f5egdieV&Q$OAp$ofyj>%)Nr5EtsTAMCT2v<qu{s6^VyIL
zpb=r*g@TL0B>nF<0XtA}_Y*S5h2DHYpGEuD-^r-yCvnkaY3JiHQms!VxEx3`Fs2?P
zgV=pj?1$b53MDz8IEbU?XO7gGw0{eCv<WOa_l%%MEOl9gH&MD2y~YYEz+FI3<cZoH
zkL^5Jq7D<Aw!S$m3S%_r$kiyt0(xqb9Q-^-n5?jZ`JOWy!#ofHn{aSaq=J}=9oF07
zCDg?18>Jp086u_=NGN8aaU6l?Z|)>wPB_X3_Y}f1&PHmH6*u8j`R?(5xpF#4d9DIB
zM-UCkJVY5A#c)8MMeU)WdePCKq(#v7(b0m$MbIb>HlH=R{qXmXSZmEF0CwZHrt&I=
zRk)<e7D_D46}YDpk9VQ_h90P4Ni-0yDB~`9+{bSJt#7eIK2_mI)#}>WW-J#4k7vN<
z0enCK4O~pNh!E(<{B8yr;fGWpVdy-P)|NdE)F|7-?(dn1fzs?<&99h0z7i_jCV|U5
zzf!9y)~N|TB2Pb5OeqUe0n^HYOuNEydzZ|!go>T?vo)BsS=H$Gg8G(vCsEa<HZw%G
zx&Zp0&Sn#MZrD$I#EnuH^PeAMYeD{=-z{%7Io1-C38{Qb#TeN?x|=6vAB5mQoF~Q;
zgdnO+`gUr@h7esm6o*#>H!?);XLX<WEdX~*C5%pJkT8;>i_BgExKzBLJ8*L>UNX<4
z`l98Fx>0CLe6$m)bs9QdxR117kX)h_FiTxYcwfg9s~OUah+=~aT2;_ROI;w7l0%*y
ztb)VDR^wD-Q){rmJ?rz|hKA44dnl9X3yMZDNsDr;!(VrS*`YT)e<DZg7@=-gFl~?7
zkkWg>L=$*bm^$GD5Q*9o_kJS_%~1J;nY_-d#6aeXJDtcZ3D~Y7@g@gzYG^F&32q^%
zYI^M&FZic?-U@*1gN6-?y!Nx-`m_}wQQiIYIMOG99Gk$3(tu8qZd(&_DlDHsb392l
z8VOHxLE?)Ld<iN3pos~hW#;*=vx_*GLjSI5%WboV%a5W2;DGWOc_g&#!@hWI;H5~l
z62@ZActFuJBDXz_7l^cKjzYKTq$3H@5G`vZe81EHE_f~U_XQ9)g)dcU5AQOb44&=v
zPIX^*lfQQ5>yeInuCm3eezx@OTZ|FBT(gI{tLDplnaDrJCR)&yY>!QD|M498+6%t_
z+5!&AF*_j#ro7-u4n3d87l~8f<f|}HkER*2{;K2Y`^t2--MEt0A3`+au6J3$i;Rzq
zj_{(d{2lD>5N~O$y-^vq#&uTleI?ftkdus1cy(aH>P0uG1pR#N=i*Zy8`K$0LbVUZ
z3jQS)k^g(t7}qJ+Tvn{8`+@T%fjyvDTfnuR<g(utz+0?k(KGSyo(?v<Ykh2<PH6B+
z0iQPLm_IY(t_poa@kj<;(etjEjjjkyckR<C<M1j=<tKDMI4G#$I~2<Oqu@kYCn$xd
zp`eZD#6>@)jJ7u1q%@$QeN4qqysu>pz*t#0f%|HV=;fa53tw!R>-MLjT-U`aO|g9a
zwtTH0_^E^b`OhTm9n?t5xB$Ki@=r#q1Hzv=Lv*x^m;>J%poV@36ys?k#o)u>1X5ri
z*NY(VRxKx?G}Fs++_dMY&~PR}TV>LY4_Oh`w>B?xBxW~_ls5=K#5c*?uP<yM@`Mg0
zIGKNRMI~|XK6K|<YyC5tkK|*00tiIM%cJZF+|493gi@1G1XH<%7^azi-YNUaCsI)8
zFV!ud+bB|i$FO`jwCboWhq%>1E-?NGSFnpFHA)ucNY*Elve9k_edB7|eEE$OR_H5=
zcM|A<miHpw8}#Qj*z-5+FSkNhVD#8s8G}edIRS5bP`jJbQbKuzazdJm-Py`!g?r5q
zklqw9?o20cp(47_>Uhj=a-!cN!6{p{TkCJq#lEr8x)~XlWR?MbF|OU_!4$#OS!8mZ
z{{=6eNVjQ~BQi!o+X&fQ^ux8qf9s$Dng(eGvLLxe5&!uG!cHiRfBr%RFXVf_!>t^s
z5soIy=h`X8{aa!4)VPYuy&Y`l!^C?GSdD7wjRzl4X!-g;1|I3+J63Y-nN(yc^^AXs
zp`Eb0rZ`DpA4>r%HSe-Yj2eVp2_Px);pJ13RiEd)d@<M0XH|5<kKKPx!s)A)rs87?
zKl~=M4Hfb576`u)1plr-zR`D-?1h?31-S_!HRiLSzxf3Lg^chmtKvDn8WG|MK;4sF
zqHWh6WP*inf%(36v=kyxUv`x?uq^T5ZXek8Yx2-sQlVI2)Z*CiwKw#y^UK?w1<tpM
zPl`u0Ji6FcF75|wTYuh<oSrj7SEX<R{)ig^c6D<<7j+4N-C^Uh`S!8D<8gvGjjc4o
z7@B2=P&;Mj_}}Syb5$Kh=sbFPfWDEOA9P`i&I06gM2B6E$NG-$_I}E;eeN6ZKJAy+
zU|5Q@B-;v`C1|jhi`E&jR)xtUd0ZK|`Nve%qGNRdq<EjO{tM=EnYY9BM-ojzs&QP6
zEQhU&-@U8ZX@!DTf1t74I47#c=<riiNbve$+yWs(<Xi1Rj9XeJZCG_dK%+_-sr@tI
zp0mCa-ie;GF?XVr6Ha0m6ElMi{?F9R-VBpS*i7HjWUbq3Rk!AVQN4{N;+?N3*=S>@
zpP&o$&oboI(t3JRha?EP#M{}XP;4VyYZK0zyaLOI;SAd+kIqBkD=g9-7{a2oMbZ4O
zp<h44%m4PUuXElsl<jNZ0N|HJ`UgFdq9LW{qRINLEbZOnXSTlNfIx=)JZQgGh0)o(
z6$%iCgMw!o3wHvALC@py{?0GTMVWb~3xC2Kg^r-d`>emAjHiH7n5G+I6hLWwWd5@(
zzVfyhc=EOc@VsB*iZlD~J-=DbjCeYgVvfGVEyLqt@NbD3(jfZi0w2q=pOB5*-HOwK
zOCC<Y4|-hTm;MU8nGD!IWMI@IWFS27FEypq)39{+t_A-DrK|)GdGK6S6Y>v|GWj^Y
zo4$Rz$pm{bi#zr69o0U5sKlmewTyV=HwP6?yl--y@HjdYnY|AczM>_TNi9AeWfT6-
zS5l*%fKm5|tb)xTu<*NnSWN4XWIi~P7e~4VXAq%Ux$k+kdNX)k?c(xG<H#o2S7abe
z<wBg#FrIpx+>iz&mu1iD;z%r)C86L(?!R~LYxgG{h6FP`)~9zSx+%0RV?gX<52}qb
z?z_0#mQP#7Q~2PYR(6hTZ}KW$#8=BtqEbez6Q7NFLZ==BuI6GFZu3v0VA&fzsC0HM
z7-<@?yj|bQO#-g!<=adeZoClhWd1i$E-zX9);robrV%@S7<yHr?Qx!DDjBAV#LEO7
zdG>&sSY!p-M`iA##BS0XH+Z>s`>vE&V%<ssv5Rr^8hg4v#fxgQwzpw=E|Xmc>IcAg
zd8|DnVC7hK@hF1+R`al|fIz4rQ|K|TF&(4iE8f2wUU$EWe2rmgFR{gCRRt+USw0OE
z&WgOl<~I834Dog`#qWejM?Ph%+PBHdbB69Vl?q?C_eDDZylJh=`mQPeM|jwOiMU94
z4WTtfhOdJ)4Qfz6=y{89<r2A@k(7=~UyLE8fDu7|qjG#dwhU5fF$V}L0&;2ikK)1T
zBG=C<GKB!bE}?=ax2B0DN0)cfzzF4t`;K;DXBSQ;337ni7*mmx<AW^_{21*8jp)&b
zVZ2L-G_fx^Us-oN_dmlK_p^V3sz1{cwp9m2HC_>)kM&?5=Fc>I$Db9Q8OD$gGHQWv
z86HouzFAC+nCv+F8>p+Pyz{V6&j=uKXDG;bc!7X=9mAZFIo6Ek8AVW=nAld|#>NBF
z4dza-ApGt~IOaOuL<Fmd9Yddw*Om4C>8SVpDZJU2EPLwtQL(?DwBD}lgI6~UO)#h^
zXIiKxY`7c*pjE#59E`&N>;8R~^V>j8J8YKNf)(n8%Fn+WfsPM(%!oyJFoKumM7qFM
zVV;!sEwVauh$?R(t3A20+?fV!<xDm4&FqE=&)R8F!@2@bgm|A4$P`GX>FhP&ri5Q1
zd^rgja9|=C-of{`u36@KZd+DT`J{FZdDMN!>OKeg?)^i&Z<YWfW+{%bkP~2Jcu#Nl
zXVLMm(eX#D?%{sQmJF*vYy8=xCQ}&`f7O{hba-s7{13z>F4mj3@h(0BHeiSHAeP?J
zy!_g%AwZloZQDJfwCF1(A73sFr^BbWsjToH!}&qM^8Yj)pN?lPMGlwoeL{klXqDf=
z{t^g+nCN=nl5WS?8Rti3kB_49s^?wy?1gg5y<o22ei_ZS+_H)5cw~pF9H)F~Kd?4L
z1+<8ma6O^?A~HC1(ymDxGM{C*VP~rJe#s8B!?5B~+X^)QM%M36y^Ev;Ef*pJxSOPZ
zg96<#r?7ao<opw_Yu5*QT@%3|_1D=hOn}*uZQbxuGj|1<>YV+>@OjX?i{T`w;YpsS
zV#AoMv90pO><s2V{#-|B=3fvS|2D46G>cHaW+>bLzR!7iE?U65j-W)jw&#eLJ5@`K
zMsRXF#HO$ROHRmIpIjsQa3+{>ni1qin$;0%!liGl(qPjwg7d>YUKgI)>W})m9w2$j
zt)o~~Rf%`FK4&5XRzdNU=RM#QMD>&>I^ZnYEI#jk-@-MEP9Ah19jXT@j5z*QoG~BG
za1wcU?sK^g&5^^CmwO0y|68=*BWbK+D%c}5{y|kU#G)Qgy_fXqDJ9@$-8ir2w8Cl=
z^WPAqS)`fWom+Yo*^@;{`s9{82~?huSiS^DV8%JRcF~#bTMaOPJ_x-iDf8Fg7dRX}
zVW9PW-fxyjOt_+>m_PX~n4jpx*`lovYjE0}e_H}~>MQJrvMKPU4$|${^ZX3+O4wW5
ziM)&?+;8XE^TsU!O{F{X?4N}CkXxYCrw<htK0c0>`TH8;?`zS2NKv$j0)AP{s90xl
zLYQlECAIRH*<w^LI~U)KG81Es?o8g;c&PU-$Ig2wie|?d_E2k=U8n;pziw%+mKp1v
zPRb_JYe<?YmUG9De9H@_mz?Q|5{P<r^Ugbu(oD41)E_hOr#m&^k+}kWLYPU0fx8Np
zMcT|!9mZNPtL4Mt_56i;0eDx7^nL2-l7SkNg!2pL_1uJtWBtCr6}CzK0VC$GBFBWg
z;$#~jJqy71yRX(Vx%Bj?#&yng>&XSLAr7lcItO0xCL8hR6GoW1inFaCQ>-B;I}s;e
z+)H21y()p%NTAnA5CNdj5-U~HEb=p<UHK%WlzqqCdc7LY3spHU&}8#dh1+JO_o~Et
zoJs8MJ1WrgVES}i=G)3k%vl*LigBrFhb6g{#wfoE{&UnVUlHroj@EEECri@IWpv~!
zZ<Fvm*4SuAIN#XHX?_M1OUrU(&QgU@?tzU}U)4M^@E19Jt~f3(H!)d$yDo5*se@#9
zA-<PO?)>6={79@gfFvs+jyq29B!z2cY6;6IFYA4swQ<3k>>7op1>W09|50x=5NiUc
zSQ|XpS(+2|2*1F*`R}B2Z5(>Tar#(5+ST`#7(h-HQ5GSRY1a$*20}c=oP~`w)O;1d
zFb+r(mr_B&m*+L+*o&LJ5isU(iJMK5__BeSpTl~j+BR4KoUlXW2&ioCix=${P2oK3
z=HNU8&seviWytfIbM57>Bn6tPpk&BTH&7`O-EdOP&gqr03GPAh??JB_AfzBlJ=~;2
z2$PgkvA8t%l)N|gumpw72hZ4#iT2aMBA0+Tz>YH)Ctkkf7bpnegxb@Zpbj%|hZ*8t
z7W&mmx>z<aiF<WY6fE#u66~F)bW?wo(;E94%y5y+VBd@V!1bP;1J?@qR!ph-{P)AH
z(?n;6Ax#c1eFx#}M7zaN9xtqtF#2?0${nSVvFG>Z=0HM1_}(u47TD<Zx_owPbR5QA
z7vo-#ENF1$Ya{YDCrBl%L0F4cLOqVV=Zc*9f-MD{)XpZkajo1;Ca*-};w>&#US-KY
z^*hAAv0Bd(Hr(5?R<hg1(*5o%<0K-M43JMvM?po7ZW;bY@Wl1rnSIwb(L2PBG46X#
zgJ;rPD+p7h$B|z@i=5vFDN#lKFranOk(~;i$k&*s_Xv3$-!y&7m>A2xsP%;at9!L(
zwKE6MNSX~9%T+&W>MvucNMG9MmBmrWn9(!~96r1#dodgTeiJ1=%Z?&R!&1t)$oj`P
zgHnm_H1dlR>upp}@5Zx_lIajwYe1GKhFg{!*6y)u6(dm*M+ldLQhTOB&b&BhMu9&s
z%a!y}v=59yx%&Q`6U0mC;jh@<rJ9{$>5>C1o|WsUOvIvM-jCkK1ncu_5ij)H6bKC-
zmD{?Sdmyduoc6z#3yILMoN2gMw`mYT_9q>W?*4Voe70mSY;JxpHTIArAgZmNuTbY}
z{N9gw{~&G<^K&c5u|95Y#B@9g%sw^3yAuT-MTCe-*vnWcM{1ATqAxC6(AvEbAZP&Y
z8??S4uRz*k#Xb{7|GvkbETFD%5IC|HlFD(w^BFR@SrLm8Dq!=x{?e9z_UbsCcY_}~
zX9oJ3<3Q`<O8hm4m)1wB;KtXecOv&j7Q9PQj<ufQlT(u$x#6`Q(_LiM@C9c&m2IlY
zWvI1z3a71^db|Rbe#!T68?0ppW<Lg^`a9TBuCrfr6${5jbJ#H$-}WN)+Bg`g3mC7K
z{bnXPTNbg<S-jxa=A)!?`|p44yi8KQR0IHHAQ!3rH<Law=@tA_+V+(|h=aW9@&2~D
zq>iSorKSsuIEJ}$Mb*rLbw}cE?L*Vj+os&+)RiwcoI6Nb>{D@^{HU&zpk;uQLTRpM
zpwZS^RWd>HahX2W7PT;!Wfs`)Z==3XQ9Ts~XGjd^c3SQ@YVq3-1a%vMy|(@bdN0gr
zbdgMS!_NA&R9(wBykG;(@JfuVdd9j6L%eA4fFk3ku?<`quonMR+0aT2T{nmw`eT*s
zyX=2vs#5LJrZHI#g#@78b3yN`Iz5%gExY`qsyrK8)mbW(ReG?_aWTBws$HM(go~BV
zORcA3?(3c%oP87vc%d~RM)8tE62LDx&?lQJeyuS^`2>!)XF`9WW>>Om;22nzQEVe!
z`7tm53u|l&Ne?U^%7S9^!EeraBHxN^Fbigx!s%-@_5dGGFaWyALn>?_?t_E{>ID|U
zNr(F2aie-(Y6lI3vPtpIr}ou!Q!*EGLPOjPO@ETxWRuw_b`-%Wo}07|(z`UQte62_
zJ__^$O9{9?u?YUIsRyo<rk*j7Y-W_iFEngE4sh)2<kt94na$~%o1H=ZSJq<&t?JJQ
zLEZeXDk$S-9KgxBwyL1&(Sz4-u@jzevSoVzeE4@rccTL18p>D)4^qFu-SjdAeXnO(
z#NRzE{tTi%Y)pq_H>0F|d8^Pnh{il)OxS@YTv;}lgCx?jOMz{(?pwbbBs9_pg6~c;
zWBFns@ZZR+Y#@C%bdhPxhX<Bcc-VQTaMlE_tzHZ$qLlk=3|BtE=TGcWFr6YvG{w`%
zyEF6eM4*w^Y35&4z?3f_KGFtrx=otsFU>8%73zRiJaqT6LJyP&Z}=u}DegXnu?tP{
z?Ce;Rm3~W+&cZ+Yl0@j-06M&}nkPIwdqDZdEpAiDTd^0_@MDVSzaG>iI6sB9EQw>w
z0Ef@e3{Pq)V*=SRsd4<ZHpFq;&+80bty1U47|;cI8Mc+?CE_LVoMy;N#x|JU(<G(z
z`(TlMFy?`G9;SKyOEDix=`aUUDWB0U_TRh&^H=6j35ORC^MOh9xh$u*0;eg!d8)UD
z7q&Zr1*$Gr&PZfzg~U)4tjbSotzaMrbOZN<NBdj390*Ra`k{^bsVYz8_2e}yWBqhK
z@!?Rh@ZI(~|2yOPpwznh?=5eHe?IzcpWqrsTE&z?J$}()-?yIx_j6ufPsCi0ps$5t
zX$yOh{zfy+9<GCvmNIvCl57udbtGqm)^btOjPMpJPj@OcoyyC26a!Qf88;4FRIIl6
zO}}!BBbS5zraQTtO>JfIhPwUR-^ywYbo+-@di%_8__E+mWBx2)D8r>*?Y0=g<ukpr
z&ulS@;~SiJUD9(dB(UEz4TcoH4&J2EdMlSo>?6jq&hpg|htMUU?_*ObQ2JYZ_;n$&
zzc)5HgN0+&X>U9#$O%AUo#gG|5JqL4B<kUy@fp{Bm~?UKrCmJ0sW|<a*QxvBu6CAD
zf#CW}kgR5!<L~5t`{|_Ksz|E!g~wFSs42gD&0AM3oc-&B&+7kPB3d5rUnB~N(%4JT
zz#GDk=qWmZ(j&<Pk_GvM6?~nzcjGJ;;(Yz+ib9|50N)2$SY&nh_cZ?VIj2Tb-W>(^
z5DMaYcr>SOe!6-Xk(ZXCXGmJmStH@!DPI^GE#gF;+KL+m5|@*aa&}?yt9Vr?pXQb?
zvt&FvUr5MtBb78XL%#h}`9)c86)bX&DrOv}6ajL;#mA#L4_G<peK5|B>l}`)-z5mg
zkj0DL0c_{1)C3ELWU`Bf(je$JBw$LtF(0uVc=u<x_d!qp5Dld21vWX3ud1(9Ag+V{
z)H6YTc0z%g;6-B<o(|%0yXXW*C4LJ+ACaeA;(*}rtu!aiwBlMcsE}q^(5WV|bi}`s
z6Q2dcJPc%VFNKZ}_PNNs%{3R??C_lD|L7Le1NadbcflVK_BN8ER}aKn?D{WLKC{W~
z*yL1r;Sz$Fl7n0jXc6%bEaH&iuFNS-*EVm*?sM><4we%Aqz&NGh_p4tj~qW-Cg#;}
z?vxDM9Alfhg4zGqHT=bS=a(FIcmQ?emp{)A%y#e$kye+=c|~E88MxDIYQ^gx2qM)9
zfCG6Pmwr}g`iHwC%z$jqG1)#sq{&R<(5MHmmca%AovR(S8*go`*Eo+D@S=qn;B6_Y
zPaBAfWfE7}2^Zu$h3Q>r<>saN`~>;+18g=}*t-jJ6oGL-<2e`taSV+1IzH9?VulOO
z;>-gvNTsY8{sS$fI(;Yc=%w`&{UPlGd}fv4m5#LUjf%@TBKTaHKPWMc){B1G&#}nf
zVP*0YpPGPfP^J1&!pN&}HRDs|VYyS2mowrF!`q9>Ge{L)@813HR#>1tIMx|)oj?L_
z@Yg`lZ{@^lol@>t7cU}>=H=3mu_@oAv5-to+@6HB#l#%`d(4y)E$rbA!0}2S$S|*t
zbZvkr!atzS#5TRfX|~J!CiZx-B81F~?*QHPgV(38zAbkn(M?bSH&oCHr^gn%Ez1=8
z>z@C2LsoV&qd&c0*(~Vj17;3GDT@#82lE&Tip<l@Jh+a+jh)PCd1jIO_gT^oq&To=
z2z<<20_nHT6J9#Ok|^N$+HN2Lc%bZ11xhF<B{E$jwXuYiUsinA-6`)P?d7z=;E<0S
z=K*5=OX$}zs(J&H07l1ja=q`StjKv&QVKAen4-HQ!r=;Uo?EH!7MsWW;W(kp7dtqt
zC#DE4`P%8iER!LEhmnG}`0QqUo^{Pab2g7|q=@6dzpg#p>K={i9%v0<bM58hblhJ@
z(NEd<IPBJqGz>;cWI9r^buu4`7ZB3(QPhyC>LltFj)T1K_%@wj_z&9rebhHE8W+K)
z<GZ<$!hbAU>q167)vxyBdi;PniXF3y@WWBO`+y*I*n|8kejx&%WRj(En^)|cx>OEU
z?dO><R#~cPM4z)SzX5gbymUDG-`L>O`w|G$mwh7NzjjL`cE#3Q)-&+nkw_nBI!1oO
zSjI}@pNo7u#%Nh+$5@!WOZ9OmtNx`I7;)X`ye}Z{k-%>qyCQ8l%JS=t^25U3C{u1}
z*y?t}^@pQ}@z!GkU1|H$25TV|8?~?G4CRdQp_PYOQ846(fJJKYS|^R(C`?T<3%kA6
zRi<1P=XiZu4WtMps$4BiX)22_-6=_&Vmgk@U56;j5fRb`T$EpH(!c)&tekx-DM-}3
zAR&2u)p1lw0+X%P*p(j>0<o#nhnEfOSWeTI{tOrKUGvr5Wg;DRmJB;J7Z!@U@7R|w
zIS1-xTGEc4fP`bGgyT1=QKn>Sd!0qL${rFbt{e$F$v7VJuiI4s8vj-h=B#l@*c;Db
zM1rjmag@~3efSX~KVC7RH<?D#4RmRddj0nUOojj7ro}=f<M<Nf`&!?hj#8~5j|N3S
zLlkAy+WZTt5edh*#^tLR%q;5&m8HIKfPQ5u+m_ys$zP!~$K{I^huTl96-qrOdj4(o
zZIw^ORK~nNX~!vvb+(~N49JYTLvyICwbSCxk`m97G#?oIJ`S>YQ#`%c@E`}OfMKNH
zj0O=58M2Slphp^i9iT_zC%)enY225vL?zS_YR?{0rZ?TVP8pUokr1GH<YF2M_#$vj
zoN^CQKC2gtt@nz|dQoxJ#p0HU!BJdVWY^jE7;hVUgrfSmru>LqI=eU=$EdnL<K~)C
zv53<*xlO$N{Uca<RoGaEd+e8O;ovEq*=v9=Z9a*~zC3p8yqZkZqn?Du>_|~mKO0Wm
z{JQb_3AJ+$d;Vg*zvQ9%UziX4KL@>;3m%{uZFTXQs#?1a#*hnG=s*5Jl(>+V?bMg{
zA7e-XYuADIhBSgu_&^DMXWbpP-YzC0MF|gdHir3CkRej-Wtpz;GwOUI2^z%xW<~>B
zNfrm~8!xsa)=WQO(jiC=k1@W;r0D$)Z59j7sbv!Sq+Aqppy2FejtKBLL62or-~igE
ztdY4D5W_Qy=Vx^*bPZ_k>krKg*Ubihf~yo?{mv36?4qA{40N`tPZ(Svbq`T_Z@6}6
zw2MF1@W&F?c$0V{lH;NjU1)jBGB-bwDu`d1m(YH2<z5V0NQ6nt?PPe)gy}j-LA!@1
zy<4A_ibgdgc^LFP0#Y)w0$cB<vfMSOwvxOyT($eI@As?*Re$*|@=kjFrZo6f%dNEc
zJKE#2!bRIwk-Zl3Og$50i9`~4xb1g9xBr^j>>ulV9UE26qoLxna^i*3mb=XA>Z3la
zj-e%Wm)qY459k~v<t=@X;?s-!BI^h&s#N!qKlKTem+#A~Ede!4#QUH?D&o4P`g8u|
zPx=kLzpMvs-7~5KBvseA`C3KC_^8ivQ-oZ&liC@yoo0-rG&JI*^eiSx3rC<VNR7^F
z1JBKlDh$Ldu$&3TQ}1AZuE^usO0k@=h7buPUHMlwpuSaFG}@6^W)YlyTKaO&S9g3P
z;ZtP2rN8IS-T}D$+GlX?`lW0=vUL*uROmh~$anUeJnXRgPv6#zfU>=h46kaj$u#P6
zC`g~g(a(nmdKqy+xkRZH+(X4?yN8jNG>w5hCkt_8o?b!@L8Y4jTb7?Vsy}yH4@Y4(
zLMiIj4M_dOU;3kjWwJvh&S5n3g1&ywdB3oEonmV;^a<c2Y0v5S9bB-dbI_G(=?R??
z<MIkA?N?GG6<v&8c42-zg!HMF<h!2aeWl<op9FZ}wF!DXmWNzq1pTvE3>=!Hgx`e#
zxyS+9=f1QvXkQ-Ah3~9>Weyxi(3h3EtW0Wlho+{^f$qNCVS3es1MeE`y<%;jw1}I@
zphX&3^ZJ3jU~KW=mIBmT>!C8Zk|YTHxJ8$BopL&u$>*p39~)N&8t8U=4V`BaxLfA1
za{qA=w>+L7$>KWT!IHs;zaLk1hvKpPcHo!`nzuPb$v580*3pZ+ejW^RJ9e{+#(7z{
zE8P(((ZZV7zk0*H!!IwZnLP7+gV1I?L3EBY!3M5g+NzlAgcpwN+O2MuoP*n4bdHzk
z7rB-Nx%PBz^bB-VimbOkEB5whn(!!R82GeU{P+`EU5#>Ii&Y(|@Y6hUe4fk!xg{3^
zNQWBhi}T}jcK}K+=hht857c;v0>6|IBiJk)btr`~>kLuPa^4>@6H<^=W}GVg^ww*B
zpa5X}nRB7{=G_Awax`oL^9qs!&lPNTYt+{Xx>zdDt=gA{7~HaSsn@X2i`z(+y4-`$
zRJ(Hi-JS~YT4=16Xy7S;xdK;8gi#TnsuGW%Olxr0yg2+-=%Q$Cey{g4ZQ=VM<MkU*
zT;-xz5~0{_q91KvXquznqWUf6wSuC(BLPsx+BW7+?&gr_QGiy)Kbg~!ImR%(;l#lF
z{wX+F=0R;?c&;SZ?{d<C`NlAk5#BE;)qF-0;M!-PByhS6olTu$n-GB%-0>JpLB6se
zKYw=}D$!~$Q#e*o-GgLQ@$EZ~PX3pg(wa8Gk*+y`&1(=RqM8j#@$d9`Qyy=|CxB2u
z?et0g-TgyzuyAd7t735Jds8l7n>rg-uEug1q2FoqlIe+y#Qi$!Q?4^DdpXe`{lh5o
zGh34DEPj1w8sS@R)Z5(PS{jn|tAZTx?BTCd;lDA7UdmUjNli>BPJ?XswO)9R+-K25
zdWBQOE=bYOQPE!0+OO(27hI}-mB5qldg4n#rW<pJM@hXGG+0<ap_i_=c&lO~j~RAY
zQ*&f{{%Kf7kU4A?jxIGi4x~oATPoJjKA9*wy9F5x-<clqQa~;Zm!Ii8JcO@ZzWd_u
zC`4j@Ws8dv;*>7J(opn61`z>wE<h{>2g|WBH?9CW7{o*?5Q~Gw_few+uDpFd)N&Rk
zo(wD5zLiiuBZ!b=oKjUxq5X4qTuOCaO6A)<QS^`Dc*ZmkW_?6MgckBiU&*m7Za*S^
zt(RM*T{?#Jg<MANU9M5F--5Yk`D);&*@y79Ew5&o?3Y%&N~wc$;iN?0=ITUSjs7Z5
zM92lfPu5UD@Amqc8{-HL@G7u!SAl+$Y=Ug$F8rEl?Rs}F{p=Np5P_gAJqcA!nDK+^
z=2pG^pTY(mWo~6_cvkjoOfE&p?0S!aj1eW(iC@Sh$tFW?)8OPx=jz24`t=N+Kyo&u
z0iWvPLivCUi#5T*lHvwoKGwm3R!-^Dc74A@0dN?ZmEOK++J6WM(BQYH{NmEab#5rZ
zT)gmAYi9ltD8V5<*M~G{q12ISG*#_cZYzWLFL-j@NL*p+Z^2}mS7k^_2!uF8^yvnl
zTMZ(|{Xdkg{!)k!`5Ro7+cZvaX6F2TZMVbuMOuRuUQ3n2DXl|Oup&wX6V(VT7T+m;
z*B50E^UUJ_&B?+6z>@lBbH*jt|F8y32i(H!4Wwcpf_!-z#NRZZljV^gvG4NAI(1#&
zN^|66o(86vy;|!8z0&J^$oiuh^-4?CwN>3$RLc@4Zy`SoO*WS<<n@WRN%e<pX^L$(
zD-|^Jot>alTnSVXa^h4}H!#&;QAUgBJ0iC5s?8#00(h@`ig#Ah2DKE~HU@Z&VDRfH
zr3!dg0THDj_;qn3lRcl?Y~0gH>gJz`PUnR{weEraZ6Ek-asWm$@%Bn2YLV+v)vo$m
zIpO}k+m5$#xL};b%S*@T^Uvj+YuwqNEQQbUd)$(*pS;fggTAsM7^&sjN-Fkz0D-}z
zG*869T3U5@yDy~@FMZf5Gd<}n65Sf+ZM%oLVk1T=hYwyB2zS1SgLnL<x6K(FZJ0jy
zfcWh1hHw=s*nUC$+C(tPh&2Qh$R-fmi^q#J6lP5HwvTJK5fudxe&34G5teT(7LxFX
z;<tOJWVm`|N1%Q#>DE^Gdr)sH%hgn>Erketa55fk-RIRCLM`Sa$B1s>g-}UcqX;E>
z$y;N1Yz+q-Fbl4Kg~#{HM~QjPg}(+6{ixKJP>7-)4aba%ZgF1350F>$A*2*GIN)L0
zq{A4vg=fbs@{I?0+dj6VFY$UZDwN}dsy#@XKYBNQK)+M9#rqc=Au?1sw=9Tc5pn^!
zC0fw7D767h--#lPC>KpT)t}wd1TBf;m(4HGUk6y@)6CmK4dxm!iO-0}qhYX|Ez_!2
zw>h{;A%<5Krm{#BH=#J|kgs#Qg1UDwyPWe)7COQT{z-y3?V3dd4)5aUPiY=pBwF@g
zb|q%PQ_~Fn1=kj?v)&m$ZyY(=58eU#N#-9i4UsrcGvPc(Is;1k<S~4>4hyXZ0!KQ#
z-}lKAgzs2{p@;`5KgxW9jXrNThcNdl+)99AX*wRoe}e5#mFJpfR^$ijrpRMla2zTd
z!i=)w@1sP|inDqnM)I;H19bV|yQ7f*G{ignq~yV`kQt!j%khv>hi=?61DtINQsu_>
zC;11oeH(;dOaZnuIb*i;8T~K5ogd!_;%qCE^yIHkKeId@HXb1eCO}APYj>wzd-7u-
zlr;Oh(Np}|R()qP&j4o>95o5a94u#8f*E@>0h!WX2c4zkkr9lD?2#30MSq*a2`B0X
zZV6-iWT;H*zH4996W_K9Y@?sMs}Q*$CyPqyqb@*Zs1ia$j%^eZ=))y9xd)Ge-;7hW
z+pt5KE+07d87E?d&q&5r(dJp@V!ryt0Gf5Jzd07*qV;Yh+so|N%O}`b>p>mgU9OMC
zBjKY%7a;|aK0{X7`a`Xvaw3S=o?qrpTEh7T9nMe?88=3W;y54y^<hSF@wjpUtb=~z
z?h+ef?s6sR#_|1>kupp3gE?<xw)zRte>@};2)B`5c1U)oXc8q=jO%k?J#A#7G+Bnp
zC^GrRy`!y>VVG^&cS$-&ENh{y5IbqC)I`#3N?z^^=Rj3b^~Xp-e3gEdunhvf<Cs;2
zh{i`Y%b1#~7NoI2*q+}ifpxCHXB2rHz5^47<MXT^I0Z`QIzze<Ja@_ib*UqWA)<`=
zzYVcNz6{#8n`=|)NgrG?AnTb`@F=R>U{NQiYW*;w&ocUS%i;Hz@ftKHd4!i|RYMxX
zw%|!XMYn2h;;*`8S5K;lPtzAKo*ZFbzTkCueiwdt=fHXd+`(_0lHf(29(V_+Cdrix
zGL=v!y-mG4g6ZnZOvZA9b!h9omF}1Q)sJDpP~3xAVu<mafJQUko1K$Lj!(<?(`FUe
z5rNH(wje=zO0v5CU&}5<YQ+p`bv4O%u+(c9siea@OvEG$-iYQy3QTecCPWBFdAd&L
z$rkh|^kdIJcOG4HQHa=ODUD&~AFCsyDs|q~lm&VRk(EYv1o}M{d2z~nQwt^DPod4w
z>mVhxMxdpeQ=RvZ22(z%TdnxLZ_2d#o1pO(trpj^z1+uWCP?nHjgp7T;>fd(VgT>l
z*@2Gfv44&w=-5ATV0Hu?cynnbDcrp*Z*1wsuuB14O_lvDHx!a7!*5Y!C(#fsN+7dL
z4i36|FA)4RinroB61$Jy(q4-F9-6~c8Tk}1w#t7qP%6CV*g-?`9KF9}Uj_TW*ycM7
zkNk>pcxT<4CF9F+!Zb<r=_gqu_vD>IURkK`s*7_JPw8ePwg)Qjj<C=0xFw4eL`wVt
z@$RRM{;civErGD^4fW;38zn{WRjY^w@Jbt;?{77lzX+Q;D}18`!O50+J^|~(!B;<7
z;Al#+alC#E(QUrC2E>4MK~86}A9=^WmniT;RkMV&@tn=xQe?h9jS8OM{t&SlJAZ|g
zk(#O<hZ9yBil)HljsXwfhJ&gVC7gVKH&W+N-q7yd33G_A(YzPqk4U8D<%%k=j?N_Y
zWdMwCUiDJT`jYSgBRPi8KcSod&u{Y|w~bKp#WLB%z-K`fQ(gF2<T~=PD|7?uZ0ZS8
z=@nt=p?yr#ZGB~%T|MC;7U?vyOuld0SS*xNaeLo7JRw&XAWS7C6@vl6^-i{Wb<DrF
zdCOW%U%WG`2{|N}GR`HA3nJSO6G=i=hB0R4=dxQszuJ%5W>x5`rK87*uXlPU6k)T5
z@nyoJlyN@<m#JT7y0IrqezNHfJ^T*^@LG5;@$cb`uVKc=kyNiAGj!qwGt?V*uO#Qe
zn;1=Pk^OamW%v>x%Y2e9&T%KhHP?Ea{-g2szl5bsU|Mm2-*F(bxTRzIb(=^F`rimE
zc{XLUCLvWfN6xefS%u{vH3A8)I*}87(7qc6s2j8qY-@>rM!-T@AGa6zRNukUs2zt=
zwb7hvQesW*>a%#uClM~RZ3>xad0y;+YkBj#7;qRvHvMUp$s*HBfz=M198w<9(@Ynw
z>lpa`%vP<r_L3br^;BFV@3s@!0fI9^&7(#&eX^_iOhaQbZ#{YNGh}}5-qH~P41Ai0
zzG44zXf2ha?ppck&*Wv@s)>uE&}t<CzSC9IM0=8GCrEc`!47DXP*m9-4b}2_W+}O`
zBtVrr`0sm6m1}TYE%hE<tL`B}@YenoMOr9bsH(}IC*&c|i<>t5y?+DQ^!MiQr5kb%
z>&v9L!wH@BXdI)qw7EiyY+8JWMjUA_Kb?p5GPYjOK9YOsXy>(2KQ8l(k}b$tRXfe#
zyex5Ux-RdoPO@~Qn)0|Y{;G(9x6b7mwE$X>+7q4nm5Wzb8Mu!{_lpz%aU3)uYL7I<
z35@=L%;>!(ZIfK-@9(1t!XFa8a_Xo_+wmC$oiqG%*SqxSs9E0f8EhPHyw`m%6h1t1
zdrvfOH9N^E^gYePeSYm5-shK%+>u=bv2}EV+d1mXB+Faf$>JG{*K>RQe(F?3xB@;Z
zhw>rv0X;SPD;s2=f{G{98d%W#R)5UvCl18;XLO7$le;mKErRW}dQiF_Wz2;Hcd#5^
z{OJizgMR(+f_=`fR+E;RDVKa#tnv-3{^J7UCq_mOc0MdT9r*;QQZ&vTXr;1#h#tt^
zskdl9Pa}**JQRK7bz^y%aN(e5a|wi>O`~6LU;pVHM4@5H-rNoLO<Z11xY~{v6c>;k
z6IZ~U)CixZ*&Ccc+x*f#H~u2tJI;2pje7}!%W?xDog!`jgKmFoxgD|Ss$6<_w1QzT
z1g;5rQQ?p(cQ|kfa~(IYs`B!(7*%72+ofm8G+1xW+0JAmB*VWmq-nPIlQVEOq-1A)
zOj<GbYhZ75%l(PcXiQU<cM`cP!o}BZLU6%LQzl#W`w-qh+0I-KUEum(gwm<`xu+G^
zfVu!9{CK8+Vb*NY#+givibJ158*s+M*?R0`2(_11d3fYLMo{JCGeS<}bV=pl{M$6l
zQWZ&Qq+U!tPIuH=gL~c@dp#g9(d2b<^vjHG{0+HnrN`#?mNIWBtMq~H477cLekoPC
z*@@LoHAFY~Uyi`?#%g`n!VMajPkYZ&$;R(4l;E|t{IBp!42<mE+;CMeHe9HcBY6GR
zjt2iY#;7*d4dlnW7u%|wsCk=GJ?s#DVP|ga`KKtgZo@F<702m>`w9rigHwLw(~_lY
z*lYryY@qNnQS)l)8a&Brgh2a}HpHv!x+i26mq}ng5tZLrAIG?Ny;r+uJYN5oWA$e_
zuJT^{d}@Pd0!wyw?ou{*rz*{<1KY{DEUn<%;QnlpVJI{9{N=;T)X`4w<x&_EzG6aA
zCAOa)-gL>=c(o>5fbGlJP;bx@pA*~*b>roDeCc+oLkBjCu~Pir*6q8C-z%;h?t%6<
z<o;Yz#@j-}n4yLgN44${^iRMlD59%1SUmcvpq?3(ut-GJeAQ%;7Fj1;d%Zkl8&6V;
zg%5Td^_UsYt&V@Es6vIg(fR3;<7XRwn(0hlwYp7yDEu)xfH8$1m}EN>w#8ARNRM=$
zd#-;>yP=;?X#4HF7}eE)?}D-Fb!=1|<iRYBh?C`lu%XtO#ZKs6(C@j_Nr^MmvG|jI
z`n#rRj&EZ`O*z|Wce0g==jVybdBd0-9H*DYw4IW8vCt3;ylMRP&onaoAx2MpS)d%y
z+z)|0>M^@hfY7R09t7ntC!GRv7(!Cc{l|>>PU<3L#*}@BDR~m27t`=DS#nC<$t;+P
zWvvK%a1fn6bqh$GKpd_^Ke28a_`l_Gy=wVjF6LwzO2OL*ugq{}y3Fblm$=@`@d|M|
z8_rM2vJA5~PhHZt@vAsqtsrdDq9}AkonSi|*Q8MZUW5Dbora+&*onp^dM{F{b;x}@
zt`qo*=p`^t1i<g{oKDRw#fykm_eeHeJ2u?|KRVr!h6vtlwTa70!x%GcCjo}5>{(J;
zFCx0Y++7zx7}59$aAru2(F0)~?{|U%-tY9fB^3h5eTSdg`nF8r6AEvh&vpH=GJYjc
z%`P7Tk!ii|S7Qb4u6R=A(6Ist%y;>lhAas!Yd<{%^?mZK&@kwJ*@p%oy3z8aiUl~)
zN&Iz6%a_&a=qrE<ml&0sm5?_b3zCN-7x|1V5w_I>!ISQ9|Mi7#F~34gs08mLI4m5g
znCUdQUmb%(dz3^-)m($ggE`P#AS43*4pmGBD9Xu@P|swkxyJuWzPro0yX!)x7RI>I
zc-wzg{p)g^Q5p{eWFTW7MAnNQGQywwWsKDu26X*NN=_hT-ZYNfalp1uHf96qt2s`*
zpDk9js=Q%9K;Us*IO~q_qNKsls5)!ggIj^>P>>tdf2hcz__$6!`#i{6)qnOb+j3!m
zkVNi9lg0k*-|Z(jh=)?f9@y#C^9)AUD-*W259s6bC!fU~@@OCc+&Qrw2U_XBfj}Jt
z4@Af&9NxA7M2I~cUVv-I_4<Yx$0w!)4!AkzUA$o1^BFFm1|LlopMNXaZUf%a`~lY;
z6g<=XhGYf-A87Zza#fQm3d?BCJsKDgC+_9lMF*X+@chvOhdv|1-s4iPzWuAvJL1?(
z4>3I9PqnQqjXd>r%*A2(@?8<_ldmtPWjPJ?3uMy+4UFag;08Z$xogIryZ+dWO;*_I
zRX;CPJiW`bNQd(uI+ZXG`uO-=&Y}jBZ{PN(_UX>FZ&V3P=C51&b7U+6kP{TUC9l?0
zrn~ZDjDaK2u<?i}<TNZ{->#4@IO6|3;IeXRdYK)Nh#Aiw>({gJKD3e=SXnmN#0^o#
z1Ui@{IGZV>1k-){^bxCisXax~O~vi|&Gtn%%>Mt1e*G^@{1@m#JuX||@5?ZY4nYTU
z0S`X#jFYDg$+=uaaQIT6+%du`xb<Uq9~FkOKL|)ucndf1lqzt-8CPW&?9k}uQQ;hW
z9&c--zpwCpp!_Q6JyDLXX$A+@wCAbYv^VVC8VKkQABDv-ASl1&lB3|<?o*0xHK6Aq
z3WX#`#OQnt$8+Hf1DlDW#UN83{u>*&6dMLa)t>RyUdxGRapxY5Y{sIS=(v}dC7e=|
z->vm*E&@SYsD@gVc)k7s0g%vx9tsRWf$#7bPS3HzQuQ;N-{1n7X|JR%NY-`B1YAAt
zTkQ@lyJ=@2M&&1~DF>_|o}aI$zqi|e^rdt%yCv!2;si%%j_KxN?nU|AlKE<a=OmDG
zI*j;#+PVs$IGS|}fndQsWYHxo7Tn!6EV?+sH3WkD4hbF{g1fr}f+i4L7IzPB0fGgB
z^Y*{>Ue&wzy{Yb*n(i~*Urp6?_4N0h({RcfofLCho&OF*RG0RN+Ebu{pypG*j}oTr
z?wmp2FJD_3gSU*1$nZyX`-2`coN6j(S?RbN4hmS|rL?&WTCW5?o2kpGT~86e<65UU
zyj%DvzB_9>D7a6VXIyhr*9F7{dUVh<+TLcFZc$ixf9yU%4_n860Tfx0q9|<*1&ig(
zCvDeqgfp(Spv<om8N_}GM}3Ap&8=9;Ncd&3u{U)vSVdLtHa9l7f-jCf6Y)`O@J*Pu
ziJXX14&w^#-Jw^|s}j`w9EhQqXTn@<yi-!1(Pj?LfWj3%c-Io1(0#`kc0CvZCE1ec
zQFjf`*&>u2q=zTS0(V<JKhX<=#*`=R9uI!pYuU)Kpc_y^z`4Or)s>N=xKH<KLkE3%
z3t2Nkp_Zb!w^{Ikla}t2N~0WJ+(f*KlizndsxyIPfI)X^Ten`d#{i=D#r0E(rADT$
zG+DHlVHhg-c#Js^`F<WQlucG}N1o0`991>X6=#~w)ZhRS;5k|RSdnwY1_mEWlkR}Y
zFjhd{?;eV?q=W{_DTMB3nGYqq)DMcm`*z2B3Q}vUMkeQeDsy6+<hnJ>ei}O8p!G^M
z6VOZzt6{r&&PSqGj}O)Y2AhqCLrY`>w<hvejJ&1-SM)CiuX(nht^-+HaiV7*2gamQ
zI=o4nmjl6o2)ZKw(*n|D{7Q&&kWCj+GoS7Z^948!@`A0Ym&_NFK|Z_ux?O_rU4dBt
z>=uU>G*#DBpMom&WJm;dE9f_40KVtVUIUwa3ll`He3dKIufVRV_1exSBNL5%65c{x
zgUg|PRw?>6P<CN`P1jlmA8Gyg-A@&ti<ENFhS7mmw91KXm5yuW)vL))&`WHRcJS<M
z-vAGuws2R={w(4h?*}0Sg*0fJZzI*PXTtfI{t>%Jvz=>0sS#7_XwE*7-*el;#bC`r
zDS&F~-LRhPR8eBFNYq;L>yJh}K0zAB<4wn_9SCfFZoSNQke(`o9{&D0rKnmAbf+lL
zdIb17s~~cc&xqQ2EP4Gc`UAzwKci;L&I3D$OXBuEn7saO0@-R{?i*^)Il3ar{PC_Q
zmHQR^6E3Cy@?Lt?`hP4CNUejwd2R2+?fcZ)S{)YkR%9{rVO6Hot&^((Z%T_|-Brhv
zIPa;$zW!|MT05*5A}@HS+n}P8sxSD<5}2u=IxSP7W+UrIZr|Vt60uI5ung0Bd35@V
zuj;#oWgj{FvB#4oUv@Lu&Ew$7auG!kd&{t~t}9)|mXxkCW~5Xgi}5;lutfMhk8hUR
zr6{IP5~J?TO3kYzDjzb2sQUQo&rWy+;?S#JIyR02PaQVe+!U6*8OFP|sQSXBOyFge
zv7NGNazCV6C%howONC2)*jc&b`pvqUi1Mqo+N?#vD*X3_aOVl)Q6WF?!m4FP%t94>
zr6f=st1w-XKbcmjPuHOms6!_KYu8IMQOZGwGk!c;VdHgo(JNey7pyeA2FKCyW}*2E
z`;<>NMkuPhw6K4G5^cU6tsBPvt_7wzZr-&V#LF$wa!7mPdrZN4(%G_ftlo_}T!L5F
zXN<Ib`^tXf9BGy{nHCE%mGP6?F0&wmlm^$E6S`fteT1sr-y17$R7*b6{^-e=M`KX7
zPLDCp7(XiOuqQZ3Hx?Z!Q&tj#UEnF;;aWxsUG>R<g29JkhXg+sOsD4`m;eGg`Y%x!
zgYN5NlZ<dZTi4feaRXdL6<wDUw?V?k$L6~ddtv7l@WP5qA<?zknou~fn)i#md0tD!
zSP8asQ?b$7V7zWok!%SyOj1~K*S@NIC(zt)ST$6!PDEGVEo!J27t*ztfsEk(8i-ys
z`>tp&?QH|6jF;ovsDZHT1)%jpZH0NrD<F+{hcofJy_w8(RnW~5yjjEK-H_!?O;C&U
zpWjyM&S9jj1ANL-`PFI$U#-8Cn0L)U{<5Oyw)Z!-R2<%Wss+s1RSEik8M3hj<5Z6b
z9A8mS_}NaR{1)cduE;EFVhL;HLdjEEPU=?*i6v;d>Iu+W$tResJ_a%~5mNRSm%kD4
z=5U~c7d>V|s3{6{&3VVdfOmCo!<-Nym0HC9F^BRmyUZFd3iZq1{M?l39Wc~8`M13B
z;7+pIaiz3w)p>8G#O@MVia23$|MrI!$v{_Wiai19b?=#~CF0NI-wyNw7A_u$_$2|k
zEaxOP;R@qHgYAUB3qTF+u-i>oQOH31R$Ra!{cS@1Xi}!f??dG3N=r}YDhctc$6n`@
zICM|Ms4RE!#l(@Y#Tl6W5!EJ5Dki};<0sR(x%Zic`n&Hoc4Ma1Rk7|yJ>`4`Sid2l
z=A8Fy@U9QH*qFZ|yB}^N(0)T0sUAmTy_oVAY_WwGZ6~75{eg79MJhU<#?yB^t5*W+
zQO+czR{{oh{;J7(zcr}Z47rX=-t!h^biTv{U6%go0<&k|B@A}{!N#0I^3ZbLbKM^b
z{*mJWEAlAs-EF@3Vdd~$AVry}o9HOm3I859X+RUwC~GzHd|0=<TAdvX{U=dSbtY`j
z+|I)qT<ZZ~sk_)e%r8_XWWCSoDfo+udB3qq7x{YeBy^Vke%`MCHAI*h*CE(w8{5NV
zzX{I>d)~-6UvIZu>W3az8Clafb-CdYpF?vkYg5(l>5wLZU!}>9@6GjXj#Y5A+#=f3
zU~2joP0@z;O|1@kUDd@sl>Li2(IVIs^1Hvi+2_Il-7J)odYIz(l@;zHpr_)mp$64v
zEKXu9lUo_k&bQEqGp&qq%V|R!U0a0#5iJGx4>$6h4ri>yO@7dMXCyl+@+p{gUPe@c
zKeO{zF9R<TE>?WusR8IR8&e;@_*sopR{huiMx%VwGVd(<Iueq#D_;C8Y5&_M=cVhf
zGPMx^-!qioY)oaa@EHw9#oIq{Y(+@|mi5d9NG9)Xu%#6v2pn`M>OyKe(1WtfF1z|l
zORg3>JvfUbEFwN`D<U@Mt{^*f%iNYMYIoDyVt6TkYz^mUJ1|~Q{@~z1w7G(gX?enK
zN1T9x7_j+?>!nsnH&$^KU#%3KRj7FDX`}<>qP842WOz3-W1u{TmM(Sh&UhH*Dxi>G
zZYQ<#3$8Rjrxf9u!%g!0i<bVu`aXA4qTHqHE;zu~j~^;nA?pWwtsnE^%USa)rDSgL
z(*F@XGKTb)hZb-Z8xB;4(xh%pVHs`^N)Rs&Wa?u_4qk-j-oEK(7wS1T3zGw0cj1?X
zP~W)|)LpjJqAjc;3$5~^uaQKEch?aHp#@HincUu8&x8IUe_I?8@(?SlGe5*(M_5f;
zxF=TIJ%-cAak+=CD$&J{k)B=etRh()$#%lp>Mo6roP2`n<mnlZ%od-nv<wJ{gke3E
zaL{LGCqmX&Nh!SxVi9Qv_=gNJ(z^ZGn`QkIsLHaGeZ-jQC~ffaj{K^Mh9qV??mc^$
z75&f$c7j{vP-iFT3v=CLd+MH=qKjMRszlVR&~-{d9P=aY{ar}#CTAQ$#PF}J1|8f3
zQe6t~;qi95q~}eD_uhEe%JNrRyZemkbA*uVRC_hSP@@iPLly%UfT)TuZy#@fDf(5_
zw7PRDQVPVr$g040Qf2Uxu%c=W5UWJecjyl`<}@!1hd9OIHIpN2i1sdnphaxA>9F7e
z3CdHP{)+RL#V5$o3hMzo@cbmalr}I>i#axdm>Sw8&3Z==&1_AGf|Lm*{5v8Yd^knd
zmn3$WD|^Lep2P_R$vsU{l0A&}ew{?n!8iPwK+1hC4jdY8L&WmND#7iu5N=ekjTvFU
zR5LfZ3soU_uFT!7pWtq@mE-rgy?+B-zB$fMRq$(N6O?k{@ot5()4Xfds2<2~vf-W6
z9J?e?dQ<jD<a=UxVX;gn3slTK{Cv&Bi9hG<Cx<!GjGqp;Q1cat?D3>Z2#-y9Y)Bnq
zM_2%KH({slcogbqX1HDnN3gkVQfU@pTBte```PMu>{koSjDNIt-&}QH!z3qRw{J<8
z-`?rngd|r+IM4H#gf<;9#%8AcYAt_NRtz*NKpfzjyIl9d-G4}sIw|>uj6;<dgUE4x
z<26Z@94VlhseKY&k3-|~rql8hZ#=HGfVf*BJ`vr^54VxdKeOXqL$BN;Pa+!kyqA`E
z2OKCyMsIA-E+gF~Hga4;|FYP6=Wz7wOohz*Bh1fP!bVC!0y(bp{=PH<IU@7^DqZ`M
z_d6-9kt0L?g|US%(7uisGTm5zDi<DNO{~1HU~m9#qPey4^VNmJB}}j;61V+!F9>gE
zKcg*c<G)uI?hxNb`TIw#Lp&Pf0wy|Bhtpb@VJw5=U)GM&>}&5`miuZSu?5P8AKBj!
z7av=J7q`U!h8aSINhP*5uH5Ny)RO_R!=<z8(?}5Jhhh+Vx+|d_LOORVI!v075%myJ
z#|}V?&N>N8Udt6scS>m!H{NZP%oI^sCTL=O8;Vax{sWYwvXvBZ!LeDQN{Ys7mQ{tr
zrdW30i<pGlCTySLnX_|~y(A&IKbggWn26XHH3Uw2Sszop8D;Z8_!L2f&rd(|(n4}5
zE__R+0}F7a2tM=^^5K>4Zt4c(r>7>ItO5`VdAldDNEa!N)+&dRpp2U)<udPThjd5O
zcYHq;>C;{AuF1#!Glzk?P@k)A=gX8;_>3+HE)48Y!*h+UzVg@X%qXOhUCdB_X=BJh
zsmfR_!!jtC-@q%-l=sqJsjmKn@2M^t;6GngZJrj~pOHTaL18!ub8cRoEBa->2TYrU
z49O;#PFbQa7T+IelurkVW0DEx-Zsx+&vc9@7vnq`HMJY1JERbi9L*ty*GyT%Yt(pY
zK1-U|lt9T-7-Gkhg5=O7-EbQ)xIPtM^OvE86*GEX*GmRUmq&+f(qU~nT3N{pmMB5_
z$*5TZm~PT0i3)o&n$m3xh##E(0+WGuA|Y4=dD~an&4ibXLlk?NzsbA3OQ-MAFunx&
zH3Ox388R*}^j_@w|C;q=jgTy>W8Lz1ZvV**10{|gkFyufB;jVL-~U|N`ln=CKt|P2
z<kzPm$7yZ+G$ip&K%5{=joM1!<(KIuILzDu^Z_$oNqdYcrq3ort-b=lU(!QtL>)Sh
zDcDb4=OOu@|02GbV2vbf``!B95%;53vtTwCgVxer0}l=r0~j3fi_;Uh_Hu%2@ftT4
zyysLb%So~;1`N;L8P8YVmSp-JeRiwK;^3Qu+EconfMIwNh2_eRnk->@#h^E7uEmQi
zw&hvb$SfjduEGHL<=l;8YmvMcq;Qe=lqcP!E8exV9B*lOdC2`LgVXCd<e&5myvgx@
z$h;F2jnfjfXgw5bl-!l^)6ze+h{bMtk6|n`8aQvP(Z5YZ^Uty`b2{s^2^#I)%<Un*
z7F^JgG%tnaJZUqZj#$Mb{(FlK5DK2Zu{ol9&bf5h9Z;At-zk9SX~xANka9KVJgu(F
z>GXw$Dt}p*x?0QcB1Ctt7ByI$sZQOA?X_oxiBCl1rs%t=4~lQsS5s2UVxA{<y$Y3R
z?C-&d9@2TjVWU2K$#^JmB)qNMp-e6ijX~SZNpO%DmChE*=cL6wmGmNs4j5k0!q<B(
zY|P!zY{7SypUi<qKBa8NjY`KYcTYq!#olqmI{AjH)Q_}?cr$E`2${Kg@&Ij*;U{<E
z_(34$LvJ}^QJM*9Z}tKqy|49*@(EE`C?#^*zJV-cX&9PnWqssj-;ajq6xlx0#ga-g
z;l_!QY-3|MCHZ7NU7Vx=vO@CbPPZB|siJr=4~Ok4c4L2bGH-T3TYIJT->mA)3H~&X
zs1&o+N9=TGKgaa50Uav;Ec=B~bAp}q+x%Rx!E1bg+#>&ZScDCTDcvR2uFpJw!6(&j
z$1MLjwq^TYzw!}2CY-<ryLI`d8TT+{#fF7?x(UZF>g(PNW}X-afct~nn&|e30(G04
zdEbYk=a|Vh&pIcqw<VXH3Ge6>X63B3;oAy*sK}bnNJ)ZHvYU?Ai5gtlh`NDzCE}g$
zC*8#cR*bG7{3NGm(Ve$17C*vu)nq^r|KJ~fmdQ3u^sp|@P!iO*cZJ?Zbl-E}sYsP^
z1^!-p(!pe3{nR5sS}^99OA&+V{Sk%7q{2;I$2a}XhswGBHwMQCmTo^jZqHz}nKM+?
zmtK4^-j|=NWrUSEn9Pcxrt2kX5R_^mB19H7YcxA!Riy(Af+_L&*>`no8xK(OyA%J3
z9A|N#)X~Es))y3oy-8u7Ak^FzL<kWD@KaNHSXz4-bg=+JtP*@Tjv|$?itV<C?Q+Ma
zUjE9b>l`x#dYHz`u%?@s@)a_j>6Cr?IdeLwey#)S?tM8&^)px%he!bXX}cZ@bg#cx
z?wIL4_0saf3+Kk!c!p)p&rebdXUT}T>>El-RK1H{i9N}7%0T-r9e~1BRC@g9!u&&P
z|3;wBuY*pY&Np`a)1}dm8iJK_QR9P>t|pyadm$z>g<8n%i;O@Iwp^a7hoTz9QM>VT
z?3zFKEoX1Cx9}m70s_0b^-y{)<hL&Eq`FDwy2LDN|MZ0KCY<02_7VzQFhF1MvIl0a
zRa<9Dy{Od|BwIm;nIxA(f*^pI<ObfG%xV}l2r&X)6}NRWyEKtUFK3b@mpYwDKkPnR
zsSl6OvD>pSkVVdE9PnbT{ty;FiCQNqE>jwz`bonZn3+#E%0=7DrA=34^0YAl@dFn1
z_KKN2{?m2h29+_oL9Xlb(5v{ohe(cUt8hk-=d6CGgee<Z^^5!^D_o03b>OfDk%!M4
zt&*X@%WuI)Xf$rkTUH&p!{)kHR>%Otdx7dS8(lL-PHrtkVpU7`pIE~U(yubIGxg~V
z#WmM1-}n1XCFC{L#EYuEwAGAwL`9=D^}11~aUWL1hwUXjxoSFpG>Wd#&Nq2IAl()v
z{6})*xEQ?+?GsNV@+H3L@rI4=`3yrXJ<4nW0dHL1=zagG<QJ)`x{Yc9J>0L0(yP*l
z%%wETmT3Bn+^L@+aCR^9(Bi2eY^is-&Dl>yL3MApi)!Ulg1vjL32eH4SwVw!8fs>y
z!|UsP?cYaFwo3#wvm8e*7B+m(wsN#jjX)XKw)dY^vnEH&xXjaab1+KvsjZywJI3z>
zdPi~dt@XO)B1jzP4hEaW+*==DWvk=-zT<sECf%<2fo;Li!wYAT25lCPzNj8S>wuCM
zJuNb7gC^&tnYee(*vI2y<FCFG!hSU_Z%RC6+L|36rfcTnu9O-pfLNr$PXYo%OZc_j
zJR-lg;SEn<;mca5en)-%PUW1+JULVuXyxXO%i=QE<w;y@mj)Er_{+*5=rHY|_w4Y2
z#&Jx3<tDEiG|!~0PaYOcB8Z%Xn5oYX0Y-}vi=d`G#WLMN@x5<45SV=?B=W*Ma=5r|
zcILIrH!XcyL-CT2X1c5{u<~w?pd47hZuEnBMbCv*sNP?PlCy(4ev+1pgUVvSwT-C*
zmIU3$57p+WmcN@~Rm?*O;lTPdOL<~s<YVajBizNziAjpmsP46Mv(K4!g~EK2;vLJ5
z;g@DM%v{o>@?bDWYeVuyx8kgc4Bar3h1YkzY-hEuA1s^B>))}Uyi}KCR?pf5kP!hp
z_%nlcX%?g_+bg+|KgsXcu4Vy$rm6@}-o1r=@=Zds)mIsdzrGl`d-BQM23oghTF92`
zf<N4!G=68p+D;U!JUM3dGXf;dz;IP=a0s}hdVz;Qx9>W0Kq!Y~L8maz*h6JYQDvlS
z62u<!AxRjwGAf4fEb<4SQouRbcgNPsom%`JEIK2;?RGll*iP{2wJV?^GRU$|o=`Aw
z*5<>XbTP0@aO@Cgx4V+0eun-v$A#l1&uEccA5jWVO!Ma~MPmeLLrZ};`r*inCH{E|
zu_lLNk4fv7#+D5H5Cz?=5_4!V-*6w#<Hx#T$XiaFkjqTSmC_uB`S<goTOB-56TuNR
z5nZ3Zth&a#I!%i|FR6f5{n>HBRw4F0vq92zEtMXTwVcmX2+Jp!w)mE;U}fkd!>m#|
zcam+b)w8}&D0MAprEyFJ#tATrs`yfcsQ8eRNMXeygb*vNF-}E3nNv!R)@*g2{BL+|
z_xVTNQ<^#M6Jil}ZlJW{tXikP8XPsk8)K5>a#$W^sb>xP_6hKplY_Z#&x-eocNP|k
z=u|{8D&Et|XsPK$F+U5Y^pPvf@GDi8rK_7{cs^2W&8M-4!*th$IIZD{0g_&AnZ|F|
z#8ID>`Tz}I(0n!6HZgU^n0ZeZ=h64kIX)7kkZs+$4skc}#Iz*23|B>2I>oC;qB(x_
zg9#OjOtKn=vH^Z{1L}w`-D?O}!<c)gd7cqN<zOk50i`%M!?@#5*aoAfGRf!m2A6J)
zJRD-ueIXFKnx)n2P2xDRPrqV(6?0l{|F_02sK7xE8;b$QjE6dv+e=?mxVP=<;`Ybg
zlhgyVr{;`ezC?8`z)X_KeESUme@D=N2s|E;4csks;+$QBklyQ)El?Q5bgz}pRB38Z
zI2}4V;qDq!oan}vbtje%{XOpP`pNqASP*{RZ>%jBCoj0DFcFQHcW|FCKXV&cSSw!I
zJU|pvdBdax^Jd|5*7=O(x6!m7wNa(8fB>~wnm-H&V$$x2FK0?Ux03bh#rdlSoQxe4
z+2=F(lamdWYJ3fehEg7Nt(;7#K-BEWqV%IKt*?0&<9?(?T95b_M1l`^QD-P=v~f4m
zFcC=x=;;Tq!9Db?Y0{0h82ywAE;|1GK5?5)9HZL3G`$7I9yTouK0BpWL1+#O=*jZ7
zc0N(h2%q<25h%*AY`!N5KmVu!Y>g7K><nO!==qRhM?um{uq#cOyuy99+}FYnJ04Ev
zuD^Z@M0!;~!D|hR$IOR4$Jo)1mI|@iv=Q{X{!&|+1mXU91mVc}ikslczw0)n$tn)8
zpzp8d+?B5_3z5WHXWA-@XvvM^>1v;&@AJX4xt%0(fDdtQG1RW3Uu4_Izn~dB;EcR%
zctV+|K;a)olj#?=;-bgD6TEY?B$uaUb5~ug=!{=9Ec}^gR|AnL%QCpz&n?2oPP47W
z({)6>hc`W+4px(}*%;f#KTLh5m3$w%-Gb^bLwRm3_Qovn2zKPrP+_-w@4Vl7J~wUA
zuJjCA2t0*MKI88Ef9zLEMa$eKZ9P3U#lq&r*rvz2Qu;p7N97LUCfX3qA@a>8IL(^E
z$ITa%eCu4ux^61r_M7CS6%i}_cl?5qXm_Ub0A&+xWtw(e)aIIi9=Ug;UQ6rSh#6jk
zgYxChPuEw^m-!qf-2v#S0#|@4P&uZHF7{{0KTQv{JTKB3FQ6b2tuA*jq4{&n*ZfzS
zSc>E&d#_bGl+p@@`nYgN|KLX28WWVbB;<#XX)(CSXFiR<Em_}NM!j>zvA;ft<m=f-
zL84{2ClM3TuoN{_;rXGQqfEM-j@yU3so<5);2(nG=Qp(3D?pcG>r)5(Tm%~=#lhvH
zXY{sH1Dj{cO;6i3)<|6b?5j-E;LP*LI5#+v>nNuTJliyQS^C-)C-Qo%qzOJT%WRr%
z^JIE-^Ck8I&0*_TH_adZC1c6Q*Z9P)_%lPoI-I8Azv8!P!{#Q*8dk{+N2NW5F&DN$
zRw-_ACh%<8U|?B#-xWvvddyE|k_T!e)i}=_eHLm3<x=|r&bY)T32WU3{YvJPTR97P
zL*R-pIwX9^zFS+L**$8rT2G!!`z@pHaFsmZ6uJIi=Xh&+nf?k`(aoqCm;1Z=`1DgF
z{a?R@P3$YN+l|)m%<pff+RBI6gsAUOx|Ve31O-+E{eYy8us-Xlzaz6dPKYPuuBkzI
z>#(Um0+x#*6`;$S%ieZJpoV7X@qrV?%*+G!+qZZ7@%VAEU`AW>Vq7Qa(Bmo({;lTW
z_QwXwpKUMeNS7Bewi@XVPDoL%+Q;)pG!0cuEbl~e?m}8rlzn~-6b)6>ClqL;C|Fon
zC{%Cq3{$FDQJ;&Tq96}bS8GQ%PL6-h|A{&tJuUkOgn^ENLh=vxzmG!HWHwYV%|8v*
zij!SeA&Wss7~%iaBd>+1Dbj4HbpOJT=wGd{AnVPapr8=_I|g7wrT-UZYQDT+0$Im~
z#8CY^rkxFy6%E-}$^jcHl^7}x1`3L|Bd43YkE694hxa?j|Frs{#51H037V(>Ppea;
z*-^np|Cnt+kqGren$(1bf<o|b-C-kdk<EKKyS}w>c7FT+b@0DmEaksFobrPml^vsk
J3)wQte*w39zsUdq
delta 73377
zcmZs?1yCMK*DZ`g&;)mPcXxLuxVyUs7&JHpcXxMpC%8-S;O=ghbKd`Z@BOR3sy#JR
zQ}y(8_tU-h-fQjt*n_xQfk04{0f#^Zfq{VmdG<@IMIZzP|Gd{Tf_nV>5MK^<_|J>@
zBya{`^(*THJ2D%ulo7G`j<zksbj!Pxz3b%}9XOQehW9Dg!Mm5eefg1i^KT>%)y4UO
z5vMr6Z{Mlw%YL62C2hn)fOEt(FAB;v`I-Dt?PD_J<Na~c0}YuX8ZAVwBezJzDNYs6
zW)ZC^n_@v<xx_n=udg&bh@lTkcjGP020`x$Y`H+ot_zYv7odXA`n)tjOA6&eB9If(
z)dghLfp!d)Lv}hR%~RXp=|tgA5OoT%L9|zmwJ8xqy<yz?yx-2oq*2%ZpaLx@EimW<
zM_S~-7U&I()tF&v<Zfug5G22XZL&W+?1;k0$6%RF@Z^%eNpHxY4aZ5^th+ii9&Rh)
z5dd}7*-(B9^nke4w&VKwB-FB*g><uY+BjxE^9rUY0}T^L;h0Ya3IbvX1_JW`o7nny
z2=xEVEC$pUuz#nR1m+Uz-v@N0#{bOq<X1Z2L^6&Z<|EPg$v2frWWTpd=j5CzQ;l1T
znuevFyuC{YTuM>+3#kTS3F+O5zIzPFmv7tK5Q98wo~WRNeV}0HwU0Yvz^lNj*xh!a
z#iD8F>r{4!{#rIa>X;=TO>)e~(;V<|b#`!DjC8`TKY3lIhyMAhO5@}9<8=vmRRcJt
zPKxs^1Oz|!o&^9etJQ^%=SN3AA8Pcc=VUK6+U?N}J9JODkcpk)yE3Y4ELSa60-vQQ
z0s3pFr}(_f?lcvP`5R9zx~}=Ti9C&_a7h(aPdJ5cUuyM}=s#|5$eo(;ACTP*Ke9GR
ze3jJiZ#x_W?Um%yy>zEm^^5L=1%N-7>ShG>9No@Le0#m<o;MwuZ}36tmpkO9YE3*|
zL)rYaMIR^oj+z`#1pybJNJ$C;HaL${A%M_@|IHB(K3DcR7284VmGC1g0~zz8e*!>W
zX`wJC@D*;76#XI$Qs8YV<Rc}qN7myumumlW=!p;A_<gi*M<hCV@*k8DK=<N@YYCts
zumJejkFMyp()!(XW*?5*-|1(c9An!-&Wf6^dSCxgLYr$!nPGyRD5%Pg9YM$d)BI6+
zGI%kE+g)(b<}mf~xZGas>t{cJ+09Ns{?z98<F$LQ!smG^dsbigajo7c%f1Z#+*dat
zMuF}t7<um0N4Hr!!=M)|5C`_~JSgy*$KaX%u>`Q*=@Vdk*L*z3P<^kujQzMN28-5z
zKlymLygC-(@9Mdcz1vebc51EIGXL0MpRNd6ntfkt$aotbM%Vhg-SuQ%^~9`?`tx4D
z<vvEPQxl8ZdyjkfY<~JRz3}Oy=!eHoz0E<ruG}TIRcmIUMU|aIAa@60$+1&=acsSB
z{s4Lj`e*1dFlAO0<7|CaubEVNB=4?MeI497)maGbo(x^3pq4zA&+zii!((dXJuBAd
zXWznG;`YyM@4t_Xi1p35AF25$?->lErk#`JPHlkzfm1!aw;_SaN>apnL)I=MC#$Jm
zs@{Nl)dLboN1KxzaQYl|a$UH>TP4r~f0G;BTQj(FBf|GFZAUJ~vaWj9#>&_0e*Y9A
z@Bv=&&4AHr6l3c=xli;wjpV`LnU+Jx+WUcPZ8<llW)!FR1$(`<GQN5%mD>EfpeX{{
zV<+T%hD1V7nw4DFn!#Ra$*3AvV3*=anM{Vf73COO6X;(LpkJ-)aMVf8G_cXT)T-UG
z)asH_SM#s2%iUhZ5R`QaaY@OoVZ1R@Wx5pC;Gc>$+8WyVO{fq0a4d8g;!eFj*eLD=
zHF@1d2O}+>@?zZmaPtBg0T%bPzl{UgAnt)&NU)Dmrr-imR&rr%hcXu?odLhgR%m7O
zBaxA(02<<EU`@h{HHx6iHK4Uw-<LD-#|AuXudgBur{24_JvJ(sS0rbo&cmYwU?wFO
z;igVEs>!6bW`K>-GWoz&p-X+({tlB|)Z-*M!pR6>ynCo^;8VGImRv2deqyG2LU6CW
z`G;Y1g<*4*K>*^wL8axO=$EnoCcx&XQc{#cD}}NIxW_D0HPp>v4<sHGUB0cMM*l6E
zo|L;ETgpFo?Qfh+ZlNgC#-xM0^ODB(`f<1B-&&=&HK01H@t7B4URH`OK~eji(^{)$
z>G-wn@j;w}%R4wvodYTH-rd2v+uOX`+rIntYgYf_OjadHG}?tPN3E-9Ostub$G|LY
zCTxlW0It1mdIegHw*&XuclWOSqRL8ec%qFV|E=5M*<}xkyeWE!E~Ct7VYdivF8EMK
zA|E2yI`d+)DPFzayK%AcU9+M(>k=dh6)p~=L{LT-RX5C<a+-T<n?`pq%K0UMAq-nm
zRhx6{xzG;hRMdT0c!HED+<r|zU`vuck7+Cn7@?=SA48hqibK92BQtxzY$lfqJ7NkT
z4VxoT3VUL^cb<%VuC>*D*XW%znuxmBSz@sBzAHZ95zx7Kq2O@yb?+>v*=+gEd3Iix
z;Tv=2ME{;*9WD4Ci39o?g7#?c6~V#O-P^-~l<r@cf5NEi(rBa~D8{X(AD%?r=J}@e
z{qNP!XdD|Y&iJAX;@00q!GjNNI#rqGe}-)`t!^^%r@s{<FFw1%#X<eRRMf6q?H)a<
zmkKa?!8PvoE^e9OK~C`qy5w_+;!}Jz?VXC<@f4tlJ}{<>7ssFl-fAL&$r9NbyacK>
z&@p&BWDmQf9#`5}{v<3NBrt}+bD^zv54Ovzl>o}<E1SdNT%_Xu`M{llu(kO+K)w{-
zHyY1kzj&H{GysBt-7TN<b)}d&z}FFKDv6V7?N5lgWIbcBc{4omZ{M#{oKkIXX4s<0
zC+cq*FeJZ+Jv+02rBh{QE<jOAoQ~*BV5j}<`mW^1dZg7`zwe3m%O20m-jA2Pkll<Y
z%Jq8X(Mbt_rB+!w<{Rh*!G*YnFr0?c4zK<EMiIK)l6Sp#5Z0D)Rij>w9fy<BsJz_9
zf;t0x?d+FkwTLP&wScs@eluII=Zn&oE#Ay!*HL*IS7ReUN&AP_Hs`}3wJcZsU#y~E
zg@MO;c}_(*iY9wGCTSQl^G~SLE_d^Ii9hqf9>kZ?d{GEt<<%4-pc*tansVf{6Ba76
zlC?`Jw5OqY=F5kMosTtZgMKX31pnz#EyN!rl`7SZJ59d$w6kP_S!YtJRT<?W>Dg>@
zsnPjS`cR-VfAI7mGP%IEbP<DG>2I4)K=lnv$;%(_+IN^=x#WhZg^}x^p4ruF)1=ZA
zYxfpX2i`RTgYMD0)gg8S@6@ZsNQ3B$y!A%+y?Oo}`z8KhsJq}UT@jU19glW6%Vm^m
zf_f8ZUw+kM(cL+q1ez493GG$%;LJ~*ICV2txYh#HZFy_QED8k)P>jKd&4tfA!3Zf;
zpgH9OZN@=)fFPU<C)l*EI;@-|fjWq1xt2sBNzJiVnV4ngI$l<Dc_6ih{*Rw}Imh3-
zO*)BJCbeG^8#HVUKyn_K=??KH8!}W~cVuaf5uRPCb2Vl~wimxmKU%66K0sDV6Rs0x
z8p#9pzp2<CGj62g&!`~}54L^g=m>EBL<W4vzx^{trRG3X=SOyf!mD0+0TxbZrBC1X
zl2q-wApBykA<n^ecyd+XWki`K@ob>z?`g3QQUi;9uNeq;3HH-dHJc~m96^vkhf_(j
zwEHnZ!}3N#@QXp^#^1;GqDp&2`-(zCr_MYe1PnE=heC|)Bkw%NPg6u6S?%RH?|q^`
zJueZc<iGFcxJ*CtOc%}s4faW&`vMYEbH@Eq{<3{?{f!?&PbWD-t&l#sCOJn1hd0P8
z|8Wp>LtPdLjg~!Amb*rx7lk31_$ol)8x3%Fc~SmMwtT5bm!W=Yoc3k@@$d~9PYx7V
zNvZ6@H;LKzXClRCUj0cHEcX+mH*Yh-aPVRfwDPnQLZP^3aTp;yL>r6JF&1g{%W`JR
zG-wlY?aoVs)D_Aa#^W~|o-Iz8zOSL8N~hbFv?M-}I7G|r1A^beA>0wFFdzh8lD>>O
zKd_*xwo)C}TZZRVF?>L_mvM#%?pmY)e@pSi3t|Yb8PZ`1N$^iijv`ZAG>AE!-}axy
zO*T7U=LctBbr{G?PJ|%{*gW{SC!wbs)VsY?aP8oT5h=0_ep#IimGl|dCjbMUw&5iF
zudBS=tD_c7Ti0U}j}}&lV|O}9-7fJdRd!2z&g$!>@iNDao}y@E_bQEb>VZ;#F*vtF
z54$C~qPnHLUv?PUbkPae0b+?Dfm*JRg;sehqJ7BN6682E=c7^nfl<`f0ZWuyf%`C|
zKlZ4bj9{4|FSYY=86_qiv5wiep?;F%^o&WgM5dA`{_^7DLdjD7==Ld5)jR9)ZYfO~
zi>TotUPPOFKuO@foA9_bs?!C4EPNg{i{atcUvSZPcjDOGj<xg};_#ro{haCWrq}Y`
z!%xq0wcIi(;DBc@a`St{b(Ej*S_lDMV%TPQHMVC6ImAQ*(&y1+m*WF095M^W0-e7#
z*Ljaz{c`FlTH2ligsf#sbJ-(K4v8P4^vhzqt9FlgstUIT6_v*vukj`DlgSx#<N)Qd
z-iz6ZeHCRMRAr4(_Un5=W`EE<cD$1=11zy5japd_vyqfG%Cpy8m2kEaL5_SbkB1m<
zXxBnrK_l^^rAsmFy3kTv#Qffu@2jD#blYP4tQRh9DMVXta#hih%B4|lYsQwldcA$T
zkd(|_2lz63l-x)*&Kgz#c}e_Gu&E#RIf(i%>4zxT^OS}qB@l`n7{gwywy<<T5=xSJ
z|Ng&hql$Q${%(Kjr5<|Ghm7eo&a0zlZ8?e_$LD^KYzYV?#wdtWA<+}<?Ti}*ZQkm(
z_)csfiq^a{KKXT{J$^`y{oa<nh+@3hF<Vo3BH}%+ba<0*@nz5ffXhkdqASEjR(xwP
zXM5J-s{}p-Kha_Gbl$?j(L874_9(5zpzoFG#f)kUEKWOLkQlv?Q1nzkhT_JQbQ}AC
z!r0UmUlvxsh2v6b%PMk<h;TH;q;36{aObo|YgYg#En_Q?AFXYcYQ8OIts3L4?Ypn*
zutZ3Kr*<rMDD@PO#;>Js6ef*dwpCtiPPL@64s}nV+O?~#Hp|;a?33b4SQr`z))rq&
zt!ntJl89bBKY{JW^T<N+RAqs?Y_;g&3x;C%5LuFJ{ky{zb_#N}v`(xao|ANtWPKv_
z+~8c?c1;g!X__aa*O+a+^|^JO=0vfux*Ufv|D+^X#i|z=M$my)`}X?Fr_rIzNpH&@
za!+F;Hh53Szgeq~8I%CcJ!EVG?ybzLwqTf0Mg2}|>lbR2YhiiiY^a=|`$Ht!mg};y
zvaPf}iZxtALh!ZPI!f8&vwF#OpnBd|S^24p+|18L$kM-C7>5$y)s)NqhwN6~o{LgS
ziy>@RwS2k&u=32V%H{5Q*O`vflXS6GFr~^|@wDc3Wk(rp8&?#?+N8TKz25M$0H+V8
z8dw55>5Jk8Sb;4#0~s9*>V-^SpLFxKw$d$bol~olE?*@uaHOK6u7vvYD&Q<MGqOGm
zTPKFjN0W)2A>$Uthc`Zw=(?v#JQJ^ELQpp(5mgOvtMP@s<E9pl%E0ksrU$#rz{!_J
za?vjsxlvjXcj(H_rSg;c4%RXv+^F~USE3+lsTxMfv%^ZFXG<6CFK^5OOTP$4N)bZ1
zh^k0g5M|N?@>)2K#tBbo6`mLt!RNP8i(jWy`BYP51_bWBCt`mqC~QvhWyXP6HFxt3
zd9e=wdcX7VgJvDi+Wq01AO2bh(MJ6SC&;Ufph`ERd<^clM+2^Qqo-}LzBC5pMekTm
z!F(k!>=lTH_%V*_lD$if{k~4rm4X8U--D}r_in60iBw*)oCE?GB>Sl*VH~Uas4|QQ
zc5pWmwWOX+AgV(FU@kk?SZ)~TD<Z=$hTQ?=b}tt=%P6hYJaY@tUoR~YSSH7F1OCXJ
zK-D%GHCm4}LTZ7CmGz~jmNhBlEEi^p`(n^;1f96|-Tl~p?*DCnPB)Bi)5*Kob-X<^
zQX7VS0b2hh##Y=@Ys?9%AL>YP94B)ZnddAB@9?c$KsUcI`fh0F)+~(D)A&%g{#Fps
zWn+;JuIzt5>ksG#G&=Z1MY5EaGL2x{f35k8y*9D7d%*s*?7QQckU3`<CeJ=qU_yHM
zQf`GPtb;BVmM&J}BrgIY!ABv*t06MT4$7rb<5|J9RP8Pfs>E*Nc>4TPD3h#dlqLe7
zuycT$5|3rX_eR-JRw0;)509g${@x5Yp7?rjuCF{(Ufy~A{#By|jJJ9s3YP}c@5|Cf
z(8)vJ9rOh)3FCzU<bLg<c6S;E<{!~sxlT%45JKA8#KGo>3o`B9I-d`D4T*gofI{YD
zJXl&3jl|vz>|fjQh-X{Wl64C*>VG+wJ{wA`zK_;?DO+KX@mT&B;(>oL{+(L`H4s+7
z4Vlt$EQ}1k7+w4hX^4>Dy6Y<aTj>p28D6oY*Xhz|ycId*No3zc+{%1&$`9|4U96>^
zHl(rmzB}tpyuo;zn~on;J%PH7oT`Q%-eA0yhI*?=+f4SsC+^QYZQYN<cJukCD9elf
zF<qGcD3GNR=SaB#^e}rj)Q3UCR{c+?ZtN%vAJc|k9xH;)z42Pr6>bghWU^=)#07I4
zC)Yl`dO|I}XEF8a2I&XuaKz~A-Id-eJcLPSc%Vy@$GWDse^9bszPI=m3pja<S8q`I
z^4;xqn96<hq|u(fzYvHou4%Ie#k$+@45Mf_Bb3fhR2+2!#v{0BVms*<aN~z?<DASE
z(Dp`*rP><&=bJJc<rtmZ4uq$F{wP1W#6w=6%T2V1Ao~t|V)taSk&0w5)nvH*HUXh$
zc5u&!Vb+kEUpOrSu{&nVPqKUEYiWa~r4mqQT-XaZ$_|G&ueCF~<$ccwqkTCgM)WFy
zppaIys?9IJ(natI(z_;SJJ7S@gO2wRq6EDc;-wWGZ;S+F&C6(B{lIQoEwxff^4nMz
z6{knZ`wp{I{pRRMv%LTGzTR`#T>aU}NMEucYOoTg1KtA$%vA)30kc?~sFPsm?teb<
z?-x!P5b{Wc74&Ims_<n7wx?m3>eHy6phJOibHhpiGZWhfA$Cx2%X7v+(WJD~0F^4*
zuvKr<F-Z@tJSnpz-;u<S^wNU#^04LCH=7&Jm5$vpfXDV-BOkq6EIHN3G%69ym-88n
zkh}Ar?yMXn&Qah=K%R8sn|8}QHBHs?JHdz<xXFXvlIe7#RBgg75xmw5OFTkf0;A^N
ziUD7y>&E+~m^{*Ps51GiKPUJX98PZDVMqK;r!ie=d<Y7yR~q9FsA({VRZQ~~P$eiZ
zdM`V_n43JS1i%oULXfWaa}Eg@x0hJq;B~NHnUrwOy+I*SsstX*a}C}>A#XG>53|L~
zq4kL{3{zURYXLfilSZ3tZ2nnLVAWA{o;G{9r^8-7s~o%pv$h81{KETC00dG!2oHIj
zosCPJS(tE+t&Tgwyp!1YufTFkCw3*qW0%~@>JeM|l01adF98#eJ)38(NyC#6vUhq~
zj3*YMv0H=(IMO?@-(4LKju9LZILDj#X>7Z6W!BG9h|q)Yep(-e5zkoRKvLwAzB}V9
zr^2A{lrfxl)FU(c9`>TCq`i{e?=%d#o)L48PR(5ly5&U+q0L2vNNyTdyL_J9X45yV
zx%`HSBI+y9=3A8M5M<pdz3EUmJ-BD}S(;_;XO8_jpQuT;y}p$X>9U5wdT^x5G|Z4#
zL>OMgj$MlUpRv)hF1)^xKp)D=V%AAOOFox+q+p&xVKMmNz@atP0IJqd%qwBe9$5t)
zcn5Nht+$|~Rvl`TEF*q|wR#Z&qhxk4LN^v4jSmm}U25^t&T7n!6-#CEleI1y!O|eA
zgHahy2tAi-a19{+<aoldEQ~cwQ#Dm9l!$wM<Wx}g=Gb!3vM&$>F#MqTze@r{_5<XT
zvGRIUAjvqV0bxOmhYvbViP1EwPP7g44AVgG;!6qEg!}*q(}IB&2XtDlG*?Hk3M&$V
zn>XsThO&OA`eQoA_BP?GhY&`~zF+mdBTV}fNg!#kOBbx#p5O^q2{-(!*c4Fki@_-1
zQLjQ7z+dlQvBjveu({Cj!iR%Q@&vi|uC+*rC00EFX+TOpBn>MfyM-?{{9nlW0fStn
zo)LT1;kwTA6Vu9s#Qnn_blJNxj(RNmRS7v7l<!uu0Z#jY`t@&&%Tf^$Jg-Z$*W;vE
z-XH31RP@|;FK&!MWN3_V?&gPD>iclNA}zbLfo9ATr{;0jo)yzvU(jcGS{K*13puXT
zlmd#cf_k4pxLLXJ2rVY$Rb3_3t(Y(<gRsE#VjI;H{xfJ=b0DiJsfc5w@K4j67!l<1
z0fiB2eA9>wlo==fNKp2l3&|hO1}IJ7TDUb|F9fP1`^=!R1#WKJ>|dCgL5XYtsq3L9
zpb_qqb@&fF4Y7R?t-XB$D1}ZpMwI}BIcTRputkk-;=@?A2d=+Gt-o7l%D=9$JSq@h
zIYiXeckxKC(~a-mp6)mSz_|Zku<6wlw4EL!>B%cF>&_&c#-?Q$iJpM=(0XER=B|KB
z?y=G&wlcMy*Ufa=0cvTillDDnP7F*Y!O&5v5=aWdzq&hwk2`Lt<5$Pyidb$Fd7;YR
z>m#(wK5y1|{0QCOTxZgwNt<Lsnq#vanQ;2vF~5t+L~}!C897?$g{vrPJJxy~=3Q|t
zwOv7ZCLP=r#e!xot4_Ul>7mF|eM9zSPpvNI6_Hb#X4t^s1Prl_+T<io4fFe-ma|wz
zfl(O;Ce-=2<Irnc^ky4yZlbD_QvYJ06$fz`$mwQZ;osT;Jqh+P&0=Qd&w^6Ih8X_J
zr9da~p*fkw?7<*9iJXJEX&1!Q_3?_LI^W&OA1pwm=4!y&1P`&R^O+Oy!!f5TVQZe^
zKB4R?c5+f|0uy5xWIqUD5q_&YwSXSwYL&{XlF?46<(H{{JalE|B|RLARae=@&f_Vm
z7ng%z<nuUI1wObIE6qh9wwIp=Rpm+iSjCm^wp*_L5b?-u{)|+%pF17ih_-y}RQ_n~
z=n<*qULvm<3{#zgO0I@Sdmn<~Xk<PHfOiqpOlIr919qq!!50!jX=Zlbw6+}-N3<af
zF~w1T?>B5v{K?h_7Amb-CBHz_=(qUdMS{N!vwh@lI%5;u;7bhQ@=82@`zJuTcPqt-
zPb1)B^z)%i!aSmeV*)ciHmN-z|DFgqfb4*ybG=)Q?|!8uWrwfp;kh5%u|%7CnvFv_
z#`}T?fWd)%yv1W+t|&N=pjGKZ@AO>t#910@PQgZsu6E*Uz{%BCZMB7cYG{aVUcVaz
z7)kc~>{~wl+R?@7yVEH#UgT)}*Nos4Xy^gnEx|ekB=P=f!4c%1Ihv$u&ld=Dq0MIR
zb+r(+_E__HnNvYp%IAY>J1dh76gyroXeTgWLTR6*w}lmQC+*{F*VU(Mr&oNmW!ybe
zdOZ8B@Rrn!<Y3*?rp=GJ!w>mqk45&?7=tHk-oH{^VGwx;dt8gu>46MaC~$sgJ!@v?
zJOL+W|NM4#jStbwG+p7IC`$T~-Ma?vZ5?`b%4PmuMbPBa+4pLO+BgWBfTIh(J{thL
zZjhN`sXWV?X6R-ZnlH#XHor8X&*>LaXWnDZcs4S&KEYB`Io?Q&so0`e0^sN64q2Kj
z|NA774|3VS1d&*jv&cEN)F$!jK~4{44pa1J7^*+d?z(CK(-3VC2ys<j%~^>9x0Xt5
zFp$1_Q$ql^R`zCGF0xV{^vZ^`&H~h3(AfJmc=y%#rm{1KMQT2Zozz&LIe5>mUDsuE
zDyDOO_a45ZIuqQl>;5R)`3-s4_2A#Hdg~RrA^2^XF@0^D>_F}6Z^zR*YAUV0>Q;5!
z?4A+haVq`dq?KM5`t1lc(>ec|I=@P8YmsZjpSrvK+7*czf%z}g_MlJwH|c<xoWg^0
zL!oH_@|M#l+$DMTkMqJZAk{e!m0kJ)A@l;@-(K4-8(_~A_YbD|9LJw)ve+S^WPiL)
zqn|9Y1_dX>un|OGgTIr%c6|~U*7t6gDbEz?KcgKLo<uyt|4U;yT<>(5c7UVf*6FqD
zPuLV^NP~_Jt+fpU<-%E7we$yx(ieuij8!|$Rw^89R>&u1ddyg^t&^No%<XB4Ac4Ur
zOWT}`DYpFn7&l-ZfivJ59-;qjyNBNudBCoMnDVhSI%iAM)<^iG#|fA8@#s7p>ja`C
zrP!lkD@lTTvnZ35d6Tn2<B@9fv%S-^4e?oL;IhVD^=K2ZagqHw3OqSDr1QTa+qUMG
zlLtt$2)b@3lU834Y^qELA*Y-Bj#OgHC3Pe@tWEKhCyUbhI7t?y)Vq`IqJK!hNwvcp
zH!k!|-2}z44=ZM7lgF+D*0!bHX9P|Zn7a{T%s3C-#P-L;FkF?ENsKxP6(87;F%WG4
zWj16e=ZnzreJ_rEb4ggDbd8b2@lf7#;i&XD$hhphH0NZ_?M#@_leQ$d9*ufVTzJ~7
zdAq)L%~#uga?wL&k$Bs{ULX}!F7HRWeYwj6dPqx>ndfDwjtg<`l;fW3>*hnCw-`-o
zyLj>u<d;E1n8-2t_f?ZL)Bug;Tbpi!rUSgl#O#Ut)?7af*rn=zM-QS^Z{ee->&ieh
z4L*|QUTtFZfo8R?(!H{>*1Ga4BsJE+Qdr{pwQSO44w6+^-|qhcAMe-&2d`ih5gd{)
zQ(3zRq|hKt837BOOj)Tp*`apYEN`##+q)lP4n}dbSyLmh6{%l6zHPO_-)&#!*?G#v
z(bTz`j_O0f$D!0G`CtKmXXNGvKP;4NbMt$f4?LX!G5j6$+FgaAO=LP$sa7-YCM$NB
zXZ}iK2`~Ek1_4q)fBRX)1KkP>Uvcag<ox?8rYY6DZ`T(=p5cngxIYc92OQ?RcQONQ
zreOwECH7f>rzwpICq|Wi$WD())04^E{yLl!c}Vj@HFyO7c@kS17uJ)KAok}U_;14d
z+4KM=KH<<WSI$=>y;<rKD)_f)B&e${4=b)Gn=}^Vy3Y3|wM@a(fzr64!8n9qjk^Dp
z)%%(iycG-$!C(Sx7xCQO^P=2}((=LAwflcTKrjLM>Bpy%*u1YqUmxkjS@)%#41WZU
z2_q|Ztc71cZ6Y7GZJk|g!^lbzV)M@gL{Bb4(LGb1M=slR<@*!&&8d|0YfDM}C!WGI
zO6)k2MmwmA8~d}Je<I(uCX9lMpa(H~|5>6V6ZTO-nGk?F7|Wya>w5QE&3Hwk_D$Y+
zbEL86qPWMxsP~>L-ltNaH*O^M4BDe=rk4pj1X2tPom8j$r0emUxp;mC(#oP9ZgA{1
zm#p{rIC%PvXt2xWbQPwILgB*wrPtxGp&xAJyi9_jfR5;iFRU_-@w{h)Nc6NgmpHvx
z|1_=anI_Pf4}Oj6xYcLwOt>dWq|lZAJbaJEO9hW)!!j94|E+<&4yuwZ=BRkhqhkG=
z%*|5$tCxmTe1~JvrCH|D042MP-<oN3x0$-q1(++w+#9s;-C)B<Ycyg+bI5M-%|1Nt
z13cG$`mm33V*vaYe4I?Nb4%#qC~)fdPK@cY0&<`nFQccTRJDJ1NwLbQEvGvF_z&eP
znCfQ;Hn+xixf&xbc4DfXKd+)Z#|YDC&cuzTh<UpVITOV<Zh5Q?E-&#e<l*z(BdSSl
z{%)^(`sWYA4t|D?J*On?pr!7h%jfUgY<8TV>669w9Rp3rPKWf${@k0yG_vO->ENnJ
z-3H+44E4|^Mq%XP)mpA-GS-=3hpl6exhKUW>p?62o+74Cx)srP7jj7J&BVPG@h##)
z7pq=N6t*#-^bf+0aZLIM7`h$0js{#)@)jiC3gM8w*_$z`VC3hjv%nn~Vb6AB7>FE(
ziE;dl^5^s|8C7G1(N`8@G0bxp(#g3ALjk1`=9HN@;@RKiDgyFQ=d8R;@S0N;twt|V
zO0Qzx?E11!rVTcY8y>20<&xq;5@fALM{?V0*q*5uH9@u>U2a7oF~4wHwFI#~w@4aW
z-p>5VX?&_mb^QcWFJuw%zyLaC6NF5p4w$L*j|kRVW^0)ELqADzn@Oqq1BZgIzk%^U
zgmI>&`hsvzemW2?#`1Q$x9<vEr+VtHfzJ0IdzGt5F@x91AFCtxNu*i&{HZ?Z#O-i<
zEr&w1wf3g<c7U&_3PRn<JEPA{d!&v4;=M__!h`(=m+FZgUQ`X-9VH@P(!0C`T_jBG
zOv{M`DM;G?0G0n+XG`S}aJa5vbZbZJdTS@}#MKZs0D2b534e5>UN1>`NOQgBPluua
z+byWZA?_KfkN{1<8s5RHVW1#*GBGFUE#+yzG!I6Yu_Ece6)IOe@<+v-JLJQO_J|-O
zgJW{7g|y2sY)`E=BmYK7FV;_SCGK)-SlQ{Op;{<-*IaM+nHlyguy8zBwn1xNlc?8x
zJnzi3BvvWY@eS3MKQ}Lf3ypT)T^^EWuN1u9)FX&1X%}f`H${AHgh_xE+H2T|6V@vV
z;!y2VBiKMdHFJc4WnAOl$-<g9HZ0=3V7jynk8M?kA4|-`!_26M><mRzv>gz#$?i^l
zfWT8t9~|Ca<fVE9ChLnfuy-Q7Yh7?yoXMI}BUU&mk`v~416VL5thuvo8x^tR<LmG!
zFbz8tQ82xpD%$@vrH`uWh8g9@)VxbW^49XRt+J9TD<)~=!OucQ`b1JtLh`9bGAE_n
zQ#a3)Jod->QGfCc%k8<5+kcQuX=i7Q9ilLee{H8QcS&FZYxGS;HKB-?&I3Zx?)p(-
z)5K>-DM8yz_v3NG+hyT&^%&9&#M-55O_A)@N?uYc(hQW^R5aQPi<Bxhqw_1Q*`=3?
z9@_9SDy29oHk8u85cG$B&&*YwS9R>ix8+{4(3RO6qNk&(r5cNGVGlw#K#o;0jqX9H
zG#xb-A<ydo5w&)LF^pvN9`tUyww2Z22fchOYJ4h$#5&KTy)Y#G7u6Ohf2rdk_-QZj
zmA9$o4<h?wBw^l)H|L?e&^$*NH7X}3h!7_*kiCCx`xZ@G!#ipD=R*Ee#I`hMg-=_(
zI3&LsUO-G=11wh9{jj7YuV|*+?y$6E{vbWt&OKZj@L*FIyv16?Uq8#x>|CDqQ{U0@
zl>*<Y3$8^?qJ>+A<H77IxA?7u{P@IVZ#Jp((ZTfwiTU*@C!<6=QATXlbJ8(cP=7mB
zkG@24sbR=pL2mFno$FTB)H5VM#uO$2JT+sUaUgYeep0=kv<k6j!^FUW*eEPeVaTRh
zRVvpBke1bOE4#ZTRDg7f@vE4lb1@>>nW8@tU&zzB6y~HKV|VtLD)rYJ<^rR2zW&^;
z_GLw52pv$xdX2XljcNQ_rd3&&tn&CW(9T^{MN@d*2-@NGs)=;IoEn{pE)27bB=`YV
zx*auROV%D-&ur+3zF`X}s4;_Z@=`sRl9rhO2caJulpsw~xTk6ldD~Q*g`Nd<KJ3}w
z#lrW!%f&yF9GQrh9A}JfT9ritWn1+X?lKyTbDLmr8mHX0dTx;$VEHOfK_Y1HWlg^H
zcQ}7eQ_l+L>yXliz1rz8CiNLF1+6jJ-R934eG4yaGxR31u4gC}o+NAPzf}o{ny;(?
zqR>3)p)7WfXG1B36th{^zk6EJ3q|9}eK~I;UX6}8%{Im>Zi+N5Gj*Ld#_2ij&Cu^c
z9XCuw64eWnTrvpNj$@9t18+|}KMb5L?#t5DypnY8p3A&AJYDV&o-H;lfXn;1G;M>>
zS!dB!2DsZo219r^vvnWCHM&Er1H5fOBIVcx4e#8UFKVvJbx|!%q;g&j+nE|O<LIH+
z0g@zVl$yEtmm>q?plXbjhX>VFJIgi0V>aB<MFT11FtWht3orK=I~D&j`CtXpjC#JU
za)q;2JGcydR-D#Y3dTf|9!ZdZTV<a;Ykw#MR%j-f+t17ThN6+`8Ygy3PWxp*?+K2J
z^$2ZGWu+RuvklC#-9C|^Y%uq^3E>N)l@5|o)zQUCTmSoGP1dP9cSE__vUo-3ufd^)
zqEuY57Hz>!gDu#GEsMl?qj!8Q*y*sOMOd`t8G3Zu#!ro)_A@Tv9aW~`A9EGp$5b4&
zS-z#oM-Z>L5z3Ey(ug0J6>bHB*&ZWnpPFxRa&M#f%4e5oTQ|tamfCY>lgXg+;4%dC
zG2c+0^jdaAV*-xeRc^~NX_X=lMBqwhOCg8Q8LfUA^%_ZiQqC(!oDR~wqXtw>ShPgk
zm_fPFkl3`QFzDirU-MRo621-L{$&0ho=+$w_ibMyRHX%Mf`r1c($5GuB?t;*xocrh
zKNuS2Cv(_2#pE-T%B8Iw{h12>7BTMM<%-DqvoG{bMmi4Y<#NbCKv~6g5kWW$qR7EW
zOK$i&RHj8EFR3XSPMFY;x!Art<rV#cVdG!grp))S@K<qNA<U&9d7@lCcb;9#Juorz
z`?>O%UgO~c5(@eK;e0R9_5emSc~rzyC1FfN9Qc|3-cPWk3rLqtF{g(knW->YAKiw`
zgi$V<spKAz&(x~HDMWU`oZF16XghrKhpzy$9RC=)=aL}|goEAXe4%Z6618-aB+Zg`
zkvS{)(j`Gb{b+cs*O`8_MF}ii2b8fVATB=<St;*j4wY||HyHrIFz$h5MqPilkTt%s
zXiZzNa}Sa1C@DP{6CHPb(ilym>k7!Gq+d-K$H?$;N%<G2<p~%^N62-d(`!@MZkUTj
zqT4HOr5tSHM&bje?qOkN#2fk|Lcd#}(HV0`ads3~1Y@99I#OMH#y#hQJTF?lCFn0<
z;fO*7*waos#=U^su_E35ozqIWk$L_aOp^IOQjfu~^w)ciG>Xjn0G$Eo__~zFgXdzV
z7oQ5*(SV+s^t#l9T<9`SNRMxUb<0+YX6!j(43>)M`qMd)g>0GKee%a>L%x(VgV-D8
zH?LNxXwgt-k+>eHT98S{{gj5Fs0WRz<(#Ztr#YN>ra+*ZzF0A*E~*wsTDR4Y#-%Ey
z7-F>ukvqarkNF8(QJHFp#^USk9DTZsJg>sFc|=-^L@W?|S1)95GBnB`X!L4ee}oml
zQogN!tH~`I5o)+{(r%t7_~K3m#vrbQA$$0_4Kk;3BfMCp=Sd>CK)s5#Rl_VT8LRaQ
z*kk!+lK@2sYE_g|IK%VE94Z@TUFiLVd4K%c_%_YccsZo~)&|XuLFlpelt%9tvs;sh
z#`XAY(f8T~AseR7bQ?jbs8rO6__B3adBj~*ZMlo_R0JcUdjHQP6dwaW$d>=C6A!ti
zzx|lh77(|cI=p17MkDsIK%7-M=9V1FBem(H1Ym{xz(4c;{QzTz01wr+z{iRnqN`qP
zIy2i|{`5QiunjB7TAqvt+Ix$+49CnD<ZP>GbXIn}yb0X12=fh#Fa9DyCrei?Jw!In
zf<@?!O#a?$roKoq>zg}D=sJB2t)E2Zz~cOs1$pX#p2d_XD#3Vz(W3Nm{fsQlcg7#P
zK(Q|-Jo{tmfGffGJveiCtYVDqE=NZZBO<%d{}F9eyhS29=s=X#d;a#01PG&k`=8o~
zui2*SUkNI3j20WVB4)PO7gJYQ7)JX*dn}n8{1&t<S)*d=BQ7<}@U|nNny<*Ba5Rhn
z-oy!wUqNhkDO__{w65j=0`27t@_J;Fh7HLfONkVInRGS}4Gw1*+W@oFU=WITr$!Pk
zZ`@Jr11F6-FZH=3?Ev1V>!@+R0T<;Lj@%La-5Nj{hRiv{+&E+)iP!`5{oHS1`iUTe
zdYM`nmi}|NNg&J`B?=u4j(l5kO$J8duU2q>3A{A@m-qUC$*+h&61wD1DeTAl7Y_ZC
z-TaKqmiM}vX-=aD6ZjIJWSFbd&$R7y{a5A83)tv#@H%!9evxd*Y?qP@VyNfe+EY6n
zH&VUkWjVnIukrJ&k@F^3iNCr*XTybp3PB~G+~7Y2B~rZp48JQHAzJey+tfPC@1OD_
zWvK-h{}TrT4sYAL*&j)uZ{Xl{hb1f1)JhIIsN|Zc@R-w|Az-<a;hGIuao@P%i-{o*
z&iL!XY4$H2WV3yJlTOP&#j*W#IImzEBo)Hn3t4pi(+nU-**QT6-5MFMc_IY+k<yN<
z|L$tj;`wB_qiNLUJV&QhxXI<u17t^s$y_&l04W%-^_iH+jQiO$!(N(d|ER)f<+s>U
zBnjcl1D}Gs!ju`;kLY*zD^F%6%+CIb>PCNjm~+ecjGBPzFd79u&^|4-Cb5~5(kAjP
zuU7&$j|m3V0uH(V8lpb&86=ua1LC_0E!WoM7q};1mLVM3Q;m%S(yyeqBnH`2I`Rpm
zEukfV7RcddO2N%*ri3|sJ8tQT3GOp*)f3XT_Qt1X@vi_J5>N0zcY|-R9t5cduss75
zu&!fyoMCy!I7OrhobFnCpQTHkKd9sjV*UFg7%y91!NPv&3;t7pVh4)}i};!tyVB=4
zPEJ_#KbZ#+7aXk|qJd>!fOj|G%f_7E=VMTh4XNaTJI)+NYDbe)Lk*GH0jptR(sW2X
zjvi&qPNd-Xze)rduPyeiryvz%xNTQwy}Sj3ecre--c94hIB+q87~8cTxG`V8rvI-$
zB{c^%_zemI$ShNWb*HHrNZJ44{Ye}rYQ$*xRffLL;5R1}iX!9o^Igm8dZhKcNXyHA
zOJ+Eq95<PlK~JPL)SvaEhAO0};f+cMjH~x5YA!XrzTx9QdwdZ%{@+CnQgb1l-=Ke`
zHT;f7c|$Fsfel8vSr^7oO+tE&pkCqek?$D2Eyz4Wrtl$2I><ZH^r4PqJAeODpv%g1
zy2E?v7-+yw#~JB_px=t+&{0p1movAw9WnUW%w<G^)gprqApf&B`&0a|8^T2@*O%=0
za;@3OC6NffkAg{dZ=|FMxbp1Bbl!4e8yriI+p8P{#TdPHvyQ28Dnu%E|CuOdbt9Fx
z0L9ubhbP8r3RY0A$oOaf6=e#{pA3qiMX5}cGN#<cH&jBE|B~sUBZ+U!*E8ueRZhsd
zQ^%QPPR}_?DpM0meQv;cFa$a0@qCl{`p6%n1br%N|6NwMv^|t}0PyDq18(VcZd_kF
z^THI=Mlrf|>?cO9HvG;`dKN5}ZBh=ZPW70l=CXLR<Cl09BE$c$m&>0#f($csB6`-&
z|I<0H^+M=N5>vdvF3d!_(#hbA0>fVj0g1)vhu}>VauWz<y{4%X`@ZhR_dg|rDfj#C
zfD;#7`CfKt-*oo7ZYPrFFBZX{l~F*4@xhskDvWcJE7TaLEMmN=@3AsgtJ_z4zAa3u
z2yAZ_@^m@ZwPV8jb)lf~`2gbtZ7322g+aR0a?bQ0e=zE4+`Ob7Sd*5qw6T)V1$X^^
z<<ISV!?njB;o>Pb$y>soCTn#pURrau0psnX;@QW<E0yZh^3(C$N=*oRrm1LS$sLYK
zg9(V+e_7Dj&`&1Hem5UJgiX?=lRc~e7UI}xf`!JoGv~^n>HmVU$OU==b<eDdx~Uzk
zQB*F;IReO!!yYuhE<TH-=S5PmBhYav&BNXDnH##slQ)6lSV9+q6En@pWl<onbRAFb
z-b9Ly-=SMKmCp1j1V74CKYHGk8<7zEvlQ===%4zD|B!!P=z<COAbAOpCg)L5KBd>K
z{!hQ<@{E6!%?BXTF}|^L=ni0{(i@$)eB<hF-&j!F5<1e?_1r(&iSwV<G&+za*kPn>
zdMeOp=8jH$C-$sHtQP~uR+@{z<UeJ3nTZXpBT9R^Cbr{V%1hu-sp5+A*0ERAi*c&U
zftyg13J!lA$N#4)H2Q<CdrqjNP2Ti1$wTR5A{(x%mGj>7shRj<w~2{k(lXa}&aC4l
z=Bjraa5tH&^>A!eTYxxS)ilW2I7#z_nVyeP1lC0U$>MPyY5<gRO2WNuNuJ-nKvuak
zLZMc;d%Nt&p|GCx-?~!$3>ww3cDTIt8z`i`zB9<8OIXtU>zV6LONjmzG5*jlYBsjZ
zUDp^6?tO*jCx;y5u3U?6X0*u0XQ9OcIyd>4YIlC|dWFzt{W&I`K}1{*d@)^1i)kPD
z=I183RmWqr<p#nnTNjm5T1(l`M7{jZl-X-<qC5vC+bXM)$-$Evdfe_Ry!XB{VDz3T
z)7TBeuOttg&BFb4JK|iUZ`^V_9z+={FT*aVMeJFxpuMc;oPuo4<$~k<P@Xg(k-3`E
zZW;RG|JD7UniMX}nhY#7_axgW687kMN2q?*5}+fS1)vZyK843%)3iVsO~(7x85uk`
z?pVr#m&_7cXWTt89&oad5;JSjo0b`Vpt;17YOOnkDOXc3^ITLrFsV6Zva{7U4u(;N
zp@8C7wisfC(IkYoJ+D|!`J##~uoNTfhw{02Qn|q0*{Q2&R<R3-r<J4_Wlg`v?eJDz
z&5#jC0E((c8kZ)&r)uL1zgIV%`U#oQzCTPHswNz9))2`O4=Wpi5?X6t#-0*y*rd`S
zo?_fQlee4TYJBdkddZ;>f3o5{b#quU)Jrowk7n_0LluYQmnk7(W+lMzTyak;O#Vu8
zPr49NNmsQduSyRW@z}IG>jCLrNVN^c^+Rw9u(VoYQW0(=3864gY*t|7BWqHd`HB8C
zz*}kxruFHYPcUCJyd}g6KAkiDbEX%)SEg50bsc&kWiR1KEW1%JW`jo2VR?{{HB&7a
z6s~d@gK-)nOZgACeFD;SF+G4IuR9fw<Tc}oBJ^SSuIO(iG|LBZfZYwjD{?yITiiPk
zNL%X+;e*@vuhUKc$LTU}(xT?$zAi6<Rj)3;`th36?!Or5?L)3JPvOZLpf6*AbM;#F
zk1Q1DP2Rie8LVgFbQ;ym40)M`Wj0RYKpWRj6tAbNJ42}%4r#EhZIGkX*ls`T4&x8w
z3c#+K{WFYmFZwhZFM90H3&^wQ#8SlG3Dr@t%>a7ZSkNus*AK-LEwejW9Y`*g%^B(q
z*6*+zsI5s(^arFEa1IKRzsP(2C$ch3|2#GpX(-$)qVPYWy@|Q!p((T?hq2IzK;-D8
ztmmPa)ZuVogM2FF%)<8(@eS?;im5J*(26#)n;Ng*p+M2+_|f6KMdz@;FFQXsyE5+b
zqIw|eRo7=?&vlx3Tc~LHx<mbKJ3dvwvwF()(%7BbUM0cHb=mAJ2fLy!R?0-)Z%i?;
z1O3Xeh9LgfWS2ocJl=yq`&z!<K(ozDuJ(gUKdO&nYxbYKYAg`TKs7<BiOmL7xUR7W
zc17C*ps#x2!%!E_is)_Sn^G$cREd-b=XqBZ6M(5fNJ^ar8K8DikquFbGvJ^Fy~`IY
zEaC3og2p`Hx#lAXOz8Uyt7_FS0#=zOV=8Fb-^n^xLKG}Evc*`KQdDDEi+}?y$`|ou
zxO1=>1s<~Hk~;Wz`O1*b7Iysh<}sHpvURl^Fu?#_sdubO?o)XAEM_pXhpwvx>Xj;n
zTMb|p{voaZQ>|22uftdm?vPnqaz!9MHdo=?E1O4%EvptbVplvsKSGb3z*-MQ7B#Mt
zycJFL*~|skx)DgAr8R5C)R3nsEYknmQU`NAIC@4c$T`8M!UCLm(98bhO&;YnUn<if
zg|TFxq+mh$W%$1aJ|iAM$>~0pi;cCLpidJT^LI%3{bq|q-Bp0i-;5Q9O?33Op)KK+
z(wb`BomkCSy8K*IH>u@hGPk6mKuD(pI@(|%zUU!Xx}+9b4&+wDuw9y201%leTjMz1
zN$Heg2HpG=A1!^cD*Pn2+ik3;`u9o?luQ_qz#TpD={X%cBhW`%HU@(!E9|enF4cy<
z8(|%~+Db~TBMapF>3%{}cEGU@1DD2u=s~)ai>kRQ201tn2OQHYf1zhX(;YSuFE17u
z-_Wl;?_%eHkYcy!*UNceoCR!?U%y&9u?@c)^o%bZH~x={f*;nXt8bc5r9;kAxn|}Z
zlmEk*W0~DMQRL#=4?FI-3P%(C$9)S}Z0hp&0d)&y<dOyjKjz+j25GQFDC#ea!;nc>
zy(3bGT5@8B?SJBl(Q7*2t&)f#t2})ZeqISi@(M-r^P;WhvGK?Ot6ni0Z<i+HW7$=F
z?eDRl<+>d^2%B9K*>K)+h=&TtsaI@ozwi&fTRBj$wIpNnUUqNs*&IDA$3>kyH3KOt
zvlokdmaK}}*So(M^kK;_^D0*<f9{UFW;Ow-=4LYbM*kQ<s;%X%x1g=u*5eg+l;X_d
z{EYk`1OB-=b%Q&r7=&lDN-?*qqvr7NnVIkzecTtPVzFJLdTkKW&?+E!I%+rJGU!31
z?fx!lgz67ZhM@4YI;dm=(~Fhg2z^9KK~Frqw71^(W*0HdbuyAWT2*a3Rn9B7ax6J_
z-E%28Gi>7Se5%tsWz2r!wMV~864smgL1qfb=)3sjF4|C?;9D$nRXxt|wTP{ONv)0J
z_q@^=E;9Lx$;h*3XN8QRPl?=sOo{A(OvyCj7{dyOnZ5nV{ALErdV};AlcYU_NN;FD
zxPaqZEx-5+=Q1zEGA=t()`Bu(&YvvFkPgZ8g;iaQ@7)t~YjF2po^5dwm7MqyLlb?0
zb@$R<HemS3n@?=}W;~CB-l*&rw^=!mr?j_oerx;IoZqOYWY`b4>~^aA&C0C1M0*RQ
zYZuXD3TnJ-k;eJFj-knyL=nh}3<oDj(WH;l_%yo=b=pneXeug48+wf07@PeL$-n<t
z=n9MY&X5*<tcxzQP-MV-^Y8?4z1A`u>HW74NJ~}n6dJNjAOrv2u;oqT(Va1sQ@K;J
z;Ku8;8$re%`Dqe$L`(c1>d8pj-6eXiF{3BOiAXsWPG+AO%Q*Hw)^9?K5P#*_Z!)_h
zi|+e!w=tf|&0zR7#E#WqVqhrk^H{dI21_fv^&e*x=7<X!uZC-2ezL}JJIpcC{>pOU
zLcksI4u5RUalIV;r5a8#mjiVL+y}y0TsuxO;Fn}Tj>ag#CBSSqFFzUovw;GEmiO^w
zb9^@EhD>=QWm}%LF<hk6AZVM|-`JDcYGNxrn5eUav4+TVY6QPuC4EvoN)x{YKfY+l
zL=y9+Xhv3_;o1j~v!%@qkh0R2UD2z@4_KF@1^Xop_KSJ!lUxRIm~ezn>HSV0Ez*!3
zK&-~4%RG97-0DFWC`U@>EHnTU9xA-L^?jO}PgB85qvU3Z!R%<}3t=GP=xlD)YCv<<
zF%}N_z@p>4i4julSVe1n#HfPX@83ZZy6P-02?5&#)R$I3CR+YrE$7xTL!OD`f>3xk
z+V^pzxji3v=xb(bGrOg=y6DjYSJas9Jl*Vrd_Rw_kZ`n3b<ZhKDFms+fR#8!^|(H!
z&!c)0#qh~4R9{S0z_wwhiGIro?b?u^WG#Uk@bPa{Y0@22jnGEFa*jY<@3z+Q`e?AR
z#SnO6gtd(U@rLYQv%b2kTRHGuM{{_;NOg@TK5SHcH|u)rW1Yg7$QyoJPZ!0}YiV-W
zqCMq1E-J~9K!Bt1)2uzq>$$N$RGK;8g@lH>DH3_i{ePCNyXU|%pX|J`qogy$coldx
z_APH}vqG(S!#C`~za&J;3IURQUx@D>0nYBZ(ed3K;aBMx2O74Pc<eP91blg5pJe~$
z$M~>OboaZN8Go?1xG(H+_I8Pt5WgXe$KKCbl~{##^gs1a?!N3HR|h<qjpBx-nZfL}
z^F`(2T#nV_<Kt#QHhN=_lwRa=t><~#Wf#f>Wi1=_F3aGYfrD*Z{2MXRBpv=BK;+e3
z$4Q#@fDo9`3XT_l6$h_C!JbTzxQTDYtVo<38Lg!7OW(%Hc0E2^l<!-+rU_UlU35Po
zwnZ2(oZ!oaT<h-r;D*>W>$S=IJKuFx)!M)(0a%?1ml#TI#spiy#Pe(D)G;gD`^EC%
zuf<bk*~lC<`0Q*h3mO?08%skF;N*ooO2zswvI;~eoF8_@58&IV`Oqxg6H3NFKKruR
zOLW%Y9QKb8P&)I%J;TU!dVi<KYT`q4xLvG_vb8mg7GP?VW9T?koC;`zxroF&>W>|_
z53{V;>~=0$?BtdNi+p{gHQQIuUjH!V%nI2Va{lsgOS(44gY<Cg)dCa`gGFzS*R*3C
z$r<C4_2>Qp`%%TA#%CO9*%856aBY$xQKkvGBZjf}1ovEUJpj@dlK7=VndL-+_hc!;
z>;F*o&e54PK=)v5OzdQ4V%s(+wrx%9j*W?J+nAUW+qP{dn|F7=@3(tSbyuI~k3QYi
zcy3qKy;XW{sz0U1`fd`g+kpippIz$djDS`{$3|5USw>k`uJbDm@C7Mj@0t{pmf{F&
ztkc{xr)n=fa5s|Cyw87yO~L`hdR=&-R`35Av{^e&iq}gyy^U?rrzv}Yrj5G!6=TVE
z*0mrHi?RsmlzG#gfOZqYcYJ(onwFk{Z1v+U&3M-SqR@yO=f?QprQHRWi&@>3;;13t
z?%t5VPqC@y0CMv<rm4#xS#85ewmY%{A3abvP9@!{T?sc%@2_-Y20ejK2If4l!#obe
z4r_C)U5#&>Y<Bk3!}hzSp?1c4W2@gb@u2o@P{YvB!q7BwFfa*BbsGfgpYrTmY$Mzu
zRSp}qCr<xalk7^`my`EYzC<ALuv|Qw83!v?xuf>ewW{ie`32?PO;e#rH%JFEiSWRU
zz|0@P9t{@;c_SCzyCnb*BV&C+MRM>1;8?&{4q~HrPRtOUznB<$UfFQ}%bfOdxF$N3
zJ$$uFdot&?bS<yC`5j}FxRFFB8XOFfukW6ma!lLk?6Q&33(U4ew@ujCylBnvcaC+S
zuJ6uzf>L|#@<NMUCHvz^*~aw<a9tT;5Z>K`AZgz`otw_ffz)&6)u;Dxm#CIj-5)sE
z?c0ZCLIgcvueFML-};*MJrRU5@+J4m)T!{?Nb-A8m>CNICpiO@A{o@8NDVQw-G4rq
zOatn)gac>(;nhDmgDrevEPZRkJ3x%;Jp?7F&m@9eNd|3+Fb}hsBnFp332uZ4DoJMs
zDe`lPL^`880sn_{b<+|03>usokrFm3G<HSZYW18F=$bfjg_yZLVV6tn#sL*RYQYi#
z&F@Bz^w2y{3=mH=WG`~J#(UI%*c=7faiIo#259e)jC>g|o|FA7-eVam>3bSFA!h4b
zGbV1a@|Ej&Z;}b%o~hd@QRVYlo>4PSr0vV-drCVYfa1C?eR?*UU8>+lCQD?e`)7nQ
z(-?j|&b+cC`VU{Z4z#B`^#1uSgq;&DVO;TpzoT8oGDcY|oQ_!1)-U1HCM#;pC8seE
z&fc(d_oVV_^~2p=!$cT}Pj}G#JN8|J+cZTl^VXwhubTHbBt@}H{%2r#_5qhB+M3>0
zTe^;_Kv`A12}BZ)=6ft*W#>SC;s%NZerb_4)oR{Ay{WEpcAq}VK@7O6H>~<SseWR|
z4?hKLD{vhh;kK^E%>a3C%(l1tiLrECp&&sbeLqk;C@{N~xZ*ERw==D9wclLT5yVT{
z{Z$W1dGYJc(t*0iR6hJ=!`6C3YCo6Ut)K@6h<n50^FD_V{nkfDy4S$IK@J8N=H((2
zhS@~6c^mZj{uNLmZ*KIFv3sl_p?7Ja+z$zg1RLZ>4RmSN3Cl~edsZ%SWUjJDR^0gQ
z<!}E|F(UH3S5%Znj8tQZSmU&qn?gJH$WNqw^3r<z{a7OXbckdDPw~2G@L%41!I$Jf
zz4g)ePM;HSLY6;B@Ro2HjTZ3CmM3~ptoM~ArC4bLyLlz0faF{PDO;xRiD}*MqH~A@
zGPL@NtEFQZ(Gwf^MkWQKqNDj!U2jKokzlCuq6{O34ToPj$BqhgzH4bisr#gcYV1be
z#@ed>ny`fxEC;szC{stppkNoAhfDg(KZ9aOS&x(MKl9einxUm_q;!;cA-X{M;3C%z
z-0VrDojeyY!q1wt>u4}>ef2<~zV>2=J)<5SOXn2xqu$-o<`jGA93|Igf|aXHFolFK
z4^1b7$mxOcc*9=Zk#@(w)B5~r;fixSp<35JDJ=lW!E5*_>4S`Tukr0B+Y}id;6HYW
ztf3=H34LZ`Xz<$SO?n$`>3UIpR3n?n1QZ_CKI1N``C{ri4Ub&pcXk1-xfJf|#$}7)
zW{~QqUvo885sMwjN{<~6)a1?;UTF(gP$??05R)&cJg4c79XDM88W^?9y5J3kcVHv-
zL^(fEj0y$|f{=6X*1z{`9rD=&E!Ex`U{akT>a;SDVe3J|mx7Ia5#b-R_(6S}A)mi?
z-AdvlO+a7&sQq=mP1hA$5Cd!MgqV9lmH)cwE#G4WD(ON0=Lczl^WjOaeg|Heg~LCk
za*;qt^*6@uJfSys?eSIlWe>$FT$eUaDjKV1*sJ>3iX_P|11gfDj2o><$|V_!=zCH+
z_wJ6RWwXziL;Q%$j@ogaV8H^^f6|1JB87q=_u}@!eS_llWze5)v3tyl{Q>@nD2$W<
z_<4c}`{W?_x%Wl-`+1@)AXvvb+ohPh_J|Un!p&{aG5c<vfrDHO^tSK7h;fD2o$Ezl
zDKp^y<^Q8U2nhHSa3ejFa+$vBYdfuN@t95Igiu4#_&mzhiyGvB<fCIwZ7={eL4*#j
zDqRPoJH+238zDiF+ehu25tZ7*#=;Y}@>22yY)D*h`SJ==J9v{i(j_}hmbCoQ!C@8W
z@R{Thpmx6x_)apwO?i}zb!h7?2Y>OR{inF9B2YAAfV1rmur6{inuEu5jcpW)0_mVA
zoTWJ^wk;HOlhHk>CTINm2E>Y`{Lz|s(M+iT_#(vpu%2|Mq7sO}#c-sYnnLRgckoxq
zTh%yH7D_8$*6c;9`sxp{4$F;lE770$@~yfzYy%txjW49Hmeu~1s&WGhG`5NYTLN$}
z6@P#014#H!yZz(MVOoJjdOt3{cYNcO@A$S(+5Qc&%l;HcK}3;=Q6*d^O+QZ$*;AgY
zdMcj<I<`39%8g3M;zTKMh69n}MJ#W|_3!U*@)Fkcv$4|CrNqt#Y8Em2xOd-HeO*0R
zjllc}`d_Vc-Ts`$@Cptu4um*7E6a{Fv7K@Ri~=Bk{b)_Elb6m+F|=7s8Kuu@{D@%D
zVyr%eUuOQplLO{tv3OYM9304)NFFuz-9mLhT9m2(6@x3HN{$~S_6AEk6ibVY@<w+s
z0^s6(=(^a}dNZCjwUr0+wX=#A7*L|O<{nt<*%J9RY=6@>`zvhlS!*oQU^CD?lTJ%u
z6sx;YUn)IGDI=N;0{2T7VIA!BRXfSCkY$|)J+jFHPA4gm>eNQ9OeCc&iKxtTzl@6p
z<EaSgL|CP`f6hB+gN;g+BWLc`qeJXuUFYHPNHZSIexE`S16OZ0fS0&xU1%EB3p((K
z#WpQ=;)Qas@4n2J6ts8yXnm>7vporrW?Bq(NKNk`XpC$be682|7*DV5^z|DG`2CG@
z6~E|UsIXn=$B9qJw_*eO$YYs2CPWjry*7ihGKBQ0e}kn<Y9IzD)ZGjNp=hzmPuToO
zBP4Td%YJp!(L#_Ud1fZ4LXeBgwr54ywi8jj7M2%1_n;B+pB7Djks4wgxB7$t!*9K$
zq5X`f!V}^HaCxH$I{AiQdQ&U6nw<jS7x-5jL!9*>(NB=}vjf*^PaN%k+sQxOvEa-7
z4ItO))Sk=Z9v@1TcZJ)qPFl(5CD6IH^-p;Y%`<mEYEi>tYv?jaBh~6#e}8d^3v{nU
zGFzH_kyvG({t4X3AdyV&34rYZ;IM!ApI3>7MUb74pT5mLc4|-<T6Ew>I9&hs3%HIm
z^k9~<PYO>{8A!dOmIEcb->gcZ0D0?MjDW3!kZC_fzJDtyeKTyRa@Sm2ang>~JTBjm
zLcAz|dQ=PunazF<&Ga1d>h4MYd|M4jO>b+NJ5u7RQA3~^dV_k{&LCt2+}SV5h{c_U
zSvmh`#}BSw2ix(V>qcoNDyUG>x7Oc#C^#PY`9TCiqkg0NzfpR|2UYY_4YWQqjpo}t
zz6gaph|3?3i|#Jw8o^0KB0&lcjJl@uai}KWsqD3}u|HUdFyo5cgVt<YyMpXTbIW66
z2-$V%L?dpYegO~Dfi*zfrPV;EnE#b_x#`O;XHBirWIFf2OX`B~zJqQFx=74lIBNF6
z_i6a50EPu}%}odR__+e&mi_GPWuY&OZJ=#$(Zory$sh$MP*mdx(v9wd1d_Zn@x#%3
zrgxwwyQccw^UAxM{LIAZ7_L)JK!wBi!ridta&`M5DVAda5eIlzbCNUdCkk7DM%5&e
zF!yFatweTHGxefQ)J-;8(H?o=^cJ!mPsd@OlQ#GHp8M<<cmR!>2HbGFjk+5kmmq6M
zyseylN1;Mz8_Dy-jV!)bo<DNEQKpezI>AnjIe#m^Ffrw6TE$}Td_i;4)8lzONyp>Z
zRDeDZLqd4Xt^%~>j{8gQoN)v!To{e)92!4=9mIZ)MK5{{QZkqZeF~@;y967z9n7~w
zAZ^lSdNGzBLMDMUbTbQ>=*Vp2adKL^+ta6iddAbcw03IbzxBaXSz&9SvzR!cP_4^>
zs+SJTF;Z|xDC+PjJ9?ZzW|lKp=v4YZd;GI$!{t$V_5xZ!kSkVa1)VvLE;R77yE&yY
zH4feLPfw#s3|04)=SSbszD{Mbl*PkIn`r15ZPu&tqO2wU(sH14#hLdm^{}uL__ZRW
zvg&+k0yM0h$27fCKS{g>%zvbwCjV0Dj!$5|f7$-nFIxdhEgn&kS?`Ho#GPGBbm`_j
zE2UVU0VD6_OFbeKUqPk&V7t}{XN>!ZCsyPxN40ak{R(v>0;x#wstwm_-R>St0@C{+
z8&5Z#D@QFaDNPd@MswOu#A0<BmaaS^WK$c;t&b2}n5Di`jb?f91sdhF{%9g1!M;4A
za}*+<`hPc&bUUTwb8X*Iv}2tivQLW6b>ZIT0MpNdQRiiqhr7{xL6(n3_vL19sD#r(
za{=TwyVh#ViCa9u?)<v(Oe%Wa)?yIM>hSS;9|iRw>gUcP+0Hqgzg=Nm=8JdV=KTog
z=dF5IG_&0m79WVz7wvVRe@VY2M0l}Vj4T`Zd6d?@2A!C{KujXDhxmxVrpmw)vULYY
z0kn9z8*?u>eqb`~NblikBjG+U(O9kZGtSP2lH%*gJue@Li?idoe0GjcZ<XN0|2myJ
z@))aiG0NO5vsv_xxxB2)E+(5^?iXzMyup41!L1|D1~y;y;=&Q7<Ri(3a2#JWf^lvV
zy?Hu5-TZpa3+r7iJgm%Vnrn2fRa^`81CE`L6KXH=J2`!&89sUf*e6=YlV3OgZqRNQ
zT$ga*yFkBKtn8R*UQ%1ZxpQ1rIX8lpL0b?@UJw?ppRZacnJgBd(ILoBGgTFP1fk&5
zm-PPrB32t;492=|rF)`m!L;nfs1(4_2(Q4%>&}pLBZBQGUQ<*e*dl^uhM~_w0<Snn
z`_pqg@b={bCV2u-{lutPC0f5G`m%U6hgN*v4P;vgJ#eQY(VPHWnth&C#j5jj=&=aS
z%d<>~RSZlEwQR4+o}hIMnlqm%FuEyt&idEW<;m;!x2i=iHB+nJrb$LV&u2{z1{a&g
zv;FkEWi`Pq{fN3Hl~&m$lMRA1!0N<cUa<Pq@KL**t3stn-nMPDMy5ARXb}lMzmKbE
z66{3z5}~puZ5{VgU~wMRqEHRCtk7rS0^-;6tYsIC?^o{u%VPkhf#hgNkY<6QiAs<4
zuZ=cn#dU+iMGW`m?jb!Xb8TCeChpavHuQPN=8_aO4=!4RsJd(o#<s9lpz5S!*3vwn
z(CQaPhWnOy3AA4<P+AnJGA;8+zFk*U4a%?D`0J6;;O59D)LmH_j2mVV-(y!yloC&r
z!X#hc?nnX3B<6<PGXZBPzg>Xi3WW#Gp5kADRQ!_jd30j#Cf<trYbT!LMuNPCi+d`!
zve-@k*8DDJv7sS%Jpn%f;N*82L#=K54aL+R55r<lYcWeLK2Xs*-rm?6t?8X)P`e4k
zrspOc6G!QNLLw6RvigW<OMZ$#p`&t<^W56ym8}fv5~;vkaU0(0#8lU^)bD(|T(gPC
z<$Rhdx4a8K>$Ff?;jqhvzQ&l1+buY5Tb}|4DOfQhQ9iuh;f9?PKn>5z)E!#sUQhAn
z5H|6|ATwZ+$G+*ezmEP3+H9J-^`he^>(%LZsZz<G=Yx-RS#x1z{8OKmV*^8*Y<xUh
z#w$XJaJ#SFmam(u1ETZ2Mg!~MnD3il_3W_D?Vdg+ixy5G@%XjSFg|_4*tHO)fHVc9
zIqYP8KfGs>+Yc)+z||<2M>w<Pdsv9q*o=S29;O<&DceEodnRh=+?mw8p^NM1aMU;g
z^~M>x2xSA_`TOd_)}q%XCFGDE6W_ps?NxU)o#gp!$MueUC9+BeY}o~f*t^X$3>UIC
z0<A%;#lhnrjnBw>TKGaIjNF7O|BhVoWn|vEnTH{<RbqG>K>Jf<1z!e+0_EYXLujG*
z<lmVnzF4L)!dirz<`Fx4we?Jo^Si2zzRIVapcsvU#zl35#fjR=fFJHgL<8=Ib=e3i
z9y#~rli=4uS%j6TzlBh?je()prn#S~a$oH^y+T<&DP%}0&^oLDG6KyaL~w~`#*VFL
zKkF!zl+{sy+~LE9jCd$QIK>tDpt+Hp)a)%i5<j4Ho+>*Q%DujboW2N8#s4LhO0#e6
z50fk}$$RD=w@Ob)`NMqGGy>}-ffa$}NpU+T%?9Cu9kRth=pf#&%UWe*P5$PSXG)pB
zRdcO*>=o)dm@f|=CAlwUo-+59D(}@7Cr!ldw8)8omtG&VSTm&d2xfvNVp0ROXnO0y
zxaPWLJ<WpUZ)u>dxoP$>CGpffy6>R9WQ6wLR%$Z*eeXfZZGZB`5td&U#7Vk|EY-=d
zsV2uhDtmQKu<kUui~TS>mytXv)=PX}y5MFSz#Tp`rl8l+Oa9$D>m~L9!)0lrZjB1V
zl5-T$TAA8;1)aB$98sLgp}GK#Dn5a=;&K~W@iY3;%DE%Rz$no?wOlmR<YdWmIf|z$
zq*zf-j`n#*>WHu?jdw;-$!xL`OT;t=mGaW}CH74v*c!*5L>*95Ot*Elku95{EV3bw
zqWsCMUXC$Y73RuT8G!5ll6tDLJQKA@yUYXF%}Hz9>8HzD%9XI5nAzfv1+R0ZV^%gc
zn|J!U8)_b6xLhyw^5}_<d9l)6C@ewBOF^T}x1cjvJJtn@g%Ha-LlsN~&ZrG4NXbgu
zCQOfE&e-z(<PO2sDuAWpH1O%m<o`GIeSl2Nu3sG&Wg?U?Q37i;!O%(o*+wN(aqkr1
z5U@H0Sw{mWzcacC5fUe(5k#T-N|W+NO#NxpY-jXz35*k@kgMfa%+yC4LFKX`Yg`Fn
zlBDm0UkM1tYJf%*|MJA=g2KauED2}-<N9vT1i#+k=0mvlOpF7)B8CThB&K2#YyXCa
z+c-FD9hmB;<>-cnhaouu_k!)?mIwX<dXN8K_FMKsBO$ng@i2;0SBS!-dYiIy+gQC-
zos-iWi@aD>mJJ$go9GQeR+fHfn3$M0=)Xm=pin-%0bMFKNr-Yr(M`9Yu*R$mr*0w9
z^*};8muX%`*!75G1g%^^a)a-<BQn+bZ|5TnfY%GwstyE7`>yBzLLTf%+GF3W!ahAh
zyEyYY+DsF2>K4Mo+ABF?>?7Wk`(bUWv(R)4dnXghxZ~3xRH$ThU=l6Bm-?qCg$`D9
zfB+l{KP#ajKQ-ZGnPS<cJXg4%E!-cD1*`l{6-(gX1Q;SAtZ>baYgP$a)Jl_l6x)<K
z@KvV8ViZ<m%hVZI-Hj>=mMdnE=7AvXhNFHpooG;aozn?I{x#rmkORr}Qn!<Y;bQMd
z;=d@ktCLu^tEABLfcBAe$CoXb4YImrc8^x7j-i}Olt<O7&NX?D|5y{D-9ZO^EyqMu
zECmi}&269r=Yh1wZfW#$4LhkG>HEMU0KFC6c@;i*u-BxyhmcjWof63JO7O#uVJdPI
z5B<hHKs$LR&F%M@$w*3naff=E;>S1wqLe-$nqqli7%>)b+OjAVqr7D0j$?AvUtT8i
zPMpMd-t$H=<ynFL5+n%a$wtMzmTnN{$-HE2a1}Zi^%KE6-4wg+3!spl;Gl>D72B8V
ziJU8H1(l)ibF6!6d&il7G)WyqNyP2-!o?0i!VB;PViUkAaB=)1Y_bDP{h2mSu$+}I
z#fZ6d4+n}UJwif==K|5k5eC`weMJ=+swLnKFeEtxe^Q3Xe=$?5OUzg?YE@-jP0?9r
zEcCS52~#ky`o9e|oh&U^kyi=<#C9ZY9;p9WG>bj%;z!6G$p4mc{D6aQ<T&h*xo)}X
z4di@~91ZxSTBbEL#R3tZ7)XtPgf={8c&gJRhRA&DKP0Ke!SP-b^kmD?Mwsz5DEk51
zltc)VqO%=#n<*S&<UGUf5z<LlneVPTx4gwQ(S6qqBrLN)DqV(#EhY#X_97~xIr&In
zw9ov;!iBvuMr(oHQswyrQNt0DxpCuJQtlPokPnga@v|}FWN~udWK9|I>!;ZX{EMwy
zcsSlgqv$+6cyqhCc61(Zt{)pWE|yD#O*A}3jP@<VA7<KIZ6?uChP}+>*g{(|msSlC
zcvAi`h7(mFB@c=F4sCP3$ub3pU{u+JFNSG<5zENuZmACgw=(^w=iYsZStA-`d(G!t
zo5ot<lP1qNxRRIeim9e-*-oFw3OWn{pO1NjvlSt{zjP!d@hpj`Vp@TORDAyiO6uno
zR6`AdEPe+?J$6jPbQlR<rbONUx{3N}Ak2e}3&l#!@o{{tAv0=%VTw|&yo^%VdN?Ja
zo}jwHFSViMu+mw`35Laybn#fa-hD1f|5t2t4wAXTxGE@NcDh+Myh7^%<*#kTwB@Ap
zYbUp3^U%su_v+|dNu6`N9whuq@YXu}DLGNdMvEHJ4t_Rx5v-q<AQ57_V{Si(fk^VW
zF}EeWoiP;oD{}3_zYu1vxC=7hvIA+I5QO=Yjv%5<ii#qaW=V_Q#to5839VGmOUy3N
zMBD!`dLB(|kmDU;xEo#>oLY=NZHY~{HBVrAX7hg<=Pk59Hf?VH+D<F(wz2pbfj)yr
zMlY!{AhL9n7jDYtX1F0KYs01(4HO*7#G+?X#^o`KDmoP%wI9hSAV<Wg_diWU4v15c
zD()0sbQ6b>2S2Y&O$9Wro3%yPt;f)Syd73Y4zEx)^BKw=2E0plW{aTrl~hISw_1-T
z3+1?tEA6%LH;qxGC{$n2ydE<Ej(1K@Pfa%KoalG_R@V>mqVi|ips?I;fLKOE(~+D$
zX4MmUz5&u}dJ2vN)3;C(aK9rSaK93>@83w<0~zCk!?7`fexLjs{%(ve_idwz)eUA<
z$>lkM1`1RSKhopjy)%3BKJ9V@R;pJHEu!@he6d4Y-#9!?Y2MUa80h-(NVeOe#sn8i
zlJ9%OlkZz%hW@Sg=$^=w0$`m{@K&_bf1R8yo1(YtNe8Ln6?d<_Ql7GzmnOI~eXelU
z-^6yEmyk+EmpqPJ8UzWp9LFDl3N8!B^0ET4S6m7v`1c6%*Bm8wE>UPvN+n?NUSg#D
z9glor!r2^-E21<0H9!qRE3dqKT&()GNL0f4U`*;Bg2l7DBYdDt0HDZMuXYeYI~)LW
zY!WK0S}pUTX_mK|dLVWsbd}}^91mjx|NRlf1)uW}T8n}7SmqEJoz8vLj^<HSrFdqA
z?J9V`bON`N%*w@kR+K`AmX8i1(W+u1XcBb^A&o&YDp;(gqjNA{Ai}H}jtrJU{tnU4
zxA=@tUc0}m$J$Qo26P2^sI|z-XFYUB-I3-z#PKH~xPJcOIQTyeCo~6tu_>?;9O<A&
zRI>8Sad3l<M5R`mIcipY#CT^TL)pg}(nm#8gB=mloHm#OeDQs1Q+14MEow)f#*m1}
z*F4?~Zz1wpmaKi<8Bav0>DiclBAGl1Yk6<>9j5`A5jqi+HQ-((H!J~^N7MKZDCFM?
zyT?=66qjjwkjgWQH;w9h(zNjAX9L)k`{87{HXPB=<4l?t==C(GRY$J@;#Q!eKs?}w
zQ}6;xXtkjix*HXbUe4fP#oVNDVl><a2ICq|TCq{S_?yYeLH&AM3DzY2I=v?i)jbje
zO%32svVMR@acU}rL|m?2*~};~1cp~~I3q@h{XuMZ<fN9LJ&zf~+Locp#3BOqPeU_h
zcrAwbwwqnNQnoD5-fgcaallwH_8Xgk=|w72!4)yWbCj^0d9!b*C+0UstJ*7eN9;y*
zJOPNTLosk#N;#yvOOAEi5W=R#YUjrMEk)p<C-~fTpNv5F@sM0h6!(jDz4MwH<30YE
zUgo<pfnMN@C}g4gbhUmuv13uT@vv&SG4J^$Ppl-J;^E)AM$T0^UX^vbPb_nWcZf4w
zzJ)va%ALCycOzX&1n=?H4yO>4h8HC3DCa`sbY|E3X_r5jdb}1>aNFGsT?<dV4-Op1
z^2XuC6~llXbVk_!z1)$xG&2aM_5=AeQ%n2D3m%=)`1dJ&S)Azsf+MQ9g#T&~!+sz4
zpAvS`xZ+WVS{QB&%TXw4K(sp3QK&esQ$H~xm*H>@aT3D+I9Z<qVwYRbvwvx7Z!w(c
zk`-6BAn3uuJks#OSqfDqKycSmhLP49vHla^f-=QHd`6Jk8O&u&K-J24fq4<$9lr^b
z*Jj<Wsx*pezZoK<iwuKIr}%P*iRNKt=~`*1Q<)H!rwaBmrCZJgMB6SOA`g#OOLIuc
zEM>9IsOU1jiYt|UX6p}{rG_x*1#<`WOJcspfr2Tu&ymIOaE&c50I`7-9Bs)hV_1wP
zh&!y%o}AIHJho*;tgr7p`|^kFfhQ;zd~Yhm$Ic$;5FV+FUt?-I#h@U&iWMun5*vQ3
zxVr|=*m0C}^Pbrv)f{hrWJ(mj!vM{?6K?tU>pm8oGkkZCn)OM&sfa|4&ff%GYB_xB
zxq8%QHYi#SsqgLs0116$z~e9FO*zjUr78BLDTIwwjT#%?JFSW7HQ4f?`t@n|!$voQ
z2gX|Caun$%+%$TGXN%q6uoFuMDYwXwpwbNpA#v8djL<pyj@XZ9oQ4aS+avgnq)4oE
zSP<a-zT`>t=dq+qS>zfWbse9wxui_>;Uq|fg^CokiM_GX04dw)l1z|!=KY4!^+Ab`
zV*}%$C<@`z|9SkoP?W~=+Q5p^MAPA9Sn*cR_jj^>iHsRc>G`l~jSj4k{EP_p8kreU
zv!ZLZezOgL`Dn`WyeA(Z7QZD9*2@1)O~3JWq?l0UE`|SDFDO@(0LKQ6_>e|LU!%RE
zd<%FimtV;Jrw*Q=UOf;uhJ@_QqgU1TP*#>Em+rBcx#;X{AhxNE^_Py_yc536y<PVJ
z&VCBn$?2^LG!8$5g2gnpx~-K886u~t`lviz5<CXHwFi*`=1K-sKv0&m>k5{dU=zE#
zdj)ydX=+j+?YW|0R)lYHzsi45GpT^K0BFP4{E_%!GWC#%E$+lzE?9hOour&5j!$YF
z%Z+W(BG;jxloS^$MT1jX;~J@ND)PEU1B)gYvB<0*X5?aMJO{gy^!>q~VJO&0b}WXo
za-fmf$MvCR$*|()FgsH3(9`bqeI32Z9j^P7qBxQ+rcvB4RtR!8HNmn@=Q!`Y9Uw7#
zwNtn|;lM^uin+^gD>m6lG?X#F_zhe`A6#8y8zn$@a&i@ttVlxce_d;%!Nh!W7_rF-
zl7sFK`pvOu#abpM-}l%<5Aa(3QcyQbJ*H0TD-r8j=D%Gx<Nv~H6Vhpt9O4IvZN!!y
z;=Q;7*!RXfs$rk*Ht|>}XvPgffx8fU0OurpP$TjTb^u)W*S~A3MV_Ef1MA!|MBzY_
zy6=ALQLG_~YxQJdoC(kHMmE^gR&g9M>kNc@;`_rrt9soH77u(;HVY)=DW!v@qQb7D
z5Q%%)_u7b=yr0WwG<AzSU-EJFH0mA=ZLs-oQf<GTyKi^vLI>iGg=tdxfExBOe{?6+
z9~xn1VDXPK_=ZTEZ#Rhs4ngHqo?X^k7UQ!@JqtFN!1eQS@6)QHJs=1DXm&S!xbgV<
ztW*75wMLOun^C@DO>h4GA?oP)HpcU?apP)$ttrKcDNQ+O$d@3Pq&UYRe;`)S9VJ<q
zo|CuGhYihVVTN)nY+|<qfW4Wi%#iVV@fyr}t@|+Dc<22YXZT&8>j@!OnSnlec0#;e
z@7~k8i{hMRr7Ak=0;T%-F+8qJ2*26R#D6_eOf!uJT8#yau*&(PKsLQ2Y(<ui%uIDW
zy~)!esi^Ps9G0tWB&Ar0gOZ3zN)~iOgrTPhFh{>eU=hNLGtoH$2&?#@aEQtzHQl*0
zN^Im|^g|-ZZ?YT$xA5`UKc*>3X1)_t47(e8JCf9^+v|vHwAU&p45YhLaqKVT({9NA
z;F{QpDhzGXHI1#kbF&%~J22!0Z|ZnnaspKF8ag<KHdj&!2r%uCe=}FaIRC?v(qp2<
zVdoz=57<{@qEib4Qpeson2^03GwLY#l`{Id6v9Fbet8oW&O9oRd2bHFA~Y<*ncd|g
zynPpq5lApfS*o}>dE84Jn6?|UZ3qMVoxkJ?y^5BlZm}*{|1P^CSl_{VWC(?eMj0Xb
z(}Yn{%#_h!6&%k_KA(#k`Om1OQspy8XIKIQNi1qG395e<AOXYm>L`#I|Cj1PBDk|y
z{pF#;Koa>yR=woq-<fYLgvV$GgaucqZ(lrhp}xy7sUZ>xCi>fIqS?Y_hW+8~PE>}#
z5|0K1v3sUy?<o89&IbNW=tc|%JGI`Gc?Vg&A%b*gKSC+C^ap9RB^`X7DU5JIBMCP9
zg0vqJD&-U?;3<qAE^y4p%tF<JIxeLT9S4)|ip(OXp7ClISz$iK0~2gf;%3Mi^hS+o
zN@);4zL#=@{>m6<AgOY*pH_=3c_t}Fc7{4igLKII%DVX*>T-kzrHK%`-o8k$j+s8$
zt#@n%wI)lVyY&DhKv05-Y^4W$lP8?fn7cwmU^03a0M5ifgCS+!(A78iknijt0!2eU
zO;s<+6^d1)cs9E?XgWOF>Pr)rqU)r>&dYAZT%Lc93%o8rzWewrT6LZxybEusr2b8Z
zoFhkLq8M&d4o>N7)2fjh!3Eh%7WNrzGDo52&rrg_!{Ay-Ei|%OHZcx_p1~nDV~{&@
z#OVzHI!l!}s4GAUc=AUgWVaDEJEuqwo(iR04T_tnU#Vo}?WZzDuJA_LEyx*lF}n9;
zYrSZkLKU56rW-~E%H%1(Gd?6bz)&UA?^PbX!T)hzucEqU-3C`-fR6JdIJ31(fdX}f
zP6US{A4n;DQoy`N%?4u^xL3@!Ae63{n?=L`CI<>!KpL|#{|aj`xf;(d^VTz+&>Z3W
z_<Ly0Q@23Mi*^-ym#-t#!`r!jQWY(gc-}ryt@vkYbs!ddQmUxUCSS2mbGp4EJ!mKu
zp-Wli0-Okozhv2S(%2XaoyZeqSEPTdCD*s-YH}WH5|lyC>1~DN)Bcm@WkxR4L5=VO
zRvnn=@SwzxeDHI>-n196lu@K-kZ2ByAn0(e0faA*elIh~$Mi)<_uevE+pn-?+{3+L
z)=J)WdXOgEWx@urKOp=hJ)mG<Lw0@MtsnGd&;#+^gptLv78-PKE~c!T6)vV|F!rGc
z%-N5IcyP0?V8}`DjbPWEHo6;9pi>n9=z6dY3r0gIW_`yy2GS1qngb6R{r$|Yq{N$F
zfja%=NVCcLv7858qKMXoR7+J;dWcYBB`0$&1N9#XNT%?Mv@g!ixffMq5ywyke|y`7
zenm^JALa~rc=X3=&a){GxXK`fDEF-<C)9ObP+6&X20eosaq=tXEZ@WZi_35ZL}f_=
z!bF%-BnndS!q6Q9-U)rsO;DB-20?`|kNhjZKS}*+q>pf<Nbp<U@A2|?W0_p8&<}4d
zzy9uqA954hH1x%BD81sdUfbrj(z=Woi}fB18Z}aGOQJj%h-UKF{(r^bW)CPN*bq{{
zTVM4U4jTE*U<UxrN}^RVy{WRs2_x0|$9q`N?Sh+ld&!IJGyX`|qMT}t?DQ{qKv9==
z1XE0QBq?lKO$Cy8PtGc`LVS7n)n(iMs=dgW#UtVnp2mr<!*JQE0C6xvIPX^l=A2Er
zhuv@O5O)&0EJkxhzu%wZ4ztS&1>k--X5z6DF6d##;yu8|RD=?}s^AUp4a$wu%$8Y;
z3p_(YIWo5~i|?qm&Evr;FKJxXU(vYQpMw<M=!)6;ZcBb+wf#v#NU}|b77oeFi4O;J
z29jimSE(%BF%2pDt8xxY6I-YfUB%voyDvT;Lmw!=yCzsd6P=gK4zzL}E`KSgJgfel
zr?pxtQJDa&c$clm#YB52I}&l%BoQwPp^)G3ZosGd%-{Lbbo5jIh-=5e!l<m&*GcFk
zt$!LAKPvm}>-t{Df&;#a*AU6{g^)=4ubJke$v6Knj}9%H@}vt{kV+H&`E}50{8KPB
zeh}Zh>VWsqC?q^<!&>}L9+%;L+eJ)OmXtV5nF)wH>U?E{F5aafnYmTuDBvXyO#pZ8
z`goZit5bvk$@*CYMT%_2JlVN=$xm?nm@Vb=S-SU_9ewvIC;swY9JdKjJ^!ye{Mz)1
z8TLvV9!p{?txg6NWD8aP5<5=Bq{eGnrJznvKnB_JKDe>Xb~v3@WuuwaLk0-=-ylQx
zLk!_>Z!18iFz(@_rp0d3iU(_%tbWShSzAfuX3)3N@1iT`_qaC3u(ekAPL(@-KXZMX
zuKm}|Mn-U$WJl)6A3fH0Y<Dif;UNZL(G3@}Y(X_I24QZ){4LrSEBdS9{Lpk8W`p-3
zdhAPN{~1n^QcsWz_0Vh;YaJ;6QKbB(Q(<Bqt~9*KoA|b_1Y0LZI`pxpX5a74tIoHd
zGhN-qD6I-PB4)5Nm}TH(dd&JPZQDn;oW<mls=4({Jz>9p_Ug^wb;`Plftf*X+PUvx
zT^r$EpD4BDNo8<(%s1QJ9m!4r-B~|Q=}xqAU8EqfB!@}z+wjp=&J!r{95ImB`_zY$
z%~a%bFtXbk?oqN@$zZ26Xp<x(EhU}#OtvDM0W2Sji7XTy4(j!83E<t-WT(^SCl+*1
zY_Vxj7!JIiElsT`s{pEj`%88G?%Ca~$%GL8jz4u;IR_x_+@Xq#q)|dAW!T)5TWKy)
zLda7xU)^ubpNzLH4?qbNzUj~oO|7XJJH4@IG$XxnSjnBKvB3>uX7W&cpV7k1O?-x#
zts9s@JxxtYk&^FA#qu_P{nv0R=WN==VR8^hSxLK0xn%5<vK+Xbkmp;)bQ=N0D8=x7
zs|}p=E!?79had{`^|IS^NU9SF?oKxv0n(PG_9;KE=8SnrO@P%<hkDxC36`g0G5625
zQFSYS^)L&!*T1R)wAm_it=62zi1FwhjZ@StY|A_C@e9}o6y=_+33c=o6Ib!v%<IGh
zG%8=awmRY<=cl<*Z*L`<)eHUDYUF!|rfN%8`AZ32BK<vOmX+NxK@JYR%Gv^U@WN=T
zu*OWLlw9%B8vt|jVXPF6L)Sq2)bPH5ALUIQqtF^DpH-mq99PFt^PX6_GS|0$^xZS0
zvl}F)5zY<vRK>&xadfWkqKuZ8n#DXEbCva8WHq;fQS=y{O?}Gr^c#q5F(Zcy=lXG4
zok0)!)ksQVX{)^@Ajn+r9!}^OtX20L=f_M6PWs^U4NyP+y8|WH%>Pg{!EXjUg?NBT
z*1JK$kIBA~C_onf%*c&mQxt%d!90sEgfo4)XVgc3o0kk!$;$V=Aq4%1T8{oxNA%}h
zI#87!Hc3*%Q8<YLnXku@_58;!WrWe^Z<{Pwr=ozVsNiy^Bz5>V&SiVp=p~=xlSH%#
z-RC4mI>4Aa^E5M4bNju%qh6y9+i8;r^oxmL_(?!fHc?T)B{r;JW)RC-(!;TI*|_9P
ztC|iahJh`^c=XG)j`r{5o6#hfF!Ys^_7r&Z)H{dJ7m!4?bYcP9Mr1@|hpU{p%JkrR
zR}UQg5oRxODC8u3)91_N1^!zlPLDQe55W8J288wE8S-h8hw3ya!FwYNohpSX5{c@f
zTXJJHSO=IS$G9+roo>I+(2VhL>!v-(pers^Y#}?ctttzS8K8#@%i|=3D}JDuJu(6N
zPB)j4|NgAxF|IkLXGn`1>BIU|VWFk0tkgm2P|9;@-OR?8l_;D8PUp0*gp{zNR2tt3
zfH=sW|C%P(d98d|cK@zs*ig<ZoX0QS#`#Us%2j*&%SoLA%vxrb#;0Sw3wj()6LjMX
z)(lWj_eyKMyYSzlm^7Fe(o^1rmk2p*j<Jx@<aOmEU1@Z4zQ-%9RUE+uSLN$~-{tx`
zsZS4biLB!}oaC(OEvqoN^!)7$^Uyd2JS3@KF_Q<(2?AMvI+pB*Smu`P=k|2=AFeOn
z2shdv)HGEqC)ZJ$HE0&WxhNnPjVP{HDkCd#fK1FuKvB72jH*$k-^Bh&$B~^4bt<<X
z7&krNs_qY&G4V^(<mFm0eG*XDC}Dd7XK0MND46W?LCX5uGvcVG(O0TdXjLr&Ah*bN
zVHgU?ObaLCTF9H|Fb~OKnHXU+a}r>g5+~B|Dh|&O@87Dor0SlA#EzJ4zmCZA-m4@j
z(&t(bHJrNf^~zwuCUONk_>Lm71omn#wIE4QTs!0MgcBWjYa19d=>K(5F<oHBA6Dm%
z;U9B3O=bEXx^AHFl%@KrT<yRHT=+aph@k7a!vUYHH&q|TEL^F^Y;lsN#LGi&xYn<E
zp2A`u6D0L9GEA@E{vU42XQ_DmLjBW_`fDWrI3`i5@pX^V8fG`sbD9AM_j)yt4wTXu
ziD$G--QkefilZ^{IVaO_7IFO9|G2u_ug$JOA?t5})b)UdS<%!3hg1m8xVxdd(rq{V
z>iOOFh~en<ez3*>Y%@VvH_Tj730;L#D|g{=Qx4Oz1UypHJH9Rtsg-<n*Jy4dzaYc7
zHqjBBsq50!=BfA~Skb&7+k_Kw{EncpA`i?%Ft!~YtIyZ!T##|Y#dvYrgjXp#vTwJ`
zo6!^77~tCLfWK`?M|ku7N)#2WEofsG(|Zlh1_k8jIB2G_I;R@X#Y&11EKB4^M<Q=9
z6gRRYsw~R~>83FAx3{mAf)MpokSN_47rtD`+dW-1YGD2SfnRgmGK83F4D}Vp?`Mc;
zQ!HlTQG(={DBSRp%XL{c6934sTNn>HhZ_1ifshdfaPIoMDVs^t?(7cguVbg$@BXiE
zJ*toddiTPuuX(dqtdi|E+ju8dl8i7lq4|6K4W@B!(6!=#eP{U%R-n+&nF_Pz*xy$#
z&27}oyOiquk?|}N!9B}v9x5M(ejW9$#q>jYu@zX7{~0?|7sx8%oOr`$v4J8H1@NcA
z)pwS!v+rvbSpc7L5MP~JyNAEZXguF-O0qNvI_QnI=8m6P+;4F*9M`XSzR84#05_xD
zJL_2kVwm;qqt?|8@E+et!8=VXR78#N=yqKZlarPnAJuFvO|`3LDfs&yd7fA|J#}$9
zT<p$xxjsvTJ1*wKZm)Bc%|DEEf%y<zv6dXTqSAuFES$y`{?<u5P4UQpNlu~1T^Qc0
zaZotoeO2GmHVRA4le|i_qjre+q6%nZGiwA7vQeibr}RO$7WX~yl`k@m*4X$>Y`dp+
zb71f1%`)@rj%nPaE7`M`8L{wo{rTa`{de*5w3WGIa6{WW`~82G!^AxC08j6|IKfu$
zGKV%t{Z22o2NPHao%Mdj+On`d^TO<Nw1Q26$2eZmhW&QW>#s#bGJ+JQU`*>ly=-Or
zU|J13yRA_<wbawMcX1I6=71v9|14TWX!!x#(;|908YER-FfrWb1FM(O@#Q_oC1=NC
z@mm>$@C7<UlqjFhF*^Wp&-z`)9KMl8f88(DC+W5Mf`%PE2OJ#n+*3fS;hs3d#E+b9
zyqy^k+J_>gV1f?}oH9ifN|%JOA^XvA))u(UC87j{UyTO0mE79GC5N^~xY8WJ`^09{
zQF1w^tDP!l*U^m!AwNVzx2)K0+;mByRuu{Tn^C`xvtfd=nGiT1afX}z4H~Zz{$xo&
zb}@{&i3lK`JmBA3+$7Gvie>tIlRK}OezULCn=Ca!bR)}LYYq(0^12$OAE~T5C#Id;
ztP%O`RB=#N3MbE2?7X88YNj4CK5x=6G)I04<vY>Wm(NN1{I3r_IBK-Ok6kBU_%$gV
ztUfzZEM}RbWEPM)@WD@o?)>Y#yVC}ZfO?wYmL8V`C}#fNMI|D?sGIVqHwnucaK%UC
zjVKnHuIG`#J<{`L8x(2g7jo5NT2wcp;Y=ZHdD7r1<(G|28Bh{P61N3{_{q$|@H(lb
zz`cUh$g8s)3HIR>4B)Id#tlM(Fq}0LQ$FbR6ay<wn*mGbH?yO^1tU;&LXew?W0P)K
zU<EQNLly5>^q$VN4GEbsROT^}jfX<6nl2s5g;iVUTaCNp2O`Ca+l`u2I}4-(1Zxcf
z*di{S?jmi2MS*%j9oy0d&6o=atvMI+({i8TNt55tRkZX$v3?0{*1j<?BYieS8BU_M
z5{V!A*#XghPpBqq87)-bvx)ND9YU45h)j*gwsum7lpdlL0x89GkjH;2vBPPX|C?~_
z*x2gv3*Y4XG$7<@x4jC54hS*B;c=n0Elus|Ya80y)_{ts?i3Fg%wF62-AkN->JdZk
zw3L@6dyz(tHBOB!UWAv%c|AG7lj3%!&s0gC;s7{>sXDgK4PxhpjSxVNt?HXA+&@bk
zjH(t!Wnc1JRhL1-@RX>$vS%7#yE!UrVekGo_e&ONew#EbSdcmN!O#4<b_`mtynaRs
zj*d-i^Ei-nu+U&;!xl9Z@}2`j>Ga2M*s%2=myg+Fg6Og>%dl`_S>dSEZT_*BHXG|V
z!1*l(47dggofcdz_vMC@Psu_^*}`B#jAg5Kg1zG6LSvP6CMw=#N~*NC&m@E6^RBUg
zz~+A+X^7LoguA_lVT{8yG7UD~mg~hYwo_<PzG~ZUrpxl`wmZ+@#gg!imc+&;Td&df
z>3d-%6$rT+njgp}CLBRE8czPPd3}ul`KE-~&A)5=8P`=$Pvv%AW&b;}>b})o?*QKG
zcZ1IxD^6$3FDRW7R9TORz0`Wu6%pGc5ci*Lwf`kMgGG<%1lpKKl}a%94Za~JyV9_B
ze=9sUaEry*;PCXV;w{Ha{C_#+J{y2IlDox3t*=c=DjFm;=zoMZ;6Fy2{Ywo0&KJws
zkH+`2d2<}U1QDzk+eHu@DUt@?9B*RN3aML3-eO?-e*I8;bJP3v^0LT&Tq$KTlQS}^
z#<Vn7wfcH<ZEQ6*s5w!MbH1T=p>rj3A^)K>T9}E@d=;!%djft=m9IzGoH=kpu9Lf>
zZRm|<df#+d0UsSefFQ$V_oZe!7O)h9%-BjdT02j1C?8PBael=St&`zhOzY`)-Oci?
z?S6g7s`sUA;FNmva~f!O>QU??)4OilrzYgA8=M&;lqUA%aWIZ?zbJ05H@kmt^Z1G;
zr(*c+2CQQP)v@dUClR4HkCINt%Vx6uv6%wsRQsn+Q(1Qx)6kBLDKy|G*YRCBU}|;V
zVzKA<k9YaS9m}z+Fv_=7+W-7*^Yb^Y6&6U>`dD*C`Ab9LUP>zsKI$y0s@~^D_YU5M
z7?u_U1lBOPL;9ps#k`NVu$u2@;_CN#%K6?8NA!+X+jSI;GeY<>8kL#^0Arj9dI%fn
z*eXu2gKGVO9?5%D6bL7mmS>~VD1;8<x8wC|Kza9{6k%zRpD}8071U%c#CZo&t-@vY
zvAl`0Vi?Jv|Fw#1h@)_$n=rMkYf8?3gK)W}@A0#q8OEyBE}OqR6-PA%-yZEuOI6q~
zO8!RoZA1B!HVbO`;*d8V18rtl(jXuFU1<bj8{VszJVDTFNfX=R^d|U}1f0KWU2rC`
zVPJxgE?(Uz5<j80=3<m*%qSSL(f?I53YV;#xd1qHbz%d9muXreKN3ZL@Y>mqcxX>(
zvb;UWF(*?Wu?snJ*_9-WTWd$BC8a5inqHbZMfbX<Wg0T)o6S@t0Fw2JUvN*uF$mQ=
zmH`XG($beTw=RFAVr-r?E&8NsV<9}KJUraw(e${at>s*HYQ7H0(K_<j;Gg=LJ3aAh
zmQ^<={h00YLa~b?wX_+++_04XXmxS@{Pg{tXtX`m4+?t}u4qn_ar9b^HsY@XW%f@?
z_<gT@07;dRB#G(~_$rh97&q~dNS$7P4Cz3!o4k9GkMR)2iOgtK*tg6lTP<p<$x?le
z@OZ@zJkUVYN3ve}CPxR8;axT_{xhdZZ62dF`BqVJagczy#droHT@uZjEQ%_XrOX}y
z*G$2`$8-ilschwK)T`PoZ@bnM<I_epz->jO&shifqth(}*n(3pIlO@8z#3^|cODK4
zM-HZ&_lH(-SqjPsf_}cWBg2_z8Ew9DY`VjBHKV_5p|8V88%6i^u3$^|&A_6};QXq=
z?gx9PpATy<FJV4MBkN0@A#h@TaeF#<@?K8-uJe4`%1X_{QjJhoxp6aTo)z^!$mTr0
zZm}MazTzmje@%4nJE9C_AMxiHgW8Uwz0+?tgbrA$GV1=GG_(neIP$aJ3nuznF~I7h
zb8K#`34p}$zup-0^LK5Z+mf}kr)PEBBFaD*VeD0d8-cj<=w@oP^XKUr48uQpes6|m
zCb#TgKwhW8zWO0eYX>I{$JDt?StaOY=YR;@Ffl(qqyA@6{p-sQF*OY*_`fp6y;Lxp
zXNlIyv0o0<FZ2mfNvGE01sorOOOEa-N{mmQr9jUh!L%N_9q9F;CF-}6u#R-3;}BEg
z3L&|b(gFI-Tb3$>3T>R(m2K*J8w2i`I%@Yx<dy?Z{@w^?M-KRy{9pT71GmX<z@PEa
z)V=v>P?~)5=Tou5hAJuL-@iZzpV?cjo45}Zyql}$KJ3?H<9<xNfMU>4{=!yWpjMya
zH>x62xBv4VK6}B?a(QYSTi&Imp3%O;S-%EZu@?1z;3N1XA_E_K5;hUs$TwmM{V+a<
zT&!L={-$svWXng6iaX#{&9oyg$7M;*EsI-#%iUo>=+DrV4l0f&X`Du3AXaSul};Q7
zYKhtEqyo{$4$qD!T^nri<ILAcr~7nbsJ`pg1caXM;8FO&Fi~*}eQ%!dDez5vvt0SU
zKe2G0mp^2}3}#Uc`d0hiJ3=v_O{WVKRv8FKz@*_DP&o0VgDwGAxQ#v+)zvkK=H^ZQ
zzkVAVE>Ivp5<sniRLau^axO_thzO8ta@|{!qM_@%YG=an64XsBE|d@cbKhUuRi)Jh
zmM8c=t;a|@_k@pnjF<Bfy58&M0V`4jXC7ECA@F++>gTPmU$m||9W0ej8mx&{^+xRS
zSSr>wm&k%~84|$8G*4D4q<)d(6m&AF>ZdU0y+6gnlop5-Q6I5b7M@kLpK_4MBXeZN
z8Tk*gp?*{};}=Fq@kq2g%1}xH!^qrOgO^bTnV(5VK@lb(cfLH0z1JYMh2NtYZ{g8@
ze1#cd9^cqDd^)+ezYpeEcJE(87$)032zTL8Ue5Z&bUJ_n=V0no4`H-cP=hZ<e$N80
zB$wjm3H42PEShEUAod@UE6^mr=D0m6x4#?jJ{7jfd=%N>e?>wKBUk6IfBB@&llWa;
zPLq#+3;7~!8~OlpE%FVKzd*eG|D<!7U1w&0zvE3bI+#yB^hm2Cz0Z&3t_%>0EK7#~
zs-HX^hAKv?HZDS5c6Sh2V1qevJptr6Jdtf*IxrvCR}S`B%S0&(K5|0Oys-O^Bng}G
z@*nZQ3(Dy|h!?$yvl@`5A@`##j0pEBnsfoZe65qxT^#qN+RLtyl9Ah~HuIm2)W-FH
zJ>%kTMy3yq_d}kZe?AP(mCXe^e8hkjy3JnMcgW8)9BvcWqum@&IsXe@*j6*U(BII8
zQZuN13)-aS!{&%_y)9Oo0eAM^F_3*g8zb}Az>B`A+g?9zSh-5dMab`I^YDXjO*!}E
ztDW`Aoqu{X;9AljkHfER??^&7<G=gZk@QbCO=6|v?CjO&X&yC;9di?TR-*v=)t0UF
z-*5uzU;3rP77TR6Rgx0R<ZTN`IkA!@pb7%p(Q>sXBMhN18j&qv^e(B&EdCbtZ!4!S
zbj(6F(kgejcp$H^E`3ISC|n=FG?P1pe(07JWhWuEN_}?TciyN8CNA#SyEoHqE3l<t
z2lo=woS3R{syw&%z}%?Q)z<xAY`tS}rSI159osfKw(X>2TOB7WM#o;UZQFKtoQ`eV
zw$VvW{(C>qKKs1&R?Vtw-PgBOwd$_9<{aZUfXnP{V-@-e`2%>3g%#bey{?H&pX!Xn
z6Mf>?c)no_fV~iS*u*DtxtvZ?Foxd`;i6mOzbxpL>tl-Tp9Jr`a5|^_Q<gMyqxynt
zcV@{)XZ>ZeOH&jh%v}pi+p`;dt|fz2KNp*iBq8(vJPh+~USAk#-b6tOBB@g^eP8p-
z0v;g}T$bQWZ?}Fka}yA2S2BN9qfY_{2-48p|51H1{&gnLAt_8)<d;z;bBoQ)`uiH)
zz8K0)CD5z<&)3NNCd|Xjp>--hcPV$G-O#}6yO(x?nV11nj=rD|tw+^*cNkUomG)6v
z&x?YY9MQYx;kn79BrY~mzf6Q&N$DYE9#9C)$9zrEf2=v?JiJS|y9OZ>*(J?7iDhxE
zu$V_c)J-)KM(VheDgUV}X!GreXYtKf5rRAK;k6PM<-w<O9X=qx5?8Uh&b0Nj_X!_;
zH=;Cvw5FzGe*F4N_+=ADmvdYj8uLFn*)0r)6D)6a`j~SqEXJfu`~nK!eghxhra)Bk
zPCIF<myleVT*lkMp$q>U)Nahk&Q#G9VX8aKvcQKMr-1tH#Wqr1Q+R<HG*B7Z!?aa^
zaQw;J9$03U4w^JeVw_Wi*dM%F!F(n#^n4fEnlLW9fHPL&Zm;J;Ay3)7oB_BDJn~sm
zu#Z~4>n?3JpurU-PfKxmv;YO*j?vGfoq4xiB2iKDUz-By+(93a74J{mMrBzji1B@<
z9eEjcxc<9+oI?$KjC0KmWV9DdchT{srvB>@fsTXZ_@f15VsyNi>bW_SCkc9$MJj#;
zIG*}<#b+dUgBUjPA5ZOnVI&-0*@$nnfXH2sJnI*SjXVwkwIo8*KU#Ns4r5C>s~yLo
zZ2{G8eARDQr4O~5QEQ3B()?Io6}`_=<5O;c9I_wMnx36O(X*HeqMQE@tjPZp5%wUe
z<U5@H7ui3kYol}RDnC;&RBq$16(`-T3!@#ET%i9Ey`rsh18nBAelCkTMJ90Rm~IQz
z#MVF(p#JrXrXWr&Jy|#JKIBV@v^?qgfd8!Cj@6E}KS8q3Xkbry&F<S(({yosW}xsN
z;?F}oeqKeJ<2?-+`!l^U^$i>?;uPQM&(>XczfJx2o%DJqv$*s%bssB*1H!N|=%_G-
z$rD&|+02s~u924ztf5|{wKlNH{2ILhAjQI3kUQ(iB~I%r!#*2VBe9ypNroQGPGL*3
zj&sK^b`sw*E$c0Fcxkj8jL{UljGaRxY`soDsPs~<uHc1Jn_K7jx<FqV-b5`8q5b~+
zFh;Bi@Ry&&T#mo4VfxeF1#$ICwzKi`0w{(2e<?T5=9k>SBqMpcs|R8I+`bvR%L)Be
zU)me}uToV@BW;*Sry&za1y?;wGUBX6_nrC|DoQs7aW38_P3B+4+ULY;=YE)x%l7e5
zr;!V8Zs+?MnhuRwhheUdR}#oP&)@3uVI0eTXaHgRz&7@H-pDiPy)@DriZ(jBiPbZL
z4P>KgsF}wR#ue}$t8l=3(|w!qK@#&e1rkgSq5k_XdX9uh1XcviU#5CpBS-;vCI@XK
zj;U#pqX77TZKP{~ob@&>?WlynClGHNb5;oef{{YU9!=$mu)~tTpJQ&EaGZt<S??(f
zP6RrcJ>APKpUujrDRB1Ro}xC_4iP|>Rb+BQ<~YAUdGMHmbzn$?t#b_%MpY#g%=F~m
zn&~vJztv(2aIl8`)!99_jkfCxZnzpPj&Zg}m``aHt@U(=F1Ei78ySir8Ld<9U*i|*
z!z)N2&{%Q7V>dV}OcJ3)^&_r49(+{uh0>A+yvV+5rEw+tL%=|xk>E)A8Ik}&1J0R5
zHy_oajFz93qjoU%j*M{O=KQzzJdh+>J($4{{kLxZg3#?-RvSSL#_<ATo*-S(=e<CY
z(L!tz5L)I^0e5BT?KHQp%JgerW@NGUFCw^e;LCLyk3Xagi^v$A5URubXz@y2)<v8m
zfMRoKq*T1Ua`dv;<U89tj1rJ8zim*Mi9Mu@2dwfQJog4VKx-cnFWJzmOn9g!2%RC~
z6T&?4ugjdFL^c>WyPR^mDxDWbTV=&exo0@&jDG!8lbxrFo_h0bvR@7lKL_RBFbfm{
z)MjpSqP%SBVVd~*9~d-My>b^wA|kRT`E6K#hZ#dKG3sq+Bns!Dd3@jie0C1DEz1_S
z(=@ZPaU7L5nfsHB`b~5BX^EASy2!Gn&R%VSGv8?~@4UHz8(V2nB6BYZ2lo&81wJvp
zwiJMcMgHNwxLa|K^PF?^4WpX!^bb9^&eKa*=SS`AO4qNPt(c|?8^VVX4#I~Ur_v$l
zH`>$HI>C$VEw{`?y%pf$m``&R(!#;V6R|?4&+tLMjg0*M%XHx>k%ocJw_K&_Hx9G4
zY@WYiG2E~EWnA-Ei9Y4weTC=8$`3!6V1-cHgl5DHgYoEZ^}0YldTp%RrMo6+z7r)B
zj;4qn+G3Fit9j)wf9H8Gd0*2t?(gpCMf2b;Jr;jPIh~MeQ`G_5s3l*jDOk%JrToIE
zmg?4U*KVfOq(xAPoJpypr+n%9QBykE@P;<Fq4V<?4t-f^r7W)g0-gR=sT7W`6N*xo
zq-piU+~C46u5gi$9d^JVycst=)Hr%K?@t%(mPj<_=^{q8=WWS%_(rHkMO1Jjo*~z=
z(ShI1YSv5cuv$JqJv9uOaI1<o1{PVOj+j^JcTacSGjH(kC#`D9Rz1<DCC?t$fcx}O
zn&ju=JbLBc{HmpEY!0@56WbfPJp{&c%wWfWK=hP@54qNJ+B8e#u~bKSvnAs|1H>-9
z@{h&Sg(HVN9h)$3&Dn6UB56!3DCN|joVv!4Ji((8J+@UqOSp%EvMkppFiCvVq!T0<
zl?zO3rWd+;(s?*7aZpTev~iSNzGtL(J!V7{!BCH%d!PONHSmM!jt)VWL#UqHnT3F?
z`xU!5V=H2zVbR;ANN=Y6zd~K96$rw4k`VG97!pOOv58?FZz>H1p?a(qb0V-v0xJD^
zf9bEkIlD*#Q}vf%jY7{v?xthK?!T;6jz)pe6ukSv!bIo@!88?A;IuxSV3AURmxU_~
zuNTFxrgX<E=@6jpC(N1Fkp6ki`!ue7pOOs-3r6b>q#yO-?x;wp?k`egATd7UNEGfz
zo(y$WOP3QT=`RZAwM*Oqxo40_E8Ge-@w4Yu_&@G|T-%R~g{z-&&)ffzoMwHDOa9$r
zGlA7AOcWZ|c_W#}k26vt&A~dqJ8!>?+&6;}t!$aM$+hl$;Qm5I%%9-f#eh*OIkBxd
z3Y7e|D5!E*vu07<YzhdstiIdaDQBnxPwkA|O9~D2?Yt!3K2;~|Jk%p5FKbsDU<0O5
z%v7FgYH`YCdxqbgv}yG;z+mB2w)x-GTB+NHTe4~5WTVo)3MTzv8frwCCkV=_;Ksoo
z|7IAd4Y3!XT{pp!Oax{_G@d0WABTg+QxKjYyw@*J1A#tXNP4&ujAq`}6RQ_gfEqS7
zytOn0NYj~W<V%7OAS>|W=r(dRfB=q$QG<P7!!J49A2HhIS&T`z;H31_Gpr|n9Tevi
z+L=5mX65y-(;k+@qpZL9RPQT+?LRfR-*1Y2*L*^a5KEq;mlVR44-fnaOA9t)K@%61
z0;X#Rhbc_JO{^K9pH<v8?(13&HqE9F$E_Q;M(2c*CcKj8ca6Bqb=!1X91VQiLXYvk
zI;Y%sEH~~6qJ@gGS2%XrMbCoh?!O8(;6_tiXaxTpdN#Ng%{F&h#%|$rolUr2_let8
z(j%^54j0MJYR{=OW@VVLyke(A;Ih2oCY?ES0AIl|U%=1;`wn4Y6IAS~?aC4b2f}7m
ziRn?E<Iw@~%TX!BqAjV_ofFvCL**O7qH3rb!iEf|6Cob*TVdA~pM}_jnL;Gwt%cbM
zbTiyR=XT*7ql^pzCb6U@vYib?QqLx8jdjcJgZLgHJs>DqTY`xZm-PmNFJ-&19O6oP
z1vRP(07q_JBHRElzIy)Ko$Gg&OWUXv-DC+zp80kAp94sbOD%=6$y}WL;+Y~RGRnGT
z&UPoABF8@v^CGAKFC0{9JT^gc;-$q*I1-RRp-Q673Q5M09uS`*=WjZKA@y}&aDR&f
zlg#=%E}6C1s0qh?mY_SR%{*OCTJR-}6jb2nn8sdv+QP2afMcaQ&8D4SyUVg(`i%N$
z{LS>)54;#_9J?6PW@8*jab6wFBD+DTUG%Uk1=Ikl3mm+n_#Bm9^Nopx8>>fkg09+V
z78w@GM%Z4FUEiEK2+xnapgkKmEB9uhVgSFxdK)a}!yTiwz!uf65QUKx)H~)oyI?}f
zsB{-63M4wFwGU)FI}MWQdLdCXL6SYevyBvmfXakMBftBKkjk#?ogqPcn;V12Vj&xQ
zP7#`S{UKr-pW%vzk^C`M{5wg{x7b)QLn*m4xAzk)=B}d_<w(mL$<`}PSuT%_ws!gI
zBSp@QX@BM-H!7KKwFC*s*2l5^YVBl+Ma-ug7v&cR`E8Tw*0Ps2!6*AYG>7XAG+4zU
z45$Q$^k?%IEvM?@-CfAlkeqbBX*s4$icUU8FKLn}chFI=1B{o37ODA-qnnuqb};WA
zs147o5rk0=fx{1VCs@&CJ1Vd2dW??`>wTYHK(^ATGm1<)Qg1w`s?8h0VWIJ<oE5zb
z=$^~dYJ^y`pc+l?-bdKX-=G8|b!uFVVBo*cdLh06ZcZU{4c7;+^U?eix9-fP)BIjp
zbmaR?Y5r^Zy_18plR-Q^MsH24py>>}KU|rfjoA|7sa{io26vr2AxEp=Yh6jIY(uB9
zoG_pLXu4^du=yCzBuQYzS$~~k-CII=LJ4f#o<dhLS=H(hd%u##v9|f^JAf0|4=rh#
z>B$2Imc%-A`)2PupKuu~p+m+mW1qH%I<luhOa^Jsb2g=o-gMel|HOBko4Y@Xrf+zs
zb-h>u0Eb~;G@@+-1t9I@!Ep!`GhO9nAh(m&wuySE+!`8>Igk+RI<n0&hm-r7_)^k@
zkBBkrK~<Z{5eW~T!h$ymn0FGh12xOScqZabBuMypeG&)0aC!N;Mo$MfDHd(MFVXh^
zBU_tx1Rqsrj+Of5LqV052^9LgPdf<1up~|T#t`)7eXYBwynN5|pkqC3(b9lSgr`s1
zWeQUH8>|%3jUsb{y=)L52q>eUV!dB)eoYA$AmG?Htl*<e6)pn-ws5oV=N*LS10O1y
zf?SQ;W8f|@V!%kdT`m~1s0U17Bztpg-mE?&luT3}476?@Q3Mcfk9@)?2qfFB`Xr}b
zN#9fcL*{dMJ>%V7Cc4ITbeP!?8Yi_9MN|cCNJP|5DTbmYf9vJ;UFzj-VTckiFgG{G
z8om+78U|iHgD!d7H^qV?;#F*CotjyvfYmtZm*MlxQ37dn&7tu6^=nF2?9%5B3JMTp
zf&*WYTin@Ph^}~<;1}9XeR_8%l;00wAmFSX*7Mm^Pj#o(vZTmXT=Y4$NWBb~{}lLK
z1Ih!@d6`JEbSXV@4+X@+mK+EcNB^g{zXZ1G@1vQXLg4~huQ!%U&kyxcsN50EB6`a4
zA-fpC*)8Qe$%W1HNp6fG(~Y0V2eTAWlPy*viczvC&W(zVdKKgV-K|Q!G9D2E`p;Ti
zveklIvOc$r<%;g*pBE8{uAIC5@yaJOtUwl>C4L6GQ+(Kg5Ht*Y86_KPk@|dy0btJ8
zdn;<aPfrX<som?@7+{JSO%j;g#fQMwp9s#Vf5_$q)_ASg3MOh@12QN<m1MZ26rk4^
zUuVsY=88zM%<=CFF<4i`sX)CxqH{bz)$DW@9L0DMYGQF%-S8AfWRgkK`G)S8vdB%h
zbob%EbfRSW!lQX2p8$MdZ$k9GAPt2Vb+IWjMI3XIaBpJn3&WGRfFaYaa7H`+odhed
zsZneQE~&fYo4wI~`!QOcz9}r^%>_Pq!#@geddG{}fKS3DZ$)nevb!(RpiHeRRZ@kH
zxKi;%NyTKQw}$g!n_0fXZ0&|7(Oq(d+PsW<>VV@0$MlAa&l!-Qzvg)1XLAh_QqjzI
zz37x4w|}&L8iT_;g^^-xFg;%CL^heTP|QD5)gAX++A(TbSqUDUAJ~W|da>idGrlaY
zDB3dTW2a@%K@#+iFV~8VX|yEl2%QcVnSH8(CQT{KdwDj$y5o;<JVP6-QCgTR32-HA
zkF$Hup4?P_9|CEp5vOh!%CEcAwHaF{NnV|F+SE7j-PCLi%7@wBn!U@_J&mXrz8o;{
z>UiA?v6pXNVzC&H={WI5FdMOC_dQ%sY(n2s6{yJ?KqO)@reL>$7Q6ULlV})(TG}S8
z-!)gz3pwoNj9RIs3)GYT=1|w?opL!%7Y<`D>hg=DgaOr6Yu0j&Tof_wUhlTr&m$y2
zbGM3!AN2msqa|DWj3fGgJG1k}K20(#wD(M0gJ_I(Ow%1h^pUv=>|hsg+)g?wAJYlx
zD@vU+%S|Z>>=EhD9Abxwry49LrEdk_etzW~q@3}LWEO<D$h}MHx)u0!1N~_Q9?Y)3
zj7LE|wA3WhpDXGhMiT}L<vIr^e~f>9Z>GrMfQQR86vRt46io2;BO8HE>m+52oPHv6
zpz*JfJ#pGlDkqx(5|M4M3a}Osq2Sl|oP7CWdgH;2$%GIKjV#1-ejrZEZOY-aL$++y
zZv=EVtuTDYVt*Vnx3e{c2Kq~`GStocGL<|yR_%bvR#)Io?SwrM*lo`co^$_cp7{uj
zd+Z)Lf=qS*gP*=&8_S=pbv0bUk9L}lCa303$TNHlAt5966o#y;@L!0{jO!?Jrd0JM
z3m1TPo)-%v!<v6525ipcv>5GD>a*6VZ=YOX4LEZR%mGMuct4c$fL_g~BjbEn*lU$^
zc3nJAzFSjQo)c~d8e%`*I<(Je&0itb*NHCSyj-al+f+39oU^Vfxa~3S5;6>*%MSRj
zPV1(akX$Uv7eE(23U}D&(~0=THW_BZhy;#hJCZAA^$a4U!x^r7=&e!dtoJ%R{&)GK
zypO^M&o4IuByuM*^BO|&^v7QATrDJOA^f?$-g$HOrGPL}h1AXV&#G?{zEV>=xEGsT
zp^?04cS9uzR<yg<rbzAEXj@6R?ELllVF$Ow52=8l{oSkHE9(Fgw{s@a;2&>10YYZ6
z!Zw9mW^?86PPJRq%+%>cO{4rO`@=W$kRf7d4ICKY7<Um*!dDWe%HUJt)<!(Z{q$B?
z-^OKkW;Fjd*!KgP!?D+Ttz_Ls>N<r6QKSNkqCgvRo?(fEKpS?n*l3B}`uLzB2{a;n
zX?Gj)o%$IMcboY>6EY;r_HN^pzi_e98{Bxb!rI1lElq34;#UF2E1SU5YW6)h3~4PJ
za-(|Sj1+x}ZFdiLkaQyUJC}NgK-Ct}tO9n7rNNuda!UhR5x#Vs9l1zbJj6+Z5aArw
z0Ignp=&Q7x?*0m4Ya!7j{!hb=cg;p8siF?lz-2|KnQC|A;7Jfm1<^l`_-3`ZH|ZeE
zn58_UmtSI+?1)4PPXO&?nBt5ADS(G<B6AMt$vdY*p$7b>%f%ZE@BC`mT%khv9iW#7
z{t=ak0qYw>{;b`YDqSzcNGIY<1V{L!beslh)SclpHUKv)%fC!d)i=z|FW_E|PZScv
z1S&Q}rW!MpplM0(ksQ;$H!=K0wt)WqpH)Pu&>d>(gYf*aN$YqOTKE$QE%189Z%E5Z
zT=gz}Z`n=-FK;;@&$kuul__?Wpwr8i`<`+28{}c5z~Y)10Z3;)ljby}4Z~iy{O#NG
zY<q&rut+D(xPEE<z6+kLerX05l)v5H&ob(@bti!>$>+p`exo44io8f6D+Xp}G~+jx
zvN@9|X?$aUW*Q8C-f)p*VW4H$V9zlifYhQ+j{2KQ#*0H%tM=*Y!)5)~(jZseIc<r#
zJ}CPZqaFF>XSyO+N{0?Tq;j5wXh}Up`XHJqUTl!uUVNM-y~zJw$i`WE6Pe;Yk<4)$
z4p}<wR%yWnj;pRat;h<N<Kt&S9yO#-&^_=P4_-ui7U#SG&zHO<V~ivR8Dc1ornMZA
zqQL<;L`MXpoIpMVH*J<7q<n#6RwV7ikB#wlxVGB_Zh2^5CH`j7fd|e|@6TR0er-*H
zP_j_P5g+!Hb;-T>%R-yCfscdz$$b5%Q@OebEk}xI3e8!qUStzkA^sNzf*V6*{HPVf
zdLZ+hdnh7sP&x_W#wmv=B(lLU@aARN&}Il~LXhX5Pu_x@II;auE02k2sNn>ftrtYQ
zy60Og3?6HxNUY}zkstncEqzg38wU&MJz?21j8$K(iCj${z)hz+K^L~HZ+ZQGDqikU
zD&A9Fd)mNS+B0@N(lC5m=s0nj#m)XU+lo*53b3Zo+3Bav!bCdDovNLH4%ZNxfGQVu
zZ2#kzU$8=d8t_wvsXWV=7SDDtrbmB+$6;zLB5EG{Wv@YPP1YUVB2F~<J-rkBx!^N7
z_MgmY+5m}91UO2;@9!#n9A84mn@b|=Z<kffnn?Li^2!%hX{D(!Oq`h-0z4XOqgkSn
zK&JT&j~c#eE~a~QeM9MK0@`Cg{YAQIj*MWvzC<y_Wp@I>k$*KyJI<Wk2`@x)xQ%(c
z#D{)e^SBryo6{*drRvkzI(1G4x0je{0}Pl-o&Y%SBiruo%w7&f|HS>Eh3dej@iV~A
zxwQueT@EvyN|%;%D%L{-e;W+4v@~#();uELI_tzvzP!H-3@sLtGSC^2i6-IK<`}^N
z7@;v*BsWQe6d(Sck>rP9J^fZcvQ+ll-Vnu7cr4al#PaP#xlU!_z($^f1HSSj)MSFq
zeiEZkbwjKy@vV|Q!VqyzRYY6EzPvZS;xM#ApOC(dqwgcBZN0LhSgcTo-U&EPRdQNc
zP{H}EnrW=}tFAQUR6>9l!-5k+T$ZOIZ>4R}MD9#t5w%e?TgZ8yL(U?2W^bF|-GOm1
z4r@xp&^g6EjZ~($)dcn^W~#4sk7$yxahe@HnCsHv(%G<aXpUCrOoqI3Sf+p1_3ulj
zbx50H>%(*MFzoj`mmAPD>_*@`y{`W*hazey%pK0)LmI|HM<1Bc>=3)Fn)Zn}I3vvU
zPv*CSf<9Chz|xOeo<ns(8t0z$iKJCmzMzUV==+L;x*S!sA<xFk+@hU&hS$<IiZNCD
zKLLef{>Ju%^9B$Pn!=JzNJZO!?&MW_RE2FrO&~so(I&R?8%}-uJbwY3n6F|l#dRN#
z6A=AV%0zlt9?@ChlkdFy_HrhK$9w+*(|r0&AWy%75fDKu$64`|TDa~EukBK=-HT-1
z>05(_5@er$|Fc&MUpd)8sa0VRQj7eWir`3d`_S*)*Y8sj$=dDSc!2oKf*+$};e5{V
z(@|t+x~GwUkSLHVA^{DKutEsQ=o&T@8aibpc5lOj#;DL3bEEnXRvzKsb*xG&S<X|W
zq<p@SK7<F&Q=zHkW`)jE2^0w$)w@ul8WzNR+FQ^L%mqN2*+%0fb?{xY$?m{4CFOSX
zzw8d?emDyxM}x?$xB2+rYIaQS(<yFVU`?oS3&4u>lHD?FzW~QH*+LsZOG*)`&8R=!
zKeP@f5El9BSo&azpAebaN7H*a5i}%7wyW9t=r`&_(=eS7bl}#SJX`z!ZaO)`^$MHd
zd~EsKqH)l1{zmsNiG|z<vijZIBU2thh*|60pd=|A(EvMs_TUMPz5QofyF^WQH``zo
zs)Fgen6A&1%qp;~?ALPkk9+M2e@V|8<_E_oY~W0R)(l&m2zXPKMX7p1NqPCsi?dlN
z<2;Pkam80`7SF6M$Lx8Tj&5yU0|V7E@+Q~@qRc(5_Th0~nBL8KL&yYf&ASq2@d?iu
zVqGt<+o{C+rn;U>{=9}%)+}Fd#0{)I2*6$cNL4RD5Du8gJJ;@2fvr?Zym&bETw^s_
z!|hX$sZ_mO(U8NwL4#@f1ARI7$H7~MAhcDZhB}rO|B+s|`7T=3Ilj=+=PB*$V&twz
z^Z~p8{JY$IqDVMwfx&I@haZ#pT!QYn0gqYD58m3BDBn*y?_}&jCW%;OaIsI*EHU5R
zpAk)_Stmg0-pm}+^w2o-j9`{xzbG0~(|{Ta!Hfb3!EgED_%Nih=-pf;jVVM16QuNI
zY{B%=9saA)r5YU?&1Uvvt_01$<h?6XHaKF}zV@B>n<*5YB`Mj(zo_+%p52340&!Pc
zV-g8C!;0*t++<8XDqJH^#mX6WKMFD5!8@hbi4%d1Itz;_7Y5%}ddL$H<%ZnAZ}3uk
z`Rj|Aky*%OQGR0_1T<7br8P6cFc-?ky)pt??$ioKsP9>wlLlE;V6_^TiFhbaaOcRY
zPR6bd(-y)_<@!|ly{X4(?N~~Tq@&P#l@}?uiVPnA{~P*i;FLEK*&~7h+M?RQVP-mN
z@(#QWNuQAwLXHkkF~s!xH86gEGn}E7E3|_=RrWG_c#+QpM*j{XU)2s^TN65p$61(V
zgkMGfXh43ourS?~=?JnCdx?Z)6c=TiFnI=yJ7dR9mCv*#f-DbRX)0j9cQC?`6gf`l
zti~^Kh2AX!n#U#9L9yqiH!BxCwVx>cLc2*Yl5HP)#HYfIx9vLvARWSfAmIN<4w+iQ
z-%={wy35+i@3<Y`_Ip5;lu^3>Aav*-le101T|6Ov$~aj3<KWX2D~!AcRn(u(UKcts
z^Al!!0<FcAEsFqubwU)ILQmG2M#nk#NvRT9-Ap$Rm~cU=)@G+Jh@5SKjH<%Dkj!v?
zYv}ZL++nl$Tihr37oWcmfqIGD^m$PuJl>_l;0mOrs8~MX(Zdwy6Pl1TjhX&=#k@y&
ztdXUmXdywbGDc~=K%UlYBZ-VwV(wH_gUr!S*T8-^Xv%E<Ry1dFSxmbb`af6F=M%0P
z;T;nI;HWfxb(yiHILB;R=vN>5OYCY;d10fg?OastF*brr^4LCAsKR-ptkMF0^F#hw
z{y%W2o%<!%{uTkUv>=Wjtt`;L6);ALUdpcq`Yb~!py|1q_nr3nVy;_d=}VZuh+<VQ
zL43K`uMZHthqz`%dI)R2{!jUxt}#F+gL*F(I^O&|rrDAHk2{Qa@C@c{n6)bkfaFgq
z7JO@SM@|}sfP}xM_spFK#98SmXaG^EL3x-XZF6#gv#6lvvfnIx6_jwYND0gE(BJyd
z=xkA865PZ|q$EnV6pEI?!!f)_aB;o-Y`dwEcc4ba%KROP0X^fv2?E03R=|PeDsukc
zBWU8X%;Dnh<v`J}I)Thoi&9B6el07+y~gwc_Zq*J&l?HNGJRU;Y?1!<yzI8t;Ytyh
z_1PnNyFI>l{|o%n1`>1#n>I}<%VR7>ojMNXhls|k7vPzkV7ph)ZRcuLHaN~hONDd}
zP3`d*5CCg2_sQtWnIhxX2K;pIJe7D_El-T}u9V@xJr9G*xaKG>0UOprbc4z=iQsgb
zZ0UaloQ%qe-Blm>u!wmBHu=}@lF~#38_V=)DBbqoPz&%x!dSWkV8B(N(q1WH&=90>
z2O0B;%47N7n89!SBbE2XSq>%!>3KQJ<-J_dX{?X0SI+g~+Cs%OfV|V5U%l9z_M+Aa
z#V%e^%k}Gz`B?Nz?@hcjh+YX11<6&@x(m?F`P%jT1FTgvren74HtSCTCCam-8d94c
z+8+`p2iSgPIFehtHi>QPc(jDruY$?vyecC#WX=5@$TX8aaS1>2`*<q;2-k?ley37E
z=Tl01j1p2=G~Ba41SVmWLumwZEBrN5(aF)Tp2hLjT55DOk)WM*%k(QMbaeO!Mh#!1
zHu@@X`A<HLr2wgJgm<}B9$_yyEzPHx=E&0*j;64`e(V(z#A7+S@)3krWnlbNMJ_}w
zVkAx`y+@S>{duJJGR)_l=&fP+-X7tNwgZ(i#k5X*JKP9(ueaHmda-0FLs4>Yb8&r|
z65cWD`Z{Yvl&p_6_|O4KWWl1X{ja62>Yu#fsGG;S=f=ii{X0{h7emsUw)CUgS3d60
z!uOrM%*u)k;tJYdx2NUS505Y@rW6+DM;z4;Wie-MH3^x)QUTqnupbJ=C@AF^VBZ9o
zAil4PRRdMAOg;ce<mnaMAo}~}eGtF+n?0=+J5svn?0l`FGp~Yq?R<?>N+SCwfd3K@
zo+0elovlnxu%g$Em9*G6LPsECF`2rjbYoPM&FEBn4=@PKGU?L{d8|aTE%S*ojkNfQ
zf3r~|V$p2{kAqAGQ8g5GY7DB|xt;sDbIT(N{I|;l9QhCeGlzSanw{lvU#<*++RAs|
zSZ0b@>Ki|C?;_=ND<4ZURSIdzV-VUeewvc=07zVbf=HV-NIU*<EUucjk^iFDttyt+
zr+uTQXhr;A=9rLjZx5?X^_BT5(=I+gNZFl8eDJVbo^F3<$3HQuG#TQw;*Ey(-N5B4
zf@gDAGGniu*lKAp;qoqvPELw*2g&(k`NPn!@UDU@`Q%#J+kNnQdhMBblovJ8eN~#j
z;<Ulth6a9DP#C!sVGesls^K1XCWf8}+W}@EM@HG0%YDs70;YloWC&?uW<_uva)xXe
zRDBqX`~qG{mG|Gm7w6)`7gcFyJb|<nI*O8mT{!<Q`R-r2Ta82^S-0*vxKXku0!5zS
zLQFX+NdQhCO*`k7U$dtf(FH27A_^1`JcQvSjTa&yPRj&5?=~F+nT4+tGZGvdhg#QT
zh_DO_6iwX8)4OV-k#l#`yG@~3rTngdmQ7hqKq}yb1jtLL80oD;7sHnriQtb_^nAx<
z*OFS$QL2*k<V@Z))?zTr=a{nk?q)FJQhnNfcd3XOYIU^KF66J1@kg3<YK<7Ra!NNK
zDb+*0-0>=*@*Ajg%m6-IvN0AE4VDk>K!IX(&BxQ<H{+D`A5Ql^J?h}c>@;PRd61yR
zRd6f|hCq~ANB-|;q*{Ec2$TJY!NpF<LJB-2*SVip)!I=QzULm&K{R5}`M<ORNMz04
z=CvFzOHL?+{o@@RY5$CrLr|5H?d<=5bS?j+Hz}O$4A5NNTeql5v2_+)Lr-$@R}(aL
z+1W~4E_VU3HPBOV?w)ef9DqZ&6AH8G%L1De+0uhC>)fupLICR_$++CYT|#KHQ4zM0
zTujbGLxO3BnD@C-V`V!vl1%AV*Xu$#W>3T<b{<2>D}9@igSKG03NXUagNDH}_DC_8
zlfRW&HTd`P>s6_ywrxdB(NIopZ4>{1t8CvEKE4;>ni=R4Sy>~z0fj>^0BwuTzn<L+
z?KYBPojZa}-2EZnAI(5lb3)c%4F@$}+*3}QtAwK=N|z3t>-!7>krWR)j%nE?56%kw
zp}{HC9;8^zk9|Z~s&7LA=9Q*1bOh)QuJgez6(9w9H8dPvYaLe>Pc^iHD-YwvWtR<w
zaRVK;TqYR$A~8@%fC5Y;!i(T7Y(x^BZ!d0pAc-rWgHu=;_95xWXO^mlafw67w)J+=
zg-Eh8I4%wGEMTlO62g=NFost!=e5A{pG`PVMPD<P*8gY5vh~oj69s)dKDd|;7P?0r
z1%;2AqqVtj4OmI)#770t{C!^<e!CABSz-mkVo#F);KmP!Z@e%Xw~d5FoWIYBs8Mml
zY%28)Nj_Q~k3^fzl$NrmB<)NOx^ECdN?8fFHkdK@jV0Bti<G8~fAJJY#*Zc^u&{Uc
z#A)j(=rH2TDe4&UK64zii5POlYhEAy`$Ye%A>Q!vi*wrch^3zlvLFYh#s;f2F$oS-
zYb46csLv@gm^ds<7yUI$f_q%&p%ZM@KJv&rz!!WaXJ<y!nk=%R98Sw7X~cc3ap)83
z<agkFX=b5~N6p1H`h&<&h|Meav7hSZw?Gb%u`9qjryp&zEqy`KllV+gFzh}fx=)-V
z-M`tF6A5zyEHZ);%o$ys-JkV1YQzgD2!~1*{f%8b(m22mt!WzqQ~ut`G&zZ=ExrC`
zAsr-2JJimYwZgxuZk{=X`fBV;#V4&p4?7@&heiR}wL*8;&zIZ(u=Ca`Xxf?s+hlQ(
zKcD=jnfr7qUK{hOz`tBRh}dj>D%L*PjZk4*!%9WWcvV~Q&aUS(z&u4^zLySku^auP
zbU$cDWlpmZTlh6kmn`q=7o~Q=sQxB1v(7fEB#l?-B7)*Y?L}iD%|_3fG{G)9HOlM{
z=cxlwCNQ#rr#A7)QfesxAzz~{7qH<p`S}Z<jWd(RhBI<qq)aVGLz?E;fQKh~vlAaD
zd<1|-nJJxS!-<w?w#Ia_!Ce7V`dRd7U#au}NozN1*{P0=-_cZSm>J^HEL61h^S_X^
z>XJWJ16|p$yiIoXP2pDM`2#8N6|1uB=f7>)pk#EyuTJd7^V8<Hr3ak?$dvV3d<1E*
zc`W%;-!zk+PMPQD%B?i|XxPYPQ0yp0ey2n10MLRmv!Qo@009^-6VhS(s8jNpKC|7{
z8zql~Wv%+^`26vz=gXd_bcXA9O(=Z#E8FfhUlzHS>%zNY9QJSc;oyxImAm2tJ|r6Y
zWhg#xRx_1LoxF@TNV%n##689GY*Xe%7bOi!$%JhDRG!s4h_^kad+T0oG?$)~1A0@F
zcjptH!#0CJQ9EFoSe+@aOcQn~c%x5_)=IBANPiI9y17>lBLM*<0?jMcUP-caoekxm
zh7~ET6kFuB53_Xere<$-jce8I2_7iobk26n4ngx26Ow6MfFxtfBsz%+gQ)sJ6;v3E
zR@=qLV(oLm+d}}7{y#Y)y7b7o#RgMv(B!<fjh{g8N!r{+>OhAp^_UzhUGs;e?j+U5
z-$g>WgcOa=SyfWYj+91Y=?vW-MYkDVI9QN(neDw@t<c=&^kvR{=b0{5x66n=Ze`FD
z{eQ5A7#dMJ`Aj`hw9RoO!W!JBm{%YHI5C6k>A)Y{cj;{Q{)zGF;rSD@BgQkB0+10$
zPMSdL%|&XTKT(q?^wl|QBEMTJFX!ijr8Q*W4%ZGH2GZ>vqX;9TDT`_SMa7fTPaVs!
z-aI$5uQcxuJX?i+eYx%XwU_uBj#nhis;}geoGM(Or~wu6f{J!(dU`@TCi!3ArbUhZ
z_5_YiB3~WxgTCT;u+y^!=}Z4oG5c2mVgaa@J=GRWzxc1+csq~2{7!|Z7L8wTfYdZo
z@0G!{R+%0D8Q!Bfy$~;BOw5h%L!|F@+lY%<=2foBQtE5ox!&@{8FNTQP9@bdB5mq;
z!m=@9=680<-sjF&Cwt~vB#E=&klKL?btwVR`-tHZFCTpNFLs~WqHNEl0X5wO&_KMn
zrhBm>-(wokF>CJuY7}A%+c-r&F4*|o95{-O!NSs337wY&>LN#wz)SgU0p7xF*j}Io
zstA4^yd&1dj+v__M9n;k6P2>>#|f4rAywz%VKm*=!+ia^qto7Dv-MO>a1qoJ+0~bm
zd8!mYDmFS(wOF}-Cv_AOE}m@!NOk;&B{1JD!>x8Ey^J*VKC?of8b06d+2>nkilw|y
zS&O>z)-*5(Pkqwnm(n~l1f+U|m4=eLGY&*4ZPsgK8>@X%byJ&l@sMi8iIGNT$m!7O
zsIfu5NI25zNfZ9-S&2Gkc99AqW^}=`7X88k+@6jS<e;N~-`QYNrHni=@OZmmwbtnO
za(UvJ`8)lE=jVLw!H0hBo2n<4`v${t1RNnU*=So&sK<%#<_>0}0E5+UCBnsOR@rwW
zTAWR6cp19ixo9kC22ZX?4;-yZZbzvD-W7u{mRuQgo-SP;)n0+F3zethm0ctGtN48e
zZ`giHwX)UHGm<sB@|~ACK-?wLHuS|ab@}?a`2mi}zt?>`3_Xg#6PyQ%-11RId!C~j
z;)I}$|Hb$~>r>Cnz?k@yNGCupDv|h~J%p$&zV>F#iMoUkilun;fi5&6mg(Lj142}<
z2t9?nevNXcr47wJl~lTO1zV538B3UQCJEXpo|%{aP_6$COs^RRsZT7oZ8l(?aXVIj
zE45r`TG-&ZiWfjecm}FX`qi|G<MB)5{l+&&nZR(3#`(@Bd_RP&5)p>)SstofP>54B
zz)0b%D5Iqs+RdU;FmBmPJq#t<J6nODNsO^|!%kYCKKrA!{_*v3qSp~NF~jZM&${cW
z!H)TPYhAk+m}At=E{l{41!C@+CPdkq;cSQtmIzk;y-jCE-O{&uIPD1)&?7O>6M%IO
zfjKbg@41<*t3Ih*?D70t{BwH(GeIx|Shh|ib1G(Q2-hc!MsX^x&SX9}i{4RD0tkP2
zNFgO0t`brJ_(=a#47e}_IC@$j-UHEMqAp3hB*00SreIav*3{6tOsQe`4cb2<iUHvI
z0TU^I^spCMmqqWcr4^as4^Ofvm-lWFrG(D@wLjlOGx^at_=ha_KJ=dCzeWOIX|<ho
zL!MRj6YrXAd%<XX!K`~eKcvF@-C0X-vInw`xG0PHwoaTn(|S~j7|ssxfPDv9tl2-J
z7Ml;ES?TH>$mv4S{;Q7a9p_EV7O%Hs@!9Ak(dZ<p>R89^H3VZe2ZrL4W5L;oC9(JS
zjsv_2qWAYK$cZJ<{;Q5|ey;DCEZXgSiLnJW7MXBPD4pI-dj?ph2AFV4V>pBl+kJtO
z=>3>w!Q6o|V|wZ7LMea`t&Eqw_;buy(^@U#|69-ek20R;17M%Px6t%XXB4l92m<6^
zQS<`B+=jK2w~Jo3I__{lstp;ebX<mboUe*TWC!V99=C#xL{t!N|J6rN85E)_ZDl=<
zu05^5WDgK8R(L$c0NNU6{8DUg1HoK?f--wpgf&)K=+I>Hbir&e1j6Wc0JgwMihMAy
zizkJ#w}-5N`U6>dDNMAm{h49~?+xXTMtACZ+Anq$=A4h0$S3gsu?awbBzj24ZFeEN
z1;Ji^qG6L3_V@W1?e29k!#bydFSF<juwH~ySR(*$g~pMTv?cqEP@cnu;$%|Rk&NIK
zC|mVS(D1a&;)cQ%!=q}Pp$rBSi^z;o=hV<tFIiIf_Vk}ZuKcOL$8>EsvTD{M`$Yn@
z6Lfq*$GAH}u1w3f7zxiSr_?s$SsTC2OBEx0lP|64Db|zsP!11bR3onH#IQz?mw^6C
zBI5wA{y5|wJ7M^2|I++aNlH_keAUk7aqG_zl|Zu!0hQrn0T~~)th`IM#z8#z^(rck
zs`oIS<Kok(wkZ*JAUs3+mqcU<OsLUHP@wwdJi&Vapxyc%A=K?X&brG@!0pr{_|xjS
zkprG+sdaf)t|S5s-CdqN4sNwy22(cp8K|B#{M*0|Ge?)$In#v+37}Y8ekuiP!jq>A
zaR~1va*ik*S<+)VAWP(NMo-l1zaHJ-ZV3Bt<%6W9*cMv<o+!csx@o@5*})LTst~L)
zRw7KNG8)`TuF|GD$R%~R6-<w~oSB53aeip|o2XEXbCz&X$}^FLgzaUI{}PZb>sreR
z5~}+;s0;=x;!V$ML(A=gJ~%OG)ycNqm5U9IW$h$N@9n@s@2)A$cHy6>fLf3L>dOwv
z7%z<$h~R&3rel`p^wOXUjYFxTDpt|n9*j4bn0v*9DGi`2m;V`mtN5DgXskx4!ervQ
zk^4=wgi5Ner2wryFSEtF+_bA6xRl$o+Ma^HW`0fWy&B2dNI2`O_@TO9Xm%IUzd5|b
z(gciCU3t<lD5a?V#ZMECzCrm0HtRyo`KufM&FQZbLAVskq!_%yK-ETjo)Nat@{IIO
z(Y<B65g7O@=dC$9w9ito3-5)W{}p$w8}rL2<yZC9p(OBWcEcb5)FcMn{3)mdR5E51
zZHi0M+WW^s9*1B-lM+<=hTq&-ejO3M!}gNU_}{WU0dh;;I?mnjKNiqo0&JepR}0}D
zWT2XgU_S(49SGfq@Vk5jYdJ0S((E(Pu(k5Q$hi7a<OrBOmmLjeO0h=a5>EB}H<`vR
z<unTur4WIYY|BzhpR^8KihmX#=O0*_3p4K(d-AP(@>U4DTYZn;t44Z<70t7CfNud-
z`yQuNqnukt2V0pPqvg2or$bhASZd<A+v!&R5RuhRzk@5{AM!lI`c}j|!e}JV7AZ^7
z3I{m`=rkq*m_XNaARN5VdM>0vehoo4Ic!j?5OD#IvFwv?h}JLacQAe5OjCYh5|Ox?
zxN+~)^$R;$E#SIef&KcD3{Vw=7Ct?SO3#W(&r0r2+q|`<?*j-^s6=LRAjG}UFfOE(
z*x#1R3L~0oB1G3jX|!J41-w^H_K5xh21^C9=lLE3xbL87^>g&WP2j$H5j=^T7kcJE
z#(n@3H*h=Hw)>vua-NGOZ2B8aEf-<E$V4m@!SV%QgC5CIRuhFS9@9}1rPw*+6Iyk4
z3j|?Cdvdx2u03Izu^Y2&25CFAW|!+Q@L4f+I1YCAJXI%VM0Q{$H1wU&yS-pJ&{`kK
z_g53+tnJAiFQUKK2*CdDg`#N93ebE|osS0DXdz}&^S6~^HL5LGEws58eU!~4VJUC-
z-_+c;dM-n;l(alXZ>}%qvvAaTCccSUi%|D(|2sNydp7)!jwhC`I}AIl*C*M@CVtqM
zbcP)~Bpn@@F@4NqhF0>#<97<B%AP6Oj4b6!XWRwovNSH*{ob5uzdOm`8Q@W7;bVVa
zkAl)GEhO~_WJ*3E>YXQd!;pm7bKr~^?U%o6eOSIDU+Q`WGr|QllQ>fC2ZTJJ{4dD&
zFE7no(EH-X1vT<69;o{CsLyg0e4~^@(TBw-I>k3a8q^<N%h+n6Zb;knvM;r~T#cQt
z6(363!zB^s%lf?m0<iFcFTf*W78m5h2Q7<7#YX9@Qg90Qz<o<BowY2*;$AoWM48~y
z0+sT#i-fPe>CE<}cb(A4Q)1ZR*{+ys)y#LJ6*!DqkBA4XpXz_PDEu%#swSeQl=I|l
z-R;e14do!@N<{PJtu7?mdbr=7{g_3nmR|X08K}gI;aQ~$<UQOjxPeb&A8J3#TrKq<
zsXR?-gNgR6)Py8!V@`HbuMag8n;WgHDvT0+d_rGSU7nn-e}InSHnP*XK0^2MBN=ig
zwh~Jo`rF5V_?PaOj-uwiLJ&c#A;U6~bic7bs2}&9n@@2<Jqx5QyS=dZ{Y<!_$V)3-
z@!3-SVX8%27y<<>ngVt*y{x|_ObK{NZX0J-MhT(qJWvEJrK0E?h`Rg0?mSG1xxW+j
zo;Bv3=K|Rpb4BlamldI-hGxGhYRbCebX5u{f^R7X({WYW?Pq2;R9;_94hNXU3!x2}
ztsRva52aRuomJg3P=9&ijO&*<Nb-^crP#&Y{mfS{rxmp&-GSw~OCDnQagVV07~FG7
z7%jy)^Tn!XOwf2fQGt<rf1?0=>g99<yP0M)J+5YAsGr&LkhL{gM&Gf1<6<#PaAcNj
zYS!(AWTcx#ibTKvEURbAAM6Uk%l(@i12KLDivz#?@gf8OT?6lxP9g^%bI#dxU3!eu
zYfQ_Ig>BTMxdpZnD;K#$mDQXZpoi8OUmSQ3(1T6+=3E`Qbsn}mHVo~K&oS2H9o920
zQ8;jsOufp@om%4{!&^bFbSD<mGdw@u$d%+RTvjLrAaG66=O%58Xot&}L*-@i!Z!$5
zx<;%Ln6_Fdb^N@8J!5cL8`@Q}q^TKE-Dsz)M&7zcpa;GQ<0`u$V&McqE;>aPyh%rX
zQRvoG_RAPzhz~rUew0&Km4_v(c4C>uVEX?G9hhNZ5OG_@GHcg8aE=mUTPkhy{K>uS
z0`0t%e)o996KK#Lpl&~7+)o1sgp9-`sMnxiAJMcX*z;q&4+#Bq<LN75UY<mXMUb4Y
z|I^vhCJ9tEYy^B>WHjg}F~me(H#aqk=m}gIz@5(-+)hFo0UhUf<f^#zTCE;Sx5+AK
z5jyXK>-u$@2C}-Gbf-J>%T8XlHTRj!&Zc!m34_~K^L$h)c{wxqb3!%QM{@5pG<U=+
zWYmvU?_JfZ^{X5{@&b>%i)sCCQ<?=^g{LJn;eqnfgiAOA(15D<cB{<W9)nDZRs)+1
zm!X?bS_{|+EPcT%n|$b*9R$|Nj=uk4_3)5j;PP(o5%raB<N6ZJ#RRP1syYrxssD8j
zVpp;aX|1M#EFvtr^O7JDwD!MIY~)=@CAjg3s12sziT?gfr<jK3!7Mo0WqP$E`v@fZ
zkn%zX7MXN1tq?vZZ214r0n9P!+-hXM=D~Pbq60KmI2rfvIFR<uzNVvz`pJMvgp9UX
z!$1a?`6)gZ)_vORdBNvOFG77tS%U+MmfD%p@tzaP{r~3x<}9^uHPT*_rA(!P%4%bh
zcby^9>$n^9m{BtVu>gn0+5IeypbsX$M~xM(4|t6qi{krrzKV=+=8NN05t9`2rLNvq
zft~EBztMY-Bf9)@$}IWx_+!QT$N)+XG7@do5#}r*UfYG0rXQ-n{-zy#ZzK+_eP7(8
z#=}#(oi~L1Rj1YScEt%|NJIT8&bGTRs{ztw3b`HI1O_x*tK{*QL%tixM}q5g`8CBm
zPjoj@#53Q1ItR#KCwQpPvG>0}EV<-Vz!-Q_8bU4{-_{JRRl7&FpsP<$(MzpqGb$3V
zAMSZfd%qapRbw@{rnrNA42e&5|2_HLNaU!TTIPplDp9o<`V#hHu7DGikWuh3f%u|k
zoijq^x(IL|I!EiHtsalMK|qmJ>7HSP^0KyLo?duFTrK*_{o1;Viz?v9oB9<b*(Y(#
zDVHR{nk>?F*FMM<+alZtw{>u$!7!@i69SqyXKU}0Js?J7+GW4>qzBKRN@MxuE3HYW
zl+zaw^>bNa@A;o6r%ui5wsC@qhq7B~f#QBd-~hn`L1n?v)|;pFSuRm6wg8tdH;KJI
zHH`(&@sDwho(ymVP|$bh_1{w{|F&bsoQ4UnK@?tD$Hj-L9VUQB;J3NTa(0{VZ<}}I
zIe?f`(h##M>nn(IZyoGinwv;0*w5C!GIIPryn?AR7w41|I6*!Uu`7o9{M_7ZZUriv
zYGZ%U5x#w~uF6XNX{p1w-@gB@y^IuS^jy?oG56_1Ygv&H1s^tfTgn};085smpfR0F
zPvZ<$OC}j^JGe7FM6T(D)ZDp!_7a@u-w{3w0Fwl^-&2}$MzidyVL<1^2{&~ZgO^Oe
zrbN4AQtQb*8vvib({IPN-rJ;1umDBl&A^o)guxDc{xsP1%emP!d@yKb#=Fnfo=09{
zZBN>MhTMPK^w0}6ANYe?A92#WpK93ONq#jd6a$a+iB0gqq|o;n9QYX-cTVB^*C1&8
zSWcE8X?p{}8-Yb*tRD({6g@r8^wz7+o$E1B%XS9bv)ks=+=15I38-|C-U71GW2qIP
zGnI}q5+!B1s$s?#hG9tDu3dfJ(tW+fjQi<~+be6DcwZivJuwBM0H>r!QViUZRxIe-
zIhvpNZs1$3a6-S~uzv)P?Ona3kMh)|q1?lf-k)VnL@_3^!_LK924HFB>0bFcza~dp
zjXSXomkb&RU01G@FTFW>&H<g;Xo@q`-py27ARAP$D+yPj;N_i!w>Ks~1k|Fi&L<PV
zTi(6ugx?;wJC)c3LpNZN+R+JIskqM-vO+dsq1(~PHy@L=kad}Mv<3^c7@O+Auo7+M
zDVs`liQ=bo?Bo!O2@I*YdlbeY&WB&mvgO~u0NW-su0$HX4jKem%D{*bf1d#GHwfrQ
zSfq3GQh%Rb&^L(isTa1Ij6r6&p*rQr-FPMl24vzB^b%+aiS5)whf)fq*O7eR0I~Oe
zx%t?tZbG7%h3|SL?6G}s5TQ@7lf+sMA3c(vx8@l~eqI4Vdx9_E3=u@@@ZuOA65=ZQ
zH%goPnOQh!1_+no>A=m-fW8Na(6jLL-$dHLm*s`zN&lAC5tfEfgB@;jgFifPa7Ya3
z1UjzwioPWdNGOz2=cnseL)29UwGk>T8eA%?3^g93G>J)`$=T5v?9wmkNJBq7yQEKH
z^4a87lKRhj`Fy;Kb@vxsa&eh!dD&LZh%LV998I8gFG`Y|90F~*$YnZcIq4GPAFW_C
zqH*t6(K-j6e=B9{YQDv&7pF9WiBOc7H}U2*V)4TLbZ~rD_cwnn*#=L7r9)XOvuUQ%
z)MvQ7ed~2EuD*lTtK4)w4CBGJ6(O#Z|LKE>J}RRr{I(j+^Ej?7&)mu-duQ8hU9Yrt
z##6>%f9+tfnGfvqUp&#h3tVr!p($Yf1>JqRjnQp4>ax{D^I*%E(Wdu*xcbVdyuoH$
ziWV<W{Kehf-3k<Uio3f@A-KD{7mB;POL2F1cbCg|&RXZ*bJv=zNq!_xk{`*;?7e3+
zY+D=DaUbe4-wVA~ckj(`g^JCr)&>zHre7w4<9o8KojWu<V_$x2_YQ`?fZLeP(ci}3
zM!V^h-SCtf2gJsPW79XKY;CjFDRY_?6Mh+Y6v&iXWZWzsM97v!@bCwQT{l|adUc<v
zdv&?FUZ2of@f?qyK97%kb$=oOnlryPRvGSvFO48R&fiE#$Y?ikDi_+Adl4h}y|&fe
zQd<Vg!n<Kyu+W1Qef!5b84=e@TCndQm$C6~7n=zXj^D}|oTSFO#IxaVmb~o6NVqpV
z-ayS2VeS$Yo2!#h2S5<LtfL4fk}!<~>s`-;9ooPadz2#8-XipmFq+TEEFJ2vNo@~x
zNNP^mrr@t`-<n-?4tMcqir;_I%fpU!U^W+^G9I1vH5<8~-|z3M{d*dUnTjvL8T_Cb
zc$clZ<e#&9Kuj5yPkQ0^W~v0eV`ozR9U*9>ZL}ocqy`R5R)Ef~9*peK2(^tai+mdP
zbc0_`%E4QV#@+fOe!U4$!BpWhjK)WLBXNB`0ME@my7{DVY8c8%a1xZrR*RMl%EoX*
zL~B__R}8~Cnyklbf7I6N(9!D|!a=ZAJ6)q(PLv#vEeFZxz0ycS>WDm)l#-cX)6u9q
z3v_KaEOi^@0*>C5;cU=zT2?NIW{>O(j<9VRDjl<fY|KHUC~q2#Z=Ng3b(lCA`tORI
zW|&%9tFEokYkCW5Jz-D1Oq&#-i%>TK)kxk|A}(adB+x!B*XXaTATB8w$0SnW*E<e?
zp@#o}82ca~H?UjEtk5reNKGhpF97B_xOTGhEARd^P>bms2eZDy0VJ-SrEh<^wN@!x
z?@}~hV$&hn;G(nD%wygW$UhE0o8Nd5UY>7aZ-;$W>y)6mue8(;D{N%*vWhRi5k{T}
z^RMM^3Vlh<nr=wxZ>(uo2Wk(UjL<$Z$hhjX9n4ziR_qd<g~#oUItxmJg(zzUO|yK3
z%@ij9(xny1XzDH_Ec=9llxt!LI~_WsoLk*d&FCZgKJa*Lz0*E<aoJgCVc(6Q6dsZ!
z{U9ozs}$lZ+$ikd;gEK)pWSA=eCmA@X86&W9i9bXM}a#Qa59*?8B{zxy)N%3YQ4@3
z*n26Y(`3*hgQ?$}1NkBYSCy`VUgvI?_pmSUw#&!z%vBtVgeDm0a}R`I4}be&ggRhh
zluY&q&x{0#PwALaM+}c5<qLr~D#o%QJs;qb7r;NUzWr6Bjf&&naWaQmuqp!9cDKv&
z9AdR<K}DU{!qyNn@;bf+f^vm_B141SsUG)97RDMHQzonjVhfP!@pGwb>Ni;Y7@7v~
z`l=mnh#?X6OYd%yr8mT#B_btF|FkcU;=4s5rvaSZ(AT(K<k#Dx;h3O^oSfF^ZKSE5
z5oon7G%3L+>P#zg8X<==$l+?#U1?RnjH4g4TqeG|DNu3$bxA_GPZ#`)P?EfBg20=u
zwtHA#UQXP*udc49_~)`~ycGup;E6)DOR%whd2=v2aTN#Z6m)n6=Ze=AoZmn~hFv)K
zYPK8kh+MDZ0Y)%}6_7~9xne+jf({7~*MqtF(k4xn#Eh$ID6)>ae|kk?NNqPuHy~-y
zELFn>HPR+EG#pL-?26VZGMlSjx5iyz@{E)vv<;Q9#`g=(54QGw<(|s}y40oh<XeQW
zT!a5ucT~IN6b=whXx<Rpg)e`HS_N%JYF2&iR^uUM>rsSU7Ao&o(y4?WAx(HB`pPvC
zs_sztb$E(+*SzlQ(Ihdcq|swzb{ZujCv^^^4q{BtPeI+r_<z1?`eH*=s(sjB;72<B
z(S-!U(CCC&_(F%DHQmrvfH(ECjX?vRHar#)&QECzFBzwKO>`)~%V_KkqvNpteq8V9
zF#I+(ci(OvQBYi>ejZv3b*49KW>hdeo}hLd;bUO7IH@(x9wSoxl{ecT&(TdPu~S7|
zD2e1Fqv)&F`G1`d5=8|4p?oGL2~IWdH3I}rP?UNKd<|Z}m&crS;30dx-&z~l^!Yo6
zs<i?-vS^*m(hC|zzBdc<coHasj*C+>3))l)W;}`X{k3<3Jc-@iB_V)VTHMM&Lk9}i
zEA2qGfhXvIo`SdpaF-JmiU+08aWQI|u+%4(d?=Tx$s8@PBf%ztP-(eH)g2@l-8WJi
z#9*#4V6oW1GaH})!%Jg@oShsa)SWzOa+7epCQfpqb%OWL4l04+wX8lLyN=ogdvkL;
z&sVvtZSEH;KRR-Ck%wK#&E(6_n%a<w(RSISt%Y5sPwB`1VxeBKqW<p7`>4xylx<wm
zp=)STtfbL)n+4WWu3P#*$0A2#iH$Tdd5(*Sbt^4Ig5)p2fOxf!ggfTPbyT~3^f!TM
zz(pwhIvsrYI5!T?e|-ms+>b<93OlGLc+95Y%qLYg9e;C#9M0YtP0TiaczipjhY42q
z{kXAvFoS}b&VECCeJk9W$yHaaO%ejQfR#JtW5J6t9RI?#4~p4IMH;%2hS^Q=7d1pe
zjpX{=a|8tWpR=-yHFp2vz+%21!w@<f26#?$;{MVyGuN9+A0-oQ$Pn`gKe8H2ks9h$
zPiebt(-JQDo9_r4i`sAr`4%Qs-?dr00Cw6al_E7VHkP;6qpgK@G<@cHx9b~q00mbF
zsXdD3B&il12p(_X_tiA5i!)q2FtvU&#lVD)lNh+nhOUk%l8LVN|2;se`ZP0P7LK?L
zNs~Y+Gf4AYQ7gXkc-TzUXePhsDyH1}S$*#UN^5g71s(*NxHTm|v2}epsBMBtc}#;N
zMR)wGKbjlFbPx@4d>`7Kkgu|nRX|k1VbsqvfI*Hh=bgL=#e8tf0i}1D>&sM+7bRYb
zaRCuKse*c=UwoNhAO~1{1#8~ty;$|^9OW!KaU8JpNA&}kf>8!QKP28kt3!b%5HMKI
z1so2;noPw}NOoB9@*Dl)o!mH^@&l47ky@%|<}y=rC%;9yn2cIUdNl`~2o2otGZ{-`
zBl+1|achYW(}*u(aKfD;ZCq7Y|7k<bBLD`q>}M+N+>)nUbV<{%sZ`NtxQO1^M6_2K
zF?|Bh$7mYk-BG(xEP}-lCc%4M5lpa%@3+0Q)!iwmRA_8bF2doK<db$ab0AjUtfPz1
z2OnoTxByLv!VN$F)5MZ*T#h!Vrmnz2`wE_wf(Wjkok;*0&Bbw;;^-g6)yA-Y33NQN
zwlTO|cBJ(E2`RX$?sw^tHm=5!dkmZJYY;)>ERQ;7o3#hOdU+-L`o=x1>wY!R&Z<5D
zX6>Wkuril28Q#Mv(cS52J#o~Kll*?0WE7s)J_E9qKV3gF(_X(z4R}_pW-u5bcy+h)
zFZ2LR;=s5l`nyxF4%jZ-4@F-V03A@4fpsQ_Bmgyd^1B#0TAStfy}*9$*_q)S#hGvI
zV9Q5G_m2l-M?(?si|{}y+mUyjpc$|J_tT|h$O?03fERHLg3S<VHiAn&zAYz&5x0;D
zk{A~hErBGCYIDz?0zwDLvyfLeW(U--4k(ZNp%h5|vp6<J%5HC_W|u1ivh7}}FHLyQ
zC^DXcgF7MCBXrl~IJ02w;_hxv=7S_29Tz-*FB*IlI}c7=(4+`DA2O5`=~9r7TL*)|
zlp1Iv_q(iwYwAz4#VCCW-B&cvW;>S=btuUB(&+NhLg_a4)c)8DRfNrLiqs5<=z5pc
zeOwn#x;FS=udmKy)Y2dUvCv_6KJ$4vHpeQdE3?gN^O)G{BDFQ$kTy3acH-yKk3KcM
ztXk=F+m(Z`54)UuNw8Fn(u9m#@Xt`F_hmER))s}F3{idGB*7q{r^fP}GWcULf)YxL
zb2n8KjR%)@<pse^0P&Jj!+>!RoJrmwQzq7n{f5kaLe3jJ^(q=*u{>G^ZA!A2ovh2f
zzqy~{pT08#ibjKxl$GeaY2A=chn$x#CB}~a9c^y^sC6N6gSB*yr6|J8g6Y(==O^2w
zHF;C<m{{?d1clG_wysOhC&SW7H_=YPCX;b*@w%Xm8**@s8FJWHEd_`Qez>2j3G6(j
zkcJ|NBgklIDCGmVG3)1#cMQK%#b{wEXblKLBXO1vmBX>9F0&hrBbOR)A@mej6cP66
z?oK%7@|sS<XwF<$&>J=STUXx2Kp98vN#2rgOba@fFAnEfr=^BfA-}(<QEj@HV_tTh
zOSzdM!@t$R2~6wPQ$C7CQf3afDNn+}@KAtGGcurgC}M$`aEYA9B7r_<1NnZ^@d0~P
zGySm&Y6>Bwnj-~5apB&v6qsS;y4XmQ*f(8=odYLJ3wA<<BNJC$W%wqoR-yZMUFRKB
zRq`nSWpu;{zb(TKzYg|5NJ>YZVnAf!m+1MnxsB#F*dT1^?R&6#th!piU=(LkUD+Ts
ziM_P+*KHsW%`YWDA_P{b?LL6;9U~;*du!m}v6_2{m`?eqr8>eN0|l$Qm0wy1W6Kd2
z#+tS_F1}x0Z|mfF(KD$MBhCLx$^A*C9N9W++4E-zdoSn;MS*6!!G85QX`2}=dWTpu
zP~oO90cSStpR56ia_l*KYhR>61u1FhAD__B*-in8%ll!Hf2+BQeKw%W-;H@iLfy49
zdUw%~;wc!ggb9#02GW`+)(gYGwh;Q|qp*f{>0tItP)Wv4ViE;HMvcTgLUO<UP@H)-
zaC(VE{oI&Q(rJD4eP+=(Ei8Vbic(U96JyIL$)m!&$WeZKARq{h6+NE<+qhPg9cAPB
z#9zG|M@mnYvmS#np5TVSycnQyE_opE?2l%0z9?RzOoA=lPq>!$XHQyw^i{kZAicA$
z1a9oT(a?zn&uXF4!@&-+NpMyO_1Gh#Mp+83b2*V<>oxishUBVl3WSO?`VTJhDWd<F
zskjR5<&&VSdpJnlVB@denv5sJ7ZcA5>;~Gt8s4>#8st(iL<MGzMg(Trb&S9slxB<;
zK*rovx-6KTk6|{*3x3J}(WAA1c~8*&UFobPZ@`vAuSA3G@oax8;oIyoc#ASRGO`|`
zcUhR0re8N>n^}-+43DwdRDyP7<V~(J0-5xWkb>CYek5GhaB;`m2i$RU?yZbMv?!oG
z#_lvQe`BPUe(M`%T)-)+_qOnMpE;%huSm@GwR3y<H6k0C{8>lNo+Ug9B_GPD5iKdm
zkZ21Fepq^-r|o&83HNba<*{3(X_H!O`hiwND=kM3oL(k?{|EPYBI>a<cd;9i0#PpE
zMD_>K_X$*VKUy>e&W6^w>+2%C%rGF!YT!?v+^lrDQpP-$?1@Rs*NM`P$X4GAtv~{;
zK=_ItGOvjtZUlstZ*?*j^ZLA*<UICZmjOK^-tRNWPGs!TE*OQ(*b{FBoQnzF%C-49
z^fg;ojsj#`hA|m$D9`%zHB+gfi2`n<P9bl*=tnVjqi+Os=NT9<dgZ!Bk`X{F_#=ji
z4KF(fTTZ*$TlnNqCEbDd*n!|$0E9EzxB$o2t7H7k<Z7RgV|)Zi@h!C$jUJDYuG(#6
zDm+N>hD2EQrQXvd;V8gyREBeK)rh=~yYijm9J<31-P;bGz6maQaN{P|h6;vE<@@yA
zO*?Q>P}W&4Et(RTkCKq2_BnrmJ9srwt#-(z_O(TVO2F@O#<a(Y(f!EXTl+K2d25k?
zMdTHz+>WC=AGx1syKYS=U4KxCim<cLaWm@oEf0gxoHN%eb?8zRBa#sSK8ke15v9pR
z2?wb`vVZMXWEc&HlLqzPEQqPElOIHXjF42iAt;K5)kuNeQ)J8#hX72;WxBk(b4ZTL
zt3BU4o0&xA55I8ndn?V__FRhL9<+alF|E4lWO#}1?==kEkpJ?4eo$P>DW_ekvh^2!
zG+et(wpT`F*Xb)<>+{oHzJOe5*y%e#&WssoI2t45%hJEF`$aNM{B~AV76?chdcmq~
zaLCfsCW>F3O9FVE<Mu$TA37$Lx;<ynw%vF>aLVHB7$ZX_;e2xwli2SgN?W5mjDnqt
z@%3?LE()A*7QR}BEznwV7=PB%Fg?Dr$ENpnr;>2)a+$ziWa@CQKB_C(RwLbCCD{&S
z?OaXMcrT(&jp4om{3T%RAc@2{M(w_<v0y~%zRK)iF~IK8_XWaw!O`(1I3#Ki<YB8K
zp}$@ShJsx(%!@-MF{{J;Lx32Bd2}xn>H+KOkbveMf$<5%4r+mnVVunFMd=pvf!@KQ
zv$B(x7Crwy(`71&6=qJrw&&yfGcI$YlTUg2?6=_tp$1`_ES^%-q1Sa_yPWJjzrh{7
zZtKIal4o{-r!H`Q;iVk@3b#_m)VXEd?9mqxyikb7j^o@Z{PO22xU{r|N<;ndyG->D
zAA;pA%oNPgHkvhfwU_)aS4>5O_@#;Dq^IG5bSuaU`?hN-I}N%HcY8fl7xQnS)+_Ug
zbT(2n<}0(Rb?t25T*Jj@k-SbB%HcKI#&Z`FERED{gM@*p<QQ+gFk{_5L-=xBH~yhy
z5*F3Pj?FFHScYIMpRYogH;~%XbE!v*-6H6)`rg+(@Fh(IC`Q!NR=jwFry-XWhc-8C
z2=~rV(_fZ*T{j8Hbq@2(3xC%!fD5F{wl_qxQ(d~-y(<+<Sdg<y%?~!liZC#1D-KT1
z1ycBN<!}O!%JyIXZhw>SC(1cyg;eJH`j;5x--IZI1Xd~4XFdUsH7BR@_j$PB7>&i~
zdbuR~b*)4IEm(!cUcG;-Dy&x@J-C+|DOjcGDS!sXLWPv|8JBIGMz$ZlavMplDuwB|
z6tkq`v%cF``FvcjqWkurvk_ETy7l^fyTc&-(E%7}8YG1O%0W8(U#L<4zC}*HCd|A#
z74EYfXLZQ0%}6>wm=Y1=W|o~FZIqw0c;z0<eGIhU|Ihbn@9N=IdJPX!J=X2aRG|0=
zw%WL;C^M}1I7A)itTWE~kj~#3BTs}#+_1o0ZoLq#)eCrBVvcGehtN5h`(=PTJG12@
zJCrm2?#7@!!1@i`QSX*2n8U03{MfSfW1I=5M0<>9<$Ca~;?;gJVZo(Q+wk0Q^_$X^
zv&sb|??`&dKGzpyzX9BBE<gHcpd$E<!dd=2LG+Kni@C5lqg6=vU(85#^EyFRd!Ld-
zNJ&mao%!Htz3CtO*_cB=itd5fVO^#<aYdZ<j&=I9@@%|>Y1siifn#abzbEUPR`{Jt
zqnXV5A+o{hlUt7UatB*mRKdYTAbeRJ`Ik)nk{^krv1w7?Q@Ib_eu6J&zr_+OorKYf
zp+-5fO>b{f2_#q=+)MN(Z~GKLvH$@t@0XrAv5}oNEy9D`CAWMD=_i1J<P}SY^eRNr
z6HB#y4gaEBx`x1hzq5+%Bpa4=*U4b8SiL_|#IKXBy5EyOqupD^UN7}p`$U>?ex7vL
z9vW0LXoysp&zMuuaVKuUAU}%PL|dO{i%rKcmloc%#VC!#bM3Xo48wz8$C?B=lz3Ig
zcu*IGj+^h^QsWprILZQw{#6k3Bm-VyK?|*MCS37joJo${Xo_-N5`24vcTVI5S<^8s
zUc}Zq&fa@Ff_DiJb4p0ca$NF!e2B_&c=CLIgq%C$buEPML`j!I=0v4VvJY?%50KaY
zZV(*Jm*s_~h7ANJ%Qjz5|5un=38-}3mSSPbbMJxwECT6e0uDZRQv$cCVO*2;KZ)Br
zy&p<bgqpW0BY8V;>YAP_GKk0jRBmymO<&qSrY`dr0?8YPD1L7z0jXQXO5D88?NB$P
zhAQZ-#%oH4NlEYvUARKt;`tlW#?f!=4j(OW4*?pyQWpPG#(U+J#&=lvcx7j1x@Km-
z$SI+oyb6t;0Q0HJ<mL&Hd<SOkIZ)cZM63kK=*_wX8Xq&}lD9B86i~HrC?Z$8Cth6b
zM_g+OiXPL5=<PGk{9x*}Jq{o#SF*B89w)r!!B-5o+2E}!5*lsGx9*p&?{?148^Hut
zu9{8_I>*;L(4&l{2IeD~7^U!x^t`uZkJ8~RYJok4Ks~a)y{__oO@p*WSL1u5tTY=4
zlzwmD+)p{Bz)ivUK&FkiLrN-PJbk`WW!rZfA*@de87nI;A&EE2PKKgN{7>3Ksily*
zPg-=s1D~qghQi>jfTHkLrby`-b!A#j@+iH7@{cVynhn{>&ZtTDX<k*X?^aXK-yAO?
zpq9A}DClsgW|)5=wh_*)^C-gr5^-rTezq2pvu8?H9^}(AGxXYy<hD`;pT}YLMddNl
zh72)kh4kqWDsJB^{k#SGx(NM_7?B_|;@r*%`i%OCy6Qw1K~9Y_eAQu|kzJcd%6gY9
z;0Ju$BNP?eZr$(nV)Y_3k)29okPb>>)GuuS<pNdkK_MtBUG~p;Kj$w+gEC91KdMja
zfFGm=dY69OK^k|8?N8#mY~ay(4Z2k}->r?BB=C$JqC5613Jx+^HlV(PljQgBp&vJe
zA(*R=Tx)4*#DAYHtJE99O&TZCYZ(?~u|-_;%&6)(dwk?fTz<a%{g<zIanvT=MiqPm
z6oSUnvx064k;c;%<rgkY1Hy1)WFXB!ZdUvSoYE|eY;mRx4RcDU?^l|j4hl7qj1}9F
z=C?u?A@v&m<sLhl+?}YEesN3u^d-{97gO~nidpj18%$X)U@PIjoc{Ho!77<n&5ptn
zr*xH-ZUOappA)y=sPC^@ALWf~K<91@;S_^Hfe|OyT;H7~Gd9A?eHKfmp~3v>l`Dst
z{@P(cOlREWhYtBk<;a^)3q!Aug=|?z56di$b=IEz(1R|r@G6UND+|4u;{cTPIOi(s
zj-ArAFX3c7j*mFZhDc8Ej0Ft;7$w-}^h$5cCt47Ku>QWnX^iTr!3c&Zz`koO^o!FN
zp13AI`*%A-5eHvUy5gHp$;S3hT|;Jrn<(A=iA}UhRL+MLzG|wyy77R1;*xn*=jTvs
zOHqqbg3}2E+EioVA-i4pAL0Mf*`#C9jtGVdYo`T_SYk&aM5tMiibqX|6OG>HdGkih
zHs1^E<o<q1?ERd>(>uzE0I=*Zj-Ik2usAY~M)dsk{t%7GgzklO%o4|x)bDptsxZU6
zm2Pw5lKT0GI56=LFrhG@pNbu9Y{F74UGwf7hy>uJOl#bf1%dOj);aA+2GTp0w$M#p
zBEksVnr}>+btaBEE{<`&vg}+=oU*>MI9^UfAe?(_xn_=$8uI6p0ZAt>tD@O%uG&_|
zC#Wusc)67fP6cEuz*qkV(*Ru0`{k&*g0AGiL-PKH%Ye6b1B`;_NYCN_jk-GU2%7xx
zW$Og){HapALt~KGeu9g^(`eR`+*>jqow$pNW>|rDy<TTY40!IMM>C}wOABt05O2p2
z3j(cgTNy(bK5H9G@(6m?O&m;iEAK}<{RX;yvD(QT`)1e7N#$=iVR8lNhnfHl+MACE
zek~D673j{#eaMhKke8T3^(R6<p>Y^x!RR-GPzYRmZRT`77~fIUnwiHhiK9NU%&`5O
zk!*D3r&zc@u8DC6zJGVec#5>e#uVV#*#-_wSbRlm_yw8&ZFk(xywn7&R*v~UF(d8&
z<4j@T84G1`{MHsB%_kLbJz?dbg#KlepPfEt`&gw}GhGP2Jn`RPn3i|jqzX&A!yGS3
zTSD!E%Ul5vc=L5+4;R5Pe@l>_RhNB+Exs%|8aa!9e_(ary80I(rJtnWt!*CV+&$19
z>`-ubbIC6}-p|XGJSY%l+HyhYfgPCg`d&(KK7_E0)*l<OZGS1Lfv@OEUTs-(1UltT
z_j%yY4)i|dmTK1L*b7=q-30ymYz|hOb83{qU_9`oXaX8Yvd6-8KQY@;8E6QHO{kCL
zNZVI1Lb^<fl~}S3m>cC*2lt~Bw*VyIR`$nk%d*?e<|hhGy!<Z3+0z2)J9h^rj^@uW
z=Ih_35p|DLQ#zZLdNJ+%z+gZTj4=Cl<9fxf2^+fsY!wg2AWgn~E-@2OP_jK1zI!*N
z57E-D@|Oe=aiVZLrU><{bCfS-F?*uHG2Qqhz07k&Z6|s&ScQq4NfYi{Xh2WHp(UHI
z=!{G>+u9Urj@s*0@CMfP_CIg;>HtR#;a12ou`{}=P3P1C+=FLd!<BJT(=jy-`KkMh
zyi>=9Wq7@@yX~cg@|XRvUZu>hZJzgA<6(bouTAQ~M6ecdPoT2Ww9OZ0)dH}$G(Rkd
zii1lp^VKFyjf&x)x!f`NoB-#=pu#U!g1L>@vbtp?ul*^s(gWZef2uQ_mJ);xodi%x
zZU-9~Bd3g6MyF}<oCOs@9(OXg9hZBh#2O*`w_@)|L%L6-KQ@^B-r8e7S3!AhB|Pf>
z#bLSX{Aj;!`_}rMge)6M{C;k@Ip~w{p!=<!Z<ZU6#F0%l<`9pD6nN^V8f7zc3Z<A?
z8YXn8%Y?)RS}!eMSe@?lg|~AqFXq9-7L=M$==L6mO^I(#CRi-4iQ2id#k9Fha6H(4
z9n{f&@Ee-E*{*87{ZAT>4@^wd{o-7f?n(G~Jz6m7HfN!lif}E}mWkTjc7ott!$Q2=
z9r9X5k5&Y9_FdEM`n<K#S)5fyXH~k7N;aM5JWisNosgnD++QOFl+=$X%L>rhZ!OCr
z2{Xu;aj8mqxBomjt8|E}4G&;}h-2XMYjbr?KO1D0@oJk&8llbqtNMM8^Q!iEmyAI6
z+do;ms~h^8#yW;&rhG?LDOqb?CzV}#8&#L=Do_iIRo<dEN--+p&)a0`DuFW2=3izg
zEch6j*GWDtbe-hj4xg*KCsYqJQrwrRwR;jxzejgbg@U}$6~|C`lM~J$9*k20!ExU0
zrprdl6kJwM$Vk}B)Pu&yx6jybSdJ;5aTct)%Ic?b2vLtQ4mFfPy!2NiT4+@BCc7>?
zUSI$!c@%@+rG*W4>HTJPqtws_KP-Cktg&%#th^H#WH{QmamaTN*oRl!%IGjySxd^<
zX;i5^w7sMtaPs5m6M5vmas9nxbMyajS{yfcJjyppt=VClM+oh26Cfo&Bu|~uWaZ*X
zZg1C&z{E8M><O{f)*<ak_kmnBq&X@0-+#cOZlV4<t1>ISp~?PVlM{9~&H>?3=q~|p
zmnThPN1}wnOw+cC%M~rtZ5o|FmB#kJIha#bbv<7ODxQ+izgaogyRmpt=tiN!Js#s$
zNhGNmt8oOtm8MclZ?{0{T*4-ayjfnxdwRm6{VeDFqYCt0n_>h>sSWOS!d6IahMb`A
z7B)G+qE}dw&+$9YW<eUgEkVf`g1Pw<MnS|zd>6=+e-+Yv9m(zpyOtwtBlsHd@K<U=
z&HLw}?MsmDJ2>Zq%+(}%y2_V%g}P1-olM@MJ%x6k5<txi_<$p^Md;UhfORwtHcea?
zXew&*T?ABC^77b`sTMpHD;}`uJjWS3bAaztUehz=L8C`Rq^hqBdBIqe%otmXBiU2!
zhQDmdPcy^|oQ>mcrxp33x0YZ8UROEN)C)~lnfcO-n@AUVdH?ixNJMU87y19k8fk}{
zjE5!d?Trs}+K6CB-~ZuaF0ewUP@zoxLPo0rTvDV?8%om843*MAB06jcx)FClN*(Fh
z?_1Gd<{R^zV~Xu$b(1HBKB2>9HnO0VfbvVEE=sRHy{uC0_+E+yy_{y7%hrBqITW$E
zN6a5xYrJ!~XRTkNakE{_v)K_Et7eMvnL=XUDqK2OBXL(TwTo@LO5ccJ27^GLf67h3
zXVnb<V<_9a6QU-Fl=^w9^9rHd(3JIBCM_mV&Q(R$jPHmV7Na$<wR~%=0@gWOP*uQ-
z@bo6$Rl^p<TJLDn)d~$;WN^%W0`Bdi);1U6pUzQEvfc^~+nbshQqoy=cB4a^Zs6qx
z-n!yaO|4fSt7ccmoqs{oq@4*<&hQ-wPaI#=die8F0}+0t{XvbnpkhO_o>M2L^4^Tw
z0ZCGPUU2E3+nYAgRRf2tjM?a(Xo&rDac`u-%E=t@A;6FnUqNHaxtt!%=$GM-+TSd%
zX$=8nN;7kXO~UM480Wc(Plw)rU3FRS^@740sB<HHM~;O!Vy6^(L)&{X*0ZgFN^ux#
zI!5C%-CNz10UIt?xlu)=+RpCiY2V<nqx_FqxU;muk%S-~pTvLuR8|@+0=kw0Z0Z#2
zNOE}RPdE_x^sK@5kGHCwifwyH5SzH@eGZysTUDjml!W{Rc~~<o2f^DSNMXoal>8Zf
z+hjNeD&LR4T7`DKX%N?Ea{X8V9OHcUxW*GAx|EZRe5b9dI8!2=X?usTsU$hq2+*cj
zgV0^RiygWB`G&`&+R?k{eh0z!_`Bc_h{;Aa=Q^AJ$xvEm<8IXcMqR!m6SW<zccA7u
zaHo7mEq`Dxq|TOA#X1;#5$5p0@OcqqTq7X$_Kl5eEuS+)V3+Vc#{W?SK-xx@`}8o|
z$WUtpuOa4UlR8~eVywr=+kf8~%T)->nZ%vGGA$8>1O~XZBN4r4yM&~!g4OV!N;n9b
z=*I<%K$M1{+75#Bpdx3`WLdasaQ~&3bWG16dF(j1{%PJ@D<sVtX?$-%%M9GXV*Kxl
zq(G@@W`8bb04ec1P#OK+Vc;(vZf5jUXq;M+=e*^sW$|yub4b+gNR9xu^kH{x{FEr+
zFTvgZ{v%mKM)8xApFt+*wUDY({)OhPacR~>uBFSGyTXM=+rr`$q12%Cp`0=6NW*Ij
zMZk~17IRxdHVA#a#KsPyrD>h7%b;mQ(<_&aUOu=7an+9=cr}NA+z$pX>$wTm4oud;
z{I^{8kEu3}&RO34&%#0d51TD!FBAv^0-H*vg|0ju+uQy|F@IeH@I4UeVN4IrXlk38
zg>-9KuSKH=4A5?teCe$psC!px-R7{87U<Bqubqh8dyH8*iEnXp<LJmU!GF529IS@L
z&-vZIXrdDzNV>H=C_6hY|7Bx4Whj%(i0jySjc)@hz_j3lg4;kG{hXt=eF>SBLx&X9
ztf25=w-AgHExxl_#<=Zu7pfrVkdN=&tz3-Y4l4c$aiuDa<cow(LK=!j@CLcScpfas
zh68SB^0gqOpWvuaJOV)Lc+6gh=@EGEujF`-&9gZH3VFQ2B21Bdl)dT@7lkbCp$2?u
z>X!EAoLiw}7LuS}`8=hBe=Yf+8QvT6Jo4?W(RnM|v<&=qSL^CB+}+We%VA|DJG8Nu
zhT~d9VSk3!^RzC*)Qo@m%@V=(7k>G~9D+lg(=e#Db?{~$4}aOevSnq^qKf;LfWP@p
zT$jrbnDS2V?8G}b{WZ2G-<Zrfitti9IJRTwa<aboE|fOYE|cp57@n=)Ec2qXq#z=0
zDtC6?FFnP3o@*gYWDcC8+co%5K~ea0AlSa)TXS&c^$?>2<$x$_z7Hre_^RzHh6F4S
z^yTogN@(@fNu6I`*fy2;18ZpNw^{7Dgj*jlK*i;yE=|rMTMej7>)5LECT-ks;})eF
zW!sT2QS1)!6N%r$a@EKU#d`J34DsiR+`~$Gj7Lv+%c!|DBpYg`rcGa23I<9jCtG<0
zXp{~w@z1CJ+E8-&a_4beu46i1)K|A~7O(4AjPc~q+)IJviH~(7152;9LobH=<r@p2
z-lf}CtXPTkt!7r!w-nSd4nNja;rfK==V>M+LR7U;?O9|nb7t3?6I}(-;!BaZqsvO>
z)0V4z+y6-({g?%G^QUq}kIbyQ?u50E{F>Jdls3|N0>NkNIjWghmhhGO>S}2gFR*9}
ze7wf1`XNA2WwlLv?vpFryxUw~{dEE3ef|_^XO?!H>J~Uni1u!lhafXZXbpCP1a0p*
zgIx9vr>BAOB@d}Bv)69P&Y-4h-0uj^rf_?gzwgWwIWX-11{)w#>;|h`+1#7HSrl0X
z`|T;+nj%vUah+UL3sgU-BgF;5`6skojP0LxEB_@p#p?;5LSMb!;%GQ}pJfKjZIH8j
z@8{cl-+pzv*c;b-Y=o53zV7LjO^3CK{9%b*k}6GXE$kQ$Rf!;0WwKbO9-!Gb$V!oF
z;b!@q<k`UZXVA6hIsG2ubulkd7V(noKDQW8+v6E4TQ=${K#az#y_(M}v)YT?HnJ@H
zWLCkF)$;C7&-asbaj>8hXPsj}B-Gz2umi5Q+NVdmT-@4g^;UcoxM?c8Q!i^BZ)uvJ
zWI+n$W?ng-{KjIXGny{2Sag<{OK{}@+nckOakqh&u?u4wj2=9d_c6bbu9U}7bmQUp
z^LF1Iq3x0tTIZ1QvM1tvtZ$%C{<20eDw1VM*|q|%1lP34b;oL&QHB<ns#!Q0SSrOT
zG>v;4dM<7A2%x*)=C++rS*#kJN-)@8>!|wp8Y>k6(NM#O%JC!-=|GF5(wXEV%$M+t
zWR^8%=%^PU7=E~O*lW+G^iRIRYM~TvVZF*0T=jJ8{B5l!S{^Nm+l0N+(4nm_W```O
z=n9o2I2kKetLNkO_$&_iq-H?eFDdXA!kRye?MkHIxJcCyZP4ZG)o4BsSH*L1S8B%P
znK=J5Bd?4t+dz_Q;n>w*y3aEZY4@}34af5bS74N?B#E-evXAIJWF64oWkkx4$+8U4
zt?tGDilu;*FFCRWiMT_ucKfxzFwGkw?!i>3h7qpf74F?*RYVb(<%P-~<{~}OjPJy&
zh`j4KDt}PJI)jSRxWOFATfcc7U8?%W%R9%p=YxHVKH}v(DyhMc>`{y4C}ynqtZ~B&
zo|@v00`L67DQ*9D8-&|uU_1$~gtK2rF2IXB`t~wEp2~xZuLtFUgKNU)2n%pf2(OFY
zxVfMV)`oLttxW-NS7q_yvJ}~b|4=eB;7!rQ2A!POr|~k!Q^O0n97O?uZ(Qs4BY_2T
zY<E<QMPyABgiOEfW`{E9AI^!d<%EMw@9=pf`Q;^<U?B=J)Kc6)W03B7f8ivV{4s~@
z+ZGftdE+P9{P#Y3=Xlxw4=kpr12){er4b;wU!+IQ@wYU~T|~Ie!(wqtb#Z;lc{A8X
zMxRY9`SpBoYJH}CExO(@ens@#28ZiJ|N0T0W*kh?U$<Z>Fd*D8<gB}}fAU&wR)R-w
z!20Co3Ez5^Ub4#WTtpNKRYUFCbX*-6NyU34hhM#Jtvkg<gCw^l+}q3*2v}M;>Rb%@
zZZTebV*!ICU9cNG*YL+vX&xY1zbaY9Mfn--)U{s-;q<pA31YTfg{uqhxo(i)ba+ec
zZDd5kUL9F(Vj_cW@%`VKp~5e2?82-msH!F8aF&O(q;0*+5PDlxGJ1u2O{hXEf0z<m
z?`F#?y~}b7LT4f{y;DkgL7+2R!w~$<aTVJY%kMys=VYi5Yi!3$40J)W?WVg66;G&~
z(ufs}^$rtlk@kVk^;#KX#Gw7UMbH8LzChWb`rWZNInePHV)5vEm01}0y)VvRooMhM
zVcf$j5ed*ciS}&Q$Qnj0i$-kCOU`WE^&>5FTMpG`(d~iN)^w=cWq=hmjK^wc4+Kqq
zxOiIRJd2Z(=J$uL9k31!G{D~HV@c^SS?wvaQwaw>;zy<f{uAZ)kT{AsKQRLqwD1qx
zJz@mIz+aYA=+xf0`n2@u9Wt22N^pj5!=mPcf0dJ2qy;L#5BuzsgxVztNDx}kzxsxb
zs3cH2760^Cr-+mEmj;-sJxPL(zE4RPO;mR_QZzJ%>&>p9bu<bvd(TZBy%tiYvKl@=
z$xNMGrAsK>l<~5-OBubj9anA8CPj1Zm0x>C-VxQlb(k^wu3H2P-Ja(xX_q3~U55ar
z;0+n_0X@*QKh^$J|EAaT?wB&cOVNPWvOA4-b^ASAOXGuz+YTTM*CSIbdU5wgFCZ0g
zCLMlzNzz*U4n5SDpX&0mJ^u}ZroE5}KfB!-x=aGs(tY}B3}O084-@r|zY<pT*c|?-
z;KA*CYfIymi?P4n0H0M;d*z;H<vo6nYr-h5A?LhWUv)>`jJj@Y?{gTrx^8Ia$_gR>
zuZ&3IHPNu6hdTh0hLAh+3B7n2>Egg$ymIi7SZwU%l0}3&_O4pM5Zui&wVaKmnL#5i
z{)PXZ)fnb?QD+cr2Th5AOy94NCQbzuOp35#yHEI^_g#Vi1RF`0JZ<wIB`|UL#5~nx
zSfDlN=9U51_$_lhC3JeYV+(m7uN~ho=sR1b?I`JJ%pFj9Exw9)lIb4$(yO9#jGQym
zm8<zWajsL_XNTW+aq;t1a^H-cA8oqtSAUr{VTbiU{}k}cUsIg@?U)Hklf3?$*(BFC
zWq$tAS!$j-gT<S_UBNs-I-rSF27(`*B7l<wlpP7V@{_l?jd#sjCc)~>d>Pa&#%s5L
zPr)t%&nIGr_Ggtd&S7WBTsm_||5%h&=^#4*opHw}F#=nrE5IJ1!hsv07$LVuH|X)=
zdq<)=zUWr@Tk0&+dXFqnn<BK)r1qX!dg)*K-|rv`*;$(t0Sjf)(d2l}Sw9t3AuSS%
z(ID-Mzn0;L6_u=MSBT!U)~=e>l?MWr;;baFPs|h#D>Bb;dCaD+;Fv<d_SxjZ6?y)%
zE1DNa>+c!O=&iN7Gd=3#_A8`O{=ybb{zrq9U=QJDy8G;hf`*stLiTu?3Tf*QyqCT4
zab+IID92b;Y-{p)M|s`L{FinM{);dJ{J=qm|NON7?da~+t{+{xL5}S_6>ap92%7-p
zs6-oLPoWYSvZp9pyP~_gYheo{w=sF|Nud&>r0=7jWDL)Z|6T6Q6OYQ9(Mp;~)t$;;
zPvUZL{uWQ0w0<&Fxln|rHdF|08%ei*jQmWh6Wt{oo)%aemOA>q##=`l9l05HeJbx^
z`MJcbexkRKW@X$6Kx7hMwb4_!SVxEzj(#4fmk}>6qu!~7B71~=+E+-<E#5CIhqFx8
zB64c|^&Qdbt!y*T-Ad{<?V>hHF#NXyubH7qd-+IkzjM1KyI4mri0sh4zR8#9iwP)Y
zl5v61DlB8Lfs$hZYNWIdSNm>pK8@H^_);I`Jm19z?BcIKP?Ym_ko&bOjJ}@yTL|4!
z+H)b}&kY@m^b>g8j?DS(K=T;QW4w3B7sIez<>gCH|606P50W1+Bu4_&4Tr;~S<>E0
z4^$NQY&>UMrr~GuLY<!&qut00B;7x1+lP(W-UE@E<TE?#$nE8ArL*tBrwozp<Ku4Y
z4@9r?z3hz}z<ZBlaqz@FI>%mz5BRk|3!1FH<K<FS0M)`<;>n(#GmF>@lX}BVN8HJl
zo82-`7XlGDliM(cH*K46irniCulO!1C|1f&l)f9KxzAkmlf}~vi8p!bi1i5LfjdPz
z#!K=>nrsQ*zDQ7@oq^vY9U{2{VruKu`O2a=OS_W+q)5V{IhiqIRo$G3t<%~{)ixi7
z=Ul?8pErK}l1t<8%N8E8dcNJVlFndIP*ca;D^xSt(n7!vwgbu8eL{u*wXb-$?`)QT
z=&J+U8=loo$uu6eekpW5E8D(!U4LQyx9`*n=LzsdtI-IIjERNbd;x@PnfMBvD=*IQ
zjlVCU02HuQi_XCs^8H=gmnpUE!*|fIYz9W24CgC1Q+Fl&8+~~m#bRizp<fE=B2jSo
zeo@E_tcwA+sOB-j7oBJc3LP@h^c3v8$g=3abqyoE)s73|{m#Mmk(dkI7T<6%M<Urp
z1jS(-DSqGzW2)i$jDae0rP8E}@4$6)&gPZ{07S$un*OGST40AW^@d}N>wN7{J8)`b
zt#5-c6b-VKgu$jFl=_YxOWAy?n(6}htdr;Hec~_ZzDh8jo|Vb_8LHE^?dQ>F*f)<B
zemkYGQI#%rHM}R!NNh5FXxbYWAJiTW%bY^tDWpZ_%V1EWp);xG2Hc$3`YmpJCTVV&
zz^0Lbi5+td|7e-!=~k0Sb@(efbbpu3{Q1vdhbr+ym7J$0x+-PVHKK+@M0#I_(MuWp
zmy5K#7G|e!8I-tq@A9^;4Xtn_xyP~szoWCn-u^t`hUy@LY=*t*IX<J~+in(UTNeuH
zWF-Jl#R@A~>T>4HKw*L@r;hf#=8a1SHYIHQNSb3Y5sY&fyNy7D=9lbQr}Id#GBF_9
zO6GQsNPRAXz9UM(>J-vk?BmIRvmgtvI>(@t{*C9=g`!NB6u1MH%1;9320njof9=id
z6U?kbe0T&|(~!E~js$EJ37PDt3nn2uWOaMzyfz4lU^Dm;CK;qGcl%(udjz~v))ZHh
z|CmoZbPYzU9E?Y;M8lRECH)zDx26Bl?2m{s`VH&#XLOt17ur!?gJ|~K#HjC`0kYA$
z<u2}O8{N6W5DE(Dt%(iaEK*KO%IZVQyV|XO2|15yStTX=(})w)V>W*F{r^!q$5bKx
zbX29)M8R0Ar=@Aw+Nb`_>+cWXanvKF&VLx*l>H_b`oLu$X+Fvsalc`!VbsNafk6m{
z+V~>I;gaNDIjLPLjLVsNBUxKOX8uw%II+}IvMl1D-Ci-+rU!a|r)a%KWxnAtIg0Bi
zgEJRg+9su$Uw#g3l;00(Jdap?B;$yYbV3E(sN?c9P$WnvEhTJc_hA-550WSGBMg}v
zViPGCje&GIC4NAbESj0_b0VZL_*A9Vv0iceX7owxq~*Aq)A+zSM)2wAbJ~Mg+1azu
zZfjq%$gE##y(wA*c;?Cyn*n2yg|cLK$NKD{HMy`WaS@6J10)YF@9D-R-F_$2pK={{
zaGXCSNcOLqAqNjoLD_&*#=rq8QnpkKZK3X)jzZpq7iUyFRUwvwe||*gi7|st_V_lX
z*ZGNDnOt*0uz^V%DO0={87D^Krn<79p#p4_nAkeY^Gks($=OAG8{*^!#q_X+%A;!6
z#@BYQ1VLK@vW*h4LO(lh({iU2wYUPpxA#^xnm@UJ3M5&hrig*)O&0e=#STu)JcNC!
zKf5)AKk4C#-TUvCaqEvyMm=8#)_Pnkdj4DE8rN|kpSzNxzR3h#FM6kZ7=%%@EF%NW
zEJ%lF6oTCX{>TW07<olwe5+QZp_*d$t6vf%%`+qw97Ad@948Q4#QH_8h88LB%8Z)A
zj4uQO-TNK|SUPq4gJ?=^Jw)|sXVS#qes$WE432qupQvd?A(3)%$Lt;o#^poAy5bKi
zgh|qEra&>eY%^utyC%fud!k+0yhh1Q+Xax`{xLJMibG4l)yk6DeI!pGAGxBVAYS|Z
zD5)O*skJ=?ZCo#=a75)~fw|Uq(k}vAy(`xxr+UD_iT3Y*sb$199kR#^X?N9Lnl2M9
zfNTHO5mK$5zRwq6f~jR27EFBoQz}Tql@++_hH=fB73k!K5r>p=Gqa(BFiwkx4*4_E
zAa(NEMP_a8WRPr5MF+$rJ|2-m(j3AS7oI|58b>npT<*@fH~n}2vf!2c+c4C0tQH~O
zus-k_*Za6<j@9YJ=q*WnVk+=jVk$3-K4PDtsiCg3cXGB%NT+KYlLhu7kP+xTc>5py
zRZL;PdxP!ceq~LomlCg2zsaX$t!~BOQ?jP?!9^E6?Z6x%t2w*>47Ow#0XtTI5`-Br
zve8^w%E>EsFbhg$4i`@m8RB>@S4&VR0KRe|BPD}C^jw@7ZG`mwN?=n3BbN+d=2iQ$
zO!xlM`HkI1m=0AAlESmI)GIyVq2Icjko%norn>>EIDw_h$7-G|E|<a8MLb8t2Wcx$
zolhhT@%I7s>t|j4lYbfAd0>jO-_;O@FlT>H&>4ii$Q~iejD#;N1!1|Eh=2YHz$LYf
zeB(pm+3m$7W`1Hy&JqwMAi7NvV<s!~A3RzxC=t7|Q%PLtcbP)86~+yIDDt>vqktr*
z<&su+NU7Ro)F0OG*+ovsg}YP7Es=<Bu$$en{!41QU<YO>NnC#sin0JU@CyfWYY{mP
zLrp6Y%>}V!35NCd#6=V{C8Y2QxXK_Tlj=uo2*b59&1<<i22KbZE~R*Th<4iw=;I(@
z$Y790X10|iU|<qR@9zl!KLc~Yly5(@8FwP}1T}PW4ISKFTL_L!IxQ~2-DU0y3BOx|
zL%i-pPZFd@c5K?8gfK89*~v;BZvJ{oOtezqfVy+)yt|-%G;Wj5gvnF@{OI>#TM9~P
zs<22Zaz#-I$G?bof5Ad3BOlg-%;tZb<Eky4l@D0rJYc7*q)g_fW2~Ra$MG)4&n04}
zQ%&HP6BT>hiO}FNVwgWLJb$FDC*J{m|0kxF@Q4h@_+hIr)v)%+=0$Es!8IxCkdt{@
z8xnDSJ!F+-V~WO8jW7=ZC?HVM6FRwxdgRA|+eHf!u=I(6Q{Ae{Y)Vo)bNz5bZu!w9
zF9hllH;*AZTCpoJ?L(@=jGsc_f9zEmoY9*Mh7En`xWZtch`iS=eS;973b>%Sl8#~6
z7wkxZc-l_&{kEO@O?Oo2HxtZNKd2AW@tf{%jR2p;FS`cQC?A8Jz*~t43n8RAWgH5n
za5zoLEB*}YbFf~`8cGSeEK>LTBcA=^G|}T<9)6Rr<WSC+L$4)2>wQ$b6}sKpyD6-t
z`?+m!pEf)1YRG3(AYKiSF2lLHqF?#o4Ewq^!{Nihf~T;8XY68ofMHgEKI#+6%e)32
zm)h)&oOwfftc=Qmoc`|K3!8LUR(~rGUlH3t?sudPjd?mr!52~ZFM%J@sR_|d*V~bv
z=3~W{h}yT%d>ydq{htgl3xX+&3tjnmy7RD#CQYBTjbzc^OfSOzy3?^96A%XmNEzW=
zc2RAF(+rFy4ESUfjGH03ZBxYEi{6GX&Eb*@M#KTGR&V)$!jgE2EF8`J6WhQ85nHCk
zQ}gniOnH8n>MlD|mR;N@x2WeSF7ka!_w=v*8x)7PY~%T+?^Au6g+e6<8UMD}0q@D{
zW*H}EDf0MNLoM2&EXD}}&i$&MlwP=D_?~5+8H565A`YZ)D2Gs0IMJA>{MiU51U!NU
z(gr|wh)NycoUEK1CjOP3u3UWqjnUwhn$dt4k>q)ebGsAbM}#i+57Iqf=9kDhqi`Af
zc-_6G-6`9?dyE%{RfnyFVsGMR=h)qOv2`O9%-gdU*S}Ygsww7vIzdvzsYhS0Q@c9i
z^pzjgdzOutanN{D^riED3v9f2hW8^F9wu}*wZ?1%Vf%3F1J0673vq}Of(n(c>9~{A
zu7B&QMoL;8ByTZ)jtmm=zI-2m=j<ptWf@%UNk3_EpW$!Fk=VN)tDt+$+)E_QoQccX
z(RpfxJ#zMpq?*K3LnLpcrO~FWt}44LEyh6ak^aM<#N9f2F3Ce(x7?c7d!BE3KX}qx
z6NM28P<ZukcYl|kS3>gq4kU+r`tOAZqfa<GMskI)?h{U@jPLnyDl~N&e&s{*)W2oV
zJT*qL!HJhRkn0>{VQ(r<$dwSskkh~^)XWIc5n|6+7^bAs&52j&G9P_v8_1Zj<efQ4
zEQ=PXn|%sucq;6%#w{tnH#`Y~Is6`}(~D#dXmXIR#JqP1F|gytZH3;;hjU@E?(0pa
z_zM{#L6Z@Pfr5YaSTTc|Sjex2v%Mb$*d?@3MJ}+-nGjvr8R^UamJJ%UvXnL<G?Nwz
z$$g5=m_f1L^<(D)5qnjp<E_rsM=@8+XBC3RE-GtDeI7q$H1bp_LivjN6*EPrZlv6S
z>~u<T?GNE=uUHKM`}dSj^&GZijOD0M#g%!C<*8r=6Kw3~s@`Ia*k6qD4F3GE7dLa~
zc3;}5Azlz0tRwxNY2gu+`XcO${Wfm(Lx7VybLxV2XcMcODKMXt1XHSLeIa=!J!?jW
z2h?kCHxE&#J6GJmRS{4(_5J6c_IF~S)7%5jreofctf<T~|Dmz`_uMSa>N#yv|J^0p
zrjfsE9qrb4YQwJhGwXG*;~I7LKZOGHcNkD4X>?4Xc+eb{$&D)IUjN37;ZlsPt{Q^O
z|4G2KF7(>vmS|zVTxaum`eRWQf4K1_Fpd<^fgd{>p5%E-d@xCe@AsCEr<tAu)x{V8
z-n~~^S}G$GvDX(>+K=Kd>CU1oKk%8rOxDrQO+EPMOdHlpu#EJ_`L&xE?uXy9@GmYg
zU9H`N^?6q+oX2lrXXoWEIu3)v9|tL<BC!yqZUkLAQ^MU1=#P%|zYX}-ok&CCFqx_c
z5E_CF2(8}h6ElT6a=eN$(5DgszTfQzC3rFht6-$b#d%<2|4&(00Tf5GZg+7Hx=0oX
zy4d2b!Cis`cXt+t0E<I#cL>2H!9obGL4r$=AOV(Ofgk~b!`uAtzIyN8H`UW!(|!7z
zuezqDx_i#~CYdj=`PFR)ymO0}e43Yf+kcKTALS4;KVQgn#`gipEfx$Y*uSJg%I0}?
zFICJMjU|_94`}o4WcGP5%ZI@kG+qzLmdC(z30gKY1mHV1w&vr{-8+c1)P&tz@EMY3
znpD>rktrGqCh<`JZ3W+5u%U13o#Lb40e;(S6PqX6Ib2Nl(HNs&$oQhBB(eGIA~NDD
z34ykzu#$ubzP2V<NrH~&L^Gt72m99!7T`XWIff+9L~8oS?T<mpx-V+9i;-tAbz#~?
zn~G$1Lvu{J>Is~F$+A@m)>RUd=w8eCmu%ww;iL6MVBI1QtpIqx^foqTChdJ>QMLV#
zDhRgun>W|<bD@=n1!XW{tDtEFce`fTs)v=LY>RlfVxAnI4<EuCnY=1?Sq;slGSm(C
z3IF&}yVMD_=8pKNICEriGb4#~GlOJ@)NZOIz2H&JkFQ^QdthYtfjue*5;;}RMl6$o
z`AO^vIVL+4a8DfO_B(<bIm3OZ5<2<9#lm)1_sPu*+KX-gC*Hxadf038I_{%JH|&+L
ziiMT%A%0ifr6bZD;ibs58QOk%9uHBP`0ctGS^(#_J%;Z`cILe1h<UM6=tq3?s6ogp
zPuuS9rb?fBJxt^(`t<yZ)2dahdqkG2xM8-Skbf5?T!mTPk;_^5V1QSKBx5>3ib}HY
zcCmxdIAl3{LUN|_WtGX%@zbI@4NW(}h#jrHEuFe4=UZ|q?~vo}f`jzBHTayl#-r0p
zQxw!1y`e!6lpEJk`y0bry?;g%OQrSsDK<Ha<fbq&_HgR6+oV{zxK*s)7VU%_;xQ~=
z#q?MYIKqR0IBnA7VP5K-vKicB(&ujnB0*iJLOshmIlpJ1oj(^^iK94YHXvfmkrxzw
zdX#D)QnYYV;HH$AVdHXTSD0;q6|kq)>(k0oF-svi{VD8ChLCzvG|*s~d~s)C)$><T
z@AEMGi|JM`^K5E`tYqex5*o5Y{iTS-#VyY+_>#clb)<QV9=)bbs140_II%a6<}{LY
z+@_E>f~V-%RgyA}cMtti@uKdtr5R&0u23UNR=O&l@?~?Lq4h|%CEDwP&scYzxJ@(F
z6hPJ!TMB93xro2h(BS*m)sb6Tj0Lqm{cT3H!AMHhH%kRZ9tr0wF9Jp$YtmBrcB*?g
zffttL5w;Yy)NAvqmD5N!bHY>W5e3MBZ%|nn!Up<gf2MH!d{09-`6%)XS+vXa&yc0f
ziMNx)<ff#Ugx7y=nZ`gQrMrx0m6m5xIA=9|>Jml~V%?<O!#_#xJ+{d4D2R+iGN}1P
zux)~uG`58TKJbpEnd&?B4oEf!vB1e>U-t?TC%LA0xI{!+KV<~3gx;kpxoUhL%0s-f
z2nZV{4Y+61XtRwTkWo@X^y*9HGV>rA*f!QRd{8{UAQCjqrcI7;d*02k`%RAXbfP3=
zT%m9X>$w~<d-8Uf_+fZ}_tKA~3EEA%R=1y9bi1hA3TZ9jf;AQY=>Wfg({0A$ysYg%
ztqDp>zDACFqZGCS4GqybDjs*1sFrmC47^F`eD&m>Z0i}InVUdnl^T=i_jA-RcK;<v
z%!yF+d@z_%^hE?tBMIWgepMiwnvbqTLTn0MWb6?Z4i~R7o(i~IPUeg$meX+yP4z8`
z0FJ6k{7TP;-xyoZaMdAv`!_yO;V%ZLgBhgo#O(1T-2(4#1eQX63D5a+MC_{{neBel
zu<Z6TL<mK@;m317t2Fn<j=mL!8{5%~v5bRk)_Jbou(L0YL}etH2AWETH@GuU7c|FK
z|1@;#p!5v=@1!~$B|p3gC2~D{q{MKs59a<m@{m`%qhG`gJTT%Br>8CrdfNA=Ict+n
zY*3=Fypy%INP14<yM-KYPqf!kaKGiH@-c=K;tk{3>c$u3I~~zU47FjjDv&;j^}?co
zf%;1O10V!j-hoA01RM2Ap$~}J6*|)0O%2sZ{pKOUh3^E?f*n;t!MzObep-AI%VfJV
zb;8NM0wf`DeZEb<!M@|Th;=f|9(IBd{mQ=M(Xe&0*Ev0pG3FlwuOucFDin<<dL6oi
zip?9VvJ^$0r@e>IeO2p0EkgkO2Z1L}%mB@W<APz?LoG7QN_GMbeQ-gYu&`+%MrG~D
z3nAjiho8xJ<#+`&U--kyFGf6N#@K81+MvMeXM!d0p8^GA%5;y@-?ww6NOKSyK7)M+
zPRyMe3-D#vd_?!3T5yaj8^MY$xTRXyCB5^M8!MbKG|?arhwOj_Q-;SdJOkB@jX3%4
z=k7EsDrE2l&ePFUiAa$COF;OX5sR5D?qD<MX2L%%e)V1J$b=KKxAMX;B=Wk=yGfbD
zdq4+1R*0NPete7Kv`$`V9?*6&8HaoPPB`0ju+1gChaBqfz#nQ24&4VP(@~I5mkdL3
zsW-GzmDcsG3>`j*jlt5`jb66#h{)U<GcuVwMKUuLo3HM&$VtUZNn*^PK+Z1F+#Y9F
zu4GiN+FN=aCsf2Py|*PAQ|aYH1tw^b|1yQA)}Kbt=$CXsk3ow8xVL4AB9d+(p$1U@
zmaAFb6Tt1yX!4IsFQbk$C{Rpyb7hOn)+}2V+ONIz_hzjhDfvypU|W5p&7sm+mbXB+
zH&2&o5Alqo-0EXJW}M7g9oUB=mTLowHf$~o?1+YxVrM!gX=JUx#g{nxCU|;i$cMwz
zXzzF)Ghs_)(u8r|KYq%^&ykkLjk1)PVL8{Z8k{lAub4eu(AB{@PKirA4(01pZ3;=U
zTsz|4jN+6Kx0)4djfoj{Y8(}ygEfXrR=T^E#v?ZaYttM3{*?bxz3$!%dSdnVUA+yf
z|IKY3*AcQt$(1M}y!yqHf?a|-;UKsk?5ai--&~KNyGBXwymTF{%H{Lnvow`}1$+K}
zqxzrfZN@z_57st9uXq+}?Ciu|f=6qFGxR3p48Po%J|^5b4O>>m4QP<X6tWSBN!(OQ
z&Ix1E=rNXDW4?t&r2C3~&ze2ilOttmnujS63h4B;hJKC1ReEn1sLoFH222m<&y@A9
z@Z{x9M}#U30#oD8a$Xh;H;YbK8;M{Q)6;d-KTHEgD{3anMikm04vyO-;uH8H?d4oF
zYqPnd*`9xs5MSfr{}aL{G?rPD$cjD}2PP58qQ4;Mtx#&%(}$na+ZK~_j$)aXM$LCk
zeKLpdSNYmI?>!1pkT;jB(~z7jXJ1M?6#T}{`8C2$`_b7ZT<3$-b^)j{>^<dSy9LX;
z`ja>7Qg2*})-C_aZrF`YN_=mEIovGfFmF|C(pEDKT*&hgIBUH^L%68PT^~a9H<a6?
z8ktsK=2(B=dN&PGBj2#PkI{RiJLJBd^45X_DswJvy=N%8159WN_Vz7VwuVSGm#xZi
zBgyj+TC#(0qiYoLOJBI~3Oo_iO>eM7;kJy8rW3E>?}f5y8*rlrl2%j9xo!|4Po5@L
z&rHb*U<g<LGg*33n$*}N#e`ZYLdhmiB#VWya|EEJbRLIEs7+!`_#xp!iTGgY91cr)
zyRMWXpLalvF%t2*3C$~iC|3z}i$57C#AD$1Td;^KP#bep&2fF(>v%fdQ;Qi2)5`jX
zo$E(P|CE*wtDH}IA_G-Ghu|w?ebsIM)4N;^+Wjea_T!P%NjY&Hf>Sk-&wSg2QyH@2
zb901KU!}!$h|BH{pIqlreJ0_C-_C@`XX$<F_!3*c9}k%FrjNTEG$h^MKh{aPo=-uQ
z)FHT1vqyRJcVp&_|4BSp1ejWKH<XZpDxpJg&d60o#Dd3Mou<V*(>psdBSqZQc_Lfv
zXmjCSz><*_<+id0{dE$et15HNOz#92Wl-AMmwQ;3v~7P~vZlU%lf4CZGmS?aMwOKj
zyficB_Ai|<Ug;u-Uz6o~8+VVMa)KIme~vfKnO*D{NO4%)H}^NBjr5JPdvSp5^aS3C
z_*9#KS^&O!rqfbd+1_O^Z&$ODd78z*ou=5QhinG*P>a(Al-6ikPWO0$Ebd}$Jtwip
zrtf<<6$)YB!*7DhC9vQ;b+dH~LNA;3(Sy(w)y;;kR65GDjKp)?>*DPS*L$s=9BIR0
zT?6yR0rp2#t0uCtUbzI5Mrtb9>{_zDK?b_l>UH^g0nSP2-!D-JG0(gjr`ym?sunKq
z6BiF8`RP`<zM>qK^5PSrJF4kcu=|(c-=W>LR{NcxO#lhgI@{qwi!o$-pjy-+hdRuI
z9Vmi{x%IYX`D47VpLGbCWI4F&V<Vt6_|ejDh1|jtM@!YZdw<lb3krHUpy~y$>n6vv
z?}*?!co=tGz;y0S$0RX>nJx*(9~j+oI)AMYRJ^0p+C$%X#TR3{2KOjjA?8>k@2Hrb
zvRHHgOOx|}BH>AtdfQbNa5A#y1>zWl-KiG;&WFmNV0oWy_xowVQMI$eBg4<anpo{Q
zkiE3JI`aJy@Dt08;Z?!6+S=db1L0~w#W<8yL;$0O+4G0C$urUe16>sI{nV7y$*59~
zRA>bMv^{G@_iNcR@_`qFbiAWmS{)uStqV!`=xc=2Q24$0Lfu*e#c(|-=OOyLFV;)6
z8$1!J8qBlG)EaUs6@?E2$FX@-8feTdX$<LNtP|7~>y(Lez1aA?v`le1@0dG#rGiVC
z*-r!0$(VkMTyz!^ucgm?!%l3cA}IHza-g;FeYMz+hxwT28w0n9|9%4zme%xOK7T_E
z`u)_aR0Q6san|>8if-rgxWj$qOESBph&PrHelIhjK^(hGd9FDyjDM~?&~;aV!pM8S
zE+UnDD=^fwKOl%=t+d|}w?ewgZD#<4d8{%Fa^X&SMgwDx6loOCp?<6D#x9|Z5Pwfg
zWm39F`$l9H^d!J`Ou_4k#?3M}1n5yYc4e$zZVCsz%Ntgis#ABf|6I~P()tvQ$XKiZ
z<chAttnty+zGB;IG4Ib}RDg^SMFtg@A1ZD<*cY#&L0~<1Rw4Tw;;YsTt$D>jXpb);
z^64Ty3Hw9}U0n7y0=Y-EXXG~s@?+o@5b{mJ7>r`I0y0zcF%8H?PN61<Bo>y9iIshS
zZvk&nAf%ug;3p_{G+i3TIulS^{8$)&Q%$l15$kewP7rRMp38rTve2s`@*O1q_G72G
z@?htCXK%|P#8zjC<Ihdy$E^mNZgcYc4A*4m1aIAa1W3)eJ^d%|WX`qcCk0>a7rAyV
z7WA|neu=rJ(mblBt(@nZ6+??P>t~}ujSKLff!vD+uYN%;@=F?Z0%`dSHGkUqgdVW#
z@KWPJ>`gMSAO=YonV$Sr8Ku(YVEj0+>>r(<{y!Nj)Wno;AhLY7>XW_%uh^I<HKp$H
zdcX3TgtNpcbn7=aN8=YLwiL>us6jl<f-0<bsbSl5zroaWOHyGIcumh2rVd{5Q<TE(
zUklihUq*ZkDD;!fFuL_kc>hhJ&q39XVurTE<%ND%d3zr~PBshAAlsNvAcIW;aDLoT
zf870u_$I<}irl(rc?guF3&G^74JyTYw=W*3HyRbI)J90OuN$4Hb}3&bI23Jco1+J=
zXY=vbV=Xk?(uaRacptz>{h`Lel3NVEso`6rKg5MDKWFG&HWhr2Jzz3UxnoCMJaSVQ
zENM$C+xC=Zsd!-$m7}PTq&RpK9j?^2@q|@TLq)_>JCI6*)n`PRRhjwblhl>0Q-qY9
zp*a2b+5Wtn5K(7}Z|A~KJ$Y?qnS=JeD12y&?)pd7R2*>`BJjp3%=%AV8w5W4Zb^Sv
znOhx)Nx@8JdQe<C+uO%LppT8Ue?Fa*naK?Nv^eQYMZTzbRYn=-eY^pPl14YHpAAZ3
z3{--NHPEV8z!~!=jX*DC-nmCgxoM8VO0|=oW={T4NWJjVno(S06TC)6?4G>pE4vDH
zrtrst4u!Al*}}~CtXGI1HsP#_*(xIKx}!7Y+DV-94{~T)ywq^hO+gE79qJ=pm8Qan
zCvU3-SL8A<w3FybXAv~)v+x)fepSUeM{0b~;}z&2+}u!vQ*RVjJ)3L7*7P9YDOH4*
zTHkaemK>;e7Ym~Ng)lYLr_t#}KRK$2<m>tF$?-13+Oiys%f4-30RK@x2o&u5#R|^+
zA|GeAww#DL3AtFZv@WN7Kl~8uSiM=ss7=3VT{c4be&q5xlGDEa?bx?w&Ra@D)@+$)
z+uB$ui@%QU+fYX^0s=H8O5In3|M%<5zS!_N`3sb|SezU+2;VqZLqj2zE#&r^s|Ur7
z`R#KG<z!ZPB<W>+&Eet)_lKVKytRk($4fSwKZr<_Z)(vRLp<KRNpI69@WfIk7&mRe
z*pMwHVM@jRFT%tczEs!{FXYu=&DCY@x(^Ru1|j2UVvAOD16^Z>c~6qEiY5za{+vTg
zl#)~wT67`)b;Lb*%q+)yV+_`_kz+$vR(u;2CI)A`+I^zWKSNm5rNNou?At#|`tEuo
z#Gfxphj|?1&swst#W!)z6!Y;xaUSH8VdKth0T?LlFUvM89*CE>$kM<k1Y2=a*tk}B
zkaC-q>KWTeN8bvjvQD53mcF&G$Ypl6b5MyuU7lrJ7zEhn_LeJvvE{-Ts@2_ER|Y7b
zJHgZJVn2KQ@U@HQh-2JYAJ;`;&-~J50TSurr+-x~1@RXAHTC#c35Mo=F{yyc@UUl7
zmcY>dYg`VClDwL3i(bHnk3rxsOXvTDO!+4y!5sLfw1TA^a`E-)#!j&PQ>=Uzvy+Wq
zF?yB`9}4B*y|DYT+W1#E7bk}7(4fVL-H^qz1M||$(#8v`nY`d*o?g$GYrdng<q(Ud
z+hDpyCb6{axh-K#1v@ZBF3iGaC@l5I@$igjb2Byd2~R(idI{&8C7<rpl>5sjFQ(}@
zWA${%<;ggTI9<X+BL!EDa)7Ouj+=^T*@I&HuhRnu5uJLb%EdJJ+(GX1jsKWE|JAR3
z9hV;C#hJLetdGnygq#vK2bEcuHBebUSF;(JG-JXKRv4y_os=X5%JOjnP|S{6@6IR_
zL0QA{06M1C0TPo{q0dx#E<UC%7HggG8#hX*{f?TBY(tP@PpSKT{-p=>LjVwkMH>F!
z@hyPL)2m7*T8cvrSq^dxWH{E6$`nj|c=Z$tVbQsk*on1POvF(S+9UAKJ}@dqm@vMC
zJwaXei;+><<JXfm+|*=Io;FdXQJMNavV(nNW?=hg`JopNR}olyr?dZ(GNK3|bS`|r
zDqS?vyPvH-Ed9u5KkJKt2miUyD#>Cq(TYgGbxMIr<MVP>N&6aUMT`T_cyT<hrxue#
z5(O=aw5!n$e*2Tjj7C7SUq9~aJ6~9RETUX{wuO|Z%APdkV$m2rI{FK`nq8M>+JeQi
zVJ9X-eO{E9Q?`}zd?R2v&eD{$#~|jf(CtI?vd>1w$@+{U;Y9cF*C2IAQp^vw;PI@9
z$Zt)#bhx|(9Am-_99z9j38-U9-S(yO$IB}vdy+e*4?U0MypA2_pQ4H2a~ZX?&r0r(
zA5mVdc>H-avx#|J>>HwE@}u?Aab0&%AP9ViLbaM9^eMQl_ES6BSVC?4!A~E!uknwD
zv;n>)e6vNL#Wx0RwjP;le<lRiK@-Q@I;ZQ8=&`sQ^>ONz*Ef&%=Emo+(J=zK`4O!c
zuA1bP-#w42XckX<xTw^s8y?X<ci+~!9i1oNuRoG&sbXRo4HOh)Q33(4Sug-vsz4NS
zR8jyI78c+pG%vfI8%QM@20$L>p0+MtT%3RN{{R^sPo7qb0s#OFGys6)FZN$YSy(m!
z50HTdX~?KSg6#S|vL1}Y5&jPVSt2o-JiurFVA3G4QdVTUB?<sQ^zWEN9v~g+Uxylb
zfK<S+>~S6-o8e!(Z;cLjW{`dIk@v>`w>~%+0D!*>mzQ^di>()@zpKlCy8Te;8`Xpa
zEz$iyw>5eH<+dSty2dM{`A?_-z>|M7pPj-Br2WV3|2uvZ|Bjj91#(~%vLOus{tIli
BzZU=i
diff --git a/data/antimicrobials.rda b/data/antimicrobials.rda
index bf21b3da32bb2b4d1f6e590cfb4584d058d0abb6..534c1b03a4284ad57cce10fae592e665e2f2255b 100644
GIT binary patch
literal 45376
zcmV(jK=!}=H+ooF0004LBHlIv03iV!0000G&sfakyZx~PT>vQ&2UJ%g<Ze>RpOV=m
z?~(SQxTJTDlT=umZ5D<bfey$^MK%`j^J7*ptY5?(5rTGz6xB*W0%j#Pe?5+ZSguq*
z7?a;A@xPd_ORX~dkA>DQi}8F}^{f-5e-l2luHGd4fx1@b&AO)u)W>!bt*Z$+EhsxN
zp<y8n2!)d@DU{G|qn|?e?MN;S2buKQ_>HxllZI@9l+S}^OgOjYWiZa&^WfcfV+Oo~
zcGUcg5NbftAKRzX$y+LwAvC`we`Ak9u5>KhPOxdd;oO9`5Q2Z?uR&FtxXWI9N9czw
zYg7hDpA<GlRnXUq_1Vzxge$D+`bWQm_)NgXP^X65uC|q;*>fWQlAqTf#_nH)o;x<J
zKGGzbZZp?Y<j(bG=2cepwMn@Q9)&~SEsP?IB_3}brM{;?6MH#iPx;hUrcZ~LJW^*j
zSIlaTsl+}#_Z2#8P@OY)`FGS|^>GxfRAxd7vdt7|5Z478B|TNpwlgnWjx2C?6mDk4
z%=n_zo-ndqT-%tc<EtY+1{9IW6b?7u@mQ7ChuwSEEeX!sbMJHcb=s_K`2Y!xS~K_a
zSUJ<Z_e!8w@)iZ4ot$=jV3#1@y4uWw(qqzrt6cn`;GOv0XWhTGr!q2}(-=&2q5M?H
z@LEh>t}*|aERyHkQOa$!;1PL>|D8V8NX%bZ&OV;KY2P{EqvUj8+<S3B7<&|!D+e%r
zKfpFMxcK(KW|rE>DoRHNze}Eyk4_C)3<&Lvh33k-Ljj@(-DwUn6J6x$;;~6RP<3yF
z6-vZhB*<54*u+7CP-2SoLlWhJN8l}-Awi&JtDYF2G=&3mX-7&f3T6#z;u?DUfY`M^
zpm0=V5mXV1HUYex|5=v12<Hl_8S7RdHd?N65?Ww<+y%Vz!9MZbE%?P1))|o)j1lSe
zpIPzx$CMJ%L<K0RjAIJRrSkT-`2^#~^`jZ^+#7~zvP3KG8RJl<j>BkIA!As}QyX8(
zLE99EUWGMg*9ii|(~*O8$;Hfd!Xhm67sNG35u^d~@kQd`ctTAtO{;Y?f3U3EGzar4
zF;JlU<|@EYS1Rp!+`mQK`;^@sKLCs}*1_c_8RGh_x?umQpVDevIhPBS-v-?1u|$rW
zMeP}P+u@8FGBa0yxnPq^cnIomKUMfUM+VD6{umSN;$E$s3_;(?Q9Tm%0HcdUekTJg
zi0I*V1WWSPX@WG+Z48X}&zMfnKGzo$>8R(!E_;5~N0CCPnaDR0t#JJoQP!$vF1UJS
z{3{;!(ynLM!b3XYs~r&3l0<EeC`&-d1<d8<m`|4RF_x)01&x#;_DsyI;wpuE943Wr
zBtdK@r4&{0r0S%#kEr}63c|p&<e#~uTgX7~Sx6@mW3_6I7?vuhkmw;B%81AJp;T<9
zEkS87cIYXz6Nne*|I9zRq3!b&$_g-hY*3xK1pl@~kg(p!)*X2B1Cehd>|9Gx_4?E^
zmqFRnbq09Y%WuC~)XLhUa6h7NE<RIg?otk2b+m&_O6!_h)`p?L?V7yr@qDSTx!#gY
zk~sI>CUSH*fFQzf=o9rtkB&jm;~Gv^66raO^JV%Rll@prQNfA)5$w%Vh40MRK1{Wl
z1X62dQ9JmQ0qu$6-DAM#px^-VS~`=ioownZ;qR|)2`Mk=Zh;Wr)C6M5W4>X09T8q0
zXe1*N+igsrsp$AP(sH{GXuAKk$d&&~Q3h_w{B_wp|E)$p$_gdb@)6ev_Ras%f9|jW
zb%#C^*s?QIi|=vNlr0GZXtfnyf<mGj_qN^rPlh}!M08!SZ|w=EV5@e`7ugLK#u5Vf
z@SJwPnhhY2p=JeB>vpm%M<E|bfu4FBDV;4N3_U1e<wp>TCsjp<FpIN`!p%4bf>KJT
zHhf{S-tNC+`Y#}X2JfNcRrC)rPd5}5hv4gTmi1nlVpH8S1S_57SL|ct>^}b}h>d|l
zPF_OY{P(#NJwk=zUU{#)qE=UHS};nAgSnpwcLyg$hFG$?O6)O}b+t!2*Yfu%Trxb1
z<HQJvO%aqWkCBGmluDBn5{GirZ}b&rSWb{Ry}prHx1i&x){kv&cC)BE%u3%Od)ruy
z*%n2MlJc0WMV>Rx#5Nnz^+W=db2Q@6|M=rF$gQ;B3{oWeN<`sgJP|kMiN#76<H~PC
zRZWtd-?z1Tww9)3MPV_VmVS7qkdaP&?{ej_p@0xD1_W>jqHU`$TGXktSBao_Jwf;7
zagr&)t-F*1BsU((8Vc6kf>j)UXcwkeZe(ea0uk2A^Of?A&GQA!byrI4;CU?NnC?Ev
zM3}_u(P8%g{Bm?r76L*(Db`{A^MSJ@D!Nv03w7eJ5YJ86Va>9bN1*EI4)U8l2Memj
zJSZrxK%rHIb~g5}QcMhW3T;}Nk*ejjA9m(=ZbPcD$aBtGvrr%S`CS>6G7#2xH^(`u
zA|G745LYIn1ql^T5F|jcD+!>G@o}{FiH7m2&q3=YrAuG^sbpK?cq7xz{W+MoYzu?1
zn9Cb5zHgv8qR4cL?MU%Uyx|E*uNuF&|LUsjbPt(idk+mtlJ>3J7^wv;Bi6w;#iA}<
zAum50hD8VWr_ahm<DGXqEPrI<=apdD^!P<FMsd|>=wZ5C9tt1gRbg^^2PFU{=6<Ak
zFNwah-sC}^zCtZ8#EdLyXGbe?&ReYQRas;5%5eS71Te!oOx{1UvP;Kn>mu;|RaicG
z2<1pq-KeaC&TX?MUfdy%HY}FIs$iI<ooSiS0z(JN3MUm%)~&p798h&iXH~$k6R_?R
z)I9c>0@X-rn-}+P?7~qjEOZXS{-B4S#Zgh69S^<Z!JNAjDGZM<x9cVFOwioXJ;qN;
zn#ejLyBp3^kFD}?KLI!T3svMYf9ZKd#g+~l5FJg}BFQ-5kB>u&a1P#N^~s0#cW%^f
zc)v+OyFmp1f)Pwlg(Eq}&PkK+&Oe+o7nDp<3uN{)HMi6vR5E@hEgu)U8K2B#&)JpI
z5kF8^pcs)RK6VSGSSvuUdcn5}3cM#18ga^1lw=n)RwtH~OaEBY_~Xv214mMzB(oAs
zOy<LVjsJPz)KLqb^i8$YFp)<gbDb7T%+O|wuUxuk6!MzZ4eZ!|W4={_l=1232#f{|
zzy4XA@-+{&j|LLJYq=FshnIc-pFLZ*T>@ihq73)!7r#xl<08~*3IyWj4Gm%3&;5|B
z*m5PQr<H&MN1V_={_Ggll8ceMNwEW#b99F4!4vS=fE}RsIjy6LWe5Jwj@Ln%#e`R<
ztpH}C%tXJMlcFjC#eji^nIiUAT{;HA&;OWLY2*Zs#owc!WH;OhUz)usm}j=jd0BgU
z0MS@{B^{xbD92CDb!Yi=A@vg%dXSjiR0W8)TMomA;^$bK;Q;o_AURN{0aBqG<1M=<
z0dI&W#8xJr7$mh17q%xQ&O0(DvbKi!Ds^tq6#an`EB*8F%du^xj-eQLGzzXlZ~&MV
zF<>20e`whS(2Cb=;<I1-LGqypkNT64(}U!Mb4{Vq2G8M=fO3S!WLHE8V&wm-e2AE$
ztgYsy?KM>ilMO=JRSv?NlFqyX94yTaywWNwW1_QR{40heK}?>sLlJPZGd%yeZvJ9G
zQIti$U+C@m%`Y(W_N@E#+;?|9UDe&SP>eNBDXjk8jNU35n;J%+;_xrdj*0p0K8pnN
zbXqtyW~G^>HECKl&zU8Y$SX+)OJ_a{pUB+z{flc>ZBv5O7W9q8U9li}B@drhis?*U
z8(C825^<uSI4Pw<o4#HvL$v9f_GbCn^Kh^3rTEhmO`;6i^YhywD$t_@n62=2Q*zS_
z5&cslRad!N;`I%x5>B=Dg0z!-xvQn<O4ePNWm9MY;T6+ymEH1B--qH08l&pIn~MWL
zi2h~i;}z`Fw2jbcpdJxGq?YFUnvqLtdXlvNf-vr0PTCFz(N+eT`&gqc@qtPkDlf35
zU;da6eV8k8F7a*ck7LJQ#<cO@J=%~0S#N@lE`bBRt+omQpVf~`xo4xA-4Fm{ztJSj
z8l1bHkZLg!f<DAIuID4+l)u<Q7JU|?N?5JRlu=<<3Ax+BgSYUPMHjK3?$$`X6XM;}
zD+~jgs*}!(#+>NgyS_y9;5q&|7S@=10d^UXZ;1**wjIL+q4`<x$nuz;BIvP(Rly<7
z5ub%$S~=rm@FBKUfZ32fyFhu!dc?t5FAP#UB}&Xf4Nq$)dHn2QK!LrvtgKlq&vtxb
z>oy1q)u!sZEpNL^vH46hHJ8J0V`+Qs(n^U%hSXO~ig$!qd41?1V5m1OD)7J`f{GaG
z=1G@MK(0DV7h3E+8+A!dw*{>b?|=S1U`Vq96%U%pRWb&lQgc9Dx@Hw91FU#K{K?xF
zAPGzbT*V*liB>oNh|9_2npb65>`PIEtYfh3&bbZ@ZzH%lImn9V^MWxjQEzFx98E<}
zR6wt)5tm3=H4_rQ@Qk7)!RbSk=-2wFeKDYHlGV>(klt^ud>0~Z^^w02G0{XDLwte;
zj7eTv0LV11$@q`?y@Jrms3+g%-~H~|my$apnb&bAiYt;d&UQU!8t9?=DCM-=zE5NM
zyf^$QcvT#I?(w?$EptLO+S4k#^2q^^;}0QPl?0`4Io}O5xYr<}&9+;JLW&S58;@9>
zF{6lYEjJI$#ycxMkjQH4Hjgo+E{v5pW>&iZEdj#vV4JGQ0&YuiCPQ^roWwv6L1jfp
z<p>WQHP2#LWAT;s&$0-oL5;TvcbQws7~Mrug_A8@Q^WeJ)SNeDJL9W{1WCD5Jv%$?
z;P}ZaRmljFOy$0%mMFQ|5KO)W3D6@-H?tMq5B!)_=i+upa%2Pp5dnP;feB<sXKoO6
zZ9TuQ6XWOC$`H&X)n^F)@M#JQO%#dn@VOKJ`f5^z66<k8JZwm0uyGbiit)4b$Gt?_
zl>|GT6M*r~d2w$0VWeg86+L;XT$&BW=)G8egQJ?o?6s@)5{fwXk)gd%j1j8Qv`B-V
zcH^cj{S-h+$3t4VkrPN2`>Y}T)sgCk*JFo$0SMwY3@dZ9z=8h~<gWO%#~tzl1gwAq
z2D+AR%|#+?YNI7tBeMC(&(NKDLPx2|c-2#3#IQk{_e6ba;&jMz40|3a(r?(Kih3iK
z8xm8nqgIe0`yAM#m9vOJnc-X%xgMe_bev|^vV`*M?PMcMvqwoAbk#YjoKpytLSuZC
za6Xg`Y*3vbQ5W2@nu5`IA))}r&<5NBNFQ%F62@7()er!tv4_Hv#Ob$Z;zaYVz+Sri
zNtyO#U1#dAfFulZMFhbA0kOcr1SoNX;@f17g^v4Y@L_;lzX3^qCZ;gQ84D0@4gKVg
z>ApV=kozQX$bSk~*H6!C&nErO{j<sEi#oNr9!6^>>ti)q2H^?G%Onj+h;MVty!Ut_
zFJ(H!`lXa+PtGQO$P}^{Me-J?CenEz!+{SsDuL@Q)0d1em(wxurbxm-!k+k_$3i*q
z07N*hU0V`9lDCAEz{8Qt1bQ6a_D><g>Cgs~4xXcFy*No%<SJX1>?@Rl$jX{2mY`?j
zs{5-j93phx&p$AZberT?{W{6NnKRFuO5z8MLR+L>TbNc7h%yJ>23y<F_I*q|I@SaZ
z*cH}5&ppB1iwdRm|FG!nznR%}MigP9?6dM@=3zg_9NIpbZ!V~eOcRy!ab=Y_rw1b)
z8ZX)<kk}I!StmPX!S_nTOCo}Q4PkEmYMsM~403>UE5Rv5HU^OAb@Or<{Y%&weC{+y
zE`x)xsrijV&xi!#n~S#+BO*bT`L?I4hd5Zk6?7n6jpC#$j`r%2%=}Diuh`v@p;a(%
zec5W**oL2k1kDMZamUF9P_>=^6@Y>u=HjB$$NS%!AqCp!F6jUY!$xEC0T|u?nrK4Y
z@S?>6`Th|F!;3x+Dx9dM)UZoFUfwsy^A-Q7Rm&XF%DkBPFh+ZMj<iEd4$c4JHULvS
zc+Qs_lQ*)xsCD_vr#%Fjuts6tN-zb|DYXbq_%Q06G^&{!ul)n5c;mVTxB!N-^J)Ve
zNdH3$l!9;u7lBX$H!u_$f5%j(0rdKuwf8rnQjXoWPRCf`&9%&Lkk8$qSak(J0?j}A
z5;+>n3&xI%7|V7M;~5b$x2+FfLB5rM4?l#qfaqf|p_KoIvw!GrFz-;#A)J{<^Ltjo
zE_3<}LQ`zoIOg`t6%APhCt|EXSgpq)=!;J33t|Ki_ZCx~->>RRkBWrVOIUKS9|uVv
zoijOeU$2PZJW$|%J1i>4LcI1Oa*uUjAF2l0Fv#1_$bTfWsuJ77FE@IxFMHw+S{$hO
z*i|KT(7o*kJX1iDLcTmkTruZ%bF&n7?Z*%nNB<zR_rw<^31s$3^8>wyuDrzM((`&G
z{2a)0nP~1q!A7U?be%lIx|ud7aJ!Ff>?WerJJqJ$g@eik=CQz?)CONH@+GR2XPvGh
zc#bqz3pB-tSo<oq9S6t@x~a!pTTun-bPySWG-N3!`)I*6rr$$q23|F48otly{-fj1
zj{Kecldp!2J9alJgT2Jbo8MsNW+kwV3iG(Ak-OF<1_BJWi@(v+)U@79Jw*BVSnph<
zS0RA+B&z9^Ja2_~q5eIXZ@ki|ZjdrRe%ny2(6&3tNki9LGo3vx<x_5;hC)#Nd^;t_
znXN^62NH^!WMAeC2flJ=YY!>Y&8E+UyieD_++p1;-WufV*1)8W=~9r^O~<cn&GXgE
z?L(=){&~0uTQDX87u@@Qho$aiYN(5Jgw5L*TFz$A8Ovr1x|}1AFFF=cl?R$gh5_A2
zEv|e8xk1lJ5r!H@w;cj_VLQ!4fW7T_n)PXjh%Cv1=t0qRFjkm4k_m2H3O<m^+K%ns
zMuI9RU;X_GdCLJZnSNvh-Q3{)GMFEVnI}NROT%iQa1zI9`sv<d8{vP!HGD@8dErxx
zfAj!9$_;5q)seQ-@*K4iU|Dzek@8GcLbPC#jN%>JLmpO8fLHa)k#>`6g)b8;?8unr
z^g|6mlU<YUQ{bn%f{9nFj{*HO%|yEwg}`_B3WKvx!uecG^)1i)SEQ`qnxKASnI%)+
zCe%q?m&X*MGFQ%Cu-lC2oD26Q<!Dela^|lzzJE{!zZ_@TI{Eqii5Db)i`v>?(es
z`B?1$MM%a*w)c$5rvLLt0TO{J&bxn}z!iUc&I{;3@ftv}S2L;n>31*et-3UBLJP=_
zq3#uz$NtqqZRMs!kXj<2E?DalGNNk-|7n627Z^v82Jtn7Gd%^p<bvWFQ1<{lANo26
z*}T{`oN2*^7Ay=lCXAkS5=YN6LiVe?ROq7o3ZXiFLJkyp;NnLPVmHL5*K#V8|3#I|
z$HE>;!L5lSZ4A!Gftp4I!n8vQb9Rd%c^U%;mPnbiy|b2Sa_V<)uwNPsG1BSO2?SvI
zf&l6ug-;S69N?Sh<?o<4wWusZR8cxiSJX)!FezNz!Ub&pO+c+g5?O_}$fLMmjbf<U
zecZT8Dc8;AL*-RF!UZgkN};0f;ukQ}<RhPwo+*V#6n{bXwA?=g>%GOATWERB9tR*a
z=qu68l{%=Y)ls-Ntd8>4;)Vtt<=!*>*B~?>EJPlJx1FMRsaRpyT2I2IRL3QjYffxK
zGv#r~OqrPF!`)`5B+XM$T~JF^UBbxolo6cTsk}VTYEP9g^qJ0&Hi41<eEXJuoQ0)I
z+gYcDQg=#=gx6Ky;W1gv+bUyrlFz0xZ6A&ttr9KFt>j4?J`CS74_p(G*p>36No3de
zY3XtL5ST_5W~eMq<;=2GaF{8;38ZSXeMY8qbb`VnIY@ZlP}pQwy|~!8w}^*>5c@pP
z>bFHmbkEcWba1-=geuqt&4dK>g2V)pfv=fViv0hVvC~+r!kcc5kA%O?b=5u_v?&e|
zQ@HOfmWB@d{FxM*9yyDigj4i6$~(2ExYq{DL(?!ID{Y(O`DYfJEG~%WX3IKEM5f@f
zzsnzlXy_*pE1n6X(nAd|fDG5{N#f7nwm|3#VePAFgG&YrVFI78pDY4cA1Ueo@n{lM
z_w6^zODlxU*qO1JZ@)ZG;ir`FfTAi%wS}&}{PJ)BK(2x~C_XZ&BLz|RcnJ$<4KJVW
z_ZqziBwgnZlr_}6Z*>=ZJNs)X@KerG^`E$}`$nYrcJJ7*AKmd4`pGJZHMyd!$HqAd
zbtW&NI9PtWl1u9~A}(8Cu?J=LaaD;1PR{fjt;NG##zY!0ukz>6v0)}7+9>qkG2Ik-
znTJ2!9q{lHv(i>R7Eql(YMD{|I7FOTaYCiomVCVfPuLmCa%-(2lzd<!9A_f-RkqSh
zjdD{^#%n-#D3ywnD;FaPl0zBpC%0koL>08Y0d_*5$ET%@$#ZE8-G;2o0aLmNy}x7Z
z+GbSAjcjR~sM^Juuy+=PjE@Nj?|62ytPoO5g`ME$fchwqZhKwZ6mTrMNn=dpMiss3
z2b%f>2o}cu;2R}!17jcclzu0)CsB6~=vsr^<(lhh?I+rA?y$F>Z{E|z%d+wS-5Sl+
z1(L^>`bx=IDZW*zIpUILcfyndtkBnVpcD8zUCyk?BejZ7siOZzyF3UEuHHJA7Z7po
zxs>PjR~nEYSt$P(5N84BeJ)_%1{JSKBI1P{;!5h1DaA5r<-tnMLms@%w#Kd<)OX#;
zod@P}Q=xp~SB@9P=1GEdq{N0nrhz6$AvA6g(Qj-^YC}H!!JP6UrrnQ}(r==re@WBa
z*eX@-&{C8c_rXO%8$fWMK3wrI<R`z9!r|!uDOxnY9uE({<%O;DrMO<5+<L?8k1k7$
z==>xdrc&0hC$c=vfn(HWVLJb75e`8yK@UnoWMlHUs`xH&1r{37{zJ|Vjrj#2WyF>D
zSbC|Q_Lte5Od!Z;RR&D$nCO=ROwb013B;Ky_5KdXqTHF4rDw(L17cH3{)=SScq^y#
zhM1c$e1Iw7#uGira=r+wcV=qq4(_3D)7p$w8AP#{I<xc#ok|!@m|K_aa7O3bumSsD
znZ}2XvgKRNT*{Om5xdf_W81T8-X#`Yk5%o2ZX1V6eyUYXnPR;Gia__}4tN29b`1qe
zGxBq3jkxDhz<N38%=BCzRv&}HXUWA?qe)APlCwr-=+u(q$)M^thcKh-AXN#ZY->mj
z_FtbdRE?}3)UH~cSat7-%RU?M_?tvdFOw9^NlKlmoY+&TDlfaHU#$I^I%fx*X$@`2
zj$6%Ftm5*o(zt3as_Q3&*YSQ(mJd-`gU?zPlsXny6OTf7?NowHf4P5LHr%^4pK1#v
zN6e@&4qFdw3GY<1!OOv!`=6MhA1?M@xJeM7MkNA{>*s{~!4IdEHeP#}{&-P(f7P&s
zSpV5Xl3vwysjqvu@@DItZ#v3mE6PAcNcbwJJjAwt#TB54phQg?6GMAJoR#k))9Y%D
zqwt;vTc67RnT;$vH1TnbCdN?xYp@2tv@6IJ{U;A<z202i2A&9tgXZi^qV^=VUACsO
zOmp5)gG?geKL@DULv+v;&XsD7tKA{&rQ8~X<O`IA1q?=lK0()r$Uj>ED0tYTP6u^a
z#Y)R61bC0<xR!Sw;V_c+NbMHeOybMip-}dtw0{a5QzUs@%`52%?cuzeX1l~J6Jy`?
zPmsGBnCbG0NaV6u3V`j?xL1h8SeHP^=F49txQOPhAaIv#$Y@OD8&luevzPFb=r)xE
zSJ|lVbF#&kpsekiWU|lk`=JxxS#8<js_UT|C$23qqz~R3%{mR@m>cM>;QzxjQrr}(
zR(JMWePX7-Lo)d7?bPKY)-0x8t#{?k!xSNg*5}5RIKzh?sWFCMxa1_QVmCNYP>B+V
zflnOhMUU>t11){^fa?0ZIvi-*|66d=cw{OWjZ$7he8xDjn%>b2E$2(p)f6a%dpC<#
znJBzf7o0LEPrlqgHR*$mj1UO7>j-!b9S)A<TOu)xWaQ^wE+i2~aOYOAt`qj!i7=}L
zroER0vD)jKyahL!1c)+HzG^F3YY0WI+*M<`I`CVhEM8c5la5O%bkyh)EC_Iy*b~yy
zt6M3u3uh3bAE?#r={bEIdSq}t>-+Kq#x*WcCidr4@cf>AM~*Yd5QoJ^YR$^B=VgPZ
z{WkC9u!vcr1;)8o3z8qi(5O6i*T-xSGVz5w=WI>TA2p#JtC@vU@V&2B#{)w?s*kJa
zp+=iXbl<SBnMk0mV(|3qM^0XQRU+vWL9YGi=aGHG9g371$?4_$54|$OLlxGNkkhsi
zOK?lBa;IbR7dYd+ob4<Rz9@eIB6+a8djlPBjy90k7)j7$6n!u^M{UP1+p&ZMuQLp3
zbnW98QZ1!(laP9?ZM_)*w67~GaF}EY(dN@+B;M=c5Xwhpr!NHZk|&ky<gIgGjvg|0
zAW(;q-oGfW|3E7cEaT<t6GwT^^*QrADqe(%R>FL)|0@%%$EnT-#Pd|MetgN2t86BJ
ziwy|r@6yG0717cxSg&0DLct~Oyiy;n9fg$9v_=}wh%0cpyjwpCn`EQ!^pnQ5$Kc;{
za%(@-!NPmx>Pw$yOR8pii&I6tEhh<+vW^YFAZ56>j(Fs7u=9z`siHX(m?+@#2pJwQ
z=^s#VODZrp98J9JgjcZ9>X|M;5-U8hG~+%5+uA$)RGyDSEouY(gN?lI-7=b!S}=Q^
zMla!4{zvztNi;gYcCS|p!B{!fP!aHM8b+8hGnYGvRkw<3(Y2C>iFDy}fLllNaykU6
zl7Cyx92)mL_+zN)mY>yPv;dRBm)(g<xv7dy$i!`ybM(SXQLiXzJ;SWkbK^VjJ+K17
zcoJ_?FwTdxSLPap2($Y(ZW-9y-8t1yL-tQ$W&iS`pO$V@4r-le^iBXygD>(<NFn`H
zK&Y)?edT^3;@s=NlYB_I$^P762{|wEeYxkkc{81N+_#I^{yH^|aE=2uUW6}Rb&N)X
zE9Byjp5#vE=o|6Bd%XU}jZUZ6xMaoJ@h|$p;Ck#d{o2o|7;?d_QO^~{n#0*OCE}np
zcv@#k%)D?5YGM*y4YoNyue%#&XS9#3%`NI)cjJ@7-d_?7j%eI*kX6$w-F>e+RNL00
zVh|pKi&mJ7-+Z%T?%@ympEZGKKkZ@Har2kBcRYES__Q$EKs&7eo^Uu(>V@koOkdI&
zk`OStkwc1h^qd`sUhqVse$2B3aj??Jc~5KR&(m;`0dzBZ0;eb*)k0d&Sda?!_pJ9a
z$LSFXE6gW4fg}uTK@*qQEpummv#oo$yTygr2QYzR$^MMexH@e&LShF(Vvo<F;8A}Q
z$Al(fM6A?Nb^kLHEz@+_0Q2}bPChISD()zlYjo%&Q~eY3YT!%oPC9<Ye5JAT9LfNH
z-#f+ROLe`ro9oViJjB`r8#0qy*8}1f5D??xTf7(R_flKI&(F<``b=lFFKG)qk_499
zU@^`5^q}y^gt`IMSJh&6jB~>6u}O-ocYwm&oLW6qz?6*ZSs9~`BTxWF!qy4#)n;5H
zG9q*LqyY>5wCmS$H-n|MkCp_N3ZQ5yq$E)(tZfa5-0g9v$X)}1HqIB8i7<a)V-Lzf
z@FGzUS)kvu;=5HC!3*%^nqU(}Q8QH1YCkvzrG5};&Mbhm>ogAPm5T}2Eqwq{iwm)v
zaMVaa>?+!QfYr)!D}+LTUz}_XSa73Q1=02tvv`v;-G-inqu)@X!3}7lsO0W^VAc|%
zOPr>!I1<s2A0M9a#7K)yzRh`|n<#400vhwY@KCxT*&Jfh=AD7-2BAucl|p^VCOjF!
zFdO1KCsndxii?D0U!)riLv6dt?8cMQjYq$?f}<FqeJp}%udx4Lrsu+D2kO={UmcPG
zsM)X^zg<3zu0^an+oSq_knCzO5S90^8TCCS>Bcz>D~b_yB2~6MYc*WhU{rk+vknf2
zyzdM?@^lgxsbT9&6TZc6w^)Pv>CEELG+vU$RP|{*$;laRG+Z>!)$cc{=WJM4X!ZRH
zUv#s*b*{DH(V}7QeLwH%67nw-Jh3=|1%MWqdGAj<%S*30P!0ym&P6b;0?PA9DI*H1
zq2K)QIQxdUiZ#vwm3$*Jd3#H4XaGJ8%v6vWY7#+{f(aB*9Dn8#<-?qEbOcQ(!+l0!
zvzc%K0Kd{1_D&r2)l#8rxv*~RAOX9jEBiQLMVII3$60mp`;nUv>emz3CJGJNY<IKA
zie%Fv7pK*vp-Ym*2v=T8E$~)!r2uSn6u8a?=Hd#<5^u>2b*PtIjMl>Ij^IW99Q{ho
z7V~l)AE;Zf{j(FU2fvvl@*}$)c|72#4q{fsU+qV7)#lwI#OJqyg2o5BHvYaOAg~@i
zN>0FuK85w=@mz!bcTd@sm{;^;6=d-?T83k)VI*^L(0pZD3_iBPmHw(jt2iSMnrGCI
z08ata9R8|=v1DpPZ3)FwZLyfy0&yI5d6p(+bN|x5UZE`ai|d<}1k+BG^X8mXD*q=1
zh<Y5|aU3`ntA^=P9xhis!GN#Ngck>6Z<Sv-KPg*zqhGB9U7rlfuE&3ZcV}h^-C(^#
zMQ{8=#~gRK{;rcFUXh+ZmXXkU+P9YV8<Khy!$cE{lX8FEAq63>Jl1PIRW$NHj|<Pt
znmR(>Rba^-MC;OQSpK>wG9_DoSeHw{+!?NSW6W(#F%<%a1vaWSEOeFD3Oea=VV7p^
zx%d}nXi$+F81g6$)ktIW8N45tL<!QpZEJHi`rEg$!2yxHrQO_(gUMaSQk;PSXO|Ot
z<ajVD0%1{cvTh_?f$6Ol2@VZw4vofYw_t=Edc6s~iM_SFIBD*I3T%B|i-rl5bdEF0
zB;{d|{)fEoiqxg1hPmH#sOECPU7r11VXz{HqTQaz45&-3+utc6J9i;Eq2;EbG1i@i
zUDNRuD78WB!*(!<FsO}c*7K5WL`QTDi6^;Lyy%G&+|Ioi_Pm_5qu4)mAu8>?ve*A%
zT9gyyuZ6+=ck^hvrqC3M$?GL>9Ya%nCA!><t4>Q2<*HwCTWoep$U=+iOh#O48h3w9
z{lmQ{=Hx0YeIeb&Up}eiQ4#K%bY~#TSKhh18W*WUl|H;S8JP4m%#K#HkYUt6Z@VM9
zbB)aPVP1KM2>YS>BryYa$!e5rI4a(w+wE}0!$hrf&4b3=9S^Z3Xw7+n=}z{hMNp4>
zxMsr}lT#>bi&-tZb7Hl3-I2bWyYI{^^9cDLlG2YA1zWg$iUvb-eaQ4pjj8}7N!}`&
z!sH-LC~wN1qu_71StYkOpKA<JR@Z~tDSZ_EQxXoobBGGzxunHF3Pa54{DvgbL}&`w
zsPpfc4zww^5-iEO=<WHYadNBW^gl{q$f~#*AvQejs`M__G}`}XjB5)I6W{1S9pF>o
z(r{g9y`vAm4)E_QZZ-}nc6xw~58Il3^HVYec&y!T<<z`~+><q_9BvQN_2%1lg=ZNN
zzGd(kEg##sx~;_UKG_ia`jtu3Qc6R0M_Wo}>$oR+m!QbC!_Hv`NdTW9yB3r0Wt{A@
zFl=y(-}jAR<fO`|IO2~R%@a)tMHBv1UC+`yJ8F}yBv#q6+roODe)kNUUii%hDvY`o
z{X8blR;#&+@$&+V)|18Re5hZCl-!FVt3wKYaDA+;Yp*W1qDuu>yd!IVm%8K52g&CH
za)1=)7|do4BDY?XH3nLfx|yxrh$#K~WChOhrJMsxr;CpKv+a%0k;NVA>F78gq<o-d
zA*WgZToF?`3e2QgY&U<xlBCx|RQ!u+S~rm51avEDbSL#}13yht2_$e8*~+M(HTpue
zQEHe`l_q^Q;|&c;%~}@3^;?Kh0uYr_vG$G-pp6`c?794W%;;y{9uFK}C~RRNKW*0c
zNI?qtF9BtS<x8yTelbgKigC)oG5)E{Z<N6k3?MrC#?T0!u<3FclhD0-966K4#(6hp
zEy0v7;n`Wt|NYv%e!M0_1D!c>ZF~M)jak5V9s11Wgb>_itq31hAi0PKj1p>D1EaBe
zp0&ol52JGAx8+l3_YBlVl1zyC?&8o^IP>wJd(a1WW>K!obz9%V|LMfnZnuugF;07)
z&<<ST18pNsvQM$Zzjs88ThY+1lYJd*Fa_>=K5AN_iK%5o6t#yi;tFGWLFnT^4CNRS
zB^$9UL3U-@kZr|lhxXjrK~Zu2TV#GlR^|&!1I2k-_}3mjVe+iPaxle3eu!c&pp((}
zY)D$?@K9jq!qkZQxUSGm--B$Fh3?uAf9FqW)Am{%eH@gCbEK6s^3bgy*_0-<=)aNm
zXx<BEM$25m+Dv;ZJV4}_cQOkg#QSv41zdT(6RQ5FpJbCmb&0iNp>eg#?$GBDB<4Ta
zhB2qLe1j!!rZ4uCe1hLzrI_Lx4q6`6>Q!1}`AW!9+0HCycx~MJ;;1uEy8uCOp-8XY
z>B-ORrB=Lqn5KlQuVpC}7_=MixF4#P%`D{tPK{1-Qj6mis93x}%@z^$;amjs@jkAf
zY&6b3h#YabzVvL5oAZ;(_P9>o*UkbY*i52fa6NNf&>A>i0;?fgRyJwPq-5nGF%}+@
zN@7%xR?0J(WK-Ndi_aKMK42UqdA1s^vvYQ(-F;a_D*nVaHcyoO@zk}i(8IIf!u6OA
zYX;SjATTR#TF34LB8+x}kGGm1Oup<nRI#5YhW;j$ZO+qDR6>9c5mr@wO>QQyx>)*o
zM7n-D?$?-a{d4{UlM>^!`Vlw>M4Vz(6WhqU{Lc{#5)_q4NR&5~hVu0APm=+N_vQ$J
zNgGD@KxWQKPJ6BWd;mz`>$ReMrt!UMu?~Yj7Hq&7n4B5K$7Pl8z@TQpZW1;;%?TsC
zCLy?y9weNgb<^Nx(FE$L*$H)0QLN;-Pv71!AxXmI{HJUc3F6&YpZeM~gP|$rg!s^P
z&jAWoHq<tihURMFvIGli$_MVQd1&<DwJmruM9RR#U1bI#o@+jpWBQ0sF&*;uPP7E^
zsv)Bw+1NyAgA`8p!@iV`18_j79;Y1r*D$*)l^<fJw1<lnRlJZhIc+3x&IRvbh9rSb
zNN6Vt=E_&6kz)B?fmzPPUe1y-?=gg%-NBdzmml_&7(%tFP$9v?>kqxi5OCVud2Uo#
z!iUb%ecxfL=X8Bi)Kqz=x^d%V$<}C1@&GV4z8%mNS$?dRiGv2MC%(`7!zDEZVvahq
zH{pjCk6&sY!~Dz@F3=#a&G*!#TH46>ZF3DEV;odAUe1K{HSIA=!3@Uth?WZ-*FXtw
zJ^1DNBlINwAEv_Zm5=7Diezgt8a3+4s^`P?m2I|wd5TQfTLxSI&33OWoR?L?2?zlg
z{Di_u7h8IF1I~(hxk4Ha8U9VI@27gk9iCr>v*86$=x(WXqp>qa^BR@FL<K#Sy)NjO
z>V{=y?n%k{Y<d3k_ts>B3Q{>qRN9dS_B`pKSJEKbjX3dDNl>$+u5g8v5y|pAN$Wr}
z*jU-*0!mAfLBjSw0!@hUg1b=pt?9po^8u<iRQXVk!bmFXa&E6M=YfV;E}X`e+=#FJ
zl7;ee+AC8Sjqw}N48g_#O-*r0bO=lg-KaN~PXfIr*f!R>Jh7<V^8_pB8*zzZq_eg1
zp<YbS^zev!u^<uqvJy$EQN+)0``0#+P-J0xJAT%B@{i~xmEqAKuFANs(a<hO(u`9=
zz5;D(Y6}R3LMq@qjo<xDw*s!Iy<OUHn`Hq$kuU}(m6K&uO`!d8VJk|97S4K@Ign=2
zaKmmg$N2ubFbmV(futwQvOge$`emY$ZHIAxU+}#*$CtME1`BFlk-RXR^c4TrGu<vs
z3bORR8x8F)=o#yYOY1NpDdNwL?+=O<j&)2am>l)NvAnv3M!&C~yjw)IGk^r_x}r7q
z7Xpd_p5YC@z%hhEB3sf6*>Il9a}~?%hQY@w$7>}MK*yw7p6sKWpX?G_n|C)*T(gqQ
z2Z0b~K_MZDTsOw6z)_LbQRxM<dvWUf<uE^4AxWVMs#-O+N1{gKe)|rr)q<%TEmY7-
zM1TWZnjBVM&j+Xwo1LBUr5ssc8$a$QOd@;{GFRMOVZ*6!ci7ByZK#aUCKQwL1jN%U
zoco+YzUR_&7-}LOrz}VD$ns|28~h}h^5(6G2b6>G|FAZNS8Nf8a8G&AM_~+(q=tzB
z4SDjHHiUP}>j_FU7y!Ca1;U`R7IB*pSE^(y`1}&*#1E;#!Vwu%C9=VCGrbPxOb6(C
zl7S*Kc`^9ZW!j=b!Dn1)t_??17=f|>jdNpvg*sHICZ$O#Wb_gbOSv_!C=fgR_gh**
zZxt&$b#;W3i<qiVI>DM9p6PWI)0`axjK@g#kpmX*4EfP~;v%X}y;O5<SmLkmzG#9A
zlU)_7TIoiT9|O(U2n5}Dc&_9`e7^}tVty}Yw(19GRLB~Zb_0*fj#^mCsSCNk!<_-R
z<CYeYik~~Ypf`1jRpY0mx0A3xO-mZnJ0^|*(B-({R`r9W|K0CU5HfSt=;06+4%#&D
zcQJo?hT{8Pae=pEDZ1rvmJQ{=@?roz7*k?O?R!Gqny6zRT5`@o98Bp|%LEm4!&n2j
zh0b<OrDytWhm|yde)VSQ5vNPwkAGaPuK!v^iy@KF`lODwq1~f^atJoifFdkrMu2!t
z#lHO13hKdDHE?;}o7S*rzs)z{DOe-oi%T#6JlyS>blAaFTtlaFIW@Rv5SJOU9}UEv
zd7O{f$|bs8LhN*1Kw%<=5=t<w0O8tCkL&5*U4p_E(VMol=P@@-@+R=+j=OX{nInks
zj_k+)lB<zR38}Ao3Fk4x>B<7AZ6%t1`V?!K&y`Z*R&+}Iz`+8^xI3wFHmtPW9Xx0G
zrZ?-MnTYw}<PgRmBTPhl0!{jcf6qv{csL{otMa3qv8?%FpN7ojB$0kIVeEpV9IMa7
ztAqk-Vc+AILbodP%P#U0xAYD!!DYC&4wcDTI2&znc<El9q+;_EeB6uzs$J0x<?JCY
zCjj?Wyic;Jb~xu)zISuJ)|kt-Q+j%Yo7!cL?ymJWki?eE$ni<CvP?_B(zBSL^KE1R
z7c1d@RN*vXv7@^<{rXh@W%xwZn=78pO5yj{s&b@8)SjA{-Tl~r7~{XoJa|lZh^3BF
zL|&-f`(_Z^3WD{BR4+#sG8yK)sT&m@Y^u?s&TE{n)}y!!-Yi6-grhY$pLsIzqPjsX
zT;#WjC|n)B>G=@ffo>&m2;RTT>c)LJBfaqSVAO=1)Dfl$Bia@*P-!=C25bvFk7|Ce
zW~hqo<!?r&mqVqWi*Ue57E2Qy{-yBWv{uuwhl|yl0J%oA4B}O-_;*xoI#t#?{o^-A
zI_pIaeMPvYXYeDZPuX#`2YU7Zsj#&N;BOA+39K=D(THeu<^C&5)&onNr_n)22){i7
ztwWCP(1X-YWdhMFnXDSc7QK?WXLwRy0VZyAA8)a=D}HbE*M{lxjqj<=Sd=273ME4G
zm5AN}%p_z1L~2m78ERClz4}^(zao6xf(KVFMGFi;meap3OX&sb!2E_5ft)j-2#Egd
z)x2RPM0Pkcx2$ae8opCFBh+jFbnxLb`+%cB<0_L@PK)IdgS1jLf?FHhHJhJ%rKXHY
z*zG*eVXf2wxHnUJ!drT2i|H<H$*RNeMv=CaMpLKj>=MuAsL23Q;E_ENRpbkCB4u$X
zifk^Tvm>vmRIWh+!LBYJ98-*VtakbzL-Wiq!={L!&E&-219N?#pwQbBRBr)ADuGg#
zXA3xk#a?lMoJhtj+W<_ZLDRI@_v}j$ys`zFU6>p3rg7@>5JPEvE=B8_l@7+kK8c#i
z{<sQ$M&ZUWi)M5_2Akl{LUU`~IFi4^$OU0Hthut%@dNL~)*D&=Ueu`K8glyXkd1YG
zfsSf+XVzkN=2dV!z1MELT?kmXzJm|TP(=+lL=!7$q{Gn>9JxywMF~6=VuRZxI<u1A
z?6llj40_LIsBkxDZ|h@d28bm<o(7&Q=QL2)4ly7qQMKYBQdMMvJBKJqsqI989s+Zb
z1Ml|>%Y<RxrnBu~*ue<Ak%xw3Cp#H81En~$uL>w&tqDN#S(RIW3$FpZhe?fdXQ?l+
zoFH^|y6~8Y=+a4j*j0Qb!J9}I>qw%^Ww-Q~qeXHS1~=P;b&JSq5H+wb<r*dkK|Fo9
zj!F%%tuu_<=#VSzij=D`<Z!_YGj<C*TDZEAqB8{O4GM=Tr^AJcG);1E4u8gu5t0>Q
zn`~-my+ZK;>vO}@VkCC%12ZESL-_`PY9s1>#XB&l*IqRvb2R#n9zA7S3pAe2k4|?%
z64VFy$ezXKj5#H-*9Kj5lZ}4t>zv)9#e%5I+4&;ecKH_=zH0G7_muh6Ig1eU=wUeT
znD85XtTsz-mv}W|<+_r-?9B5N7Pq;82OC0Uz^Q>YD15;pf_>_k$oj%AH!E(em(2l2
zc?Z1QtA9%I2c@Mp+^-R<UMo|pMLo2js302^xy}L#NCOehJvJl5T|Ey2--vI!Xy_Fe
z6uw89dq8OoukldbsClnX*BcSFrJVm7=k%#6)Lh}b|9+&<+H8L&q6I>yv7&gwbevXq
zYiddSIf4Ced2kj<xuKaHKG;kE`>bQN`j=gOp?%F81QcXoXF=`ub+dke7~afrpsS4W
zfo{sT_2PoYhY1aST>Jc_`m}~(xy~?L1eC-mK=Raa*$H9|gJrq!rEVe2Z?pXYKRFe*
zvrPtk-kmuk=@`bqZ3407?8O`D!GJyjOT81qm)>XGz6b(-o0x08Bj;xBY@*RC52OU2
z<w<z-91A3)&L%t6gN?vhjBeCw>|Mv_?;uF@*z8=^(#TrI(9eNVwYH(IXN4K?Yom^s
zC-IY^KOr%s(Nq#Fv-uRST=O+M@Km~4z}aOx--Rw{tc(f^m6`&&!4P1<^smvGBWIG7
zgHCFV>|zj!**1V(E)LPcs50B^_LmEs4%Z8t7@l543tpz9=%$@7XNw~OHq|$mP4*o8
z>lJlZ_;(?53%_+qD6uemCC`$W21A_q6`dJTXx>Hln`vT_P-)5lk%@d-SYcwqVgDY@
zAV_ywVy|Oti?Qi3rseX4A9v4BibUS7N`!M$09<UR<%A}nXNS=j#-+2|>jOGkvPZfl
zR9F$~FJJ()9h-#_zJ`W)f-m2BtA(EyQw_=hd#sn(vOs!e)}2nuHG#l5bckxP30h&E
zIp8qH(HrCml!U+oVfQ6S??sy>tx*lR%K?=rK{2iQJ`e7w|1hR8F4Z->__$pDy3fL_
zvV2H-ESr%VdZ&amq%)Qb6C6x1L(UwQVjiNSzSMp7o7~|t*yYT)hJGDuy<T$|6gO-T
zd`YvLMaWQg<B!X|aQA3%7?YI4b)`t%kN)GV>2`I<M&tIzvM0$p3oUWT{_^sA6}Y1a
zSZ>i);v&I=QDc<xFTKXbo1>>Zt{gB{X&}C^!?eCrWXrSYf`P)n*54g6ud~9ydI8>f
z12K#Iy5;KgsoX_b)~>5ZQxS2T-cXCmEMnlGP6tsD{SFKP!)HOu-$D9v4F<9xtCq5c
z2`l~_P_tCE`+-N^syFvGSJFgBK-Dd<XsA1$PMiRtOu3u;ALbt+fN3MW?+|CQp+IeF
z=8ukkn$%kQ@MBJsti+V`<Kf4`1k<~W!${*iH)J}y{{_CDBRoN=yYD5j+5L`|#%C=u
zo2g4@jkEt9Fu-!2B`%ynwT6`kBm-g@ZKpviv35$gCGGX?vZb32cu8KQ_LdlB3b9@R
zlOEUTbSItueIP>k9yPchr0_eBi?Eri)~H;)yr()$87UE`^yE6ShkQ2#{G7>1^;U>t
zj?V9Se&Q5--(Jg$eckCKJ{3_nuo#sdJD9iwK13FEw^rA*ODNV0#IlgL7lNw}_Ci7B
zuk`3j%P;MI+FBFZeM--u=_wOOHJv|O;C)NB{zfyvfKs+EBK-C*X@rs4;STR>S%IOu
zbf?+Y(Q!!XXHr_Y$@Tn5DxNz(5sFj>VL!H_Z~y2JQD9;6ZWJ+B{lpW!5#E}PQ})T0
z0<<+ZeF!Mgx9ikeH3p)4j;TGfORcSl)3T}XoTpMij-uV@c3eSa=D?6g!@rIh6p=oR
zDK2}o^56;>A8xw(r=K~+*oiYhq^Imb+iSss>lbbP*(;;aHDuC%X{s1yS61$qQ3^_)
z%0eHO7pN!&Obxys!GPz;I=hlVY}?kn9$OZn%N3%N#s-`#$qx4dG%C6~xn66I4|)Go
zc0jKd&=xfyL?XSh*_D(y%K=~|RW~)ioB}$L)+@e}YPyG8RP4X%si(tju@TqVHd3$Z
zGh!>dfT4<hMJmFhnRGBldL8-(Sp(n2+)^5CvfQM4>S0w)Bx7=`e4SYVe&Uv`d=h+q
z3EXj3TMPJaRQ~Gs1^;(giu_qPuluPLLR#Ye7KZSLM0VZ`AZjYLFsw~gh8m;uA8~I+
zaCxI664-0_>t_QwO`u>#UA$-R<aXX+WmqcpLIHo1VUD?B%p^bY(N|sdVKf`nO)WJ`
z_o+g}5vi?Q)vJ)0g(h*}e^~88Oc(bOYw(MsbyWw8tBvbD3pih-0<oOS!Zf4+M3GQk
zGE6hQE)c+f_jF2omc&IO8C)PXu~JN4^GXO%{W}iYxuA5yTjkS~hS2-E*jZ)Pp9s@|
zhl`s3tA@+kSNm4{>HK79TUv(-GC0>K7bZ!vI0N8hc*>tTLHC)Clgoxee^4Wpyna~O
zNq-1czFHegzrAk|IVDc7r=s!n9|v;gdR^Ah<z5Ry)rLVlg13jWYOPjZm*DCY9V+WV
zR+cb4;G^7m9rGcJ(&w$ag}X$#M;a*e<7t{vitqn7WIM}adp~`5J;k+Z&sSgK|6>2l
z_fTtU*;z+qw^Sz8hdrwS^cL!8{FLO#xHww3z1wKI)xi^w%;y||q_#q>HgPv9{ve7a
z&(me@&=4yFw|uIgTJpU@=iEI3LB!3&;RUu02Cg`DEa;@sN4w6))j*jy^Y)on>TOlA
zX6UNQa!aiV8@3sX24_y01DTXN+sL?^9Tc+9r>*k%Vuv%^x8FiXc2xm})e{GJ<4+11
zUzmEG2W(7p5b@<qZmiGfYa#ciT=pP(B=O42IFdF3dV(?aR(K&<;4}k+3i0v@0yR@|
zcC%tgWADKWu!{wg9W~{9fGTeNk1AbZw&rW?;TDlB@Oao<<;jB|vJ4i5DP*TVA$k|7
zpSh-c*80uPcN~x2lX!f$#-PCCTWrhr+497-OqNbbsqUJt7u#J?sI?dxGdsqho&I=0
zH%ZlH=K*B2$UG_J0$U44lz&o1uA_*z3{8ERuH<z{j-fRl6~o;^J=DCIukE$kdZL>B
z8&x`S?Xi$NnfrkIIA*UVv+)4<KT7P>p0lBv7=sz+;oh@1H)!ykB=#2J;81Z|Lbr;5
zzH`Tl>+5zogAHA~{lVWl&36el&wMb{50(b!!=L{p0ENr*E8PN1iZW+CZHhumOP9xZ
z(d8MDm1`7;uTOEWltEfRhQH+yeosN4usvocc}-AiTSqBU3+cRm?KpmVB4=s!m(F=?
zAj?pM<Cb+MT|sw@@qI{%{Dur4JWBYY0$1aqP>Tr<l4GkQ6W59am@hY>Y5nt00-ck{
zHb=-dRezwqPne0Yg>)sdq11uHT?5uB+79KurI!{no(_4`7dPhcYtnm`oUby;e#he+
zl>GF5H~Eb(sz{!@>5K=KD6CQDv)(@#p>sOg*(!y)&q$B3*Q${WEfl<7SHLfDXlUJ?
ztqH3f)ymXZE5$U&a7hzw4!|?O05d?$zu@q<jf#!*t$sFMF&~yJMC%j=9@>#A>W1C!
z?T?%p&33$8dYrOche38C?@sUmJ5cACj|`HPeO|n&_{Duhx@izVDA{tzrkxKY2kg=(
z7cyq9tw<zhUX}_<m!wfe5pRPYj$L{djyH7^OC)@fJB0h`eaxIRXQ}L#_XIZ+%(0ca
zKy$weGXHMbAMwmLwZfu3vG(EJ6<mM#q9teHW!bkyUdyuYEL(=TzV2DP%7(?Yyp|B{
zJRl1VQ|F0R2(}3fZ=OfO{;I0VsU_lGy^Tq#{^4#i+Umq$3TlBz*>5F{+7r9|Bgd74
zs(n?@4fBHPV9!@}9P|BTVvJie+bbAS(zgJt1WpJYN8}cQzs*UrhHTK)rSxA+L%6li
z081tu&XRgOYwV;lvNIi<Y0j)wpP$m``!3D08>evAD~;H~FD+(7*Ss_?1BTqfM&a!l
zmN$)OM(+Hal@MKK6$%?@S(DAp^0DYao@&1tdYUncjJ(fX-s_-+f@!XJqTrBadT~CV
zq~m?J6PQfXNhI$+_<6ra)s1@gL4?aS|LRI<Efn(BJ+h&Lw^pfmhA3r&k4^^zzxU6s
z0+w<iDKq>%1@)Zc#}>O6D(}^phkk$i{(|FG($x=s=9~+2y6`c%GjmLaVF$wPbu!R)
z4p?V9B4oO*wBHqs$?vRBmZ35~VQn&x26Ni83Rq8WwKjk{TTzs$PyoY;{7%LDN1uta
zrMV|{IRE)bLP`i)h_{X_691dncb<qyWtL#xp+PduWU%-`24<whZu2hWhk^@L<xS$_
z#N%}f2jUR3>ZI&?54ijj05X~vgvN%RdP!SNDes)79?|2;Ew+bKUc=u`nxqW+_o|5+
z5yViPOr>LxyUZ2WZ4%jk&r3Pd!BsHYFWPCO|AfY3<&-g?Xre8p0ob|ZB%Bt7wAtmi
zbi>`e6YOanqUMB@ABinQFVqFitI>+&Mjv)}E>r7&xLf1OTA?}|+q+V|0<r7$`CMTG
znOwdml0u`vb(Yj2QzvWRXZ+|KxqyL^_l%cVawr<Q*?`Pb*nxQ`{oJ3)XG;$pp<;fm
z+{+z61+;vb8+CG@9q^L240nX<nIjmw#FrRi^zM!9k1m`3Q{_4P*~~r&x?)=1z0mGx
zp4ChC(9TWoV;*F5=@=3BByh)1Yf!{bh%@@n@@M2&SrOc>2syiADLc>SkV18XROGP(
zF!chfQEYkg1ir&XqoW1NDT+c7zJH!05A)Yck_&vg2&9Avxh7GaoZt)uve^Ma$LWJK
zI8b<&JrsY?*yhXG>q9VmMua6+Vlx_0%)HI|s#<~QgsFw%{#1{)^UA?dv{!%rm{rQ^
z!(FbeL}A{ufm7y^x{%xqwUk=i$5@KI0Xh2r9OK`X2b9c-@5uPoP@Tj4rGrJojUXpr
zZMA-JPN!N4*D!&cIyAa)-HzRYMAf22mwlouj4>rQz-%%+y~XJyu^;qnf`zS7kZ^_F
z5qsktcfR1aFl7f$BXHr?O=i`hhmydFF-0|l!$Sye=dAHJSPEfFn%WZ$HYHk3T1ALc
zp|F`wj?wtcK=w27lQ4+*3{M4TX#YqPN7S2tQtg<T=tY;Cqn(Uird8iQ*ZA<2oT`m8
zC>{0Rhz$-=d+nCZ#r0)s8O~=}m^qJ=0jLl)k+J|96${n@$g!MsM?(-nGK1hc4}K>(
zoyMA+k##}Pb+R3$-aGV2w~(E%ERQsEbv{#KcR-d<(OH!X%ba}0VBg!3&&_oufHRQl
zz^&yAfrd2W){m=ts$;1Th_;|scSh5?;=mw_OYrAXb$U3u`FRioXE43(w#WZ4OT76E
z?qn&X-R*=*>G@#hU2DE^g|YhlVvm6*6ZB&uY);b%)K9N36qYF|E)XrWDYQFj@B}l{
zsMH>zZ63?7?~Y@fgxJrc|7q#67Y$ZnDC&$=2fYP{OQ=7loxOsTze&Civ41_Lv_*2l
zDzYYJju=FR;>Ho#4Bf*cD%9g%6SX0%8Wg`FnIOz*;cQXNXc21D6D$JnDf|6QPp?Y6
zf#<9*3|`v$kSw>5Au?J>(Bn%rw5q0}48c=(r||KkT!G|a8B#}<jU_Lx+t8Y5Hw^lC
zI%3RZFSf^BdNK`Cv|WJ^=GsopjUXKyC}lVmBw`(@6f0^TTK2;wNx-;D&3Q4VAqHJs
zlqku2u#_}OUHJ+lO#Qug-bIkXTV34@KV#Y^O_dggu-txJpD;K58}`P)9+J{PB833R
z&7zk<&L%<Wxhf}_5ISQu@G70S!@_DSo^}Y~)~)tMog}0xm3;et%B{lv&2mS_lJIyH
z3e`FsS;m*@(@w{ZE=Hzx{=rk6!E4WR>aq}u)b%0+Vm}lRr?L2@8emhv?)huAJK#M$
zZ3|IFnPr8IG#WHc5rKgfm;hL*cDkLn)cNH`cuLwbJRNgK3?_3BYO-R}@AC$v-E9kC
z%I?{Q)nOU@SRAT@XL#E<<${5UCpD+!H_Uf7w=o!?5)sf9q?`6UAFD=cx`Gu9FM7id
z){~ew5kenTjU%0GDyFB!Jf8tLigyb0Hs#S0+|x^)Br5}S?7yC1#X5MV2;F*$K$q7T
z?8-MHB5%V#h!&n5Gm`YP)jAfF-4o@QO0)kpsJ};eu<%)-JZWKX$sRX_&Q4y+a0J|6
z8P^Zh3;AQ$1uZk2H@GR$#^L99FG7^0307TH8Nr(zJpHR|^LodBwnrnLk-$B1U0tK#
zP7^k_<O-U<u;<*3zV!w+pQ@vicT{cgkJRd>HCm!v`zNKVP7U)@grj>x;dI<z8fMJa
z*2fioOIS1qQOVDBy`HmI_6(=&sV~Eqm*t@wn@Wr=;2?L|oFF1{sbGWAx%Ga~Sk0z{
zy{HU+0p)Z61-3>bGX&Ci0x7Sv4&c>O^mc_0vmE`S`E@Ge^TpY5Jub3T9V4ex1T^?R
z46X0VGR_$7ud#M7^*9k)Trw@>fK^)A(Cx|?=1C>3>($Oq<v^!16<Hb>kRDTBl<PfS
z8-DQopc$lfVKtLj(RoCxkBp4+nXk$Z&#|)J`)XBag|coU^l!)>@F+n65H9gacaF>M
zoBmnrMNKLt!oQ|mgNTa^44%SF4z|B>q!sr+dNttYRQl9qY&2OfaMWJG7&%iWlP45<
zCmMCFtf^~O9Xs5`Zh>~c(p6?ze5G|`j8c?-8l4m+nR4LIH%T@Vl#7L@Z}o8*m}|qk
z8}v&a1^j`gaRy|hJdXn3pdJJkaxH&dUcb4Uhl0UE&Mf^iNBize0+87t9UXQJYc7|H
z7G!$c58^%UmPSrUO(nXYiE(=7>vUSrVD1Op0xKu^7Qhv%cFK3t*d->I{u)-zfDx?!
z1SbX4j+Moml+;ky5K8bDNWj?2SP9N}KhU=<bK<^{Qi-wRA;;cGZwENVOaUTU>oD$U
zMPZ9v`rvfMCw^g(gYej!ro8)?jfgHk@i(nAbCw{}$ajny&3uQN95LzX5MgM#m5$w^
zA)6Q1J1>+g*4O#t_qoPNP=m^xtHN+<?Rh^!CRc+%D8yQ+fR&C~uJKi0Ez#jv*{NVE
ze>CL*aW9KV`3{tdw}P4zBV1B^vbc*7ILY~pMN2vLbz!?*>JLH_ln6U={+fc@0a?Q6
zTd;#FtlY}B@29lHg=<E3^;>DUz!i+m-V<;`9X%I)Wkd{1G0S62WyH$Ewy1mcvyshX
ze>2}{`!>eGG4me}<b*vQtr#?f)}=wCLlh+qGGxz}$pt6ok6nqv{<%!ugyvg)CDF<O
znC|t^kk-<OCPiTzPcg_)qwl+vnI*6#P{?Sd4ZdM-k19$V!tGvDYFdptby!5_0p3=h
zT;a;(1RgF0@WIT-=txO~qM5wtr+2K53{9d+wdTQg*l7}9vMj!S-Qw)p*o29{j7TaZ
zHOP@ovlS}hzAWdP<IPHwirJXMWAt~r>?X;kp1cFRH_^DUNS$m0EGed%3>d<7vdBqm
zt|B=j<eEF4Ob}8(75{qt%<li(r4@-XZ2g)Ln;ho9tbDx-)x22fC6jjHzsIH)^0wCk
zh@%i!(rKNI;#DPjf73micNeWJ2*$c7I<ND`Q5^iCI=EQ}C+){XYQDLD;_E1qM5KC;
znN3Sn{;hTx-6+;<S#sOETOE2YLkD&$Z&5Zgiq2rarq|@q%y%cO!NJPxJm-=qR~9sk
z4Jdk^jgdaPt44JNQK0S-Bk(Gq7ozAcw34O&<!Fh$-#;k0>jm7sy0(C=MK<bK&oL*8
zKT<h5+RFUdk$XJJZx!4oN4>J;tO2*sah%k3h&1*MWn*XD%#SD=a>1>rj}2BYhm?a0
zCTQu=F1+J7tD>klw*-`{rG=>~T~Xr1v@HS)|8QA{LJCd(bFz_a=&V#?SZGfoAO^r<
zC_RnbuMMn_l>$p=u1obI4v5I-^Zia{;JR<0nVp4iz1?pnK}mxv$kWe_KQD2VD3}U+
z<w>U;2otQ1ldOMbyH&0tE`c6zCs0Ql90}gdl*EUlrG2vvj#T_bRH12V>L}Js?_ILF
zL9AwUR`xxN;3^AhVj8`xiQ4N;a>A_>xsM|=7P0u|d%*{0$1>1xdm%dA$cOk;?8vv7
zrAJ~M<{WTeI0SDgo6TolN(WSdtSQl1gf&kri78lwhYg%e<Y^9+fSdP^R80(#J?fwO
ziss7wxy26WN;9!1o22ujn=BMsa=Z-;ne#Sf$6eyOWnuB`+hnCK$Xj~Z1>!;ge$rNG
zC^C&(WT3N|+HO@!H^g3b&$--_v}Vl^hE<J8oafYmh}@QD4!9ss7sA<6n}B73)`>s;
zzV}7eb<c*nT|(gS{*Fjf$2$|odSsqr`4qzv^iDmshozdC1eV{~AVj&C*2a;*pW>U`
zs7CLBh0>62JMMG<+NESBGUX?**!it~gF+uRd#y8Q3pu{8vafKIf7o_}N;=qTXOS5u
z)_VbU5bO(3MozKw%_vnG*1qS-LiDG>xxw-O9yDf9P;62p$&%H`fc5cE{j&eGXfHy!
zWAIV;yuz&t<s|<KGp;wVB%z{!9AY4oRn?g?yzmD)3<qrNl#=GC^j!omy0_A6ij8Zu
z*7aKm^2h-TxZ?ijXTcbpS1id(aW&b=CXMNRu|EiR`mZ?{OMV|YWv^6(*8Z2QfO){;
zsj1%gBoW23?Jhw<o<Cv`IehCQkddh~X$-RqF_{5=BG~2z_(Efco@*b&aim()4gM&9
zGUgYutL53^drw$lY-XPQGkeWhu?O83q2NUf<vD!L6fiu7R<p?%rHt6N>cFrI9?!!$
zO!{&V$lmJxj30O)MC?X^tO7|yHIX~S>Z+J3hp09UboOL|cl}7YCYdFV9z!0Ps_}XL
z62;!Vv#HOscPzZr9w#O+9{E-QnPhH10uE#*a2G7m>%VCu&?r{Yz}i#$u6%-T03EPz
zJ5K(z8LqseLBsNi#QF-$rx8V1T(hT=j!AF)C`8+Xcm15E2`u3_nz8Ajh$`1n;TurK
zM$~8Z_LH6|qRD@rv*vl|{<R~q@1uM!LvSa*OG<an;i4y~#1H1dh5t`j%JM*=e0~Mk
zHR(cjKo$#iN+l};53_AQD^|-r0*QMvHWF{zSzB6J4YaHpEimA)2gq^0yoSL++p$kn
z9Lw=)`s!`KE;&LXZ8J!@6StUo#hQYes5IsBVno_Q7@vy=OOFLR@@t8(Evrf0D59Ff
z!(ICF&Na)ceX^uOsrF=RK);AKn9yaJ*L+@kv-4DoyYb~=5x*H&jj`iys8zj^Ed?R@
zf(SpK6;{@V3>ZazxPujOEmgoRlHZdsRiDL^#o?Zhg$do;%yU(=11l1-j#TJdH20L>
z8Zi^Yr=^Ud1e3T%@Lxj^;>Difx-n;G7mM)}PmDmkN<e8}t32>%12P5oYz`iafw;+{
z_}!7k{Qd#Yl}$0$F19<KyQ$RAoW6bW;fT)wR!vgmnK|`ChJFpbJDz^PI(uy#d;O@M
zdSGZ<<9Aa!QTtrY<K_s;F{6RxY5m;DS~)eZEU*B_x@OTz?PQra)24`j^@As2rd8Y^
zPA^yiGM|^Dl|U{NM@mFc{c3-Xnze#yIHc1*cJ5k`1lyE0GK=(EURM9pYfn12Gg<=@
z&6Z(gR^bm>5%RXS{r%8cstFa5bWfbngVX9=jp3iYxyd`vsND1&Hd82?UpUdw9q1XC
zs<5wd8c0}-e;}BgbL|~D>}R*QWA7Wh;w8r=hRgsQ!o_?b>P96JYTKBaWt#*cSUXUX
z`_m2<lNkYET@eCb!n79XUriPX5%_u@3xVzwq}*5_Q~TD;Atyq;k}oO@HuO)jc!;ks
zDb^HSCTLj8IUWH^G29LOKx&}<Uk*^emwQ7hv#w(4O#U9AO;uGoNw3@G@6+3Kh>VNi
zH)oj<3X7+t`&X1Q7dL0L_p66rxrfGid<ag0pI(K3Y3{zkLiduDFH!s}9!DSz(Y~l-
zhEy-4c?mF)9?TSR6L^HiGMN&D)Wu1X##+$D*)ZhC$^Lj3Y3YLUPrV@v{yloo!#R^c
zx~{59+fN0b0ZH9bm5-|786&n`ZZ{T;nPB3{1W!uz=Yu8s)jYDfAFcTOPL8#V`P26`
z=J)&El1GTi3sbrf5t<Ss%#D-Ls{l0g`(=C|FA`GOu{MV;mLJp3f7P>#qQIir6?m@Q
zb^Df${9LM%xH)smNBa0Y>bY2vU{k(jsgnEd(tep&K=Ot{_Gy$c)4_Nj9v~NPIwjD$
z6Fn4@IoZL*{=t;!i&t1f+R~Qc<VIvma~r)WI03xRY%|G9S8TTvTjd!oMoXC)(Fks*
z#4@C@C%}7ChH7<D5cE))g%geQE03;wd6hc%g2smb_+u)#uZr%ULOlwv<C+9?;0zBg
zLt#*D9`gfitKHCO9mAd$0@d*|RElLHlKRW|Op3*|H5g(wvOIEL0D<yGKV9^dA3EcY
zyN=c$o+kL_Fz{prUmaJgS2KEXJ-J`eX446LX77O^U|#P{lW{Pd-S<c$xQzw7mF+vT
zP18Q}P)zcF8DvOWx67YtG@>44*C$T8tiS^tP~{58JKdM4iBM;F5}kBKz&-_UC1~8V
zeu_GZi^<_ZkuVWEqdC1`41y6|3ZV;?$yvPz++fvgz%3Le?Sxd?M<hn9Jx~yw!lgDC
z3qn_J2X5GJxkWIc_9hS=Q-Zr8d(*8d?{cnNO*8;gt=!{?7sS8c^h%_(fiEX{r>4_W
zas8vAuM??m4}FWu`p;He0QH~Ub32G~Y!I4BT)Y0;Q|6d9XRUibRp^qH!~QU0-Q%~}
z9-}A)Pt@SGiyrg=HeXH>l5XY<O#Iw`sx`&aUVaj^8{zP_M>DY3JYRmUwhNT17kH6v
zi55UH6xdZ_Q+NA<g3Nze55v&2nJ?*IxTPd8JWH)DJbw+&!^JVUxxwmaIqoE{Ai>uC
zU&z+KLeox7>Bdx@Da=v8Ojwzq;#Ld!V#p%6)Tok3*;mAapVsXoqtz2(Ej3MBp}jk|
zlBgU8U45mrOC4Oz|KD16qs6X1ejLp^MDg8tocz<Y>oUD}QGXNzOfL`F2n#KpvG_Fx
z$#nCm9z2i>g8LWRi{6>PsfGl9L~cdiFOaH9>r079#VT<OD}UwNWAuVVDPn|E!tT-q
zN+>mZ;)n*L@GB8knZFa^o*E9I0=GVe@f;v9*)X+iq>6Jk;QvAt=!h~gw)YZ2e%d`D
zGtp|ncK1dRu;K|fVoWjses-NuDJX#ngUYykcgvp?)sB1SLF!;o9E?=`8}i;0=-#qJ
zm&1jb4R7dOdP6KEozh-skV~x<ZtqMH;%Vp)T-ucyop~$oud21WTx*&nTkA}QS@&le
zVKg}PiBP%0R~4_<g<HO330CA+EbOtW9TXb3S|lk<_7NdT?Q<qg8h6*cZQ9W7j!O;A
zH@*rMb9FFx=<Kf`+{Gys?3)!K&jAwmz(vfW(Y+U#4aG~EXx|pAhc$6#azo#zgubTp
zI~oo{ii@6vC}<;8nWdR{6Eh^@<ewFA%<^y<Jl_=2-LVR=E!on42;KS;1O8-&ikB;%
zsI4lWaK=`q%QF_RYMc6q+C6-X-aGv<)wvqaDt;{LC;^ON6gj<U!n}@V=whb{>SsrA
z_`&rE917+^7d7Kb>{}rR$>TMbBukM*T|HEF^;)YKYYLj}?fUpBP8EPVduF~s?6!&L
z=+vAwRb>I-5N>khI|h}6`z>V&y**hFc}Vzr9pViOO-Of>JRa0#M?`owYEnWx*NU^g
z1MjV3Wn8e=tcY^j-DI7OB9UC|#@)P#X+C9rB&Uh_kPw$6$q}=q{@o_`m1%605Id35
zHdhQrea5SWEzjMUg8X-(JbBK$0=_*#z6+{#M@#1JUHA7z!*yiGtaON8a1s|Ddq{Ak
zJkj`mJkGPt(U;xY!yYXV5*IK79~V4VI7W^d^zCs5BB?gfgN!=UpAi*(odiE-&LgX7
z)I4CZe!MkAkmi?hUIq%nqe{w0+Jx?`UsZ6~%}VJwu)XxEO(?NmUm}uIXgq>O)<oKW
z?g0fOUn)no?!fmlIv24+ee|A<c1`iFb+z>2ZR#OM-}|k2WKD~Idh3RX5;e4Fn=BJY
z&JbIa3yFFm5%tiV>lV`lF-~Za&AFf0zriy4j8M7EEhSWpgzZ<0sGYkZg>8Yfbvb#*
zusqo!rf#AmUm{qprYh8LaJ*Lv*Tnm#K48ph-@?A6XKtRlAcX5d^AHEr_0ts;=EWZc
zln=~or;1-y`{U+@m|KuT=Ss&OV1j&LqhfR(M<xysb|198fo#jVHU%_ZBi*f1;401s
zNA2!_hh03Af+q%1!R(8K9YU(%c>xj|vF_(S!rTF+g{LZD=btqC`e6XLVZDke5e82m
zJ5|EG!|Rs<y?Tg}OKutyS{PtL><(@7Py8EGSXnwr7NXV8Ir)n0`43T?{DeCHy{^}`
z-3p(ylK~Vd-rSTOXlBs!XUsuZk1+GNKreidmJOaT_k4qR+4of2YK~B+%oL<HEP6!v
z*PhhLZaZb6QCaiJdZ4`noD~eV4#>$DazTLHMyFhlkuNm<kvh8P7>zB&Le+rOG7*rm
zNYriFKs1$2877uawfmz;Q)T1hK>12Bhy84mDU)9Y<I~w?fdF1H@(lYzFhh@AOD6k8
z<_Z^x5UcI;Bz>NxC=?0QzbDfulyCSxl+>7NXR)zt#{4=Eg6<SdxLanQ4zDw(6{47E
z17MOehS5TtAKlbuLS%H1wwTmddUl8pS-!al%Dqr9JN1$RsKi;y(S{bJnASW5O{M_E
zX6ReFV%y4cn9kT*t2na6g!L^cH&I?Y=*_LWh(<9a%#}Qz0gP#!OIlNx0Jg`<pk8o}
z=x?A3UGFQ;+tcBue)><(&e6!zq~xYU%nTvLz$C+F+-KrVE~XpX?|-2|uc^uWJ={U%
z=T=ZIiE~jaEO4S0$>+Ew9}7;wkPk~*Z#QT~l8Bm>netckLZ-|r<{64LUjDXamHb&=
z9of)|L3jM4#)}q7P+BQixQ}?{lxf0fWOiPyLN)4eobG+~p7tV@WqykOX^yi<iA_;O
z5TunR|H;YJ!St-6Cl#6c>H$2!#uMPE_zaKF=)#5-X?*%1eYaMB!G$Jkz4h$@5d*nL
z;Ki`zTr%d|5d%HqssLX>4<8Sd8aw|NoyA1Qm6;lN|C<0V(*C3N0tufD#((x~#W2X?
zK|?ky8$A4<)0NE2GFkp@{CGq3I5{_Pr>oV`?E~=y#><w0-cSBz4JWF9I41|#Fs^_h
zUzr<?iLuO1A{U+MZdX~3wDAV09Oo-J%+IA-e7W)NEB|6fy250=YLGit9BJzUuiY7E
zuq)iN|1@oRnUh&C&Zhm%k9fkJ(=?Mi&=1`on&&NorKMWI9z%%N{cYLWr1Q*2Xm6$I
zsGCv?(tlwpW}nlXZ=hVUSL|)-VzkR5JEtRzpV67K#r<!Q>rFZKHLe>d@YVMzk{6rI
z@VWx-@r)oo9WW9?VjRvb@mJ-<ekIF}1-bZ%?V{*CoDZrip>_+UVdBZg_PDwhU-CH6
zzQ3ba_V96yg@{qH0a9z6<x%bh42%+9HMjAaUb}`hT)gOYoDBbKqUQfim6C(|<!b-h
zK&kI|QGb^R7nn~d?CkNybo`vYuP2gSKF3~4zvMCf{8jki7)3gCd4Ex|uklXndO@|I
zL%jGMc%!=wei=_O#7|;Mb&J7x;8$7V?Wj!%=+1cO4;<U-3#9#uh1wOhaMehJ3}Wr0
z`mgt}iT8G$hYj^wDhk>jFPANztHtF{q1a(r|9t^aJ*c*7EM`B;FSGUm6`k{~nA~Sc
zPmtJCL~8r#c*kX#*dj}8dSW^rEVK7g?CkA2-QMKn<46=OUS0RQQ|y{z$(YQ9SIlqY
zQ`^X#ub?AjK}FWMdl7zLU^N&i3>$L-HAWRY<`KZ0s#+T+>4NukrRVqiL5(t-I(dIj
zmIm(vZ+b8CGw0&70R6E{uIwfP2W{sEk#Tq8`1>AULL?(vn=!ZyGdHVCSs6zIToI6h
zF%-#qM-^sGV`$A@-A3yB9ksv!)5~b0MDq}*5#ytXckTk8Er>ZOpsiJGL6bg&c^9uU
zpRf_F4pu+1WalR&1j<oNOeHVsI*#^c^e@{^g*`8eD2>Es=$wZYWbFGeRA){8oDiZC
zrCN+|qjkco)EPrXx_r#s0piS5aWi4C-Vu+`0zfo2=FUL^&y6&Nc<KQT_d;?o7bXc+
z0q^KT>UMipJ6q3Xzx0*Qa~Zb7nR5xb{bba~ojy=~zPa#W)uEUQ=?nu|Zn+&p2`NI`
z;B>jRcgkmXa0}!z(_;R-x5CL<jK-f=AoYntXGu+z!XSR4-<)=P<t_rX0N+l)|A*Mu
z)IPJ<_((uY{&!reQhqWImcxZ#sXjsL&j9@B*h-(XmUQ5|?fx87_aOXg<Du^MD7l`c
zFF-(mmcmkr9(E*+_jRwlQ)GY8?oOIV@&98^e=!aQzr&30DPo7+${WvVswrGQEB%Lf
z*Rd{<HI;e-OLDaVjN*GxD>$fYyZO_tZ48JC19x!4<h1qVcHuv%@oFMGmsjJPE~Q85
z84hcH_N;k_nU5TIromaNpV`PqDojo>c!+qAx_Borx8xNQz(@v`*R4WjHKMf5tl3EZ
zbP*KGq<f3vuTu;8lsYm2zS?g_Y+&A!%?Ap=;><u$$L?D=7u<FHUk-J(eJMa+_WZ2|
zpl}o}CyTjUfD)bS%_+{kLWNY2!TfFF{QXmA2qE)p7lBDa<I`8WzQ~q|tj2px(2<(v
zrYY0(V(-z3Qt;oPoyi%euMEK0C;@w@!~$%gcuvz_=T^!1=I8qdequXchR(?zcZLmn
zL+QRPN!Sx1sD+>%aMw8raJd^&Q)9hi`;7-Jj&nZO4ZVUsUgG$VnrHXBVN0(dl?mM;
zVC%HT0#@ca9L?0yg1dqnPeWz(qhT}nj3xqO^AgGA0KN|^xL*fFOqS>~!K@cqYzoVn
zqI2S!MFtC!tUh&$V5SDXU8h?Z-aU+h&xTX?bm;F6>sD~@wB(}+qvc8R6J@gJFa)@J
zd)Si>gA|5u9`#!0b|REr(MA!#EY77gbgV(^N^$s%^%{%K9%xs=<zOi_RfZ{|z!Q}k
zlcmkv)^0RGu1~f~5lxo!QQOs?5K7!HA{p_*gU{5gi!a40)77XN5ZwEXEwd%(@gEx=
z;}cBl-bqOjOSj3KD&L71uFSvZ*l?VcX5C1t@2<U6MFFK2pj^tL3>8!XMjf*IGkpiR
zGU1iz$X;Z5+FhKAh7EI4TA=oN0KFhEIH80ALc1(N&oq&tkb*H+vA<r5`X-390W@+e
zo_>B41ZQu^Vh#os<>!SWn0d@wS2Vkq08o6>F#*Utwk`iX=oz)DiUkB?88bnaIpG?q
zTmMQ_oQZIAo-rF1fyNU%wKlNV$s~jCGE^ABtMjdLEDTTgPty?%Cd~M!>j5d?2q~n#
zD5@SS?}lh|*NZ~{$KWOrOETJ1?hpk|B~cCb=Epnj9qeLD+SWOz_$7pZ5okGz^+{Zb
z2a@SO6LI(p--sVeDY}z&-YVgNDvb&FhDJ?AeT9Zu!-<$Hb(xNB`<c$RZJ@udojBj{
zAmy3$Z6;%FiB7OfxVVi^QAm41_!Uot%^gCd415=r24b_zSL|>&tP0Kk)kD_g7LjAG
zcI=%Y{1;I1qIpWh{>JP#9&Y3WBwXEwWeon{)KeACT8#CsNJ*M|xr<ob_4QmDL1&ek
z7}#@0;2Q!uysLD2aQ9t1$_|aAgi^z$YCCklYRQmxo55QSj1kKB!vmF%OCs=nF$<av
zUDoz>oGmw62;h67ZhBWQ*E`>Wr4URH+kelLZz~SB>-UKee5wvqz$|5df@RA6)#t`B
zt(azf0OJN7&OK^cyn$Y@vA29?pz~!#z*BX7^vxBjD_V6akftUl)Iz6bSDq*eZa1F#
z%7Mf76B&w_juyxsO{G-=&OZl!&!Qhzmhf=GwKs`XH^^-e9^ZBA?sazW*DnBye-L-&
zFJ?$4`}ZdM4FZj~5c0oc|3Gi_i#r9gdI=hd3gHPK6S)BZPz1xCm(HDN&mmuQH3b9d
zvLAc%q#8GJR04JRBX+(1#Nx<?(XZ%u`Qvg@)XZJUQ862YaZ(B+iM}7JM~aOKM?N>c
z#m+BTt!M(A*tBPp$U(jPO)tbk*_dh=KNNFG)^>&>G2(1>$6=Fb-{i2BI-wX&h8hr+
zI#(|rJWdSs^)evg`_P^9#0^C60aYbU4s(P~2>`H86{$ND<*Dt_i(Dn>QNwzRw@3UE
zrDQaLbG8RRlud2*O4DM*+a-ogIDxIHgcHGWjNx;xB=5IJmy8_)=_CA0N@`YBxC?@<
z&ZeK&B8ndj&u5vv&#@h{N(2b{WXj*blG8#Ob{AG6FE-Xz4KS#ijUcv7I_Iq9vOq=A
zL-33o3JZQnK>AyQC)-kzU5t-qm^>Fg#r)$|%#-O}-9bU`&;M$aiI_b_9s8jfN}2-y
zZ=ELP$oXpdJzoq6DC*Baf&{Qfi*#;b(f8CE#bp0^Me!FY3PgJ8EI%Fgi68hnLi)jn
zY<`|r3@GxMRkp77jQx`g1PPeC;au#U9e{Dize%9P+8ph{SCe-r5*h+o)NXsjzJ|4z
zEgUjB&jW8s+rE45{kU!<P6&blrraC-c`W5Vs-kuTB?j*ZTm#wQeV}9y>%QUz{A%On
zAN3!}OL2eKQOQf}zWbB8UL03%-c3|P6T&htLZ^4tlgD1I@-TP3v`GF+yy;tef5v6G
z55hF=o!KVf$G9NgbwL}Yjp#|@*B7TQJlK=9g^9Yx`lDTo%+Ze{{L;1y8Krb=V8|QS
zc-n;}Jm`RylVR+=rqQ7O9@CP_dV6^X+9{=4mWxOj7|;TzeSK{#o}5~`#_VCDXoLwh
zzLh8jXKj&3yP$yez|kp>=M<=j!e~2>YQ;&~U)F1Crg+70$H6F!rh>&qie3<gumE=P
zjMs@C9!C9wRk-!cVrc;_ra9KS>FKr|h3NaS0N>&$24|g!9|^MBOc|LF8CTXGth;^R
z7nGP`jp}Y8RsgDGfnO#SP}CrW27i<+4CKb=6?o?XlMDPOZG9@Zo!f*EoR0-h^HY-}
zr!NoW1LNfoWI3$srgk@s==SUsbPBxx+?cLgqiblkO}>=J$$v7BI?>BUiH}giF4}M5
z3w^Q#+l_6N$;ixy0mPj9HJRi>wGlt)8SOn{|1xpMGrRx<OLaw9syH&&`%{stfvXqa
z1J}aIt{)J4%>A+y#n&I@giV-<S>REp1`Ho&<gFavZ;l`D$aI?gH^l4pc)x`Wg(vO$
z{6oM#lVVt;U2SXk%obYVIyjm}GezY+QLAF4Z|*K0MEYI;#W)AYNHU$?qT}mVs!}}n
z1K*t>PU80eCMs1|0^Z|5trsfYK(GSA*Te6*<WhuN^902bDjW0)>@j_rR!#e<bZaD`
z{M(b)H7X0c#1C!gIqR46z0xFCPIhyLC;tA|wuoN$@#<xOkG$5z-&dX%44MZ9bmbnp
zSU=kt9ao)^0DSU%sVLYWOpAY0vi|9iwOFgSte!vLX{*KaYCl(>d{I7xUSUU7I=z@|
zGaC1E7IP{3EAuw=UoM)Uo$rT;(m6vE=7<Ehj_IE4O>gkav$L6lbVGEHuTj$zhg3A+
zU;8OnVTr~=v=3zS9p*rbWK69Yb;=r6UlU<}WB3RYoT7V~Olh5({`*MUc*t`={NR%N
zC|}K0QutF0yMsC#6j7(?1zI__7@vQtE2!+SQAtg(#se)kblZ>9VOatiUv>9wiBeN=
zt3tz$oZ|tuz#4L<6f-3sHFM{%bnko%ib3XW$$lHO!cY^;NJ-2Hh`)xjJCu%Eg$}Zm
zf)mLYiIzzA&Io%KS->B&dWC%!+|pqNyTsC2Cr7HQ)0&BA4Mua!buqdB%dcMlX?lkg
zK7(=SUg)AsW?u^%?5t(ScUU>}eyXq$8jDaT_@Rd}7~YI$vlducoZLwd=ck<7rO_};
z^leo1CZ`HmkjN6sXxX>WWRw`;xNGj8&%Ps07E7By_NsJU`r$uYEWK4i-yAN$5%)(&
zt{K!*o0w93?6k{I!fa|RCbK>FAV>5z)svoAZmhBryDoJ3C9J0``}GBB<V;B7Kv!)E
z%pe1?doRgu+$7;aZZ2#D!)Ox$+*bVp665~wsi*z3jlCNv+w@jat$-~;(!<W;F(I$J
zg6a3c3u}}}o*;CNG>>Rr>%C@bn#&KFNymr=jc>*Y2uxBuiF@6QS=bSL4wr|Qu$fIr
zR4U}(ak8jfDTOO!kDBHkJbu@cMgh&2OD1a=3N~)53dC!R3Z9<%E$cD7W|&@|LqVQ;
zuH1td4&$iZgfJ{8v|8*^8J*W%M$#lefPSAbH;5<)th@Vg!jCbaeazxr`XD}ph!em2
zL|neaD!JafMb2NenT7OSLxB{xw?;C>e_v$84pYaputm0%^EGNR;i3NzOShcQBg=$E
zkoN|G^{0fmX5RqL=dKIflwzOjE@V?OWu1$2v`2StGbq3y9z&U#G^0Z85ln0WH+LPP
z;bCGSB43I44uX^eG|1=y>RY;o$wP5%E!Br<`eO|q;BhFxkozXF(c}~W6!I`O_rUsq
z;aIUoJPj4+g>KZI<fShqKI$iESyZ&>IUF_3e?>lz_a&>8Zuuc6`$O|3U}ef)-2@B{
zWusueu1e(-^i^z%0?~S_r3i)z{sLYwe;^ovsQ`EBgOs_B5d%vh`R{}RgZ`yMmbvOp
zb&g7m&g#JbCem<jj`NCOBjl~a(p>smrYn}_OX`Py8F=Yhll=2?w@5CCOdHc`!-y(5
zIa&#M7z&!!ACVbh+MGL}kl|a_n!mkR$$6yFk~EDp2*+02pD_(O5Ddi9mxYPkrLw7;
zT!b;q^6rHQx%f%756Z1Lb=u`cd)Ze`Ld7ud;>|3lPljvAY~GK|kx;${3FO75rZt~W
zvN8Z{jx*wbZirV7oV_UVu%m~v3Gn>Ai#=yn99iqsFn;dl42O0W#AW(~!U1P_x*yh4
zR{FdPLMqI(fW$d46j$P>m&Og;Rl%yJ5dnUjZAuj^_^66@+XYDt+MB5j(CHc!CO6{3
znfSY0QC`54Ub`JI(quO`rBGx4a&a&gQ9xzKxs$MbzUw5@39`lfGjW&aZY;}jcrA{t
z-0h)^{eZ@pk}vL?n@1qn0JaX}LG!JF`vaR=29mm|mi&~24YVb~)tdZ!uT;)v^ePkW
zK?y$kgTeJ?R`CX9Gt&#T2u>RTWf;!FyMPA0FQ2s2dN`+;wbEa+@HquQ>AaC5)U3s(
z_3Na$aN|C=8RdNz2;;&&i~aj#0s4}9L{=5mukmT&C)P9#h<)XVbKE<u)R)i3fF*7L
z4gv%(;L-2T?0tITbjuW-8+-CU9lHpDAFZ&bEW!p)=x-OVeaw3^GENPy6Nf(f+mK`@
z+Xq$0Y+}oiOTOhK9XR3J>SCWRL6+z@P&wbUFTh_V2ARj0R<^6AT|CRnL%-#N&Oo~Z
zO&Y~P`8;LdL|^Mti2R$84DGE<hT8oky}qgtOHMm!c%=*ZSnwHlU?#U;UNz?E$hXed
z8)*8QU`$Vs;#r9ON#?@nMInz@9TsvH^`?T&>RH&ELw9=yo55C%;o`QX794#{D(V;+
z`)2>Xo$~81?T9By9*#9x1HXx7$}xXC$@HV65Tv7dZ*mhtYg+$$Y1%TC0ASKDBt8O8
zgpa+hFq--J>mrdE01DWqyFTs1NZaK5XHmg}|CZp)V3&kI!eV)}?ju$zJ00^sgSRbr
z7#NXSL4KvTze`O8r;|#Bzr&yB0pfjZ3HBztUM}e-*zVJ0BFEETbHx=%O6*N6<057V
zaj@e{-4thQ4!aCC9RuZ)(Tb_4wI+4i0s*_=n9a&yX&pQO83$BF&?AAgj@ag#bJ407
zHOT^^4*s1m12+-}zc5BTyx8WLMGrXH@;*bYUWO%p+kx{UKcDzU>Ex5P3oaiJYI6bx
zyctTeq>B(#*hI`ka&9_7VALa1;!S4TuO(|bs{Uz=50{;4N0&XIlGc**DS7%c%j}B5
z_Ynei)LaE}7R@uuxhCyvc9FT3aP`>YvSP-^XsYBl_jTd%oBUk?{Y*x(5%88%Rz4xB
ziVGbX)$77VBQ6z@SVAmdiNT%+NA~+m!V{~5b1D7PzSy&^P=zyI{5RaW@wCC0?eDy)
zxcwv95%D_u!1bs(XM<9^kB_II@5U+Un}M(Xo$yppRBEf7J$J+iO@X4Ou3+T=<4sr{
zU_LAbcrh(3#sAIin_Kdz!YUPxo{N3L06gxic>e}@C;f4$s4J%j3dpD;O{anTyybMX
z(L9nKYZX3??6u~(7_4qg5!!P7LKVj>chdvY#IUJ)qwIYA7C6ny-}p7!jf!7*26WDB
zbkJZwh1^Ul?(c6zz^l#*?mGvp*fRu0HZ+HL>56Q@G-%-V?DXXg212OOGk=35E{g2T
z2&{L_Fyjxe)dx%~uvt>J3%|;dB0nbTa%1bN=3*q6KQ56PTgm?%lMac#7cqL~_97A`
zTt)`a0wD<PX(yRh-JV)vqeYA_vE4^f63I^Ub5sbRS?KD7XI8Y&uAiD}D!?rC^7kwK
zt}g(tS}|)?;MEFydUx6(OB$>r?qlo|AxQ?2|I4Qe@vB;tr6BjJdXBLuPKV*k$0>53
zbkc@BO~E(sr>)4%D6aW`s!y0@e1z<HTPr#z>&&dvRE|T1u7U~pes@ncd-pg#Jjph^
z@Kqzhr=1X^%fLfMRNQDkeI=8(d2HG%mU6OSXMe=SS)tReO+Yc)#<M&If>6^B!JBH-
z_|HxtC$g^h@Tn^;eFDnNU!RokI*i;xkCZw2PS>c*pc<IPNyjjmlsEwCIah@ZwMDBo
zak!`aF<H;$VU@N_c?Cx2U%qo-0ZN+Euir+l4QhPqPhOw<^D$n_atS=pbWB#ZFqi;|
zJ~p&b*Xz7DrG|`Z6_z1MDxwaVeG<Y03mGe8ENM_K7@S-lJYHrjRt{Wox^K1z#Wb4e
zj*=WgRbFK>ifapDp2LMZ0{%j;;QOqrbf?8w%Q30WM+bw%h*^x*h*~KL*XIuTy>w%z
zZ*kU<o=8Vy-Q636E?YsZB>4L&y=<s7M|_%FMA^`u6|+O{_8OYbpRVNQ(7r@x*8!pq
zhwBr$5}h+BW6OIBjqjbTbH(t~iv&#{{s_OFK4{8bBkcwvpgOd*sA6Ljlb@ELf0aVk
zne-90`aDfk9TNpsD0U~-_z`=1is2^OzQ#7f@1ONN>xQ}fqB;`Qe{#_d6X?AnaNB&M
z-wy4*{%9R?&#v53=*>((I*V5+rvX<%i{?5Ka_pu{{!C6PG(&a$h-9Q|A0xN!)=LE;
zciPsYR#7l>NAa>^#Zc?qjyl;FOFu{y2B}j#>>lVFB@aY8b;V2F><OZ)3qpb&Ry#nc
z)<Zna0GY%n8)uc7{##|PnShqXUlN96#<f^<N>xDzC)M9|H!a1D$Wh-*wFet+#D8Ju
zD?3ssaWN}dsm@9BlU@PJWV0X-L*C0x&V41#B`;MP=SA}b-8c{ulrWy7f$32#_m4kV
z-WdLJ2P>zC_*_0VA!-f=6BxAmJiv72aJ77p91^iVWmr#jSJ$A+kTKmPLaKzGjfTZI
z@JV~4RYB))^8?}gGR+G?J2a7{M>gXZs@`m^1jv$IdvFWb|Kla?$XfuJjb&$5z2y=M
z<uC5Hth8iH1zKu-uj?Lpn~i<9TNipWek){o=x<n&T~KQ1azHiGm-R1vYLzv4UXtV~
zr&5&S7kHjZH<n+4&I2A||07_F(iwmed?es=;t_<KwX9|{gthf=>c^CyYPGoJvRt2-
z|M_t>UZCBZ?Sc@GKvB#T8EY3>_uAJRoz+DQcHoVDqDdA#^4oObnCYb-WC^ky;zlqB
zgV7%cHC1AA)QJO12dqAze!6I8ACOb4%&i-a!}GgbB+{MmDQKAFwmkhEC0AtWKa)o;
zz{$KL)~PeeS@79+?z`ce%&G8lVONgQ<ANOpB<;jMU#{omJy_|JOga8zyS;hzv`7?=
z(d_3<^N|qg=Z54iC3xV42E+RX7&i(l)9rNByr`~lW+42q;sBu&KXqS0eo^>MQn03%
z7N%|2KmU9V2$6wXgYd5|ttpg9AIJ6FcShYWfdb5|S;pIv!=oUcjzJ2fWe75KPygj@
z4qj1s$1KKJ<6@i-(_>L=CnV?!tQYXl0<n&;g+pJC!P$e_|BCs5<RP<e@F&F4)NquF
zKrBK3AzT#Z(pdbR+HkrhBBa6l!-8g?KtTgScQ?48YC60yWm1041ineB)7Ny`UH0N9
zBmtvh?bK4N)c=_G4G3v%qGhip(Ac+@4jv0`Qq`WDTbzH_00@w!>fISEfyv2*PwHBH
zyx-33AY1)4aAm2}VMmdt5Ha*j1lu9g7+gsU(3l-^4E($%$Mv^uq_fjI(ZYMf{Q1*N
z8GBSpznogKr0-MLRaXKRtljr~x9%JaZ$2eQo-cY82InLX+v!8Sc<JM$B=T`N-?q+X
z2?*~p&AP(i6EgiLNft5o+oTRvMguD2Ge6|8zwFpwF8H9m(Y6=|#YXpi@42;7CtG2W
z77e#P&6{w7xfNRt&aZy~&1h>QFO@NY!)dkGT^KsoiN|;@YkAQQ01wK`4F=IKLV=<B
zR_VRc`fl}3m2VFyKx)5bHGj;`iT6;n3KPiBuZbY*$Gp0%(0poXA#gdM`I?zcJ3xRq
zgr)>h{?DJ_PF~jWkV;08NeN}f=*35JsS)$5{bg>EC(S)U#)2N`>NszKBueABuN{mh
zV{ED75#}+?xyj9=M!0EOFO0Ecl>|AQRUtsrc~pYn6CRHcBl~a3nE|J?jIN;ryH%x_
z%^^}%yO1Dy58pF7UvU;%3}urz0zXWIAmmi-2pqYzkg;hvXb%S&&N)8-8qd;vl%=D3
zpk^4@1P2FA8Bf}UJ+}B&utE{+DJhhm;y>DRLB->B7I|u$(8F%FwaeAj*e<%!2$T4z
zE}*XRx=Z0*{l52a(aT_KT)etP3krS%IWE5AtYx-B^_Lpa2Wsyx{3Zt)vu~&E<M~Tw
zaddT{Xb4?qc-B3{C_mlIcmyP88Sf7Y7Whz{T!S5Kd>Ro2!%1!-%$)43d~FQF&T4c8
zLh%IfZ+AZ$WEn_K?Ita-5K#xW1Zg%|5ZERxmQ6Xneyd=Zs703jgAnV>7aXRAv#x7!
z>#al!_xT(U`o&Q2<?QFYct-E!TPi}giRXzJlQQP{MvkE5(^*;epchvg8qVIxUn0%Z
zrJ%h+8nD_(0P+#YTR=P2n=b@>xfQ*rS*oBk^`xl}5|W?7A4#0@LbIGGoCcY`1-%-0
zQJMBwj`MT_wNiB#^1F^*Cb8|pkP+Z&MZYdx1CBcii1sF1$E!L^wKDiD_%V%I#=91N
z#z<Nq3WMP)+Abe9(&jMl+LGMa0#X!B0(DJEh9r8e34$46G+)iU|J7sV`r=jlr8+x?
ztvL|~cVlgC%gEg+U3RQn^Nlo)NWbD_9{xLQ5;n30tU6jhdlq{@L7DPpw100dW=5nd
zq42a7ooT(5EN|hSPLcH2`?4MO>}X2@k0A+(@K5mD6%Kta;mV9AhCKRJ6ta}=5Z(eV
z+L7=9OuHNaSU`xfO20Zdk*N4w%GP@1@c&}O<zMP=39d{j17K~mGn`$OzkCd(=9urI
z?8^PQX$rkodi06tS8V5B`l^E{8I+gnDa0AVr?Jb*^;XE!=u)rrs0UC=CfyqScBzH@
zt%8?iFgcb|>3~%A+@`iagPnG=Ih?V8gm(EGpuVfl+>V*Ann|sBC_T5a$D7jGkP{Wd
zRKe4^nXsq}hWP4zKS9)*X~Joe<NxMgSuDo|xoh`=d7d@W_niftOHo6xl=G+iJ92Xn
z>Rxcy%~EEdXVyB;=Gw|e)*W9V!oRt7u8YEjJ*AFl@;F1iP70js@rYVIu$VVQXJa+K
zni2XgUGD15S$aJOwj@&TyFHE{^L32=zC(g}Oki65)%s+50)xiFJxIb^(#uJ+uIy(d
z5~tqdZfcw9`%07a&lBn4j!oXG2cI)ERfuyZv+zQW@5w%|oTH8$HQ7>al^hOS(k-5t
z9ucm<j4b&mH0+F?eiVAabbBDHf~1!$Upf{imnP846Hhm;^})=wc8#}g*l=6xt{|}%
z5#jqSH%(-#+3I(lz)?!(Rfgr8jBv})2dH)d^7%4R?Ng>1ag}#K1EM`B;v(XD{eYGP
z!rR1VgW6f~S{|Gl+*UIDzs%j)Dz1cK5sCjWVEjumE&}7bDpHE&PjoIGF#iu%@t9;=
zOk`ntCrwDwS()HpQ-a@vq4<2E04<w_A~Cntv@8kqHWDr3)Z*eeA5SM&RKp#h&b-h#
zvExgs6~?g>zT#KBfxw_`$lA9!5<P|+%-&4VgAz3+C=*5Or`qKk5EaI=K^#pg#5TjZ
znlgB8E3QC@-vZxJt2)7}_~oE$h}pQtqe0y^>czG%zR|sUKvq6b`|);%TV!*px8~*r
z2K!)^RHc;NlSJiPD4s}6<@W**!{kaHdgeYKT~vt&Z+IjhK;vOU0N%W@`Qt9-R~h_8
zo^+t6{F-ZcKEh9r$_09RL^L{itN#Gt0%`dFnFw-Sar{yx%tE;&Ly|gWU3L%bXTKjx
zUf9AD_k_QewDK*VfL~naHV>J=Dx$ZruE*LS#+El$$_d%+0Zq$iq^s{X1-F$LO)g3V
zxiNxZ=-dX%T)M*zmjF2!oJj$H9fHG&$xG+gv=G?#O7gO{p+ZqH#;nj91!N*k%6O0L
z-|*;$IwOOHCrm8BT5=={X5miqOwmbG{R%S9CML`P8NB2ma4E&a?}^Jq2=XwVZ{JRQ
z3HkqdtBwsNBm8tv6!M0aE5-HN3s;?#1k7JO?n$Dbbn~pEs;d~Box&uRB;0Tc!t{q^
zkkMso*h35|RQagsWK=|8Qovv5*YkrNB4bjPn-m(vPq@_l0S|`Xvi#>W&lK1#-|CHk
z*-D5MJxuGejr5<-7-nY~1XP;U`}~N#wr2ZXsfS}<x13`$XmwG2&hMeV{st7z_zw*w
zA&v0=4&`T_1bH1<b}ky-cb1?&J)AOUpT_R%&TQT33Co2`<eaT-%&Uc=M*sbopPs5@
z4Eh9Tbb7@TQ>E+u0u#*+#o|IH)=!$^pjbS3ZKUkfYg!IR+IBO?)z1d5P2w+ZhiCpo
z@g9Gulq=+8k0PMEyZj3!vP3lunos)*g{~UH0R%Do&Ubx%S97u;KouW`L2EMVh`bmk
z7=Ewe5qfDyK=x+FwpsP<&#&!hWZEV;nZTK_GQ-RbT|X21tMgum0OVTSECfBHl$6}d
z-b_sJcEtI0ua45pD7_rXXA28XSRYzn1D!1By25?=KQV?6p|dn-=;}*2v3~)muluf<
z-Q2AH9_MKBK(WLE1)T<Buhq;Ff$*rTurF}NmTbsN&~pb3epXqpt8%G8`lTK2-3Ki|
zqh+LbJ)tT{fW6tmfBo7y0U4!DWy2Yes`@IOV*}RtjvYLoODm5D1MepvR(h(k>y8A{
z46fJ)EAbg@7PBni1ZLh@br_y6NEmt+1FIA;FgOAYdJ#3d3(oP-&-n)DF?@bb@R=1_
zAY2(9r(w^fpD&I%EwL641shwAhr-e+y(Yoc&OTf!w|P#N|1?{KEC+pdaPN%0V8Nt5
zxM744>nX(Sl6i#X6ED>9{=|pv2Ix?rs~!L2ST}2oHu*8|AL%P5Ujyq+4s;515QzJQ
zHS(04hKhMUa~%ur>@EX@f@BmTHaQ}E%Fi61Z*sMm`HZorh^_HI6${P^*hV83%-|WC
z-8P(3ejdd~rrdB<-4MF9nRqwKF*}Cm_%Tk;Na|QZhC+1Q(baFp`fZEl;JAVZ*xz0b
zK^-XTwHbJr30L$>K>Eozn&78yKCLsCNf}#_sN#RP$GhVrq|V^~mQ1ebxh4hEe0Qr{
zhR*zO%6yo@#9LC>^nUjjwkIt~OeyLC3W;M}SExNb(ydk~>FFhe#ltO9&uO+pGnl|=
zQY<PD=iD2b5?r+V7V$D03<&t-&Vg`SmS%*CCbn*DtnPr5779gjDT1ZxCGJWrSM!KM
zg_#$9bj`5|W>`MyA!s>OTCUfwk||@wn0;WgBh!d&3Zx!r_fi51gB%rZrgc!w2YGC_
zWT>Y0PP<d&Es<vp8B8lP+Zci3rzWoXJo;WqNisP-FwVl>C}kAXdRlnaX6YYfz}&jK
z@1Gxh$nu!#j3BvA{^-_&PsJS%fJHJRy!uv$(~Z#o1n^g?!Nxbp%;z0?v}6|@vWTMU
zd#O+;Djx+w5P|xQi17=<UAyXS$T7_dG|lMRE||Ab_RcUWD_q>P5)aS_Ot`Ry<XnqE
zrqRJ7fF4`>A$}z>ojBqlcRZ9zfV8U6!^wg8P<W4QiSVkIos6C6X;C_X*DSIr-V&Fi
z0<P7BOJ}XMB&oIf2Ed*Uj+_yx|AXAp5isihs64TSo6!abvu#=TE1#TKFSmdX%n|zA
zap0m6D+VV11h>M#uND`$>Ug6o!+Iq0d3l;BQ`pAPz&jzk17!nb%eQVZE$Eiw`LOax
zT`Hyg8g~6~{p~@J`vt@h-xLxqF#{c$fikOW$GJFh<(<x?e;RTRl#c_*)PHV#%)UZ5
z&8{AB`>4`3qnq;0L5Tt0Gv-=;aAHq*N>$uCgS7-`4vLJLJX1XdT@Z1xr<yI`qZ6ai
z()r!w!8U5dN1NXmCsU4#njH&8KF1+rw-kJVPU5}#?3#wPiq8?X460AJjCs{{W*aJ+
zmOru#)glbe{-dddoZG=a;=gx;cUTXXyWntz=-}s8Zm$FlQ2L7P#Q@H&FIXo#XSua^
zRJk$G!M`{Ix+z9m?nd_RTs+Il&9acyU?UhJ?Js>)7wcevM5b^8JrIlUDHzP_wp8pU
zOONZ~1G>kE!2tZMk8{|FPfCAgMUhj2>D1tuANzzLsOQ!|>mXfX>q(El*^oP9coV*z
zf13A;Sm<urH1jFOL~fE=+<3U<Q}7>lc>4K>5$E%yu%n~dGHqXgK*3Q8le5N7(}i4e
z7BB$;cUoqWD92*@H=H)#f`Qo5X=!HMX$N*W!RMx6LqI6-RGj0Ry-lY?*ZJ&u?06d)
z7N+GUeu4N}Oe(t<hjB$Z)|Ddi!?AK0=x{5_+&`lU%qlr)8=RQzVjnV+hM67pMF>Hf
zq#w73{KT>s(ph$M-y|g!SZ}%btGh-*(G!$^nQ%FB$&u&^HaqqXEcI3Cnhy*IWOBc?
z53;5%dIv(pHpX(wU|KPtnNJJvZ@(CKOC(~3iM-3S8=@0S{$<M;5}pH%!$PpNy7v^D
z=2kU#{jk^7w%1g6sIC7~pe16z{$!Uj5vHSb>U=YQGjnpovMn^Fp1=eV$lW2vkOBPq
z@QlEUI)uQ5w{JoT5X3bDVQ|cjPC`@%(>8I0q8+ff3Ijh;CXz3sWs+?h=R!lhxJmT+
z(E?t*WvEaf-hHoi5k%gtv~fDT0<S*T<Z{}@^D&KVIr=LTZ<)~qcACKN$Qj#>9-_jO
zHa7~iV9*+ep!o}t6Q&)LK2@@0SF><LQ+PHpDcLQr8@>&j<`oO(*$>frBD$n*S~Lc9
zhWaWE`-XJ1RNz92c9QSixw{N4h;EAtOXxK)*H;R`=s46}uMk>zISK?kaCdXrgf+<o
z;D4hermMAMoggr%?!&jEm8~7d%@ZdUp0S2`nyLhke*zQ7uXr9hDk%!sr?LuO6&PGr
zowN)WwXo@U{Cf-{ghv`mWqadr(vpt=<f%=wY=ki)g9lR4+xRl~rNC!&;Hl&@uLfFm
zqhFy+)IlJZHgLBpWdkNgPj$LqR3ZJWOq1N!I;OJieQ>*-CM79%4Kit75=Bi|9e-lv
z0|PPGc!Dcra;~OXEOXK>qxo(t$YKZraL53;Mdi21K~xk@5b+5pt^sp5wA$4O<#V$C
z!5pm4qo_LLRxSr>YUE!n6;}U{Ml+s?1>|Cp=B`OO8_>U00Or}dEPuLVRI^XX*o)2V
zm~%@I1^c|=$kBB}6o{IlI($x6gHXCAG3=qOf>-3m#y*V1FjLi6O1lShgE(};5{;2y
zI0rv3roE}$jmviIxXvy=Z6h8HX_%`+1(sn(Q}!1ao^aRB?)18>jD-K-l<Ra5<Y26=
zmri)UO7?nW{0LsI5Aykm`b`6!#E)?eIF#u6q}fJJEu4|IsiUoglRSky;d<(8h&`Da
z)N-~=ir`Jv;KhIGSXU~7xaHAE$5C~mOK;;7N2DtmlV7p6mg=Df2@1e`OzzU06=&9B
z^V0~MX5xKbBQt6JJVRKJ8_xznm)7fZEoYzvZ$=49ykwkzxEYt8D!tfr6Lb#$(m6!Y
z5=_?G2I#;X@8grBaIf(2LyTs<aM-thS;2T5AJZEkLo<%E5k*An(MqWs92lN|7nCu_
zafyJ$qa^8>gqOmB#La$M(i|#1OqV1mZM8&QT{+@ve`PDQ#y6Y&tcCZRc*<qc4R3Gi
z%9d=6Rq&9>MO1?4it30sb$T@&JV^l+8ZC&>gX1S^$m;!UY*a%hjG9&F{9v>=5(rEF
zelLr4$m$LjWwtA8rV2_9IG!ghC-lj=$b`*QuS+O_*{AuVo^J9j09mi740t$!54h2e
z`&B#m7TtaV2|3!C+FY}WV83iu|8-OL)^I~57yB75x%itE3K75@P9G(MMJ6}paiL){
zHAii!8u@FmXnIKwH))JNS6B4IVZ^VubXv|z3TR`RLGC3mhGq#YOe9Fb7DPGFd?ArZ
zhG&Otu435<xu^>QEN-lsK(p!)bJfnBW~%YVGuVa-++@R)JGJBte%Gxx<#g$<^U9|#
zuRLob2~VQgOR?3^1RzUAGl^>hiO%;fna!gsoBA%sP9rD07DwrCwL9t~>P|V`e9xzK
zvuLTg_a+#c@bASW)vW&|r%xHMaD>qo{}PPSa*m93<V6H3!k^bmaAO(6eO2AOFAGpO
zX-O|n=Psk#eyY?6H+{07#+oa33h&*=jw0bTsVLR|em3fUc4zs+BSxgv7C{n`<!{YC
zMY!I$ytzy^`=pN6h|pn~xg*=n$|m+>wSpCiRq4u7rOd7ZI+xa%rV*im7F?q}IcIp*
z<BI!v_9$y?6rh#@Gl?2E0^-zpe0i$HURb`QF|D^7%fBSj7Zw1>Oa8|6OqayXw4W)z
zzu3W#+A5RISeDS~o_Sj_Q04#kaZzvKhj!{emlMMLM@hcGqFcB*)*E4o%L#{`XuY6F
zg|u3S|IrZP1PMaV2NG5vHl>UZL4yz~<M4X?mx!9jHyD*8ssz}>q}gI~{3=a+r-LXY
zRq?UyD+NQQv8Hk{#=ph(Io@v_>dM>Py4&qGUY+>Aw}Gro^Kas!%<MGK`%|2z(=U-0
zeb`hNE3}Jv1iCW`6V<7;2xn=cIZ`iV3j9A&(dD>+T0@VJ)T_rlLU!F85Yy^@!R1vy
z9SC*{{$2Yq6g=gn4TriYsU_-Ze&wxqM}TssZpW|7R1$NK00oM*$I6={JuU_)agVS9
z{53=2R7%YGf1gix+;&#;K-S=n*Qp42HXQ0@%Cw>8Ni#B8WYudOH}IVl)U@(RqSo11
z#HE~GtAGDgc4G8YpzMdX9AP$yz?NzK3)iV295zsCUDTFLbeVf={CenEWmCW1_4An(
z#emxy9_FZj=L7`wY9$O=Oo4RiQ*W4#8FMW>!{+_lLge0eB`)DF$850zWX1VLT4A92
z%hm(hjC3^hVrya=ST{}o%m3=#dHl<=${QwM@c;rN&pAy^bK-pwxbVv~gnU3SmD~4{
z*v_g!3!%^Y-C#|Te%LMn{b*FU)R~MIL5tc4!VKb%w0pY;UpL8vjcNFSz?g95Swdt3
zMdXnK{lE%nnx8}hOI8vUO7D}BvF|m_nV;?g=eMMcVz`1%*(0`L48arN`o#z8Zj?gW
zwGvi3Os7hS!p6l$^vfErk-{R-EeQ2rN8dLjr=0#E{r`i)7t%i{?pqp^V=^J9iiLeH
z4=XLg`uVRKDx1xfGkg$UT8Ys@TI%D=>sZ3X{l{Ls77MSo6%Tw{+s)eFkxH8b#6$mz
zsL&0{1gv1OTsQT=Q7vux`+YC_=W>WGWmlR7<qAVAg^{lO9|Z@fl}N^oMiZ?AW|a2j
z--<S(wqy&KAKjDa2i-OZ-{>l42aAltpfVL`994B&Is<vciX{$Dj5K!QV(S}iw{rg#
zW-!UW<D)E!NOH=+o?imdtn!$vA%p@7L5G3{mr3QP6JJsdTEUV}=8f@6XBCT38c9#2
zVi=2=PY90Ln3mtM_0`^k424%GKHH`=VgU3=OLeK}5})sc!(SJTyJFUXIOHxGn8c@r
zfYQ+o-G3Odp6O3BH*vhS!V0b0%Bhb!037_+yKPrj7*%Z}-&|k{4e#coVB-oWc`1tu
zzDYsck_5%pP{Jql-8*;0Amqz05rtMS_MVqmC=3j>yZPcUPqW|?FKKUSZ-LIeQZ{gF
z8VYm?vgDisY71vzIB1jbj%N*!!-{%67RbuhHmv@pZZ)uiMJ4wMc5#ip&A@alR`5lJ
z-35n?Y!~=Aysi5Ypb#GF2RS^k>Id9Uv<|-Fn>cif{S3kNfxlb2k@R<_ikis^TFb{p
z{>k@k_i}PFVu(l^dTkR2RPw47f-Pbm2zZ3D$1L~cui<GsRI*_MS;&+$_RAK<jUEre
zQ9I-q6*u#{V!@}nSz0a}(CXtuRVMq=etY_Wr;+TJPNia}2ZbK=|9h{`M>abp!gjdB
z1-(K{@j+hrL<vHA2fB5gsXN4|^0Sj71F&XJo>Z95mYyTDuM#8y2>JU7cWQV?lOcjl
zCtNfvh4=qS;mX_A&QL}230fJSY-(O~CLQdTEx>HZx?M`D#+Bfx;%2l3Y&Vx6Dz<rh
zf-L!aOn3mqXT#D2_A{Z8q7gGg!#S!7%3A_EnWgytu0F4I5A~}R?%iW<z1j0Ro;*F`
zI}yd@=6bqnU-FUa{(v>~^m4`$U-3SQ_u&a=o<Y11j_ixecEH(TjP8q3$X9@S1p!o)
znmm4*?+sInuq~VglXqaYh<jqV@CZ5Mb~O~FT=!WpJ@n(&%wyCZu<}MkU4{Hj=SqzS
z&^&<0;Q|3{t=IK$Mrm3Fh`?vzhfodo6B1Uvo!pSHL+_UOi$$UHd-U0AFQ$n5{!{u3
zZ`FY>kNo5Hy+Q6WnvQc`$92}kyWfNJIBwTIf5m;Pq7$QAW&EVbjweo1vNyDo!hWI_
zT$&y)rgH{>?H8Za8*PFG6{+DmrAgP->paq!Y(`D_mzr>?lbU)SF`kC(@H|K1DI}yL
z!sok$KNDnFs3kRfh{Y>mnwTPOw*a{FR8jJ~1Tz+ZqziTHF9zLz9ulK0I_m>kY7;I_
z=sqF|4wSQPfMSgLsE;dGxu1PZ@dZK68y#&1$JboQpsK&GkV}i<`IxX-54)nNg_Dta
zYIdTs3F2?97Pm<C1tE%z?7%-Tb#)pil~6B*NA@n%iOCvZF^wv#2#H&~OU`lHrpt4X
zR$&N0Xy6(X3hXxP%KoO-pHeg!AH}BpFuL2s@BP7RW`qsOGVM0<`vU-tBA3&|E9rsz
z00Rfz8F9X0pj$DV=mlfyo|n*|8YLi=ywB)so!}%1D>~cq0r;?uCJ#7nNPi1ue8MG3
z&Z$9$honT#POTmZ<zj$J!CnyY5Uq`s(om|5@fq!&NdlLRw3#)XKb`8wicekj=^KDf
z*>a}cr=`lzA+$kL<fv9pG#IEeg0RVbrNXtri;mwOp#y=&oy8^KGX3xC8)zT^uh>*^
z@$n}B4V;PpL=G!Hm5ld+X5}PCSbi*4Qt78WYTs`pnrvBVg}nf`Ea>xDgKX5YGq|A{
zCckRisZo&5{6>TI-YukZ`kJ3qq^Db<<_=brf}-+<X-m8+suYMBH6GL>t37O*(Jc!e
z8uR?W+=<gl;%AP&nqbcqe=Tw)WszR{a9UV}l*OHfSx2Q_V2Z_|1egg3TRWv5UMgiK
z8{4!zb*nIl6ZW_jWCWQ|(oJ_1DrTk9;yS={-PFHE5%GW|j$#{j;9a^;wsNva9F%IQ
zI(nPMSsrhBzMSuYKdB#EK%4_$>;Fl_in>DLfk3fdtIE?NF-oz?Kd76Ki!<cfBSzl3
zKPu*$Yv4CctlMnqs*FqL;*`Hs#-2>`3gz7zuWuFvQDNfXelGN%8n^cV>5g&<j7>Vo
zQ{D^y%@m>V#q*XFP=*aRb+$-<RV7@9i9_y{Gd{eh<apvG=HpL<8b9Ib=R?kz-zOa#
zv?Xt|vstWj^}bKM)JPp&ddqX!y;v!SgDc2_nIu4SP#knEv@|n{c3>oq0_%tpB4wHT
znyh=<uDGlCtc`ESTaHkNa}(UngZ&vkxe?w}`|oqW`%|vagj5)kit0o+XuX9*%=5{|
zVCtT!Ye_F?1@H^F+sDAwXCOj=dtySxU#^1AxY$ezoF3vi^uG@XApC(9<64p2Q&>_C
zoHchq6B@K(Ms<JRJwRTsvl^0F73c8PxK$VH>LM+Dv|R_>ENLTLWhwfkdut~rn%nW8
zT+ZkZir&eIi-o3t@MJRr7vMW>8G#p#P}mtQXlM)wq7n!5($RL#RHSO3yDvgNt=tJO
zk<e|B9F2%WS>@h;<*0NB-7y+_!EG4!*6EnupBiX>J5s9yibRcs!QY@5=sUIcUo{@8
zHQW8jSAEgpQ>Y3bsFWL&+Yg942-l|1I~TaLu4h221!g$zzJR9hZ4lvubo@glsCrFq
zORbAqBKKRF?IlICJ`n@}nxJWr)5YF{W9Tvwp!<Z2Aj<l3*KGMkwmTWa(sO_lR*C>+
z7Zgl?;3RTpmAvkjFKwoMz%DY@Z2xc)wB_r_6MV8;08ao2%SKTatfZA9su=iJ3mv<G
z)z(;qY)Gg0G;43h?Pex@of*>_Vt!1IG<DQI>Rf-OS!H}t1<l)R_FLX@il_y4=R~>N
z7g3Ne)XHZQn3JYm;!~y9s+!Ny`m&i2^Hb!-{pj1e+0}VeX?oB7oU^EX1AW5^DtB_e
z*Vh*xX7iL~Wk>gL#_v!sr*$)YMAs%lPmpz^s^HdJKbt`g9JDe|L^WjDY{_wUY!Wp(
zA60u?7Kp6g6Av%At2)(k(u;Ik4R4{4G?6Sg*_3ZI8LS=R1A!t$PF;j)r1-jE1g3Z8
zb6vzoE1RyF#xU!|YgYCUWE9KrlrdOSKix3OAatHgcbf?2Yb-<dm29P)GtY)JH*%*x
zNyD)FxtDkYVa6X4zH;0!pk^PJH*U-UGOP|Wx>EHc?0#mX)yt)Z64P*OfDYj)Zw}cW
zVi5chO?kUHgc%$@MgAgWJ3w{JphC>Obu;cTsTQZr2eOmlh02-pd=~L+0t$t6QqUHa
z?%1BcP~>O$R==#13ht{^BiDC(Ke>>>3SG8b6e!01sQSik+f-t`#l^4GB+Cf8Kahez
zYQ_ME8-{b36t5NC3i@aQ=K<)FHl>H`r+yjQz%${9cYPTu7*(ocSh|>1aTBSDQ^Emf
zCT0-raY1;Ah@?Nz{7nuxv&qkb=yt3A|0gP7;oz0c*m?cypd9nEM$+R$4-Stz>(NtK
zxI|ub&4a;yF6J86zk#^-Oj0;Aa5uvx+Uhv%*#X>nAu04P;(~Z`yFg=jW`I~<JDN~p
zNY*|nhT7Fgw%-G^WZ`JZB<M*A_&OlWOv*u0y?Ivq1M#bPu5Yun^j3NBJ?h&>8o5*2
zV$G%rg9CHrb{A~gPJ^h4cS|O@;jeU;<C5wjH_ADWncCZdyBL!^<EVp8CDcqPb+3KO
z!Y^Iaj$e>8EiU$BC9U%z60n>D(Sjmsf+fGH8~Hqcg-@w6rft^RRPN<YmH934G0*nU
z%&AXU6L8!lbGSFlk?Ts{1=9%uJr+IHa@ru7kb?zVl>xHzj?<l)cMgwhkZYlA?Y_};
zD2B-+U(B1Ir#O$KpaON6eP{URBum<579X1dv5rLdr-SZ7NVJSlW>K@*gwdzBx$Ic8
zci$tpa)u9h2tJJ+w;=h}Q`=Y4CTD@KlEe&|Bf(|Y%}0kRd~f!*&czs!_Lzfmxqe*F
zC`3lYV@Pu3kNw)VIb&_w^hh!8%MqBo6eXA{Ci`VA3RQY5I<)FxMeGwq^MM;`=?U@l
zz`2+T|B5|4?_8!f#;+)X;`Ani+5D=tP4UZ&T%Hl2p35ipvVQec(#OGgQEBrs55P~6
z_ch9z@1-#Bg;mGz0c!p;6z?QqUWN=lS%49RyIS+sXEM_JmUB-Z?9=h32E>S?dfuyJ
z?7UN@8GJf9$D^cJ!G(~=Y|N4xWm3TV6|?BI+`?t<n4>jeyjR={s;0epwLds1J94)2
zC%V$}`)MGO<0g?*Y}{n99K!bYV`~`NJS!SVec<2yfgxIPq4(=WPHH-esD2e#d_RH^
zgt>wuq=cSYe{>PcPPRGo$gt0tbb4n*_KLKp(H?!x`VUK-L3qZ`zbol{vw6U!CqxiJ
z64OlN2773Rl;@jLfbvPAjtKVTh#oAjnLjmb@++VM;0k4V{H`#^E2n+h;ZxvqfiK&>
zP9NeR&4sm9i6Ue?)PB6rk%3z|k*6t^0934(We4yts^l~=Adh|(@Wo)3w2mq=*S<Hc
zD3)|To$$_i(scfgvO*%Kw>3+nGE3Us+P53eg$LmjkKgO8EHsz*7ISJGVSpkE^euGT
zHB-d6xp{z!vKbF#o8!d~sSBN`s34`&l4ACdW6@M7M!04A+?b&_inzGW0`Y9H^kQv+
z4uSip`tOOR{dqy)@O}tdNt`D!UjE0Se?E!PUD71Dcj;J=!#IiwA?;=+5P(0Zn)_ny
z>G!*v$VnGp&8pwmz$1ks9JZbl*KR=(9%P<HRTudTuxaT&)d4!Op^Rx}V=`#tKKK
zET=kQ#MQo0BTt(Z7-5h#hb{us_C-r5n8o1lpD`cib#X&0O`3k-8zz|_RZ>YEqM;uy
zJg@m~-PQ<`sQ^#l5vCP6X^vB`Bnsw1fQ07?M()j5Iq5G4PrSU00}eCn9c&Kp&$u(~
zq!Ml@HCH|_XZntN7Ekk(AWL?l$4`j|W^aZga^BvSXYD1PYTAXq`F~r~85<741Qz;W
zF;~%Zku4a_?gYMWznQEJjFy1J5cN+1H{QVOlj$V`xg#wRis~Gg^0;VewqS$AqbdcK
zpq=><s;km^RCv82s8|Iqx_p2V#@n!d8?K$Rm+>@rr{*2`XVghaVE=US+R&0CX0&Xc
z>ZCW!o(_W|y0AR^rM_kQ;1jZEsR7^gsP5P&eW5<{)YZBV-*7lZac9j`y7{jrCtJyX
zYDL<pi4;^!J3&+e8VgBaivPMg<~hM^B2H+F=*hyh7*b|Iw-A8^dEd;_MAjH18uEsn
z5Kg1r1<nqB{9k`%csx6)z{!cF7h--_9;u2E0iK&AxAb}4@0X?#mHtO_I0q>f;wP=G
zvLi5I@!m>elC6o5z0<m5;7c`eGQk3#C&Zh!fTMRuvSyk_K=Mp|BRv(Ta#d)4F|<ag
zcpde$uWZ+h1S7s<Djg@tRxV^`uV2y2aP3OIIu-nzOWdg>Wrgj~_tjImey{WD#j#2j
zo^9SH2*r`z7;p`R6r_8zP3Ad{6;&7?KTRVO=exfZ@s)#?4P1B!k_O1ZB$mxRA*@2P
zT?zMRKM@Q#Xuxdu?g;zm9G=^SS-0cmI>dY*s~%h&tlQc04C|>~Do~F+TB<z-<Yk+C
z4j!VhAS(r}Z{Bf1deLVQ<?)NARz@^f4)^fh=*)qYRN*!~R#GwLR{=^N<ax{6H6vM!
z2YK!@<bRy7kPOxjSQT_rj@Gi0C`<fMO*=~53C)M;p}4L?YQWfZF|H?56_ybn`fp^q
zWHvB~pB<>G=gRHUi^wTJWqTy`A8&7Z)z=>d4TY~*@!7HH1U<QUz8`rBFVYb&-*XrL
zf$+Z~`a-VuOr0iV*7zcTAN}TtknLx*7p+&w2tO~pR_bqNZW8CQeqS(}3?7RTUzmw}
z-cVwz6Of`a@@qX0+lSQ6XoP^N3PIB<lE$J*)p)KWA75{znXmMD03A?1*&PER6o^WH
zk@M02DB{)d9j+Hb*^9-y4svDAg%b|oEcu}6oDKwz=z<3vQI36#y+iMZIEJU6Hs7iu
zbHsPJUUWtt6o${Ie_L)<`d)9x3Wl9D^`;idHI0H+LSrk8fAuf~NSKmkA%vm0^{B<f
z@Dx>W(@-hVNc>2x83assWX?zk^MoF2_6-yD06l2bH~Jx|$zNhI!Ox6lPrABDj6?Xj
zY(qfn@@b}R6mQ1B0I3oY@5YR9!c%WVQ_z{zapQ%NQaJOKlT`hJRu{XNCiEraKM{bf
zqo26EhR@NrSP+-5o+1ldIU)3#p*!wC`8PDduEWm}l+nN3SkRV8b)VQ#6>XbKEh}u+
z^-DuV3$XjJ^ezyh4hS&L^I1N=%~=5+3<u;Cz#X+-9G+tskJ;8i0}Lyp%RR>x&mdxn
zM;A-6eQ$zMAXWc6x|{s5fe|j(7IL2$Ql4vMMRKt_>sVN6$b@1dTo*q)C0;$gsCtLC
z)-m{6lml+YovwhxA77odRdbVL`_wvfX-{(Ndm~v`0mOoDRv^A3A5mG%8esEG7g3m<
z1Fxa`Akb13sz)Hd#l{Nhm-<X<J)1)i%=X??@Ke%pxJRf;Tvu=Q3-s5IV#HO6N?p`S
zhW{M5{6ISxggk;6wuFjJ0QECw)5l}4k9vx2yN>poW=DC;UaT&rm1w>^!4W8EBe3j=
z5e^1hbHi>)rCU={$T}726lPjLK7utzy}i<3n_86ermSR4;THkeQV!ngqEmOd>AK`d
z5Ikt?ESgal^>NLo$E$6FEc+~MG`hkTK?JHG+y5>;XLmWN^PMaQ5}aYL0x&?&xR~Z`
zTC7aBXje%(h2sn{%?Hy&si!*MW9n>FG*^<iUbXkgz~i#<u_!wF-w;yq2#I@9N~g)7
zxiG*KdSX6oHLZ)FV+qd3V`D!wW5b72+^ZZ=ds^w#ff)BX+}%Y+L^Wif931A|zT=aY
z2~eraIJ8apYU#e(px(bcdsh@Mr{H!FL<k}*`vsm+eC4cf)o2X3!i%>j{%PzN%vQc4
zZy0YirI0QIVh}6iFibii2punAcP^K~#tz+CbOxRQJE_9Oh1sdc%Es&JIq2G6x=Tq0
zE!3gtSY^$Z?=U^Y=?$Eaw8ugk951NH$(}Kim^KNvb)N3ZYFLu@P}_()wZ2)i!j*m7
zR4+<C;&=}wE~3CdvR~4X@G}J@wJr_SIB<^6Z?Pu>7+D@1E4SsK^VWz%h##sZ)1LF9
z6>WiZ|78>1Z>jOS6p&sEe{SxY+Qh{~lQQZej&EpW7M}o^r1k#(-;f}w;uy*i6V~(7
z55pRt#H+_a8I+!Xu4#*Ut*P@6aVAM^=R$7f%ciYl<xdqp!G)#XR;3%OUx9;S1levk
z?MRdn(kY%4;msy55Xp(<i|`)*^F?<FX=A^kB?ONx>Na3`NvcH^vGBGSq9rq-z^)t}
zLp)d#+=RUr6BnKvm2A17<qVT!IO>x(kUzaYG7j8RqSs$!B2LWrihbf%+4-u*paC5L
zBtLA`NKfFSgXH&^;svq9fH7lPgV%l9O<VxftY8h8Tco3b0j2VElm;B9<u^T4*zWpN
zB|bRfeJr5R0lK@OFlh?gxp0{Vt|jN(cEu8jMIlnT3}hbq<UTyQ_rPceQe^BW|N57+
z<L}8EaD*`yk3s>>nHK#gA%>x>qxUW#sG2O;Lv6Y1u5ENytv^Dy?u>;xS^_mok%}JU
z<j&eF2QfW?`E;FSlK5~XO+~9Jw`u57MiXX2j-LZ#@b}`Jppmff--GVCc8GgUuacNf
zJN>>SXQsBar!}};1S&`|P81C(g>BoZf>*rXw=q0uLt2vtlc|+=ljA{IvxHNl2?2^5
z{lsP!zBikmVeQH@gyKqoI|6U;0-dGaE!QHLNhHe6AeA2E`%*0*)n6X1Ic%gsw+hK@
zE14E2X1H!;*O$}}p6HNL`o^E^A4t^X&0Zxlj<$@AU+QnfT$S2ucf;eIPxLG6I{Vq6
zwvsXs(gPjG3V|xxz@2uk%P_*-+aXv%0q^ZqX3#t6?`VW7JyGzUp=`G_re%ZDCkC?#
zbFU|-dOj~o-fsV9{cA<#98cE{ME@SCGZYFK=g#$`QoKzTMBRWPYjggL%wlo@2n5@2
z0S3I*i1#+v(@RigLQ#E&JFxuV2NBP`sC-337$xJ<+CQLh>nVCUi<X%ss5-hjF9TUJ
zH9J3o-TJTeM2SJjCiY-;Wt2gly#ma|Pg@Lu{leBS*V2}@m=N29nK^bAdf<z(oWS%O
z50bzJLtA+j+M68wQAGw`D=!AiiS-72E`jP5*dH7h?!GG1R7cc;oHyGnTiST6dIJ2e
z4|mo;t>nF#&6)uSQVJlxp`CwJkFLVBU7qZdTo%=`c)H}W*8Q<7xefo(b6+(;xB`6r
zfUll41Nvz{oKlpZ|0>6Okv6Ra<@EGxReHbDMvBTwso7<Y=EKT%R6o|9)y!2_eZ%lL
zd$U?eR6pS2V}m$WL6T|LIU#hB?~}Qn<dO4p*JUs*SPE62N^`i3!2Eewk#iQo2UnIV
zVYi-zbMj;}t>LWsuj+tGVRd+|Nd~j4XGs2V&)so;hqu<x26cwmBeUbSV0kS*S6l}x
z^%1N<9hvVyuO->xH>A=sT44LC7Ilo^drms!MpFObt#B_6Qz$|pczIx9r6=MaDon+s
zy??-M=9=O<Vo3{o(cn|B2M}fSozq15(5mv~_=sgJyUpXtLVem(Qu(Gsp5^eEs{|t3
zq5cl;=6Z2=r6V-krH>TkbFps~lY|ATSuvkdt5TjiNS@<?%8Q7U%36_;HGjln{O4i|
ztXbv=@&VJEIlW7%fPCl(5C~Uf(oFg1Rywi+|5h><OnnGug%8+Hm;#*p(E`K2st~4|
zy!7yE(X9wJ0&*EMCVGQqwqP;b#qsX2lc?nU<|j@iWj3g$q;0_Zgd^GujhcjfCO_jG
zz(}hnOeLX)?t*5`23q4(O~|x~z?GEnr$@i1Ning(roLtYr%&HoA0N7nVZN!&Ti<t-
zA9AR|nJg_0duQUSxx+t7P<rAo*cUs}J+OW+)u$4jEW0=(U6YgfpE#rKsnxId5J~Yk
zBQpotj!Cw>Q@_<Cb@jX|7Yr!7hP8O7p=zTGikI1QYex%n=0eY)wtRA;i(yWl$GFHK
zZeO^6SmoQ}p#KQ>h5Ih}K_A}x&+wR_rz}xTbjhQ?YJ<2F<rL8}<YlG37)(>U!6b(&
zh|dsb4b-^2i~c#a*_S}-_P;&f1YB!+KUa}G-fEROg6a>aEO@!nvJ}<g-IWbt`?cpf
zl^eu}1p+}jCP><dDIDQ!JpBC?A%Zh5sA)NFkWeZbF(O~Kt<wn?24CpM`8;@^@GkN!
zXq4fQuv-8w+s_%Inw_~Y?*miOd{=8ziK7Odx+bAKiJ=g0C1{&M6IZjW0g`y@?LQVb
zvq<PU*rLR$!rM!BP_oaIPSEIP-+)=SFe~mJASHwd>tJ$HBa^3}`}55}F|L;DEw)i@
zFld9o1J8+}moS+yPjqUOl<l^>uGN#<^}++Ea^m$5Bxmw}e?sw~<RMgRu31nr1spzZ
z(zv7$LN5QsvB3nF#t|Y1GqFNb$yBInr(ZZeDyY3gVB0bO2pK1mY=y998bogFiKUkf
ztuQ9s%LQ>u5kKN1roYM4B1Y-T$E;+FF{7ytgb>*TXu^?|BOlb4IAI~VVl^P#vgOo|
zPM*y5@Wn9kXe;|!Cqx9YNRSDq3I4&ed-<FAzKA&AuzWuvFh^*Qq48srwq~hx8@f#N
z+3Rc)KKvGjRXWBXGJ|<%hGJU8W<dAA7QZe}5%YIZyt~saAs+>>YH$t1h79}7ekk8I
zbzS}3#Xn=7W^dWE<kX>FAecP_8K+B}R{d5o-Oz46e44f0AV(OIN`;c<HK?L8nQ^E{
ztRg3PMD1O_F<#Pz>-Q&3`<&QNnV$84ShZ<0$E=20fMCEf#ASo&%A3Bwso&90PT%+O
zwI)HW;;3rREQM1gy?2nv0aOA`gQejZxK3w<Y~u19B*1o{M{RJx8uNz2FtH{bq&-oP
zF@u_#s*eOvc(E^t|2)J{HD!`%EqSr0HVYZFQ-EK$Ep#-92N;lD(B`G8s^KoA53HGQ
zd7~!4pd+%<K+_w6^TejvpWOyaP`ANtsvN<bw)MXw&qG)0Z3B5j=nJ(aq$B)$b5dCa
zL|`-DxaPP6oXbhZeaXfPm=;QzrlxC|M%&;K^}KGE=U3-6Jhz61D<?35sV+;-<afWE
z9j5B^sad3*FT_jW_V!FZFt96|!Fmwhj*9U@*G20<M{Sji_|G1ggEJnYv^gX<zO4QC
zOr><G#ZQz_;)AM?ko&3OzNX+w*|K8&a@mD*O~KMLgMDY;TBLfBszBcD36c9Cq4C29
zQP0TO_+_g)iA3r1S{I`wO*3^(1tI&#co{SzzriZ*jJp*TrY1TqfJR`qug`OYOlf=8
zNV$ml`zhk=t!!R*ICv0QR;Xo3FRUp@W)NMQU-xYnlE*00NnF`<Jmui5tr1ihvBK1D
zIx2dZUy=;$_;87xZJ@j+8+K!MlQuz#KiV3!QUFf~How=fwtaq|N;|hsVlJz;1?vL|
zvBhwqG-rPmV*Rd0?>@~+8c7Wl;Qk1$M=eaTi+#SVX#8r@G0}7pxq+7`7!j^BFR!{5
zZ3IU-2^o?~jLdLAcO$sT7vAa%(@NsCvcdtFrS8(zYUeWDuCNF*lLbYxW!(3^{0(X2
zP!{)scww|#^^1QEZD98S%)S5$8+rT6!%r=PzyaIE@Qh^L9kyNsHoQ0URSsbfNu)+n
zIF4wF)ZinZT!9*J`;^m;ab}h;Ut{-*O|Z?Xz9{zVMM4>|)tY9mR&SDAw?E+w@{k|8
z*w6TBa>SpOT4mxLW>4<yi>p4x+S4K?YE$KVGnze*jY~-O9M*XpfUz9H*7Z_gw5`;W
z`kgyTusGAE>0c(tO$Fb1ol#^0%oUS+Ucl>2vsEc0od~FDp<M?vw~ab{uJ?&{m#lvR
zgfseX$YtMK0%fZ#k2(vpOdE$+OQwnc1s^4=KT{o6N%Ji^lTjMFJYH2*R8$l5e;a9O
zNN*=o4$Jn;TbXkwfW(#~&(-{md1|kh{|2PQyk;MbrZU&F4%(a4FlP_B-h<ikg6cK-
z0ZN!wJv+`a)@g>fMXSG64Ie$69bA9O%}AEg<lLc3Q7>$WW274u^jB2X;cV_Pc(D^d
z*twM=lMk2*vgx1G_;!9rdFid!wr%`N9VVaTuD-lXvi`1aIdZ^lrt&FTB+-QHF!w><
z>{6=pBj%GQd?O`vjTB{eAj*m>$dr%D5qW5{k;NRJF}r_%RmQ`t@m;P};8~@vU|0$L
z5U;En-uFumqT_j=>K(C~?=H6SJ5IEOdqWu6&2S;%EBdEF)UI^<om8mJLiS!di*@&>
zxeHhFW|pNKLA&xqagGs?*$?+6Z)w%6-4W6`^!NAtM+|d}m>34qg4~ADj{lx<I`Zb_
z`#tLudxiyXbIwkj+)@13mv|r-3lLS>Gl9hY4{3`4qX7_<1StjU2Avx>X>(KvwNs6|
zZ23hzD$%Fh1eZF;y+^@&m?)vu-t89f9#OLt>~>BUI4`A57al-Vs8b<A8lE!|u7v6h
zP4Z?Xlv7MP!B5yz`}qlrY&l|1UW$^#qNp!9M>cn+F`CLlf280#B&!vl^PGeH`zr8c
zwruM@Ftgh(<`}AaxKh(n8qx3o030OXi~s?f;sXBn4$f-!Pd+dWivj=u00045S~a$M
A`~Uy|
literal 44532
zcmV(lK=i-;H+ooF0004LBHlIv03iV!0000G&sfakqk*lsT>vQ&2UJ%g<Ze>RpOV>D
zs)9rkVDrO9@CKe(@YECUelWOVArpCN)-b(j#!$c1X{{im2F3-QjojjI$(5;CeP6m6
zT>4h7aS~!Mq3_ZVg{ekFTvKMYR&(qB5i936Fry^lh>*0p_batRm$N}S!8YxWyd`QL
z4Y(PMAqQV;(WO*j1d<XGrpLq<1`ng^wE%?K_s~T(U%3fqek}|AG$$;?_788*?%W`v
zhvB5ax+hAW7Mw>{dE5p`5uSHJW}4MitTGj+a78G2-LBrxcBZz^BO+W^5%7`586uMi
zGc)RUpC&-ZRL2MMqodAy#s!|ctl0uH$VDZ;C|SwqMQRC~XgvHm3@!D^Kt=^>wbS_-
zL=K(*2X>dr{aAhzh^`EYr>3oN*>9iH%rOE#X?u{;D)pPRI_dLznuLZZ!Pl_EYGq_#
zE2OQey=|MnHfmM7Vy@DnR;y<`5qY`FcUhn*u1#bC1(%2*x_eDhK*#ra&L^T9oliOX
z2($bRoYQ{{?6jQp)VtiJ`7+bPILauukct8xF6teJVk`tT8$(&h#zi}4h_+7@5e2E7
zT+W;2!!dynDquKs!gvj+uqJ&BZpydP^ixC#`)vfr{b7oZ`KpbYSn1|mREF~`@L;^6
zD0VB%3)E=Wze^uG1Qm#dnxbi8q?UW0sgR-dB*t|0bNn%l4zp+fUYtjXKbP7Qh{Dls
zPU=&oCg`x33x&w7lW4fzJsSI*U*uM0U)QEIU}CweGwi#A03h<8f^zLjL|q~!At&96
z!ek*MUZyMr77AL;Tc9*?g{881r`H7;$pt=Kho~O#zG26V<PlA;-qCXz_A&vi%2Lg~
zMC(zrvM;7n)ZQsKgaeJ>BG=BZ5YhE=Qeign8}S@eaSk$an>9y#xQ7|O!Y#oSG&G2p
zmt;H=zz1b`G#1&{3l3boN8(=nD>b&$Tv;PAr<>)gv16MAD6v(Cj8cTvFX&Ims?eno
z(;Bs)4?d75bMvaKSsR7t(<YOTqHSO4<v#)pct)L{crB&`DYdExZ_4<+1dQhgKwE@U
zZ2>&3r}WZ4GV0I{Wm56|Lje*RK%ChP1k5x_Kip0g3lXx&JFwnTruAzWHHf2S1c3dH
ztXKz2uJ#1YpEF3Z=mVSh2Pr67+XAxiXt?G1^v-x_y`(A(NA}~~zpuz|b!VejYy5;l
zbXDY1JYK?itxC8H_=8?~YO!xCm4^n^@WtW4T<7P;BvN_Xwg5QMGxPNM1EV-|xia(}
zCTFoo&bHOxL<Oz=cc{H9d>vC2)F85Lk-1Xf;1Hs~v4j%z^$ej72VVa5R|z4P_<#aF
zSnG(=J+;DkfW+??^v#WdDuHP5<v3I89wRgS4$ewvT70S#rlX^KOOaEo*u1Dp5~&Tf
z!EzBXue-4G`U8g_ZqV`o3(N%70KH1DZN%vst3?Jp)`P{1wc=X2Jpi=<MheatNfwgi
z7A4BHQPNYBz}%$Kqhutu+=g*SQuS=d+&z>;v*3d-fh>Z*5uy!UwWMIc0o~R2y|tHc
z1|!@dRenxkqXyg5jGyB~I1c)d9HG$S2muZ$Ca}tI<a9srC&Yc{V{5%OuhoZWP23!b
zumP7**;Ew?TG_{dB4WP2|NiwLF2@G(M8TArwrGv>q1UJ0VurVY^pIJotI5$UI=W$J
z46qoIARGN3PH&=PW(`lh`R-V2=>s~RW%?3INgJB{6Wq^&foNaf?dT*TQAV%)dF1=?
zoVu*Sx$_2Wrlpv(u#~l)#hzJNFzG#0k}g!cZYccZ+%4;w&kI6ShNvLDh3n$;35z~R
z9a1?_YGW5*oU_BfmOc_MKOZ>rjb10re$%0USG#!8^psFiq4Df-pz;(R8o-=)h+(tw
z=ysVX=Endt-r14#3FIDyMMD%PDNUzZa!{)4W&F~I$AdRq41Z8T1A(-8XnG5iyHTeu
z4Y0huA8O#0&|&w)tnlyD3(XMxJl?N9d*q63f>dg*HHNdr45OF1je<^)Y;$N{xvVb1
z**pQWSM&S!?=V2yVfl@<T(R?ch+&vHP|pH?P;lu^^_^?voG5}%WZ59ZC9U6kpi>u8
zzwH&}$E+{}Mo;cWU?UJkUi;O+5Io_pycZhu1q#-UxV=<&ZsqHn8HNAU5B^5Z8YD{6
z{DWcdEJF|GVs8TdyPvToStKluS4f#ie6Drs@&oOAe+19)kP8%1;>j#jw_3rFg1PM*
zMd(8dh0viwmX?D8)_Is`2np6Z9b9B3HQ507!gQmm&dx)8PLo=t3OPL^8x6^c^Oser
z{^2lL>;o7FJD@#8aUsbFk1)iesA-iyF8WGNLL5-2B;V%(I7<Droa}#$_BwAogum;_
zIRkBSZIa{J60_!fD#atJ)L8>@`3*mzT0uQ|aPg}+J)U3Lt@T!duCD^@zpFa84;R~Z
zyA>~*CCvtr8d^MiyEAAS&;7G9g876a4x*+W;bn%o0FJKb(&UPqsz;g<MnQ@8IUpib
ze3)FMVd^p?fQ>?|n@+bkFVV#kL*xD(MU4#LR$r|3`E)Dd;(t(9=<e}Fbg0^>l}pJV
z&>10G?3ME5X^Y~Xd7}aK>^8I(bbNBO20a|vPs!LU8iB-jtE&Z1Bj8>%nRfZODJKdO
zhUDOi_N-B~iCG|mYwC<Kb5GD*cA#I>OfZqNL2G;>W*3?#K*N1(oS_c*)IU1i#}wwP
z)B5QOM37Y7@pmj@Qj|3~S9^I*D=K}+dKuACIlS0EGH+mP*H~K|uc~A9N%|(tSB{lV
zYt`|FuSyStku3Q^hHz$@@44C%qA++;g+ln8=<m5N6!#5cm0IkDW8<ZVL{)(B`kfx>
z2|D(O+(keshALoD|5ruHT%N|5%%QHZ*>y1>7@OEMwSXPrOP{$dK^VtquqNZPFu2!%
zL8-NZ-?$)mBYygm$KZCns<wCuQt)|?8LjMz0|lZYA?s*%mqUP$-2(+o&3T)Q38QE)
z(T*|l*(#S|Db0dDEWiea5}Nr?>v49>ypIls?;#|`6B4>{<bkQX#d#Vodxi=HMvk=i
z4Wt`Mq}$1Jn3!Hrp)IfHu!e@H>HY$SR)W{b)Yph4^)JPj$24Nbqw$Roy=@yI+o9x{
z>AT=ao^{UONB7Wt=gcC6jqs=1+F7WL&@9QV__qPrYA1^~DEgxdBRd^vqa2uk0!<$r
z64_x&L(6qqKsp^mYr?j=)MG@9?^t52_#-CXeSIlvRw}o3Pa0x^kik(!Sf!YWeFjg8
z>*Wc`ggiUW4>%jrGi__cq`#!b`BOH4_029@>&|qx!hTESr3h*jw~KaFRn7pp>#~-k
zuxQGuVPnh^4dYhG3|6^yiVIQ{t8r?@sptRZ>=~-8)^hS}ibp~s#fz4*&?Z*9byzdW
zF}h3r@0Lm%eo`WD3EQ314{ZM$uAlQ?y{b5**25R$svgBXS9x|d+;k{La)<3@g%|=0
zD8u@$x62dV4{LR@^5tXcW2sIzP|LkoBJ)!qnRovQr%GhV3=G4Wm|=>0iS!#V7XuXf
zPG@O*+N8&5x|uekNnDBhOtAWS!#OO!VI1rpu($plA<T9Vo5iy3I3F0QT@M%`Ua8C^
z{4su|&RiCd;S%TaCQj<<iFtoQwc^hSWICxv0s9+x@=yOP!?(xoH5{)^e3kvvozgPC
zy9z&w{L`CuySw#gIo4Fprt_RX=3Ut@F191VWkBwRf+aFqp)^}{^=$R?7&v8+U}nWe
zGpAV;C;TSObEM#?*(fnz-t>@f&HLYRf+%l|jFco|%l-+ed4ARbqG(<4e!efSR8rj~
zHzxnql9~wym2G}vrJ^};)%tFg8|Sd-!zz$H2Bqadmr>^lt~|;8*a}yyij36v8TJrM
zbZu1w?3RCD!gO95XU-!Bh^=yTV(YD+-0=jI2yP$ADJ8U33-EKfZjbiAtP(v`taw+X
zQc>q2U%AkX7jHU8qB)osco`PRUiJgnKZhWY_HQ5Z;yi@qyl>B<oQE~yiCx{Ih$hGJ
z9Y=nEHi6Z!bI49VbePyjtp<hCY58i6f&XrX87Yy=r^k|YO-ZxGW^|;NMW`u;b#AjQ
zM96>pxp%umx;T^*A#ZN8F26~aZo>$nrNGJaYcSaRWFS$~@8D%chMPXs0xZ=|-%Y~V
zjI99g$X`os5hPFVyA(%P?Hv3~dmW#E6`uC4i<!pDPn}hI&3R$w+4`|?LWU;s|0og?
zVym)4XD5RJBY-hgS6W0qDiNQHo@O%QF#t6rpsIFiQz#@@|9dzxMgqE3BBjG7e~aD2
z4LH9nfBN@O7~J|A;c}KVB+N!LhPCV3eiNVtw(VYJ6{KRC!JbkPTV<NonRyN4aI}h!
zW`8%k!s%1MJUr0YAzTnCh(hG9ICx|h?i2RvfJq%DjyhGR6N5VpA0ZIm_4bm;^Qyug
z=qxOJ#KS-Nub1YwHDDYMhf#TB0Ob3|90qEDbhcLG^$Ye_d9Vea29cD;Ae;g4j%KR1
z1MN~oN9Yg8+4WT-DzC+rRvK*Z5YDwwRFKkTlj`5h(f=kvalW9x7G4P(*3(1$7&WD;
zP{xPDO=A2=&(7Zux~W}be}{%;GZdON$nJC)E*I5H5Lr{~D7uKhOg1aZ%IF_Uo9;2R
z@GsZ3*b&%3=AOP_Q^`LftSLpuu6Ipm{jG(tG#Q=2!W+tczOu$hFIT0%Do>#~zkUFK
zMuY}@@Xk=%L69=17$@4<jx!r*Nx#Qm+O@3dB$Bbp|FOP&oUdj#Z3w0SHJD#REf?wM
z8O0LN<Xz||rK-@-;LKV%%%SJ;*h`7F{`sYdh#d@TpS&K&)WdA4tSX}%VXNv!OUvry
z(?ap<HBKP7T6@qiAm4n6B(^r?L`ZL@MZ}*wH+>m<bPsS<EaXiAWq+73Zr*4n|CU-B
zSroJ|HiqDNYb=D-f1R1zx=nMgv@Q6WRmpTo>NG4KsL{ykh-68VDc4Z<08A{9&g0Td
zsq;uqp`H!C#vbyoZ^mURHd>bCDp-WhbJ+8kzM3vYA~t&d4&p%*KH?S0m^X2f!si%|
z<iFxlcBZqXo}#8T-4FlpO)3P^VY-Jze_Xw(4`WA1-Z<7goMaxAd4%m}r1osO`x88B
zDFb{0nR@TII|H*603OUlK^uQ7&9a4<U@<2Jpzt`-V@Bwe7Hvtu=mj1jne&ZusbO$b
z^~?s)*VZix7&3usAP1*a8TNsTggAYmE+G*D;G%<zxi4xH+Hh`ZnS;~2k@$X`<hcpJ
z{z`v?k8bwypdmJp^?x!)(~|Y5K$_V9!-`-&YG}&q((9RV0uEdp<uwy&N(H=m0M>PK
zLOu@o2UPIdaJI1`%DA%^URJa)sJy0SX=Dx!YHTsS0+PR8@s2<i6?$p-tj;}1l<Wn4
z1_{T!YX-g6`m4nHPBn8>Iy~Lplb$_G<#!u}TLS~Z<a0RaLjphM8hvuGIo$x?uAS)-
zyM7m!(f9>L%prEU%T76^IwoD<xga;)d(1vC=}8gZd932TYg?h-t(c3X)TaC22}$fI
z4TFw4P@mEqzGQ-Q1%W|=@7}dnYkEqQEU%?pQTS=Zg7a9x@63>}>dja)Ye$sOiZ?vu
zf6FvtdZw>euDt8}$+9I~b1p^Bn)DSLP#fi$l;nhxVup?TEIm;Dg)DrB5_DDwDAgVQ
zAJ{Y<^t347dzN+wn42e5?~_O^WCrmq^ZkHtD@vDb^!|EOB9E}vWnNwF=(htD(I>)Q
zIzJ^iHO;2hx*j;fu;f;M@+dH-4q7%ZzQrF2<7~7=&7lxMOE1}RI>j6!65{xDM{b#y
z;-;;UhUk~Rm56bcMxhQ$db4qQuA-&+g-_T4QJHK#sEo*)ef4V;a7@)TgoKm~%-h`g
zwZUjK=?2fefh-McR1e;RCsi2GZ^!Iyj*NyeBKtu0ny`fAll^D;H(`wa*tHsRr<o($
zK<{E`P^*rCQ-UE?)N|M1eRp~4=HhCxjlwQ&Cg<Dv;Ti?duR`}GJw$*Q9q`)JUsPo9
z&mmF0BAAc+viTQ*^+Zr7`UR6C#}lDTLgE;#iO!00<ywH&?GseHODDx_x?CfQf>mbA
z^7#f;0uDU<?mUPL`VoDBzuV`H3I#{@om_cB@?T=tR4xf1u6ZYqiuxaej-<9!_ZsNt
zb8W&ffl*}_!9rn3Fd$c7odL*Zx-HQYn9rJ#Gpum4X`Yt0!2is#rbTF#jSYbL5rj;!
zmf)oUo@Kke2&-}}juf?_z942Eo_?^8>=boE0k`M$1#)gTWDu9x7mAJ57X6?!VtKps
zZcX5xn|&#A*AZ5hj<Hz(wA0eOX&AVs;yFwxAp-Gh+P7Aswn(cmma0BB-$B(|Dz?SQ
zmm<$kJI<k+(@8s!ugr90zf1T!3%fkFmsP6Qic-TRhlF!>`yuuaG_r3ue^^QO><9hW
zVJ%EvC|_F0^fH!X^rVDfGQBd^409=(?2~tTa>&^j*$eQ$gPV@N=d`AFc1{uC0v;`N
z!$~K%)bq=1`WJ<-+u*^W;3bhp6mgbb!0%|4pJ>ge`!Ca}E-ZsBjaCWA?v{e2i79}%
z1ekvK<e2P&@e^wTj>OF`MfXxnCIxY@SNX5M(UXB|CpdVj|343yHs)XdZ!6MiY=y(b
zW_6=W{`_>sWo(Rj1bac0xarg6f)z1l+FSNkj;Vxo)(Vk4*oCE0O(d+mJz@08IWFnQ
zC&XMF4H>dnued~ll!ujM=w5cN;EfP%j4u;r0ZZN<IFr-t0`WhO54I0!BRn!g#~~p#
z?wlSp@R}TnP8pA&5)%!_#(sKrF{*T@@`YvFCfMb{?&O^q4z-7(iw1`-Pb+w>k=cUR
z955F?a-o4CY2U)?y+}ggymUe3bStk16izio5ws!Or1Dz3ySf;+Zi~-$^URr6N?k@`
z`pQt0nllM%6A2ckd0L;=`4aT^cnZ>7+T)9R6f(k!n_G5uoSHM!3r+4LEd4|GZ>9pi
z5j;a{WI;;7{T7FOD(fb8yLLywaoz5(q`LwnYEx>_HsMro@l02a533#~Nsjm>epJFw
zQ1_ASfY?Zmv3yU}6|+G-x)RBEd=+bl`kCchOC`*(4VL~7)6Pe~!|(YOKKXJIc&uw_
z!V}~<<AC$%tOsdemE%PV*6Ty$cV=X<&DEBGo9d36o5u-kE}Cey>N1wsm*33RI9O`o
zFR&;;xeN=@lqku@*P}WvBjowljW1rzAgFq)<(JK(_z6pIu>fC;G2E=|r8<;j)|}b!
z7%4R}htLg<G-1?7YZ1G5jbR5@9BlJ6=mXdW8ch7+X>7WuGaP>G$X^V^oC->dD^y36
z<=8aCC0gHldoM5p5$<eOCW^cnQWJhGj$S_kfv@t1nk2HRVCV$CK%Z686balZXc=Q$
zpf$WI97UIfB4ztgM<5Db(xz~Eft5S6E?=XXq+YAE^JRDtQoUVZj|MDkMlG6=D_|zG
zKWrsWv(D{^G0>`@00FXO5*)Vtd|sO4J;>w;)b@kkpkEt7<Ci?&LC9vFeOylfEFU?v
z{-E_wSaOnXmy>~IYT3`L@=D}(y=ktU>_7b&4H>YMbK2k>sj-_w=5^K(sL&zAE%W-d
zzt7HIkOxDEs@88`J_p*VEk*HZ9<*~DGG5ZbUi;XVOz5k!O~Ws^PpTR8br!7#FxKQM
z7zBkZC7Qc$-P$7y?#?hbn0n43>ImCz(MQ7ektb%;`W)D%61>Y?=cXe8{>U}B%q=tr
zV@2mZd0JWfv7*z{1e1Vq`EvfRek(SecEANguu$49@83bB)wl-V$`_-b)D3NA2v{xb
z4;l>vC?^9E$=`erMe4<}qu?Ohr`14$B31Gk9og+@u?}m)oP{HFnVvBi$+u!nf5W`H
zNaxcOH$=_qDAcZo@8Cce8>7s83;G;`r<0hX%gbn_aQ!lq{(FDTK+)We<eQ{fRwNN?
z-X7dTV`W{ey&jg;xa6lmEMPISm=cTJ!f~G+7VkPfFj^Ca^2S1Ft2ml_bJ-B>2s*B-
zp9@|~J=F4UnW-VFsk7ZfHiQWXv|Wb0-YPeIktmb|vm>Ip$5q?!S8jP+tRxjWkyvoR
zpsbdD$|J_RwgUL!%!R)#g5Q?C+BgVyzQz(fprFQ~IXPg0!Zv@%eAXtnc>zm<kezen
z8CfU!3Wf;Hq9+CB6V7qd0D-enj!){Ug8p@pOUyI#9Kt5dH{XWkV2W>{$O_@}D@$Xs
zmbPn^e!eQe_0Fl7A>dc#`7Zha#xWOQnqwQOpypF%Ad@@QZ^|OJf&pXt^t2#V3=V@6
zi5gE3sSL7?t}GPN_2~*(=@&pGM#^3z4LEHs(AZq<05a_+<VD$Vk=GzRZFp~7gd=a%
zqz<`dUtfAp2zg|XYE-vDCBat#bvSJ)>RTFjnyADgk%lP^ZUB@|@Qbk_1wbBs{N`X#
z+OhPUo#uzIp&NJSj+x?;Z29}dI#D~U(bU+PNgf4isuW(S!ZS%KmT<oRV*n|ejVkIr
zBMJ|F4}5odX$$lh-oS#V#U`9f3UycXr7V2a#HDqXYU-kFJ^9=6ZjRP<m4`>~ur-WR
zv-|3P-TUj~FF>9?EkswY*|md=BkYU_xeRTXl5`fD2!}tZO!%>LE19ONnJlUAU4KP`
zB$fAvdZ`vm>%<f>E!ed(@`op2<R`d2qGh0fv#nZf8?r?Ki%8y?L-VEf9+++?y$GA%
z2WPc24hoX*!~;)#y3od~_qw9?4Rwi^C)AZh;Ogsif*BZ&fk7ZtpjoJXn(Lk})L23P
zTle<R5$Vg@L!9fXS-M9+qEM=6ypF?byCF8>H`(Rri{x@K8YnlF9v9#uSt?>MV#i==
zGO@U=vu{SMca_u$;ouIA+czz0c&UrT#%4z_-g5lh#%QMKD`KL?D5CK&R@0`?;qv~g
z17?q6-k_A5VToPqnl<6$=~vN`LUp-h2>rhL<r9l<`0@Vd&muLkf|1d2l}KE-kvhPa
z!qy&Lim~<d{zn4GlPpink~~%=G_}l4`2SUn>}fCwicldCvJ%Ay$ziHAuuqVwN?w`{
zjfg+Zd-`Jf-Hk5gJy(WkPnoPl-H`3H40!b6X(=SFhB1<`h675-9wDptr%$`u<fCbZ
z*eIR`(cy*bMYU<k%rXX*KTeFb)a?UEUA1zF{W0@HHkaHGh7PBT>8~X?Vo#6Ye>Z=B
zTn>{2uo|eg0puzq>%po|WHf}S%-7Khn@v$;t*gt|0=tRh0FM*v1Sr^GOA^H?)+gaZ
z()lFqoHU%jqT@>TJj)_S$iwj=`u~fCoDorEf?BnvY{bLL1Q%lxUXtqrkaO1)N^xwd
zRc+fo3(Ivq(uZM4?kzSuO3t}2+!_t})Pea{G3=Sqn|WXsz0!|dNKUqSfrG&AJ6BQu
zB>*JeQSS%o5i9WGQ<K#$j?q7a<3dhI;Q7u|*#Q>9$Y_Y2H#Cb5EWVO^xp;pCI9+}&
zq_kJb;#}Rp2+4s$FxXa6I&nQDW)y-s(LJigYEBe`o|!YSF_zzqZw0<G2XSiZ3VLp6
zEF~1E*MC^8@CqVVQL@BD!5G1ktz6VaTQmhTM!%5KM23RljNuIC>vyj!#d2h^vH+u8
z$7FHm`K*rV)D9@O(@N&kP3Z!0^KrJQWf#Wmlmtia5QiIXW#y(5aXq8@t@6vBVQ&pL
zto~@lY6mFv><f&t(JX%}R8vCs(b#oLza=>?aVRy@V-op&JpSxPNUVI52fW+95T*ET
ze>so;RO8AW2epDRQ^XV&gKBn`2ozd(|Bks&Fr+(?IIQKGk*3T9m3E!S)_fS+!ZR*q
zllOj&7(2qOc-G;eqAJOkSBq%9z>(GmT~0diJzOnm<7bwvDO$%x_<<Tp_jjSXlD3+t
zmJsJkHZihB4F_LCe?qQQgyTMCCH2nwleuaHjh-LS?rS8@&?eV46Piu{(%~xZW=a+)
zc~X}mg&~payBp*Xj!xNVCLA!&-I#c4DobyM`4(W4i^D0W0^q;fTB~Y3gxu*x-h>65
z?YEgPBr_JO%tRS!><E-L-h@3+X*le?S7{N*w2o`P_!2M{A37J;Ia!4Gv^Iwd(Ecj)
z)%;W|;(F9=3d#k?l0~efK5aj0nE$Oiuo)y+mp2Bd45;_dMbI#D^ar8;rj3cV)XH5V
z>U?hvY!yLev>@u0xI9!ty0rV}QjtZ6BEDJfI$uhx6FVNt+we30+<9ePwKiqRcVIpG
zv!%Q5r-W*C<0dScdr4$oDT!O`s)vXhL+jrnsX>>56Q7}+j#tqj1_rv)KLy#lQh(Pt
zj-9<{)Na&s;yUAZZy~}ev)K9M9W8kme~W|@3hBCx+|Yh9TvT~|#rX&}Lfn!u^;XC0
zFiq71ms9%f%jWc9&;wpgmDXBct0q*9EX4)+9+|M>cX$s?I8Ygl5)8mXkc{c%ej*0e
zR)|Lj*^HL46eo^6T3o0Rnk6Nyr?{%e!DG5HZdq%Uq_G<YO@PD$XZ}`Th|(*^1|{P0
zfdJ*FNjkk_EoU4zHmu6yf3r7}Th&GY0N=wCDrJtD0Kp@DC*y!#Wldm!>+w5`p6F1v
zuxOXi$zv9oz3rtlDWkABEtDtP>?gLt%vpv@9)?jGC>G)n7E-Xe(YeP;6$8!wgG8z=
zF^5M)S2fH^%mn*$2$WN*Wjx=bFp6#kCy`Qc+juGSLggFaoB9Y#M)JIj$<+YM-2YM!
zc!yo~kV!YuQe~tTP64I;$c2|@8|xp|soD?`^HsGCY}4q+1j|Y*PS?5^!1iz~;^6Um
z9BmEKwW=(`KgE$guEH_a=qJR23jU+mOv^Vdxl|eTCvZ|6SoZSk=`O_FGU~1Fo6Xx&
zXuV!CQ&Z9|5G~f-)f!#nii;zvhOr5%+JSCI)s{gk_jJIV#EVpCQFN`?n)Pi6F!<r!
zrCfw;2(b2pyqnR;QbTC5@*5yzD}ur&+#eoE{?Xl1+8LZjoiM=_SBS7Mg6jWB?9U+^
zsX1@TdKeqZol}?9O`gEoINSD(SVTYhzSDSTFvz6PsqYVs7341`iy_~Zt(<6@5!T`5
z4HoLDgQB5WLxFGfE1KF~F1vj|U);^R$^K5TQ0lT-obg@4_?1+TOc{tvZd+3K^U2B}
z8E5w%p8<6sG6J5mK3~@DdF=<8lVDxOBRudMTVSl9Kk?8nz<M$9Z5v@B_=(;;bI5xk
z`U=3>^L=U3>0e%r&g@i5<*zMlU(h6L%F(AYG-h%<jVQVY-gikl34T&vx74P}9lk59
zOPpo(NgZF~(1spq32(SCkD0+23r8X0kWzw{+Sg2gn99!_y>*t+|56RNy(C7z*hJ$9
z37fBC7AABHH7wgq@I7QPn!%IaSZ02FBywLwM7ql#XJmH=j&v<q-w*fze(5Zc?_r&Y
z8rflh`u%0@ZfljI+nG{Po@?+{C1W{J!lTQ~f%~06@%}}4x)@=|IwZnq0hkX=NYq4#
z(<FP4yo=@bl{8(p&!a483GGDk4N(aJm3G`DBO>T?^;@O2q2eAA91Je1J8^{XELUoS
zg=TfNqeU7P);u~F+d@;yYHtI(mVC?RK2n*i&1wQ(1*Lyx9o*R#g5!r{W!~O|GMg?4
zS-@J65ljAn25~uSb_cE7%dci2_r}>CQ+S)7ssx!*)00_PvpPx9H^MwPLy)1%`JiJ6
zWLx&hOmDB|<*F0W+!5ZYQ6NDTnU)}T516h`zzu`JbLzl2a4g}Q^>*34<i11$!_GW%
zm@or(_iipD3iN~q2zAs|Hj!xClb4In6KnS>-VY%M5K<f-DP>6t$~hl!7$*2T?!N_<
z=wH-c$I*%oH!;3K$D{U15C;!BbUY+I3!B?hak2WBjGXv9-CBg<rXX@DU=T#`&qd9~
zd6EI}RIYk>8@OCnAMF3RciI2@1;>8&HFljW`}&r^eudR>8NY*prL(>no1F{Jog%65
zfyxi;f+<CPpYL>t;ua9`a?YkMyAXIJ;I7*iAD`;N+BiB-Xw^K_nI<)_kUelmfm78#
zEyZ68uVc*CT>4Yflc|XVl4bcmXF%bz?2VWPIS0DKFISxaI9Y=zFFy{*b+j3DoNUvT
zTw-~}v8hW2hUv&Z8d~n4B;U<nYR{l0y8MOAi70stb$6SukxK7Dv|isRLWEz<0Luo6
zpy&0ihC!2xpPxN7Q4MMR6uux7W-I-#eCIXXv4M>nKZwIQjuks$i~#Cg=_Zqg^w_`e
zVr|)9tOr+R{7;KGu5p0W_HgEC+Jpw;^nMbuSyxN-*#0Z)w0J3bDT=$2KI=>=%QoNd
z`?iYV?)_vqT+8Wv)q6rU(=eF(nziYO%*L2H0_u<J;(~RZduBwooVp8B>Z(jsYt+_+
zN<8Gv-1+H!_Yv^sxh#tpIavnhl@B-jOA#6Oi)?hF9(AXiGw)#OEp<$mzW;d{r#Xl>
zZ8$xFc$T-B*OCt!CDLny#~ybGupY!yg=q|gq2-c26OGpFjwOzEMt@Rkn)=W1O>%t`
zmH84ocilD?NZ5$^6hyGF_?lpQQUuR0`O$3f@`-|hUH)bYXokusy$3>%;p>yG^#AZ!
z4G-f`ev1aTh6AKwpWP|}-E(9{W!p_tJ`)}+qx%FoS`P{mG<qN`k;YRXtw~Lj7EbbC
zzcp%(k337hbLUA94?!1!RW)mFz;lfn)S?$C5{b@yw87NTTkM|D!Lbuxj@7E%Z3n9k
zjyz&ou4=0tj_R-Q%rs+Fb)l4q25?zXvS|eyrh3`qWvNhn-Q$OytYq{`fL5Rt>K1Ce
z*|&gvY7wG*B`Bma*r42VFuc?6)gN=NJ>Ip-H<69h2>wcCg?ex}rOwREA3*l+yrduX
zLfkq9Lceh#88SFGB6fR~uATbOA&j2453aNZ`34TNYKgun%Z<@I1oXjdOVlWzTU(HZ
z=#jNM-=ZAOtr~Y2Q>34u*25f^&j>&=4N4*NOKMWgL$jCF5|_&OgKS;)bOnpZEN?E4
z(;ZaITm~U-rah8J^24c;qs=8VSD%ftz(5?EO9>fDl8mYwnMn8Rt)l%<KuK`gyyz(y
z3&Bo9M3k)5sT4nAsDzt=BM4ZM2`Nw()D2h8V9IhJbeGo!r6Cxd&!)$f7T?Xr2pr!;
zhYbeh_sfC$k4rS9tKD9n8o%65vm<%qp-AU{8YncF@4eC$Uvs1RN?HjjQ=m{xl8E8`
ze$RVI)wZ=TT7`DY$d@YNXfL_(uIJZJtf@o?Jy77)^?Vn3b94SfcYM^aOhwc<qm*yE
ziY$vDil6OKn}^SOG2k3I0&q5a;Zsqv6Ylt>MJKF;9o6^NA<qnH@JYW(==Of#vvL-$
zjQ5-<lr=^%b<?FuA)_ED$lw2lOW>_OhFFjYlHyo`UgiaH1skTLF}e)@mCGsn`zbwr
z!Bh({5K|L}ZoP#Jqc|3$`u93!TNX_xmwEhA(C{t6@x4@$O0`3wuRU)hYal`8GWn!9
zU;DXZILPKIA&g#Cg0^c)c;3<?_2s>Wus~pve)*G3a@q*beyOX_OLUZJAU)AHVpMdm
zqwU#bT|T~+Nm32E%r#R6u0h)FyHllvb|(+|Zwi|AM*B59J6-ET<<25fX^%TzY`GJo
z+`%pQ&pal?%MODy`Fwn5J3{hzJ`hb6S83f@^a-UF^hTT5nnxh}zc^%m8al&_zJ5Bi
z)ieeV#5Gw3Vn?FvqZ#5}ex6|%-^W>hlw5J6fIKeD>oM&-oZXv}03bJg%Ff6J0Y^IM
zQU*zLi^_|{wpH3Q5H6scWnb(Fa#k$fAh@fw^vDy%+OcOyQ}Fn>hQgmmk>RbuqUDM(
z`nIVEw&D3dwHmByo_lCB!*UqEL~JQjcq9gwg+eVw9PAuz&87HK4l9)kUF=QlW?bV@
zS#u>2TA8ZK`Cii?8&5AzbVQzc(v#BsC;9b>cQCH(O$m7j=1EGC-F{m1;_Vc#jq|ai
zD*0E2Yvb|w5#Y&(63m<uOL4tYE%rkxA0v#4`)shcHYqrecNK%qV4=lz4y^9nAzVx-
z^36B>x2oL&S_JBfuC`fs3S{>q<!ag;sTu48yIAutFq|j4jv35YEfOE40@XF3*+kM0
z>EZWQ;a}ZW#l^dC9ZZE5j-oPc`Oq3XN)&5|^}Za;`MWnJaZxEU#Fc$!y#T+&!JKod
zN1%2T12>_q)}4&>N9nwScCfRd+qQlA8DpKL)&8nKV;>@qvi<vG!G=Ea2X35pB>m+W
zMYKy|;I}eSo}T%S91ATSr>M7MrD18TVDEFp;Wt2g!9KK8hd;(^fOXr*h&$tL7c<3Q
z9|hYlM+q?ZY1#xymYUU2;#SKxV}6{yCB<olwHPgmJ*;H7+ruOi?k2z^uIGZJx_`M+
zH=u^Sq=@Pj?6PlVDalQ81qHCrs38k?6yd;K)#*TkO-k%`4ybQJ4}JHGx(1GnjxNrl
za3Qqqb({jMqGjK$_mg~MSSK*7(^hPK31<pve05Gb4G?H2@baW9q;!wP(;WySi=#k%
zDm!<h8Sme<?pn<2|0o||nsB#yIXnAu+#e;D3(W6f**sFgbxJgE7Whs!`v>92G5D_Q
zqho-d+<r>|f{<+;zey?{YG<mhUq2scst^O)Vsb6QVCR#g>**dG&XNOo7|v=_NwR*H
zeZ(Qg$PD#$cFZS+c<x$htBBJ#$!@ukz`za<{m1z+U@!GvWfzvck04w~N#TgV<gS<U
zl6Q|rRnpy%3QNco>pz}1>_v?ymq;rZLg>FkcNk5?y-<6CRdLkgx9j?3p^>TK)HP~>
z)pmIhOX1y9Kz;_63&0{}sASeTk1~1XMi2~}z<Wlysms~71K<AKV<`C-G!?o2GHsjh
zcxHe0Q|Y`t_IEZ|y;{^p&As>nquIJw2_aVM0I-t$21v!dn2BBk9U`3N{d69K84>i_
zn{4{xRL;RRA*>Mabyo&iX8Ci=xhelDuhm==`NZ9Pk72Ed4ro?M_w(4`oGZ^uq01PY
z#p6{JRj5%VK)H*uK5lNo`WTVSgdrtrn><UN2BZUTy03xIxuw29PFjY%*##zb$3H4I
z%0FF*9Z(fz?4<C(-d`+OCV(_<`TvAu;mf!NuBn8%e6E3HQ;W#G-!={%@`H7G{;(DN
z5R;}fvOs3#jhQ2;)Jzc`w8luV$Uj9PA@ajwyI9MQn*t@5#RMXk1Z@4|rVpc5=UMEZ
zTq2}VO&fl@qQ6<PivTJ|``~a+NMq!20*ZhhN06$m>`p}+v2nT&vk;)0z5dIA62}eg
zW@(GH%95pEY{Cs72tis#rB|@5xkb;KzDUiZCy7&H0QG)@6iDjeOan|LS`!eS2yrRn
z#KOD#(J{z!&!bA=gDhCZ+jWsN$eFrGu`w&u;@sB&aV`?zH4`#kB1*27#`M0h^4HOX
zuewNOGO*R+fZxW&fJhl+31Z?nxDKwv2MIy_LH1xK;dXa*Xk^JhOV2XYH<gNNQpzT1
zY`2MP6*MTM3*_MYdij~P2!`mp7V3~>BR~h9$XePox6|Ko4!rk6G78X78%SZe%o6FD
zn`*pvVUlPZ`SD=!xl&=qu^^aV)<q1k09e>NEC^CdlU)cW%WKP^;y@od49!FWY=Lk8
z!{KCNOY-hIN@xnMu8;YklVc|QsV2k1$LQD%hZ|k54?n=D%d!65<iDM>1ItJf7d=f%
zA(~J7iiy;D%;iy;-5~ilwE21z23wRdJIo5bIiWcV(t_@P`T*6MdR28ME!Zg{RYlb4
zOj`9j%1qDoojnv6z=IMDKhxzELsjVSAR50%exqV8IK$X?nZdu=*|hu!O?4(A;+$P)
z|BktX(fL5TPEitfKN0A>x64UI9)VJ@(nVmaP>n(D3b;fph@(beSL3<nwHiR{qW5lN
zdK-UyA7)}v|GjDow)XJ{mGC8UFja!ah-oS>s}=Fa!E-paI(U3N*-3i@#VaOvI^D8(
zb+5-d1nQ_kyhfi4#fiSHPPY5^2lRhWy5-%3F*#ln)ylz+0(bh|`CXNzKIO{CZxzeL
z_g^Gk<ok6ZKYC*$V_g~wVw&8OWh5uxl-%b9NjlnBd56LYO!S7rX-nN&Mwg7#AULaD
z?>IceDL=&_s%Ev;FD{#b_W)ZAc{zB%xlep>8;4&w8vIlB<^?^0tO<)FM+$g{mx+^z
zNvkS-2+P_mwPHL<4N!1<Vve>$F7Quyz-Ck93jHvUaQXuF{|H7^5u$LS)(sCGj&b
zyh9b51XFiNkO1v7)?ZX{#SRj}p0($7O^1A%xQjGVEp)i50gh5?p|~aSj~jmt<5Dxv
z1g`k_yQVj8v0o|3WBup3ads@48Cw%Dr7XYeWW5Fx&z5f%E&6|9bgDLl7<Qm_6M#+5
z7RJBmDBe?fwB1?q>=}BwUD^dT`1b4E)Y7rfs4lPxqy<!x4!xgioGIIfQ!U@6(P?s1
zBDyV|?ty--)eTlQMOPGOgV)5+U%Rly0jMiQJegWxoLya%CkZV$N)Ug7#Y@|)f?W)m
z?lt88k{qK)TeqggusvcXyO-8c>le{_cjh0Ffhh|PXt@~IJ@71XOCa~GL@APr7B-h9
zQ^})4sZ&R<k53eiQ;Ah{LH2@Gn`}Nn0P1xKLTq;HhABGjVt%gjm}K%c=diXi$PbY&
z6b{0HGati|q4QUx__{Fv8C?cgj@ia|mE@f6*@%76q&6+@SekejvJ7+R0Zoo@&G5h1
zw{I9$+#A4nn3N3k2TZ~G{wYEgEec<pWPaSrH{<x)RZr-Ol;dhO2_ZrbGI8^|t$64)
z9kI!myM3w~3Ob#XMUJ&=0l7mF%KVJ!N3|X8=_(sXb@*y4bg8SdvE4=yN30y3bw0@}
z?_?u;Z=J|3+WpOk>{;hbCdF)QN84xwo+iTnVqRi_+@3kONYk8vE6lG{9pQL~hUop;
zW4O%;W+;>f<lWlM0$OhfpVy#A1e_kL)4Is9Z5Rg2`e@uvUyY5S*PZNfsY;wWemJ7>
z;8y|gRpF!XpfFsI2;;!DE!HMa%BY*2l;52cvbfYqre7(yY}1aRDiwNEU%ZebN_T+;
zAc5#l8?{6R6@0<s=}|sH8+H>|K$1pGF{dSGHpn&zvl-<m@MUpD3qkvvCAMV43Tcxd
zHXP#LsJ4Ue!K3s@veJgHu=!DTN}dUK#N3{--NZ)&-gQaoBm*)O$Tx5!YGv-eIt~6=
zvq{kjw|Rk0&h$=<8MUqxq>P!OLiAKGf<Y;|b(;xRnrqBw@Y+Lw(L#-B$x<^ln4$^4
z7g^k^&ZjV8%5Cla1H1Pv%mV0%=yK?b>ty6G5ZpZV!+S(7;;kq@)%6lm`hbG3d^X?w
z{{a~(1;bH6{^!Hi_p$XC_draK{e{)AJae6B(3Or|%n*yHo*np8ko}O*z4t<kY()oB
zx=<_ZwF1#dl#pECR=jV6sT;h)OEfYds7@+Yd0Y@e??CAX#`Y8B)EdO5VP!mkn|*Yu
z8fb;M+go8Air}PiO4p<3?!!dk_oSq$*yeAT|3=wf`IDRZds=afw1Gz>5Gg=y06K0C
zG%r99yt{+^>{KU%$^}kpTt+q!d=&k`ac=_t45WbJr?0h!ss$OeQEcJ&YskCeTKC8E
z*at{<FvhFiqo3w#sDKOkS)0e~I_9A&zd`&jI%j3Zh36ez@IYsy%PK|(E~rZn%qRK^
z>;$t*-#N(Wviao}b!-jHP)K%B0DYDe;nP=Ku!lku2wW)9MLXj6aYabC7C`CDxMMuD
zNbO&y*f~FHU)TIpiEADWwa^qb&6#~%m}593aNmTi;unqI?|W!;hA;_>73+~|-it^Z
zdr}vF6=Ur#v=EB-DNxT$;7E?!(SK^tFHnFwox=9L)|w=SiF_!gw&qr;h@)SHSjVc}
zdCI2^t6JMMc7(-EjQ#fdLz$>^0O+Db9<%2^^qx)-ujr||l&o=&tP1X#T_6;3u84R0
zx2U)C<6?BghtpJ#5Q|FLEwOW=zqcezh)dlxM1q$gg+PrE!d_>k$9Qll)+W0QpxS+}
zw0aDJ>&ENptkSW7trS2<;V6CCrKbIBOu#l19U7UnW{og`=)m84)7v7Fg}@j0fN=3s
zd~(}W(eC7UawJ&4^MRXNqTcvU@sRjXe|_5XDT-k!?chh4c$l3gH+7LHi%R(eO`PZ>
zGw{=rN!Pb2gS-4AQv3wn@@_Bpr?|rL&x+eO)8%FB*!?o?z&PV~wd4S3-sgp=p5yxF
z0L6x6>F|IM9?tVP-omNuPaAJr%c(Z^aT9~T>MkQ3G-`}coY?_KbMmp$q_@r?Qlh<&
zfZ3UOdgUtsSthg(G!WEDu$*OJD+xH(W$B*9*t<QJ|GmC8VV3U4(_8}N#k8R3D;F#T
ziLtb1U=WdGc<=hjn%X;wA?5>tN_baeQVlB58Yze;pZt>uz%hNED@183`%8JOIX(OM
zS0E<0EC1gNt=!<7gfT)CR4eaR1U4FFD=^A-)Xxk7@q+uSz|nFPKNw?qmU?KYm8G^B
z8r<&w)o-<g$fD>KaJsck#-6^_4&i!>-|DawNJ-%hiqCjLKux;>;=P|PbYVFLLi7DT
z=zVM|pa1v8fg2_TT>UG2va7Whu-5v<-&1{~2fY>_6!qN`*F-SQ@-ozqHKTUq54pna
zKNpOj224;#m^%KO;~8=;8~2sN(<5!&@qJl%Ig2da1$XI92<En!)VHQ8S4epK=ibMd
ziS`XoX?_6M)@bQV_ChPi^h{D%fdsx!o#O=sAff&%Ji{LbQx2pc%|tZ+-OyqKU(Qo*
zh;J@2tz#yOzU%siDh|{bHX#S^#hCP@OvZIRN|XjC9kT<5ov@=!YL`Judv&=TtM`+l
zWJ+UTQwGWB48Gadv&_iueDMKTNJpU%Hu%5BtV8c(bu6yGyr5#Z>HSL`Iw<f0w)ygJ
zIKP*h7TJaI@^nrIc4rnLXDIxriq?&>A!cLx)gs<;5&2&?6{!P8do;qBMvSbRp`?&8
zR^iA0*}Pi4S}*;bQ>f61WNqh;nqrU~MWB>M%qfRKos?RqDIB==339@H4DwRgyDxAr
z>2s011^^xd>@G|%F?uH<fByX|i2oJ02_-xKk4}0+XsS3$00b|Hi@o#mq&TMUy=)Mf
zI%MoX)D(`p$Rb-RO<|k+&pM>U*pL<_6x(M~jnTs4d-DL##oQ?~p$^MmC2oPxGDtCT
zCkOwqT)>~w+J;5APB+xYotG10l9xir-S(vefes>91rQt)^9T?JU7ET(V^u*#Y+FkD
zUuc2{yw!NRG)t;jEPf*5csLPdfA9!KQ|<mBG%`&$DJ`EIAuZIUlbRvKd?(PjNAB9X
zC0+Y`yFdT7-><fAWLM})1dGr_XD&yCQ~+hU89r!UK9tPHJxTdws{5p`W}MNjl9}V;
zi1d?>qWFhewT~2v08}MK-gT_E+2e;s+FST*?~LeeIKxrmmUA6o;VT*E^%!gD0%|My
zXcYMC$$oloAdEuR6kgRP4dwm>o}7f^-68bX`PNg%yO|mAvPLm`eZPh1JsTDlic?v2
z05N?Cy&)7C#d=E1Gnn6-hZK9cBF!M;F~2r<7a=jxdHwOaFc;aX@f73ztwASF*fAu;
zAe?MHQuv=0oWgI~;C#}-vJWobQk;bo=iWY82vc$?<vU}-tdN#r)N|$gx}16P7mL8l
zLBB{n)!a^o2q>{eI%mfBrDUywC4af5VUI3)z?!q2YHuV=91+aYE&~f+3C}}6@2ybn
zdTZ!Z!X7)JSsY-$#c!K?RQ?`@lK4+!w(6fe(+fIseiV64+gTT>w_Yw6)|8XIWJjb>
zR@SP1;~pT~7bDVCWg_cSOz8l3qRz$T#&w>nv6Aj*=O1$)Y9W|ch+s&6!QSgCdSYZ5
zDDeSTIk&#*GIKO8x09;TtBii^3sn+B@q>I8zJwQE-i9s<2KQ>*nN?_*o$55JcVCl)
zm2def{5Szh(YKmQm~(T*u7>i9^H_5uz%bJ(6A9<km3jay3*x(D%y!?jewxTaEdCPD
zdN>L>x+$457K=&N#6n;eB{KsYUXAM9jl4jk2?{^J^H-jX0<egdX>I3_#U8<>01`z`
zc{p1hz55$?rpzvqgkJun0$6ikqHbYv_!x$~w8>c9s}U5>^*9A;(SToNbO*emwIBy|
zv`igdO|aGaF=FwplH+JRl~kv;{Hkye@$%UW7IsoV2(wg(*QuylLIOI(X<N7Pvnaqg
z^hbIt_>~O!43*Q|5dfp3w5a1SSU7A7(&_gp#!lxOF-?>4#^&{$0B%D;;T$QFfyng5
z`(x3$YqT%)>(jxFmRLLq*n3}SCRgX#py1#w^#Ex>`HX^O?-WsGJG@edumkBdBZk+s
z<{dr4A`FX@z;au}{J-#(HNxxlsYGq4<s8tG*8M7n+}~#@o^V#8NQn}W)wqhdcF(D3
zOQ20`XCKZ69?7;!kvtU`KL()nokLy}&Dz@yulow!6JD&oTi{dtCY=Xv?t)W|cG9Fu
zw=~j2aYB&U(V7_2z{0PlTE8U%q(wCC9!g-$A8bToL;+cUu*gfGqhbR}#apU9Es%BN
zhSMMJ#2rua7mu>WE+Qzc4EQcKvnIPAXz#RZTbtIrx`F?NVib}Eij^hy2qqv3BlAO@
zROc*s0+p-}<as>-(EhbH%WA<6T$3fp6$7Q#OkYG<WvaZ`=P`XeP|BxS_WcIWwwMtT
zo05L9_}8&-#2k)7+fmou)df!~W&&G#91T1l19Hkeb5DCzSn`n-SYgNkbGA-;VQADb
zQ>V{-#Lam5%AqMIWxTqu-qHtGVDKm5d8x8ufGv@6clP7=ZKy*b&Y+HuML8z2LTP_Y
zN;jdW|C=uQOeIep3hR&Pj4~(;2P@nE^#Kc@sV@EZk~tFO{riS4<-^?$_eTI&OqMUx
zmFCVG|9w%)2WUH|a(CpF+yEQlk^iHGGb%&I&Y%Ven=uq4;$M^FU6L#^So?-;$nX--
ziJx%A7MYvV()GkI)t{GVzHw#dI=oM7Lh9IqJR`+s<U!0(Q#l&><EL6W8hLiUJfOeR
zVGqDlAcVA4tDH?us1M);!e^sP+50QC6Mx{#qVE0d-nGR+LSuTJOBoG{0B92r3q2-o
zyU7?h6KHSZm2CoQANogk>^wa%c|f;e-I@~JsP{62T`#3uy0ReS$u;$oj06A`^e8k;
zzc2N#4LT8zkEFFe#OSdEqc^N1D(F!AxZV{TD`1p)I#xCU&|4~+#N6ttc&Ijp?{#J~
z_-p~7$!NmR<B2bR_WNfK_mh^T1r@nn@)zNQo_09JG%@WS<SjwBy5=G3a?FS@*(9A-
zmQy`nBz>A$4eqU#ydy>58KIYy6uEe`BL>7PA<4Dv!=G@v(=oPW^sk{XQ7*;p{y~xK
z7)B$A?9yAuU)~ztnYzJIP96c~1wjiDeZvBoq2;Vy+yg=kL$<B{<x~po#ESnDpo;gl
zdxR70DY84?@H<&wa6H2#hvcAmVr3Dcp-*<j#LP2?1)ed;-D3I}dk(+k@+IhmRn9!q
z+Ee1b9n#`rmfs;puu9}w?vbIyEpvI9JUBtCypmcAU*q-IoHKcTdcNq-vLGagzQuqJ
z0Hhwjw`^q2Zb(?M|NQ(&dLh4DVkl3t)Vs+Tw~FT-2^Bq=z%mN=N#rR3#)U+I&N<gY
zy#TYyP4L1a8x}20-fw7}`6$5Jw4VSSK;pkDl3f^l&0!_s>BAia%jnMh*<qb`8Cpau
z`5_@H4VxcSCk$rBfNG~9U2VReSa0`c7vLRzlzlq}0)RhEdtmb>42U=r3}mg+GgQ4k
zNn|Ebum^;6@l1p{VBXazLQIxR+Y}#MRCC^5N&?jcJLXjyq7*b+YMr+CY&4{Z$7GIm
z*^#QOpyQhOdWv!@-2>+9T}wtj&5YY4!8Pd(@id`3vg_l{89tJphJj{&AViRSF%&&1
zy0y3V+OU|@fj0Z^n9Eaf3b-7(5`@NJP7_fdsxijmaQRnNnizR|ns+9D-;lb!y|s-`
z28DS0qFPsbl;(ymFCa=pa@nBc!F?6;1+RWHxBG#4IFVlk%JLtGl-DFmMs;^o8aA08
z<&$zZ)?)UFp@MNX^kX$lGwg%g6i7W*7(19d9rwP?^1)Fq@mM_IV)!4(7w=hX6Y2y#
zYY3M69>$+!N(H+sc`RMGc4YtM-!E>AmBaWpr$TT#zsCx7Yr@@{p_GVG^x*r*Z^_zk
z*#ETmB77Chep;|fBQ%e!wn^7oH4Y{)g~A93B$>O6v`hM#yigGWmt$N<|C2aj5Q&3A
z66-=QrPWYWkVeFX_w)D5uC`L55eGtt`h$ovEtc8AEsTqgVk#`jnmI4H^bmc~KIFqH
z>)p^6%Y}#_FqvqkCn<d|=7Ea*!$*L&-nE(Uo&A@_W==s7Xcgx05-{m7HKRNC`7RDA
z;zL_H1tC1lE6`~i>jLDq9>FWZ1?|mU^@hv=<&pqY|Liuq+JoWV$tOD+peftivLJ#1
z#gNwUs|LLhWUCQ(UV28Tt0SuK!Y8r|PO2tOaF1m$Bhbb9BUJqDxSPa|S32frqbpFL
z>^6Ap=tb4?q|+a|?YQ<ozBvQS@qLp+yj>i>AU?g^$KP~u%B}xKod!@ZAi`%-_{Ng(
z`#Q#1gY_$=ID}qZzQT%5F80YaKbS+tMpb&x+*rF>EX4pxB-4K0<i(kqsE1*ELdbvF
zWrYfj-0#?k;a4r=14o(*cmKip-*7Q~jTS=Y>yo4$ZMG&kaxrm?=i8f?MU2tj2Xuto
zbL(x)ESvpCovfwo4))YPu}&HqDZSUj&r2gj5!D;0roE#XJRF&EYQ%0z^Yw{%pQ|-W
zETc)Gf7q(pt&GIP4qGY-y;%XdjaAO<J@}X7)i(6-B83Ltzn>mEEFpnfQ50?DCE}=T
zl-WLUV~t-j?yU;7j75!!uiF-f1j2f^N}F<ng7KCe`CXu~q&*TV0DWC!$RV&LBc^Tn
ziEV9~l#AnyH27~c(ffs?p&Vv#`@c9`bi!;Miv*VHYGH)XiN~P#`05vP1>2Nt9s$^6
zBmkD&zC7*Q=!!)czBV*QJZoaR9@+w~3LkrcP&*ITq1rxUpohbE4$BQgD!BV*!Xo8t
znay#{_zGg2>WKq-oR26oNN1UsMv%K}_BZ@$1ptdsg*QLZMvsp?KSf=nptd0+I9^Mm
zFkh?b0)Ly@rO32FqkC3#Ks^X91zIX(J5%sq25+TA8tfQ1)N7=Z&9>2qByYg3xcEB{
zkF=A6a#1~-gH}$pS?m@TSuQ+6CA!ali{A}P7`2@DP3gp{j#-3)XjZizTaMXrvmDWo
zUgF#+y@4Kokpm>o4IwtDOmwaj&AsJ@Zf}`eL%Ql*1yQItosyW}StHwx)$lNNuPY?^
ztoRq_Hu=QQ%!X^dWGJdrXpDR$_OAn#5h24M-${SV`axQVX{rE?y|aaU@=5ZC6DV#U
z4&Xm-XmAn^74xk$FN%MwAm!dgzvmNz=HnXV-bRGrtE+9n6j=+EXEwRbs~0QwAGi{^
z6L}jd-J!wZw_p=y%pf0BaYl3}<QRRUxhbmrvjuEG%Npgs3K>SFf)a|`cK<*#wd{`a
zJwE-SMG;<t7FAp->&}+bY7^wptC$(}k}Rhktrm#k^mPNT%oStQBJc4*afEWCY1609
z#aV`bZ*2zG&)BCZsfQv(fJjCMf3wcuz^m+QC~s_dnw<tRCG4$D)kraG|D-z4XAfM_
za4CyE!)7nRA$ZQ`+3w>;KL~!405>%_AI=_3&!Ij@Lo84-B47Pq&gy66I&GD!y_M_L
z1RYix;ZS71<H4(U2zi%&T<n!ANYl&0@A({==;++Td5$s90@uup`WdOLO4E=Mlel8m
zAHF_HrZP0yZyX(Ve}2<F#)??6<o2P-!W<5lbe8i&L4z3^R9o#TxhHox4KcggYMxCe
zMM->9ZWyDaia0;Dx=23D)VvvhN;U8jA|xHN!Xr}b;{^IJafpi#LH8M1fQe8)MZ`@L
z<gRvUy`^xK4&Q|AZ)fqgZ+#B{0-D;u_?8blCxigk5Ergnn*_P$Oixq)rL{gbWVrPr
zjLW$V1W^Srgzza`$~DHOf36C4m3?JGwGx(uaOplQ^W+OM1reh}nmp;J!oOW5xSpRW
zgCnVlyQ~zM5Ql)}UgpTpD`w>S2$O~H8nW#je;Hx96n75g;d>{bxSgXqQOrd|qD@oB
z9)>2l0Wii4nmDU~uotgC?fZB3E4Yt7wPGpM^R&a^DQeU>VXX88agVcGSjw26la@6x
zRA5*0QfXc+yL|MDPN1972^)ES>-!~cT6AJd4&??i;1vA1@rA^Y9owRm3}C9cF>cST
zAV|fqi@fvCHsqy^@*LaHlZ^55^;S@DO&Fc`c}8YIO=aa_5iKd)K(F`8Xftr~Vt1_y
z8?8Z+?oiSsiwH8!Vd$s1eo^F)3s9*liSb4^IA)a!_jBHEky^#*S#8!xe!<;m;w=kZ
zlQVe;Dq+&vB-2b3jMme=J99#3O_@ObNg5y`{)&4U6b~OI>QtWyi<qaI;EM&zg-fzK
zDo)R#hx`f%=9Duj0$wR+)Znj*0WPdqf!B&Oqo(@hRB~Tjy8*yL(-z$uKSF-Kd#~-F
zj<&^qJppue_DvHKJj7l@6Tn7|^!=}&Kb~PfJk`qK_BBk=tFcaCcR`66Ge($x=u39z
z;0eXJw1f+uoa99~X6j|N=geQ;`u0D2hj))CKdLyxjCp2EA`08qG;OPEMz|94&|g8&
zz-h<V0B|FGC+v54x|LD)*gnJ>N8XJxoWpWN-=vx`ydIzM^vAJD7$P*|f{xFCj5j@f
ze8$FP(%caXT&n)>KC~eHm50vT2!;{i#FTRvu_g5nnY8dI^MpFciL>(tf71_NfQSRm
zqiH|y>N9<p%WCQtgL&)$EF5oVSf4XR&U^He`#kQ>%58brzZbcvDV%$<)0_``J14j+
zLr)Ww)W>6rchs4he2i0iA(YUW&N3xpCiKp&V#rNkn8b>#liwrBI83$d7zFG3ljp{P
z0fRKH`8Q3A&UIC-LWcp0K!X`<Eo1Gk#KMrIz;P+y=iu5_`}ZSsiu?7)aBN8>l#@OG
zt$i+RU~SDm4S{(iVMNqFQDY&q!Xb(kUmswL9*7_6O}^LDD3Wy@r9SlpP!q`m6K|T0
z*%Fquh?bSH^UqFpa_O&9m@@XaZxQ~Aj`4Xk1w!J)5VN!ZB0UUIh(A@KU}4AOX+f&i
z)7(WEqtnn2wdj^}1$mbcf8qD0*1m<x@&04$Ah=U+FN(Q3+|{)^KDQ+RIMQQ(NM#-`
zTxqKo6&*N5V@-K2R~21*%SaGbEN5m%W~xCA<oPgl*6l<^h`>mG99dL(??;}gMj|k`
zFh!y9$8r3r_QV3o(n%s3Yv|gLc~ru9oEgiSmyZw^#bWeJbQG7tq(%ViAa-sRPXfEf
z@Q7{-UjCW>HGE9OW|wrN1nAI>qHkhljpWX8_@(d<1o@rYdx!y;y@&h1IsNd>0s){J
z*ezVWeNWmlilrFOfKCNW`t$kVXMn|xP_O3EKRv>@r!}ukIQQ_-oHIExg{hJ)UZeM!
zzilN*)}?|HHwmy6cj|*JLrFxoCb(!FOs7NvT`bCmEA_-Bowl4^Nos;@@cS2e#Wh7{
zJbL~Z+Lx8Fga(<%uH#|560{(~yQIms!yq$gF0MR4#}Cr>+1y>}&p_D+Uf*G(<8$Yh
z5GlW1lTkP(s$Est3<E6?BRWeQFl7Ip&SI2@XudZWcQgS{ntX#}RS=wRW9de>8v%rK
zU^)VTOukRnG}{mKmU~AI+m<qSeez}axF?e(ogAhty9>pW=reYTKVDM%O}BN+A|T_!
z@>WlYR}yDU7&FG+1rhdjPooH^KB^zI1=<hm7OnQ?Y30y+o0P{sx*S_^DM@B5Q_kh?
zx6q~@o%#Ivmt$-M^Y*CPfZXRKRevnA?P+lB`ngvWb!W=t*}%hO++>4su~(QF;f|}_
zAUv$(pP@4ox&*z7l-F<F!(JDMH5ZHwFLjGlS;XapIC&%(jFH-pBu|Y5l+dL&Z!vSx
zPjNFf?G^|^ZtX4LE>ZagMns1`6HINo2o?j-&|Ti@d(~Ad&Q7fJ$?1@+AEzY8NrR9d
zkNKc;C=b~O5)3^m|J;<de6Is=yawi}HA%WaI)7om+ugUwpuwDxr1X~XW96T~_f$dK
zZZ1P{MZV437bN;70EmUbGUCGq84+FhIyR!ijtZ1cBmC3}yI4c5<O_t<l|Hos=~Sc{
z@Qv3y7!Pq<ov=Lv?Sy-IYeb<Yfz59aw{f?c#7vh#qdGTB&y98s-*ga{0MDR7$vMEi
z;W{g(?EZQBfku9T0dk+*0p_|&n{>;dR4Z%YqRH-5a7%mj`&DsQ7sM*V^Anl$3ZOU^
z&=~uCOgcC#PL`ZjN2rVCb1td>RDRfFj}JqAB6cpD`O8ABzQ(`vEZ?F+Cq$=LAfCRv
zvLndR`1smqya$z`7b(G~fULdUypU}Qv$O=`f<E}Jb`NQk5+yy88>HH-V;*H5CRLkV
zi!sLhHW)kM$K60Z2?$-+PwjNZ#`AH}PN7`F^AX&-e~n_5GkgrukxNklkX&l^N~9z`
z3J$6nc2`f#PO7H&LHnJq+rt2h_&4a_&@EQemO-kt&`Y(AZ`3Yvsl{V2ga)q~B0%F0
zBRw~&K=u*2rdPCRGu@ft7IDwWR1_?ir2DleTJ-YZ6|^m%roXbw+RLRhax<<_aD9`_
zuyUJ4Ce;B%8dJks;dN(tsqA{#uZ|5-c2Zzu>)Y@+qU|P7%F<kO>fvu+6o*UmOhxSA
z#xYfGq!Rw&pYI|x+A|&^|7F+NO&jtxc^qeaEJqY^t^6%WH3CvQ_3j8bb!%uS(;Y{$
zh0Si(2E$ZWsm5V;D0l}CLMBo)M2)XuZD=Lis?V-xkyOJE@zsjn=`<yH+8?o~f{SmG
zCpgo{j5SsWVdo67l8~>omXCofh;u=ddV4ecr}s7qHc46pY=got7g7-jF|h>^w$x!W
zU#pJ<0!;d$GU#IsVvHC^wZsl4v;d9(6diSTqHVRVG5l1!gaHaVqm<v?86uSt-C^V=
zh2%uA%HHKNlEImzjbrxKtki2qIl#vm8XZ#pHzP2o`skei`-_XL0b}=>m~7LhO@{U?
zqj~=D_h1$M!xOK+rS_qqPtGgkKw9ly|8ShhWnII@z)&{%C+$<>a)jqV3f{vg_AWPB
zr*YFo{(%*SY^gYzZ?&<BRG8!&E{rLd&W%3fd>FlRuRfor`R(JD_IKfMKz}@I@@&C&
zG*KkMg7UE2)M+8&S0qW`7b8)${khGjqNT)adD^o!cEkkqoMML)4K%A251JJzG)g-f
zm!SmJ4daUAO>FUM-r;Bkxx@K_gY4c^y?wW*<<{9NN2}Lg#H{o%Vy>}LMVt<cdB~5s
zTU_sdj9$CjD$h-sp<QXK0myZ;zZy3Kd($GrLB1ae(7rz9zrhK#luk^(i}vZB3}&KF
zz0IZizam!UB`Thlw_BdWmU@_gZ@6gNoKmQVCz>6Xd4$f>>hQW%$yR3QgJQ<3)NKMr
zJ?e5gAIX5Iwe$f}Vv?eesuiNQY#EuB<XQsZ^ek07w<6-3;Bl6+3*T#?)-F1r``-<P
zc*Y&%Wz;uDRzd)b9*&2q*>EUMb4f_Bl4I5aw%W}&1h_B)6F=u@c@Ls0ofr<y>_<Uo
zLJs0alVFfOwN}&@zNW34Jv4rrm4a}_+YAh@uY%e`@P$yK!OMZfsn5q6$6I{wZw2LO
zeqlK%t+NiI#B`L!2os8~29l4q^oYCn9nXQ|oIk&_PS(tRA^`4vd4aae8g64zScjLy
z018T|MsP;*3bK|#W#$TK8Qi#ujUM75iG|2Bs6=pC21Flae|=AEe)S%mG%M!n_TRh1
zz^{A_6Wh^1c-;0AP&i$?tK`kL_Dk640NH(0KIVSKtV23J@HyvI3^*sJGHt!-1yLWT
zt3uT>a9;Y72iajqJ$h>W?i7a)jihNa8xCL7W3F5MDDzieS7vNFm&Bl{xIeuZy@Sq^
z!=#wvPy)VDF8RgJhkNk|q|E-Ui6yA7U?iHI7gxc0Axo1I(MF{iCKIi)Ux&=6Be?&F
zjd==fa?;Na2k{tq6kQ-l)$|U&r4asOQ|%vvbh`=v%UxW!;xct%vUMZU9(ToasuuK1
zu-V=`d+V~=@XU$`2MI;hN^NB5P4y$^3WaV->Fg}01)xG{-pzX!UnAS{QaZ7ATZqln
z@qrEk`&Koj@IP&+pG%^@rQ>t~jj9YwFP>>a4R=w#UfzJjb#-vTWa;%5GF}PK9=^9X
zJfFPoX=bKBD&0u=j9vzZ3dz%Ftq7zdFB`z;Kesk$u%;fAZ+DfaIQe<-Js%#NPw#JT
zSkV!f1IoF$vaspaG}2o=RDVOHULd2~@O={gPe-M4?+WD;J#K&DC0tKd0WTk#rj->S
zd_4D3pAs?ABwdFdrHd>7_!K-j;(MRnUr{ezP)ZwxoCJ+CExokn(9EpCAQX>iULu6=
zvK5DF)Q-78++!glb;;2!l$ycfA&Npp+gk1z1uss5M9>s1$?mZ4tw(}(?7PnmOyK}+
z{>rZ%dN1YWrWCInS5DCU|9d$hDQH*k{Bo~ql=}7pp^|^XWLL9cl!(1MSnTWx4pFe;
z&N0a^kgi~)%eyi+fbAecgxoP{;Y!704qzV*6?l~Wcq?;MypoPX6*;ZSGZIhKo<)km
zj_d0#rFD`pAO{MK?jvY33Sf6v-^YG<m>G~(^~~)b-6mTGp8|VAkhZzBL1w_+QzbTF
z;uit^Abxgu!~NSxw6bc?pE>$&)0jfaMF?adkqG!&pKXlsh;k9UPf>FXeyVd2Y<)H~
z8~NYc#j6>GNb~zgVC7%+%8nsPTC8mJ!kjitnfJAMqg381kHYQc#ea(F-4+V?JNv2O
z3K$&a+uj6>K4&UH2{neb<LEGGg&~*rva0$HsZ&%{`A=}Dk4T_oE_enD7yp>~W}XaL
zyb;p-u_j+!x$z=yu1vJ_Fx}VqWH8CWMB+#RxZ^(+!J--0Q&eMmM1<}?)i*5~yGabQ
zTf6JtUrA~(`wo<Ubx^4y8=bjDOfwWeRoZi4cW!`@=0tKnG@N|36m-J25Y{p&pK@}_
z6LE(4tXbA$Y^94Oy;2Vi3jGayuSvSGZYqrXBW((=foRf>7mCm|?H^73mN}!Q^p~JA
z43Y(v@8(mz8Z;DGsFu=@uMg<r;u#-Ra%P}N7l#JMDappWeTpxWq&;i{o9*;ufptVH
z93igYK9`feu5WVOAh+!DC|9BG2+llloHFqQ-}jq97>Pi86LS}FVqjE+j`2&o#m4lO
zI$}uZL+{Z@yf|>*!$_u)-Ayq1z3zQik%)DBSW`jx3Nrkq`NFcDdyC*mnUKhyye4if
ziZ`+<3qkiEovuQ#>GJm&BAHC*0Ib>@ybhoz+XUHXM@^mw_cPkeL$D1xrd$Pk%rnkN
zp9lq%O7$#oq1KDJ-BpkqH_l(xV3MHp;Q`w-c}5jcB6FT&F0t1f>wcFSzTY92kec?l
zc?OYKo*+658=`$sA-Snv62aJtFmMQx0e}f7JK$>Fa`UmYsGyJp4u3yMhVQiUa`Y(u
zK?Sm3#cSyME%`O$7dQr#i&cMK*~1&9AGJaWssEApc1E%rGnzrj)@#9t<7d9ujqv+1
zMo^{+JT<;#bevfuQqCmC6YN}aqToypLO*Ai6~0P4&m1Mfv-;%PKX86Hd|$A2Y$C19
zEBWkUV-;1Z%=?{pDTJw+xk$SY7-av4hESZ-?-U(v?63X<naN>TdB%RRU1U8#6tRKp
z>d>A<g>^F<qWGTZWc>?-ZUGoI1<QvreO_@**y+S{8JMaG%8gQBBJoipY&7kFlpx=u
z8<Hug#_R9y1f!4V9-vHh>7`lOuJkfOu;|Nz8d3en0vth%U<~P1SyYb}Nl*Dg#9xEs
zN@j1DQ8hhA5p*p@h%HwnXMRH|4c%^tGiAlW10c7_DVJGBEK%M(X?b_NzDj;BF^)Qt
z!DhV#>uY4<uDb*JVKj@QOqKHjodW>%C08?_nH8a1SE(u9o$o1NbjHbckG9$T7}?@%
zep%j4v^taT<qIp}AG?jfunld(L3LewB3!(2hF{j5X88qR*{)`rba0!jrFy*9?^f!?
ztepfwi(d$8HiBfi8Sdyxo!EFA&4#0)Ri7whxF^=pTx@+wP$Y6k87cRFXG{4cWr3L3
z#}U)Iz$$Ml^Oi{^wfjX6HYUTRlHID5IOUr2q}AgawNG!K6r>{Kztz7CR*6}PkKpM=
zWqO%qrl!MW<xHl!eed4)JL+`JC$u&~^Uxr-1vhUm#kkCCJV~#P!$5$CMDTx!8r0o8
z?1WSvAEkchmnL`2!$6TLfWo?<l~6So4<FxFNrYKT{AaTZeY%7@L)EMvuWB^s4~s6O
z9wU75{it35<q01mWTVcE=)8A@rShml)UzSGW=A&}#~-*yfhVGRTHc=%lVp7Aj!}SN
zXr1jDS6M#;Ead)uD*^tmNNHyir*!Bmfr1=LZBDGmv3f*$IR7A^sfzoaEmL;XSq6Qd
z8MB-4_0+=a-F0^=qZHe{g#RzAIYWD6sBXbn3=|?c!>Tkmp3s{R>K#OWL0%<i;_r+D
zkwA|Nw0Q#MwNl79TzwGsShZ^8z%$i6+79UyYMf$v>rb@xK=+R?@{AawwLD~Se(ayG
zN!wyG2@~-#Jh`sGi+kM>m^E-_f&{)Cix*3RITF#`|DwDirkYd<31pprS8&WwT*mCD
z4#9o98dg%d4A=bq3|e^RV{4C5ls816T-NasL0oEBo2jD{^obMS=Hh$`jLb|bbE{tv
zg*ROUg=YV&a9nXFpk9v;6|<jnXZ92V6<<lR7WE&HK!&@H0&1}gzq{ddeG=!5mb2Wb
z;a^?uP8bd|u2ltu19aJR4mSE0vA9z))=;qN2(qqn0VO^H@V|{eN{S%f^*Q(@pFNdQ
zAAmTx+$USr`2B|ODxn(<?c2T@w8pzb3s&gW<P!1RDzWL<H9$@G;Jpm_p-mD|mLMuk
zgq#)D8&Vs+z68ro_6@BteU(VWn5DSQHT`xwZEp7-ZY%MSKPH#&Iz+1dJ1$bif&wBS
z9}LB@^&oU%PIPR#5sGP<3^aA6Aa3sCZ4=!o;D#l?Kae(8Fz3_Lgc3?T!mcUv4B5PA
zw1`!qyHKP)X`X$m^gJ|Pm}lYocfgTdtXg>-6saC7q3_G|^HpST!?GK;PrKuih`Dap
zDFaH3np7sb-l!wBilyczpEgPg-%EK5({wA|QhBq1bI*KZHp7zkm38mR<Wh1$Z<jPo
zHj=)%OVv85gMIe?srv<QibQY+uewuWF6|OqSu#Tit{K{I57CGPR@F3JwaVqyvYfuE
zrv5}J%<iL(A|lg6<#TTxqe1mwzp)=qLAxiUIKe_f6aNo{$nsm2RFm3Xn({f0Ne)Vj
z4EivQUr$v7`ATSMI`dc+CWEokU;zxy_wy6l5}<m-V+nqs@N4SFJ6<k7|0;a^%Y>K*
z4B^h96W%U&^rJzYf3;ffBN8thh#Jh<0lfgG#1vzAXJoVWZ^uFBI{gGd#WqPP_8f;*
zb%?I?jcCH_Ku2vySK?u|mbrPE-7UhIA2X#i9iPx8HA0>Jl!hJhB~0ln(y{dvA8$w3
zD)j|?z5wba8ZtvM;Rm^Wcdw;HD`$O(PN?384)}@>{I&TbidHW-ezsjnZ({g#u#M5J
zonJ2qY&-Mm(p_w=-B?*TAUaP*9)1!eg#Gr!yg4lA)JL6%q1~xv4kJ&_Z0*URCDYeN
zfpht_hiNxtiQi~;{Qvyi<1({%VCo<4zCZQK9Uew>>c(hQP*rSvZZuYKL(#$-BDFUg
zY56=8hcQ=__>AkwRJgG6nCBP#3Zm2A8_yHIZbM|mS3apz!Coeq&);i#wEpPe70hoC
z?zP_DP)aM9!4osKCD!JYyf@bHKZfl5RqioWG<w+LwwPj}FuO=s6s#vqks{bF8`RQk
z2BDYU4U(5jb{HBjJi43Mjd_QsyDCA+FfP=2%$b(-#q(^iXP0k$*uDBNMb%4wYmtS{
z?f#HnnCa{qdrexe2G%!50reFz7{Z2m9z3@dzBM1#>rdejuWAa=)Dxj&jR0n{M?aUz
zFvU5zxxl^6TcuL^3nzxGkde_pS9V>fIVyW1%enn6#c<OzC!60|ZMI#;VA#5f#vo)a
zN`aro^aUyQH4Hx*kpv+A*bc!1-=v2I$+LV$KoDHHB&)Ei9ENCrpBd1Qq$KnFs=<|r
zDRjBDr_+BLXUD^wRI|3-u&-AaBN*d{a2m4px%`m-!W|o>lc&(7-T3UG(Z%!Cd=|TB
z5RQ6hy-U$w{^tS5HzbMQ6=1gOV8~YwOwDHnUg8-rUQmc^snUDVt`}0+hO8+7ABFfT
zC3F`*g|e?gnjpXV5q1WGo(SxtH%i=^P5_^n>MiLaFL`661L`CcX}!pzZFMb$1e?Ks
zTj3f5q$d<2)&0r>8$IplD~hQ+iR)H7kCEdpXH=3S4I-uuKLrIV%bjLj(mO7Jz%6gB
zfAX9Wdg+Rj(<SfxU4?Q-je7ov(8lyfZ;#xn+@9>|D`l&Wv<-?Ax^Bv4Os3*uoC%Z^
z%yllD*+u44O=w+-IP+|@ncdHH{`~&><N^4RZjveN&uq-j+-=IiO^Kj5iI|&3gTPX~
z_I+(`&cvm>USRu8Kr`U(H*<mO3oC^2{XHsk`W+Kb#y4GKWur@=lNpxLlJls6J0D==
zT;#IQy|TWHR0&~8P}Ap@(cy7imt!8upGAU1H`{{>)EHToS=Gj$>qFq+CfIU!nA-OS
z|A8$+mEeqvIvKJ40*`-@1YZ>*6GW1loU-6W{mo<fS9J_Jg7=vb4fk_#o()^7e;HF<
z-!4%aM#)(3vZtI{v`xVB^9wg|Njqi0xTe6U_Yv#}aICeJ&PYsO1lX$Pf=swN05mD!
z6+hZ;DofDMO&aHZy7luLCgIhqb!FI?<ZtzDEm)9J&lv~hFu`OzhhU~q9`x<3Rm!K$
z=zn@WietB}EQKbkQ-85wGVAwa5+z8sYuuf*21BW8WDmeajK+{e$6wcYJFc1yoQ@Jt
zRF)L<OmB+m4@u^^?|UpqFn{A2mH{K(OFUD7l=1&bo2-mER=t2Ci?S(1+{0+G7z!@a
z!PscDP$||d=RDnj0@H1^xX1&hT2(JhQ^^~A`Q>`6eKt$3LoZ5?c3lpnDgGc+f4>?)
zIO2VuldEU29Q^_67Ff=~v{zyMJyXew)A%4*i|eb@@j$)oh$%7o`0Ze%e3J;Y+Dn(}
zvwfU516uv)*y73AYf?~Bju<&QSkdQKV7l6UD!*-cKGw6m^)fW5h}{1m3p@^fGOtMs
zIrc=wYw8bIF`q`|99$+=)<p}vE*gP0l@e?dRwu}xLMJO%T9pmDTLHDnkzm;Cx7pA6
zCmTrL&P8D>Vo>+d(_iyWSy}`+9}Et!3KQc5Gv8o%T~)}$gmScZU`bzWfNcrqIEL;d
zxxyVss<^B2-P@~*#D~UX-X7VLWPghb@l)TT$#u0Ka5rQn?I2z;5#&|jc8y^r@x}&E
z6z2*ehB*GNBD@QT9kyIJWS`0~en(Fg{0dXiYZzZ&G{{4^_rpk)#&oYOb_{aDwrh48
zz9aHctxRtqNh{|4Y+Z7Ik<wl?)@ps<xY3B)q83g`ujPM>(a81xH{lG9R&FAsH!%Tu
zs~pFPx;fpGM@>nv7oo3vzDwUv%(k6wG1ht}HnvTp3-tHa4Jvo_LeoCtkX|D;9-z}g
zp6{MeNR-)LyZ8m)pb!zxJBxsxPMb->e24FN$r1Ym@3cmfHSmx^>AG$VwqEvXBq%T%
zU!*~F?j7U;MH`S_^RW)i_K?}Y2}{y*Eb>Q%PX7Y??HCSNxE$e*Qztg@RZjEDFCvS$
zmH<*@wWl|kI<}Xl68|)K&nCR>V$TIPd1%9cgQHwki==+goF!*Oz`Tz{v@HTh*LR2`
z<#J&jnbH2}5f|dtU6d73QRh-y7Y<o=e_Apd{D6s<k_ls>_tgeT@c$*B>2*E1;2on-
z^oVbNgla6dLaYOmH~l*WsaoW}XYe-#wg#g1G-`xYi%3A$0m0|zu3V0n#Wjr-xD98w
zQP0d4ia8APkj2G0s-%JGtaiwg0ew?sJ6uavAKjpkWX?LiqOQ+`Cm9N75ZT>Gk+<O9
zFma;YqDp__l4B|beB?HJcNFOSQmzykm@aT<o-xhYoP3(@KR<u1^Lj@&zD`x?kyz?6
zLB$Pnw7RwE^FM_Y@QEq8Y2YJ-qu$#Mnz9w!4QY@=sbF9DYL~XrhW;|svwizxA}H;H
zrx4aUC=mkzw|E%%K&R;wpNxuxF{J?v$wTgg$%*&<6#|`Z3so_K360F>WUlVZ!)kkY
z;lBlX)<@JvC-B$Gf$VFE)RthuP{pn<7*e896>Qb?g6e7|XzD)81be3jYi}ZvmejEG
zFYXgabH1J%w4`;eVi{D!#k;o4c<6gBN<eoWC``pKT<z<MMrfxZTxH*1jp*!mgm-{q
zNP@Hnld*Lb|A7>=x4b+Jyi1bW0%b#({evGuUh@SdUSqg2b=W0O^+k!n24|)k3`3uR
zrX@Iv@?=e4Rm^?esi@hUZqxvpl)8>L{{bjYh&ksT<$y`6vsj<&9y6-dw2})zL9r-r
zUKqJR=gcn?2i%tx^%q(qYIe2AuC?^Eh#JUTc@RBVB~VTL@yjSL*_<<P7N88*!5VWE
z&x7NAwl=#q;9z721D8>}&dNx<u)ls-Ch70}K@YHg)2BAoil4ay*m{+xM@)#PLT@D!
zL=j;h(KyUF-#(s&MqNAO50UG1PvGil78K$0Pg!}!A;5=B4j6M=;<oS%kc~Yg`n8Df
zbaQPDK|AVQ^WLLA^-$#jS+0WFbAkaC)iPLh@%}09sP4|qC>^-e?sQCY$RrzpQ@6Vd
zmh$=r@<Hnt{&emT@^O>^1qmu$xbLPnj!>?~W}gztqb>l$FYcYFK8ZrH3|;`Zg0qcY
z+iwX4kk-HLS8&ipyj?^XDXXzbF&CF(AhN8VyWLjN)5I!mikC*x*;Vf+DCg;ksVVn4
zwLXggAWv73+7*nvs;}__Litjlz>8gWD#$dqFGT8-bg!Xd8M1Fo`=OXTAG@COOgY!v
zyW*Wq`U;u-I2H67`a50R>j4YKv``ELJ1gwdQO4`Kx8C9vO6P8Ptf@{T=zDME8lceY
znlk@~9Ip6L5FSu@8t@Y?siyD@2^)7{3^CZHng%4iEeh_GSpS_YLW}~@lT4A%gkkAZ
zIi4_wd;-zQ0#kos00|%hf^iaVbOsCg`JpZ4$h+amll@fap=Po^B9JEZ!Xr!+TE*3i
zYWO_0KZ+RGS${_5!_r?wfOtugHO5SREjV%%w+k*+mPmU+!lBVkqiCpo1+0LbXuMvd
z*DWw=U@VA_r19%LwQ|{J`bSV(s$8@-fDuYqfO8DC@EAF|S(qc(`jF=*hb`E{$RiMt
zVfizXNN)~AA5m|mEQPof3R#w=)Vj5elgmimQBmtnf)wzz^X)~u(JOBBrfs*4a8kk3
zYX7}t|L?f7QQimQ)toZquD<zMtt`berT*gx4GMrD$(j5?EIthd?5~-{l^DeUWhpj)
zeY8aiFWb$#oN}}~+pk&GV}%sUw;vI7Lz-twui{e6cI{%fkeqouaDm}MM<_Cs>s2lz
zgPF7tu-9;P`thNWZ>3@nBjeC|0@zc%cx5NSpQ*#v`01*~tYAs?C|oq4S4C4?WqA^=
zUS=C7>DNd-F^pphUjamaTh1Ac0<fU$ad?`YDk?T-x=px=0MlE>WsaJp^f?|Jun~DZ
zN_=x1{^6L=*%N-U9d&TD1Ak=U$0W#O?QrF4<!aHXZQn8=+evG@`yO!6GMr7uDDy~o
z^=7y=a|tME4Vpdym(Q-4#Sb1b)x6uk10@SYCRI&U6iY~4=GK}<#Se3f5q-WVEjG@O
zbNJFF1rYnCL3Mkl;kPSbmbF%2Q6tbJYxN<zjXUQMvsRdC2*XV%2jTeR4XcX*R`NzW
zESrNIu^cdXAH$6Lr64Chn-*SclOn_&A;g=lkrxJm5-W2?%6}6J*{g<e-XO@6CT#vM
zp(ubI<qZxf3Re)SF<=*hQ|KB>&GZ_0wirOh|Dh~dM_yVfB_hr+KW&O=K)^c+NW3R!
zgBx7Q_jw)2{ImIfgGBLV5sYKmuR1vD+^>oy=^HAJ=?_)-9YdG+G|04_8D0e!d|yba
z-Q6U5O9PK*1+0H~(g3Ic>((wv74e(SI+Y9C5*h<nzJ*8k;6@<UuDil_;agQ{{x|2A
z>YwB~I26CBB}U-?0)^z)voPw8|9A3qR;!wJ<>HtG&Jv*yFv<cXEYbceyu(PAah&U1
z{Sru!It$x9m8d?+=`+|K!BeZ7HmVe`KSNjsq!|Dg;Ei?DP{>1MA@A7<pu(l`E+^P7
zpc8ZkLup(6871eQ=H<2!CB&^T&ig9JjaI}S*YAnhPJO0)T9Qzu#IT2M?yBbd1q`{>
zZ;(MM<cZ+`g3mrPql!rCK=cpbnKVTo?yeBZM~=#JD(fMpN#zqV3^w<v$Fx1GFRRIM
zDZy^>d^2Z{KqWWk5J3`zy!)!ui?T_~Z6i%0lMhk4kED%i#nIDosg!v=Ib{sUxtxOg
z7AJo0|MZ;AF0mEEV<(dM4@ys!#}4m#H$9{}Ez3)nNC?ZdR_{cVx^POb4O|E7ZC3pz
zblxODtLtML+ri{L%=ZX-y<xoo11<UKGFm>~vb}_o^`CGx>^3&1s)u%8y^ONJ1(erj
zA8OTHXnQM(;j6a<eHgKgX;sL6v_hq20@L)LU{Tg=w^qp>%9be$sBAiWE?z4Q+9^NI
z%ap82=iC{WpTy*;&<a(f>qD|2ozOY=vX3Fz;<0#ATXg0F($+>O-*XJpd^&$#)V}_i
zn{HS2^nd}W7e1o*J}+Y!q^|Y!)Ffr^h!;n7-o2V%F647MFb+`k_a6MaQmMjzAu4SH
z*JV9tJNXHpja_z$z54Prh-YmC4S5S`Y+Ja>`I@?9p<s^#*d}4sgB(8fw)Wp+7kK+0
zZ<OaoHVz^XIkNJA3haqvW#e>-Csh3B#FRFYwLzR%#CXJZO6x<fyWi_VF{DSqz%U<q
zTp%06g1HVndRoESoN2+!qhAy9+6=7VBWaGkRsKadu6bWjUbhf0xhmS3PC)7F7A!Kw
zZ{Yd1NTNRoMbWvh6j9e{%Wh`l_b_TJ(j)g-aNuf@K6Zgn8g<7V$gf~3BXiKe^DG!u
z5+ENWBB2`zl76FeoxM?E$VfZTnciX<tKLjOjC{IMrP()1x7Cd7eC5EX&K4Rw>7GRW
zMaS1nw@}i+uu@YMSbvjlg&3(61rLT57>H?%-#Fu^18hy9<yo5W(ltJ*nGu+<e*f<a
zb9qsk$B2z)u}?IQr$F1)6mB&;b7UM5B`6QRC!Md8^P035bdo=V5^_@GVjt1<Y^P>?
ze3IRu<3GcDa5=)ADEg6}kU~1r5vOKosGd{+9T~?P(zICy2qY20kbzKLcgHF+kde`b
z608>C-lm*02>yQJr9f?b^@U+YIcWwYDr>pY1R@5omWriaps-NO8Wbs3_eT`y{4lok
ztuL5%tKl-6TB)`3+Y;AXdtlZ(wiWkXwe3K5W2k~UvMyN3BvG*p&i#m+|GSJw3*)jL
zMW>3oL~cz2wiGxWz57<ss>E2hoyh?L53tSaI%pDdTt3sSvH{po;NT!`d>>2%q@^CQ
zjoI;F=mMj5yn(f^-B-yNNT#_fPm}M{-<wHQ6So3Vz8F}LaA=j}tzEt~<fv$+crcSk
z^=mCyR6h_cV#E+u0om;;-=w$LO^9O>NB#s0ob0n*58{C0z}}4hI!&=;Qx_oT$SJ^s
zBm6;PF@1O4ONPEWp^Dp3qn&F$iH;Xmsv1QuWX|;bEBhE223Huk5#iJ=4-Vg(GikA)
z2KtAP6B@x{Fczm_^n3+7XM3VcTpY7HmNlNRJ4l=mdHLqaid6g;tj@lG44YzGmXfEL
zV$OzzKp~4mSP@tMi|Vs!36Q{d0Ss)wBJjw<SLD^%is_{9S<x(y69yYc(@i@%_S4a)
zlgb%yQ@+bEK+v)~5q#!dEgH>DRHPJGjMt^R5yag@j@ou_BungKn@@ua<u5?bV2s*g
zQ8A(oqqa>Q=X&<6|78{r&3B%eRqzQ7C%sxNQDHFBK*(>93=lQ@H-qN3^ue^$Lc@FM
zP)&(am@Miz1(fp6`iENPvnVxils6xh*fM&3$oYW@jyq;EcOFWAuf{yRB8(}~f#2h8
z)-~mkZzH3hG>ZWk<Z*;1z?^`D+w<%0(Nz4umr{qGp~CJ0+KS;}k;e6oF1{`3wgJvh
zUK^LxzN@gU#npNdK~>QTW-QD~@y2;D<7u;;EyidohIJsF^I<0DJ>0%RE@g=5<4wCa
zqgKT@XKxwKwt-o|{9mQsoFu2&z7jQ6ss)chtH;NMi0Apv3x`L^TIVdhwK#v6K9x4E
z(kmoLZsHZ87sjV4WyigN(U5-b3Eqbo!)Mo%9CAPtz~+uHFP6Z$t!v7}NpAlc-E5=y
z<M!70-UnTtYoPKqOOWhCq>7)b??Eqs6VJa$!BR1(4TIG|>}8T`#R*ddgJc3M1z0y}
z8n^_>mJ;|EML{-P`4#NzrzFQ`=p-fa0q@4B7EpH@)hup<sw(d0&9E$7*CPQNeS{wo
z!czg)W(KBKg<6~|iDEmYq=)W}3-oy%ELB&K&NHFY-DP0}=%zi<3BVlq6i*C(WtRrm
z&P%QQRWqxE0Zs?MXs9GO@Uk8IT6^7E{57LFh)k&;1w>{D#8u%=(g1)?<&=ofj;W;J
zPJlTqgA?Sx>T{=UexzoiKo18y=1tGZpgJHIDxnAA>#o3sBHip8kJoT1;aRAPga&{&
zX*<F)+lqx<e$5|VpA=lh<P*7*r^sxEXdfaUdYNz_jcaNoTqR)z>3S@t1lokn{}8l%
z&{iOdYmp54)A)mqb`lTOV4n!YHn;LSYmcVNnmOkyoOJ1|W3$~LP_Cv)xd!+hPn?8s
z7=wb=O3<Z&(U#`Ficovsl)O90cyP})zpja(SXoWnCDb$ex5ESi-(4Ac=oC;}X{Sp|
zIWH(@mQ(k0y`GNg9v4NGPQL0H1e9)DNc?8%c>PyXbGBU-^=RFTk8M`=ne{<F;7I>k
zmW2V#bA2Fez<y!jE3i4Q1B*UELp7YFFroajn~{*Ng9h7+`QfKxEe6PV`#lg=`<CE|
zih9l`iB?b^)Lm6g)}(L~=SRrQ{!nc0@dJra43}LG$VltLJZ6k}C(^W`x9$*dD%4t-
z*P2t_9A903)FbgENFd*oy(0h97Hke^4^<qblK%vU89@6VS<g}BSw`T+%fK5RbD8ZG
zLH(~VF2s2yQINRq{P-q8|Cq74575USGC?t+eb5^Dpl|D5qxo`@jU71>*mKMqct^zW
z-2+Yk_?$L4SU~^or@g@t#-LgEN47&j-`Pz~j(}o!;ECm_5(6k4kR-&tevq=5n*f+I
zad~>9h1Ozf;p_`aB6{2U_M&_RpOw!x4D`l71T#+CgBHB|BRgQt*|lg=qF!g#d0&ka
zY*HKTsU|?zA#8X~fidTbx3QU_-0Kh%k_OGN?$%NtfH7^}(2Www1roUHx~^X!&~eeC
zjB2ZGD@PFy3=r-~u@)m4dbT-hmqP{^QAd?nnTVTwQuS&eiKX27aIVr5=A>s1eeL7H
zZGPcJ*e}okCjpGtK}@|+RhHrK-HMg-DG6nfz0Ju1EJ}*_#xf|=wA+_U;b(kXo{O>`
z`B+n78u6o62S7CDA0}}-n_V!z<g_-G!Mh>%sZlRV<s2mks#-|htvICpn#(R9H_a%h
zXKAo|I(1o&e&iQ^Zf)Km=9#;-V|AM+w*<Fp!a{^suV_k&Q-R$v>SB`!F-Q>V&JHU^
z?LX#~QtpJXGnZBYcYoaK-jCRaM45JR^4&;ez~+gIM29Y{(SR%RO@DRTcpBwWhq@;N
zp?Q?y&LF4YMAXL9AD!u8_$-p@s@ho_=3$D;yBw}aD0O(HKkG4&8<WoNS|$8je^FR1
zgF{d&Mwlwp?xK>VR7;!C0+k7#7;1U(aL=lyOW1c&yEruN5$@CR{71e*U;7G0r&bv%
z4-fE==4+gco+NKYTxc4!K06WZ;UWUPYn><=9hrzmA|l5-7+f{u2Hi@ldUvp%k*(ht
zJY8c=0V@U2jppI<j|%vZ&*MTUjm8pA*kj%IF_|eEVewjNGOdodpFZ$tGG^5lwICw7
z2C3l3XGX>d2{r^jX&jXr&8+8n6ob`OPrr#yuqI(x81n>i77?II)0C}5*Lwa?_rtx^
z{lT!}x>Uzc&r(Q*2tB~_j8OwexN7#>-ubAslmw2Ufccg2qDizetR|+dqZMS0z{qR(
z4b+P2nr{h{hU_2iBdh0S3yyq8^}1S$CJU-LavzyXcvDwc7fg+_S&phvxue5zbfxl)
zO#XnA$t_k)tiQ$0M(Yj%Jyv>lMyg(@s*Tc{7_}n8frmZ#U7#ArvpUJo+wk|)At9oY
z#nd~2%b2gT##d*Hw6eC9(zhXROZp#hjL=s<B-ByCDH2W!OyDHpt#2EbNTWK`T{U~+
zOPH`K*K(U2Ue|$dqfti1#s?J}se&G2<ede~jvzFe^S2u*G2MTKo+#%B<$<muTOSwD
z5e8FJq<kLB4f}^qHQO9+NUP~FkN0V_7xns-{T^7p8kMI>o&)b53vxmphQ~?jm>u&x
zNKN2NY}p~!Ur|ujg(D3;{|A@DPqhT3iwc{0#&C+37s(-l;qz1Cx}C?x{V;lw6WoC-
z?RYJ57FNsrk{xW{bm%p?v*x2wWTruQ=(e12Hrfc&^dfallZnXd$?tw*Y6y+Rb~vr}
znP2w#NA$vw;!SlAo*>52VqG{%_h&%?(?#(I>-GIvyYNTIs_^Dhm$seaUO*q<)z|{D
zLXcU`p7jb$aBEmEIn%}V4iN&<`|_zmDVKJwqN-X$M=Y)uuS~cpt%IWgurwg??syhy
zoZ|Jl?8B}j`je-N8*BLIH*^$12BNCF5N)80Go5*oLr!X;y~3DjyMZRc(^u25t?BqM
zb1&{}FwTIx$pcB;FOc}YCappiXS^}9X(#CSHsXkwElNw{<=-kI!Rm3F`Ms2<Ppk}g
zgmXcl+gpXy6k#Kxw+~Bi3u}bJ_`Z)Ay;BxN9ndMsl?Q8AKHJR+Py!eRc<K~BC<$dW
zw9DZTP+Ej95eRH9vMTLP>{{ds1~H@ak7|Da(B_!_is2^<K1ei<23Vk#jP%>hj?X)P
zpFEa%4h}!j`44dBqzF1m9@aVO-x*deaL42O7p1#z?n$3gdtXHN$fDcOTJjXFFqlG#
z>!gqgBI|E&sBb9;&+qRAdBwy@Hwzc&0!0YTmLu%<G?ARQTf)DskL!ev*LOyTMP8#v
zbt9kauPJRRJcW`r_uGI6D*zI_6*3_D|C`QB2X-XfxHp+RHgV(;`9-Tz_qN^}sgBBB
zaOkL+#8D`P^rqQeSQr<Wh_vmIhbgQ(oT_`Jh55d;bxPf<566WTqkiVkhnAL+JCSxM
z?wpDd*w+q(AL4!ER2jMq-m0L16R2NDW^bZd1vV_jV#Ab}ra#3qC1<gH9RZ_Ni(Mz1
zH&$QiLAh-%l`a1%-TP0lx#2cG`%)C8XE2em1rsgsZtghuPeN~Ik~WXS0^N-Z8-;Z8
zQtq#G+9l{ICsm!iD>VZ?Q}vO_=NPQj{gAY62`r9Z66-9ga*>Tg$o}^F)IlMJCh}(t
z2nJ%K6?9@H+<e1iU?XmHzPo}UiUoW;5!<d&|G{C^g<)~^Je@D%<3@NC!bdIo(VW$Q
z)z61-FKOpQABUM+f6^9)KrRO4sr+=P$)x_;HP(YTvr<EcbFp+<4y9LeHHfzadk2pP
zES0IjXl@V=P4P#Xt)x|TEELWUXZ0v`(VbpFodFI1tvuq2?5CajKKc-=o2prK9`)ci
z$vxr=g&7pgbaSgDvq4uiFw_>bu3{Hdw@pIb_(JVi+}Q4cvJBoLQ=HUhv8~ixC3kXx
z%k>N@=BBIm2DUCFYg3hThS5fQ^7S1d1}7mz%$;9D+7Y!A(|RYiV~)O@sjmosl6+c=
zLa2W1(ch(re7fn!Vp#(n;165b_VrH&-n?McG<>^liXA4-0RL%HdDBx$9@xbBtYgkF
z-}rvUt7D$?jhg+vd!B|~`c8mqLVB)7us*VMAr>qfhb&wpQ&Sm-B+I4{uv3%0@ZRYK
zQ4nS2ny`H=;7?-OptdBI#8FEN^qIEnQx-D_4nKcQcL!yLLD^qA9_r%c?{wag4P-~Y
zsj!s+Jf<7V)RoljapUb#bpN}JtU>QhaR%<)lpx@VgC%FxYt|ne!H&YxEcR8vhuhl+
z51n`Jm@mnO(oOp^Yu@#|A3oo-+nz7$vLkTAoNq88Zr7Iw$35~CAEuou^7J&iy{W1Q
z{Ul|q8vF)iItq2WCN&-mw{BtX)tASsq%6w0cjz^TG?|G}n9?yUlZ9!0sH^91*$JX^
z$)n?+o{xgNn!s~)n)CODLKpAMbJ^szW~ti&0nBb<yzqx4!*V0()?>PU^>VT_H!jw3
zHwsIa3AW^?-*l}ug@Q$Z6W-nOg%?5qojI#y@)9`Q<+RLh)YRRQf^^aahT2oXc!I1O
z;jAQ}2kIDc2oq-)RoA&+!iu4IK54{hVlc&^thXKF8%lY26vaW3k$hhMb7Qv|U5g)s
z^sa^X_p3@GD+FGt!_=m1sV?MMCk#J0bN12wLm33$KyZ}XPFXwV**cz<rw2LFjgC7X
zR#IxK*BfzXE}b2lG^1PQbLy*A1C2nBj6JjO%6^MH=JOkw3zMN$9`NmOu(Lg##dH4!
zd7Uqf|L>dWRM8doEoIN1D!hOxd?;<n{kUs#vgUoZp3aHitVWmp^as&4g5%#|>kl5d
z8*4o!?4ohn1vEDUu+aS;zMPNJ4V}+;Il37jcUeBH8HH?PdC8TeRcMNYO3uYFl2FJg
zuCt)K74gZd$o#ZiO|O5hLlr9wyYc9x(m!fvKTbDr7C`mI(E5LB3VjG%%ZX&Je!5&~
zS-FJR6^CN1a<f}}BDp*1VE+LIXh6Qq38~W}NVrkB6<K>{^g@|@P=s9}^J=Y85E$RX
zF%q^g6cuUsj&+Xe*Bgqs$#exla`1t5Fq><oP8&j7OX}efs+)KFEhEXNM#d5p)$H^z
z`m`g22JklO?KvCL>%PVQ?$x@8Am{Nn<Q)(1gBXRd+&`Ciy>|kAv@R`y@TdoXnsEX+
z6Vc#|_Qwlq0n9Bk(#50SwOqk*wdTWc$C5k5Dd>ISftfGU!H^?hf*qi(27dKFPQ!_6
zVYB`ieADE)+E{umb%k9W+7*fOI$4AD{Z>Vf*EA4iN9k_LTFO!fg!z}kp+6S7E<$OD
z4Ny=94piu5;oGW_`8qSLefl)8q7Hc(<-~B(+Sj=+_Vb5MFJ`CrpH4p5Rp4My5!jOb
zeRaa#eZ1W6xL{Ofnfs%cPkmYm)PU&_R;}+xj3<e=+q&y4Krym3Q`k-exgog&ERUQ<
zHOz~lkTWdkzw&dy*nM7$WB@p0wV=n~3PP?c8s&)|uC~(!(5R>5hC~g*9w_zTjQ;ET
z8{x9+h(IpKKts-)3EQ^p8)m=m&_PJ{f}C|3#hb%ewsc48WabGB{GW9KyR~z({#c>`
z{x4Rwvs67&d)bS-?p@v>_Cd1cFrAsez1$qM1Dev^iN<E;{>w{n<+ldV#&Z?v!2O@p
zVxtq!?PY0PbpHoOawWkFGqqhAd!UXASX{{egp<CGVo2&k?-Ho9L}&@Pg7X27ua1cx
z<0k<2w{e-bWJIr*UJNlMn3a|uO~1lwr)1MI62obp1lLV$%EOIq(W_O2ikg5eM~=(-
z92YwqiaO!qjEn=p#f-E?5Akjui5g~(n`Bk`SEYOJsp#(?d@Z&eZ1kGLNwmo6uBC7r
z<G$M4MF#Pkl(|`$r7UUk$;t?m;>OX|Lcl`DL31d!=6kZt7}7?*C#vu-2ta0e=1iBi
zDVeVB^h?w<XU`Q$7BMJrk)ToE=_nWw`{9%Ng}E0eAt(d3dN%J7MbN(hj%Z&sLK>oR
z-19Mrb+nD@e)PYR{NFswjyc-($1V(jn#y_-W9Op~WCz3O<}vkk<t%@z7lwmkrX<Kw
z4cHf2BH)C?jOh{XLtR$o?8&>}B&2XR`6{xHg0@@<2xhRsIdtwKaherjie!IlN+TWo
zcF5k);(3pq_KPr4)Kv+7k8ls(^Wugo#sI3RBS0|I<=ZgZp^=^W4}u6N&h-CjQspR@
zQ7T0|(ABwV8b*ZSYC-U&HyCzKJlB62i=D}=q(p#+KkuB3@WWb_b=$;u!S`<-!GGcX
zcg!Jd4S0pXU@HPd>Mxx$fCdI09(<HD#Af{l)#|FM(&|?4DU*#zx+3{d3cu{s`k}q&
zq6d)cEX8BJ`Sf4{Ro;JMn7vH+{3FM%Q%2li5RIpvJmbZowPz^H$fbUoonZOryPW+!
z9yCkDmNm}_#7C?2q~w<M(>SxGmc*v$>Gk;5g06GUE}1qp=J>d}yZW-(QJ@o@6w81T
zMFH`6Fq2GO{&<D*^{J}{+_GFM=m6Aci*IJpo)2i%8kNZ(TXIn<qtN>Xjo4O>e${<=
z1dii8_Z^p(LDOD4BPcM<Y$rx=_5Y@lZTx`4L&{<wh{maw%oB$e=%C3}y=#o{8f!Cf
z9lKkQ=LA+zt%Z=XyVxsQ33t|ReBW<;AZhpB(4Jj9@#}wqKi0b!t~{WUNoz6zL^ZL`
zg9y@uM|>~)vRJx-y++DTX_DORVqRY{o298J2hs+Pf?8>|;v(1A51y&;cF{YQl8^g?
zAiVBM+iSTR9T&jUYDxi36uESuKM7XczABA;q|XMe)b*7Xe0atJwM!)o>D$kCcgbAT
z=lq&fxXz(3pgQ5D$CZ~2Q1(}W;j_w#u7tHi1uran*9A2FE3L2k3h2_~gfVxz(94w*
zRUciQvQkNQnKej_o~t{_)k?9^uE>9%;k_wE)CCoUTD=i;GrdD2`4J3K6<^|_4_pjA
zut>wlt}&6D;Q@iw&bs<hW@#%eZM23Twn!~0rgI8kNVvDJKmTr9?_qrwM`d!N<!SnO
z`Dga=!1bC{wAY@>{#<u9Y+9~zo_{{bUG9;!Ca+4xfh$j!AU5L2=V=8YY!CXWV-ODh
zy|0qAZOj#{GcqbaXmc-76W4PzHJ|3{&zmJoUcW=-R8AOtp#EtK{pj0y?=SVy2&SKf
zR?4SyOS8x(gBhQyZD9o04Xfe8eFvjKe=VHT1>0Ys?)!ysr*YWj26HdQ@T4xk6ZcU#
z0ke%zpu}s2N6{w)an#<WEKF=KL*@^Ugo^(18w|mA4+ba!bW>LFxhw}yoCRmHqy}OV
zJe#+B1=&B#E+*8~bqn3F6g&TdD^2juAZ#Nhbi;w5#ZxH`AQ?jB)+Y8fQ;&qppW|1~
z&hceQMxEpX@q{WEhiiv1SzH|-*d;~tp~<qL17ib6MP-CcO5x!~WL@CYw@<sLR7~5X
zNGf154f!<;5IAeUIL(XFZ6um0Ua<Qmc1pYV2zi}E2Z<x5D>b~B?Npzpu%3q+A~gv;
zr`E6OQZc!Nzmc5>D{gY4ZQ2oNQ^<MQ?vJP+6$5g(DiFG@A}nz;A_VrFQC64f4h{j2
zb0K0b$%j<_WJmLTAA2+oNT^OHplR_lLsuh4p6J|aCbhLs<mrM*kyP04VIx;Bq?Hda
zPtxE)Mx^)3`S#@^EZ$j&&&#lPsL_t8Sk;@LCGuH=dErB6fKFeoWN{{0R44sWXvS)>
z$Ido$;3lsbqBJ5(dV;Ly!%Glk2f19n)Oi@lzG|#9lU+&_E(yozP2t5|MEqTiBFQsJ
zsFph}UE^Hzgm`B#7Vqp=yhm^rA^>*46{Ljc?=MqLE`^uf6aj6bos*gOIEA6w7@^R3
z+zMmw|7lH>UR4%DY=d(#SHH<}VO*7KTpfXsnXI*^v_r-G;>ol^7K@cGlM+0Jfh&|T
zo&KrMJ|2lA4HP;jdDUlDHFe2iKFdGHOH6VvpS@`_+!5D<MqH4LH*0zhQh{fUoknj*
z7pm{H5Os8(FKNw6rJM7tNYfpPU#O36Q)cPsbiRJ{uTBXFr8ny4z3yi%)>z+c0Iz+d
z3!p@@Lx*ZynFu}tb^0<Xv5qmd%E==T`OajI$_lhyfh<8k>1E_1+!_$4`>{4w2T2(s
z|BSGpXjlnXaSkx&ZANI(#GUfplg)~vcf^q&nB)EFWP2UrD3a}rZ=~VuWsi-L%So_W
z?G>gtm|YNFv@y@(=!LJK(&Q?ov~-O67oDgu<66ef1sV%0D|{s*G`L`5jX&-)_6O>-
zLwJL!esPDY^%%4an(tdHT(l@gmpR5W!&XlPfw&rZ%<?O@@ZjGGgAofP-p0|Tur&SH
z)bInK?mf~2Q(Uz72qFZd8pfL$ux_?Q{6MVI$aOz2It`e|pC421Y!qTC{!#`G%OyEE
zk+`FZYAmEN;y5#jyHFNfx;TO&%pYuini%b%f%Df%$sO7wYx)F+1yaNa`3Leu>7IqK
z3U)DU`(Eqb9VPDTx{Mn5P3F}36Dg7Vx95mSsR*oMg2~t@P(+RMij81TG6yG6;8a7}
zxrAyGi2V`;h!GFq4K9&OBsgU3Kg9WPEDkF{D9qz$8&+E8AGMWc?0=p@TgW^1IJ??3
zn+v`b@yyIUhkkdxEB}b67w=}W|CF!0AC?Sb55L4XO%UInm6#ON$})+0W6eVf;-88l
ze~R#ocoC1MT|iZ(EhqgKqQvNATQ|RX9>H`27KY?)8vXYN{}%HUO|*xA2TIvYiRo@e
ziG@Uu8l;%QK4G0jFMJRnz9az=UZrr=GjtvI6}-1Smg;r0db#=_@0&<a1AZ>f9om
zVR#we%4*#JXl<on6fa8;B*=FjF4?oyMO5mLuE>jXEQP&SzrY6zCX^^r)Tt$v`x-ba
zVtdzyK(N*`K2Z3wyTpUzGGUNsyg<n;Wdd~`#b&@I24Niqq!8zPZSVCss@*bs2ufye
z?|gQ1#Vj-~T~C`SagOf)XXN58Rs2~15#!?G4<^(f%^#;0by>7D71hMqhF1E!bO$w|
z{wDnUn4{W=1txI4P+l@)cakOh<6Ha<{R^xIvehU<jE+%~j6x7ptaA=5)F2wag3!F2
zZl&p=MIz!-sF?KyN_vI|_47tY1&R;EYzpzpCwzfKOO@T{>4N<%&9`u-X{C#u7nLn1
zW*O!q#hKjA=B11rw}Tp4muHMh-uI)M-hG8mUMR~z1jxhM_6t2DF^{!65t%UtuolzJ
z|5s*I?uH=q4WkmSqS2+-`U#r4a8~=f&IUX&nUOC@c;AzvM%>*eWVcN}fYxHXppGaK
z!r;!Hld6QsD-`9kCX>?nfcCCDd|VN25}P%-ZS7#JMYyx@6Md+|HcTOpt}qp?$vzn9
z^#HQq&L1bjaC&o4tPcj>)I@j6-qnD2GZylI=|i##t85FfBs3L11TvA#k`SqXjhgQV
zCl%&$1Wk_%zXATXhRf%rx2;qsXJ<V`3Xg3IEWoo7CB)wvi*)2hn_eI%X$f^LB1)0V
z!5@lNf(u98tW$+mi-5*7&kw3V&_HQo`e9+69jX7m=!WoiCO=XB*Cz=Bn-qiPsT|vE
zLcFM9aK<)2^6pj~<aa~Ng{@V1B7~!Nn`;IChvJ(F&bWbAmxp3hS^0JLRUkD8nxa{T
z)+;QES>16EjjJ?B7k5Wg_|D!+obp9IG|#(eYeNbjBP##90;2E{=KpIeQB9tDbnTm!
zw@<k0UAhK~8%J4j6EXU(RWB^;qxX5tZ=Q36@-$ZUDllhQ4-^c(rxwcu!pC#@$^vS@
zxKl}hoP`4?-EhR%YqSh3hN}&y;fv8ZZ%kBDd!?hd8Ft=&g19|>)E~0y>{jK&Wl+^~
z<Kc;j$WaSxRp8C>4oXsQmHj(;XCqFHDMcnH-zHLfcZW=>-~SFEGSK|CcEKJxAW6V8
z6J+TDITVd7cwua@68<skpybESrs)oiI`EhN3-<#Q?pO{#7(l;nty&JFeP%S$XRYKx
zOne37V9?7}ReN9#nb@F+`gxW#aRZdNc*;Bg^^B&KT6_4eP*5{B|FZvkM42BZf%|<h
z8@bJ0NPNdmh6ZG2vaNH%++V--ztXyzT|5yLZpLoRuJa{D*Gx(Ln<niE>8u205L4s=
zH4+v!v>EqgRdqp37l*E{*Kzumq==m=TiLZ`5^$U7Q(-lNC;c!;#4c(+S(}w4$F!RF
znjU{qN3yA+ew4c56&TfFfujDHp88kJ+BIGxf){KFBFv#<miYnn4#sbZB+2mgbgeJr
zc=bvvtOyU1I3}p#0D(UMsf4~Qxdd>M1v-s|T7YqM?}1HyO7HAE*$XTg*$|mj%Xd9<
zO}-}!r(`Fvm;P`@`|Belg3BXxbv754cjydGj&s{7{kn&NA7l@!$pFQRWt!;P6`(e3
zShkYKs8{)`?P60<$nG;*|5CSaw2*R-918D=aamDbA;1X6V~XQcA*7nrXJVV8SXrEs
zk#g#CiCxsqW|L7XKi-`%11-|F-+tdMr3l0f)b}A5_v+hYb-J#_w;!$A(w_v$8i?;|
z;7B%qZCj)9zY*`Nt<MO%TspO6>L53h*?LcM^E{k9zjP1RRLok!t2ZLZ9ox${26LH*
zvYYptsJUmvT4soKDSgr|$U|U>Z^;~=u-ch)FLw?~riIA04fBY0cXkUwPKP^iM5SGC
zBY+2`K(#(SEy{dp1_gM2pQs$Kw~<c;m&^Pj)_)e1ypnVYB`#zGPi{XyE=gHO?lVnA
z7R0>G^U><R*^&!9$Z7M^{bb+Q?2gmCH9=gMRi1oL|Kt7q%}z#Jz#>`C6Y<*U&$$E*
z&R5(yMt}{E4l38$hlWWGTNqkLI{)1LOXj@2tu^<tq=Y<0u~sB$DSpX&Ww!^CSsV3-
zLi27#|Gu2<%~6$f^_~>$*xXfmdfL+y8%FneOmYS^8zdXUXKEaza%tBRKT?mLt=Nsy
z7>e#sZKnGA2g@EdwRbOuQINwsRsZWM9ob63?!+S3%t3r@0G>C-P`1k7+n}l~AN0SC
zwIvN*ORyP#E2qwE2MlOPg8bz1iwo=!`*Sbu{+`INF^<*?>kh;{HMGFUVfYg^rU%Cf
z%}!GZY0Hci#Yw!xHvjwjte*)QH`<c?f1G~GtSKDN;-p~TP14fjID5DxwSM}dqioOy
z(@F8Ah|yHlYq+TWLwo7;fiMTduJxnN6lUBl-1t}qK4f~)+e(Z5xAqovMpqBX5u5Z<
z6m4JbBAUrwSb_Cl7nngym&)*l)&6tU&Cd4`ty#U}8XImtRREqsgL~3=K3S_P#G;PJ
z`hmU%#d+1r5?BxzcbgsqjD<0(6yaFo3ZP)%K)ZiPtT|8x@n`vQ1;E	@g!64|82
z%X~e5(M{p~rXcnD3f9B;DuKNbqAu)E5%ZVj#e^o1vunkDzy#z^N(zE@`%gP?5)3sB
zQ|+q?yo44z^bBZN5)EhfOvhO{`Y{F8r-*2+on%TJ%ZMgk34+V(maYB6HU11VT2H(~
zj;@A^3oAsY#;iwv)r|4dJc|@O3UY9*n6#KI(sCQQiHe!)dE<mT2_?v97SNx-jE<eg
z)^$cZFOLaU`$sY;5Q}LN*U>fNaIt>%8LA)>)JE^pX_c7|88K@owrn-iSKPALl7UK4
zQan;%2iV-PhRnu*3CIb&LM^Uz?#`)UA8S^$daR4c%L6eX2l|oVO*{qe_F0P}ZEd{5
zSmeZQm9Q8|8#9b*4BA$ouwAMEf33EWPQ0klS0EUHuB^J8p!xB$G>FB-bjjL}z#Q?e
z`uRl{Pl1>NDRqjY5gR8gztu5LEy@tcAP=cIA{|LkDD)P|A8qph)Tl^L0cOou2#KwZ
z^o}PU16bXdvx%hj;#sTdzqtQSqrRm3iEY-2G2rx9GEI`O4w-MZ$czUa8Y#0<)^~cg
z8&6+p*B)Ryqye;bS`qxeFXC8&=N7Tk>C!aF>=Ui7jofaXgZ?0U?+Nz6zLz3sWNqmt
zy}mO^M))_6;rlpe;M1gxS(Sa0IorL0-6UPId4Vp%;y(egB;&v|(xX`4oaeFbf<id{
z3^)gG<SlyCJ8H5aaicAvR1uY&NsDy@K-(!WsIytN^q7u=M9s$L-x1hL5xS~2ux`gz
zhd7>(6mk*i60czdDQze4*>T{E@BguKT>gF(wh*m>SC^}vXhd_9J2E5OFvJcGB;?9p
z&2o<sjJ=S=d-7N1_0qUT!P9+k>_e`QaZ#VeF-M{0Z)}{_B?ie~LuFIk-Z<9^3x0BY
zbm$(^p<IGs+db+eMf$ys6#+iE+pJ%t8G_cO^$xU{h~p&?!8&e3&e$G@*XWaWuV6O0
z_y!BU0&r79)5I5vsj<45drcO`?b%rfSMZzjM!Pq|%zEq#A=x%-7)DE@Kch<W9=NE*
z0FAer)}rhr!@aup=QK0h(WDEAX5j~yH^tzkK>!FgmRJgFG5un#CDaLGU#r1Re{RK2
zwY}!Bg69DF(E!q0P<(TQp)3M#BecY$%3Iqd79qqcQ#rJ80XUo^TQd2{oa;lgLi#l}
zCGoR25BX+qF#T=)ZC+loup(-ny}imI4P6^)l!j0Q@hr9;`QnWG2fpI6$g-W@jV$-e
zL7#)K`p(WsBASP@JY-@?VgbdZW?tebZ)%-f3tF~bci%9QSn4l~YT8>Yg=>prfx(6a
z?KgYMS=-$O-&<j>HC0s=dM>W8px|G6^gtgF7q}lHX&8*|S8j0?v79m#me(dgp8V1%
z;rTB)_J584?FmVE`Z~w6dxWf#SviW+byb~UONSdnr<?9cH-eb?1S<cfa%M_-soXZA
zio-yIz;&>%jeU0q1XDv*879xp(<x2V01f*ZSjo?qN8{wPNb`Go86xu&M@yca3V2+B
z5TZ5Oo!i_8k3{yY47?Tjmj|gavW(%==A5j<g|3mI-l^*3&r9mW=}E(vS@)O%9frge
zmOL6K>RwYtgy&beHUSr7kPtIZ);lb#d>mz5c9V6eaB}|swafz^tW|t-a6)-S3I6A-
zJbxD5?7ObDq1w5Gn>YzYVHD&Kyz6Om9%5@dhgk^}sj#>GUKMOu%;Ftk^?|?ZrUyUS
zk(HSGeu~R<GhO6C+-d<1lSaqVt~ZN-FZq@~=HC|1z5Gyr=IxMtS7q*oudAUcFlkrc
z=ow%-?CeHFl@#X-K)vFT$PNSyFP_&M$`p1v?{J~Fu!CQxdI}cE1?RcOW=s2ck>tf>
z8RI<BN&X;1q%r0`&2B1!T?2J=$H~TM>px~~jNa2YAo3T51J3LT=0%7v-LUjG`FXRy
zLecNyga?OvcLTx18j`D5sJ0Hy*{?vA{?&{Zll{e-A%&8BRnYCeUa|aQCQHR`*kcyb
zQo&d&C29%gD{r<ZHX?jEsdW3fUUhZa^D$#y=D7k$7{|f;kl#fOH``JLbM&ylL;T8p
zkW!q8N(gENxl`L0c2h{lWZ5T@`a}F+x|&H*rh>u_7P8PJdCmf3yJTHn)s)VhTrh^W
zbS)RBWynERhq{DgK3;{&@Z(e^)t5j%bD``+8}gPUSgRN1g7kV+hM7TAh#O2Y@D;aw
ziwqdmp=ji`b@mCzkgxl9LbK{8_GB6-h_@02+0FUJ-Jo{%Akfbzmy6V<7^hozuCUk)
zzuErL<};pe2oq)l_C=*BQT!5Y*B?0)c}45D)lxA2c`?bhE{R8S`VtTMV~^dG^a6^6
zSjD&2DJ4v%tZWW5NfU2S$mHS7{A~NlcA78%!E`CObynWgbs6)d7<}T!9&JN|$#?k3
z0#7zFCuYE%kel59?xG%>bq|LPh0`^Gsuq>^S0X)5O4pO(q9c}@dU=PrQ+YoS?f4Iy
zH`WOMF#xro@Aryo%{IUO`LmE9B$$g8(dWI0?41M3mwub*Osvx$6ZbeqRW1l7)5XjA
z$I9a?dno<^(8fmA^>BAxL|NXEKqwH*%PkITXdm%9xjU9z8HCgfP1M2Bxk@7d98gS!
zjLjE%AAu=276A;B^V6=9piCVjHM}&;RKg67(%E+S@p3Z}%6G%{<xYh0m}Gm(ZZ!gX
zKm)abmVf_2I=k%}hr+_%H6tH#P|UU#SCWl_!obc{JN~-)L4Uum`N@|G@-H~S{wxZ|
zR>25Ye_Re~B+x^Dpzti}R|Q*wzR!M*{4Vm(7|JklnT+lwQu_cPg}WtyoyZ($8&l_X
z$95CFi=CQI&bTaY^w}oZ1;I#gl?rx9ekDDjzC`>;r~_TXkSRkz%WLomk*tbQhd*YZ
zl({mherXreU1MHjp#6pIc_}Z_FBYOX=d&8IP3!l6eAQTQqY$;Y3ImR^9GLDxO4L10
z#M)#>OkuCq=Q-Z0pZI%3-E>ts&XbQ|kLMy92b37-{<?qxXdNG$35>#q=$zhsVyhMe
zCbrfZVKoocW$M^43T1%?h33*8zNNB5xofQv@=+DAU_BsXoiegeYU(fI8vm&id99b&
zdr2NoDWI#qwnvKetV~eB8cwc>>RZKJXYIAkMD5CpoW<Y*&97>I4t2!*d6(;}Tn`=~
z->T2Zz|bES3tr04{3j(N)-?rS8acw!45j+-7YNt*r=UDumIsI0da!vkE*HZO{{i#U
zjY1J=4(Enk8&bFJEmCDJJaRNH4VUm5m+|W3`So4igWb=USKZE0{4fO1Ve>`fnTNYK
zw{5}_#>1%96p$gb9(&d5JpRex^-FXA&TgsRv#<3N<_Z9T(D$@_UmpWvgA<%7m*k!8
zlecX{w82zQSSHH=&6vUIvil7ikQgIIP@a@1l8vXObwetp0uFf-EFIyp(O0Am>v$rk
z59^Il5;fA(X@eutfDvQhc2CZ&m;ZsvhnE2yg4k*MXd)qImYDf|nFmd8#u}fyM~%xK
zi9nH>oCZ{q#1u=|mN9}QU6U^8t%mk_q0Tbmwtt3yAIR_TLwEY686#HK9lon#Xu006
zU2FoS;k^T96bl?&{v$u>=X?;>@9Yjt-(0zZ2eUk3@i`aZNizs@f#*1Aj~``g<nEb7
zle)@uvHp}QF2T8NVpTlx2{3Vz4c(1XPmp8qn2jVoVzZjsFAxG&)Nymq!q7^dn8m~Y
zN0=j&iV!GR2T=2(0HjEj88<oKhlvd-Sy9#iFDc0XMg*dN+RTZ>M;z;#IU3VTGPsy9
z^_(s7UyF6Msd&gBU0cFMwqs&KvhOkN<wbFr_&s^WG_jsTA~zL{HWJ>iC3d2PI4y|x
z$N5Nz`z`-Pn=SuuhSpr5pJcY9sauT<d^W2NTH!e`*b}9z(A$$~Ct2hIova*X`3XnH
z)o7^^5THckzvCK>%SrnSRC=uO9E>;wNhd;p8M2t(w?cYMyOrwU#lSl-$VD3eCeXeR
z8-AT`S|L&hd;3RoF$M!7enyX3UMs?R8*L6$*_~FPGnb&}fu9##6o};G1p3;j{e>uZ
zU626vACvhQ@26?#gzv5A?!<$8K6dX5s!f@SlO^xKTe}of(&In0uRjwV+C-c?o}3zD
zzdU-cI+!(0)k00@ShwaK1aRS^lWnD6$fUng-!Crsb^n-h2zGWerf*?x|7M;ESp}gQ
zuLwNN^74c$gxvb|O1uHxJo1q<pT)#9zS5i#>(r=1obfe-h1H)ljBHyiw+m3Z&)8Y}
zHQ`TGU?GE*pl6UFhSO&CooQ2+WvH{=iR6DZ!yClMkTkpzf?lc8IgTn=^=ehA_lTcl
z`E6DZL?DZIwxR8APn8wfdA%|QQ&8N8$_{{2r)OxYb@Uf8ar()nA9XQ~Fb5u0Ygv+`
zsw^Bvyckav+**j_>FSPz36e;cy0;H~k&wgKEP_A|Kgt12N3JMp=ZEA$xfsKmL5`QG
z+VzNv20`cgSq3*Vjc4<T$v1W^nOy{YL}KhGk9+&>kPO6uu?y1Y>`tv>YBnm7;i1o?
z-siCHfqzGEz9KWHjicp7S7t3)LCGI;qP1;M3T0fjrC3`#fqcUL%Y)(CVjq-CWWuKz
zcrO+&K5H2CpTgm3#p_(XyZ<C=Wk8P@jM&ZKWiFE9E}(F0)9>L#91|wn?vanl@`H`D
z%FqJZN{T+Z6;BI`SwqEsgWbc|Xj~ZZ$Qas_&{fI;f(yy{U(Ktp*0g4zbSN2!JJ8!#
z=*{Cb9>5oE9yDwiepaW4*9N2+XVR{95r<$@wzIweWr1j!SP0e<RnKlg45Q-hp68{*
zG5b1b6Hik(Qcbkbxc9hBp)qeWF*7}A!ZRd01W;3(=6<MjCub?l9v?cr6PAqTw655D
zyIy^-XCHqv1w~bG2i3AfgMdL0u^y2TEoi!fPSQK;bP*Jm#c_J|0H}31EK6x)5L`8f
zeHdE2@2J+h;@v?X^+`d@lEwvo6#XJ2t-~GENK7Xx!Qj(gi`4QvXdiIDgcw_Ef(@^T
z<<RNL5Y&>_fLep7OCfi_Awh}8P!nVz(;)A1BqC>I*UZ(Hy>Rj0EAnVjXbYcWHQ}=k
zU)To@lv2db^V!%97p?wCzeIR$oaja;2SiXl#jGa8d#462pIx}*i~*YP-FXv`fJ91-
z-ZgOg>#~M)#6v514;vV8k7gy2X5A8es5)b`ZUHa&M)oW`><+Br_)x2^#-oLxLQYP5
zX-z_o(^Nk?a*_4m>jW&er<ddv$|24Z5YKDFrJ)FktM-qlLiS33o{??x-*a{}V@WX;
z!nTpk2%7TBH`CVD8t%=aD0Pb0Bv8zzCUUyMcY{N5vqMF;#lr$t{K878@gi?`0NQ_b
z2Th4sVyR6jr?5U&O+De_p}G&uKw^}=(q3B}b(|0748iW%wKy1&Lr1k*gL=3EqF;#^
zX^xJts4#n{jpeJM9NowzoV6Z0aIZU^UoAF7cgr^dGu3~MPo=VM&GDlF_{YuCM~_M%
z>PKCm(98C{qwd4Y%b<oX!m^d;&K<3yAZ}$_kK!gqbd*ISd1sOzf)lO?rdG&RVqOek
zb4nX{NBd2xP~jlhjUmDQQA>=y)h*%8vcN*>WRh`T(?Dv?Tp~B$EPTuRx>>eo9@WM|
z)oOVcUf|J}Od}QLhv^}LhT(u7KSZ#_gq|wXi&k$hqD6$~#9b%WIh_S=?$gr`{rbC^
zgP@sr6$-k{mcW<Ygj5Y;`A(X)*u}v1c(2^WzH3dTV|Ru4Z2g)eK`)>DL_7nc)wIjs
z=JUM<Jl-|kV_}riNo0!PodhtKWCSBsAZO}tM{QJ{s;rBMl6NgA<Ne(WJpke>838hE
zw=}Os%&H1y>)$!qdu?Z_x^owE@URXkqqOkq!y%Ir_5-q_7E+i%Z~jrfiK=>}f6)zj
zUl~#cX<2(}_TnnHv~kSA`sDub9aaK@Upp3$Cq9aC+$8h9qYHZU^WE-0Ut?&lzB_DY
zF9jv9x&8DaqxWFR8CU{)Je?*<O;>JH078I1^jtJQU~Yl|Jd^uAw&Offs}6n@O`vc{
z?jHTCRTKVUI_<q20E;83S=RldyX=H*<B(7QS&&ZSoGy2q?qG!+oJ$vU3BiI52qZ8<
zh}?TR)yA0}brJmZTa|j+`BZCvX+m~aKm6{n3tltKYpnT~+byQg9Md~xkpu<@$$RD_
ztset6hayf)g_kWmDCuqFJUG7seHWp-QqdQJ1Wl;=YGC+cA<ZK$Oq`%HkNKnc)Q4sK
z3+cRm{u93eg>M)A$``qkhR{pW$Q0Q-!^!Ue45)a<`Lo$(D(`Dp4rV0!Zi5spCKcbv
zQi0{FHQL!UBa%m$e02qPHheb@Hc0bSn~^%|VDKebiGnNA0-v|4+C()-V|>*}B0qFh
zbZqGPj*pHpY_W)72rDHRg0;d<hzO$py07k)1%EnJtl1%?*AjRx7n6d&w(4Gs@0`%*
z<a4mUWez)ypTLQyfTiJX+*g}-!>NY?)qgH3knp4l7k)MI8n;eGq6Hy;yftM38Js5i
z<i;gj)zN6JNZaGb&(Q8MmVA()tKp_^5Kkba27hgr(qh!R&*RzmHbQ^llx5fx<8OHW
zKgmMa=b``%&fGB1!Zz6VjRddl3*Qbrpqqt=%{Cs9S~1M`5b-bHL~~mt(2Cv}G$sFo
z{e#w&Sd~N$xR<Y+c?yAWn@PSXF})%xVQ8#)DC;Gc@8YSw%zbd4NLPc$w=Et~tvyp9
z2=63eWC5*fP1Qe!gfnm`>slnx)ZgWDvE1B8){p**c6fpbwjmY{(;l48C|OkdP1o`o
zJ|MwzSr3%G%+U2~%`~Y`(D#a9A{ot-*Lbodk*gtV<92bX{;Yt<c@jp<L4xvTglX8&
zczt*71#V5!@|{yhIhAik*-g5yH7p4KUz7usK8lqGypP)66YZ)=t6?C2cUkBo9V{7y
zZyNranBifJtR~+aKp<(qn%^B<voE@r^`@)XIichquw|dzV-kQsda>OSFSM5fgZH*)
zhG`R}JsHSh_VM8oCgHyawq0DhCdab?$BbJQ>mX-=Qc>2AXFAPjIj3aQ`(w^hmDOys
zB^(E4bcUg+G+E5k5a$-QXE#BertEJ%$euC~+-jsZPWLG0qEwIxx$XES7k#p2>28P<
zRaoJ;<ud$7HV&3krr#GIVjdrEK`V}h&L?0Tt4QjeZZPTq=&h?qy3kr=lS@ZPuIol9
z$CY;1bYzebPVdCIvi)<U;BdpqTF&B;Pqb^tHVjc-?(3u;=&-!l@RD?n|Bp(pJz8Cd
zAx5{7pcjjW!~di)*$=6kr*p;}B?NJgC=6c}=3sd2TXtktRy{yo{-|ss&@>2@vGLv^
z$`-9aDyBl5i2dC)%w6hI$6oO#gc54BJk8U=-wl-zjrO@VdV09=1B4|O|Mq*Yn8pv4
zKo|n;LK9b?=4k^Uc}nHPGq&WPo}fAJ1H-uHWu87J*&WlCv9WjhFfFoJg`)@c{C174
z>+~iUyTI$8`e?m0e_IYw?Hi{gK2BGVM;|u<<PVDlWayoD(#gw#;uhYwd7Z(RHwn85
z#0f1&MNtJthk>`2AUd!!fe0_bZMX(o$m9uELyrnXAxJlnwH9{kC!1D4=9L62xpqR>
z|6mpCK*H;u*oZAN(!%r(h7c0Kyg@4!Ff0_?*<ooIEK=6z^$=}E{SW^T*XJ9u9?2aj
z9Rqe(xOTXKlCVWLQNe{nrVVV`=fb^wvs_WeVEs-GHjj~PBcgjgMY#;RJA3fOg%Q2d
zt(Oa6`0NY39H^G!{h1oMaDtNM2o4^0<&sP{jD0X_hk5{5m6ua!z+H2xBkYF3Sc?#=
z|LqvNBHf!h#bwO!o5qMCXpyVvv5e|2_Y$D>yO7^>(_7x$q+JwX8^$ZxjagO55dx<f
z&&c;0CNGu!(}?(#9YCysIOZ50gtd)X<o43x=_!agfHvyl&w$e>K&lk&Q#%wi@+#VC
zUd94<G<BBBTT-u}Z%+7v$_DLnBNZfQGH>qd-eBA6RvMPN2mvUbZWCkt*N=2VU0yH{
zy`WQKrxEC2>5vg<u_7KF&8_)zUl<Hmdd>Qy*j3Dmpa3%DVRyx81&ewfIsh7|&+EPr
zl<Mcf0fA&v!U0>Ydo+XNqU<8}V^uRQuY!7oE{SnnAlNF|SbL5->v4gyl31hM`_BHh
zCKapbGgcW&zGb5`Tr}Uc6Pi)*xy)B-i+nSw9DdlQUoN_xatX{;T481GHTWaNb>~4h
zT4M`G)@pAtyNlCB758;4cB~Pxn){jjck0;N5fA#3)3FbB-exQc+P!;B_8vWa6WGE1
zG}^~Oqg%l8CWUbA{=Hq|LV~yHwv<oL0s5uMPZNhMvX$i~G2bxjb6>nP=P3jg%_2w}
z<DGlhriJTRqv3E)Q28wYIsWHzDFBr4F5NWi(E3x3euQuLiX`=-y`J&*qeSVHw$#wA
z;|d%A*9#^A|1kOnUb`J3)|4>K-2iPwBrMqp|1*d+a+2ygjYJwl#OcV~)w$36(j~G$
zuyE_JN9=-$CxT7n-b28UkrjrCeS@q}ZXLkJ9=ZZB?PsmD|7**3mW!JL)hy$CU~V<R
z;)OPe!5B@HK~$O;Z8kBjt6m-|ckXg(Xp^53?+rO_6KrKh^gsSZ=v6n{Z?YD&?!>{C
zCPR==Ux@)3f8$pyD^==pk8Vg6qmIK;mQ6`f5?DeseiyF809N?4PY~1-dP-ET&2pTu
z9I~u;NH&TX=679tBG@1fWvhH(!$jrZ(UNNa_A3PO0FFws03M~ddv7#l=_{AU)H0q}
zgH9F!1hZAvA$CSRKH+^0=XZ)jutM80MyWvs3c|B{W(xSZha6l=E(C^;ac(iO6{`_Z
ze!xKv$BQV}N1kU@aC26|OmS_ZoCQu4Ri8G<s?dD7WNX*qgF{6=Sh5#qDbX1%j>ckJ
z{~*+!-X@F`66lL3k?c4Z?8hnURsfp(PrEB0df;yRHRH6wv0*G{D!*MXN8$G6h_*AI
z%@<0+{6RZD2?xxe55Sgh`5GwYX}k*VIq$Pre@3n3U4h2N>v)`PMi3cJamHtor|nzc
zwbP6#PkwlqwRc^cKtRGYtW}+6GkSo=_DfX7lgJYaH-X;&xEaD{L6^G%|ELacs@0!L
zv}6slJvcDmh7EbgZ4vq=M^vD7fls6eVl=F8w@5C|9QUH5-t|zh?O*m=It1y9nL99z
z!=|P~oQnw&Z6bTmdBPSC14rNfQY^2hDhrc$JPgh^sI?RBN`|Qua_U&wDoTqO;^gmn
o>S4JB54^qr0MT8sbN~U++X8~e4pHs(1U@hgivj=u00045S^?pK<^TWy
diff --git a/index.md b/index.md
index aec3d208f..23f3c9cdc 100644
--- a/index.md
+++ b/index.md
@@ -155,9 +155,10 @@ example_isolates %>%
#> ℹ Using column 'mo' as input for mo_fullname()
#> ℹ Using column 'mo' as input for mo_is_gram_negative()
#> ℹ Using column 'mo' as input for mo_is_intrinsic_resistant()
-#> ℹ Determining intrinsic resistance based on 'EUCAST Expected Resistant Phenotypes' v1.2 (2023). This note will be shown once per
-#> session.
-#> ℹ For aminoglycosides() using columns 'GEN' (gentamicin), 'TOB' (tobramycin), 'AMK' (amikacin), and 'KAN' (kanamycin)
+#> ℹ Determining intrinsic resistance based on 'EUCAST Expected Resistant
+#> Phenotypes' v1.2 (2023). This note will be shown once per session.
+#> ℹ For aminoglycosides() using columns 'GEN' (gentamicin), 'TOB'
+#> (tobramycin), 'AMK' (amikacin), and 'KAN' (kanamycin)
#> ℹ For carbapenems() using columns 'IPM' (imipenem) and 'MEM' (meropenem)
#> # A tibble: 35 × 7
#> bacteria GEN TOB AMK KAN IPM MEM
@@ -195,9 +196,9 @@ output format automatically (such as markdown, LaTeX, HTML, etc.).
``` r
antibiogram(example_isolates,
antimicrobials = c(aminoglycosides(), carbapenems()))
-#> ℹ For aminoglycosides() using columns 'GEN' (gentamicin), 'TOB' (tobramycin), 'AMK' (amikacin), and 'KAN' (kanamycin)
+#> ℹ For aminoglycosides() using columns 'GEN' (gentamicin), 'TOB'
+#> (tobramycin), 'AMK' (amikacin), and 'KAN' (kanamycin)
#> ℹ For carbapenems() using columns 'IPM' (imipenem) and 'MEM' (meropenem)
-#> ℹ 502 combinations had less than minimum = 30 results and were ignored
```
| Pathogen | Amikacin | Gentamicin | Imipenem | Kanamycin | Meropenem | Tobramycin |
@@ -220,7 +221,6 @@ yield higher empiric coverage:
antibiogram(example_isolates,
antimicrobials = c("TZP", "TZP+TOB", "TZP+GEN"),
mo_transform = "gramstain")
-#> ℹ 3 combinations had less than minimum = 30 results and were ignored
```
| Pathogen | Piperacillin/tazobactam | Piperacillin/tazobactam + Gentamicin | Piperacillin/tazobactam + Tobramycin |
@@ -238,7 +238,6 @@ antibiogram(example_isolates,
mo_transform = "gramstain",
ab_transform = "name",
language = "uk") # Ukrainian
-#> ℹ 3 combinations had less than minimum = 30 results and were ignored
```
| Збудник | Гентаміцин | Тобраміцин | Ципрофлоксацин |
@@ -322,13 +321,15 @@ out <- example_isolates %>%
# calculate AMR using resistance(), over all aminoglycosides and polymyxins:
summarise(across(c(aminoglycosides(), polymyxins()),
resistance))
-#> ℹ For aminoglycosides() using columns 'GEN' (gentamicin), 'TOB' (tobramycin), 'AMK' (amikacin), and 'KAN' (kanamycin)
+#> ℹ For aminoglycosides() using columns 'GEN' (gentamicin), 'TOB'
+#> (tobramycin), 'AMK' (amikacin), and 'KAN' (kanamycin)
#> ℹ For polymyxins() using column 'COL' (colistin)
#> Warning: There was 1 warning in `summarise()`.
#> ℹ In argument: `across(c(aminoglycosides(), polymyxins()), resistance)`.
#> ℹ In group 3: `ward = "Outpatient"`.
#> Caused by warning:
-#> ! Introducing NA: only 23 results available for KAN in group: ward = "Outpatient" (minimum = 30).
+#> ! Introducing NA: only 23 results available for KAN in group: ward =
+#> "Outpatient" (minimum = 30).
out
#> # A tibble: 3 × 6
#> ward GEN TOB AMK KAN COL
diff --git a/man/antimicrobials.Rd b/man/antimicrobials.Rd
index f54fd9046..912fe8213 100644
--- a/man/antimicrobials.Rd
+++ b/man/antimicrobials.Rd
@@ -29,7 +29,7 @@
\itemize{
\item \code{av}\cr Antiviral ID as used in this package (such as \code{ACI}), using the official EARS-Net (European Antimicrobial Resistance Surveillance Network) codes where available. \emph{\strong{This is a unique identifier.}} Combinations are codes that contain a \code{+} to indicate this, such as \code{ATA+COBI} for atazanavir/cobicistat.
\item \code{name}\cr Official name as used by WHONET/EARS-Net or the WHO. \emph{\strong{This is a unique identifier.}}
-\item \code{atc}\cr ATC codes (Anatomical Therapeutic Chemical) as defined by the WHOCC
+\item \code{atc}\cr ATC codes (Anatomical Therapeutic Chemical) as defined by the WHOCC, see \emph{Details}
\item \code{cid}\cr Compound ID as found in PubChem. \emph{\strong{This is a unique identifier.}}
\item \code{atc_group}\cr Official pharmacological subgroup (3rd level ATC code) as defined by the WHOCC
\item \code{synonyms}\cr Synonyms (often trade names) of a drug, as found in PubChem based on their compound ID
@@ -59,9 +59,13 @@ antivirals
Two data sets containing all antimicrobials and antivirals. Use \code{\link[=as.ab]{as.ab()}} or one of the \code{\link[=ab_property]{ab_*}} functions to retrieve values from the \link{antimicrobials} data set. Three identifiers are included in this data set: an antimicrobial ID (\code{ab}, primarily used in this package) as defined by WHONET/EARS-Net, an ATC code (\code{atc}) as defined by the WHO, and a Compound ID (\code{cid}) as found in PubChem. Other properties in this data set are derived from one or more of these codes. Note that some drugs have multiple ATC codes.
}
\details{
-Properties that are based on an ATC code are only available when an ATC is available. These properties are: \code{atc_group1}, \code{atc_group2}, \code{oral_ddd}, \code{oral_units}, \code{iv_ddd} and \code{iv_units}.
+Properties that are based on an ATC code are only available when an ATC is available. These properties are: \code{atc_group1}, \code{atc_group2}, \code{oral_ddd}, \code{oral_units}, \code{iv_ddd} and \code{iv_units}. Do note that ATC codes are not unique. For example, J01CR02 is officially the ATC code for "amoxicillin and beta-lactamase inhibitor". Consequently, these two items from the \link{antimicrobials} data set both return \code{"J01CR02"}:
-Synonyms (i.e. trade names) were derived from the PubChem Compound ID (column \code{cid}) and consequently only available where a CID is available.
+\if{html}{\out{<div class="sourceCode r">}}\preformatted{ab_atc("amoxicillin/clavulanic acid")
+ab_atc("amoxicillin/sulbactam")
+}\if{html}{\out{</div>}}
+
+Synonyms (i.e. trade names) were derived from the PubChem Compound ID (column \code{cid}) and are consequently only available where a CID is available.
}
\section{Download Our Reference Data}{
diff --git a/man/as.sir.Rd b/man/as.sir.Rd
index c2c206ed1..78d2f7648 100644
--- a/man/as.sir.Rd
+++ b/man/as.sir.Rd
@@ -122,7 +122,7 @@ The default \code{"standard"} setting ensures cautious handling of uncertain val
\item{reference_data}{A \link{data.frame} to be used for interpretation, which defaults to the \link{clinical_breakpoints} data set. Changing this argument allows for using own interpretation guidelines. This argument must contain a data set that is equal in structure to the \link{clinical_breakpoints} data set (same column names and column types). Please note that the \code{guideline} argument will be ignored when \code{reference_data} is manually set.}
-\item{substitute_missing_r_breakpoint}{A \link{logical} to indicate that a missing clinical breakpoints for R (resistant) must be substituted with R - the default is \code{FALSE}. Some (especially CLSI) breakpoints only have a breakpoint for S, meaning the outcome can only be \code{"S"} or \code{NA}. Setting this to \code{TRUE} will convert the \code{NA}s to \code{"R"} only if the R breakpoint is missing. Can also be set with the package option \code{\link[=AMR-options]{AMR_substitute_missing_r_breakpoint}}.}
+\item{substitute_missing_r_breakpoint}{A \link{logical} to indicate that a missing clinical breakpoints for R (resistant) must be substituted with R - the default is \code{FALSE}. Some (especially CLSI) breakpoints only have a breakpoint for S, meaning that the outcome can only be \code{"S"} or \code{NA}. Setting this to \code{TRUE} will convert the \code{NA}s in these cases to \code{"R"}. Can also be set with the package option \code{\link[=AMR-options]{AMR_substitute_missing_r_breakpoint}}.}
\item{include_screening}{A \link{logical} to indicate that clinical breakpoints for screening are allowed - the default is \code{FALSE}. Can also be set with the package option \code{\link[=AMR-options]{AMR_include_screening}}.}
@@ -138,7 +138,7 @@ The default \code{"standard"} setting ensures cautious handling of uncertain val
\item{col_mo}{Column name of the names or codes of the microorganisms (see \code{\link[=as.mo]{as.mo()}}) - the default is the first column of class \code{\link{mo}}. Values will be coerced using \code{\link[=as.mo]{as.mo()}}.}
-\item{parallel}{A \link{logical} to indicate if parallel computing must be used, defaults to \code{FALSE}. This requires no additional packages, as the used \code{parallel} package is part of base \R. On Windows and on \R < 4.0.0 \code{\link[parallel:clusterApply]{parallel::parLapply()}} will be used, in all other cases the most efficient \code{\link[parallel:mclapply]{parallel::mclapply()}} will be used.}
+\item{parallel}{A \link{logical} to indicate if parallel computing must be used, defaults to \code{FALSE}. This requires no additional packages, as the used \code{parallel} package is part of base \R. On Windows and on \R < 4.0.0 \code{\link[parallel:clusterApply]{parallel::parLapply()}} will be used, in all other cases the more efficient \code{\link[parallel:mclapply]{parallel::mclapply()}} will be used.}
\item{max_cores}{Maximum number of cores to use if \code{parallel = TRUE}. Use a negative value to subtract that number from the available number of cores, e.g. a value of \code{-2} on an 8-core machine means that at most 6 cores will be used. Defaults to \code{-1}. There will never be used more cores than variables to analyse. The available number of cores are detected using \code{\link[parallelly:availableCores]{parallelly::availableCores()}} if that package is installed, and base \R's \code{\link[parallel:detectCores]{parallel::detectCores()}} otherwise.}
@@ -269,11 +269,10 @@ Visit \href{https://amr-for-r.org/articles/datasets.html}{our website for direct
\examples{
example_isolates
-summary(example_isolates) # see all SIR results at a glance
-# For INTERPRETING disk diffusion and MIC values -----------------------
+summary(example_isolates[, 1:10]) # see all SIR results at a glance
-# example data sets, with combined MIC values and disk zones
+# create some example data sets, with combined MIC values and disk zones
df_wide <- data.frame(
microorganism = "Escherichia coli",
amoxicillin = as.mic(8),
@@ -289,6 +288,11 @@ df_long <- data.frame(
disks = as.disk(c(6, 10, 14, 18)),
guideline = c("EUCAST 2021", "EUCAST 2022", "EUCAST 2023", "EUCAST 2024")
)
+# and clean previous SIR interpretation logs
+x <- sir_interpretation_history(clean = TRUE)
+
+
+# For INTERPRETING disk diffusion and MIC values -----------------------
# most basic application:
as.sir(df_wide)
@@ -409,13 +413,6 @@ if (require("dplyr")) {
## Using base R ------------------------------------------------
-as.sir(df_wide)
-
-# return a 'logbook' about the results:
-sir_interpretation_history()
-
-# using parallel computing, which is available in base R
-as.sir(df_wide, parallel = TRUE)
# for single values
as.sir(
@@ -444,6 +441,7 @@ barplot(sir_data) # for frequencies
# as common in R, you can use as.integer() to return factor indices:
as.integer(as.sir(c("S", "SDD", "I", "R", "NI", NA)))
+
# but for computational use, as.double() will return 1 for S, 2 for I/SDD, and 3 for R:
as.double(as.sir(c("S", "SDD", "I", "R", "NI", NA)))
@@ -459,7 +457,7 @@ if (require("dplyr")) {
example_isolates \%>\%
mutate_if(is_sir_eligible, as.sir)
- # since dplyr 1.0.0, this can also be:
+ # since dplyr 1.0.0, this can also be the more impractical:
# example_isolates \%>\%
# mutate(across(where(is_sir_eligible), as.sir))
}
diff --git a/man/eucast_rules.Rd b/man/eucast_rules.Rd
index e221b2ed1..b1c52e573 100644
--- a/man/eucast_rules.Rd
+++ b/man/eucast_rules.Rd
@@ -102,7 +102,7 @@ To define antimicrobials column names, leave as it is to determine it automatica
The following antimicrobials are eligible for the functions \code{\link[=eucast_rules]{eucast_rules()}} and \code{\link[=mdro]{mdro()}}. These are shown below in the format 'name (\verb{antimicrobial ID}, \href{https://atcddd.fhi.no/atc/structure_and_principles/}{ATC code})', sorted alphabetically:
-Amikacin (\code{AMK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB06&showdescription=no}{J01GB06}), amoxicillin (\code{AMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA04&showdescription=no}{J01CA04}), amoxicillin/clavulanic acid (\code{AMC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR02&showdescription=no}{J01CR02}), ampicillin (\code{AMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA01&showdescription=no}{J01CA01}), ampicillin/sulbactam (\code{SAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR01&showdescription=no}{J01CR01}), apramycin (\code{APR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07AA92&showdescription=no}{QA07AA92}), arbekacin (\code{ARB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB12&showdescription=no}{J01GB12}), aspoxicillin (\code{APX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA19&showdescription=no}{J01CA19}), azidocillin (\code{AZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE04&showdescription=no}{J01CE04}), azithromycin (\code{AZM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA10&showdescription=no}{J01FA10}), azlocillin (\code{AZL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA09&showdescription=no}{J01CA09}), aztreonam (\code{ATM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF01&showdescription=no}{J01DF01}), bacampicillin (\code{BAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA06&showdescription=no}{J01CA06}), bekanamycin (\code{BEK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB13&showdescription=no}{J01GB13}), benzathine benzylpenicillin (\code{BNB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE08&showdescription=no}{J01CE08}), benzathine phenoxymethylpenicillin (\code{BNP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE10&showdescription=no}{J01CE10}), benzylpenicillin (\code{PEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE01&showdescription=no}{J01CE01}), besifloxacin (\code{BES}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AE08&showdescription=no}{S01AE08}), biapenem (\code{BIA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH05&showdescription=no}{J01DH05}), bleomycin (\code{BLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=L01DC01&showdescription=no}{L01DC01}), brodimoprim (\code{BDP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EA02&showdescription=no}{J01EA02}), carbenicillin (\code{CRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA03&showdescription=no}{J01CA03}), carindacillin (\code{CRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA05&showdescription=no}{J01CA05}), carumonam (\code{CAR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF02&showdescription=no}{J01DF02}), cefacetrile (\code{CAC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB10&showdescription=no}{J01DB10}), cefaclor (\code{CEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC04&showdescription=no}{J01DC04}), cefadroxil (\code{CFR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB05&showdescription=no}{J01DB05}), cefalexin (\code{LEX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB01&showdescription=no}{J01DB01}), cefaloridine (\code{RID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB02&showdescription=no}{J01DB02}), cefalotin (\code{CEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB03&showdescription=no}{J01DB03}), cefamandole (\code{MAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC03&showdescription=no}{J01DC03}), cefapirin (\code{HAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB08&showdescription=no}{J01DB08}), cefatrizine (\code{CTZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB07&showdescription=no}{J01DB07}), cefazedone (\code{CZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB06&showdescription=no}{J01DB06}), cefazolin (\code{CZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB04&showdescription=no}{J01DB04}), cefcapene (\code{CCP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD17&showdescription=no}{J01DD17}), cefdinir (\code{CDR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD15&showdescription=no}{J01DD15}), cefditoren (\code{DIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD16&showdescription=no}{J01DD16}), cefepime (\code{FEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE01&showdescription=no}{J01DE01}), cefepime/amikacin (\code{CFA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA06&showdescription=no}{J01RA06}), cefetamet (\code{CAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD10&showdescription=no}{J01DD10}), cefiderocol (\code{FDC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI04&showdescription=no}{J01DI04}), cefixime (\code{CFM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD08&showdescription=no}{J01DD08}), cefmenoxime (\code{CMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD05&showdescription=no}{J01DD05}), cefmetazole (\code{CMZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC09&showdescription=no}{J01DC09}), cefodizime (\code{DIZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD09&showdescription=no}{J01DD09}), cefonicid (\code{CID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC06&showdescription=no}{J01DC06}), cefoperazone (\code{CFP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD12&showdescription=no}{J01DD12}), cefoperazone/sulbactam (\code{CSL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD62&showdescription=no}{J01DD62}), ceforanide (\code{CND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC11&showdescription=no}{J01DC11}), cefotaxime (\code{CTX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD01&showdescription=no}{J01DD01}), cefotaxime/clavulanic acid (\code{CTC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD51&showdescription=no}{J01DD51}), cefotetan (\code{CTT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC05&showdescription=no}{J01DC05}), cefotiam (\code{CTF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC07&showdescription=no}{J01DC07}), cefovecin (\code{FOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD91&showdescription=no}{QJ01DD91}), cefoxitin (\code{FOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC01&showdescription=no}{J01DC01}), cefozopran (\code{ZOP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE03&showdescription=no}{J01DE03}), cefpiramide (\code{CPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD11&showdescription=no}{J01DD11}), cefpirome (\code{CPO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE02&showdescription=no}{J01DE02}), cefpodoxime (\code{CPD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD13&showdescription=no}{J01DD13}), cefprozil (\code{CPR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC10&showdescription=no}{J01DC10}), cefquinome (\code{CEQ}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QG51AA07&showdescription=no}{QG51AA07}), cefroxadine (\code{CRD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB11&showdescription=no}{J01DB11}), cefsulodin (\code{CFS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD03&showdescription=no}{J01DD03}), ceftaroline (\code{CPT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI02&showdescription=no}{J01DI02}), ceftazidime (\code{CAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD02&showdescription=no}{J01DD02}), ceftazidime/clavulanic acid (\code{CCV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD52&showdescription=no}{J01DD52}), cefteram (\code{CEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD18&showdescription=no}{J01DD18}), ceftezole (\code{CTL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB12&showdescription=no}{J01DB12}), ceftibuten (\code{CTB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD14&showdescription=no}{J01DD14}), ceftiofur (\code{TIO}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD90&showdescription=no}{QJ01DD90}), ceftizoxime (\code{CZX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD07&showdescription=no}{J01DD07}), ceftobiprole medocaril (\code{CFM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI01&showdescription=no}{J01DI01}), ceftolozane/tazobactam (\code{CZT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI54&showdescription=no}{J01DI54}), ceftriaxone (\code{CRO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD04&showdescription=no}{J01DD04}), ceftriaxone/beta-lactamase inhibitor (\code{CEB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD63&showdescription=no}{J01DD63}), cefuroxime (\code{CXM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC02&showdescription=no}{J01DC02}), cephradine (\code{CED}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB09&showdescription=no}{J01DB09}), chloramphenicol (\code{CHL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01BA01&showdescription=no}{J01BA01}), chlortetracycline (\code{CTE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA03&showdescription=no}{J01AA03}), ciprofloxacin (\code{CIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA02&showdescription=no}{J01MA02}), ciprofloxacin/metronidazole (\code{CIM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA10&showdescription=no}{J01RA10}), ciprofloxacin/ornidazole (\code{CIO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA12&showdescription=no}{J01RA12}), ciprofloxacin/tinidazole (\code{CIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA11&showdescription=no}{J01RA11}), clarithromycin (\code{CLR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA09&showdescription=no}{J01FA09}), clindamycin (\code{CLI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF01&showdescription=no}{J01FF01}), clometocillin (\code{CLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE07&showdescription=no}{J01CE07}), clomocycline (\code{CLM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA11&showdescription=no}{J01AA11}), cloxacillin (\code{CLO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF02&showdescription=no}{J01CF02}), colistin (\code{COL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB01&showdescription=no}{J01XB01}), cycloserine (\code{CYC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB01&showdescription=no}{J04AB01}), dalbavancin (\code{DAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA04&showdescription=no}{J01XA04}), danofloxacin (\code{DAN}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA92&showdescription=no}{QJ01MA92}), daptomycin (\code{DAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX09&showdescription=no}{J01XX09}), delafloxacin (\code{DFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA23&showdescription=no}{J01MA23}), demeclocycline (\code{DEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA01&showdescription=no}{J01AA01}), dibekacin (\code{DKB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB09&showdescription=no}{J01GB09}), dicloxacillin (\code{DIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF01&showdescription=no}{J01CF01}), difloxacin (\code{DIF}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA94&showdescription=no}{QJ01MA94}), dirithromycin (\code{DIR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA13&showdescription=no}{J01FA13}), doripenem (\code{DOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH04&showdescription=no}{J01DH04}), doxycycline (\code{DOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA02&showdescription=no}{J01AA02}), enoxacin (\code{ENX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA04&showdescription=no}{J01MA04}), enrofloxacin (\code{ENR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA90&showdescription=no}{QJ01MA90}), epicillin (\code{EPC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA07&showdescription=no}{J01CA07}), eravacycline (\code{ERV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA13&showdescription=no}{J01AA13}), ertapenem (\code{ETP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH03&showdescription=no}{J01DH03}), erythromycin (\code{ERY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA01&showdescription=no}{J01FA01}), fleroxacin (\code{FLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA08&showdescription=no}{J01MA08}), flucloxacillin (\code{FLC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF05&showdescription=no}{J01CF05}), flurithromycin (\code{FLR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA14&showdescription=no}{J01FA14}), fosfomycin (\code{FOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX01&showdescription=no}{J01XX01}), framycetin (\code{FRM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D09AA01&showdescription=no}{D09AA01}), fusidic acid (\code{FUS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XC01&showdescription=no}{J01XC01}), gamithromycin (\code{GAM}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA95&showdescription=no}{QJ01FA95}), garenoxacin (\code{GRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA19&showdescription=no}{J01MA19}), gatifloxacin (\code{GAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA16&showdescription=no}{J01MA16}), gemifloxacin (\code{GEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA15&showdescription=no}{J01MA15}), gentamicin (\code{GEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB03&showdescription=no}{J01GB03}), grepafloxacin (\code{GRX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA11&showdescription=no}{J01MA11}), hetacillin (\code{HET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA18&showdescription=no}{J01CA18}), imipenem (\code{IPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH51&showdescription=no}{J01DH51}), imipenem/relebactam (\code{IMR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH56&showdescription=no}{J01DH56}), isepamicin (\code{ISE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB11&showdescription=no}{J01GB11}), josamycin (\code{JOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA07&showdescription=no}{J01FA07}), kanamycin (\code{KAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB04&showdescription=no}{J01GB04}), kitasamycin (\code{KIT}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA93&showdescription=no}{QJ01FA93}), lascufloxacin (\code{LSC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA25&showdescription=no}{J01MA25}), latamoxef (\code{LTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD06&showdescription=no}{J01DD06}), levofloxacin (\code{LVX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA12&showdescription=no}{J01MA12}), levofloxacin/ornidazole (\code{LEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA05&showdescription=no}{J01RA05}), levonadifloxacin (\code{LND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA24&showdescription=no}{J01MA24}), lincomycin (\code{LIN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF02&showdescription=no}{J01FF02}), linezolid (\code{LNZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX08&showdescription=no}{J01XX08}), lomefloxacin (\code{LOM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA07&showdescription=no}{J01MA07}), loracarbef (\code{LOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC08&showdescription=no}{J01DC08}), lymecycline (\code{LYM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA04&showdescription=no}{J01AA04}), marbofloxacin (\code{MAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA93&showdescription=no}{QJ01MA93}), mecillinam (\code{MEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA11&showdescription=no}{J01CA11}), meropenem (\code{MEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH02&showdescription=no}{J01DH02}), meropenem/vaborbactam (\code{MEV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH52&showdescription=no}{J01DH52}), metacycline (\code{MTC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA05&showdescription=no}{J01AA05}), metampicillin (\code{MTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA14&showdescription=no}{J01CA14}), meticillin (\code{MET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF03&showdescription=no}{J01CF03}), mezlocillin (\code{MEZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA10&showdescription=no}{J01CA10}), micronomicin (\code{MCR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AA22&showdescription=no}{S01AA22}), midecamycin (\code{MID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA03&showdescription=no}{J01FA03}), minocycline (\code{MNO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA08&showdescription=no}{J01AA08}), miocamycin (\code{MCM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA11&showdescription=no}{J01FA11}), moxifloxacin (\code{MFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA14&showdescription=no}{J01MA14}), nadifloxacin (\code{NAD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D10AF05&showdescription=no}{D10AF05}), nafcillin (\code{NAF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF06&showdescription=no}{J01CF06}), nalidixic acid (\code{NAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB02&showdescription=no}{J01MB02}), nemonoxacin (\code{NEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB08&showdescription=no}{J01MB08}), neomycin (\code{NEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB05&showdescription=no}{J01GB05}), netilmicin (\code{NET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB07&showdescription=no}{J01GB07}), nitrofurantoin (\code{NIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XE01&showdescription=no}{J01XE01}), nitroxoline (\code{NTR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX07&showdescription=no}{J01XX07}), norfloxacin (\code{NOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA06&showdescription=no}{J01MA06}), norfloxacin/metronidazole (\code{NME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA14&showdescription=no}{J01RA14}), norfloxacin/tinidazole (\code{NTI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA13&showdescription=no}{J01RA13}), novobiocin (\code{NOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01XX95&showdescription=no}{QJ01XX95}), ofloxacin (\code{OFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA01&showdescription=no}{J01MA01}), ofloxacin/ornidazole (\code{OOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA09&showdescription=no}{J01RA09}), oleandomycin (\code{OLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA05&showdescription=no}{J01FA05}), omadacycline (\code{OMC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA15&showdescription=no}{J01AA15}), orbifloxacin (\code{ORB}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA95&showdescription=no}{QJ01MA95}), oritavancin (\code{ORI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA05&showdescription=no}{J01XA05}), oxacillin (\code{OXA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF04&showdescription=no}{J01CF04}), oxytetracycline (\code{OXY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA06&showdescription=no}{J01AA06}), panipenem (\code{PAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH55&showdescription=no}{J01DH55}), pazufloxacin (\code{PAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA18&showdescription=no}{J01MA18}), pefloxacin (\code{PEF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA03&showdescription=no}{J01MA03}), penamecillin (\code{PNM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE06&showdescription=no}{J01CE06}), penimepicycline (\code{PNM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA10&showdescription=no}{J01AA10}), pheneticillin (\code{PHE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE05&showdescription=no}{J01CE05}), phenoxymethylpenicillin (\code{PHN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE02&showdescription=no}{J01CE02}), piperacillin (\code{PIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA12&showdescription=no}{J01CA12}), piperacillin/tazobactam (\code{TZP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR05&showdescription=no}{J01CR05}), pirlimycin (\code{PRL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ51FF90&showdescription=no}{QJ51FF90}), pivampicillin (\code{PVM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA02&showdescription=no}{J01CA02}), pivmecillinam (\code{PME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA08&showdescription=no}{J01CA08}), plazomicin (\code{PLZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB14&showdescription=no}{J01GB14}), polymyxin B (\code{PLB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB02&showdescription=no}{J01XB02}), pradofloxacin (\code{PRA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA97&showdescription=no}{QJ01MA97}), pristinamycin (\code{PRI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FG01&showdescription=no}{J01FG01}), procaine benzylpenicillin (\code{PRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE09&showdescription=no}{J01CE09}), propicillin (\code{PRP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE03&showdescription=no}{J01CE03}), prulifloxacin (\code{PRU}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA17&showdescription=no}{J01MA17}), quinupristin/dalfopristin (\code{QDA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FG02&showdescription=no}{QJ01FG02}), ribostamycin (\code{RST}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB10&showdescription=no}{J01GB10}), rifampicin (\code{RIF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB02&showdescription=no}{J04AB02}), rokitamycin (\code{ROK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA12&showdescription=no}{J01FA12}), rolitetracycline (\code{RLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA09&showdescription=no}{J01AA09}), roxithromycin (\code{RXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA06&showdescription=no}{J01FA06}), rufloxacin (\code{RFL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA10&showdescription=no}{J01MA10}), sarafloxacin (\code{SAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA98&showdescription=no}{QJ01MA98}), sarecycline (\code{SRC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA14&showdescription=no}{J01AA14}), sisomicin (\code{SIS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB08&showdescription=no}{J01GB08}), sitafloxacin (\code{SIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA21&showdescription=no}{J01MA21}), solithromycin (\code{SOL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA16&showdescription=no}{J01FA16}), sparfloxacin (\code{SPX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA09&showdescription=no}{J01MA09}), spiramycin (\code{SPI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA02&showdescription=no}{J01FA02}), streptoduocin (\code{STR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA02&showdescription=no}{J01GA02}), streptomycin (\code{STR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA01&showdescription=no}{J01GA01}), sulbenicillin (\code{SBC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA16&showdescription=no}{J01CA16}), sulfadiazine (\code{SDI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC02&showdescription=no}{J01EC02}), sulfadiazine/tetroxoprim (\code{SLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE06&showdescription=no}{J01EE06}), sulfadiazine/trimethoprim (\code{SLT1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE02&showdescription=no}{J01EE02}), sulfadimethoxine (\code{SUD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED01&showdescription=no}{J01ED01}), sulfadimidine (\code{SDM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB03&showdescription=no}{J01EB03}), sulfadimidine/trimethoprim (\code{SLT2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE05&showdescription=no}{J01EE05}), sulfafurazole (\code{SLF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB05&showdescription=no}{J01EB05}), sulfaisodimidine (\code{SLF1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB01&showdescription=no}{J01EB01}), sulfalene (\code{SLF2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED02&showdescription=no}{J01ED02}), sulfamazone (\code{SZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED09&showdescription=no}{J01ED09}), sulfamerazine (\code{SLF3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED07&showdescription=no}{J01ED07}), sulfamerazine/trimethoprim (\code{SLT3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE07&showdescription=no}{J01EE07}), sulfamethizole (\code{SLF4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB02&showdescription=no}{J01EB02}), sulfamethoxazole (\code{SMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC01&showdescription=no}{J01EC01}), sulfamethoxypyridazine (\code{SLF5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED05&showdescription=no}{J01ED05}), sulfametomidine (\code{SLF6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED03&showdescription=no}{J01ED03}), sulfametoxydiazine (\code{SLF7}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED04&showdescription=no}{J01ED04}), sulfametrole/trimethoprim (\code{SLT4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE03&showdescription=no}{J01EE03}), sulfamoxole (\code{SLF8}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC03&showdescription=no}{J01EC03}), sulfamoxole/trimethoprim (\code{SLT5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE04&showdescription=no}{J01EE04}), sulfanilamide (\code{SLF9}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB06&showdescription=no}{J01EB06}), sulfaperin (\code{SLF10}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED06&showdescription=no}{J01ED06}), sulfaphenazole (\code{SLF11}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED08&showdescription=no}{J01ED08}), sulfapyridine (\code{SLF12}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB04&showdescription=no}{J01EB04}), sulfathiazole (\code{SUT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB07&showdescription=no}{J01EB07}), sulfathiourea (\code{SLF13}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB08&showdescription=no}{J01EB08}), sultamicillin (\code{SLT6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR04&showdescription=no}{J01CR04}), talampicillin (\code{TAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA15&showdescription=no}{J01CA15}), tebipenem (\code{TBP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH06&showdescription=no}{J01DH06}), tedizolid (\code{TZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX11&showdescription=no}{J01XX11}), teicoplanin (\code{TEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA02&showdescription=no}{J01XA02}), telavancin (\code{TLV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA03&showdescription=no}{J01XA03}), telithromycin (\code{TLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA15&showdescription=no}{J01FA15}), temafloxacin (\code{TMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA05&showdescription=no}{J01MA05}), temocillin (\code{TEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA17&showdescription=no}{J01CA17}), tetracycline (\code{TCY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA07&showdescription=no}{J01AA07}), ticarcillin (\code{TIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA13&showdescription=no}{J01CA13}), ticarcillin/clavulanic acid (\code{TCC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR03&showdescription=no}{J01CR03}), tigecycline (\code{TGC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA12&showdescription=no}{J01AA12}), tilbroquinol (\code{TBQ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=P01AA05&showdescription=no}{P01AA05}), tildipirosin (\code{TIP}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA96&showdescription=no}{QJ01FA96}), tilmicosin (\code{TIL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA91&showdescription=no}{QJ01FA91}), tobramycin (\code{TOB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB01&showdescription=no}{J01GB01}), tosufloxacin (\code{TFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA22&showdescription=no}{J01MA22}), trimethoprim (\code{TMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EA01&showdescription=no}{J01EA01}), trimethoprim/sulfamethoxazole (\code{SXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE01&showdescription=no}{J01EE01}), troleandomycin (\code{TRL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA08&showdescription=no}{J01FA08}), trovafloxacin (\code{TVA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA13&showdescription=no}{J01MA13}), tulathromycin (\code{TUL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA94&showdescription=no}{QJ01FA94}), tylosin (\code{TYL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA90&showdescription=no}{QJ01FA90}), tylvalosin (\code{TYL1}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA92&showdescription=no}{QJ01FA92}), vancomycin (\code{VAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA01&showdescription=no}{J01XA01})
+Amikacin (\code{AMK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB06&showdescription=no}{J01GB06}), amoxicillin (\code{AMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA04&showdescription=no}{J01CA04}), amoxicillin/clavulanic acid (\code{AMC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR02&showdescription=no}{J01CR02}), amoxicillin/sulbactam (\code{AXS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR02&showdescription=no}{J01CR02}), ampicillin (\code{AMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA01&showdescription=no}{J01CA01}), ampicillin/sulbactam (\code{SAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR01&showdescription=no}{J01CR01}), apramycin (\code{APR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07AA92&showdescription=no}{QA07AA92}), arbekacin (\code{ARB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB12&showdescription=no}{J01GB12}), aspoxicillin (\code{APX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA19&showdescription=no}{J01CA19}), azidocillin (\code{AZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE04&showdescription=no}{J01CE04}), azithromycin (\code{AZM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA10&showdescription=no}{J01FA10}), azlocillin (\code{AZL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA09&showdescription=no}{J01CA09}), aztreonam (\code{ATM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF01&showdescription=no}{J01DF01}), aztreonam/avibactam (\code{AZA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF51&showdescription=no}{J01DF51}), aztreonam/nacubactam (\code{ANC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF51&showdescription=no}{J01DF51}), bacampicillin (\code{BAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA06&showdescription=no}{J01CA06}), bekanamycin (\code{BEK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB13&showdescription=no}{J01GB13}), benzathine benzylpenicillin (\code{BNB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE08&showdescription=no}{J01CE08}), benzathine phenoxymethylpenicillin (\code{BNP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE10&showdescription=no}{J01CE10}), benzylpenicillin (\code{PEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE01&showdescription=no}{J01CE01}), besifloxacin (\code{BES}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QS01AE08&showdescription=no}{QS01AE08}), biapenem (\code{BIA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH05&showdescription=no}{J01DH05}), bleomycin (\code{BLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=L01DC01&showdescription=no}{L01DC01}), brodimoprim (\code{BDP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EA02&showdescription=no}{J01EA02}), carbenicillin (\code{CRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA03&showdescription=no}{J01CA03}), carindacillin (\code{CRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA05&showdescription=no}{J01CA05}), carumonam (\code{CAR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF02&showdescription=no}{J01DF02}), cefacetrile (\code{CAC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB10&showdescription=no}{J01DB10}), cefaclor (\code{CEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC04&showdescription=no}{J01DC04}), cefadroxil (\code{CFR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB05&showdescription=no}{J01DB05}), cefalexin (\code{LEX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB01&showdescription=no}{J01DB01}), cefaloridine (\code{RID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB02&showdescription=no}{J01DB02}), cefalotin (\code{CEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB03&showdescription=no}{J01DB03}), cefamandole (\code{MAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC03&showdescription=no}{J01DC03}), cefapirin (\code{HAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB08&showdescription=no}{J01DB08}), cefatrizine (\code{CTZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB07&showdescription=no}{J01DB07}), cefazedone (\code{CZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB06&showdescription=no}{J01DB06}), cefazolin (\code{CZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB04&showdescription=no}{J01DB04}), cefcapene (\code{CCP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD17&showdescription=no}{J01DD17}), cefdinir (\code{CDR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD15&showdescription=no}{J01DD15}), cefditoren (\code{DIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD16&showdescription=no}{J01DD16}), cefepime (\code{FEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE01&showdescription=no}{J01DE01}), cefepime/amikacin (\code{CFA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE51&showdescription=no}{J01DE51}), cefepime/clavulanic acid (\code{CPC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE51&showdescription=no}{J01DE51}), cefepime/enmetazobactam (\code{FPE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE51&showdescription=no}{J01DE51}), cefepime/nacubactam (\code{FNC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE51&showdescription=no}{J01DE51}), cefepime/tazobactam (\code{FPT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE51&showdescription=no}{J01DE51}), cefepime/zidebactam (\code{FPZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE51&showdescription=no}{J01DE51}), cefetamet (\code{CAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD10&showdescription=no}{J01DD10}), cefiderocol (\code{FDC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI04&showdescription=no}{J01DI04}), cefixime (\code{CFM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD08&showdescription=no}{J01DD08}), cefmenoxime (\code{CMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD05&showdescription=no}{J01DD05}), cefmetazole (\code{CMZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC09&showdescription=no}{J01DC09}), cefodizime (\code{DIZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD09&showdescription=no}{J01DD09}), cefonicid (\code{CID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC06&showdescription=no}{J01DC06}), cefoperazone (\code{CFP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD12&showdescription=no}{J01DD12}), cefoperazone/sulbactam (\code{CSL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD62&showdescription=no}{J01DD62}), ceforanide (\code{CND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC11&showdescription=no}{J01DC11}), cefotaxime (\code{CTX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD01&showdescription=no}{J01DD01}), cefotaxime/clavulanic acid (\code{CTC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD51&showdescription=no}{J01DD51}), cefotaxime/sulbactam (\code{CTS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD51&showdescription=no}{J01DD51}), cefotetan (\code{CTT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC05&showdescription=no}{J01DC05}), cefotiam (\code{CTF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC07&showdescription=no}{J01DC07}), cefovecin (\code{FOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD91&showdescription=no}{QJ01DD91}), cefoxitin (\code{FOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC01&showdescription=no}{J01DC01}), cefozopran (\code{ZOP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE03&showdescription=no}{J01DE03}), cefpiramide (\code{CPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD11&showdescription=no}{J01DD11}), cefpirome (\code{CPO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE02&showdescription=no}{J01DE02}), cefpodoxime (\code{CPD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD13&showdescription=no}{J01DD13}), cefpodoxime/clavulanic acid (\code{CDC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD64&showdescription=no}{J01DD64}), cefprozil (\code{CPR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC10&showdescription=no}{J01DC10}), cefquinome (\code{CEQ}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QG51AA07&showdescription=no}{QG51AA07}), cefroxadine (\code{CRD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB11&showdescription=no}{J01DB11}), cefsulodin (\code{CFS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD03&showdescription=no}{J01DD03}), ceftazidime (\code{CAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD02&showdescription=no}{J01DD02}), ceftazidime/avibactam (\code{CZA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD52&showdescription=no}{J01DD52}), ceftazidime/clavulanic acid (\code{CCV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD52&showdescription=no}{J01DD52}), cefteram (\code{CEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD18&showdescription=no}{J01DD18}), ceftezole (\code{CTL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB12&showdescription=no}{J01DB12}), ceftibuten (\code{CTB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD14&showdescription=no}{J01DD14}), ceftiofur (\code{TIO}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD90&showdescription=no}{QJ01DD90}), ceftizoxime (\code{CZX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD07&showdescription=no}{J01DD07}), ceftobiprole medocaril (\code{CFM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI01&showdescription=no}{J01DI01}), ceftolozane/tazobactam (\code{CZT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI54&showdescription=no}{J01DI54}), ceftriaxone (\code{CRO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD04&showdescription=no}{J01DD04}), ceftriaxone/beta-lactamase inhibitor (\code{CEB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD63&showdescription=no}{J01DD63}), cefuroxime (\code{CXM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC02&showdescription=no}{J01DC02}), chloramphenicol (\code{CHL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01BA01&showdescription=no}{J01BA01}), chlortetracycline (\code{CTE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA03&showdescription=no}{J01AA03}), ciprofloxacin (\code{CIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA02&showdescription=no}{J01MA02}), clarithromycin (\code{CLR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA09&showdescription=no}{J01FA09}), clindamycin (\code{CLI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF01&showdescription=no}{J01FF01}), clometocillin (\code{CLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE07&showdescription=no}{J01CE07}), clomocycline (\code{CLM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA11&showdescription=no}{J01AA11}), cloxacillin (\code{CLO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF02&showdescription=no}{J01CF02}), colistin (\code{COL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB01&showdescription=no}{J01XB01}), cycloserine (\code{CYC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB01&showdescription=no}{J04AB01}), dalbavancin (\code{DAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA04&showdescription=no}{J01XA04}), danofloxacin (\code{DAN}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA92&showdescription=no}{QJ01MA92}), daptomycin (\code{DAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX09&showdescription=no}{J01XX09}), delafloxacin (\code{DFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA23&showdescription=no}{J01MA23}), demeclocycline (\code{DEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA01&showdescription=no}{J01AA01}), dibekacin (\code{DKB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB09&showdescription=no}{J01GB09}), dicloxacillin (\code{DIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF01&showdescription=no}{J01CF01}), difloxacin (\code{DIF}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA94&showdescription=no}{QJ01MA94}), dirithromycin (\code{DIR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA13&showdescription=no}{J01FA13}), doripenem (\code{DOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH04&showdescription=no}{J01DH04}), doxycycline (\code{DOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA02&showdescription=no}{J01AA02}), enoxacin (\code{ENX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA04&showdescription=no}{J01MA04}), enrofloxacin (\code{ENR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA90&showdescription=no}{QJ01MA90}), epicillin (\code{EPC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA07&showdescription=no}{J01CA07}), eravacycline (\code{ERV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA13&showdescription=no}{J01AA13}), ertapenem (\code{ETP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH03&showdescription=no}{J01DH03}), erythromycin (\code{ERY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA01&showdescription=no}{J01FA01}), fleroxacin (\code{FLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA08&showdescription=no}{J01MA08}), flucloxacillin (\code{FLC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF05&showdescription=no}{J01CF05}), flurithromycin (\code{FLR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA14&showdescription=no}{J01FA14}), fosfomycin (\code{FOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX01&showdescription=no}{J01XX01}), framycetin (\code{FRM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D09AA01&showdescription=no}{D09AA01}), fusidic acid (\code{FUS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XC01&showdescription=no}{J01XC01}), gamithromycin (\code{GAM}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA95&showdescription=no}{QJ01FA95}), garenoxacin (\code{GRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA19&showdescription=no}{J01MA19}), gatifloxacin (\code{GAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA16&showdescription=no}{J01MA16}), gemifloxacin (\code{GEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA15&showdescription=no}{J01MA15}), gentamicin (\code{GEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB03&showdescription=no}{J01GB03}), grepafloxacin (\code{GRX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA11&showdescription=no}{J01MA11}), hetacillin (\code{HET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA18&showdescription=no}{J01CA18}), isepamicin (\code{ISE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB11&showdescription=no}{J01GB11}), josamycin (\code{JOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA07&showdescription=no}{J01FA07}), kanamycin (\code{KAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB04&showdescription=no}{J01GB04}), kitasamycin (\code{KIT}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA93&showdescription=no}{QJ01FA93}), lascufloxacin (\code{LSC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA25&showdescription=no}{J01MA25}), latamoxef (\code{LTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD06&showdescription=no}{J01DD06}), levofloxacin (\code{LVX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA12&showdescription=no}{J01MA12}), levonadifloxacin (\code{LND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA24&showdescription=no}{J01MA24}), lincomycin (\code{LIN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF02&showdescription=no}{J01FF02}), linezolid (\code{LNZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX08&showdescription=no}{J01XX08}), lomefloxacin (\code{LOM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA07&showdescription=no}{J01MA07}), loracarbef (\code{LOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC08&showdescription=no}{J01DC08}), lymecycline (\code{LYM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA04&showdescription=no}{J01AA04}), marbofloxacin (\code{MAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA93&showdescription=no}{QJ01MA93}), mecillinam (\code{MEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA11&showdescription=no}{J01CA11}), meropenem (\code{MEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH02&showdescription=no}{J01DH02}), metacycline (\code{MTC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA05&showdescription=no}{J01AA05}), metampicillin (\code{MTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA14&showdescription=no}{J01CA14}), meticillin (\code{MET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF03&showdescription=no}{J01CF03}), mezlocillin (\code{MEZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA10&showdescription=no}{J01CA10}), micronomicin (\code{MCR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QS01AA22&showdescription=no}{QS01AA22}), midecamycin (\code{MID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA03&showdescription=no}{J01FA03}), minocycline (\code{MNO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA08&showdescription=no}{J01AA08}), miocamycin (\code{MCM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA11&showdescription=no}{J01FA11}), moxifloxacin (\code{MFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA14&showdescription=no}{J01MA14}), nadifloxacin (\code{NAD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D10AF05&showdescription=no}{D10AF05}), nafcillin (\code{NAF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF06&showdescription=no}{J01CF06}), nalidixic acid (\code{NAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB02&showdescription=no}{J01MB02}), nemonoxacin (\code{NEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB08&showdescription=no}{J01MB08}), neomycin (\code{NEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB05&showdescription=no}{J01GB05}), netilmicin (\code{NET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB07&showdescription=no}{J01GB07}), nitrofurantoin (\code{NIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XE01&showdescription=no}{J01XE01}), nitroxoline (\code{NTR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX07&showdescription=no}{J01XX07}), norfloxacin (\code{NOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA06&showdescription=no}{J01MA06}), novobiocin (\code{NOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01XX95&showdescription=no}{QJ01XX95}), ofloxacin (\code{OFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA01&showdescription=no}{J01MA01}), oleandomycin (\code{OLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA05&showdescription=no}{J01FA05}), omadacycline (\code{OMC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA15&showdescription=no}{J01AA15}), orbifloxacin (\code{ORB}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA95&showdescription=no}{QJ01MA95}), oritavancin (\code{ORI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA05&showdescription=no}{J01XA05}), oxacillin (\code{OXA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF04&showdescription=no}{J01CF04}), oxytetracycline (\code{OXY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA06&showdescription=no}{J01AA06}), pazufloxacin (\code{PAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA18&showdescription=no}{J01MA18}), pefloxacin (\code{PEF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA03&showdescription=no}{J01MA03}), penamecillin (\code{PNM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE06&showdescription=no}{J01CE06}), penimepicycline (\code{PNM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA10&showdescription=no}{J01AA10}), pheneticillin (\code{PHE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE05&showdescription=no}{J01CE05}), phenoxymethylpenicillin (\code{PHN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE02&showdescription=no}{J01CE02}), piperacillin (\code{PIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA12&showdescription=no}{J01CA12}), piperacillin/sulbactam (\code{PIS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR05&showdescription=no}{J01CR05}), piperacillin/tazobactam (\code{TZP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR05&showdescription=no}{J01CR05}), pirlimycin (\code{PRL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ51FF90&showdescription=no}{QJ51FF90}), pivampicillin (\code{PVM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA02&showdescription=no}{J01CA02}), pivmecillinam (\code{PME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA08&showdescription=no}{J01CA08}), plazomicin (\code{PLZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB14&showdescription=no}{J01GB14}), polymyxin B (\code{PLB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB02&showdescription=no}{J01XB02}), pradofloxacin (\code{PRA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA97&showdescription=no}{QJ01MA97}), pristinamycin (\code{PRI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FG01&showdescription=no}{J01FG01}), procaine benzylpenicillin (\code{PRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE09&showdescription=no}{J01CE09}), propicillin (\code{PRP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE03&showdescription=no}{J01CE03}), prulifloxacin (\code{PRU}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA17&showdescription=no}{J01MA17}), ribostamycin (\code{RST}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB10&showdescription=no}{J01GB10}), rifampicin (\code{RIF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB02&showdescription=no}{J04AB02}), rokitamycin (\code{ROK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA12&showdescription=no}{J01FA12}), rolitetracycline (\code{RLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA09&showdescription=no}{J01AA09}), roxithromycin (\code{RXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA06&showdescription=no}{J01FA06}), rufloxacin (\code{RFL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA10&showdescription=no}{J01MA10}), sarafloxacin (\code{SAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA98&showdescription=no}{QJ01MA98}), sarecycline (\code{SRC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA14&showdescription=no}{J01AA14}), sisomicin (\code{SIS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB08&showdescription=no}{J01GB08}), sitafloxacin (\code{SIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA21&showdescription=no}{J01MA21}), solithromycin (\code{SOL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA16&showdescription=no}{J01FA16}), sparfloxacin (\code{SPX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA09&showdescription=no}{J01MA09}), spiramycin (\code{SPI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA02&showdescription=no}{J01FA02}), streptoduocin (\code{STR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA02&showdescription=no}{J01GA02}), streptomycin (\code{STR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA01&showdescription=no}{J01GA01}), sulbenicillin (\code{SBC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA16&showdescription=no}{J01CA16}), sulfadiazine (\code{SDI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC02&showdescription=no}{J01EC02}), sulfadimethoxine (\code{SUD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED01&showdescription=no}{J01ED01}), sulfadimidine (\code{SDM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB03&showdescription=no}{J01EB03}), sulfafurazole (\code{SLF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB05&showdescription=no}{J01EB05}), sulfaisodimidine (\code{SLF1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB01&showdescription=no}{J01EB01}), sulfalene (\code{SLF2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED02&showdescription=no}{J01ED02}), sulfamazone (\code{SZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED09&showdescription=no}{J01ED09}), sulfamerazine (\code{SLF3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED07&showdescription=no}{J01ED07}), sulfamethizole (\code{SLF4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB02&showdescription=no}{J01EB02}), sulfamethoxazole (\code{SMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC01&showdescription=no}{J01EC01}), sulfamethoxypyridazine (\code{SLF5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED05&showdescription=no}{J01ED05}), sulfametomidine (\code{SLF6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED03&showdescription=no}{J01ED03}), sulfametoxydiazine (\code{SLF7}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED04&showdescription=no}{J01ED04}), sulfamoxole (\code{SLF8}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC03&showdescription=no}{J01EC03}), sulfanilamide (\code{SLF9}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB06&showdescription=no}{J01EB06}), sulfaperin (\code{SLF10}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED06&showdescription=no}{J01ED06}), sulfaphenazole (\code{SLF11}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED08&showdescription=no}{J01ED08}), sulfapyridine (\code{SLF12}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB04&showdescription=no}{J01EB04}), sulfathiazole (\code{SUT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB07&showdescription=no}{J01EB07}), sulfathiourea (\code{SLF13}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB08&showdescription=no}{J01EB08}), sultamicillin (\code{SLT6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR04&showdescription=no}{J01CR04}), talampicillin (\code{TAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA15&showdescription=no}{J01CA15}), tedizolid (\code{TZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX11&showdescription=no}{J01XX11}), teicoplanin (\code{TEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA02&showdescription=no}{J01XA02}), telavancin (\code{TLV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA03&showdescription=no}{J01XA03}), telithromycin (\code{TLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA15&showdescription=no}{J01FA15}), temafloxacin (\code{TMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA05&showdescription=no}{J01MA05}), temocillin (\code{TEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA17&showdescription=no}{J01CA17}), tetracycline (\code{TCY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA07&showdescription=no}{J01AA07}), ticarcillin (\code{TIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA13&showdescription=no}{J01CA13}), ticarcillin/clavulanic acid (\code{TCC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR03&showdescription=no}{J01CR03}), tigecycline (\code{TGC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA12&showdescription=no}{J01AA12}), tilbroquinol (\code{TBQ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=P01AA05&showdescription=no}{P01AA05}), tildipirosin (\code{TIP}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA96&showdescription=no}{QJ01FA96}), tilmicosin (\code{TIL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA91&showdescription=no}{QJ01FA91}), tobramycin (\code{TOB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB01&showdescription=no}{J01GB01}), tosufloxacin (\code{TFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA22&showdescription=no}{J01MA22}), trimethoprim (\code{TMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EA01&showdescription=no}{J01EA01}), troleandomycin (\code{TRL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA08&showdescription=no}{J01FA08}), trovafloxacin (\code{TVA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA13&showdescription=no}{J01MA13}), tulathromycin (\code{TUL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA94&showdescription=no}{QJ01FA94}), tylosin (\code{TYL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA90&showdescription=no}{QJ01FA90}), tylvalosin (\code{TYL1}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA92&showdescription=no}{QJ01FA92}), vancomycin (\code{VAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA01&showdescription=no}{J01XA01})
}
\section{Download Our Reference Data}{
diff --git a/man/mdro.Rd b/man/mdro.Rd
index 71c0d3d02..ae6a9ae62 100644
--- a/man/mdro.Rd
+++ b/man/mdro.Rd
@@ -182,7 +182,7 @@ To define antimicrobials column names, leave as it is to determine it automatica
The following antimicrobials are eligible for the functions \code{\link[=eucast_rules]{eucast_rules()}} and \code{\link[=mdro]{mdro()}}. These are shown below in the format 'name (\verb{antimicrobial ID}, \href{https://atcddd.fhi.no/atc/structure_and_principles/}{ATC code})', sorted alphabetically:
-Amikacin (\code{AMK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB06&showdescription=no}{J01GB06}), amoxicillin (\code{AMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA04&showdescription=no}{J01CA04}), amoxicillin/clavulanic acid (\code{AMC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR02&showdescription=no}{J01CR02}), ampicillin (\code{AMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA01&showdescription=no}{J01CA01}), ampicillin/sulbactam (\code{SAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR01&showdescription=no}{J01CR01}), apramycin (\code{APR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07AA92&showdescription=no}{QA07AA92}), arbekacin (\code{ARB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB12&showdescription=no}{J01GB12}), aspoxicillin (\code{APX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA19&showdescription=no}{J01CA19}), azidocillin (\code{AZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE04&showdescription=no}{J01CE04}), azithromycin (\code{AZM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA10&showdescription=no}{J01FA10}), azlocillin (\code{AZL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA09&showdescription=no}{J01CA09}), aztreonam (\code{ATM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF01&showdescription=no}{J01DF01}), bacampicillin (\code{BAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA06&showdescription=no}{J01CA06}), bekanamycin (\code{BEK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB13&showdescription=no}{J01GB13}), benzathine benzylpenicillin (\code{BNB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE08&showdescription=no}{J01CE08}), benzathine phenoxymethylpenicillin (\code{BNP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE10&showdescription=no}{J01CE10}), benzylpenicillin (\code{PEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE01&showdescription=no}{J01CE01}), besifloxacin (\code{BES}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AE08&showdescription=no}{S01AE08}), biapenem (\code{BIA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH05&showdescription=no}{J01DH05}), bleomycin (\code{BLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=L01DC01&showdescription=no}{L01DC01}), brodimoprim (\code{BDP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EA02&showdescription=no}{J01EA02}), carbenicillin (\code{CRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA03&showdescription=no}{J01CA03}), carindacillin (\code{CRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA05&showdescription=no}{J01CA05}), carumonam (\code{CAR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF02&showdescription=no}{J01DF02}), cefacetrile (\code{CAC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB10&showdescription=no}{J01DB10}), cefaclor (\code{CEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC04&showdescription=no}{J01DC04}), cefadroxil (\code{CFR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB05&showdescription=no}{J01DB05}), cefalexin (\code{LEX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB01&showdescription=no}{J01DB01}), cefaloridine (\code{RID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB02&showdescription=no}{J01DB02}), cefalotin (\code{CEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB03&showdescription=no}{J01DB03}), cefamandole (\code{MAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC03&showdescription=no}{J01DC03}), cefapirin (\code{HAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB08&showdescription=no}{J01DB08}), cefatrizine (\code{CTZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB07&showdescription=no}{J01DB07}), cefazedone (\code{CZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB06&showdescription=no}{J01DB06}), cefazolin (\code{CZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB04&showdescription=no}{J01DB04}), cefcapene (\code{CCP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD17&showdescription=no}{J01DD17}), cefdinir (\code{CDR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD15&showdescription=no}{J01DD15}), cefditoren (\code{DIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD16&showdescription=no}{J01DD16}), cefepime (\code{FEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE01&showdescription=no}{J01DE01}), cefepime/amikacin (\code{CFA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA06&showdescription=no}{J01RA06}), cefetamet (\code{CAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD10&showdescription=no}{J01DD10}), cefiderocol (\code{FDC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI04&showdescription=no}{J01DI04}), cefixime (\code{CFM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD08&showdescription=no}{J01DD08}), cefmenoxime (\code{CMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD05&showdescription=no}{J01DD05}), cefmetazole (\code{CMZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC09&showdescription=no}{J01DC09}), cefodizime (\code{DIZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD09&showdescription=no}{J01DD09}), cefonicid (\code{CID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC06&showdescription=no}{J01DC06}), cefoperazone (\code{CFP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD12&showdescription=no}{J01DD12}), cefoperazone/sulbactam (\code{CSL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD62&showdescription=no}{J01DD62}), ceforanide (\code{CND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC11&showdescription=no}{J01DC11}), cefotaxime (\code{CTX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD01&showdescription=no}{J01DD01}), cefotaxime/clavulanic acid (\code{CTC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD51&showdescription=no}{J01DD51}), cefotetan (\code{CTT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC05&showdescription=no}{J01DC05}), cefotiam (\code{CTF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC07&showdescription=no}{J01DC07}), cefovecin (\code{FOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD91&showdescription=no}{QJ01DD91}), cefoxitin (\code{FOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC01&showdescription=no}{J01DC01}), cefozopran (\code{ZOP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE03&showdescription=no}{J01DE03}), cefpiramide (\code{CPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD11&showdescription=no}{J01DD11}), cefpirome (\code{CPO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE02&showdescription=no}{J01DE02}), cefpodoxime (\code{CPD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD13&showdescription=no}{J01DD13}), cefprozil (\code{CPR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC10&showdescription=no}{J01DC10}), cefquinome (\code{CEQ}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QG51AA07&showdescription=no}{QG51AA07}), cefroxadine (\code{CRD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB11&showdescription=no}{J01DB11}), cefsulodin (\code{CFS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD03&showdescription=no}{J01DD03}), ceftaroline (\code{CPT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI02&showdescription=no}{J01DI02}), ceftazidime (\code{CAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD02&showdescription=no}{J01DD02}), ceftazidime/clavulanic acid (\code{CCV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD52&showdescription=no}{J01DD52}), cefteram (\code{CEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD18&showdescription=no}{J01DD18}), ceftezole (\code{CTL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB12&showdescription=no}{J01DB12}), ceftibuten (\code{CTB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD14&showdescription=no}{J01DD14}), ceftiofur (\code{TIO}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD90&showdescription=no}{QJ01DD90}), ceftizoxime (\code{CZX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD07&showdescription=no}{J01DD07}), ceftobiprole medocaril (\code{CFM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI01&showdescription=no}{J01DI01}), ceftolozane/tazobactam (\code{CZT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI54&showdescription=no}{J01DI54}), ceftriaxone (\code{CRO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD04&showdescription=no}{J01DD04}), ceftriaxone/beta-lactamase inhibitor (\code{CEB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD63&showdescription=no}{J01DD63}), cefuroxime (\code{CXM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC02&showdescription=no}{J01DC02}), cephradine (\code{CED}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB09&showdescription=no}{J01DB09}), chloramphenicol (\code{CHL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01BA01&showdescription=no}{J01BA01}), chlortetracycline (\code{CTE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA03&showdescription=no}{J01AA03}), ciprofloxacin (\code{CIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA02&showdescription=no}{J01MA02}), ciprofloxacin/metronidazole (\code{CIM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA10&showdescription=no}{J01RA10}), ciprofloxacin/ornidazole (\code{CIO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA12&showdescription=no}{J01RA12}), ciprofloxacin/tinidazole (\code{CIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA11&showdescription=no}{J01RA11}), clarithromycin (\code{CLR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA09&showdescription=no}{J01FA09}), clindamycin (\code{CLI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF01&showdescription=no}{J01FF01}), clometocillin (\code{CLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE07&showdescription=no}{J01CE07}), clomocycline (\code{CLM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA11&showdescription=no}{J01AA11}), cloxacillin (\code{CLO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF02&showdescription=no}{J01CF02}), colistin (\code{COL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB01&showdescription=no}{J01XB01}), cycloserine (\code{CYC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB01&showdescription=no}{J04AB01}), dalbavancin (\code{DAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA04&showdescription=no}{J01XA04}), danofloxacin (\code{DAN}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA92&showdescription=no}{QJ01MA92}), daptomycin (\code{DAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX09&showdescription=no}{J01XX09}), delafloxacin (\code{DFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA23&showdescription=no}{J01MA23}), demeclocycline (\code{DEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA01&showdescription=no}{J01AA01}), dibekacin (\code{DKB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB09&showdescription=no}{J01GB09}), dicloxacillin (\code{DIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF01&showdescription=no}{J01CF01}), difloxacin (\code{DIF}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA94&showdescription=no}{QJ01MA94}), dirithromycin (\code{DIR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA13&showdescription=no}{J01FA13}), doripenem (\code{DOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH04&showdescription=no}{J01DH04}), doxycycline (\code{DOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA02&showdescription=no}{J01AA02}), enoxacin (\code{ENX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA04&showdescription=no}{J01MA04}), enrofloxacin (\code{ENR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA90&showdescription=no}{QJ01MA90}), epicillin (\code{EPC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA07&showdescription=no}{J01CA07}), eravacycline (\code{ERV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA13&showdescription=no}{J01AA13}), ertapenem (\code{ETP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH03&showdescription=no}{J01DH03}), erythromycin (\code{ERY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA01&showdescription=no}{J01FA01}), fleroxacin (\code{FLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA08&showdescription=no}{J01MA08}), flucloxacillin (\code{FLC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF05&showdescription=no}{J01CF05}), flurithromycin (\code{FLR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA14&showdescription=no}{J01FA14}), fosfomycin (\code{FOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX01&showdescription=no}{J01XX01}), framycetin (\code{FRM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D09AA01&showdescription=no}{D09AA01}), fusidic acid (\code{FUS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XC01&showdescription=no}{J01XC01}), gamithromycin (\code{GAM}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA95&showdescription=no}{QJ01FA95}), garenoxacin (\code{GRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA19&showdescription=no}{J01MA19}), gatifloxacin (\code{GAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA16&showdescription=no}{J01MA16}), gemifloxacin (\code{GEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA15&showdescription=no}{J01MA15}), gentamicin (\code{GEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB03&showdescription=no}{J01GB03}), grepafloxacin (\code{GRX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA11&showdescription=no}{J01MA11}), hetacillin (\code{HET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA18&showdescription=no}{J01CA18}), imipenem (\code{IPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH51&showdescription=no}{J01DH51}), imipenem/relebactam (\code{IMR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH56&showdescription=no}{J01DH56}), isepamicin (\code{ISE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB11&showdescription=no}{J01GB11}), josamycin (\code{JOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA07&showdescription=no}{J01FA07}), kanamycin (\code{KAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB04&showdescription=no}{J01GB04}), kitasamycin (\code{KIT}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA93&showdescription=no}{QJ01FA93}), lascufloxacin (\code{LSC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA25&showdescription=no}{J01MA25}), latamoxef (\code{LTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD06&showdescription=no}{J01DD06}), levofloxacin (\code{LVX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA12&showdescription=no}{J01MA12}), levofloxacin/ornidazole (\code{LEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA05&showdescription=no}{J01RA05}), levonadifloxacin (\code{LND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA24&showdescription=no}{J01MA24}), lincomycin (\code{LIN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF02&showdescription=no}{J01FF02}), linezolid (\code{LNZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX08&showdescription=no}{J01XX08}), lomefloxacin (\code{LOM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA07&showdescription=no}{J01MA07}), loracarbef (\code{LOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC08&showdescription=no}{J01DC08}), lymecycline (\code{LYM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA04&showdescription=no}{J01AA04}), marbofloxacin (\code{MAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA93&showdescription=no}{QJ01MA93}), mecillinam (\code{MEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA11&showdescription=no}{J01CA11}), meropenem (\code{MEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH02&showdescription=no}{J01DH02}), meropenem/vaborbactam (\code{MEV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH52&showdescription=no}{J01DH52}), metacycline (\code{MTC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA05&showdescription=no}{J01AA05}), metampicillin (\code{MTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA14&showdescription=no}{J01CA14}), meticillin (\code{MET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF03&showdescription=no}{J01CF03}), mezlocillin (\code{MEZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA10&showdescription=no}{J01CA10}), micronomicin (\code{MCR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=S01AA22&showdescription=no}{S01AA22}), midecamycin (\code{MID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA03&showdescription=no}{J01FA03}), minocycline (\code{MNO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA08&showdescription=no}{J01AA08}), miocamycin (\code{MCM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA11&showdescription=no}{J01FA11}), moxifloxacin (\code{MFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA14&showdescription=no}{J01MA14}), nadifloxacin (\code{NAD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D10AF05&showdescription=no}{D10AF05}), nafcillin (\code{NAF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF06&showdescription=no}{J01CF06}), nalidixic acid (\code{NAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB02&showdescription=no}{J01MB02}), nemonoxacin (\code{NEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB08&showdescription=no}{J01MB08}), neomycin (\code{NEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB05&showdescription=no}{J01GB05}), netilmicin (\code{NET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB07&showdescription=no}{J01GB07}), nitrofurantoin (\code{NIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XE01&showdescription=no}{J01XE01}), nitroxoline (\code{NTR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX07&showdescription=no}{J01XX07}), norfloxacin (\code{NOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA06&showdescription=no}{J01MA06}), norfloxacin/metronidazole (\code{NME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA14&showdescription=no}{J01RA14}), norfloxacin/tinidazole (\code{NTI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA13&showdescription=no}{J01RA13}), novobiocin (\code{NOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01XX95&showdescription=no}{QJ01XX95}), ofloxacin (\code{OFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA01&showdescription=no}{J01MA01}), ofloxacin/ornidazole (\code{OOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01RA09&showdescription=no}{J01RA09}), oleandomycin (\code{OLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA05&showdescription=no}{J01FA05}), omadacycline (\code{OMC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA15&showdescription=no}{J01AA15}), orbifloxacin (\code{ORB}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA95&showdescription=no}{QJ01MA95}), oritavancin (\code{ORI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA05&showdescription=no}{J01XA05}), oxacillin (\code{OXA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF04&showdescription=no}{J01CF04}), oxytetracycline (\code{OXY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA06&showdescription=no}{J01AA06}), panipenem (\code{PAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH55&showdescription=no}{J01DH55}), pazufloxacin (\code{PAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA18&showdescription=no}{J01MA18}), pefloxacin (\code{PEF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA03&showdescription=no}{J01MA03}), penamecillin (\code{PNM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE06&showdescription=no}{J01CE06}), penimepicycline (\code{PNM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA10&showdescription=no}{J01AA10}), pheneticillin (\code{PHE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE05&showdescription=no}{J01CE05}), phenoxymethylpenicillin (\code{PHN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE02&showdescription=no}{J01CE02}), piperacillin (\code{PIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA12&showdescription=no}{J01CA12}), piperacillin/tazobactam (\code{TZP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR05&showdescription=no}{J01CR05}), pirlimycin (\code{PRL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ51FF90&showdescription=no}{QJ51FF90}), pivampicillin (\code{PVM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA02&showdescription=no}{J01CA02}), pivmecillinam (\code{PME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA08&showdescription=no}{J01CA08}), plazomicin (\code{PLZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB14&showdescription=no}{J01GB14}), polymyxin B (\code{PLB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB02&showdescription=no}{J01XB02}), pradofloxacin (\code{PRA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA97&showdescription=no}{QJ01MA97}), pristinamycin (\code{PRI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FG01&showdescription=no}{J01FG01}), procaine benzylpenicillin (\code{PRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE09&showdescription=no}{J01CE09}), propicillin (\code{PRP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE03&showdescription=no}{J01CE03}), prulifloxacin (\code{PRU}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA17&showdescription=no}{J01MA17}), quinupristin/dalfopristin (\code{QDA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FG02&showdescription=no}{QJ01FG02}), ribostamycin (\code{RST}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB10&showdescription=no}{J01GB10}), rifampicin (\code{RIF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB02&showdescription=no}{J04AB02}), rokitamycin (\code{ROK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA12&showdescription=no}{J01FA12}), rolitetracycline (\code{RLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA09&showdescription=no}{J01AA09}), roxithromycin (\code{RXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA06&showdescription=no}{J01FA06}), rufloxacin (\code{RFL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA10&showdescription=no}{J01MA10}), sarafloxacin (\code{SAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA98&showdescription=no}{QJ01MA98}), sarecycline (\code{SRC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA14&showdescription=no}{J01AA14}), sisomicin (\code{SIS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB08&showdescription=no}{J01GB08}), sitafloxacin (\code{SIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA21&showdescription=no}{J01MA21}), solithromycin (\code{SOL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA16&showdescription=no}{J01FA16}), sparfloxacin (\code{SPX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA09&showdescription=no}{J01MA09}), spiramycin (\code{SPI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA02&showdescription=no}{J01FA02}), streptoduocin (\code{STR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA02&showdescription=no}{J01GA02}), streptomycin (\code{STR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA01&showdescription=no}{J01GA01}), sulbenicillin (\code{SBC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA16&showdescription=no}{J01CA16}), sulfadiazine (\code{SDI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC02&showdescription=no}{J01EC02}), sulfadiazine/tetroxoprim (\code{SLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE06&showdescription=no}{J01EE06}), sulfadiazine/trimethoprim (\code{SLT1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE02&showdescription=no}{J01EE02}), sulfadimethoxine (\code{SUD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED01&showdescription=no}{J01ED01}), sulfadimidine (\code{SDM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB03&showdescription=no}{J01EB03}), sulfadimidine/trimethoprim (\code{SLT2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE05&showdescription=no}{J01EE05}), sulfafurazole (\code{SLF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB05&showdescription=no}{J01EB05}), sulfaisodimidine (\code{SLF1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB01&showdescription=no}{J01EB01}), sulfalene (\code{SLF2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED02&showdescription=no}{J01ED02}), sulfamazone (\code{SZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED09&showdescription=no}{J01ED09}), sulfamerazine (\code{SLF3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED07&showdescription=no}{J01ED07}), sulfamerazine/trimethoprim (\code{SLT3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE07&showdescription=no}{J01EE07}), sulfamethizole (\code{SLF4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB02&showdescription=no}{J01EB02}), sulfamethoxazole (\code{SMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC01&showdescription=no}{J01EC01}), sulfamethoxypyridazine (\code{SLF5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED05&showdescription=no}{J01ED05}), sulfametomidine (\code{SLF6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED03&showdescription=no}{J01ED03}), sulfametoxydiazine (\code{SLF7}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED04&showdescription=no}{J01ED04}), sulfametrole/trimethoprim (\code{SLT4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE03&showdescription=no}{J01EE03}), sulfamoxole (\code{SLF8}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC03&showdescription=no}{J01EC03}), sulfamoxole/trimethoprim (\code{SLT5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE04&showdescription=no}{J01EE04}), sulfanilamide (\code{SLF9}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB06&showdescription=no}{J01EB06}), sulfaperin (\code{SLF10}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED06&showdescription=no}{J01ED06}), sulfaphenazole (\code{SLF11}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED08&showdescription=no}{J01ED08}), sulfapyridine (\code{SLF12}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB04&showdescription=no}{J01EB04}), sulfathiazole (\code{SUT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB07&showdescription=no}{J01EB07}), sulfathiourea (\code{SLF13}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB08&showdescription=no}{J01EB08}), sultamicillin (\code{SLT6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR04&showdescription=no}{J01CR04}), talampicillin (\code{TAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA15&showdescription=no}{J01CA15}), tebipenem (\code{TBP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH06&showdescription=no}{J01DH06}), tedizolid (\code{TZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX11&showdescription=no}{J01XX11}), teicoplanin (\code{TEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA02&showdescription=no}{J01XA02}), telavancin (\code{TLV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA03&showdescription=no}{J01XA03}), telithromycin (\code{TLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA15&showdescription=no}{J01FA15}), temafloxacin (\code{TMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA05&showdescription=no}{J01MA05}), temocillin (\code{TEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA17&showdescription=no}{J01CA17}), tetracycline (\code{TCY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA07&showdescription=no}{J01AA07}), ticarcillin (\code{TIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA13&showdescription=no}{J01CA13}), ticarcillin/clavulanic acid (\code{TCC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR03&showdescription=no}{J01CR03}), tigecycline (\code{TGC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA12&showdescription=no}{J01AA12}), tilbroquinol (\code{TBQ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=P01AA05&showdescription=no}{P01AA05}), tildipirosin (\code{TIP}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA96&showdescription=no}{QJ01FA96}), tilmicosin (\code{TIL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA91&showdescription=no}{QJ01FA91}), tobramycin (\code{TOB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB01&showdescription=no}{J01GB01}), tosufloxacin (\code{TFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA22&showdescription=no}{J01MA22}), trimethoprim (\code{TMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EA01&showdescription=no}{J01EA01}), trimethoprim/sulfamethoxazole (\code{SXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EE01&showdescription=no}{J01EE01}), troleandomycin (\code{TRL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA08&showdescription=no}{J01FA08}), trovafloxacin (\code{TVA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA13&showdescription=no}{J01MA13}), tulathromycin (\code{TUL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA94&showdescription=no}{QJ01FA94}), tylosin (\code{TYL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA90&showdescription=no}{QJ01FA90}), tylvalosin (\code{TYL1}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA92&showdescription=no}{QJ01FA92}), vancomycin (\code{VAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA01&showdescription=no}{J01XA01})
+Amikacin (\code{AMK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB06&showdescription=no}{J01GB06}), amoxicillin (\code{AMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA04&showdescription=no}{J01CA04}), amoxicillin/clavulanic acid (\code{AMC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR02&showdescription=no}{J01CR02}), amoxicillin/sulbactam (\code{AXS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR02&showdescription=no}{J01CR02}), ampicillin (\code{AMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA01&showdescription=no}{J01CA01}), ampicillin/sulbactam (\code{SAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR01&showdescription=no}{J01CR01}), apramycin (\code{APR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07AA92&showdescription=no}{QA07AA92}), arbekacin (\code{ARB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB12&showdescription=no}{J01GB12}), aspoxicillin (\code{APX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA19&showdescription=no}{J01CA19}), azidocillin (\code{AZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE04&showdescription=no}{J01CE04}), azithromycin (\code{AZM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA10&showdescription=no}{J01FA10}), azlocillin (\code{AZL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA09&showdescription=no}{J01CA09}), aztreonam (\code{ATM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF01&showdescription=no}{J01DF01}), aztreonam/avibactam (\code{AZA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF51&showdescription=no}{J01DF51}), aztreonam/nacubactam (\code{ANC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF51&showdescription=no}{J01DF51}), bacampicillin (\code{BAM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA06&showdescription=no}{J01CA06}), bekanamycin (\code{BEK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB13&showdescription=no}{J01GB13}), benzathine benzylpenicillin (\code{BNB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE08&showdescription=no}{J01CE08}), benzathine phenoxymethylpenicillin (\code{BNP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE10&showdescription=no}{J01CE10}), benzylpenicillin (\code{PEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE01&showdescription=no}{J01CE01}), besifloxacin (\code{BES}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QS01AE08&showdescription=no}{QS01AE08}), biapenem (\code{BIA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH05&showdescription=no}{J01DH05}), bleomycin (\code{BLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=L01DC01&showdescription=no}{L01DC01}), brodimoprim (\code{BDP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EA02&showdescription=no}{J01EA02}), carbenicillin (\code{CRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA03&showdescription=no}{J01CA03}), carindacillin (\code{CRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA05&showdescription=no}{J01CA05}), carumonam (\code{CAR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DF02&showdescription=no}{J01DF02}), cefacetrile (\code{CAC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB10&showdescription=no}{J01DB10}), cefaclor (\code{CEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC04&showdescription=no}{J01DC04}), cefadroxil (\code{CFR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB05&showdescription=no}{J01DB05}), cefalexin (\code{LEX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB01&showdescription=no}{J01DB01}), cefaloridine (\code{RID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB02&showdescription=no}{J01DB02}), cefalotin (\code{CEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB03&showdescription=no}{J01DB03}), cefamandole (\code{MAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC03&showdescription=no}{J01DC03}), cefapirin (\code{HAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB08&showdescription=no}{J01DB08}), cefatrizine (\code{CTZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB07&showdescription=no}{J01DB07}), cefazedone (\code{CZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB06&showdescription=no}{J01DB06}), cefazolin (\code{CZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB04&showdescription=no}{J01DB04}), cefcapene (\code{CCP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD17&showdescription=no}{J01DD17}), cefdinir (\code{CDR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD15&showdescription=no}{J01DD15}), cefditoren (\code{DIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD16&showdescription=no}{J01DD16}), cefepime (\code{FEP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE01&showdescription=no}{J01DE01}), cefepime/amikacin (\code{CFA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE51&showdescription=no}{J01DE51}), cefepime/clavulanic acid (\code{CPC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE51&showdescription=no}{J01DE51}), cefepime/enmetazobactam (\code{FPE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE51&showdescription=no}{J01DE51}), cefepime/nacubactam (\code{FNC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE51&showdescription=no}{J01DE51}), cefepime/tazobactam (\code{FPT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE51&showdescription=no}{J01DE51}), cefepime/zidebactam (\code{FPZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE51&showdescription=no}{J01DE51}), cefetamet (\code{CAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD10&showdescription=no}{J01DD10}), cefiderocol (\code{FDC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI04&showdescription=no}{J01DI04}), cefixime (\code{CFM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD08&showdescription=no}{J01DD08}), cefmenoxime (\code{CMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD05&showdescription=no}{J01DD05}), cefmetazole (\code{CMZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC09&showdescription=no}{J01DC09}), cefodizime (\code{DIZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD09&showdescription=no}{J01DD09}), cefonicid (\code{CID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC06&showdescription=no}{J01DC06}), cefoperazone (\code{CFP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD12&showdescription=no}{J01DD12}), cefoperazone/sulbactam (\code{CSL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD62&showdescription=no}{J01DD62}), ceforanide (\code{CND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC11&showdescription=no}{J01DC11}), cefotaxime (\code{CTX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD01&showdescription=no}{J01DD01}), cefotaxime/clavulanic acid (\code{CTC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD51&showdescription=no}{J01DD51}), cefotaxime/sulbactam (\code{CTS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD51&showdescription=no}{J01DD51}), cefotetan (\code{CTT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC05&showdescription=no}{J01DC05}), cefotiam (\code{CTF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC07&showdescription=no}{J01DC07}), cefovecin (\code{FOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD91&showdescription=no}{QJ01DD91}), cefoxitin (\code{FOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC01&showdescription=no}{J01DC01}), cefozopran (\code{ZOP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE03&showdescription=no}{J01DE03}), cefpiramide (\code{CPM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD11&showdescription=no}{J01DD11}), cefpirome (\code{CPO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DE02&showdescription=no}{J01DE02}), cefpodoxime (\code{CPD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD13&showdescription=no}{J01DD13}), cefpodoxime/clavulanic acid (\code{CDC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD64&showdescription=no}{J01DD64}), cefprozil (\code{CPR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC10&showdescription=no}{J01DC10}), cefquinome (\code{CEQ}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QG51AA07&showdescription=no}{QG51AA07}), cefroxadine (\code{CRD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB11&showdescription=no}{J01DB11}), cefsulodin (\code{CFS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD03&showdescription=no}{J01DD03}), ceftazidime (\code{CAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD02&showdescription=no}{J01DD02}), ceftazidime/avibactam (\code{CZA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD52&showdescription=no}{J01DD52}), ceftazidime/clavulanic acid (\code{CCV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD52&showdescription=no}{J01DD52}), cefteram (\code{CEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD18&showdescription=no}{J01DD18}), ceftezole (\code{CTL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DB12&showdescription=no}{J01DB12}), ceftibuten (\code{CTB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD14&showdescription=no}{J01DD14}), ceftiofur (\code{TIO}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01DD90&showdescription=no}{QJ01DD90}), ceftizoxime (\code{CZX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD07&showdescription=no}{J01DD07}), ceftobiprole medocaril (\code{CFM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI01&showdescription=no}{J01DI01}), ceftolozane/tazobactam (\code{CZT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DI54&showdescription=no}{J01DI54}), ceftriaxone (\code{CRO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD04&showdescription=no}{J01DD04}), ceftriaxone/beta-lactamase inhibitor (\code{CEB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD63&showdescription=no}{J01DD63}), cefuroxime (\code{CXM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC02&showdescription=no}{J01DC02}), chloramphenicol (\code{CHL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01BA01&showdescription=no}{J01BA01}), chlortetracycline (\code{CTE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA03&showdescription=no}{J01AA03}), ciprofloxacin (\code{CIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA02&showdescription=no}{J01MA02}), clarithromycin (\code{CLR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA09&showdescription=no}{J01FA09}), clindamycin (\code{CLI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF01&showdescription=no}{J01FF01}), clometocillin (\code{CLM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE07&showdescription=no}{J01CE07}), clomocycline (\code{CLM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA11&showdescription=no}{J01AA11}), cloxacillin (\code{CLO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF02&showdescription=no}{J01CF02}), colistin (\code{COL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB01&showdescription=no}{J01XB01}), cycloserine (\code{CYC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB01&showdescription=no}{J04AB01}), dalbavancin (\code{DAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA04&showdescription=no}{J01XA04}), danofloxacin (\code{DAN}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA92&showdescription=no}{QJ01MA92}), daptomycin (\code{DAP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX09&showdescription=no}{J01XX09}), delafloxacin (\code{DFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA23&showdescription=no}{J01MA23}), demeclocycline (\code{DEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA01&showdescription=no}{J01AA01}), dibekacin (\code{DKB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB09&showdescription=no}{J01GB09}), dicloxacillin (\code{DIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF01&showdescription=no}{J01CF01}), difloxacin (\code{DIF}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA94&showdescription=no}{QJ01MA94}), dirithromycin (\code{DIR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA13&showdescription=no}{J01FA13}), doripenem (\code{DOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH04&showdescription=no}{J01DH04}), doxycycline (\code{DOX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA02&showdescription=no}{J01AA02}), enoxacin (\code{ENX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA04&showdescription=no}{J01MA04}), enrofloxacin (\code{ENR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA90&showdescription=no}{QJ01MA90}), epicillin (\code{EPC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA07&showdescription=no}{J01CA07}), eravacycline (\code{ERV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA13&showdescription=no}{J01AA13}), ertapenem (\code{ETP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH03&showdescription=no}{J01DH03}), erythromycin (\code{ERY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA01&showdescription=no}{J01FA01}), fleroxacin (\code{FLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA08&showdescription=no}{J01MA08}), flucloxacillin (\code{FLC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF05&showdescription=no}{J01CF05}), flurithromycin (\code{FLR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA14&showdescription=no}{J01FA14}), fosfomycin (\code{FOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX01&showdescription=no}{J01XX01}), framycetin (\code{FRM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D09AA01&showdescription=no}{D09AA01}), fusidic acid (\code{FUS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XC01&showdescription=no}{J01XC01}), gamithromycin (\code{GAM}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA95&showdescription=no}{QJ01FA95}), garenoxacin (\code{GRN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA19&showdescription=no}{J01MA19}), gatifloxacin (\code{GAT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA16&showdescription=no}{J01MA16}), gemifloxacin (\code{GEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA15&showdescription=no}{J01MA15}), gentamicin (\code{GEN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB03&showdescription=no}{J01GB03}), grepafloxacin (\code{GRX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA11&showdescription=no}{J01MA11}), hetacillin (\code{HET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA18&showdescription=no}{J01CA18}), isepamicin (\code{ISE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB11&showdescription=no}{J01GB11}), josamycin (\code{JOS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA07&showdescription=no}{J01FA07}), kanamycin (\code{KAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB04&showdescription=no}{J01GB04}), kitasamycin (\code{KIT}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA93&showdescription=no}{QJ01FA93}), lascufloxacin (\code{LSC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA25&showdescription=no}{J01MA25}), latamoxef (\code{LTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DD06&showdescription=no}{J01DD06}), levofloxacin (\code{LVX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA12&showdescription=no}{J01MA12}), levonadifloxacin (\code{LND}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA24&showdescription=no}{J01MA24}), lincomycin (\code{LIN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FF02&showdescription=no}{J01FF02}), linezolid (\code{LNZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX08&showdescription=no}{J01XX08}), lomefloxacin (\code{LOM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA07&showdescription=no}{J01MA07}), loracarbef (\code{LOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DC08&showdescription=no}{J01DC08}), lymecycline (\code{LYM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA04&showdescription=no}{J01AA04}), marbofloxacin (\code{MAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA93&showdescription=no}{QJ01MA93}), mecillinam (\code{MEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA11&showdescription=no}{J01CA11}), meropenem (\code{MEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01DH02&showdescription=no}{J01DH02}), metacycline (\code{MTC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA05&showdescription=no}{J01AA05}), metampicillin (\code{MTM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA14&showdescription=no}{J01CA14}), meticillin (\code{MET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF03&showdescription=no}{J01CF03}), mezlocillin (\code{MEZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA10&showdescription=no}{J01CA10}), micronomicin (\code{MCR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QS01AA22&showdescription=no}{QS01AA22}), midecamycin (\code{MID}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA03&showdescription=no}{J01FA03}), minocycline (\code{MNO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA08&showdescription=no}{J01AA08}), miocamycin (\code{MCM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA11&showdescription=no}{J01FA11}), moxifloxacin (\code{MFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA14&showdescription=no}{J01MA14}), nadifloxacin (\code{NAD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=D10AF05&showdescription=no}{D10AF05}), nafcillin (\code{NAF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF06&showdescription=no}{J01CF06}), nalidixic acid (\code{NAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB02&showdescription=no}{J01MB02}), nemonoxacin (\code{NEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MB08&showdescription=no}{J01MB08}), neomycin (\code{NEO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB05&showdescription=no}{J01GB05}), netilmicin (\code{NET}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB07&showdescription=no}{J01GB07}), nitrofurantoin (\code{NIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XE01&showdescription=no}{J01XE01}), nitroxoline (\code{NTR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX07&showdescription=no}{J01XX07}), norfloxacin (\code{NOR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA06&showdescription=no}{J01MA06}), novobiocin (\code{NOV}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01XX95&showdescription=no}{QJ01XX95}), ofloxacin (\code{OFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA01&showdescription=no}{J01MA01}), oleandomycin (\code{OLE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA05&showdescription=no}{J01FA05}), omadacycline (\code{OMC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA15&showdescription=no}{J01AA15}), orbifloxacin (\code{ORB}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA95&showdescription=no}{QJ01MA95}), oritavancin (\code{ORI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA05&showdescription=no}{J01XA05}), oxacillin (\code{OXA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CF04&showdescription=no}{J01CF04}), oxytetracycline (\code{OXY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA06&showdescription=no}{J01AA06}), pazufloxacin (\code{PAZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA18&showdescription=no}{J01MA18}), pefloxacin (\code{PEF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA03&showdescription=no}{J01MA03}), penamecillin (\code{PNM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE06&showdescription=no}{J01CE06}), penimepicycline (\code{PNM1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA10&showdescription=no}{J01AA10}), pheneticillin (\code{PHE}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE05&showdescription=no}{J01CE05}), phenoxymethylpenicillin (\code{PHN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE02&showdescription=no}{J01CE02}), piperacillin (\code{PIP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA12&showdescription=no}{J01CA12}), piperacillin/sulbactam (\code{PIS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR05&showdescription=no}{J01CR05}), piperacillin/tazobactam (\code{TZP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR05&showdescription=no}{J01CR05}), pirlimycin (\code{PRL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ51FF90&showdescription=no}{QJ51FF90}), pivampicillin (\code{PVM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA02&showdescription=no}{J01CA02}), pivmecillinam (\code{PME}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA08&showdescription=no}{J01CA08}), plazomicin (\code{PLZ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB14&showdescription=no}{J01GB14}), polymyxin B (\code{PLB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XB02&showdescription=no}{J01XB02}), pradofloxacin (\code{PRA}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA97&showdescription=no}{QJ01MA97}), pristinamycin (\code{PRI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FG01&showdescription=no}{J01FG01}), procaine benzylpenicillin (\code{PRB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE09&showdescription=no}{J01CE09}), propicillin (\code{PRP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CE03&showdescription=no}{J01CE03}), prulifloxacin (\code{PRU}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA17&showdescription=no}{J01MA17}), ribostamycin (\code{RST}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB10&showdescription=no}{J01GB10}), rifampicin (\code{RIF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J04AB02&showdescription=no}{J04AB02}), rokitamycin (\code{ROK}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA12&showdescription=no}{J01FA12}), rolitetracycline (\code{RLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA09&showdescription=no}{J01AA09}), roxithromycin (\code{RXT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA06&showdescription=no}{J01FA06}), rufloxacin (\code{RFL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA10&showdescription=no}{J01MA10}), sarafloxacin (\code{SAR}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01MA98&showdescription=no}{QJ01MA98}), sarecycline (\code{SRC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA14&showdescription=no}{J01AA14}), sisomicin (\code{SIS}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB08&showdescription=no}{J01GB08}), sitafloxacin (\code{SIT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA21&showdescription=no}{J01MA21}), solithromycin (\code{SOL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA16&showdescription=no}{J01FA16}), sparfloxacin (\code{SPX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA09&showdescription=no}{J01MA09}), spiramycin (\code{SPI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA02&showdescription=no}{J01FA02}), streptoduocin (\code{STR}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA02&showdescription=no}{J01GA02}), streptomycin (\code{STR1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GA01&showdescription=no}{J01GA01}), sulbenicillin (\code{SBC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA16&showdescription=no}{J01CA16}), sulfadiazine (\code{SDI}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC02&showdescription=no}{J01EC02}), sulfadimethoxine (\code{SUD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED01&showdescription=no}{J01ED01}), sulfadimidine (\code{SDM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB03&showdescription=no}{J01EB03}), sulfafurazole (\code{SLF}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB05&showdescription=no}{J01EB05}), sulfaisodimidine (\code{SLF1}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB01&showdescription=no}{J01EB01}), sulfalene (\code{SLF2}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED02&showdescription=no}{J01ED02}), sulfamazone (\code{SZO}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED09&showdescription=no}{J01ED09}), sulfamerazine (\code{SLF3}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED07&showdescription=no}{J01ED07}), sulfamethizole (\code{SLF4}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB02&showdescription=no}{J01EB02}), sulfamethoxazole (\code{SMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC01&showdescription=no}{J01EC01}), sulfamethoxypyridazine (\code{SLF5}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED05&showdescription=no}{J01ED05}), sulfametomidine (\code{SLF6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED03&showdescription=no}{J01ED03}), sulfametoxydiazine (\code{SLF7}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED04&showdescription=no}{J01ED04}), sulfamoxole (\code{SLF8}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EC03&showdescription=no}{J01EC03}), sulfanilamide (\code{SLF9}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB06&showdescription=no}{J01EB06}), sulfaperin (\code{SLF10}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED06&showdescription=no}{J01ED06}), sulfaphenazole (\code{SLF11}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01ED08&showdescription=no}{J01ED08}), sulfapyridine (\code{SLF12}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB04&showdescription=no}{J01EB04}), sulfathiazole (\code{SUT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB07&showdescription=no}{J01EB07}), sulfathiourea (\code{SLF13}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EB08&showdescription=no}{J01EB08}), sultamicillin (\code{SLT6}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR04&showdescription=no}{J01CR04}), talampicillin (\code{TAL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA15&showdescription=no}{J01CA15}), tedizolid (\code{TZD}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XX11&showdescription=no}{J01XX11}), teicoplanin (\code{TEC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA02&showdescription=no}{J01XA02}), telavancin (\code{TLV}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA03&showdescription=no}{J01XA03}), telithromycin (\code{TLT}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA15&showdescription=no}{J01FA15}), temafloxacin (\code{TMX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA05&showdescription=no}{J01MA05}), temocillin (\code{TEM}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA17&showdescription=no}{J01CA17}), tetracycline (\code{TCY}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA07&showdescription=no}{J01AA07}), ticarcillin (\code{TIC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CA13&showdescription=no}{J01CA13}), ticarcillin/clavulanic acid (\code{TCC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01CR03&showdescription=no}{J01CR03}), tigecycline (\code{TGC}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01AA12&showdescription=no}{J01AA12}), tilbroquinol (\code{TBQ}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=P01AA05&showdescription=no}{P01AA05}), tildipirosin (\code{TIP}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA96&showdescription=no}{QJ01FA96}), tilmicosin (\code{TIL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA91&showdescription=no}{QJ01FA91}), tobramycin (\code{TOB}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01GB01&showdescription=no}{J01GB01}), tosufloxacin (\code{TFX}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA22&showdescription=no}{J01MA22}), trimethoprim (\code{TMP}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01EA01&showdescription=no}{J01EA01}), troleandomycin (\code{TRL}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01FA08&showdescription=no}{J01FA08}), trovafloxacin (\code{TVA}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01MA13&showdescription=no}{J01MA13}), tulathromycin (\code{TUL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA94&showdescription=no}{QJ01FA94}), tylosin (\code{TYL}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA90&showdescription=no}{QJ01FA90}), tylvalosin (\code{TYL1}, \href{https://atcddd.fhi.no/atcvet/atcvet_index/?code=QJ01FA92&showdescription=no}{QJ01FA92}), vancomycin (\code{VAN}, \href{https://atcddd.fhi.no/atc_ddd_index//?code=J01XA01&showdescription=no}{J01XA01})
}
\section{Interpretation of SIR}{
diff --git a/pkgdown/extra.css b/pkgdown/extra.css
index 1ef9a9a11..7490db2a9 100644
--- a/pkgdown/extra.css
+++ b/pkgdown/extra.css
@@ -174,10 +174,7 @@ this shows on top of every sidebar to the right
}
}
@media (max-width: 575.98px) {
- footer .pkgdown-footer-left {
- text-align: center;
- }
- footer .pkgdown-footer-right {
+ footer * {
text-align: center;
}
}
diff --git a/tests/testthat/test-sir.R b/tests/testthat/test-sir.R
index 227222f95..4cd25bddf 100644
--- a/tests/testthat/test-sir.R
+++ b/tests/testthat/test-sir.R
@@ -30,7 +30,7 @@
test_that("test-sir.R", {
skip_on_cran()
- # Existing SIR ------------------------------------------------------------
+ # Existing SIR ----------------------------------------------------------
# we must only have EUCAST and CLSI, because otherwise the rules in as.sir() will fail
expect_identical(
@@ -124,7 +124,7 @@ test_that("test-sir.R", {
expect_equal(as.sir(c("", "-", NA, "NULL")), c(NA_sir_, NA_sir_, NA_sir_, NA_sir_))
- # Human -------------------------------------------------------------------
+ # Human -----------------------------------------------------------------
# allow for guideline length > 1
expect_equal(
@@ -345,7 +345,7 @@ test_that("test-sir.R", {
)
- # Veterinary --------------------------------------------------------------
+ # Veterinary ------------------------------------------------------------
# multiple guidelines
sir_history <- sir_interpretation_history(clean = TRUE)
@@ -390,7 +390,7 @@ test_that("test-sir.R", {
)
)
- # ECOFF -------------------------------------------------------------------
+ # ECOFF -----------------------------------------------------------------
expect_equal(
suppressMessages(as.sir(as.mic(2), "E. coli", "ampicillin", guideline = "EUCAST 2020", breakpoint_type = "ECOFF")),
@@ -398,4 +398,42 @@ test_that("test-sir.R", {
)
# old method
expect_warning(as.sir(as.mic(2), "E. coli", "ampicillin", guideline = "EUCAST 2020", ecoff = TRUE))
+
+
+ # Parallel computing ----------------------------------------------------
+
+ # MB 29 Apr 2025: I have run the code of AVC, PEI, Canada (dataset of 2854x65), and compared it like this:
+
+ # system.time({
+ # data_2022_2023_SIR_parallel <- data_2022_2023_clean |>
+ # as.sir(amikacin:tiamulin,
+ # col_mo = "mo",
+ # guideline = "CLSI 2024",
+ # host = "Species",
+ # uti = "isUTI",
+ # parallel = TRUE)
+ # })
+ # # user system elapsed
+ # # 271.424 2.767 45.762
+ #
+ # history_parallel <- sir_interpretation_history(clean = TRUE)
+ #
+ # system.time({
+ # data_2022_2023_SIR <- data_2022_2023_clean |>
+ # as.sir(amikacin:tiamulin,
+ # col_mo = "mo",
+ # guideline = "CLSI 2024",
+ # host = "Species",
+ # uti = "isUTI")
+ # })
+ # # user system elapsed
+ # # 120.637 5.406 128.835
+ # history <- sir_interpretation_history()
+
+
+ # and then got this:
+ # identical(history[, -1], history_parallel[, -1])
+ #> [1] TRUE
+
+ # so parallel on Apple M2 is 2.8x faster, with identical history -> GREAT!
})